,entities,start_tokens,end_tokens,start_chars,end_chars,text,pmid,lf_chemicals_distsv,lf_disease_distsv,label,orig_index,olabel
4,Calcitriol,2,3,12,22,"BACKGROUND: Calcitriol therapy suppresses serum levels of parathyroid hormone (PTH) in patients with renal failure but has several drawbacks, including hypercalcemia and/or marked suppression of bone turnover, which may lead to adynamic bone disease.",10027919_1,0,-1,0,4,0
5,parathyroid hormone,8,10,58,77,"BACKGROUND: Calcitriol therapy suppresses serum levels of parathyroid hormone (PTH) in patients with renal failure but has several drawbacks, including hypercalcemia and/or marked suppression of bone turnover, which may lead to adynamic bone disease.",10027919_1,0,-1,0,5,0
47,methylprednisolone,9,10,67,85,"Hypotension, bradycardia, and asystole after high-dose intravenous methylprednisolone in a monitored patient.",10074612_0,0,-1,0,47,0
64,methylprednisolone,16,17,100,118,This study reviews the current proposed mechanisms of sudden death after a high dose of intravenous methylprednisolone (IVMP).,10074612_6,0,-1,0,64,0
86,selegiline,32,33,180,190,OBJECTIVES: The United Kingdom Parkinson's Disease Research Group (UKPDRG) trial found an increased mortality in patients with Parkinson's disease (PD) randomized to receive 10 mg selegiline per day and L-dopa compared with those taking L-dopa alone.,10091617_1,0,-1,0,86,0
87,selegiline,7,8,37,47,"Recently, we found that therapy with selegiline and L-dopa was associated with selective systolic orthostatic hypotension which was abolished by withdrawal of selegiline.",10091617_2,0,-1,0,87,0
90,selegiline,23,24,159,169,"Recently, we found that therapy with selegiline and L-dopa was associated with selective systolic orthostatic hypotension which was abolished by withdrawal of selegiline.",10091617_2,0,-1,0,90,0
95,selegiline,29,30,174,184,The aims of this study were to confirm our previous findings in a separate cohort of patients and to determine the time course of the cardiovascular consequences of stopping selegiline in the expectation that this might shed light on the mechanisms by which the drug causes orthostatic hypotension.,10091617_4,0,-1,0,95,0
99,selegiline,17,18,116,126,METHODS: The cardiovascular responses to standing and head-up tilt were studied repeatedly in PD patients receiving selegiline and as the drug was withdrawn.,10091617_5,0,-1,0,99,0
102,selegiline,18,19,107,117,"RESULTS: Head-up tilt caused systolic orthostatic hypotension which was marked in six of 20 PD patients on selegiline, one of whom lost consciousness with unrecordable blood pressures.",10091617_6,0,-1,0,102,0
106,selegiline,9,10,67,77,Orthostatic hypotension was ameliorated 4 days after withdrawal of selegiline and totally abolished 7 days after discontinuation of the drug.,10091617_8,0,-1,0,106,0
107,selegiline,1,2,9,19,Stopping selegiline also significantly reduced the supine systolic and diastolic blood pressures consistent with a previously undescribed supine pressor action.,10091617_9,0,-1,0,107,0
111,selegiline,9,10,58,68,CONCLUSION: This study confirms our previous finding that selegiline in combination with L-dopa is associated with selective orthostatic hypotension.,10091617_10,0,-1,0,111,0
115,monoamine oxidase,14,16,104,121,The possibilities that these cardiovascular findings might be the result of non-selective inhibition of monoamine oxidase or of amphetamine and metamphetamine are discussed.,10091617_11,0,-1,0,115,0
123,povidone-iodine,6,7,44,59,A high percentage of kanamycin-colistin and povidone-iodine irrigations were associated with erosive cystitis and suggested a possible complication with human usage.,1009330_3,0,-1,0,123,0
132,platelet aggregation,12,14,86,106,Effects of tetrandrine and fangchinoline on experimental thrombosis in mice and human platelet aggregation.,10193204_0,0,-1,0,132,0
135,bisbenzylisoquinoline,16,17,87,108,Tetrandrine (TET) and fangchinoline (FAN) are two naturally occurring analogues with a bisbenzylisoquinoline structure.,10193204_1,0,-1,0,135,0
138,platelet aggregation,29,31,161,181,"The present study was undertaken to investigate the effects of TET and FAN on the experimental thrombosis induced by collagen plus epinephrine (EP) in mice, and platelet aggregation and blood coagulation in vitro.",10193204_2,0,-1,0,138,0
142,acetylsalicylic acid,36,38,153,173,"In the in vivo study, the administration (50 mg/kg, i.p.) of TET and FAN in mice showed the inhibition of thrombosis by 55% and 35%, respectively, while acetylsalicylic acid (ASA, 50 mg/kg, i.p.), a positive control, showed only 30% inhibition.",10193204_3,0,-1,0,142,0
153,antiplatelet,17,18,94,106,These results suggest that antithrombosis of TET and FAN in mice may be mainly related to the antiplatelet aggregation activities.,10193204_6,0,-1,0,153,0
159,lysosomal,28,29,222,231,"Urine N-acetyl-beta-D-glucosaminidase--a marker of tubular damage?BACKGROUND: Although an indicator of renal tubular dysfunction, an increased urinary N-acetyl-beta-D-glucosaminidase (NAG) activity might reflect increased lysosomal activity in renal tubular cells.",10193809_0,0,-1,0,159,0
161,Puromycin aminonucleoside,2,4,9,34,METHODS: Puromycin aminonucleoside (PAN) was administered to Sprague Dawley rats to induce proteinuria.,10193809_1,0,-1,0,161,0
165,isoenzyme,23,24,118,127,"The morphological appearance of the kidneys was examined on days three, four, six, eight and thirty three and the NAG isoenzyme patterns on days zero, four, eight and thirty three.",10193809_3,0,-1,0,165,0
174,lysosomal,10,11,64,73,"CONCLUSIONS: This animal model demonstrates that an increase in lysosomal turnover and hence urine NAG activity, occurs when increased protein is presented to the tubular cells.",10193809_8,0,-1,0,174,0
179,lignocaine,10,11,66,76,Cauda equina syndrome after spinal anaesthesia with hyperbaric 5% lignocaine: a review of six cases of cauda equina syndrome reported to the Swedish Pharmaceutical Insurance 1993-1997.Six cases of cauda equina syndrome with varying severity were reported to the Swedish Pharmaceutical Insurance during the period 1993-1997.,10225068_0,0,-1,0,179,0
185,lignocaine,10,11,64,74,All were associated with spinal anaesthesia using hyperbaric 5% lignocaine.,10225068_1,0,-1,0,185,0
190,lignocaine,6,7,26,36,The dose of hyperbaric 5% lignocaine administered ranged from 60 to 120 mg.,10225068_3,0,-1,0,190,0
193,lignocaine,15,16,84,94,Three of the cases were most likely caused by direct neurotoxicity of hyperbaric 5% lignocaine.,10225068_4,0,-1,0,193,0
198,lignocaine,4,5,29,39,We recommend that hyperbaric lignocaine should be administered in concentrations not greater than 2% and at a total dose preferably not exceeding 60 mg.,10225068_7,0,-1,0,198,0
200,sirolimus,5,6,46,55,Systemic toxicity following administration of sirolimus (formerly rapamycin) for psoriasis: association of capillary leak syndrome with apoptosis of lesional lymphocytes.,10328196_0,0,-1,0,200,0
201,rapamycin,8,9,66,75,Systemic toxicity following administration of sirolimus (formerly rapamycin) for psoriasis: association of capillary leak syndrome with apoptosis of lesional lymphocytes.,10328196_0,0,-1,0,201,0
204,Sirolimus,2,3,12,21,BACKGROUND: Sirolimus (formerly rapamycin) is an immunosuppressive agent that interferes with T-cell activation.,10328196_1,0,-1,0,204,0
205,rapamycin,5,6,32,41,BACKGROUND: Sirolimus (formerly rapamycin) is an immunosuppressive agent that interferes with T-cell activation.,10328196_1,0,-1,0,205,0
209,sirolimus,14,15,101,110,After 2 individuals with psoriasis developed a capillary leak syndrome following treatment with oral sirolimus lesional skin cells and activated peripheral blood cells were analyzed for induction of apoptosis.,10328196_2,0,-1,0,209,0
214,apoptotic,21,22,142,151,OBSERVATIONS: A keratome skin specimen from 1 patient with sirolimus-induced capillary leak syndrome had a 2.3-fold increase in percentage of apoptotic cells (to 48%) compared with an unaffected sirolimus-treated patient with psoriasis (21%).,10328196_3,0,-1,0,214,0
218,sirolimus,28,29,194,203,"Activated peripheral blood T cells from patients with psoriasis tended to exhibit greater spontaneous or dexamethasone-induced apoptosis than did normal T cells, particularly in the presence of sirolimus.",10328196_4,0,-1,0,218,0
220,sirolimus,6,7,39,48,"CONCLUSIONS: Severe adverse effects of sirolimus include fever, anemia, and capillary leak syndrome.",10328196_5,0,-1,0,220,0
231,modulators,28,29,200,210,"Because patients with severe psoriasis may develop capillary leak from various systemic therapies, clinical monitoring is advisable for patients with inflammatory diseases who are treated with immune modulators.",10328196_7,0,-1,0,231,0
317,anti-inflammatory agents,4,6,31,55,Investigation of more specific anti-inflammatory agents and hemodiluting agents are warranted in intracerebral hemorrhage.,10406016_10,0,-1,0,317,0
323,cefotetan,9,10,67,76,Severe immune hemolytic anemia associated with prophylactic use of cefotetan in obstetric and gynecologic procedures.,10411803_0,0,-1,0,323,0
326,cefotetan,6,7,56,65,"Second- and third-generation cephalosporins, especially cefotetan, are increasingly associated with severe, sometimes fatal immune hemolytic anemia.",10411803_1,0,-1,0,326,0
331,cefotetan,18,19,108,117,We noticed that 10 of our 35 cases of cefotetan-induced hemolytic anemias were in patients who had received cefotetan prophylactically for obstetric and gynecologic procedures.,10411803_2,0,-1,0,331,0
336,nonsteroidal anti-inflammatory,2,4,11,41,Effects of nonsteroidal anti-inflammatory drugs on hemostasis in patients with aneurysmal subarachnoid hemorrhage.,10414674_0,0,-1,0,336,0
339,nonsteroidal anti-inflammatory,5,7,33,63,Platelet function is impaired by nonsteroidal anti-inflammatory drugs (NSAIDs) with prominent anti-inflammatory properties.,10414674_1,0,-1,0,339,0
346,adenosine diphosphate,8,10,52,73,Maximal platelet aggregation induced by 6 microM of adenosine diphosphate decreased after administration of ketoprofen.,10414674_6,0,-1,0,346,0
349,platelet aggregation,21,23,144,164,"In contrast, maximal platelet aggregation increased in the acetaminophen group on the third postoperative day as compared with the pretreatment platelet aggregation results (P < .05).",10414674_8,0,-1,0,349,0
363,atracurium,2,3,16,26,Accumulation of atracurium in the intravenous line led to recurarization after flushing the line in the recovery room.,10457883_2,0,-1,0,363,0
372,propofol,4,5,28,36,The haemodynamic effects of propofol in combination with ephedrine in elderly patients (ASA groups 3 and 4).The marked vasodilator and negative inotropic effects of propofol are disadvantages in frail elderly patients.,10520387_0,0,-1,0,372,0
376,propofol,25,26,165,173,The haemodynamic effects of propofol in combination with ephedrine in elderly patients (ASA groups 3 and 4).The marked vasodilator and negative inotropic effects of propofol are disadvantages in frail elderly patients.,10520387_0,0,-1,0,376,0
377,propofol,13,14,82,90,We investigated the safety and efficacy of adding different doses of ephedrine to propofol in order to obtund the hypotensive response.,10520387_1,0,-1,0,377,0
380,propofol,17,18,77,85,"The haemodynamic effects of adding 15, 20 or 25 mg of ephedrine to 200 mg of propofol were compared to control in 40 ASA 3/4 patients over 60 years presenting for genito-urinary surgery.",10520387_2,0,-1,0,380,0
383,propofol,5,6,29,37,The addition of ephedrine to propofol appears to be an effective method of obtunding the hypotensive response to propofol at all doses used in this study.,10520387_3,0,-1,0,383,0
385,propofol,18,19,113,121,The addition of ephedrine to propofol appears to be an effective method of obtunding the hypotensive response to propofol at all doses used in this study.,10520387_3,0,-1,0,385,0
387,propofol,13,14,85,93,"However, marked tachycardia associated with the use of ephedrine in combination with propofol occurred in the majority of patients, occasionally reaching high levels in individual patients.",10520387_4,0,-1,0,387,0
395,synthase,24,25,134,142,"This study was designed to discern whether the reduction in urinary NOx in lead-induced hypertension is, in part, due to depressed NO synthase (NOS) expression.",10523326_2,0,-1,0,395,0
399,drinking water,19,21,105,119,"Male Sprague-Dawley rats were randomly assigned to a lead-treated group (given lead acetate, 100 ppm, in drinking water and regular rat chow), a group given lead and vitamin E-fortified chow, or a normal control group given either regular food and water or vitamin E-fortified food for 12 weeks.",10523326_3,0,-1,0,399,0
404,malondialdehyde,9,10,51,66,"Tail blood pressure, urinary NOx excretion, plasma malondialdehyde (MDA), and endothelial and inducible NOS (eNOS and iNOS) isotypes in the aorta and kidney were measured.",10523326_4,0,-1,0,404,0
415,Vitamin E,0,2,0,9,"Vitamin E supplementation ameliorated hypertension, lowered plasma MDA concentration, and raised urinary NOx excretion while significantly lowering vascular, but not renal, tissue eNOS and iNOS expression.",10523326_6,0,-1,0,415,0
419,Vitamin E,0,2,0,9,"Vitamin E supplementation had no effect on either blood pressure, plasma MDA, or NOS expression in the control group.",10523326_7,0,-1,0,419,0
434,stimulatory,20,21,111,122,"This is, in part, due to ROS-mediated NO inactivation, lead-associated inhibition of NOS activity, and perhaps stimulatory actions of increased shear stress associated with hypertension.",10523326_10,0,-1,0,434,0
437,Glyceryl trinitrate,0,2,0,19,Glyceryl trinitrate induces attacks of migraine without aura in sufferers of migraine with aura.,10524660_0,0,-1,0,437,0
443,nitric oxide,12,14,79,91,"In recent years, increasing evidence has suggested that the messenger molecule nitric oxide (NO) is involved in pain mechanisms of migraine without aura.",10524660_2,0,-1,0,443,0
446,glyceryl trinitrate,27,29,151,170,"In order to clarify whether the same is true for migraine with aura, in the present study we examined the headache response to intravenous infusion of glyceryl trinitrate (GTN) (0.5 microg/kg/min for 20 min) in 12 sufferers of migraine with aura.",10524660_3,0,-1,0,446,0
459,Gemcitabine,0,1,0,11,Gemcitabine plus vinorelbine in nonsmall cell lung carcinoma patients age 70 years or older or patients who cannot receive cisplatin.,10526274_0,0,-1,0,459,0
460,vinorelbine,2,3,17,28,Gemcitabine plus vinorelbine in nonsmall cell lung carcinoma patients age 70 years or older or patients who cannot receive cisplatin.,10526274_0,0,-1,0,460,0
462,cisplatin,20,21,123,132,Gemcitabine plus vinorelbine in nonsmall cell lung carcinoma patients age 70 years or older or patients who cannot receive cisplatin.,10526274_0,0,-1,0,462,0
467,vinorelbine,8,9,55,66,"Recent reports indicate that single agent therapy with vinorelbine (VNB) or gemcitabine (GEM) may obtain a response rate of 20-30% in elderly patients, with acceptable toxicity and improvement in symptoms and quality of life.",10526274_3,0,-1,0,467,0
469,gemcitabine,13,14,76,87,"Recent reports indicate that single agent therapy with vinorelbine (VNB) or gemcitabine (GEM) may obtain a response rate of 20-30% in elderly patients, with acceptable toxicity and improvement in symptoms and quality of life.",10526274_3,0,-1,0,469,0
474,cisplatin,28,29,170,179,In the current study the efficacy and toxicity of the combination of GEM and VNB in elderly patients with advanced NSCLC or those with some contraindication to receiving cisplatin were assessed.,10526274_4,0,-1,0,474,0
476,cisplatin,33,34,171,180,"METHODS: Forty-nine patients with advanced NSCLC were included, 38 of whom were age >/= 70 years and 11 were age < 70 years but who had some contraindication to receiving cisplatin.",10526274_5,0,-1,0,476,0
508,enzyme inhibitor,12,14,100,116,"Predictors of decreased renal function in patients with heart failure during angiotensin-converting enzyme inhibitor therapy: results from the studies of left ventricular dysfunction (SOLVD)BACKGROUND: Although angiotensin-converting enzyme inhibitor therapy reduces mortality rates in patients with congestive heart failure (CHF), it may also cause decreased renal function.",10539815_0,0,-1,0,508,0
510,enzyme inhibitor,28,30,234,250,"Predictors of decreased renal function in patients with heart failure during angiotensin-converting enzyme inhibitor therapy: results from the studies of left ventricular dysfunction (SOLVD)BACKGROUND: Although angiotensin-converting enzyme inhibitor therapy reduces mortality rates in patients with congestive heart failure (CHF), it may also cause decreased renal function.",10539815_0,0,-1,0,510,0
519,enzyme inhibitor,20,22,146,162,OBJECTIVE: To quantify specific clinical predictors of reduction in renal function in patients with CHF who are prescribed angiotensin-converting enzyme inhibitor therapy.,10539815_2,0,-1,0,519,0
530,creatinine,21,22,146,156,"We used time-to-event analysis to identify potential predictors of decrease in renal function including age, baseline ejection fraction, baseline creatinine, low systolic blood pressure (<100 mm Hg), history of hypertension, diabetes, and use of antiplatelet, diuretic, and beta-blocker therapy.",10539815_6,0,-1,0,530,0
533,antiplatelet,43,44,246,258,"We used time-to-event analysis to identify potential predictors of decrease in renal function including age, baseline ejection fraction, baseline creatinine, low systolic blood pressure (<100 mm Hg), history of hypertension, diabetes, and use of antiplatelet, diuretic, and beta-blocker therapy.",10539815_6,0,-1,0,533,0
549,RR,31,32,173,175,"Older age was associated with a greater risk of developing decreased renal function in both groups, but significantly more so in the enalapril group (enalapril: risk ratio [RR] 1.42 per 10 years, 95% confidence interval [CI] 1.32-1.52 with enalapril; placebo: RR 1.18, 95% CI 1.12-1.25).",10539815_9,0,-1,0,549,0
551,RR,53,54,260,262,"Older age was associated with a greater risk of developing decreased renal function in both groups, but significantly more so in the enalapril group (enalapril: risk ratio [RR] 1.42 per 10 years, 95% confidence interval [CI] 1.32-1.52 with enalapril; placebo: RR 1.18, 95% CI 1.12-1.25).",10539815_9,0,-1,0,551,0
555,RR,18,19,113,115,"Diuretic therapy was likewise associated with a greater risk of decreased renal function in the enalapril group (RR 1.89, 95% CI 1.70-2.08) than in the placebo group (RR 1.35, 95% CI 1.09-1.66).",10539815_10,0,-1,0,555,0
557,RR,34,35,167,169,"Diuretic therapy was likewise associated with a greater risk of decreased renal function in the enalapril group (RR 1.89, 95% CI 1.70-2.08) than in the placebo group (RR 1.35, 95% CI 1.09-1.66).",10539815_10,0,-1,0,557,0
559,RR,9,10,60,62,"Conversely, enalapril had a relative renoprotective effect (RR 1.33, 95% CI 1.13-1.53) compared with placebo (RR 1.96, 95% CI 1.57-2.44) in patients with diabetes.",10539815_11,0,-1,0,559,0
560,RR,23,24,110,112,"Conversely, enalapril had a relative renoprotective effect (RR 1.33, 95% CI 1.13-1.53) compared with placebo (RR 1.96, 95% CI 1.57-2.44) in patients with diabetes.",10539815_11,0,-1,0,560,0
563,RR,15,16,84,86,"A lower risk of renal impairment was seen in both groups with beta-blocker therapy (RR 0.70, 95% CI 0.57-0.85) and higher baseline ejection fraction (RR 0.93 per 5% increment, 95% CI 0.91-0. 96).",10539815_12,0,-1,0,563,0
564,RR,31,32,150,152,"A lower risk of renal impairment was seen in both groups with beta-blocker therapy (RR 0.70, 95% CI 0.57-0.85) and higher baseline ejection fraction (RR 0.93 per 5% increment, 95% CI 0.91-0. 96).",10539815_12,0,-1,0,564,0
575,olanzapine,4,5,35,45,Hypomania-like syndrome induced by olanzapine.,10565806_0,0,-1,0,575,0
579,olanzapine,26,27,159,169,We report a female patient with a diagnosis of a not otherwise specified psychotic disorder (DSM-IV) who developed hypomania shortly after the introduction of olanzapine treatment.,10565806_1,0,-1,0,579,0
580,receptor antagonist,4,6,24,43,"A selective dopamine D4 receptor antagonist, NRA0160: a preclinical neuropharmacological profile.",10579464_0,0,-1,0,580,0
589,adrenoceptor,27,28,146,158,"NRA0160 has negligible affinity for the human cloned dopamine D3 receptor (Ki=39 nM), rat serotonin (5-HT)2A receptors (Ki=180 nM) and rat alpha1 adrenoceptor (Ki=237 nM).",10579464_3,0,-1,0,589,0
604,smooth muscle,48,50,336,349,"Warfarin-induced artery calcification is accelerated by growth and vitamin D.The present studies demonstrate that growth and vitamin D treatment enhance the extent of artery calcification in rats given sufficient doses of Warfarin to inhibit gamma-carboxylation of matrix Gla protein, a calcification inhibitor known to be expressed by smooth muscle cells and macrophages in the artery wall.",10669626_0,0,-1,0,604,0
640,vitamin K,4,6,18,27,"High doses of the vitamin K antagonist Warfarin are also known to cause calcification of the artery media, but at treatment times of 2 weeks or longer yet not at 1 week.",10669626_10,0,-1,0,640,0
659,gamma-carboxyglutamate,6,7,46,68,"These observations indicate that although the gamma-carboxyglutamate residues of matrix Gla protein are apparently required for its function as a calcification inhibitor, they are not required for its accumulation at calcification sites.",10669626_15,0,-1,0,659,0
684,DOPAC,4,5,26,31,Dopamine turnover ratios (DOPAC:DA and HVA:DA) were found to be lower in those animals exposed to the exploratory box when compared to their home cage counterparts.,10683478_9,0,-1,0,684,0
709,alpha-tocopherol,11,12,66,82,The hemolytic effect of TAM is prevented by low concentrations of alpha-tocopherol (alpha-T) and alpha-tocopherol acetate (alpha-TAc) (inactivated functional hydroxyl) indicating that TAM-induced hemolysis is not related to oxidative membrane damage.,10704919_6,0,-1,0,709,0
710,alpha-tocopherol acetate,16,18,97,121,The hemolytic effect of TAM is prevented by low concentrations of alpha-tocopherol (alpha-T) and alpha-tocopherol acetate (alpha-TAc) (inactivated functional hydroxyl) indicating that TAM-induced hemolysis is not related to oxidative membrane damage.,10704919_6,0,-1,0,710,0
740,nitric oxide,15,17,83,95,"Changes of sodium and ATP affinities of the cardiac (Na,K)-ATPase during and after nitric oxide deficient hypertension.",10706004_0,0,-1,0,740,0
750,N(G)-nitro-L-arginine methyl ester,34,37,222,256,"To assess the molecular basis of disturbances in transmembraneous transport of Na+, we studied the response of cardiac (Na,K)-ATPase to NO-deficient hypertension induced in rats by NO-synthase inhibition with 40 mg/kg/day N(G)-nitro-L-arginine methyl ester (L-NAME) for 4 four weeks.",10706004_4,0,-1,0,750,0
751,L-NAME,38,39,258,264,"To assess the molecular basis of disturbances in transmembraneous transport of Na+, we studied the response of cardiac (Na,K)-ATPase to NO-deficient hypertension induced in rats by NO-synthase inhibition with 40 mg/kg/day N(G)-nitro-L-arginine methyl ester (L-NAME) for 4 four weeks.",10706004_4,0,-1,0,751,0
753,L-NAME,4,5,31,37,"After 4-week administration of L-NAME, the systolic blood pressure (SBP) increased by 36%.",10706004_5,0,-1,0,753,0
797,bromocriptine,5,6,29,42,"In control rats, intravenous bromocriptine (150 microg/kg) induced significant hypotension and tachycardia.",10721819_4,0,-1,0,797,0
800,domperidone,0,1,0,11,domperidone (0.5 mg/kg).,10721819_6,0,-1,0,800,0
815,bromocriptine,13,14,72,85,"They suggest that, in normal conscious rats, the central tachycardia of bromocriptine appears to predominate and to mask the bradycardia of this agonist at peripheral dopamine D2 receptors.",10721819_10,0,-1,0,815,0
819,phosphodiesterase,3,4,11,28,The use of phosphodiesterase inhibitors such as milrinone in the treatment of severe heart failure is frequently restricted because they cause vasodilation and hypotension.,10728962_1,0,-1,0,819,0
820,milrinone,7,8,48,57,The use of phosphodiesterase inhibitors such as milrinone in the treatment of severe heart failure is frequently restricted because they cause vasodilation and hypotension.,10728962_1,0,-1,0,820,0
823,milrinone,11,12,83,92,"In patients with decompensated heart failure with hypotension after treatment with milrinone, low doses of vasopressin restored blood pressure without inhibiting the inotropic effect of milrinone.",10728962_2,0,-1,0,823,0
827,milrinone,26,27,186,195,"In patients with decompensated heart failure with hypotension after treatment with milrinone, low doses of vasopressin restored blood pressure without inhibiting the inotropic effect of milrinone.",10728962_2,0,-1,0,827,0
832,adrenoceptor,20,21,141,153,"Under controlled conditions, infant rats emit ultrasonic vocalizations during extreme cold exposure and after administration of the alpha(2) adrenoceptor agonist, clonidine.",10737864_1,0,-1,0,832,0
846,oral contraceptives,4,6,23,42,Recurrent use of newer oral contraceptives and the risk of venous thromboembolism.,10739826_0,0,-1,0,846,0
852,oral contraceptives,16,18,105,124,"The epidemiological studies that assessed the risk of venous thromboembolism (VTE) associated with newer oral contraceptives (OC) did not distinguish between patterns of OC use, namely first-time users, repeaters and switchers.",10739826_1,0,-1,0,852,0
863,second generation,27,29,124,141,"The adjusted rate ratio of VTE for repeat users of third generation OC was 0.6 (95% CI:0.3-1.2) relative to repeat users of second generation pills, whereas it was 1.3 (95% CI:0.7-2.4) for switchers from second to third generation pills relative to switchers from third to second generation pills.",10739826_5,0,-1,0,863,0
865,second generation,56,58,273,290,"The adjusted rate ratio of VTE for repeat users of third generation OC was 0.6 (95% CI:0.3-1.2) relative to repeat users of second generation pills, whereas it was 1.3 (95% CI:0.7-2.4) for switchers from second to third generation pills relative to switchers from third to second generation pills.",10739826_5,0,-1,0,865,0
901,cyclosporine,8,9,65,77,Treatment of tacrolimus-related adverse effects by conversion to cyclosporine in liver transplant recipients.,10743694_0,0,-1,0,901,0
908,tacrolimus,6,7,37,47,"Of 388 liver recipients who received tacrolimus as primary immunosuppression, 70 required conversion to CyA. We recorded indication for conversion, whether conversion was early or late after transplantation, tacrolimus dose and trough blood level at conversion, and incidence of rejection after conversion.",10743694_3,0,-1,0,908,0
911,tacrolimus,31,32,208,218,"Of 388 liver recipients who received tacrolimus as primary immunosuppression, 70 required conversion to CyA. We recorded indication for conversion, whether conversion was early or late after transplantation, tacrolimus dose and trough blood level at conversion, and incidence of rejection after conversion.",10743694_3,0,-1,0,911,0
925,(1,96,98,413,415,"Indications for early conversion were neurotoxicity (20), (insulin-dependent) diabetes mellitus (IDDM) (5), nephrotoxicity (3), gastrointestinal (GI) toxicity (6), and cardiomyopathy (1), and for late conversion were neurotoxicity (15), IDDM (12), nephrotoxicity (3), GI toxicity (5), hepatotoxicity (6), post-transplant lmphoproliferate disease (PTLD) (2), cardiomyopathy (1), hemolytic anemia (1), and pruritus (1).",10743694_5,0,-1,0,925,0
1002,low-dose,28,29,146,154,"METHODS: Patients with a clinical diagnosis of ischemic stroke (within 24 hours) were consecutively allocated to receive placebo (n=100), 1 mg/h (low-dose) nimodipine (n=101), or 2 mg/h (high-dose) nimodipine (n=94).",10835440_3,0,-1,0,1002,0
1007,low dose,21,23,103,111,"RESULTS: Two hundred sixty-five patients were included in this analysis (n=92, 93, and 80 for placebo, low dose, and high dose, respectively).",10835440_5,0,-1,0,1007,0
1035,neuroprotective,8,9,42,57,These results do not confirm or exclude a neuroprotective property of nimodipine.,10835440_12,0,-1,0,1035,0
1044,CP,2,3,18,20,"Cyclophosphamide (CP), an antitumoral agent known to produce toxic effects on the bladder wall through its main toxic metabolite acrolein, was used to induce cystitis.",10840460_2,0,-1,0,1044,0
1048,CP,4,5,23,25,"MATERIALS AND METHODS: CP was administered at doses of 50, 100 and 200 mg./kg.",10840460_3,0,-1,0,1048,0
1051,(1,14,16,95,97,i.v.) on CP-induced behavioral modifications were tested administered alone and after naloxone (1 mg./kg.,10840460_6,0,-1,0,1051,0
1052,CP,6,7,30,32,"In addition, 90 minutes after CP injection, that is, at the time of administration of morphine, the bladder was removed in some rats for histological examination.",10840460_8,0,-1,0,1052,0
1055,CP,19,20,118,120,"Finally, to show that the bladder is essential for the CP-induced behavioral modifications, female rats also received CP at doses of 200 mg./kg.",10840460_9,0,-1,0,1055,0
1059,CP,4,5,14,16,"i.v. RESULTS: CP dose-relatedly induced marked behavioral modifications in male rats: breathing rate decrease, closing of the eyes and occurrence of specific postures.",10840460_13,0,-1,0,1059,0
1065,CP,19,20,92,94,A dose of 0.5 mg./kg. produced a reduction of almost 50% of the behavioral score induced by CP 200 mg./kg.,10840460_15,0,-1,0,1065,0
1069,CP,4,5,16,18,"In female rats, CP 200 mg./kg.",10840460_18,0,-1,0,1069,0
1071,CP,2,3,16,18,"intravesically, CP did not produce any behavioral effects, whereas acrolein at 0.5 mg.",10840460_21,0,-1,0,1071,0
1073,CP,8,9,73,75,intravesically induced behavioral modifications identical to those under CP 200 mg./kg.,10840460_22,0,-1,0,1073,0
1130,P100,28,29,174,178,"With institutional approval, 35 Sprague-Dawley rats were randomly allocated to receive daily subcutaneous doses of 10 mg/kg prednisolone (P10 group), 100 mg/kg prednisolone (P100 group), or an equal volume of saline (S group) for 7 days.",10910842_3,0,-1,0,1130,0
1133,P100,14,15,63,67,A fourth group of rats was pair fed (food restricted) with the P100 rats for 7 days (FR group).,10910842_4,0,-1,0,1133,0
1139,d-tubocurarine,21,22,117,131,"On Day 8, the nerve-evoked peak twitch tensions, tetanic tensions, and fatigability, and the dose-response curves of d-tubocurarine in the tibialis cranialis muscle were measured in vivo and related to muscle mass or expression of AChRs.",10910842_5,0,-1,0,1139,0
1145,P100,9,10,46,50,"Rate of body weight gain was depressed in the P100, FR, and P10 groups compared with the S group.",10910842_6,0,-1,0,1145,0
1149,P100,7,8,40,44,Tibialis muscle mass was smaller in the P100 group than in the P10 or S groups.,10910842_7,0,-1,0,1149,0
1153,P100,11,12,61,65,"The evoked peak twitch and tetanic tensions were less in the P100 group than in the P10 or S groups, however, tension per milligram of muscle mass was greater in the P100 group than in the S group.",10910842_8,0,-1,0,1153,0
1157,P100,33,34,166,170,"The evoked peak twitch and tetanic tensions were less in the P100 group than in the P10 or S groups, however, tension per milligram of muscle mass was greater in the P100 group than in the S group.",10910842_8,0,-1,0,1157,0
1159,d-tubocurarine,6,7,26,40,The 50% effective dose of d-tubocurarine (microg/kg) in the tibialis muscle was smaller in the P10 (33.6 +/- 5.4) than in the S (61.9 +/- 5.0) or the P100 (71.3 +/- 9.6) groups.,10910842_9,0,-1,0,1159,0
1165,P100,37,38,150,154,The 50% effective dose of d-tubocurarine (microg/kg) in the tibialis muscle was smaller in the P10 (33.6 +/- 5.4) than in the S (61.9 +/- 5.0) or the P100 (71.3 +/- 9.6) groups.,10910842_9,0,-1,0,1165,0
1173,d-tubocurarine,31,32,138,152,"The evoked tensions correlated with muscle mass (r(2) = 0.32, P < 0.001), however, not with expression of AChR. The 50% effective dose of d-tubocurarine did not correlate with muscle mass or AChR expression.",10910842_11,0,-1,0,1173,0
1183,Cyclosporine,0,1,0,12,Cyclosporine and tacrolimus-associated thrombotic microangiopathy.,11007689_0,0,-1,0,1183,0
1188,cyclosporine,13,14,79,91,The development of thrombotic microangiopathy (TMA) associated with the use of cyclosporine has been well documented.,11007689_1,0,-1,0,1188,0
1189,cyclosporine,7,8,57,69,"Treatments have included discontinuation or reduction of cyclosporine dose with or without concurrent plasma exchange, plasma infusion, anticoagulation, and intravenous immunoglobulin G infusion.",11007689_2,0,-1,0,1189,0
1197,tacrolimus,8,9,42,52,The last decade has seen the emergence of tacrolimus as a potent immunosuppressive agent with mechanisms of action virtually identical to those of cyclosporine.,11007689_4,0,-1,0,1197,0
1199,cyclosporine,23,24,147,159,The last decade has seen the emergence of tacrolimus as a potent immunosuppressive agent with mechanisms of action virtually identical to those of cyclosporine.,11007689_4,0,-1,0,1199,0
1200,tacrolimus,6,7,26,36,"As a result, switching to tacrolimus has been reported to be a viable therapeutic option in the setting of cyclosporine-induced TMA.",11007689_5,0,-1,0,1200,0
1202,tacrolimus,6,7,40,50,"With the more widespread application of tacrolimus in organ transplantation, tacrolimus-associated TMA has also been recognized.",11007689_6,0,-1,0,1202,0
1206,cyclosporine,16,17,105,117,"However, literature regarding the incidence of the recurrence of TMA in patients exposed sequentially to cyclosporine and tacrolimus is limited.",11007689_7,0,-1,0,1206,0
1207,tacrolimus,18,19,122,132,"However, literature regarding the incidence of the recurrence of TMA in patients exposed sequentially to cyclosporine and tacrolimus is limited.",11007689_7,0,-1,0,1207,0
1209,cyclosporine,21,22,137,149,We report a case of a living donor renal transplant recipient who developed cyclosporine-induced TMA that responded to the withdrawal of cyclosporine in conjunction with plasmapheresis and fresh frozen plasma replacement therapy.,11007689_8,0,-1,0,1209,0
1211,tacrolimus,2,3,16,26,Introduction of tacrolimus as an alternative immunosuppressive agent resulted in the recurrence of TMA and the subsequent loss of the renal allograft.,11007689_9,0,-1,0,1211,0
1215,cyclosporine,5,6,31,43,Patients who are switched from cyclosporine to tacrolimus or vice versa should be closely monitored for the signs and symptoms of recurrent TMA.,11007689_10,0,-1,0,1215,0
1216,tacrolimus,7,8,47,57,Patients who are switched from cyclosporine to tacrolimus or vice versa should be closely monitored for the signs and symptoms of recurrent TMA.,11007689_10,0,-1,0,1216,0
1221,dopaminergic,4,5,26,38,Apomorphine was the first dopaminergic drug ever used to treat symptoms of Parkinson's disease.,11009181_1,0,-1,0,1221,0
1252,(1,9,11,50,52,"This study assessed the effect of normal aging on (1) the tropicamide-induced increase in pupil diameter, and (2) the reversal of this effect with pilocarpine.",11022397_2,0,-1,0,1252,0
1259,tropicamide,4,5,14,25,"In 1 session, tropicamide (20 microL, 0.01%) was administered to one eye and placebo to the other.",11022397_8,0,-1,0,1259,0
1261,tropicamide,4,5,20,31,"In another session, tropicamide (20 microL, 0.01%) was administered to both eyes, followed 23 minutes later by the application of pilocarpine (20 microL, 0.1%) to one eye and placebo to the other.",11022397_9,0,-1,0,1261,0
1264,eye drops,1,3,4,13,All eye drops were given in a randomized order.,11022397_10,0,-1,0,1264,0
1271,tropicamide,11,12,68,79,OUTCOME MEASURES: Pupil size at time points after administration of tropicamide and pilocarpine; scopolamine-induced impairment in word recall.,11022397_12,0,-1,0,1271,0
1276,tropicamide,16,17,107,118,RESULTS: There was no significant difference between elderly and young volunteers in pupillary response to tropicamide at any time point (p > 0.05).,11022397_13,0,-1,0,1276,0
1287,tropicamide,15,16,93,104,CONCLUSION: There is an age-related pupillary response to pilocarpine that is not found with tropicamide.,11022397_16,0,-1,0,1287,0
1299,CP,13,14,84,86,"By using a placebo-controlled, two-way factorial design, tolerance to cold-pressor (CP) pain was examined, both before and after oral administration of therapeutic doses of common opioid (hydromorphone 2 mg) and nonsteroidal anti-inflammatory (ketorolac 10 mg) analgesic agents.",11027904_3,0,-1,0,1299,0
1303,nonsteroidal anti-inflammatory,37,39,212,242,"By using a placebo-controlled, two-way factorial design, tolerance to cold-pressor (CP) pain was examined, both before and after oral administration of therapeutic doses of common opioid (hydromorphone 2 mg) and nonsteroidal anti-inflammatory (ketorolac 10 mg) analgesic agents.",11027904_3,0,-1,0,1303,0
1304,analgesic agents,44,46,261,277,"By using a placebo-controlled, two-way factorial design, tolerance to cold-pressor (CP) pain was examined, both before and after oral administration of therapeutic doses of common opioid (hydromorphone 2 mg) and nonsteroidal anti-inflammatory (ketorolac 10 mg) analgesic agents.",11027904_3,0,-1,0,1304,0
1305,CP,10,11,71,73,"Results showed that MM individuals were significantly less tolerant of CP pain than control subjects, replicating previous work.",11027904_4,0,-1,0,1305,0
1352,methylprednisolone,3,4,14,32,The dosage of methylprednisolone recommended by the NASCIS 3 is the highest dose of steroids ever being used during a 2-day period for any clinical condition.,11058428_3,0,-1,0,1352,0
1359,methylprednisolone,34,35,211,229,"Further, steroid myopathy recovers naturally and the neurological improvement shown in the NASCIS may be just a recording of this natural motor recovery from the steroid myopathy, instead of any protection that methylprednisolone offers to the spinal cord injury.",11058428_5,0,-1,0,1359,0
1361,methylprednisolone,14,15,84,102,"To our knowledge, this is the first discussion considering the possibility that the methylprednisolone recommended by NASCIS may cause acute corticosteroid myopathy.",11058428_6,0,-1,0,1361,0
1364,rapamycin,2,3,14,23,Conversion to rapamycin immunosuppression in renal transplant recipients: report of an initial experience.,11063349_0,0,-1,0,1364,0
1367,cyclosporine,18,19,103,115,BACKGROUND: The aim of this study is to evaluate the effects of RAPA conversion in patients undergoing cyclosporine (CsA) or tacrolimus (Tac) toxicity.,11063349_1,0,-1,0,1367,0
1369,tacrolimus,23,24,125,135,BACKGROUND: The aim of this study is to evaluate the effects of RAPA conversion in patients undergoing cyclosporine (CsA) or tacrolimus (Tac) toxicity.,11063349_1,0,-1,0,1369,0
1372,rapamycin,11,12,72,81,METHODS: Twenty renal transplant recipients were switched to fixed dose rapamycin (RAPA) (5 mg/day) 0 to 204 months posttransplant.,11063349_2,0,-1,0,1372,0
1379,(3,19,21,98,100,"The indications for switch were chronic CsA or Tac nephrotoxicity (12), acute CsA or Tac toxicity (3), severe facial dysmorphism (2), posttransplant lymphoproliferative disorder (PTLD) in remission (2), and hepatotoxicity in 1.",11063349_4,0,-1,0,1379,0
1407,vigabatrin,11,12,77,87,PURPOSE: Symptomatic visual field constriction thought to be associated with vigabatrin has been reported.,11077455_1,0,-1,0,1407,0
1411,vigabatrin,8,9,45,55,Six of the patients were no longer receiving vigabatrin.,11077455_3,0,-1,0,1411,0
1432,vigabatrin,11,12,75,85,CONCLUSION: Marked visual field constriction appears to be associated with vigabatrin therapy.,11077455_11,0,-1,0,1432,0
1435,vigabatrin,9,10,75,85,The field defects and some electrophysiological abnormalities persist when vigabatrin therapy is withdrawn.,11077455_12,0,-1,0,1435,0
1448,dobutamine,19,20,107,117,The aim of the present study is to examine whether myocardial ischemia due to coronary spasm is induced by dobutamine.,11078231_3,0,-1,0,1448,0
1459,dobutamine,5,6,35,45,"DSE was performed with intravenous dobutamine infusion with an incremental doses of 5, 10, 20, 30, and 40 microg/kg/min every 5 minutes.",11078231_7,0,-1,0,1459,0
1466,dobutamine,4,5,29,39,These findings indicate that dobutamine can provoke coronary spasm in some patients with coronary spastic angina.,11078231_10,0,-1,0,1466,0
1476,dobutamine,10,11,58,68,"STUDY OBJECTIVE: To determine the effect of metoprolol on dobutamine stress testing with technetium-99m sestamibi single-photon emission computed tomography imaging and ST-segment monitoring, and to assess the impact of intravenous glucagon on metoprolol's effects.",11079278_1,0,-1,0,1476,0
1478,technetium-99m,14,16,89,103,"STUDY OBJECTIVE: To determine the effect of metoprolol on dobutamine stress testing with technetium-99m sestamibi single-photon emission computed tomography imaging and ST-segment monitoring, and to assess the impact of intravenous glucagon on metoprolol's effects.",11079278_1,0,-1,0,1478,0
1486,dobutamine,4,5,33,43,INTERVENTION: Patients underwent dobutamine stress tests per standard protocol.,11079278_5,0,-1,0,1486,0
1489,dobutamine,1,2,7,17,"Before dobutamine was begun, no therapy was given during the first visit, and patients were randomized on subsequent visits to receive metoprolol or metoprolol plus glucagon 1 mg.",11079278_6,0,-1,0,1489,0
1500,dobutamine,3,4,19,29,"CONCLUSION: During dobutamine stress testing, metoprolol attenuates or eliminates evidence of myocardial ischemia.",11079278_12,0,-1,0,1500,0
1505,GPi,5,6,37,40,Evidence of functional somatotopy in GPi from results of pallidotomy.,11099450_0,0,-1,0,1505,0
1508,GPi,17,18,99,102,The objective of this study was to explore the functional anatomy of the globus pallidus internus (GPi) by studying the effects of unilateral pallidotomy on parkinsonian 'off' signs and levodopa-induced dyskinesias (LID).,11099450_1,0,-1,0,1508,0
1516,GPi,26,27,118,121,"We also found a highly significant correlation (P: < 0.0001, r = 0.8) between the volume of the ventral lesion in the GPi and the improvement in LID in the contralateral limbs, whereas there was no correlation between the ventral volume and the improvement in parkinsonian 'off' signs.",11099450_3,0,-1,0,1516,0
1527,GPi,8,9,37,40,"Whereas cells in a wider area of the GPi may be implicated in parkinsonism, the ventral GPi seems to be crucial for the manifestation of LID.",11099450_6,0,-1,0,1527,0
1528,GPi,17,18,88,91,"Whereas cells in a wider area of the GPi may be implicated in parkinsonism, the ventral GPi seems to be crucial for the manifestation of LID.",11099450_6,0,-1,0,1528,0
1530,GPi,17,18,109,112,"We suggest that our observations are additional proof of the functional somatotopy of the systems within the GPi that mediate parkinsonism and dyskinesias, especially along the dorsoventral trajectory used in pallidotomy.",11099450_7,0,-1,0,1530,0
1534,GPi,13,14,79,82,"The outcome of pallidotomy in which the lesion involves the ventral and dorsal GPi could be the net effect of alteration in the activity of pathways which mediate different symptoms, and hence could be variable.",11099450_8,0,-1,0,1534,0
1535,Paclitaxel,0,1,0,10,"Paclitaxel, cisplatin, and gemcitabine combination chemotherapy within a multidisciplinary therapeutic approach in metastatic nonsmall cell lung carcinoma.",11135224_0,0,-1,0,1535,0
1536,cisplatin,2,3,12,21,"Paclitaxel, cisplatin, and gemcitabine combination chemotherapy within a multidisciplinary therapeutic approach in metastatic nonsmall cell lung carcinoma.",11135224_0,0,-1,0,1536,0
1537,gemcitabine,5,6,27,38,"Paclitaxel, cisplatin, and gemcitabine combination chemotherapy within a multidisciplinary therapeutic approach in metastatic nonsmall cell lung carcinoma.",11135224_0,0,-1,0,1537,0
1547,paclitaxel,20,21,104,114,"METHODS: The objective of this study was to determine the feasibility, response rate, and toxicity of a paclitaxel, cisplatin, and gemcitabine combination to treat metastatic NSCLC.",11135224_3,0,-1,0,1547,0
1548,cisplatin,22,23,116,125,"METHODS: The objective of this study was to determine the feasibility, response rate, and toxicity of a paclitaxel, cisplatin, and gemcitabine combination to treat metastatic NSCLC.",11135224_3,0,-1,0,1548,0
1549,gemcitabine,25,26,131,142,"METHODS: The objective of this study was to determine the feasibility, response rate, and toxicity of a paclitaxel, cisplatin, and gemcitabine combination to treat metastatic NSCLC.",11135224_3,0,-1,0,1549,0
1556,paclitaxel,26,27,175,185,"Thirty-five consecutive chemotherapy-naive patients with Stage IV NSCLC and an Eastern Cooperative Oncology Group performance status of 0-2 were treated with a combination of paclitaxel (135 mg/m(2) given intravenously in 3 hours) on Day 1, cisplatin (120 mg/m(2) given intravenously in 6 hours) on Day 1, and gemcitabine (800 mg/m(2) given intravenously in 30 minutes) on Days 1 and 8, every 4 weeks.",11135224_4,0,-1,0,1556,0
1558,cisplatin,41,42,241,250,"Thirty-five consecutive chemotherapy-naive patients with Stage IV NSCLC and an Eastern Cooperative Oncology Group performance status of 0-2 were treated with a combination of paclitaxel (135 mg/m(2) given intravenously in 3 hours) on Day 1, cisplatin (120 mg/m(2) given intravenously in 6 hours) on Day 1, and gemcitabine (800 mg/m(2) given intravenously in 30 minutes) on Days 1 and 8, every 4 weeks.",11135224_4,0,-1,0,1558,0
1560,gemcitabine,57,58,310,321,"Thirty-five consecutive chemotherapy-naive patients with Stage IV NSCLC and an Eastern Cooperative Oncology Group performance status of 0-2 were treated with a combination of paclitaxel (135 mg/m(2) given intravenously in 3 hours) on Day 1, cisplatin (120 mg/m(2) given intravenously in 6 hours) on Day 1, and gemcitabine (800 mg/m(2) given intravenously in 30 minutes) on Days 1 and 8, every 4 weeks.",11135224_4,0,-1,0,1560,0
1570,paclitaxel,15,16,76,86,"After 154 courses of therapy, the median dose intensity was 131 mg/m(2) for paclitaxel (97.3%), 117 mg/m(2) for cisplatin (97.3%), and 1378 mg/m(2) for gemcitabine (86.2%).",11135224_9,0,-1,0,1570,0
1571,cisplatin,25,26,112,121,"After 154 courses of therapy, the median dose intensity was 131 mg/m(2) for paclitaxel (97.3%), 117 mg/m(2) for cisplatin (97.3%), and 1378 mg/m(2) for gemcitabine (86.2%).",11135224_9,0,-1,0,1571,0
1572,gemcitabine,36,37,152,163,"After 154 courses of therapy, the median dose intensity was 131 mg/m(2) for paclitaxel (97.3%), 117 mg/m(2) for cisplatin (97.3%), and 1378 mg/m(2) for gemcitabine (86.2%).",11135224_9,0,-1,0,1572,0
1578,paclitaxel,5,6,32,42,"CONCLUSIONS: The combination of paclitaxel, cisplatin, and gemcitabine is well tolerated and shows high activity in metastatic NSCLC.",11135224_14,0,-1,0,1578,0
1579,cisplatin,7,8,44,53,"CONCLUSIONS: The combination of paclitaxel, cisplatin, and gemcitabine is well tolerated and shows high activity in metastatic NSCLC.",11135224_14,0,-1,0,1579,0
1580,gemcitabine,10,11,59,70,"CONCLUSIONS: The combination of paclitaxel, cisplatin, and gemcitabine is well tolerated and shows high activity in metastatic NSCLC.",11135224_14,0,-1,0,1580,0
1589,venlafaxine,10,11,72,83,This concerns 2 male patients who experienced incontinence while taking venlafaxine.,11147747_3,0,-1,0,1589,0
1592,venlafaxine,35,36,224,235,"In the present paper the authors describe 2 female patients who developed incontinence secondary to the selective serotonin reuptake inhibitors paroxetine and sertraline, as well as a third who developed this side effect on venlafaxine.",11147747_4,0,-1,0,1592,0
1593,lithium carbonate,11,13,50,67,"In 2 of the 3 cases the patients were also taking lithium carbonate and beta-blockers, both of which could have contributed to the incontinence.",11147747_5,0,-1,0,1593,0
1628,sodium valproate,2,4,16,32,Contribution of sodium valproate to the syndrome of inappropriate secretion of antidiuretic hormone.,11195262_0,0,-1,0,1628,0
1630,antidiuretic hormone,11,13,79,99,Contribution of sodium valproate to the syndrome of inappropriate secretion of antidiuretic hormone.,11195262_0,0,-1,0,1630,0
1631,sodium valproate,11,13,61,77,We report the case of a 62-year-old man who was administered sodium valproate (VPA) and who subsequently developed the syndrome of inappropriate secretion of antidiuretic hormone (SIADH).,11195262_1,0,-1,0,1631,0
1634,antidiuretic hormone,26,28,158,178,We report the case of a 62-year-old man who was administered sodium valproate (VPA) and who subsequently developed the syndrome of inappropriate secretion of antidiuretic hormone (SIADH).,11195262_1,0,-1,0,1634,0
1648,alpha-2 adrenergic,2,4,17,35,Centrally acting alpha-2 adrenergic agonists are one of several pharmacologic agents used in the treatment of spasticity related to disorders of the central nervous system.,11198499_1,0,-1,0,1648,0
1659,alpha-2,30,31,210,217,"The authors present a 10-year-old boy chronically treated with lisinopril, an angiotensin converting enzyme inhibitor, to control hypertension who developed hypotension following the addition of tizanidine, an alpha-2 agonist, for the treatment of spasticity.",11198499_4,0,-1,0,1659,0
1666,GABA(A,20,21,169,175,Two mouse lines selected for differential sensitivities to beta-carboline-induced seizures are also differentially sensitive to various pharmacological effects of other GABA(A) receptor ligands.,11206082_0,0,-1,0,1666,0
1667,receptor ligands,22,24,177,193,Two mouse lines selected for differential sensitivities to beta-carboline-induced seizures are also differentially sensitive to various pharmacological effects of other GABA(A) receptor ligands.,11206082_0,0,-1,0,1667,0
1674,GABA(A) receptor,13,16,87,103,"injection of methyl beta-carboline-3-carboxylate (beta-CCM), an inverse agonist of the GABA(A) receptor benzodiazepine site.",11206082_2,0,-1,0,1674,0
1675,GABA(A) receptor,18,21,111,127,Our aim was to characterize both lines' sensitivities to various physiological effects of other ligands of the GABA(A) receptor.,11206082_3,0,-1,0,1675,0
1686,GABA(A) receptor,41,44,256,272,"Results presented here show that the differential sensitivities of BS and BR lines to beta-CCM can be extended to diazepam, picrotoxin, and pentylenetetrazol, suggesting a genetic selection of a general sensitivity and resistance to several ligands of the GABA(A) receptor.",11206082_5,0,-1,0,1686,0
1687,nitric oxide,2,4,15,27,Association of nitric oxide production and apoptosis in a model of experimental nephropathy.,11208990_0,0,-1,0,1687,0
1689,nitric oxide,8,10,51,63,BACKGROUND: In recent studies increased amounts of nitric oxide (NO) and apoptosis have been implicated in various pathological conditions in the kidney.,11208990_1,0,-1,0,1689,0
1702,synthase,32,33,173,181,"These two groups were then divided into: group 1, animals receiving saline; and group 2, animals receiving aminoguanidine (AG) which is a specific inhibitor of inducible-NO synthase.",11208990_5,0,-1,0,1702,0
1715,apoptotic,8,9,48,57,"However, in the ADR-nephropathy group, numerous apoptotic cells were identified in the tubulointerstitial areas.",11208990_12,0,-1,0,1715,0
1718,apoptotic,5,6,47,56,"Double staining revealed numerous interstitial apoptotic cells to stain for ED1, a marker for monocytes/macrophages.",11208990_13,0,-1,0,1718,0
1736,ketamine-,13,14,73,82,Melatonin 0.5 and 5 mg/kg influenced the duration but not the latency of ketamine- or diazepam-induced narcosis.,11226639_6,0,-1,0,1736,0
1763,radionuclide,14,15,110,122,"Cardiotoxicity was defined by reductions in left-ventricular ejection fraction, assessed by serial multigated radionuclide angiography scans, or congestive heart failure (CHF).",11230490_3,0,-1,0,1763,0
1783,L-NAME,6,7,48,54,"The effects of N-nitro-L-arginine-methyl ester (L-NAME) a nitric oxide (NO) synthase inhibitor and L-arginine, a NO precursor, were investigated on lidocaine-induced convulsions.",11243580_1,0,-1,0,1783,0
1784,nitric oxide,9,11,58,70,"The effects of N-nitro-L-arginine-methyl ester (L-NAME) a nitric oxide (NO) synthase inhibitor and L-arginine, a NO precursor, were investigated on lidocaine-induced convulsions.",11243580_1,0,-1,0,1784,0
1785,synthase,14,15,76,84,"The effects of N-nitro-L-arginine-methyl ester (L-NAME) a nitric oxide (NO) synthase inhibitor and L-arginine, a NO precursor, were investigated on lidocaine-induced convulsions.",11243580_1,0,-1,0,1785,0
1786,L-arginine,17,18,99,109,"The effects of N-nitro-L-arginine-methyl ester (L-NAME) a nitric oxide (NO) synthase inhibitor and L-arginine, a NO precursor, were investigated on lidocaine-induced convulsions.",11243580_1,0,-1,0,1786,0
1789,L-arginine,17,18,83,93,"In the first experiment, four groups of mice received physiological saline (0.9%), L-arginine (300 mg/kg, i.p.), L-NAME (100 mg/kg, i.p.) and diazepam (2 mg/kg), respectively.",11243580_2,0,-1,0,1789,0
1790,L-NAME,26,27,113,119,"In the first experiment, four groups of mice received physiological saline (0.9%), L-arginine (300 mg/kg, i.p.), L-NAME (100 mg/kg, i.p.) and diazepam (2 mg/kg), respectively.",11243580_2,0,-1,0,1790,0
1791,L-NAME,0,1,0,6,"L-NAME (100 mg/kg, i.p.) and diazepam (2 mg/kg) significantly decreased the incidence of lidocaine (50 mg/kg)-induced convulsions.",11243580_5,0,-1,0,1791,0
1793,L-arginine,4,5,17,27,"In contrast, the L-arginine treatment increased the incidence of lidocaine (80 mg/kg, i.p.)-induced convulsions significantly.",11243580_6,0,-1,0,1793,0
1796,recombinant human,14,16,72,89,The aim of this study was to examine the impact of anemia prevention by recombinant human erythropoietin (rHuEPO) treatment on the cytotoxicity of cyclophosphamide in solid experimental tumors.,11245434_1,0,-1,0,1796,0
1800,carboplatin,8,9,42,53,Anemia was induced using a single dose of carboplatin (50 mg/kg i.v.) resulting in a long-lasting reduction (30%) of the hemoglobin concentration.,11245434_2,0,-1,0,1800,0
1804,carboplatin,6,7,40,51,three times/week starting 7 days before carboplatin application.,11245434_4,0,-1,0,1804,0
1805,carboplatin,3,4,16,27,"Four days after carboplatin treatment, tumors (DS-sarcoma of the rat) were implanted s.c. onto the hind food dorsum.",11245434_5,0,-1,0,1805,0
1808,carboplatin,1,2,8,19,Neither carboplatin nor rHuEPO treatment influenced tumor growth rate per se.,11245434_6,0,-1,0,1808,0
1825,antineutrophil cytoplasmic,2,4,46,72,Propylthiouracil-induced perinuclear-staining antineutrophil cytoplasmic autoantibody-positive vasculitis in conjunction with pericarditis.,11250767_0,0,-1,0,1825,0
1834,antineutrophil cytoplasmic,7,9,67,93,Serologic evaluation revealed the presence of perinuclear-staining antineutrophil cytoplasmic autoantibodies (pANCA) against myeloperoxidase (MPO).,11250767_5,0,-1,0,1834,0
1835,pANCA,11,12,110,115,Serologic evaluation revealed the presence of perinuclear-staining antineutrophil cytoplasmic autoantibodies (pANCA) against myeloperoxidase (MPO).,11250767_5,0,-1,0,1835,0
1840,her,18,19,114,117,"Propylthiouracil therapy was withdrawn, and she was treated with a 1-month course of prednisone, which alleviated her symptoms.",11250767_6,0,-1,0,1840,0
1848,losartan,4,5,36,44,Repeated transient anuria following losartan administration in a patient with a solitary kidney.,11256525_0,0,-1,0,1848,0
1853,losartan,25,26,161,169,We report the case of a 70-year-old hypertensive man with a solitary kidney and chronic renal insufficiency who developed two episodes of transient anuria after losartan administration.,11256525_1,0,-1,0,1853,0
1859,losartan,9,10,41,49,"Surprisingly, the first dose of 50 mg of losartan resulted in a sudden anuria, which lasted eight hours despite high-dose furosemide and amine infusion.",11256525_4,0,-1,0,1859,0
1863,losartan,7,8,28,36,"One week later, by mistake, losartan was prescribed again and after the second dose of 50 mg, the patient developed a second episode of transient anuria lasting 10 hours.",11256525_5,0,-1,0,1863,0
1869,angiotensin II,4,6,23,37,"Under such conditions, angiotensin II receptor blockade by losartan probably induced a critical fall in glomerular filtration pressure.",11256525_9,0,-1,0,1869,0
1870,losartan,9,10,59,67,"Under such conditions, angiotensin II receptor blockade by losartan probably induced a critical fall in glomerular filtration pressure.",11256525_9,0,-1,0,1870,0
1891,cyclosporine-,3,4,17,30,The reduction of cyclosporine- or tacrolimus trough levels and the administration of calcium channel blockers led to relief of pain.,11263551_7,0,-1,0,1891,0
1892,tacrolimus,5,6,34,44,The reduction of cyclosporine- or tacrolimus trough levels and the administration of calcium channel blockers led to relief of pain.,11263551_7,0,-1,0,1892,0
1893,calcium channel blockers,12,15,85,109,The reduction of cyclosporine- or tacrolimus trough levels and the administration of calcium channel blockers led to relief of pain.,11263551_7,0,-1,0,1893,0
1898,cyclosporine,16,17,91,103,"The Calcineurin-inhibitor Induced Pain Syndrome (CIPS) is a rare but severe side effect of cyclosporine or tacrolimus and is accurately diagnosed by its typical presentation, magnetic resonance imaging and bone scans.",11263551_8,0,-1,0,1898,0
1899,tacrolimus,18,19,107,117,"The Calcineurin-inhibitor Induced Pain Syndrome (CIPS) is a rare but severe side effect of cyclosporine or tacrolimus and is accurately diagnosed by its typical presentation, magnetic resonance imaging and bone scans.",11263551_8,0,-1,0,1899,0
1909,Brain natriuretic peptide,0,3,0,25,Brain natriuretic peptide is a predictor of anthracycline-induced cardiotoxicity.,11279304_0,0,-1,0,1909,0
1918,brain natriuretic peptide,6,9,32,57,We measured the plasma level of brain natriuretic peptide (BNP) to determine whether BNP might serve as a simple diagnostic indicator of anthracycline-induced cardiotoxicity in patients with acute leukemia treated with a daunorubicin (DNR)-containing regimen.,11279304_3,0,-1,0,1918,0
1924,daunorubicin,34,35,221,233,We measured the plasma level of brain natriuretic peptide (BNP) to determine whether BNP might serve as a simple diagnostic indicator of anthracycline-induced cardiotoxicity in patients with acute leukemia treated with a daunorubicin (DNR)-containing regimen.,11279304_3,0,-1,0,1924,0
1929,radionuclide,5,6,38,50,Cardiac functions were evaluated with radionuclide angiography before chemotherapies.,11279304_5,0,-1,0,1929,0
1930,atrial natriuretic peptide,4,7,21,47,The plasma levels of atrial natriuretic peptide (ANP) and BNP were measured at the time of radionuclide angiography.,11279304_6,0,-1,0,1930,0
1931,ANP,8,9,49,52,The plasma levels of atrial natriuretic peptide (ANP) and BNP were measured at the time of radionuclide angiography.,11279304_6,0,-1,0,1931,0
1933,radionuclide,18,19,91,103,The plasma levels of atrial natriuretic peptide (ANP) and BNP were measured at the time of radionuclide angiography.,11279304_6,0,-1,0,1933,0
1940,radionuclide,34,35,198,210,The plasma levels of BNP in all the patients with clinical and subclinical heart failure increased above the normal limit (40 pg/ml) before the detection of clinical or subclinical heart failure by radionuclide angiography.,11279304_9,0,-1,0,1940,0
1944,ANP,4,5,20,23,The plasma level of ANP did not always increase in all the patients with clinical and subclinical heart failure.,11279304_11,0,-1,0,1944,0
1954,L-type,18,19,132,138,BACKGROUND: Atrial tachycardia-induced remodeling promotes the occurrence and maintenance of atrial fibrillation (AF) and decreases L-type Ca(2+) current.,11282081_1,0,-1,0,1954,0
1956,L-type,8,9,47,53,"There is also a clinical suggestion that acute L-type Ca(2) channel blockade can promote AF, consistent with an AF promoting effect of Ca(2+) channel inhibition.",11282081_2,0,-1,0,1956,0
1962,channel blockers,14,16,72,88,"METHODS: To evaluate the potential mechanisms of AF promotion by Ca(2+) channel blockers, we administered verapamil to morphine-chloralose anesthetized dogs.",11282081_3,0,-1,0,1962,0
1997,Calcitonin gene-related peptide,0,3,0,31,Calcitonin gene-related peptide levels during nitric oxide-induced headache in patients with chronic tension-type headache.,11284996_0,0,-1,0,1997,0
1999,nitric oxide,5,7,26,38,It has been proposed that nitric oxide (NO) induced headache in primary headaches may be associated with release of calcitonin gene-related peptide (CGRP).,11284996_1,0,-1,0,1999,0
2001,calcitonin gene-related peptide,21,24,116,147,It has been proposed that nitric oxide (NO) induced headache in primary headaches may be associated with release of calcitonin gene-related peptide (CGRP).,11284996_1,0,-1,0,2001,0
2002,CGRP,25,26,149,153,It has been proposed that nitric oxide (NO) induced headache in primary headaches may be associated with release of calcitonin gene-related peptide (CGRP).,11284996_1,0,-1,0,2002,0
2003,CGRP,11,12,62,66,In the present study we aimed to investigate plasma levels of CGRP during headache induced by the NO donor glyceryl trinitrate (GTN) in 16 patients with chronic tension-type headache and 16 healthy controls.,11284996_2,0,-1,0,2003,0
2004,glyceryl trinitrate,19,21,107,126,In the present study we aimed to investigate plasma levels of CGRP during headache induced by the NO donor glyceryl trinitrate (GTN) in 16 patients with chronic tension-type headache and 16 healthy controls.,11284996_2,0,-1,0,2004,0
2013,CGRP,9,10,51,55,There was no difference between the area under the CGRP curve (AUCCGRP) on GTN vs. placebo day in either patients (P=0.65) or controls (P=0.48).,11284996_6,0,-1,0,2013,0
2018,CGRP,6,7,31,35,"Both in patients and controls, CGRP levels changed significantly over time, on both the GTN and placebo days (P < 0.05).",11284996_8,0,-1,0,2018,0
2022,CGRP,14,15,97,101,The present study indicates that NO-induced immediate headache is not associated with release of CGRP.,11284996_9,0,-1,0,2022,0
2068,gentamicin sulfate,25,27,171,189,"Two patients developed acute tubular necrosis, characterized clinically by acute oliguric renal failure, while they were receiving a combination of cephalothin sodium and gentamicin sulfate therapy.",1130930_1,0,-1,0,2068,0
2074,apoptotic,7,8,44,53,"In vivo protection of dna damage associated apoptotic and necrotic cell deaths during acetaminophen-induced nephrotoxicity, amiodarone-induced lung toxicity and doxorubicin-induced cardiotoxicity by a novel IH636 grape seed proanthocyanidin extract.",11334364_0,0,-1,0,2074,0
2083,proanthocyanidins,8,9,43,60,"Grape seed extract, primarily a mixture of proanthocyanidins, has been shown to modulate a wide-range of biological, pharmacological and toxicological effects which are mainly cytoprotective.",11334364_1,0,-1,0,2083,0
2178,antidepressant drugs,48,50,278,298,"Patients who experienced a manic or hypomanic switch were compared with those who did not on several variables including age, sex, diagnosis (DSM-IV bipolar I vs. bipolar II), number of previous manic episodes, type of antidepressant therapy used (electroconvulsive therapy vs. antidepressant drugs and, more particularly, selective serotonin reuptake inhibitors [SSRIs]), use and type of mood stabilizers (lithium vs. anticonvulsants), and temperament of the patient, assessed during a normothymic period using the hyperthymia component of the Semi-structured Affective Temperament Interview.",11379838_3,0,-1,0,2178,0
2179,selective serotonin reuptake inhibitors,55,59,323,362,"Patients who experienced a manic or hypomanic switch were compared with those who did not on several variables including age, sex, diagnosis (DSM-IV bipolar I vs. bipolar II), number of previous manic episodes, type of antidepressant therapy used (electroconvulsive therapy vs. antidepressant drugs and, more particularly, selective serotonin reuptake inhibitors [SSRIs]), use and type of mood stabilizers (lithium vs. anticonvulsants), and temperament of the patient, assessed during a normothymic period using the hyperthymia component of the Semi-structured Affective Temperament Interview.",11379838_3,0,-1,0,2179,0
2269,receptor ligands,5,7,29,45,"Therefore, three novel sigma receptor ligands with antagonist activity were evaluated in Swiss Webster mice: BD1018 (3S-1-[2-(3,4-dichlorophenyl)ethyl]-1,4-diazabicyclo[4.3.0]nonane), BD1063 (1-[2-(3,4-dichlorophenyl)ethyl]-4-methylpiperazine), and LR132 (1R,2S-(+)-cis-N-[2-(3,4-dichlorophenyl)ethyl]-2-(1-pyrrolidinyl)cyclohexylamine).",11426838_2,0,-1,0,2269,0
2287,GABA(A,19,20,122,128,"The three compounds vary in their affinities for sigma2 receptors and exhibit negligible affinities for dopamine, opioid, GABA(A) and NMDA receptors.",11426838_4,0,-1,0,2287,0
2300,receptor agonist,24,26,160,176,"In contrast to the protection provided by the putative antagonists, the well-characterized sigma receptor agonist di-o-tolylguanidine (DTG) and the novel sigma receptor agonist BD1031 (3R-1-[2-(3,4-dichlorophenyl)ethyl]-1,4-diazabicyclo[4.3.0]nonane) each worsened the behavioral toxicity of cocaine.",11426838_7,0,-1,0,2300,0
2306,stimulatory,22,23,138,149,"At doses where alone, they produced no significant effects on locomotion, BD1018, BD1063 and LR132 significantly attenuated the locomotor stimulatory effects of cocaine.",11426838_8,0,-1,0,2306,0
2309,antisense,20,21,129,138,"To further validate the hypothesis that the anti-cocaine effects of the novel ligands involved antagonism of sigma receptors, an antisense oligodeoxynucleotide against sigma1 receptors was also shown to significantly attenuate the convulsive and locomotor stimulatory effects of cocaine.",11426838_9,0,-1,0,2309,0
2311,stimulatory,35,36,256,267,"To further validate the hypothesis that the anti-cocaine effects of the novel ligands involved antagonism of sigma receptors, an antisense oligodeoxynucleotide against sigma1 receptors was also shown to significantly attenuate the convulsive and locomotor stimulatory effects of cocaine.",11426838_9,0,-1,0,2311,0
2330,metformin hydrochloride,14,16,98,121,We report a patient who developed cholestatic jaundice shortly after initiation of treatment with metformin hydrochloride.,11467664_1,0,-1,0,2330,0
2338,Metformin hydrochloride,0,2,0,23,"Metformin hydrochloride was discontinued, and the patient's jaundice resolved slowly over a period of several months.",11467664_5,0,-1,0,2338,0
2347,bupivacaine,6,7,37,48,"We compared the systemic toxicity of bupivacaine, levobupivacaine, and ropivacaine in anesthetized rats.",11524350_1,0,-1,0,2347,0
2349,ropivacaine,11,12,71,82,"We compared the systemic toxicity of bupivacaine, levobupivacaine, and ropivacaine in anesthetized rats.",11524350_1,0,-1,0,2349,0
2351,local anesthetics,13,15,77,94,We also compared the ability to resuscitate rats after lethal doses of these local anesthetics.,11524350_2,0,-1,0,2351,0
2352,Bupivacaine,0,1,0,11,"Bupivacaine, levobupivacaine, or ropivacaine was infused at a rate of 2 mg.",11524350_3,0,-1,0,2352,0
2354,ropivacaine,5,6,33,44,"Bupivacaine, levobupivacaine, or ropivacaine was infused at a rate of 2 mg.",11524350_3,0,-1,0,2354,0
2362,ropivacaine,6,7,44,55,The cumulative doses of levobupivacaine and ropivacaine that produced seizures were similar and were larger than those of bupivacaine.,11524350_9,0,-1,0,2362,0
2363,bupivacaine,18,19,122,133,The cumulative doses of levobupivacaine and ropivacaine that produced seizures were similar and were larger than those of bupivacaine.,11524350_9,0,-1,0,2363,0
2367,ropivacaine,17,18,125,136,"The cumulative doses of levobupivacaine that produced dysrhythmias and asystole were smaller than the corresponding doses of ropivacaine, but they were larger than those of bupivacaine.",11524350_10,0,-1,0,2367,0
2368,bupivacaine,26,27,173,184,"The cumulative doses of levobupivacaine that produced dysrhythmias and asystole were smaller than the corresponding doses of ropivacaine, but they were larger than those of bupivacaine.",11524350_10,0,-1,0,2368,0
2369,Ropivacaine,11,12,59,70,"However, a smaller dose of epinephrine was required in the Ropivacaine group than in the other groups.",11524350_12,0,-1,0,2369,0
2371,ropivacaine,13,14,90,101,We conclude that the systemic toxicity of levobupivacaine is intermediate between that of ropivacaine and bupivacaine when administered at the same rate and that ropivacaine-induced cardiac arrest appears to be more susceptible to treatment than that induced by bupivacaine or levobupivacaine.,11524350_13,0,-1,0,2371,0
2372,bupivacaine,15,16,106,117,We conclude that the systemic toxicity of levobupivacaine is intermediate between that of ropivacaine and bupivacaine when administered at the same rate and that ropivacaine-induced cardiac arrest appears to be more susceptible to treatment than that induced by bupivacaine or levobupivacaine.,11524350_13,0,-1,0,2372,0
2374,bupivacaine,38,39,262,273,We conclude that the systemic toxicity of levobupivacaine is intermediate between that of ropivacaine and bupivacaine when administered at the same rate and that ropivacaine-induced cardiac arrest appears to be more susceptible to treatment than that induced by bupivacaine or levobupivacaine.,11524350_13,0,-1,0,2374,0
2388,terfenadine,10,11,79,90,"Pharmacokinetic/pharmacodynamic assessment of the effects of E4031, cisapride, terfenadine and terodiline on monophasic action potential duration in dog.1.",11569530_0,0,-1,0,2388,0
2399,terfenadine,17,18,87,98,TDP is a side-effect that has led to withdrawal of several drugs from the market (e.g. terfenadine and terodiline).,11569530_2,0,-1,0,2399,0
2405,terfenadine,13,14,78,89,"Four compounds known to increase QT interval and cause TDP were investigated: terfenadine, terodiline, cisapride and E4031.",11569530_5,0,-1,0,2405,0
2417,terfenadine,10,11,53,64,"These data indicate that the free ED50 in plasma for terfenadine (1.9 nM), terodiline (76 nM), cisapride (11 nM) and E4031 (1.9 nM) closely correlate with the free concentration in man causing QT effects.",11569530_9,0,-1,0,2417,0
2423,terfenadine,10,11,49,60,"For compounds that have shown TDP in the clinic (terfenadine, terodiline, cisapride) there is little differentiation between the dog ED50 and the efficacious free plasma concentrations in man (< 10-fold) reflecting their limited safety margins.",11569530_10,0,-1,0,2423,0
2457,opioid analgesic,3,5,13,29,"Fentanyl, an opioid analgesic, is frequently used in the neonatal intensive care unit setting for these very purposes.",11581460_2,0,-1,0,2457,0
2463,Sirolimus,0,1,0,9,Sirolimus and mycophenolate mofetil for calcineurin-free immunosuppression in renal transplant recipients.,11583940_0,0,-1,0,2463,0
2464,mycophenolate mofetil,2,4,14,35,Sirolimus and mycophenolate mofetil for calcineurin-free immunosuppression in renal transplant recipients.,11583940_0,0,-1,0,2464,0
2467,Calcineurin,0,1,0,11,"Calcineurin inhibitors, such as cyclosporine and tacrolimus, have been available for almost 20 years.",11583940_1,0,-1,0,2467,0
2468,cyclosporine,5,6,32,44,"Calcineurin inhibitors, such as cyclosporine and tacrolimus, have been available for almost 20 years.",11583940_1,0,-1,0,2468,0
2469,tacrolimus,7,8,49,59,"Calcineurin inhibitors, such as cyclosporine and tacrolimus, have been available for almost 20 years.",11583940_1,0,-1,0,2469,0
2478,mycophenolate mofetil,6,8,49,70,"Two recently available immunosuppressive agents, mycophenolate mofetil and sirolimus (rapamycin), have no nephrotoxicity.",11583940_5,0,-1,0,2478,0
2479,sirolimus,9,10,75,84,"Two recently available immunosuppressive agents, mycophenolate mofetil and sirolimus (rapamycin), have no nephrotoxicity.",11583940_5,0,-1,0,2479,0
2480,rapamycin,11,12,86,95,"Two recently available immunosuppressive agents, mycophenolate mofetil and sirolimus (rapamycin), have no nephrotoxicity.",11583940_5,0,-1,0,2480,0
2496,Neurofilament,9,10,68,81,"Histological and immunohistochemical investigations (HE-LFB, CD-68, Neurofilament) revealed degeneration of myelin and axons as well as pseudocystic transformation in areas exposed to vincristine, accompanied by secondary changes with numerous prominent macrophages.",11587867_4,0,-1,0,2496,0
2507,citalopram,7,8,49,59,Palpebral twitching in a depressed adolescent on citalopram.,11642480_0,0,-1,0,2507,0
2511,citalopram,8,9,49,59,We report a favorable response to treatment with citalopram by a 15-year-old boy with major depression who exhibited palpebral twitching during his first 2 weeks of treatment.,11642480_2,0,-1,0,2511,0
2515,citalopram,8,9,36,46,This may have been a side effect of citalopram as it remitted with redistribution of doses.,11642480_3,0,-1,0,2515,0
2517,sulphasalazine,25,26,144,158,"A 34-year-old lady developed a constellation of dermatitis, fever, lymphadenopathy and hepatitis, beginning on the 17th day of a course of oral sulphasalazine for sero-negative rheumatoid arthritis.",11672959_1,0,-1,0,2517,0
2528,anti-nuclear autoantibodies,13,15,80,107,"A week later, fulminant drug-induced hepatitis, associated with the presence of anti-nuclear autoantibodies (but not with other markers of autoimmunity), and accompanied by multi-organ failure and sepsis, supervened.",11672959_3,0,-1,0,2528,0
2530,her,10,11,61,64,She subsequently died some 5 weeks after the commencement of her drug therapy.,11672959_4,0,-1,0,2530,0
2541,sulphasalazine,34,35,203,217,"It is thought that the clinico-pathological features and chronology of this case bore the hallmarks of the so-called ""3-week sulphasalazine syndrome"", a rare, but often fatal, immunoallergic reaction to sulphasalazine.",11672959_6,0,-1,0,2541,0
2575,paracetamol,4,5,31,42,Tolerability of nimesulide and paracetamol in patients with NSAID-induced urticaria/angioedema.,11694026_0,0,-1,0,2575,0
2578,paracetamol,8,9,59,70,"Previous studies evaluated the tolerance of nimesulide and paracetamol in subjects with cutaneous, respiratory and anaphylactoid reactions induced by nonsteroidal anti-inflammatory drugs (NSAIDs).",11694026_1,0,-1,0,2578,0
2580,nonsteroidal anti-inflammatory,20,22,150,180,"Previous studies evaluated the tolerance of nimesulide and paracetamol in subjects with cutaneous, respiratory and anaphylactoid reactions induced by nonsteroidal anti-inflammatory drugs (NSAIDs).",11694026_1,0,-1,0,2580,0
2583,paracetamol,11,12,77,88,In this study we investigated tolerability and reliability of nimesulide and paracetamol in a very large number of patients with an exclusive well-documented history of NSAID-induced urticaria/angioedema.,11694026_2,0,-1,0,2583,0
2585,paracetamol,17,18,102,113,"Furthermore, we evaluated whether some factors have the potential to increase the risk of reaction to paracetamol and nimesulide.",11694026_3,0,-1,0,2585,0
2588,paracetamol,8,9,72,83,A single-placebo-controlled oral challenge procedure with nimesulide or paracetamol was applied to 829 patients with a history of NSAID-induced urticaria/angioedema.,11694026_4,0,-1,0,2588,0
2591,paracetamol,14,15,73,84,A total of 75/829 (9.4%) patients experienced reactions to nimesulide or paracetamol.,11694026_5,0,-1,0,2591,0
2594,paracetamol,26,27,131,142,"Of the 715 patients tested with nimesulide 62 (8.6%) showed a positive test, while of 114 subjects submitted to the challenge with paracetamol, 13 (9.6%) did not tolerate this drug.",11694026_6,0,-1,0,2594,0
2600,paracetamol,12,13,76,87,"Taken together, our results confirm the good tolerability of nimesulide and paracetamol in patients who experienced urticaria/angioedema caused by NSAIDs.",11694026_8,0,-1,0,2600,0
2649,interferon-alpha,20,21,175,191,OBJECTIVES: Recently published studies have demonstrated increased efficacy and cost-effectiveness of combination therapy with interferon and alpha-2b/ribavirin compared with interferon-alpha monotherapy in the treatment of chronic hepatitis C (CHC).,11705128_1,0,-1,0,2649,0
2698,atrial natriuretic factor,22,25,148,173,"At termination of the experiments, mice underwent echocardiography, quantitation of abundance of molecular markers of CM (ventricular mRNA encoding atrial natriuretic factor [ANF] and sarcoplasmic calcium ATPase [SERCA2]), and determination of plasma LA.",11706060_3,0,-1,0,2698,0
2699,ANF,26,27,175,178,"At termination of the experiments, mice underwent echocardiography, quantitation of abundance of molecular markers of CM (ventricular mRNA encoding atrial natriuretic factor [ANF] and sarcoplasmic calcium ATPase [SERCA2]), and determination of plasma LA.",11706060_3,0,-1,0,2699,0
2700,ATPase,31,32,205,211,"At termination of the experiments, mice underwent echocardiography, quantitation of abundance of molecular markers of CM (ventricular mRNA encoding atrial natriuretic factor [ANF] and sarcoplasmic calcium ATPase [SERCA2]), and determination of plasma LA.",11706060_3,0,-1,0,2700,0
2713,ANF,5,6,20,23,"After 10 days, only ANF was elevated, and only in the TG + HAART cohort.",11706060_11,0,-1,0,2713,0
2718,cisplatin,5,6,20,29,A Phase II trial of cisplatin plus WR-2721 (amifostine) for metastatic breast carcinoma: an Eastern Cooperative Oncology Group Study (E8188).BACKGROUND: Cisplatin has minimal antitumor activity when used as second- or third-line treatment of metastatic breast carcinoma.,11745184_0,0,-1,0,2718,0
2719,WR-2721,7,8,35,42,A Phase II trial of cisplatin plus WR-2721 (amifostine) for metastatic breast carcinoma: an Eastern Cooperative Oncology Group Study (E8188).BACKGROUND: Cisplatin has minimal antitumor activity when used as second- or third-line treatment of metastatic breast carcinoma.,11745184_0,0,-1,0,2719,0
2720,amifostine,9,10,44,54,A Phase II trial of cisplatin plus WR-2721 (amifostine) for metastatic breast carcinoma: an Eastern Cooperative Oncology Group Study (E8188).BACKGROUND: Cisplatin has minimal antitumor activity when used as second- or third-line treatment of metastatic breast carcinoma.,11745184_0,0,-1,0,2720,0
2723,Cisplatin,24,25,153,162,A Phase II trial of cisplatin plus WR-2721 (amifostine) for metastatic breast carcinoma: an Eastern Cooperative Oncology Group Study (E8188).BACKGROUND: Cisplatin has minimal antitumor activity when used as second- or third-line treatment of metastatic breast carcinoma.,11745184_0,0,-1,0,2723,0
2729,cisplatin,16,17,76,85,Older reports suggest an objective response rate of 8% when 60-120 mg/m2 of cisplatin is administered every 3-4 weeks.,11745184_1,0,-1,0,2729,0
2731,cisplatin,8,9,55,64,"Although a dose-response effect has been observed with cisplatin, the dose-limiting toxicities associated with cisplatin (e.g., nephrotoxicity, ototoxicity, and neurotoxicity) have limited its use as a treatment for breast carcinoma.",11745184_2,0,-1,0,2731,0
2734,cisplatin,15,16,111,120,"Although a dose-response effect has been observed with cisplatin, the dose-limiting toxicities associated with cisplatin (e.g., nephrotoxicity, ototoxicity, and neurotoxicity) have limited its use as a treatment for breast carcinoma.",11745184_2,0,-1,0,2734,0
2739,WR-2721,0,1,0,7,WR-2721 or amifostine initially was developed to protect military personnel in the event of nuclear war.,11745184_3,0,-1,0,2739,0
2740,amifostine,2,3,11,21,WR-2721 or amifostine initially was developed to protect military personnel in the event of nuclear war.,11745184_3,0,-1,0,2740,0
2743,Amifostine,0,1,0,10,Amifostine subsequently was shown to protect normal tissues from the toxic effects of alkylating agents and cisplatin without decreasing the antitumor effect of the chemotherapy.,11745184_4,0,-1,0,2743,0
2746,cisplatin,16,17,108,117,Amifostine subsequently was shown to protect normal tissues from the toxic effects of alkylating agents and cisplatin without decreasing the antitumor effect of the chemotherapy.,11745184_4,0,-1,0,2746,0
2748,cisplatin,3,4,16,25,"Early trials of cisplatin and amifostine also suggested that the incidence and severity of cisplatin-induced nephrotoxicity, ototoxicity, and neuropathy were reduced.",11745184_5,0,-1,0,2748,0
2749,amifostine,5,6,30,40,"Early trials of cisplatin and amifostine also suggested that the incidence and severity of cisplatin-induced nephrotoxicity, ototoxicity, and neuropathy were reduced.",11745184_5,0,-1,0,2749,0
2753,cisplatin,10,11,48,57,"METHODS: A Phase II study of the combination of cisplatin plus amifostine was conducted in patients with progressive metastatic breast carcinoma who had received one, but not more than one, chemotherapy regimen for metastatic disease.",11745184_6,0,-1,0,2753,0
2754,amifostine,12,13,63,73,"METHODS: A Phase II study of the combination of cisplatin plus amifostine was conducted in patients with progressive metastatic breast carcinoma who had received one, but not more than one, chemotherapy regimen for metastatic disease.",11745184_6,0,-1,0,2754,0
2758,amifostine,2,3,18,28,"Patients received amifostine, 910 mg/m2 intravenously over 15 minutes.",11745184_7,0,-1,0,2758,0
2759,amifostine,4,5,24,34,"After completion of the amifostine infusion, cisplatin 120 mg/m2 was administered over 30 minutes.",11745184_8,0,-1,0,2759,0
2760,cisplatin,7,8,45,54,"After completion of the amifostine infusion, cisplatin 120 mg/m2 was administered over 30 minutes.",11745184_8,0,-1,0,2760,0
2763,cisplatin,9,10,69,78,Intravenous hydration and mannitol was administered before and after cisplatin.,11745184_9,0,-1,0,2763,0
2770,cisplatin,5,6,32,41,CONCLUSIONS: The combination of cisplatin and amifostine in this study resulted in an overall response rate of 16%.,11745184_17,0,-1,0,2770,0
2771,amifostine,7,8,46,56,CONCLUSIONS: The combination of cisplatin and amifostine in this study resulted in an overall response rate of 16%.,11745184_17,0,-1,0,2771,0
2775,amifostine,16,17,107,117,Neither a tumor-protective effect nor reduced toxicity to normal tissues was observed with the addition of amifostine to cisplatin in this trial.,11745184_18,0,-1,0,2775,0
2776,cisplatin,18,19,121,130,Neither a tumor-protective effect nor reduced toxicity to normal tissues was observed with the addition of amifostine to cisplatin in this trial.,11745184_18,0,-1,0,2776,0
2777,Oral contraceptives,0,2,0,19,Oral contraceptives and the risk of myocardial infarction.,11752354_0,0,-1,0,2777,0
2779,oral contraceptives,8,10,46,65,"BACKGROUND: An association between the use of oral contraceptives and the risk of myocardial infarction has been found in some, but not all, studies.",11752354_1,0,-1,0,2779,0
2781,progestagen,10,11,59,70,"We investigated this association, according to the type of progestagen included in third-generation (i.e., desogestrel or gestodene) and second-generation (i.e., levonorgestrel) oral contraceptives, the dose of estrogen, and the presence or absence of prothrombotic mutations METHODS: In a nationwide, population-based, case-control study, we identified and enrolled 248 women 18 through 49 years of age who had had a first myocardial infarction between 1990 and 1995 and 925 control women who had not had a myocardial infarction and who were matched for age, calendar year of the index event, and area of residence.",11752354_2,0,-1,0,2781,0
2783,desogestrel,17,18,107,118,"We investigated this association, according to the type of progestagen included in third-generation (i.e., desogestrel or gestodene) and second-generation (i.e., levonorgestrel) oral contraceptives, the dose of estrogen, and the presence or absence of prothrombotic mutations METHODS: In a nationwide, population-based, case-control study, we identified and enrolled 248 women 18 through 49 years of age who had had a first myocardial infarction between 1990 and 1995 and 925 control women who had not had a myocardial infarction and who were matched for age, calendar year of the index event, and area of residence.",11752354_2,0,-1,0,2783,0
2785,second-generation,22,23,137,154,"We investigated this association, according to the type of progestagen included in third-generation (i.e., desogestrel or gestodene) and second-generation (i.e., levonorgestrel) oral contraceptives, the dose of estrogen, and the presence or absence of prothrombotic mutations METHODS: In a nationwide, population-based, case-control study, we identified and enrolled 248 women 18 through 49 years of age who had had a first myocardial infarction between 1990 and 1995 and 925 control women who had not had a myocardial infarction and who were matched for age, calendar year of the index event, and area of residence.",11752354_2,0,-1,0,2785,0
2786,levonorgestrel,26,27,162,176,"We investigated this association, according to the type of progestagen included in third-generation (i.e., desogestrel or gestodene) and second-generation (i.e., levonorgestrel) oral contraceptives, the dose of estrogen, and the presence or absence of prothrombotic mutations METHODS: In a nationwide, population-based, case-control study, we identified and enrolled 248 women 18 through 49 years of age who had had a first myocardial infarction between 1990 and 1995 and 925 control women who had not had a myocardial infarction and who were matched for age, calendar year of the index event, and area of residence.",11752354_2,0,-1,0,2786,0
2787,oral contraceptives,28,30,178,197,"We investigated this association, according to the type of progestagen included in third-generation (i.e., desogestrel or gestodene) and second-generation (i.e., levonorgestrel) oral contraceptives, the dose of estrogen, and the presence or absence of prothrombotic mutations METHODS: In a nationwide, population-based, case-control study, we identified and enrolled 248 women 18 through 49 years of age who had had a first myocardial infarction between 1990 and 1995 and 925 control women who had not had a myocardial infarction and who were matched for age, calendar year of the index event, and area of residence.",11752354_2,0,-1,0,2787,0
2803,oral contraceptive,38,40,220,238,"An analysis for factor V Leiden and the G20210A mutation in the prothrombin gene was conducted in 217 patients and 763 controls RESULTS: The odds ratio for myocardial infarction among women who used any type of combined oral contraceptive, as compared with nonusers, was 2.0 (95 percent confidence interval, 1.5 to 2.8).",11752354_4,0,-1,0,2803,0
2808,oral contraceptives,21,23,116,135,"The adjusted odds ratio was 2.5 (95 percent confidence interval, 1.5 to 4.1) among women who used second-generation oral contraceptives and 1.3 (95 percent confidence interval, 0.7 to 2.5) among those who used third-generation oral contraceptives.",11752354_5,0,-1,0,2808,0
2810,oral contraceptives,40,42,227,246,"The adjusted odds ratio was 2.5 (95 percent confidence interval, 1.5 to 4.1) among women who used second-generation oral contraceptives and 1.3 (95 percent confidence interval, 0.7 to 2.5) among those who used third-generation oral contraceptives.",11752354_5,0,-1,0,2810,0
2811,oral contraceptives,4,6,21,40,"Among women who used oral contraceptives, the odds ratio was 2.1 (95 percent confidence interval, 1.5 to 3.0) for those without a prothrombotic mutation and 1.9 (95 percent confidence interval, 0.6 to 5.5) for those with a mutation CONCLUSIONS: The risk of myocardial infarction was increased among women who used second-generation oral contraceptives.",11752354_6,0,-1,0,2811,0
2817,oral contraceptives,59,61,332,351,"Among women who used oral contraceptives, the odds ratio was 2.1 (95 percent confidence interval, 1.5 to 3.0) for those without a prothrombotic mutation and 1.9 (95 percent confidence interval, 0.6 to 5.5) for those with a mutation CONCLUSIONS: The risk of myocardial infarction was increased among women who used second-generation oral contraceptives.",11752354_6,0,-1,0,2817,0
2818,oral contraceptives,9,11,56,75,The results with respect to the use of third-generation oral contraceptives were inconclusive but suggested that the risk was lower than the risk associated with second-generation oral contraceptives.,11752354_7,0,-1,0,2818,0
2820,oral contraceptives,26,28,180,199,The results with respect to the use of third-generation oral contraceptives were inconclusive but suggested that the risk was lower than the risk associated with second-generation oral contraceptives.,11752354_7,0,-1,0,2820,0
2822,oral contraceptives,11,13,67,86,The risk of myocardial infarction was similar among women who used oral contraceptives whether or not they had a prothrombotic mutation.,11752354_8,0,-1,0,2822,0
2866,tacrolimus,7,8,56,66,BACKGROUND: The calcineurin inhibitors cyclosporine and tacrolimus are both known to be nephrotoxic.,11773892_1,0,-1,0,2866,0
2924,tranexamic acid,9,11,80,95,Epileptic seizures following cortical application of fibrin sealants containing tranexamic acid in rats.,11807648_0,0,-1,0,2924,0
2927,aprotinin,10,11,58,67,"In order to increase clot stability, FS typically contain aprotinin, a natural fibrinolysis inhibitor.",11807648_2,0,-1,0,2927,0
2930,tranexamic acid,7,9,52,67,"Recently, synthetic fibrinolysis inhibitors such as tranexamic acid (tAMCA) have been considered as substitutes for aprotinin.",11807648_3,0,-1,0,2930,0
2932,aprotinin,18,19,116,125,"Recently, synthetic fibrinolysis inhibitors such as tranexamic acid (tAMCA) have been considered as substitutes for aprotinin.",11807648_3,0,-1,0,2932,0
2937,aprotinin,4,5,22,31,METHOD: FS containing aprotinin or different concentrations of tAMCA (0.5-47.5 mg/ml) were applied to the pial surface of the cortex of anaesthetized rats.,11807648_6,0,-1,0,2937,0
2952,aprotinin,5,6,27,36,"In contrast, FS containing aprotinin did not evoke any paroxysmal activity.",11807648_11,0,-1,0,2952,0
2954,Tranexamic acid,2,4,16,31,INTERPRETATION: Tranexamic acid retains its convulsive action within FS.,11807648_12,0,-1,0,2954,0
2986,(3,21,23,133,135,"Subsequent treatments included alternative anticoagulants (11 patients), thrombolytic drugs (3 patients), inferior vena cava filters (3 patients) and, eventually, warfarin (11 patients).",11827497_13,0,-1,0,2986,0
2994,serotonergic,9,10,53,65,"BACKGROUND: Risperidone, a potent antagonist of both serotonergic (5HT2A) and dopaminergic D2 receptors is associated with hyperprolactinemia in adults and children.",11838826_1,0,-1,0,2994,0
3008,cabergoline,9,10,82,93,We report the successful treatment of risperidone-induced hyperprolactinemia with cabergoline in youth.,11838826_4,0,-1,0,3008,0
3012,cabergoline,16,17,124,135,METHODS: We undertook a retrospective case review of four children with risperidone-induced hyperprolactinemia treated with cabergoline.,11838826_5,0,-1,0,3012,0
3018,cabergoline,51,52,261,272,"RESULTS: Four males (age 6-11 years) with Diagnostic and Statistical Manual of Mental Disorders (fourth edition) bipolar disorder or psychoses, with risperidone-induced elevations in serum prolactin levels (57.5-129 ng/mL, normal 5-15 ng/mL), were treated with cabergoline (mean dose 2.13 +/- 0.09 mg/week).",11838826_6,0,-1,0,3018,0
3023,cabergoline,19,20,92,103,"When serum prolactin levels normalized in all four subjects (mean 11.2 +/- 10.9 ng/mL), the cabergoline dose was reduced to 1 mg/week in three of four subjects.",11838826_7,0,-1,0,3023,0
3025,cabergoline,6,7,34,45,"The mean duration of therapy with cabergoline was 523.5 +/- 129.7 days, and the mean duration of therapy with risperidone was 788.5 +/- 162.5 days.",11838826_8,0,-1,0,3025,0
3029,Cabergoline,0,1,0,11,Cabergoline was well tolerated without adverse effects.,11838826_9,0,-1,0,3029,0
3031,Cabergoline,2,3,13,24,"CONCLUSIONS: Cabergoline may be useful for the treatment of risperidone-induced hyperprolactinemia in youth; however, further research is needed.",11838826_10,0,-1,0,3031,0
3043,dipyrone,7,8,46,54,No other medications were involved except for dipyrone for analgesia.,11847945_4,0,-1,0,3043,0
3044,alanine aminotransferase,1,3,4,28,The alanine aminotransferase was elevated to a peak concentration of 1533 U/L and the serum bilirubin reached a peak of 17.0 mg/dL. There was slow improvement over 4 months.,11847945_5,0,-1,0,3044,0
3049,dipyrone,6,7,40,48,Accidental reexposure by the patient to dipyrone was uneventful.,11847945_6,0,-1,0,3049,0
3055,metoclopramide,5,6,30,44,Torsade de pointes induced by metoclopramide in an elderly woman with preexisting complete left bundle branch block.,11858397_0,0,-1,0,3055,0
3059,metoclopramide,6,7,39,53,"However, the torsadogenic potential of metoclopramide, a commonly used antiemetic and prokinetic drug, has not been reported in the literature, despite its chemical similarity to procainamide.",11858397_2,0,-1,0,3059,0
3061,procainamide,29,30,179,191,"However, the torsadogenic potential of metoclopramide, a commonly used antiemetic and prokinetic drug, has not been reported in the literature, despite its chemical similarity to procainamide.",11858397_2,0,-1,0,3061,0
3065,metoclopramide,24,25,162,176,We report on a 92-year-old woman with preexisting complete left bundle branch block who developed torsade de pointes after intravenous and oral administration of metoclopramide.,11858397_3,0,-1,0,3065,0
3069,class IB,13,15,106,114,These two episodes were suppressed successfully after discontinuing the offending drugs and administering class IB drugs.,11858397_5,0,-1,0,3069,0
3070,metoclopramide,6,7,37,51,This is the first documentation that metoclopramide provokes torsade de pointes clinically.,11858397_6,0,-1,0,3070,0
3072,Metoclopramide,0,1,0,14,Metoclopramide should be used cautiously in patients with a risk of torsade de pointes.,11858397_7,0,-1,0,3072,0
3076,muscarinic,10,11,71,81,Dopamine D2 receptor signaling controls neuronal cell death induced by muscarinic and glutamatergic drugs.,11860278_0,0,-1,0,3076,0
3077,glutamatergic,12,13,86,99,Dopamine D2 receptor signaling controls neuronal cell death induced by muscarinic and glutamatergic drugs.,11860278_0,0,-1,0,3077,0
3089,kainic acid,9,11,62,73,"We compared these results with those previously obtained with kainic acid (KA), a potent glutamate agonist.",11860278_5,0,-1,0,3089,0
3090,glutamate agonist,17,19,89,106,"We compared these results with those previously obtained with kainic acid (KA), a potent glutamate agonist.",11860278_5,0,-1,0,3090,0
3098,dopaminergic,3,4,14,26,"Moreover, the dopaminergic control of epilepsy-induced neurodegeneration seems to be mediated by distinct interactions of D2R signaling with these two neurotransmitters.",11860278_9,0,-1,0,3098,0
3103,pregnenolone,10,11,87,99,Steroid structure and pharmacological properties determine the anti-amnesic effects of pregnenolone sulphate in the passive avoidance task in rats.,11860495_0,0,-1,0,3103,0
3104,Pregnenolone,0,1,0,12,"Pregnenolone sulphate (PREGS) has generated interest as one of the most potent memory-enhancing neurosteroids to be examined in rodent learning studies, with particular importance in the ageing process.",11860495_1,0,-1,0,3104,0
3109,glutamatergic,16,17,111,124,The mechanism by which this endogenous steroid enhances memory formation is hypothesized to involve actions on glutamatergic and GABAergic systems.,11860495_2,0,-1,0,3109,0
3110,GABAergic,18,19,129,138,The mechanism by which this endogenous steroid enhances memory formation is hypothesized to involve actions on glutamatergic and GABAergic systems.,11860495_2,0,-1,0,3110,0
3112,modulator,11,12,68,77,This hypothesis stems from findings that PREGS is a potent positive modulator of N-methyl-d-aspartate receptors (NMDARs) and a negative modulator of gamma-aminobutyric acid(A) receptors (GABA(A)Rs).,11860495_3,0,-1,0,3112,0
3115,modulator,21,22,136,145,This hypothesis stems from findings that PREGS is a potent positive modulator of N-methyl-d-aspartate receptors (NMDARs) and a negative modulator of gamma-aminobutyric acid(A) receptors (GABA(A)Rs).,11860495_3,0,-1,0,3115,0
3116,gamma-aminobutyric,23,24,149,167,This hypothesis stems from findings that PREGS is a potent positive modulator of N-methyl-d-aspartate receptors (NMDARs) and a negative modulator of gamma-aminobutyric acid(A) receptors (GABA(A)Rs).,11860495_3,0,-1,0,3116,0
3129,epipregnanolone,19,20,107,122,"The analogs tested were: 11-ketopregnenolone sulphate (an agent that is inactive at GABA(A)Rs and NMDARs), epipregnanolone ([3beta-hydroxy-5beta-pregnan-20-one] sulphate, an inhibitor of both GABA(A)Rs and NMDARs), and a newly synthesized (-) PREGS enantiomer (which is identical to PREGS in effects on GABA(A)Rs and NMDARs).",11860495_6,0,-1,0,3129,0
3144,epipregnanolone,11,12,70,85,"The results show that, unlike PREGS, 11-ketopregnenolone sulphate and epipregnanolone sulphate failed to block the effect of scopolamine, suggesting that altering the modulation of NMDA receptors diminishes the memory-enhancing effects of PREGS.",11860495_9,0,-1,0,3144,0
3192,dehydrogenase,12,13,85,98,In addition PJ34 significantly reduced the DOX-induced increase in the serum lactate dehydrogenase and creatine kinase activities but not metalloproteinase activation in the heart.,11861791_9,0,-1,0,3192,0
3193,creatine kinase,14,16,103,118,In addition PJ34 significantly reduced the DOX-induced increase in the serum lactate dehydrogenase and creatine kinase activities but not metalloproteinase activation in the heart.,11861791_9,0,-1,0,3193,0
3194,metalloproteinase,19,20,138,155,In addition PJ34 significantly reduced the DOX-induced increase in the serum lactate dehydrogenase and creatine kinase activities but not metalloproteinase activation in the heart.,11861791_9,0,-1,0,3194,0
3234,exo,10,11,85,88,Sequential observations of exencephaly and subsequent morphological changes by mouse exo utero development system: analysis of the mechanism of transformation from exencephaly to anencephaly.,11875660_0,0,-1,0,3234,0
3237,exo,6,7,34,37,We examined this theory using the exo utero development system that allows direct and sequential observations of mid- to late-gestation mouse embryos.,11875660_2,0,-1,0,3237,0
3242,exo,19,20,108,111,"We observed the exencephaly induced by 5-azacytidine at embryonic day 13.5 (E13.5), let the embryos develop exo utero until E18.5, and re-observed the same embryos at E18.5.",11875660_3,0,-1,0,3242,0
3292,glucaric acid,6,8,48,61,A new infarct-avid radiopharmaceutical based on glucaric acid was prepared in the hospital radiopharmacy of the INCMNSZ.,11897407_3,0,-1,0,3292,0
3312,hexamethonium,10,11,72,85,"Intraperitoneal administration of atropine, naloxone, mecamylamine, and hexamethonium to mice reduced catalepsy induced by a combination of morphine with nicotine.",11900788_4,0,-1,0,3312,0
3314,hexamethonium,5,6,47,60,"Intracerebroventricular injection of atropine, hexamethonium, and naloxone also decreased catalepsy induced by morphine plus nicotine.",11900788_5,0,-1,0,3314,0
3318,hexamethonium,12,13,108,121,"Intraperitoneal administration of atropine, but not intraperitoneal or intracerebroventricular injection of hexamethonium, decreased the effect of a single dose of morphine.",11900788_6,0,-1,0,3318,0
3348,(r,12,14,86,88,"Severity of peak-dose dyskinesias was strongly correlated with grip force in ON-state (r = 0.79 with peak force, P < 0.01).",11912119_9,0,-1,0,3348,0
3352,dopaminergic,18,19,97,109,No correlation was observed between forces and the motor score as well as with the daily dose of dopaminergic medication.,11912119_10,0,-1,0,3352,0
3358,Bupropion,0,1,0,9,Bupropion (Zyban) toxicity.,11928786_0,0,-1,0,3358,0
3360,Bupropion,0,1,0,9,Bupropion is a monocyclic antidepressant structurally related to amphetamine.,11928786_1,0,-1,0,3360,0
3363,sustained-release formulation,3,5,9,38,"Zyban, a sustained-release formulation of bupropion hydrochloride, was recently released in Ireland, as a smoking cessation aid.",11928786_2,0,-1,0,3363,0
3364,bupropion,6,7,42,51,"Zyban, a sustained-release formulation of bupropion hydrochloride, was recently released in Ireland, as a smoking cessation aid.",11928786_2,0,-1,0,3364,0
3371,bupropion,30,31,165,174,"We report a case of a 31 year old female who required admission to the Intensive Care Unit for ventilation and full supportive therapy, following ingestion of 13.5g bupropion.",11928786_8,0,-1,0,3371,0
3378,GLEPP1,0,1,0,6,GLEPP1 receptor tyrosine phosphatase (Ptpro) in rat PAN nephrosis.,11961407_0,0,-1,0,3378,0
3379,Ptpro,5,6,38,43,GLEPP1 receptor tyrosine phosphatase (Ptpro) in rat PAN nephrosis.,11961407_0,0,-1,0,3379,0
3381,Glomerular epithelial protein 1,0,4,0,31,Glomerular epithelial protein 1 (GLEPP1) is a podocyte receptor membrane protein tyrosine phosphatase located on the apical cell membrane of visceral glomerular epithelial cell and foot processes.,11961407_2,0,-1,0,3381,0
3382,GLEPP1,5,6,33,39,Glomerular epithelial protein 1 (GLEPP1) is a podocyte receptor membrane protein tyrosine phosphatase located on the apical cell membrane of visceral glomerular epithelial cell and foot processes.,11961407_2,0,-1,0,3382,0
3384,cell membrane,19,21,124,137,Glomerular epithelial protein 1 (GLEPP1) is a podocyte receptor membrane protein tyrosine phosphatase located on the apical cell membrane of visceral glomerular epithelial cell and foot processes.,11961407_2,0,-1,0,3384,0
3389,GLEPP1,6,7,36,42,"To better understand the utility of GLEPP1 as a marker of glomerular injury, the amount and distribution of GLEPP1 protein and mRNA were examined by immunohistochemistry, Western blot and RNase protection assay in a model of podocyte injury in the rat.",11961407_4,0,-1,0,3389,0
3393,Puromycin aminonucleoside,0,2,0,25,"Puromycin aminonucleoside nephrosis was induced by single intraperitoneal injection of puromycin aminonucleoside (PAN, 20 mg/100g BW).",11961407_5,0,-1,0,3393,0
3395,puromycin aminonucleoside,10,12,87,112,"Puromycin aminonucleoside nephrosis was induced by single intraperitoneal injection of puromycin aminonucleoside (PAN, 20 mg/100g BW).",11961407_5,0,-1,0,3395,0
3397,acute phase,29,31,108,119,"Tissues were analyzed at 0, 5, 7, 11, 21, 45, 80 and 126 days after PAN injection so as to include both the acute phase of proteinuria associated with foot process effacement (days 5-11) and the chronic phase of proteinuria associated with glomerulosclerosis (days 45-126).",11961407_6,0,-1,0,3397,0
3413,GLEPP1,15,16,63,69,"By day 45-126, at a time when glomerular scarring was present, GLEPP1 was absent from glomerulosclerotic areas although the total glomerular content of GLEPP1 was not different from normal.",11961407_11,0,-1,0,3413,0
3415,GLEPP1,27,28,152,158,"By day 45-126, at a time when glomerular scarring was present, GLEPP1 was absent from glomerulosclerotic areas although the total glomerular content of GLEPP1 was not different from normal.",11961407_11,0,-1,0,3415,0
3416,GLEPP1,3,4,17,23,"We conclude that GLEPP1 expression, unlike podocalyxin, reflects podocyte injury induced by PAN.",11961407_12,0,-1,0,3416,0
3419,GLEPP1,0,1,0,6,GLEPP1 expression may be a useful marker of podocyte injury.,11961407_13,0,-1,0,3419,0
3420,MK-801,3,4,22,28,Behavioral effects of MK-801 on reserpine-treated mice.,11999899_0,0,-1,0,3420,0
3424,MK-801,5,6,28,34,"The effects of dizocilpine (MK-801), a noncompetitive N-methyl-D-aspartate (NMDA) receptor antagonist, were studied on dopamine-related behaviors induced by reserpine treatments.",11999899_1,0,-1,0,3424,0
3426,receptor antagonist,14,16,82,101,"The effects of dizocilpine (MK-801), a noncompetitive N-methyl-D-aspartate (NMDA) receptor antagonist, were studied on dopamine-related behaviors induced by reserpine treatments.",11999899_1,0,-1,0,3426,0
3429,glutamatergic,24,25,138,151,"This study focuses on behavioral syndromes that may used as models for Parkinson's disease, or tardive dyskinesia, and its response after glutamatergic blockage.",11999899_2,0,-1,0,3429,0
3430,(1,1,3,10,12,"Reserpine (1 mg/kg), administered once every other day for 4 days, produced increases in orofacial dyskinesia, tongue protrusion and vacuous chewing in mice, which are signs indicative of tardive dyskinesia.",11999899_3,0,-1,0,3430,0
3435,MK-801,0,1,0,6,"MK-801 (0.1 mg/kg), administered 30 min before the observation test, prevented the vacuous chewing movements, tongue protrusions and catalepsy induced by reserpine.",11999899_5,0,-1,0,3435,0
3439,MK-801,2,3,9,15,"However, MK-801 injection produced a significant increase of tremor in reserpine-treated mice.",11999899_6,0,-1,0,3439,0
3441,(1,1,3,10,12,"Reserpine (1 mg/kg), administered 90 min before the test and followed by apomophine injection (0.1 mg/kg) 5 min before the test, did not produce oral dyskinesia in mice.",11999899_7,0,-1,0,3441,0
3445,MK-801,0,1,0,6,MK-801 (0.1 mg/kg) administration attenuated the catalepsy and tremor induced by reserpine.,11999899_9,0,-1,0,3445,0
3447,(1,3,5,28,30,"Pretreatment with reserpine (1 mg/kg) 24 h before the observation test produced increases in vacuous chewing movements and tongue protrusion, as well as increases in tremor and catalepsy, whereas MK-801 (0.1 mg/kg) injection 90 min before the test reversed the effects of reserpine.",11999899_10,0,-1,0,3447,0
3451,MK-801,33,34,196,202,"Pretreatment with reserpine (1 mg/kg) 24 h before the observation test produced increases in vacuous chewing movements and tongue protrusion, as well as increases in tremor and catalepsy, whereas MK-801 (0.1 mg/kg) injection 90 min before the test reversed the effects of reserpine.",11999899_10,0,-1,0,3451,0
3456,glutamatergic,1,2,4,17,"The glutamatergic blockage produced by NMDA can restore these signs, such as vacuous chewing movements, tongue protrusions, catalepsy and tremor according to the employed model.",11999899_12,0,-1,0,3456,0
3478,Antithymocyte globulin,0,2,0,22,Antithymocyte globulin in the treatment of D-penicillamine-induced aplastic anemia.,12041669_0,0,-1,0,3478,0
3480,antithymocyte globulin,4,6,23,45,A patient who received antithymocyte globulin therapy for aplastic anemia due to D-penicillamine therapy is described.,12041669_1,0,-1,0,3480,0
3482,D-penicillamine,12,13,81,96,A patient who received antithymocyte globulin therapy for aplastic anemia due to D-penicillamine therapy is described.,12041669_1,0,-1,0,3482,0
3486,antithymocyte globulin,2,4,7,29,Use of antithymocyte globulin may be the optimal treatment of D-penicillamine-induced aplastic anemia.,12041669_3,0,-1,0,3486,0
3489,Topiramate,0,1,0,10,Topiramate is a recently developed antiepileptic medication that is becoming more widely prescribed because of its efficacy in treating refractory seizures.,12042105_1,0,-1,0,3489,0
3492,anhydrase,18,19,125,134,Urologists should be aware that this medication can cause metabolic acidosis in patients secondary to inhibition of carbonic anhydrase.,12042105_2,0,-1,0,3492,0
3497,Metamizol,0,1,0,9,Metamizol potentiates morphine antinociception but not constipation after chronic treatment.,12063090_0,0,-1,0,3497,0
3500,antinociceptive,4,5,24,39,This work evaluates the antinociceptive and constipating effects of the combination of 3.2 mg/kg s.c.,12063090_1,0,-1,0,3500,0
3502,metamizol,0,1,0,9,metamizol in acutely and chronically treated (once a day for 12 days) rats.,12063090_3,0,-1,0,3502,0
3504,antinociceptive,5,6,17,32,"On the 13th day, antinociceptive effects were assessed using a model of inflammatory nociception, pain-induced functional impairment model, and the charcoal meal test was used to evaluate the intestinal transit.",12063090_4,0,-1,0,3504,0
3509,metamizol,5,6,45,54,Simultaneous administration of morphine with metamizol resulted in a markedly antinociceptive potentiation and an increasing of the duration of action after a single (298+/-7 vs. 139+/-36 units area (ua); P<0.001) and repeated administration (280+/-17 vs. 131+/-22 ua; P<0.001).,12063090_5,0,-1,0,3509,0
3510,antinociceptive,10,11,78,93,Simultaneous administration of morphine with metamizol resulted in a markedly antinociceptive potentiation and an increasing of the duration of action after a single (298+/-7 vs. 139+/-36 units area (ua); P<0.001) and repeated administration (280+/-17 vs. 131+/-22 ua; P<0.001).,12063090_5,0,-1,0,3510,0
3512,Antinociceptive,0,1,0,15,Antinociceptive effect of morphine was reduced in chronically treated rats (39+/-10 vs. 18+/-5 au) while the combination-induced antinociception was remained similar as an acute treatment (298+/-7 vs. 280+/-17 au).,12063090_6,0,-1,0,3512,0
3515,antinociceptive,1,2,6,21,"Acute antinociceptive effects of the combination were partially prevented by 3.2 mg/kg naloxone s.c. (P<0.05), suggesting the partial involvement of the opioidergic system in the synergism observed.",12063090_7,0,-1,0,3515,0
3521,metamizol,20,21,135,144,"The combination inhibited intestinal transit similar to that produced by morphine regardless of the time of treatment, suggesting that metamizol did not potentiate morphine-induced constipation.",12063090_9,0,-1,0,3521,0
3523,metamizol,9,10,67,76,"These findings show a significant interaction between morphine and metamizol in chronically treated rats, suggesting that this combination could be useful for the treatment of chronic pain.",12063090_10,0,-1,0,3523,0
3528,ifosfamide,7,8,46,56,CNS toxic effects of the antineoplastic agent ifosfamide (IFX) are frequent and include a variety of neurological symptoms that can limit drug use.,12084448_1,0,-1,0,3528,0
3533,ifosfamide,25,26,146,156,"We report a case of a 51-year-old man who developed severe, disabling negative myoclonus of the upper and lower extremities after the infusion of ifosfamide for plasmacytoma.",12084448_2,0,-1,0,3533,0
3542,ifosfamide,3,4,22,32,The administration of ifosfamide was discontinued and within 12 h the asterixis resolved completely.,12084448_6,0,-1,0,3542,0
3545,ifosfamide,12,13,71,81,"In the patient described, the presence of asterixis during infusion of ifosfamide, normal laboratory findings and imaging studies and the resolution of symptoms following the discontinuation of the drug suggest that negative myoclonus is associated with the use of IFX.",12084448_7,0,-1,0,3545,0
3553,Azidothymidine,0,1,0,14,Azidothymidine (AZT)-induced anemia in mice can be reversed by the administration of IGF-IL-3 (fusion protein of insulin-like growth factor II (IGF II) and interleukin 3).,12090760_1,0,-1,0,3553,0
3555,fusion protein,14,16,95,109,Azidothymidine (AZT)-induced anemia in mice can be reversed by the administration of IGF-IL-3 (fusion protein of insulin-like growth factor II (IGF II) and interleukin 3).,12090760_1,0,-1,0,3555,0
3556,growth factor,18,20,126,139,Azidothymidine (AZT)-induced anemia in mice can be reversed by the administration of IGF-IL-3 (fusion protein of insulin-like growth factor II (IGF II) and interleukin 3).,12090760_1,0,-1,0,3556,0
3598,racemic,10,11,57,64,"Ketamine in war/tropical surgery (a final tribute to the racemic mixture).A technique of continuous intravenous anaesthesia with ketamine was used successfully during the Somalia civil war in 1994 and in north Uganda in 1999 for 64 operations in 62 patients, aged from 6 weeks to 70 years, undergoing limb and abdominal surgery including caesarian sections and interventions in neonates.",12091028_0,0,-1,0,3598,0
3609,glycopyrrolate,5,6,35,49,"After premedication with diazepam, glycopyrrolate and local anaesthesia, and induction with standard doses of ketamine, a maintenance dose of 10-20 microg/kg/min of ketamine proved safe and effective.",12091028_2,0,-1,0,3609,0
3620,glycopyrrolate,13,14,73,87,"An antisialogue was usually unnecessary in operations lasting up to 2 h, glycopyrrolate being the best choice for its lowest psychotropic and chronotropic effects, especially in a hot climate.",12091028_6,0,-1,0,3620,0
3641,cidofovir,7,8,54,63,Experience is greatest with intravenous ribavirin and cidofovir.,12093990_5,0,-1,0,3641,0
3650,cidofovir,3,4,11,20,"The use of cidofovir in severe adenovirus infection has been limited by adverse effects, the most significant of which is nephrotoxicity.",12093990_9,0,-1,0,3650,0
3663,cidofovir,8,9,61,70,The bone marrow transplant patient also received intravenous cidofovir for progressive disseminated disease.,12093990_13,0,-1,0,3663,0
3672,cidofovir,2,3,7,16,Use of cidofovir in 1 child was associated with progressive renal failure and neutropenia.,12093990_20,0,-1,0,3672,0
3697,paracetamol,17,18,74,85,"A 51 year old man took a mixed overdose including 1.8-3.6 g of diltiazem, paracetamol, aspirin, isosorbide nitrate, and alcohol.",12101159_1,0,-1,0,3697,0
3701,activated charcoal,15,17,94,112,He initially presented to hospital after six hours with mild hypotension and was treated with activated charcoal and intravenous fluids.,12101159_2,0,-1,0,3701,0
3717,oral anticoagulant,5,7,32,50,"BACKGROUND: The interruption of oral anticoagulant (OAC) administration is sometimes indicated in patients with mechanical heart valves, mainly before noncardiac surgery, non-surgical interventions, and pregnancy.",12109865_1,0,-1,0,3717,0
3722,Unfractionated heparin,0,2,0,22,Unfractionated heparin (UH) is currently the substitute for selected patients.,12109865_2,0,-1,0,3722,0
3754,metoclopramide,4,5,33,47,Cardiac arrest after intravenous metoclopramide - a case of five repeated injections of metoclopramide causing five episodes of cardiac arrest.,12139551_0,0,-1,0,3754,0
3755,metoclopramide,13,14,88,102,Cardiac arrest after intravenous metoclopramide - a case of five repeated injections of metoclopramide causing five episodes of cardiac arrest.,12139551_0,0,-1,0,3755,0
3758,metoclopramide,8,9,53,67,We describe a patient where intravenous injection of metoclopramide was immediately followed by asystole repeatedly.,12139551_1,0,-1,0,3758,0
3759,metoclopramide,3,4,21,35,The patient received metoclopramide 10 mg i.v.,12139551_2,0,-1,0,3759,0
3761,metoclopramide,23,24,146,160,"five times during 48 h. After interviewing the attending nurses and reviewing the written documentation, it is clear that every administration of metoclopramide was immediately (within s) followed by asystole.",12139551_3,0,-1,0,3761,0
3765,metoclopramide,10,11,58,72,We interpret this as episodes of cardiac arrest caused by metoclopramide.,12139551_6,0,-1,0,3765,0
3770,nitric oxide,6,8,47,59,"Immunohistochemical study on inducible type of nitric oxide (iNOS), basic fibroblast growth factor (bFGF) and tumor growth factor-beta1 (TGF-beta1) in arteritis induced in rats by fenoldopam and theophylline, vasodilators.",12180796_0,0,-1,0,3770,0
3772,fibroblast growth factor,13,16,74,98,"Immunohistochemical study on inducible type of nitric oxide (iNOS), basic fibroblast growth factor (bFGF) and tumor growth factor-beta1 (TGF-beta1) in arteritis induced in rats by fenoldopam and theophylline, vasodilators.",12180796_0,0,-1,0,3772,0
3774,TGF-beta1,24,25,137,146,"Immunohistochemical study on inducible type of nitric oxide (iNOS), basic fibroblast growth factor (bFGF) and tumor growth factor-beta1 (TGF-beta1) in arteritis induced in rats by fenoldopam and theophylline, vasodilators.",12180796_0,0,-1,0,3774,0
3775,fenoldopam,32,33,180,190,"Immunohistochemical study on inducible type of nitric oxide (iNOS), basic fibroblast growth factor (bFGF) and tumor growth factor-beta1 (TGF-beta1) in arteritis induced in rats by fenoldopam and theophylline, vasodilators.",12180796_0,0,-1,0,3775,0
3776,fenoldopam,7,8,43,53,"Arteritis induced in rats by vasodilators, fenoldopam and theophylline, was examined immunohistochemically for expressions of inducible type of nitric oxide synthase (iNOS), basic fibroblast growth factor (bFGF) and tumor growth factor-beta1 (TGF-beta1).",12180796_1,0,-1,0,3776,0
3781,fibroblast growth factor,28,31,180,204,"Arteritis induced in rats by vasodilators, fenoldopam and theophylline, was examined immunohistochemically for expressions of inducible type of nitric oxide synthase (iNOS), basic fibroblast growth factor (bFGF) and tumor growth factor-beta1 (TGF-beta1).",12180796_1,0,-1,0,3781,0
3783,TGF-beta1,39,40,243,252,"Arteritis induced in rats by vasodilators, fenoldopam and theophylline, was examined immunohistochemically for expressions of inducible type of nitric oxide synthase (iNOS), basic fibroblast growth factor (bFGF) and tumor growth factor-beta1 (TGF-beta1).",12180796_1,0,-1,0,3783,0
3784,fenoldopam,3,4,23,33,Rats were administered fenoldopam for 24 hours by intravenous infusion with or without following repeated daily oral administrations of theophylline.,12180796_2,0,-1,0,3784,0
3794,TGF-beta1,37,38,232,241,"Irrespective of theophylline administration, iNOS antigens were remarkably abundant in ED-1-positive cells on day 5 and 8 post-fenoldopam-infusion (DPI); bFGF antigens were remarkably abundant in ED-1-positive cells on 1 and 3 DPI; TGF-beta1 antigens were observed in ED-1-positive cells on and after 5 DPI.",12180796_3,0,-1,0,3794,0
3803,TGF-beta1,5,6,19,28,"On the other hand, TGF-beta1 was not considered to have a suppressive effect on iNOS expression in these models.",12180796_5,0,-1,0,3803,0
3812,cholinergic agents,19,21,140,158,"BACKGROUND: The septo-hippocampal cholinergic pathway has been implicated in epileptogenesis, and genetic factors influence the response to cholinergic agents, but limited data are available on cholinergic involvement in alcohol withdrawal severity.",12198388_1,0,-1,0,3812,0
3819,carbachol,5,6,36,45,"Animals were administered nicotine, carbachol, or neostigmine via timed tail vein infusion, and the latencies to onset of tremor and clonus were recorded and converted to threshold dose.",12198388_4,0,-1,0,3819,0
3826,carbachol,11,12,74,83,"RESULTS: Sensitivity to several convulsion endpoints induced by nicotine, carbachol, and neostigmine were significantly greater in WSR versus WSP mice.",12198388_8,0,-1,0,3826,0
3875,receptor 1,13,15,70,80,"The aim of the present study was to find out whether the metabotropic receptor 1 (mGluR1) and group II mGluRs, localized in the striatum, are involved in antiparkinsonian-like effects in rats.",12231232_1,0,-1,0,3875,0
3877,group II,19,21,94,102,"The aim of the present study was to find out whether the metabotropic receptor 1 (mGluR1) and group II mGluRs, localized in the striatum, are involved in antiparkinsonian-like effects in rats.",12231232_1,0,-1,0,3877,0
3880,(1,1,3,12,14,"Haloperidol (1 mg/kg ip) induced parkinsonian-like muscle rigidity, measured as an increased resistance of a rat's hind foot to passive flexion and extension at the ankle joint.",12231232_2,0,-1,0,3880,0
3890,group II,33,35,216,224,"(RS)-1-aminoindan-1,5-dicarboxylic acid (AIDA; 0.5-15 microg/0.5 microl), a potent and selective mGluR1 antagonist, or (2R,4R)-4-aminopyrrolidine-2,4-dicarboxylate (2R,4R-APDC; 7.5-15 microg/0.5 microl), a selective group II agonist, was injected bilaterally into the striatum of haloperidol-treated animals.",12231232_3,0,-1,0,3890,0
3897,group II,17,19,97,105,"The present results may suggest that the blockade of striatal mGluR1, but not the stimulation of group II mGluRs, may ameliorate parkinsonian muscle rigidity.",12231232_6,0,-1,0,3897,0
3901,receptor ligands,3,5,18,34,Effects of 5-HT1B receptor ligands microinjected into the accumbal shell or core on the cocaine-induced locomotor hyperactivity in rats.,12369736_0,0,-1,0,3901,0
3905,receptor ligands,11,13,63,79,The present study was designed to examine the effect of 5-HT1B receptor ligands microinjected into the subregions of the nucleus accumbens (the shell and the core) on the locomotor hyperactivity induced by cocaine in rats.,12369736_1,0,-1,0,3905,0
3915,CP,31,32,176,178,"Male Wistar rats were implanted bilaterally with cannulae into the accumbens shell or core, and then were locally injected with GR 55562 (an antagonist of 5-HT1B receptors) or CP 93129 (an agonist of 5-HT1B receptors).",12369736_2,0,-1,0,3915,0
3919,CP,16,17,72,74,"Given alone to any accumbal subregion, GR 55562 (0.1-10 microg/side) or CP 93129 (0.1-10 microg/side) did not change basal locomotor activity.",12369736_3,0,-1,0,3919,0
3929,CP,15,16,74,76,"When injected into the accumbens shell (but not the core) before cocaine, CP 93129 (0.1-10 microg/side) enhanced the locomotor response to cocaine; the maximum effect being observed after 10 microg/side of the agonist.",12369736_7,0,-1,0,3929,0
3936,(1,12,14,89,91,The later enhancement was attenuated after intra-accumbens shell treatment with GR 55562 (1 microg/side).,12369736_8,0,-1,0,3936,0
3938,receptor ligands,11,13,81,97,"Our findings indicate that cocaine induced hyperlocomotion is modified by 5-HT1B receptor ligands microinjected into the accumbens shell, but not core, this modification consisting in inhibitory and facilitatory effects of the 5-HT1B receptor antagonist (GR 55562) and agonist (CP 93129), respectively.",12369736_9,0,-1,0,3938,0
3941,receptor antagonist,34,36,234,253,"Our findings indicate that cocaine induced hyperlocomotion is modified by 5-HT1B receptor ligands microinjected into the accumbens shell, but not core, this modification consisting in inhibitory and facilitatory effects of the 5-HT1B receptor antagonist (GR 55562) and agonist (CP 93129), respectively.",12369736_9,0,-1,0,3941,0
3943,CP,43,44,278,280,"Our findings indicate that cocaine induced hyperlocomotion is modified by 5-HT1B receptor ligands microinjected into the accumbens shell, but not core, this modification consisting in inhibitory and facilitatory effects of the 5-HT1B receptor antagonist (GR 55562) and agonist (CP 93129), respectively.",12369736_9,0,-1,0,3943,0
3962,angiogenic factor,24,26,150,167,"OBJECTIVES: To evaluate the toxicity and activity of thalidomide in patients with advanced metastatic renal cell cancer and to measure changes of one angiogenic factor, vascular endothelial growth factor (VEGF)165, with therapy.",12448656_1,0,-1,0,3962,0
3963,vascular endothelial growth factor,27,31,169,203,"OBJECTIVES: To evaluate the toxicity and activity of thalidomide in patients with advanced metastatic renal cell cancer and to measure changes of one angiogenic factor, vascular endothelial growth factor (VEGF)165, with therapy.",12448656_1,0,-1,0,3963,0
3965,IL-2,10,11,62,66,Fifty-nine per cent of patients had had previous therapy with IL-2 and 52% were performance status 2 or 3.,12448656_4,0,-1,0,3965,0
3974,low level,8,10,48,57,CONCLUSION: These results are consistent with a low level of activity of thalidomide in renal cell carcinoma.,12448656_9,0,-1,0,3974,0
3988,rocuronium,41,42,190,200,"Group PS, the control group, received normal saline and succinylcholine 1.5 mg x kg(-1); Group LS, lidocaine 1.5 mg x kg(-1) and succinylcholine 1.5 mg x kg(-1); Group PR, normal saline and rocuronium 0.6 mg x kg(-1).",12452237_2,0,-1,0,3988,0
3993,rocuronium,20,21,101,111,"Anesthesia was induced with 5 mg.kg(-1) thiopental iv. followed by succinylcholine (Group PS, LS) or rocuronium (Group PR) for tracheal intubation.",12452237_4,0,-1,0,3993,0
4012,receptor agonist,6,8,39,55,Rizatriptan is a selective 5-HT(1B/1D) receptor agonist with rapid oral absorption and early onset of action in the acute treatment of migraine.,12464714_1,0,-1,0,4012,0
4050,sodium channel,1,3,8,22,"Reduced sodium channel density, altered voltage dependence of inactivation, and increased susceptibility to seizures in mice lacking sodium channel beta 2-subunits.",12481039_0,0,-1,0,4050,0
4051,sodium channel,19,21,133,147,"Reduced sodium channel density, altered voltage dependence of inactivation, and increased susceptibility to seizures in mice lacking sodium channel beta 2-subunits.",12481039_0,0,-1,0,4051,0
4052,Sodium channel,0,2,0,14,"Sodium channel beta-subunits modulate channel gating, assembly, and cell surface expression in heterologous cell systems.",12481039_1,0,-1,0,4052,0
4053,cell surface,10,12,68,80,"Sodium channel beta-subunits modulate channel gating, assembly, and cell surface expression in heterologous cell systems.",12481039_1,0,-1,0,4053,0
4055,beta2,10,11,56,61,"We generated beta2(-/-) mice to investigate the role of beta2 in control of sodium channel density, localization, and function in neurons in vivo.",12481039_2,0,-1,0,4055,0
4056,sodium channel,14,16,76,90,"We generated beta2(-/-) mice to investigate the role of beta2 in control of sodium channel density, localization, and function in neurons in vivo.",12481039_2,0,-1,0,4056,0
4061,beta2(-/-),20,22,128,138,Measurements of [(3)H]saxitoxin (STX) binding showed a significant reduction in the level of plasma membrane sodium channels in beta2(-/-) neurons.,12481039_3,0,-1,0,4061,0
4062,beta2,3,4,12,17,The loss of beta2 resulted in negative shifts in the voltage dependence of inactivation as well as significant decreases in sodium current density in acutely dissociated hippocampal neurons.,12481039_4,0,-1,0,4062,0
4075,sodium channel,13,15,86,100,Our observations show that beta2-subunits play an important role in the regulation of sodium channel density and function in neurons in vivo and are required for normal action potential generation and control of excitability.,12481039_8,0,-1,0,4075,0
4080,carboplatin,9,10,67,78,Severe ocular and orbital toxicity after intracarotid injection of carboplatin for recurrent glioblastomas.,12483326_0,0,-1,0,4080,0
4087,carboplatin,2,3,11,22,"Generally, carboplatin is said to have milder side effects than cisplatin, whose ocular and orbital toxicity are well known.",12483326_4,0,-1,0,4087,0
4089,cisplatin,11,12,64,73,"Generally, carboplatin is said to have milder side effects than cisplatin, whose ocular and orbital toxicity are well known.",12483326_4,0,-1,0,4089,0
4093,carboplatin,16,17,101,112,"However, we experienced a case of severe ocular and orbital toxicity after intracarotid injection of carboplatin, which is infrequently reported.",12483326_5,0,-1,0,4093,0
4095,carboplatin,10,11,62,73,CASE: A 58-year-old man received an intracarotid injection of carboplatin for recurrent glioblastomas in his left temporal lobe.,12483326_6,0,-1,0,4095,0
4099,carboplatin,7,8,47,58,Various ocular symptoms and findings caused by carboplatin toxicity were seen.,12483326_8,0,-1,0,4099,0
4110,carboplatin,7,8,54,65,"CONCLUSION: When performing intracarotid injection of carboplatin, we must be aware of its potentially blinding ocular toxicity.",12483326_12,0,-1,0,4110,0
4117,antiepileptic drug,4,6,31,49,Zonisamide is a broad-spectrum antiepileptic drug used to treat various types of seizures.,12523465_1,0,-1,0,4117,0
4132,vigabatrin,15,16,107,117,The authors present three patients with de novo absence epilepsy after administration of carbamazepine and vigabatrin.,12536034_1,0,-1,0,4132,0
4136,gamma-aminobutyric,1,2,4,22,The gamma-aminobutyric acid-transmitted thalamocortical circuitry accounts for a major part of the underlying neurophysiology of the absence epilepsy.,12536034_3,0,-1,0,4136,0
4148,bupropion,5,6,36,45,Acute liver failure with concurrent bupropion and carbimazole therapy.,12549952_0,0,-1,0,4148,0
4152,bupropion,16,17,94,103,OBJECTIVE: To report a case of fatal liver failure possibly associated with concurrent use of bupropion and carbimazole.,12549952_1,0,-1,0,4152,0
4157,propranolol,18,19,112,123,CASE SUMMARY: A 41-year-old Chinese man with a history of hyperthyroidism had been treated with carbimazole and propranolol for the past 5 years.,12549952_2,0,-1,0,4157,0
4158,bupropion,6,7,31,40,He received a 10-day course of bupropion as an aid for smoking cessation 10 weeks prior to presentation.,12549952_3,0,-1,0,4158,0
4167,bupropion,3,4,20,29,"The likelihood that bupropion induced hepatotoxicity in our patient was possible, based on the Naranjo probability scale.",12549952_8,0,-1,0,4167,0
4171,bupropion,11,12,79,88,"DISCUSSION: Although there is increasing evidence of hepatotoxicity induced by bupropion, this is the first case of fatality that could have resulted from acute liver failure in a patient receiving bupropion while on concomitant treatment with carbimazole.",12549952_9,0,-1,0,4171,0
4173,bupropion,32,33,198,207,"DISCUSSION: Although there is increasing evidence of hepatotoxicity induced by bupropion, this is the first case of fatality that could have resulted from acute liver failure in a patient receiving bupropion while on concomitant treatment with carbimazole.",12549952_9,0,-1,0,4173,0
4175,bupropion,15,16,92,101,CONCLUSIONS: Clinicians should be aware of the possibility of acute liver insult induced by bupropion given concurrently with other hepatotoxic drugs.,12549952_10,0,-1,0,4175,0
4203,iohexol,41,42,246,253,"METHODS: We conducted a randomized, double-blind, prospective, multicenter study comparing the nephrotoxic effects of an iso-osmolar, dimeric, nonionic contrast medium, iodixanol, with those of a low-osmolar, nonionic, monomeric contrast medium, iohexol.",12571256_3,0,-1,0,4203,0
4206,end point,2,4,12,21,The primary end point was the peak increase from base line in the creatinine concentration during the three days after angiography.,12571256_5,0,-1,0,4206,0
4209,creatinine,13,14,66,76,The primary end point was the peak increase from base line in the creatinine concentration during the three days after angiography.,12571256_5,0,-1,0,4209,0
4210,end points,1,3,6,16,"Other end points were an increase in the creatinine concentration of 0.5 mg per deciliter or more, an increase of 1.0 mg per deciliter or more, and a change in the creatinine concentration from day 0 to day 7.",12571256_6,0,-1,0,4210,0
4211,creatinine,8,9,41,51,"Other end points were an increase in the creatinine concentration of 0.5 mg per deciliter or more, an increase of 1.0 mg per deciliter or more, and a change in the creatinine concentration from day 0 to day 7.",12571256_6,0,-1,0,4211,0
4212,creatinine,33,34,164,174,"Other end points were an increase in the creatinine concentration of 0.5 mg per deciliter or more, an increase of 1.0 mg per deciliter or more, and a change in the creatinine concentration from day 0 to day 7.",12571256_6,0,-1,0,4212,0
4213,creatinine,3,4,13,23,RESULTS: The creatinine concentration increased significantly less in patients who received iodixanol.,12571256_7,0,-1,0,4213,0
4217,creatinine,12,13,47,57,"From day 0 to day 3, the mean peak increase in creatinine was 0.13 mg per deciliter in the iodixanol group and 0.55 mg per deciliter in the iohexol group (P=0.001; the increase with iodixanol minus the increase with iohexol, -0.42 mg per deciliter [95 percent confidence interval, -0.73 to -0.22]).",12571256_8,0,-1,0,4217,0
4219,iohexol,29,30,140,147,"From day 0 to day 3, the mean peak increase in creatinine was 0.13 mg per deciliter in the iodixanol group and 0.55 mg per deciliter in the iohexol group (P=0.001; the increase with iodixanol minus the increase with iohexol, -0.42 mg per deciliter [95 percent confidence interval, -0.73 to -0.22]).",12571256_8,0,-1,0,4219,0
4221,iohexol,42,43,216,223,"From day 0 to day 3, the mean peak increase in creatinine was 0.13 mg per deciliter in the iodixanol group and 0.55 mg per deciliter in the iohexol group (P=0.001; the increase with iodixanol minus the increase with iohexol, -0.42 mg per deciliter [95 percent confidence interval, -0.73 to -0.22]).",12571256_8,0,-1,0,4221,0
4224,(3,9,11,46,48,"Two of the 64 patients in the iodixanol group (3 percent) had an increase in the creatinine concentration of 0.5 mg per deciliter or more, as compared with 17 of the 65 patients in the iohexol group (26 percent) (P=0.002; odds ratio for such an increase in the iodixanol group, 0.09 [95 percent confidence interval, 0.02 to 0.41]).",12571256_9,0,-1,0,4224,0
4225,creatinine,18,19,81,91,"Two of the 64 patients in the iodixanol group (3 percent) had an increase in the creatinine concentration of 0.5 mg per deciliter or more, as compared with 17 of the 65 patients in the iohexol group (26 percent) (P=0.002; odds ratio for such an increase in the iodixanol group, 0.09 [95 percent confidence interval, 0.02 to 0.41]).",12571256_9,0,-1,0,4225,0
4226,iohexol,38,39,185,192,"Two of the 64 patients in the iodixanol group (3 percent) had an increase in the creatinine concentration of 0.5 mg per deciliter or more, as compared with 17 of the 65 patients in the iohexol group (26 percent) (P=0.002; odds ratio for such an increase in the iodixanol group, 0.09 [95 percent confidence interval, 0.02 to 0.41]).",12571256_9,0,-1,0,4226,0
4232,iohexol,20,21,103,110,"No patient receiving iodixanol had an increase of 1.0 mg per deciliter or more, but 10 patients in the iohexol group (15 percent) did.",12571256_10,0,-1,0,4232,0
4233,creatinine,5,6,23,33,"The mean change in the creatinine concentration from day 0 to day 7 was 0.07 mg per deciliter in the iodixanol group and 0.24 mg per deciliter in the iohexol group (P=0.003; value in the iodixanol group minus the value in the iohexol group, -0.17 mg per deciliter [95 percent confidence interval, -0.34 to -0.07]).",12571256_11,0,-1,0,4233,0
4235,iohexol,29,30,150,157,"The mean change in the creatinine concentration from day 0 to day 7 was 0.07 mg per deciliter in the iodixanol group and 0.24 mg per deciliter in the iohexol group (P=0.003; value in the iodixanol group minus the value in the iohexol group, -0.17 mg per deciliter [95 percent confidence interval, -0.34 to -0.07]).",12571256_11,0,-1,0,4235,0
4237,iohexol,44,45,226,233,"The mean change in the creatinine concentration from day 0 to day 7 was 0.07 mg per deciliter in the iodixanol group and 0.24 mg per deciliter in the iohexol group (P=0.003; value in the iodixanol group minus the value in the iohexol group, -0.17 mg per deciliter [95 percent confidence interval, -0.34 to -0.07]).",12571256_11,0,-1,0,4237,0
4264,cyclosporine A,9,11,73,87,"Kidney function and morphology after short-term combination therapy with cyclosporine A, tacrolimus and sirolimus in the rat.",12584269_0,0,-1,0,4264,0
4265,tacrolimus,12,13,89,99,"Kidney function and morphology after short-term combination therapy with cyclosporine A, tacrolimus and sirolimus in the rat.",12584269_0,0,-1,0,4265,0
4266,sirolimus,14,15,104,113,"Kidney function and morphology after short-term combination therapy with cyclosporine A, tacrolimus and sirolimus in the rat.",12584269_0,0,-1,0,4266,0
4267,Sirolimus,2,3,12,21,BACKGROUND: Sirolimus (SRL) may supplement calcineurin inhibitors in clinical organ transplantation.,12584269_1,0,-1,0,4267,0
4269,calcineurin,8,9,43,54,BACKGROUND: Sirolimus (SRL) may supplement calcineurin inhibitors in clinical organ transplantation.,12584269_1,0,-1,0,4269,0
4275,calcineurin,12,13,65,76,In a number of treatment protocols where SRL was combined with a calcineurin inhibitor indications of a synergistic nephrotoxic effect were described.,12584269_3,0,-1,0,4275,0
4280,cyclosporine A,26,28,161,175,"The aim of this study was to examine further the renal function, including morphological analysis of the kidneys of male Sprague-Dawley rats treated with either cyclosporine A (CsA), tacrolimus (FK506) or SRL as monotherapies or in different combinations.",12584269_4,0,-1,0,4280,0
4282,tacrolimus,32,33,183,193,"The aim of this study was to examine further the renal function, including morphological analysis of the kidneys of male Sprague-Dawley rats treated with either cyclosporine A (CsA), tacrolimus (FK506) or SRL as monotherapies or in different combinations.",12584269_4,0,-1,0,4282,0
4283,FK506,34,35,195,200,"The aim of this study was to examine further the renal function, including morphological analysis of the kidneys of male Sprague-Dawley rats treated with either cyclosporine A (CsA), tacrolimus (FK506) or SRL as monotherapies or in different combinations.",12584269_4,0,-1,0,4283,0
4287,FK506,17,18,67,72,"METHODS: For a period of 2 weeks, CsA 15 mg/kg/day (given orally), FK506 3.0 mg/kg/day (given orally) or SRL 0.4 mg/kg/day (given intraperitoneally) was administered once a day as these doses have earlier been found to achieve a significant immunosuppressive effect in Sprague-Dawley rats.",12584269_5,0,-1,0,4287,0
4301,FK506,4,5,14,19,"RESULTS: CsA, FK506 and SRL all significantly decreased the GFR.",12584269_8,0,-1,0,4301,0
4305,FK506,11,12,67,72,"A further deterioration was seen when CsA was combined with either FK506 or SRL, whereas the GFR remained unchanged in the group treated with FK506 plus SRL when compared with treatment with any of the single substances.",12584269_9,0,-1,0,4305,0
4309,FK506,25,26,142,147,"A further deterioration was seen when CsA was combined with either FK506 or SRL, whereas the GFR remained unchanged in the group treated with FK506 plus SRL when compared with treatment with any of the single substances.",12584269_9,0,-1,0,4309,0
4316,FK506,1,2,4,9,The FK506 plus SRL combination showed only a marginally higher degree of fibrosis as compared with controls (P=0.05).,12584269_12,0,-1,0,4316,0
4322,FK506,16,17,98,103,"CONCLUSION: This rat study demonstrated a synergistic nephrotoxic effect of CsA plus SRL, whereas FK506 plus SRL was better tolerated.",12584269_13,0,-1,0,4322,0
4324,troponin I,3,5,22,32,"Evaluation of cardiac troponin I and T levels as markers of myocardial damage in doxorubicin-induced cardiomyopathy rats, and their relationship with echocardiographic and histological findings.",12589964_0,0,-1,0,4324,0
4391,mAbs,22,23,135,139,"Although there was a discrepancy between the amount of cTnI and cTnT after DOX, probably due to heterogeneity in cross-reactivities of mAbs to various cTnI and cTnT forms, it is likely that cTnT in rats after DOX indicates cell damage determined by the magnitude of injury induced and that cTnT should be a useful marker for the prediction of experimentally induced cardiotoxicity and possibly for cardioprotective experiments.",12589964_22,0,-1,0,4391,0
4407,somatostatin,7,8,59,71,"Pulmonary hypertension developed after administration of a somatostatin analogue, octreotide, to enhance resolution of the fistula.",12596116_2,0,-1,0,4407,0
4408,octreotide,10,11,82,92,"Pulmonary hypertension developed after administration of a somatostatin analogue, octreotide, to enhance resolution of the fistula.",12596116_2,0,-1,0,4408,0
4411,edaravone,3,4,21,30,Protective effect of edaravone against streptomycin-induced vestibulotoxicity in the guinea pig.,12600698_0,0,-1,0,4411,0
4415,edaravone,8,9,81,90,This study investigated alleviation of streptomycin-induced vestibulotoxicity by edaravone in guinea pigs.,12600698_1,0,-1,0,4415,0
4417,Edaravone,0,1,0,9,"Edaravone, a free radical scavenger, has potent free radical quenching action and is used in clinical practice to treat cerebral infarction.",12600698_2,0,-1,0,4417,0
4424,edaravone,15,16,77,86,"Streptomycin was administered to the inner ear by osmotic pump for 24 h, and edaravone (n=8) or saline (n=6) was intraperitoneally injected once a day for 7 days.",12600698_3,0,-1,0,4424,0
4428,edaravone,12,13,89,98,Animals injected with saline showed statistically smaller gains than those injected with edaravone.,12600698_5,0,-1,0,4428,0
4429,edaravone,4,5,27,36,These results suggest that edaravone suppresses streptomycin-induced vestibulotoxicity.,12600698_6,0,-1,0,4429,0
4433,ethinyl estradiol,13,15,95,112,The risk of venous thromboembolism in women prescribed cyproterone acetate in combination with ethinyl estradiol: a nested cohort analysis and case-control study.,12615818_0,0,-1,0,4433,0
4437,ethinyl estradiol,6,8,46,63,BACKGROUND: Cyproterone acetate combined with ethinyl estradiol (CPA/EE) is licensed in the UK for the treatment of women with acne and hirsutism and is also a treatment option for polycystic ovary syndrome (PCOS).,12615818_1,0,-1,0,4437,0
4445,oral contraceptives,20,22,144,163,Previous studies have demonstrated an increased risk of venous thromboembolism (VTE) associated with CPA/EE compared with conventional combined oral contraceptives (COCs).,12615818_2,0,-1,0,4445,0
4486,creatinine,8,9,63,73,"Nephrotoxicity was assessed by measuring the concentrations of creatinine and urea in the plasma and reduced glutathione (GSH) in the kidney cortex, and by light microscopic examination of kidney sections.",12617329_3,0,-1,0,4486,0
4487,reduced glutathione,15,17,101,120,"Nephrotoxicity was assessed by measuring the concentrations of creatinine and urea in the plasma and reduced glutathione (GSH) in the kidney cortex, and by light microscopic examination of kidney sections.",12617329_3,0,-1,0,4487,0
4492,creatinine,13,14,96,106,"The results indicated that concomitant treatment with gum Arabic and GM significantly increased creatinine and urea by about 183 and 239%, respectively (compared to 432 and 346%, respectively, in rats treated with cellulose and GM), and decreased that of cortical GSH by 21% (compared to 27% in the cellulose plus GM group) The GM-induced proximal tubular necrosis appeared to be slightly less severe in rats given GM together with gum Arabic than in those given GM and cellulose.",12617329_4,0,-1,0,4492,0
4504,docetaxel,9,10,70,79,Increased frequency of venous thromboembolism with the combination of docetaxel and thalidomide in patients with metastatic androgen-independent prostate cancer.,12627929_0,0,-1,0,4504,0
4510,docetaxel,24,25,160,169,STUDY OBJECTIVE: To evaluate the frequency of venous thromboembolism (VTE) in patients with advanced androgen-independent prostate cancer who were treated with docetaxel alone or in combination with thalidomide.,12627929_1,0,-1,0,4510,0
4515,docetaxel,7,8,55,64,"INTERVENTION: Each patient received either intravenous docetaxel 30 mg/m2/week for 3 consecutive weeks, followed by 1 week off, or the combination of continuous oral thalidomide 200 mg every evening plus the same docetaxel regimen.",12627929_5,0,-1,0,4515,0
4518,docetaxel,35,36,213,222,"INTERVENTION: Each patient received either intravenous docetaxel 30 mg/m2/week for 3 consecutive weeks, followed by 1 week off, or the combination of continuous oral thalidomide 200 mg every evening plus the same docetaxel regimen.",12627929_5,0,-1,0,4518,0
4521,docetaxel,11,12,64,73,"MEASUREMENTS AND MAIN RESULTS: None of 23 patients who received docetaxel alone developed VTE, whereas 9 of 47 patients (19%) who received docetaxel plus thalidomide developed VTE (p=0.025).",12627929_7,0,-1,0,4521,0
4523,docetaxel,27,28,139,148,"MEASUREMENTS AND MAIN RESULTS: None of 23 patients who received docetaxel alone developed VTE, whereas 9 of 47 patients (19%) who received docetaxel plus thalidomide developed VTE (p=0.025).",12627929_7,0,-1,0,4523,0
4525,docetaxel,7,8,43,52,CONCLUSION: The addition of thalidomide to docetaxel in the treatment of prostate cancer significantly increases the frequency of VTE.,12627929_8,0,-1,0,4525,0
4533,ticlopidine,11,12,87,98,"CASE SUMMARIES: Two patients developed prolonged cholestatic hepatitis after receiving ticlopidine following percutaneous coronary angioplasty, with complete remission during the follow-up period.",12639165_2,0,-1,0,4533,0
4537,ticlopidine,6,7,51,62,"T-cell stimulation by therapeutic concentration of ticlopidine was demonstrated in vitro in the patients, but not in healthy controls.",12639165_3,0,-1,0,4537,0
4543,ticlopidine,7,8,57,68,"Our patients developed jaundice following treatment with ticlopidine and showed the clinical and laboratory characteristics of cholestatic hepatitis, which resolved after discontinuation of the drug.",12639165_5,0,-1,0,4543,0
4549,ticlopidine,17,18,106,117,An objective causality assessment revealed that the adverse drug event was probably related to the use of ticlopidine.,12639165_7,0,-1,0,4549,0
4557,ticlopidine,10,11,63,74,CONCLUSIONS: Cholestatic hepatitis is a rare adverse effect of ticlopidine that may be immune mediated.,12639165_10,0,-1,0,4557,0
4561,ticlopidine,12,13,68,79,This complication will be observed even less often in the future as ticlopidine is being replaced by the newer antiplatelet agent clopidogrel.,12639165_12,0,-1,0,4561,0
4563,Epithelial sodium channel,0,3,0,25,Epithelial sodium channel (ENaC) subunit mRNA and protein expression in rats with puromycin aminonucleoside-induced nephrotic syndrome.,12653683_0,0,-1,0,4563,0
4564,ENaC,4,5,27,31,Epithelial sodium channel (ENaC) subunit mRNA and protein expression in rats with puromycin aminonucleoside-induced nephrotic syndrome.,12653683_0,0,-1,0,4564,0
4565,puromycin,14,15,82,91,Epithelial sodium channel (ENaC) subunit mRNA and protein expression in rats with puromycin aminonucleoside-induced nephrotic syndrome.,12653683_0,0,-1,0,4565,0
4573,epithelial sodium channel,10,13,73,98,The rate-limiting constituent of collecting duct sodium transport is the epithelial sodium channel (ENaC).,12653683_3,0,-1,0,4573,0
4574,ENaC,14,15,100,104,The rate-limiting constituent of collecting duct sodium transport is the epithelial sodium channel (ENaC).,12653683_3,0,-1,0,4574,0
4575,ENaC,5,6,29,33,We examined the abundance of ENaC subunit mRNAs and proteins in puromycin aminonucleoside (PAN)-induced nephrotic syndrome.,12653683_4,0,-1,0,4575,0
4576,puromycin aminonucleoside,11,13,64,89,We examined the abundance of ENaC subunit mRNAs and proteins in puromycin aminonucleoside (PAN)-induced nephrotic syndrome.,12653683_4,0,-1,0,4576,0
4604,vigabatrin,6,7,39,49,Sub-chronic low dose gamma-vinyl GABA (vigabatrin) inhibits cocaine-induced increases in nucleus accumbens dopamine.,12684739_0,0,-1,0,4604,0
4609,novo,6,7,50,54,This non-receptor mediated inhibition requires de novo synthesis for restoration of functional GABA catabolism.,12684739_2,0,-1,0,4609,0
4616,low dose,33,35,209,217,"OBJECTIVES: Given its preclinical success for treating substance abuse and the increased risk of visual field defects (VFD) associated with cumulative lifetime exposure, we explored the effects of sub-chronic low dose GVG on cocaine-induced increases in nucleus accumbens (NAcc) dopamine (DA).",12684739_3,0,-1,0,4616,0
4624,low dose,5,7,25,33,"Finally, we examined the low dose of 150 mg/kg (50 mg/kg per day) using a similar washout period.",12684739_5,0,-1,0,4624,0
4629,low dose,3,5,25,33,"CONCLUSIONS: Sub-chronic low dose GVG potentiates and extends the inhibition of cocaine-induced increases in dopamine, effectively reducing cumulative exposures and the risk for VFDS.",12684739_7,0,-1,0,4629,0
4657,tacrolimus,27,28,180,190,Our objective was to investigate brain MR imaging findings and the utility of diffusion-weighted (DW) imaging in organ transplant patients who developed neurologic symptoms during tacrolimus therapy.,12695819_1,0,-1,0,4657,0
4661,tacrolimus,17,18,111,121,"Brain MR studies, including DW imaging, were prospectively performed in 14 organ transplant patients receiving tacrolimus who developed neurologic complications.",12695819_2,0,-1,0,4661,0
4677,L-arginine,0,1,0,10,L-arginine transport in humans with cortisol-induced hypertension.,12707296_0,0,-1,0,4677,0
4681,L-arginine,5,6,40,50,We investigate whether abnormalities in L-arginine uptake contribute to this deficiency.,12707296_2,0,-1,0,4681,0
4687,L-arginine,0,1,0,10,"L-arginine uptake was assessed in mononuclear cells incubated with L-arginine (1 to 300 micromol/L), incorporating 100 nmol/L [3H]-l-arginine for a period of 5 minutes at 37 degrees C. Forearm [3H]-L-arginine extraction was calculated after infusion of [3H]-L-arginine into the brachial artery at a rate of 100 nCi/min for 80 minutes.",12707296_7,0,-1,0,4687,0
4698,L-arginine,9,10,64,74,Deep forearm venous samples were collected for determination of L-arginine extraction.,12707296_8,0,-1,0,4698,0
4701,L-arginine,1,2,8,18,"Neither L-arginine transport into mononuclear cells (placebo vs active, 26.3+/-3.6 vs 29.0+/-2.1 pmol/10 000 cells per 5 minutes, respectively, at an l-arginine concentration of 300 micromol/L) nor L-arginine extraction in the forearm (at 80 minutes, placebo vs active, 1 868 904+/-434 962 vs 2 013 910+/-770 619 disintegrations per minute) was affected by cortisol treatment; ie, that L-arginine uptake is not affected by short-term cortisol treatment.",12707296_11,0,-1,0,4701,0
4703,l-arginine,25,26,150,160,"Neither L-arginine transport into mononuclear cells (placebo vs active, 26.3+/-3.6 vs 29.0+/-2.1 pmol/10 000 cells per 5 minutes, respectively, at an l-arginine concentration of 300 micromol/L) nor L-arginine extraction in the forearm (at 80 minutes, placebo vs active, 1 868 904+/-434 962 vs 2 013 910+/-770 619 disintegrations per minute) was affected by cortisol treatment; ie, that L-arginine uptake is not affected by short-term cortisol treatment.",12707296_11,0,-1,0,4703,0
4704,L-arginine,32,33,198,208,"Neither L-arginine transport into mononuclear cells (placebo vs active, 26.3+/-3.6 vs 29.0+/-2.1 pmol/10 000 cells per 5 minutes, respectively, at an l-arginine concentration of 300 micromol/L) nor L-arginine extraction in the forearm (at 80 minutes, placebo vs active, 1 868 904+/-434 962 vs 2 013 910+/-770 619 disintegrations per minute) was affected by cortisol treatment; ie, that L-arginine uptake is not affected by short-term cortisol treatment.",12707296_11,0,-1,0,4704,0
4705,L-arginine,68,69,386,396,"Neither L-arginine transport into mononuclear cells (placebo vs active, 26.3+/-3.6 vs 29.0+/-2.1 pmol/10 000 cells per 5 minutes, respectively, at an l-arginine concentration of 300 micromol/L) nor L-arginine extraction in the forearm (at 80 minutes, placebo vs active, 1 868 904+/-434 962 vs 2 013 910+/-770 619 disintegrations per minute) was affected by cortisol treatment; ie, that L-arginine uptake is not affected by short-term cortisol treatment.",12707296_11,0,-1,0,4705,0
4709,l-arginine,15,16,107,117,We conclude that cortisol-induced increases in blood pressure are not associated with abnormalities in the l-arginine transport system.,12707296_12,0,-1,0,4709,0
4724,low-dose,24,25,128,136,"Data suggest that this sensitive hemoglobin assay is useful for ICH detection, and that a model with a small ICH induced with a low-dose collagenase should be used for evaluation of drugs that may affect ICH.",12716030_6,0,-1,0,4724,0
4731,cold remedies,11,13,74,87,Phenylpropanolamine (PPA) is a sympathetic amine used in over-the-counter cold remedies and weight-control preparations worldwide.,12734532_1,0,-1,0,4731,0
4748,creatine kinase,5,7,37,52,Differential diagnosis of high serum creatine kinase levels in systemic lupus erythematosus.,12739036_0,0,-1,0,4748,0
4756,creatine kinase,7,9,37,52,"At the same time, slightly increased creatine kinase (CK) levels were noted.",12739036_4,0,-1,0,4756,0
4775,bupropion,7,8,64,73,Seizure associated with sleep deprivation and sustained-release bupropion.,12745515_0,0,-1,0,4775,0
4779,bupropion,10,11,83,92,This case report describes a generalized seizure associated with sustained-release bupropion use and sleep deprivation.,12745515_1,0,-1,0,4779,0
4784,bupropion,24,25,171,180,"The subject, a 31-year-old female smoker, was participating in a clinical trial evaluating an investigational medication for smoking cessation that used sustained-release bupropion as an active control.",12745515_2,0,-1,0,4784,0
4786,bupropion,4,5,17,26,"After 5 weeks of bupropion use, the subject experienced a generalized tonic clonic seizure after staying up nearly all night packing and moving to a new residence.",12745515_3,0,-1,0,4786,0
4795,kainic,9,10,73,79,Estrogens protect ovariectomized rats from hippocampal injury induced by kainic acid-induced status epilepticus (SE).,12757899_1,0,-1,0,4795,0
4820,interleukin-6,3,4,13,26,"In addition, interleukin-6 (IL-6) as an early marker of inflammation was assessed in a subgroup of 10 patients pretreated with saline.",12760988_7,0,-1,0,4820,0
4826,interleukin-6,14,15,100,113,"Furthermore, there was no significant relationship between postoperative myalgia and time course of interleukin-6 concentrations, a marker of inflammation.",12760988_11,0,-1,0,4826,0
4831,growth hormone,9,11,64,78,Acromegaly is an endocrine disorder caused by chronic excessive growth hormone secretion from the anterior pituitary gland.,12789195_1,0,-1,0,4831,0
4839,growth hormone,19,21,113,127,"Pseudoacromegaly, on the other hand, is the presence of similar acromegaloid features in the absence of elevated growth hormone or insulin-like growth factor levels.",12789195_3,0,-1,0,4839,0
4840,growth factor,23,25,144,157,"Pseudoacromegaly, on the other hand, is the presence of similar acromegaloid features in the absence of elevated growth hormone or insulin-like growth factor levels.",12789195_3,0,-1,0,4840,0
4853,leuprolide acetate,5,7,27,45,"All patients received CAB [leuprolide acetate (LHRH-A) 3.75 mg, intramuscularly, every 28 days plus 250 mg flutamide, tid, per Os] and were evaluated for anemia by physical examination and laboratory tests at baseline and 4 subsequent intervals (1, 2, 3 and 6 months post-CAB).",12820454_3,0,-1,0,4853,0
4855,flutamide,21,22,107,116,"All patients received CAB [leuprolide acetate (LHRH-A) 3.75 mg, intramuscularly, every 28 days plus 250 mg flutamide, tid, per Os] and were evaluated for anemia by physical examination and laboratory tests at baseline and 4 subsequent intervals (1, 2, 3 and 6 months post-CAB).",12820454_3,0,-1,0,4855,0
4858,(1,45,47,245,247,"All patients received CAB [leuprolide acetate (LHRH-A) 3.75 mg, intramuscularly, every 28 days plus 250 mg flutamide, tid, per Os] and were evaluated for anemia by physical examination and laboratory tests at baseline and 4 subsequent intervals (1, 2, 3 and 6 months post-CAB).",12820454_3,0,-1,0,4858,0
4859,D2,3,4,20,22,"Patients with stage D2-3 disease, abnormal hemoglobin level or renal and liver function tests that were higher than the upper limits were excluded from the study.",12820454_5,0,-1,0,4859,0
4884,(3,11,13,85,87,Severe and clinically evident anemia was easily corrected by subcutaneous injections (3 times/week for 1 month) of recombinant erythropoietin (rHuEPO-beta).,12820454_13,0,-1,0,4884,0
4892,P450,12,13,73,77,Effect of lindane on hepatic and brain cytochrome P450s and influence of P450 modulation in lindane induced neurotoxicity.,12842176_0,0,-1,0,4892,0
4897,P450,31,32,147,151,"Oral administration of lindane (2.5, 5, 10 and 15 mg/kg, body weight) for 5 days was found to produce a dose-dependent increase in the activity of P450 dependent 7-ethoxyresorufin-O-deethylase (EROD), 7-pentoxyresorufin-O-dealkylase (PROD) and N-nitrosodimethylamine demethylase (NDMA-d) in rat brain and liver.",12842176_1,0,-1,0,4897,0
4900,demethylase,44,45,267,278,"Oral administration of lindane (2.5, 5, 10 and 15 mg/kg, body weight) for 5 days was found to produce a dose-dependent increase in the activity of P450 dependent 7-ethoxyresorufin-O-deethylase (EROD), 7-pentoxyresorufin-O-dealkylase (PROD) and N-nitrosodimethylamine demethylase (NDMA-d) in rat brain and liver.",12842176_1,0,-1,0,4900,0
4904,low dose,19,21,119,127,A significant increase in the hepatic and brain P450 monooxygenases was also observed when the duration of exposure of low dose (2.5 mg/kg) of lindane was increased from 5 days to 15 or 21 days.,12842176_2,0,-1,0,4904,0
4908,P450 enzymes,10,12,65,77,"Western blotting studies have indicated that the increase in the P450 enzymes could be due to the increase in the expression of P450 1A1/1A2, 2B1/2B2 and 2E1 isoenzymes.",12842176_4,0,-1,0,4908,0
4909,P450,22,23,128,132,"Western blotting studies have indicated that the increase in the P450 enzymes could be due to the increase in the expression of P450 1A1/1A2, 2B1/2B2 and 2E1 isoenzymes.",12842176_4,0,-1,0,4909,0
4911,isoenzymes,28,29,158,168,"Western blotting studies have indicated that the increase in the P450 enzymes could be due to the increase in the expression of P450 1A1/1A2, 2B1/2B2 and 2E1 isoenzymes.",12842176_4,0,-1,0,4911,0
4918,P450,39,40,244,248,"In vitro studies using organic inhibitors specific for individual P450 isoenzymes and antibody inhibition experiments have further demonstrated that the increase in the activity of PROD, EROD and NDMA-d are due to the increase in the levels of P450 2B1/2B2, 1A1/1A2 and 2E1 isoenzymes, respectively.",12842176_5,0,-1,0,4918,0
4920,isoenzymes,45,46,274,284,"In vitro studies using organic inhibitors specific for individual P450 isoenzymes and antibody inhibition experiments have further demonstrated that the increase in the activity of PROD, EROD and NDMA-d are due to the increase in the levels of P450 2B1/2B2, 1A1/1A2 and 2E1 isoenzymes, respectively.",12842176_5,0,-1,0,4920,0
4926,P450,43,44,258,262,"Induction studies have further shown that while pretreatment of 3-methylcholanthrene (MC), an inducer of P4501A1/1A2, did not produce any significant effect in the incidence of lindane induced convulsions, pretreatment with phenobarbital (PB), an inducer of P450 2B1/2B2 or ethanol, an inducer of P450 2E1 catalysed reactions, significantly increased the incidence of lindane induced convulsions.",12842176_6,0,-1,0,4926,0
4927,P450,51,52,297,301,"Induction studies have further shown that while pretreatment of 3-methylcholanthrene (MC), an inducer of P4501A1/1A2, did not produce any significant effect in the incidence of lindane induced convulsions, pretreatment with phenobarbital (PB), an inducer of P450 2B1/2B2 or ethanol, an inducer of P450 2E1 catalysed reactions, significantly increased the incidence of lindane induced convulsions.",12842176_6,0,-1,0,4927,0
4937,ethinylestradiol,14,15,102,118,Absolute and attributable risk of venous thromboembolism in women on combined cyproterone acetate and ethinylestradiol.,12851669_0,0,-1,0,4937,0
4941,ethinylestradiol,19,20,118,134,"OBJECTIVE: To achieve absolute risk estimates of venous thromboembolism (VTE) among women on cyproterone acetate plus ethinylestradiol (CPA/EE), and among women on combined oral contraceptives (COCs).",12851669_1,0,-1,0,4941,0
4943,oral contraceptives,29,31,173,192,"OBJECTIVE: To achieve absolute risk estimates of venous thromboembolism (VTE) among women on cyproterone acetate plus ethinylestradiol (CPA/EE), and among women on combined oral contraceptives (COCs).",12851669_1,0,-1,0,4943,0
4968,acetylsalicylic acid,7,9,51,71,Comparison of developmental toxicology of aspirin (acetylsalicylic acid) in rats using selected dosing paradigms.,12852481_0,0,-1,0,4968,0
4969,nonsteroidal anti-inflammatory,7,9,43,73,BACKGROUND: Analysis of the literature for nonsteroidal anti-inflammatory drugs (NSAIDs) suggests that a low incidence of developmental anomalies occurs in rats given NSAIDs on specific days during organogenesis.,12852481_1,0,-1,0,4969,0
4971,acetylsalicylic acid,2,4,9,29,"Aspirin (acetylsalicylic acid [ASA]), an irreversible cyclooxygenase 1 and 2 inhibitor, induces developmental anomalies when administered to Wistar rats on gestational day (GD) 9, 10, or 11 (Kimmel CA, Wilson JG, Schumacher HJ.",12852481_2,0,-1,0,4971,0
5019,flumazenil,6,7,46,56,Reversal of central benzodiazepine effects by flumazenil after intravenous conscious sedation with diazepam and opioids: report of a double-blind multicenter study.,1286498_0,0,-1,0,5019,0
5021,opioids,14,15,112,119,Reversal of central benzodiazepine effects by flumazenil after intravenous conscious sedation with diazepam and opioids: report of a double-blind multicenter study.,1286498_0,0,-1,0,5021,0
5023,Flumazenil,1,2,4,14,"The Flumazenil in Intravenous Conscious Sedation with Diazepam Multicenter Study Group II.The efficacy and safety of a new benzodiazepine antagonist, flumazenil, were assessed in a double-blind multicenter study.",1286498_1,0,-1,0,5023,0
5025,flumazenil,21,22,150,160,"The Flumazenil in Intravenous Conscious Sedation with Diazepam Multicenter Study Group II.The efficacy and safety of a new benzodiazepine antagonist, flumazenil, were assessed in a double-blind multicenter study.",1286498_1,0,-1,0,5025,0
5027,Flumazenil,0,1,0,10,"Flumazenil (mean dose, 0.76 mg) or placebo (mean dose, 8.9 ml) was administered intravenously to 130 and 67 patients, respectively, who had been given diazepam in conjunction with an opioid (fentanyl, meperidine, or morphine) for the induction and maintenance of intravenous conscious sedation for diagnostic or therapeutic surgical procedures.",1286498_2,0,-1,0,5027,0
5034,flumazenil,10,11,70,80,The group assessable for efficacy comprised 122 patients treated with flumazenil and 64 patients given placebo.,1286498_3,0,-1,0,5034,0
5043,Flumazenil,0,1,0,10,"Flumazenil was well tolerated, with no serious adverse effects reported.",1286498_7,0,-1,0,5043,0
5051,flumazenil,11,12,64,74,The most common adverse effects were nausea and vomiting in the flumazenil group and nausea and injection-site pain in the placebo group.,1286498_9,0,-1,0,5051,0
5053,Flumazenil,0,1,0,10,Flumazenil was found to promptly reverse sedation induced by diazepam in the presence of opioids.,1286498_10,0,-1,0,5053,0
5055,opioids,14,15,89,96,Flumazenil was found to promptly reverse sedation induced by diazepam in the presence of opioids.,1286498_10,0,-1,0,5055,0
5083,mGluR5,7,8,44,50,"Neuroprotective action of MPEP, a selective mGluR5 antagonist, in methamphetamine-induced dopaminergic neurotoxicity is associated with a decrease in dopamine outflow and inhibition of hyperthermia in rats.",12907309_0,0,-1,0,5083,0
5087,metabotropic glutamate receptor 5,11,15,49,82,The aim of this study was to examine the role of metabotropic glutamate receptor 5 (mGluR5) in the toxic action of methamphetamine on dopaminergic neurones in rats.,12907309_1,0,-1,0,5087,0
5088,mGluR5,16,17,84,90,The aim of this study was to examine the role of metabotropic glutamate receptor 5 (mGluR5) in the toxic action of methamphetamine on dopaminergic neurones in rats.,12907309_1,0,-1,0,5088,0
5089,toxic action,20,22,99,111,The aim of this study was to examine the role of metabotropic glutamate receptor 5 (mGluR5) in the toxic action of methamphetamine on dopaminergic neurones in rats.,12907309_1,0,-1,0,5089,0
5090,dopaminergic,25,26,134,146,The aim of this study was to examine the role of metabotropic glutamate receptor 5 (mGluR5) in the toxic action of methamphetamine on dopaminergic neurones in rats.,12907309_1,0,-1,0,5090,0
5093,mGluR5,4,5,26,32,"A selective antagonist of mGluR5, 2-methyl-6-(phenylethynyl)pyridine (MPEP; 5 mg/kg ip), when administered five times immediately before each methamphetamine injection reversed the above-mentioned methamphetamine effects.",12907309_3,0,-1,0,5093,0
5101,mGluR5,10,11,55,61,The results of this study suggest that the blockade of mGluR5 by MPEP may protect dopaminergic neurones against methamphetamine-induced toxicity.,12907309_7,0,-1,0,5101,0
5103,dopaminergic,15,16,82,94,The results of this study suggest that the blockade of mGluR5 by MPEP may protect dopaminergic neurones against methamphetamine-induced toxicity.,12907309_7,0,-1,0,5103,0
5109,mGluR5,24,25,170,176,"Neuroprotection rendered by MPEP may be associated with the reduction of the methamphetamine-induced dopamine efflux in the striatum due to the blockade of extrastriatal mGluR5, and with a decrease in hyperthermia.",12907309_8,0,-1,0,5109,0
5138,gamma-aminobutyric acid,18,20,125,148,The present study was designed to evaluate two endogenous and one synthetic neuroactive steroid that positively modulate the gamma-aminobutyric acid (GABA(A)) receptor against the increase in sensitivity to the convulsant effects of cocaine engendered by repeated cocaine administration (seizure kindling).,12921865_3,0,-1,0,5138,0
5139,GABA(A)) receptor,21,25,150,167,The present study was designed to evaluate two endogenous and one synthetic neuroactive steroid that positively modulate the gamma-aminobutyric acid (GABA(A)) receptor against the increase in sensitivity to the convulsant effects of cocaine engendered by repeated cocaine administration (seizure kindling).,12921865_3,0,-1,0,5139,0
5140,convulsant effects,32,34,211,229,The present study was designed to evaluate two endogenous and one synthetic neuroactive steroid that positively modulate the gamma-aminobutyric acid (GABA(A)) receptor against the increase in sensitivity to the convulsant effects of cocaine engendered by repeated cocaine administration (seizure kindling).,12921865_3,0,-1,0,5140,0
5143,Allopregnanolone,0,1,0,16,"Allopregnanolone (3alpha-hydroxy-5alpha-pregnan-20-one), pregnanolone (3alpha-hydroxy-5beta-pregnan-20-one) and ganaxolone (a synthetic derivative of allopregnanolone 3alpha-hydroxy-3beta-methyl-5alpha-pregnan-20-one) were tested for their ability to suppress the expression (anticonvulsant effect) and development (antiepileptogenic effect) of cocaine-kindled seizures in male, Swiss-Webster mice.",12921865_4,0,-1,0,5143,0
5145,pregnanolone,5,6,57,69,"Allopregnanolone (3alpha-hydroxy-5alpha-pregnan-20-one), pregnanolone (3alpha-hydroxy-5beta-pregnan-20-one) and ganaxolone (a synthetic derivative of allopregnanolone 3alpha-hydroxy-3beta-methyl-5alpha-pregnan-20-one) were tested for their ability to suppress the expression (anticonvulsant effect) and development (antiepileptogenic effect) of cocaine-kindled seizures in male, Swiss-Webster mice.",12921865_4,0,-1,0,5145,0
5149,allopregnanolone,16,17,150,166,"Allopregnanolone (3alpha-hydroxy-5alpha-pregnan-20-one), pregnanolone (3alpha-hydroxy-5beta-pregnan-20-one) and ganaxolone (a synthetic derivative of allopregnanolone 3alpha-hydroxy-3beta-methyl-5alpha-pregnan-20-one) were tested for their ability to suppress the expression (anticonvulsant effect) and development (antiepileptogenic effect) of cocaine-kindled seizures in male, Swiss-Webster mice.",12921865_4,0,-1,0,5149,0
5153,modulators,6,7,30,40,"All of these positive GABA(A) modulators suppressed the expression of kindled seizures, whereas only allopregnanolone and ganaxolone inhibited the development of kindling.",12921865_6,0,-1,0,5153,0
5154,allopregnanolone,16,17,101,117,"All of these positive GABA(A) modulators suppressed the expression of kindled seizures, whereas only allopregnanolone and ganaxolone inhibited the development of kindling.",12921865_6,0,-1,0,5154,0
5156,Allopregnanolone,0,1,0,16,"Allopregnanolone and pregnanolone, but not ganaxolone, also reduced cumulative lethality associated with kindling.",12921865_7,0,-1,0,5156,0
5157,pregnanolone,2,3,21,33,"Allopregnanolone and pregnanolone, but not ganaxolone, also reduced cumulative lethality associated with kindling.",12921865_7,0,-1,0,5157,0
5161,convulsant,8,9,68,78,These findings demonstrate that some neuroactive steroids attenuate convulsant and sensitizing properties of cocaine and add to a growing literature on their potential use in the modulation of effects of drugs of abuse.,12921865_8,0,-1,0,5161,0
5164,radiocontrast,6,7,46,59,Potential deleterious effect of furosemide in radiocontrast nephropathy.,1300436_0,0,-1,0,5164,0
5166,radiocontrast,21,22,124,137,The purpose of the study was to determine the efficacy of furosemide in addition to intravenous fluids in the prevention of radiocontrast nephropathy.,1300436_1,0,-1,0,5166,0
5167,radiocontrast,6,7,27,40,"18 patients, referred to a radiocontrast study, considered at risk because of preexisting renal insufficiency, were enrolled in a prospective, randomized, controlled trial, performed at the secondary care center of a 1,100-bed private university hospital.",1300436_2,0,-1,0,5167,0
5174,contrast material,24,26,129,146,"In addition to fluids, the treatment group received furosemide (mean dose 110 mg) intravenously 30 min prior to the injection of contrast material.",1300436_3,0,-1,0,5174,0
5177,contrast material,11,13,87,104,"Radiological studies were mostly angiographies performed with both ionic and non-ionic contrast material, at an average dose of 245 ml.",1300436_5,0,-1,0,5177,0
5192,radiocontrast,8,9,51,64,Furosemide may be deleterious in the prevention of radiocontrast nephropathy.,1300436_8,0,-1,0,5192,0
5193,Progestational agents,0,2,0,21,Progestational agents and blood coagulation.,133615_0,0,-1,0,5193,0
5196,oral contraceptive,5,7,42,60,Thromboembolic and other complications of oral contraceptive therapy in relationship to pretreatment levels of blood coagulation factors: summary report of a ten-year study.,133615_2,0,-1,0,5196,0
5201,oral contraceptives,21,23,119,138,"During a ten-year period, 348 women were studied for a total of 5,877 patient months in four separate studies relating oral contraceptives to changes in hematologic parameters.",133615_3,0,-1,0,5201,0
5208,blood group,9,11,38,49,All four patients were of the A or AB blood group.,133615_11,0,-1,0,5208,0
5213,oral contraceptive,19,21,109,127,It appears from these data that hematologic work-ups may be useful in women who are about to start long-term oral contraceptive therapy.,133615_13,0,-1,0,5213,0
5224,(3,35,37,163,165,2. Conscious SHR (male 300-350 g) were subjected to 90 degrees head-up tilts for 60 s following acute administration of prazosin (0.1 mg kg-1 i.p.) or rauwolscine (3 mg kg-1 i.v.).,1355091_2,0,-1,0,5224,0
5250,(3,5,7,42,44,"Conversely, administration of rauwolscine (3 mg kg-1 i.v.) in chronic prazosin treated SHR decreased the basal MAP by 12-31% (n = 4), and subsequent tilts induced further drops of MAP by 19-23% in these rats.",1355091_9,0,-1,0,5250,0
5257,(1,26,28,142,144,"4. The pressor responses and bradycardia to the alpha 1-agonist cirazoline (0.6 and 2 micrograms kg-1 i.v.), the alpha 2-agonist Abbott-53693 (1 and 3 micrograms kg-1 i.v.), and noradrenaline (0.1 and 1.0 micrograms kg-1 i.v.) were determined in conscious SHR with and without chronic prazosin pretreatment.",1355091_10,0,-1,0,5257,0
5272,modulators,3,4,18,28,Effect of humoral modulators of morphine-induced increase in locomotor activity of mice.,137340_0,0,-1,0,5272,0
5275,modulators,4,5,22,32,The effect of humoral modulators on the morphine-induced increase in locomotor activity of mice was studied.,137340_1,0,-1,0,5275,0
5282,methscopolamine,4,5,18,33,"In contrast, both methscopolamine and neostigmine, which do not penetrate the blood-brain barrier, had no effect on the hyperactivity produced by morphine.",137340_4,0,-1,0,5282,0
5286,alpha-methyltyrosine,4,5,26,46,"Pretreatment of mice with alpha-methyltyrosine (20 mg/kg i.p., one hour), an inhibitor of tyrosine hydroxylase, significantly decreased the activity-increasing effects of morphine.",137340_5,0,-1,0,5286,0
5323,creatinine,18,19,109,119,HP failed to accentuante progression of renal failure and in fact tended to increase GFR and decrease plasma creatinine levels in lithium pretreated rats.,1378968_7,0,-1,0,5323,0
5347,dipyridamole,13,14,72,84,"Treatment has included use of plasma exchange, prednisone, aspirin, and dipyridamole.",1415380_4,0,-1,0,5347,0
5353,fusidic acid,6,8,34,46,Treatment of Crohn's disease with fusidic acid: an antibiotic with immunosuppressive properties similar to cyclosporin.,1420741_0,0,-1,0,5353,0
5355,cyclosporin,16,17,107,118,Treatment of Crohn's disease with fusidic acid: an antibiotic with immunosuppressive properties similar to cyclosporin.,1420741_0,0,-1,0,5355,0
5356,Fusidic acid,0,2,0,12,Fusidic acid is an antibiotic with T-cell specific immunosuppressive effects similar to those of cyclosporin.,1420741_1,0,-1,0,5356,0
5359,cyclosporin,14,15,97,108,Fusidic acid is an antibiotic with T-cell specific immunosuppressive effects similar to those of cyclosporin.,1420741_1,0,-1,0,5359,0
5364,fusidic acid,27,29,161,173,"Because of the need for the development of new treatments for Crohn's disease, a pilot study was undertaken to estimate the pharmacodynamics and tolerability of fusidic acid treatment in chronic active, therapy-resistant patients.",1420741_2,0,-1,0,5364,0
5368,Fusidic acid,0,2,0,12,Fusidic acid was administered orally in a dose of 500 mg t.d.s. and the treatment was planned to last 8 weeks.,1420741_4,0,-1,0,5368,0
5370,fusidic acid,10,12,41,53,Five of 8 patients (63%) improved during fusidic acid treatment: 3 at two weeks and 2 after four weeks.,1420741_6,0,-1,0,5370,0
5375,fusidic acid,8,10,45,57,The results of this pilot study suggest that fusidic acid may be of benefit in selected chronic active Crohn's disease patients in whom conventional treatment is ineffective.,1420741_10,0,-1,0,5375,0
5378,fusidic acid,12,14,67,79,"Because there seems to exist a scientific rationale for the use of fusidic acid at the cytokine level in inflammatory bowel disease, we suggest that the role of this treatment should be further investigated.",1420741_11,0,-1,0,5378,0
5381,propranolol,4,5,34,45,Amnestic syndrome associated with propranolol toxicity: a case report.,1423339_0,0,-1,0,5381,0
5383,propranolol,12,13,78,89,An elderly woman developed an Alzheimer-like subacute dementia as a result of propranolol toxicity.,1423339_1,0,-1,0,5383,0
5394,betaxolol,24,25,147,156,We performed a preliminary study in order to determine any difference between a non selective beta-blocker (timolol) and a selective beta-blocker (betaxolol) regarding CNS side effects.,1428568_2,0,-1,0,5394,0
5406,betaxolol,4,5,27,36,These results suggest that betaxolol could be less of a depression-inducer than timolol in predisposed patients.,1428568_6,0,-1,0,5406,0
5416,glutamate receptor,22,24,178,196,"LY274614, 3SR,4aRS,6SR,8aRS-6-[phosphonomethyl]decahydr oisoquinoline-3- carboxylic acid, has been described as a potent antagonist of the N-methyl-D-aspartate (NMDA) subtype of glutamate receptor.",1436384_1,0,-1,0,5416,0
5421,MK-801,13,14,85,91,"This prolonged depletion of dopamine in the striatum was antagonized by dizocilpine (MK-801, a non-competitive antagonist of NMDA receptors) or by LY274614 (a competitive antagonist of NMDA receptors).",1436384_4,0,-1,0,5421,0
5429,at 10,10,12,68,73,"The protective effect of LY274614 was dose-dependent, being maximum at 10-40 mgkg (i.p.).",1436384_5,0,-1,0,5429,0
5439,receptor antagonist,27,29,188,207,The data strengthen the evidence that the neurotoxic effect of amphetamine and related compounds toward nigrostriatal dopamine neurons involves NMDA receptors and that LY274614 is an NMDA receptor antagonist with long-lasting in vivo effects in rats.,1436384_9,0,-1,0,5439,0
5444,cefotetan,10,11,71,80,We describe a patient who developed anemia while receiving intravenous cefotetan.,1445986_2,0,-1,0,5444,0
5449,cefotetan,13,14,70,79,"The eluate also reacted weakly with red blood cells in the absence of cefotetan, suggesting the concomitant formation of warm-reactive autoantibodies.",1445986_4,0,-1,0,5449,0
5486,low dose,10,12,77,85,A diet promoting sugar dependency causes behavioral cross-sensitization to a low dose of amphetamine.,14596845_0,0,-1,0,5486,0
5490,low dose,19,21,130,138,The present study examined whether female rats on various regimens of sugar access would show behavioral cross-sensitization to a low dose of amphetamine.,14596845_2,0,-1,0,5490,0
5499,low dose,12,14,72,80,Nine days later locomotor activity was measured in response to a single low dose of amphetamine (0.5 mg/kg).,14596845_6,0,-1,0,5499,0
5510,mesna,4,5,26,31,Use of dexamethasone with mesna for the prevention of ifosfamide-induced hemorrhagic cystitis.,14633084_0,0,-1,0,5510,0
5515,ifosfamide,14,15,78,88,AIM: Hemorrhagic cystitis (HC) is a limiting side-effect of chemotherapy with ifosfamide (IFS).,14633084_1,0,-1,0,5515,0
5517,mesna,15,16,90,95,"In the study presented here, we investigated the use of dexamethasone in combination with mesna for the prevention of IFS-induced HC.",14633084_2,0,-1,0,5517,0
5522,mesna,21,22,84,89,METHODS: Male Wistar rats (150-200 g; 6 rats per group) were treated with saline or mesna 5 min (i.p.) before and 2 and 6 h after (v.o.) administration of IFS.,14633084_3,0,-1,0,5522,0
5524,mesna,7,8,27,32,"One, two or three doses of mesna were replaced with dexamethasone alone or with dexamethasone plus mesna.",14633084_4,0,-1,0,5524,0
5525,mesna,17,18,99,104,"One, two or three doses of mesna were replaced with dexamethasone alone or with dexamethasone plus mesna.",14633084_4,0,-1,0,5525,0
5529,mesna,14,15,67,72,"RESULTS: The replacement of the last dose or the last two doses of mesna with dexamethasone reduced the increase in bladder wet weight induced by IFS by 84.79% and 89.13%, respectively.",14633084_6,0,-1,0,5529,0
5533,mesna,12,13,65,70,"Moreover, the addition of dexamethasone to the last two doses of mesna was more efficient than three doses of mesna alone when evaluated microscopically.",14633084_8,0,-1,0,5533,0
5534,mesna,20,21,110,115,"Moreover, the addition of dexamethasone to the last two doses of mesna was more efficient than three doses of mesna alone when evaluated microscopically.",14633084_8,0,-1,0,5534,0
5535,mesna,6,7,46,51,CONCLUSION: Dexamethasone in combination with mesna was efficient in blocking IFS-induced HC.,14633084_9,0,-1,0,5535,0
5538,mesna,9,10,46,51,"However, the replacement of last two doses of mesna with saline or all of the mesna doses with dexamethasone did not prevent HC.",14633084_10,0,-1,0,5538,0
5539,mesna,16,17,78,83,"However, the replacement of last two doses of mesna with saline or all of the mesna doses with dexamethasone did not prevent HC.",14633084_10,0,-1,0,5539,0
5541,trans-retinoic,1,2,5,19,All- trans-retinoic acid-induced erythema nodosum in patients with acute promyelocytic leukemia.,14648024_0,0,-1,0,5541,0
5545,trans-retinoic acid,5,7,38,57,Erythema nodosum associated with all- trans-retinoic acid (ATRA) for acute promyelocytic leukemia (APL) is very rare.,14648024_1,0,-1,0,5545,0
5579,calcitonin gene-related peptide,8,11,54,85,NO-induced migraine attack: strong increase in plasma calcitonin gene-related peptide (CGRP) concentration and negative correlation with platelet serotonin release.,14659530_0,0,-1,0,5579,0
5580,CGRP,12,13,87,91,NO-induced migraine attack: strong increase in plasma calcitonin gene-related peptide (CGRP) concentration and negative correlation with platelet serotonin release.,14659530_0,0,-1,0,5580,0
5581,calcitonin gene-related peptide,13,16,70,101,"The aim of the present study was to investigate changes in the plasma calcitonin gene-related peptide (CGRP) concentration and platelet serotonin (5-hydroxytriptamine, 5-HT) content during the immediate headache and the delayed genuine migraine attack provoked by nitroglycerin.",14659530_1,0,-1,0,5581,0
5582,CGRP,17,18,103,107,"The aim of the present study was to investigate changes in the plasma calcitonin gene-related peptide (CGRP) concentration and platelet serotonin (5-hydroxytriptamine, 5-HT) content during the immediate headache and the delayed genuine migraine attack provoked by nitroglycerin.",14659530_1,0,-1,0,5582,0
5588,CGRP,1,2,7,11,Plasma CGRP concentration increased significantly (P<0.01) during the migraine attack and returned to baseline after the cessation of the migraine.,14659530_6,0,-1,0,5588,0
5590,CGRP,3,4,16,20,"However, plasma CGRP concentrations failed to change during immediate headache and in the subjects with no migraine attack.",14659530_8,0,-1,0,5590,0
5591,CGRP,1,2,6,10,Basal CGRP concentration was significantly higher and platelet 5-HT content tended to be lower in subjects who experienced a migraine attack.,14659530_9,0,-1,0,5591,0
5593,CGRP,7,8,36,40,"In conclusion, the fact that plasma CGRP concentration correlates with the timing and severity of a migraine headache suggests a direct relationship between CGRP and migraine.",14659530_11,0,-1,0,5593,0
5595,CGRP,24,25,157,161,"In conclusion, the fact that plasma CGRP concentration correlates with the timing and severity of a migraine headache suggests a direct relationship between CGRP and migraine.",14659530_11,0,-1,0,5595,0
5596,CGRP,21,22,129,133,"In contrast, serotonin release from platelets does not provoke migraine, it may even counteract the headache and the concomitant CGRP release in this model.",14659530_12,0,-1,0,5596,0
5603,prostaglandin F2 alpha,12,15,99,121,"Conservative treatment, including bladder irrigation with physiological saline and instillation of prostaglandin F2 alpha, failed to totally control hemorrhage.",1468485_2,0,-1,0,5603,0
5610,antiepileptic drug,6,8,40,58,The development of psychosis related to antiepileptic drug treatment is usually attributed to the interaction between the epileptic brain substratum and the antiepileptic drugs.,14698717_1,0,-1,0,5610,0
5612,antiepileptic drugs,22,24,157,176,The development of psychosis related to antiepileptic drug treatment is usually attributed to the interaction between the epileptic brain substratum and the antiepileptic drugs.,14698717_1,0,-1,0,5612,0
5617,convulsants,3,4,15,26,Effect of some convulsants on the protective activity of loreclezole and its combinations with valproate or clonazepam in amygdala-kindled rats.,14704468_0,0,-1,0,5617,0
5621,clonazepam,16,17,108,118,Effect of some convulsants on the protective activity of loreclezole and its combinations with valproate or clonazepam in amygdala-kindled rats.,14704468_0,0,-1,0,5621,0
5628,clonazepam,11,12,60,70,"The combinations of loreclezole (2.5 mg/kg) with valproate, clonazepam, or carbamazepine (applied at their subprotective doses) also exhibited antiseizure effect in this test.",14704468_2,0,-1,0,5628,0
5635,L-type calcium channels,15,18,100,123,"Among several chemoconvulsants, bicuculline, N-methyl-D-aspartic acid and BAY k-8644 (the opener of L-type calcium channels) reversed the protective activity of loreclezole alone and its combination with valproate.",14704468_4,0,-1,0,5635,0
5640,anticonvulsive,13,14,75,89,"On the other hand, bicuculline, aminophylline and BAY k-8644 inhibited the anticonvulsive action of loreclezole combined with clonazepam.",14704468_5,0,-1,0,5640,0
5642,clonazepam,19,20,126,136,"On the other hand, bicuculline, aminophylline and BAY k-8644 inhibited the anticonvulsive action of loreclezole combined with clonazepam.",14704468_5,0,-1,0,5642,0
5645,GABAergic,21,22,154,163,The results support the hypothesis that the protective activity of loreclezole and its combinations with other antiepileptics may involve potentiation of GABAergic neurotransmission and blockade of L-type of calcium channels.,14704468_6,0,-1,0,5645,0
5646,L-type,26,27,198,204,The results support the hypothesis that the protective activity of loreclezole and its combinations with other antiepileptics may involve potentiation of GABAergic neurotransmission and blockade of L-type of calcium channels.,14704468_6,0,-1,0,5646,0
5647,calcium channels,28,30,208,224,The results support the hypothesis that the protective activity of loreclezole and its combinations with other antiepileptics may involve potentiation of GABAergic neurotransmission and blockade of L-type of calcium channels.,14704468_6,0,-1,0,5647,0
5657,(1,8,10,56,58,METHODS: Rats were treated with intravenous doxorubicin (1 mg kg(-1) week(-1)) for 7 weeks and were sacrificed either 1 week ('short-term') or 30 weeks ('long-term') following the last dose.,14736955_3,0,-1,0,5657,0
5669,cytochrome-c oxidase,21,23,140,160,"RESULTS: The 'long-term' group had significant glomerular and tubular lesions, depressed activities of mtDNA-encoded NADH dehydrogenase and cytochrome-c oxidase (COX) and increased citrate synthase activity.",14736955_8,0,-1,0,5669,0
5670,synthase,29,30,189,197,"RESULTS: The 'long-term' group had significant glomerular and tubular lesions, depressed activities of mtDNA-encoded NADH dehydrogenase and cytochrome-c oxidase (COX) and increased citrate synthase activity.",14736955_8,0,-1,0,5670,0
5716,anastrozole,7,8,48,59,"Patients participating in a randomised trial of anastrozole, tamoxifen alone or combined (ATAC) (n=94) and a group of women without breast cancer (n=35) completed a battery of neuropsychological measures.",14745746_3,0,-1,0,5716,0
5750,transcriptional,6,7,37,52,"Doxorubicin depletes cardiac p300, a transcriptional coactivator that is required for the maintenance of the differentiated phenotype of cardiac myocytes.",14975762_2,0,-1,0,5750,0
5767,bcl-2,8,9,50,55,"Expression of p300 increased the cardiac level of bcl-2 and mdm-2, but not that of p53 or other members of the bcl-2 family.",14975762_7,0,-1,0,5767,0
5770,bcl-2,22,23,111,116,"Expression of p300 increased the cardiac level of bcl-2 and mdm-2, but not that of p53 or other members of the bcl-2 family.",14975762_7,0,-1,0,5770,0
5776,propafenone,5,6,57,68,Transient platypnea-orthodeoxia-like syndrome induced by propafenone overdose in a young woman with Ebstein's anomaly.,14976857_0,0,-1,0,5776,0
5784,propafenone,26,27,146,157,"This shunt of blood via a patent foramen ovale occurred in the presence of a normal pulmonary artery pressure, and was probably precipitated by a propafenone overdose.",14976857_2,0,-1,0,5784,0
5794,Methimazole,0,1,0,11,Methimazole is a widely used and generally well-tolerated antithyroid agent.,14982270_1,0,-1,0,5794,0
5795,antithyroid agent,8,10,58,75,Methimazole is a widely used and generally well-tolerated antithyroid agent.,14982270_1,0,-1,0,5795,0
5796,methimazole,12,13,76,87,A 43-year-old woman had severe jaundice and itching 1 month after receiving methimazole (10 mg tid) and propranolol (20 mg tid) for treatment of hyperthyroidism.,14982270_2,0,-1,0,5796,0
5797,propranolol,19,20,104,115,A 43-year-old woman had severe jaundice and itching 1 month after receiving methimazole (10 mg tid) and propranolol (20 mg tid) for treatment of hyperthyroidism.,14982270_2,0,-1,0,5797,0
5800,propranolol,6,7,51,62,"Methimazole-induced cholestasis was diagnosed, and propranolol therapy was resumed.",14982270_5,0,-1,0,5800,0
5801,methimazole,19,20,112,123,"Over the following 9 days, the symptoms improved and plasma bilirubin levels were normal after 12 weeks without methimazole.",14982270_6,0,-1,0,5801,0
5804,methimazole,19,20,110,121,"Physicians and patients should be aware of this adverse effect so that, upon occurrence, they can discontinue methimazole therapy and avoid unnecessary invasive procedures.",14982270_8,0,-1,0,5804,0
5826,hexamethonium chloride,8,10,63,85,These responses were blocked by systemic pre-administration of hexamethonium chloride (20 mg/kg).,15009014_6,0,-1,0,5826,0
5829,(1,15,17,103,105,"The evoked increases in dural blood flow were also abolished by topical pre-administration of atropine (1 mm) and [Lys1, Pro2,5, Arg3,4, Tyr6]-VIP (0.1 mm), a vasoactive intestinal polypeptide (VIP) antagonist, onto the exposed dura mater.",15009014_7,0,-1,0,5829,0
5833,vasoactive,34,35,159,169,"The evoked increases in dural blood flow were also abolished by topical pre-administration of atropine (1 mm) and [Lys1, Pro2,5, Arg3,4, Tyr6]-VIP (0.1 mm), a vasoactive intestinal polypeptide (VIP) antagonist, onto the exposed dura mater.",15009014_7,0,-1,0,5833,0
5842,organophosphorus,1,2,5,21,"Such organophosphorus (OP) compounds as diisopropylfluorophosphate (DFP), sarin and soman are potent inhibitors of acetylcholinesterases (AChEs) and butyrylcholinesterases (BChEs).",15036754_1,0,-1,0,5842,0
5843,diisopropylfluorophosphate,7,8,40,66,"Such organophosphorus (OP) compounds as diisopropylfluorophosphate (DFP), sarin and soman are potent inhibitors of acetylcholinesterases (AChEs) and butyrylcholinesterases (BChEs).",15036754_1,0,-1,0,5843,0
5844,DFP,9,10,68,71,"Such organophosphorus (OP) compounds as diisopropylfluorophosphate (DFP), sarin and soman are potent inhibitors of acetylcholinesterases (AChEs) and butyrylcholinesterases (BChEs).",15036754_1,0,-1,0,5844,0
5851,DFP,14,15,93,96,The protective action of subcutaneously (SC) administered antidotes or their combinations in DFP (2.0 mg/kg BW) intoxication was studied in 9-10-weeks-old Han-Wistar male rats.,15036754_3,0,-1,0,5851,0
5856,receptor agonist,24,26,137,153,"The rats received AChE reactivator pralidoxime-2-chloride (2PAM) (30.0 mg/kg BW), anticonvulsant diazepam (2.0 mg/kg BW), A(1)-adenosine receptor agonist N(6)-cyclopentyl adenosine (CPA) (2.0 mg/kg BW), NMDA-receptor antagonist dizocilpine maleate (+-MK801 hydrogen maleate) (2.0 mg/kg BW) or their combinations with cholinolytic drug atropine sulfate (50.0 mg/kg BW) immediately or 30 min after the single SC injection of DFP.",15036754_4,0,-1,0,5856,0
5860,hydrogen maleate,44,46,257,273,"The rats received AChE reactivator pralidoxime-2-chloride (2PAM) (30.0 mg/kg BW), anticonvulsant diazepam (2.0 mg/kg BW), A(1)-adenosine receptor agonist N(6)-cyclopentyl adenosine (CPA) (2.0 mg/kg BW), NMDA-receptor antagonist dizocilpine maleate (+-MK801 hydrogen maleate) (2.0 mg/kg BW) or their combinations with cholinolytic drug atropine sulfate (50.0 mg/kg BW) immediately or 30 min after the single SC injection of DFP.",15036754_4,0,-1,0,5860,0
5861,cholinolytic,56,57,317,329,"The rats received AChE reactivator pralidoxime-2-chloride (2PAM) (30.0 mg/kg BW), anticonvulsant diazepam (2.0 mg/kg BW), A(1)-adenosine receptor agonist N(6)-cyclopentyl adenosine (CPA) (2.0 mg/kg BW), NMDA-receptor antagonist dizocilpine maleate (+-MK801 hydrogen maleate) (2.0 mg/kg BW) or their combinations with cholinolytic drug atropine sulfate (50.0 mg/kg BW) immediately or 30 min after the single SC injection of DFP.",15036754_4,0,-1,0,5861,0
5862,atropine sulfate,58,60,335,351,"The rats received AChE reactivator pralidoxime-2-chloride (2PAM) (30.0 mg/kg BW), anticonvulsant diazepam (2.0 mg/kg BW), A(1)-adenosine receptor agonist N(6)-cyclopentyl adenosine (CPA) (2.0 mg/kg BW), NMDA-receptor antagonist dizocilpine maleate (+-MK801 hydrogen maleate) (2.0 mg/kg BW) or their combinations with cholinolytic drug atropine sulfate (50.0 mg/kg BW) immediately or 30 min after the single SC injection of DFP.",15036754_4,0,-1,0,5862,0
5863,DFP,75,76,423,426,"The rats received AChE reactivator pralidoxime-2-chloride (2PAM) (30.0 mg/kg BW), anticonvulsant diazepam (2.0 mg/kg BW), A(1)-adenosine receptor agonist N(6)-cyclopentyl adenosine (CPA) (2.0 mg/kg BW), NMDA-receptor antagonist dizocilpine maleate (+-MK801 hydrogen maleate) (2.0 mg/kg BW) or their combinations with cholinolytic drug atropine sulfate (50.0 mg/kg BW) immediately or 30 min after the single SC injection of DFP.",15036754_4,0,-1,0,5863,0
5865,atropine sulfate,4,6,26,42,"The control rats received atropine sulfate, but also saline and olive oil instead of other antidotes and DFP, respectively.",15036754_5,0,-1,0,5865,0
5867,DFP,18,19,105,108,"The control rats received atropine sulfate, but also saline and olive oil instead of other antidotes and DFP, respectively.",15036754_5,0,-1,0,5867,0
5868,DFP,12,13,58,61,All rats were terminated either 24 h or 3 weeks after the DFP injection.,15036754_6,0,-1,0,5868,0
5875,DFP,8,9,63,66,Atropine-MK801 did not offer any additional protection against DFP toxicity.,15036754_9,0,-1,0,5875,0
5877,DFP,26,27,155,158,"In conclusion, CPA, diazepam and 2PAM in combination with atropine prevented the occurrence of serious signs of poisoning and thus reduced the toxicity of DFP in rat.",15036754_10,0,-1,0,5877,0
5880,B-cell,9,10,72,78,"Atrial fibrillation following chemotherapy for stage IIIE diffuse large B-cell gastric lymphoma in a patient with myotonic dystrophy (Steinert's disease).The authors describe the unusual association between diffuse B-cell gastric lymphoma and myotonic dystrophy, the most common form of adult muscular dystrophy, and sudden atrial fibrillation following one cycle of doxorubicin-based chemotherapy in the same patient.",15042318_0,0,-1,0,5880,0
5883,B-cell,29,30,215,221,"Atrial fibrillation following chemotherapy for stage IIIE diffuse large B-cell gastric lymphoma in a patient with myotonic dystrophy (Steinert's disease).The authors describe the unusual association between diffuse B-cell gastric lymphoma and myotonic dystrophy, the most common form of adult muscular dystrophy, and sudden atrial fibrillation following one cycle of doxorubicin-based chemotherapy in the same patient.",15042318_0,0,-1,0,5883,0
5897,dilevalol,7,8,46,55,OBJECTIVE: To assess lymphocyte reactivity to dilevalol and to serum containing putative ex vivo dilevalol antigens or metabolites in a case of dilevalol-induced liver injury.,1504402_1,0,-1,0,5897,0
5899,dilevalol,15,16,97,106,OBJECTIVE: To assess lymphocyte reactivity to dilevalol and to serum containing putative ex vivo dilevalol antigens or metabolites in a case of dilevalol-induced liver injury.,1504402_1,0,-1,0,5899,0
5904,dilevalol,19,20,118,127,METHODS: Peripheral blood mononuclear cells collected from the patient were cultured in the presence of a solution of dilevalol and also with sera collected from a volunteer before and after dilevalol intake.,1504402_3,0,-1,0,5904,0
5905,dilevalol,31,32,191,200,METHODS: Peripheral blood mononuclear cells collected from the patient were cultured in the presence of a solution of dilevalol and also with sera collected from a volunteer before and after dilevalol intake.,1504402_3,0,-1,0,5905,0
5908,dilevalol,20,21,119,128,RESULTS: No lymphocyte proliferation was observed either in the patient or in the healthy volunteer in the presence of dilevalol solutions.,1504402_5,0,-1,0,5908,0
5910,dilevalol,8,9,62,71,A significant proliferative response to serum collected after dilevalol intake was observed in the case of the patient compared with the proliferative response to the serum collected before the drug intake.,1504402_6,0,-1,0,5910,0
5917,dilevalol,16,17,120,129,"CONCLUSIONS: The methodology used allowed the detection of lymphocyte sensitization to sera containing ex vivo-prepared dilevalol antigens, suggesting the involvement of an immunologic mechanism in dilevalol-induced liver injury.",1504402_8,0,-1,0,5917,0
5919,ENaC,7,8,51,55,Increased expression and apical targeting of renal ENaC subunits in puromycin aminonucleoside-induced nephrotic syndrome in rats.,15075188_0,0,-1,0,5919,0
5920,puromycin,10,11,68,77,Increased expression and apical targeting of renal ENaC subunits in puromycin aminonucleoside-induced nephrotic syndrome in rats.,15075188_0,0,-1,0,5920,0
5926,ENaC,7,8,44,48,We hypothesized that epithelial Na channel (ENaC) subunit dysregulation may be responsible for the increased sodium retention.,15075188_3,0,-1,0,5926,0
5930,puromycin aminonucleoside,8,10,47,72,"An experimental group of rats was treated with puromycin aminonucleoside (PAN; 180 mg/kg iv), whereas the control group received only vehicle.",15075188_4,0,-1,0,5930,0
5940,IM,26,27,138,140,The protein abundance of alpha-ENaC and beta-ENaC was increased in the inner stripe of the outer medulla (ISOM) and in the inner medulla (IM) but was not altered in the cortex.,15075188_6,0,-1,0,5940,0
5943,IM,11,12,60,62,"gamma-ENaC abundance was increased in the cortex, ISOM, and IM.",15075188_7,0,-1,0,5943,0
5949,plasma membrane,21,23,179,194,"Immunoperoxidase brightfield- and laser-scanning confocal fluorescence microscopy demonstrated increased targeting of alpha-ENaC, beta-ENaC, and gamma-ENaC subunits to the apical plasma membrane in the distal convoluted tubule (DCT2), connecting tubule, and cortical and medullary collecting duct segments.",15075188_8,0,-1,0,5949,0
5955,plasma membrane,12,14,93,108,"Immunoelectron microscopy further revealed an increased labeling of alpha-ENaC in the apical plasma membrane of cortical collecting duct principal cells of PAN-treated rats, indicating enhanced apical targeting of alpha-ENaC subunits.",15075188_9,0,-1,0,5955,0
5961,cotransporter,18,19,93,106,"In contrast, the protein abundances of Na(+)/H(+) exchanger type 3 (NHE3), Na(+)-K(+)-2Cl(-) cotransporter (BSC-1), and thiazide-sensitive Na(+)-Cl(-) cotransporter (TSC) were decreased.",15075188_10,0,-1,0,5961,0
5963,cotransporter,27,28,151,164,"In contrast, the protein abundances of Na(+)/H(+) exchanger type 3 (NHE3), Na(+)-K(+)-2Cl(-) cotransporter (BSC-1), and thiazide-sensitive Na(+)-Cl(-) cotransporter (TSC) were decreased.",15075188_10,0,-1,0,5963,0
5965,alpha(1)-subunit,6,7,31,47,"Moreover, the abundance of the alpha(1)-subunit of the Na-K-ATPase was decreased in the cortex and ISOM, but it remained unchanged in the IM.",15075188_11,0,-1,0,5965,0
5968,IM,24,25,138,140,"Moreover, the abundance of the alpha(1)-subunit of the Na-K-ATPase was decreased in the cortex and ISOM, but it remained unchanged in the IM.",15075188_11,0,-1,0,5968,0
5969,ENaC,9,10,56,60,"In conclusion, the increased or sustained expression of ENaC subunits combined with increased apical targeting in the DCT2, connecting tubule, and collecting duct are likely to play a role in the sodium retention associated with PAN-induced nephrotic syndrome.",15075188_12,0,-1,0,5969,0
5987,pyridoxine hydrochloride,6,8,45,69,The administration of pharmacologic doses of pyridoxine hydrochloride led to a disappearance of symptoms.,150790_2,0,-1,0,5987,0
5989,niacinamide,7,8,29,40,"A placebo had no effect, but niacinamide was as effective as pyridoxine.",150790_4,0,-1,0,5989,0
5996,her,17,18,106,109,The patient has been followed for six years and has required pharmacologic doses of pyridoxine to control her behavior.,150790_8,0,-1,0,5996,0
6089,alpha2-adrenergic,5,6,39,56,Differential modulation by estrogen of alpha2-adrenergic and I1-imidazoline receptor-mediated hypotension in female rats.,15145918_0,0,-1,0,6089,0
6094,alpha2-,12,13,89,96,The present study investigated whether this effect of estrogen involves interaction with alpha2- and/or I1-receptors.,15145918_2,0,-1,0,6094,0
6097,rilmenidine,8,9,56,67,"Changes evoked by a single intraperitoneal injection of rilmenidine (600 microg/kg) or alpha-methyldopa (100 mg/kg), selective I1- and alpha2-receptor agonists, respectively, in blood pressure, hemodynamic variability, and locomotor activity were assessed in radiotelemetered sham-operated and ovariectomized (Ovx) Sprague-Dawley female rats with or without 12-wk estrogen replacement.",15145918_3,0,-1,0,6097,0
6098,alpha-methyldopa,14,15,87,103,"Changes evoked by a single intraperitoneal injection of rilmenidine (600 microg/kg) or alpha-methyldopa (100 mg/kg), selective I1- and alpha2-receptor agonists, respectively, in blood pressure, hemodynamic variability, and locomotor activity were assessed in radiotelemetered sham-operated and ovariectomized (Ovx) Sprague-Dawley female rats with or without 12-wk estrogen replacement.",15145918_3,0,-1,0,6098,0
6117,rilmenidine,4,5,23,34,"In sham-operated rats, rilmenidine or alpha-methyldopa elicited similar hypotension that lasted at least 5 h and was associated with reductions in standard deviation of mean arterial pressure.",15145918_5,0,-1,0,6117,0
6118,alpha-methyldopa,6,7,38,54,"In sham-operated rats, rilmenidine or alpha-methyldopa elicited similar hypotension that lasted at least 5 h and was associated with reductions in standard deviation of mean arterial pressure.",15145918_5,0,-1,0,6118,0
6123,alpha-methyldopa,5,6,25,41,SDRR was reduced only by alpha-methyldopa.,15145918_6,0,-1,0,6123,0
6126,alpha-methyldopa,7,8,55,71,"Ovx significantly enhanced the hypotensive response to alpha-methyldopa, in contrast to no effect on rilmenidine hypotension.",15145918_7,0,-1,0,6126,0
6127,rilmenidine,15,16,101,112,"Ovx significantly enhanced the hypotensive response to alpha-methyldopa, in contrast to no effect on rilmenidine hypotension.",15145918_7,0,-1,0,6127,0
6128,alpha-methyldopa,2,3,13,29,The enhanced alpha-methyldopa hypotension in Ovx rats was paralleled with further reduction in SDRR and a reduced locomotor activity.,15145918_8,0,-1,0,6128,0
6137,alpha-methyldopa,23,24,146,162,"Estrogen replacement (17beta-estradiol subcutaneous pellet, 14.2 microg/day, 12 wk) of Ovx rats restored the hemodynamic and locomotor effects of alpha-methyldopa to sham-operated levels.",15145918_9,0,-1,0,6137,0
6139,alpha2-,6,7,51,58,These findings suggest that estrogen downregulates alpha2- but not I1-receptor-mediated hypotension and highlight a role for the cardiac autonomic control in alpha-methyldopa-estrogen interaction.,15145918_10,0,-1,0,6139,0
6152,biochemical markers,41,43,286,305,"A 35-year-old woman whose cervix uteri was inadvertently injected with 8 mg of epinephrine developed myocardial stunning that was characterized by severe hemodynamic compromise, profound, albeit transient, left ventricular systolic and diastolic dysfunction, and only modestly elevated biochemical markers of myocardial necrosis.",15188772_3,0,-1,0,6152,0
6159,TCR,4,5,23,26,"Tincture of Crataegus (TCR), an alcoholic extract of the berries of hawthorn (Crataegus oxycantha), is used in herbal and homeopathic medicine.",15233872_1,0,-1,0,6159,0
6164,TCR,11,12,67,70,The present study was done to investigate the protective effect of TCR on experimentally induced myocardial infarction in rats.,15233872_2,0,-1,0,6164,0
6167,TCR,2,3,16,19,"Pretreatment of TCR, at a dose of 0.5 mL/100 g bodyweight per day, orally for 30 days, prevented the increase in lipid peroxidation and activity of marker enzymes observed in isoproterenol-induced rats (85 mg kg(-1) s. c. for 2 days at an interval of 24 h).",15233872_3,0,-1,0,6167,0
6170,TCR,0,1,0,3,TCR prevented the isoproterenol-induced decrease in antioxidant enzymes in the heart and increased the rate of ADP-stimulated oxygen uptake and respiratory coupling ratio.,15233872_4,0,-1,0,6170,0
6174,TCR,0,1,0,3,TCR protected against pathological changes induced by isoproterenol in rat heart.,15233872_5,0,-1,0,6174,0
6176,TCR,6,7,40,43,The results show that pretreatment with TCR may be useful in preventing the damage induced by isoproterenol in rat heart.,15233872_6,0,-1,0,6176,0
6178,nonsteroidal antiinflammatory agents,8,11,69,105,Effects of the cyclooxygenase-2 specific inhibitor valdecoxib versus nonsteroidal antiinflammatory agents and placebo on cardiovascular thrombotic events in patients with arthritis.,15266215_0,0,-1,0,6178,0
6191,diclofenac,35,36,209,219,"The incidence of cardiovascular thrombotic events (cardiac, cerebrovascular and peripheral vascular, or arterial thrombotic) was determined by analyzing pooled valdecoxib (10-80 mg daily), nonselective NSAID (diclofenac 75 mg bid, ibuprofen 800 mg tid, or naproxen 500 mg bid) and placebo data from 10 randomized osteoarthritis and rheumatoid arthritis trials that were 6-52 weeks in duration.",15266215_3,0,-1,0,6191,0
6194,low-dose,19,20,89,97,The incidence rates of events were determined in all patients (n = 7934) and in users of low-dose (< or =325 mg daily) aspirin (n = 1051) and nonusers of aspirin (n = 6883).,15266215_4,0,-1,0,6194,0
6216,dobutamine,20,21,145,155,"The 47-year-old female patient, known to have hypertrophic cardiomyopathy, was admitted with biventricular failure and managed aggressively with dobutamine infusion and other drugs while being assessed for heart transplantation.",15266362_2,0,-1,0,6216,0
6223,dobutamine,13,14,81,91,It is likely that the hypersensitivity (eosinophilic) myocarditis was related to dobutamine infusion therapy.,15266362_6,0,-1,0,6223,0
6228,lignocaine,7,8,55,65,Treatment of tinnitus by intratympanic instillation of lignocaine (lidocaine) 2 per cent through ventilation tubes.,1527456_0,0,-1,0,6228,0
6235,lignocaine,12,13,81,91,"This paper presents the results of treating IST by intratympanic instillation of lignocaine (lidocaine) 2 per cent through a grommet, for five weekly courses.",1527456_2,0,-1,0,6235,0
6249,ion channels,3,5,22,34,nAChRs are pentameric ion channels usually composed of alpha and beta subunits.,15275829_2,0,-1,0,6249,0
6293,sevoflurane,3,4,15,26,The effects of sevoflurane on lidocaine-induced convulsions.,15278670_0,0,-1,0,6293,0
6294,sevoflurane,3,4,17,28,The influence of sevoflurane on lidocaine-induced convulsions was studied in cats.,15278670_1,0,-1,0,6294,0
6299,sevoflurane,43,44,201,212,"The convulsive threshold (mean +/- SD) was 41.4 +/- 6.5 mg. l(-1) with lidocaine infusion (6 mg.kg(-1).min(-1)), increasing significantly to 66.6 +/- 10.9 mg. l(-1) when the end-tidal concentration of sevoflurane was 0.8%.",15278670_2,0,-1,0,6299,0
6301,sevoflurane,17,18,60,71,"However, the threshold (61.6 +/- 8.7 mg. l(-1)) during 1.6% sevoflurane was not significant from that during 0.8% sevoflurane, indicating a celling effect.",15278670_3,0,-1,0,6301,0
6302,sevoflurane,26,27,114,125,"However, the threshold (61.6 +/- 8.7 mg. l(-1)) during 1.6% sevoflurane was not significant from that during 0.8% sevoflurane, indicating a celling effect.",15278670_3,0,-1,0,6302,0
6304,sevoflurane,10,11,72,83,There was no significant difference in the convulsive threshold between sevoflurane and enflurane.,15278670_4,0,-1,0,6304,0
6306,sevoflurane,12,13,76,87,"The rise in blood pressure became less marked when higher concentrations of sevoflurane or enflurane were administered and the blood pressure at convulsions decreased significantly in 1.6% sevoflurane, and in 0.8% and 1.6% enflurane.",15278670_5,0,-1,0,6306,0
6308,sevoflurane,28,29,189,200,"The rise in blood pressure became less marked when higher concentrations of sevoflurane or enflurane were administered and the blood pressure at convulsions decreased significantly in 1.6% sevoflurane, and in 0.8% and 1.6% enflurane.",15278670_5,0,-1,0,6308,0
6312,potassium channels,7,9,49,67,"Apamin, a selective blocker of calcium-dependent potassium channels, was administered intracerebroventricularly in rats anesthetized with 0.8% sevoflurane to investigate the mechanism of the anticonvulsive effects.",15278670_7,0,-1,0,6312,0
6313,sevoflurane,19,20,143,154,"Apamin, a selective blocker of calcium-dependent potassium channels, was administered intracerebroventricularly in rats anesthetized with 0.8% sevoflurane to investigate the mechanism of the anticonvulsive effects.",15278670_7,0,-1,0,6313,0
6319,sevoflurane,4,5,21,32,It is suggested that sevoflurane reduces the convulsive effect of lidocaine toxicity but carries some risk due to circulatory depression.,15278670_9,0,-1,0,6319,0
6330,paclitaxel,5,6,26,36,"STUDY DESIGN: We combined paclitaxel, melphalan and high-dose cyclophosphamide, thiotepa, and carboplatin in a triple sequential high-dose regimen for patients with metastatic breast cancer.",15325671_3,0,-1,0,6330,0
6332,carboplatin,15,16,94,105,"STUDY DESIGN: We combined paclitaxel, melphalan and high-dose cyclophosphamide, thiotepa, and carboplatin in a triple sequential high-dose regimen for patients with metastatic breast cancer.",15325671_3,0,-1,0,6332,0
6362,salbutamol,4,5,23,33,"Tremor side effects of salbutamol, quantified by a laser pointer technique.",15338796_0,0,-1,0,6362,0
6365,salbutamol,8,9,43,53,"OBJECTIVE: To study tremor side effects of salbutamol an easily applicable, quick and low-priced method is needed.",15338796_1,0,-1,0,6365,0
6372,salbutamol,19,20,133,143,To determine sensitivity we assessed tremor in 44 patients with obstructive lung disease after administration of cumulative doses of salbutamol.,15338796_5,0,-1,0,6372,0
6380,Salbutamol,2,3,9,19,RESULTS: Salbutamol significantly increased tremor severity in patients in a dose-dependent way.,15338796_12,0,-1,0,6380,0
6383,(r,10,12,69,71,There was no agreement between the questionnaire and tremor severity (r = 0.093; P = 0.53).,15338796_14,0,-1,0,6383,0
6388,Yohimbine,0,1,0,9,Yohimbine treatment of sexual side effects induced by serotonin reuptake blockers.,1535072_0,0,-1,0,6388,0
6390,serotonin reuptake,8,10,54,72,Yohimbine treatment of sexual side effects induced by serotonin reuptake blockers.,1535072_0,0,-1,0,6390,0
6392,yohimbine,8,9,58,67,BACKGROUND: Preclinical and clinical studies suggest that yohimbine facilitates sexual behavior and may be helpful in the treatment of male impotence.,1535072_1,0,-1,0,6392,0
6395,yohimbine,6,7,35,44,A single case report suggests that yohimbine may be used to treat the sexual side effects of clomipramine.,1535072_2,0,-1,0,6395,0
6397,yohimbine,3,4,21,30,This study evaluated yohimbine as a treatment for the sexual side effects caused by serotonin reuptake blockers.,1535072_3,0,-1,0,6397,0
6399,serotonin reuptake,14,16,84,102,This study evaluated yohimbine as a treatment for the sexual side effects caused by serotonin reuptake blockers.,1535072_3,0,-1,0,6399,0
6403,serotonin reuptake,25,27,168,186,"METHOD: Six patients with either obsessive compulsive disorder, trichotillomania, anxiety, or affective disorders who suffered sexual side effects after treatment with serotonin reuptake blockers were given yohimbine on a p.r.n.",1535072_4,0,-1,0,6403,0
6404,yohimbine,30,31,207,216,"METHOD: Six patients with either obsessive compulsive disorder, trichotillomania, anxiety, or affective disorders who suffered sexual side effects after treatment with serotonin reuptake blockers were given yohimbine on a p.r.n.",1535072_4,0,-1,0,6404,0
6406,yohimbine,3,4,17,26,Various doses of yohimbine were used to determine the ideal dose for each patient.,1535072_6,0,-1,0,6406,0
6409,yohimbine,13,14,87,96,RESULTS: Five of the six patients experienced improved sexual functioning after taking yohimbine.,1535072_7,0,-1,0,6409,0
6410,yohimbine,7,8,38,47,One patient who failed to comply with yohimbine treatment had no therapeutic effects.,1535072_8,0,-1,0,6410,0
6411,therapeutic effects,11,13,65,84,One patient who failed to comply with yohimbine treatment had no therapeutic effects.,1535072_8,0,-1,0,6411,0
6413,yohimbine,3,4,16,25,"Side effects of yohimbine included excessive sweating, increased anxiety, and a wound-up feeling in some patients.",1535072_9,0,-1,0,6413,0
6414,yohimbine,9,10,52,61,CONCLUSION: The results of this study indicate that yohimbine may be an effective treatment for the sexual side effects caused by serotonin reuptake blockers.,1535072_10,0,-1,0,6414,0
6416,serotonin reuptake,22,24,130,148,CONCLUSION: The results of this study indicate that yohimbine may be an effective treatment for the sexual side effects caused by serotonin reuptake blockers.,1535072_10,0,-1,0,6416,0
6418,yohimbine,13,14,92,101,Future controlled studies are needed to further investigate the effectiveness and safety of yohimbine for this indication.,1535072_11,0,-1,0,6418,0
6429,mesna,19,20,122,127,"In an attempt to obviate the inconvenience of bladder irrigation, we conducted a feasibility trial of uroprophylaxis with mesna, which neutralizes the hepatic metabolite of cyclophosphamide that causes hemorrhagic cystitis.",1545575_3,0,-1,0,6429,0
6441,raloxifene,6,7,43,53,Safety and adverse effects associated with raloxifene: multiple outcomes of raloxifene evaluation.,15458908_0,0,-1,0,6441,0
6442,raloxifene,11,12,76,86,Safety and adverse effects associated with raloxifene: multiple outcomes of raloxifene evaluation.,15458908_0,0,-1,0,6442,0
6443,raloxifene,7,8,36,46,OBJECTIVE: To examine the effect of raloxifene on major adverse events that occur with postmenopausal estrogen therapy or tamoxifen.,15458908_1,0,-1,0,6443,0
6445,Raloxifene,6,7,34,44,"METHODS: The Multiple Outcomes of Raloxifene Evaluation, a multicenter, randomized, double-blind trial, enrolled 7,705 postmenopausal women with osteoporosis.",15458908_2,0,-1,0,6445,0
6448,raloxifene,5,6,32,42,Women were randomly assigned to raloxifene 60 mg/d or 120 mg/d or placebo.,15458908_3,0,-1,0,6448,0
6452,raloxifene,10,11,47,57,"RESULTS: During a mean follow-up of 3.3 years, raloxifene was associated with an increased risk for venous thromboembolism (relative risk [RR] 2.1; 95% confidence interval [CI] 1.2-3.8).",15458908_5,0,-1,0,6452,0
6456,RR,24,25,139,141,"RESULTS: During a mean follow-up of 3.3 years, raloxifene was associated with an increased risk for venous thromboembolism (relative risk [RR] 2.1; 95% confidence interval [CI] 1.2-3.8).",15458908_5,0,-1,0,6456,0
6458,raloxifene,3,4,12,22,"Risk in the raloxifene group was higher than in the placebo group for the first 2 years, but decreased to about the same rate as in the placebo group thereafter.",15458908_7,0,-1,0,6458,0
6460,Raloxifene,0,1,0,10,"Raloxifene did not increase risk for cataracts (RR 0.9; 95% CI 0.8-1.1), gallbladder disease (RR 1.0; 95% CI 0.7-1.3), endometrial hyperplasia (RR 1.3; 95% CI 0.4-5.1), or endometrial cancer (RR 0.9; 95% CI 0.3-2.7).",15458908_8,0,-1,0,6460,0
6461,RR,8,9,48,50,"Raloxifene did not increase risk for cataracts (RR 0.9; 95% CI 0.8-1.1), gallbladder disease (RR 1.0; 95% CI 0.7-1.3), endometrial hyperplasia (RR 1.3; 95% CI 0.4-5.1), or endometrial cancer (RR 0.9; 95% CI 0.3-2.7).",15458908_8,0,-1,0,6461,0
6463,RR,22,23,94,96,"Raloxifene did not increase risk for cataracts (RR 0.9; 95% CI 0.8-1.1), gallbladder disease (RR 1.0; 95% CI 0.7-1.3), endometrial hyperplasia (RR 1.3; 95% CI 0.4-5.1), or endometrial cancer (RR 0.9; 95% CI 0.3-2.7).",15458908_8,0,-1,0,6463,0
6465,RR,36,37,144,146,"Raloxifene did not increase risk for cataracts (RR 0.9; 95% CI 0.8-1.1), gallbladder disease (RR 1.0; 95% CI 0.7-1.3), endometrial hyperplasia (RR 1.3; 95% CI 0.4-5.1), or endometrial cancer (RR 0.9; 95% CI 0.3-2.7).",15458908_8,0,-1,0,6465,0
6467,RR,51,52,192,194,"Raloxifene did not increase risk for cataracts (RR 0.9; 95% CI 0.8-1.1), gallbladder disease (RR 1.0; 95% CI 0.7-1.3), endometrial hyperplasia (RR 1.3; 95% CI 0.4-5.1), or endometrial cancer (RR 0.9; 95% CI 0.3-2.7).",15458908_8,0,-1,0,6467,0
6468,Raloxifene,2,3,12,22,"CONCLUSION: Raloxifene was associated with an increased risk for venous thromboembolism, but there was no increased risk for cataracts, gallbladder disease, endometrial hyperplasia, or endometrial cancer.",15458908_9,0,-1,0,6468,0
6500,desferrioxamine,3,4,24,39,"Subjects were receiving desferrioxamine (DFO) chelation treatment with a mean daily dose of 50-60 mg/kg, 5-6 days a week during the first six years of the study, which was then reduced to 40-50 mg/kg for the following eight years.",15515654_4,0,-1,0,6500,0
6532,mitoxantrone,11,12,77,89,"However, caution is required when cyclophosphamide or anthracyclines such as mitoxantrone are used in patients with a possible underlying heart damage, for example, systemic sclerosis patients.",15517007_7,0,-1,0,6532,0
6540,vitamin C,2,4,18,27,"Does supplemental vitamin C increase cardiovascular disease risk in women with diabetes?BACKGROUND: Vitamin C acts as a potent antioxidant; however, it can also be a prooxidant and glycate protein under certain circumstances in vitro.",15531665_0,0,-1,0,6540,0
6543,Vitamin C,13,15,100,109,"Does supplemental vitamin C increase cardiovascular disease risk in women with diabetes?BACKGROUND: Vitamin C acts as a potent antioxidant; however, it can also be a prooxidant and glycate protein under certain circumstances in vitro.",15531665_0,0,-1,0,6543,0
6546,vitamin C,11,13,63,72,These observations led us to hypothesize that a high intake of vitamin C in diabetic persons might promote atherosclerosis.,15531665_1,0,-1,0,6546,0
6547,vitamin C,10,12,61,70,OBJECTIVE: The objective was to examine the relation between vitamin C intake and mortality from cardiovascular disease.,15531665_2,0,-1,0,6547,0
6549,vitamin C,7,9,40,49,"DESIGN: We studied the relation between vitamin C intake and mortality from total cardiovascular disease (n = 281), coronary artery disease (n = 175), and stroke (n = 57) in 1923 postmenopausal women who reported being diabetic at baseline.",15531665_3,0,-1,0,6549,0
6557,vitamin E,49,51,306,315,"Diet was assessed with a food-frequency questionnaire at baseline, and subjects initially free of coronary artery disease were prospectively followed for 15 y. RESULTS: After adjustment for cardiovascular disease risk factors, type of diabetes medication used, duration of diabetes, and intakes of folate, vitamin E, and beta-carotene, the adjusted relative risks of total cardiovascular disease mortality were 1.0, 0.97, 1.11, 1.47, and 1.84 (P for trend < 0.01) across quintiles of total vitamin C intake from food and supplements.",15531665_4,0,-1,0,6557,0
6560,vitamin C,86,88,490,499,"Diet was assessed with a food-frequency questionnaire at baseline, and subjects initially free of coronary artery disease were prospectively followed for 15 y. RESULTS: After adjustment for cardiovascular disease risk factors, type of diabetes medication used, duration of diabetes, and intakes of folate, vitamin E, and beta-carotene, the adjusted relative risks of total cardiovascular disease mortality were 1.0, 0.97, 1.11, 1.47, and 1.84 (P for trend < 0.01) across quintiles of total vitamin C intake from food and supplements.",15531665_4,0,-1,0,6560,0
6562,vitamin C,4,6,30,39,"When dietary and supplemental vitamin C were analyzed separately, only supplemental vitamin C showed a positive association with mortality endpoints.",15531665_6,0,-1,0,6562,0
6563,vitamin C,12,14,84,93,"When dietary and supplemental vitamin C were analyzed separately, only supplemental vitamin C showed a positive association with mortality endpoints.",15531665_6,0,-1,0,6563,0
6564,Vitamin C,0,2,0,9,Vitamin C intake was unrelated to mortality from cardiovascular disease in the nondiabetic subjects at baseline.,15531665_7,0,-1,0,6564,0
6567,vitamin C,4,6,19,28,CONCLUSION: A high vitamin C intake from supplements is associated with an increased risk of cardiovascular disease mortality in postmenopausal women with diabetes.,15531665_8,0,-1,0,6567,0
6577,Ethambutol,0,1,0,10,Ethambutol is an antimycobacterial agent often used to treat tuberculosis.,15565293_2,0,-1,0,6577,0
6578,antimycobacterial agent,3,5,17,40,Ethambutol is an antimycobacterial agent often used to treat tuberculosis.,15565293_2,0,-1,0,6578,0
6579,ethambutol,4,5,26,36,"A serious complication of ethambutol is an optic neuropathy that impairs visual acuity, contrast sensitivity, and color vision.",15565293_3,0,-1,0,6579,0
6586,ethambutol,8,9,42,52,"METHODS: Three subjects with a history of ethambutol (EMB)-induced optic neuropathy of short-, intermediate-, and long-term visual deficits were administered a full neuro-ophthalmologic examination including visual acuity, color vision, contrast sensitivity, and fundus examination.",15565293_5,0,-1,0,6586,0
6632,ethambutol,17,18,105,115,"Additionally, in terms of management of EMB-induced optic neuropathy, it is important to properly manage ethambutol dosing in patients with renal impairment and to achieve proper transition to a maintenance dose once an appropriate loading dose has been reached.",15565293_15,0,-1,0,6632,0
6656,(r,37,39,212,214,"Baseline renal ACE positively correlated with the relative rise in proteinuria after adriamycin (r = 0.62, P<0.01), renal interstitial alpha-smooth muscle actin (r = 0.49, P<0.05), interstitial macrophage influx (r = 0.56, P<0.05), interstitial collagen III (r = 0.53, P<0.05), glomerular alpha-smooth muscle actin (r = 0.74, P<0.01) and glomerular desmin (r = 0.48, P<0.05).",15572383_10,0,-1,0,6656,0
6658,(r,48,50,258,260,"Baseline renal ACE positively correlated with the relative rise in proteinuria after adriamycin (r = 0.62, P<0.01), renal interstitial alpha-smooth muscle actin (r = 0.49, P<0.05), interstitial macrophage influx (r = 0.56, P<0.05), interstitial collagen III (r = 0.53, P<0.05), glomerular alpha-smooth muscle actin (r = 0.74, P<0.01) and glomerular desmin (r = 0.48, P<0.05).",15572383_10,0,-1,0,6658,0
6661,(r,70,72,356,358,"Baseline renal ACE positively correlated with the relative rise in proteinuria after adriamycin (r = 0.62, P<0.01), renal interstitial alpha-smooth muscle actin (r = 0.49, P<0.05), interstitial macrophage influx (r = 0.56, P<0.05), interstitial collagen III (r = 0.53, P<0.05), glomerular alpha-smooth muscle actin (r = 0.74, P<0.01) and glomerular desmin (r = 0.48, P<0.05).",15572383_10,0,-1,0,6661,0
6676,vascular endothelial growth factor,19,23,114,148,"In this study, we developed a new hypoxia-responsive reporter vector using a hypoxia-responsive element of the 5' vascular endothelial growth factor untranslated region and generated a novel hypoxia-sensing transgenic rat.",15579441_2,0,-1,0,6676,0
6681,puromycin,14,15,74,83,"With this model, we were able to identify diffuse cortical hypoxia in the puromycin aminonucleoside-induced nephrotic syndrome and focal and segmental hypoxia in the remnant kidney model.",15579441_4,0,-1,0,6681,0
6685,puromycin aminonucleoside,18,20,128,153,"Expression of the hypoxia-responsive transgene increased throughout the observation period, reaching 2.2-fold at 2 weeks in the puromycin aminonucleoside model and 2.6-fold at 4 weeks in the remnant kidney model, whereas that of vascular endothelial growth factor showed a mild decrease, reflecting distinct behaviors of the two genes.",15579441_5,0,-1,0,6685,0
6687,vascular endothelial growth factor,35,39,229,263,"Expression of the hypoxia-responsive transgene increased throughout the observation period, reaching 2.2-fold at 2 weeks in the puromycin aminonucleoside model and 2.6-fold at 4 weeks in the remnant kidney model, whereas that of vascular endothelial growth factor showed a mild decrease, reflecting distinct behaviors of the two genes.",15579441_5,0,-1,0,6687,0
6720,biological response,9,11,25,44,"A 34.4% (12/27) of SVR + biological response in group A was higher than 10% (1/10) in group B ( P = 0.051), with slight significance.",15580403_8,0,-1,0,6720,0
6759,loop diuretics,20,22,137,151,"Patients who developed renal insufficiency had lower baseline body weight and higher baseline serum creatinine, required higher doses of loop diuretics, and were more likely to be treated with thiazide diuretics than controls.",15632880_9,0,-1,0,6759,0
6761,thiazide diuretics,31,33,193,211,"Patients who developed renal insufficiency had lower baseline body weight and higher baseline serum creatinine, required higher doses of loop diuretics, and were more likely to be treated with thiazide diuretics than controls.",15632880_9,0,-1,0,6761,0
6780,Nuclear Antigen,5,7,58,73,Immunohistochemical reactions for Anti-Proliferating Cell Nuclear Antigen (PCNA) were performed.,15638391_5,0,-1,0,6780,0
6811,(r,11,13,77,79,The perfusion defect correlated significantly with the anatomic area at risk (r = 0.74; p less than 0.002).,1564236_5,0,-1,0,6811,0
6819,(r,16,18,105,107,The size of the perfusion defect during stenosis correlated significantly with the anatomic area at risk (r = 0.61; p = 0.02).,1564236_8,0,-1,0,6819,0
6824,(r,28,30,189,191,Thallium-201 SPECT demonstrated a perfusion defect in all 14 dogs analyzed during dipyridamole-induced hyperemia; the size of the perfusion defect correlated with the anatomic area at risk (r = 0.58; p less than 0.03) and with the perfusion defect by contrast echocardiography (r = 0.58; p less than 0.03).,1564236_9,0,-1,0,6824,0
6826,(r,46,48,277,279,Thallium-201 SPECT demonstrated a perfusion defect in all 14 dogs analyzed during dipyridamole-induced hyperemia; the size of the perfusion defect correlated with the anatomic area at risk (r = 0.58; p less than 0.03) and with the perfusion defect by contrast echocardiography (r = 0.58; p less than 0.03).,1564236_9,0,-1,0,6826,0
6879,MK-801,8,9,41,47,"Second, we investigated the effect of IT MK-801 (30 mug) on the histopathologic changes in the spinal cord after morphine-induced spastic paraparesis.",15673851_5,0,-1,0,6879,0
6887,MK-801,1,2,3,9,IT MK-801 significantly reduced the number of dark-stained alpha-motoneurons after morphine-induced spastic paraparesis compared with the saline group.,15673851_8,0,-1,0,6887,0
6892,opioids,3,4,16,23,We suggest that opioids may be neurotoxic in the setting of spinal cord ischemia via NMDA receptor activation.,15673851_10,0,-1,0,6892,0
6897,antiarrhythmic drug,4,6,35,54,Amiodarone represents an effective antiarrhythmic drug for cardioversion of recent-onset atrial fibrillation (AF) and maintenance of sinus rhythm.,15686794_1,0,-1,0,6897,0
6929,amphetamine-,27,28,185,197,"To examine the relationship between quantitative stimulant drug levels, catecholamines, and psychotic symptoms, nineteen patients in a psychiatric emergency service with a diagnosis of amphetamine- or cocaine-induced psychosis were interviewed, and plasma and urine were collected for quantitative assays of stimulant drug and catecholamine metabolite levels.",15764424_1,0,-1,0,6929,0
6958,amisulpride,3,4,29,40,Pheochromocytoma unmasked by amisulpride and tiapride.,15811908_0,0,-1,0,6958,0
6959,tiapride,5,6,45,53,Pheochromocytoma unmasked by amisulpride and tiapride.,15811908_0,0,-1,0,6959,0
6961,amisulpride,13,14,83,94,OBJECTIVE: To describe the unmasking of pheochromocytoma in a patient treated with amisulpride and tiapride.,15811908_1,0,-1,0,6961,0
6962,tiapride,15,16,99,107,OBJECTIVE: To describe the unmasking of pheochromocytoma in a patient treated with amisulpride and tiapride.,15811908_1,0,-1,0,6962,0
6966,amisulpride,22,23,134,145,CASE SUMMARY: A 42-year-old white man developed acute hypertension with severe headache and vomiting 2 hours after the first doses of amisulpride 100 mg and tiapride 100 mg.,15811908_2,0,-1,0,6966,0
6967,tiapride,26,27,157,165,CASE SUMMARY: A 42-year-old white man developed acute hypertension with severe headache and vomiting 2 hours after the first doses of amisulpride 100 mg and tiapride 100 mg.,15811908_2,0,-1,0,6967,0
6968,nicardipine,12,13,85,96,"Both drugs were immediately discontinued, and the patient recovered after subsequent nicardipine and verapamil treatment.",15811908_3,0,-1,0,6968,0
6977,amisulpride,19,20,120,131,"In our case, use of the Naranjo probability scale indicated a possible relationship between the hypertensive crisis and amisulpride and tiapride therapy.",15811908_6,0,-1,0,6977,0
6978,tiapride,21,22,136,144,"In our case, use of the Naranjo probability scale indicated a possible relationship between the hypertensive crisis and amisulpride and tiapride therapy.",15811908_6,0,-1,0,6978,0
6982,tiapride,14,15,98,106,Physicians and other healthcare professionals should be aware of this potential adverse effect of tiapride and amisulpride.,15811908_8,0,-1,0,6982,0
6983,amisulpride,16,17,111,122,Physicians and other healthcare professionals should be aware of this potential adverse effect of tiapride and amisulpride.,15811908_8,0,-1,0,6983,0
7018,Valproic acid,0,2,0,13,"Valproic acid I: time course of lipid peroxidation biomarkers, liver toxicity, and valproic acid metabolite levels in rats.",15858223_0,0,-1,0,7018,0
7021,biomarkers,9,10,51,61,"Valproic acid I: time course of lipid peroxidation biomarkers, liver toxicity, and valproic acid metabolite levels in rats.",15858223_0,0,-1,0,7021,0
7023,valproic acid,15,17,83,96,"Valproic acid I: time course of lipid peroxidation biomarkers, liver toxicity, and valproic acid metabolite levels in rats.",15858223_0,0,-1,0,7023,0
7025,valproic acid,4,6,17,30,"A single dose of valproic acid (VPA), which is a widely used antiepileptic drug, is associated with oxidative stress in rats, as recently demonstrated by elevated levels of 15-F(2t)-isoprostane (15-F(2t)-IsoP).",15858223_1,0,-1,0,7025,0
7027,antiepileptic drug,15,17,61,79,"A single dose of valproic acid (VPA), which is a widely used antiepileptic drug, is associated with oxidative stress in rats, as recently demonstrated by elevated levels of 15-F(2t)-isoprostane (15-F(2t)-IsoP).",15858223_1,0,-1,0,7027,0
7049,S-transferase,10,11,72,85,Liver toxicity was evaluated based on serum levels of alpha-glutathione S-transferase (alpha-GST) and by histology.,15858223_7,0,-1,0,7049,0
7081,cyclosporine,5,6,28,40,"Three cases were related to cyclosporine, and 1 case was secondary to both cyclosporine and tacrolimus.",15859940_8,0,-1,0,7081,0
7082,cyclosporine,14,15,75,87,"Three cases were related to cyclosporine, and 1 case was secondary to both cyclosporine and tacrolimus.",15859940_8,0,-1,0,7082,0
7083,tacrolimus,16,17,92,102,"Three cases were related to cyclosporine, and 1 case was secondary to both cyclosporine and tacrolimus.",15859940_8,0,-1,0,7083,0
7091,cyclosporine,5,6,35,47,"Other causes include drug-related (cyclosporine, tacrolimus) toxicity, procoagulant status, and antibody-mediated rejection.",15859940_11,0,-1,0,7091,0
7092,tacrolimus,7,8,49,59,"Other causes include drug-related (cyclosporine, tacrolimus) toxicity, procoagulant status, and antibody-mediated rejection.",15859940_11,0,-1,0,7092,0
7098,cyclosporine,16,17,106,118,"We found that the most-frequent cause of thrombotic microangiopathy was drug related, secondary mainly to cyclosporine.",15859940_12,0,-1,0,7098,0
7154,immune globulin,31,33,185,200,"Assessment was done on the following: prenatal screening for hepatitis B and rubella, administration of the hepatitis B vaccine birth dose to all infants, administration of hepatitis B immune globulin to infants who were born to hepatitis B surface antigen-positive mothers, rubella immunity, and administration of in-hospital postpartum rubella vaccine to rubella nonimmune women.",15867025_3,0,-1,0,7154,0
7165,immune globulin,15,17,100,115,All infants who were born to hepatitis B surface antigen-positive mothers also received hepatitis B immune globulin.,15867025_6,0,-1,0,7165,0
7170,rubella vaccine,2,4,23,38,In-hospital postpartum rubella vaccine administration was documented for 75.6% of nonimmune women.,15867025_10,0,-1,0,7170,0
7183,Sch,19,20,98,101,"Here, we describe a case of severe masseter muscle rigidity (jaw of steel) after succinylcholine (Sch) administration during general anesthetic management for rigid bronchoscopic removal of a tracheal foreign body.",15893386_3,0,-1,0,7183,0
7185,propofol,5,6,43,51,Anesthesia was continued uneventfully with propofol infusion while all facilities were available to detect and treat malignant hyperthermia.,15893386_4,0,-1,0,7185,0
7187,Dexrazoxane,0,1,0,11,Dexrazoxane protects against myelosuppression from the DNA cleavage-enhancing drugs etoposide and daunorubicin but not doxorubicin.,15897593_0,0,-1,0,7187,0
7189,etoposide,9,10,84,93,Dexrazoxane protects against myelosuppression from the DNA cleavage-enhancing drugs etoposide and daunorubicin but not doxorubicin.,15897593_0,0,-1,0,7189,0
7190,daunorubicin,11,12,98,110,Dexrazoxane protects against myelosuppression from the DNA cleavage-enhancing drugs etoposide and daunorubicin but not doxorubicin.,15897593_0,0,-1,0,7190,0
7196,Dexrazoxane,0,1,0,11,Dexrazoxane (ICRF-187) is recommended for protection against anthracycline-induced cardiotoxicity.,15897593_2,0,-1,0,7196,0
7197,ICRF-187,2,3,13,21,Dexrazoxane (ICRF-187) is recommended for protection against anthracycline-induced cardiotoxicity.,15897593_2,0,-1,0,7197,0
7200,dexrazoxane,15,16,109,120,"EXPERIMENTAL DESIGN: Because of their widespread use, the hematologic toxicity following coadministration of dexrazoxane and these three structurally different DNA cleavage enhancers was investigated: Sensitivity of human and murine blood progenitor cells to etoposide, daunorubicin, and doxorubicin +/- dexrazoxane was determined in granulocyte-macrophage colony forming assays.",15897593_3,0,-1,0,7200,0
7202,etoposide,36,37,259,268,"EXPERIMENTAL DESIGN: Because of their widespread use, the hematologic toxicity following coadministration of dexrazoxane and these three structurally different DNA cleavage enhancers was investigated: Sensitivity of human and murine blood progenitor cells to etoposide, daunorubicin, and doxorubicin +/- dexrazoxane was determined in granulocyte-macrophage colony forming assays.",15897593_3,0,-1,0,7202,0
7203,daunorubicin,38,39,270,282,"EXPERIMENTAL DESIGN: Because of their widespread use, the hematologic toxicity following coadministration of dexrazoxane and these three structurally different DNA cleavage enhancers was investigated: Sensitivity of human and murine blood progenitor cells to etoposide, daunorubicin, and doxorubicin +/- dexrazoxane was determined in granulocyte-macrophage colony forming assays.",15897593_3,0,-1,0,7203,0
7204,dexrazoxane,44,45,304,315,"EXPERIMENTAL DESIGN: Because of their widespread use, the hematologic toxicity following coadministration of dexrazoxane and these three structurally different DNA cleavage enhancers was investigated: Sensitivity of human and murine blood progenitor cells to etoposide, daunorubicin, and doxorubicin +/- dexrazoxane was determined in granulocyte-macrophage colony forming assays.",15897593_3,0,-1,0,7204,0
7209,etoposide,10,11,49,58,"Likewise, in vivo, B6D2F1 mice were treated with etoposide, daunorubicin, and doxorubicin, with or without dexrazoxane over a wide range of doses: posttreatment, a full hematologic evaluation was done.",15897593_4,0,-1,0,7209,0
7210,daunorubicin,12,13,60,72,"Likewise, in vivo, B6D2F1 mice were treated with etoposide, daunorubicin, and doxorubicin, with or without dexrazoxane over a wide range of doses: posttreatment, a full hematologic evaluation was done.",15897593_4,0,-1,0,7210,0
7211,dexrazoxane,20,21,107,118,"Likewise, in vivo, B6D2F1 mice were treated with etoposide, daunorubicin, and doxorubicin, with or without dexrazoxane over a wide range of doses: posttreatment, a full hematologic evaluation was done.",15897593_4,0,-1,0,7211,0
7214,dexrazoxane,5,6,27,38,"RESULTS: Nontoxic doses of dexrazoxane reduced myelosuppression and weight loss from daunorubicin and etoposide in mice and antagonized their antiproliferative effects in the colony assay; however, dexrazoxane neither reduced myelosuppression, weight loss, nor the in vitro cytotoxicity from doxorubicin.",15897593_5,0,-1,0,7214,0
7217,daunorubicin,12,13,85,97,"RESULTS: Nontoxic doses of dexrazoxane reduced myelosuppression and weight loss from daunorubicin and etoposide in mice and antagonized their antiproliferative effects in the colony assay; however, dexrazoxane neither reduced myelosuppression, weight loss, nor the in vitro cytotoxicity from doxorubicin.",15897593_5,0,-1,0,7217,0
7218,etoposide,14,15,102,111,"RESULTS: Nontoxic doses of dexrazoxane reduced myelosuppression and weight loss from daunorubicin and etoposide in mice and antagonized their antiproliferative effects in the colony assay; however, dexrazoxane neither reduced myelosuppression, weight loss, nor the in vitro cytotoxicity from doxorubicin.",15897593_5,0,-1,0,7218,0
7221,dexrazoxane,29,30,198,209,"RESULTS: Nontoxic doses of dexrazoxane reduced myelosuppression and weight loss from daunorubicin and etoposide in mice and antagonized their antiproliferative effects in the colony assay; however, dexrazoxane neither reduced myelosuppression, weight loss, nor the in vitro cytotoxicity from doxorubicin.",15897593_5,0,-1,0,7221,0
7225,dexrazoxane,9,10,63,74,"CONCLUSION: Although our findings support the observation that dexrazoxane reduces neither hematologic activity nor antitumor activity from doxorubicin clinically, the potent antagonism of daunorubicin activity raises concern; a possible interference with anticancer efficacy certainly would call for renewed attention.",15897593_6,0,-1,0,7225,0
7228,daunorubicin,25,26,189,201,"CONCLUSION: Although our findings support the observation that dexrazoxane reduces neither hematologic activity nor antitumor activity from doxorubicin clinically, the potent antagonism of daunorubicin activity raises concern; a possible interference with anticancer efficacy certainly would call for renewed attention.",15897593_6,0,-1,0,7228,0
7230,etoposide,6,7,39,48,Our data also suggest that significant etoposide dose escalation is perhaps possible by the use of dexrazoxane.,15897593_7,0,-1,0,7230,0
7231,dexrazoxane,16,17,99,110,Our data also suggest that significant etoposide dose escalation is perhaps possible by the use of dexrazoxane.,15897593_7,0,-1,0,7231,0
7234,dexrazoxane,8,9,60,71,Clinical trials in patients with brain metastases combining dexrazoxane and high doses of etoposide is ongoing with the aim of improving efficacy without aggravating hematologic toxicity.,15897593_8,0,-1,0,7234,0
7235,etoposide,13,14,90,99,Clinical trials in patients with brain metastases combining dexrazoxane and high doses of etoposide is ongoing with the aim of improving efficacy without aggravating hematologic toxicity.,15897593_8,0,-1,0,7235,0
7245,illicit drug,3,5,19,31,"Thyroid disorders, illicit drug or stimulant use, and acute alcohol intoxication are among these causes.",15899738_3,0,-1,0,7245,0
7258,unfractionated heparin,10,12,62,84,"The patient was admitted to the hospital, anticoagulated with unfractionated heparin, and given intravenous diltiazem for rate control and intravenous amiodarone for rate and rhythm control.",15899738_8,0,-1,0,7258,0
7293,propofol,12,13,83,91,Assessment of the onset and persistence of amnesia during procedural sedation with propofol.,15930398_0,0,-1,0,7293,0
7296,propofol,20,21,127,135,"OBJECTIVES: To assess patients' ability to repeat and recall words presented to them while undergoing procedural sedation with propofol, and correlate their recall with their level of awareness as measured by bispectral index (BIS) monitoring.",15930398_1,0,-1,0,7296,0
7300,propofol,17,18,124,132,"METHODS: This was a prospective, single-intervention study of consenting adult patients undergoing procedural sedation with propofol between December 28, 2002, and October 31, 2003.",15930398_2,0,-1,0,7300,0
7327,serotonergic,12,13,97,109,The selective 5-HT6 receptor antagonist Ro4368554 restores memory performance in cholinergic and serotonergic models of memory deficiency in the rat.,15957009_0,0,-1,0,7327,0
7335,serotonergic-,33,34,256,269,"The present study sought to characterize the cognitive-enhancing effects of the 5-HT(6) antagonist Ro4368554 (3-benzenesulfonyl-7-(4-methyl-piperazin-1-yl)1H-indole) in a rat object recognition task employing a cholinergic (scopolamine pretreatment) and a serotonergic- (tryptophan (TRP) depletion) deficient model, and compared its pattern of action with that of the acetylcholinesterase inhibitor metrifonate.",15957009_3,0,-1,0,7335,0
7337,metrifonate,17,18,116,127,"Initial testing in a time-dependent forgetting task employing a 24-h delay between training and testing showed that metrifonate improved object recognition (at 10 and 30 mg/kg, p.o.), whereas Ro4368554 was inactive.",15957009_4,0,-1,0,7337,0
7339,at 10,22,24,157,162,"Initial testing in a time-dependent forgetting task employing a 24-h delay between training and testing showed that metrifonate improved object recognition (at 10 and 30 mg/kg, p.o.), whereas Ro4368554 was inactive.",15957009_4,0,-1,0,7339,0
7343,metrifonate,16,17,63,74,"Both, Ro4368554 (3 and 10 mg/kg, intraperitoneally (i.p.)) and metrifonate (10 mg/kg, p.o., respectively) reversed memory deficits induced by scopolamine and TRP depletion (10 mg/kg, i.p., and 3 mg/kg, p.o., respectively).",15957009_5,0,-1,0,7343,0
7351,receptor antagonists,45,47,272,292,"In conclusion, although Ro4368554 did not improve a time-related retention deficit, it reversed a cholinergic and a serotonergic memory deficit, suggesting that both mechanisms may be involved in the facilitation of object memory by Ro4368554 and, possibly, other 5-HT(6) receptor antagonists.",15957009_6,0,-1,0,7351,0
7362,receptor antagonists,8,10,51,71,Two prodrugs of potent and selective GluR5 kainate receptor antagonists actives in three animal models of pain.,15974569_0,0,-1,0,7362,0
7364,Amino acids,0,2,0,11,"Amino acids 5 and 7, two potent and selective competitive GluR5 KA receptor antagonists, exhibited high GluR5 receptor affinity over other glutamate receptors.",15974569_1,0,-1,0,7364,0
7366,receptor antagonists,13,15,67,87,"Amino acids 5 and 7, two potent and selective competitive GluR5 KA receptor antagonists, exhibited high GluR5 receptor affinity over other glutamate receptors.",15974569_1,0,-1,0,7366,0
7368,glutamate receptors,23,25,139,158,"Amino acids 5 and 7, two potent and selective competitive GluR5 KA receptor antagonists, exhibited high GluR5 receptor affinity over other glutamate receptors.",15974569_1,0,-1,0,7368,0
7377,baclofen,6,7,49,57,Discontinuation of azithromycin and therapy with baclofen finally resolved hiccups.,15985056_4,0,-1,0,7377,0
7380,methylprednisolone,4,5,35,53,"Corticosteroids (dexamethasone and methylprednisolone), benzodiazepines (midazolam) and general anaesthesia have been the specific agents mentioned most frequently in the literature as being associated with the development of hiccups.",15985056_7,0,-1,0,7380,0
7394,monoclonal antibody,4,6,30,49,Evaluation of the anticocaine monoclonal antibody GNC92H2 as an immunotherapy for cocaine overdose.,16005948_0,0,-1,0,7394,0
7419,Calcium carbonate,0,2,0,17,Calcium carbonate toxicity: the updated milk-alkali syndrome; report of 3 cases and review of the literature.,16006300_0,0,-1,0,7419,0
7428,parathyroid hormone,16,18,93,112,"RESULTS: The 3 patients had acute renal insufficiency, relative metabolic alkalosis, and low parathyroid hormone (PTH), PTH-related peptide, and 1,25-dihydroxyvitamin D concentrations.",16006300_3,0,-1,0,7428,0
7433,pamidronate,10,11,69,80,"The 2 patients with the higher serum calcium concentrations received pamidronate intravenously (60 and 30 mg, respectively), which caused severe hypocalcemia.",16006300_6,0,-1,0,7433,0
7435,(1,13,15,74,76,"Of the 3 patients, 2 were ingesting acceptable doses of elemental calcium (1 g and 2 g daily, respectively) in the form of calcium carbonate.",16006300_7,0,-1,0,7435,0
7436,calcium carbonate,27,29,123,140,"Of the 3 patients, 2 were ingesting acceptable doses of elemental calcium (1 g and 2 g daily, respectively) in the form of calcium carbonate.",16006300_7,0,-1,0,7436,0
7441,calcium carbonate,22,24,144,161,CONCLUSION: Milk-alkali syndrome may be a common cause of unexplained hypercalcemia and can be precipitated by small amounts of orally ingested calcium carbonate in susceptible persons.,16006300_9,0,-1,0,7441,0
7443,Pamidronate,0,1,0,11,"Pamidronate treatment is associated with considerable risk for hypocalcemia, even in cases of initially severe hypercalcemia.",16006300_11,0,-1,0,7443,0
7496,dopaminergic,7,8,47,59,Cognitive functions may also be involved since dopaminergic and serotonergic cellular elements at the brainstem level are also implicated.,1610717_10,0,-1,0,7496,0
7497,serotonergic,9,10,64,76,Cognitive functions may also be involved since dopaminergic and serotonergic cellular elements at the brainstem level are also implicated.,1610717_10,0,-1,0,7497,0
7527,paclitaxel,19,20,127,137,"For human glioblastoma recurrences, the feasibility, safety, and short-term effects of a surgical intracavitary application of paclitaxel and carboplatin encapsulated by liquid crystalline cubic phases are examined in a pilot study.",16132524_4,0,-1,0,7527,0
7528,carboplatin,21,22,142,153,"For human glioblastoma recurrences, the feasibility, safety, and short-term effects of a surgical intracavitary application of paclitaxel and carboplatin encapsulated by liquid crystalline cubic phases are examined in a pilot study.",16132524_4,0,-1,0,7528,0
7534,paclitaxel,20,21,138,148,A total of 12 patients with a recurrence of a glioblastoma multiforme underwent re-resection and received an intracavitary application of paclitaxel and carboplatin cubic phases in different dosages.,16132524_5,0,-1,0,7534,0
7535,carboplatin,22,23,153,164,A total of 12 patients with a recurrence of a glioblastoma multiforme underwent re-resection and received an intracavitary application of paclitaxel and carboplatin cubic phases in different dosages.,16132524_5,0,-1,0,7535,0
7536,paclitaxel,9,10,45,55,"Six of the patients received more than 15 mg paclitaxel and suffered from moderate to severe brain edema, while the remaining patients received only a total of 15 mg paclitaxel.",16132524_6,0,-1,0,7536,0
7538,paclitaxel,30,31,166,176,"Six of the patients received more than 15 mg paclitaxel and suffered from moderate to severe brain edema, while the remaining patients received only a total of 15 mg paclitaxel.",16132524_6,0,-1,0,7538,0
7543,Lamotrigine,0,1,0,11,Lamotrigine associated with exacerbation or de novo myoclonus in idiopathic generalized epilepsies.,16157917_0,0,-1,0,7543,0
7549,lamotrigine,11,12,72,83,Five patients with idiopathic generalized epilepsies (IGE) treated with lamotrigine (LTG) experienced exacerbation or de novo appearance of myoclonic jerks (MJ).,16157917_1,0,-1,0,7549,0
7551,novo,19,20,121,125,Five patients with idiopathic generalized epilepsies (IGE) treated with lamotrigine (LTG) experienced exacerbation or de novo appearance of myoclonic jerks (MJ).,16157917_1,0,-1,0,7551,0
7578,(1,6,8,39,41,"Administration of graded doses of U-II (1-10,000 ng/mouse) provoked: (1) a dose-dependent reduction in the number of head dips in the hole-board test; (2) a dose-dependent reduction in the number of entries in the white chamber in the black-and-white compartment test, and in the number of entries in the central platform and open arms in the plus-maze test; and (3) a dose-dependent increase in the duration of immobility in the forced-swimming test and tail suspension test.",16160878_6,0,-1,0,7578,0
7579,(1,14,16,69,71,"Administration of graded doses of U-II (1-10,000 ng/mouse) provoked: (1) a dose-dependent reduction in the number of head dips in the hole-board test; (2) a dose-dependent reduction in the number of entries in the white chamber in the black-and-white compartment test, and in the number of entries in the central platform and open arms in the plus-maze test; and (3) a dose-dependent increase in the duration of immobility in the forced-swimming test and tail suspension test.",16160878_6,0,-1,0,7579,0
7587,(3,71,73,363,365,"Administration of graded doses of U-II (1-10,000 ng/mouse) provoked: (1) a dose-dependent reduction in the number of head dips in the hole-board test; (2) a dose-dependent reduction in the number of entries in the white chamber in the black-and-white compartment test, and in the number of entries in the central platform and open arms in the plus-maze test; and (3) a dose-dependent increase in the duration of immobility in the forced-swimming test and tail suspension test.",16160878_6,0,-1,0,7587,0
7623,raloxifene,4,5,26,36,"The effects of short-term raloxifene therapy on fibrinolysis markers: TAFI, tPA, and PAI-1.BACKGROUND: Markers of fibrinolysis, thrombin-activatable fibrinolysis inhibitor (TAFI), tissue-type plasminogen activator (tPA), and plasminogen activator inhibitor-1 (PAI-1) levels were studied for the evaluation of short-term effects of raloxifene administration in postmenopausal women.",16167916_0,0,-1,0,7623,0
7626,thrombin-activatable fibrinolysis inhibitor,21,24,128,171,"The effects of short-term raloxifene therapy on fibrinolysis markers: TAFI, tPA, and PAI-1.BACKGROUND: Markers of fibrinolysis, thrombin-activatable fibrinolysis inhibitor (TAFI), tissue-type plasminogen activator (tPA), and plasminogen activator inhibitor-1 (PAI-1) levels were studied for the evaluation of short-term effects of raloxifene administration in postmenopausal women.",16167916_0,0,-1,0,7626,0
7628,tissue-type plasminogen activator,28,31,180,213,"The effects of short-term raloxifene therapy on fibrinolysis markers: TAFI, tPA, and PAI-1.BACKGROUND: Markers of fibrinolysis, thrombin-activatable fibrinolysis inhibitor (TAFI), tissue-type plasminogen activator (tPA), and plasminogen activator inhibitor-1 (PAI-1) levels were studied for the evaluation of short-term effects of raloxifene administration in postmenopausal women.",16167916_0,0,-1,0,7628,0
7630,raloxifene,52,53,331,341,"The effects of short-term raloxifene therapy on fibrinolysis markers: TAFI, tPA, and PAI-1.BACKGROUND: Markers of fibrinolysis, thrombin-activatable fibrinolysis inhibitor (TAFI), tissue-type plasminogen activator (tPA), and plasminogen activator inhibitor-1 (PAI-1) levels were studied for the evaluation of short-term effects of raloxifene administration in postmenopausal women.",16167916_0,0,-1,0,7630,0
7634,raloxifene hydrochloride,4,6,29,53,Twenty-five women were given raloxifene hydrochloride (60 mg/day) plus calcium (500 mg/day).,16167916_2,0,-1,0,7634,0
7641,raloxifene,5,6,25,35,"RESULTS: Three months of raloxifene treatment was associated with a significant decrease in the plasma TAFI antigen concentrations (16% change, P < 0.01), and a significant increase in tPA antigen concentrations (25% change, P < 0.05).",16167916_7,0,-1,0,7641,0
7648,raloxifene,13,14,80,90,"CONCLUSION: We suggest that the increased risk of venous thromboembolism due to raloxifene treatment may be related to increased tPA levels, but not TAFI levels.",16167916_9,0,-1,0,7648,0
7715,Amisulpride,0,1,0,11,Amisulpride related tic-like symptoms in an adolescent schizophrenic.,16225977_0,0,-1,0,7715,0
7719,olanzapine,13,14,89,99,"Tic disorders can be effectively treated by atypical antipsychotics such as risperidone, olanzapine and ziprasidone.",16225977_1,0,-1,0,7719,0
7723,quetiapine,22,23,134,144,"However, there are two case reports that show tic-like symptoms, including motor and phonic variants, occurring during treatment with quetiapine or clozapine.",16225977_2,0,-1,0,7723,0
7725,amisulpride,16,17,120,131,We present a 15-year-old girl schizophrenic who developed frequent involuntary eye-blinking movements after 5 months of amisulpride treatment (1000 mg per day).,16225977_3,0,-1,0,7725,0
7727,amisulpride,11,12,71,82,The tic-like symptoms resolved completely after we reduced the dose of amisulpride down to 800 mg per day.,16225977_4,0,-1,0,7727,0
7728,her,2,3,9,12,"However, her psychosis recurred after the dose reduction.",16225977_5,0,-1,0,7728,0
7729,her,3,4,15,18,We then placed her on an additional 100 mg per day of quetiapine.,16225977_6,0,-1,0,7729,0
7730,quetiapine,12,13,54,64,We then placed her on an additional 100 mg per day of quetiapine.,16225977_6,0,-1,0,7730,0
7735,quetiapine,25,26,185,195,"Together with previously reported cases, our patient suggests that tic-like symptoms might occur in certain vulnerable individuals during treatment with atypical antipsychotics such as quetiapine, clozapine, or amisulpride.",16225977_9,0,-1,0,7735,0
7736,amisulpride,30,31,211,222,"Together with previously reported cases, our patient suggests that tic-like symptoms might occur in certain vulnerable individuals during treatment with atypical antipsychotics such as quetiapine, clozapine, or amisulpride.",16225977_9,0,-1,0,7736,0
7737,acitretin,3,4,24,33,Recurrent dysphonia and acitretin.,16274958_0,0,-1,0,7737,0
7738,acitretin,15,16,80,89,We report the case of a woman complaining of dysphonia while she was treated by acitretin.,16274958_1,0,-1,0,7738,0
7739,Her,0,1,0,3,Her symptoms totally regressed after drug withdrawal and reappeared when acitretin was reintroduced.,16274958_2,0,-1,0,7739,0
7741,acitretin,10,11,73,82,Her symptoms totally regressed after drug withdrawal and reappeared when acitretin was reintroduced.,16274958_2,0,-1,0,7741,0
7756,methyl ester,1,3,17,29,Nitro-L-arginine methyl ester: a potential protector against gentamicin ototoxicity.,16298782_0,0,-1,0,7756,0
7758,nitric oxide,1,3,4,16,"The nitric oxide (NO) inhibitor nitro-L-arginine methyl ester (L-NAME) may act as an otoprotectant against high-frequency hearing loss caused by gentamicin, but further studies are needed to confirm this.",16298782_1,0,-1,0,7758,0
7759,methyl ester,8,10,49,61,"The nitric oxide (NO) inhibitor nitro-L-arginine methyl ester (L-NAME) may act as an otoprotectant against high-frequency hearing loss caused by gentamicin, but further studies are needed to confirm this.",16298782_1,0,-1,0,7759,0
7760,L-NAME,11,12,63,69,"The nitric oxide (NO) inhibitor nitro-L-arginine methyl ester (L-NAME) may act as an otoprotectant against high-frequency hearing loss caused by gentamicin, but further studies are needed to confirm this.",16298782_1,0,-1,0,7760,0
7771,L-NAME,2,3,18,24,The otoprotectant L-NAME was administered topically to 12/27 animals.,16298782_5,0,-1,0,7771,0
7774,L-NAME,0,1,0,6,"L-NAME reduced gentamicin-induced hearing loss in the high-frequency range, but gave no protection in the middle or low frequencies.",16298782_7,0,-1,0,7774,0
7841,antinociceptive,8,9,57,72,"These findings indicate that gabapentin has a measurable antinociceptive effect and a stronger antihyperalgesic effect most evident in the brain areas undergoing deactivation, thus supporting the concept that gabapentin is more effective in modulating nociceptive transmission when central sensitization is present.",16330766_9,0,-1,0,7841,0
7859,cytochrome c oxidase,29,32,184,204,"In this study, we investigated whether increased generation of FR during status epilepticus would be sufficient to provoke abnormalities in mtDNA and in the expression and activity of cytochrome c oxidase (CCO), complex IV of the respiratory chain, in the chronic phase of the pilocarpine model of temporal lobe epilepsy.",16337777_3,0,-1,0,7859,0
7879,acute phase,24,26,156,167,"Although evidences of mitochondrial abnormalities were found in previously published studies, our results do not suggest that the FRs, generated during the acute phase, determined important abnormalities in mtDNA, in expression of CCO-I, and in CCO activity.",16337777_7,0,-1,0,7879,0
7892,uric acid,34,36,198,207,The direct nephrotoxic effects of a single dose of 15 mg of suprofen were compared in the recirculating isolated rat kidney perfused with cell-free buffer with or without the addition of 5 mg/dL of uric acid.,1636026_2,0,-1,0,7892,0
7898,uric acid,22,24,138,147,"In contrast, a significant decline in glomerular filtration rate was found after the introduction of suprofen to the kidney perfused with uric acid; no changes were found with suprofen in the absence of uric acid.",1636026_4,0,-1,0,7898,0
7900,uric acid,35,37,203,212,"In contrast, a significant decline in glomerular filtration rate was found after the introduction of suprofen to the kidney perfused with uric acid; no changes were found with suprofen in the absence of uric acid.",1636026_4,0,-1,0,7900,0
7901,uric acid,9,11,57,66,"A significant decrease in the baseline excretion rate of uric acid was found in rats given suprofen, compared with drug-free controls.",1636026_5,0,-1,0,7901,0
7905,uric acid,6,8,37,46,"However, the fractional excretion of uric acid was unchanged between the groups over the experimental period.",1636026_6,0,-1,0,7905,0
7910,uric acid,20,22,126,135,"In summary, suprofen causes acute declines in renal function, most likely by directly altering the intrarenal distribution of uric acid.",1636026_7,0,-1,0,7910,0
7912,ritanserin,2,3,18,28,Microinjection of ritanserin into the CA1 region of hippocampus improves scopolamine-induced amnesia in adult male rats.,16364460_0,0,-1,0,7912,0
7914,ritanserin,3,4,14,24,The effect of ritanserin (5-HT2 antagonist) on scopolamine (muscarinic cholinergic antagonist)-induced amnesia in Morris water maze (MWM) was investigated.,16364460_1,0,-1,0,7914,0
7921,DMSO,11,12,59,63,"One week later, they received repeatedly vehicles (saline, DMSO, saline+DMSO), scopolamine (2 microg/0.5 microl saline/side; 30 min before training), ritanserin (2, 4 and 8 microg/0.5 microl DMSO/side; 20 min before training) and scopolamine (2 microg/0.5 microl; 30 min before ritanserin injection)+ritanserin (4 microg/0.5 microl DMSO) through cannulae each day.",16364460_3,0,-1,0,7921,0
7925,ritanserin,29,30,150,160,"One week later, they received repeatedly vehicles (saline, DMSO, saline+DMSO), scopolamine (2 microg/0.5 microl saline/side; 30 min before training), ritanserin (2, 4 and 8 microg/0.5 microl DMSO/side; 20 min before training) and scopolamine (2 microg/0.5 microl; 30 min before ritanserin injection)+ritanserin (4 microg/0.5 microl DMSO) through cannulae each day.",16364460_3,0,-1,0,7925,0
7929,ritanserin,55,56,278,288,"One week later, they received repeatedly vehicles (saline, DMSO, saline+DMSO), scopolamine (2 microg/0.5 microl saline/side; 30 min before training), ritanserin (2, 4 and 8 microg/0.5 microl DMSO/side; 20 min before training) and scopolamine (2 microg/0.5 microl; 30 min before ritanserin injection)+ritanserin (4 microg/0.5 microl DMSO) through cannulae each day.",16364460_3,0,-1,0,7929,0
7932,DMSO,61,62,332,336,"One week later, they received repeatedly vehicles (saline, DMSO, saline+DMSO), scopolamine (2 microg/0.5 microl saline/side; 30 min before training), ritanserin (2, 4 and 8 microg/0.5 microl DMSO/side; 20 min before training) and scopolamine (2 microg/0.5 microl; 30 min before ritanserin injection)+ritanserin (4 microg/0.5 microl DMSO) through cannulae each day.",16364460_3,0,-1,0,7932,0
7943,ritanserin,4,5,25,35,"However, scopolamine and ritanserin co-administration resulted in a significant decrease in escape latencies and traveled distances as compared to the scopolamine-treated rats.",16364460_8,0,-1,0,7943,0
7947,ritanserin,6,7,41,51,Our findings show that microinjection of ritanserin into the CA1 region of the hippocampus improves the scopolamine-induced amnesia.,16364460_9,0,-1,0,7947,0
7979,/- 2,12,14,80,84,"In contrast, in the nitrendipine-treated group albuminuria increased from 12.8 +/- 2 progressively to 163 +/- 55 compared with 19.2 +/- 9 mg/24 hr in the hypertensive controls.",1639466_9,0,-1,0,7979,0
8010,Her,0,1,0,3,Her QT interval returned to normal upon withdrawal of ketoconazole.,16403073_3,0,-1,0,8010,0
8014,her,8,9,43,46,Genetic study did not find any mutation in her genes that encode cardiac IKr channel proteins.,16403073_4,0,-1,0,8014,0
8026,antineutrophil cytoplasmic antibodies,13,16,73,110,"A rare cause, drug-induced vasculitis, may result from the production of antineutrophil cytoplasmic antibodies (ANCAs) in response to a medication.",16418614_2,0,-1,0,8026,0
8031,ANCA,21,22,153,157,"The diagnosis of propylthiouracil (PTU)-associated vasculitis was made by observation of consistent clinical features, the detection of elevated ANA and ANCA in the blood, and the observed clinical resolution of symptoms following withdrawal of PTU.",16418614_4,0,-1,0,8031,0
8051,Daidzein,0,1,0,8,Daidzein activates choline acetyltransferase from MC-IXC cells and improves drug-induced amnesia.,16428827_0,0,-1,0,8051,0
8062,daidzein,15,16,105,113,"Via the sequential isolation of Pueraria thunbergiana, the active component was ultimately identified as daidzein (4',7-dihydroxy-isoflavone).",16428827_3,0,-1,0,8062,0
8065,daidzein,7,8,39,47,"In order to investigate the effects of daidzein from Pueraria thunbergiana on scopolamine-induced impairments of learning and memory, we conducted a series of in vivo tests.",16428827_4,0,-1,0,8065,0
8069,daidzein,2,3,18,26,"Administration of daidzein (4.5 mg/kg body weight) to mice was shown significantly to reverse scopolamine-induced amnesia, according to the results of a Y-maze test.",16428827_5,0,-1,0,8069,0
8075,daidzein,8,9,38,46,"By way of contrast, mice treated with daidzein prior to the scopolamine injections were noticeably protected from this performance impairment (an approximately 12%-21% decrease in alternation behavior).",16428827_7,0,-1,0,8075,0
8078,daidzein,4,5,28,36,"These results indicate that daidzein might play a role in acetylcholine biosynthesis as a ChAT activator, and that it also ameliorates scopolamine-induced amnesia.",16428827_8,0,-1,0,8078,0
8082,tolterodine,14,15,89,100,Urinary symptoms and quality of life changes in Thai women with overactive bladder after tolterodine treatment.,16471092_0,0,-1,0,8082,0
8087,tolterodine,22,23,120,131,OBJECTIVES: To study the urinary symptoms and quality of life changes in Thai women with overactive bladder (OAB) after tolterodine treatment.,16471092_1,0,-1,0,8087,0
8091,Tolterodine,0,1,0,11,"Tolterodine 2 mg, twice daily was given.",16471092_3,0,-1,0,8091,0
8094,Short form,0,2,0,10,Short form 36 (SF36) questionaires (Thai version) were given before and after 8 weeks of treatment.,16471092_5,0,-1,0,8094,0
8107,Tolterodine,2,3,12,23,CONCLUSION: Tolterodine was well tolerated and its effects improved the quality of life in Thai women with OAB.,16471092_12,0,-1,0,8107,0
8110,Remifentanil,0,1,0,12,Remifentanil pretreatment reduces myoclonus after etomidate.,16563323_0,0,-1,0,8110,0
8112,etomidate,5,6,50,59,Remifentanil pretreatment reduces myoclonus after etomidate.,16563323_0,0,-1,0,8112,0
8114,remifentanil,16,17,85,97,STUDY OBJECTIVE: The aim of the study was to compare the effect of pretreatment with remifentanil 1 microg/kg and the effect of gender on the incidence of myoclonus after anesthesia induction with etomidate.,16563323_1,0,-1,0,8114,0
8116,etomidate,33,34,197,206,STUDY OBJECTIVE: The aim of the study was to compare the effect of pretreatment with remifentanil 1 microg/kg and the effect of gender on the incidence of myoclonus after anesthesia induction with etomidate.,16563323_1,0,-1,0,8116,0
8120,remifentanil,12,13,85,97,PATIENTS: Sixty patients were pretreated in a randomized double-blinded fashion with remifentanil 1 microg/kg or placebo.,16563323_4,0,-1,0,8120,0
8122,remifentanil,3,4,18,30,"Two minutes after remifentanil or placebo injection, etomidate 0.3 mg/kg was given.",16563323_5,0,-1,0,8122,0
8123,etomidate,8,9,53,62,"Two minutes after remifentanil or placebo injection, etomidate 0.3 mg/kg was given.",16563323_5,0,-1,0,8123,0
8124,remifentanil,12,13,72,84,MAIN RESULTS: The incidence of myoclonus was significantly lower in the remifentanil group (6.7%) than in the placebo group (70%) (P < 0.001).,16563323_8,0,-1,0,8124,0
8128,etomidate,16,17,110,119,"In the placebo group, male patients were associated with significantly increased incidence of myoclonus after etomidate administration.",16563323_10,0,-1,0,8128,0
8130,remifentanil,4,5,30,42,"CONCLUSION: Pretreatment with remifentanil 1 microg/kg reduced myoclonus after etomidate induction without side effects such as sedation, apnea, nausea, or pruritus.",16563323_11,0,-1,0,8130,0
8131,etomidate,10,11,79,88,"CONCLUSION: Pretreatment with remifentanil 1 microg/kg reduced myoclonus after etomidate induction without side effects such as sedation, apnea, nausea, or pruritus.",16563323_11,0,-1,0,8131,0
8133,etomidate,9,10,65,74,Men experience increased incidence of myoclonus than women after etomidate administration.,16563323_12,0,-1,0,8133,0
8156,serotonin transporter,3,5,20,41,Memory function and serotonin transporter promoter gene polymorphism in ecstasy (MDMA) users.,16574713_0,0,-1,0,8156,0
8199,polyphenol,12,13,66,76,"The current study dealt with the protective role of mangiferin, a polyphenol from Mangifera indica Linn. (Anacardiaceae), on isoproterenol (ISPH)-induced myocardial infarction (MI) in rats through its antioxidative mechanism.",16584858_1,0,-1,0,8199,0
8208,dehydrogenase,37,38,204,217,"Subcutaneous injection of ISPH (200 mg/kg body weight in 1 ml saline) to rats for 2 consecutive days caused myocardial damage in rat heart, which was determined by the increased activity of serum lactate dehydrogenase (LDH) and creatine phosphokinase isoenzymes (CK-MB), increased uric acid level and reduced plasma iron binding capacity.",16584858_2,0,-1,0,8208,0
8212,uric acid,50,52,281,290,"Subcutaneous injection of ISPH (200 mg/kg body weight in 1 ml saline) to rats for 2 consecutive days caused myocardial damage in rat heart, which was determined by the increased activity of serum lactate dehydrogenase (LDH) and creatine phosphokinase isoenzymes (CK-MB), increased uric acid level and reduced plasma iron binding capacity.",16584858_2,0,-1,0,8212,0
8219,superoxide dismutase,7,9,45,65,"The heart tissue antioxidant enzymes such as superoxide dismutase, catalase, glutathione peroxidase, glutathione transferase and glutathione reductase activities, non-enzymic antioxidants such as cerruloplasmin, Vitamin C, Vitamin E and glutathione levels were altered in MI rats.",16584858_4,0,-1,0,8219,0
8220,glutathione peroxidase,12,14,77,99,"The heart tissue antioxidant enzymes such as superoxide dismutase, catalase, glutathione peroxidase, glutathione transferase and glutathione reductase activities, non-enzymic antioxidants such as cerruloplasmin, Vitamin C, Vitamin E and glutathione levels were altered in MI rats.",16584858_4,0,-1,0,8220,0
8221,glutathione transferase,15,17,101,124,"The heart tissue antioxidant enzymes such as superoxide dismutase, catalase, glutathione peroxidase, glutathione transferase and glutathione reductase activities, non-enzymic antioxidants such as cerruloplasmin, Vitamin C, Vitamin E and glutathione levels were altered in MI rats.",16584858_4,0,-1,0,8221,0
8224,Vitamin C,28,30,212,221,"The heart tissue antioxidant enzymes such as superoxide dismutase, catalase, glutathione peroxidase, glutathione transferase and glutathione reductase activities, non-enzymic antioxidants such as cerruloplasmin, Vitamin C, Vitamin E and glutathione levels were altered in MI rats.",16584858_4,0,-1,0,8224,0
8225,Vitamin E,31,33,223,232,"The heart tissue antioxidant enzymes such as superoxide dismutase, catalase, glutathione peroxidase, glutathione transferase and glutathione reductase activities, non-enzymic antioxidants such as cerruloplasmin, Vitamin C, Vitamin E and glutathione levels were altered in MI rats.",16584858_4,0,-1,0,8225,0
8226,glutathione,34,35,237,248,"The heart tissue antioxidant enzymes such as superoxide dismutase, catalase, glutathione peroxidase, glutathione transferase and glutathione reductase activities, non-enzymic antioxidants such as cerruloplasmin, Vitamin C, Vitamin E and glutathione levels were altered in MI rats.",16584858_4,0,-1,0,8226,0
8230,dimethyl sulphoxide,14,16,78,97,Upon pretreatment with mangiferin (100 mg/kg body weight suspended in 2 ml of dimethyl sulphoxide) given intraperitoneally for 28 days to MI rats protected the above-mentioned parameters to fall from the normal levels.,16584858_5,0,-1,0,8230,0
8265,natriuretic peptide,7,9,48,67,"Diagnostic markers such as N-terminal pro brain natriuretic peptide (NT-proBNP) or high-sensitive C-reactive protein might help in the early identification of patients at risk, thus avoiding the occurrence of serious cardiovascular toxicity.",16586083_5,0,-1,0,8265,0
8275,convulsant,17,18,81,91,"Male Sprague-Dawley rats were injected with saline on postnatal day (P) 20, or a convulsant dose of pilocarpine on P20 or P45.",16596970_4,0,-1,0,8275,0
8277,P45,24,25,122,125,"Male Sprague-Dawley rats were injected with saline on postnatal day (P) 20, or a convulsant dose of pilocarpine on P20 or P45.",16596970_4,0,-1,0,8277,0
8280,P45,11,12,76,79,"Pilocarpine on either day induced status epilepticus; status epilepticus at P45 resulted in CA3 cell loss and spontaneous seizures, whereas P20 rats had no cell loss or spontaneous seizures.",16596970_5,0,-1,0,8280,0
8291,P45,3,4,20,23,Status epilepticus (P45) rats failed to acquire either sound-source location or sound-silence discriminations.,16596970_9,0,-1,0,8291,0
8297,Nerve growth factor,0,3,0,19,Nerve growth factor and prostaglandins in the urine of female patients with overactive bladder.,16600756_0,0,-1,0,8297,0
8308,PGE2,2,3,5,9,"NGF, PGE2, PGF2alpha and PGI2 were measured using enzyme-linked immunosorbent assay and compared between the groups.",16600756_6,0,-1,0,8308,0
8309,PGF2alpha,4,5,11,20,"NGF, PGE2, PGF2alpha and PGI2 were measured using enzyme-linked immunosorbent assay and compared between the groups.",16600756_6,0,-1,0,8309,0
8315,PGE2,5,6,22,26,"RESULTS: Urinary NGF, PGE2 and PGF2alpha were significantly increased in patients with OAB compared with controls (p <0.05).",16600756_8,0,-1,0,8315,0
8316,PGF2alpha,7,8,31,40,"RESULTS: Urinary NGF, PGE2 and PGF2alpha were significantly increased in patients with OAB compared with controls (p <0.05).",16600756_8,0,-1,0,8316,0
8321,PGE2,5,6,29,33,In patients with OAB urinary PGE2 positively correlated with volume at first desire to void and maximum cystometric capacity (p <0.05).,16600756_10,0,-1,0,8321,0
8323,PGF2alpha,3,4,13,22,"Urinary NGF, PGF2alpha and PGI2 did not correlate with urodynamic parameters in patients with OAB.",16600756_11,0,-1,0,8323,0
8349,Recombinant human,0,2,0,17,Recombinant human erythropoietin has been used to manage ribavirin-associated anemia but has other potential disadvantages.,16629641_7,0,-1,0,8349,0
8395,amsacrine,5,6,22,31,Phase II study of the amsacrine analogue CI-921 (NSC 343499) in non-small cell lung cancer.,1664218_0,0,-1,0,8395,0
8403,topoisomerase II,12,14,117,133,"CI-921 (NSC 343499; 9-[[2-methoxy-4-[(methylsulphonyl)amino]phenyl]amino] -N,5-dimethyl- 4-acridinecarboxamide) is a topoisomerase II poison with high experimental antitumour activity.",1664218_1,0,-1,0,8403,0
8457,Ethambutol,2,3,14,24,"INTRODUCTION: Ethambutol is used in the treatment of tuberculosis, which is still prevalent in Southeast Asia, and can be associated with permanent visual loss.",16710500_1,0,-1,0,8457,0
8471,ethambutol,4,5,28,38,"TREATMENT: Despite stopping ethambutol on diagnosis, visual function continued to deteriorate for a few months.",16710500_6,0,-1,0,8471,0
8477,Ethambutol,2,3,13,23,CONCLUSIONS: Ethambutol usage is associated with permanent visual loss and should be avoided if possible or used with caution and proper ophthalmological follow-up.,16710500_10,0,-1,0,8477,0
8481,ethambutol,7,8,39,49,"The author postulates that in cases of ethambutol associated chiasmopathy, ethambutol may initially affect the optic nerves and subsequently progress to involve the optic chiasm.",16710500_11,0,-1,0,8481,0
8483,ethambutol,11,12,75,85,"The author postulates that in cases of ethambutol associated chiasmopathy, ethambutol may initially affect the optic nerves and subsequently progress to involve the optic chiasm.",16710500_11,0,-1,0,8483,0
8500,creatine phosphokinase,6,8,40,62,"Laboratory tests showed an elevation of creatine phosphokinase (2218 IU/L), aspartate aminotransferase (134 IU/L), alanine aminotransferase (78 IU/L), and BUN (27.9 mg/ml) levels.",16720068_5,0,-1,0,8500,0
8501,aspartate aminotransferase,13,15,76,102,"Laboratory tests showed an elevation of creatine phosphokinase (2218 IU/L), aspartate aminotransferase (134 IU/L), alanine aminotransferase (78 IU/L), and BUN (27.9 mg/ml) levels.",16720068_5,0,-1,0,8501,0
8502,alanine aminotransferase,20,22,115,139,"Laboratory tests showed an elevation of creatine phosphokinase (2218 IU/L), aspartate aminotransferase (134 IU/L), alanine aminotransferase (78 IU/L), and BUN (27.9 mg/ml) levels.",16720068_5,0,-1,0,8502,0
8503,bromocriptine,3,4,21,34,The patient received bromocriptine and diazepam to treat his symptoms.,16720068_6,0,-1,0,8503,0
8521,local anesthetics,26,28,234,251,Down-regulation of norepinephrine transporter function induced by chronic administration of desipramine linking to the alteration of sensitivity of local-anesthetics-induced convulsions and the counteraction by co-administration with local anesthetics.,16725121_0,0,-1,0,8521,0
8523,local anesthetics,23,25,149,166,Alterations of norepinephrine transporter (NET) function by chronic inhibition of NET in relation to sensitization to seizures induce by cocaine and local anesthetics were studied in mice.,16725121_1,0,-1,0,8523,0
8525,P2,19,20,118,120,"Daily administration of desipramine, an inhibitor of the NET, for 5 days decreased [(3)H]norepinephrine uptake in the P2 fractions of hippocampus but not cortex, striatum or amygdalae.",16725121_2,0,-1,0,8525,0
8527,bupivacaine,4,5,32,43,"Co-administration of lidocaine, bupivacaine or tricaine with desipramine reversed this effect.",16725121_3,0,-1,0,8527,0
8538,local anesthetics,6,8,32,49,Inhibition of Na(+) channels by local anesthetics may regulate desipramine-induced down-regulation of NET function.,16725121_8,0,-1,0,8538,0
8546,carbachol,5,6,33,42,Case report: acute unintentional carbachol intoxication.,16740173_0,0,-1,0,8546,0
8547,carbachol,4,5,33,42,"INTRODUCTION: Intoxications with carbachol, a muscarinic cholinergic receptor agonist are rare.",16740173_1,0,-1,0,8547,0
8552,plant extracts,16,18,100,114,METHODS: The son of an 84-year-old male discovered a newspaper report stating clinical success with plant extracts in Alzheimer's disease.,16740173_3,0,-1,0,8552,0
8556,carbachol,22,23,106,115,"The mode of action was said to be comparable to that of the synthetic compound 'carbamylcholin'; that is, carbachol.",16740173_4,0,-1,0,8556,0
8557,carbachol,5,6,18,27,"He bought 25 g of carbachol as pure substance in a pharmacy, and the father was administered 400 to 500 mg.",16740173_5,0,-1,0,8557,0
8558,Carbachol,0,1,0,9,Carbachol concentrations in serum and urine on day 1 and 2 of hospital admission were analysed by HPLC-mass spectrometry.,16740173_6,0,-1,0,8558,0
8580,carbachol,13,14,72,81,"Serum samples from the first and second days contained 3.6 and 1.9 mg/l carbachol, respectively.",16740173_18,0,-1,0,8580,0
8589,carbachol,12,13,66,75,"For the first time, an analytical method for the determination of carbachol in plasma and urine has been developed.",16740173_21,0,-1,0,8589,0
8590,carbachol,2,3,13,22,The analysed carbachol concentration exceeded the supposed serum level resulting from a therapeutic dose by a factor of 130 to 260.,16740173_22,0,-1,0,8590,0
8593,cholinergics,11,12,77,89,"Especially in old patients, intensivists should consider intoxications (with cholinergics) as a cause of acute cardiovascular failure.",16740173_23,0,-1,0,8593,0
8607,Diazepam-,0,1,0,9,"Diazepam-, scopolamine- and ageing-induced amnesia served as the interoceptive behavioral models.",16755009_4,0,-1,0,8607,0
8608,scopolamine-,2,3,11,23,"Diazepam-, scopolamine- and ageing-induced amnesia served as the interoceptive behavioral models.",16755009_4,0,-1,0,8608,0
8622,acetylcholinesterase,16,17,77,97,"Daucus carota extract (200, 400 mg/kg, p.o.) reduced significantly the brain acetylcholinesterase activity and cholesterol levels in young and aged mice.",16755009_9,0,-1,0,8622,0
8631,Valproic acid,0,2,0,13,Valproic acid induced encephalopathy--19 new cases in Germany from 1994 to 2003--a side effect associated to VPA-therapy not only in young children.,16787750_0,0,-1,0,8631,0
8635,Valproic acid,0,2,0,13,Valproic acid (VPA) is a broad-spectrum antiepileptic drug and is usually well-tolerated.,16787750_1,0,-1,0,8635,0
8637,antiepileptic drug,8,10,40,58,Valproic acid (VPA) is a broad-spectrum antiepileptic drug and is usually well-tolerated.,16787750_1,0,-1,0,8637,0
8645,antioxidant effects,3,5,14,33,"To assess the antioxidant effects of atorvastatin (atorva) on dexamethasone (dex)-induced hypertension, 60 male Sprague-Dawley rats were treated with atorva 30 mg/kg/day or tap water for 15 days.",16820346_1,0,-1,0,8645,0
8673,nitrate/nitrite,1,2,7,22,"Plasma nitrate/nitrite (NOx) was decreased in dex-treated rats compared to saline-treated rats (11.2 +/- 1.08 microm, 15.3 +/- 1.17 microm, respectively, P < 0.05).",16820346_5,0,-1,0,8673,0
8684,cytosine arabinoside,17,19,110,130,"The central nervous system toxicity of high-dose cytosine arabinoside is well recognized, but the toxicity of cytosine arabinoside in the peripheral nervous system has been infrequently reported.",16826348_1,0,-1,0,8684,0
8697,methylprednisolone,34,35,234,252,"This neuropathy was gradually resolving; however, after the patient received allogeneic bone marrow transplantation, the symptoms worsened, with the development of graft-versus-host disease, and the symptoms subsequently responded to methylprednisolone.",16826348_6,0,-1,0,8697,0
8702,alpha-tocopherol,2,3,10,26,Effect of alpha-tocopherol and deferoxamine on methamphetamine-induced neurotoxicity.,16844102_0,0,-1,0,8702,0
8703,deferoxamine,4,5,31,43,Effect of alpha-tocopherol and deferoxamine on methamphetamine-induced neurotoxicity.,16844102_0,0,-1,0,8703,0
8709,alpha-tocopherol,6,7,34,50,"This study examined the effect of alpha-tocopherol (alpha-TC), a scavenger of reactive oxygen species, and deferoxamine (DFO), an iron chelator, on the MA-induced neurotoxicity.",16844102_2,0,-1,0,8709,0
8711,deferoxamine,19,20,107,119,"This study examined the effect of alpha-tocopherol (alpha-TC), a scavenger of reactive oxygen species, and deferoxamine (DFO), an iron chelator, on the MA-induced neurotoxicity.",16844102_2,0,-1,0,8711,0
8713,chelator,26,27,135,143,"This study examined the effect of alpha-tocopherol (alpha-TC), a scavenger of reactive oxygen species, and deferoxamine (DFO), an iron chelator, on the MA-induced neurotoxicity.",16844102_2,0,-1,0,8713,0
8727,reduced glutathione,9,11,51,70,The level of lipid peroxidation was higher and the reduced glutathione concentration was lower in the MA-treated rats.,16844102_7,0,-1,0,8727,0
8761,histaminergic,10,11,63,76,Experimental and clinical evidence points to a role of central histaminergic system in the pathogenesis of schizophrenia.,16867021_1,0,-1,0,8761,0
8803,SCH,8,9,52,55,"2. Dopamine antagonist fluphenazine, D-1 antagonist SCH 23390 or D-2 antagonist sulpiride induced catalepsy.",1687392_2,0,-1,0,8803,0
8805,sulpiride,13,14,80,89,"2. Dopamine antagonist fluphenazine, D-1 antagonist SCH 23390 or D-2 antagonist sulpiride induced catalepsy.",1687392_2,0,-1,0,8805,0
8806,sulpiride,5,6,31,40,The effect of fluphenazine and sulpiride was dose-dependent.,1687392_3,0,-1,0,8806,0
8808,SCH,2,3,15,18,Combination of SCH 23390 with sulpiride did not induce catalepsy potentiation.,1687392_4,0,-1,0,8808,0
8809,sulpiride,5,6,30,39,Combination of SCH 23390 with sulpiride did not induce catalepsy potentiation.,1687392_4,0,-1,0,8809,0
8811,SKF 38393,4,6,15,24,"3. D-1 agonist SKF 38393 or D-2 agonist quinpirole decreased the catalepsy induced by fluphenazine, SCH 23390 or sulpiride.",1687392_5,0,-1,0,8811,0
8814,SCH,17,18,100,103,"3. D-1 agonist SKF 38393 or D-2 agonist quinpirole decreased the catalepsy induced by fluphenazine, SCH 23390 or sulpiride.",1687392_5,0,-1,0,8814,0
8815,sulpiride,20,21,113,122,"3. D-1 agonist SKF 38393 or D-2 agonist quinpirole decreased the catalepsy induced by fluphenazine, SCH 23390 or sulpiride.",1687392_5,0,-1,0,8815,0
8829,bupivacaine,18,19,115,126,The following case is a report of cauda equina syndrome possibly caused by epidural injection of triamcinolone and bupivacaine.,16904497_3,0,-1,0,8829,0
8839,bupivacaine,6,7,36,47,"After verifying the epidural space, bupivacaine and triamcinolone diacetate were injected.",16904497_7,0,-1,0,8839,0
8845,her,15,16,93,96,The neurologic evaluation revealed loss of sensation in the saddle area and medial aspect of her right leg.,16904497_10,0,-1,0,8845,0
8886,reverse transcriptase,8,10,45,66,"However, the administration of lamivudine, a reverse transcriptase inhibitor, for 23 months dramatically improved her liver severity.",16960342_6,0,-1,0,8886,0
8894,e antigen,8,10,47,56,"Moreover, both hepatitis B surface antigen and e antigen were observed to have disappeared in this patient.",16960342_9,0,-1,0,8894,0
8907,channel blockers,8,10,48,64,"Digitalis arrhythmia, which is suppressed by Na channel blockers, was induced by intermittent intravenous (i.v.) injection of ouabain in pentobarbital-anesthetized dogs.",1700207_2,0,-1,0,8907,0
8910,channel blockers,8,10,49,65,"Adrenaline arrhythmia, which is suppressed by Ca channel blockers, was induced by adrenaline infusion in halothane-anesthetized dogs.",1700207_3,0,-1,0,8910,0
8930,(-)-isomer,8,9,69,79,"The stronger antiarrhythmic effect of (-)-cibenzoline indicates that (-)-isomer may have an effect nearly 5-20 times stronger in suppressing Na channels, but effects of both drugs on Ca channels may be almost equipotent.",1700207_9,0,-1,0,8930,0
8960,antithrombotic,5,6,34,48,"Pooled data from trials comparing antithrombotic treatment with placebo have shown that warfarin reduces the risk of stroke by 62%, and that aspirin alone reduces the risk by 22%.",17020434_2,0,-1,0,8960,0
8962,vitamin K,15,17,81,90,"Ximelagatran, an oral direct thrombin inhibitor, was found to be as efficient as vitamin K antagonist drugs in the prevention of embolic events, but has been recently withdrawn because of abnormal liver function tests.",17020434_4,0,-1,0,8962,0
8973,Factor Xa inhibitor,3,6,15,34,"Idraparinux, a Factor Xa inhibitor, is being evaluated in patients with atrial fibrillation.",17020434_6,0,-1,0,8973,0
8976,enzyme inhibitors,1,3,23,40,Angiotensin-converting enzyme inhibitors and angiotensin II receptor-blocking drugs hold promise in atrial fibrillation through cardiac remodelling.,17020434_7,0,-1,0,8976,0
8977,angiotensin II,4,6,45,59,Angiotensin-converting enzyme inhibitors and angiotensin II receptor-blocking drugs hold promise in atrial fibrillation through cardiac remodelling.,17020434_7,0,-1,0,8977,0
8988,quetiapine,9,10,62,72,Placebo-level incidence of extrapyramidal symptoms (EPS) with quetiapine in controlled studies of patients with bipolar mania.,17042884_0,0,-1,0,8988,0
8994,quetiapine,14,15,81,91,"OBJECTIVES: To evaluate extrapyramidal symptoms (EPS), including akathisia, with quetiapine in patients with bipolar mania.",17042884_1,0,-1,0,8994,0
8998,quetiapine,3,4,22,32,"Two studies evaluated quetiapine monotherapy (up to 800 mg/day) (n = 209) versus placebo (n = 198), with lithium or haloperidol monotherapy as respective active controls.",17042884_3,0,-1,0,8998,0
9002,quetiapine,3,4,22,32,"Two studies evaluated quetiapine (up to 800 mg/day) in combination with a mood stabilizer (lithium or divalproex, QTP + Li/DVP) (n = 196) compared to placebo and mood stabilizer (PBO + Li/DVP) (n = 203).",17042884_4,0,-1,0,9002,0
9004,divalproex,19,20,102,112,"Two studies evaluated quetiapine (up to 800 mg/day) in combination with a mood stabilizer (lithium or divalproex, QTP + Li/DVP) (n = 196) compared to placebo and mood stabilizer (PBO + Li/DVP) (n = 203).",17042884_4,0,-1,0,9004,0
9017,quetiapine,16,17,97,107,"RESULTS: The incidence of EPS-related adverse events, including akathisia, was no different with quetiapine monotherapy (12.9%) than with placebo (13.1%).",17042884_6,0,-1,0,9017,0
9033,quetiapine,9,10,52,62,"The incidence of akathisia was low and similar with quetiapine monotherapy (3.3%) and placebo (6.1%), and with QTP + Li/DVP (3.6%) and PBO + Li/DVP (4.9%).",17042884_9,0,-1,0,9033,0
9040,quetiapine,20,21,95,105,"Lithium was associated with a significantly higher incidence (p < 0.05) of tremor (18.4%) than quetiapine (5.6%); cerebellar tremor, which is a known adverse effect of lithium, may have contributed to the elevated rate of tremor in patients receiving lithium therapy.",17042884_10,0,-1,0,9040,0
9046,quetiapine,41,42,180,190,"Haloperidol induced a significantly higher incidence (p < 0.001) of akathisia (33.3% versus 5.9%), tremor (30.3% versus 7.8%), and extrapyramidal syndrome (35.4% versus 5.9%) than quetiapine.",17042884_11,0,-1,0,9046,0
9048,quetiapine,6,7,49,59,No significant differences were observed between quetiapine and placebo on SAS and BARS scores.,17042884_12,0,-1,0,9048,0
9050,quetiapine,7,8,45,55,Anticholinergic use was low and similar with quetiapine or placebo.,17042884_13,0,-1,0,9050,0
9054,quetiapine,15,16,79,89,"CONCLUSIONS: In bipolar mania, the incidence of EPS, including akathisia, with quetiapine therapy is similar to that with placebo.",17042884_14,0,-1,0,9054,0
9055,Anti-oxidant effects,0,2,0,20,Anti-oxidant effects of atorvastatin in dexamethasone-induced hypertension in the rat.1.,17042910_0,0,-1,0,9055,0
9060,nitric oxide,10,12,101,113,Dexamethasone (Dex)-induced hypertension is characterized by endothelial dysfunction associated with nitric oxide (NO) deficiency and increased superoxide (O2-) production.,17042910_1,0,-1,0,9060,0
9065,synthase,21,22,103,111,"In the present study, we investigated whether 50 mg/kg per day, p.o., Ato could prevent endothelial NO synthase (eNOS) downregulation and the increase in O2- in Sprague-Dawley (SD) rats, thereby reducing blood pressure.",17042910_3,0,-1,0,9065,0
9073,drinking water,20,22,68,82,2. Male SD rats (n = 30) were treated with Ato (50 mg/kg per day in drinking water) or tap water for 15 days.,17042910_4,0,-1,0,9073,0
9090,/- 2,13,15,60,64,"In rats treated with Dex alone, SBP was increased from 109 +/- 2 to 133 +/- 2 mmHg on Days 4 and Day 14, respectively (P < 0.001).",17042910_10,0,-1,0,9090,0
9096,/- 2,13,15,52,56,"In the Ato + Dex group, SBP was increased from 113 +/- 2 to 119 +/- 2 mmHg on Days 4 to 14, respectively (P < 0.001), but was significantly lower than SBP in the group treated with Dex alone (P < 0.05).",17042910_11,0,-1,0,9096,0
9119,cardiac depressant,1,3,4,22,The cardiac depressant actions of phenytoin and hypothermia can be additive.,17049862_4,0,-1,0,9119,0
9131,her,21,22,140,143,"This report describes a patient with mild language delay and mental retardation, who was found to have nonketotic hyperglycinemia following her presentation with acute encephalopathy and chorea shortly after initiation of valproate therapy.",17074608_4,0,-1,0,9131,0
9139,bumetanide,3,4,30,40,"Reported medications included bumetanide, pravastatin, and paroxetine.",17111419_4,0,-1,0,9139,0
9142,calcium gluconate,4,6,37,54,"Empirical treatment with intravenous calcium gluconate was initiated, and muscle contractions slowly subsided over approximately 10 to 15 minutes.",17111419_7,0,-1,0,9142,0
9149,bumetanide,9,10,58,68,"Upon additional retrospective analysis, it was noted that bumetanide is a loop diuretic that may cause significant hypocalcemia.",17111419_9,0,-1,0,9149,0
9150,loop diuretic,12,14,74,87,"Upon additional retrospective analysis, it was noted that bumetanide is a loop diuretic that may cause significant hypocalcemia.",17111419_9,0,-1,0,9150,0
9191,Sirolimus,0,1,0,9,Sirolimus is a novel immunosuppressant with potent antiproliferative actions through its ability to inhibit the raptor-containing mammalian target of rapamycin protein kinase.,17147461_1,0,-1,0,9191,0
9195,Sirolimus,0,1,0,9,Sirolimus represents a major therapeutic advance in the prevention of acute renal allograft rejection and chronic allograft nephropathy.,17147461_2,0,-1,0,9195,0
9201,sirolimus,1,2,8,17,"Because sirolimus does not share the vasomotor renal adverse effects exhibited by calcineurin inhibitors, it has been designated a 'non-nephrotoxic drug'.",17147461_4,0,-1,0,9201,0
9203,calcineurin,12,13,82,93,"Because sirolimus does not share the vasomotor renal adverse effects exhibited by calcineurin inhibitors, it has been designated a 'non-nephrotoxic drug'.",17147461_4,0,-1,0,9203,0
9206,sirolimus,11,12,66,75,"However, clinical reports suggest that, under some circumstances, sirolimus is associated with proteinuria and acute renal dysfunction.",17147461_5,0,-1,0,9206,0
9214,sirolimus,6,7,32,41,"It has also been suggested that sirolimus directly causes increased glomerular permeability/injury, but evidence for this mechanism is currently inconclusive.",17147461_8,0,-1,0,9214,0
9218,sirolimus,6,7,44,53,The acute renal dysfunction associated with sirolimus (such as in delayed graft function) may be due to suppression of compensatory renal cell proliferation and survival/repair processes.,17147461_9,0,-1,0,9218,0
9224,sirolimus,21,22,132,141,"Although these adverse effects occur in some patients, their occurrence could be minimised by knowledge of the molecular effects of sirolimus on the kidney, the use of sirolimus in appropriate patient populations, close monitoring of proteinuria and renal function, use of angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers if proteinuria occurs and withdrawal if needed.",17147461_10,0,-1,0,9224,0
9225,sirolimus,29,30,168,177,"Although these adverse effects occur in some patients, their occurrence could be minimised by knowledge of the molecular effects of sirolimus on the kidney, the use of sirolimus in appropriate patient populations, close monitoring of proteinuria and renal function, use of angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers if proteinuria occurs and withdrawal if needed.",17147461_10,0,-1,0,9225,0
9228,enzyme inhibitors,46,48,296,313,"Although these adverse effects occur in some patients, their occurrence could be minimised by knowledge of the molecular effects of sirolimus on the kidney, the use of sirolimus in appropriate patient populations, close monitoring of proteinuria and renal function, use of angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers if proteinuria occurs and withdrawal if needed.",17147461_10,0,-1,0,9228,0
9229,angiotensin II receptor blockers,49,53,317,349,"Although these adverse effects occur in some patients, their occurrence could be minimised by knowledge of the molecular effects of sirolimus on the kidney, the use of sirolimus in appropriate patient populations, close monitoring of proteinuria and renal function, use of angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers if proteinuria occurs and withdrawal if needed.",17147461_10,0,-1,0,9229,0
9231,sirolimus,8,9,60,69,Further long-term analysis of renal allograft studies using sirolimus as de novo immunosuppression along with clinical and laboratory studies will refine these issues in the future.,17147461_11,0,-1,0,9231,0
9232,novo,11,12,76,80,Further long-term analysis of renal allograft studies using sirolimus as de novo immunosuppression along with clinical and laboratory studies will refine these issues in the future.,17147461_11,0,-1,0,9232,0
9234,sirolimus,4,5,32,41,Proteinuria after conversion to sirolimus in renal transplant recipients.,17175308_0,0,-1,0,9234,0
9236,Sirolimus,0,1,0,9,"Sirolimus (SRL) is a new, potent immunosuppressive agent.",17175308_1,0,-1,0,9236,0
9240,sirolimus,11,12,65,74,"More recently, proteinuria has been reported as a consequence of sirolimus therapy, although the mechanism has remained unclear.",17175308_2,0,-1,0,9240,0
9269,(3,20,22,99,101,Mean urinary protein of patients who returned to dialysis was 1.26 (0.5 to 3.5) g/d before and 4.7 (3 to 12) g/d after conversion (P = .01).,17175308_18,0,-1,0,9269,0
9276,novo,4,5,22,26,The possibility of de novo glomerular pathology under SRL treatment requires further investigation by renal biopsy.,17175308_22,0,-1,0,9276,0
9280,parachlorophenylalanine,9,10,58,81,"Serotonin was depleted beginning on postnatal day 26 with parachlorophenylalanine (PCPA 100 mg/kg, every other day); controls received saline.",17194457_2,0,-1,0,9280,0
9281,PCPA,11,12,83,87,"Serotonin was depleted beginning on postnatal day 26 with parachlorophenylalanine (PCPA 100 mg/kg, every other day); controls received saline.",17194457_2,0,-1,0,9281,0
9294,PCPA,0,1,0,4,PCPA significantly and substantially depleted 5-HT and 5-HIAA in all brain regions examined.,17194457_7,0,-1,0,9294,0
9302,PCPA,20,21,117,121,"Chronic T treatment significantly decreased 5-HT and 5-HIAA in certain brain areas, but to a much lesser extent than PCPA.",17194457_8,0,-1,0,9302,0
9304,PCPA,3,4,20,24,"Chronic exposure to PCPA alone significantly decreased locomotor activity and increased irritability but had no effect on sexual behavior, partner preference, or aggression.",17194457_9,0,-1,0,9304,0
9324,ifosfamide,19,20,121,131,The renal function of 74 children with malignant mesenchymal tumors in complete remission and who have received the same ifosfamide chemotherapy protocol (International Society of Pediatric Oncology Malignant Mesenchymal Tumor Study 84 [SIOP MMT 84]) were studied 1 year after the completion of treatment.,1720453_1,0,-1,0,9324,0
9329,ifosfamide,9,10,45,55,"Total cumulative doses were 36 or 60 g/m2 of ifosfamide (six or 10 cycles of ifosfamide, vincristine, and dactinomycin [IVA]).",1720453_2,0,-1,0,9329,0
9330,ifosfamide,16,17,77,87,"Total cumulative doses were 36 or 60 g/m2 of ifosfamide (six or 10 cycles of ifosfamide, vincristine, and dactinomycin [IVA]).",1720453_2,0,-1,0,9330,0
9331,dactinomycin,21,22,106,118,"Total cumulative doses were 36 or 60 g/m2 of ifosfamide (six or 10 cycles of ifosfamide, vincristine, and dactinomycin [IVA]).",1720453_2,0,-1,0,9331,0
9332,cisplatin,5,6,26,35,None of them had received cisplatin chemotherapy.,1720453_3,0,-1,0,9332,0
9339,creatinine,22,23,142,152,"Renal function was investigated by measuring plasma and urinary electrolytes, glucosuria, proteinuria, aminoaciduria, urinary pH, osmolarity, creatinine clearance, phosphate tubular reabsorption, beta 2 microglobulinuria, and lysozymuria.",1720453_6,0,-1,0,9339,0
9341,beta 2,29,31,196,202,"Renal function was investigated by measuring plasma and urinary electrolytes, glucosuria, proteinuria, aminoaciduria, urinary pH, osmolarity, creatinine clearance, phosphate tubular reabsorption, beta 2 microglobulinuria, and lysozymuria.",1720453_6,0,-1,0,9341,0
9348,beta 2,46,48,253,259,Two subsets of patients were identified from this latter group: the first included four patients (5% of the total population) who developed major toxicity resulting in Fanconi's syndrome (TDFS); and the second group included five patients with elevated beta 2 microglobulinuria and low phosphate reabsorption.,1720453_8,0,-1,0,9348,0
9349,beta 2,6,8,42,48,The remaining seven patients had isolated beta 2 microglobulinuria.,1720453_9,0,-1,0,9349,0
9351,ifosfamide,13,14,77,87,"Severe toxicity was correlated with the higher cumulative dose of 60 g/m2 of ifosfamide, a younger age (less than 2 1/2 years old), and a predominance of vesicoprostatic tumor involvement.",1720453_10,0,-1,0,9351,0
9355,ifosfamide,18,19,83,93,This low percentage (5%) of TDFS must be evaluated with respect to the efficacy of ifosfamide in the treatment of mesenchymal tumors in children.,1720453_11,0,-1,0,9355,0
9365,stimulatory,16,17,115,126,"Earlier studies have demonstrated that antagonism of sigma1 receptors attenuates the convulsive, lethal, locomotor stimulatory and rewarding actions of cocaine in mice.",17241657_1,0,-1,0,9365,0
9390,receptor antagonists,7,9,39,59,"Together, the data suggest that sigma2 receptor antagonists have the potential to attenuate some of the behavioral effects of cocaine, and further development of more selective, high affinity ligands are warranted.",17241657_7,0,-1,0,9390,0
9393,MHC-I,5,6,43,48,Progressive myopathy with up-regulation of MHC-I associated with statin therapy.,17241784_0,0,-1,0,9393,0
9401,MHC-I,10,11,62,67,In all cases there was diffuse or multifocal up-regulation of MHC-I expression even in non-necrotic fibres.,17241784_5,0,-1,0,9401,0
9408,MHC-I,24,25,162,167,The mechanism of this myopathy is uncertain but may involve the induction by statins of an endoplasmic reticulum stress response with associated up-regulation of MHC-I expression and antigen presentation by muscle fibres.,17241784_8,0,-1,0,9408,0
9438,muscarinic,17,18,113,123,"In cyclophosphamide-induced cystitis in the rat, detrusor function is impaired and the expression and effects of muscarinic receptors altered.",17244258_1,0,-1,0,9438,0
9443,muscarinic,25,26,183,193,"Responses of urinary strip preparations from control and cyclophosphamide-pretreated rats to electrical field stimulation and to agonists were assessed in the absence and presence of muscarinic, adrenergic and purinergic receptor antagonists.",17244258_3,0,-1,0,9443,0
9446,(1,22,24,143,145,"Generally, atropine reduced contractions, but in contrast to controls, it also reduced responses to low electrical field stimulation intensity (1-5 Hz) in inflamed preparations.",17244258_4,0,-1,0,9446,0
9453,pirenzepine,23,24,159,170,"The muscarinic receptor antagonists atropine, 4-diphenylacetoxy-N-methylpiperidine (4-DAMP) ('M(1)/M(3)/M(5)-selective'), methoctramine ('M(2)-selective') and pirenzepine ('M(1)-selective') antagonized the tonic component of the electrical field stimulation-evoked contractile response more potently than the phasic component.",17244258_6,0,-1,0,9453,0
9457,phasic,44,45,309,315,"The muscarinic receptor antagonists atropine, 4-diphenylacetoxy-N-methylpiperidine (4-DAMP) ('M(1)/M(3)/M(5)-selective'), methoctramine ('M(2)-selective') and pirenzepine ('M(1)-selective') antagonized the tonic component of the electrical field stimulation-evoked contractile response more potently than the phasic component.",17244258_6,0,-1,0,9457,0
9461,pirenzepine,12,13,89,100,4-DAMP inhibited the tonic contractions in controls more potently than methoctramine and pirenzepine.,17244258_7,0,-1,0,9461,0
9462,muscarinic,5,6,30,40,"In inflamed preparations, the muscarinic receptor antagonism on the phasic component of the electrical field stimulation-evoked contraction was decreased and the pirenzepine and 4-DAMP antagonism on the tonic component was much less efficient than in controls.",17244258_8,0,-1,0,9462,0
9463,phasic,10,11,68,74,"In inflamed preparations, the muscarinic receptor antagonism on the phasic component of the electrical field stimulation-evoked contraction was decreased and the pirenzepine and 4-DAMP antagonism on the tonic component was much less efficient than in controls.",17244258_8,0,-1,0,9463,0
9466,pirenzepine,22,23,162,173,"In inflamed preparations, the muscarinic receptor antagonism on the phasic component of the electrical field stimulation-evoked contraction was decreased and the pirenzepine and 4-DAMP antagonism on the tonic component was much less efficient than in controls.",17244258_8,0,-1,0,9466,0
9471,carbachol,3,4,22,31,"While contractions to carbachol and ATP were the same in inflamed and in control strips when related to a reference potassium response, isoprenaline-induced relaxations were smaller in inflamed strips.",17244258_10,0,-1,0,9471,0
9479,muscarinic,11,12,109,119,"While postjunctional beta-adrenoceptor-mediated relaxations are reduced, effects by prejunctional inhibitory muscarinic receptors may be increased.",17244258_12,0,-1,0,9479,0
9480,hyperpolarization-activated,4,5,29,56,Direct inhibition of cardiac hyperpolarization-activated cyclic nucleotide-gated pacemaker channels by clonidine.,17261653_0,0,-1,0,9480,0
9481,pacemaker channels,7,9,81,99,Direct inhibition of cardiac hyperpolarization-activated cyclic nucleotide-gated pacemaker channels by clonidine.,17261653_0,0,-1,0,9481,0
9496,hypnotic effects,9,11,68,84,"Alpha2ABC-/- mice were completely unresponsive to the analgesic and hypnotic effects of clonidine; however, clonidine significantly lowered heart rate in alpha2ABC-/- mice by up to 150 bpm.",17261653_4,0,-1,0,9496,0
9503,hyperpolarization-activated,19,20,124,151,Clonidine inhibited the native pacemaker current (I(f)) in isolated sinoatrial node pacemaker cells and the I(f)-generating hyperpolarization-activated cyclic nucleotide-gated (HCN) 2 and HCN4 channels in transfected HEK293 cells.,17261653_7,0,-1,0,9503,0
9504,HCN,23,24,177,180,Clonidine inhibited the native pacemaker current (I(f)) in isolated sinoatrial node pacemaker cells and the I(f)-generating hyperpolarization-activated cyclic nucleotide-gated (HCN) 2 and HCN4 channels in transfected HEK293 cells.,17261653_7,0,-1,0,9504,0
9505,HCN4,27,28,188,192,Clonidine inhibited the native pacemaker current (I(f)) in isolated sinoatrial node pacemaker cells and the I(f)-generating hyperpolarization-activated cyclic nucleotide-gated (HCN) 2 and HCN4 channels in transfected HEK293 cells.,17261653_7,0,-1,0,9505,0
9512,HCN pacemaker channels,6,9,42,64,"CONCLUSIONS: Direct inhibition of cardiac HCN pacemaker channels contributes to the bradycardic effects of clonidine gene-targeted mice in vivo, and thus, clonidine-like drugs represent novel structures for future HCN channel inhibitors.",17261653_9,0,-1,0,9512,0
9517,HCN,31,32,214,217,"CONCLUSIONS: Direct inhibition of cardiac HCN pacemaker channels contributes to the bradycardic effects of clonidine gene-targeted mice in vivo, and thus, clonidine-like drugs represent novel structures for future HCN channel inhibitors.",17261653_9,0,-1,0,9517,0
9520,sevoflurane,9,10,57,68,Cardiac arrest in a child with cerebral palsy undergoing sevoflurane induction of anesthesia after preoperative clonidine.,17263743_0,0,-1,0,9520,0
9521,alpha2-adrenergic,5,6,39,56,Clonidine is a frequently administered alpha2-adrenergic agonist which can decrease heart rate and blood pressure.,17263743_1,0,-1,0,9521,0
9526,baclofen,26,27,153,161,"We present a case of a 5-year-old child with cerebral palsy and seizure disorder, receiving clonidine for restlessness, who presented for placement of a baclofen pump.",17263743_2,0,-1,0,9526,0
9548,enzyme inhibitor,1,3,23,39,"Angiotensin-converting enzyme inhibitor (ACEI)-induced angioedema was suspected, and anti-hypertensive medications were discontinued.",17285209_8,0,-1,0,9548,0
9550,Her,0,1,0,3,"Her symptoms improved within the next 24 hours, and repeat CT after 72 hours revealed marked improvement in stomach and small bowel thickening and resolution of ascites.",17285209_9,0,-1,0,9550,0
9553,angiotensin receptor blocker,9,12,59,87,"The recognition of angiotensin-converting enzyme (ACE) and angiotensin receptor blocker (ARB) intestinal angioedema constitutes a challenge to primary care physicians, internists, emergency room personal and surgeons.",17285209_10,0,-1,0,9553,0
9557,clavulanic acid,8,10,62,77,Granulomatous hepatitis due to combination of amoxicillin and clavulanic acid.,1728522_0,0,-1,0,9557,0
9562,drug combination,13,15,70,86,"This type of lesion broadens the spectrum of liver injury due to this drug combination, mainly represented by a benign cholestatic syndrome.",1728522_2,0,-1,0,9562,0
9566,clavulanic acid,26,28,159,174,"As penicillin derivatives and amoxicillin alone are known to induce such types of lesions, the amoxicillin component, with or without a potentiating effect of clavulanic acid, might have a major role.",1728522_4,0,-1,0,9566,0
9592,dobutamine,21,22,135,145,"To develop a more sensitive echocardiographic screening test for cardiac damage due to doxorubicin, a cohort study was performed using dobutamine infusion to differentiate asymptomatic long-term survivors of childhood cancer treated with doxorubicin from healthy control subjects.",1732369_2,0,-1,0,9592,0
9600,dobutamine,1,2,7,17,"Graded dobutamine infusions of 0.5, 2.5, 5 and 10 micrograms/kg per min were administered.",1732369_4,0,-1,0,9600,0
9603,Dobutamine,0,1,0,10,Dobutamine infusion at 10 micrograms/kg per min was discontinued after six studies secondary to a 50% incidence rate of adverse symptoms.,1732369_6,0,-1,0,9603,0
9604,at 10,2,4,20,25,Dobutamine infusion at 10 micrograms/kg per min was discontinued after six studies secondary to a 50% incidence rate of adverse symptoms.,1732369_6,0,-1,0,9604,0
9612,dobutamine,43,44,311,321,"The most important findings were that compared with values in control subjects, end-systolic left ventricular posterior wall dimension and percent of left ventricular posterior wall thickening in doxorubicin-treated patients were decreased at baseline study and these findings were more clearly delineated with dobutamine stimulation.",1732369_7,0,-1,0,9612,0
9619,dobutamine,11,12,86,96,End-systolic left ventricular posterior wall dimension at the 5-micrograms/kg per min dobutamine infusion for the doxorubicin-treated group was 14.1 +/- 2.4 mm versus 19.3 +/- 2.6 mm for control subjects (p less than 0.01).(ABSTRACT TRUNCATED AT 250 WORDS),1732369_9,0,-1,0,9619,0
9624,adrenergic neuron,4,6,30,47,Detection of abnormal cardiac adrenergic neuron activity in adriamycin-induced cardiomyopathy with iodine-125-metaiodobenzylguanidine.,1732442_0,0,-1,0,9624,0
9626,metaiodobenzylguanidine,1,2,13,36,"Radiolabeled metaiodobenzylguanidine (MIBG), an analog of norepinephrine (NE), serves as an index of adrenergic neuron integrity and function.",1732442_1,0,-1,0,9626,0
9627,MIBG,3,4,38,42,"Radiolabeled metaiodobenzylguanidine (MIBG), an analog of norepinephrine (NE), serves as an index of adrenergic neuron integrity and function.",1732442_1,0,-1,0,9627,0
9628,adrenergic neuron,15,17,103,120,"Using a rat model of adriamycin-induced cardiomyopathy, we tested the hypothesis that abnormal cardiac adrenergic neuron activity may appear and be exacerbated dose-dependently in adriamycin cardiomyopathy.",1732442_2,0,-1,0,9628,0
9641,MIBG,5,6,19,23,"In the 5-wk group, MIBG accumulation in the right and left ventricular wall was 35% and 27% of that in controls, respectively (p less than 0.001).",1732442_7,0,-1,0,9641,0
9643,MIBG,5,6,19,23,"In the 8-wk group, MIBG accumulation in the right and left ventricular wall was 18% and 14% of that in controls, respectively (p less than 0.001).",1732442_8,0,-1,0,9643,0
9645,MIBG,2,3,6,10,"Thus, MIBG accumulation in the myocardium decreased in an adriamycin dose-dependent manner.",1732442_9,0,-1,0,9645,0
9648,adrenergic neuron,5,7,35,52,The appearance of impaired cardiac adrenergic neuron activity in the presence of slight myocardial impairment (scattered or focal vacuolar degeneration) indicates that MIBG scintigraphy may be a useful method for detection of adriamycin-induced cardiomyopathy.,1732442_10,0,-1,0,9648,0
9651,MIBG,24,25,168,172,The appearance of impaired cardiac adrenergic neuron activity in the presence of slight myocardial impairment (scattered or focal vacuolar degeneration) indicates that MIBG scintigraphy may be a useful method for detection of adriamycin-induced cardiomyopathy.,1732442_10,0,-1,0,9651,0
9689,illicit drugs,7,9,46,59,"As heroin addicts sometimes faint while using illicit drugs, doctors might attribute too many episodes of syncope to illicit drug use and thereby underestimate the incidence of TdP in this special population, and the high mortality in this population may, in part, be caused by the proarrhythmic effect of methadone.",17344330_3,0,-1,0,9689,0
9697,buprenorphine,25,26,154,167,"METHODS: In this cross-sectional study interview, ECGs and blood samples were collected in a population of adult heroin addicts treated with methadone or buprenorphine on a daily basis.",17344330_4,0,-1,0,9697,0
9707,buprenorphine,3,4,23,36,No association between buprenorphine and QTc was found.,17344330_10,0,-1,0,9707,0
9712,buprenorphine,6,7,34,47,None of the subjects treated with buprenorphine had QTc interval >0.440 s((1/2)).,17344330_12,0,-1,0,9712,0
9732,antipsychotic drugs,11,13,85,104,"Although conventional neuroleptics are more frequently associated with NMS, atypical antipsychotic drugs like ziprasidone may also be a cause.",17366349_3,0,-1,0,9732,0
9811,antiepileptic drugs,14,16,75,94,"By using this strategy to study the involvement of MRP2 in brain access of antiepileptic drugs (AEDs), we recently reported that phenytoin is a substrate for MRP2 in the BBB.",17437408_3,0,-1,0,9811,0
9907,methylprednisolone,6,7,48,66,Side effects of postoperative administration of methylprednisolone and gentamicin into the posterior sub-Tenon's space.,17466854_0,0,-1,0,9907,0
9910,methylprednisolone,15,16,98,116,PURPOSE: To assess the incidence of postoperative emetic side effects after the administration of methylprednisolone and gentamicin into the posterior sub-Tenon's space at the end of routine cataract surgery.,17466854_1,0,-1,0,9910,0
9919,lignocaine,25,26,181,191,METHODS: A double-blind double-armed prospective study comprised 40 patients who had uneventful sutureless phacoemulsification under sub-Tenon's local infiltration of 3 mL of plain lignocaine.,17466854_3,0,-1,0,9919,0
9922,methylprednisolone,19,20,66,84,"At the end of the procedure, Group A (n = 20) had 20 mg/0.5 mL of methylprednisolone and 10 mg/0.5 mL of gentamicin injected into the posterior sub-Tenon's space and Group B (n = 20) had the same combination injected into the anterior sub-Tenon's space.",17466854_4,0,-1,0,9922,0
9930,methylprednisolone,5,6,35,53,"CONCLUSIONS: The administration of methylprednisolone and gentamicin in the posterior sub-Tenon's space was related to a high incidence of side effects including nausea, vomiting, and headache.",17466854_8,0,-1,0,9930,0
9936,dopaminergic,6,7,48,60,Peripheral iron dextran induced degeneration of dopaminergic neurons in rat substantia nigra.,17490790_0,0,-1,0,9936,0
9941,dopaminergic,9,10,69,81,"To demonstrate the relationship between peripheral iron overload and dopaminergic neuron loss in rat substantia nigra (SN), in the present study we used fast cyclic voltammetry, tyrosine hydroxylase (TH) immunohistochemistry, Perls' iron staining, and high performance liquid chromatography-electrochemical detection to study the degeneration of dopaminergic neurons and increased iron content in the SN of iron dextran overloaded animals.",17490790_2,0,-1,0,9941,0
9947,dopaminergic,53,54,346,358,"To demonstrate the relationship between peripheral iron overload and dopaminergic neuron loss in rat substantia nigra (SN), in the present study we used fast cyclic voltammetry, tyrosine hydroxylase (TH) immunohistochemistry, Perls' iron staining, and high performance liquid chromatography-electrochemical detection to study the degeneration of dopaminergic neurons and increased iron content in the SN of iron dextran overloaded animals.",17490790_2,0,-1,0,9947,0
9957,dopaminergic,23,24,138,150,"These results suggest that peripheral iron dextran can increase the iron level in the SN, where excessive iron causes the degeneration of dopaminergic neurons.",17490790_6,0,-1,0,9957,0
9959,dopaminergic,9,10,53,65,The chronic iron overload may be more destructive to dopaminergic neurons than the acute iron overload.,17490790_7,0,-1,0,9959,0
9962,dopaminergic,6,7,48,60,Attenuated disruption of prepulse inhibition by dopaminergic stimulation after maternal deprivation and adolescent corticosterone treatment in rats.,17490864_0,0,-1,0,9962,0
9973,receptor agonist,2,4,17,33,"The serotonin-1A receptor agonist, 8-OH-DPAT, induced a significant disruption of PPI in all groups.",17490864_5,0,-1,0,9973,0
9977,dopaminergic,28,29,171,183,"These results show an inhibitory interaction of early stress, caused by maternal deprivation, combined with 'adolescent' stress, simulated by corticosterone treatment, on dopaminergic regulation of PPI.",17490864_7,0,-1,0,9977,0
9999,dobutamine,12,13,85,95,Simultaneous measurements of ECG and brachial artery dP/dtejc were performed at each dobutamine level.,17491223_4,0,-1,0,9999,0
10002,dobutamine,7,8,44,54,The increase in dP/dtejc during infusion of dobutamine in this group was severely impaired as compared to the non-ischemic group.,17491223_6,0,-1,0,10002,0
10040,interferon alpha-2b,15,17,99,118,An extremely rare case of delusional parasitosis in a chronic hepatitis C patient during pegylated interferon alpha-2b and ribavirin treatment.,17511042_0,0,-1,0,10040,0
10046,interferon alpha-2b,14,16,102,121,We present a 49-year-old woman who developed a delusional parasitosis during treatment with pegylated interferon alpha-2b weekly and ribavirin.,17511042_5,0,-1,0,10046,0
10047,her,11,12,62,65,She complained of seeing parasites and the larvae of fleas in her stools.,17511042_6,0,-1,0,10047,0
10049,interferon alpha-2b,7,9,56,75,All the complaints disappeared after stopping pegylated interferon alpha-2b and reappeared after restarting it.,17511042_8,0,-1,0,10049,0
10059,bromocriptine,32,33,204,217,"In the present study, we investigated the changes occurring at the protein level in striatal samples obtained from the unilaterally 6-hydroxydopamine-lesion rat model of PD treated with saline, L-DOPA or bromocriptine using two-dimensional difference gel electrophoresis and mass spectrometry (MS).",17532790_3,0,-1,0,10059,0
10069,gamma-enolase,18,19,112,125,"Out of these 67 proteins, LID significantly changed the expression level of five proteins: alphabeta-crystalin, gamma-enolase, guanidoacetate methyltransferase, vinculin, and proteasome alpha-2 subunit.",17532790_6,0,-1,0,10069,0
10088,iopamidol,16,17,96,105,"METHODS AND RESULTS: The present study is a multicenter, randomized, double-blind comparison of iopamidol and iodixanol in patients with chronic kidney disease (estimated glomerular filtration rate, 20 to 59 mL/min) who underwent cardiac angiography or percutaneous coronary interventions.",17562951_2,0,-1,0,10088,0
10109,N-acetylcysteine,14,15,72,88,"In 414 patients, contrast volume, presence of diabetes mellitus, use of N-acetylcysteine, mean baseline SCr, and estimated glomerular filtration rate were comparable in the 2 groups.",17562951_6,0,-1,0,10109,0
10113,iopamidol,18,19,74,83,"SCr increases > or = 0.5 mg/dL occurred in 4.4% (9 of 204 patients) after iopamidol and 6.7% (14 of 210 patients) after iodixanol (P=0.39), whereas rates of SCr increases > or = 25% were 9.8% and 12.4%, respectively (P=0.44).",17562951_7,0,-1,0,10113,0
10117,iopamidol,22,23,92,101,"In patients with diabetes, SCr increases > or = 0.5 mg/dL were 5.1% (4 of 78 patients) with iopamidol and 13.0% (12 of 92 patients) with iodixanol (P=0.11), whereas SCr increases > or = 25% were 10.3% and 15.2%, respectively (P=0.37).",17562951_8,0,-1,0,10117,0
10121,iopamidol,7,8,53,62,"Mean post-SCr increases were significantly less with iopamidol (all patients: 0.07 versus 0.12 mg/dL, 6.2 versus 10.6 micromol/L, P=0.03; patients with diabetes: 0.07 versus 0.16 mg/dL, 6.2 versus 14.1 micromol/L, P=0.01).",17562951_9,0,-1,0,10121,0
10123,end points,11,13,75,85,"CONCLUSIONS: The rate of contrast-induced nephropathy, defined by multiple end points, is not statistically different after the intraarterial administration of iopamidol or iodixanol to high-risk patients, with or without diabetes mellitus.",17562951_10,0,-1,0,10123,0
10125,iopamidol,23,24,160,169,"CONCLUSIONS: The rate of contrast-induced nephropathy, defined by multiple end points, is not statistically different after the intraarterial administration of iopamidol or iodixanol to high-risk patients, with or without diabetes mellitus.",17562951_10,0,-1,0,10125,0
10142,non-specific,34,35,213,225,"At autopsy, analysis of liver parenchyma revealed rich portal inflammatory infiltrate, which consisted of mixed eosinophil and monocyte cells, associated with several foci of necrosis surrounded by a hard ring of non-specific granulomatous tissue.",17574447_3,0,-1,0,10142,0
10153,neuroprotective effects,12,14,80,103,"A novel compound, maltolyl p-coumarate, attenuates cognitive deficits and shows neuroprotective effects in vitro and in vivo dementia models.",17600377_0,0,-1,0,10153,0
10169,neuroprotective effects,4,6,21,44,We also examined the neuroprotective effects of maltolyl p-coumarate in vitro using SH-SY5Y cells.,17600377_4,0,-1,0,10169,0
10177,cytochrome c,16,18,117,129,"We found that maltolyl p-coumarate significantly decreased apoptotic cell death and reduced reactive oxygen species, cytochrome c release, and caspase 3 activation.",17600377_6,0,-1,0,10177,0
10178,caspase 3,21,23,143,152,"We found that maltolyl p-coumarate significantly decreased apoptotic cell death and reduced reactive oxygen species, cytochrome c release, and caspase 3 activation.",17600377_6,0,-1,0,10178,0
10186,lipopolysaccharide,9,10,91,109,Attenuation of methamphetamine-induced nigrostriatal dopaminergic neurotoxicity in mice by lipopolysaccharide pretreatment.,17608141_0,0,-1,0,10186,0
10190,dopaminergic,11,12,85,97,Immunological activation has been proposed to play a role in methamphetamine-induced dopaminergic terminal damage.,17608141_1,0,-1,0,10190,0
10191,lipopolysaccharide,9,10,40,58,"In this study, we examined the roles of lipopolysaccharide, a pro-inflammatory and inflammatory factor, treatment in modulating the methamphetamine-induced nigrostriatal dopamine neurotoxicity.",17608141_2,0,-1,0,10191,0
10196,Lipopolysaccharide,0,1,0,18,Lipopolysaccharide pretreatment did not affect the basal body temperature or methamphetamine-elicited hyperthermia three days later.,17608141_3,0,-1,0,10196,0
10199,lipopolysaccharide,2,3,14,32,"Such systemic lipopolysaccharide treatment mitigated methamphetamine-induced striatal dopamine and 3,4-dihydroxyphenylacetic acid depletions in a dose-dependent manner.",17608141_4,0,-1,0,10199,0
10202,(1,5,7,24,26,"As the most potent dose (1 mg/kg) of lipopolysaccharide was administered two weeks, one day before or after the methamphetamine dosing regimen, methamphetamine-induced striatal dopamine and 3,4-dihydroxyphenylacetic acid depletions remained unaltered.",17608141_5,0,-1,0,10202,0
10203,lipopolysaccharide,10,11,37,55,"As the most potent dose (1 mg/kg) of lipopolysaccharide was administered two weeks, one day before or after the methamphetamine dosing regimen, methamphetamine-induced striatal dopamine and 3,4-dihydroxyphenylacetic acid depletions remained unaltered.",17608141_5,0,-1,0,10203,0
10205,lipopolysaccharide,3,4,19,37,"Moreover, systemic lipopolysaccharide pretreatment (1 mg/kg) attenuated local methamphetamine infusion-produced dopamine and 3,4-dihydroxyphenylacetic acid depletions in the striatum, indicating that the protective effect of lipopolysaccharide is less likely due to interrupted peripheral distribution or metabolism of methamphetamine.",17608141_6,0,-1,0,10205,0
10206,(1,5,7,51,53,"Moreover, systemic lipopolysaccharide pretreatment (1 mg/kg) attenuated local methamphetamine infusion-produced dopamine and 3,4-dihydroxyphenylacetic acid depletions in the striatum, indicating that the protective effect of lipopolysaccharide is less likely due to interrupted peripheral distribution or metabolism of methamphetamine.",17608141_6,0,-1,0,10206,0
10210,lipopolysaccharide,28,29,225,243,"Moreover, systemic lipopolysaccharide pretreatment (1 mg/kg) attenuated local methamphetamine infusion-produced dopamine and 3,4-dihydroxyphenylacetic acid depletions in the striatum, indicating that the protective effect of lipopolysaccharide is less likely due to interrupted peripheral distribution or metabolism of methamphetamine.",17608141_6,0,-1,0,10210,0
10212,lipopolysaccharide,8,9,49,67,We concluded a critical time window for systemic lipopolysaccharide pretreatment in exerting effective protection against methamphetamine-induced nigrostriatal dopamine neurotoxicity.,17608141_7,0,-1,0,10212,0
10231,atazanavir,16,17,107,117,"Severe rhabdomyolysis and acute renal failure secondary to concomitant use of simvastatin, amiodarone, and atazanavir.",17615423_0,0,-1,0,10231,0
10232,atazanavir,16,17,89,99,"OBJECTIVE: To report a case of a severe interaction between simvastatin, amiodarone, and atazanavir resulting in rhabdomyolysis and acute renal failure.",17615423_1,0,-1,0,10232,0
10240,atazanavir,42,43,188,198,"The patient was taking 80 mg simvastatin at bedtime (initiated 27 days earlier); amiodarone at a dose of 400 mg daily for 7 days, then 200 mg daily (initiated 19 days earlier); and 400 mg atazanavir daily (initiated at least 2 years previously).",17615423_3,0,-1,0,10240,0
10242,creatine kinase,5,7,42,57,"Laboratory evaluation revealed 66,680 U/L creatine kinase, 93 mg/dL blood urea nitrogen, 4.6 mg/dL creatinine, 1579 U/L aspartate aminotransferase, and 738 U/L alanine aminotransferase.",17615423_4,0,-1,0,10242,0
10244,creatinine,16,17,99,109,"Laboratory evaluation revealed 66,680 U/L creatine kinase, 93 mg/dL blood urea nitrogen, 4.6 mg/dL creatinine, 1579 U/L aspartate aminotransferase, and 738 U/L alanine aminotransferase.",17615423_4,0,-1,0,10244,0
10245,aspartate aminotransferase,20,22,120,146,"Laboratory evaluation revealed 66,680 U/L creatine kinase, 93 mg/dL blood urea nitrogen, 4.6 mg/dL creatinine, 1579 U/L aspartate aminotransferase, and 738 U/L alanine aminotransferase.",17615423_4,0,-1,0,10245,0
10246,alanine aminotransferase,26,28,160,184,"Laboratory evaluation revealed 66,680 U/L creatine kinase, 93 mg/dL blood urea nitrogen, 4.6 mg/dL creatinine, 1579 U/L aspartate aminotransferase, and 738 U/L alanine aminotransferase.",17615423_4,0,-1,0,10246,0
10251,creatine kinase,6,8,30,45,Nine days later the patient's creatine kinase had dropped to 1695 U/L and creatinine was 3.3 mg/dL. The patient was discharged and continued outpatient dialysis for 1 month until his renal function recovered.,17615423_6,0,-1,0,10251,0
10253,creatinine,14,15,74,84,Nine days later the patient's creatine kinase had dropped to 1695 U/L and creatinine was 3.3 mg/dL. The patient was discharged and continued outpatient dialysis for 1 month until his renal function recovered.,17615423_6,0,-1,0,10253,0
10256,CYP3A4,4,5,30,36,Simvastatin is metabolized by CYP3A4.,17615423_8,0,-1,0,10256,0
10257,atazanavir,2,3,15,25,Amiodarone and atazanavir are recognized CYP3A4 inhibitors.,17615423_9,0,-1,0,10257,0
10258,CYP3A4 inhibitors,5,7,41,58,Amiodarone and atazanavir are recognized CYP3A4 inhibitors.,17615423_9,0,-1,0,10258,0
10261,CYP3A4 inhibitors,9,11,56,73,"In patients requiring the concurrent use of statins and CYP3A4 inhibitors, pravastatin, fluvastatin, and rosuvastatin carry the lowest risk of drug interactions; atorvastatin carries moderate risk, whereas simvastatin and lovastatin have the highest risk and should be avoided in patients taking concomitant CYP3A4 inhibitors.",17615423_11,0,-1,0,10261,0
10262,rosuvastatin,17,18,105,117,"In patients requiring the concurrent use of statins and CYP3A4 inhibitors, pravastatin, fluvastatin, and rosuvastatin carry the lowest risk of drug interactions; atorvastatin carries moderate risk, whereas simvastatin and lovastatin have the highest risk and should be avoided in patients taking concomitant CYP3A4 inhibitors.",17615423_11,0,-1,0,10262,0
10265,CYP3A4 inhibitors,47,49,308,325,"In patients requiring the concurrent use of statins and CYP3A4 inhibitors, pravastatin, fluvastatin, and rosuvastatin carry the lowest risk of drug interactions; atorvastatin carries moderate risk, whereas simvastatin and lovastatin have the highest risk and should be avoided in patients taking concomitant CYP3A4 inhibitors.",17615423_11,0,-1,0,10265,0
10266,levofloxacin,4,5,33,45,Interaction between warfarin and levofloxacin: case series.,17639754_0,0,-1,0,10266,0
10268,oral anticoagulant,6,8,33,51,Warfarin is the most widely used oral anticoagulant and is indicated for many clinical conditions.,17639754_1,0,-1,0,10268,0
10270,Levofloxacin,0,1,0,12,"Levofloxacin, a fluoroquinolone, is one of the most commonly prescribed antibiotics in clinical practice and is effective against Gram-positive, Gram-negative, and atypical bacteria.",17639754_2,0,-1,0,10270,0
10276,levofloxacin,14,15,109,121,"While small prospective studies have not revealed any significant drug-drug interaction between warfarin and levofloxacin, several case reports have indicated that levofloxacin may significantly potentiate the anticoagulation effect of warfarin.",17639754_3,0,-1,0,10276,0
10278,levofloxacin,22,23,164,176,"While small prospective studies have not revealed any significant drug-drug interaction between warfarin and levofloxacin, several case reports have indicated that levofloxacin may significantly potentiate the anticoagulation effect of warfarin.",17639754_3,0,-1,0,10278,0
10279,levofloxacin,20,21,121,133,We report 3 cases of serious bleeding complications that appear to be the result of the interaction between warfarin and levofloxacin.,17639754_4,0,-1,0,10279,0
10280,levofloxacin,13,14,90,102,Physicians should be aware of this potential interaction and use caution when prescribing levofloxacin to patients taking warfarin.,17639754_5,0,-1,0,10280,0
10302,capecitabine,27,28,174,186,"RESULTS: We identified 27 reports of toxic leukoencephalopathy in patients treated with methotrexate (intrathecal, systemic), 5-fluorouracil and its derivative carmofur, and capecitabine.",17682013_6,0,-1,0,10302,0
10407,reverse transcriptase,7,9,42,63,"Serum samples were PCR amplified with HBV reverse transcriptase (RT) primers, followed by direct sequencing across the tyrosine-methionine-aspartate-aspartate (YMDD) motif of the major catalytic region in the C domain of the HBV RT enzyme.",17854040_5,0,-1,0,10407,0
10415,Roche,12,13,66,71,"HBV viral load was performed with Amplicor HBV Monitor test v2.0 (Roche Diagnostics, Penzberg, Germany).",17854040_6,0,-1,0,10415,0
10443,protease inhibitor,11,13,83,101,Estrogen prevents cholesteryl ester accumulation in macrophages induced by the HIV protease inhibitor ritonavir.,17879945_0,0,-1,0,10443,0
10446,protease inhibitors,14,16,83,102,Individuals with HIV can now live long lives with drug therapy that often includes protease inhibitors such as ritonavir.,17879945_1,0,-1,0,10446,0
10455,protease inhibitor,25,27,164,182,"In the present study, we have investigated the molecular mechanisms by which female hormones influence cholesterol metabolism in macrophages in response to the HIV protease inhibitor ritonavir.",17879945_5,0,-1,0,10455,0
10461,E2,27,28,151,153,"Briefly, cells were differentiated for 72 h with 100 nM PMA to obtain a macrophage-like phenotype in the presence or absence of 1 nM 17beta-estradiol (E2), 100 nM progesterone or vehicle (0.01% ethanol).",17879945_7,0,-1,0,10461,0
10465,E2,0,1,0,2,E2 decreased the accumulation of cholesteryl esters in macrophages following ritonavir treatment.,17879945_9,0,-1,0,10465,0
10468,scavenger receptor,6,8,42,60,"Ritonavir increased the expression of the scavenger receptor, CD36 mRNA, responsible for the uptake of LDL.",17879945_10,0,-1,0,10468,0
10472,transcription factor,14,16,97,117,"Additionally, ritonavir treatment selectively increased the relative levels of PPARgamma mRNA, a transcription factor responsible for the regulation of CD36 mRNA expression.",17879945_11,0,-1,0,10472,0
10474,E2,2,3,15,17,"Treatment with E2, however, failed to prevent these increases at the mRNA level.",17879945_12,0,-1,0,10474,0
10475,E2,0,1,0,2,"E2 did, however, significantly suppress CD36 protein levels as measured by fluorescent immunocytochemistry.",17879945_13,0,-1,0,10475,0
10477,E2,4,5,24,26,This data suggests that E2 modifies the expression of CD36 at the level of protein expression in monocyte-derived macrophages resulting in reduced cholesteryl ester accumulation following ritonavir treatment.,17879945_14,0,-1,0,10477,0
10486,antimicrobial agents,4,6,23,43,"With widespread use of antimicrobial agents, however, hepatic injury occurs frequently, and among adverse drug reactions, idiosyncratic reactions are the most serious.",17919553_2,0,-1,0,10486,0
10495,alanine aminotransferase,7,9,44,68,"Admission laboratory tests were as follows: alanine aminotransferase, 67 U/L (reference range, 10-37 U/L); aspartate aminotransferase, 98 U/L (10-40 U/L); alkaline phosphatase, 513 U/L (0-270 U/L); gamma-glutamyltransferase, 32 U/L (7-49 U/L); amylase, 46 U/L (0-220 U/L); total bilirubin, 20.1 mg/dL (0.2-1.0 mg/dL); direct bilirubin, 14.8 mg/dL (0-0.3 mg/dL); and albumin, 4.7 mg/dL (3.5-5.4 mg/dL).",17919553_5,0,-1,0,10495,0
10498,aspartate aminotransferase,22,24,107,133,"Admission laboratory tests were as follows: alanine aminotransferase, 67 U/L (reference range, 10-37 U/L); aspartate aminotransferase, 98 U/L (10-40 U/L); alkaline phosphatase, 513 U/L (0-270 U/L); gamma-glutamyltransferase, 32 U/L (7-49 U/L); amylase, 46 U/L (0-220 U/L); total bilirubin, 20.1 mg/dL (0.2-1.0 mg/dL); direct bilirubin, 14.8 mg/dL (0-0.3 mg/dL); and albumin, 4.7 mg/dL (3.5-5.4 mg/dL).",17919553_5,0,-1,0,10498,0
10521,fluocinolone acetonide,8,10,59,81,Intraocular pressure in patients with uveitis treated with fluocinolone acetonide implants.,17923537_0,0,-1,0,10521,0
10524,fluocinolone acetonide,22,24,131,153,OBJECTIVE: To report the incidence and management of elevated intraocular pressure (IOP) in patients with uveitis treated with the fluocinolone acetonide (FA) intravitreal implant.,17923537_1,0,-1,0,10524,0
10597,caspase 3,20,22,123,132,"These changes were associated with an increased sarcolemmal expression of Fas and FasL, as well as increased activation of caspase 3, translocation of calpain 1 to the sarcolemma and sarcomere, and increased numbers of cells undergoing apoptosis.",17943461_7,0,-1,0,10597,0
10598,calpain,25,26,151,158,"These changes were associated with an increased sarcolemmal expression of Fas and FasL, as well as increased activation of caspase 3, translocation of calpain 1 to the sarcolemma and sarcomere, and increased numbers of cells undergoing apoptosis.",17943461_7,0,-1,0,10598,0
10601,troponin I,9,11,61,71,"These were associated with changes in dystrophin and cardiac troponin I localization, as well as loss of sarcolemmal integrity.",17943461_8,0,-1,0,10601,0
10603,apoptotic,28,29,188,197,"CONCLUSIONS: The expression of Fas ligand in the myocardium, as identified in HIV-positive patients, might increase the susceptibility to HAART-induced cardiomyopathy due to activation of apoptotic pathways, resulting in cardiac dilation and dysfunction.",17943461_9,0,-1,0,10603,0
10609,diclofenac sodium,14,16,107,124,"Gastrointestinal tolerability of etoricoxib in rheumatoid arthritis patients: results of the etoricoxib vs diclofenac sodium gastrointestinal tolerability and effectiveness trial (EDGE-II).OBJECTIVE: A randomised, double-blind study to compare the gastrointestinal (GI) tolerability, safety and efficacy of etoricoxib and diclofenac in patients with rheumatoid arthritis (RA).",17965424_0,0,-1,0,10609,0
10615,diclofenac,43,44,322,332,"Gastrointestinal tolerability of etoricoxib in rheumatoid arthritis patients: results of the etoricoxib vs diclofenac sodium gastrointestinal tolerability and effectiveness trial (EDGE-II).OBJECTIVE: A randomised, double-blind study to compare the gastrointestinal (GI) tolerability, safety and efficacy of etoricoxib and diclofenac in patients with rheumatoid arthritis (RA).",17965424_0,0,-1,0,10615,0
10618,diclofenac,32,33,151,161,PATIENTS AND METHODS: A total of 4086 patients (mean age 60.8 years) diagnosed with RA were enrolled and received etoricoxib 90 mg daily (n = 2032) or diclofenac 75 mg twice daily (n = 2054).,17965424_1,0,-1,0,10618,0
10621,end point,3,5,25,34,The prespecified primary end point consisted of the cumulative rate of patient discontinuations due to clinical and laboratory GI adverse experiences (AEs).,17965424_3,0,-1,0,10621,0
10628,diclofenac,30,31,123,133,"RESULTS: Mean (SD; maximum) duration of treatment was 19.3 (10.3; 32.9) and 19.1 (10.4; 33.1) months in the etoricoxib and diclofenac groups, respectively.",17965424_6,0,-1,0,10628,0
10631,diclofenac,14,15,95,105,"The cumulative discontinuation rate due to GI AEs was significantly lower with etoricoxib than diclofenac (5.2 vs 8.5 events per 100 patient-years, respectively; hazard ratio 0.62 (95% CI: 0.47, 0.81; p<or=0.001)).",17965424_7,0,-1,0,10631,0
10637,diclofenac,24,25,167,177,The incidence of discontinuations for hypertension-related and oedema-related AEs were significantly higher with etoricoxib (2.5% and 1.1% respectively) compared with diclofenac (1.5% and 0.4% respectively; p<0.001 for hypertension and p<0.01 for oedema).,17965424_8,0,-1,0,10637,0
10639,diclofenac,2,3,15,25,"Etoricoxib and diclofenac treatment resulted in similar efficacy (PGADS mean changes from baseline -0.62 vs -0.58, respectively).",17965424_9,0,-1,0,10639,0
10644,diclofenac,19,20,126,136,CONCLUSIONS: Etoricoxib 90 mg demonstrated a significantly lower risk for discontinuing treatment due to GI AEs compared with diclofenac 150 mg.,17965424_10,0,-1,0,10644,0
10668,paracetamol,11,12,79,90,Acute liver failure in two patients with regular alcohol consumption ingesting paracetamol at therapeutic dosage.,18004067_0,0,-1,0,10668,0
10673,paracetamol,17,18,115,126,BACKGROUND: The possible role of alcohol in the development of hepatotoxicity associated with therapeutic doses of paracetamol (acetaminophen) is currently debated.,18004067_1,0,-1,0,10673,0
10678,paracetamol,1,2,2,13,A paracetamol serum level obtained in one of these patients was not in the toxic range.,18004067_3,0,-1,0,10678,0
10684,paracetamol,15,16,106,117,Possible risk factors for the development of hepatotoxicity in patients treated with therapeutic doses of paracetamol are discussed.,18004067_4,0,-1,0,10684,0
10688,paracetamol,4,5,20,31,We propose that the paracetamol dose should not exceed 2 g/day in such patients and that their liver function should be monitored closely while being treated with paracetamol.,18004067_6,0,-1,0,10688,0
10691,paracetamol,27,28,163,174,We propose that the paracetamol dose should not exceed 2 g/day in such patients and that their liver function should be monitored closely while being treated with paracetamol.,18004067_6,0,-1,0,10691,0
10692,propofol,7,8,58,66,Reduction of pain during induction with target-controlled propofol and remifentanil.,18006530_0,0,-1,0,10692,0
10693,remifentanil,9,10,71,83,Reduction of pain during induction with target-controlled propofol and remifentanil.,18006530_0,0,-1,0,10693,0
10694,propofol,6,7,33,41,BACKGROUND: Pain on injection of propofol is unpleasant.,18006530_1,0,-1,0,10694,0
10695,propofol,3,4,21,29,We hypothesized that propofol infusion pain might be prevented by infusing remifentanil before starting the propofol infusion in a clinical setting where target-controlled infusions (TCI) of both drugs were used.,18006530_2,0,-1,0,10695,0
10697,remifentanil,11,12,75,87,We hypothesized that propofol infusion pain might be prevented by infusing remifentanil before starting the propofol infusion in a clinical setting where target-controlled infusions (TCI) of both drugs were used.,18006530_2,0,-1,0,10697,0
10698,propofol,15,16,108,116,We hypothesized that propofol infusion pain might be prevented by infusing remifentanil before starting the propofol infusion in a clinical setting where target-controlled infusions (TCI) of both drugs were used.,18006530_2,0,-1,0,10698,0
10705,remifentanil,20,21,131,143,"A prospective, randomized, double-blind, placebo-controlled trial was performed to determine the effect-site concentration (Ce) of remifentanil to prevent the pain without producing complications.",18006530_3,0,-1,0,10705,0
10708,remifentanil,21,22,122,134,"METHODS: A total of 128 patients undergoing general surgery were randomly allocated to receive normal saline (control) or remifentanil to a target Ce of 2 ng ml(-1) (R2), 4 ng ml(-1) (R4), or 6 ng ml(-1) (R6) administered via TCI.",18006530_4,0,-1,0,10708,0
10710,R4,40,41,184,186,"METHODS: A total of 128 patients undergoing general surgery were randomly allocated to receive normal saline (control) or remifentanil to a target Ce of 2 ng ml(-1) (R2), 4 ng ml(-1) (R4), or 6 ng ml(-1) (R6) administered via TCI.",18006530_4,0,-1,0,10710,0
10712,propofol,10,11,50,58,"After the target Ce was achieved, the infusion of propofol was started.",18006530_5,0,-1,0,10712,0
10714,remifentanil,6,7,60,72,"Remifentanil-related complications were assessed during the remifentanil infusion, and pain caused by propofol was evaluated using a four-point scale during the propofol infusion.",18006530_6,0,-1,0,10714,0
10715,propofol,13,14,102,110,"Remifentanil-related complications were assessed during the remifentanil infusion, and pain caused by propofol was evaluated using a four-point scale during the propofol infusion.",18006530_6,0,-1,0,10715,0
10716,propofol,22,23,161,169,"Remifentanil-related complications were assessed during the remifentanil infusion, and pain caused by propofol was evaluated using a four-point scale during the propofol infusion.",18006530_6,0,-1,0,10716,0
10727,propofol,9,10,57,65,"CONCLUSIONS: During induction of anaesthesia with TCI of propofol and remifentanil, a significant reduction in propofol infusion pain was achieved without significant complications by prior administration of remifentanil at a target Ce of 4 ng ml(-1).",18006530_11,0,-1,0,10727,0
10728,remifentanil,11,12,70,82,"CONCLUSIONS: During induction of anaesthesia with TCI of propofol and remifentanil, a significant reduction in propofol infusion pain was achieved without significant complications by prior administration of remifentanil at a target Ce of 4 ng ml(-1).",18006530_11,0,-1,0,10728,0
10729,propofol,17,18,111,119,"CONCLUSIONS: During induction of anaesthesia with TCI of propofol and remifentanil, a significant reduction in propofol infusion pain was achieved without significant complications by prior administration of remifentanil at a target Ce of 4 ng ml(-1).",18006530_11,0,-1,0,10729,0
10731,remifentanil,29,30,208,220,"CONCLUSIONS: During induction of anaesthesia with TCI of propofol and remifentanil, a significant reduction in propofol infusion pain was achieved without significant complications by prior administration of remifentanil at a target Ce of 4 ng ml(-1).",18006530_11,0,-1,0,10731,0
10802,Her,0,1,0,3,Her vocal change and weakness began to improve spontaneously about 3 weeks after transfer.,18023325_11,0,-1,0,10802,0
10808,levetiracetam,3,4,26,39,Encephalopathy induced by levetiracetam added to valproate.,18081909_0,0,-1,0,10808,0
10810,levetiracetam,9,10,48,61,BACKGROUND: We report on the manifestation of a levetiracetam (LEV)-induced encephalopathy.,18081909_1,0,-1,0,10810,0
10851,yohimbine,41,42,291,300,"In experiments using specific adrenergic antagonists, we found that pretreatment with the beta-adrenergic receptor antagonist propranolol blocked cocaine-induced anxiety-like behavior in Dbh +/- and wild-type C57BL6/J mice, while the alpha(1) antagonist prazosin and the alpha(2) antagonist yohimbine had no effect.",18083142_7,0,-1,0,10851,0
10856,Dexmedetomidine,0,1,0,15,Dexmedetomidine and cardiac protection for non-cardiac surgery: a meta-analysis of randomised controlled trials.,18086064_0,0,-1,0,10856,0
10863,dexmedetomidine,9,10,51,66,We conducted a systematic review of the effects of dexmedetomidine on cardiac outcomes following non-cardiac surgery.,18086064_1,0,-1,0,10863,0
10867,dexmedetomidine,8,9,62,77,"We included prospective, randomised peri-operative studies of dexmedetomidine that reported mortality, cardiac morbidity or adverse drug events.",18086064_2,0,-1,0,10867,0
10874,Dexmedetomidine,0,1,0,15,"Dexmedetomidine was associated with a trend towards improved cardiac outcomes; all-cause mortality (OR 0.27, 95% CI 0.01-7.13, p = 0.44), non-fatal myocardial infarction (OR 0.26, 95% CI 0.04-1.60, p = 0.14), and myocardial ischaemia (OR 0.65, 95% CI 0.26-1.63, p = 0.36).",18086064_6,0,-1,0,10874,0
10881,dexmedetomidine,5,6,41,56,A randomised placebo-controlled trial of dexmedetomidine is warranted.,18086064_9,0,-1,0,10881,0
10884,clomiphene citrate,6,8,51,69,Myocardial infarction in pregnancy associated with clomiphene citrate for ovulation induction: a case report.,18161408_0,0,-1,0,10884,0
10886,Clomiphene citrate,2,4,12,30,BACKGROUND: Clomiphene citrate (CC) is commonly prescribed for ovulation induction.,18161408_1,0,-1,0,10886,0
10896,troponin I,7,9,38,48,Cardiac enzymes showed a peak rise in troponin I to 9.10 ng/mL. An initial exercise stress test was normal.,18161408_7,0,-1,0,10896,0
10913,female fertility,12,14,105,121,We first tested whether chronic hyperprolactinemia inhibited two neuroendocrine parameters necessary for female fertility: pulsatile LH secretion and the estrogen-induced LH surge.,18162529_3,0,-1,0,10913,0
10918,sulpiride,7,8,62,71,"Chronic hyperprolactinemia induced by the dopamine antagonist sulpiride caused a 40% reduction LH pulse frequency in ovariectomized rats, but only in the presence of chronic low levels of estradiol.",18162529_4,0,-1,0,10918,0
10921,Sulpiride,0,1,0,9,Sulpiride did not affect the magnitude of a steroid-induced LH surge or the percentage of GnRH neurons activated during the surge.,18162529_5,0,-1,0,10921,0
10923,GnRH,15,16,90,94,Sulpiride did not affect the magnitude of a steroid-induced LH surge or the percentage of GnRH neurons activated during the surge.,18162529_5,0,-1,0,10923,0
10929,STAT5,22,23,165,170,"To test the hypothesis that estrogen increases PRL-R expression and sensitivity to prolactin, we next demonstrated that estradiol greatly augments prolactin-induced STAT5 activation.",18162529_7,0,-1,0,10929,0
10933,-3,13,14,75,77,"Lastly, we measured PRL-R and suppressor of cytokine signaling (SOCS-1 and -3 and CIS, which reflect the level of prolactin signaling) mRNAs in response to sulpiride and estradiol.",18162529_8,0,-1,0,10933,0
10935,sulpiride,29,30,156,165,"Lastly, we measured PRL-R and suppressor of cytokine signaling (SOCS-1 and -3 and CIS, which reflect the level of prolactin signaling) mRNAs in response to sulpiride and estradiol.",18162529_8,0,-1,0,10935,0
10936,Sulpiride,0,1,0,9,"Sulpiride induced only SOCS-1 in the medial preoptic area, where GnRH neurons are regulated, but in the arcuate nucleus and choroid plexus, PRL-R, SOCS-3, and CIS mRNA levels were also induced.",18162529_9,0,-1,0,10936,0
10938,GnRH,11,12,65,69,"Sulpiride induced only SOCS-1 in the medial preoptic area, where GnRH neurons are regulated, but in the arcuate nucleus and choroid plexus, PRL-R, SOCS-3, and CIS mRNA levels were also induced.",18162529_9,0,-1,0,10938,0
10946,GnRH,4,5,21,25,These data show that GnRH pulse frequency is inhibited by chronic hyperprolactinemia in a steroid-dependent manner.,18162529_12,0,-1,0,10946,0
10984,Tacrolimus,0,1,0,10,"Tacrolimus, MMF, and steroids were given as immunosuppressant.",18186898_3,0,-1,0,10984,0
10986,her,11,12,69,72,Lamivudine was added because of de nova hepatitis B infection during her follow-up.,18186898_4,0,-1,0,10986,0
10990,tacrolimus,1,2,9,19,"Although tacrolimus was suspected to be the cause of late post-transplant renal acidosis and was replaced by sirolimus, acidosis, and electrolyte imbalance got worse.",18186898_6,0,-1,0,10990,0
10991,sirolimus,17,18,109,118,"Although tacrolimus was suspected to be the cause of late post-transplant renal acidosis and was replaced by sirolimus, acidosis, and electrolyte imbalance got worse.",18186898_6,0,-1,0,10991,0
10993,her,6,7,46,49,Proximal muscle weakness has developed during her follow-up.,18186898_7,0,-1,0,10993,0
11000,tacrolimus,20,21,134,144,We suggest that our patient's tubular dysfunction and myopathy may have resulted from mitochondrial dysfunction which is triggered by tacrolimus and augmented by lamivudine.,18186898_9,0,-1,0,11000,0
11006,telmisartan,28,29,172,183,"Results of a comparative, phase III, 12-week, multicenter, prospective, randomized, double-blind assessment of the efficacy and tolerability of a fixed-dose combination of telmisartan and amlodipine versus amlodipine monotherapy in Indian adults with stage II hypertension.",18201582_0,0,-1,0,11006,0
11007,amlodipine,30,31,188,198,"Results of a comparative, phase III, 12-week, multicenter, prospective, randomized, double-blind assessment of the efficacy and tolerability of a fixed-dose combination of telmisartan and amlodipine versus amlodipine monotherapy in Indian adults with stage II hypertension.",18201582_0,0,-1,0,11007,0
11008,amlodipine,32,33,206,216,"Results of a comparative, phase III, 12-week, multicenter, prospective, randomized, double-blind assessment of the efficacy and tolerability of a fixed-dose combination of telmisartan and amlodipine versus amlodipine monotherapy in Indian adults with stage II hypertension.",18201582_0,0,-1,0,11008,0
11013,telmisartan,23,24,120,131,OBJECTIVE: The aim of this study was to evaluate the efficacy and tolerability of a new fixed-dose combination (FDC) of telmisartan 40 mg + amlodipine 5 mg (T+A) compared with amlodipine 5-mg monotherapy (A) in adult Indian patients with stage II hypertension.,18201582_1,0,-1,0,11013,0
11014,amlodipine,27,28,140,150,OBJECTIVE: The aim of this study was to evaluate the efficacy and tolerability of a new fixed-dose combination (FDC) of telmisartan 40 mg + amlodipine 5 mg (T+A) compared with amlodipine 5-mg monotherapy (A) in adult Indian patients with stage II hypertension.,18201582_1,0,-1,0,11014,0
11016,amlodipine,35,36,176,186,OBJECTIVE: The aim of this study was to evaluate the efficacy and tolerability of a new fixed-dose combination (FDC) of telmisartan 40 mg + amlodipine 5 mg (T+A) compared with amlodipine 5-mg monotherapy (A) in adult Indian patients with stage II hypertension.,18201582_1,0,-1,0,11016,0
11032,end points,2,4,17,27,"Primary efficacy end points were reduction in clinical systolic BP (SBP)/ diastolic BP (DBP) from baseline to study end and number of responders (ie, patients who achieved target SBP/ DBP <130/<80 mm Hg) at end of study.",18201582_4,0,-1,0,11032,0
11091,immunomodulatory,26,27,174,190,"Thalidomide has limited single-agent activity in relapsed or refractory indolent non-Hodgkin lymphomas: a phase II trial of the Cancer and Leukemia Group B.Thalidomide is an immunomodulatory agent with demonstrated activity in multiple myeloma, mantle cell lymphoma and lymphoplasmacytic lymphoma.",18217897_0,0,-1,0,11091,0
11110,lenalidomide,31,32,215,227,"Our results failed to demonstrate an important response rate to single agent thalidomide in indolent lymphomas and contrast with the higher activity level reported with the second generation immunomodulatory agent, lenalidomide.",18217897_8,0,-1,0,11110,0
11118,antinociceptive,12,13,74,89,"In acute pain models, N-methyl-D-aspartate (NMDA) antagonists enhance the antinociceptive effects of morphine to a greater extent in males than females.",18221780_1,0,-1,0,11118,0
11133,dextromethorphan,7,8,46,62,"In males, the non-competitive NMDA antagonist dextromethorphan enhanced the antihyperalgesic effect of low to moderate doses of morphine in a dose-and time-dependent manner.",18221780_5,0,-1,0,11133,0
11138,dextromethorphan,5,6,43,59,"Enhancement of morphine antinociception by dextromethorphan was seen in both males and females in the acute pain models, with the magnitude of this effect being greater in males.",18221780_7,0,-1,0,11138,0
11146,APOE,6,7,45,49,Increased mental slowing associated with the APOE epsilon4 allele after trihexyphenidyl oral anticholinergic challenge in healthy elderly.,18239197_0,0,-1,0,11146,0
11148,trihexyphenidyl,10,11,72,87,Increased mental slowing associated with the APOE epsilon4 allele after trihexyphenidyl oral anticholinergic challenge in healthy elderly.,18239197_0,0,-1,0,11148,0
11149,APOE,13,14,82,86,OBJECTIVES: The objectives of this study were to examine the relationship between APOE epsilon4 and subjective effects of trihexyphenidyl on measures reflecting sedation and confusion and to investigate the relationship between trihexyphenidyl-induced subjective effects and objective memory performance.,18239197_1,0,-1,0,11149,0
11152,trihexyphenidyl,19,20,122,137,OBJECTIVES: The objectives of this study were to examine the relationship between APOE epsilon4 and subjective effects of trihexyphenidyl on measures reflecting sedation and confusion and to investigate the relationship between trihexyphenidyl-induced subjective effects and objective memory performance.,18239197_1,0,-1,0,11152,0
11158,APOE,14,15,79,83,"METHODS: This study comprised 24 cognitively intact, health elderly adults (12 APOE epsilon4 carriers) at an outpatient geriatric psychiatry research clinic.",18239197_2,0,-1,0,11158,0
11164,trihexyphenidyl,8,9,43,58,All participants received 1.0 mg or 2.0 mg trihexyphenidyl or placebo administered in counterbalanced sequences over a period of three consecutive weeks.,18239197_4,0,-1,0,11164,0
11171,trihexyphenidyl,7,8,31,46,RESULTS: A 2.0-mg oral dose of trihexyphenidyl resulted in increased subjective ratings of mental slowness in carriers of the APOE epsilon4 allele only.,18239197_6,0,-1,0,11171,0
11174,APOE,20,21,126,130,RESULTS: A 2.0-mg oral dose of trihexyphenidyl resulted in increased subjective ratings of mental slowness in carriers of the APOE epsilon4 allele only.,18239197_6,0,-1,0,11174,0
11176,trihexyphenidyl,10,11,63,78,Drug effects as determined by difference scores between 2.0 mg trihexyphenidyl and placebo on ratings of mental slowness significantly correlated with total and delayed recall on the Buschke Selective Reminding Test in carriers of the APOE epsilon4 allele only.,18239197_7,0,-1,0,11176,0
11179,APOE,35,36,235,239,Drug effects as determined by difference scores between 2.0 mg trihexyphenidyl and placebo on ratings of mental slowness significantly correlated with total and delayed recall on the Buschke Selective Reminding Test in carriers of the APOE epsilon4 allele only.,18239197_7,0,-1,0,11179,0
11201,cyclosporine,11,12,72,84,"In this study, long-term cardiac transplant patients were switched from cyclosporine to Srl-based IS.",18261172_4,0,-1,0,11201,0
11203,mycophenolate mofetil,4,6,28,49,Concomitant IS consisted of mycophenolate mofetil +/- steroids.,18261172_5,0,-1,0,11203,0
11254,receptor antagonists,6,8,64,84,Synthesis of N-pyrimidinyl-2-phenoxyacetamides as adenosine A2A receptor antagonists.,18329269_0,0,-1,0,11254,0
11275,nicotinic,10,11,60,69,"The stimulant action of nicotine was blocked by the central nicotinic antagonist mecamylamine but not by the peripheral nicotinic blocker hexamethonium, indicating that the response is probably mediated by central nicotinic receptors.",1833784_6,0,-1,0,11275,0
11277,nicotinic,18,19,120,129,"The stimulant action of nicotine was blocked by the central nicotinic antagonist mecamylamine but not by the peripheral nicotinic blocker hexamethonium, indicating that the response is probably mediated by central nicotinic receptors.",1833784_6,0,-1,0,11277,0
11278,hexamethonium,20,21,138,151,"The stimulant action of nicotine was blocked by the central nicotinic antagonist mecamylamine but not by the peripheral nicotinic blocker hexamethonium, indicating that the response is probably mediated by central nicotinic receptors.",1833784_6,0,-1,0,11278,0
11279,nicotinic,31,32,214,223,"The stimulant action of nicotine was blocked by the central nicotinic antagonist mecamylamine but not by the peripheral nicotinic blocker hexamethonium, indicating that the response is probably mediated by central nicotinic receptors.",1833784_6,0,-1,0,11279,0
11282,SCH,9,10,74,77,"Nicotine-induced hyperactivity was blocked by the selective D1 antagonist SCH 23390, the selective D2 antagonist raclopride and the D1/D2 antagonist fluphenazine.",1833784_7,0,-1,0,11282,0
11283,D2,14,15,99,101,"Nicotine-induced hyperactivity was blocked by the selective D1 antagonist SCH 23390, the selective D2 antagonist raclopride and the D1/D2 antagonist fluphenazine.",1833784_7,0,-1,0,11283,0
11284,raclopride,16,17,113,123,"Nicotine-induced hyperactivity was blocked by the selective D1 antagonist SCH 23390, the selective D2 antagonist raclopride and the D1/D2 antagonist fluphenazine.",1833784_7,0,-1,0,11284,0
11287,D2,3,4,22,24,"Pretreatment with the D2 agonist PHNO enhanced nicotine-induced hyperactivity, whereas the D1 agonist SKF 38393 had no effect.",1833784_8,0,-1,0,11287,0
11291,SKF 38393,14,16,102,111,"Pretreatment with the D2 agonist PHNO enhanced nicotine-induced hyperactivity, whereas the D1 agonist SKF 38393 had no effect.",1833784_8,0,-1,0,11291,0
11295,dopaminergic,14,15,85,97,"The effect appears to be mediated by central nicotine receptors, possibly located on dopaminergic neurons, and also requires the activation of both D1 and D2 dopamine receptors.",1833784_10,0,-1,0,11295,0
11303,clomiphene citrate,13,15,78,96,OBJECTIVE: To report a case of central retinal vein occlusion associated with clomiphene citrate (CC).,18343374_1,0,-1,0,11303,0
11322,bronchodilator effects,1,3,4,26,"The bronchodilator effects of a single dose of ipratropium bromide aerosol (36 micrograms) and short-acting theophylline tablets (dose titrated to produce serum levels of 10-20 micrograms/mL) were compared in a double-blind, placebo-controlled crossover study in 21 patients with stable, chronic obstructive pulmonary disease.",1835291_1,0,-1,0,11322,0
11331,ipratropium,42,43,204,215,"Mean peak forced expiratory volume in 1 second (FEV1) increases over baseline and the proportion of patients attaining at least a 15% increase in the FEV1 (responders) were 31% and 90%, respectively, for ipratropium and 17% and 50%, respectively, for theophylline.",1835291_2,0,-1,0,11331,0
11333,ipratropium,13,14,77,88,The average FEV1 increases during the 6-hour observation period were 18% for ipratropium and 8% for theophylline.,1835291_3,0,-1,0,11333,0
11334,ipratropium,9,10,47,58,The mean duration of action was 3.8 hours with ipratropium and 2.4 hours with theophylline.,1835291_4,0,-1,0,11334,0
11337,ipratropium,4,5,24,35,These results show that ipratropium is a more potent bronchodilator than oral theophylline in patients with chronic airflow obstruction.,1835291_6,0,-1,0,11337,0
11341,Amikacin,0,1,0,8,Amikacin is an aminoglycoside commonly used to provide empirical double gram-negative treatment for febrile neutropenia and other suspected infections.,18356633_1,0,-1,0,11341,0
11342,aminoglycoside,3,4,15,29,Amikacin is an aminoglycoside commonly used to provide empirical double gram-negative treatment for febrile neutropenia and other suspected infections.,18356633_1,0,-1,0,11342,0
11353,aminoglycoside,15,16,113,127,Forty patients with a diagnosis consistent with a hematologic/oncologic disorder that required treatment with an aminoglycoside were randomized to either conventional or extended-interval amikacin.,18356633_4,0,-1,0,11353,0
11355,amikacin,23,24,188,196,Forty patients with a diagnosis consistent with a hematologic/oncologic disorder that required treatment with an aminoglycoside were randomized to either conventional or extended-interval amikacin.,18356633_4,0,-1,0,11355,0
11358,amikacin,17,18,108,116,The occurrence of nephrotoxicity by means of an increase in serum creatinine and evaluation of efficacy via amikacin serum concentrations with respective pathogens were assessed.,18356633_5,0,-1,0,11358,0
11361,at 10,13,15,100,105,"The occurrence of nephrotoxicity was similar between the conventional and extended-interval groups, at 10% and 5%, respectively (P = 1.00).",18356633_6,0,-1,0,11361,0
11369,dexmedetomidine,2,3,10,25,High dose dexmedetomidine as the sole sedative for pediatric MRI.OBJECTIVE: This large-scale retrospective review evaluates the sedation profile of dexmedetomidine.,18363626_0,0,-1,0,11369,0
11372,dexmedetomidine,20,21,148,163,High dose dexmedetomidine as the sole sedative for pediatric MRI.OBJECTIVE: This large-scale retrospective review evaluates the sedation profile of dexmedetomidine.,18363626_0,0,-1,0,11372,0
11377,dexmedetomidine,19,20,110,125,"AIM: To determine the hemodynamic responses, efficacy and adverse events associated with the use of high dose dexmedetomidine as the sole sedative for magnetic resonance imaging (MRI) studies.",18363626_1,0,-1,0,11377,0
11379,Dexmedetomidine,2,3,12,27,BACKGROUND: Dexmedetomidine has been used at our institution since 2005 to provide sedation for pediatric radiological imaging studies.,18363626_2,0,-1,0,11379,0
11381,dexmedetomidine,9,10,53,68,"Over time, an effective protocol utilizing high dose dexmedetomidine as the sole sedative agent has evolved.",18363626_3,0,-1,0,11381,0
11384,dexmedetomidine,10,11,66,81,Data were analyzed from all 747 consecutive patients who received dexmedetomidine for MRI sedation from April 2005 to April 2007.,18363626_5,0,-1,0,11384,0
11386,dexmedetomidine,11,12,52,67,"RESULTS: Since 2005, the 10-min loading dose of our dexmedetomidine protocol increased from 2 to 3 microg.kg(-1), and the infusion rate increased from 1 to 1.5 to 2 microg.kg(-1).h(-1).",18363626_6,0,-1,0,11386,0
11388,dexmedetomidine,21,22,134,149,"The current sedation protocol progressively increased the rate of successful sedation (able to complete the imaging study) when using dexmedetomidine alone from 91.8% to 97.6% (P = 0.009), reducing the requirement for adjuvant pentobarbital in the event of sedation failure with dexmedetomidine alone and decreased the mean recovery time by 10 min (P < 0.001).",18363626_7,0,-1,0,11388,0
11389,dexmedetomidine,48,49,279,294,"The current sedation protocol progressively increased the rate of successful sedation (able to complete the imaging study) when using dexmedetomidine alone from 91.8% to 97.6% (P = 0.009), reducing the requirement for adjuvant pentobarbital in the event of sedation failure with dexmedetomidine alone and decreased the mean recovery time by 10 min (P < 0.001).",18363626_7,0,-1,0,11389,0
11391,dexmedetomidine,1,2,9,24,"Although dexmedetomidine sedation was associated with a 16% incidence of bradycardia, all concomitant mean arterial blood pressures were within 20% of age-adjusted normal range and oxygen saturations were 95% or higher.",18363626_8,0,-1,0,11391,0
11395,Dexmedetomidine,2,3,12,27,CONCLUSION: Dexmedetomidine in high doses provides adequate sedation for pediatric MRI studies.,18363626_9,0,-1,0,11395,0
11399,dexmedetomidine,5,6,23,38,"While use of high dose dexmedetomidine is associated with decreases in heart rate and blood pressure outside the established 'awake' norms, this deviation is generally within 20% of norms, and is not associated with adverse sequelae.",18363626_10,0,-1,0,11399,0
11405,Dexmedetomidine,0,1,0,15,Dexmedetomidine is useful as the sole sedative for pediatric MRI.,18363626_11,0,-1,0,11405,0
11408,sulfasalazine,3,4,31,44,Hepatotoxicity associated with sulfasalazine in inflammatory arthritis: A case series from a local surveillance of serious adverse events.,18405372_0,0,-1,0,11408,0
11420,disease modifying anti-rheumatic drugs,15,19,104,142,We report an investigation from a local surveillance for serious adverse drug reactions associated with disease modifying anti-rheumatic drugs that was triggered by the occurrence of liver failure in two of our patients.,18405372_2,0,-1,0,11420,0
11425,sulfasalazine,7,8,37,50,"Patients', who had hepatotoxicity on sulfasalazine and met a definition of a serious ADR, were identified.",18405372_4,0,-1,0,11425,0
11430,sulfasalazine,6,7,44,57,The likely frequency of hepatotoxicity with sulfasalazine was estimated by making a series of conservative assumptions.,18405372_6,0,-1,0,11430,0
11442,sulfasalazine,7,8,52,65,The likely frequency of serious hepatotoxicity with sulfasalazine was estimated at 0.4% of treated patients.,18405372_14,0,-1,0,11442,0
11445,sulfasalazine,6,7,51,64,CONCLUSION: Serious hepatotoxicity associated with sulfasalazine appears to be under-appreciated and intensive monitoring and vigilance in the first 6 weeks of treatment is especially important.,18405372_15,0,-1,0,11445,0
11516,aspartate,25,26,159,168,"The present study aimed to investigate the anticonvulsant activity as well as the effects on the level of hippocampal amino acid neurotransmitters (glutamate, aspartate, glycine and GABA) of N-(2-propylpentanoyl)urea (VPU) in comparison to its parent compound, valproic acid (VPA).",18439803_1,0,-1,0,11516,0
11520,valproic acid,43,45,261,274,"The present study aimed to investigate the anticonvulsant activity as well as the effects on the level of hippocampal amino acid neurotransmitters (glutamate, aspartate, glycine and GABA) of N-(2-propylpentanoyl)urea (VPU) in comparison to its parent compound, valproic acid (VPA).",18439803_1,0,-1,0,11520,0
11530,aspartate,18,19,149,158,In vivo microdialysis demonstrated that an intraperitoneal administration of pilocarpine induced a pronounced increment of hippocampal glutamate and aspartate whereas no significant change was observed on the level of glycine and GABA.,18439803_3,0,-1,0,11530,0
11535,aspartate,26,27,156,165,Pretreatment with either VPU (50 and 100 mg/kg) or VPA (300 and 600 mg/kg) completely abolished pilocarpine-evoked increases in extracellular glutamate and aspartate.,18439803_4,0,-1,0,11535,0
11538,aspartate,26,27,153,162,"In addition, a statistically significant reduction was also observed on the level of GABA and glycine but less than a drastic reduction of glutamate and aspartate level.",18439803_5,0,-1,0,11538,0
11542,aspartate,38,39,256,265,Based on the finding that VPU and VPA could protect the animals against pilocarpine-induced seizure it is suggested that the reduction of inhibitory amino acid neurotransmitters was comparatively minor and offset by a pronounced reduction of glutamate and aspartate.,18439803_6,0,-1,0,11542,0
11546,aspartate,17,18,114,123,"Therefore, like VPA, the finding that VPU could drastically reduce pilocarpine-induced increases in glutamate and aspartate should account, at least partly, for its anticonvulsant activity observed in pilocarpine-induced seizure in experimental animals.",18439803_7,0,-1,0,11546,0
11574,vitamin D2,44,46,280,290,"The aim of this study is to examine the role of gastric acid back-diffusion, mast cell histamine release, lipid peroxide (LPO) generation and mucosal microvascular permeability in modulating gastric hemorrhage and ulcer in rats with atherosclerosis induced by coadministration of vitamin D2 and cholesterol.",18442015_2,0,-1,0,11574,0
11578,corn oil,15,17,90,98,Male Wistar rats were challenged intragastrically once daily for 9 days with 1.0 ml/kg of corn oil containing vitamin D2 and cholesterol to induce atherosclerosis.,18442015_4,0,-1,0,11578,0
11579,vitamin D2,18,20,110,120,Male Wistar rats were challenged intragastrically once daily for 9 days with 1.0 ml/kg of corn oil containing vitamin D2 and cholesterol to induce atherosclerosis.,18442015_4,0,-1,0,11579,0
11581,corn oil,3,5,22,30,Control rats received corn oil only.,18442015_5,0,-1,0,11581,0
11590,low-density lipoprotein,12,14,82,105,"Elevated atherosclerotic parameters, such as serum calcium, total cholesterol and low-density lipoprotein concentration were obtained in atherosclerotic rats.",18442015_8,0,-1,0,11590,0
11628,alanine aminotransferase,10,12,69,93,Comparison of the mean ALT values revealed significantly higher mean alanine aminotransferase (ALT) values in the control group than the prophylactic lamivudine group; 154:64 (p < 0.32).,18464113_13,0,-1,0,11628,0
11636,vasoactive,6,7,52,62,Exaggerated expression of inflammatory mediators in vasoactive intestinal polypeptide knockout (VIP-/-) mice with cyclophosphamide (CYP)-induced cystitis.,18483878_0,0,-1,0,11636,0
11639,Vasoactive,0,1,0,10,Vasoactive intestinal polypeptide (VIP) is an immunomodulatory neuropeptide distributed in micturition pathways.,18483878_1,0,-1,0,11639,0
11667,(1,4,6,30,32,The genes presented represent (1) greater than 1.5-fold change in either direction and (2) the p value is less than 0.05 for the comparison being made.,18483878_6,0,-1,0,11667,0
11670,IL-1beta,9,10,82,90,Several regulated genes were validated using enzyme-linked immunoassays including IL-1beta and CXCL1.,18483878_7,0,-1,0,11670,0
11674,IL-1beta,15,16,79,87,"CYP treatment significantly (p < or = 0.001) increased expression of CXCL1 and IL-1beta in the urinary bladder of WT and VIP(-/-) mice, but expression in VIP(-/-) mice with CYP treatment was significantly (p < or = 0.001) greater (4.2- to 13-fold increase) than that observed in WT urinary bladder (3.6- to 5-fold increase).",18483878_8,0,-1,0,11674,0
11690,Debrisoquine,0,1,0,12,Debrisoquine phenotype and the pharmacokinetics and beta-2 receptor pharmacodynamics of metoprolol and its enantiomers.,1848636_0,0,-1,0,11690,0
11691,beta-2,6,7,52,58,Debrisoquine phenotype and the pharmacokinetics and beta-2 receptor pharmacodynamics of metoprolol and its enantiomers.,1848636_0,0,-1,0,11691,0
11700,racemic,30,31,191,198,"The two metabolic phenotypes, extensive (EM) and poor metabolizers (PM), show different stereoselective metabolism, resulting in apparently higher beta-1 adrenoceptor antagonistic potency of racemic metoprolol in EMs.",1848636_2,0,-1,0,11700,0
11706,racemic,8,9,74,81,"By using pharmacokinetic pharmacodynamic modeling the pharmacodynamics of racemic metoprolol and the active S-isomer, were quantitated in EMs and PMs in terms of IC50 values, representing metoprolol plasma concentrations resulting in half-maximum receptor occupancy.",1848636_5,0,-1,0,11706,0
11707,S-isomer,13,14,108,116,"By using pharmacokinetic pharmacodynamic modeling the pharmacodynamics of racemic metoprolol and the active S-isomer, were quantitated in EMs and PMs in terms of IC50 values, representing metoprolol plasma concentrations resulting in half-maximum receptor occupancy.",1848636_5,0,-1,0,11707,0
11716,racemic,13,14,77,84,"Blood samples for the analysis of plasma potassium, terbutaline, metoprolol (racemic, R- and S-isomer), and alpha-hydroxymetoprolol concentrations were taken at regular time intervals, during 8 hr after metoprolol.",1848636_8,0,-1,0,11716,0
11717,R-,15,16,86,88,"Blood samples for the analysis of plasma potassium, terbutaline, metoprolol (racemic, R- and S-isomer), and alpha-hydroxymetoprolol concentrations were taken at regular time intervals, during 8 hr after metoprolol.",1848636_8,0,-1,0,11717,0
11718,S-isomer,17,18,93,101,"Blood samples for the analysis of plasma potassium, terbutaline, metoprolol (racemic, R- and S-isomer), and alpha-hydroxymetoprolol concentrations were taken at regular time intervals, during 8 hr after metoprolol.",1848636_8,0,-1,0,11718,0
11726,racemic,9,10,57,64,"There was a difference in metoprolol potency with higher racemic metoprolol IC50 values in PMs (72 +/- 7 ng.ml-1) than EMs (42 +/- 8 ng.ml-1, P less than .001).(ABSTRACT TRUNCATED AT 250 WORDS)",1848636_11,0,-1,0,11726,0
11731,everolimus,8,9,72,82,Recovery of tacrolimus-associated brachial neuritis after conversion to everolimus in a pediatric renal transplant recipient--case report and review of the literature.,18503483_0,0,-1,0,11731,0
11741,T2,3,4,30,32,MRI demonstrated hyperintense T2 signals in the cervical cord and right brachial plexus roots indicative of both myelitis and right brachial plexitis.,18503483_5,0,-1,0,11741,0
11746,IVIG,12,13,82,86,"Symptoms persisted for three months despite TAC dose reduction, administration of IVIG and four doses of methylprednisolone pulse therapy.",18503483_6,0,-1,0,11746,0
11747,methylprednisolone,17,18,105,123,"Symptoms persisted for three months despite TAC dose reduction, administration of IVIG and four doses of methylprednisolone pulse therapy.",18503483_6,0,-1,0,11747,0
11749,everolimus,16,17,122,132,Improvement and eventually full recovery only occurred after TAC was completely discontinued and successfully replaced by everolimus.,18503483_7,0,-1,0,11749,0
11750,vasoactive,6,7,39,49,The hemodynamics of oxytocin and other vasoactive agents during neuraxial anesthesia for cesarean delivery: findings in six cases.,18513945_0,0,-1,0,11750,0
11787,puromycin aminonucleoside,5,7,38,63,Protective effects of antithrombin on puromycin aminonucleoside nephrosis in rats.,18541230_0,0,-1,0,11787,0
11792,puromycin,17,18,101,110,"We investigated the effects of antithrombin, a plasma inhibitor of coagulation factors, in rats with puromycin aminonucleoside-induced nephrosis, which is an experimental model of human nephrotic syndrome.",18541230_1,0,-1,0,11792,0
11797,puromycin aminonucleoside,23,25,119,144,Antithrombin (50 or 500 IU/kg/i.v.) was administered to rats once a day for 10 days immediately after the injection of puromycin aminonucleoside (50 mg/kg/i.v.).,18541230_2,0,-1,0,11797,0
11799,puromycin,5,6,43,52,Treatment with antithrombin attenuated the puromycin aminonucleoside-induced hematological abnormalities.,18541230_3,0,-1,0,11799,0
11801,Puromycin,0,1,0,9,Puromycin aminonucleoside-induced renal dysfunction and hyperlipidemia were also suppressed.,18541230_4,0,-1,0,11801,0
11810,puromycin,7,8,56,65,"In addition, antithrombin treatment markedly suppressed puromycin aminonucleoside-induced apoptosis of renal tubular epithelial cells.",18541230_6,0,-1,0,11810,0
11812,puromycin,2,3,13,22,"Furthermore, puromycin aminonucleoside-induced increases in renal cytokine content were also decreased.",18541230_7,0,-1,0,11812,0
11815,puromycin,13,14,84,93,These findings suggest that thrombin plays an important role in the pathogenesis of puromycin aminonucleoside-induced nephrotic syndrome.,18541230_8,0,-1,0,11815,0
11820,sevoflurane,12,13,78,89,"Omitting fentanyl reduces nausea and vomiting, without increasing pain, after sevoflurane for day surgery.",18544179_0,0,-1,0,11820,0
11822,sevoflurane,13,14,94,105,"BACKGROUND AND OBJECTIVE: Despite advantages of induction and maintenance of anaesthesia with sevoflurane, postoperative nausea and vomiting occurs frequently.",18544179_1,0,-1,0,11822,0
11826,sevoflurane,23,24,139,150,METHODS: This double-blind study examined the incidence and severity of postoperative nausea and vomiting and pain in the first 24 h after sevoflurane anaesthesia in 216 adult day surgery patients.,18544179_3,0,-1,0,11826,0
11830,opioids,13,14,94,101,"Combining the two fentanyl groups revealed further significant benefits from the avoidance of opioids, reducing postoperative nausea and vomiting and nausea prior to discharge from 35% and 33% to 22% and 19% (P = 0.049 and P = 0.035), respectively, while nausea in the first 24 h was decreased from 42% to 27% (P = 0.034).",18544179_8,0,-1,0,11830,0
11840,sevoflurane,33,34,234,245,"CONCLUSION: As fentanyl exacerbated postoperative nausea and vomiting without an improvement in postoperative pain and also had adverse cardiorespiratory effects, it appears to be an unnecessary and possibly detrimental supplement to sevoflurane in day surgery.",18544179_11,0,-1,0,11840,0
11845,pergolide,11,12,73,82,Valvular heart disease in patients with Parkinson's disease treated with pergolide.,18560792_0,0,-1,0,11845,0
11850,pergolide,17,18,103,112,Valvular heart abnormalities have been reported in patients with Parkinson's disease (PD) treated with pergolide.,18560792_2,0,-1,0,11850,0
11857,pergolide,11,12,57,66,METHODS: All PD patients in the Amiens area treated with pergolide were invited to attend a cardiologic assessment including transthoracic echocardiography.,18560792_5,0,-1,0,11857,0
11861,pergolide,13,14,75,84,A second echocardiography was performed (median interval: 13 months) after pergolide withdrawal (n=10 patients).,18560792_7,0,-1,0,11861,0
11869,pergolide,28,29,150,159,"The number of affected valves (n=2.4+/-0.7) and the sum of regurgitation grades (n=2.8+/-1.09) were higher (p=0.008 and p=0.006, respectively) in the pergolide group.",18560792_10,0,-1,0,11869,0
11870,pergolide,7,8,50,59,Severity of regurgitation was not correlated with pergolide cumulative dose.,18560792_11,0,-1,0,11870,0
11872,pergolide,12,13,75,84,"A restrictive pattern of valvular regurgitation, suggestive of the role of pergolide, was observed in 12/30 (40%) patients including two with heart failure.",18560792_12,0,-1,0,11872,0
11874,Pergolide,0,1,0,9,"Pergolide was discontinued in 10 patients with valvular heart disease, resulting in a lower regurgitation grade (p=0.01) at the second transthoracic echocardiography and the two patients with heart failure returned to nearly normal clinical examination.",18560792_13,0,-1,0,11874,0
11882,pergolide,15,16,102,111,This study supports the high frequency of restrictive valve regurgitation in PD patients treated with pergolide and reveals that a significant improvement is usual when the treatment is converted to non-ergot dopamine agonists.,18560792_14,0,-1,0,11882,0
11909,platelet aggregation,2,4,20,40,The heparin-induced platelet aggregation test was negative in these patients.,18589141_12,0,-1,0,11909,0
11938,ATPase,21,22,118,124,"We then examined the morphology, expression of beclin 1 gene, mitochondrial permeability transition (MPT), and Na+-K+ ATPase activity in vivo.",18619688_5,0,-1,0,11938,0
11941,mitochondrial membrane,6,8,33,55,"We also assessed cell viability, mitochondrial membrane potential changes and counted autophagic vacuoles in cultured cardiomyocytes.",18619688_6,0,-1,0,11941,0
11967,B1,13,14,107,109,Doxorubicin cardiomyopathy-induced inflammation and apoptosis are attenuated by gene deletion of the kinin B1 receptor.,18627295_0,0,-1,0,11967,0
11972,B1,8,9,44,46,"To elucidate the possible role of the kinin B1 receptor (B1R) during the development of DOX cardiomyopathy, we studied B1R knockout mice (B1R(-/-)) by investigating cardiac inflammation and apoptosis after induction of DOX-induced cardiomyopathy.",18627295_2,0,-1,0,11972,0
11984,AKT,9,10,55,58,"This was associated with a reduced activation state of AKT, as well as an increased bax/bcl2 ratio in Western blots, indicating cardiac apoptosis.",18627295_4,0,-1,0,11984,0
11993,interleukin 6,26,28,152,165,"In DOX B1R(-/-) mice, cardiac dysfunction was improved compared to DOX control mice, which was associated with normalization of the bax/bcl-2 ratio and interleukin 6, as well as AKT activation state.",18627295_6,0,-1,0,11993,0
11994,AKT,32,33,178,181,"In DOX B1R(-/-) mice, cardiac dysfunction was improved compared to DOX control mice, which was associated with normalization of the bax/bcl-2 ratio and interleukin 6, as well as AKT activation state.",18627295_6,0,-1,0,11994,0
11999,mToR,0,1,0,4,"mToR inhibitors-induced proteinuria: mechanisms, significance, and management.",18631865_0,0,-1,0,11999,0
12001,calcineurin,10,11,74,85,"Massive urinary protein excretion has been observed after conversion from calcineurin inhibitors to mammalian target of rapamycin (mToR) inhibitors, especially sirolimus, in renal transplant recipients with chronic allograft nephropathy.",18631865_1,0,-1,0,12001,0
12002,rapamycin,16,17,120,129,"Massive urinary protein excretion has been observed after conversion from calcineurin inhibitors to mammalian target of rapamycin (mToR) inhibitors, especially sirolimus, in renal transplant recipients with chronic allograft nephropathy.",18631865_1,0,-1,0,12002,0
12003,mToR,18,19,131,135,"Massive urinary protein excretion has been observed after conversion from calcineurin inhibitors to mammalian target of rapamycin (mToR) inhibitors, especially sirolimus, in renal transplant recipients with chronic allograft nephropathy.",18631865_1,0,-1,0,12003,0
12004,sirolimus,23,24,160,169,"Massive urinary protein excretion has been observed after conversion from calcineurin inhibitors to mammalian target of rapamycin (mToR) inhibitors, especially sirolimus, in renal transplant recipients with chronic allograft nephropathy.",18631865_1,0,-1,0,12004,0
12009,sirolimus,5,6,31,40,Whether proteinuria was due to sirolimus or only a consequence of calcineurin inhibitors withdrawal remained unsolved until high range proteinuria has been observed during sirolimus therapy in islet transplantation and in patients who received sirolimus de novo.,18631865_3,0,-1,0,12009,0
12011,calcineurin,11,12,66,77,Whether proteinuria was due to sirolimus or only a consequence of calcineurin inhibitors withdrawal remained unsolved until high range proteinuria has been observed during sirolimus therapy in islet transplantation and in patients who received sirolimus de novo.,18631865_3,0,-1,0,12011,0
12012,sirolimus,24,25,172,181,Whether proteinuria was due to sirolimus or only a consequence of calcineurin inhibitors withdrawal remained unsolved until high range proteinuria has been observed during sirolimus therapy in islet transplantation and in patients who received sirolimus de novo.,18631865_3,0,-1,0,12012,0
12013,sirolimus,34,35,244,253,Whether proteinuria was due to sirolimus or only a consequence of calcineurin inhibitors withdrawal remained unsolved until high range proteinuria has been observed during sirolimus therapy in islet transplantation and in patients who received sirolimus de novo.,18631865_3,0,-1,0,12013,0
12014,novo,36,37,257,261,Whether proteinuria was due to sirolimus or only a consequence of calcineurin inhibitors withdrawal remained unsolved until high range proteinuria has been observed during sirolimus therapy in islet transplantation and in patients who received sirolimus de novo.,18631865_3,0,-1,0,12014,0
12016,mToR,10,11,76,80,"Podocyte injury and focal segmental glomerulosclerosis have been related to mToR inhibition in some patients, but the pathways underlying these lesions remain hypothetic.",18631865_4,0,-1,0,12016,0
12017,mToR,10,11,66,70,We discuss herein the possible mechanisms and the significance of mToR blockade-induced proteinuria.,18631865_5,0,-1,0,12017,0
12033,penicillin-G potassium,17,19,106,128,"After a short period of basal activity recording, epileptic focus was induced by injecting 400IU/2 microl penicillin-G potassium into the left lateral ventricle while the cortical activity was continuously recorded.",18657397_4,0,-1,0,12033,0
12044,(1,26,28,153,155,"Spectral analyses were conducted by dividing the whole spectrum into different frequency bands including delta, theta (slow and fast), alpha-sigma, beta (1 and 2) and gamma (1 and 2) bands.",18657397_6,0,-1,0,12044,0
12045,(1,33,35,173,175,"Spectral analyses were conducted by dividing the whole spectrum into different frequency bands including delta, theta (slow and fast), alpha-sigma, beta (1 and 2) and gamma (1 and 2) bands.",18657397_6,0,-1,0,12045,0
12047,beta-2,14,15,75,81,"Our results show that the most affected frequency bands were delta, theta, beta-2 and gamma-2 bands during the epileptiform activity and there were marked differences in terms of spectral densities between three investigated episodes (basal activity, latent period and epileptiform activity).",18657397_7,0,-1,0,12047,0
12078,fatty-acid,14,15,115,125,"This cardioprotection is accompanied by decreased cardiac oxidative stress and triglycerides and increased cardiac fatty-acid oxidation, ATP synthesis, and upregulated JAK/STAT3 pathway.",18674790_3,0,-1,0,12078,0
12097,(1,11,13,65,67,"Mechanistic studies revealed that OB rats are sensitized due to: (1) higher oxyradical stress leading to upregulation of uncoupling proteins 2 and 3, (2) downregulation of cardiac peroxisome proliferators activated receptor-alpha, (3) decreased plasma adiponectin levels, (4) decreased cardiac fatty-acid oxidation (666.9+/-14.0 nmol/min/g heart in ND versus 400.2+/-11.8 nmol/min/g heart in OB), (5) decreased mitochondrial AMP-alpha2 protein kinase, and (6) 86% drop in cardiac ATP levels accompanied by decreased ATP/ADP ratio after doxorubicin administration.",18674790_7,0,-1,0,12097,0
12101,peroxisome,33,34,180,190,"Mechanistic studies revealed that OB rats are sensitized due to: (1) higher oxyradical stress leading to upregulation of uncoupling proteins 2 and 3, (2) downregulation of cardiac peroxisome proliferators activated receptor-alpha, (3) decreased plasma adiponectin levels, (4) decreased cardiac fatty-acid oxidation (666.9+/-14.0 nmol/min/g heart in ND versus 400.2+/-11.8 nmol/min/g heart in OB), (5) decreased mitochondrial AMP-alpha2 protein kinase, and (6) 86% drop in cardiac ATP levels accompanied by decreased ATP/ADP ratio after doxorubicin administration.",18674790_7,0,-1,0,12101,0
12102,(3,38,40,231,233,"Mechanistic studies revealed that OB rats are sensitized due to: (1) higher oxyradical stress leading to upregulation of uncoupling proteins 2 and 3, (2) downregulation of cardiac peroxisome proliferators activated receptor-alpha, (3) decreased plasma adiponectin levels, (4) decreased cardiac fatty-acid oxidation (666.9+/-14.0 nmol/min/g heart in ND versus 400.2+/-11.8 nmol/min/g heart in OB), (5) decreased mitochondrial AMP-alpha2 protein kinase, and (6) 86% drop in cardiac ATP levels accompanied by decreased ATP/ADP ratio after doxorubicin administration.",18674790_7,0,-1,0,12102,0
12104,fatty-acid,51,52,294,304,"Mechanistic studies revealed that OB rats are sensitized due to: (1) higher oxyradical stress leading to upregulation of uncoupling proteins 2 and 3, (2) downregulation of cardiac peroxisome proliferators activated receptor-alpha, (3) decreased plasma adiponectin levels, (4) decreased cardiac fatty-acid oxidation (666.9+/-14.0 nmol/min/g heart in ND versus 400.2+/-11.8 nmol/min/g heart in OB), (5) decreased mitochondrial AMP-alpha2 protein kinase, and (6) 86% drop in cardiac ATP levels accompanied by decreased ATP/ADP ratio after doxorubicin administration.",18674790_7,0,-1,0,12104,0
12107,protein kinase,73,75,436,450,"Mechanistic studies revealed that OB rats are sensitized due to: (1) higher oxyradical stress leading to upregulation of uncoupling proteins 2 and 3, (2) downregulation of cardiac peroxisome proliferators activated receptor-alpha, (3) decreased plasma adiponectin levels, (4) decreased cardiac fatty-acid oxidation (666.9+/-14.0 nmol/min/g heart in ND versus 400.2+/-11.8 nmol/min/g heart in OB), (5) decreased mitochondrial AMP-alpha2 protein kinase, and (6) 86% drop in cardiac ATP levels accompanied by decreased ATP/ADP ratio after doxorubicin administration.",18674790_7,0,-1,0,12107,0
12122,dopaminergic,7,8,68,80,Prenatal protein deprivation alters dopamine-mediated behaviors and dopaminergic and glutamatergic receptor binding.,18703024_0,0,-1,0,12122,0
12123,glutamatergic,9,10,85,98,Prenatal protein deprivation alters dopamine-mediated behaviors and dopaminergic and glutamatergic receptor binding.,18703024_0,0,-1,0,12123,0
12132,dopamine transporter,10,12,76,96,PD female rats also showed increased (3)H-haloperidol binding and decreased dopamine transporter binding in striatum.,18703024_7,0,-1,0,12132,0
12141,Papaverine hydrochloride,2,4,12,36,BACKGROUND: Papaverine hydrochloride is a direct-acting vasodilator used to manage vasospasm during various neurosurgical operations.,18726058_1,0,-1,0,12141,0
12188,ezetimibe,10,11,64,73,"However, hepatotoxic events have not been widely published with ezetimibe or the combination agent simvastatin-ezetimibe.",18752389_2,0,-1,0,12188,0
12209,Her,0,1,0,3,"Her aminotransferase levels returned to normal by postoperative day 23, and her 2-year follow-up showed no adverse events.",18752389_9,0,-1,0,12209,0
12210,her,12,13,76,79,"Her aminotransferase levels returned to normal by postoperative day 23, and her 2-year follow-up showed no adverse events.",18752389_9,0,-1,0,12210,0
12212,Ezetimibe,0,1,0,9,"Ezetimibe undergoes extensive glucuronidation by uridine diphosphate glucoronosyltransferases (UGT) in the intestine and liver and may have inhibited the glucuronidation of simvastatin hydroxy acid, resulting in increased simvastatin exposure and subsequent hepatotoxicity.",18752389_10,0,-1,0,12212,0
12223,ezetimibe,15,16,124,133,We postulate that the mechanism of the simvastatinezetimibe-induced hepatotoxicity is the increased simvastatin exposure by ezetimibe inhibition of UGT enzymes.,18752389_12,0,-1,0,12223,0
12245,kinase 1,3,5,36,44,Serum- and glucocorticoid-inducible kinase 1 in doxorubicin-induced nephrotic syndrome.,18768591_0,0,-1,0,12245,0
12248,epithelial sodium channel,4,7,41,66,Doxorubicin-induced nephropathy leads to epithelial sodium channel (ENaC)-dependent volume retention and renal fibrosis.,18768591_1,0,-1,0,12248,0
12253,ENaC,16,17,126,130,The aldosterone-sensitive serum- and glucocorticoid-inducible kinase SGK1 has been shown to participate in the stimulation of ENaC and to mediate renal fibrosis following mineralocorticoid and salt excess.,18768591_2,0,-1,0,12253,0
12329,laminin,20,21,134,141,"Taking into account that the sarcolemmal integrity is stabilized by the dystrophin-glycoprotein complex (DGC) that connects actin and laminin in contractile machinery and extracellular matrix and by integrins, this study tests the hypothesis that isoproterenol affects sarcolemmal stability through changes in the DGC and integrins.",18808529_3,0,-1,0,12329,0
12337,integrin,8,9,46,54,We found different sensitivity of the DGC and integrin to isoproterenol subcutaneous administration.,18808529_4,0,-1,0,12337,0
12345,gamma-sarcoglycan,7,8,43,60,"Subsequently, after lysis of myofilaments, gamma-sarcoglycan, beta-dystroglycan, beta1-integrin, and laminin alpha-2 expressions were reduced followed by their breakdown, as epiphenomena of the myocytolytic process.",18808529_7,0,-1,0,12345,0
12346,beta-dystroglycan,9,10,62,79,"Subsequently, after lysis of myofilaments, gamma-sarcoglycan, beta-dystroglycan, beta1-integrin, and laminin alpha-2 expressions were reduced followed by their breakdown, as epiphenomena of the myocytolytic process.",18808529_7,0,-1,0,12346,0
12358,Alpha-lipoic acid,0,2,0,17,Alpha-lipoic acid prevents mitochondrial damage and neurotoxicity in experimental chemotherapy neuropathy.,18809400_0,0,-1,0,12358,0
12362,alpha-lipoic acid,4,6,26,43,"The study investigates if alpha-lipoic acid is neuroprotective against chemotherapy induced neurotoxicity, if mitochondrial damage plays a critical role in toxic neurodegenerative cascade, and if neuroprotective effects of alpha-lipoic acid depend on mitochondria protection.",18809400_1,0,-1,0,12362,0
12363,neuroprotective,7,8,47,62,"The study investigates if alpha-lipoic acid is neuroprotective against chemotherapy induced neurotoxicity, if mitochondrial damage plays a critical role in toxic neurodegenerative cascade, and if neuroprotective effects of alpha-lipoic acid depend on mitochondria protection.",18809400_1,0,-1,0,12363,0
12367,neuroprotective effects,27,29,196,219,"The study investigates if alpha-lipoic acid is neuroprotective against chemotherapy induced neurotoxicity, if mitochondrial damage plays a critical role in toxic neurodegenerative cascade, and if neuroprotective effects of alpha-lipoic acid depend on mitochondria protection.",18809400_1,0,-1,0,12367,0
12368,alpha-lipoic acid,30,32,223,240,"The study investigates if alpha-lipoic acid is neuroprotective against chemotherapy induced neurotoxicity, if mitochondrial damage plays a critical role in toxic neurodegenerative cascade, and if neuroprotective effects of alpha-lipoic acid depend on mitochondria protection.",18809400_1,0,-1,0,12368,0
12376,paclitaxel,32,33,191,201,"We used an in vitro model of chemotherapy induced peripheral neuropathy that closely mimic the in vivo condition by exposing primary cultures of dorsal root ganglion (DRG) sensory neurons to paclitaxel and cisplatin, two widely used and highly effective chemotherapeutic drugs.",18809400_2,0,-1,0,12376,0
12377,cisplatin,34,35,206,215,"We used an in vitro model of chemotherapy induced peripheral neuropathy that closely mimic the in vivo condition by exposing primary cultures of dorsal root ganglion (DRG) sensory neurons to paclitaxel and cisplatin, two widely used and highly effective chemotherapeutic drugs.",18809400_2,0,-1,0,12377,0
12379,alpha-lipoic acid,7,9,52,69,This approach allowed investigating the efficacy of alpha-lipoic acid in preventing axonal damage and apoptosis and the function and ultrastructural morphology of mitochondria after exposure to toxic agents and alpha-lipoic acid.,18809400_3,0,-1,0,12379,0
12384,alpha-lipoic acid,29,31,211,228,This approach allowed investigating the efficacy of alpha-lipoic acid in preventing axonal damage and apoptosis and the function and ultrastructural morphology of mitochondria after exposure to toxic agents and alpha-lipoic acid.,18809400_3,0,-1,0,12384,0
12385,cisplatin,5,6,34,43,Our results demonstrate that both cisplatin and paclitaxel cause early mitochondrial impairment with loss of membrane potential and induction of autophagic vacuoles in neurons.,18809400_4,0,-1,0,12385,0
12386,paclitaxel,7,8,48,58,Our results demonstrate that both cisplatin and paclitaxel cause early mitochondrial impairment with loss of membrane potential and induction of autophagic vacuoles in neurons.,18809400_4,0,-1,0,12386,0
12389,Alpha-lipoic acid,0,2,0,17,"Alpha-lipoic acid exerts neuroprotective effects against chemotherapy induced neurotoxicity in sensory neurons: it rescues the mitochondrial toxicity and induces the expression of frataxin, an essential mitochondrial protein with anti-oxidant and chaperone properties.",18809400_5,0,-1,0,12389,0
12390,neuroprotective effects,3,5,25,48,"Alpha-lipoic acid exerts neuroprotective effects against chemotherapy induced neurotoxicity in sensory neurons: it rescues the mitochondrial toxicity and induces the expression of frataxin, an essential mitochondrial protein with anti-oxidant and chaperone properties.",18809400_5,0,-1,0,12390,0
12396,anti-oxidant,30,31,230,242,"Alpha-lipoic acid exerts neuroprotective effects against chemotherapy induced neurotoxicity in sensory neurons: it rescues the mitochondrial toxicity and induces the expression of frataxin, an essential mitochondrial protein with anti-oxidant and chaperone properties.",18809400_5,0,-1,0,12396,0
12398,paclitaxel,11,12,70,80,In conclusion mitochondrial toxicity is an early common event both in paclitaxel and cisplatin induced neurotoxicity.,18809400_6,0,-1,0,12398,0
12399,cisplatin,13,14,85,94,In conclusion mitochondrial toxicity is an early common event both in paclitaxel and cisplatin induced neurotoxicity.,18809400_6,0,-1,0,12399,0
12401,Alpha-lipoic acid,0,2,0,17,"Alpha-lipoic acid protects sensory neurons through its anti-oxidant and mitochondrial regulatory functions, possibly inducing the expression of frataxin.",18809400_7,0,-1,0,12401,0
12403,anti-oxidant,7,8,55,67,"Alpha-lipoic acid protects sensory neurons through its anti-oxidant and mitochondrial regulatory functions, possibly inducing the expression of frataxin.",18809400_7,0,-1,0,12403,0
12406,alpha-lipoic acid,4,6,28,45,These findings suggest that alpha-lipoic acid might reduce the risk of developing peripheral nerve toxicity in patients undergoing chemotherapy and encourage further confirmatory clinical trials.,18809400_8,0,-1,0,12406,0
12411,methemoglobin,17,18,204,217,Toxicity in rhesus monkeys following administration of the 8-aminoquinoline 8-[(4-amino-l-methylbutyl)amino]- 5-(l-hexyloxy)-6-methoxy-4-methylquinoline (WR242511).INTRODUCTION: Many substances that form methemoglobin (MHb) effectively counter cyanide (CN) toxicity.,18821488_0,0,-1,0,12411,0
12448,oral contraceptives,10,12,70,89,Etiologic factors in the pathogenesis of liver tumors associated with oral contraceptives.,188339_0,0,-1,0,12448,0
12453,Oral Contraceptives,7,9,46,65,"The Registry for Liver Tumors Associated with Oral Contraceptives at the University of California, Irvine, has clearly identified 27 cases.",188339_2,0,-1,0,12453,0
12489,therapeutic uses,8,10,51,67,The effects may be further exploited for potential therapeutic uses.,18951540_9,0,-1,0,12489,0
12490,Ifosfamide,0,1,0,10,Ifosfamide continuous infusion without mesna.,1899352_0,0,-1,0,12490,0
12491,mesna,4,5,39,44,Ifosfamide continuous infusion without mesna.,1899352_0,0,-1,0,12491,0
12493,ifosfamide,6,7,39,49,Twenty patients received 27 courses of ifosfamide administered as a 24-hour continuous infusion for 14 days without Mesna.,1899352_2,0,-1,0,12493,0
12494,Mesna,17,18,116,121,Twenty patients received 27 courses of ifosfamide administered as a 24-hour continuous infusion for 14 days without Mesna.,1899352_2,0,-1,0,12494,0
12496,ifosfamide,16,17,78,88,The goal of the study was to deliver a dose rate and total cumulative dose of ifosfamide that would be comparable to standard bolus or short-term infusions administered with Mesna.,1899352_3,0,-1,0,12496,0
12498,Mesna,29,30,174,179,The goal of the study was to deliver a dose rate and total cumulative dose of ifosfamide that would be comparable to standard bolus or short-term infusions administered with Mesna.,1899352_3,0,-1,0,12498,0
12505,(1,16,18,87,89,"At 550 mg/m2/d, three patients experienced nonurologic toxicity; confusion (1), nausea (1), and Grade 2 leukopenia (1).",1899352_7,0,-1,0,12505,0
12507,(1,24,26,115,117,"At 550 mg/m2/d, three patients experienced nonurologic toxicity; confusion (1), nausea (1), and Grade 2 leukopenia (1).",1899352_7,0,-1,0,12507,0
12514,Mesna,22,23,132,137,"The frequency and predictability of hematuria are not precise, and at least daily monitoring by urine Hematest is essential, adding Mesna to the infusate in patients with persistent hematuria.",1899352_10,0,-1,0,12514,0
12518,ifosfamide,5,6,37,47,The protracted infusion schedule for ifosfamide permits convenient outpatient administration without Mesna and reduces the drug cost of clinical usage of this agent by up to  890 per cycle.,1899352_11,0,-1,0,12518,0
12519,Mesna,11,12,101,106,The protracted infusion schedule for ifosfamide permits convenient outpatient administration without Mesna and reduces the drug cost of clinical usage of this agent by up to  890 per cycle.,1899352_11,0,-1,0,12519,0
12567,green tea,2,4,10,19,Effect of green tea and vitamin E combination in isoproterenol induced myocardial infarction in rats.,19058010_0,0,-1,0,12567,0
12568,vitamin E,5,7,24,33,Effect of green tea and vitamin E combination in isoproterenol induced myocardial infarction in rats.,19058010_0,0,-1,0,12568,0
12571,green tea,11,13,67,76,"The present study was aimed to investigate the combined effects of green tea and vitamin E on heart weight, body weight, serum marker enzymes, lipid peroxidation, endogenous antioxidants and membrane bound ATPases in isoproterenol (ISO)-induced myocardial infarction in rats.",19058010_1,0,-1,0,12571,0
12572,vitamin E,14,16,81,90,"The present study was aimed to investigate the combined effects of green tea and vitamin E on heart weight, body weight, serum marker enzymes, lipid peroxidation, endogenous antioxidants and membrane bound ATPases in isoproterenol (ISO)-induced myocardial infarction in rats.",19058010_1,0,-1,0,12572,0
12575,serum marker,23,25,121,133,"The present study was aimed to investigate the combined effects of green tea and vitamin E on heart weight, body weight, serum marker enzymes, lipid peroxidation, endogenous antioxidants and membrane bound ATPases in isoproterenol (ISO)-induced myocardial infarction in rats.",19058010_1,0,-1,0,12575,0
12577,endogenous antioxidants,30,32,163,186,"The present study was aimed to investigate the combined effects of green tea and vitamin E on heart weight, body weight, serum marker enzymes, lipid peroxidation, endogenous antioxidants and membrane bound ATPases in isoproterenol (ISO)-induced myocardial infarction in rats.",19058010_1,0,-1,0,12577,0
12579,ATPases,35,36,206,213,"The present study was aimed to investigate the combined effects of green tea and vitamin E on heart weight, body weight, serum marker enzymes, lipid peroxidation, endogenous antioxidants and membrane bound ATPases in isoproterenol (ISO)-induced myocardial infarction in rats.",19058010_1,0,-1,0,12579,0
12585,serum marker,35,37,150,162,"Adult male albino rats, treated with ISO (200 mg/kg, s.c.) for 2 days at an interval of 24 h caused a significant (P<0.05) elevation of heart weight, serum marker enzymes, lipid peroxidation and Ca+2 ATPase level whereas there was a significant (P<0.05) decrease in body weight, endogenous antioxidants, Na+/ K+ ATPase and Mg+2 ATPase levels.",19058010_2,0,-1,0,12585,0
12587,ATPase,43,44,200,206,"Adult male albino rats, treated with ISO (200 mg/kg, s.c.) for 2 days at an interval of 24 h caused a significant (P<0.05) elevation of heart weight, serum marker enzymes, lipid peroxidation and Ca+2 ATPase level whereas there was a significant (P<0.05) decrease in body weight, endogenous antioxidants, Na+/ K+ ATPase and Mg+2 ATPase levels.",19058010_2,0,-1,0,12587,0
12589,endogenous antioxidants,58,60,279,302,"Adult male albino rats, treated with ISO (200 mg/kg, s.c.) for 2 days at an interval of 24 h caused a significant (P<0.05) elevation of heart weight, serum marker enzymes, lipid peroxidation and Ca+2 ATPase level whereas there was a significant (P<0.05) decrease in body weight, endogenous antioxidants, Na+/ K+ ATPase and Mg+2 ATPase levels.",19058010_2,0,-1,0,12589,0
12591,ATPase,63,64,312,318,"Adult male albino rats, treated with ISO (200 mg/kg, s.c.) for 2 days at an interval of 24 h caused a significant (P<0.05) elevation of heart weight, serum marker enzymes, lipid peroxidation and Ca+2 ATPase level whereas there was a significant (P<0.05) decrease in body weight, endogenous antioxidants, Na+/ K+ ATPase and Mg+2 ATPase levels.",19058010_2,0,-1,0,12591,0
12592,ATPase,66,67,328,334,"Adult male albino rats, treated with ISO (200 mg/kg, s.c.) for 2 days at an interval of 24 h caused a significant (P<0.05) elevation of heart weight, serum marker enzymes, lipid peroxidation and Ca+2 ATPase level whereas there was a significant (P<0.05) decrease in body weight, endogenous antioxidants, Na+/ K+ ATPase and Mg+2 ATPase levels.",19058010_2,0,-1,0,12592,0
12593,green tea,2,4,18,27,"Administration of green tea (100 mg/kg/day, p.o.) and vitamin E (100 mg/kg/day, p.o.) together for 30 consecutive days and challenged with ISO on the day 29th and 30th, showed a significant (P<0.05) decrease in heart weight, serum marker enzymes, lipid peroxidation, Ca+2 ATPase and a significant increase in the body weight, endogenous antioxidants, Na+/K+ ATPase and Mg+2 ATPase when compared with ISO treated group and green tea or vitamin E alone treated groups.",19058010_3,0,-1,0,12593,0
12594,vitamin E,12,14,54,63,"Administration of green tea (100 mg/kg/day, p.o.) and vitamin E (100 mg/kg/day, p.o.) together for 30 consecutive days and challenged with ISO on the day 29th and 30th, showed a significant (P<0.05) decrease in heart weight, serum marker enzymes, lipid peroxidation, Ca+2 ATPase and a significant increase in the body weight, endogenous antioxidants, Na+/K+ ATPase and Mg+2 ATPase when compared with ISO treated group and green tea or vitamin E alone treated groups.",19058010_3,0,-1,0,12594,0
12597,serum marker,48,50,225,237,"Administration of green tea (100 mg/kg/day, p.o.) and vitamin E (100 mg/kg/day, p.o.) together for 30 consecutive days and challenged with ISO on the day 29th and 30th, showed a significant (P<0.05) decrease in heart weight, serum marker enzymes, lipid peroxidation, Ca+2 ATPase and a significant increase in the body weight, endogenous antioxidants, Na+/K+ ATPase and Mg+2 ATPase when compared with ISO treated group and green tea or vitamin E alone treated groups.",19058010_3,0,-1,0,12597,0
12599,ATPase,56,57,272,278,"Administration of green tea (100 mg/kg/day, p.o.) and vitamin E (100 mg/kg/day, p.o.) together for 30 consecutive days and challenged with ISO on the day 29th and 30th, showed a significant (P<0.05) decrease in heart weight, serum marker enzymes, lipid peroxidation, Ca+2 ATPase and a significant increase in the body weight, endogenous antioxidants, Na+/K+ ATPase and Mg+2 ATPase when compared with ISO treated group and green tea or vitamin E alone treated groups.",19058010_3,0,-1,0,12599,0
12601,endogenous antioxidants,66,68,326,349,"Administration of green tea (100 mg/kg/day, p.o.) and vitamin E (100 mg/kg/day, p.o.) together for 30 consecutive days and challenged with ISO on the day 29th and 30th, showed a significant (P<0.05) decrease in heart weight, serum marker enzymes, lipid peroxidation, Ca+2 ATPase and a significant increase in the body weight, endogenous antioxidants, Na+/K+ ATPase and Mg+2 ATPase when compared with ISO treated group and green tea or vitamin E alone treated groups.",19058010_3,0,-1,0,12601,0
12602,ATPase,70,71,358,364,"Administration of green tea (100 mg/kg/day, p.o.) and vitamin E (100 mg/kg/day, p.o.) together for 30 consecutive days and challenged with ISO on the day 29th and 30th, showed a significant (P<0.05) decrease in heart weight, serum marker enzymes, lipid peroxidation, Ca+2 ATPase and a significant increase in the body weight, endogenous antioxidants, Na+/K+ ATPase and Mg+2 ATPase when compared with ISO treated group and green tea or vitamin E alone treated groups.",19058010_3,0,-1,0,12602,0
12603,ATPase,73,74,374,380,"Administration of green tea (100 mg/kg/day, p.o.) and vitamin E (100 mg/kg/day, p.o.) together for 30 consecutive days and challenged with ISO on the day 29th and 30th, showed a significant (P<0.05) decrease in heart weight, serum marker enzymes, lipid peroxidation, Ca+2 ATPase and a significant increase in the body weight, endogenous antioxidants, Na+/K+ ATPase and Mg+2 ATPase when compared with ISO treated group and green tea or vitamin E alone treated groups.",19058010_3,0,-1,0,12603,0
12605,green tea,81,83,422,431,"Administration of green tea (100 mg/kg/day, p.o.) and vitamin E (100 mg/kg/day, p.o.) together for 30 consecutive days and challenged with ISO on the day 29th and 30th, showed a significant (P<0.05) decrease in heart weight, serum marker enzymes, lipid peroxidation, Ca+2 ATPase and a significant increase in the body weight, endogenous antioxidants, Na+/K+ ATPase and Mg+2 ATPase when compared with ISO treated group and green tea or vitamin E alone treated groups.",19058010_3,0,-1,0,12605,0
12606,vitamin E,84,86,435,444,"Administration of green tea (100 mg/kg/day, p.o.) and vitamin E (100 mg/kg/day, p.o.) together for 30 consecutive days and challenged with ISO on the day 29th and 30th, showed a significant (P<0.05) decrease in heart weight, serum marker enzymes, lipid peroxidation, Ca+2 ATPase and a significant increase in the body weight, endogenous antioxidants, Na+/K+ ATPase and Mg+2 ATPase when compared with ISO treated group and green tea or vitamin E alone treated groups.",19058010_3,0,-1,0,12606,0
12608,green tea,8,10,61,70,These findings indicate the synergistic protective effect of green tea and vitamin E during ISO induced myocardial infarction in rats.,19058010_4,0,-1,0,12608,0
12609,vitamin E,11,13,75,84,These findings indicate the synergistic protective effect of green tea and vitamin E during ISO induced myocardial infarction in rats.,19058010_4,0,-1,0,12609,0
12622,bupropion,7,8,55,64,Effect of increasing intraperitoneal infusion rates on bupropion hydrochloride-induced seizures in mice.,19105845_0,0,-1,0,12622,0
12623,controlled release,6,8,35,53,"This is important, since different controlled release formulations of bupropion release the active drug at different rates.",19105845_2,0,-1,0,12623,0
12624,bupropion,10,11,70,79,"This is important, since different controlled release formulations of bupropion release the active drug at different rates.",19105845_2,0,-1,0,12624,0
12648,bupropion,21,22,128,137,"CONCLUSION: In conclusion, the demonstration of an inverse relationship between infusion time of a fixed and convulsive dose of bupropion and the risk of convulsions in a prospective study is novel.",19105845_10,0,-1,0,12648,0
12650,everolimus,4,5,43,53,Graft-versus-host disease prophylaxis with everolimus and tacrolimus is associated with a high incidence of sinusoidal obstruction syndrome and microangiopathy: results of the EVTAC trial.,19135948_0,0,-1,0,12650,0
12651,tacrolimus,6,7,58,68,Graft-versus-host disease prophylaxis with everolimus and tacrolimus is associated with a high incidence of sinusoidal obstruction syndrome and microangiopathy: results of the EVTAC trial.,19135948_0,0,-1,0,12651,0
12656,calcineurin,1,2,2,13,A calcineurin inhibitor combined with methotrexate is the standard prophylaxis for graft-versus-host disease (GVHD) after allogeneic hematopoietic stem cell transplantation (HSCT).,19135948_1,0,-1,0,12656,0
12661,Everolimus,0,1,0,10,"Everolimus, a derivative of sirolimus, seems to mediate antileukemia effects.",19135948_2,0,-1,0,12661,0
12662,sirolimus,5,6,28,37,"Everolimus, a derivative of sirolimus, seems to mediate antileukemia effects.",19135948_2,0,-1,0,12662,0
12664,everolimus,6,7,30,40,"We report on a combination of everolimus and tacrolimus in 24 patients (median age, 62 years) with either myelodysplastic syndrome (MDS; n = 17) or acute myeloid leukemia (AML; n = 7) undergoing intensive conditioning followed by HSCT from related (n = 4) or unrelated (n = 20) donors.",19135948_3,0,-1,0,12664,0
12665,tacrolimus,8,9,45,55,"We report on a combination of everolimus and tacrolimus in 24 patients (median age, 62 years) with either myelodysplastic syndrome (MDS; n = 17) or acute myeloid leukemia (AML; n = 7) undergoing intensive conditioning followed by HSCT from related (n = 4) or unrelated (n = 20) donors.",19135948_3,0,-1,0,12665,0
12686,difluoromethylornithine,13,14,86,109,Longitudinal assessment of air conduction audiograms in a phase III clinical trial of difluoromethylornithine and sulindac for prevention of sporadic colorectal adenomas.,19139001_0,0,-1,0,12686,0
12689,difluoromethylornithine,17,18,108,131,A phase III clinical trial assessed the recurrence of adenomatous polyps after treatment for 36 months with difluoromethylornithine (DFMO) plus sulindac or matched placebos.,19139001_1,0,-1,0,12689,0
12723,paracetamol,20,21,142,153,Renal papillary necrosis (RPN) and a decreased urinary concentrating ability developed during continuous long-term treatment with aspirin and paracetamol in female Fischer 344 rats.,1919871_1,0,-1,0,12723,0
12741,sulphasalazine,10,11,117,131,Proteinase 3-antineutrophil cytoplasmic antibody-(PR3-ANCA) positive necrotizing glomerulonephritis after restarting sulphasalazine treatment.,19203554_0,0,-1,0,12741,0
12746,sulphasalazine,20,21,141,155,"A 59-year-old woman with ulcerative colitis developed red eyes, pleural effusion, eosinophilia and urinary abnormalities after restarting of sulphasalazine treatment.",19203554_1,0,-1,0,12746,0
12751,cytoplasmic antibody,2,4,28,48,"Proteinase 3-antineutrophil cytoplasmic antibody (PR3-ANCA) titer was elevated at 183 ELISA units (EU) in sera (normal range less than 10 EU), myeloperoxidase-ANCA was negative.",19203554_3,0,-1,0,12751,0
12757,sulphasalazine,3,4,22,36,"Although cessation of sulphasalazine treatment resulted in improvements in fever, red eyes, chest pain, titer of C-reactive protein and volume of the pleural effusions, we initiated steroid therapy, because PR3-ANCA titer rose to 320 EU, eosinophil count increased to 1,100 cells/microl, and the pleural effusion remained.",19203554_5,0,-1,0,12757,0
12766,sulphasalazine,4,5,24,38,This case suggests that sulphasalazine can induce PR3-ANCA-positive necrotizing glomerulonephritis.,19203554_7,0,-1,0,12766,0
12770,angiotensinogen,6,7,67,82,Testosterone-dependent hypertension and upregulation of intrarenal angiotensinogen in Dahl salt-sensitive rats.,19211690_0,0,-1,0,12770,0
12780,angiotensinogen,20,21,115,130,"In contrast to the systemic renin-angiotensin system, which is suppressed in response to HS in male DS, intrarenal angiotensinogen expression is increased, and intrarenal levels of ANG II are not suppressed.",19211690_3,0,-1,0,12780,0
12787,angiotensinogen,19,20,116,131,"In this study, the hypothesis was tested that there is a sexual dimorphism in HS-induced upregulation of intrarenal angiotensinogen mediated by testosterone that also causes increases in BP and renal injury.",19211690_4,0,-1,0,12787,0
12797,angiotensinogen,9,10,53,68,Ovariectomy of female DS had no effect on intrarenal angiotensinogen expression on either diet.,19211690_7,0,-1,0,12797,0
12805,angiotensinogen,16,17,100,115,"Testosterone replacement in castrated DS rats increased BP, renal injury, and upregulation of renal angiotensinogen associated with HS diet.",19211690_10,0,-1,0,12805,0
12827,GPi,11,12,62,65,Six patients were operated on in the globus pallidus interna (GPi) and four in the subthalamic nucleus (STN).,19234905_4,0,-1,0,12827,0
12854,GPi,13,14,74,77,The findings of this study suggest that lesions of the unilateral STN and GPi are equally effective treatment for patients with advanced PD refractory to medical treatment.,19234905_11,0,-1,0,12854,0
12909,enzyme inhibitors,8,10,70,87,The hemodynamic effects of captopril and other angiotensin-converting enzyme inhibitors may be mediated by the endogenous opioid system.,1928887_1,0,-1,0,12909,0
12911,opioid antagonist,1,3,4,21,The opioid antagonist naloxone has been shown to block or reverse the hypotensive actions of captopril.,1928887_2,0,-1,0,12911,0
12916,chondroitin sulfate,13,15,93,112,Identification of a simple and sensitive microplate method for the detection of oversulfated chondroitin sulfate in heparin products.,19289093_0,0,-1,0,12916,0
12919,chondroitin sulfate,18,20,109,128,"Recently, a number of commercial lots of heparin products were found to be contaminated with an oversulfated chondroitin sulfate (OSCS) derivative that could elicit a hypotensive response in pigs following a single high-dose infusion.",19289093_2,0,-1,0,12919,0
12938,co-trimoxazole,21,22,132,146,"Pneumocystis pneumonia (PCP), a common opportunistic infection in HIV-infected individuals, is generally treated with high doses of co-trimoxazole.",19299179_1,0,-1,0,12938,0
12944,co-trimoxazole,31,32,214,228,"Here, we report two cases of severely immunocompromised HIV-infected patients who developed severe intrahepatic cholestasis, and in one patient lesions mimicking liver abscess formation on radiologic exams, during co-trimoxazole treatment for PCP.",19299179_3,0,-1,0,12944,0
12947,co-trimoxazole,18,19,112,126,"Whereas patient 1 showed lesions of up to 1 cm readily detectable on magnetic resonance imaging under prolonged co-trimoxazole treatment, therapy of patient 2 was switched early.",19299179_4,0,-1,0,12947,0
12965,her,18,19,134,137,"A 79-year-old woman presented with typical ischemic chest pain, elevated cardiac enzymes with significant ST-segment abnormalities on her electrocardiogram.",19300240_5,0,-1,0,12965,0
12981,Bradykinin,0,1,0,10,Bradykinin receptors antagonists and nitric oxide synthase inhibitors in vincristine and streptozotocin induced hyperalgesia in chemotherapy and diabetic neuropathy rat model.,19300402_0,0,-1,0,12981,0
12986,synthase,11,12,71,79,"PURPOSE: The influence of an irreversible inhibitor of constitutive NO synthase (L-NOArg; 1.0 mg/kg ip), a relatively selective inhibitor of inducible NO synthase (L-NIL; 1.0 mg/kg ip) and a relatively specific inhibitor of neuronal NO synthase (7-NI; 0.1 mg/kg ip), on antihyperalgesic action of selective antagonists of B2 and B1 receptors: D-Arg-[Hyp3,Thi5,D-Tic7,Oic8] bradykinin (HOE 140; 70 nmol/kg ip) or des Arg10 HOE 140 (70 nmol/kg ip) respectively, in model of diabetic (streptozotocin-induced) and toxic (vincristine-induced) neuropathy was investigated.",19300402_1,0,-1,0,12986,0
12989,synthase,27,28,154,162,"PURPOSE: The influence of an irreversible inhibitor of constitutive NO synthase (L-NOArg; 1.0 mg/kg ip), a relatively selective inhibitor of inducible NO synthase (L-NIL; 1.0 mg/kg ip) and a relatively specific inhibitor of neuronal NO synthase (7-NI; 0.1 mg/kg ip), on antihyperalgesic action of selective antagonists of B2 and B1 receptors: D-Arg-[Hyp3,Thi5,D-Tic7,Oic8] bradykinin (HOE 140; 70 nmol/kg ip) or des Arg10 HOE 140 (70 nmol/kg ip) respectively, in model of diabetic (streptozotocin-induced) and toxic (vincristine-induced) neuropathy was investigated.",19300402_1,0,-1,0,12989,0
12991,synthase,43,44,236,244,"PURPOSE: The influence of an irreversible inhibitor of constitutive NO synthase (L-NOArg; 1.0 mg/kg ip), a relatively selective inhibitor of inducible NO synthase (L-NIL; 1.0 mg/kg ip) and a relatively specific inhibitor of neuronal NO synthase (7-NI; 0.1 mg/kg ip), on antihyperalgesic action of selective antagonists of B2 and B1 receptors: D-Arg-[Hyp3,Thi5,D-Tic7,Oic8] bradykinin (HOE 140; 70 nmol/kg ip) or des Arg10 HOE 140 (70 nmol/kg ip) respectively, in model of diabetic (streptozotocin-induced) and toxic (vincristine-induced) neuropathy was investigated.",19300402_1,0,-1,0,12991,0
12995,B2,59,60,322,324,"PURPOSE: The influence of an irreversible inhibitor of constitutive NO synthase (L-NOArg; 1.0 mg/kg ip), a relatively selective inhibitor of inducible NO synthase (L-NIL; 1.0 mg/kg ip) and a relatively specific inhibitor of neuronal NO synthase (7-NI; 0.1 mg/kg ip), on antihyperalgesic action of selective antagonists of B2 and B1 receptors: D-Arg-[Hyp3,Thi5,D-Tic7,Oic8] bradykinin (HOE 140; 70 nmol/kg ip) or des Arg10 HOE 140 (70 nmol/kg ip) respectively, in model of diabetic (streptozotocin-induced) and toxic (vincristine-induced) neuropathy was investigated.",19300402_1,0,-1,0,12995,0
12996,B1,61,62,329,331,"PURPOSE: The influence of an irreversible inhibitor of constitutive NO synthase (L-NOArg; 1.0 mg/kg ip), a relatively selective inhibitor of inducible NO synthase (L-NIL; 1.0 mg/kg ip) and a relatively specific inhibitor of neuronal NO synthase (7-NI; 0.1 mg/kg ip), on antihyperalgesic action of selective antagonists of B2 and B1 receptors: D-Arg-[Hyp3,Thi5,D-Tic7,Oic8] bradykinin (HOE 140; 70 nmol/kg ip) or des Arg10 HOE 140 (70 nmol/kg ip) respectively, in model of diabetic (streptozotocin-induced) and toxic (vincristine-induced) neuropathy was investigated.",19300402_1,0,-1,0,12996,0
12997,bradykinin,66,67,373,383,"PURPOSE: The influence of an irreversible inhibitor of constitutive NO synthase (L-NOArg; 1.0 mg/kg ip), a relatively selective inhibitor of inducible NO synthase (L-NIL; 1.0 mg/kg ip) and a relatively specific inhibitor of neuronal NO synthase (7-NI; 0.1 mg/kg ip), on antihyperalgesic action of selective antagonists of B2 and B1 receptors: D-Arg-[Hyp3,Thi5,D-Tic7,Oic8] bradykinin (HOE 140; 70 nmol/kg ip) or des Arg10 HOE 140 (70 nmol/kg ip) respectively, in model of diabetic (streptozotocin-induced) and toxic (vincristine-induced) neuropathy was investigated.",19300402_1,0,-1,0,12997,0
13002,bradykinin,11,12,62,72,RESULTS: The results of this paper confirm that inhibition of bradykinin receptors and inducible NO synthase but not neuronal NO synthase activity reduces diabetic hyperalgesia.,19300402_3,0,-1,0,13002,0
13004,synthase,16,17,100,108,RESULTS: The results of this paper confirm that inhibition of bradykinin receptors and inducible NO synthase but not neuronal NO synthase activity reduces diabetic hyperalgesia.,19300402_3,0,-1,0,13004,0
13005,synthase,21,22,129,137,RESULTS: The results of this paper confirm that inhibition of bradykinin receptors and inducible NO synthase but not neuronal NO synthase activity reduces diabetic hyperalgesia.,19300402_3,0,-1,0,13005,0
13013,synthase,10,11,53,61,It was also shown that both products of inducible NO synthase and neuronal NO synthase activation as well as bradykinin are involved in hyperalgesia produced by vincristine.,19300402_5,0,-1,0,13013,0
13014,synthase,14,15,78,86,It was also shown that both products of inducible NO synthase and neuronal NO synthase activation as well as bradykinin are involved in hyperalgesia produced by vincristine.,19300402_5,0,-1,0,13014,0
13015,bradykinin,19,20,109,119,It was also shown that both products of inducible NO synthase and neuronal NO synthase activation as well as bradykinin are involved in hyperalgesia produced by vincristine.,19300402_5,0,-1,0,13015,0
13023,B1,8,9,51,53,CONCLUSIONS: Results of these studies suggest that B1 and B2 receptors are engaged in transmission of nociceptive stimuli in both diabetic and toxic neuropathy.,19300402_7,0,-1,0,13023,0
13024,B2,10,11,58,60,CONCLUSIONS: Results of these studies suggest that B1 and B2 receptors are engaged in transmission of nociceptive stimuli in both diabetic and toxic neuropathy.,19300402_7,0,-1,0,13024,0
13028,synthase,6,7,53,61,"In streptozotocin-induced hyperalgesia, inducible NO synthase participates in pronociceptive activity of bradykinin, whereas in vincristine-induced hyperalgesia bradykinin seemed to activate neuronal NO synthase pathway.",19300402_8,0,-1,0,13028,0
13030,bradykinin,12,13,105,115,"In streptozotocin-induced hyperalgesia, inducible NO synthase participates in pronociceptive activity of bradykinin, whereas in vincristine-induced hyperalgesia bradykinin seemed to activate neuronal NO synthase pathway.",19300402_8,0,-1,0,13030,0
13032,synthase,24,25,203,211,"In streptozotocin-induced hyperalgesia, inducible NO synthase participates in pronociceptive activity of bradykinin, whereas in vincristine-induced hyperalgesia bradykinin seemed to activate neuronal NO synthase pathway.",19300402_8,0,-1,0,13032,0
13035,synthase,13,14,95,103,"Therefore, concomitant administration of small doses of bradykinin receptor antagonists and NO synthase inhibitors can be effective in alleviation of neuropathic pain, even in hospital care.",19300402_9,0,-1,0,13035,0
13039,valproic acid,9,11,55,68,"Confusion, a rather serious adverse drug reaction with valproic acid: a review of the French Pharmacovigilance database.",19308880_0,0,-1,0,13039,0
13042,valproic acid,11,13,77,90,INTRODUCTION: Confusion is an adverse drug reaction frequently observed with valproic acid.,19308880_1,0,-1,0,13042,0
13047,valproic acid,18,20,114,127,"METHODS: Using the French Pharmacovigilance database, we selected the cases of confusion reported since 1985 with valproic acid.",19308880_4,0,-1,0,13047,0
13048,valproic acid,9,11,51,64,RESULTS: 272 cases of confusion were reported with valproic acid: 153 women and 119 men.,19308880_5,0,-1,0,13048,0
13049,valproic acid,9,11,63,76,Confusion mostly occurred during the two first weeks following valproic acid exposure (39.7%).,19308880_6,0,-1,0,13049,0
13052,valproic acid,8,10,48,61,"CONCLUSION: This work shows that confusion with valproic acid is a serious, rather frequent but reversible adverse drug reaction.",19308880_9,0,-1,0,13052,0
13124,sirolimus,7,8,67,76,Clinically significant proteinuria following the administration of sirolimus to renal transplant recipients.,19356053_0,0,-1,0,13124,0
13126,Sirolimus,2,3,12,21,"BACKGROUND: Sirolimus is the latest immunosuppressive agent used to prevent rejection, and may have less nephrotoxicity than calcineurin inhibitor (CNI)-based regimens.",19356053_1,0,-1,0,13126,0
13129,calcineurin,19,20,125,136,"BACKGROUND: Sirolimus is the latest immunosuppressive agent used to prevent rejection, and may have less nephrotoxicity than calcineurin inhibitor (CNI)-based regimens.",19356053_1,0,-1,0,13129,0
13132,sirolimus,16,17,105,114,To date there has been little documentation of clinically significant proteinuria linked with the use of sirolimus.,19356053_2,0,-1,0,13132,0
13135,sirolimus,11,12,91,100,We have encountered several patients who developed substantial proteinuria associated with sirolimus use.,19356053_3,0,-1,0,13135,0
13136,sirolimus,12,13,76,85,"In each patient, the close temporal association between the commencement of sirolimus therapy and proteinuria implicated sirolimus as the most likely etiology of the proteinuria.",19356053_4,0,-1,0,13136,0
13137,sirolimus,17,18,121,130,"In each patient, the close temporal association between the commencement of sirolimus therapy and proteinuria implicated sirolimus as the most likely etiology of the proteinuria.",19356053_4,0,-1,0,13137,0
13140,sirolimus,26,27,166,175,METHODS: We analyzed the clinical and laboratory information available for all 119 patients transplanted at the Washington Hospital Center between 1999-2003 for whom sirolimus was a component of their immunosuppressant regimen.,19356053_5,0,-1,0,13140,0
13144,creatinine,22,23,139,149,"In these patients, the magnitude of proteinuria was assessed on morning urine samples by turbidometric measurement or random urine protein:creatinine ratios, an estimate of grams of proteinuria/day.",19356053_6,0,-1,0,13144,0
13147,sirolimus,10,11,69,78,"Laboratory results were compared between prior, during and following sirolimus use.",19356053_7,0,-1,0,13147,0
13149,sirolimus,16,17,92,101,In 7 of the 28 patients there was a striking temporal association between the initiation of sirolimus and the development of nephrotic-range proteinuria.,19356053_10,0,-1,0,13149,0
13151,sirolimus,5,6,42,51,Proteinuria correlated most strongly with sirolimus therapy when compared to other demographic and clinical variables.,19356053_11,0,-1,0,13151,0
13153,sirolimus,6,7,37,46,"In most patients, discontinuation of sirolimus resulted in a decrease, but not resolution, of proteinuria.",19356053_12,0,-1,0,13153,0
13154,Sirolimus,2,3,13,22,CONCLUSIONS: Sirolimus induces or aggravates pre-existing proteinuria in an unpredictable subset of renal allograft recipients.,19356053_13,0,-1,0,13154,0
13157,sirolimus,10,11,52,61,"Proteinuria may improve, but does not resolve, when sirolimus is withdrawn.",19356053_14,0,-1,0,13157,0
13165,essential oils,2,4,12,26,"These lemon essential oils showed strong ability to improve memory impaired by scopolamine; however, s-perillyl alcohol relieved the deficit of associative memory in PA only, and did not improve non-associative memory significantly in OFH.",19356307_2,0,-1,0,13165,0
13177,acetylcholinesterase,13,14,85,105,"Simultaneously, we found that these two lemon essential oil components could inhibit acetylcholinesterase activity in vitro using the Ellman method.",19356307_4,0,-1,0,13177,0
13269,dehydrogenase,10,11,81,94,"Isoproterenol-treated rats showed significant increases in the levels of lactate dehydrogenase, aspartate transaminase, creatine kinase and malondialdehyde and significant decreases in the activities of superoxide dismutase, catalase and glutathione peroxidase in serum and heart.",19445921_5,0,-1,0,13269,0
13270,aspartate transaminase,12,14,96,118,"Isoproterenol-treated rats showed significant increases in the levels of lactate dehydrogenase, aspartate transaminase, creatine kinase and malondialdehyde and significant decreases in the activities of superoxide dismutase, catalase and glutathione peroxidase in serum and heart.",19445921_5,0,-1,0,13270,0
13271,creatine kinase,15,17,120,135,"Isoproterenol-treated rats showed significant increases in the levels of lactate dehydrogenase, aspartate transaminase, creatine kinase and malondialdehyde and significant decreases in the activities of superoxide dismutase, catalase and glutathione peroxidase in serum and heart.",19445921_5,0,-1,0,13271,0
13272,malondialdehyde,18,19,140,155,"Isoproterenol-treated rats showed significant increases in the levels of lactate dehydrogenase, aspartate transaminase, creatine kinase and malondialdehyde and significant decreases in the activities of superoxide dismutase, catalase and glutathione peroxidase in serum and heart.",19445921_5,0,-1,0,13272,0
13273,superoxide dismutase,26,28,203,223,"Isoproterenol-treated rats showed significant increases in the levels of lactate dehydrogenase, aspartate transaminase, creatine kinase and malondialdehyde and significant decreases in the activities of superoxide dismutase, catalase and glutathione peroxidase in serum and heart.",19445921_5,0,-1,0,13273,0
13274,glutathione peroxidase,31,33,238,260,"Isoproterenol-treated rats showed significant increases in the levels of lactate dehydrogenase, aspartate transaminase, creatine kinase and malondialdehyde and significant decreases in the activities of superoxide dismutase, catalase and glutathione peroxidase in serum and heart.",19445921_5,0,-1,0,13274,0
13294,antioxidant activity,11,13,68,88,The results of our study suggest that salvianolic acid A possessing antioxidant activity has a significant protective effect against isoproterenol-induced myocardial infarction.,19445921_10,0,-1,0,13294,0
13298,paclitaxel,10,11,90,100,Long-term glutamate supplementation failed to protect against peripheral neurotoxicity of paclitaxel.,19473225_0,0,-1,0,13298,0
13301,paclitaxel,12,13,89,99,"Toxic peripheral neuropathy is still a significant limiting factor for chemotherapy with paclitaxel (PAC), although glutamate and its closely related amino acid glutamine were claimed to ameliorate PAC neurotoxicity.",19473225_1,0,-1,0,13301,0
13326,alpha-2b,30,31,218,226,Development of ocular myasthenia during pegylated interferon and ribavirin treatment for chronic hepatitis C.A 63-year-old male experienced sudden diplopia after 9 weeks of administration of pegylated interferon (IFN) alpha-2b and ribavirin for chronic hepatitis C (CHC).,19581773_0,0,-1,0,13326,0
13335,acetylcholinesterase inhibitors,8,10,58,89,"The acetylcholine receptor antibody titer and response to acetylcholinesterase inhibitors were negative, and the results of thyroid function tests were normal.",19581773_3,0,-1,0,13335,0
13339,alpha-2b,14,15,104,112,The patient's ophthalmological symptoms improved rapidly 3 weeks after discontinuation of pegylated IFN alpha-2b and ribavirin.,19581773_4,0,-1,0,13339,0
13343,alpha-2b,10,11,75,83,"The ocular myasthenia associated with combination therapy of pegylated IFN alpha-2b and ribavirin for CHC is very rarely reported; therefore, we present this case with a review of the various eye complications of IFN therapy.",19581773_5,0,-1,0,13343,0
13361,recreational drug,20,22,140,157,"Using functional imaging and a face-learning task, we investigated neural correlates of encoding and recalling face-name associations in 20 recreational drug users whose predominant drug use was ecstasy and 20 controls.",19631624_3,0,-1,0,13361,0
13393,tenofovir,8,9,45,54,Acute renal failure in patients with AIDS on tenofovir while receiving prolonged vancomycin course for osteomyelitis.,19642243_0,0,-1,0,13393,0
13397,tenofovir disoproxil fumarate,16,19,104,133,Renal failure developed after a prolonged course of vancomycin therapy in 2 patients who were receiving tenofovir disoproxil fumarate as part of an antiretroviral regimen.,19642243_1,0,-1,0,13397,0
13399,Tenofovir,0,1,0,9,Tenofovir has been implicated in the development of Fanconi syndrome and renal insufficiency because of its effects on the proximal renal tubule.,19642243_2,0,-1,0,13399,0
13406,tenofovir,5,6,32,41,Clinicians should be aware that tenofovir may raise the risk of renal failure during prolonged administration of vancomycin.,19642243_4,0,-1,0,13406,0
13414,aldehyde dehydrogenase,14,16,91,113,Contact with the skin can result in percutaneous absorption of the substance that inhibits aldehyde dehydrogenase and can induce acetaldehyde syndrome in case of alcohol use.,19657887_2,0,-1,0,13414,0
13442,Sulpiride,0,1,0,9,Sulpiride is a selective D2-receptor antagonist with antipsychotic and antidepressant properties.,1967484_1,0,-1,0,13442,0
13446,sulpiride,15,16,104,113,We studied a 37-year-old man who developed persistent segmental dystonia within 2 months after starting sulpiride therapy.,1967484_3,0,-1,0,13446,0
13454,prostaglandin E synthase-1,14,17,100,126,The present study was undertaken to assess lithium-induced polyuria in mice deficient in microsomal prostaglandin E synthase-1 (mPGES-1).,19692487_3,0,-1,0,13454,0
13470,cotransporter,9,10,55,68,"Similarly, the total protein abundance of the Na-K-2Cl cotransporter (NKCC2) in the medulla but not in the cortex of the +/+ mice was significantly reduced by lithium treatment.",19692487_10,0,-1,0,13470,0
13475,PGE(2,4,5,33,38,We conclude that mPGES-1-derived PGE(2) mediates lithium-induced polyuria likely via inhibition of AQP2 and NKCC2 expression.,19692487_12,0,-1,0,13475,0
13480,fenoldopam,9,10,65,75,Preservation of renal blood flow during hypotension induced with fenoldopam in dogs.,1969772_0,0,-1,0,13480,0
13485,receptor agonists,11,13,48,65,"Specific dopamine-1, (DA1) and dopamine-2 (DA2) receptor agonists are now under clinical investigation.",1969772_2,0,-1,0,13485,0
13487,receptor agonist,6,8,38,54,Fenoldopam mesylate is a specific DA1 receptor agonist that lowers blood pressure by vasodilatation.,1969772_3,0,-1,0,13487,0
13490,fenoldopam,3,4,20,30,The hypothesis that fenoldopam could be used to induce hypotension and preserve blood flow to the kidney was tested.,1969772_4,0,-1,0,13490,0
13497,fenoldopam,34,35,229,239,"Systemic aortic blood pressure and renal blood flow were measured continuously with a carotid arterial catheter and an electromagnetic flow probe respectively, in order to compare the cardiovascular and renal vascular effects of fenoldopam and sodium nitroprusside in ten dogs under halothane general anaesthesia.",1969772_5,0,-1,0,13497,0
13498,sodium nitroprusside,36,38,244,264,"Systemic aortic blood pressure and renal blood flow were measured continuously with a carotid arterial catheter and an electromagnetic flow probe respectively, in order to compare the cardiovascular and renal vascular effects of fenoldopam and sodium nitroprusside in ten dogs under halothane general anaesthesia.",1969772_5,0,-1,0,13498,0
13502,fenoldopam,16,17,85,95,Mean arterial pressure was decreased 30 +/- 8 per cent from control with infusion of fenoldopam (3.4 +/- 2.0 micrograms.kg-1.min-1) and 34 +/- 4 per cent with infusion of sodium nitroprusside (5.9 micrograms.kg-1.min-1) (NS).,1969772_6,0,-1,0,13502,0
13506,sodium nitroprusside,34,36,171,191,Mean arterial pressure was decreased 30 +/- 8 per cent from control with infusion of fenoldopam (3.4 +/- 2.0 micrograms.kg-1.min-1) and 34 +/- 4 per cent with infusion of sodium nitroprusside (5.9 micrograms.kg-1.min-1) (NS).,1969772_6,0,-1,0,13506,0
13512,Sodium nitroprusside,0,2,0,20,Sodium nitroprusside is a non-selective arteriolar and venous vasodilator that can produce redistribution of blood flow away from the kidney during induced hypotension.,1969772_8,0,-1,0,13512,0
13514,Fenoldopam,0,1,0,10,Fenoldopam is a selective dopamine-1 (DA1) receptor agonist that causes vasodilatation to the kidney and other organs with DA1 receptors and preserves blood flow to the kidney during induced hypotension.,1969772_9,0,-1,0,13514,0
13515,receptor agonist,8,10,43,59,Fenoldopam is a selective dopamine-1 (DA1) receptor agonist that causes vasodilatation to the kidney and other organs with DA1 receptors and preserves blood flow to the kidney during induced hypotension.,1969772_9,0,-1,0,13515,0
13520,levofloxacin,3,4,25,37,Seizures associated with levofloxacin: case presentation and literature review.,19707748_0,0,-1,0,13520,0
13523,levofloxacin,17,18,103,115,"PURPOSE: We present a case of a patient who developed seizures shortly after initiating treatment with levofloxacin and to discuss the potential drug-drug interactions related to the inhibition of cytochrome P450 (CYP) 1A2 in this case, as well as in other cases, of levofloxacin-induced seizures.",19707748_1,0,-1,0,13523,0
13525,cytochrome P450,30,32,197,212,"PURPOSE: We present a case of a patient who developed seizures shortly after initiating treatment with levofloxacin and to discuss the potential drug-drug interactions related to the inhibition of cytochrome P450 (CYP) 1A2 in this case, as well as in other cases, of levofloxacin-induced seizures.",19707748_1,0,-1,0,13525,0
13529,levofloxacin,9,10,52,64,The main search terms utilized were case report and levofloxacin.,19707748_3,0,-1,0,13529,0
13532,levofloxacin,9,10,62,74,Drug-drug interactions related to the inhibition of CYP1A2 by levofloxacin are likely involved in the clinical outcome of these cases.,19707748_6,0,-1,0,13532,0
13534,levofloxacin,11,12,76,88,CONCLUSIONS: Clinicians are exhorted to pay close attention when initiating levofloxacin therapy in patients taking medications with epileptogenic properties that are CYP1A2 substrates.,19707748_7,0,-1,0,13534,0
13541,dextran,3,4,24,31,A biodegradable polymer dextran has been utilized as a carrier for synthesis of etodolac-dextran conjugates (ED) to improve its aqueous solubility and reduce gastrointestinal side effects.,19719056_2,0,-1,0,13541,0
13546,dextran,19,20,118,125,"An activated moiety, i.e. N-acylimidazole derivative of etodolac (EAI), was condensed with the polysaccharide polymer dextran of different molecular weights (40000, 60000, 110000 and 200000).",19719056_3,0,-1,0,13546,0
13557,acetic acid,8,10,71,82,"Acute analgesic and antiinflammatory activities were ascertained using acetic acid induced writhing model (mice) and carrageenan-induced rat paw edema model, respectively.",19719056_10,0,-1,0,13557,0
13591,Ca(2+),34,37,231,237,These data suggest that pilocarpine produced antiarrhythmic actions on arrhythmic rat and guinea pig models induced by aconitine or ouabain via stimulating the cardiac M(3)-mAChR. The mechanism may be related to the improvement of Ca(2+) handling.,19721134_6,0,-1,0,13591,0
13594,oxycodone,8,9,71,80,Comparative cognitive and subjective side effects of immediate-release oxycodone in healthy middle-aged and older adults.,19729346_0,0,-1,0,13594,0
13598,oxycodone,16,17,116,125,"This study measured the objective and subjective neurocognitive effects of a single 10-mg dose of immediate-release oxycodone in healthy, older (> 65 years), and middle-aged (35 to 55 years) adults who were not suffering from chronic or significant daily pain.",19729346_1,0,-1,0,13598,0
13602,oxycodone,17,18,112,121,"Seventy-one participants completed 2 separate study days and were blind to medication condition (placebo, 10-mg oxycodone).",19729346_2,0,-1,0,13602,0
13603,oxycodone,1,2,7,16,"Plasma oxycodone concentration peaked between 60 and 90 minutes postdose (P < .01) and pupil size, an indication of physiological effects of the medication, peaked at approximately 90 to 120 minutes postdose (P < .01).",19729346_3,0,-1,0,13603,0
13620,oxycodone,28,29,183,192,"This study suggests that for healthy older adults who are not suffering from chronic pain, neurocognitive and pharmacodynamic changes in response to a 10-mg dose of immediate-release oxycodone are similar to those observed for middle-aged adults.",19729346_6,0,-1,0,13620,0
13624,oxycodone,18,19,116,125,"PERSPECTIVE: Study findings indicate that the metabolism, neurocognitive effects, and physical side effects of oral oxycodone are similar for healthy middle-aged and older adults.",19729346_7,0,-1,0,13624,0
13638,glutamatergic,29,30,189,202,"However, the observation that antagonists of the glutamate N-methyl-D-aspartate (NMDA) receptor produce schizophrenic-like symptoms in humans has led to the idea of a dysfunctioning of the glutamatergic system via its NMDA receptor.",19759529_2,0,-1,0,13638,0
13641,glutamatergic,25,26,159,172,"As a result, there is a growing interest in the development of pharmacological agents with potential antipsychotic properties that enhance the activity of the glutamatergic system via a modulation of the NMDA receptor.",19759529_3,0,-1,0,13641,0
13650,MK-801,30,31,197,203,"This study aimed at investigating the potential antipsychotic-like properties of SSR103800, with a particular focus on models of hyperactivity, involving either drug challenge (ie, amphetamine and MK-801) or transgenic mice (ie, NMDA Nr1(neo-/-) and DAT(-/-)).",19759529_5,0,-1,0,13650,0
13655,receptor antagonist,19,21,107,126,"Results showed that SSR103800 (10-30 mg/kg p.o.) blocked hyperactivity induced by the non-competitive NMDA receptor antagonist, MK-801 and partially reversed spontaneous hyperactivity of NMDA Nr1(neo-/-) mice.",19759529_6,0,-1,0,13655,0
13656,MK-801,22,23,128,134,"Results showed that SSR103800 (10-30 mg/kg p.o.) blocked hyperactivity induced by the non-competitive NMDA receptor antagonist, MK-801 and partially reversed spontaneous hyperactivity of NMDA Nr1(neo-/-) mice.",19759529_6,0,-1,0,13656,0
13659,dopamine transporter,15,17,102,122,"In contrast, SSR103800 failed to affect hyperactivity induced by amphetamine or naturally observed in dopamine transporter (DAT(-/-)) knockout mice (10-30 mg/kg p.o.).",19759529_7,0,-1,0,13659,0
13662,olanzapine,10,11,56,66,"Importantly, both classical (haloperidol) and atypical (olanzapine, clozapine and aripiprazole) antipsychotics were effective in all these models of hyperactivity.",19759529_8,0,-1,0,13662,0
13663,aripiprazole,14,15,82,94,"Importantly, both classical (haloperidol) and atypical (olanzapine, clozapine and aripiprazole) antipsychotics were effective in all these models of hyperactivity.",19759529_8,0,-1,0,13663,0
13669,dopaminergic,25,26,175,187,"Together these findings show that the GlyT1 inhibitor, SSR103800, produces antipsychotic-like effects, which differ from those observed with compounds primarily targeting the dopaminergic system, and has a reduced side-effect potential as compared with these latter drugs.",19759529_10,0,-1,0,13669,0
13680,(1,7,9,53,55,"The rats were treated with intraperitoneal reserpine (1 mg/kg, ip) for 3 days every other day.",19761039_2,0,-1,0,13680,0
13689,superoxide dismutase,17,19,135,155,"Biochemical analysis of brain revealed that the reserpine treatment significantly increased lipid peroxidation and decreased levels of superoxide dismutase (SOD), catalase (CAT) and glutathione reductase (GSH), an index of oxidative stress process.",19761039_5,0,-1,0,13689,0
13706,transcription factor,19,21,108,128,Pyrrolidine dithiocarbamate (PDTC) has a dual mechanism of action as an antioxidant and an inhibitor of the transcription factor kappa-beta.,19767176_1,0,-1,0,13706,0
13707,NF-kappaB,12,13,69,78,"Both, production of reactive oxygen species as well as activation of NF-kappaB have been implicated in severe neuronal damage in different sub-regions of the hippocampus as well as in the surrounding cortices.",19767176_2,0,-1,0,13707,0
13718,low-dose,6,7,33,41,Administration of 50 mg/kg PDTC (low-dose) did not exert major effects on the development of a status epilepticus or the mortality rate.,19767176_5,0,-1,0,13718,0
13727,Low-dose,0,1,0,8,Low-dose PDTC treatment almost completely protected from lesions in the piriform cortex.,19767176_7,0,-1,0,13727,0
13736,NF-kappaB,4,5,19,28,"In conclusion, the NF-kappaB inhibitor and antioxidant PDTC protected the piriform cortex, whereas it did not affect hilar neuronal loss.",19767176_9,0,-1,0,13736,0
13740,NF-kappaB,14,15,91,100,These data might indicate that the generation of reactive oxygen species and activation of NF-kappaB plays a more central role in seizure-associated neuronal damage in the temporal cortex as compared to the hippocampal hilus.,19767176_10,0,-1,0,13740,0
13753,suxamethonium,27,28,189,202,"We report an undiagnosed case of myotonia congenita in a 24-year-old previously healthy primigravida, who developed life threatening masseter spasm following a standard dose of intravenous suxamethonium for induction of anaesthesia.",19803309_1,0,-1,0,13753,0
13771,muscle relaxants,8,10,51,67,"Increasing doses of catecholamines, sedatives, and muscle relaxants administered through a central venous catheter were ineffective.",19843802_2,0,-1,0,13771,0
13787,creatinine,12,13,73,83,"Patients were admitted to the hospital for measurement of lithium level, creatinine clearance, urine volume, and maximum osmolality.",1987816_3,0,-1,0,13787,0
13795,creatinine,20,21,115,125,"The dosing schedule, duration of lithium treatment, and daily dose of lithium did not affect maximum osmolality or creatinine clearance.",1987816_5,0,-1,0,13795,0
13812,(1,8,10,55,57,MAIN EXPOSURE: Reported maternal use of antibacterials (1 month before pregnancy through the end of the first trimester).,19884587_3,0,-1,0,13812,0
13841,antibacterial agents,1,3,6,26,"Other antibacterial agents that showed associations included erythromycins (2 defects), penicillins (1 defect), cephalosporins (1 defect), and quinolones (1 defect).",19884587_8,0,-1,0,13841,0
13845,(1,27,29,154,156,"Other antibacterial agents that showed associations included erythromycins (2 defects), penicillins (1 defect), cephalosporins (1 defect), and quinolones (1 defect).",19884587_8,0,-1,0,13845,0
13854,P120,8,9,57,61,Differential impact of immune escape mutations G145R and P120T on the replication of lamivudine-resistant hepatitis B virus e antigen-positive and -negative strains.,19889778_0,0,-1,0,13854,0
13873,HBeAg,43,44,286,291,"We therefore systematically analyzed the functional impact of the most prevalent immune escape variants, the sG145R and sP120T mutants, on the viral replication efficacy and antiviral drug susceptibility of common treatment-associated mutants with resistance to lamivudine (LAM) and/or HBeAg negativity.",19889778_3,0,-1,0,13873,0
13893,HBeAg,6,7,39,44,"However, the concomitant occurrence of HBeAg negativity (PC/BCP), sP120T, and LAM resistance resulted in the restoration of replication to levels of wild-type HBV.",19889778_7,0,-1,0,13893,0
13901,tenofovir,17,18,110,119,"In all clones with combined immune escape and LAM resistance mutations, the nucleotide analogues adefovir and tenofovir remained effective in suppressing viral replication in vitro.",19889778_8,0,-1,0,13901,0
13918,end points,14,16,75,85,"The new approach to ex vivo blood vessel experiments in which not only the end points of vessels response within the time interval is considered, but also dynamics of this response, was used in this paper.",19893084_2,0,-1,0,13918,0
13923,vitamin C,4,6,26,35,The beneficial effects of vitamin C administration to gentamicin-treated animals are also confirmed through: lower level of blood urea and creatinine and higher level of potassium.,19893084_4,0,-1,0,13923,0
13926,creatinine,21,22,139,149,The beneficial effects of vitamin C administration to gentamicin-treated animals are also confirmed through: lower level of blood urea and creatinine and higher level of potassium.,19893084_4,0,-1,0,13926,0
13933,Vitamin C,0,2,0,9,Vitamin C administration induced slowdown of pressure change back to the control values.,19893084_6,0,-1,0,13933,0
13941,vitamin C,37,39,262,271,"The pressure dynamic properties, quantitatively defined by comparative pressure dynamic and total pressure dynamic, confirm the alteration in dynamic response of blood vessels during the change of pressure in gentamicin-treated animals and beneficial effects of vitamin C administration.",19893084_7,0,-1,0,13941,0
13943,tacrolimus,5,6,45,55,Reversible myocardial hypertrophy induced by tacrolimus in a pediatric heart transplant recipient: case report.,19917396_0,0,-1,0,13943,0
13946,Tacrolimus,0,1,0,10,Tacrolimus is a potent immunosuppressant that is frequently used in organ transplantation.,19917396_1,0,-1,0,13946,0
13951,tacrolimus,8,9,63,73,Herein we describe transient myocardial hypertrophy induced by tacrolimus after heart transplantation.,19917396_3,0,-1,0,13951,0
13954,brain natriuretic peptide,14,17,89,114,The hypertrophy caused no clinical symptoms but was noted because of elevation of plasma brain natriuretic peptide concentration and confirmed at echocardiography.,19917396_4,0,-1,0,13954,0
13959,tacrolimus,2,3,10,20,"The blood tacrolimus concentration was higher than usual at that time; thus, tacrolimus dosage was reduced.",19917396_6,0,-1,0,13959,0
13960,tacrolimus,14,15,77,87,"The blood tacrolimus concentration was higher than usual at that time; thus, tacrolimus dosage was reduced.",19917396_6,0,-1,0,13960,0
13962,tacrolimus,10,11,85,95,"Myocardial hypertrophy completely resolved upon reducing the target concentration of tacrolimus and did not recur, as confirmed at echocardiography and myocardial biopsy.",19917396_7,0,-1,0,13962,0
13964,tacrolimus,5,6,23,33,"Thus, we conclude that tacrolimus induces reversible myocardial hypertrophy.",19917396_8,0,-1,0,13964,0
13966,tacrolimus,3,4,22,32,"In patients receiving tacrolimus therapy, blood concentration should be carefully controlled and extreme attention paid to cardiac involvement.",19917396_9,0,-1,0,13966,0
14046,her,8,9,43,46,"Two weeks after the initiation of therapy, her hematocrit had decreased from 44.1% to 20.4%, and she had a positive direct Coombs antiglobulin test and an elevated indirect bilirubin.",1992636_6,0,-1,0,14046,0
14052,Metabotropic glutamate,0,2,0,22,Metabotropic glutamate 7 receptor subtype modulates motor symptoms in rodent models of Parkinson's disease.,19940105_0,0,-1,0,14052,0
14057,Metabotropic glutamate,0,2,0,22,Metabotropic glutamate (mGlu) receptors modulate synaptic transmission in the central nervous system and represent promising therapeutic targets for symptomatic treatment of Parkinson's disease (PD).,19940105_1,0,-1,0,14057,0
14110,nicorandil,3,4,17,27,Addition of oral nicorandil reduced his symptoms and maintained stable angina status.,19944333_8,0,-1,0,14110,0
14135,Tacrine,0,1,0,7,"Tacrine, administered in LiCl pre-treated rats, induces electrocorticographic seizures and delayed hippocampal damage.",19944736_2,0,-1,0,14135,0
14142,tacrine,16,17,100,107,"The toxic effects of tacrine-loaded poly-L-lactid acid nanoparticles (5mg/kg), a saline solution of tacrine (5mg/kg) and an empty colloidal nanoparticle suspension were compared following i.p.",19944736_3,0,-1,0,14142,0
14143,nanoparticle,24,25,140,152,"The toxic effects of tacrine-loaded poly-L-lactid acid nanoparticles (5mg/kg), a saline solution of tacrine (5mg/kg) and an empty colloidal nanoparticle suspension were compared following i.p.",19944736_3,0,-1,0,14143,0
14147,nanoparticles,6,7,44,57,"All the animals treated with tacrine-loaded nanoparticles showed an earlier outcome of CNS adverse symptoms, i.e. epileptic onset, with respect to those animals treated with the free compound (10 min vs. 22 min respectively).",19944736_5,0,-1,0,14147,0
14152,nanoparticles,4,5,28,41,"In addition, tacrine-loaded nanoparticles administration induced damage of neuronal cells in CA1 field of the hippocampus in all treated animals, while the saline solution of tacrine only in 60% of animals.",19944736_6,0,-1,0,14152,0
14156,tacrine,27,28,175,182,"In addition, tacrine-loaded nanoparticles administration induced damage of neuronal cells in CA1 field of the hippocampus in all treated animals, while the saline solution of tacrine only in 60% of animals.",19944736_6,0,-1,0,14156,0
14157,nanoparticles,1,2,6,19,Empty nanoparticles provided similar results to control (saline-treated) group of animals.,19944736_7,0,-1,0,14157,0
14170,propofol,15,16,76,84,"METHODS: Following induction of anesthesia by fentanyl (0.15 mg kg(-1)) and propofol (2.0 mg kg(-1)), 13 patients received phenylephrine (0.1 mg iv) and 12 patients received ephedrine (10 mg iv) to restore mean arterial pressure (MAP).",19957053_3,0,-1,0,14170,0
14201,aprotinin,20,21,124,133,These events were temporally coincident with the initial use of high-dose tranexamic acid (TXA) therapy after withdrawal of aprotinin from general clinical usage.,19996135_2,0,-1,0,14201,0
14226,thrombin inhibitors,3,5,19,38,BACKGROUND: Direct thrombin inhibitors (DTIs) provide an alternative method of anticoagulation for patients with a history of heparin-induced thrombocytopenia (HIT) or HIT with thrombosis (HITT) undergoing cardiopulmonary bypass (CPB).,20003049_1,0,-1,0,14226,0
14257,reversal agents,5,7,25,40,"Because DTIs do not have reversal agents, surgical teams and transfusion services should remain aware of the possibility of massive transfusion events during anticoagulation with these agents.",20003049_7,0,-1,0,14257,0
14280,propranolol,27,28,203,214,The ventricular arrhythmias responded to intravenous administration of lidocaine and to direct current electric shock; ventricular pacing was required in some instances and intravenous administration of propranolol combined with ventricular pacing in one.,2004_6,0,-1,0,14280,0
14290,antidepressant drugs,19,21,138,158,A prospective clinical trial is suggested to quantify the risk of cardiac complications to patients receiving phenothiazines or tricyclic antidepressant drugs.,2004_10,0,-1,0,14290,0
14291,azidothymidine,8,9,66,80,Sensitivity of erythroid progenitor colonies to erythropoietin in azidothymidine treated immunodeficient mice.,2004015_0,0,-1,0,14291,0
14301,drinking water,14,16,71,85,Mice in the early stage of LP-BM5 MuLV disease were given AZT in their drinking water at 1.0 and 2.5 mg/ml.,2004015_3,0,-1,0,14301,0
14335,propofol,40,41,256,264,"PATIENTS AND METHODS: We performed a double-blind, randomized controlled trial at an academic medical center of elderly patients (>or=65 years) without preoperative delirium or severe dementia who underwent hip fracture repair under spinal anesthesia with propofol sedation.",20042557_2,0,-1,0,14335,0
14348,propofol,6,7,29,37,CONCLUSION: The use of light propofol sedation decreased the prevalence of postoperative delirium by 50% compared with deep sedation.,20042557_8,0,-1,0,14348,0
14354,bupropion,5,6,30,39,The effects of the adjunctive bupropion on male sexual dysfunction induced by a selective serotonin reuptake inhibitor: a double-blind placebo-controlled and randomized study.,20067456_0,0,-1,0,14354,0
14356,selective serotonin reuptake inhibitor,13,17,80,118,The effects of the adjunctive bupropion on male sexual dysfunction induced by a selective serotonin reuptake inhibitor: a double-blind placebo-controlled and randomized study.,20067456_0,0,-1,0,14356,0
14359,bupropion,10,11,62,71,"OBJECTIVE: To determine the safety and efficacy of adjunctive bupropion sustained-release (SR) on male sexual dysfunction (SD) induced by a selective serotonin reuptake inhibitor (SSRI), as SD is a common side-effect of SSRIs and the most effective treatments have yet to be determined.",20067456_1,0,-1,0,14359,0
14361,selective serotonin reuptake inhibitor,25,29,140,178,"OBJECTIVE: To determine the safety and efficacy of adjunctive bupropion sustained-release (SR) on male sexual dysfunction (SD) induced by a selective serotonin reuptake inhibitor (SSRI), as SD is a common side-effect of SSRIs and the most effective treatments have yet to be determined.",20067456_1,0,-1,0,14361,0
14365,bupropion,6,7,34,43,"The men were randomly assigned to bupropion SR (150 mg twice daily, 117) or placebo (twice daily, 117) for 12 weeks.",20067456_3,0,-1,0,14365,0
14377,bupropion,26,27,124,133,"RESULTS: After 12 weeks of treatment, the mean (sd) scores for CGI-SF were significantly lower, i.e. better, in patients on bupropion SR, at 2.4 (1.2), than in the placebo group, at 3.9 (1.1) (P= 0.01).",20067456_6,0,-1,0,14377,0
14379,bupropion,3,4,17,26,"Men who received bupropion had a significant increase in the total IIEF score (54.4% vs 1.2%; P= 0.003), and in the five different domains of the IIEF.",20067456_7,0,-1,0,14379,0
14383,bupropion,14,15,80,89,"Total ASEX scores were significantly lower, i.e. better, among men who received bupropion than placebo, at 15.5 (4.3) vs 21.5 (4.7) (P= 0.002).",20067456_8,0,-1,0,14383,0
14384,bupropion,10,11,42,51,The EDITS scores were 67.4 (10.2) for the bupropion and 36.3 (11.7) for the placebo group (P= 0.001).,20067456_9,0,-1,0,14384,0
14390,Bupropion,2,3,13,22,CONCLUSIONS: Bupropion is an effective treatment for male SD induced by SSRIs.,20067456_12,0,-1,0,14390,0
14391,bupropion,11,12,74,83,These results provide empirical support for conducting a further study of bupropion.,20067456_13,0,-1,0,14391,0
14394,acute phase,16,18,114,125,Prevention of seizures and reorganization of hippocampal functions by transplantation of bone marrow cells in the acute phase of experimental epilepsy.,20080419_0,0,-1,0,14394,0
14420,modafinil,3,4,23,32,Normalizing effects of modafinil on sleep in chronic cocaine users.,20080983_0,0,-1,0,14420,0
14422,modafinil,15,16,89,98,OBJECTIVE: The purpose of the present study was to determine the effect of morning-dosed modafinil on sleep and daytime sleepiness in chronic cocaine users.,20080983_1,0,-1,0,14422,0
14426,modafinil,10,11,80,89,"METHOD: Twenty cocaine-dependent participants were randomly assigned to receive modafinil, 400 mg (N=10), or placebo (N=10) every morning at 7:30 a.m. for 16 days in an inpatient, double-blind randomized trial.",20080983_2,0,-1,0,14426,0
14434,modafinil,4,5,23,32,"Compared with placebo, modafinil decreased nighttime sleep latency and increased slow-wave sleep time in cocaine-dependent participants.",20080983_7,0,-1,0,14434,0
14438,modafinil,3,4,14,23,The effect of modafinil interacted with the abstinence week and was associated with longer total sleep time and shorter REM sleep latency in the third week of abstinence.,20080983_8,0,-1,0,14438,0
14448,modafinil,23,24,151,160,"Comparison of slow-wave sleep time, total sleep time, and sleep latency in cocaine-dependent and healthy participants revealed a normalizing effect of modafinil in cocaine-dependent participants.",20080983_9,0,-1,0,14448,0
14450,Modafinil,0,1,0,9,"Modafinil was associated with increased daytime sleep latency, as measured by the Multiple Sleep Latency Test, and a nearly significant decrease in subjective daytime sleepiness.",20080983_10,0,-1,0,14450,0
14455,modafinil,3,4,27,36,"CONCLUSIONS: Morning-dosed modafinil promotes nocturnal sleep, normalizes sleep architecture, and decreases daytime sleepiness in abstinent cocaine users.",20080983_11,0,-1,0,14455,0
14469,Flumazenil,18,19,88,98,OBJECTIVE: to analyze aspects of TEE safety associated to the use of Midazolan (MZ) and Flumazenil (FL) and the influence of the clinical variables on the event rate.,20084309_2,0,-1,0,14469,0
14498,methylergonovine,6,7,49,65,Effect of direct intracoronary administration of methylergonovine in patients with and without variant angina.,2008831_0,0,-1,0,14498,0
14501,methylergonovine,6,7,47,63,The effects of intracoronary administration of methylergonovine were studied in 21 patients with variant angina and 22 patients with atypical chest pain and in others without angina pectoris (control group).,2008831_1,0,-1,0,14501,0
14506,Methylergonovine,0,1,0,16,Methylergonovine was administered continuously at a rate of 10 micrograms/min up to 50 micrograms.,2008831_2,0,-1,0,14506,0
14520,low dose,16,18,105,113,"These results suggest that spasm provocation tests, which use an intracoronary injection of a relatively low dose of methylergonovine, have a high sensitivity in variant angina and the vasoreactivity of the right coronary artery may be greater than that of the other coronary arteries.",2008831_7,0,-1,0,14520,0
14521,methylergonovine,19,20,117,133,"These results suggest that spasm provocation tests, which use an intracoronary injection of a relatively low dose of methylergonovine, have a high sensitivity in variant angina and the vasoreactivity of the right coronary artery may be greater than that of the other coronary arteries.",2008831_7,0,-1,0,14521,0
14545,her,4,5,38,41,"A comprehensive examination including her medical history, panoramic radiograph, and intraoral examination revealed 19 carious lesions, which is not very common for a healthy adult.",20098969_6,0,-1,0,14545,0
14549,her,2,3,13,16,She reported her use of methamphetamine for five years and had not experienced any major carious episodes before she started using the drug.,20098969_7,0,-1,0,14549,0
14566,transcription factor,4,6,20,40,Nrf2 is the primary transcription factor that controls the antioxidant response essential for maintaining cellular redox homeostasis.,20103708_2,0,-1,0,14566,0
14595,transforming growth factor-beta1,27,30,173,205,"Mechanistic studies in both in vivo and in vitro systems showed that the Nrf2-mediated protection against diabetic nephropathy is, at least, partially through inhibition of transforming growth factor-beta1 (TGF-beta1) and reduction of extracellular matrix production.",20103708_8,0,-1,0,14595,0
14596,TGF-beta1,31,32,207,216,"Mechanistic studies in both in vivo and in vitro systems showed that the Nrf2-mediated protection against diabetic nephropathy is, at least, partially through inhibition of transforming growth factor-beta1 (TGF-beta1) and reduction of extracellular matrix production.",20103708_8,0,-1,0,14596,0
14604,TGF-beta1,12,13,85,94,"Furthermore, activation or overexpression of Nrf2 inhibited the promoter activity of TGF-beta1 in a dose-dependent manner, whereas knockdown of Nrf2 by siRNA enhanced TGF-beta1 transcription and fibronectin production.",20103708_10,0,-1,0,14604,0
14607,siRNA,23,24,152,157,"Furthermore, activation or overexpression of Nrf2 inhibited the promoter activity of TGF-beta1 in a dose-dependent manner, whereas knockdown of Nrf2 by siRNA enhanced TGF-beta1 transcription and fibronectin production.",20103708_10,0,-1,0,14607,0
14608,TGF-beta1,25,26,167,176,"Furthermore, activation or overexpression of Nrf2 inhibited the promoter activity of TGF-beta1 in a dose-dependent manner, whereas knockdown of Nrf2 by siRNA enhanced TGF-beta1 transcription and fibronectin production.",20103708_10,0,-1,0,14608,0
14625,cytochrome c,16,18,111,123,"Mitochondrial analysis, respiration intensity, levels of reactive oxygen species, permeability transition, and cytochrome c release were assessed 3 and 6 days after gentamicin administration.",20164825_3,0,-1,0,14625,0
14635,cytochrome c,9,11,68,80,"We found that gentamicin treatment depleted respiratory components (cytochrome c, NADH), probably due to the opening of mitochondrial transition pores.",20164825_8,0,-1,0,14635,0
14636,NADH,12,13,82,86,"We found that gentamicin treatment depleted respiratory components (cytochrome c, NADH), probably due to the opening of mitochondrial transition pores.",20164825_8,0,-1,0,14636,0
14642,contrast media,7,9,50,64,Risk of nephropathy after consumption of nonionic contrast media by children undergoing cardiac angiography: a prospective study.,20195852_0,0,-1,0,14642,0
14654,contrast media,11,13,72,86,"This prospective study determined the incidence of CIN for two nonionic contrast media (CM), iopromide and iohexol, among 80 patients younger than 18 years and compared the rates for this complication in relation to the type and dosage of CM and the presence of cyanosis.",20195852_2,0,-1,0,14654,0
14656,iohexol,19,20,107,114,"This prospective study determined the incidence of CIN for two nonionic contrast media (CM), iopromide and iohexol, among 80 patients younger than 18 years and compared the rates for this complication in relation to the type and dosage of CM and the presence of cyanosis.",20195852_2,0,-1,0,14656,0
14659,iohexol,19,20,90,97,"The 80 patients in the study consecutively received either iopromide (group A, n = 40) or iohexol (group B, n = 40).",20195852_3,0,-1,0,14659,0
14661,creatinine,12,13,38,48,"Serum sodium (Na), potassium (K), and creatinine (Cr) were measured 24 h before angiography as baseline values, then measured again at 12-, 24-, and 48-h intervals after CM use.",20195852_4,0,-1,0,14661,0
14736,para-aminohippurate,19,20,100,119,"Glomerular filtration rate (GFR) and effective renal plasma flow (ERPF) were measured by inulin and para-aminohippurate (PAH) clearance, respectively.",2021202_2,0,-1,0,14736,0
14756,converting enzyme,5,7,38,55,"Since the introduction of angiotensin converting enzyme (ACE) inhibitors into the adjunctive treatment of patients with congestive heart failure, cases of severe hypotension, especially on the first day of treatment, have occasionally been reported.",2024540_1,0,-1,0,14756,0
14773,selective serotonin reuptake inhibitors,9,13,62,101,A cross-sectional evaluation of the effect of risperidone and selective serotonin reuptake inhibitors on bone mineral density in boys.,20331935_0,0,-1,0,14773,0
14809,selective serotonin reuptake inhibitors,10,14,66,105,"Controlling for relevant covariates, we also found treatment with selective serotonin reuptake inhibitors (SSRIs) to be associated with lower trabecular BMD at the radius (P = .03) and BMD z score at the lumbar spine (P < .05).",20331935_10,0,-1,0,14809,0
14828,non-specific,20,21,114,126,"RATIONALE AND OBJECTIVES: The light-enhanced startle paradigm (LES) is suggested to model anxiety, because of the non-specific cue and the long-term effect.",20394767_1,0,-1,0,14828,0
14838,yohimbine,12,13,85,94,"METHODS: Male Wistar rats received each dose of the alpha(2)-adrenoceptor antagonist yohimbine (0.25-1.0mg/kg), the 5-HT(2C) receptor agonist m-chlorophenylpiperazine (mCPP, 0.5-2.0mg/kg) or the GABA(A) inverse receptor agonist pentylenetetrazole (PTZ, 3-30mg/kg) and were subsequently tested in either LES or FPS.",20394767_5,0,-1,0,14838,0
14841,GABA(A,34,35,195,201,"METHODS: Male Wistar rats received each dose of the alpha(2)-adrenoceptor antagonist yohimbine (0.25-1.0mg/kg), the 5-HT(2C) receptor agonist m-chlorophenylpiperazine (mCPP, 0.5-2.0mg/kg) or the GABA(A) inverse receptor agonist pentylenetetrazole (PTZ, 3-30mg/kg) and were subsequently tested in either LES or FPS.",20394767_5,0,-1,0,14841,0
14845,yohimbine,15,16,83,92,"RESULTS: None of the drugs enhanced LES, whereas mCPP increased percentage FPS and yohimbine increased absolute FPS values.",20394767_6,0,-1,0,14845,0
14846,yohimbine,2,3,13,22,"Furthermore, yohimbine increased baseline startle amplitude in the LES, while mCPP suppressed baseline startle in both the LES and FPS and PTZ suppressed baseline startle in the FPS.",20394767_7,0,-1,0,14846,0
14853,tacrolimus,5,6,47,57,Rosaceiform dermatitis associated with topical tacrolimus treatment.,20466178_0,0,-1,0,14853,0
14862,immunomodulators,4,5,26,42,"Continuous topical use of immunomodulators such as tacrolimus or pimecrolimus should be regarded as a potential cause of rosaceiform dermatitis, although many cases have not been reported.",20466178_3,0,-1,0,14862,0
14863,tacrolimus,7,8,51,61,"Continuous topical use of immunomodulators such as tacrolimus or pimecrolimus should be regarded as a potential cause of rosaceiform dermatitis, although many cases have not been reported.",20466178_3,0,-1,0,14863,0
14885,antidiuretic hormone,41,43,202,222,"CNS complications included posterior reversible leukoencephalopathy syndrome (n = 10), stroke (n = 5), temporal lobe epilepsy (n = 2), high-dose methotrexate toxicity (n = 2), syndrome of inappropriate antidiuretic hormone secretion (n = 1), and other unclassified events (n = 7).",20470218_6,0,-1,0,14885,0
14888,nuclear factor kappa B,11,15,71,93,"Cocaine causes memory and learning impairments in rats: involvement of nuclear factor kappa B and oxidative stress, and prevention by topiramate.",20477932_0,0,-1,0,14888,0
14890,topiramate,22,23,134,144,"Cocaine causes memory and learning impairments in rats: involvement of nuclear factor kappa B and oxidative stress, and prevention by topiramate.",20477932_0,0,-1,0,14890,0
14894,Nuclear factor kappa B,0,4,0,22,Nuclear factor kappa B (NFkappaB) is a sensor of oxidative stress and participates in memory formation that could be involved in drug toxicity and addiction mechanisms.,20477932_2,0,-1,0,14894,0
14895,NFkappaB,5,6,24,32,Nuclear factor kappa B (NFkappaB) is a sensor of oxidative stress and participates in memory formation that could be involved in drug toxicity and addiction mechanisms.,20477932_2,0,-1,0,14895,0
14904,topiramate,26,27,148,158,"Therefore NFkappaB activity, oxidative stress, neuronal nitric oxide synthase (nNOS) activity, spatial learning and memory as well as the effect of topiramate, a previously proposed therapy for cocaine addiction, were evaluated in an experimental model of cocaine administration in rats.",20477932_3,0,-1,0,14904,0
14911,glutathione peroxidase,19,21,112,134,"NFkappaB activity was decreased in the frontal cortex of cocaine treated rats, as well as GSH concentration and glutathione peroxidase activity in the hippocampus, whereas nNOS activity in the hippocampus was increased.",20477932_4,0,-1,0,14911,0
14918,glutathione peroxidase,21,23,118,140,"In contrast, learning of new tasks was enhanced and correlated with the increase of nNOS activity and the decrease of glutathione peroxidase.",20477932_6,0,-1,0,14918,0
14920,NFkappaB,15,16,103,111,These results provide evidence for a possible mechanistic role of oxidative and nitrosative stress and NFkappaB in the alterations induced by cocaine.,20477932_7,0,-1,0,14920,0
14921,Topiramate,0,1,0,10,"Topiramate prevented all the alterations observed, showing novel neuroprotective properties.",20477932_8,0,-1,0,14921,0
14922,neuroprotective,9,10,65,80,"Topiramate prevented all the alterations observed, showing novel neuroprotective properties.",20477932_8,0,-1,0,14922,0
14929,cisplatin,2,3,13,22,injection of cisplatin (5 mg/kg).,20510337_2,0,-1,0,14929,0
14931,cisplatin,21,22,102,111,"Coenzyme Q10 treatment (10 mg/kg/day, i.p.) was applied for 6 consecutive days, starting 1 day before cisplatin administration.",20510337_3,0,-1,0,14931,0
14935,cisplatin,15,16,107,116,Coenzyme Q10 significantly reduced blood urea nitrogen and serum creatinine levels which were increased by cisplatin.,20510337_4,0,-1,0,14935,0
14937,reduced glutathione,11,13,87,106,"Coenzyme Q10 significantly compensated deficits in the antioxidant defense mechanisms (reduced glutathione level and superoxide dismutase activity), suppressed lipid peroxidation, decreased the elevations of tumor necrosis factor-alpha, nitric oxide and platinum ion concentration, and attenuated the reductions of selenium and zinc ions in renal tissue resulted from cisplatin administration.",20510337_5,0,-1,0,14937,0
14938,superoxide dismutase,15,17,117,137,"Coenzyme Q10 significantly compensated deficits in the antioxidant defense mechanisms (reduced glutathione level and superoxide dismutase activity), suppressed lipid peroxidation, decreased the elevations of tumor necrosis factor-alpha, nitric oxide and platinum ion concentration, and attenuated the reductions of selenium and zinc ions in renal tissue resulted from cisplatin administration.",20510337_5,0,-1,0,14938,0
14941,nitric oxide,32,34,237,249,"Coenzyme Q10 significantly compensated deficits in the antioxidant defense mechanisms (reduced glutathione level and superoxide dismutase activity), suppressed lipid peroxidation, decreased the elevations of tumor necrosis factor-alpha, nitric oxide and platinum ion concentration, and attenuated the reductions of selenium and zinc ions in renal tissue resulted from cisplatin administration.",20510337_5,0,-1,0,14941,0
14944,cisplatin,53,54,368,377,"Coenzyme Q10 significantly compensated deficits in the antioxidant defense mechanisms (reduced glutathione level and superoxide dismutase activity), suppressed lipid peroxidation, decreased the elevations of tumor necrosis factor-alpha, nitric oxide and platinum ion concentration, and attenuated the reductions of selenium and zinc ions in renal tissue resulted from cisplatin administration.",20510337_5,0,-1,0,14944,0
14946,cisplatin,8,9,56,65,"Also, histopathological renal tissue damage mediated by cisplatin was ameliorated by coenzyme Q10 treatment.",20510337_6,0,-1,0,14946,0
14953,nuclear factor-kappaB,17,19,153,174,"Immunohistochemical analysis revealed that coenzyme Q10 significantly decreased the cisplatin-induced overexpression of inducible nitric oxide synthase, nuclear factor-kappaB, caspase-3 and p53 in renal tissue.",20510337_7,0,-1,0,14953,0
14954,caspase-3,20,21,176,185,"Immunohistochemical analysis revealed that coenzyme Q10 significantly decreased the cisplatin-induced overexpression of inducible nitric oxide synthase, nuclear factor-kappaB, caspase-3 and p53 in renal tissue.",20510337_7,0,-1,0,14954,0
15012,etoposide,5,6,33,42,"Salvage therapy with nelarabine, etoposide, and cyclophosphamide in relapsed/refractory paediatric T-cell lymphoblastic leukaemia and lymphoma.",20528871_0,0,-1,0,15012,0
15017,etoposide,14,15,54,63,A combination of 5 d of nelarabine (AraG) with 5 d of etoposide (VP) and cyclophosphamide (CPM) and prophylactic intrathecal chemotherapy was used as salvage therapy in seven children with refractory or relapsed T-cell leukaemia or lymphoma.,20528871_1,0,-1,0,15017,0
15037,etoposide,14,15,87,96,"Our experience supports the safety of giving AraG as salvage therapy in synchrony with etoposide and cyclophosphamide, although neurological toxicity must be closely monitored.",20528871_5,0,-1,0,15037,0
15041,dopaminergic,15,16,99,111,"It is widely believed that dopamine (DA) mediates methamphetamine (METH)-induced toxicity to brain dopaminergic neurons, because drugs that interfere with DA neurotransmission decrease toxicity, whereas drugs that increase DA neurotransmission enhance toxicity.",20533999_1,0,-1,0,15041,0
15048,alpha-methyl-para-tyrosine,16,17,112,138,Here we show that the recently reported ability of L-dihydroxyphenylalanine to reverse the protective effect of alpha-methyl-para-tyrosine on METH-induced DA neurotoxicity is also confounded by drug effects on body temperature.,20533999_3,0,-1,0,15048,0
15057,dopaminergic,17,18,119,131,"In addition, we demonstrate that mice genetically engineered to have unilateral brain DA deficits develop METH-induced dopaminergic deficits that are of comparable magnitude on both sides of the brain.",20533999_5,0,-1,0,15057,0
15080,salbutamol,5,6,55,65,Swallowing-induced atrial tachyarrhythmia triggered by salbutamol: case report and review of the literature.,20552622_0,0,-1,0,15080,0
15085,salbutamol,14,15,81,91,The patient noticed that before these episodes he had been using an inhalator of salbutamol.,20552622_4,0,-1,0,15085,0
15097,Salbutamol,2,3,12,22,CONCLUSION: Salbutamol is presented here as a possible trigger for SIAT.,20552622_10,0,-1,0,15097,0
15101,salbutamol,21,22,111,121,"Although it is difficult to define causality in a case report, it is logical to think that a beta-agonist like salbutamol (known to induce tachycardia) may be the trigger of adrenergic reflexes originating in the esophagus while swallowing and that a beta-blocker such as atenolol (that blocks the adrenergic activity) may relieve it.",20552622_11,0,-1,0,15101,0
15117,bethanechol,25,26,148,159,"3. Insulin treatment also prevented the increases in contractile responses of bladder body strips from diabetic rats to nerve stimulation, ATP, and bethanechol.",2055425_3,0,-1,0,15117,0
15124,bethanechol,22,23,139,150,"Insulin treatment reversed the increases in contractile responses of bladder body strips from diabetic rats to nerve stimulation, ATP, and bethanechol.",2055425_7,0,-1,0,15124,0
15128,Glutamatergic,0,1,0,13,Glutamatergic neurotransmission mediated by NMDA receptors in the inferior colliculus can modulate haloperidol-induced catalepsy.,20558148_0,0,-1,0,15128,0
15136,excitatory amino acid,21,24,142,163,"Functional evidence relating the IC to motor behavior derives from experiments showing that activation of the IC by electrical stimulation or excitatory amino acid microinjection causes freezing, escape-like behavior, and immobility.",20558148_2,0,-1,0,15136,0
15140,(1,26,28,192,194,The present study examined the influence of excitatory amino acid-mediated mechanisms in the IC on the catalepsy induced by the dopamine receptor blocker haloperidol administered systemically (1 or 0.5 mg/kg) in rats.,20558148_4,0,-1,0,15140,0
15143,receptor antagonists,11,13,106,126,"Haloperidol-induced catalepsy was challenged with prior intracollicular microinjections of glutamate NMDA receptor antagonists, MK-801 (15 or 30 mmol/0.5 microl) and AP7 (10 or 20 nmol/0.5 microl), or of the NMDA receptor agonist N-methyl-d-aspartate (NMDA, 20 or 30 nmol/0.5 microl).",20558148_5,0,-1,0,15143,0
15144,MK-801,14,15,128,134,"Haloperidol-induced catalepsy was challenged with prior intracollicular microinjections of glutamate NMDA receptor antagonists, MK-801 (15 or 30 mmol/0.5 microl) and AP7 (10 or 20 nmol/0.5 microl), or of the NMDA receptor agonist N-methyl-d-aspartate (NMDA, 20 or 30 nmol/0.5 microl).",20558148_5,0,-1,0,15144,0
15153,MK-801,7,8,58,64,"The results showed that intracollicular microinjection of MK-801 and AP7 previous to systemic injections of haloperidol significantly attenuated the catalepsy, as indicated by a reduced latency to step down from a horizontal bar.",20558148_6,0,-1,0,15153,0
15165,puromycin aminonucleoside,16,18,109,134,"Permeability, ultrastructural changes, and distribution of novel proteins in the glomerular barrier in early puromycin aminonucleoside nephrosis.",20588063_0,0,-1,0,15165,0
15167,puromycin aminonucleoside,1,3,6,31,"Using puromycin aminonucleoside nephrosis (PAN) rats, we studied early ultrastructural and permeability changes in relation to the expression of the podocyte-associated molecules nephrin, a-actinin, dendrin, and plekhh2, the last two of which were only recently discovered in podocytes.",20588063_2,0,-1,0,15167,0
15228,TAA,16,17,87,90,"PURPOSE: This study was designed to establish a rat model of thoracic aortic aneurysm (TAA) by calcium chloride (CaCl(2))-induced arterial injury and to explore the potential role of a disintegrin and metalloproteinase (ADAM), matrix metalloproteinases (MMPs) and their endogenous inhibitors (TIMPs) in TAA formation.",20621845_1,0,-1,0,15228,0
15232,metalloproteinase,35,36,201,218,"PURPOSE: This study was designed to establish a rat model of thoracic aortic aneurysm (TAA) by calcium chloride (CaCl(2))-induced arterial injury and to explore the potential role of a disintegrin and metalloproteinase (ADAM), matrix metalloproteinases (MMPs) and their endogenous inhibitors (TIMPs) in TAA formation.",20621845_1,0,-1,0,15232,0
15236,TAA,53,54,303,306,"PURPOSE: This study was designed to establish a rat model of thoracic aortic aneurysm (TAA) by calcium chloride (CaCl(2))-induced arterial injury and to explore the potential role of a disintegrin and metalloproteinase (ADAM), matrix metalloproteinases (MMPs) and their endogenous inhibitors (TIMPs) in TAA formation.",20621845_1,0,-1,0,15236,0
15269,TAA,6,7,37,40,"CONCLUSION: This study establishes a TAA model by periarterial CaCl(2) exposure in rats, and demonstrates a significant elevation of expression of MMP-2, MMP-9, ADAM10 and ADAM17 in the pathogenesis of vascular remodeling.",20621845_9,0,-1,0,15269,0
15277,Suxamethonium,0,1,0,13,Suxamethonium induced prolonged apnea in a patient receiving electroconvulsive therapy.,20633755_0,0,-1,0,15277,0
15279,Suxamethonium,0,1,0,13,Suxamethonium causes prolonged apnea in patients in whom pseudocholinesterase enzyme gets deactivated by organophosphorus (OP) poisons.,20633755_1,0,-1,0,15279,0
15280,pseudocholinesterase,8,9,57,77,Suxamethonium causes prolonged apnea in patients in whom pseudocholinesterase enzyme gets deactivated by organophosphorus (OP) poisons.,20633755_1,0,-1,0,15280,0
15282,organophosphorus,13,14,105,121,Suxamethonium causes prolonged apnea in patients in whom pseudocholinesterase enzyme gets deactivated by organophosphorus (OP) poisons.,20633755_1,0,-1,0,15282,0
15297,T4,8,9,53,55,The condition is treated with intravenous thyroxine (T4) or intravenous tri-iodo-thyronine (T3).,20635749_4,0,-1,0,15297,0
15298,tri-iodo-thyronine,12,13,72,90,The condition is treated with intravenous thyroxine (T4) or intravenous tri-iodo-thyronine (T3).,20635749_4,0,-1,0,15298,0
15299,T3,14,15,92,94,The condition is treated with intravenous thyroxine (T4) or intravenous tri-iodo-thyronine (T3).,20635749_4,0,-1,0,15299,0
15309,Curcumin,0,1,0,8,Curcumin ameliorates cognitive dysfunction and oxidative damage in phenobarbitone and carbamazepine administered rats.,20667451_0,0,-1,0,15309,0
15313,antiepileptic drugs,1,3,4,23,"The antiepileptic drugs, phenobarbitone and carbamazepine are well known to cause cognitive impairment on chronic use.",20667451_1,0,-1,0,15313,0
15319,antiepileptic drugs,19,21,122,141,The increase in free radical generation has been implicated as one of the important mechanisms of cognitive impairment by antiepileptic drugs.,20667451_2,0,-1,0,15319,0
15320,Curcumin,0,1,0,8,"Curcumin has shown antioxidant, anti-inflammatory and neuro-protective properties.",20667451_3,0,-1,0,15320,0
15321,neuro-protective,7,8,54,70,"Curcumin has shown antioxidant, anti-inflammatory and neuro-protective properties.",20667451_3,0,-1,0,15321,0
15322,curcumin,14,15,82,90,"Therefore, the present study was carried out to investigate the effect of chronic curcumin administration on phenobarbitone- and carbamazepine-induced cognitive impairment and oxidative stress in rats.",20667451_4,0,-1,0,15322,0
15323,phenobarbitone-,17,18,109,124,"Therefore, the present study was carried out to investigate the effect of chronic curcumin administration on phenobarbitone- and carbamazepine-induced cognitive impairment and oxidative stress in rats.",20667451_4,0,-1,0,15323,0
15327,curcumin,3,4,32,40,Pharmacokinetic interactions of curcumin with phenobarbitone and carbamazepine were also studied.,20667451_5,0,-1,0,15327,0
15334,malondialdehyde,14,15,80,95,"At the end of study period, serum phenobarbitone and carbamazepine, whole brain malondialdehyde and reduced glutathione levels were estimated.",20667451_8,0,-1,0,15334,0
15335,reduced glutathione,16,18,100,119,"At the end of study period, serum phenobarbitone and carbamazepine, whole brain malondialdehyde and reduced glutathione levels were estimated.",20667451_8,0,-1,0,15335,0
15338,curcumin,1,2,12,20,Concomitant curcumin administration prevented the cognitive impairment and decreased the increased oxidative stress induced by these antiepileptic drugs.,20667451_10,0,-1,0,15338,0
15341,antiepileptic drugs,16,18,133,152,Concomitant curcumin administration prevented the cognitive impairment and decreased the increased oxidative stress induced by these antiepileptic drugs.,20667451_10,0,-1,0,15341,0
15342,Curcumin,0,1,0,8,Curcumin co-administration did not cause any significant alteration in the serum concentrations of both phenobarbitone as well as carbamazepine.,20667451_11,0,-1,0,15342,0
15345,curcumin,4,5,24,32,These results show that curcumin has beneficial effect in mitigating the deterioration of cognitive functions and oxidative damage in rats treated with phenobarbitone and carbamazepine without significantly altering their serum concentrations.,20667451_12,0,-1,0,15345,0
15350,curcumin,4,5,26,34,The findings suggest that curcumin can be considered as a potential safe and effective adjuvant to phenobarbitone and carbamazepine therapy in preventing cognitive impairment associated with these drugs.,20667451_13,0,-1,0,15350,0
15376,(3,12,14,75,77,"In Alzheimer's disease groups, rats were injected with STZ-icv bilaterally (3 mg/kg) in first day and 3 days later, a similar STZ-icv application was repeated.",20683499_4,0,-1,0,15376,0
15403,angiogenesis inhibitors,25,27,175,198,Can angiogenesis be a target of treatment for ribavirin associated hemolytic anemia?BACKGROUND/AIMS: Recently ribavirin has been found to inhibit angiogenesis and a number of angiogenesis inhibitors such as sunitinib and sorafenib have been found to cause acute hemolysis.,20698227_0,0,-1,0,15403,0
15404,sunitinib,29,30,207,216,Can angiogenesis be a target of treatment for ribavirin associated hemolytic anemia?BACKGROUND/AIMS: Recently ribavirin has been found to inhibit angiogenesis and a number of angiogenesis inhibitors such as sunitinib and sorafenib have been found to cause acute hemolysis.,20698227_0,0,-1,0,15404,0
15408,interferon alpha,14,16,97,113,METHODS: Fourteen patients chronically infected with hepatitis C virus were treated by pegylated interferon alpha 2a and ribavirin.,20698227_2,0,-1,0,15408,0
15409,vascular endothelial growth factor,8,12,58,92,"Serum hemoglobin, haptoglobin and angiogenesis markers of vascular endothelial growth factor and angiopoetin-2 were investigated before and after therapy.",20698227_3,0,-1,0,15409,0
15415,local anesthetic,9,11,58,74,Reduction in injection pain using buffered lidocaine as a local anesthetic before cardiac catheterization.,2070391_0,0,-1,0,15415,0
15430,serotonergic,3,4,20,32,BACKGROUND: Altered serotonergic neural transmission is hypothesized to be a susceptibility factor for psychotic disorders such as schizophrenia.,20705401_1,0,-1,0,15430,0
15435,olanzapine,20,21,128,138,"The serotonin 6 (5-HT6) receptor is therapeutically targeted by several second generation antipsychotics, such as clozapine and olanzapine, and d-amphetamine-induced hyperactivity in rats is corrected with the use of a selective 5-HT6 receptor antagonist.",20705401_2,0,-1,0,15435,0
15437,receptor antagonist,36,38,235,254,"The serotonin 6 (5-HT6) receptor is therapeutically targeted by several second generation antipsychotics, such as clozapine and olanzapine, and d-amphetamine-induced hyperactivity in rats is corrected with the use of a selective 5-HT6 receptor antagonist.",20705401_2,0,-1,0,15437,0
15439,d-amphetamine,9,10,58,71,"In addition, the disrupted prepulse inhibition induced by d-amphetamine or phencyclidine was restored by 5-HT6 receptor antagonist in an animal study using rats.",20705401_3,0,-1,0,15439,0
15440,receptor antagonist,16,18,111,130,"In addition, the disrupted prepulse inhibition induced by d-amphetamine or phencyclidine was restored by 5-HT6 receptor antagonist in an animal study using rats.",20705401_3,0,-1,0,15440,0
15485,capecitabine,2,3,10,22,Safety of capecitabine: a review.,20722491_0,0,-1,0,15485,0
15491,capecitabine,14,15,84,96,AREAS COVERED IN THIS REVIEW: This article reviews the pharmacology and efficacy of capecitabine with a special emphasis on its safety.,20722491_2,0,-1,0,15491,0
15492,capecitabine,16,17,82,94,"WHAT THE READER WILL GAIN: The reader will gain better insight into the safety of capecitabine in special populations such as patients with advanced age, renal and kidney disease.",20722491_3,0,-1,0,15492,0
15496,capecitabine,8,9,50,62,We also explore different dosing and schedules of capecitabine administration.,20722491_4,0,-1,0,15496,0
15497,Capecitabine,4,5,19,31,TAKE HOME MESSAGE: Capecitabine is an oral prodrug of 5-FU and was developed to fulfill the need for a more convenient therapy and provide an improved safety/efficacy profile.,20722491_5,0,-1,0,15497,0
15505,capecitabine,7,8,44,56,"The most commonly reported toxic effects of capecitabine are diarrhea, nausea, vomiting, stomatitis and hand-foot syndrome.",20722491_7,0,-1,0,15505,0
15507,Capecitabine,0,1,0,12,"Capecitabine has a well-established safety profile and can be given safely to patients with advanced age, hepatic and renal dysfunctions.",20722491_8,0,-1,0,15507,0
15519,glutamatergic,18,19,114,127,"In patients with schizophrenia, ketamine exacerbates the core symptoms of illness, supporting the hypothesis of a glutamatergic dysfunction.",20727411_3,0,-1,0,15519,0
15584,metabotropic glutamate,27,29,191,213,"Recent preclinical and clinical data from promising lines of research focus on the differential role of presynaptic versus postsynaptic mechanisms, dopamine receptor subtypes, ionotropic and metabotropic glutamate receptors, and non-dopaminergic neurotransmitter systems in the pathophysiology of levodopa-induced dyskinesias.",20880751_5,0,-1,0,15584,0
15610,receptor antagonist,3,5,23,42,The neurotensin type-1 receptor antagonist SR48692 blocked both the behavioral and the electrophysiological effects induced by neurotensin.,20882060_7,0,-1,0,15610,0
15634,receptor antagonist,8,10,52,71,In vivo characterization of a dual adenosine A2A/A1 receptor antagonist in animal models of Parkinson's disease.,20973483_0,0,-1,0,15634,0
15638,receptor antagonist,10,12,60,79,The in vivo characterization of a dual adenosine A(2A)/A(1) receptor antagonist in several animal models of Parkinson's disease is described.,20973483_1,0,-1,0,15638,0
15644,receptor antagonist,7,9,34,53,"Compound 1 is a potent A(2A)/A(1) receptor antagonist in vitro (A(2A) K(i) = 4.1 nM; A(1) K(i) = 17.0 nM) that has excellent activity, after oral administration, across a number of animal models of Parkinson's disease including mouse and rat models of haloperidol-induced catalepsy, mouse model of reserpine-induced akinesia, rat 6-hydroxydopamine (6-OHDA) lesion model of drug-induced rotation, and MPTP-treated non-human primate model.",20973483_3,0,-1,0,15644,0
15656,Butyrylcholinesterase,0,1,0,21,Butyrylcholinesterase gene mutations in patients with prolonged apnea after succinylcholine for electroconvulsive therapy.,21029050_0,0,-1,0,15656,0
15662,butyrylcholinesterase,14,15,81,102,"The duration of action may be prolonged in patients with genetic variants of the butyrylcholinesterase enzyme (BChE), the most common being the K- and the A-variants.",21029050_2,0,-1,0,15662,0
15668,butyrylcholinesterase,15,16,84,105,The aim of the study was to assess the clinical significance of genetic variants in butyrylcholinesterase gene (BCHE) in patients with a suspected prolonged duration of action of succinylcholine after ECT.,21029050_3,0,-1,0,15668,0
15702,penicillin G,37,39,143,155,"In group-1 (n=10) hippocampal DBS was off and in the group-2 (n=10) hippocampal DBS was on (185 Hz, 0.5V, 1V, 2V, and 5V for 60 sec) following penicillin G injection intracortically.",21294084_4,0,-1,0,15702,0
15706,penicillin-G,9,10,61,73,"EEG recordings were obtained before and 15 minutes following penicillin-G injection, and at 10th minutes following each stimulus for analysis in terms of frequency, amplitude, and power spectrum.",21294084_6,0,-1,0,15706,0
15738,alanine transaminase,5,7,38,58,"Potential renal toxicity and elevated alanine transaminase (ALT) concentration were reported in 12.2% and 48.8% of dogs, respectively.",21418164_6,0,-1,0,15738,0
15758,her,14,15,83,86,A report is given on an 83-year-old female who acquired central vein thrombosis in her seeing eye one day after having started topical medication with dipivalyl epinephrine for advanced glaucoma discovered in the other eye.,2220369_1,0,-1,0,15758,0
15810,desferrioxamine,8,9,64,79,Ocular and auditory toxicity in hemodialyzed patients receiving desferrioxamine.,2234245_0,0,-1,0,15810,0
15813,desferrioxamine,10,11,70,85,During an 18-month period of study 41 hemodialyzed patients receiving desferrioxamine (10-40 mg/kg BW/3 times weekly) for the first time were monitored for detection of audiovisual toxicity.,2234245_1,0,-1,0,15813,0
15825,Desferrioxamine,0,1,0,15,"Desferrioxamine withdrawal resulted in a complete recovery of visual function in 1 patient and partial recovery in 3, and a complete reversal of hearing loss in 3 patients and partial recovery in 3.",2234245_6,0,-1,0,15825,0
15829,desferrioxamine,10,11,65,80,This toxicity appeared in patients receiving the higher doses of desferrioxamine or coincided with the normalization of ferritin or aluminium serum levels.,2234245_7,0,-1,0,15829,0
15832,desferrioxamine,15,16,113,128,The data indicate that audiovisual toxicity is not an infrequent complication in hemodialyzed patients receiving desferrioxamine.,2234245_8,0,-1,0,15832,0
15838,uridine,4,5,42,49,"Increased extracellular concentrations of uridine (Urd) have been reported to reduce, in vitro, azidothymidine (AZT)-induced inhibition of human granulocyte-macrophage progenitor cells without impairment of its antihuman immunodeficiency virus (HIV) activity.",2257294_1,0,-1,0,15838,0
15840,azidothymidine,17,18,96,110,"Increased extracellular concentrations of uridine (Urd) have been reported to reduce, in vitro, azidothymidine (AZT)-induced inhibition of human granulocyte-macrophage progenitor cells without impairment of its antihuman immunodeficiency virus (HIV) activity.",2257294_1,0,-1,0,15840,0
15854,drinking water,15,17,83,97,"In mice rendered anemic and leukopenic by the administration of AZT for 28 days in drinking water (1.5 mg/mL), the continued administration of AZT plus daily BAU (300 mg/kg, orally) partially reversed AZT-induced anemia and leukopenia (P less than .05), increased peripheral reticulocytes (to 4.9%, P less than .01), increased cellularity in the marrow, and improved megaloblastosis.",2257294_4,0,-1,0,15854,0
15877,mazindol,5,6,34,42,"Randomized, double-blind trial of mazindol in Duchenne dystrophy.",2266990_0,0,-1,0,15877,0
15879,growth hormone,4,6,23,37,There is evidence that growth hormone may be related to the progression of weakness in Duchenne dystrophy.,2266990_1,0,-1,0,15879,0
15882,mazindol,7,8,44,52,"We conducted a 12-month controlled trial of mazindol, a putative growth hormone secretion inhibitor, in 83 boys with Duchenne dystrophy.",2266990_2,0,-1,0,15882,0
15883,growth hormone,11,13,65,79,"We conducted a 12-month controlled trial of mazindol, a putative growth hormone secretion inhibitor, in 83 boys with Duchenne dystrophy.",2266990_2,0,-1,0,15883,0
15889,Mazindol,0,1,0,8,Mazindol did not benefit strength at any point in the study.,2266990_5,0,-1,0,15889,0
15891,mazindol,4,5,29,37,"Side effects attributable to mazindol included decreased appetite (36%), dry mouth (10%), behavioral change (22%), and gastrointestinal symptoms (18%); mazindol dosage was reduced in 43% of patients.",2266990_6,0,-1,0,15891,0
15896,mazindol,35,36,152,160,"Side effects attributable to mazindol included decreased appetite (36%), dry mouth (10%), behavioral change (22%), and gastrointestinal symptoms (18%); mazindol dosage was reduced in 43% of patients.",2266990_6,0,-1,0,15896,0
15897,mazindol,3,4,14,22,"The effect of mazindol on GH secretion was estimated indirectly by comparing the postabsorptive IGF-I levels obtained following 3, 6, 9, and 12 months in the mazindol treated to those in the placebo groups.",2266990_7,0,-1,0,15897,0
15901,mazindol,29,30,158,166,"The effect of mazindol on GH secretion was estimated indirectly by comparing the postabsorptive IGF-I levels obtained following 3, 6, 9, and 12 months in the mazindol treated to those in the placebo groups.",2266990_7,0,-1,0,15901,0
15905,IGF-I,16,17,121,126,"Although mazindol-treated patients gained less weight and height than placebo-treated patients, no significant effect on IGF-I levels was observed.",2266990_8,0,-1,0,15905,0
15906,Mazindol,0,1,0,8,Mazindol doses not slow the progression of weakness in Duchenne dystrophy.,2266990_9,0,-1,0,15906,0
15911,cycloheximide,5,6,36,49,"Amnesia produced by scopolamine and cycloheximide were reversed by morphine given 30 min before the test trial (pre-test), and pre-test morphine also facilitated the memory retrieval in the animals administered naloxone during the training trial.",2273650_1,0,-1,0,15911,0
15919,cycloheximide,16,17,120,133,"Similarly, pre-test scopolamine partially reversed the scopolamine-induced amnesia, but not significantly; and pre-test cycloheximide failed to reverse the cycloheximide-induced amnesia.",2273650_2,0,-1,0,15919,0
15929,alpha-methyldopa,6,7,36,52,The hypotensive effect of 100 mg/kg alpha-methyldopa was also partially reversed by naloxone.,227508_2,0,-1,0,15929,0
15939,opiate receptors,17,19,140,156,These findings indicate that in spontaneously hypertensive rats the effects of central alpha-adrenoceptor stimulation involve activation of opiate receptors.,227508_5,0,-1,0,15939,0
15941,alpha-methyldopa,29,30,177,193,"As naloxone and clonidine do not appear to interact with the same receptor site, the observed functional antagonism suggests the release of an endogenous opiate by clonidine or alpha-methyldopa and the possible role of the opiate in the central control of sympathetic tone.",227508_6,0,-1,0,15941,0
15973,Her,0,1,0,3,Her incontinence resolved with the change of medication.,2304736_5,0,-1,0,15973,0
15981,isosorbide dinitrate,6,8,61,81,Myocardial infarction following sublingual administration of isosorbide dinitrate.,2312209_0,0,-1,0,15981,0
15985,isosorbide dinitrate,19,21,138,158,A 78-year-old with healed septal necrosis suffered a recurrent myocardial infarction of the anterior wall following the administration of isosorbide dinitrate 5 mg sublingually.,2312209_1,0,-1,0,15985,0
15993,ifosfamide,5,6,37,47,Lethal anuria complicating high dose ifosfamide chemotherapy in a breast cancer patient with an impaired renal function.,2320800_0,0,-1,0,15993,0
15998,cisplatin,11,12,76,85,"A sixty-year-old woman with advanced breast cancer, previously treated with cisplatin, developed an irreversible lethal renal failure with anuria, the day after 5 g/m2 bolus ifosfamide.",2320800_1,0,-1,0,15998,0
16000,ifosfamide,28,29,174,184,"A sixty-year-old woman with advanced breast cancer, previously treated with cisplatin, developed an irreversible lethal renal failure with anuria, the day after 5 g/m2 bolus ifosfamide.",2320800_1,0,-1,0,16000,0
16007,Ifosfamide,0,1,0,10,Ifosfamide is a known nephrotoxic drug with demonstrated tubulopathies.,2320800_5,0,-1,0,16007,0
16010,ifosfamide,11,12,62,72,"We strongly suspect that this lethal anuria was mainly due to ifosfamide, occurring in a patient having received previous cisplatin chemotherapy and with poor kidney perfusion due to transient hypotension.",2320800_6,0,-1,0,16010,0
16011,cisplatin,20,21,122,131,"We strongly suspect that this lethal anuria was mainly due to ifosfamide, occurring in a patient having received previous cisplatin chemotherapy and with poor kidney perfusion due to transient hypotension.",2320800_6,0,-1,0,16011,0
16013,ifosfamide,5,6,28,38,We recommend careful use of ifosfamide in patients pretreated with nephrotoxic chemotherapy and inadequate renal perfusion.,2320800_7,0,-1,0,16013,0
16018,D2,8,9,75,77,"Nociceptive effects induced by intrathecal administration of prostaglandin D2, E2, or F2 alpha to conscious mice.",2322844_0,0,-1,0,16018,0
16019,E2,10,11,79,81,"Nociceptive effects induced by intrathecal administration of prostaglandin D2, E2, or F2 alpha to conscious mice.",2322844_0,0,-1,0,16019,0
16020,F2 alpha,13,15,86,94,"Nociceptive effects induced by intrathecal administration of prostaglandin D2, E2, or F2 alpha to conscious mice.",2322844_0,0,-1,0,16020,0
16026,acetic acid,20,22,134,145,The effects of intrathecal administration of prostaglandins on pain responses in conscious mice were evaluated by using hot plate and acetic acid writhing tests.,2322844_1,0,-1,0,16026,0
16027,D2,1,2,14,16,Prostaglandin D2 (0.5-3 ng/mouse) had a hyperalgesic action on the response to a hot plate during a 3-60 min period after injection.,2322844_2,0,-1,0,16027,0
16030,Prostaglandin E2,0,2,0,16,"Prostaglandin E2 showed a hyperalgesic effect at doses of 1 pg to 10 ng/mouse, but the effect lasted shorter (3-30 min) than that of prostaglandin D2.",2322844_3,0,-1,0,16030,0
16033,(3,20,22,109,111,"Prostaglandin E2 showed a hyperalgesic effect at doses of 1 pg to 10 ng/mouse, but the effect lasted shorter (3-30 min) than that of prostaglandin D2.",2322844_3,0,-1,0,16033,0
16034,D2,30,31,147,149,"Prostaglandin E2 showed a hyperalgesic effect at doses of 1 pg to 10 ng/mouse, but the effect lasted shorter (3-30 min) than that of prostaglandin D2.",2322844_3,0,-1,0,16034,0
16035,acetic acid,5,7,33,44,Similar results were obtained by acetic acid writhing tests.,2322844_4,0,-1,0,16035,0
16037,D2,5,6,41,43,"The hyperalgesic effect of prostaglandin D2 was blocked by simultaneous injection of a substance P antagonist (greater than or equal to 100 ng) but not by AH6809, a prostanoid EP1-receptor antagonist.",2322844_5,0,-1,0,16037,0
16038,substance P,13,15,87,98,"The hyperalgesic effect of prostaglandin D2 was blocked by simultaneous injection of a substance P antagonist (greater than or equal to 100 ng) but not by AH6809, a prostanoid EP1-receptor antagonist.",2322844_5,0,-1,0,16038,0
16043,substance P,22,24,121,132,"Conversely, prostaglandin E2-induced hyperalgesia was blocked by AH6809 (greater than or equal to 500 ng) but not by the substance P antagonist.",2322844_6,0,-1,0,16043,0
16044,Prostaglandin F2 alpha,0,3,0,22,Prostaglandin F2 alpha had little effect on pain responses.,2322844_7,0,-1,0,16044,0
16046,D2,6,7,50,52,"These results demonstrate that both prostaglandin D2 and prostaglandin E2 exert hyperalgesia in the spinal cord, but in different ways.",2322844_8,0,-1,0,16046,0
16047,prostaglandin E2,8,10,57,73,"These results demonstrate that both prostaglandin D2 and prostaglandin E2 exert hyperalgesia in the spinal cord, but in different ways.",2322844_8,0,-1,0,16047,0
16050,D-penicillamine,0,1,0,15,D-penicillamine in the treatment of localized scleroderma.,2334179_0,0,-1,0,16050,0
16059,D-penicillamine,15,16,95,110,"Case reports of 11 patients with severe, extensive localized scleroderma who were treated with D-penicillamine are summarized in this article.",2334179_3,0,-1,0,16059,0
16066,D-penicillamine,3,4,12,27,The dose of D-penicillamine associated with a favorable response was as low as 2 to 5 mg/kg per day given over a period ranging from 15 to 53 months.,2334179_7,0,-1,0,16066,0
16069,D-Penicillamine,0,1,0,15,D-Penicillamine caused nephrotic syndrome in 1 patient and milder reversible proteinuria in 3 other patients; none developed renal insufficiency.,2334179_8,0,-1,0,16069,0
16072,D-penicillamine,4,5,24,39,These data suggest that D-penicillamine may be effective in severe cases of localized scleroderma.,2334179_9,0,-1,0,16072,0
16078,bupivacaine,19,20,106,117,infusion of morphine (mean 73.6 mg) and five patients receiving a continuous extradural infusion of 0.25% bupivacaine (mean 192 mg) in the 24-h period following upper abdominal surgery.,2334618_3,0,-1,0,16078,0
16088,antifibrinolytic,8,9,51,67,Cerebral sinus thrombosis as a potential hazard of antifibrinolytic treatment in menorrhagia.,2339463_0,0,-1,0,16088,0
16091,epsilon-aminocaproic acid,17,19,127,152,We describe a 42-year-old woman who developed superior sagittal and left transverse sinus thrombosis associated with prolonged epsilon-aminocaproic acid therapy for menorrhagia.,2339463_1,0,-1,0,16091,0
16092,antifibrinolytic agent,1,3,5,27,This antifibrinolytic agent has been used in women with menorrhagia to promote clotting and reduce blood loss.,2339463_2,0,-1,0,16092,0
16095,epsilon-aminocaproic acid,12,14,90,115,"Although increased risk of thromboembolic disease has been reported during treatment with epsilon-aminocaproic acid, cerebral sinus thrombosis has not been previously described.",2339463_3,0,-1,0,16095,0
16097,epsilon-aminocaproic acid,3,5,15,40,Careful use of epsilon-aminocaproic acid therapy is recommended.,2339463_4,0,-1,0,16097,0
16098,imipenem,3,4,22,30,Seizure activity with imipenem therapy: incidence and risk factors.,2343592_0,0,-1,0,16098,0
16104,imipenem/cilastatin,30,31,179,198,Two elderly patients with a history of either cerebral vascular accident (CVA) or head trauma and no evidence of renal disease developed seizures while receiving maximum doses of imipenem/cilastatin.,2343592_1,0,-1,0,16104,0
16147,dipyridamole,8,9,48,60,"Therefore, we studied the hyperemic response to dipyridamole in seven open-chest anesthetized dogs after pretreatment with either pentoxifylline (0, 7.5, or 15 mg/kg i.v.) or theophylline (3 mg/kg i.v.).",2348231_4,0,-1,0,16147,0
16152,Dipyridamole,0,1,0,12,Dipyridamole significantly increased coronary blood flow before and after 7.5 or 15 mm/kg i.v.,2348231_6,0,-1,0,16152,0
16174,Midazolam hydrochloride,0,2,0,23,Midazolam hydrochloride is commonly used for dental or endoscopic procedures.,2375138_1,0,-1,0,16174,0
16187,her,1,2,6,9,"After her strength returned, repetitive stimulation was normal, but single fiber EMG revealed increased jitter and blocking.",2385256_5,0,-1,0,16187,0
16193,neuromuscular effects,7,9,44,65,Patients who are unusually sensitive to the neuromuscular effects of magnesium should be suspected of having an underlying disorder of neuromuscular transmission.,2385256_8,0,-1,0,16193,0
16243,B3,9,10,57,59,"It is concluded therefore that, unlike the ventrolateral B3 cells which mediate a methyldopa-induced hypotension via descending projections, the midline serotonin B3 cells in the medulla contribute to the hypotensive action of methyldopa, either by way of an ascending projection which does not pass through the median forebrain bundle, or through a projection restricted to the caudal brainstem.",2422478_6,0,-1,0,16243,0
16252,ribosomal RNA,9,11,57,70,"On two paradoxical side-effects of prednisolone in rats, ribosomal RNA biosyntheses, and a mechanism of action.",2425813_0,0,-1,0,16252,0
16258,ribosomal RNA,12,14,61,74,In the liver both the content of RNA and the biosynthesis of ribosomal RNA increased while both the RNA content and ribosomal RNA biosynthesis were reduced in the gastrocnemius muscle.,2425813_2,0,-1,0,16258,0
16259,ribosomal RNA,21,23,116,129,In the liver both the content of RNA and the biosynthesis of ribosomal RNA increased while both the RNA content and ribosomal RNA biosynthesis were reduced in the gastrocnemius muscle.,2425813_2,0,-1,0,16259,0
16285,gamma-hexachlorocyclohexane,3,4,24,51,Differential effects of gamma-hexachlorocyclohexane (lindane) on pharmacologically-induced seizures.,2440413_0,0,-1,0,16285,0
16286,Gamma-hexachlorocyclohexane,0,1,0,27,"Gamma-hexachlorocyclohexane (gamma-HCH), the active ingredient of the insecticide lindane, has been shown to decrease seizure threshold to pentylenetrazol (PTZ) 3 h after exposure to gamma-HCH and conversely increase threshold to PTZ-induced seizures 24 h after exposure to gamma-HCH (Vohland et al. 1981).",2440413_1,0,-1,0,16286,0
16287,gamma-HCH,2,3,29,38,"Gamma-hexachlorocyclohexane (gamma-HCH), the active ingredient of the insecticide lindane, has been shown to decrease seizure threshold to pentylenetrazol (PTZ) 3 h after exposure to gamma-HCH and conversely increase threshold to PTZ-induced seizures 24 h after exposure to gamma-HCH (Vohland et al. 1981).",2440413_1,0,-1,0,16287,0
16292,gamma-HCH,30,31,183,192,"Gamma-hexachlorocyclohexane (gamma-HCH), the active ingredient of the insecticide lindane, has been shown to decrease seizure threshold to pentylenetrazol (PTZ) 3 h after exposure to gamma-HCH and conversely increase threshold to PTZ-induced seizures 24 h after exposure to gamma-HCH (Vohland et al. 1981).",2440413_1,0,-1,0,16292,0
16295,gamma-HCH,43,44,274,283,"Gamma-hexachlorocyclohexane (gamma-HCH), the active ingredient of the insecticide lindane, has been shown to decrease seizure threshold to pentylenetrazol (PTZ) 3 h after exposure to gamma-HCH and conversely increase threshold to PTZ-induced seizures 24 h after exposure to gamma-HCH (Vohland et al. 1981).",2440413_1,0,-1,0,16295,0
16298,gamma-HCH,26,27,152,161,"In this study, the severity of response to other seizure-inducing agents was tested in mice 1 and 24 h after intraperitoneal administration of 80 mg/kg gamma-HCH.",2440413_2,0,-1,0,16298,0
16299,gamma-HCH,6,7,37,46,"One hour after the administration of gamma-HCH, the activity of seizure-inducing agents was increased, regardless of their mechanism, while 24 h after gamma-HCH a differential response was observed.",2440413_3,0,-1,0,16299,0
16301,gamma-HCH,25,26,151,160,"One hour after the administration of gamma-HCH, the activity of seizure-inducing agents was increased, regardless of their mechanism, while 24 h after gamma-HCH a differential response was observed.",2440413_3,0,-1,0,16301,0
16313,gamma-HCH,3,4,10,19,"In vitro, gamma-HCH, pentylenetetrazol and picrotoxin were shown to inhibit 3H-TBOB binding in mouse whole brain, with IC50 values of 4.6, 404 and 9.4 microM, respectively.",2440413_5,0,-1,0,16313,0
16325,gamma-HCH,20,21,122,131,"The pharmacological challenge data suggest that tolerance may occur to seizure activity induced by PTZ and PTX 24 h after gamma-HCH, since the response to only these two seizure-inducing agents is decreased.",2440413_7,0,-1,0,16325,0
16328,gamma-HCH,18,19,100,109,The in vitro data suggest that the site responsible for the decrease in seizure activity 24 h after gamma-HCH may be the GABA-A receptor-linked chloride channel.,2440413_8,0,-1,0,16328,0
16329,GABA-A,22,23,121,127,The in vitro data suggest that the site responsible for the decrease in seizure activity 24 h after gamma-HCH may be the GABA-A receptor-linked chloride channel.,2440413_8,0,-1,0,16329,0
16330,chloride channel,24,26,144,160,The in vitro data suggest that the site responsible for the decrease in seizure activity 24 h after gamma-HCH may be the GABA-A receptor-linked chloride channel.,2440413_8,0,-1,0,16330,0
16383,gamma benzene hexachloride,19,22,130,156,Is the treatment of scabies hazardous?Treatment for scabies is usually initiated by general practitioners; most consider lindane (gamma benzene hexachloride) the treatment of choice.,2476560_0,0,-1,0,16383,0
16392,amantadine,4,5,33,43,Mouse strain-dependent effect of amantadine on motility and brain biogenic amines.,2484011_0,0,-1,0,16392,0
16394,amantadine hydrochloride,3,5,14,38,"The effect of amantadine hydrochloride, injected i.p. in 6 increments of 100 mg/kg each over 30 hr, on mouse motility and whole brain content of selected biogenic amines and major metabolites was studied in 4 strains of mice.",2484011_1,0,-1,0,16394,0
16400,Amantadine,0,1,0,10,Amantadine treatment produced a biphasic effect on mouse motility.,2484011_3,0,-1,0,16400,0
16403,amantadine,4,5,20,30,The initial dose of amantadine depressed locomotor activity in all mouse strains studied with the BALB/C mice being the most sensitive.,2484011_4,0,-1,0,16403,0
16406,amantadine,1,2,11,21,Subsequent amantadine treatments produced enhancement of motility from corresponding control in all mouse strains with the BALB/C mice being the least sensitive.,2484011_5,0,-1,0,16406,0
16411,amantadine,27,28,172,182,"The locomotor activity was decreased from corresponding controls in all strains studied, except for the ICR mice, during an overnight drug-free period following the fourth amantadine treatment.",2484011_6,0,-1,0,16411,0
16413,amantadine,2,3,20,30,"Readministration of amantadine, after a drug-free overnight period, increased motility from respective saline control in all strains with exception of the BALB/C mice where suppression of motility occurred.",2484011_7,0,-1,0,16413,0
16417,amantadine,2,3,15,25,"Treatment with amantadine did not alter whole brain dopamine levels but decreased the amounts of 3,4-dihydroxyphenylacetic acid in the BALB/C mice compared to saline control.",2484011_8,0,-1,0,16417,0
16423,amantadine,11,12,85,95,"Conversely, brain normetanephrine concentration was increased from saline control by amantadine in the BALB/C mice.",2484011_9,0,-1,0,16423,0
16426,amantadine,7,8,49,59,The results suggest a strain-dependent effect of amantadine on motility and indicate a differential response to the acute and multiple dose regimens used.,2484011_10,0,-1,0,16426,0
16430,amantadine,22,23,122,132,The BALB/C mouse was the most sensitive strain and could serve as the strain of choice for evaluating the side effects of amantadine.,2484011_11,0,-1,0,16430,0
16434,monoamine oxidase,22,24,152,169,The biochemical results of brain biogenic amines of BALB/C mouse strain suggest a probable decrease of catecholamine turnover rate and/or metabolism by monoamine oxidase and a resulting increase in O-methylation of norepinephrine which may account for a behavioral depression caused by amantadine in the BALB/C mice.,2484011_12,0,-1,0,16434,0
16437,amantadine,41,42,286,296,The biochemical results of brain biogenic amines of BALB/C mouse strain suggest a probable decrease of catecholamine turnover rate and/or metabolism by monoamine oxidase and a resulting increase in O-methylation of norepinephrine which may account for a behavioral depression caused by amantadine in the BALB/C mice.,2484011_12,0,-1,0,16437,0
16442,ifosfamide,11,12,97,107,Chloroacetaldehyde and its contribution to urotoxicity during treatment with cyclophosphamide or ifosfamide.,2505783_0,0,-1,0,16442,0
16455,mesna,21,22,122,127,"When instilled directly into the bladder, CAA exerts urotoxic effects, it is, however, susceptible to detoxification with mesna.",2505783_4,0,-1,0,16455,0
16481,Azidothymidine,17,18,114,128,"Nature, time course and dose dependence of zidovudine-related side effects: results from the Multicenter Canadian Azidothymidine Trial.To characterize the nature, time course and dose dependency of zidovudine-related side effects, we undertook a multicenter, prospective, dose-range finding study.",2528969_0,0,-1,0,16481,0
16524,hepatitis B e antigen,26,30,156,177,This program consists of double screenings of pregnant women and prophylactic treatment to the infants born to both hepatitis B surface antigen (HBsAg) and hepatitis B e antigen (HBeAg) positive mothers.,2533791_1,0,-1,0,16524,0
16525,HBeAg,31,32,179,184,This program consists of double screenings of pregnant women and prophylactic treatment to the infants born to both hepatitis B surface antigen (HBsAg) and hepatitis B e antigen (HBeAg) positive mothers.,2533791_1,0,-1,0,16525,0
16527,immune globulin,10,12,61,76,These infants are treated with two injections of hepatitis B immune globulin (HBIG) and at least three injections of plasma derived hepatitis B vaccine.,2533791_2,0,-1,0,16527,0
16533,HBeAg,1,2,4,9,The HBeAg positive rate in HBsAg positive was 23 to 26%.,2533791_5,0,-1,0,16533,0
16549,propranolol,20,21,138,149,"Akathisia appeared to be a common side effect of fluoxetine and generally responded well to treatment with the beta-adrenergic antagonist propranolol, dose reduction, or both.",2549018_4,0,-1,0,16549,0
16552,dopaminergic,14,15,111,123,"The authors suggest that fluoxetine-induced akathisia may be caused by serotonergically mediated inhibition of dopaminergic neurotransmission and that the pathophysiology of fluoxetine-induced akathisia and tricyclic antidepressant-induced ""jitteriness"" may be identical.",2549018_5,0,-1,0,16552,0
16566,opioid-agonists,27,28,252,267,"The intradermal injection of mu (morphine, Tyr-D-Ala-Gly-NMe-Phe-Gly-ol and morphiceptin), kappa (trans-3,4-dichloro-N-methyl-N[2-(1-pyrrolidinyl) cyclohexyl]benzeneactemide) and delta ([D-Pen2.5]-enkephalin and [D-Ser2]-[Leu]enkephalin-Thr) selective opioid-agonists, by themselves, did not significantly affect the mechanical nociceptive threshold in the hindpaw of the rat.",2557556_1,0,-1,0,16566,0
16569,opioid-agonists,10,11,52,67,"Intradermal injection of mu, but not delta or kappa opioid-agonists, however, produced dose-dependent inhibition of prostaglandin E2-induced hyperalgesia.",2557556_2,0,-1,0,16569,0
16576,opioids,7,8,41,48,We conclude that the analgesic action of opioids on the peripheral terminals of primary afferents is via a binding site with characteristics of the mu-opioid receptor and that this action is mediated by inhibition of the cyclic adenosine monophosphate second messenger system.,2557556_5,0,-1,0,16576,0
16580,mu-opioid receptor,24,26,148,166,We conclude that the analgesic action of opioids on the peripheral terminals of primary afferents is via a binding site with characteristics of the mu-opioid receptor and that this action is mediated by inhibition of the cyclic adenosine monophosphate second messenger system.,2557556_5,0,-1,0,16580,0
16581,adenosine monophosphate,37,39,228,251,We conclude that the analgesic action of opioids on the peripheral terminals of primary afferents is via a binding site with characteristics of the mu-opioid receptor and that this action is mediated by inhibition of the cyclic adenosine monophosphate second messenger system.,2557556_5,0,-1,0,16581,0
16585,enzyme inhibitor,5,7,29,45,The effect of the converting enzyme inhibitor (CEI) enalapril was assessed in Munich-Wistar rats with established adriamycin nephrosis.,2559236_1,0,-1,0,16585,0
16597,/- 2,13,15,85,89,"These short-term studies showed that enalapril reduced arterial blood pressure (101 +/- 2 vs. 124 +/- 3 mm Hg, group 2 vs. 1, P less than 0.05) and glomerular capillary pressure (54 +/- 1 vs. 61 +/- 2 mm Hg, P less than 0.05) without reducing albuminuria (617 +/- 50 vs. 570 +/- 47 mg/day) or GFR (1.03 +/- 0.04 vs. 1.04 +/- 0.11 ml/min).",2559236_5,0,-1,0,16597,0
16601,/- 1,40,42,183,187,"These short-term studies showed that enalapril reduced arterial blood pressure (101 +/- 2 vs. 124 +/- 3 mm Hg, group 2 vs. 1, P less than 0.05) and glomerular capillary pressure (54 +/- 1 vs. 61 +/- 2 mm Hg, P less than 0.05) without reducing albuminuria (617 +/- 50 vs. 570 +/- 47 mg/day) or GFR (1.03 +/- 0.04 vs. 1.04 +/- 0.11 ml/min).",2559236_5,0,-1,0,16601,0
16602,/- 2,45,47,196,200,"These short-term studies showed that enalapril reduced arterial blood pressure (101 +/- 2 vs. 124 +/- 3 mm Hg, group 2 vs. 1, P less than 0.05) and glomerular capillary pressure (54 +/- 1 vs. 61 +/- 2 mm Hg, P less than 0.05) without reducing albuminuria (617 +/- 50 vs. 570 +/- 47 mg/day) or GFR (1.03 +/- 0.04 vs. 1.04 +/- 0.11 ml/min).",2559236_5,0,-1,0,16602,0
16653,Dexmedetomidine,0,1,0,15,"Dexmedetomidine, acting through central alpha-2 adrenoceptors, prevents opiate-induced muscle rigidity in the rat.",2569282_0,0,-1,0,16653,0
16669,L-isomer,23,24,111,119,"Animals (n = 42) were treated intraperitoneally with one of the following six regimens: 1) L-MED (the inactive L-isomer of medetomidine), 30 micrograms/kg; 2) D-MED, 10 micrograms/kg; 3) D-MED, 30 micrograms/kg; 4) D-MED [30 micrograms/kg] and the central-acting alpha-2 antagonist, idazoxan [10 mg/kg]; 5) D-MED [30 micrograms/kg] and the peripheral-acting alpha-2 antagonist DG-5128 [10 mg/kg], or; 6) saline.",2569282_5,0,-1,0,16669,0
16670,medetomidine,25,26,123,135,"Animals (n = 42) were treated intraperitoneally with one of the following six regimens: 1) L-MED (the inactive L-isomer of medetomidine), 30 micrograms/kg; 2) D-MED, 10 micrograms/kg; 3) D-MED, 30 micrograms/kg; 4) D-MED [30 micrograms/kg] and the central-acting alpha-2 antagonist, idazoxan [10 mg/kg]; 5) D-MED [30 micrograms/kg] and the peripheral-acting alpha-2 antagonist DG-5128 [10 mg/kg], or; 6) saline.",2569282_5,0,-1,0,16670,0
16674,alpha-2,55,56,263,270,"Animals (n = 42) were treated intraperitoneally with one of the following six regimens: 1) L-MED (the inactive L-isomer of medetomidine), 30 micrograms/kg; 2) D-MED, 10 micrograms/kg; 3) D-MED, 30 micrograms/kg; 4) D-MED [30 micrograms/kg] and the central-acting alpha-2 antagonist, idazoxan [10 mg/kg]; 5) D-MED [30 micrograms/kg] and the peripheral-acting alpha-2 antagonist DG-5128 [10 mg/kg], or; 6) saline.",2569282_5,0,-1,0,16674,0
16675,idazoxan,58,59,283,291,"Animals (n = 42) were treated intraperitoneally with one of the following six regimens: 1) L-MED (the inactive L-isomer of medetomidine), 30 micrograms/kg; 2) D-MED, 10 micrograms/kg; 3) D-MED, 30 micrograms/kg; 4) D-MED [30 micrograms/kg] and the central-acting alpha-2 antagonist, idazoxan [10 mg/kg]; 5) D-MED [30 micrograms/kg] and the peripheral-acting alpha-2 antagonist DG-5128 [10 mg/kg], or; 6) saline.",2569282_5,0,-1,0,16675,0
16677,alpha-2,74,75,358,365,"Animals (n = 42) were treated intraperitoneally with one of the following six regimens: 1) L-MED (the inactive L-isomer of medetomidine), 30 micrograms/kg; 2) D-MED, 10 micrograms/kg; 3) D-MED, 30 micrograms/kg; 4) D-MED [30 micrograms/kg] and the central-acting alpha-2 antagonist, idazoxan [10 mg/kg]; 5) D-MED [30 micrograms/kg] and the peripheral-acting alpha-2 antagonist DG-5128 [10 mg/kg], or; 6) saline.",2569282_5,0,-1,0,16677,0
16682,alfentanil,6,7,32,42,"Each rat was then injected with alfentanil (ALF, 0.5 mg/kg sc).",2569282_7,0,-1,0,16682,0
16714,serotonin uptake inhibitor,12,15,79,105,"We investigated the effect of repeated treatment with fluvoxamine, a selective serotonin uptake inhibitor, on behavioral effects of dopaminomimetics and methoxamine and on the animal behavior in the ""behavioral despair"" test.",2576810_1,0,-1,0,16714,0
16717,methoxamine,22,23,153,164,"We investigated the effect of repeated treatment with fluvoxamine, a selective serotonin uptake inhibitor, on behavioral effects of dopaminomimetics and methoxamine and on the animal behavior in the ""behavioral despair"" test.",2576810_1,0,-1,0,16717,0
16722,nomifensine,4,5,29,40,The hyperactivity induced by nomifensine in mice remained unaffected by fluvoxamine.,2576810_3,0,-1,0,16722,0
16725,methoxamine,8,9,80,91,The stimulation of locomotor activity by intracerebroventricularly administered methoxamine was not affected by repeated treatment with fluvoxamine.,2576810_4,0,-1,0,16725,0
16732,citalopram,10,11,77,87,"The results indicate that fluvoxamine given repeatedly acts differently than citalopram, another selective serotonin uptake inhibitor, and differs also from other antidepressant drugs.",2576810_6,0,-1,0,16732,0
16733,serotonin uptake inhibitor,14,17,107,133,"The results indicate that fluvoxamine given repeatedly acts differently than citalopram, another selective serotonin uptake inhibitor, and differs also from other antidepressant drugs.",2576810_6,0,-1,0,16733,0
16734,antidepressant drugs,23,25,163,183,"The results indicate that fluvoxamine given repeatedly acts differently than citalopram, another selective serotonin uptake inhibitor, and differs also from other antidepressant drugs.",2576810_6,0,-1,0,16734,0
16741,N-methyl-N-nitrosourea,59,60,319,341,"To test the validity of the hypothesis that hypomethylation of DNA plays an important role in the initiation of carcinogenic process, 5-azacytidine (5-AzC) (10 mg/kg), an inhibitor of DNA methylation, was given to rats during the phase of repair synthesis induced by the three carcinogens, benzo[a]-pyrene (200 mg/kg), N-methyl-N-nitrosourea (60 mg/kg) and 1,2-dimethylhydrazine (1,2-DMH) (100 mg/kg).",2578334_1,0,-1,0,16741,0
16749,CCl4,34,35,238,242,The initiated hepatocytes in the liver were assayed as the gamma-glutamyltransferase (gamma-GT) positive foci formed following a 2-week selection regimen consisting of dietary 0.02% 2-acetylaminofluorene coupled with a necrogenic dose of CCl4.,2578334_2,0,-1,0,16749,0
16763,platelet-activating factor,5,7,32,58,"Protective effect of a specific platelet-activating factor antagonist, BN 52021, on bupivacaine-induced cardiovascular impairments in rats.",2594614_0,0,-1,0,16763,0
16766,bupivacaine,5,6,40,51,"Administration of the local anaesthetic bupivacaine (1.5 or 2 mg/kg, i.v.) to rats elicited a marked decrease of mean arterial blood pressure (MBP) and heart rate (HR) leading to death (in 67% or 90% of animals respectively).",2594614_1,0,-1,0,16766,0
16771,platelet-activating factor,5,7,38,64,"Intravenous injection of the specific platelet-activating factor (PAF) antagonist BN 52021 (10 mg/kg), 30 min before bupivacaine administration (2 mg/kg i.v.) suppressed both the decrease of MBP and HR.",2594614_2,0,-1,0,16771,0
16772,PAF,8,9,66,69,"Intravenous injection of the specific platelet-activating factor (PAF) antagonist BN 52021 (10 mg/kg), 30 min before bupivacaine administration (2 mg/kg i.v.) suppressed both the decrease of MBP and HR.",2594614_2,0,-1,0,16772,0
16774,bupivacaine,21,22,117,128,"Intravenous injection of the specific platelet-activating factor (PAF) antagonist BN 52021 (10 mg/kg), 30 min before bupivacaine administration (2 mg/kg i.v.) suppressed both the decrease of MBP and HR.",2594614_2,0,-1,0,16774,0
16777,bupivacaine,2,3,13,24,injection of bupivacaine were ineffective.,2594614_4,0,-1,0,16777,0
16779,bupivacaine,13,14,61,72,"When BN 52021 (20 mg/kg i.v.) was injected immediately after bupivacaine (2 mg/kg), a partial reversion of the decrease of MBP and HR was observed, whereas the dose of 10 mg/kg was ineffective.",2594614_5,0,-1,0,16779,0
16789,PAF,41,42,208,211,"Since the administration of BN 52021, at all doses studied, did not alter MBP and HR at the doses used, the bulk of these results clearly demonstrate a protective action of BN 52021, a specific antagonist of PAF, against bupivacaine-induced cardiovascular toxicity.",2594614_7,0,-1,0,16789,0
16792,PAF,10,11,50,53,"Thus, consistent with its direct effect on heart, PAF appears to be implicated in bupivacaine-induced cardiovascular alterations.",2594614_8,0,-1,0,16792,0
16797,nonsteroidal anti-inflammatory,4,6,16,46,"Suprofen, a new nonsteroidal anti-inflammatory drug, was marketed in early 1986 as an analgesic agent.",2598570_1,0,-1,0,16797,0
16818,analgesic agents,11,13,66,82,"Possible risk factors included young age, concurrent use of other analgesic agents (especially ibuprofen), preexisting renal disease, a history of kidney stones, a history of gout, a recent increase in activity, a recent increase in sun exposure, and residence in the Sunbelt.",2598570_5,0,-1,0,16818,0
16826,uric acid,17,19,120,129,These findings are consistent with the postulated mechanism for this unusual syndrome: acute diffuse crystallization of uric acid in renal tubules.,2598570_7,0,-1,0,16826,0
16837,methyl dopa,12,14,75,86,This was accounted for by a significant number of depressions occurring in methyl dopa treated patients with psychiatric histories.,26094_4,0,-1,0,16837,0
16841,diclofenac sodium,5,7,41,58,Chronic active hepatitis associated with diclofenac sodium therapy.,2611118_0,0,-1,0,16841,0
16842,Diclofenac sodium,0,2,0,17,"Diclofenac sodium (Voltarol, Geigy Pharmaceuticals) is a non-steroidal anti-inflammatory derivative of phenylacetic acid.",2611118_1,0,-1,0,16842,0
16845,non-steroidal anti-inflammatory,10,12,57,88,"Diclofenac sodium (Voltarol, Geigy Pharmaceuticals) is a non-steroidal anti-inflammatory derivative of phenylacetic acid.",2611118_1,0,-1,0,16845,0
16849,diclofenac,21,22,147,157,"Although generally well-tolerated, asymptomatic abnormalities of liver function have been recorded and, less commonly, severe hepatitis induced by diclofenac.",2611118_2,0,-1,0,16849,0
16851,diclofenac sodium,12,14,87,104,"The patient described developed chronic active hepatitis after six months therapy with diclofenac sodium which progressed despite the withdrawal of the drug, a finding not previously reported.",2611118_3,0,-1,0,16851,0
16868,converting enzyme,6,8,39,56,Effects of an inhibitor of angiotensin converting enzyme (Captopril) on pulmonary and renal insufficiency due to intravascular coagulation in the rat.,2670794_0,0,-1,0,16868,0
16872,tranexamic acid,13,15,99,114,Induction of intravascular coagulation and inhibition of fibrinolysis by injection of thrombin and tranexamic acid (AMCA) in the rat gives rise to pulmonary and renal insufficiency resembling that occurring after trauma or sepsis in man.,2670794_1,0,-1,0,16872,0
16873,AMCA,16,17,116,120,Induction of intravascular coagulation and inhibition of fibrinolysis by injection of thrombin and tranexamic acid (AMCA) in the rat gives rise to pulmonary and renal insufficiency resembling that occurring after trauma or sepsis in man.,2670794_1,0,-1,0,16873,0
16876,converting enzyme,12,14,62,79,"Injection of Captopril (1 mg/kg), an inhibitor of angiotensin converting enzyme (ACE), reduced both pulmonary and renal insufficiency in this rat model.",2670794_2,0,-1,0,16876,0
16883,AMCA,18,19,108,112,The amount of fibrin in the kidneys was also considerably lower than in animals which received thrombin and AMCA alone.,2670794_6,0,-1,0,16883,0
16886,prostacyclin,33,34,186,198,It is suggested that the effects of Captopril on the lungs may be attributable to a vasodilatory effect due to a reduction in the circulating level of Angiotension II and an increase in prostacyclin (secondary to an increase in bradykinin).,2670794_7,0,-1,0,16886,0
16887,bradykinin,40,41,228,238,It is suggested that the effects of Captopril on the lungs may be attributable to a vasodilatory effect due to a reduction in the circulating level of Angiotension II and an increase in prostacyclin (secondary to an increase in bradykinin).,2670794_7,0,-1,0,16887,0
16905,(1,4,6,25,27,"These data indicate that (1) the apparent incidence of stroke related to cocaine use is increasing; (2) cocaine-associated stroke occurs primarily in young adults; (3) stroke may follow any route of cocaine administration; (4) stroke after cocaine use is frequently associated with intracranial aneurysms and arteriovenous malformations; and (5) in cocaine-associated stroke, the frequency of intracranial hemorrhage exceeds that of cerebral infarction.",2673163_6,0,-1,0,16905,0
16908,(3,30,32,164,166,"These data indicate that (1) the apparent incidence of stroke related to cocaine use is increasing; (2) cocaine-associated stroke occurs primarily in young adults; (3) stroke may follow any route of cocaine administration; (4) stroke after cocaine use is frequently associated with intracranial aneurysms and arteriovenous malformations; and (5) in cocaine-associated stroke, the frequency of intracranial hemorrhage exceeds that of cerebral infarction.",2673163_6,0,-1,0,16908,0
16916,nitroprusside,6,7,41,54,A randomized comparison of labetalol and nitroprusside for induced hypotension.,2696505_0,0,-1,0,16916,0
16925,Nitroprusside,0,1,0,13,Nitroprusside infusion was associated with a significant (p less than 0.05) increase in heart rate and cardiac output; rebound hypertension was observed in three patients after discontinuation of nitroprusside.,2696505_3,0,-1,0,16925,0
16930,nitroprusside,31,32,196,209,Nitroprusside infusion was associated with a significant (p less than 0.05) increase in heart rate and cardiac output; rebound hypertension was observed in three patients after discontinuation of nitroprusside.,2696505_3,0,-1,0,16930,0
16933,nitroprusside,8,9,55,68,It was concluded that labetalol offers advantages over nitroprusside.,2696505_6,0,-1,0,16933,0
16942,phlorizin,22,23,165,174,The protection from gentamicin nephrotoxicity was studied in non-diabetic rats with chronic solute diuresis induced by blockage of tubular glucose reabsorption with phlorizin (P).,2709684_2,0,-1,0,16942,0
16947,Group II,16,18,55,63,"Group 1 (P alone) received P, 360 mg/day, for 15 days; Group II (P + gentamicin); Group III (gentamicin alone) and Group IV (mild DM + gentamicin).",2709684_5,0,-1,0,16947,0
16949,Group IV,31,33,115,123,"Group 1 (P alone) received P, 360 mg/day, for 15 days; Group II (P + gentamicin); Group III (gentamicin alone) and Group IV (mild DM + gentamicin).",2709684_5,0,-1,0,16949,0
16962,Group II,1,3,3,11,"In Group II, P did not prevent gentamicin-ARF (maximal decrease in CCr at day 9.89%, P less than 0.001; peak lysozymuria, 1863 +/- 321 micrograms/day; and tubular necrosis score, 3.9 +/- 0.1).",2709684_8,0,-1,0,16962,0
17024,(R,29,31,186,188,"Resting forearm vascular resistance remained unchanged, but the reflex response to the cold pressor test was accentuated, the rise in resistance increasing from 10.5 mm Hg/ml/100 ml/min (R units) before treatment to 32.6 R units after treatment (SED +/- 6.4, p less than 0.025).",2722224_5,0,-1,0,17024,0
17042,magnesium sulfate,3,5,28,45,Neuromuscular blockade with magnesium sulfate and nifedipine.,2750819_0,0,-1,0,17042,0
17045,magnesium sulfate,14,16,98,115,A patient who received tocolysis with nifedipine developed neuromuscular blockade after 500 mg of magnesium sulfate was administered.,2750819_1,0,-1,0,17045,0
17046,tocolytics,7,8,43,53,Caution should be exercised when these two tocolytics are combined.,2750819_3,0,-1,0,17046,0
17055,lidocaine-,8,9,51,61,"Chronic oral CBZ inhibited the development of both lidocaine- and cocaine-induced seizures, but had little effect on the fully developed local anesthetic seizures.",2790457_2,0,-1,0,17055,0
17065,lidocaine-,15,16,74,84,injection of CBZ (15 mg/kg) also was without effect on the development of lidocaine- or cocaine-kindled seizures.,2790457_6,0,-1,0,17065,0
17083,creatinine,7,8,48,58,"In salt-depleted rats, amphotericin B decreased creatinine clearance linearly with time, with an 85% reduction by week 3.",2802551_2,0,-1,0,17083,0
17085,creatinine,6,7,33,43,"In contrast, in normal-salt rats creatinine clearance was decreased but to a lesser extent at week 2 and 3, and in salt-loaded rats creatinine clearance did not change for 2 weeks and was decreased by 43% at week 3.",2802551_3,0,-1,0,17085,0
17087,creatinine,25,26,132,142,"In contrast, in normal-salt rats creatinine clearance was decreased but to a lesser extent at week 2 and 3, and in salt-loaded rats creatinine clearance did not change for 2 weeks and was decreased by 43% at week 3.",2802551_3,0,-1,0,17087,0
17101,creatinine,5,6,29,39,"In conclusion, reductions in creatinine clearance and renal amphotericin B accumulation after chronic amphotericin B administration were enhanced by salt depletion and attenuated by sodium loading in rats.",2802551_7,0,-1,0,17101,0
17108,low-dose,10,11,71,79,"Magnetic resonance imaging of cerebral venous thrombosis secondary to ""low-dose"" birth control pills.",2819587_0,0,-1,0,17108,0
17116,low-dose,7,8,32,40,"The only known risk factor was ""low-dose"" oral contraceptive pills.",2819587_3,0,-1,0,17116,0
17124,oxprenolol,6,7,64,74,Beta-2-adrenoceptor-mediated hypokalemia and its abolishment by oxprenolol.,2826064_0,0,-1,0,17124,0
17128,oxprenolol,6,7,45,55,"Subsequently we investigated the efficacy of oxprenolol in antagonizing such hypokalemia, together with the pharmacokinetic interaction between both drugs.",2826064_2,0,-1,0,17128,0
17134,oxprenolol,30,31,161,171,Six healthy subjects were given a 0.5 mg subcutaneous dose of terbutaline on two occasions: 1 hour after oral administration of a placebo and 1 hour after 80 mg oxprenolol orally.,2826064_3,0,-1,0,17134,0
17142,Oxprenolol,0,1,0,10,"Oxprenolol caused decreases of 65% and 56% of terbutaline volume of distribution and clearance, respectively, and an increase of 130% of its AUC.",2826064_6,0,-1,0,17142,0
17145,oxprenolol,7,8,52,62,"In spite of higher terbutaline concentrations after oxprenolol pretreatment, the hypokalemia was almost completely antagonized by the beta 2-blocking action.",2826064_7,0,-1,0,17145,0
17148,neuropeptide,4,5,31,43,A dystonia-like syndrome after neuropeptide (MSH/ACTH) stimulation of the rat locus ceruleus.,2840807_0,0,-1,0,17148,0
17210,(1,21,23,121,123,"The present study examines the effect of 6-day epinephrine treatment (100 micrograms/kg per h, s.c.) on stimulus-induced (1 Hz) endogenous neurotransmitter overflow from the isolated perfused kidney of vehicle- and epinephrine-treated rats.",2886572_1,0,-1,0,17210,0
17224,Propranolol,0,1,0,11,Propranolol had no effect on stimulus-induced overflow in either group.,2886572_7,0,-1,0,17224,0
17236,bromocriptine,12,13,111,124,"Immunohistochemical, electron microscopic and morphometric studies of estrogen-induced rat prolactinomas after bromocriptine treatment.",2887062_0,0,-1,0,17236,0
17238,bromocriptine,5,6,26,39,"To clarify the effects of bromocriptine on prolactinoma cells in vivo, immunohistochemical, ultrastructural and morphometrical analyses were applied to estrogen-induced rat prolactinoma cells 1 h and 6 h after injection of bromocriptine (3 mg/kg of body weight).",2887062_1,0,-1,0,17238,0
17260,bromocriptine,13,14,81,94,These findings suggest that lowered serum prolactin levels in the early phase of bromocriptine treatment may result from an impaired secretion of prolactin due to decreasing numbers of cytoplasmic microtubules.,2887062_5,0,-1,0,17260,0
17269,reaction products,5,7,62,79,"Electron microscopical immunohistochemistry revealed positive reaction products noted on the secretory granules, Golgi cisternae, and endoplasmic reticulum of the untreated rat prolactinoma cells.",2887062_8,0,-1,0,17269,0
17275,reaction products,8,10,53,70,"However, only secretory granules showed the positive reaction products for prolactin 6 h after bromocriptine treatment of the adenoma cells.",2887062_9,0,-1,0,17275,0
17276,bromocriptine,15,16,95,108,"However, only secretory granules showed the positive reaction products for prolactin 6 h after bromocriptine treatment of the adenoma cells.",2887062_9,0,-1,0,17276,0
17281,bromocriptine,30,31,200,213,"An increase in the volume density of secretory granules and a decrease in the volume densities of rough endoplasmic reticulum and microtubules was determined by morphometric analysis, suggesting that bromocriptine inhibits protein synthesis as well as bringing about a disturbance of the prolactin secretion.",2887062_10,0,-1,0,17281,0
17290,aspartate,24,25,139,148,"25 mg/kg, i.v. thiopental produced anesthesia without altering respiratory rate, increased GABA, decreased glutamate, and had no effect on aspartate or glycine levels compared to controls in rat cortex and brain stem.",2893236_3,0,-1,0,17290,0
17297,amino acids,29,31,170,181,"50 mg/kg, i.v. thiopental produced respiratory arrest with further increase in GABA and decrease in glutamate again in cortex and brain stem without affecting any of the amino acids studied in four regions of rat brain.",2893236_5,0,-1,0,17297,0
17322,chloride channels,25,27,171,188,"However, the diazepam enhancement of adrenaline-induced reflex bradycardia was antagonized by pretreatment of rats with an intravenous dose of picrotoxin (an agent blocks chloride channels by binding to sites associated with the benzodiazepine-GABA-chloride channel macromolecular complex).",2894433_5,0,-1,0,17322,0
17337,sulfasalazine,25,26,179,192,"Pneumonitis, bilateral pleural effusions, echocardiographic evidence of cardiac tamponade, and positive autoantibodies developed in a 43-year-old man, who was receiving long-term sulfasalazine therapy for chronic ulcerative colitis.",2894766_1,0,-1,0,17337,0
17339,sulfasalazine,4,5,23,36,"After cessation of the sulfasalazine and completion of a six-week course of corticosteroids, these problems resolved over a period of four to six months.",2894766_2,0,-1,0,17339,0
17345,sulfasalazine,3,4,19,32,Physicians who use sulfasalazine to treat patients with inflammatory bowel disease should be aware of the signs of sulfasalazine-induced lupus syndrome.,2894766_4,0,-1,0,17345,0
17379,Glycopyrronium,0,1,0,14,Glycopyrronium requirements for antagonism of the muscarinic side effects of edrophonium.,2917114_0,0,-1,0,17379,0
17381,edrophonium,10,11,77,88,Glycopyrronium requirements for antagonism of the muscarinic side effects of edrophonium.,2917114_0,0,-1,0,17381,0
17383,glycopyrronium,13,14,70,84,"We have compared, in 60 adult patients, the cardiovascular effects of glycopyrronium 5 micrograms kg-1 and 10 micrograms kg-1 given either simultaneously or 1 min before edrophonium 1 mg kg-1.",2917114_1,0,-1,0,17383,0
17386,edrophonium,28,29,170,181,"We have compared, in 60 adult patients, the cardiovascular effects of glycopyrronium 5 micrograms kg-1 and 10 micrograms kg-1 given either simultaneously or 1 min before edrophonium 1 mg kg-1.",2917114_1,0,-1,0,17386,0
17393,glycopyrronium,2,3,7,21,"Use of glycopyrronium 5 micrograms kg-1 provided greater cardiovascular stability and, given 1 min before the edrophonium, was sufficient to minimize early, edrophonium-induced bradycardias.",2917114_4,0,-1,0,17393,0
17396,edrophonium,17,18,110,121,"Use of glycopyrronium 5 micrograms kg-1 provided greater cardiovascular stability and, given 1 min before the edrophonium, was sufficient to minimize early, edrophonium-induced bradycardias.",2917114_4,0,-1,0,17396,0
17397,low dose,1,3,5,13,This low dose of glycopyrronium provided good control of oropharyngeal secretions.,2917114_5,0,-1,0,17397,0
17398,glycopyrronium,4,5,17,31,This low dose of glycopyrronium provided good control of oropharyngeal secretions.,2917114_5,0,-1,0,17398,0
17401,antiepileptic drug,9,11,53,71,Folate depletion has often been a problem in chronic antiepileptic drug (AED) therapy.,2924746_1,0,-1,0,17401,0
17408,propylene glycol,12,14,58,74,"In the course of developing this model, a common vehicle, propylene glycol, by itself in high doses, was found to exhibit protective properties against induced seizures and inhibited weight gain.",2924746_4,0,-1,0,17408,0
17425,dipyridamole,10,11,87,99,Angina and ischemic electrocardiographic changes occurred after administration of oral dipyridamole in four patients awaiting urgent myocardial revascularization procedures.,2950248_1,0,-1,0,17425,0
17428,dipyridamole,16,17,89,101,"To our knowledge, this has not previously been reported as a side effect of preoperative dipyridamole therapy, although dipyridamole-induced myocardial ischemia has been demonstrated to occur in animals and humans with coronary artery disease.",2950248_2,0,-1,0,17428,0
17434,atrial natriuretic factor,5,8,42,67,Inhibition of sympathoadrenal activity by atrial natriuretic factor in dogs.,2951327_0,0,-1,0,17434,0
17437,natriuretic factor,4,6,32,50,infusions of human alpha-atrial natriuretic factor.,2951327_2,0,-1,0,17437,0
17442,/- 1,29,31,139,143,"Mean arterial pressure (as a percentage of control +/- SEM) during randomized infusions of 0.03, 0.1, 0.3, or 1.0 microgram/kg/min was 99 +/- 1, 95 +/- 1 (p less than 0.05), 93 +/- 1 (p less than 0.01), or 79 +/- 6% (p less than 0.001), respectively, but no tachycardia and no augmentation of the norepinephrine release rate (up to 0.3 microgram/kg/min) were observed, which is in contrast to comparable hypotension induced by hydralazine or nitroglycerin.",2951327_3,0,-1,0,17442,0
17443,/- 1,45,47,178,182,"Mean arterial pressure (as a percentage of control +/- SEM) during randomized infusions of 0.03, 0.1, 0.3, or 1.0 microgram/kg/min was 99 +/- 1, 95 +/- 1 (p less than 0.05), 93 +/- 1 (p less than 0.01), or 79 +/- 6% (p less than 0.001), respectively, but no tachycardia and no augmentation of the norepinephrine release rate (up to 0.3 microgram/kg/min) were observed, which is in contrast to comparable hypotension induced by hydralazine or nitroglycerin.",2951327_3,0,-1,0,17443,0
17446,atrial natriuretic factor,19,22,106,131,"The release rate of epinephrine (control, 6.7 +/- 0.6 ng/kg/min) declined immediately during infusions of atrial natriuretic factor to a minimum of 49 +/- 5% of control (p less than 0.001) during 0.1 microgram/kg/min and to 63 +/- 5% (0.1 greater than p greater than 0.05) or 95 +/- 13% (not significant) during 0.3 or 1.0 microgram/kg/min.",2951327_4,0,-1,0,17446,0
17452,atrial natriuretic factor,6,9,47,72,Steady state arterial plasma concentrations of atrial natriuretic factor were 39 +/- 10 pg/ml (n = 6) during infusions of saline and 284 +/- 24 pg/ml (n = 6) and 1520 +/- 300 pg/ml (n = 9) during 0.03 and 0.1 microgram/kg/min infusions of the factor.(ABSTRACT TRUNCATED AT 250 WORDS),2951327_5,0,-1,0,17452,0
17458,iohexol,5,6,33,40,"Selective injection of iopentol, iohexol and metrizoate into the left coronary artery of the dog.",2980315_0,0,-1,0,17458,0
17466,iohexol,16,17,98,105,"In twenty beagle dogs selective injections were made into the left coronary artery with iopentol, iohexol and metrizoate in doses of 4 ml, 8 ml and 16 ml.",2980315_2,0,-1,0,17466,0
17469,iohexol,5,6,35,42,"Thirty-six iopentol injections, 35 iohexol injections and 37 metrizoate injections were made.",2980315_3,0,-1,0,17469,0
17476,iohexol,2,3,13,20,Iopentol and iohexol also produced significantly less decrease in aortic blood pressure than metrizoate at the different doses.,2980315_5,0,-1,0,17476,0
17481,adenylate cyclase,5,7,27,44,It has been suggested that adenylate cyclase inhibition may be important in the development of both nephrogenic diabetes insipidus and hypothyroidism during lithium treatment.,3001299_1,0,-1,0,17481,0
17485,desmopressin,13,14,82,94,We measured serum thyroxine and urine-concentrating ability (Umax) in response to desmopressin (DDAVP) in 85 patients receiving lithium.,3001299_2,0,-1,0,17485,0
17486,DDAVP,15,16,96,101,We measured serum thyroxine and urine-concentrating ability (Umax) in response to desmopressin (DDAVP) in 85 patients receiving lithium.,3001299_2,0,-1,0,17486,0
17510,arginine vasopressin,5,7,40,60,Portal plasma concentrations of neither arginine vasopressin nor oxytocin are significantly altered in this paradigm.,3015567_2,0,-1,0,17510,0
17513,glucocorticoid synthesis,23,25,159,183,"Application of a delayed feedback signal, in the form of a 2-h systemic corticosterone infusion in urethane-anesthetized rats with pharmacological blockade of glucocorticoid synthesis, is without effect on the resting secretion of arginine vasopressin and oxytocin at any corticosterone feedback dose tested.",3015567_3,0,-1,0,17513,0
17515,arginine vasopressin,34,36,231,251,"Application of a delayed feedback signal, in the form of a 2-h systemic corticosterone infusion in urethane-anesthetized rats with pharmacological blockade of glucocorticoid synthesis, is without effect on the resting secretion of arginine vasopressin and oxytocin at any corticosterone feedback dose tested.",3015567_3,0,-1,0,17515,0
17524,delta 9-tetrahydrocannabinol,6,8,50,78,Noradrenergic involvement in catalepsy induced by delta 9-tetrahydrocannabinol.,3031535_0,0,-1,0,17524,0
17527,delta 9-tetrahydrocannabinol,15,17,95,123,"In order to elucidate the role of the catecholaminergic system in the cataleptogenic effect of delta 9-tetrahydrocannabinol (THC), the effect of pretreatment with 6-hydroxydopamine (6-OHDA) or with desipramine and 6-OHDA and lesions of the locus coeruleus were investigated in rats.",3031535_1,0,-1,0,17527,0
17547,dopaminergic,20,21,131,143,"These results indicate that noradrenergic neurons have an important role in the manifestation of catalepsy induced by THC, whereas dopaminergic neurons are important in catalepsy induced by haloperidol.",3031535_4,0,-1,0,17547,0
17554,chlorpheniramine,14,15,99,115,"Multicenter, double-blind, multiple-dose, parallel-groups efficacy and safety trial of azelastine, chlorpheniramine, and placebo in the treatment of spring allergic rhinitis.",3057041_0,0,-1,0,17554,0
17558,chlorpheniramine maleate,10,12,63,87,"Azelastine, a novel antiallergic medication, was compared with chlorpheniramine maleate and placebo for efficacy and safety in the treatment of spring allergic rhinitis in a multicenter, double-blind, multiple-dose, parallel-groups study.",3057041_1,0,-1,0,17558,0
17570,chlorpheniramine,33,34,169,185,"Medications were given four times daily; the azelastine groups received 0.5, 1.0, or 2.0 mg in the morning and evening with placebo in the early and late afternoon; the chlorpheniramine group received 4.0 mg four times daily.",3057041_4,0,-1,0,17570,0
17586,chlorpheniramine,5,6,26,42,"In contrast, although the chlorpheniramine group did have fewer symptoms than the placebo group during the study, the difference never reached statistical significance during any week of the study.",3057041_11,0,-1,0,17586,0
17613,LDL-cholesterol,18,19,104,119,"Both agents show substantial clinical efficacy, with reductions in total cholesterol of over 30% and in LDL-cholesterol of 40% in clinical studies.",3076126_5,0,-1,0,17613,0
17622,creatine kinase,3,5,20,35,Minor elevations of creatine kinase levels are reported in about 5% of patients.,3076126_11,0,-1,0,17622,0
17626,cyclosporin,31,32,192,203,"Myopathy, associated in some cases with myoglobinuria, and in 2 cases with transient renal failure, has been rarely reported with lovastatin, especially in patients concomitantly treated with cyclosporin, gemfibrozil or niacin.",3076126_12,0,-1,0,17626,0
17633,HLA-B35,2,3,17,24,Association with HLA-B35 and Cw4 antigens.,3084782_1,0,-1,0,17633,0
17637,class I,26,28,181,188,Twenty-five patients with rheumatoid arthritis (RA) who developed toxicity while taking remission inducing drugs and 30 without toxicity were studied for possible associations with class I and II HLA antigens.,3084782_2,0,-1,0,17637,0
17638,HLA,30,31,196,199,Twenty-five patients with rheumatoid arthritis (RA) who developed toxicity while taking remission inducing drugs and 30 without toxicity were studied for possible associations with class I and II HLA antigens.,3084782_2,0,-1,0,17638,0
17639,Tiopronin,12,13,76,85,"A strong association has been found between nephritis and dermatitis due to Tiopronin (a D-Penicillamine like compound) and class I antigens B35-Cw4, and between dermatitis due to gold thiosulphate and B35.",3084782_3,0,-1,0,17639,0
17640,D-Penicillamine,15,16,89,104,"A strong association has been found between nephritis and dermatitis due to Tiopronin (a D-Penicillamine like compound) and class I antigens B35-Cw4, and between dermatitis due to gold thiosulphate and B35.",3084782_3,0,-1,0,17640,0
17641,class I antigens,20,23,124,140,"A strong association has been found between nephritis and dermatitis due to Tiopronin (a D-Penicillamine like compound) and class I antigens B35-Cw4, and between dermatitis due to gold thiosulphate and B35.",3084782_3,0,-1,0,17641,0
17646,DR5,6,7,37,40,Compared to healthy controls a lower DR5 frequency was observed in patients with RA except for the Tiopronin related nephritis group.,3084782_4,0,-1,0,17646,0
17647,Tiopronin,17,18,99,108,Compared to healthy controls a lower DR5 frequency was observed in patients with RA except for the Tiopronin related nephritis group.,3084782_4,0,-1,0,17647,0
17702,Mitomycin C,0,2,0,11,Mitomycin C associated hemolytic uremic syndrome.,3108839_0,0,-1,0,17702,0
17704,Mitomycin C,0,2,0,11,Mitomycin C associated Hemolytic Uremic Syndrome (HUS) is a potentially fatal but uncommon condition that is not yet widely recognised.,3108839_1,0,-1,0,17704,0
17709,mitomycin C,14,16,113,124,"It consists of microangiopathic hemolytic anemia, thrombocytopenia and progressive renal failure associated with mitomycin C treatment and affects about 10% of patients treated with this agent.",3108839_2,0,-1,0,17709,0
17712,mitomycin C,13,15,65,76,The renal failure usually develops about 8-10 mth after start of mitomycin C treatment and the mortality is approximately 60% from renal failure or pulmonary edema.,3108839_3,0,-1,0,17712,0
17726,mitomycin C,26,28,178,189,We describe the clinical course and pathological findings in a 65 yr-old man with gastric adenocarcinoma who developed renal failure and thrombocytopenia while on treatment with mitomycin C and died in pulmonary edema.,3108839_6,0,-1,0,17726,0
17728,Ketanserin,0,1,0,10,Ketanserin pretreatment reverses alfentanil-induced muscle rigidity.,3115150_0,0,-1,0,17728,0
17732,ketanserin,3,4,27,37,"Systemic pretreatment with ketanserin, a relatively specific type-2 serotonin receptor antagonist, significantly attenuated the muscle rigidity produced in rats by the potent short-acting opiate agonist alfentanil.",3115150_1,0,-1,0,17732,0
17742,ketanserin,1,2,16,26,Intraperitoneal ketanserin administration at doses of 0.63 and 2.5 mg/kg prevented the alfentanil-induced increase in electromyographic activity compared with animals pretreated with saline.,3115150_3,0,-1,0,17742,0
17745,alfentanil,15,16,100,110,Chlordiazepoxide at doses up to 10 mg/kg failed to significantly influence the rigidity produced by alfentanil.,3115150_4,0,-1,0,17745,0
17746,ketanserin,9,10,55,65,"Despite the absence of rigidity, animals that received ketanserin (greater than 0.31 mg/kg i.p.) followed by alfentanil were motionless, flaccid, and less responsive to external stimuli than were animals receiving alfentanil alone.",3115150_5,0,-1,0,17746,0
17747,alfentanil,20,21,109,119,"Despite the absence of rigidity, animals that received ketanserin (greater than 0.31 mg/kg i.p.) followed by alfentanil were motionless, flaccid, and less responsive to external stimuli than were animals receiving alfentanil alone.",3115150_5,0,-1,0,17747,0
17748,alfentanil,36,37,214,224,"Despite the absence of rigidity, animals that received ketanserin (greater than 0.31 mg/kg i.p.) followed by alfentanil were motionless, flaccid, and less responsive to external stimuli than were animals receiving alfentanil alone.",3115150_5,0,-1,0,17748,0
17749,ketanserin,3,4,19,29,Rats that received ketanserin and alfentanil exhibited less rearing and exploratory behavior at the end of the 60-min recording period than did animals that received ketanserin alone.,3115150_6,0,-1,0,17749,0
17750,alfentanil,5,6,34,44,Rats that received ketanserin and alfentanil exhibited less rearing and exploratory behavior at the end of the 60-min recording period than did animals that received ketanserin alone.,3115150_6,0,-1,0,17750,0
17752,ketanserin,25,26,166,176,Rats that received ketanserin and alfentanil exhibited less rearing and exploratory behavior at the end of the 60-min recording period than did animals that received ketanserin alone.,3115150_6,0,-1,0,17752,0
17755,serotonergic,28,29,180,192,"These results, in combination with previous work, suggest that muscle rigidity, a clinically relevant side-effect of parenteral narcotic administration, may be partly mediated via serotonergic pathways.",3115150_7,0,-1,0,17755,0
17759,Ro15-1788,6,9,51,60,Antagonism of diazepam-induced sedative effects by Ro15-1788 in patients after surgery under lumbar epidural block.,3120485_0,0,-1,0,17759,0
17762,Ro15-1788,11,14,52,61,"The aim of this study was to assess the efficacy of Ro15-1788 and a placebo in reversing diazepam-induced effects after surgery under epidural block, and to evaluate the local tolerance and general safety of Ro15-1788.",3120485_2,0,-1,0,17762,0
17766,Ro15-1788,37,40,208,217,"The aim of this study was to assess the efficacy of Ro15-1788 and a placebo in reversing diazepam-induced effects after surgery under epidural block, and to evaluate the local tolerance and general safety of Ro15-1788.",3120485_2,0,-1,0,17766,0
17769,Ro15-1788,5,8,42,51,Antagonism of diazepam-induced effects by Ro15-1788 was investigated postoperatively in a double-blind placebo-controlled trial.,3120485_4,0,-1,0,17769,0
17779,Ro15-1788,1,4,4,13,The Ro15-1788 group showed a significant improvement in the performance test up to 120 min after administration of the drug.,3120485_7,0,-1,0,17779,0
17784,oral contraceptives,6,8,48,67,Three patients developed chorea while receiving oral contraceptives.,3123611_1,0,-1,0,17784,0
17799,alfentanil,7,8,58,68,"Following instrumentation, halothane was discontinued and alfentanil (125 mu/kg) administered iv during emergence from halothane anesthesia.",3125768_4,0,-1,0,17799,0
17809,alfentanil,16,17,77,87,"In five rats that did not become rigid, ICP and CVP did not change following alfentanil.",3125768_7,0,-1,0,17809,0
17810,alfentanil,9,10,66,76,"These observations suggest that rigidity should be prevented when alfentanil, and, presumably, other opiates, are used in the anesthetic management of patients with ICP problems.",3125768_8,0,-1,0,17810,0
17815,butylated hydroxyanisole,14,16,103,127,Co-carcinogenic effect of retinyl acetate on forestomach carcinogenesis of male F344 rats induced with butylated hydroxyanisole.,3131282_0,0,-1,0,17815,0
17817,butylated hydroxyanisole,11,13,58,82,The potential modifying effect of retinyl acetate (RA) on butylated hydroxyanisole (BHA)-induced rat forestomach tumorigenesis was examined.,3131282_1,0,-1,0,17817,0
17820,BHA,19,20,76,79,"Male F344 rats, 5 weeks of age, were maintained on diet containing 1% or 2% BHA by weight and simultaneously on drinking water supplemented with RA at various concentrations (w/v) for 52 weeks.",3131282_2,0,-1,0,17820,0
17821,drinking water,25,27,112,126,"Male F344 rats, 5 weeks of age, were maintained on diet containing 1% or 2% BHA by weight and simultaneously on drinking water supplemented with RA at various concentrations (w/v) for 52 weeks.",3131282_2,0,-1,0,17821,0
17822,BHA,5,6,19,22,"In groups given 2% BHA, although marked hyperplastic changes of the forestomach epithelium were observed in all animals, co-administration of 0.25% RA significantly (P less than 0.05) increased the incidence of forestomach tumors (squamous cell papilloma and carcinoma) to 60% (9/15, 2 rats with carcinoma) from 15% (3/20, one rat with carcinoma) in the group given RA-free water.",3131282_3,0,-1,0,17822,0
17829,BHA,5,6,17,20,"In rats given 1% BHA, RA co-administered at a dose of 0.05, 0.1, 0.2 or 0.25% showed a dose-dependent enhancing effect on the development of the BHA-induced epithelial hyperplasia.",3131282_4,0,-1,0,17829,0
17841,mitomycin C,14,16,95,106,"A prospective study on the dose dependency of cardiotoxicity induced by mitomycin C.Since 1975 mitomycin C (MMC) has been suggested to be cardiotoxic, especially when combined with or given following doxorubicin.",3137399_0,0,-1,0,17841,0
17893,cis-platin,8,9,69,79,Adverse cardiac effects during induction chemotherapy treatment with cis-platin and 5-fluorouracil.,3187073_0,0,-1,0,17893,0
17896,cis-platin,5,6,22,32,"In the present study, cis-platin (80-120 mg/m2BSA) and 5-FU (1000 mg/m2BSA daily as a continuous infusion during 5 days) were given to 76 patients before radiotherapy and surgery.",3187073_3,0,-1,0,17896,0
17928,Etoposide,7,8,39,48,"The multiple drug schema consisted of: Etoposide 16.213, Methotrexate, Cyclophosphamide, Actomycin-D, and Cisplatin.",3192036_3,0,-1,0,17928,0
17931,Cisplatin,17,18,106,115,"The multiple drug schema consisted of: Etoposide 16.213, Methotrexate, Cyclophosphamide, Actomycin-D, and Cisplatin.",3192036_3,0,-1,0,17931,0
17932,Etoposide,14,15,71,80,"On the first day of the schedule, moderate high doses of Methotrexate, Etoposide and Cyclophosphamide were administered.",3192036_4,0,-1,0,17932,0
17961,binding sites,32,34,205,218,"In rats which were pretreated with nicotine for 5 days, there was a significant increase in the nicotine-stimulated locomotor response which was associated with an increase in the number of L-[3H]nicotine binding sites and also with an elevated dopamine (DA) level in the striatum.",3220106_4,0,-1,0,17961,0
17969,binding sites,22,24,149,162,"However, this response was correlated with an elevated number of striatal [3H]spiperone binding sites, whereas the number of striatal L-[3H]nicotine binding sites and the striatal DA level were normal.",3220106_7,0,-1,0,17969,0
17972,nicotinic,23,24,163,172,"These results suggest that chronic nicotine-treated rats develop locomotor hyperactivity in response to nicotine initially due to increases of both the density of nicotinic receptors and DA concentration, followed by inducing DA receptor supersensitivity in the striatum.",3220106_8,0,-1,0,17972,0
17982,sodium nitroprusside,27,29,160,180,The effects of continuous positive airway pressure (CPAP) on cardiovascular dynamics and pulmonary shunt (QS/QT) were investigated in 12 dogs before and during sodium nitroprusside infusion that decreased mean arterial blood pressure 40-50 per cent.,322550_1,0,-1,0,17982,0
17984,nitroprusside,1,2,7,20,"Before nitroprusside infusion, 5 cm H2O CPAP significantly, P less than .05, decreased arterial blood pressure, but did not significantly alter heart rate, cardiac output, systemic vascular resistance, or QS/QT.",322550_2,0,-1,0,17984,0
17992,nitroprusside,5,6,23,36,Ten cm H2O CPAP before nitroprusside infusion produced a further decrease in arterial blood pressure and significantly increased heart rate and decreased cardiac output and QS/QT.,322550_3,0,-1,0,17992,0
17997,Nitroprusside,0,1,0,13,"Nitroprusside caused significant decreases in arterial blood pressure and systemic vascular resistance and increases in heart rate, but did not change cardiac output or QS/QT.",322550_4,0,-1,0,17997,0
18004,nitroprusside,5,6,24,37,Five cm H2O CPAP during nitroprusside did not further alter any of the above-mentioned variables.,322550_5,0,-1,0,18004,0
18010,nitroprusside,4,5,25,38,These data indicate that nitroprusside infusion rates that decrease mean arterial blood pressure by 40-50 per cent do not change cardiac output or QS/QT.,322550_7,0,-1,0,18010,0
18014,nitroprusside,1,2,7,20,"During nitroprusside infusion low levels of CPAP do not markedly alter cardiovascular dynamics, but high levels of CPAP (10 cm H2O), while decreasing QS/QT, produce marked decreases in arterial blood pressure and cardiac output.",322550_8,0,-1,0,18014,0
18020,bendrofluazide,15,16,92,106,"The beta adrenergic blocking drug, timolol, tended to correct the hypokalemia of short-term bendrofluazide treatment in 6 healthy male subjects and although the effect was small it was significant.",326460_1,0,-1,0,18020,0
18023,bendrofluazide,13,14,92,106,Timolol also reduced the rise in plasma aldosterone and urine potassium excretion following bendrofluazide and increased the urine sodium/potassium ratio.,326460_2,0,-1,0,18023,0
18031,methysergide,20,21,122,134,"A rare case of morbid vasospasm, together with striking angiographic findings, is described secondary to the ingestion of methysergide by a 48-year-old woman.",3300918_1,0,-1,0,18031,0
18033,calcium channel blockers,4,7,22,46,"Despite the advent of calcium channel blockers and beta-adrenergic antagonists, ergot preparations continue to play a major role in migraine therapy, so that the danger of St. Anthony's fire persists.",3300918_4,0,-1,0,18033,0
18043,cyclosporine,4,5,12,24,"In group I, cyclosporine was given before the procedure at a loading dose of 17.5 mg/kg and then continued after the procedure to keep a whole blood level about 1000 ng/ml.",3311455_2,0,-1,0,18043,0
18045,group II,1,3,3,11,"In group II, cyclosporine was started only after the procedure at a lower dosage and was complemented by azathioprine, which was used for the first postoperative week.",3311455_3,0,-1,0,18045,0
18046,cyclosporine,4,5,13,25,"In group II, cyclosporine was started only after the procedure at a lower dosage and was complemented by azathioprine, which was used for the first postoperative week.",3311455_3,0,-1,0,18046,0
18047,Group II,0,2,0,8,Group II showed a better perioperative renal function as determined by serum blood urea nitrogen and serum creatinine levels.,3311455_4,0,-1,0,18047,0
18052,Group II,0,2,0,8,Group II also showed a significant decrease of chronic nephrotoxicity secondary to long-term therapy with cyclosporine.,3311455_5,0,-1,0,18052,0
18054,cyclosporine,15,16,106,118,Group II also showed a significant decrease of chronic nephrotoxicity secondary to long-term therapy with cyclosporine.,3311455_5,0,-1,0,18054,0
18056,group II,8,10,49,57,"Despite this improvement in late renal function, group II still shows a slow rise in serum creatinine.",3311455_6,0,-1,0,18056,0
18058,cyclosporine,8,9,42,54,We think that even these lower dosages of cyclosporine can cause chronic nephrotoxicity and that further modification of the immunosuppressive regimen is required to completely abolish this toxic side effect.,3311455_7,0,-1,0,18058,0
18070,sodium nitroprusside,27,29,127,147,"Mean arterial pressure was decreased to 50 mm Hg for 30 minutes either by hemorrhage (HEM, n = 7) or by continuous infusion of sodium nitroprusside (SNP, n = 7).",3341566_2,0,-1,0,18070,0
18094,ritodrine,6,7,59,68,Ventricular tachyarrhythmias during cesarean section after ritodrine therapy: interaction with anesthetics.,3358181_0,0,-1,0,18094,0
18095,ritodrine,6,7,46,55,This case illustrates that patients receiving ritodrine for preterm labor may risk interactions between the residual betamimetic effects of ritodrine and the effects of anesthetics during cesarean section.,3358181_1,0,-1,0,18095,0
18098,ritodrine,19,20,140,149,This case illustrates that patients receiving ritodrine for preterm labor may risk interactions between the residual betamimetic effects of ritodrine and the effects of anesthetics during cesarean section.,3358181_1,0,-1,0,18098,0
18101,ritodrine,15,16,108,117,Such interactions may result in serious cardiovascular complications even after cessation of an infusion of ritodrine.,3358181_2,0,-1,0,18101,0
18113,benztropine,2,3,18,29,Ethopropazine and benztropine in neuroleptic-induced parkinsonism.,33969_0,0,-1,0,18113,0
18115,benztropine,9,10,60,71,In a 12-week controlled study ethopropazine was compared to benztropine in the treatment of parkinsonism induced by fluphenazine enanthate in 60 schizophrenic outpatients.,33969_1,0,-1,0,18115,0
18118,benztropine,2,3,18,29,"Ethopropazine and benztropine were found to be equally effective in controlling parkinsonian symptoms and were as efficacious as procyclidine, their previous antiparkinsonian drug.",33969_2,0,-1,0,18118,0
18121,benztropine,2,3,9,20,"However, benztropine treated patients had a significant increase in tardive dyskinesia compared to their condition during procyclindine treatment, and significantly more anxiety and depression than ethopropazine treated patients.",33969_3,0,-1,0,18121,0
18124,benztropine,3,4,19,30,"This suggests that benztropine is not the anticholinergic drug of choice in the treatment of neuroleptic-induced parkinsonian symptoms, because of its more toxic central and peripheral atropinic effect.",33969_4,0,-1,0,18124,0
18132,paracetamol,13,14,80,91,"A case of metabolic acidosis, acute renal failure and hepatic failure following paracetamol ingestion is presented.",3403780_1,0,-1,0,18132,0
18161,her,18,19,114,117,We report the case of a 19-year-old Laotian patient affected by fulminant hepatitis during the third trimester of her pregnancy after a 1-month administration of quinidine phenylethylbarbiturate.,3411101_2,0,-1,0,18161,0
18166,paracetamol,1,2,5,16,"Does paracetamol cause urothelial cancer or renal papillary necrosis?The risk of developing renal papillary necrosis or cancer of the renal pelvis, ureter or bladder associated with consumption of either phenacetin or paracetamol was calculated from data acquired by questionnaire from 381 cases and 808 controls.",3412544_0,0,-1,0,18166,0
18173,paracetamol,32,33,218,229,"Does paracetamol cause urothelial cancer or renal papillary necrosis?The risk of developing renal papillary necrosis or cancer of the renal pelvis, ureter or bladder associated with consumption of either phenacetin or paracetamol was calculated from data acquired by questionnaire from 381 cases and 808 controls.",3412544_0,0,-1,0,18173,0
18178,paracetamol,12,13,67,78,"By contrast, we were unable to substantiate an increased risk from paracetamol consumption for renal papillary necrosis or any of these cancers although there was a suggestion of an association with cancer of the ureter.",3412544_2,0,-1,0,18178,0
18200,AE,8,9,43,45,A Cambodian woman with hemoglobin E trait (AE) and leprosy developed a Heinz body hemolytic anemia while taking a dose of dapsone (50 mg/day) not usually associated with clinical hemolysis.,3425586_1,0,-1,0,18200,0
18204,Her,0,1,0,3,"Her red blood cells (RBCs) had increased incubated Heinz body formation, decreased reduced glutathione (GSH), and decreased GSH stability.",3425586_2,0,-1,0,18204,0
18207,reduced glutathione,15,17,83,102,"Her red blood cells (RBCs) had increased incubated Heinz body formation, decreased reduced glutathione (GSH), and decreased GSH stability.",3425586_2,0,-1,0,18207,0
18212,AE,8,9,60,62,The pentose phosphate shunt activity of the dapsone-exposed AE RBCs was increased compared to normal RBCs.,3425586_3,0,-1,0,18212,0
18213,AE,2,3,13,15,"Although the AE RBCs from an individual not taking dapsone had increased incubated Heinz body formation, the GSH content and GSH stability were normal.",3425586_4,0,-1,0,18213,0
18218,AE,8,9,64,66,The pentose phosphate shunt activity of the non-dapsone-exposed AE RBCs was decreased compared to normal RBCs.,3425586_5,0,-1,0,18218,0
18219,AE,2,3,6,8,"Thus, AE RBCs appear to have an increased sensitivity to oxidant stress both in vitro and in vivo, since dapsone does not cause hemolytic anemia at this dose in hematologically normal individuals.",3425586_6,0,-1,0,18219,0
18228,synthase,8,9,61,69,"Recent preclinical and clinical studies with the thymidylate synthase inhibitor N10-propargyl-5,8-dideazafolic acid (CB 3717).CB 3717, N10-propargyl-5,8-dideazafolic acid, is a tight-binding inhibitor of thymidylate synthase (TS) whose cytotoxicity is mediated solely through the inhibition of this enzyme.",3431591_0,0,-1,0,18228,0
18233,synthase,26,27,216,224,"Recent preclinical and clinical studies with the thymidylate synthase inhibitor N10-propargyl-5,8-dideazafolic acid (CB 3717).CB 3717, N10-propargyl-5,8-dideazafolic acid, is a tight-binding inhibitor of thymidylate synthase (TS) whose cytotoxicity is mediated solely through the inhibition of this enzyme.",3431591_0,0,-1,0,18233,0
18236,polyglutamates,12,13,82,96,Recent preclinical studies have focused on the intracellular formation of CB 3717 polyglutamates.,3431591_1,0,-1,0,18236,0
18275,immune globulin,11,13,74,89,Type B hepatitis after needle-stick exposure: prevention with hepatitis B immune globulin.,343678_0,0,-1,0,18275,0
18279,serum globulin,9,11,46,60,"Hepatitis B immune globulin (HBIG) and immune serum globulin (ISG) were examined in a randomized, double-blind trial to assess their relative efficacies in preventing type B hepatitis after needle-stick exposure to hepatitis B surface antigen (HBsAG)-positive donors.",343678_2,0,-1,0,18279,0
18294,DNA polymerase,6,8,39,53,Available donor sera were examined for DNA polymerase (DNAP) and e antigen and antibody (HBeAg; anti-HBE).,343678_5,0,-1,0,18294,0
18296,e antigen,12,14,65,74,Available donor sera were examined for DNA polymerase (DNAP) and e antigen and antibody (HBeAg; anti-HBE).,343678_5,0,-1,0,18296,0
18297,HBeAg,17,18,89,94,Available donor sera were examined for DNA polymerase (DNAP) and e antigen and antibody (HBeAg; anti-HBE).,343678_5,0,-1,0,18297,0
18299,HBeAg,3,4,14,19,Both DNAP and HBeAg showed a highly statistically significant correlation with the infectivity of HBsAg-positive donors.,343678_6,0,-1,0,18299,0
18303,immune globulin,2,4,12,27,Hepatitis B immune globulin remained significantly superior to ISG in preventing type B hepatitis even when the analysis was confined to these two high-risk subgroups.,343678_7,0,-1,0,18303,0
18311,propafenone,17,18,110,121,"Severe complications of antianginal drug therapy in a patient identified as a poor metabolizer of metoprolol, propafenone, diltiazem, and sparteine.",3437726_0,0,-1,0,18311,0
18312,sparteine,22,23,138,147,"Severe complications of antianginal drug therapy in a patient identified as a poor metabolizer of metoprolol, propafenone, diltiazem, and sparteine.",3437726_0,0,-1,0,18312,0
18322,propafenone,16,17,86,97,"Three months later the patient was exposed to a single dose of metoprolol, diltiazem, propafenone (since he had received this drug in the past), and sparteine (as a probe for the debrisoquine/sparteine type polymorphism of oxidative drug metabolism).",3437726_7,0,-1,0,18322,0
18323,sparteine,30,31,149,158,"Three months later the patient was exposed to a single dose of metoprolol, diltiazem, propafenone (since he had received this drug in the past), and sparteine (as a probe for the debrisoquine/sparteine type polymorphism of oxidative drug metabolism).",3437726_7,0,-1,0,18323,0
18379,troleandomycin,5,6,42,56,Jaundice occurred after administration of troleandomycin for 7 days and was associated with hypereosinophilia.,3496378_2,0,-1,0,18379,0
18390,deferoxamine,8,9,63,75,Serial studies of auditory neurotoxicity in patients receiving deferoxamine therapy.,3503576_0,0,-1,0,18390,0
18394,deferoxamine,24,25,181,193,Visual and auditory neurotoxicity was previously documented in 42 of 89 patients with transfusion-dependent anemia who were receiving iron chelation therapy with daily subcutaneous deferoxamine.,3503576_1,0,-1,0,18394,0
18395,deferoxamine,1,2,5,17,"When deferoxamine therapy was discontinued and serial studies were performed, audiograms in seven cases reverted to normal or near normal within two to three weeks, and nine of 13 patients with symptoms became asymptomatic.",3503576_3,0,-1,0,18395,0
18397,deferoxamine,9,10,53,65,"Since 18 of the 22 patients were initially receiving deferoxamine doses in excess of the commonly recommended 50 mg/kg per dose, therapy was restarted with lower doses, usually 50 mg/kg per dose or less depending on the degree of auditory abnormality, and with the exception of two cases no further toxicity was demonstrated.",3503576_5,0,-1,0,18397,0
18401,deferoxamine,14,15,113,125,"Auditory deterioration and improvement, demonstrated serially in individual patients receiving and not receiving deferoxamine, respectively, provided convincing evidence for a cause-and-effect relation between deferoxamine administration and ototoxicity.",3503576_6,0,-1,0,18401,0
18402,deferoxamine,26,27,210,222,"Auditory deterioration and improvement, demonstrated serially in individual patients receiving and not receiving deferoxamine, respectively, provided convincing evidence for a cause-and-effect relation between deferoxamine administration and ototoxicity.",3503576_6,0,-1,0,18402,0
18404,deferoxamine,18,19,105,117,"Based on these data, a plan of management was developed that allows effective yet safe administration of deferoxamine.",3503576_7,0,-1,0,18404,0
18407,deferoxamine,6,7,46,58,Moderate abnormalities require a reduction of deferoxamine to 25 mg/kg per dose with careful monitoring.,3503576_10,0,-1,0,18407,0
18409,at 10,30,32,157,162,"In those with symptoms of hearing loss, the drug should be stopped for four weeks, and when the audiogram is stable or improved, therapy should be restarted at 10 to 25 mg/kg per dose.",3503576_11,0,-1,0,18409,0
18416,tobramycin sulfate,11,13,75,93,We prospectively compared the efficacy and safety of netilmicin sulfate or tobramycin sulfate in conjunction with piperacillin sodium in 118 immunocompromised patients with presumed severe infections.,3535719_1,0,-1,0,18416,0
18417,piperacillin sodium,16,18,114,133,We prospectively compared the efficacy and safety of netilmicin sulfate or tobramycin sulfate in conjunction with piperacillin sodium in 118 immunocompromised patients with presumed severe infections.,3535719_1,0,-1,0,18417,0
18455,nonsteroidal antiinflammatory agents,9,12,63,99,Hyperkalemia has recently been recognized as a complication of nonsteroidal antiinflammatory agents (NSAID) such as indomethacin.,3560096_1,0,-1,0,18455,0
18457,prostacyclin,20,21,122,134,"Several recent studies have stressed the renal sparing features of sulindac, owing to its lack of interference with renal prostacyclin synthesis.",3560096_2,0,-1,0,18457,0
18488,cefonicid,4,5,27,36,The hematologic effects of cefonicid and cefazedone in the dog: a potential model of cephalosporin hematotoxicity in man.,3629586_0,0,-1,0,18488,0
18491,Cephalosporin antibiotics,0,2,0,25,"Cephalosporin antibiotics cause a variety of hematologic disturbances in man, the pathogeneses and hematopathology of which remain poorly characterized.",3629586_1,0,-1,0,18491,0
18499,cefonicid,10,11,69,78,"In four subacute toxicity studies, the intravenous administration of cefonicid or cefazedone to beagle dogs caused a dose-dependent incidence of anemia, neutropenia, and thrombocytopenia after 1-3 months of treatment.",3629586_3,0,-1,0,18499,0
18504,cefonicid,23,24,135,144,A nonregenerative anemia was the most compromising of the cytopenias and occurred in approximately 50% of dogs receiving 400-500 mg/kg cefonicid or 540-840 mg/kg cefazedone.,3629586_4,0,-1,0,18504,0
18509,cefonicid,16,17,105,114,"Upon rechallenge with either cephalosporin, the hematologic syndrome was reproduced in most dogs tested; cefonicid (but not cefazedone)-treated dogs showed a substantially reduced induction period (15 +/- 5 days) compared to that of the first exposure to the drug (61 +/- 24 days).",3629586_6,0,-1,0,18509,0
18513,red cell,11,13,58,66,"This observation, along with the rapid rate of decline in red cell mass parameters of affected dogs, suggests that a hemolytic component complicated the red cell production problem and that multiple toxicologic mechanisms contributed to the cytopenia.",3629586_7,0,-1,0,18513,0
18515,red cell,26,28,153,161,"This observation, along with the rapid rate of decline in red cell mass parameters of affected dogs, suggests that a hemolytic component complicated the red cell production problem and that multiple toxicologic mechanisms contributed to the cytopenia.",3629586_7,0,-1,0,18515,0
18518,cefonicid,9,10,53,62,We conclude that the administration of high doses of cefonicid or cefazedone to dogs can induce hematotoxicity similar to the cephalosporin-induced blood dyscrasias described in man and thus provides a useful model for studying the mechanisms of these disorders.,3629586_8,0,-1,0,18518,0
18529,puromycin aminonucleoside,29,31,180,205,"Acute experimental models of renal damage to the proximal tubular, glomerular, and papillary regions of the rat were produced by administration of hexachloro-1:3-butadiene (HCBD), puromycin aminonucleoside (PAN), and 2-bromoethylamine (BEA), respectively.",3653576_1,0,-1,0,18529,0
18563,paracetamol,19,20,83,94,"Aspirin or salicylate ingestion had occurred in only one of the 20 cases (5%), and paracetamol (acetaminophen) had been administered in only six of the cases (30%).",3670965_3,0,-1,0,18563,0
18571,paracetamol,30,31,138,149,"In Australia, the pediatric usage of aspirin has been extremely low for the past 25 years (less than 1% of total dosage units sold), with paracetamol (acetaminophen) dominating the pediatric analgesic and antipyretic market.",3670965_7,0,-1,0,18571,0
18606,bromocriptine,4,5,32,45,Postpartum psychosis induced by bromocriptine.,3686155_0,0,-1,0,18606,0
18610,bromocriptine,16,17,113,126,"Two multigravida patients with no prior psychiatric history were seen with postpartum psychosis, having received bromocriptine for inhibition of lactation.",3686155_1,0,-1,0,18610,0
18611,Bromocriptine,0,1,0,13,Bromocriptine given in high doses has been associated with psychosis in patients receiving the drug for Parkinson's disease.,3686155_2,0,-1,0,18611,0
18615,bromocriptine,4,5,29,42,These cases demonstrate that bromocriptine may cause psychosis even when given in low doses.,3686155_3,0,-1,0,18615,0
18634,cyclosporine,3,4,12,24,The role of cyclosporine (CSA) alone or in combination with various chemotherapeutics in the development of renal toxicity was evaluated in rats.,3708922_1,0,-1,0,18634,0
18653,esterase,4,5,35,43,The correlation between neurotoxic esterase inhibition and mipafox-induced neuropathic damage in rats.,3714122_0,0,-1,0,18653,0
18657,esterase,9,10,72,80,"The correlation between neuropathic damage and inhibition of neurotoxic esterase or neuropathy target enzyme (NTE) was examined in rats acutely exposed to Mipafox (N, N'-diisopropylphosphorodiamidofluoridate), a neurotoxic organophosphate.",3714122_1,0,-1,0,18657,0
18701,amiloride,28,29,198,207,"Thus, myocardial electrical excitability was measured in patients with mild essential hypertension and known coronary artery disease after 8 weeks of treatment with a potassium-conserving diuretic (amiloride) and a similar period on a potassium-losing diuretic (chlorthalidone) in a randomised study.",3732088_3,0,-1,0,18701,0
18703,amiloride,15,16,107,116,Plasma potassium concentrations were on average 1 mmol/L lower during the chlorthalidone phase compared to amiloride therapy.,3732088_4,0,-1,0,18703,0
18707,amiloride,2,3,12,21,"Compared to amiloride treatment, the chlorthalidone phase was associated with an increased frequency of ventricular ectopic beats (24-hour Holter monitoring) and a higher Lown grading, increased upslope and duration of the monophasic action potential, prolonged ventricular effective refractory period, and increased electrical instability during programmed ventricular stimulation.",3732088_6,0,-1,0,18707,0
18729,Transketolase,0,1,0,13,Transketolase abnormality in tolazamide-induced Wernicke's encephalopathy.,3762968_0,0,-1,0,18729,0
18732,transketolase,6,7,40,53,"We studied a thiamine-dependent enzyme, transketolase, from fibroblasts of a diabetic patient who developed Wernicke's encephalopathy when treated with tolazamide, in order to delineate if this patient also had transketolase abnormality [high Km for thiamine pyrophosphate (TPP)], as previously reported in postalcoholic Wernicke-Korsakoff syndrome.",3762968_1,0,-1,0,18732,0
18735,transketolase,33,34,211,224,"We studied a thiamine-dependent enzyme, transketolase, from fibroblasts of a diabetic patient who developed Wernicke's encephalopathy when treated with tolazamide, in order to delineate if this patient also had transketolase abnormality [high Km for thiamine pyrophosphate (TPP)], as previously reported in postalcoholic Wernicke-Korsakoff syndrome.",3762968_1,0,-1,0,18735,0
18736,thiamine pyrophosphate,39,41,250,272,"We studied a thiamine-dependent enzyme, transketolase, from fibroblasts of a diabetic patient who developed Wernicke's encephalopathy when treated with tolazamide, in order to delineate if this patient also had transketolase abnormality [high Km for thiamine pyrophosphate (TPP)], as previously reported in postalcoholic Wernicke-Korsakoff syndrome.",3762968_1,0,-1,0,18736,0
18742,transketolase,21,22,133,146,We found that the above-mentioned patient and one of the diabetic kindreds with no history of Wernicke's encephalopathy had abnormal transketolase as determined by its Km for TPP.,3762968_3,0,-1,0,18742,0
18745,transketolase,21,22,171,184,These data suggest a similarity between postalcoholic Wernicke-Korsakoff syndrome and the patient with tolazamide-induced Wernicke's encephalopathy from the standpoint of transketolase abnormality.,3762968_4,0,-1,0,18745,0
18751,trihexyphenidyl,5,6,29,44,The reaction was specific to trihexyphenidyl and not to other anticholinergic drugs.,3769769_3,0,-1,0,18751,0
18759,Anti-carcinogenic,0,1,0,17,Anti-carcinogenic action of phenobarbital given simultaneously with diethylnitrosamine in the rat.,3780814_0,0,-1,0,18759,0
18781,dopaminergic,39,40,206,218,"The other rats showed a strong decrease in the rigidity and the occurrence of stereotyped (S) licking and/or gnawing in presence of akinetic or hyperkinetic (K) behaviour (AS/KS group), suggesting signs of dopaminergic activation.",3780846_4,0,-1,0,18781,0
18782,dopaminergic,21,22,96,108,"In a further series of experiments, haloperidol (0.2 mg/kg i.p.) was used in order to block the dopaminergic activation and to estimate the real degree of the tolerance to the rigidity without any dopaminergic interference.",3780846_6,0,-1,0,18782,0
18783,dopaminergic,37,38,197,209,"In a further series of experiments, haloperidol (0.2 mg/kg i.p.) was used in order to block the dopaminergic activation and to estimate the real degree of the tolerance to the rigidity without any dopaminergic interference.",3780846_6,0,-1,0,18783,0
18787,dopaminergic,29,30,153,165,"The results suggest that rigidity, which is assumed to be due to an action of morphine in the striatum, can be antagonized by another process leading to dopaminergic activation in the striatum.",3780846_9,0,-1,0,18787,0
18789,dopaminergic,9,10,52,64,The rapid alternations of rigidity and the signs of dopaminergic activation observed in the animals of the AS/KS group might be due to rapid shifts in the predominance of various DA-innervated structures.,3780846_11,0,-1,0,18789,0
18844,ethambutol,6,7,43,53,Bilateral optic neuropathy due to combined ethambutol and isoniazid treatment.,384871_0,0,-1,0,18844,0
18846,ethambutol,17,18,116,126,The case of a 40-year-old patient who underwent an unsuccessful cadaver kidney transplantation and was treated with ethambutol and isoniazid is reported.,384871_1,0,-1,0,18846,0
18849,Ethambutol,0,1,0,10,Ethambutol was stopped and only small improvement of the visual acuity followed.,384871_3,0,-1,0,18849,0
18854,ethambutol,8,9,43,53,The hazards of optic nerve toxicity due to ethambutol are known.,384871_5,0,-1,0,18854,0
18855,ethambutol,9,10,48,58,We emphasize the potential danger in the use of ethambutol and isoniazid.,384871_6,0,-1,0,18855,0
18867,Leucovorin,0,1,0,10,"Leucovorin rescue was initiated 12 hours after the end of the infusion with a loading dose of 200 mg/m2 followed by 12 mg/m2 every three hours for six doses and then every six hours until the plasma methotrexate level decreased to less than 1 X 10(-7) mol/L. The mean steady-state plasma and CSF methotrexate concentrations achieved were 1.1 X 10(-3) mol/L and 3.6 X 10(-5) mol/L, respectively.",3856631_3,0,-1,0,18867,0
18881,cyclosporin A,2,4,15,28,Interaction of cyclosporin A with antineoplastic agents.,3865016_0,0,-1,0,18881,0
18882,antineoplastic agents,5,7,34,55,Interaction of cyclosporin A with antineoplastic agents.,3865016_0,0,-1,0,18882,0
18883,etoposide,4,5,24,33,A synergistic effect of etoposide and cyclosporin A was observed in a patient with acute T-lymphocytic leukemia in relapse.,3865016_1,0,-1,0,18883,0
18884,cyclosporin A,6,8,38,51,A synergistic effect of etoposide and cyclosporin A was observed in a patient with acute T-lymphocytic leukemia in relapse.,3865016_1,0,-1,0,18884,0
18886,etoposide,4,5,34,43,The concomitant administration of etoposide and cyclosporin A resulted in eradication of hitherto refractory leukemic infiltration of bone marrow.,3865016_2,0,-1,0,18886,0
18887,cyclosporin A,6,8,48,61,The concomitant administration of etoposide and cyclosporin A resulted in eradication of hitherto refractory leukemic infiltration of bone marrow.,3865016_2,0,-1,0,18887,0
18894,cyclosporin A,12,14,83,96,This report demonstrates for the first time that the pharmacodynamic properties of cyclosporin A may not be confined strictly to suppression of normal T-cell functions.,3865016_4,0,-1,0,18894,0
18905,(1,25,27,111,113,"Reactions included thrombophlebitis (20 of 54 patients), rash (4 of 54), nephrotoxicity (4 of 50), proteinuria (1 of 50) and ototoxicity (1 of 11 patients tested by audiometry).",3934126_4,0,-1,0,18905,0
18910,aminoglycoside,18,19,144,158,Thrombophlebitis occurred only with infusion through peripheral cannulae; nephrotoxicity and ototoxicity were confined to patients receiving an aminoglycoside plus vancomycin.,3934126_5,0,-1,0,18910,0
18914,amikacin,10,11,82,90,Factors associated with nephrotoxicity and clinical outcome in patients receiving amikacin.,3950060_0,0,-1,0,18914,0
18916,amikacin,6,7,35,43,Data from 60 patients treated with amikacin were analyzed for factors associated with nephrotoxicity.,3950060_1,0,-1,0,18916,0
18923,creatinine,14,15,79,89,"Variables evaluated included patient weight, age, sex, serum creatinine level, creatinine clearance, duration of therapy, total dose, mean daily dose, organism minimum inhibitory concentration (MIC), mean peak levels, mean trough levels, mean area under the serum concentration-time curve (AUC), total AUC, mean AUC greater than MIC, total AUC greater than MIC, mean Schumacher's intensity factor (IF), total IF, In (mean maximum concentration [Cmax]/MIC).",3950060_3,0,-1,0,18923,0
18975,calcium antagonists,18,20,96,115,"These data suggest that coronary spasm may be the cause of cardiotoxicity due to 5-FU, and that calcium antagonists may probably be used in the prevention or treatment of 5-FU cardiotoxicity.",3952818_4,0,-1,0,18975,0
18984,DFP,15,16,91,94,"Tri-ortho-tolyl phosphate (TOTP), 360 mg/kg, po, and 0,0'-diisopropyl phosphorofluoridate (DFP), 1 mg/kg sc, were administered to adult White Leghorn chickens 24 hr after they were placed on diets containing 0 to 300 ppm corticosterone.",3961813_1,0,-1,0,18984,0
18991,DFP,37,38,221,224,"Although low concentrations (less than or equal to 50 ppm) of corticosterone had beneficial effects on TOTP-induced neuropathy, greater than or equal to 200 ppm exacerbated clinical signs in chickens given either TOTP or DFP.",3961813_3,0,-1,0,18991,0
18992,esterase,1,2,11,19,Neurotoxic esterase activities 24 hr after TOTP or DFP were less than 20% of values measured in chickens not given organophosphorous compounds.,3961813_4,0,-1,0,18992,0
18994,DFP,8,9,51,54,Neurotoxic esterase activities 24 hr after TOTP or DFP were less than 20% of values measured in chickens not given organophosphorous compounds.,3961813_4,0,-1,0,18994,0
18997,DFP,8,9,54,57,Chickens given 200 ppm corticosterone without TOTP or DFP had significantly elevated activity of plasma cholinesterase and significantly inhibited activity of liver carboxylesterase.,3961813_5,0,-1,0,18997,0
18998,carboxylesterase,22,23,165,181,Chickens given 200 ppm corticosterone without TOTP or DFP had significantly elevated activity of plasma cholinesterase and significantly inhibited activity of liver carboxylesterase.,3961813_5,0,-1,0,18998,0
19002,DFP,18,19,117,120,Degenerating myelinated fibers were also evident in distal levels of the peripheral nerves of chickens given TOTP or DFP.,3961813_6,0,-1,0,19002,0
19016,dietary fat,5,7,40,51,Promotional effects of testosterone and dietary fat on prostate carcinogenesis in genetically susceptible rats.,3969369_0,0,-1,0,19016,0
19026,corn oil,18,20,120,128,"Preliminary results indicate that testosterone-treated LW rats that were fed the same diet, which was supplemented with corn oil up to 20% fat, developed prostate cancer after intervals of 6-12 months.",3969369_3,0,-1,0,19026,0
19040,folic acid,22,24,133,143,"The drugs commonly used are cyclophosphamide and chlorambucil (alkylating agents), azathioprine (purine analogue), and methotrexate (folic acid analogue).",3970039_2,0,-1,0,19040,0
19103,her,12,13,80,83,"An elderly patient treated with low dose Desipramine developed a delirium while her plasma level was in the ""subtherapeutic"" range.",4027862_1,0,-1,0,19103,0
19112,Local anesthetics,0,2,0,17,"Local anesthetics that are commonly used in ophthalmic surgery (0.75% bupivacaine hydrochloride, 2.0% mepivacaine hydrochloride, and 2.0% lidocaine hydrochloride plus 1:100,000 epinephrine) were injected into the retrobulbar area of rat eyes.",4038130_2,0,-1,0,19112,0
19114,bupivacaine hydrochloride,12,14,70,95,"Local anesthetics that are commonly used in ophthalmic surgery (0.75% bupivacaine hydrochloride, 2.0% mepivacaine hydrochloride, and 2.0% lidocaine hydrochloride plus 1:100,000 epinephrine) were injected into the retrobulbar area of rat eyes.",4038130_2,0,-1,0,19114,0
19115,mepivacaine hydrochloride,17,19,102,127,"Local anesthetics that are commonly used in ophthalmic surgery (0.75% bupivacaine hydrochloride, 2.0% mepivacaine hydrochloride, and 2.0% lidocaine hydrochloride plus 1:100,000 epinephrine) were injected into the retrobulbar area of rat eyes.",4038130_2,0,-1,0,19115,0
19116,lidocaine hydrochloride,23,25,138,161,"Local anesthetics that are commonly used in ophthalmic surgery (0.75% bupivacaine hydrochloride, 2.0% mepivacaine hydrochloride, and 2.0% lidocaine hydrochloride plus 1:100,000 epinephrine) were injected into the retrobulbar area of rat eyes.",4038130_2,0,-1,0,19116,0
19133,periodic acid,1,3,9,22,"Numerous periodic acid Schiff (PAS) positive, diastase resistant cytoplasmic inclusion bodies which appeared as myelin figures in cytosegresomes under the electron microscope were identified in the proximal convoluted tubules.",4069770_3,0,-1,0,19133,0
19152,nonsteroidal anti-inflammatory agents,1,4,6,43,"Since nonsteroidal anti-inflammatory agents interfere with this compensatory mechanism and may cause acute renal failure, they should be used with caution in such patients.",4071154_4,0,-1,0,19152,0
19156,paracetamol,2,3,13,24,Induction by paracetamol of bladder and liver tumours in the rat.,4090988_0,0,-1,0,19156,0
19159,paracetamol,19,20,97,108,Groups of male and female inbred Leeds strain rats were fed diets containing either 0.5% or 1.0% paracetamol by weight for up to 18 months.,4090988_2,0,-1,0,19159,0
19170,paracetamol,12,13,67,78,A low yield of tumours at various other sites also arose following paracetamol feeding.,4090988_8,0,-1,0,19170,0
19209,Suxamethonium,0,1,0,13,Suxamethonium infusion rate and observed fasciculations.,435349_0,0,-1,0,19209,0
19211,Suxamethonium chloride,0,2,0,22,Suxamethonium chloride (Sch) was administered i.v. to 36 adult males at six rates: 0.25 mg s-1 to 20 mg s-1.,435349_2,0,-1,0,19211,0
19212,Sch,3,4,24,27,Suxamethonium chloride (Sch) was administered i.v. to 36 adult males at six rates: 0.25 mg s-1 to 20 mg s-1.,435349_2,0,-1,0,19212,0
19218,Sch,20,21,123,126,The infusion was discontinued either when there was no muscular response to tetanic stimulation of the ulnar nerve or when Sch 120 mg was exceeded.,435349_3,0,-1,0,19218,0
19225,Tiapride,0,1,0,8,Tiapride in levodopa-induced involuntary movements.,458486_0,0,-1,0,19225,0
19228,Tiapride,0,1,0,8,"Tiapride, a substituted benzamide derivative closely related to metoclopramide, reduced levodopa-induced peak dose involuntary movements in 16 patients with idiopathic Parkinson's disease.",458486_1,0,-1,0,19228,0
19230,metoclopramide,9,10,64,78,"Tiapride, a substituted benzamide derivative closely related to metoclopramide, reduced levodopa-induced peak dose involuntary movements in 16 patients with idiopathic Parkinson's disease.",458486_1,0,-1,0,19230,0
19236,Tiapride,0,1,0,8,"Tiapride had no effect on levodopa-induced early morning of ""off-period"" segmental dystonia.",458486_3,0,-1,0,19236,0
19249,SGOT,13,14,106,110,"Long-term administration of quinidine was associated with persistent elevation of serum concentrations of SGOT, lactic acid dehydrogenase, and alkaline phosphatase.",48362_1,0,-1,0,19249,0
19257,SGOT,12,13,79,83,"A challenge dose of quinidine caused clinical symptoms and abrupt elevation of SGOT, alkaline phosphatase, and lactic acid dehydrogenase values.",48362_4,0,-1,0,19257,0
19279,platelet aggregation,9,11,83,103,The common factor relating thromboembolism and thrombocytopenia is heparin-induced platelet aggregation.,591536_5,0,-1,0,19279,0
19283,anticholinesterase drug,6,8,43,66,"Galanthamine hydrobromide, a longer acting anticholinesterase drug, in the treatment of the central effects of scopolamine (Hyoscine).Galanthamine hydrobromide, an anticholinesterase drug capable of penetrating the blood-brain barrier, was used in a patient demonstrating central effects of scopolamine (hyoscine) overdosage.",603022_0,0,-1,0,19283,0
19286,anticholinesterase drug,22,24,164,187,"Galanthamine hydrobromide, a longer acting anticholinesterase drug, in the treatment of the central effects of scopolamine (Hyoscine).Galanthamine hydrobromide, an anticholinesterase drug capable of penetrating the blood-brain barrier, was used in a patient demonstrating central effects of scopolamine (hyoscine) overdosage.",603022_0,0,-1,0,19286,0
19292,flunitrazepam,2,3,18,31,administration of flunitrazepam in volunteers.,6103707_1,0,-1,0,19292,0
19293,Flunitrazepam,0,1,0,13,"Flunitrazepam 0.5, 1.0 or 2.0 mg was given by the oral or i.m.",6103707_2,0,-1,0,19293,0
19297,i.m.,3,5,15,19,The effects of i.m. administration were apparent earlier and sometimes lasted longer than those following oral administration.,6103707_6,0,-1,0,19297,0
19299,flunitrazepam,2,3,13,26,injection of flunitrazepam significantly more often than with isotonic saline.,6103707_9,0,-1,0,19299,0
19308,propranolol,18,19,89,100,"The compound GYKI-41 099, as a beta-adrenergic antagonist, is 3-8 times more potent than propranolol in vitro and in vivo.",6111982_1,0,-1,0,19308,0
19312,propranolol,6,7,51,62,Its antiarrhythmic effectiveness surpasses that of propranolol and pindolol inhibiting the ouabain arrhythmia in dogs and cats.,6111982_2,0,-1,0,19312,0
19320,bendrofluazide,3,4,21,35,Adverse reactions to bendrofluazide and propranolol for the treatment of mild hypertension.,6115999_0,0,-1,0,19320,0
19321,propranolol,5,6,40,51,Adverse reactions to bendrofluazide and propranolol for the treatment of mild hypertension.,6115999_0,0,-1,0,19321,0
19327,bendrofluazide,21,22,139,153,"Participants in the Medical Research Council treatment trial for mild hypertension are randomly allocated to one of four treatment groups: bendrofluazide, propranolol, or a placebo for either of these drugs.",6115999_2,0,-1,0,19327,0
19328,propranolol,23,24,155,166,"Participants in the Medical Research Council treatment trial for mild hypertension are randomly allocated to one of four treatment groups: bendrofluazide, propranolol, or a placebo for either of these drugs.",6115999_2,0,-1,0,19328,0
19331,bendrofluazide,6,7,40,54,"The results show an association between bendrofluazide treatment and impotence, and impotence also occurred more frequently in patients taking propranolol than in those taking placebos.",6115999_5,0,-1,0,19331,0
19332,propranolol,20,21,143,154,"The results show an association between bendrofluazide treatment and impotence, and impotence also occurred more frequently in patients taking propranolol than in those taking placebos.",6115999_5,0,-1,0,19332,0
19337,bendrofluazide,23,24,148,162,"Other adverse reactions significantly linked with active drugs include impaired glucose tolerance in men and women and gout in men, associated with bendrofluazide treatment, and Raynaud's phenomenon and dyspnoea in men and women taking propranolol.",6115999_6,0,-1,0,19337,0
19339,propranolol,37,38,236,247,"Other adverse reactions significantly linked with active drugs include impaired glucose tolerance in men and women and gout in men, associated with bendrofluazide treatment, and Raynaud's phenomenon and dyspnoea in men and women taking propranolol.",6115999_6,0,-1,0,19339,0
19340,propranolol,10,11,52,63,No corneal disease is known to have occurred in the propranolol group.,6115999_7,0,-1,0,19340,0
19342,uric acid,9,11,46,55,"Mean serum potassium level fell, and urea and uric acid levels rose, in men and women taking bendrofluazide.",6115999_8,0,-1,0,19342,0
19343,bendrofluazide,19,20,93,107,"Mean serum potassium level fell, and urea and uric acid levels rose, in men and women taking bendrofluazide.",6115999_8,0,-1,0,19343,0
19344,propranolol,2,3,7,18,"In the propranolol group, serum potassium and uric acid levels rose in both sexes, but the urea level rose significantly in women only.",6115999_9,0,-1,0,19344,0
19346,uric acid,8,10,46,55,"In the propranolol group, serum potassium and uric acid levels rose in both sexes, but the urea level rose significantly in women only.",6115999_9,0,-1,0,19346,0
19347,Serotonergic drugs,0,2,0,18,"Serotonergic drugs, benzodiazepines and baclofen block muscimol-induced myoclonic jerks in a strain of mice.",6118280_0,0,-1,0,19347,0
19348,baclofen,5,6,40,48,"Serotonergic drugs, benzodiazepines and baclofen block muscimol-induced myoclonic jerks in a strain of mice.",6118280_0,0,-1,0,19348,0
19352,muscimol,5,6,20,28,"In male Swiss mice, muscimol produced myoclonic jerks.",6118280_1,0,-1,0,19352,0
19357,muscimol,29,30,188,196,Increasing the brain serotonin levels by the administration of 5-hydroxytryptophan (80-160 mg/kg) in combination with a peripheral decarboxylase inhibitor resulted in an inhibition of the muscimol effect.,6118280_3,0,-1,0,19357,0
19362,clonazepam,4,5,24,34,"Of the benzodiazepines, clonazepam (0.1-0.3 mg/kg) was found to be several fold more potent than diazepam (0.3-3 mg/kg) in blocking the myoclonic jerks.",6118280_6,0,-1,0,19362,0
19365,muscimol,15,16,71,79,"While (-)-baclofen (1-3 mg/kg) proved to be an effective antagonist of muscimol, its (+)-isomer (5-20 mg/kg) lacked this property.",6118280_7,0,-1,0,19365,0
19366,(+)-isomer,18,19,85,95,"While (-)-baclofen (1-3 mg/kg) proved to be an effective antagonist of muscimol, its (+)-isomer (5-20 mg/kg) lacked this property.",6118280_7,0,-1,0,19366,0
19370,(-)-baclofen,10,11,61,73,Our present study indicated the possible value of MK-212 and (-)-baclofen in the management of clinical myoclonus.,6118280_9,0,-1,0,19370,0
19387,sulphasalazine,3,4,27,41,Possible teratogenicity of sulphasalazine.,6133211_0,0,-1,0,19387,0
19389,sulphasalazine,15,16,95,109,"Three infants, born of two mothers with inflammatory bowel disease who received treatment with sulphasalazine throughout pregnancy, were found to have major congenital anomalies.",6133211_1,0,-1,0,19389,0
19403,sulphasalazine,10,11,54,68,"Despite reports to the contrary, it is suggested that sulphasalazine may be teratogenic.",6133211_6,0,-1,0,19403,0
19414,anticholinergic agents,8,10,44,66,"The actions of both drugs were increased by anticholinergic agents, and there was a close correlation between the daily maintenance dose of each drug needed to control acid secretion.",6150641_4,0,-1,0,19414,0
19447,cisplatin,24,25,191,200,"Five patients with carcinoma developed thrombotic microangiopathy (characterized by renal insufficiency, microangiopathic hemolytic anemia, and usually thrombocytopenia) after treatment with cisplatin, bleomycin, and a vinca alkaloid.",6203452_1,0,-1,0,19447,0
19448,bleomycin,26,27,202,211,"Five patients with carcinoma developed thrombotic microangiopathy (characterized by renal insufficiency, microangiopathic hemolytic anemia, and usually thrombocytopenia) after treatment with cisplatin, bleomycin, and a vinca alkaloid.",6203452_1,0,-1,0,19448,0
19474,(1,9,11,61,63,Ventricular DNA content was unchanged during the early stage (1-4 days) of hypertrophic growth but increased to a new steady-state level 19% above the controls after 8 days of treatment.,6203632_7,0,-1,0,19474,0
19544,Vitamin D3,0,2,0,10,Vitamin D3 toxicity in dairy cows.,6286738_0,0,-1,0,19544,0
19547,vitamin D3,4,6,26,36,"Large parenteral doses of vitamin D3 (15 to 17.5 x 10(6) IU vitamin D3) were associated with prolonged hypercalcemia, hyperphosphatemia, and large increases of vitamin D3 and its metabolites in the blood plasma of nonlactating nonpregnant and pregnant Jersey cows.",6286738_1,0,-1,0,19547,0
19549,vitamin D3,14,16,60,70,"Large parenteral doses of vitamin D3 (15 to 17.5 x 10(6) IU vitamin D3) were associated with prolonged hypercalcemia, hyperphosphatemia, and large increases of vitamin D3 and its metabolites in the blood plasma of nonlactating nonpregnant and pregnant Jersey cows.",6286738_1,0,-1,0,19549,0
19552,vitamin D3,29,31,160,170,"Large parenteral doses of vitamin D3 (15 to 17.5 x 10(6) IU vitamin D3) were associated with prolonged hypercalcemia, hyperphosphatemia, and large increases of vitamin D3 and its metabolites in the blood plasma of nonlactating nonpregnant and pregnant Jersey cows.",6286738_1,0,-1,0,19552,0
19558,vitamin D3,11,13,73,83,Calcium concentrations 1 day postpartum were higher in cows treated with vitamin D3 about 32 days prepartum (8.8 mg/100 ml) than in control cows (5.5 mg/100 ml).,6286738_2,0,-1,0,19558,0
19561,vitamin D3,6,8,30,40,"None of the cows treated with vitamin D3 showed signs of milk fever during the peripartal period; however, 22% of the control cows developed clinical signs of milk fever during this period.",6286738_3,0,-1,0,19561,0
19566,vitamin D3,2,4,9,19,"Signs of vitamin D3 toxicity were not observed in nonlactating nonpregnant cows; however, pregnant cows commonly developed severe signs of vitamin D3 toxicity and 10 of 17 cows died.",6286738_4,0,-1,0,19566,0
19569,vitamin D3,22,24,139,149,"Signs of vitamin D3 toxicity were not observed in nonlactating nonpregnant cows; however, pregnant cows commonly developed severe signs of vitamin D3 toxicity and 10 of 17 cows died.",6286738_4,0,-1,0,19569,0
19571,vitamin D3,6,8,35,45,"Because of the extreme toxicity of vitamin D3 in pregnant Jersey cows and the low margin of safety between doses of vitamin D3 that prevent milk fever and doses that induce milk fever, we concluded that vitamin D3 cannot be used practically to prevent milk fever when injected several weeks prepartum.",6286738_6,0,-1,0,19571,0
19574,vitamin D3,21,23,116,126,"Because of the extreme toxicity of vitamin D3 in pregnant Jersey cows and the low margin of safety between doses of vitamin D3 that prevent milk fever and doses that induce milk fever, we concluded that vitamin D3 cannot be used practically to prevent milk fever when injected several weeks prepartum.",6286738_6,0,-1,0,19574,0
19577,vitamin D3,37,39,203,213,"Because of the extreme toxicity of vitamin D3 in pregnant Jersey cows and the low margin of safety between doses of vitamin D3 that prevent milk fever and doses that induce milk fever, we concluded that vitamin D3 cannot be used practically to prevent milk fever when injected several weeks prepartum.",6286738_6,0,-1,0,19577,0
19624,DOPAC,17,18,107,112,Moreover calcitonin induced a significant decrease in nigral GAD activity but no change in striatal DA and DOPAC concentration or GAD activity.,6293644_4,0,-1,0,19624,0
19628,GABAergic,15,16,89,98,The results are discussed in view of a primary action of calcitonin on the striatonigral GABAergic pathway mediating the DA-related behavioral messages of striatal origin.,6293644_5,0,-1,0,19628,0
19633,stimulatory,8,9,54,65,"Because salicylates have been reported to augment the stimulatory effects of caffeine on the CNS, attention was focused on the possibility that the presence of acetaminophen (52 micrograms/mL) reduced the CNS toxicity of caffeine.",6308277_2,0,-1,0,19633,0
19639,convulsant,27,28,142,152,"In the absence of caffeine, acetaminophen (up to 300 mg/kg) did not modify the seizures induced by maximal electroshock and did not alter the convulsant dose of pentylenetetrezol in mice (tests performed by the Anticonvulsant Screening Project of NINCDS).",6308277_5,0,-1,0,19639,0
19651,opioid receptors,26,28,169,185,"Behavioral and cardiorespiratory responses to a lethal dose of morphine were evaluated in rats pretreated with saline or naloxazone, an antagonist of high-affinity mu 1 opioid receptors.",6308526_1,0,-1,0,19651,0
19660,mu receptors,5,7,40,52,Results indicate that subpopulations of mu receptors may mediate selective behavioral and cardiorespiratory responses to morphine.,6308526_4,0,-1,0,19660,0
19687,calcium channels,6,8,44,60,These results suggested that ammonia blocks calcium channels.,6323692_5,0,-1,0,19687,0
19694,convulsant,31,32,225,235,"Both verapamil (10 mg/kg i.p.) and NH4Ac pretreatment enhanced morphine analgesia- and diazepam-induced muscular incoordination and antagonized amphetamine-induced motor activity, and neither verapamil nor NH4Ac affected the convulsant action of metrazol.",6323692_7,0,-1,0,19694,0
19696,calcium channel,7,9,46,61,The data suggest that hyperammonemia exerts a calcium channel blocking action which enhances the effects of central nervous system depressants and certain opioid analgesics.,6323692_8,0,-1,0,19696,0
19699,opioid analgesics,22,24,155,172,The data suggest that hyperammonemia exerts a calcium channel blocking action which enhances the effects of central nervous system depressants and certain opioid analgesics.,6323692_8,0,-1,0,19699,0
19710,dothiepin hydrochloride,9,11,51,74,A double-blind study of the efficacy and safety of dothiepin hydrochloride in the treatment of major depressive disorder.,6386793_0,0,-1,0,19710,0
19714,dothiepin,8,9,51,60,"In a 6-week double-blind parallel treatment study, dothiepin and amitriptyline were compared to placebo in the treatment of 33 depressed outpatients.",6386793_1,0,-1,0,19714,0
19716,Dothiepin,0,1,0,9,"Dothiepin and amitriptyline were equally effective in alleviating the symptoms of depressive illness, and both were significantly superior to placebo.",6386793_2,0,-1,0,19716,0
19721,dothiepin,24,25,143,152,"The overall incidence of side effects and the frequency and severity of blurred vision, dry mouth, and drowsiness were significantly less with dothiepin than with amitriptyline.",6386793_3,0,-1,0,19721,0
19722,Dothiepin,0,1,0,9,Dothiepin also produced fewer CNS and cardiovascular effects.,6386793_4,0,-1,0,19722,0
19725,Dothiepin,0,1,0,9,Dothiepin thus was found to be an effective antidepressant drug associated with fewer side effects than amitriptyline in the treatment of depressed outpatients.,6386793_6,0,-1,0,19725,0
19729,propranolol,5,6,35,46,Behavioral effects of diazepam and propranolol in patients with panic disorder and agoraphobia.,6387529_0,0,-1,0,19729,0
19734,propranolol,25,26,108,119,"The effects of oral doses of diazepam (single dose of 10 mg and a median dose of 30 mg/day for 2 weeks) and propranolol (single dose of 80 mg and a median dose of 240 mg/day for 2 weeks) on psychological performance of patients with panic disorders and agoraphobia were investigated in a double-blind, randomized and crossover design.",6387529_1,0,-1,0,19734,0
19740,propranolol,14,15,89,100,Both drugs impaired immediate free recall but the decrease was greater for diazepam than propranolol.,6387529_2,0,-1,0,19740,0
19743,propranolol,4,5,29,40,Patients tapped faster after propranolol than diazepam and they were more sedated after diazepam than propranolol.,6387529_4,0,-1,0,19743,0
19744,propranolol,15,16,102,113,Patients tapped faster after propranolol than diazepam and they were more sedated after diazepam than propranolol.,6387529_4,0,-1,0,19744,0
19750,sodium 2-mercaptoethane sulphonate,9,12,78,112,Treatment of ifosfamide-induced urothelial toxicity by oral administration of sodium 2-mercaptoethane sulphonate (MESNA) to patients with inoperable lung cancer.,6402369_0,0,-1,0,19750,0
19751,MESNA,13,14,114,119,Treatment of ifosfamide-induced urothelial toxicity by oral administration of sodium 2-mercaptoethane sulphonate (MESNA) to patients with inoperable lung cancer.,6402369_0,0,-1,0,19751,0
19755,thiol,8,9,52,57,The protective effect of oral administration of the thiol compound sodium 2-mercaptoethane sulphonate (MESNA) against urothelial toxicity induced by ifosfamide (IF) was tested in a group of 45 patients with inoperable lung cancer under treatment with IF (2250 mg/m2 on days 2-5) as part of a polychemotherapy regimen repeated in a 4-week cycle.,6402369_1,0,-1,0,19755,0
19756,sodium 2-mercaptoethane sulphonate,10,13,67,101,The protective effect of oral administration of the thiol compound sodium 2-mercaptoethane sulphonate (MESNA) against urothelial toxicity induced by ifosfamide (IF) was tested in a group of 45 patients with inoperable lung cancer under treatment with IF (2250 mg/m2 on days 2-5) as part of a polychemotherapy regimen repeated in a 4-week cycle.,6402369_1,0,-1,0,19756,0
19757,MESNA,14,15,103,108,The protective effect of oral administration of the thiol compound sodium 2-mercaptoethane sulphonate (MESNA) against urothelial toxicity induced by ifosfamide (IF) was tested in a group of 45 patients with inoperable lung cancer under treatment with IF (2250 mg/m2 on days 2-5) as part of a polychemotherapy regimen repeated in a 4-week cycle.,6402369_1,0,-1,0,19757,0
19759,ifosfamide,21,22,149,159,The protective effect of oral administration of the thiol compound sodium 2-mercaptoethane sulphonate (MESNA) against urothelial toxicity induced by ifosfamide (IF) was tested in a group of 45 patients with inoperable lung cancer under treatment with IF (2250 mg/m2 on days 2-5) as part of a polychemotherapy regimen repeated in a 4-week cycle.,6402369_1,0,-1,0,19759,0
19765,MESNA,0,1,0,5,"MESNA was given orally on the days of treatment with IF in 3 doses of 840 mg/m2, each administered at 0 hr (= injection of IF), 4 hr and 8 hr p.i.",6402369_2,0,-1,0,19765,0
19770,MESNA,9,10,51,56,In this group of 45 patients under protection with MESNA there were 5 complete remissions and 9 partial remissions (total 31%).,6402369_4,0,-1,0,19770,0
19781,MESNA,7,8,50,55,There were no appreciable differences between the MESNA series and the conventional prophylaxis series with respect to either haematological or systemic toxicity of the cytostatic treatment.,6402369_7,0,-1,0,19781,0
19784,MESNA,6,7,34,39,"Our results support the view that MESNA, given orally in conjunction with combined cytostatic regimens which include IF, simplifies the treatment and provides optimum protection for the urinary epithelium.",6402369_8,0,-1,0,19784,0
19788,MESNA,3,4,21,26,Protection with oral MESNA is particularly suitable for outpatients.,6402369_9,0,-1,0,19788,0
19800,synthetase,3,4,24,34,Effect of prostaglandin synthetase inhibitors on experimentally induced convulsions in rats.,6433367_0,0,-1,0,19800,0
19803,synthetase,18,19,100,110,"To investigate the relationship of prostaglandins (PGs) to seizure induction, the effects of six PG synthetase inhibitors on convulsions induced by flurothyl, picrotoxin, pentetrazol (PTZ), electroshock or bicuculline were evaluated.",6433367_1,0,-1,0,19803,0
19804,flurothyl,24,25,148,157,"To investigate the relationship of prostaglandins (PGs) to seizure induction, the effects of six PG synthetase inhibitors on convulsions induced by flurothyl, picrotoxin, pentetrazol (PTZ), electroshock or bicuculline were evaluated.",6433367_1,0,-1,0,19804,0
19809,mefenamic acid,4,6,21,35,"Ibuprofen, sulindac, mefenamic acid, and low dose meclofenamic acid increased the latency-to-onset in the flurothyl and/or PTZ models; the electroshock, picrotoxin and bicuculline models were not significantly affected by any of the pretreatment agents.",6433367_2,0,-1,0,19809,0
19812,flurothyl,17,18,106,115,"Ibuprofen, sulindac, mefenamic acid, and low dose meclofenamic acid increased the latency-to-onset in the flurothyl and/or PTZ models; the electroshock, picrotoxin and bicuculline models were not significantly affected by any of the pretreatment agents.",6433367_2,0,-1,0,19812,0
19821,valproic acid,11,13,73,86,Acute changes of blood ammonia may predict short-term adverse effects of valproic acid.,6436733_0,0,-1,0,19821,0
19822,Valproic acid,0,2,0,13,Valproic acid (VPA) was given to 24 epileptic patients who were already being treated with other antiepileptic drugs.,6436733_1,0,-1,0,19822,0
19826,antiepileptic drugs,18,20,97,116,Valproic acid (VPA) was given to 24 epileptic patients who were already being treated with other antiepileptic drugs.,6436733_1,0,-1,0,19826,0
19846,puromycin aminonucleoside,15,17,107,132,"Also, captopril treatment failed to potentiate or facilitate development of massive proteinuria invoked by puromycin aminonucleoside in SHR.",6454943_4,0,-1,0,19846,0
19848,creatinine,21,22,138,148,"Captopril had little or no demonstrable effects on serum electrolyte concentrations, excretion of urine, sodium and potassium, endogenous creatinine clearance, body weight, and food and water consumption.",6454943_5,0,-1,0,19848,0
19851,ketone bodies,2,4,9,22,"However, ketone bodies were consistently present in urine and several lethalities occurred during multiple dosing of captopril in SHR.",6454943_6,0,-1,0,19851,0
19853,glycopyrrolate,0,1,0,14,glycopyrrolate and atropine in the prevention of bradycardia and arrhythmias following repeated doses of suxamethonium in children.,6466532_1,0,-1,0,19853,0
19854,suxamethonium,14,15,105,118,glycopyrrolate and atropine in the prevention of bradycardia and arrhythmias following repeated doses of suxamethonium in children.,6466532_1,0,-1,0,19854,0
19855,glycopyrrolate,5,6,39,53,The effectiveness of administration of glycopyrrolate 5 and 10 micrograms kg-1 and atropine 10 and 20 micrograms kg-1 i.v.,6466532_2,0,-1,0,19855,0
19858,suxamethonium,16,17,115,128,"immediately before the induction of anaesthesia, to prevent arrhythmia and bradycardia following repeated doses of suxamethonium in children, was studied.",6466532_3,0,-1,0,19858,0
19860,glycopyrrolate,13,14,73,87,A control group was included for comparison with the lower dose range of glycopyrrolate and atropine.,6466532_4,0,-1,0,19860,0
19866,glycopyrrolate,5,6,30,44,"It is recommended that either glycopyrrolate 10 micrograms kg-1 or atropine 20 micrograms kg-1 i.v. should immediately precede induction of anaesthesia, in children, if the repeated administration of suxamethonium is anticipated.",6466532_7,0,-1,0,19866,0
19869,suxamethonium,31,32,200,213,"It is recommended that either glycopyrrolate 10 micrograms kg-1 or atropine 20 micrograms kg-1 i.v. should immediately precede induction of anaesthesia, in children, if the repeated administration of suxamethonium is anticipated.",6466532_7,0,-1,0,19869,0
19876,dacarbazine,4,5,35,46,Veno-occlusive liver disease after dacarbazine therapy (DTIC) for melanoma.,6503301_0,0,-1,0,19876,0
19878,dacarbazine,12,13,71,82,A case of veno-occlusive disease of the liver with fatal outcome after dacarbazine (DTIC) therapy for melanoma is reported.,6503301_1,0,-1,0,19878,0
19888,anticonvulsant drugs,8,10,45,65,Phenobarbital should be added to the list of anticonvulsant drugs that can cause movement disorders.,6504332_4,0,-1,0,19888,0
19918,organic solvent,6,8,28,43,"The effect of a widely used organic solvent, polyethylene glycol 400 (PEG 400), on the toxic action of an acute or chronic treatment with adriamycin (ADR) was evaluated in mice.",6538499_1,0,-1,0,19918,0
19920,toxic action,19,21,87,99,"The effect of a widely used organic solvent, polyethylene glycol 400 (PEG 400), on the toxic action of an acute or chronic treatment with adriamycin (ADR) was evaluated in mice.",6538499_1,0,-1,0,19920,0
19955,platelet membrane,9,11,73,90,Immunologic testing has demonstrated the presence of a heparin-dependent platelet membrane antibody.,6615052_4,0,-1,0,19955,0
19960,platelet aggregation,17,19,94,114,"If the platelet count falls to less than 100,000/mm3, while the patient is receiving heparin, platelet aggregation testing, using the patient's plasma, is indicated.",6615052_7,0,-1,0,19960,0
19964,diatrizoate,3,4,30,41,Ventricular fibrillation from diatrizoate with and without chelating agents.,663266_0,0,-1,0,19964,0
19965,chelating agents,7,9,59,75,Ventricular fibrillation from diatrizoate with and without chelating agents.,663266_0,0,-1,0,19965,0
19966,Renografin,3,4,16,26,The toxicity of Renografin 76% was compared with that of Hypaque 76% by selective injection of each into the right coronary artery of dogs.,663266_1,0,-1,0,19966,0
19969,Renografin,0,1,0,10,"Renografin contains the chelating agents sodium citrate and disodium edetate, while Hypaque contains calcium disodium edetate and no sodium citrate.",663266_2,0,-1,0,19969,0
19973,calcium disodium edetate,14,17,101,125,"Renografin contains the chelating agents sodium citrate and disodium edetate, while Hypaque contains calcium disodium edetate and no sodium citrate.",663266_2,0,-1,0,19973,0
19974,sodium citrate,19,21,133,147,"Renografin contains the chelating agents sodium citrate and disodium edetate, while Hypaque contains calcium disodium edetate and no sodium citrate.",663266_2,0,-1,0,19974,0
19976,Renografin,7,8,64,74,"Ventricular fibrillation occurred significantly more often with Renografin, suggesting that chelating agents contribute to toxicity in coronary angiography.",663266_3,0,-1,0,19976,0
19977,chelating agents,11,13,92,108,"Ventricular fibrillation occurred significantly more often with Renografin, suggesting that chelating agents contribute to toxicity in coronary angiography.",663266_3,0,-1,0,19977,0
19985,anti-arrhythmic,1,2,5,20,Both anti-arrhythmic efficacy and bioavailability were compared to oral drug.,6634932_1,0,-1,0,19985,0
20000,antiarrhythmic drugs,36,38,183,203,"Amiodarone was administered to 154 patients who had sustained, symptomatic ventricular tachycardia (VT) (n = 118) or a cardiac arrest (n = 36) and who were refractory to conventional antiarrhythmic drugs.",6637851_1,0,-1,0,20000,0
20008,antiarrhythmic drug,29,31,169,188,Six percent of the patients had a nonfatal recurrence of VT and were successfully managed by continuing amiodarone at a higher dose or by the addition of a conventional antiarrhythmic drug.,6637851_4,0,-1,0,20008,0
20017,antiarrhythmic drugs,17,19,117,137,"Although large-dose amiodarone is highly effective in the long-term treatment of VT or VF refractory to conventional antiarrhythmic drugs, it causes significant toxicity in approximately 50% of patients.",6637851_8,0,-1,0,20017,0
20038,D-penicillamine,5,6,24,39,The effect of high dose D-penicillamine treatment on aortic permeability to albumin and on the ultrastructure of the vessel.,6666578_1,0,-1,0,20038,0
20043,D-penicillamine,6,7,43,58,Male Sprague-Dawley rats were treated with D-penicillamine (D-pen) 500 mg/kg/day for 10 or 42 days.,6666578_2,0,-1,0,20043,0
20064,smooth muscle,30,32,211,224,"In experimental animals excess deposition of collagen and glycoaminoglycans was observed in the subendothelial and medial layer of the aortic wall, together with prominent basal membrane substance around aortic smooth muscle cells.",6666578_7,0,-1,0,20064,0
20071,hyaluronate,43,44,264,275,"The aorta/serum-ratio and the radioactive build-up 24 and 48 hours after injection of 131I-HSA was reduced in animals treated with D-pen for 42 days, indicating an impeded transmural transport of tracer which may be caused by a steric exclusion effect of abundant hyaluronate.",6666578_8,0,-1,0,20071,0
20082,epsilon-aminocaproic acid,2,4,8,33,Why may epsilon-aminocaproic acid (EACA) induce myopathy in man? Report of a case and literature review.,6674249_0,0,-1,0,20082,0
20086,epsilon-aminocaproic acid,9,11,46,71,A case of necrotizing myopathy due to a short epsilon-aminocaproic acid (EACA) treatment in a 72 year-old patient with subarachnoid haemorrhage (SAH) is described.,6674249_1,0,-1,0,20086,0
20152,antiinflammatory agents,25,27,171,194,We review previous reports linking RPN to antiinflammatory drug use and discuss possible advantages of sulindac in patients who have experienced renal toxicity from other antiinflammatory agents.,6699841_4,0,-1,0,20152,0
20153,metoclopramide,7,8,39,53,A case of tardive dyskinesia caused by metoclopramide.,6727060_0,0,-1,0,20153,0
20155,metoclopramide,21,22,123,137,"Abnormal involuntary movements appeared in the mouth, tongue, neck and abdomen of a 64-year-old male patient after he took metoclopramide for gastrointestinal disorder in a regimen of 30 mg per day for a total of about 260 days.",6727060_1,0,-1,0,20155,0
20157,metoclopramide,2,3,9,23,"When the metoclopramide administration was discontinued, the abnormal movements gradually improved to a considerable extent.",6727060_3,0,-1,0,20157,0
20160,aminoglycoside,3,4,23,37,Nephrotoxic effects of aminoglycoside treatment on renal protein reabsorption and accumulation.,6728084_0,0,-1,0,20160,0
20202,BCNU,1,2,15,19,Intra-arterial BCNU chemotherapy for treatment of malignant gliomas of the central nervous system.,6747681_0,0,-1,0,20202,0
20205,BCNU,7,8,43,47,"Because of the rapid systemic clearance of BCNU (1,3-bis-(2-chloroethyl)-1-nitrosourea), intra-arterial administration should provide a substantial advantage over intravenous administration for the treatment of malignant gliomas.",6747681_1,0,-1,0,20205,0
20211,BCNU,5,6,38,42,"Thirty-six patients were treated with BCNU every 6 to 8 weeks, either by transfemoral catheterization of the internal carotid or vertebral artery or through a fully implantable intracarotid drug delivery system, beginning with a dose of 200 mg/sq m body surface area.",6747681_2,0,-1,0,20211,0
20228,BCNU,25,26,164,168,"Twenty-four patients with recurrent Grade I to IV astrocytomas, whose resection and irradiation therapy had failed, received two to eight courses of intra-arterial BCNU therapy.",6747681_7,0,-1,0,20228,0
20230,BCNU,14,15,90,94,"The catheterization procedure is safe, with no immediate complication in 111 infusions of BCNU.",6747681_9,0,-1,0,20230,0
20239,(1,23,25,169,171,Cardiotoxic and possible leukemogenic effects of adriamycin in nonhuman primates.10 monkeys (macaques) received adriamycin by monthly intravenous injections at 12 mg/m2 (1 mg/kg).,6769133_0,0,-1,0,20239,0
20247,cardiotoxin,9,10,53,64,"Our results suggest that adriamycin is a more potent cardiotoxin in monkeys than in man, and that leukemia may be a consequence of prolonged treatment with this drug.",6769133_4,0,-1,0,20247,0
20263,vasodilator drugs,11,13,76,93,"It is therefore suggested that caution should be exercised when prescribing vasodilator drugs in diabetic patients, particularly those with autonomic neuropathy.",6773726_2,0,-1,0,20263,0
20266,lithium carbonate,4,6,34,51,Tricuspid valve regurgitation and lithium carbonate toxicity in a newborn infant.,6794356_0,0,-1,0,20266,0
20277,Lithium carbonate,0,2,0,17,Lithium carbonate may be a factor in the increasing incidence of congenital heart disease when taken during early pregnancy.,6794356_4,0,-1,0,20277,0
20288,(1,35,37,210,212,"The effect of aniracetam (Ro 13-5057, 1-anisoyl-2-pyrrolidinone) was studied on various forms of experimentally impaired cognitive functions (learning and memory) in rodents and produced the following effects: (1) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal hypercapnia immediately before the acquisition session; (2) partial (rats) or complete (mice) prevention of the scopolamine-induced short-term amnesia for a passive avoidance task; (3) complete protection against amnesia for a passive avoidance task in rats submitted to electroconvulsive shock immediately after avoidance acquisition; (4) prevention of the long-term retention- or retrieval-deficit for a passive avoidance task induced in rats and mice by chloramphenicol or cycloheximide administered immediately after acquisition; (5) reversal, when administered as late as 1 h before the retention test, of the deficit in retention or retrieval of a passive avoidance task induced by cycloheximide injected 2 days previously; (6) prevention of the deficit in the retrieval of an active avoidance task induced in mice by subconvulsant electroshock or hypercapnia applied immediately before retrieval testing (24 h after acquisition).",6817363_1,0,-1,0,20288,0
20293,(3,86,88,505,507,"The effect of aniracetam (Ro 13-5057, 1-anisoyl-2-pyrrolidinone) was studied on various forms of experimentally impaired cognitive functions (learning and memory) in rodents and produced the following effects: (1) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal hypercapnia immediately before the acquisition session; (2) partial (rats) or complete (mice) prevention of the scopolamine-induced short-term amnesia for a passive avoidance task; (3) complete protection against amnesia for a passive avoidance task in rats submitted to electroconvulsive shock immediately after avoidance acquisition; (4) prevention of the long-term retention- or retrieval-deficit for a passive avoidance task induced in rats and mice by chloramphenicol or cycloheximide administered immediately after acquisition; (5) reversal, when administered as late as 1 h before the retention test, of the deficit in retention or retrieval of a passive avoidance task induced by cycloheximide injected 2 days previously; (6) prevention of the deficit in the retrieval of an active avoidance task induced in mice by subconvulsant electroshock or hypercapnia applied immediately before retrieval testing (24 h after acquisition).",6817363_1,0,-1,0,20293,0
20297,cycloheximide,132,133,800,813,"The effect of aniracetam (Ro 13-5057, 1-anisoyl-2-pyrrolidinone) was studied on various forms of experimentally impaired cognitive functions (learning and memory) in rodents and produced the following effects: (1) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal hypercapnia immediately before the acquisition session; (2) partial (rats) or complete (mice) prevention of the scopolamine-induced short-term amnesia for a passive avoidance task; (3) complete protection against amnesia for a passive avoidance task in rats submitted to electroconvulsive shock immediately after avoidance acquisition; (4) prevention of the long-term retention- or retrieval-deficit for a passive avoidance task induced in rats and mice by chloramphenicol or cycloheximide administered immediately after acquisition; (5) reversal, when administered as late as 1 h before the retention test, of the deficit in retention or retrieval of a passive avoidance task induced by cycloheximide injected 2 days previously; (6) prevention of the deficit in the retrieval of an active avoidance task induced in mice by subconvulsant electroshock or hypercapnia applied immediately before retrieval testing (24 h after acquisition).",6817363_1,0,-1,0,20297,0
20299,cycloheximide,169,170,1012,1025,"The effect of aniracetam (Ro 13-5057, 1-anisoyl-2-pyrrolidinone) was studied on various forms of experimentally impaired cognitive functions (learning and memory) in rodents and produced the following effects: (1) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal hypercapnia immediately before the acquisition session; (2) partial (rats) or complete (mice) prevention of the scopolamine-induced short-term amnesia for a passive avoidance task; (3) complete protection against amnesia for a passive avoidance task in rats submitted to electroconvulsive shock immediately after avoidance acquisition; (4) prevention of the long-term retention- or retrieval-deficit for a passive avoidance task induced in rats and mice by chloramphenicol or cycloheximide administered immediately after acquisition; (5) reversal, when administered as late as 1 h before the retention test, of the deficit in retention or retrieval of a passive avoidance task induced by cycloheximide injected 2 days previously; (6) prevention of the deficit in the retrieval of an active avoidance task induced in mice by subconvulsant electroshock or hypercapnia applied immediately before retrieval testing (24 h after acquisition).",6817363_1,0,-1,0,20299,0
20308,Piracetam,0,1,0,9,"Piracetam, another pyrrolidinone derivative was used for comparison.",6817363_5,0,-1,0,20308,0
20315,low-dose,5,6,35,43,Blood pressure response to chronic low-dose intrarenal noradrenaline infusion in conscious rats.,6861444_0,0,-1,0,20315,0
20360,carbachol,10,11,68,77,Effect of calcium chloride on gross behavioural changes produced by carbachol and eserine in cats.,6892185_0,0,-1,0,20360,0
20365,carbachol,49,50,292,301,"The effect of calcium chloride injected into the cerebral ventricles of group-housed unanaesthetized cats upon vocalization (rage, hissing and snarling), fighting (attack with paws and claws, defense with paws and claws and biting), mydriasis, tremor and clonic-tonic convulsions produced by carbachol and eserine injected similarly was investigated.",6892185_1,0,-1,0,20365,0
20368,carbachol,13,14,95,104,Calcium chloride depressed or almost completely abolished the vocalization and fighting due to carbachol and eserine.,6892185_2,0,-1,0,20368,0
20370,carbachol,13,14,76,85,"On the other hand, mydriasis, tremor and clonic-tonic convulsions evoked by carbachol and eserine were not significantly changed by calcium chloride.",6892185_3,0,-1,0,20370,0
20375,carbachol,28,29,180,189,"It is apparent that calcium chloride can ""dissociate"" vocalization and fighting from autonomic and motor phenomena such as mydriasis, tremor and clonic-tonic convulsions caused by carbachol and eserine.",6892185_4,0,-1,0,20375,0
20378,carbachol,9,10,69,78,Calcium chloride inhibited the vocalization and fighting produced by carbachol and eserine most probably by a nonspecific stabilizing action on central muscarinic cholinoceptive sites.,6892185_5,0,-1,0,20378,0
20381,muscarinic,21,22,152,162,Calcium chloride inhibited the vocalization and fighting produced by carbachol and eserine most probably by a nonspecific stabilizing action on central muscarinic cholinoceptive sites.,6892185_5,0,-1,0,20381,0
20385,Thiazide diuretics,0,2,0,18,"Thiazide diuretics, hypokalemia and cardiac arrhythmias.",6942642_0,0,-1,0,20385,0
20387,Thiazide diuretics,0,2,0,18,Thiazide diuretics are widely accepted as the cornerstone of antihypertensive treatment programs.,6942642_1,0,-1,0,20387,0
20398,HCTZ,23,24,90,94,"The serum K during the control period was 4.5 +/- 0.2 mEq/l an on 50, 100, 150 and 200 mg HCTZ daily 3.9 +/- 0.3, 3.4 +/- 0.2, 2.9 +/- 0.2, and 2.4 +/- 0.3 mEq/l, respectively.",6942642_5,0,-1,0,20398,0
20411,HCTZ,8,9,42,46,In 13 patients we observed the effects of HCTZ therapy (100 mg daily) on the occurrence of PVC's during rest as well as during static and dynamic exercise.,6942642_7,0,-1,0,20411,0
20419,HCTZ,3,4,29,33,"Corresponding figures during HCTZ therapy 100 mg daily were 1.4 +/- 0.1, 3.6 +/- 0.7 and 5.7 4/- 0.8, respectively.",6942642_9,0,-1,0,20419,0
20423,thiazide diuretics,5,7,28,46,In conclusion we found that thiazide diuretics cause hypokalemia and depletion of body potassium.,6942642_11,0,-1,0,20423,0
20425,lysosomal,1,2,12,21,Circulating lysosomal enzymes and acute hepatic necrosis.,7007443_0,0,-1,0,20425,0
20427,lysosomal,4,5,22,31,"The activities of the lysosomal enzymes acid and neutral protease, N-acetylglucosaminidase, and acid phosphatase were measured in the serum of patients with fulminant hepatic failure.",7007443_1,0,-1,0,20427,0
20428,neutral protease,8,10,49,65,"The activities of the lysosomal enzymes acid and neutral protease, N-acetylglucosaminidase, and acid phosphatase were measured in the serum of patients with fulminant hepatic failure.",7007443_1,0,-1,0,20428,0
20430,acid phosphatase,14,16,96,112,"The activities of the lysosomal enzymes acid and neutral protease, N-acetylglucosaminidase, and acid phosphatase were measured in the serum of patients with fulminant hepatic failure.",7007443_1,0,-1,0,20430,0
20435,paracetamol,26,27,160,171,"Acid protease (cathepsin D) activity was increased about tenfold in patients who died and nearly fourfold in those who survived fulminant hepatic failure after paracetamol overdose, whereas activities were increased equally in patients with fulminant hepatic failure due to viral hepatitis whether or not they survived.",7007443_2,0,-1,0,20435,0
20441,aspartate aminotransferase,27,29,170,196,"A correlation was found between serum acid protease activity and prothrombin time, and the increase in cathepsin D activity was sustained over several days compared with aspartate aminotransferase, which showed a sharp early peak and then a fall.",7007443_3,0,-1,0,20441,0
20442,lysosomal,1,2,12,21,"Circulating lysosomal proteases can damage other organs, and measurement of their activity may therefore be of added value in assessing prognosis in this condition.",7007443_4,0,-1,0,20442,0
20446,creatinine,35,36,214,224,In 35 patients (ages 20 to 86 yr) receiving cimetidine therapeutically two serum samples and all urine formed in the interim were collected for analysis of cimetidine by high-pressure liquid chromatography and for creatinine.,7053303_1,0,-1,0,20446,0
20447,creatinine,6,7,37,47,"The ratio of cimetidine clearance to creatinine clearance (Rc) averaged 4.8 +/- 2.0, indicating net tubular secretion for cimetidine.",7053303_4,0,-1,0,20447,0
20470,chlorpropamide,8,9,59,73,A 65-year-old woman with adult-onset diabetes treated with chlorpropamide (Diabenese) had a toxic optic neuropathy that resolved with discontinuation of chlorpropamide therapy.,7059267_1,0,-1,0,20470,0
20473,chlorpropamide,22,23,153,167,A 65-year-old woman with adult-onset diabetes treated with chlorpropamide (Diabenese) had a toxic optic neuropathy that resolved with discontinuation of chlorpropamide therapy.,7059267_1,0,-1,0,20473,0
20480,puromycin aminonucleoside,17,19,110,135,Plasma and urinary lipids and lipoproteins during the development of nephrotic syndrome induced in the rat by puromycin aminonucleoside.,7066357_0,0,-1,0,20480,0
20483,puromycin aminonucleoside,18,20,125,150,"This study was undertaken to ascertain whether the alterations of plasma lipoproteins found in nephrotic syndrome induced by puromycin aminonucleoside were due to nephrotic syndrome per se, or, at least in part, to the aminonucleoside.",7066357_1,0,-1,0,20483,0
20485,aminonucleoside,37,38,219,234,"This study was undertaken to ascertain whether the alterations of plasma lipoproteins found in nephrotic syndrome induced by puromycin aminonucleoside were due to nephrotic syndrome per se, or, at least in part, to the aminonucleoside.",7066357_1,0,-1,0,20485,0
20487,puromycin aminonucleoside,20,22,128,153,The purpose of the present study was to investigate the changes in plasma and urinary lipoproteins during the administration of puromycin aminonucleoside (20 mg/kg for 7 days) and the subsequent development of nephrotic syndrome.,7066357_2,0,-1,0,20487,0
20494,fatty acids,7,9,43,54,"In pre-nephrotic stage the plasma level of fatty acids, triacylglycerol and VLDL decreased while that of phospholipid, cholesteryl esters and HDL remained constant.",7066357_4,0,-1,0,20494,0
20495,triacylglycerol,10,11,56,71,"In pre-nephrotic stage the plasma level of fatty acids, triacylglycerol and VLDL decreased while that of phospholipid, cholesteryl esters and HDL remained constant.",7066357_4,0,-1,0,20495,0
20497,apolipoprotein A-I,1,3,7,25,Plasma apolipoprotein A-I tended to increase (40% increase at day 5).,7066357_5,0,-1,0,20497,0
20500,low level,19,21,98,107,"At the beginning of nephrotic stage (day 6) the concentration of plasma albumin dropped to a very low level, while that of apolipoprotein A-I increased abruptly (4-fold increase) and continued to rise, although less steeply, in the following days.",7066357_6,0,-1,0,20500,0
20501,apolipoprotein A-I,25,27,123,141,"At the beginning of nephrotic stage (day 6) the concentration of plasma albumin dropped to a very low level, while that of apolipoprotein A-I increased abruptly (4-fold increase) and continued to rise, although less steeply, in the following days.",7066357_6,0,-1,0,20501,0
20503,apolipoprotein A-I,1,3,7,25,Plasma apolipoprotein A-I was found not only in HDL (1.063-1.210 g/ml) but also in the LDL density class (1.025-1.050 g/ml).,7066357_9,0,-1,0,20503,0
20509,puromycin aminonucleoside,4,6,33,58,These observations indicate that puromycin aminonucleoside alters plasma lipoproteins by lowering VLDL and increasing HDL.,7066357_11,0,-1,0,20509,0
20556,thiopentone,3,4,24,35,Midazolam compared with thiopentone as an induction agent.,7102237_0,0,-1,0,20556,0
20558,morphine (+,6,9,44,55,"In patients premedicated with scopolamine + morphine (+5 mg nitrazepam the evening before surgery), the sleep-inducing effect of midazolam 0.15 mg/kg i.v. was clearly slower in onset than that of thiopentone 4.67 mg/kg i.v.",7102237_1,0,-1,0,20558,0
20560,thiopentone,35,36,196,207,"In patients premedicated with scopolamine + morphine (+5 mg nitrazepam the evening before surgery), the sleep-inducing effect of midazolam 0.15 mg/kg i.v. was clearly slower in onset than that of thiopentone 4.67 mg/kg i.v.",7102237_1,0,-1,0,20560,0
20565,thiopentone,9,10,52,63,"On the whole, the differences between midazolam and thiopentone had no apparent clinical consequences.",7102237_3,0,-1,0,20565,0
20578,convulsant,1,2,7,17,Median convulsant (CD50) and median lethal (LD50) doses of three representative local anesthetics were determined in adult mice to evaluate the threat to life of local anesthetic-induced convulsions.,7189975_1,0,-1,0,20578,0
20582,local anesthetics,15,17,80,97,Median convulsant (CD50) and median lethal (LD50) doses of three representative local anesthetics were determined in adult mice to evaluate the threat to life of local anesthetic-induced convulsions.,7189975_1,0,-1,0,20582,0
20585,bupivacaine,13,14,62,73,"The CD50 and LD50, respectively, were 57.7 and 58.7 mg/kg for bupivacaine, 111.0 and 133.1 mg/kg for lidocaine, and 243.4 and 266.5 mg/kg for chloroprocaine.",7189975_2,0,-1,0,20585,0
20588,bupivacaine,4,5,30,41,"When given intraperitoneally, bupivacaine thus was only about twice as toxic as lidocaine and four times as toxic as chloroprocaine.",7189975_3,0,-1,0,20588,0
20593,local anesthetic,4,6,15,31,"A CD50 dose of local anesthetic (causing convulsions in 50% of mice) was fatal in 90% of bupivacaine-induced seizures, in 57% of the chloroprocaine group, and in 6% of the lidocaine group.",7189975_5,0,-1,0,20593,0
20595,convulsant,4,5,23,33,The narrow gap between convulsant and lethal doses of local anesthetics indicates that untreated convulsions present much more of a threat to life than heretofore appreciated.,7189975_6,0,-1,0,20595,0
20597,local anesthetics,9,11,54,71,The narrow gap between convulsant and lethal doses of local anesthetics indicates that untreated convulsions present much more of a threat to life than heretofore appreciated.,7189975_6,0,-1,0,20597,0
20601,serotonergic,9,10,75,87,REM sleep deprivation changes behavioral response to catecholaminergic and serotonergic receptor activation in rats.,7197363_0,0,-1,0,20601,0
20613,antidepressive,12,13,81,95,Results are discussed in terms of similarity to pharmacological effects of other antidepressive treatments.,7197363_3,0,-1,0,20613,0
20616,bupivacaine,8,9,74,85,"Neurologic effects of subarachnoid administration of 2-chloroprocaine-CE, bupivacaine, and low pH normal saline in dogs.",7199841_0,0,-1,0,20616,0
20621,bupivacaine,20,21,96,107,"The 65 dogs in the study received injections in the subarachnoid space as follows: 6 to 8 ml of bupivacaine (N = 15), 2-chloroprocaine-CE (N = 20), low pH normal saline (pH 3.0) (N = 20), or normal saline (N = 10).",7199841_3,0,-1,0,20621,0
20626,bupivacaine,6,7,34,45,"None of the animals that received bupivacaine, normal saline, or normal saline titrated to a pH 3.0 developed hind-limb paralysis.",7199841_5,0,-1,0,20626,0
20632,bupivacaine,8,9,46,57,"The spinal cords of the animals that received bupivacaine, low pH normal saline (pH 3.0), or normal saline did not show abnormal findings.",7199841_7,0,-1,0,20632,0
20641,procainamide,17,18,117,129,"In four patients, polymorphous ventricular tachycardia appeared after intravenous administration of 200 to 400 mg of procainamide for the treatment of sustained ventricular tachycardia.",7234705_2,0,-1,0,20641,0
20643,procainamide,6,7,33,45,"In the remaining three patients, procainamide was administered orally for treatment of chronic premature ventricular contractions or atrial flutter.",7234705_3,0,-1,0,20643,0
20651,procainamide,16,17,100,112,"In the seventh patient, a permanent ventricular pacemaker was inserted and, despite continuation of procainamide therapy, polymorphous ventricular tachycardia did not reoccur.",7234705_7,0,-1,0,20651,0
20653,procainamide,5,6,35,47,These seven cases demonstrate that procainamide can produce an acquired prolonged Q-T syndrome with polymorphous ventricular tachycardia.,7234705_8,0,-1,0,20653,0
20683,uric acid,14,16,94,103,The stone passed spontaneously and was found to contain a triamterene metabolite admixed with uric acid salts.,7265370_2,0,-1,0,20683,0
20688,busulfan,7,8,53,61,The similarity between the histologic appearances of busulfan cystitis and both radiation and cyclophosphamide-induced cystitis is discussed and the world literature reviewed.,7269015_3,0,-1,0,20688,0
20691,busulfan,7,8,33,41,"In view of the known tendency of busulfan to induce cellular atypia and carcinoma in other sites, periodic urinary cytology is suggested in patients on long-term therapy.",7269015_4,0,-1,0,20691,0
20713,(r,7,9,70,72,"Catheterization abnormalities correlated well with morphologic damage (r = 0.57 to 0.78) in a subgroup of patients in whom exercise hemodynamics were measured, and this relationship also exhibited a curvilinear, threshold configuration.",7282516_5,0,-1,0,20713,0
20741,sodium nitroprusside,3,5,27,47,Rebound hypertensive after sodium nitroprusside prevented by saralasin in rats.,7352670_0,0,-1,0,20741,0
20742,saralasin,7,8,61,70,Rebound hypertensive after sodium nitroprusside prevented by saralasin in rats.,7352670_0,0,-1,0,20742,0
20745,sodium nitroprusside,18,20,111,131,The role of the renin--angiotensin system in the maintenance of blood pressure during halothane anesthesia and sodium nitroprusside (SNP)-induced hypotension was evaluated.,7352670_1,0,-1,0,20745,0
20747,(1,5,7,43,45,"Control rats received halothane anesthesia (1 MAC) for one hour, followed by SNP infusion, 40 microgram/kg/min, for 30 min, followed by a 30-min recovery period.",7352670_2,0,-1,0,20747,0
20749,saralasin,17,18,89,98,"A second group of rats was treated identically and, in addition, received an infusion of saralasin (a competitive inhibitor of angiotensin II) throughout the experimental period.",7352670_3,0,-1,0,20749,0
20750,angiotensin II,23,25,127,141,"A second group of rats was treated identically and, in addition, received an infusion of saralasin (a competitive inhibitor of angiotensin II) throughout the experimental period.",7352670_3,0,-1,0,20750,0
20762,saralasin,30,31,191,200,"This study indicates that with stable halothane anesthesia, the partial recovery of blood pressure during SNP infusion and the post-SNP rebound of blood pressure can be completely blocked by saralasin.",7352670_7,0,-1,0,20762,0
20791,Gentamicin sulfate,0,2,0,18,Gentamicin sulfate and tobramycin sulfate continue to demonstrate ototoxicity and nephrotoxicity in both animal and clinical studies.,7420681_3,0,-1,0,20791,0
20792,tobramycin sulfate,3,5,23,41,Gentamicin sulfate and tobramycin sulfate continue to demonstrate ototoxicity and nephrotoxicity in both animal and clinical studies.,7420681_3,0,-1,0,20792,0
20798,gentamicin sulfate,20,22,109,127,"In this study, 62 patients with confirmed initial normal renal function and treated with 2 to 5 mg/kg/day of gentamicin sulfate or tobramycin sulfate for a minimum of seven days were followed up prospectively for the development of aminoglycoside-related renal failure, defined as at least a one-third reduction in renal function.",7420681_4,0,-1,0,20798,0
20799,tobramycin sulfate,23,25,131,149,"In this study, 62 patients with confirmed initial normal renal function and treated with 2 to 5 mg/kg/day of gentamicin sulfate or tobramycin sulfate for a minimum of seven days were followed up prospectively for the development of aminoglycoside-related renal failure, defined as at least a one-third reduction in renal function.",7420681_4,0,-1,0,20799,0
20828,adenylate,15,16,92,101,"A possible involvement of energy metabolism was suggested previously, and in this study the adenylate energy charge and phosphorylcreatine mole fraction were determined in the adriamycin-treated cells.",7423039_3,0,-1,0,20828,0
20829,phosphorylcreatine,19,20,120,138,"A possible involvement of energy metabolism was suggested previously, and in this study the adenylate energy charge and phosphorylcreatine mole fraction were determined in the adriamycin-treated cells.",7423039_3,0,-1,0,20829,0
20832,adenylate,1,2,4,13,"The adenylate energy charge was found to be significantly decreased, while the phophorylcreatine mole fraction was unchanged.",7423039_4,0,-1,0,20832,0
20835,creatine phosphokinase,6,8,41,63,Such disparity suggests an inhibition of creatine phosphokinase.,7423039_5,0,-1,0,20835,0
20838,adenylate,11,12,73,82,"In the adriamycin-treated cells, the addition of adenosine increased the adenylate charge and, concomitant with this inrcease, the cells' functional integrity, in terms of percentage of beating cells and rate of contractions, was maintained.",7423039_7,0,-1,0,20838,0
20843,Creatinine,0,1,0,10,"Creatinine clearance, maximum urinary osmolality and 24 hour urine volume have been tested in 50 affectively ill patients who have been on long-term lithium for more than one year.",7437994_3,0,-1,0,20843,0
20853,Streptomycin sulfate,0,2,0,20,Streptomycin sulfate (300 mg/kg s.c.) was injected for various periods into preweanling rats and for 3 weeks into weanling rats.,7444978_1,0,-1,0,20853,0
20867,amiloride,7,8,71,80,Attenuation of the lithium-induced diabetes-insipidus-like syndrome by amiloride in rats.,7453952_0,0,-1,0,20867,0
20868,amiloride,3,4,14,23,"The effect of amiloride on lithium-induced polydipsia and polyuria and on the lithium concentration in the plasma, brain, kidney, thyroid and red blood cells was investigated in rats, chronically treated with LiCl.",7453952_1,0,-1,0,20868,0
20873,Amiloride,0,1,0,9,Amiloride reduced the drinking and urine volume of rats in an acute (6 or 12 h) and a subacute (3 days) experiment.,7453952_2,0,-1,0,20873,0
20875,(3,21,23,95,97,Amiloride reduced the drinking and urine volume of rats in an acute (6 or 12 h) and a subacute (3 days) experiment.,7453952_2,0,-1,0,20875,0
20876,amiloride,6,7,32,41,"6 h after the administration of amiloride, a reduction was observed in the lithium content of the renal medulla but not in the other organs studied.",7453952_3,0,-1,0,20876,0
20882,amiloride,13,14,99,108,"In all the experiments, the attenuation of the lithium-induced diabetes-insipidus-like syndrome by amiloride was accompanied by a reduction of the ratio between the lithium concentration in the renal medulla and its levels in the blood and an elevation in the plasma potassium level.",7453952_6,0,-1,0,20882,0
20884,amiloride,5,6,27,36,It is concluded that acute amiloride administration to lithium-treated patients suffering from polydipsia and polyuria might relieve these patients but prolonged amiloride supplementation would result in elevated lithium levels and might be hazardous.,7453952_7,0,-1,0,20884,0
20886,amiloride,21,22,162,171,It is concluded that acute amiloride administration to lithium-treated patients suffering from polydipsia and polyuria might relieve these patients but prolonged amiloride supplementation would result in elevated lithium levels and might be hazardous.,7453952_7,0,-1,0,20886,0
20898,antithyroid drugs,4,6,27,44,Toxic hepatitis induced by antithyroid drugs: four cases including one with cross-reactivity between carbimazole and benzylthiouracil.,7504976_0,0,-1,0,20898,0
20903,antithyroid drugs,16,18,105,122,OBJECTIVE: This study was conducted to assess the occurrence of hepatic adverse effects encountered with antithyroid drugs.,7504976_1,0,-1,0,20903,0
20908,antithyroid agent,22,24,118,135,RESULTS: Four patients (1.7%) were identified with toxic hepatitis which could reasonably be attributed to the use of antithyroid agent.,7504976_3,0,-1,0,20908,0
20919,antithyroid drugs,10,12,61,78,"CONCLUSION: Toxic hepatitis is a potential adverse effect of antithyroid drugs which warrants, as for haematological disturbances, a pre-therapeutic determination and a careful follow-up of relevant biological markers.",7504976_9,0,-1,0,20919,0
20921,biological markers,29,31,199,217,"CONCLUSION: Toxic hepatitis is a potential adverse effect of antithyroid drugs which warrants, as for haematological disturbances, a pre-therapeutic determination and a careful follow-up of relevant biological markers.",7504976_9,0,-1,0,20921,0
20923,antithyroid agents,11,13,63,81,"Moreover, hepatotoxicity may not be restricted to one class of antithyroid agents.",7504976_10,0,-1,0,20923,0
20954,LCa,10,11,72,75,"Dose-dependent bradycardia induced by verapamil was potentiated by LNa, LCa, and HCa.",7516729_7,0,-1,0,20954,0
20960,LCa,38,39,191,194,"Independent but not additive effects of Na and Ca are shown by decreases in the values of [verapamil]o needed to reduce BF by 30% (IC30) with the following order of inhibitory potency: LNa > LCa > HCa > N, resulting LNa+HCa similar to LNa.",7516729_8,0,-1,0,20960,0
20968,LCa,21,22,113,116,The [verapamil]o that arrested atrial beating (AC) was also potentiated with the order LNa = LNa+LCa = LNa+HCa = LCa > HCa = N. The results indicate that rat atrial spontaneous beating is more dependent on [Na]o than on [Ca]o in a range of +/- 50% of their normal concentration.,7516729_9,0,-1,0,20968,0
20976,cyclosporin A,2,4,18,31,Nephrotoxicity of cyclosporin A and FK506: inhibition of calcineurin phosphatase.,7542793_0,0,-1,0,20976,0
20977,FK506,5,6,36,41,Nephrotoxicity of cyclosporin A and FK506: inhibition of calcineurin phosphatase.,7542793_0,0,-1,0,20977,0
20978,calcineurin,9,10,57,68,Nephrotoxicity of cyclosporin A and FK506: inhibition of calcineurin phosphatase.,7542793_0,0,-1,0,20978,0
20979,Cyclosporin A,0,2,0,13,"Cyclosporin A (CsA; 50 mg/kg) and Fujimycine (FK506; 5 mg/kg), but not the related macrolide immunosuppressant rapamycin (5 mg/kg), caused a reduction of glomerular filtration rate, degenerative changes of proximal tubular epithelium, and hypertrophy of the juxtaglomerular apparatus in male Wistar rats when given for 10 days.",7542793_1,0,-1,0,20979,0
20982,FK506,11,12,46,51,"Cyclosporin A (CsA; 50 mg/kg) and Fujimycine (FK506; 5 mg/kg), but not the related macrolide immunosuppressant rapamycin (5 mg/kg), caused a reduction of glomerular filtration rate, degenerative changes of proximal tubular epithelium, and hypertrophy of the juxtaglomerular apparatus in male Wistar rats when given for 10 days.",7542793_1,0,-1,0,20982,0
20984,rapamycin,23,24,111,120,"Cyclosporin A (CsA; 50 mg/kg) and Fujimycine (FK506; 5 mg/kg), but not the related macrolide immunosuppressant rapamycin (5 mg/kg), caused a reduction of glomerular filtration rate, degenerative changes of proximal tubular epithelium, and hypertrophy of the juxtaglomerular apparatus in male Wistar rats when given for 10 days.",7542793_1,0,-1,0,20984,0
20990,FK506,6,7,36,41,The molecular mechanisms of CsA and FK506 toxicity were investigated.,7542793_2,0,-1,0,20990,0
20992,FK506-binding protein,3,5,18,39,"Cyclophilin A and FK506-binding protein, the main intracytoplasmic receptors for CsA and FK506, respectively, were each detected in renal tissue extract.",7542793_3,0,-1,0,20992,0
20995,FK506,13,14,89,94,"Cyclophilin A and FK506-binding protein, the main intracytoplasmic receptors for CsA and FK506, respectively, were each detected in renal tissue extract.",7542793_3,0,-1,0,20995,0
20998,calcineurin,11,12,70,81,"In the kidney, high levels of immunoreactive and enzymatically active calcineurin were found which were inhibited by the immunosuppressants CsA and FK506, but not by rapamycin.",7542793_4,0,-1,0,20998,0
21000,FK506,22,23,148,153,"In the kidney, high levels of immunoreactive and enzymatically active calcineurin were found which were inhibited by the immunosuppressants CsA and FK506, but not by rapamycin.",7542793_4,0,-1,0,21000,0
21001,rapamycin,27,28,166,175,"In the kidney, high levels of immunoreactive and enzymatically active calcineurin were found which were inhibited by the immunosuppressants CsA and FK506, but not by rapamycin.",7542793_4,0,-1,0,21001,0
21004,FK506,13,14,97,102,"Finally, specific immunophilin-drug-calcineurin complexes formed only in the presence of CsA and FK506, but not rapamycin.",7542793_5,0,-1,0,21004,0
21005,rapamycin,17,18,112,121,"Finally, specific immunophilin-drug-calcineurin complexes formed only in the presence of CsA and FK506, but not rapamycin.",7542793_5,0,-1,0,21005,0
21008,FK506,10,11,62,67,These results suggest that the nephrotoxic effects of CsA and FK506 is likely mediated through binding to renal immunophilin and inhibiting calcineurin phosphatase.,7542793_6,0,-1,0,21008,0
21009,immunophilin,18,19,112,124,These results suggest that the nephrotoxic effects of CsA and FK506 is likely mediated through binding to renal immunophilin and inhibiting calcineurin phosphatase.,7542793_6,0,-1,0,21009,0
21010,calcineurin,21,22,140,151,These results suggest that the nephrotoxic effects of CsA and FK506 is likely mediated through binding to renal immunophilin and inhibiting calcineurin phosphatase.,7542793_6,0,-1,0,21010,0
21013,Carboplatin,0,1,0,11,Carboplatin has been reported to cause acute renal failure when administered in high doses to adult patients.,7565311_1,0,-1,0,21013,0
21033,excipients,23,24,115,125,"In the two patients, skin and ELISA tests with paramethasone were negative, as was the prick test with each of its excipients.",7582165_5,0,-1,0,21033,0
21037,excipients,25,26,147,157,"A single-blind parenteral challenge with Triniol was positive in both patients after the administration of 1 ml of the drug, and negative with its excipients.",7582165_6,0,-1,0,21037,0
21046,prostacyclin,7,8,55,67,Clinical evaluation on combined administration of oral prostacyclin analogue beraprost and phosphodiesterase inhibitor cilostazol.,7596955_0,0,-1,0,21046,0
21048,phosphodiesterase,11,12,91,108,Clinical evaluation on combined administration of oral prostacyclin analogue beraprost and phosphodiesterase inhibitor cilostazol.,7596955_0,0,-1,0,21048,0
21049,cilostazol,13,14,119,129,Clinical evaluation on combined administration of oral prostacyclin analogue beraprost and phosphodiesterase inhibitor cilostazol.,7596955_0,0,-1,0,21049,0
21050,prostacyclin,10,11,59,71,"Among various oral antiplatelets, a combination of a novel prostacyclin analogue beraprost (BPT) and a potent phosphodiesterase inhibitor cilostazol (CLZ) may result in untoward clinical effects due to possible synergistic elevation of intracellular cAMP (cyclic adenosine 3',5'-monophosphate).",7596955_1,0,-1,0,21050,0
21052,phosphodiesterase,19,20,110,127,"Among various oral antiplatelets, a combination of a novel prostacyclin analogue beraprost (BPT) and a potent phosphodiesterase inhibitor cilostazol (CLZ) may result in untoward clinical effects due to possible synergistic elevation of intracellular cAMP (cyclic adenosine 3',5'-monophosphate).",7596955_1,0,-1,0,21052,0
21053,cilostazol,21,22,138,148,"Among various oral antiplatelets, a combination of a novel prostacyclin analogue beraprost (BPT) and a potent phosphodiesterase inhibitor cilostazol (CLZ) may result in untoward clinical effects due to possible synergistic elevation of intracellular cAMP (cyclic adenosine 3',5'-monophosphate).",7596955_1,0,-1,0,21053,0
21068,platelet aggregation,13,15,81,101,"At various time intervals, physical examination and blood collection for ex vivo platelet aggregation and determination of intraplatelet cAMP were performed.",7596955_4,0,-1,0,21068,0
21108,ammonium salt,16,18,96,109,This coma was prevented with 1.68 mmol L-dopa given by gastric intubation 15 minutes before the ammonium salt injection.,761833_2,0,-1,0,21108,0
21121,etoposide,11,12,84,93,"The occurrence of a myocardial infarction is reported after chemotherapy containing etoposide, in a man with no risk factors for coronary heart disease.",7619765_1,0,-1,0,21121,0
21125,vitamin B12,5,7,21,32,Study of the role of vitamin B12 and folinic acid supplementation in preventing hematologic toxicity of zidovudine.,7628595_0,0,-1,0,21125,0
21126,folinic acid,8,10,37,49,Study of the role of vitamin B12 and folinic acid supplementation in preventing hematologic toxicity of zidovudine.,7628595_0,0,-1,0,21126,0
21128,vitamin B12,12,14,70,81,"A prospective, randomized study was conducted to evaluate the role of vitamin B12 and folinic acid supplementation in preventing zidovudine (ZDV)-induced bone marrow suppression.",7628595_1,0,-1,0,21128,0
21129,folinic acid,15,17,86,98,"A prospective, randomized study was conducted to evaluate the role of vitamin B12 and folinic acid supplementation in preventing zidovudine (ZDV)-induced bone marrow suppression.",7628595_1,0,-1,0,21129,0
21135,folinic acid,37,39,198,210,"Seventy-five human immunodeficiency virus (HIV)-infected patients with CD4+ cell counts < 500/mm3 were randomized to receive either ZDV (500 mg daily) alone (group I, n = 38) or in combination with folinic acid (15 mg daily) and intramascular vitamin B12 (1000 micrograms monthly) (group II, n = 37).",7628595_2,0,-1,0,21135,0
21137,vitamin B12,46,48,243,254,"Seventy-five human immunodeficiency virus (HIV)-infected patients with CD4+ cell counts < 500/mm3 were randomized to receive either ZDV (500 mg daily) alone (group I, n = 38) or in combination with folinic acid (15 mg daily) and intramascular vitamin B12 (1000 micrograms monthly) (group II, n = 37).",7628595_2,0,-1,0,21137,0
21138,group II,54,56,282,290,"Seventy-five human immunodeficiency virus (HIV)-infected patients with CD4+ cell counts < 500/mm3 were randomized to receive either ZDV (500 mg daily) alone (group I, n = 38) or in combination with folinic acid (15 mg daily) and intramascular vitamin B12 (1000 micrograms monthly) (group II, n = 37).",7628595_2,0,-1,0,21138,0
21140,group II,29,31,122,130,"Finally, 15 patients were excluded from the study (noncompliance 14, death 1); thus, 60 patients (31 in group I and 29 in group II) were eligible for analysis.",7628595_3,0,-1,0,21140,0
21142,vitamin B12,4,6,18,29,"During the study, vitamin B12 and folate levels were significantly higher in group II patients; however, no differences in hemoglobin, hematocrit, mean corpuscular volume, and white-cell, neutrophil and platelet counts were observed between groups at 3, 6, 9 and 12 months.",7628595_5,0,-1,0,21142,0
21143,group II,13,15,77,85,"During the study, vitamin B12 and folate levels were significantly higher in group II patients; however, no differences in hemoglobin, hematocrit, mean corpuscular volume, and white-cell, neutrophil and platelet counts were observed between groups at 3, 6, 9 and 12 months.",7628595_5,0,-1,0,21143,0
21146,group II,26,28,146,154,Severe hematologic toxicity (neutrophil count < 1000/mm3 and/or hemoglobin < 8 g/dl) occurred in 4 patients assigned to group I and 7 assigned to group II.,7628595_6,0,-1,0,21146,0
21147,vitamin B12,5,7,33,44,There was no correlation between vitamin B12 or folate levels and development of myelosuppression.,7628595_7,0,-1,0,21147,0
21149,Vitamin B12,0,2,0,11,"Vitamin B12 and folinic acid supplementation of ZDV therapy does not seem useful in preventing or reducing ZDV-induced myelotoxicity in the overall treated population, although a beneficial effect in certain subgroups of patients cannot be excluded.",7628595_8,0,-1,0,21149,0
21150,folinic acid,3,5,16,28,"Vitamin B12 and folinic acid supplementation of ZDV therapy does not seem useful in preventing or reducing ZDV-induced myelotoxicity in the overall treated population, although a beneficial effect in certain subgroups of patients cannot be excluded.",7628595_8,0,-1,0,21150,0
21162,immune response,7,9,51,66,Halothane hepatitis appears to involve an aberrant immune response.,7647582_2,0,-1,0,21162,0
21174,cytosolic,11,12,85,94,Enflurane administration resulted in neoantigens detected in both the microsomal and cytosolic fraction of liver homogenates and in the centrilobular region of the liver.,7647582_6,0,-1,0,21174,0
21178,fluorinated,8,9,49,60,"In the same liver, biochemical analysis detected fluorinated liver adducts that were up to 20-fold greater in guinea pigs than in rats.",7647582_7,0,-1,0,21178,0
21185,echothiophate iodide,11,13,66,86,"A patient developed a severe cholinergic syndrome from the use of echothiophate iodide ophthalmic drops, presented with profound muscle weakness and was initially given the diagnosis of myasthenia gravis.",7650771_1,0,-1,0,21185,0
21191,eye drops,18,20,140,149,Red blood cell and serum cholinesterase levels were severely depressed and symptoms resolved spontaneously following discontinuation of the eye drops.,7650771_2,0,-1,0,21191,0
21192,flumazenil,2,3,14,24,Seizure after flumazenil administration in a pediatric patient.,7651879_0,0,-1,0,21192,0
21193,Flumazenil,0,1,0,10,Flumazenil is a benzodiazepine receptor antagonist used to reverse sedation and respiratory depression induced by benzodiazepines.,7651879_1,0,-1,0,21193,0
21199,flumazenil,7,8,56,66,Little information exists concerning adverse effects of flumazenil in children.,7651879_4,0,-1,0,21199,0
21201,flumazenil,17,18,118,128,We report the occurrence of a generalized tonic-clonic seizure in a pediatric patient following the administration of flumazenil.,7651879_5,0,-1,0,21201,0
21239,malondialdehyde,4,5,26,41,"Time dependence of plasma malondialdehyde, oxypurines, and nucleosides during incomplete cerebral ischemia in the rat.",7710775_0,0,-1,0,21239,0
21247,malondialdehyde,17,18,131,146,"Plasma extracts were analyzed by a highly sensitive high-performance liquid chromatographic method for the direct determination of malondialdehyde, oxypurines, and nucleosides.",7710775_3,0,-1,0,21247,0
21250,malondialdehyde,1,2,7,22,"Plasma malondialdehyde, which was present in minimal amount at zero time (0.058 mumol/liter plasma; SD 0.015), increased after 5 min of ischemia, resulting in a fivefold increase after 30 min of carotid occlusion (0.298 mumol/liter plasma; SD 0.078).",7710775_5,0,-1,0,21250,0
21255,malondialdehyde,2,3,17,32,"Increased plasma malondialdehyde was also recorded in two other groups of animals subjected to the same experimental model, one receiving 20 mg/kg b.w. of the cyclooxygenase inhibitor acetylsalicylate intravenously immediately before ischemia, the other receiving 650 micrograms/kg b.w. of the hypotensive drug nitroprusside at a flow rate of 103 microliters/min intravenously during ischemia, although in this latter group malondialdehyde was significantly higher.",7710775_6,0,-1,0,21255,0
21258,nitroprusside,46,47,311,324,"Increased plasma malondialdehyde was also recorded in two other groups of animals subjected to the same experimental model, one receiving 20 mg/kg b.w. of the cyclooxygenase inhibitor acetylsalicylate intravenously immediately before ischemia, the other receiving 650 micrograms/kg b.w. of the hypotensive drug nitroprusside at a flow rate of 103 microliters/min intravenously during ischemia, although in this latter group malondialdehyde was significantly higher.",7710775_6,0,-1,0,21258,0
21261,malondialdehyde,63,64,424,439,"Increased plasma malondialdehyde was also recorded in two other groups of animals subjected to the same experimental model, one receiving 20 mg/kg b.w. of the cyclooxygenase inhibitor acetylsalicylate intravenously immediately before ischemia, the other receiving 650 micrograms/kg b.w. of the hypotensive drug nitroprusside at a flow rate of 103 microliters/min intravenously during ischemia, although in this latter group malondialdehyde was significantly higher.",7710775_6,0,-1,0,21261,0
21262,malondialdehyde,8,9,52,67,"The present data indicate that the determination of malondialdehyde, oxypurines, and nucleosides in peripheral blood, may be used to monitor the metabolic alterations of tissues occurring during ischemic phenomena.(ABSTRACT TRUNCATED AT 250 WORDS)",7710775_7,0,-1,0,21262,0
21267,nanoparticle,2,3,25,37,Acute doxorubicin-loaded nanoparticle (DXNP) renal toxicity was explored in both normal rats and rats with experimental glomerulonephritis.,7724492_1,0,-1,0,21267,0
21293,E2,27,28,209,211,"Prostaglandin E2-induced bladder hyperactivity in normal, conscious rats: involvement of tachykinins?In normal conscious rats investigated by continuous cystometry, intravesically instilled prostaglandin (PG) E2 facilitated micturition and increased basal intravesical pressure.",7752389_0,0,-1,0,21293,0
21300,PGE2,2,3,23,27,"Intra-arterially given PGE2 produced a distinct increase in bladder pressure before initiating a micturition reflex, indicating that the PG had a direct contractant effect on the detrusor smooth muscle.",7752389_2,0,-1,0,21300,0
21307,PGE2,4,5,29,33,"The effect of intra-arterial PGE2 could not be blocked by intra-arterial RP 67,580 or SR 48,968, which opens the possibility that the micturition reflex elicited by intra-arterial PGE2 was mediated by pathways other than the reflex initiated when the PG was given intravesically.",7752389_3,0,-1,0,21307,0
21308,RP,11,12,73,75,"The effect of intra-arterial PGE2 could not be blocked by intra-arterial RP 67,580 or SR 48,968, which opens the possibility that the micturition reflex elicited by intra-arterial PGE2 was mediated by pathways other than the reflex initiated when the PG was given intravesically.",7752389_3,0,-1,0,21308,0
21311,PGE2,28,29,180,184,"The effect of intra-arterial PGE2 could not be blocked by intra-arterial RP 67,580 or SR 48,968, which opens the possibility that the micturition reflex elicited by intra-arterial PGE2 was mediated by pathways other than the reflex initiated when the PG was given intravesically.",7752389_3,0,-1,0,21311,0
21314,PGE2,7,8,53,57,"The present results thus suggest that intra-arterial PGE2, given near the bladder, may initiate micturition in the normal rat chiefly by directly contracting the smooth muscle of the detrusor.",7752389_4,0,-1,0,21314,0
21315,smooth muscle,26,28,162,175,"The present results thus suggest that intra-arterial PGE2, given near the bladder, may initiate micturition in the normal rat chiefly by directly contracting the smooth muscle of the detrusor.",7752389_4,0,-1,0,21315,0
21318,PGE2,6,7,36,40,"However, when given intravesically, PGE2 may stimulate micturition by releasing tachykinins from nerves in and/or immediately below the urothelium.",7752389_5,0,-1,0,21318,0
21340,dobutamine,30,31,180,190,"The patient continued to remain hypotensive with complete heart block, even with multiple uses of intravenous atropine as well as high doses of pressor agents such as dopamine and dobutamine.",7785794_3,0,-1,0,21340,0
21366,creatinine,19,20,90,100,"RESULTS: Forty-two patients completed the study, 22 in Group A and 20 in Group B. BUN and creatinine increased by > 50% of baseline levels in 54 and 45% of Group A patients, respectively, compared to only 20 and 10% of Group B patients (p < 0.05).",7791169_5,0,-1,0,21366,0
21372,creatinine,6,7,28,38,"The mean increments in BUN, creatinine, and K were reduced by 63, 80, and 42%, respectively, in Group B patients compared to Group A. Response to treatment did not differ significantly between the 2 groups.",7791169_7,0,-1,0,21372,0
21401,dextromethorphan,6,7,48,64,Cognitive deterioration from long-term abuse of dextromethorphan: a case report.,7803371_0,0,-1,0,21401,0
21403,Dextromethorphan,0,1,0,16,"Dextromethorphan (DM), the dextrorotatory isomer of 3-hydroxy-N-methylmorphinan, is the main ingredient in a number of widely available, over-the-counter antitussives.",7803371_1,0,-1,0,21403,0
21486,serum-free media,5,7,29,45,Paired eyes were perfused in serum-free media with or without 10(-7) M dexamethasone for 12 days.,7843916_4,0,-1,0,21486,0
21518,folinic acid,10,12,70,82,Acute confusion induced by a high-dose infusion of 5-fluorouracil and folinic acid.,7858459_0,0,-1,0,21518,0
21521,cisplatinum,9,10,74,85,"A 61-year-old man was treated with combination chemotherapy incorporating cisplatinum, etoposide, high-dose 5-fluorouracil (2,250 mg/m2/24 hours) and folinic acid for an inoperable gastric adenocarcinoma.",7858459_1,0,-1,0,21521,0
21522,etoposide,11,12,87,96,"A 61-year-old man was treated with combination chemotherapy incorporating cisplatinum, etoposide, high-dose 5-fluorouracil (2,250 mg/m2/24 hours) and folinic acid for an inoperable gastric adenocarcinoma.",7858459_1,0,-1,0,21522,0
21524,folinic acid,21,23,150,162,"A 61-year-old man was treated with combination chemotherapy incorporating cisplatinum, etoposide, high-dose 5-fluorouracil (2,250 mg/m2/24 hours) and folinic acid for an inoperable gastric adenocarcinoma.",7858459_1,0,-1,0,21524,0
21530,folinic acid,37,39,214,226,"He developed acute neurologic symptoms of mental confusion, disorientation and irritability, and then lapsed into a deep coma, lasting for approximately 40 hours during the first dose (day 2) of 5-fluorouracil and folinic acid infusion.",7858459_2,0,-1,0,21530,0
21533,folinic acid,13,15,84,96,"This complication reappeared on day 25 during the second dose of 5-fluorouracil and folinic acid, which were then the only drugs given.",7858459_3,0,-1,0,21533,0
21534,folinic acid,1,3,8,20,"Because folinic acid was unlikely to be associated with this condition, neurotoxicity due to high-dose 5-fluorouracil was highly suspected.",7858459_4,0,-1,0,21534,0
21545,oxcarbazepine,5,6,37,50,Effect of switching carbamazepine to oxcarbazepine on the plasma levels of neuroleptics.,7862923_0,0,-1,0,21545,0
21549,oxcarbazepine,7,8,51,64,"Carbamazepine was switched to its 10-keto analogue oxcarbazepine among six difficult-to-treat schizophrenic or organic psychotic patients using concomitantly haloperidol, chlorpromazine or clozapine.",7862923_2,0,-1,0,21549,0
21556,enzyme systems,21,23,138,152,The results of this case report support the idea that in contrast with carbamazepine oxcarbazepine does not induce the hepatic microsomal enzyme systems regulating the inactivation of antipsychotic drugs.,7862923_5,0,-1,0,21556,0
21557,antipsychotic drugs,27,29,184,203,The results of this case report support the idea that in contrast with carbamazepine oxcarbazepine does not induce the hepatic microsomal enzyme systems regulating the inactivation of antipsychotic drugs.,7862923_5,0,-1,0,21557,0
21565,Bupivacaine,0,1,0,11,Bupivacaine 0.75% with adrenaline was given followed by a 24-hr continuous infusion of 0.25% bupivacaine.,7880714_2,0,-1,0,21565,0
21566,bupivacaine,16,17,93,104,Bupivacaine 0.75% with adrenaline was given followed by a 24-hr continuous infusion of 0.25% bupivacaine.,7880714_2,0,-1,0,21566,0
21570,bupivacaine,20,21,101,112,The maximum change in threshold was 35 dB at 6 kHz measured at the end of the continuous infusion of bupivacaine.,7880714_6,0,-1,0,21570,0
21576,puromycin,6,7,37,46,Time course of lipid peroxidation in puromycin aminonucleoside-induced nephropathy.,7881871_0,0,-1,0,21576,0
21578,puromycin aminonucleoside,11,13,74,99,"Reactive oxygen species have been implicated in the pathogenesis of acute puromycin aminonucleoside (PAN)-induced nephropathy, with antioxidants significantly reducing the proteinuria.",7881871_1,0,-1,0,21578,0
21582,puromycin aminonucleoside,9,11,48,73,"Rats were treated with a single IV injection of puromycin aminonucleoside, (PAN, 7.5 mg/kg) and 24 hour urine samples were obtained prior to sacrifice on days 3,5,7,10,17,27,41 (N = 5-10 per group).",7881871_3,0,-1,0,21582,0
21586,TRIS buffer,9,11,48,59,"The kidneys were removed, flushed with ice cold TRIS buffer.",7881871_4,0,-1,0,21586,0
21598,octreotide,7,8,51,61,Composition of gall bladder stones associated with octreotide: response to oral ursodeoxycholic acid.,7890216_0,0,-1,0,21598,0
21599,ursodeoxycholic acid,12,14,80,100,Composition of gall bladder stones associated with octreotide: response to oral ursodeoxycholic acid.,7890216_0,0,-1,0,21599,0
21600,Octreotide,0,1,0,10,"Octreotide, an effective treatment for acromegaly, induces gall bladder stones in 13-60% of patients.",7890216_1,0,-1,0,21600,0
21602,octreotide,28,29,173,183,"Because knowledge of stone composition is essential for studies of their pathogenesis, treatment, and prevention, this was investigated by direct and indirect methods in 14 octreotide treated acromegalic patients with gall stones.",7890216_2,0,-1,0,21602,0
21616,ursodeoxycholic acid,7,9,39,59,"Of the 12 patients considered for oral ursodeoxycholic acid (UDCA) treatment, two had a blocked cystic duct and were not started on UDCA while one was lost to follow up.",7890216_7,0,-1,0,21616,0
21623,octreotide,3,4,15,25,"In conclusion, octreotide induced gall stones are generally small, multiple, and cholesterol rich although, in common with spontaneous gall stone disease, at presentation some patients will have a blocked cystic duct and some gall stones containing calcium.",7890216_10,0,-1,0,21623,0
21653,blocking agents,6,8,57,72,Prolonged paralysis due to nondepolarizing neuromuscular blocking agents and corticosteroids.,7910951_0,0,-1,0,21653,0
21655,blocking agents,6,8,51,66,"The long-term use of nondepolarizing neuromuscular blocking agents (ND-NMBA) has recently been implicated as a cause of prolonged muscle weakness, although the site of the lesion and the predisposing factors have been unclear.",7910951_1,0,-1,0,21655,0
21669,vecuronium,2,3,10,20,"The serum vecuronium level measured in 1 patient 14 days after the drug had been discontinued was 172 ng/mL. A muscle biopsy in this patient showed loss of thick, myosin filaments.",7910951_7,0,-1,0,21669,0
21685,methylprednisolone,5,6,29,47,The patient was treated with methylprednisolone and gradually improved.,7919560_4,0,-1,0,21685,0
21702,at 10,5,7,40,45,Plasma PRL concentrations were analysed at 10 min intervals and underlying secretory rates calculated by a deconvolution procedure.,7930386_4,0,-1,0,21702,0
21722,indocyanine green,4,6,27,44,Survey of complications of indocyanine green angiography in Japan.,7977601_0,0,-1,0,21722,0
21723,indocyanine green,7,9,36,53,PURPOSE: We evaluated the safety of indocyanine green for use in fundus angiography.,7977601_1,0,-1,0,21723,0
21725,indocyanine green,9,11,61,78,"METHODS: We sent a questionnaire concerning complications of indocyanine green to 32 institutions in Japan, which were selected on the basis of the client list from the Topcon Company, which manufactures the indocyanine green fundus camera.",7977601_2,0,-1,0,21725,0
21727,indocyanine green,35,37,208,225,"METHODS: We sent a questionnaire concerning complications of indocyanine green to 32 institutions in Japan, which were selected on the basis of the client list from the Topcon Company, which manufactures the indocyanine green fundus camera.",7977601_2,0,-1,0,21727,0
21728,indocyanine green,13,15,83,100,"RESULTS: Ophthalmologists at 15 institutions responded, reporting a total of 3,774 indocyanine green angiograms performed on 2,820 patients between June 1984 and September 1992.",7977601_3,0,-1,0,21728,0
21729,indocyanine green,6,8,47,64,"Before angiography, intradermal or intravenous indocyanine green testing, or both was performed at 13 of 15 institutions.",7977601_4,0,-1,0,21729,0
21731,indocyanine green,3,5,14,31,"The dosage of indocyanine green used for angiography varied from 25 to 75 mg, depending upon the institution.",7977601_6,0,-1,0,21731,0
21735,indocyanine green,10,12,63,80,CONCLUSIONS: A comparison of frequency of adverse reactions to indocyanine green with the previously reported frequency of such reactions to fluorescein sodium indicated that indocyanine green is a safe as fluorescein for use in angiography.,7977601_10,0,-1,0,21735,0
21736,fluorescein sodium,21,23,141,159,CONCLUSIONS: A comparison of frequency of adverse reactions to indocyanine green with the previously reported frequency of such reactions to fluorescein sodium indicated that indocyanine green is a safe as fluorescein for use in angiography.,7977601_10,0,-1,0,21736,0
21737,indocyanine green,25,27,175,192,CONCLUSIONS: A comparison of frequency of adverse reactions to indocyanine green with the previously reported frequency of such reactions to fluorescein sodium indicated that indocyanine green is a safe as fluorescein for use in angiography.,7977601_10,0,-1,0,21737,0
21741,Her,0,1,0,3,"Her medical history included coronary artery disease with previous myocardial infarctions, hypertension, and diabetes mellitus.",7988234_2,0,-1,0,21741,0
21746,enzyme inhibitors,6,8,59,76,Current medications did not include angiotensin-converting enzyme inhibitors or beta-blockers.,7988234_4,0,-1,0,21746,0
21750,diphenhydramine hydrochloride,9,11,68,97,The angioedema resolved after therapy with intravenous steroids and diphenhydramine hydrochloride.,7988234_7,0,-1,0,21750,0
21751,ancrod,2,3,11,17,Failure of ancrod in the treatment of heparin-induced arterial thrombosis.,8012887_0,0,-1,0,21751,0
21755,Ancrod,0,1,0,6,"Ancrod has been used successfully for prophylaxis against development of thrombosis in patients with heparin induced platelet aggregation who require brief reexposure to heparin, but its success in patients who have developed the thrombosis syndrome is not well defined.",8012887_2,0,-1,0,21755,0
21756,platelet aggregation,16,18,117,137,"Ancrod has been used successfully for prophylaxis against development of thrombosis in patients with heparin induced platelet aggregation who require brief reexposure to heparin, but its success in patients who have developed the thrombosis syndrome is not well defined.",8012887_2,0,-1,0,21756,0
21759,ancrod,8,9,41,47,The authors present a case of failure of ancrod treatment in a patient with heparin-induced thrombosis.,8012887_3,0,-1,0,21759,0
21775,Light chain,0,2,0,11,Light chain proteinuria and cellular mediated immunity in rifampin treated patients with tuberculosis.,804391_0,0,-1,0,21775,0
21777,Light chain,0,2,0,11,Light chain proteinuria was found in 9 of 17 tuberculosis patients treated with rifampin.,804391_1,0,-1,0,21777,0
21784,phytomitogen,28,29,184,196,"Response to Varidase skin test antigen was negative for all eight tuberculosis patients tested, but there occurred a hyper-responsiveness of the lymphocytes of these eight patients to phytomitogen (PHA-P).",804391_3,0,-1,0,21784,0
21789,receptor antagonist,7,9,41,60,KF17837: a novel selective adenosine A2A receptor antagonist with anticataleptic activity.,8045270_0,0,-1,0,21789,0
21792,receptor antagonist,7,9,43,62,KF17837 is a novel selective adenosine A2A receptor antagonist.,8045270_1,0,-1,0,21792,0
21797,receptor agonist,25,27,179,195,"Oral administration of KF17837 (2.5, 10.0 and 30.0 mg/kg) significantly ameliorated the cataleptic responses induced by intracerebroventricular administration of an adenosine A2A receptor agonist, CGS 21680 (10 micrograms), in a dose-dependent manner.",8045270_2,0,-1,0,21797,0
21800,(1,8,10,58,60,KF17837 also reduced the catalepsy induced by haloperidol (1 mg/kg i.p.) and by reserpine (5 mg/kg i.p.).,8045270_3,0,-1,0,21800,0
21806,"L-3,4-dihydroxyphenylalanine",18,19,102,130,"Moreover, KF17837 (0.625 mg/kg p.o.) potentiated the anticataleptic effects of a subthreshold dose of L-3,4-dihydroxyphenylalanine (L-DOPA; 25 mg/kg i.p.) plus benserazide (6.25 mg/kg i.p.).",8045270_5,0,-1,0,21806,0
21807,benserazide,28,29,160,171,"Moreover, KF17837 (0.625 mg/kg p.o.) potentiated the anticataleptic effects of a subthreshold dose of L-3,4-dihydroxyphenylalanine (L-DOPA; 25 mg/kg i.p.) plus benserazide (6.25 mg/kg i.p.).",8045270_5,0,-1,0,21807,0
21809,receptor antagonist,11,13,73,92,These results suggested that KF17837 is a centrally active adenosine A2A receptor antagonist and that the dopaminergic function of the nigrostriatal pathway is potentiated by adenosine A2A receptor antagonists.,8045270_6,0,-1,0,21809,0
21810,dopaminergic,16,17,106,118,These results suggested that KF17837 is a centrally active adenosine A2A receptor antagonist and that the dopaminergic function of the nigrostriatal pathway is potentiated by adenosine A2A receptor antagonists.,8045270_6,0,-1,0,21810,0
21812,receptor antagonists,27,29,189,209,These results suggested that KF17837 is a centrally active adenosine A2A receptor antagonist and that the dopaminergic function of the nigrostriatal pathway is potentiated by adenosine A2A receptor antagonists.,8045270_6,0,-1,0,21812,0
21819,nicotinic,10,11,67,76,"The major teratogenic outcome is arthrogryposis, presumably due to nicotinic receptor blockade.",8073369_2,0,-1,0,21819,0
21842,nicotinic,8,9,51,60,Data from this model support a mechanism involving nicotinic receptor blockade with subsequent decreased fetal movement.,8073369_13,0,-1,0,21842,0
21899,/- 2,8,10,53,57,Left ventricular filling pressure decreased from 19 +/- 2 to 11 +/- 2 mm Hg (P less than 0.001).,809711_4,0,-1,0,21899,0
21919,methysergide,8,9,51,63,"Several drugs, including clonidine, physostigmine, methysergide, 5-MDOT, propranolol, and MK-801, markedly reduced the dyskinetic movements but at the cost of a return of parkinsonian symptomatology.",8106150_5,0,-1,0,21919,0
21921,propranolol,12,13,73,84,"Several drugs, including clonidine, physostigmine, methysergide, 5-MDOT, propranolol, and MK-801, markedly reduced the dyskinetic movements but at the cost of a return of parkinsonian symptomatology.",8106150_5,0,-1,0,21921,0
21922,MK-801,15,16,90,96,"Several drugs, including clonidine, physostigmine, methysergide, 5-MDOT, propranolol, and MK-801, markedly reduced the dyskinetic movements but at the cost of a return of parkinsonian symptomatology.",8106150_5,0,-1,0,21922,0
21925,yohimbine,2,3,9,18,"However, yohimbine and meperidine reduced predominantly the dyskinetic movements.",8106150_6,0,-1,0,21925,0
21927,Baclofen,0,1,0,8,Baclofen was also useful in one monkey against a more dystonic form of dyskinesia.,8106150_7,0,-1,0,21927,0
21933,ifosfamide,18,19,113,123,BACKGROUND: Hallucinations as a symptom of central neurotoxicity are a known but poorly described side effect of ifosfamide.,8111719_1,0,-1,0,21933,0
21944,anhydrase,1,2,9,18,Carbonic anhydrase inhibitors can cause nephrolithiasis.,8170551_1,0,-1,0,21944,0
21945,anhydrase,7,8,52,61,We studied 20 patients receiving long-term carbonic anhydrase inhibitor treatment for periodic paralysis and myotonia.,8170551_2,0,-1,0,21945,0
21955,calcium channel blockers,2,5,11,35,Effects of calcium channel blockers on bupivacaine-induced toxicity.,8231633_0,0,-1,0,21955,0
21957,calcium channel blockers,11,14,62,86,The purpose of this study was to investigate the influence of calcium channel blockers on bupivacaine-induced acute toxicity.,8231633_1,0,-1,0,21957,0
21959,calcium channel blockers,6,9,29,53,"For each of the three tested calcium channel blockers (diltiazem, verapamil and bepridil) 6 groups of mice were treated by two different doses, i.e. 2 and 10 mg/kg/i.p., or an equal volume of saline for the control group (n = 20); 15 minutes later, all the animals were injected with a single 50 mg/kg/i.p.",8231633_2,0,-1,0,21959,0
21960,bepridil,14,15,80,88,"For each of the three tested calcium channel blockers (diltiazem, verapamil and bepridil) 6 groups of mice were treated by two different doses, i.e. 2 and 10 mg/kg/i.p., or an equal volume of saline for the control group (n = 20); 15 minutes later, all the animals were injected with a single 50 mg/kg/i.p.",8231633_2,0,-1,0,21960,0
21963,bupivacaine,2,3,8,19,dose of bupivacaine.,8231633_3,0,-1,0,21963,0
21964,convulsant,1,2,4,14,"The convulsant activity, the time of latency to convulse and the mortality rate were assessed in each group.",8231633_4,0,-1,0,21964,0
21967,calcium channel blockers,11,14,90,114,The local anesthetic-induced mortality was significantly increased by the three different calcium channel blockers.,8231633_5,0,-1,0,21967,0
21968,convulsant,1,2,4,14,The convulsant activity of bupivacaine was not significantly modified but calcium channel blockers decreased the time of latency to obtain bupivacaine-induced convulsions; this effect was less pronounced with bepridil.,8231633_6,0,-1,0,21968,0
21969,bupivacaine,4,5,27,38,The convulsant activity of bupivacaine was not significantly modified but calcium channel blockers decreased the time of latency to obtain bupivacaine-induced convulsions; this effect was less pronounced with bepridil.,8231633_6,0,-1,0,21969,0
21970,calcium channel blockers,10,13,74,98,The convulsant activity of bupivacaine was not significantly modified but calcium channel blockers decreased the time of latency to obtain bupivacaine-induced convulsions; this effect was less pronounced with bepridil.,8231633_6,0,-1,0,21970,0
21971,bepridil,29,30,209,217,The convulsant activity of bupivacaine was not significantly modified but calcium channel blockers decreased the time of latency to obtain bupivacaine-induced convulsions; this effect was less pronounced with bepridil.,8231633_6,0,-1,0,21971,0
21976,amlodipine,6,7,39,49,"One commenced the closely related drug amlodipine 3 years later, with recurrence of telangiectasia.",8251368_4,0,-1,0,21976,0
21985,D-penicillamine,17,18,120,135,A 67-year-old woman with rheumatoid arthritis presented rapidly progressive glomerulonephritis (RPGN) after 5 months of D-penicillamine (250 mg/day) treatment.,8267029_1,0,-1,0,21985,0
21989,C3,8,9,57,59,"Immunofluorescence revealed scanty granular IgG, IgA and C3 deposits along the capillary walls and mesangium.",8267029_3,0,-1,0,21989,0
21994,antiplatelet agents,12,14,81,100,"The patient was treated with steroid pulse, plasmapheresis, cyclophosphamide and antiplatelet agents.",8267029_4,0,-1,0,21994,0
21997,D-penicillamine,9,10,39,54,This new case of RPGN in the course of D-penicillamine treatment emphasizes the need for frequent monitoring of renal function and evaluation of urinary sediment and proteinuria in these patients.,8267029_6,0,-1,0,21997,0
22000,D-penicillamine,4,5,30,45,The prompt discontinuation of D-penicillamine and vigorous treatment measures could allow for a good prognosis as in this case.,8267029_7,0,-1,0,22000,0
22004,D-penicillamine,13,14,80,95,A case of polymyositis in a patient with primary biliary cirrhosis treated with D-penicillamine.,8268147_0,0,-1,0,22004,0
22005,D-penicillamine,1,2,9,24,"Although D-penicillamine has been used for many rheumatologic diseases, toxicity limits its usefulness in many patients.",8268147_1,0,-1,0,22005,0
22009,D-penicillamine,10,11,83,98,"Polymyositis/dermatomyositis can develop as one of the autoimmune complications of D-penicillamine treatment, but its exact pathogenesis remains unclear.",8268147_2,0,-1,0,22009,0
22011,D-penicillamine,14,15,95,110,"We report a patient with primary biliary cirrhosis, who developed polymyositis while receiving D-penicillamine therapy.",8268147_3,0,-1,0,22011,0
22013,D-penicillamine,2,3,19,34,Patients receiving D-penicillamine therapy should be followed carefully for the development of autoimmune complications like polymyositis/dermatomyositis.,8268147_5,0,-1,0,22013,0
22029,opioids,15,16,107,114,The possible mechanisms are discussed and treatment proposals given suggesting the use of more efficacious opioids with less excitatory potency in these situations.,8278214_6,0,-1,0,22029,0
22031,prostaglandin E1,4,6,27,43,Epidural blood flow during prostaglandin E1 or trimethaphan induced hypotension.,8302922_0,0,-1,0,22031,0
22033,prostaglandin E1,5,7,26,42,"To evaluate the effect of prostaglandin E1 (PGE1) or trimethaphan (TMP) induced hypotension on epidural blood flow (EBF) during spinal surgery, EBF was measured using the heat clearance method in 30 patients who underwent postero-lateral interbody fusion under isoflurane anaesthesia.",8302922_1,0,-1,0,22033,0
22034,PGE1,8,9,44,48,"To evaluate the effect of prostaglandin E1 (PGE1) or trimethaphan (TMP) induced hypotension on epidural blood flow (EBF) during spinal surgery, EBF was measured using the heat clearance method in 30 patients who underwent postero-lateral interbody fusion under isoflurane anaesthesia.",8302922_1,0,-1,0,22034,0
22036,TMP,13,14,67,70,"To evaluate the effect of prostaglandin E1 (PGE1) or trimethaphan (TMP) induced hypotension on epidural blood flow (EBF) during spinal surgery, EBF was measured using the heat clearance method in 30 patients who underwent postero-lateral interbody fusion under isoflurane anaesthesia.",8302922_1,0,-1,0,22036,0
22045,PGE1,7,8,47,51,"An initial dose of 0.1 microgram.kg-1.min-1 of PGE1 (15 patients), or 10 micrograms.kg-1.min-1 of TMP (15 patients) was administered intravenously after the dural opening and the dose was adjusted to maintain the mean arterial blood pressure (MAP) at about 60 mmHg.",8302922_2,0,-1,0,22045,0
22047,TMP,17,18,98,101,"An initial dose of 0.1 microgram.kg-1.min-1 of PGE1 (15 patients), or 10 micrograms.kg-1.min-1 of TMP (15 patients) was administered intravenously after the dural opening and the dose was adjusted to maintain the mean arterial blood pressure (MAP) at about 60 mmHg.",8302922_2,0,-1,0,22047,0
22052,PGE1,2,3,15,19,"After starting PGE1 or TMP, MAP and rate pressure product (RPP) decreased significantly compared with preinfusion values (P < 0.01), and the degree of hypotension due to PGE1 remained constant until 60 min after its discontinuation.",8302922_4,0,-1,0,22052,0
22053,TMP,4,5,23,26,"After starting PGE1 or TMP, MAP and rate pressure product (RPP) decreased significantly compared with preinfusion values (P < 0.01), and the degree of hypotension due to PGE1 remained constant until 60 min after its discontinuation.",8302922_4,0,-1,0,22053,0
22057,PGE1,33,34,170,174,"After starting PGE1 or TMP, MAP and rate pressure product (RPP) decreased significantly compared with preinfusion values (P < 0.01), and the degree of hypotension due to PGE1 remained constant until 60 min after its discontinuation.",8302922_4,0,-1,0,22057,0
22060,PGE1,5,6,27,31,"EBFF did not change during PGE1 infusion whereas in the TMP group, EBF decreased significantly at 30 and 60 min after the start of TMP (preinfusion: 45.9 +/- 13.9 ml/100g/min.",8302922_6,0,-1,0,22060,0
22061,TMP,10,11,56,59,"EBFF did not change during PGE1 infusion whereas in the TMP group, EBF decreased significantly at 30 and 60 min after the start of TMP (preinfusion: 45.9 +/- 13.9 ml/100g/min.",8302922_6,0,-1,0,22061,0
22063,TMP,25,26,131,134,"EBFF did not change during PGE1 infusion whereas in the TMP group, EBF decreased significantly at 30 and 60 min after the start of TMP (preinfusion: 45.9 +/- 13.9 ml/100g/min.",8302922_6,0,-1,0,22063,0
22068,PGE1,4,5,27,31,These results suggest that PGE1 may be preferable to TMP for hypotensive anaesthesia in spinal surgery because TMP decreased EBF.,8302922_9,0,-1,0,22068,0
22069,TMP,9,10,53,56,These results suggest that PGE1 may be preferable to TMP for hypotensive anaesthesia in spinal surgery because TMP decreased EBF.,8302922_9,0,-1,0,22069,0
22072,TMP,17,18,111,114,These results suggest that PGE1 may be preferable to TMP for hypotensive anaesthesia in spinal surgery because TMP decreased EBF.,8302922_9,0,-1,0,22072,0
22092,puromycin,6,7,36,45,Dup 753 prevents the development of puromycin aminonucleoside-induced nephrosis.,8319760_0,0,-1,0,22092,0
22097,puromycin aminonucleoside,25,27,166,191,"The appearance of nephrotic syndromes such as proteinuria, hypoalbuminemia, hypercholesterolemia and increase in blood nitrogen urea, induced in rats by injection of puromycin aminonucleoside was markedly inhibited by oral administration of Dup 753 (losartan), a novel angiotensin II receptor antagonist, at a dose of 1 or 2 mg/kg per day.",8319760_1,0,-1,0,22097,0
22099,Dup 753,34,36,241,248,"The appearance of nephrotic syndromes such as proteinuria, hypoalbuminemia, hypercholesterolemia and increase in blood nitrogen urea, induced in rats by injection of puromycin aminonucleoside was markedly inhibited by oral administration of Dup 753 (losartan), a novel angiotensin II receptor antagonist, at a dose of 1 or 2 mg/kg per day.",8319760_1,0,-1,0,22099,0
22100,losartan,37,38,250,258,"The appearance of nephrotic syndromes such as proteinuria, hypoalbuminemia, hypercholesterolemia and increase in blood nitrogen urea, induced in rats by injection of puromycin aminonucleoside was markedly inhibited by oral administration of Dup 753 (losartan), a novel angiotensin II receptor antagonist, at a dose of 1 or 2 mg/kg per day.",8319760_1,0,-1,0,22100,0
22101,angiotensin II receptor antagonist,42,46,269,303,"The appearance of nephrotic syndromes such as proteinuria, hypoalbuminemia, hypercholesterolemia and increase in blood nitrogen urea, induced in rats by injection of puromycin aminonucleoside was markedly inhibited by oral administration of Dup 753 (losartan), a novel angiotensin II receptor antagonist, at a dose of 1 or 2 mg/kg per day.",8319760_1,0,-1,0,22101,0
22103,puromycin,14,15,97,106,The results suggest a possible involvement of the renin-angiotensin system in the development of puromycin aminonucleoside-induced nephrosis.,8319760_2,0,-1,0,22103,0
22147,Sodium bicarbonate,0,2,0,18,Sodium bicarbonate alleviates penile pain induced by intracavernous injections for erectile dysfunction.,8386779_0,0,-1,0,22147,0
22157,sodium bicarbonate,42,44,275,293,"In an attempt to determine whether penile pain associated with intracorporeal injections could be due to the acidity of the medication, we performed a randomized study comparing the incidence of penile pain following intracorporeal injections with or without the addition of sodium bicarbonate to the intracorporeal medications.",8386779_1,0,-1,0,22157,0
22159,prostaglandin E1,0,2,0,16,prostaglandin E1 with (pH 7.05) or without (pH 4.17) the addition of sodium bicarbonate (0.03 mEq.).,8386779_6,0,-1,0,22159,0
22160,sodium bicarbonate,16,18,69,87,prostaglandin E1 with (pH 7.05) or without (pH 4.17) the addition of sodium bicarbonate (0.03 mEq.).,8386779_6,0,-1,0,22160,0
22161,sodium bicarbonate,5,7,27,45,"Of the 19 patients without sodium bicarbonate added to the medication 11 (58%) complained of penile pain due to the medication, while only 1 of the 19 men (5%) who received sodium bicarbonate complained of penile pain.",8386779_7,0,-1,0,22161,0
22163,sodium bicarbonate,38,40,173,191,"Of the 19 patients without sodium bicarbonate added to the medication 11 (58%) complained of penile pain due to the medication, while only 1 of the 19 men (5%) who received sodium bicarbonate complained of penile pain.",8386779_7,0,-1,0,22163,0
22192,oral contraceptives,13,15,78,97,Hepatic adenomas and focal nodular hyperplasia of the liver in young women on oral contraceptives: case reports.,839274_0,0,-1,0,22192,0
22197,oral contraceptives,17,19,104,123,"Two cases of hepatic adenoma and one of focal nodular hyperplasia presumably associated with the use of oral contraceptives, are reported.",839274_1,0,-1,0,22197,0
22209,neurofilament proteins,5,7,47,69,Immunohistochemical studies with antibodies to neurofilament proteins on axonal damage in experimental focal lesions in rat.,8410052_0,0,-1,0,22209,0
22212,monoclonal antibodies,2,4,26,47,"Immunohistochemistry with monoclonal antibodies against neurofilament (NF) proteins of middle and high molecular weight class, NF-M and NF-H, was used to study axonal injury in the borderzone of focal lesions in rats.",8410052_1,0,-1,0,22212,0
22213,neurofilament,5,6,56,69,"Immunohistochemistry with monoclonal antibodies against neurofilament (NF) proteins of middle and high molecular weight class, NF-M and NF-H, was used to study axonal injury in the borderzone of focal lesions in rats.",8410052_1,0,-1,0,22213,0
22236,In situ,0,2,0,7,In situ hybridization methods were used to determine if glutamic acid decarboxylase (GAD) mRNA-containing neurons within the hilus of the dentate gyrus are vulnerable to seizure-induced damage in a model of chronic seizures.,8410199_1,0,-1,0,22236,0
22237,glutamic acid,9,11,56,69,In situ hybridization methods were used to determine if glutamic acid decarboxylase (GAD) mRNA-containing neurons within the hilus of the dentate gyrus are vulnerable to seizure-induced damage in a model of chronic seizures.,8410199_1,0,-1,0,22237,0
22243,In situ,0,2,0,7,"In situ hybridization histochemistry, using a digoxigenin-labeled GAD cRNA probe, demonstrated a substantial decrease in the number of GAD mRNA-containing neurons in the hilus of the dentate gyrus in the pilocarpine-treated rats as compared to controls at all time intervals.",8410199_3,0,-1,0,22243,0
22245,cRNA,9,10,70,74,"In situ hybridization histochemistry, using a digoxigenin-labeled GAD cRNA probe, demonstrated a substantial decrease in the number of GAD mRNA-containing neurons in the hilus of the dentate gyrus in the pilocarpine-treated rats as compared to controls at all time intervals.",8410199_3,0,-1,0,22245,0
22295,somatostatin analog,7,9,46,65,Prospective study of the long-term effects of somatostatin analog (octreotide) on gallbladder function and gallstone formation in Chinese acromegalic patients.,8421099_0,0,-1,0,22295,0
22296,octreotide,10,11,67,77,Prospective study of the long-term effects of somatostatin analog (octreotide) on gallbladder function and gallstone formation in Chinese acromegalic patients.,8421099_0,0,-1,0,22296,0
22304,octreotide,3,4,22,32,"During treatment with octreotide, 17 patients developed sludge, 10 had gallstones, and 1 developed acute cholecystitis requiring surgery.",8421099_2,0,-1,0,22304,0
22306,octreotide,3,4,20,30,"After withdrawal of octreotide in 10 patients without gallstones, 8 patients assessed had return of normal gallbladder contractility within 1 month.",8421099_5,0,-1,0,22306,0
22308,(3,19,21,128,130,"In 8 of the remaining 10 patients who developed gallstones during treatment, gallbladder contractility normalized in 5 patients (3 of whom has disappearance of their stones within 3 weeks), and remained depressed in 3 (2 of whom had stones present at 6 months).",8421099_6,0,-1,0,22308,0
22310,octreotide,25,26,164,174,"Our results suggest that the suppression of gallbladder contractility is the cause of the successive formation of bile sludge, gallstones, and cholecystitis during octreotide therapy in Chinese acromegalic patients.",8421099_7,0,-1,0,22310,0
22312,octreotide,14,15,94,104,It is therefore very important to follow the changes of gallbladder function during long-term octreotide therapy of acromegalic patients.,8421099_8,0,-1,0,22312,0
22372,D-penicillamine,17,18,86,101,BMT was used to treat severe aplastic anemia which was caused by gold in one case and D-penicillamine in the other.,8441146_2,0,-1,0,22372,0
22381,pentamidine,3,4,13,24,Case report: pentamidine and polymorphic ventricular tachycardia revisited.,8475949_0,0,-1,0,22381,0
22392,pentamidine,13,14,74,85,Torsade de pointes occurred after an average of 10 days of treatment with pentamidine.,8475949_4,0,-1,0,22392,0
22394,pentamidine,10,11,50,61,"In these patients, no other acute side effects of pentamidine were observed.",8475949_5,0,-1,0,22394,0
22396,pentamidine,14,15,93,104,"Torsade de pointes can be treated when recognized early, possibly without discontinuation of pentamidine.",8475949_6,0,-1,0,22396,0
22409,high-density lipoprotein,12,14,63,87,"MEASUREMENTS: Plasma total, low-density lipoprotein (LDL), and high-density lipoprotein (HDL) cholesterol, and triglycerides; and laboratory and clinical evidence of adverse events monitored periodically throughout the study.",8480959_5,0,-1,0,22409,0
22412,LDL cholesterol,29,31,133,148,"RESULTS: Among women, lovastatin (20 to 80 mg/d) produced sustained (12- to 48-week), dose-related changes (P < 0.001): decreases in LDL cholesterol (24% to 40%) and triglycerides (9% to 18%), and increases in HDL cholesterol (6.7% to 8.6%).",8480959_6,0,-1,0,22412,0
22416,LDL cholesterol,22,24,127,142,"Depending on the dose, from 82% to 95% of lovastatin-treated women achieved the National Cholesterol Education Program goal of LDL cholesterol levels less than 4.14 mmol/L (160 mg/dL), and 40% to 87% achieved the goal of 3.36 mmol/L (130 mg/dL).",8480959_7,0,-1,0,22416,0
22420,creatine kinase,7,9,42,57,"Myopathy, defined as muscle symptoms with creatine kinase elevations greater than 10 times the upper limit of normal, was rare and associated with the highest recommended daily dose of lovastatin (80 mg).",8480959_9,0,-1,0,22420,0
22434,(3,8,10,59,61,"Symptomatic hypokalemia has been reported in such patients (3-7) and in one case hypocalcemia was observed (8), but the effects of magnesium depletion were not noted in these patients.",8492347_4,0,-1,0,22434,0
22459,(1,25,27,105,107,"A palpable venous cord was present in 23% (14 of 62) of patients in the diazepam group, compared with 2% (1 of 60 patients) in the midazolam group (p < 0.002).",8514073_4,0,-1,0,22459,0
22476,clarithromycin,16,17,114,128,"Unreported in the literature is visual hallucinations occurring in association with the new macrolide antibiotic, clarithromycin.",8546130_2,0,-1,0,22476,0
22480,clarithromycin,8,9,45,59,"The combination of a relatively high dose of clarithromycin in face of chronic renal failure in a functionally anephric patient, with underlying aluminum intoxication, may have facilitated the appearance of this neurotoxic side effect.",8546130_4,0,-1,0,22480,0
22509,vinorelbine,4,5,18,29,Phase II trial of vinorelbine in metastatic squamous cell esophageal carcinoma.,8558192_0,0,-1,0,22509,0
22515,vinorelbine,25,26,167,178,European Organization for Research and Treatment of Cancer Gastrointestinal Treat Cancer Cooperative Group.PURPOSE: To evaluate the response rate and toxic effects of vinorelbine (VNB) administered as a single agent in metastatic squamous cell esophageal carcinoma. PATIENTS AND METHODS: Forty-six eligible patients with measurable lesions were included and were stratified according to previous chemotherapy.,8558192_1,0,-1,0,22515,0
22539,active agent,9,11,47,59,CONCLUSION: These data indicate that VNB is an active agent in metastatic esophageal squamous cell carcinoma.,8558192_13,0,-1,0,22539,0
22559,hexamethonium,6,7,47,60,Intravenous infusion of the ganglionic blocker hexamethonium resulted in a rapid decline in MAP that eliminated the dietary sodium chloride-induced increase in MAP in both groups.,8586822_5,0,-1,0,22559,0
22570,ophthalmic solution,7,9,59,78,Evaluation of adverse reactions of aponidine hydrochloride ophthalmic solution.,8590259_0,0,-1,0,22570,0
22596,Thiopentone,0,1,0,11,Thiopentone pretreatment for propofol injection pain in ambulatory patients.,8595686_0,0,-1,0,22596,0
22598,propofol,3,4,29,37,Thiopentone pretreatment for propofol injection pain in ambulatory patients.,8595686_0,0,-1,0,22598,0
22601,propofol,3,4,24,32,This study investigated propofol injection pain in patients undergoing ambulatory anaesthesia.,8595686_1,0,-1,0,22601,0
22605,propofol,23,24,135,143,"In a randomized, double-blind trial, 90 women were allocated to receive one of three treatments prior to induction of anaesthesia with propofol.",8595686_2,0,-1,0,22605,0
22608,thiopentone,29,30,103,114,"Patients in Group C received 2 ml normal saline, Group L, 2 ml, lidocaine 2% (40 mg) and Group T, 2 ml thiopentone 2.5% (50 mg).",8595686_3,0,-1,0,22608,0
22611,propofol,18,19,92,100,Venous discomfort was assessed with a visual analogue scale (VAS) 5-15 sec after commencing propofol administration using an infusion pump (rate 1000 micrograms.kg-1.min-1).,8595686_4,0,-1,0,22611,0
22626,(r,19,21,108,110,The VAS scores for recall of pain in the recovery room were correlated with the VAS scores during induction (r = 0.7045; P < 0.0001).,8595686_7,0,-1,0,22626,0
22631,propofol,9,10,57,65,"Assessing their overall satisfaction, 89.7% would choose propofol anaesthesia again.",8595686_9,0,-1,0,22631,0
22632,propofol,10,11,65,73,We conclude that lidocaine reduces the incidence and severity of propofol injection pain in ambulatory patients whereas thiopentone only reduces its severity.,8595686_10,0,-1,0,22632,0
22635,thiopentone,17,18,120,131,We conclude that lidocaine reduces the incidence and severity of propofol injection pain in ambulatory patients whereas thiopentone only reduces its severity.,8595686_10,0,-1,0,22635,0
22654,radionuclide,25,26,152,164,"The evaluation consisted of a history, physical examination, electrocardiogram (ECG), signal averaged ECG, 24-hour ambulatory ECG, echocardiography and radionuclide angiography.",8600333_4,0,-1,0,22654,0
22724,atracurium,6,7,44,54,Persistent paralysis after prolonged use of atracurium in the absence of corticosteroids.,8638206_0,0,-1,0,22724,0
22725,blocking agents,1,3,14,29,Neuromuscular blocking agents (NMBAs) are often used for patients requiring prolonged mechanical ventilation.,8638206_1,0,-1,0,22725,0
22729,vecuronium bromide,18,20,130,148,"Reports of persistent paralysis after the discontinuance of these drugs have most often involved aminosteroid-based NMBAs such as vecuronium bromide, especially when used in conjunction with corticosteroids.",8638206_2,0,-1,0,22729,0
22730,Atracurium besylate,0,2,0,19,"Atracurium besylate, a short-acting benzylisoquinolinium NMBA that is eliminated independently of renal or hepatic function, has also been associated with persistent paralysis, but only when used with corticosteroids.",8638206_3,0,-1,0,22730,0
22760,paclitaxel,9,10,68,78,Chemotherapy of advanced inoperable non-small cell lung cancer with paclitaxel: a phase II trial.,8643966_0,0,-1,0,22760,0
22762,Paclitaxel,0,1,0,10,"Paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) has demonstrated significant antineoplastic activity against different tumor types, notably ovarian and breast carcinoma.",8643966_1,0,-1,0,22762,0
22763,Taxol,2,3,12,17,"Paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) has demonstrated significant antineoplastic activity against different tumor types, notably ovarian and breast carcinoma.",8643966_1,0,-1,0,22763,0
22768,paclitaxel,6,7,31,41,Two phase II trials of 24-hour paclitaxel infusions in chemotherapy-naive patients with stage IIIB or IV non-small cell lung cancer (NSCLC) reported response rates of 21% and 24%.,8643966_2,0,-1,0,22768,0
22775,paclitaxel,9,10,54,64,We investigated the efficacy and toxicity of a 3-hour paclitaxel infusion in a phase II trial in patients with inoperable stage IIIB or IV NSCLC.,8643966_4,0,-1,0,22775,0
22781,Paclitaxel,0,1,0,10,Paclitaxel 225 mg/m2 was infused over 3 hours every 3 weeks with standard prophylactic premedication.,8643966_7,0,-1,0,22781,0
22798,Paclitaxel,0,1,0,10,"Paclitaxel is thus an active single agent in this patient population, with a 3-hour infusion proving comparably effective to a 24-hour infusion and superior in terms of the incidence of hematologic and nonhematologic toxicity.",8643966_13,0,-1,0,22798,0
22804,paclitaxel,5,6,30,40,"Further phase II studies with paclitaxel combined with other drugs active against NSCLC are indicated, and phase III studies comparing paclitaxel with standard chemotherapy remain to be completed.",8643966_14,0,-1,0,22804,0
22807,paclitaxel,21,22,135,145,"Further phase II studies with paclitaxel combined with other drugs active against NSCLC are indicated, and phase III studies comparing paclitaxel with standard chemotherapy remain to be completed.",8643966_14,0,-1,0,22807,0
22810,paclitaxel,5,6,22,32,A phase I/II study of paclitaxel plus cisplatin as first-line therapy for head and neck cancers: preliminary results.,8643971_0,0,-1,0,22810,0
22811,cisplatin,7,8,38,47,A phase I/II study of paclitaxel plus cisplatin as first-line therapy for head and neck cancers: preliminary results.,8643971_0,0,-1,0,22811,0
22817,paclitaxel,11,12,83,93,"Preliminary results of an Eastern Cooperative Oncology Group study of single-agent paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) reported a 37% response rate in patients with head and neck cancer, and the paclitaxel/cisplatin combination has been used successfully and has significantly improved median response duration in ovarian cancer patients.",8643971_2,0,-1,0,22817,0
22818,Taxol,13,14,95,100,"Preliminary results of an Eastern Cooperative Oncology Group study of single-agent paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) reported a 37% response rate in patients with head and neck cancer, and the paclitaxel/cisplatin combination has been used successfully and has significantly improved median response duration in ovarian cancer patients.",8643971_2,0,-1,0,22818,0
22826,paclitaxel,14,15,85,95,We initiated a phase I/II trial to determine the response and toxicity of escalating paclitaxel doses combined with fixed-dose cisplatin with granulocyte colony-stimulating factor support in patients with untreated locally advanced inoperable head and neck carcinoma.,8643971_3,0,-1,0,22826,0
22827,cisplatin,19,20,127,136,We initiated a phase I/II trial to determine the response and toxicity of escalating paclitaxel doses combined with fixed-dose cisplatin with granulocyte colony-stimulating factor support in patients with untreated locally advanced inoperable head and neck carcinoma.,8643971_3,0,-1,0,22827,0
22828,colony-stimulating factor,22,24,154,179,We initiated a phase I/II trial to determine the response and toxicity of escalating paclitaxel doses combined with fixed-dose cisplatin with granulocyte colony-stimulating factor support in patients with untreated locally advanced inoperable head and neck carcinoma.,8643971_3,0,-1,0,22828,0
22837,paclitaxel,15,16,75,85,"Treatment, given every 21 days for a maximum of three cycles, consisted of paclitaxel by 3-hour infusion followed the next day by a fixed dose of cisplatin (75 mg/m2).",8643971_7,0,-1,0,22837,0
22839,cisplatin,28,29,146,155,"Treatment, given every 21 days for a maximum of three cycles, consisted of paclitaxel by 3-hour infusion followed the next day by a fixed dose of cisplatin (75 mg/m2).",8643971_7,0,-1,0,22839,0
22840,paclitaxel,5,6,39,49,"The dose levels incorporate escalating paclitaxel doses, and intrapatient escalations within a given dose level are permitted if toxicity permits.",8643971_8,0,-1,0,22840,0
22843,paclitaxel,1,2,5,15,"With paclitaxel doses of 200 mg/m2 and higher, granulocyte colony-stimulating factor 5 micrograms/kg/d is given (days 4 through 12).",8643971_10,0,-1,0,22843,0
22845,colony-stimulating factor,10,12,59,84,"With paclitaxel doses of 200 mg/m2 and higher, granulocyte colony-stimulating factor 5 micrograms/kg/d is given (days 4 through 12).",8643971_10,0,-1,0,22845,0
22860,paclitaxel,8,9,53,63,Results thus far suggest no dose-response effect for paclitaxel doses above 200 mg/m2.,8643971_19,0,-1,0,22860,0
22861,Paclitaxel,0,1,0,10,Paclitaxel combined with carboplatin in the first-line treatment of advanced ovarian cancer.,8643973_0,0,-1,0,22861,0
22862,carboplatin,3,4,25,36,Paclitaxel combined with carboplatin in the first-line treatment of advanced ovarian cancer.,8643973_0,0,-1,0,22862,0
22867,paclitaxel,12,13,62,72,"In a phase I study to determine the maximum tolerated dose of paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) given as a 3-hour infusion in combination with carboplatin administered every 21 days to women with advanced ovarian cancer, paclitaxel doses were escalated as follows: level 1, 135 mg/m2; level 2, 160 mg/m2; level 3, 185 mg/m2; and level 4,210 mg/m2.",8643973_1,0,-1,0,22867,0
22868,Taxol,14,15,74,79,"In a phase I study to determine the maximum tolerated dose of paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) given as a 3-hour infusion in combination with carboplatin administered every 21 days to women with advanced ovarian cancer, paclitaxel doses were escalated as follows: level 1, 135 mg/m2; level 2, 160 mg/m2; level 3, 185 mg/m2; and level 4,210 mg/m2.",8643973_1,0,-1,0,22868,0
22870,carboplatin,32,33,173,184,"In a phase I study to determine the maximum tolerated dose of paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) given as a 3-hour infusion in combination with carboplatin administered every 21 days to women with advanced ovarian cancer, paclitaxel doses were escalated as follows: level 1, 135 mg/m2; level 2, 160 mg/m2; level 3, 185 mg/m2; and level 4,210 mg/m2.",8643973_1,0,-1,0,22870,0
22872,paclitaxel,44,45,251,261,"In a phase I study to determine the maximum tolerated dose of paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) given as a 3-hour infusion in combination with carboplatin administered every 21 days to women with advanced ovarian cancer, paclitaxel doses were escalated as follows: level 1, 135 mg/m2; level 2, 160 mg/m2; level 3, 185 mg/m2; and level 4,210 mg/m2.",8643973_1,0,-1,0,22872,0
22874,carboplatin,4,5,18,29,The fixed dose of carboplatin at levels 1 through 4 was given to achieve an area under the concentration-time curve (AUC) of 5 using the Calvert formula.,8643973_2,0,-1,0,22874,0
22877,carboplatin,6,7,22,33,"In levels 5 and 6 the carboplatin dose was targeted at AUCs of 6 and 7.5, respectively, combined with a fixed paclitaxel dose of 185 mg/m2.",8643973_3,0,-1,0,22877,0
22878,paclitaxel,23,24,110,120,"In levels 5 and 6 the carboplatin dose was targeted at AUCs of 6 and 7.5, respectively, combined with a fixed paclitaxel dose of 185 mg/m2.",8643973_3,0,-1,0,22878,0
22887,paclitaxel,6,7,36,46,We conclude that the combination of paclitaxel 185 mg/m2 administered as a 3-hour infusion followed immediately by a 1-hour infusion of carboplatin at an AUC of 6 can be administered safely in a 21-day schedule in the outpatient setting.,8643973_9,0,-1,0,22887,0
22890,carboplatin,21,22,136,147,We conclude that the combination of paclitaxel 185 mg/m2 administered as a 3-hour infusion followed immediately by a 1-hour infusion of carboplatin at an AUC of 6 can be administered safely in a 21-day schedule in the outpatient setting.,8643973_9,0,-1,0,22890,0
22894,paclitaxel,8,9,46,56,The recommended dose for phase III studies is paclitaxel 185 mg/m2 and carboplatin AUC 6.,8643973_10,0,-1,0,22894,0
22896,carboplatin,12,13,71,82,The recommended dose for phase III studies is paclitaxel 185 mg/m2 and carboplatin AUC 6.,8643973_10,0,-1,0,22896,0
22897,propranolol,5,6,46,57,Improvement of levodopa-induced dyskinesia by propranolol in Parkinson's disease.,8649546_0,0,-1,0,22897,0
22915,methylprednisolone,18,19,89,107,"Therefore, 60 male rats were randomly assigned to receive daily injection of saline (C), methylprednisolone (M), or triamcinolone (T) 80 mg/kg/d for 5 d. Nutritional intake, measured daily in 15 animals, showed a significant reduction of food intake in the steroid-treated groups (-50 and -79% in M and T, respectively).",8665051_3,0,-1,0,22915,0
22934,ATPase,0,1,0,6,"ATPase staining of the diaphragm, scalenus medius, and gastrocnemius showed type IIb fiber atrophy in the steroid groups and also diaphragmatic type IIa atrophy with T, whereas histologic examinations revealed a normal muscular pattern with absence of necrosis.",8665051_10,0,-1,0,22934,0
22945,(1,3,5,17,19,"We conclude that (1) short-term treatment with massive doses of steroids induced severe respiratory and limb muscle wasting; (2) both types of steroids induced predominantly type IIb atrophy, resulting in the expected alterations in diaphragm contractile properties; (3) neither steroid caused muscle necrosis; (4) type IIb atrophy was not caused by acute nutritional deprivation alone.",8665051_12,0,-1,0,22945,0
22950,(3,44,46,267,269,"We conclude that (1) short-term treatment with massive doses of steroids induced severe respiratory and limb muscle wasting; (2) both types of steroids induced predominantly type IIb atrophy, resulting in the expected alterations in diaphragm contractile properties; (3) neither steroid caused muscle necrosis; (4) type IIb atrophy was not caused by acute nutritional deprivation alone.",8665051_12,0,-1,0,22950,0
22978,mesna,4,5,42,47,Continuous subcutaneous administration of mesna to prevent ifosfamide-induced hemorrhagic cystitis.,8677458_0,0,-1,0,22978,0
22981,ifosfamide,8,9,54,64,Hemorrhagic cystitis is a major potential toxicity of ifosfamide that can be prevented by administering mesna along with the cytotoxic agent.,8677458_1,0,-1,0,22981,0
22982,mesna,15,16,104,109,Hemorrhagic cystitis is a major potential toxicity of ifosfamide that can be prevented by administering mesna along with the cytotoxic agent.,8677458_1,0,-1,0,22982,0
22983,cytotoxic agent,19,21,125,140,Hemorrhagic cystitis is a major potential toxicity of ifosfamide that can be prevented by administering mesna along with the cytotoxic agent.,8677458_1,0,-1,0,22983,0
22984,Mesna,0,1,0,5,"Mesna is generally administered by the intravenous route, although experience with oral delivery of the drug has increased.",8677458_2,0,-1,0,22984,0
22988,mesna,5,6,46,51,The continuous subcutaneous administration of mesna has the advantage of not requiring intravenous access.,8677458_3,0,-1,0,22988,0
22993,mesna,19,20,120,125,"In addition, subcutaneous delivery of the neutralizing agent will not be associated with the risk of inadequate urinary mesna concentrations, such as in a patient taking oral mesna who experiences severe ifosfamide-induced emesis and is unable to absorb the drug.",8677458_4,0,-1,0,22993,0
22994,mesna,29,30,175,180,"In addition, subcutaneous delivery of the neutralizing agent will not be associated with the risk of inadequate urinary mesna concentrations, such as in a patient taking oral mesna who experiences severe ifosfamide-induced emesis and is unable to absorb the drug.",8677458_4,0,-1,0,22994,0
22996,mesna,6,7,57,62,"Limited clinical experience with continuous subcutaneous mesna administration suggests it is a safe, practical, and economic method of drug delivery that permits ifosfamide to be administered successfully in the outpatient setting.",8677458_5,0,-1,0,22996,0
22999,ifosfamide,24,25,162,172,"Limited clinical experience with continuous subcutaneous mesna administration suggests it is a safe, practical, and economic method of drug delivery that permits ifosfamide to be administered successfully in the outpatient setting.",8677458_5,0,-1,0,22999,0
23011,lignocaine,11,12,67,77,Leg and back pain after spinal anaesthesia involving hyperbaric 5% lignocaine.,8686832_0,0,-1,0,23011,0
23012,lignocaine,12,13,54,64,"Fifty-four patients, aged 27-90 years, who were given lignocaine 5% in 6.8% glucose solution for spinal anaesthesia were studied.",8686832_1,0,-1,0,23012,0
23020,lignocaine,14,15,77,87,Leg and/or back pain is associated with the intrathecal use of hyperbaric 5% lignocaine.,8686832_5,0,-1,0,23020,0
23042,chondroitinase,28,29,214,228,"The heparan sulphate specificity of the cuprolinic blue staining was demonstrated by glycosaminoglycan-degrading enzymes, showing that pretreatment of the sections with heparitinase abolished all staining, whereas chondroitinase ABC had no effect.",8690168_3,0,-1,0,23042,0
23076,MK-486,18,19,112,118,L-Dopa (5 mg/kg i.v.) decreased blood pressure and heart rate after extracerebral decarboxylase inhibition with MK-486 (25 mg/kg i.v.) in anesthetize MAO-inhibited dogs.,869641_1,0,-1,0,23076,0
23101,FK506,4,5,47,52,Microangiopathic hemolytic anemia complicating FK506 (tacrolimus) therapy.,8701950_0,0,-1,0,23101,0
23102,tacrolimus,6,7,54,64,Microangiopathic hemolytic anemia complicating FK506 (tacrolimus) therapy.,8701950_0,0,-1,0,23102,0
23105,FK506,17,18,101,106,We describe 3 episodes of microangiopathic hemolytic anemia (MAHA) in 2 solid organ recipients under FK506 (tacrolimus) therapy.,8701950_1,0,-1,0,23105,0
23106,tacrolimus,19,20,108,118,We describe 3 episodes of microangiopathic hemolytic anemia (MAHA) in 2 solid organ recipients under FK506 (tacrolimus) therapy.,8701950_1,0,-1,0,23106,0
23107,FK506,6,7,34,39,"In both cases, discontinuation of FK506 and treatment with plasma exchange, fresh frozen plasma replacement, corticosteroids, aspirin, and dipyridamole led to resolution of MAHA.",8701950_2,0,-1,0,23107,0
23110,dipyridamole,23,24,139,151,"In both cases, discontinuation of FK506 and treatment with plasma exchange, fresh frozen plasma replacement, corticosteroids, aspirin, and dipyridamole led to resolution of MAHA.",8701950_2,0,-1,0,23110,0
23111,FK506,6,7,34,39,"In one patient, reintroduction of FK506 led to rapid recurrence of MAHA.",8701950_3,0,-1,0,23111,0
23113,FK506,9,10,51,56,"In our experience and according to the literature, FK506 does not seem to cross-react with cyclosporin A (CyA), an immuno-suppressive drug already known to induce MAHA.",8701950_5,0,-1,0,23113,0
23115,cyclosporin A,16,18,91,104,"In our experience and according to the literature, FK506 does not seem to cross-react with cyclosporin A (CyA), an immuno-suppressive drug already known to induce MAHA.",8701950_5,0,-1,0,23115,0
23125,deoxycholic acid,6,8,58,74,Increased sulfation and decreased 7alpha-hydroxylation of deoxycholic acid in ethinyl estradiol-induced cholestasis in rats.,873132_0,0,-1,0,23125,0
23126,ethinyl,9,10,78,85,Increased sulfation and decreased 7alpha-hydroxylation of deoxycholic acid in ethinyl estradiol-induced cholestasis in rats.,873132_0,0,-1,0,23126,0
23128,Deoxycholic acid,0,2,0,16,"Deoxycholic acid conjugation, transport capacity, and metabolism were compared in control and ethinyl estradiol-treated rats.",873132_1,0,-1,0,23128,0
23130,ethinyl,14,15,94,101,"Deoxycholic acid conjugation, transport capacity, and metabolism were compared in control and ethinyl estradiol-treated rats.",873132_1,0,-1,0,23130,0
23133,deoxycholic acid,11,13,62,78,"Control rats were found to have a lower capacity to transport deoxycholic acid than taurodeoxycholic acid, and both were decreased by ethinyl estradiol treatment.",873132_2,0,-1,0,23133,0
23134,taurodeoxycholic acid,14,16,84,105,"Control rats were found to have a lower capacity to transport deoxycholic acid than taurodeoxycholic acid, and both were decreased by ethinyl estradiol treatment.",873132_2,0,-1,0,23134,0
23135,ethinyl estradiol,22,24,134,151,"Control rats were found to have a lower capacity to transport deoxycholic acid than taurodeoxycholic acid, and both were decreased by ethinyl estradiol treatment.",873132_2,0,-1,0,23135,0
23137,bile acid,8,10,58,67,"During [24-14C]sodium deoxycholate infusion, [14C]biliary bile acid secretion increased, but bile flow did not change significantly in either control or ethinyl estradiol-treated rats.",873132_3,0,-1,0,23137,0
23139,ethinyl,24,25,153,160,"During [24-14C]sodium deoxycholate infusion, [14C]biliary bile acid secretion increased, but bile flow did not change significantly in either control or ethinyl estradiol-treated rats.",873132_3,0,-1,0,23139,0
23141,Ethinyl,0,1,0,7,"Ethinyl estradiol-treated animals excreted significantly less 14C as taurocholic acid than did control animals, consistent with an impairment of 7alpha-hydroxylation of taurodeoxycholic acid.",873132_4,0,-1,0,23141,0
23144,taurocholic acid,8,10,69,85,"Ethinyl estradiol-treated animals excreted significantly less 14C as taurocholic acid than did control animals, consistent with an impairment of 7alpha-hydroxylation of taurodeoxycholic acid.",873132_4,0,-1,0,23144,0
23147,taurodeoxycholic acid,22,24,169,190,"Ethinyl estradiol-treated animals excreted significantly less 14C as taurocholic acid than did control animals, consistent with an impairment of 7alpha-hydroxylation of taurodeoxycholic acid.",873132_4,0,-1,0,23147,0
23148,Ethinyl estradiol,0,2,0,17,"Ethinyl estradiol treatment did not impair conjugation of deoxycholic acid, but did result in an increase in sulfation of taurodeoxycholic acid from 1.5% in controls to nearly 4.0% (P less than 0.01).",873132_5,0,-1,0,23148,0
23149,deoxycholic acid,8,10,58,74,"Ethinyl estradiol treatment did not impair conjugation of deoxycholic acid, but did result in an increase in sulfation of taurodeoxycholic acid from 1.5% in controls to nearly 4.0% (P less than 0.01).",873132_5,0,-1,0,23149,0
23151,taurodeoxycholic acid,20,22,122,143,"Ethinyl estradiol treatment did not impair conjugation of deoxycholic acid, but did result in an increase in sulfation of taurodeoxycholic acid from 1.5% in controls to nearly 4.0% (P less than 0.01).",873132_5,0,-1,0,23151,0
23154,deoxycholic acid,15,17,89,105,These results are consistent with the hypothesis that the rat has a poorer tolerance for deoxycholic acid than do certain other species.,873132_6,0,-1,0,23154,0
23155,deoxycholic acid,5,7,30,46,"Furthermore, the rat converts deoxycholic acid, a poor choleretic, to taurocholic acid, a good choleretic.",873132_7,0,-1,0,23155,0
23157,taurocholic acid,13,15,70,86,"Furthermore, the rat converts deoxycholic acid, a poor choleretic, to taurocholic acid, a good choleretic.",873132_7,0,-1,0,23157,0
23159,ethinyl estradiol,6,8,38,55,"When this conversion is impaired with ethinyl estradiol treatment, sulfation may be an important alternate pathway for excretion of this potentially harmful bile acid.",873132_8,0,-1,0,23159,0
23162,bile acid,23,25,157,166,"When this conversion is impaired with ethinyl estradiol treatment, sulfation may be an important alternate pathway for excretion of this potentially harmful bile acid.",873132_8,0,-1,0,23162,0
23179,creatinine,4,5,27,37,"After drug administration, creatinine concentrations in the plasma and in the urine of the rats were determined, as well as creatinine clearance.",8739323_2,0,-1,0,23179,0
23180,creatinine,22,23,124,134,"After drug administration, creatinine concentrations in the plasma and in the urine of the rats were determined, as well as creatinine clearance.",8739323_2,0,-1,0,23180,0
23183,creatinine,14,15,75,85,After MTX administration a significant increase (p = 0.0228) in the plasma creatinine concentration and a significant (p = 0.0001) decrease in creatinine clearance was noted compared to controls.,8739323_4,0,-1,0,23183,0
23184,creatinine,26,27,143,153,After MTX administration a significant increase (p = 0.0228) in the plasma creatinine concentration and a significant (p = 0.0001) decrease in creatinine clearance was noted compared to controls.,8739323_4,0,-1,0,23184,0
23188,creatinine,15,16,92,102,"After the administration of NG, 5-FU and CY neither a statistically significant increase in creatinine concentration nor an increase in creatinine clearance was observed compared to the group receiving no cytostatics.",8739323_5,0,-1,0,23188,0
23189,creatinine,21,22,136,146,"After the administration of NG, 5-FU and CY neither a statistically significant increase in creatinine concentration nor an increase in creatinine clearance was observed compared to the group receiving no cytostatics.",8739323_5,0,-1,0,23189,0
23193,creatinine,18,19,105,115,"Following polytherapy according to the CMF regimen, a statistically significant decrease (p = 0.0343) in creatinine clearance was found, but creatinine concentration did not increase significantly compared to controls.",8739323_6,0,-1,0,23193,0
23194,creatinine,24,25,141,151,"Following polytherapy according to the CMF regimen, a statistically significant decrease (p = 0.0343) in creatinine clearance was found, but creatinine concentration did not increase significantly compared to controls.",8739323_6,0,-1,0,23194,0
23215,kainic acid,5,7,31,42,Partial lesions were made with kainic acid in the interpeduncular nucleus of the ventral midbrain of the rat.,8741744_1,0,-1,0,23215,0
23220,i.m.,32,34,168,172,"Compared with sham-operated controls, lesions significantly (p < 0.25) blunted the early (<60 min) free-field locomotor hypoactivity caused by nicotine (0.5 mg kg(-1), i.m.), enhanced the later (60-120 min) nicotine-induced hyperactivity, and raised spontaneous nocturnal activity.",8741744_2,0,-1,0,23220,0
23227,nicotinic,7,8,54,63,We conclude that the interpeduncular nucleus mediates nicotinic depression of locomotor activity and dampens nicotinic arousal mechanisms located elsewhere in the brain.,8741744_4,0,-1,0,23227,0
23229,nicotinic,14,15,109,118,We conclude that the interpeduncular nucleus mediates nicotinic depression of locomotor activity and dampens nicotinic arousal mechanisms located elsewhere in the brain.,8741744_4,0,-1,0,23229,0
23235,nicotinic acid,8,10,58,72,"Recently, we demonstrated the hepatoprotective effects of nicotinic acid amide, a selective inhibitor of poly(ADP-ribose) polymerase (PARP; EC 2.4.2.30) on mice suffering from acetaminophen (AAP)-hepatitis, suggesting that the AAP-induced liver injury involves a step which depends on adenoribosylation.",8742498_1,0,-1,0,23235,0
23253,nicotinic acid,28,30,179,193,"While AAP caused a 117-fold elevation of serum transaminase activities in mice kept on a standard laboratory diet, which was significantly exacerbated by ethanol and inhibited by nicotinic acid amide (NAA), adverse effects were noted in animals fed a diet free of precursors of NAD.",8742498_4,0,-1,0,23253,0
23275,divalproex sodium,10,12,76,93,Lithium-associated cognitive and functional deficits reduced by a switch to divalproex sodium: a case series.,8752018_0,0,-1,0,23275,0
23284,divalproex sodium,12,14,84,101,This report summarizes our experience in switching bipolar patients from lithium to divalproex sodium to alleviate such cognitive and functional impairments.,8752018_3,0,-1,0,23284,0
23287,divalproex sodium,17,19,94,111,"RESULTS: We report seven cases where substitution of lithium, either fully or partially, with divalproex sodium was extremely helpful in reducing the cognitive, motivational, or creative deficits attributed to lithium in our bipolar patients.",8752018_5,0,-1,0,23287,0
23290,divalproex sodium,7,9,40,57,"CONCLUSION: In this preliminary report, divalproex sodium was a superior alternative to lithium in bipolar patients experiencing cognitive deficits, loss of creativity, and functional impairments.",8752018_6,0,-1,0,23290,0
23298,serotonergic,10,11,57,69,Tramadol is a weak opioid with effects on adrenergic and serotonergic neurotransmission that is used to treat cancer pain and chronic non malignant pain.,8766220_1,0,-1,0,23298,0
23314,calcium channel,7,9,43,58,This study addressed the potential role of calcium channel blockade in tricyclic antidepressant-induced hypotension.,8800187_3,0,-1,0,23314,0
23317,calcium channel blocker,16,19,103,126,METHODS: Two interventions were studied that have been shown previously to improve blood pressure with calcium channel blocker overdose.,8800187_4,0,-1,0,23317,0
23323,NaHCO3,8,9,43,49,"Fifteen min later, animals received CaCl2, NaHCO3, or saline.",8800187_7,0,-1,0,23323,0
23340,calcium channel,8,10,41,56,These findings do not support a role for calcium channel inhibition in the pathogenesis of tricyclic antidepressant-induced hypotension.,8800187_14,0,-1,0,23340,0
23344,tacrolimus,11,12,80,90,Effect of nifedipine on renal function in liver transplant recipients receiving tacrolimus.,8829025_0,0,-1,0,23344,0
23347,tacrolimus,14,15,93,103,The effect of nifedipine on renal function in liver transplant recipients who were receiving tacrolimus was evaluated between January 1992 and January 1996.,8829025_1,0,-1,0,23347,0
23348,tacrolimus,5,6,33,43,"Two groups of patients receiving tacrolimus were compared over a period of 1 year, one group comprising hypertensive patients who were receiving nifedipine, and the other comprising nonhypertensive patients not receiving nifedipine.",8829025_2,0,-1,0,23348,0
23354,tacrolimus,12,13,90,100,The observed positive impact of nifedipine on reducing the nephrotoxicity associated with tacrolimus in liver transplant recipients should be an important factor in selecting an agent to treat hypertension in this population.,8829025_5,0,-1,0,23354,0
23360,chlormethiazole,6,7,38,53,"Three patients received high doses of chlormethiazole for alcohol withdrawal symptoms, and one took a suicidal overdose of nitrazepam.",88336_2,0,-1,0,23360,0
23362,chlormethiazole,10,11,59,74,"The patient with nitrazepam overdose and two of those with chlormethiazole intoxication conformed to the criteria of 'alpha coma', showing non-reactive generalized or frontally predominant alpha activity in the EEG.",88336_3,0,-1,0,23362,0
23366,chlormethiazole,7,8,45,60,The fourth patient who was unconscious after chlormethiazole administration exhibite generalized non-reactive activity in the slow beta range.,88336_4,0,-1,0,23366,0
23380,angiotensin II,4,6,17,31,"Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: a comparative study of the efficacy and safety against amlodipine.",8841157_0,0,-1,0,23380,0
23383,amlodipine,23,24,143,153,"Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: a comparative study of the efficacy and safety against amlodipine.",8841157_0,0,-1,0,23383,0
23385,angiotensin II,10,12,61,75,"OBJECTIVE: To compare the antihypertensive efficacy of a new angiotensin II antagonist, valsartan, with a reference therapy, amlodipine.",8841157_1,0,-1,0,23385,0
23387,amlodipine,21,22,125,135,"OBJECTIVE: To compare the antihypertensive efficacy of a new angiotensin II antagonist, valsartan, with a reference therapy, amlodipine.",8841157_1,0,-1,0,23387,0
23389,amlodipine,29,30,186,196,METHODS: One hundred sixty-eight adult outpatients with mild to moderate hypertension were randomly allocated in double-blind fashion and equal number to receive 80 mg valsartan or 5 mg amlodipine for 12 weeks.,8841157_2,0,-1,0,23389,0
23391,amlodipine,16,17,87,97,"After 8 weeks of therapy, in patients whose blood pressure remained uncontrolled, 5 mg amlodipine was added to the initial therapy.",8841157_3,0,-1,0,23391,0
23395,amlodipine,5,6,28,38,"RESULTS: Both valsartan and amlodipine were effective at lowering blood pressure at 4, 8, and 12 weeks.",8841157_7,0,-1,0,23395,0
23401,amlodipine,14,15,66,76,Responder rates at 8 weeks were 66.7% for valsartan and 60.2% for amlodipine (p = 0.39).,8841157_10,0,-1,0,23401,0
23403,amlodipine,11,12,73,83,"The incidence of drug-related dependent edema was somewhat higher in the amlodipine group, particularly at a dose of 10 mg per day (2.4% for 80 mg valsartan; 3.6% for 5 mg amlodipine; 0% for valsartan plus 5 mg amlodipine; 14.3% for 10 mg amlodipine).",8841157_12,0,-1,0,23403,0
23404,amlodipine,36,37,172,182,"The incidence of drug-related dependent edema was somewhat higher in the amlodipine group, particularly at a dose of 10 mg per day (2.4% for 80 mg valsartan; 3.6% for 5 mg amlodipine; 0% for valsartan plus 5 mg amlodipine; 14.3% for 10 mg amlodipine).",8841157_12,0,-1,0,23404,0
23405,amlodipine,45,46,211,221,"The incidence of drug-related dependent edema was somewhat higher in the amlodipine group, particularly at a dose of 10 mg per day (2.4% for 80 mg valsartan; 3.6% for 5 mg amlodipine; 0% for valsartan plus 5 mg amlodipine; 14.3% for 10 mg amlodipine).",8841157_12,0,-1,0,23405,0
23406,amlodipine,52,53,239,249,"The incidence of drug-related dependent edema was somewhat higher in the amlodipine group, particularly at a dose of 10 mg per day (2.4% for 80 mg valsartan; 3.6% for 5 mg amlodipine; 0% for valsartan plus 5 mg amlodipine; 14.3% for 10 mg amlodipine).",8841157_12,0,-1,0,23406,0
23407,amlodipine,13,14,70,80,CONCLUSIONS: The data show that valsartan is at least as effective as amlodipine in the treatment of mild to moderate hypertension.,8841157_13,0,-1,0,23407,0
23450,monoamine oxidase inhibitor,12,15,67,94,The most common cause of this syndrome is an interaction between a monoamine oxidase inhibitor (MAOI) and a specific serotonin reuptake inhibitor.,8888541_2,0,-1,0,23450,0
23451,serotonin reuptake inhibitor,21,24,117,145,The most common cause of this syndrome is an interaction between a monoamine oxidase inhibitor (MAOI) and a specific serotonin reuptake inhibitor.,8888541_2,0,-1,0,23451,0
23452,Venlafaxine,0,1,0,11,Venlafaxine is a new antidepressant agent that inhibits the reuptake of serotonin and norepinephrine.,8888541_3,0,-1,0,23452,0
23455,venlafaxine,15,16,75,86,He had been well until the morning of presentation when he took 1/2 tab of venlafaxine.,8888541_5,0,-1,0,23455,0
23478,oral contraceptives,16,18,76,95,A case is reported of the hemolytic uremic syndrome (HUS) in a woman taking oral contraceptives.,891050_1,0,-1,0,23478,0
23480,dipyridamole,6,7,30,42,"She was treated with heparin, dipyridamole and hemodialysis; and after more than three months, her urinary output rose above 500 ml; and six months after the onset of anuria, dialysis treatment was stopped.",891050_2,0,-1,0,23480,0
23481,her,17,18,95,98,"She was treated with heparin, dipyridamole and hemodialysis; and after more than three months, her urinary output rose above 500 ml; and six months after the onset of anuria, dialysis treatment was stopped.",891050_2,0,-1,0,23481,0
23571,bradykinin,13,14,73,83,The goal of this study was to determine the role of synthesis/release of bradykinin to activate B2 receptors in disruption of the blood-brain barrier during acute hypertension.,8955532_2,0,-1,0,23571,0
23572,B2,16,17,96,98,The goal of this study was to determine the role of synthesis/release of bradykinin to activate B2 receptors in disruption of the blood-brain barrier during acute hypertension.,8955532_2,0,-1,0,23572,0
23577,dextran,11,12,92,99,Permeability of the blood-brain barrier was quantitated by clearance of fluorescent-labeled dextran before and during phenylephrine-induced acute hypertension in rats treated with vehicle and Hoe-140 (0.1 microM).,8955532_3,0,-1,0,23577,0
23583,dextran,12,13,101,108,"Phenylephrine infusion increased arterial pressure, arteriolar diameter and clearance of fluorescent dextran by a similar magnitude in both groups.",8955532_4,0,-1,0,23583,0
23587,bradykinin,19,20,135,145,These findings suggest that disruption of the blood-brain barrier during acute hypertension is not related to the synthesis/release of bradykinin to activate B2 receptors.,8955532_5,0,-1,0,23587,0
23588,B2,22,23,158,160,These findings suggest that disruption of the blood-brain barrier during acute hypertension is not related to the synthesis/release of bradykinin to activate B2 receptors.,8955532_5,0,-1,0,23588,0
23592,folic acid,16,18,90,100,A phase I clinical study of the antipurine antifolate lometrexol (DDATHF) given with oral folic acid.,8958188_0,0,-1,0,23592,0
23594,antifolate,3,4,17,27,"Lometrexol is an antifolate which inhibits glycinamide ribonucleotide formyltransferase (GARFT), an enzyme essential for de novo purine synthesis.",8958188_1,0,-1,0,23594,0
23597,novo,18,19,124,128,"Lometrexol is an antifolate which inhibits glycinamide ribonucleotide formyltransferase (GARFT), an enzyme essential for de novo purine synthesis.",8958188_1,0,-1,0,23597,0
23610,folic acid,12,14,76,86,This observation prompted a Phase I clinical study of lometrexol given with folic acid supplementation which has confirmed that the toxicity of lometrexol can be markedly reduced by folic acid supplementation.,8958188_5,0,-1,0,23610,0
23612,folic acid,28,30,182,192,This observation prompted a Phase I clinical study of lometrexol given with folic acid supplementation which has confirmed that the toxicity of lometrexol can be markedly reduced by folic acid supplementation.,8958188_5,0,-1,0,23612,0
23616,folic acid,11,13,92,102,Associated studies demonstrated that lometrexol plasma pharmacokinetics were not altered by folic acid administration indicating that supplementation is unlikely to reduce toxicity by enhancing lometrexol plasma clearance.,8958188_8,0,-1,0,23616,0
23630,dopaminergic,14,15,101,113,"The epidemiologic findings are most consistent with the hypothesis that chronic cocaine use disrupts dopaminergic function and, when coupled with recent cocaine use, may precipitate agitation, delirium, aberrant thermoregulation, rhabdomyolysis, and sudden death.",8988571_6,0,-1,0,23630,0
23655,Pemoline,0,1,0,8,Pemoline induced acute choreoathetosis: case report and review of the literature.,9022662_0,0,-1,0,23655,0
23658,Pemoline,2,3,12,20,BACKGROUND: Pemoline is an oxazolidine derivative that is structurally different from amphetamines and used in the treatment of attention deficit disorder.,9022662_1,0,-1,0,23658,0
23661,Pemoline,0,1,0,8,Pemoline has not been commonly associated in the literature as a cause of acute movement disorders.,9022662_2,0,-1,0,23661,0
23664,pemoline,9,10,64,72,The following case describes two children acutely poisoned with pemoline who experienced profound choreoathetosis.,9022662_3,0,-1,0,23664,0
23668,pemoline,25,26,143,151,"CASE REPORT: Two, 3-year-old male, identical twin siblings presented to the emergency department after found playing with a an empty bottle of pemoline originally containing 59 tablets.",9022662_4,0,-1,0,23668,0
23672,pemoline,6,7,28,36,This was their first day of pemoline therapy.,9022662_6,0,-1,0,23672,0
23682,Pemoline,2,3,12,20,CONCLUSION: Pemoline associated movement disorder has been rarely reported in the acute toxicology literature.,9022662_12,0,-1,0,23682,0
23685,pemoline,12,13,94,102,The possibility of choreoathetoid movements should be considered in patients presenting after pemoline overdose.,9022662_13,0,-1,0,23685,0
23686,venlafaxine,4,5,25,36,Seizure resulting from a venlafaxine overdose.,9034419_0,0,-1,0,23686,0
23687,venlafaxine,7,8,31,42,OBJECTIVE: To report a case of venlafaxine overdose.,9034419_1,0,-1,0,23687,0
23690,venlafaxine,13,14,76,87,CASE SUMMARY: A 40-year-old woman with major depression took an overdose of venlafaxine in an apparent suicide attempt.,9034419_2,0,-1,0,23690,0
23692,venlafaxine,5,6,26,37,"After the ingestion of 26 venlafaxine 50-mg tablets, the patient experienced a witnessed generalized seizure.",9034419_3,0,-1,0,23692,0
23695,venlafaxine,10,11,53,64,"She was admitted to the medical intensive care unit, venlafaxine was discontinued, and no further sequelae were seen.",9034419_4,0,-1,0,23695,0
23696,venlafaxine,13,14,65,76,"DISCUSSION: To our knowledge, this is the first reported case of venlafaxine overdose that resulted in a generalized seizure.",9034419_5,0,-1,0,23696,0
23700,venlafaxine,7,8,62,73,"Based on nonoverdose pharmacokinetics and pharmacodynamics of venlafaxine and the potential risks of available interventions, no emergent therapy was instituted.",9034419_6,0,-1,0,23700,0
23701,venlafaxine,3,4,17,28,CONCLUSIONS: The venlafaxine overdose in our patient resulted in a single episode of generalized seizure but elicited no further sequelae.,9034419_7,0,-1,0,23701,0
23729,hydrogen peroxide,3,5,26,43,Neutrophil superoxide and hydrogen peroxide production in patients with acute liver failure.,9061311_0,0,-1,0,23729,0
23731,hydrogen peroxide,4,6,26,43,Defects in superoxide and hydrogen peroxide production may be implicated in the high incidence of bacterial infections in patients with acute liver failure (ALF).,9061311_1,0,-1,0,23731,0
23736,paracetamol,14,15,76,87,"In the present study, oxygen radical production in patients with ALF due to paracetamol overdose was compared with that of healthy volunteers.",9061311_2,0,-1,0,23736,0
23739,complement receptors,9,11,57,77,Neutrophils from 14 ALF patients were stimulated via the complement receptors using zymosan opsonized with ALF or control serum.,9061311_3,0,-1,0,23739,0
23743,hydrogen peroxide,2,4,15,32,Superoxide and hydrogen peroxide production by ALF neutrophils stimulated with zymosan opsonized with ALF serum was significantly reduced compared with the control subjects (P < 0.01).,9061311_4,0,-1,0,23743,0
23750,hydrogen peroxide,2,4,15,32,Superoxide and hydrogen peroxide production in neutrophils stimulated with formyl-methionyl-leucyl-phenylalanine (fMLP) from a further 18 ALF patients was unaffected compared with control neutrophils.,9061311_6,0,-1,0,23750,0
23751,formyl-methionyl-leucyl-phenylalanine,9,10,75,112,Superoxide and hydrogen peroxide production in neutrophils stimulated with formyl-methionyl-leucyl-phenylalanine (fMLP) from a further 18 ALF patients was unaffected compared with control neutrophils.,9061311_6,0,-1,0,23751,0
23754,C3 complement,1,3,6,19,Serum C3 complement levels were significantly reduced in ALF patients compared with control subjects (P < 0.0005).,9061311_7,0,-1,0,23754,0
23758,paracetamol,10,11,60,71,"These results demonstrate a neutrophil defect in ALF due to paracetamol overdose, that is complement dependent but independent of serum complement, possibly connected to the complement receptor.",9061311_8,0,-1,0,23758,0
23759,serum complement,20,22,130,146,"These results demonstrate a neutrophil defect in ALF due to paracetamol overdose, that is complement dependent but independent of serum complement, possibly connected to the complement receptor.",9061311_8,0,-1,0,23759,0
23760,complement receptor,27,29,174,193,"These results demonstrate a neutrophil defect in ALF due to paracetamol overdose, that is complement dependent but independent of serum complement, possibly connected to the complement receptor.",9061311_8,0,-1,0,23760,0
23769,CCl4,35,36,211,215,"In addition to its use as a stabilizer/rigidifier of membranes, cholesteryl hemisuccinate, tris salt (CS) administration has also been shown to protect rats from the hepatotoxic effects of carbon tetrachloride (CCl4).",9067481_1,0,-1,0,23769,0
23782,CCl4,30,31,155,159,"A 24-h pretreatment of both rats and mice with a single dose of CS (100mg/kg, i.p.), resulted in significant protection against the hepatotoxic effects of CCl4, CHCl3, acetaminophen and galactosamine and against the lethal (and presumably cardiotoxic) effect of adriamycin administration.",9067481_4,0,-1,0,23782,0
23800,prostaglandin E1,4,6,30,46,Combined effects of prolonged prostaglandin E1 (PGE1)-induced hypotension and haemodilution on hepatic function were studied in 30 patients undergoing hip surgery.,9088814_1,0,-1,0,23800,0
23813,dextran,23,24,132,139,"Haemodilution in groups B and C was produced by withdrawing approximately 1000 mL of blood and replacing it with the same amount of dextran solution, and final haematocrit values were 21 or 22%.",9088814_3,0,-1,0,23813,0
23817,PGE1,10,11,58,62,Controlled hypotension in groups A and C was induced with PGE1 to maintain mean arterial blood pressure at 55 mmHg for 180 min.,9088814_4,0,-1,0,23817,0
23833,SGOT,61,62,281,285,"AKBR and biological hepatic function tests showed no change throughout the time course in groups A and B. In group C, AKBR showed a significant decrease at 120 min (-40%) and at 180 min (-49%) after the start of hypotension and at 60 min (-32%) after recovery of normotension, and SGOT, SGPT, LDH and total bilirubin showed significant increases after operation.",9088814_6,0,-1,0,23833,0
23841,selective serotonin reuptake inhibitor,16,20,104,142,"A murine model of adenomyosis: the effects of hyperprolactinemia induced by fluoxetine hydrochloride, a selective serotonin reuptake inhibitor, on adenomyosis induction in Wistar albino rats.",9098464_0,0,-1,0,23841,0
23846,serotonin reuptake inhibitor,5,8,22,50,"DESIGN: Fluoxetine, a serotonin reuptake inhibitor, was given to Wistar Albino rats for 98 days to produce hyperprolactinemia.",9098464_2,0,-1,0,23846,0
23870,calcium channel blockers,7,10,53,77,Cardiovascular alterations in rat fetuses exposed to calcium channel blockers.,9100294_0,0,-1,0,23870,0
23871,calcium channel blocker,7,10,59,82,"Preclinical toxicologic investigation suggested that a new calcium channel blocker, Ro 40-5967, induced cardiovascular alterations in rat fetuses exposed to this agent during organogenesis.",9100294_1,0,-1,0,23871,0
23872,Ro 40-5967,11,15,84,94,"Preclinical toxicologic investigation suggested that a new calcium channel blocker, Ro 40-5967, induced cardiovascular alterations in rat fetuses exposed to this agent during organogenesis.",9100294_1,0,-1,0,23872,0
23874,calcium channel blockers,10,13,66,90,The present study was designed to investigate the hypothesis that calcium channel blockers in general induce cardiovascular malformations indicating a pharmacologic class effect.,9100294_2,0,-1,0,23874,0
23877,calcium channel blockers,3,6,17,41,"We studied three calcium channel blockers of different structure, nifedipine, diltiazem, and verapamil, along with the new agent.",9100294_3,0,-1,0,23877,0
23879,calcium channel blockers,7,10,45,69,Pregnant rats were administered one of these calcium channel blockers during the period of cardiac morphogenesis and the offspring examined on day 20 of gestation for cardiovascular malformations.,9100294_4,0,-1,0,23879,0
23884,calcium channel blockers,15,18,96,120,"A low incidence of cardiovascular malformations was observed after exposure to each of the four calcium channel blockers, but this incidence was statistically significant only for verapamil and nifedipine.",9100294_5,0,-1,0,23884,0
23888,Ro 40-5967,16,20,111,121,"All four agents were associated with aortic arch branching variants, although significantly increased only for Ro 40-5967 and verapamil.",9100294_6,0,-1,0,23888,0
23895,kainic,6,7,54,60,Neuroactive steroids protect against pilocarpine- and kainic acid-induced limbic seizures and status epilepticus in mice.,9121607_0,0,-1,0,23895,0
23905,kainic,30,31,245,251,"Several structurally related metabolites of progesterone (3 alpha-hydroxy pregnane-20-ones) and deoxycorticosterone (3 alpha-hydroxy pregnane-21-diol-20-ones) and their 3 beta-epimers were evaluated for protective activity against pilocarpine-, kainic acid- and N-methyl-D-aspartate (NMDA)-induced seizures in mice.",9121607_1,0,-1,0,23905,0
23926,clonazepam,44,45,312,322,"Although the neuroactive steroids were considerably less potent than the benzodiazepine clonazepam in protecting against pilocarpine seizures, steroids with the 5 alpha,3 alpha-configuration had comparable or higher protective index values (TD50 for motor impairment divided by ED50 for seizure protection) than clonazepam, indicating that some neuroactive steroids may have lower relative toxicity.",9121607_4,0,-1,0,23926,0
23928,"beta,3",8,9,40,46,"Steroids with the 5 alpha,3 alpha- or 5 beta,3 alpha-configurations also produced a dose-dependent delay in the onset of limbic seizures induced by kainic acid (32 mg/kg, s.c.), but did not completely protect against the seizures.",9121607_5,0,-1,0,23928,0
23931,kainic acid,23,25,148,159,"Steroids with the 5 alpha,3 alpha- or 5 beta,3 alpha-configurations also produced a dose-dependent delay in the onset of limbic seizures induced by kainic acid (32 mg/kg, s.c.), but did not completely protect against the seizures.",9121607_5,0,-1,0,23931,0
23932,kainic,22,23,116,122,"However, when a second dose of the steroid was administered 1 hr after the first dose, complete protection from the kainic acid-induced limbic seizures and status epilepticus was obtained.",9121607_6,0,-1,0,23932,0
23938,kainic,13,14,98,104,"We conclude that neuroactive steroids are highly effective in protecting against pilocarpine- and kainic acid-induced seizures and status epilepticus in mice, and may be of utility in the treatment of some forms of status epilepticus in humans.",9121607_8,0,-1,0,23938,0
23948,angiotensinogen,12,13,61,76,"In this work the messenger ribonucleic acid (mRNA) levels of angiotensinogen (Ao) were analyzed with the slot-blot hybridization technique in liver and other extrahepatic tissues: kidney, heart, brain, and adrenal gland from control, nephrotic, and pair-fed (PF) rats.",9154656_2,0,-1,0,23948,0
23955,puromycin,8,9,40,49,NS was induced by a single injection of puromycin amino-nucleoside (PAN).,9154656_3,0,-1,0,23955,0
23972,D2,15,16,115,117,"Risperidone, a benzisoxazole derivative antipsychotic, has high serotonin 5-HT2 receptor blockade and dose-related D2 receptor blockade.",9165568_2,0,-1,0,23972,0
23981,dantrolene,10,11,82,92,The syndrome reversed after discontinuing risperidone and starting treatment with dantrolene and bromocriptine.,9165568_6,0,-1,0,23981,0
23982,bromocriptine,12,13,97,110,The syndrome reversed after discontinuing risperidone and starting treatment with dantrolene and bromocriptine.,9165568_6,0,-1,0,23982,0
23987,sumatriptan,7,8,35,46,The site of common side effects of sumatriptan.,9195768_0,0,-1,0,23987,0
23988,sumatriptan,7,8,54,65,"Atypical sensations following the use of subcutaneous sumatriptan are common, but of uncertain origin.",9195768_1,0,-1,0,23988,0
23998,amikacin,14,15,90,98,METHODS: We present a case of presumed amikacin retinal toxicity following treatment with amikacin and vancomycin for alpha-haemolytic streptococcal endophthalmitis.,9199746_2,0,-1,0,23998,0
24009,carteolol hydrochloride,4,6,26,49,"The attenuating effect of carteolol hydrochloride, a beta-adrenoceptor antagonist, on neuroleptic-induced catalepsy in rats.",9201797_0,0,-1,0,24009,0
24018,carteolol,5,6,26,35,"Therefore, the effects of carteolol, a beta-adrenoceptor antagonist, on haloperidol-induced catalepsy in rats were behaviorally studied and compared with those of propranolol and biperiden, a muscarinic receptor antagonist.",9201797_3,0,-1,0,24018,0
24021,propranolol,24,25,163,174,"Therefore, the effects of carteolol, a beta-adrenoceptor antagonist, on haloperidol-induced catalepsy in rats were behaviorally studied and compared with those of propranolol and biperiden, a muscarinic receptor antagonist.",9201797_3,0,-1,0,24021,0
24022,biperiden,26,27,179,188,"Therefore, the effects of carteolol, a beta-adrenoceptor antagonist, on haloperidol-induced catalepsy in rats were behaviorally studied and compared with those of propranolol and biperiden, a muscarinic receptor antagonist.",9201797_3,0,-1,0,24022,0
24024,Carteolol,0,1,0,9,"Carteolol, as well as propranolol and biperiden, inhibited the haloperidol-induced catalepsy.",9201797_4,0,-1,0,24024,0
24025,propranolol,5,6,22,33,"Carteolol, as well as propranolol and biperiden, inhibited the haloperidol-induced catalepsy.",9201797_4,0,-1,0,24025,0
24026,biperiden,7,8,38,47,"Carteolol, as well as propranolol and biperiden, inhibited the haloperidol-induced catalepsy.",9201797_4,0,-1,0,24026,0
24027,carteolol,4,5,25,34,"The inhibitory effect of carteolol was almost comparable to that of propranolol, but was weaker than that of biperiden.",9201797_5,0,-1,0,24027,0
24028,propranolol,11,12,68,79,"The inhibitory effect of carteolol was almost comparable to that of propranolol, but was weaker than that of biperiden.",9201797_5,0,-1,0,24028,0
24029,biperiden,19,20,109,118,"The inhibitory effect of carteolol was almost comparable to that of propranolol, but was weaker than that of biperiden.",9201797_5,0,-1,0,24029,0
24030,Carteolol,0,1,0,9,Carteolol did not evoke postsynaptic dopamine receptor-stimulating behavioral signs such as stereotypy and hyperlocomotion in rats.,9201797_6,0,-1,0,24030,0
24034,Carteolol,0,1,0,9,Carteolol did not antagonize the inhibitory effects of haloperidol on apomorphine-induced stereotypy and locomotor activity in rats.,9201797_7,0,-1,0,24034,0
24037,carteolol,3,4,13,22,"In addition, carteolol did not evoke 5-HT1A receptor-stimulating behavioral signs such as flat body posture and forepaw treading and did not inhibit 5-hydroxytryptophan-induced head twitch in rats.",9201797_8,0,-1,0,24037,0
24041,carteolol,2,3,9,18,"Finally, carteolol did not inhibit physostigmine-induced lethality in rats.",9201797_9,0,-1,0,24041,0
24043,carteolol,5,6,36,45,These results strongly suggest that carteolol improves haloperidol-induced catalepsy via its beta-adrenoceptor antagonistic activity and is expected to be effective in the treatment of akathisia without attenuating neuroleptic-induced antipsychotic effects due to its postsynaptic dopamine receptor antagonistic activity.,9201797_10,0,-1,0,24043,0
24046,antipsychotic effects,28,30,235,256,These results strongly suggest that carteolol improves haloperidol-induced catalepsy via its beta-adrenoceptor antagonistic activity and is expected to be effective in the treatment of akathisia without attenuating neuroleptic-induced antipsychotic effects due to its postsynaptic dopamine receptor antagonistic activity.,9201797_10,0,-1,0,24046,0
24051,estrogenic effects,10,12,65,83,BACKGROUND: Increased attention has been focused recently on the estrogenic effects of tamoxifen.,9205462_1,0,-1,0,24051,0
24055,alanine transaminase,4,6,31,51,Her aspartate transaminase and alanine transaminase levels increase markedly after 6 months of tamoxifen use.,9205462_4,0,-1,0,24055,0
24059,azidothymidine,5,6,32,46,Lifetime treatment of mice with azidothymidine (AZT) produces myelodysplasia.,9209318_0,0,-1,0,24059,0
24094,stimulatory,10,11,59,70,This depression was followed by the sudden appearance of a stimulatory phase.,921394_3,0,-1,0,24094,0
24100,vascular endothelial growth factor,3,7,19,53,Over expression of vascular endothelial growth factor and its receptor during the development of estrogen-induced rat pituitary tumors may mediate estrogen-initiated tumor angiogenesis.,9214597_0,0,-1,0,24100,0
24107,factor VIII related antigen,27,31,155,182,"To elucidate the role of estrogen in the regulation of tumor angiogenesis in the pituitary of female rats, the density of blood vessels was analysed using factor VIII related antigen (FVIIIRAg) immunohistochemistry and the expression of vascular endothelial growth factor/vascular permeability factor (VEGF/VPF) was examined by Western blot and immunohistochemical analysis.",9214597_3,0,-1,0,24107,0
24110,permeability factor,43,45,281,300,"To elucidate the role of estrogen in the regulation of tumor angiogenesis in the pituitary of female rats, the density of blood vessels was analysed using factor VIII related antigen (FVIIIRAg) immunohistochemistry and the expression of vascular endothelial growth factor/vascular permeability factor (VEGF/VPF) was examined by Western blot and immunohistochemical analysis.",9214597_3,0,-1,0,24110,0
24114,VEGF receptor,3,5,18,31,The expression of VEGF receptor (VEGFR-2/Flk-1/KDR) was also examined by immunohistochemistry.,9214597_4,0,-1,0,24114,0
24117,E2,6,7,48,50,"The results demonstrated that 17beta-estradiol (E2) induces neovascularization, as well as the growth and enlargement of blood vessels after 7 days of exposure.",9214597_5,0,-1,0,24117,0
24120,tumor angiogenic,2,4,9,25,The high tumor angiogenic potential was associated with an elevated VEGF/VPF protein expression in the E2 exposed pituitary of ovariectomized (OVEX) rats.,9214597_6,0,-1,0,24120,0
24122,E2,15,16,103,105,The high tumor angiogenic potential was associated with an elevated VEGF/VPF protein expression in the E2 exposed pituitary of ovariectomized (OVEX) rats.,9214597_6,0,-1,0,24122,0
24131,E2,4,5,17,19,"After 15 days of E2 exposure, VEGF/VPF protein expression, in the non-endothelial cell population, sharply declined and was restricted to the blood vessels.",9214597_8,0,-1,0,24131,0
24136,VEGF,4,5,40,44,The function of non-endothelial-derived VEGF is not clear.,9214597_9,0,-1,0,24136,0
24141,E2,26,27,181,183,"Furthermore, immunohistochemical studies demonstrated that VEGFR-2 (flk-1/KDR), expression was elevated significantly in the endothelial cells of microblood vessels after 7 days of E2 exposure.",9214597_10,0,-1,0,24141,0
24142,VEGF,7,8,47,51,These findings suggest that over expression of VEGF and its receptor (VEGFR-2) may play an important role in the initial step of the regulation of estrogen induced tumor angiogenesis in the rat pituitary.,9214597_11,0,-1,0,24142,0
24160,E-2020,25,26,189,195,"The effects of NIK-247 on cholinesterase, scopolamine-induced amnesia and spontaneous movement were examined and compared with those of the well-known cholinesterase inhibitors tacrine and E-2020.",9228650_1,0,-1,0,24160,0
24162,tacrine,2,3,9,16,"NIK-247, tacrine and E-2020 all strongly inhibited acetylcholinesterase (AChE) in human red blood cells (IC50s = 1.0 x 10(-6), 2.9 x 10(-7) and 3.7 x 10(-8) M, respectively).",9228650_2,0,-1,0,24162,0
24163,E-2020,4,5,21,27,"NIK-247, tacrine and E-2020 all strongly inhibited acetylcholinesterase (AChE) in human red blood cells (IC50s = 1.0 x 10(-6), 2.9 x 10(-7) and 3.7 x 10(-8) M, respectively).",9228650_2,0,-1,0,24163,0
24164,acetylcholinesterase,8,9,51,71,"NIK-247, tacrine and E-2020 all strongly inhibited acetylcholinesterase (AChE) in human red blood cells (IC50s = 1.0 x 10(-6), 2.9 x 10(-7) and 3.7 x 10(-8) M, respectively).",9228650_2,0,-1,0,24164,0
24168,tacrine,5,6,25,32,"In addition, NIK-247 and tacrine, but not E-2020, strongly inhibited butyrylcholinestrase (BuChE) in human serum.",9228650_3,0,-1,0,24168,0
24169,E-2020,9,10,42,48,"In addition, NIK-247 and tacrine, but not E-2020, strongly inhibited butyrylcholinestrase (BuChE) in human serum.",9228650_3,0,-1,0,24169,0
24175,low dose,7,9,41,49,These findings suggest that NIK-247 at a low dose (0.1-1 mg/kg p.o.) improves scopolamine-induced amnesia but does not affect spontaneous movement.,9228650_8,0,-1,0,24175,0
24211,therapeutic use,1,3,10,25,"Potential therapeutic use of the selective dopamine D1 receptor agonist, A-86929: an acute study in parkinsonian levodopa-primed monkeys.",9270571_0,0,-1,0,24211,0
24212,receptor agonist,8,10,55,71,"Potential therapeutic use of the selective dopamine D1 receptor agonist, A-86929: an acute study in parkinsonian levodopa-primed monkeys.",9270571_0,0,-1,0,24212,0
24217,receptor agonists,9,11,41,58,The clinical utility of dopamine (DA) D1 receptor agonists in the treatment of Parkinson's disease (PD) is still unclear.,9270571_1,0,-1,0,24217,0
24219,therapeutic use,1,3,4,19,"The therapeutic use of selective DA D1 receptor agonists such as SKF-82958 (6-chloro-7,8-dihydroxy-3-allyl-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzaze pine hydrobromide) and A-77636 ([1R, 3S] 3-[1'-admantyl]-1-aminomethyl-3,4-dihydro-5,6-dihydroxy-1H-2-benzo pyran hydrochloride) seems limited because of their duration of action, which is too short for SKF-82958 (< 1 hr) and too long for A-77636 (> 20 hr, leading to behavioral tolerance).",9270571_2,0,-1,0,24219,0
24220,receptor agonists,7,9,39,56,"The therapeutic use of selective DA D1 receptor agonists such as SKF-82958 (6-chloro-7,8-dihydroxy-3-allyl-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzaze pine hydrobromide) and A-77636 ([1R, 3S] 3-[1'-admantyl]-1-aminomethyl-3,4-dihydro-5,6-dihydroxy-1H-2-benzo pyran hydrochloride) seems limited because of their duration of action, which is too short for SKF-82958 (< 1 hr) and too long for A-77636 (> 20 hr, leading to behavioral tolerance).",9270571_2,0,-1,0,24220,0
24222,hydrobromide,15,16,153,165,"The therapeutic use of selective DA D1 receptor agonists such as SKF-82958 (6-chloro-7,8-dihydroxy-3-allyl-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzaze pine hydrobromide) and A-77636 ([1R, 3S] 3-[1'-admantyl]-1-aminomethyl-3,4-dihydro-5,6-dihydroxy-1H-2-benzo pyran hydrochloride) seems limited because of their duration of action, which is too short for SKF-82958 (< 1 hr) and too long for A-77636 (> 20 hr, leading to behavioral tolerance).",9270571_2,0,-1,0,24222,0
24235,receptor agonist,56,58,450,466,"We therefore conducted the present acute dose-response study in four 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-exposed cynomolgus monkeys primed to exhibit levodopa-induced dyskinesias to evaluate the locomotor and dyskinetic effects on challenge with four doses (from 0.03 to 1.0 mg/kg) of A-86929 ([-]-[5aR,11bS]-4,5,5a,6,7,11b-hexahydro-2-propyl-3-thia-5-+ ++azacyclopent-1- ena[c]phenathrene-9-10-diol), a selective and full DA D1-like receptor agonist with an intermediate duration of action.",9270571_3,0,-1,0,24235,0
24237,receptor agonist,5,7,28,44,"Levodopa and the DA D2-like receptor agonist, LY-171555 ([4aR-trans]-4,4a,5,6,7,8,8a,9-o-dihydro-5n-propyl-2H-pyrazo lo-3-4-quinoline hydrochloride) were also used for comparison.",9270571_4,0,-1,0,24237,0
24272,P450,21,22,131,135,The serum of six affected workers and five controls was tested for autoantibodies that react with human liver cytochrome-P450 2E1 (P450 2E1) and P58 protein disulphide isomerase isoform (P58).,9284778_8,0,-1,0,24272,0
24273,isoform,29,30,178,185,The serum of six affected workers and five controls was tested for autoantibodies that react with human liver cytochrome-P450 2E1 (P450 2E1) and P58 protein disulphide isomerase isoform (P58).,9284778_8,0,-1,0,24273,0
24281,P450,2,3,23,27,"Autoantibodies against P450 2E1 or P58, previously associated with halothane hepatitis, were detected in the serum of five affected workers.",9284778_11,0,-1,0,24281,0
24296,non-specific,10,11,49,61,"If the patient develops a liver mass, because of non-specific clinical features and imaging appearances, biopsy may be the only way to achieve a definitive diagnosis.",9293063_3,0,-1,0,24296,0
24298,Neuropeptide-Y,0,1,0,14,Neuropeptide-Y immunoreactivity in the pilocarpine model of temporal lobe epilepsy.,9305828_0,0,-1,0,24298,0
24302,Neuropeptide-Y,0,1,0,14,Neuropeptide-Y (NPY) is expressed by granule cells and mossy fibres of the hippocampal dentate gyrus during experimental temporal lobe epilepsy (TLE).,9305828_1,0,-1,0,24302,0
24370,dopaminergic,7,8,45,57,The on-period symptoms that are resistant to dopaminergic therapy do not respond to pallidotomy.,9321531_11,0,-1,0,24370,0
24373,Clarithromycin,0,1,0,14,Clarithromycin is a relatively new macrolide antibiotic that offers twice-daily dosing.,9326871_1,0,-1,0,24373,0
24384,clarithromycin,14,15,90,104,We report a case of ventricular dysrhythmias that occurred after six therapeutic doses of clarithromycin.,9326871_5,0,-1,0,24384,0
24408,human chorionic gonadotropin,7,10,57,85,Endocrine therapy consisted of testosterone heptylate or human chorionic gonadotropin for hypogonadism and bromocriptine for hyperprolactinemia.,9334596_7,0,-1,0,24408,0
24409,bromocriptine,13,14,107,120,Endocrine therapy consisted of testosterone heptylate or human chorionic gonadotropin for hypogonadism and bromocriptine for hyperprolactinemia.,9334596_7,0,-1,0,24409,0
24421,Bromocriptine,0,1,0,13,Bromocriptine was definitely effective in cases with prolactin greater than 35 ng./ml.,9334596_19,0,-1,0,24421,0
24433,D2,9,10,75,77,Extrapyramidal side effects with risperidone and haloperidol at comparable D2 receptor occupancy levels.,9351491_0,0,-1,0,24433,0
24435,antipsychotic drug,3,5,18,36,Risperidone is an antipsychotic drug with high affinity at dopamine D2 and serotonin 5-HT2 receptors.,9351491_1,0,-1,0,24435,0
24444,D2,13,14,84,86,"To determine if routine risperidone treatment is associated with a unique degree of D2 receptor occupancy and pattern of clinical effects, we used [123I]IBZM SPECT to determine D2 occupancy in subjects treated with routine clinical doses of risperidone (n = 12) or haloperidol (n = 7).",9351491_3,0,-1,0,24444,0
24447,D2,28,29,177,179,"To determine if routine risperidone treatment is associated with a unique degree of D2 receptor occupancy and pattern of clinical effects, we used [123I]IBZM SPECT to determine D2 occupancy in subjects treated with routine clinical doses of risperidone (n = 12) or haloperidol (n = 7).",9351491_3,0,-1,0,24447,0
24452,D2,5,6,42,44,Both risperidone and haloperidol produced D2 occupancy levels between approximately 60 and 90% at standard clinical doses.,9351491_4,0,-1,0,24452,0
24460,D2,15,16,94,96,"Based on these observations, it is concluded that 5-HT2 blockade obtained with risperidone at D2 occupancy rates of 60% and above does not appear to protect against the risk for extrapyramidal side effects.",9351491_7,0,-1,0,24460,0
24463,mitoxantrone,8,9,60,72,Treatment of previously treated metastatic breast cancer by mitoxantrone and 48-hour continuous infusion of high-dose 5-FU and leucovorin (MFL): low palliative benefit and high treatment-related toxicity.,9390208_0,0,-1,0,24463,0
24466,leucovorin,17,18,127,137,Treatment of previously treated metastatic breast cancer by mitoxantrone and 48-hour continuous infusion of high-dose 5-FU and leucovorin (MFL): low palliative benefit and high treatment-related toxicity.,9390208_0,0,-1,0,24466,0
24472,mitoxantrone,3,4,30,42,"Combination chemotherapy with mitoxantrone, high-dose 5-fluorouracil (5-FU) and leucovorin (MFL regimen) had been reported as an effective and well tolerated regimen.",9390208_2,0,-1,0,24472,0
24475,leucovorin,11,12,80,90,"Combination chemotherapy with mitoxantrone, high-dose 5-fluorouracil (5-FU) and leucovorin (MFL regimen) had been reported as an effective and well tolerated regimen.",9390208_2,0,-1,0,24475,0
24478,mitoxantrone,18,19,124,136,"From October 1993 to November 1995, we treated 13 patients with previously chemotherapy-treated metastatic breast cancer by mitoxantrone, 12 mg/m2, on day 1 and continuous infusion of 5-FU, 3000 mg/m2, together with leucovorin, 300 mg/m2, for 48 h from day 1 to 2.",9390208_3,0,-1,0,24478,0
24480,leucovorin,37,38,216,226,"From October 1993 to November 1995, we treated 13 patients with previously chemotherapy-treated metastatic breast cancer by mitoxantrone, 12 mg/m2, on day 1 and continuous infusion of 5-FU, 3000 mg/m2, together with leucovorin, 300 mg/m2, for 48 h from day 1 to 2.",9390208_3,0,-1,0,24480,0
24487,mitoxantrone,16,17,88,100,Median number of courses of MFL regimen given was six and the median cumulative dose of mitoxantrone was 68.35 mg/m2.,9390208_8,0,-1,0,24487,0
24505,ticlopidine,9,10,56,67,"Agranulocytosis occurred 3-20 weeks after initiation of ticlopidine, so frequent examination of white cell count during treatment is recommended.",9401499_5,0,-1,0,24505,0
24509,colony-stimulating factors,6,8,55,81,Treatment for ticlopidine-induced aplastic anemia with colony-stimulating factors seemed to have little effect.,9401499_7,0,-1,0,24509,0
24510,calcium channel blockers,11,14,58,82,"The fact that 5 of the 6 patients who received concurrent calcium channel blockers died, should alert clinicians to be more cautious when using these two drugs simultaneously.",9401499_8,0,-1,0,24510,0
24515,arginine vasopressin,3,5,18,38,"The expression of arginine vasopressin (AVP) gene in the paraventricular (PVN) and supraoptic nuclei (SON) was investigated in rats with lithium (Li)-induced polyuria, using in situ hybridization histochemistry and radioimmunoassay.",9406968_1,0,-1,0,24515,0
24519,in situ,31,33,174,181,"The expression of arginine vasopressin (AVP) gene in the paraventricular (PVN) and supraoptic nuclei (SON) was investigated in rats with lithium (Li)-induced polyuria, using in situ hybridization histochemistry and radioimmunoassay.",9406968_1,0,-1,0,24519,0
24535,glyceryl trinitrate,2,4,10,29,Effect of glyceryl trinitrate on the sphincter of Oddi spasm evoked by prostigmine-morphine administration.,9431903_0,0,-1,0,24535,0
24537,glyceryl trinitrate,8,10,39,58,OBJECTIVE: In this study the effect of glyceryl trinitrate on the prostigmine-morphine-induced sphincter of Oddi spasm was evaluated in nine female patients with sphincter of Oddi dyskinesia.,9431903_1,0,-1,0,24537,0
24540,prostigmine,14,15,91,102,METHOD: Sphincter of Oddi spasm was induced by prostigmine-morphine administration (0.5 mg prostigmine intramuscularly and 10 mg morphine subcutaneously) and visualized by quantitative hepatobiliary scintigraphy.,9431903_2,0,-1,0,24540,0
24542,glyceryl trinitrate,6,8,41,60,The entire procedure was repeated during glyceryl trinitrate infusion (Nitrolingual 1 microg/kg/min for 120 min).,9431903_3,0,-1,0,24542,0
24565,Glyceryl trinitrate,0,2,0,19,"Glyceryl trinitrate infusion completely normalized the prostigmine-morphine-induced alterations in these quantitative parameters (TmaX over the LP: 11.33 +/- 1.13; over the HH: 18.88 +/- 1.48; and over the CBD: 36.22 +/- 1.92; and T1/2 over the LP: 28.21 +/- 1.83; over the HH: 33.42 +/- 3.10; and over the CBD: 41.66 +/- 6.33), suggesting an effective sphincter-relaxing effect of glyceryl trinitrate.",9431903_5,0,-1,0,24565,0
24580,glyceryl trinitrate,79,81,382,401,"Glyceryl trinitrate infusion completely normalized the prostigmine-morphine-induced alterations in these quantitative parameters (TmaX over the LP: 11.33 +/- 1.13; over the HH: 18.88 +/- 1.48; and over the CBD: 36.22 +/- 1.92; and T1/2 over the LP: 28.21 +/- 1.83; over the HH: 33.42 +/- 3.10; and over the CBD: 41.66 +/- 6.33), suggesting an effective sphincter-relaxing effect of glyceryl trinitrate.",9431903_5,0,-1,0,24580,0
24581,glyceryl trinitrate,12,14,77,96,CONCLUSION: These results provide the first evidence of the effectiveness of glyceryl trinitrate on the morphine-induced sphincter of Oddi spasm in humans.,9431903_6,0,-1,0,24581,0
24583,glyceryl trinitrate,1,3,6,25,"Since glyceryl trinitrate is able to overcome even the drastic effect of morphine, it might be of relevance in the treatment of sphincter of Oddi dyskinesia.",9431903_7,0,-1,0,24583,0
24585,Antinociceptive,0,1,0,15,"Antinociceptive and antiamnesic properties of the presynaptic cholinergic amplifier PG-9.The antinociceptive effect of 3 alpha-tropyl 2-(p-bromophenyl)propionate [(+/-)-PG-9] (10-40 mg kg-1 s.c.; 30-60 mg kg-1 p.o.; 10-30 mg kg-1 i.v.; 10-30 micrograms/mouse i.c.v.) was examined in mice, rats and guinea pigs by use of the hot-plate, abdominal-constriction, tail-flick and paw-pressure tests.",9495837_0,0,-1,0,24585,0
24589,antinociceptive,10,11,93,108,"Antinociceptive and antiamnesic properties of the presynaptic cholinergic amplifier PG-9.The antinociceptive effect of 3 alpha-tropyl 2-(p-bromophenyl)propionate [(+/-)-PG-9] (10-40 mg kg-1 s.c.; 30-60 mg kg-1 p.o.; 10-30 mg kg-1 i.v.; 10-30 micrograms/mouse i.c.v.) was examined in mice, rats and guinea pigs by use of the hot-plate, abdominal-constriction, tail-flick and paw-pressure tests.",9495837_0,0,-1,0,24589,0
24604,muscarinic,10,11,76,86,"The antinociception produced by (+/-)-PG-9 was prevented by the unselective muscarinic antagonist atropine, the M1-selective antagonists pirenzepine and dicyclomine and the acetylcholine depletor hemicholinium-3, but not by the opioid antagonist naloxone, the gamma-aminobutyric acidB antagonist 3-aminopropyl-diethoxy-methyl-phosphinic acid, the H3 agonist R-(alpha)-methylhistamine, the D2 antagonist quinpirole, the 5-hydroxytryptamine4 antagonist 2-methoxy-4-amino-5-chlorobenzoic acid 2-(diethylamino)ethyl ester hydrochloride, the 5-hydroxytryptamin1A antagonist 1-(2-methoxyphenyl)-4-[4-(2-phthalimido)butyl]piperazine hydrobromide and the polyamines depletor reserpine.",9495837_2,0,-1,0,24604,0
24606,pirenzepine,17,18,137,148,"The antinociception produced by (+/-)-PG-9 was prevented by the unselective muscarinic antagonist atropine, the M1-selective antagonists pirenzepine and dicyclomine and the acetylcholine depletor hemicholinium-3, but not by the opioid antagonist naloxone, the gamma-aminobutyric acidB antagonist 3-aminopropyl-diethoxy-methyl-phosphinic acid, the H3 agonist R-(alpha)-methylhistamine, the D2 antagonist quinpirole, the 5-hydroxytryptamine4 antagonist 2-methoxy-4-amino-5-chlorobenzoic acid 2-(diethylamino)ethyl ester hydrochloride, the 5-hydroxytryptamin1A antagonist 1-(2-methoxyphenyl)-4-[4-(2-phthalimido)butyl]piperazine hydrobromide and the polyamines depletor reserpine.",9495837_2,0,-1,0,24606,0
24607,dicyclomine,19,20,153,164,"The antinociception produced by (+/-)-PG-9 was prevented by the unselective muscarinic antagonist atropine, the M1-selective antagonists pirenzepine and dicyclomine and the acetylcholine depletor hemicholinium-3, but not by the opioid antagonist naloxone, the gamma-aminobutyric acidB antagonist 3-aminopropyl-diethoxy-methyl-phosphinic acid, the H3 agonist R-(alpha)-methylhistamine, the D2 antagonist quinpirole, the 5-hydroxytryptamine4 antagonist 2-methoxy-4-amino-5-chlorobenzoic acid 2-(diethylamino)ethyl ester hydrochloride, the 5-hydroxytryptamin1A antagonist 1-(2-methoxyphenyl)-4-[4-(2-phthalimido)butyl]piperazine hydrobromide and the polyamines depletor reserpine.",9495837_2,0,-1,0,24607,0
24609,opioid antagonist,30,32,228,245,"The antinociception produced by (+/-)-PG-9 was prevented by the unselective muscarinic antagonist atropine, the M1-selective antagonists pirenzepine and dicyclomine and the acetylcholine depletor hemicholinium-3, but not by the opioid antagonist naloxone, the gamma-aminobutyric acidB antagonist 3-aminopropyl-diethoxy-methyl-phosphinic acid, the H3 agonist R-(alpha)-methylhistamine, the D2 antagonist quinpirole, the 5-hydroxytryptamine4 antagonist 2-methoxy-4-amino-5-chlorobenzoic acid 2-(diethylamino)ethyl ester hydrochloride, the 5-hydroxytryptamin1A antagonist 1-(2-methoxyphenyl)-4-[4-(2-phthalimido)butyl]piperazine hydrobromide and the polyamines depletor reserpine.",9495837_2,0,-1,0,24609,0
24611,H3,42,43,347,349,"The antinociception produced by (+/-)-PG-9 was prevented by the unselective muscarinic antagonist atropine, the M1-selective antagonists pirenzepine and dicyclomine and the acetylcholine depletor hemicholinium-3, but not by the opioid antagonist naloxone, the gamma-aminobutyric acidB antagonist 3-aminopropyl-diethoxy-methyl-phosphinic acid, the H3 agonist R-(alpha)-methylhistamine, the D2 antagonist quinpirole, the 5-hydroxytryptamine4 antagonist 2-methoxy-4-amino-5-chlorobenzoic acid 2-(diethylamino)ethyl ester hydrochloride, the 5-hydroxytryptamin1A antagonist 1-(2-methoxyphenyl)-4-[4-(2-phthalimido)butyl]piperazine hydrobromide and the polyamines depletor reserpine.",9495837_2,0,-1,0,24611,0
24613,D2,47,48,389,391,"The antinociception produced by (+/-)-PG-9 was prevented by the unselective muscarinic antagonist atropine, the M1-selective antagonists pirenzepine and dicyclomine and the acetylcholine depletor hemicholinium-3, but not by the opioid antagonist naloxone, the gamma-aminobutyric acidB antagonist 3-aminopropyl-diethoxy-methyl-phosphinic acid, the H3 agonist R-(alpha)-methylhistamine, the D2 antagonist quinpirole, the 5-hydroxytryptamine4 antagonist 2-methoxy-4-amino-5-chlorobenzoic acid 2-(diethylamino)ethyl ester hydrochloride, the 5-hydroxytryptamin1A antagonist 1-(2-methoxyphenyl)-4-[4-(2-phthalimido)butyl]piperazine hydrobromide and the polyamines depletor reserpine.",9495837_2,0,-1,0,24613,0
24632,antinociceptive,13,14,69,84,"Based on these data, it can be postulated that (+/-)-PG-9 exerted an antinociceptive effect mediated by a central potentiation of cholinergic transmission.",9495837_3,0,-1,0,24632,0
24639,dicyclomine,26,27,104,115,(+/-)-PG-9 (10-40 mg kg-1 i.p.) was able to prevent amnesia induced by scopolamine (1 mg kg-1 i.p.) and dicyclomine (2 mg kg-1 i.p.) in the mouse passive-avoidance test.,9495837_4,0,-1,0,24639,0
24644,muscarinic,5,6,36,46,"Affinity profiles of (+/-)-PG-9 for muscarinic receptor subtypes, determined by functional studies (rabbit vas deferens for M1, guinea pig atrium for M2, guinea pig ileum for M3 and immature guinea pig uterus for putative M4), have shown an M4/M1 selectivity ratio of 10.2 that might be responsible for the antinociception and the anti-amnesic effect induced by (+/-)-PG-9 through an increase in acetylcholine extracellular levels.",9495837_5,0,-1,0,24644,0
24655,antinociceptive,2,3,7,22,"In the antinociceptive and antiamnesic dose range, (+/-)-PG-9 did not impair mouse performance evaluated by the rota-rod test and Animex apparatus.",9495837_6,0,-1,0,24655,0
24663,D-penicillamine,16,17,110,125,Four patients with rheumatoid arthritis developed heavy proteinuria after five to 12 months of treatment with D-penicillamine.,950631_1,0,-1,0,24663,0
24674,C3,10,11,87,89,Immunofluorescence microscopy demonstrated granular capillary wall deposits of IgG and C3.,950631_4,0,-1,0,24674,0
24677,C4,27,28,188,190,"The findings were similar to those in early membranous glomerulonephritis, differences being observed however in the results of staining for the early-acting complement components C1q and C4.",950631_5,0,-1,0,24677,0
24708,prilocaine,14,15,72,82,Two groups of 22 similar patients were studied: one group received 6 mL prilocaine 2%; and the other received 3 mL bupivacaine 0.5%.,9522143_4,0,-1,0,24708,0
24709,bupivacaine,24,25,115,126,Two groups of 22 similar patients were studied: one group received 6 mL prilocaine 2%; and the other received 3 mL bupivacaine 0.5%.,9522143_4,0,-1,0,24709,0
24710,prilocaine,2,3,15,25,Patients given prilocaine were more likely to develop hearing loss (10 out of 22) than those given bupivacaine (4 out of 22) (P < 0.05).,9522143_5,0,-1,0,24710,0
24712,bupivacaine,19,20,99,110,Patients given prilocaine were more likely to develop hearing loss (10 out of 22) than those given bupivacaine (4 out of 22) (P < 0.05).,9522143_5,0,-1,0,24712,0
24715,prilocaine,12,13,70,80,The average hearing loss for speech frequencies was about 10 dB after prilocaine and 15 dB after bupivacaine.,9522143_6,0,-1,0,24715,0
24716,bupivacaine,17,18,97,108,The average hearing loss for speech frequencies was about 10 dB after prilocaine and 15 dB after bupivacaine.,9522143_6,0,-1,0,24716,0
24720,bupivacaine,11,12,82,93,A transient neurological deficit following intrathecal injection of 1% hyperbaric bupivacaine for unilateral spinal anaesthesia.,9522152_0,0,-1,0,24720,0
24724,bupivacaine,21,22,130,141,We describe a case of transient neurological deficit that occurred after unilateral spinal anaesthesia with 8 mg of 1% hyperbaric bupivacaine slowly injected through a 25-gauge pencil-point spinal needle.,9522152_1,0,-1,0,24724,0
24739,prilocaine,11,12,78,88,Transient neurologic symptoms after spinal anesthesia: a lower incidence with prilocaine and bupivacaine than with lidocaine.,9523805_0,0,-1,0,24739,0
24740,bupivacaine,13,14,93,104,Transient neurologic symptoms after spinal anesthesia: a lower incidence with prilocaine and bupivacaine than with lidocaine.,9523805_0,0,-1,0,24740,0
24743,bupivacaine,21,22,149,160,BACKGROUND: Recent evidence suggests that transient neurologic symptoms (TNSs) frequently follow lidocaine spinal anesthesia but are infrequent with bupivacaine.,9523805_1,0,-1,0,24743,0
24744,local anesthetic,6,8,42,58,"However, identification of a short-acting local anesthetic to substitute for lidocaine for brief surgical procedures remains an important goal.",9523805_2,0,-1,0,24744,0
24746,Prilocaine,0,1,0,10,Prilocaine is an amide local anesthetic with a duration of action similar to that of lidocaine.,9523805_3,0,-1,0,24746,0
24747,local anesthetic,4,6,23,39,Prilocaine is an amide local anesthetic with a duration of action similar to that of lidocaine.,9523805_3,0,-1,0,24747,0
24749,prilocaine,9,10,66,76,"Accordingly, the present, prospective double-blind study compares prilocaine with lidocaine and bupivacaine with respect to duration of action and relative risk of TNSs.",9523805_4,0,-1,0,24749,0
24750,bupivacaine,13,14,96,107,"Accordingly, the present, prospective double-blind study compares prilocaine with lidocaine and bupivacaine with respect to duration of action and relative risk of TNSs.",9523805_4,0,-1,0,24750,0
24756,prilocaine,42,43,252,262,"METHODS: Ninety patients classified as American Society of Anesthesiologists physical status I or II who were scheduled for short gynecologic procedures under spinal anesthesia were randomly allocated to receive 2.5 ml 2% lidocaine in 7.5% glucose, 2% prilocaine in 7.5% glucose, or 0.5% bupivacaine in 7.5% glucose.",9523805_5,0,-1,0,24756,0
24757,bupivacaine,51,52,288,299,"METHODS: Ninety patients classified as American Society of Anesthesiologists physical status I or II who were scheduled for short gynecologic procedures under spinal anesthesia were randomly allocated to receive 2.5 ml 2% lidocaine in 7.5% glucose, 2% prilocaine in 7.5% glucose, or 0.5% bupivacaine in 7.5% glucose.",9523805_5,0,-1,0,24757,0
24763,prilocaine,16,17,94,104,"RESULTS: Nine of 30 patients receiving lidocaine experienced TNSs, 1 of 30 patients receiving prilocaine (P = 0.03) had them, and none of 30 patients receiving bupivacaine had TNSs.",9523805_9,0,-1,0,24763,0
24764,bupivacaine,31,32,160,171,"RESULTS: Nine of 30 patients receiving lidocaine experienced TNSs, 1 of 30 patients receiving prilocaine (P = 0.03) had them, and none of 30 patients receiving bupivacaine had TNSs.",9523805_9,0,-1,0,24764,0
24765,prilocaine,11,12,63,73,"Times to ambulate and to void were similar after lidocaine and prilocaine (150 vs. 165 min and 238 vs. 253 min, respectively) but prolonged after bupivacaine (200 and 299 min, respectively; P < 0.05).",9523805_10,0,-1,0,24765,0
24766,bupivacaine,28,29,146,157,"Times to ambulate and to void were similar after lidocaine and prilocaine (150 vs. 165 min and 238 vs. 253 min, respectively) but prolonged after bupivacaine (200 and 299 min, respectively; P < 0.05).",9523805_10,0,-1,0,24766,0
24767,Prilocaine,2,3,13,23,CONCLUSIONS: Prilocaine may be preferable to lidocaine for short surgical procedures because it has a similar duration of action but a lower incidence of TNSs.,9523805_11,0,-1,0,24767,0
24770,methylprednisolone,2,3,9,27,Value of methylprednisolone in prevention of the arthralgia-myalgia syndrome associated with the total dose infusion of iron dextran: a double blind randomized trial.,9523850_0,0,-1,0,24770,0
24782,methylprednisolone,21,22,128,146,"The purpose of this randomized, double-blind, prospective study was to investigate whether intravenous (i.v.) administration of methylprednisolone (MP) prevents this complication.",9523850_3,0,-1,0,24782,0
24799,cytochrome P450 3A4,3,6,13,32,"Cisapride, a cytochrome P450 3A4 (CYP3A4) substrate, is widely prescribed for the treatment of gastrointestinal motility disorders.",9545159_1,0,-1,0,24799,0
24800,CYP3A4,7,8,34,40,"Cisapride, a cytochrome P450 3A4 (CYP3A4) substrate, is widely prescribed for the treatment of gastrointestinal motility disorders.",9545159_1,0,-1,0,24800,0
24806,antifungal agents,23,25,154,171,"Prolongation of QT interval, torsades de pointes, and sudden cardiac death have been reported after concomitant administration with erythromycin or azole antifungal agents, but not with other CYP3A4 inhibitors.",9545159_2,0,-1,0,24806,0
24807,CYP3A4 inhibitors,30,32,192,209,"Prolongation of QT interval, torsades de pointes, and sudden cardiac death have been reported after concomitant administration with erythromycin or azole antifungal agents, but not with other CYP3A4 inhibitors.",9545159_2,0,-1,0,24807,0
24811,CYP3A4,27,28,176,182,"A possible drug interaction occurred in a 45-year-old woman who was taking cisapride for gastroesophageal reflux disorder and diltiazem, an agent that has inhibitory effect on CYP3A4, for hypertension.",9545159_3,0,-1,0,24811,0
24816,CYP3A4,15,16,91,97,"We suggest that caution be taken when cisapride is prescribed with any potent inhibitor of CYP3A4, including diltiazem.",9545159_6,0,-1,0,24816,0
24841,levofloxacin,3,4,25,37,Open-label assessment of levofloxacin for the treatment of acute bacterial sinusitis in adults.,9564988_0,0,-1,0,24841,0
24843,levofloxacin,9,10,48,60,PURPOSE: To evaluate the efficacy and safety of levofloxacin (500 mg orally once daily for 10 to 14 days) in treating adult outpatients with acute bacterial sinusitis.,9564988_1,0,-1,0,24843,0
24871,levofloxacin,7,8,43,55,Adverse events considered to be related to levofloxacin administration were reported by 29 patients (9%).,9564988_12,0,-1,0,24871,0
24874,levofloxacin,9,10,52,64,CONCLUSION: The results of this study indicate that levofloxacin 500 mg once daily is an effective and safe treatment for acute bacterial sinusitis.,9564988_14,0,-1,0,24874,0
24917,suxamethonium,21,22,125,138,The present report describes a case of cardiac arrest and subsequent death as a result of hyperkalaemia following the use of suxamethonium in a 23-year-old Malawian woman.,9587734_1,0,-1,0,24917,0
24919,suxamethonium,5,6,33,46,"Forty seconds after injection of suxamethonium, bradycardia and cardiac arrest occurred.",9587734_3,0,-1,0,24919,0
24926,suxamethonium,35,36,213,226,"Apart from the reduction in the patient's level of consciousness, there were no signs of motor neurone damage or of any of the other known predisposing conditions for hyperkalaemia following the administration of suxamethonium.",9587734_6,0,-1,0,24926,0
24928,suxamethonium,11,12,66,79,"It is postulated that her death was caused by hypersensitivity to suxamethonium, associated with her 5-day immobilization.",9587734_7,0,-1,0,24928,0
24930,her,15,16,97,100,"It is postulated that her death was caused by hypersensitivity to suxamethonium, associated with her 5-day immobilization.",9587734_7,0,-1,0,24930,0
24970,Carboplatin,0,1,0,11,Carboplatin toxic effects on the peripheral nervous system of the rat.,9636837_0,0,-1,0,24970,0
24972,carboplatin,6,7,33,44,BACKGROUND: The most striking of carboplatin's advantages (CBDCA) over cisplatin (CDDP) is its markedly reduced rate of neurotoxic effects.,9636837_1,0,-1,0,24972,0
24973,CBDCA,10,11,59,64,BACKGROUND: The most striking of carboplatin's advantages (CBDCA) over cisplatin (CDDP) is its markedly reduced rate of neurotoxic effects.,9636837_1,0,-1,0,24973,0
24974,cisplatin,13,14,71,80,BACKGROUND: The most striking of carboplatin's advantages (CBDCA) over cisplatin (CDDP) is its markedly reduced rate of neurotoxic effects.,9636837_1,0,-1,0,24974,0
24976,CBDCA,5,6,20,25,"However, the use of CBDCA higher-intensity schedules and the association with other neurotoxic drugs in polychemotherapy may cause some concern about its safety with respect to peripheral nervous system damage.",9636837_2,0,-1,0,24976,0
24981,CBDCA,8,9,50,55,MATERIALS AND METHODS: Two different schedules of CBDCA administration (10 mg/kg and 15 mg/kg i.p. twice a week for nine times) were evaluated in Wistar rats.,9636837_3,0,-1,0,24981,0
24988,CBDCA,2,3,9,14,RESULTS: CBDCA administration induced dose-dependent peripheral neurotoxicity.,9636837_5,0,-1,0,24988,0
25002,CBDCA,16,17,100,105,"Moreover, significant amounts of platinum were detected in the dorsal root ganglia and kidney after CBDCA treatment.",9636837_8,0,-1,0,25002,0
25003,CBDCA,2,3,13,18,"CONCLUSIONS: CBDCA is neurotoxic in our model, and the type of pathological changes it induces are so closely similar to those caused by CDDP that it is probable that neurotoxicity is induced in the two drugs by the same mechanism.",9636837_9,0,-1,0,25003,0
25006,CBDCA,17,18,89,94,This model can be used alone or in combination with other drugs to explore the effect of CBDCA on the peripheral nervous system.,9636837_10,0,-1,0,25006,0
25011,her,23,24,125,128,When they do occur they are often unrecognized because of denial but when significant may pose a risk to both the mother and her fetus.,9653867_2,0,-1,0,25011,0
25017,alpha1-adrenergic,6,7,49,66,Repeated trimipramine induces dopamine D2/D3 and alpha1-adrenergic up-regulation.,9660111_0,0,-1,0,25017,0
25024,dopaminergic,22,23,117,129,"The aim of the present study was to find out whether TRI given repeatedly was able to induce adaptive changes in the dopaminergic and alpha1-adrenergic systems, demonstrated by us previously for various antidepressants.",9660111_3,0,-1,0,25024,0
25035,d-amphetamine,11,12,78,91,"TRI given repeatedly to rats increases the locomotor hyperactivity induced by d-amphetamine, quinpirole and (+)-7-hydroxy-dipropyloaminotetralin (dopamine D2 and D3 effects).",9660111_6,0,-1,0,25035,0
25039,D3,20,21,162,164,"TRI given repeatedly to rats increases the locomotor hyperactivity induced by d-amphetamine, quinpirole and (+)-7-hydroxy-dipropyloaminotetralin (dopamine D2 and D3 effects).",9660111_6,0,-1,0,25039,0
25041,d-amphetamine,4,5,28,41,The stereotypies induced by d-amphetamine or apomorphine are not potentiated by TRI.,9660111_7,0,-1,0,25041,0
25045,alpha1-adrenergic receptor,39,41,231,257,"It increases the behaviour stimulation evoked by phenylephrine (given intraventricularly) in rats, evaluated in the open field test as well as the aggressiveness evoked by clonidine in mice, both these effects being mediated by an alpha1-adrenergic receptor.",9660111_8,0,-1,0,25045,0
25048,D3,24,25,158,160,"It may be concluded that, like other tricyclic antidepressants studied previously, TRI given repeatedly increases the responsiveness of brain dopamine D2 and D3 (locomotor activity but not stereotypy) as well as alpha1-adrenergic receptors to their agonists.",9660111_9,0,-1,0,25048,0
25050,alpha1-adrenergic receptors,35,37,212,239,"It may be concluded that, like other tricyclic antidepressants studied previously, TRI given repeatedly increases the responsiveness of brain dopamine D2 and D3 (locomotor activity but not stereotypy) as well as alpha1-adrenergic receptors to their agonists.",9660111_9,0,-1,0,25050,0
25153,pethidine,7,8,63,72,Pethidine-associated seizure in a healthy adolescent receiving pethidine for postoperative pain control.,9672936_0,0,-1,0,25153,0
25155,pethidine,9,10,67,76,A healthy 17-year-old male received standard intermittent doses of pethidine via a patient-controlled analgesia (PCA) pump for management of postoperative pain control.,9672936_1,0,-1,0,25155,0
25159,pethidine,2,3,12,21,Both plasma pethidine and norpethidine were elevated in the range associated with clinical manifestations of central nervous system excitation.,9672936_3,0,-1,0,25159,0
25166,pethidine,6,7,44,53,This method allowed frequent self-dosing of pethidine at short time intervals and rapid accumulation of pethidine and norpethidine.,9672936_5,0,-1,0,25166,0
25168,pethidine,15,16,104,113,This method allowed frequent self-dosing of pethidine at short time intervals and rapid accumulation of pethidine and norpethidine.,9672936_5,0,-1,0,25168,0
25170,pethidine,4,5,19,28,The routine use of pethidine via PCA even for a brief postoperative analgesia should be reconsidered.,9672936_6,0,-1,0,25170,0
25180,group II,28,30,176,184,"An increase in blood pressure, accompanied by atrial fibrillation, agitation, incomprehensible shouts and loss of consciousness, was observed in an elderly, ASA classification group II, cardiovascularly medicated male, 12 min after performance of axillary block with mepivacaine 850 mg containing adrenaline 0.225 mg, for correction of Dupuytren's contracture.",9698967_1,0,-1,0,25180,0
25205,ursodeoxycholic acid,3,5,21,41,"Despite therapy with ursodeoxycholic acid, prednisone, and then tacrolimus, her cholestatic disease was unrelenting, with cirrhosis shown by biopsy 6 months after presentation.",9721172_5,0,-1,0,25205,0
25206,tacrolimus,10,11,64,74,"Despite therapy with ursodeoxycholic acid, prednisone, and then tacrolimus, her cholestatic disease was unrelenting, with cirrhosis shown by biopsy 6 months after presentation.",9721172_5,0,-1,0,25206,0
25242,vigabatrin,5,6,39,49,Inappropriate use of carbamazepine and vigabatrin in typical absence seizures.,9746003_0,0,-1,0,25242,0
25245,vigabatrin,2,3,18,28,Carbamazepine and vigabatrin are contraindicated in typical absence seizures.,9746003_1,0,-1,0,25245,0
25251,Vigabatrin,0,1,0,10,Vigabatrin was also used in the treatment of two children.,9746003_3,0,-1,0,25251,0
25256,vigabatrin,7,8,45,55,Absences were aggravated in both cases where vigabatrin was added on to concurrent treatment.,9746003_5,0,-1,0,25256,0
25257,sodium valproate,8,10,50,66,"Optimal control of the absences was achieved with sodium valproate, lamotrigine, or ethosuximide alone or in combination.",9746003_6,0,-1,0,25257,0
25258,lamotrigine,11,12,68,79,"Optimal control of the absences was achieved with sodium valproate, lamotrigine, or ethosuximide alone or in combination.",9746003_6,0,-1,0,25258,0
25264,receptor agonist,20,22,135,151,This is a case report of euphoria and choreoathetoid movements both transiently induced by rapid adjustment to the selective mu-opioid receptor agonist methadone in an inpatient previously abusing heroine and cocaine.,9754849_2,0,-1,0,25264,0
25267,folic acid,3,5,26,36,Epileptogenic activity of folic acid after drug induces SLE (folic acid and epilepsy)OBJECTIVE: To study the effect of folic acid-containing multivitamin supplementation in epileptic women before and during pregnancy in order to determine the rate of structural birth defects and epilepsy-related side effects.,9758264_0,0,-1,0,25267,0
25268,folic acid,10,12,61,71,Epileptogenic activity of folic acid after drug induces SLE (folic acid and epilepsy)OBJECTIVE: To study the effect of folic acid-containing multivitamin supplementation in epileptic women before and during pregnancy in order to determine the rate of structural birth defects and epilepsy-related side effects.,9758264_0,0,-1,0,25268,0
25277,folic acid,8,10,53,63,"RESULTS: Of 60 epileptic women with periconceptional folic acid (0.8 mg)-containing multivitamin supplementation, no one developed epilepsy-related side effects during the periconception period.",9758264_2,0,-1,0,25277,0
25288,Her,0,1,0,3,Her pregnancy ended with stillbirth.,9758264_7,0,-1,0,25288,0
25294,folic acid,32,34,180,190,"CONCLUSIONS: The epileptic pregnant patient's autoimmune disease (probably drug-induced lupus) could damage the blood-brain barrier, therefore the therapeutic dose (> or =1 mg) of folic acid triggered a cluster of seizures.",9758264_8,0,-1,0,25294,0
25296,folic acid,8,10,30,40,"Physiological dose (<1 mg) of folic acid both in healthy and 60 epileptic women, all without any autoimmune disease, did not increase the risk for epileptic seizures.",9758264_9,0,-1,0,25296,0
25366,low dose,35,37,165,173,"METHOD: In a 6-week random-assignment, double-blind, placebo-controlled trial (phase A), haloperidol, 2-3 mg/day (standard dose), and haloperidol, 0.50-0.75 mg/day (low dose), were compared in 71 outpatients with Alzheimer's disease.",9812111_2,0,-1,0,25366,0
25370,low-dose,16,17,95,103,"For the subsequent 6-week double-blind crossover phase (phase B), patients taking standard- or low-dose haloperidol were switched to placebo, and patients taking placebo were randomly assigned to standard- or low-dose haloperidol.",9812111_3,0,-1,0,25370,0
25372,low-dose,33,34,209,217,"For the subsequent 6-week double-blind crossover phase (phase B), patients taking standard- or low-dose haloperidol were switched to placebo, and patients taking placebo were randomly assigned to standard- or low-dose haloperidol.",9812111_3,0,-1,0,25372,0
25375,low-dose,19,20,115,123,"RESULTS: For the 60 patients who completed phase A, standard-dose haloperidol was efficacious and superior to both low-dose haloperidol and placebo for scores on the Brief Psychiatric Rating Scale psychosis factor and on psychomotor agitation.",9812111_4,0,-1,0,25375,0
25380,low dose,20,22,106,114,Response rates according to three sets of criteria were greater with the standard dose (55%-60%) than the low dose (25%-35%) and placebo (25%-30%).,9812111_5,0,-1,0,25380,0
25382,low dose,6,8,36,44,"The advantage of standard dose over low dose was replicated in phase B. In phase A, extrapyramidal signs tended to be greater with the standard dose than in the other two conditions, primarily because of a subgroup (20%) who developed moderate to severe signs.",9812111_6,0,-1,0,25382,0
25386,Low-dose,0,1,0,8,Low-dose haloperidol did not differ from placebo on any measure of efficacy or side effects.,9812111_7,0,-1,0,25386,0
25397,rifampicin,8,9,56,66,Acute renal failure subsequent to the administration of rifampicin.,982002_0,0,-1,0,25397,0
25402,rifampicin,12,13,92,102,The patients had developed transient renal failure after the intermittent administration of rifampicin.,982002_3,0,-1,0,25402,0
25413,acetylsalicylic acid,2,4,11,31,"Effects of acetylsalicylic acid, dipyridamole, and hydrocortisone on epinephrine-induced myocardial injury in dogs.",983936_0,0,-1,0,25413,0
25414,dipyridamole,5,6,33,45,"Effects of acetylsalicylic acid, dipyridamole, and hydrocortisone on epinephrine-induced myocardial injury in dogs.",983936_0,0,-1,0,25414,0
25432,acetylsalicylic acid,10,12,91,111,"Mitochondrial radiocalcium uptakes were significantly decreased in animals pretreated with acetylsalicylic acid or dipyridamole or when hydrocortisone was added to the epinephrine infusion (2,682,2,803, and 3,424 counts per minute per gram of dried fraction, respectively).",983936_6,0,-1,0,25432,0
25433,dipyridamole,13,14,115,127,"Mitochondrial radiocalcium uptakes were significantly decreased in animals pretreated with acetylsalicylic acid or dipyridamole or when hydrocortisone was added to the epinephrine infusion (2,682,2,803, and 3,424 counts per minute per gram of dried fraction, respectively).",983936_6,0,-1,0,25433,0
25440,Acetylsalicylic acid,0,2,0,20,"Acetylsalicylic acid, dipyridamole, and hydrocortisone all appear to have cardioprotective effects when tested in this model.",983936_9,0,-1,0,25440,0
25441,dipyridamole,3,4,22,34,"Acetylsalicylic acid, dipyridamole, and hydrocortisone all appear to have cardioprotective effects when tested in this model.",983936_9,0,-1,0,25441,0
25476,tacrolimus,9,10,74,84,Clinical and histopathologic examination of renal allografts treated with tacrolimus (FK506) for at least one year.,9855119_0,0,-1,0,25476,0
25477,FK506,11,12,86,91,Clinical and histopathologic examination of renal allografts treated with tacrolimus (FK506) for at least one year.,9855119_0,0,-1,0,25477,0
25481,tacrolimus,17,18,119,129,BACKGROUND: We clinically and pathologically analyzed renal allografts from 1 9 renal transplant patients treated with tacrolimus (FK506) for more than 1 year.,9855119_1,0,-1,0,25481,0
25482,FK506,19,20,131,136,BACKGROUND: We clinically and pathologically analyzed renal allografts from 1 9 renal transplant patients treated with tacrolimus (FK506) for more than 1 year.,9855119_1,0,-1,0,25482,0
25496,FK506,55,56,210,215,"RESULTS: The main pathologic diagnoses (some overlap) were acute rejection (AR; n = 4), chronic rejection (CR; n=5), AR+CR (n =4), recurrent IgA nephropathy (n =5), normal findings (n =2), minimal-type chronic FK506 nephropathy (n = 9), and mild-type FK506 nephropathy (n = 11).",9855119_4,0,-1,0,25496,0
25497,FK506,65,66,251,256,"RESULTS: The main pathologic diagnoses (some overlap) were acute rejection (AR; n = 4), chronic rejection (CR; n=5), AR+CR (n =4), recurrent IgA nephropathy (n =5), normal findings (n =2), minimal-type chronic FK506 nephropathy (n = 9), and mild-type FK506 nephropathy (n = 11).",9855119_4,0,-1,0,25497,0
25500,FK506,14,15,87,92,"Of the nonepisode biopsies, 7 and 4 biopsies showed minimal-type and mild-type chronic FK506 nephropathy, respectively.",9855119_5,0,-1,0,25500,0
25501,FK506,1,2,8,13,"Chronic FK506 nephropathy consisted of rough and foamy tubular vacuolization (5 biopsies), arteriolopathy (angiodegeneration of the arteriolar wall; 20 biopsies), focal segmental glomerulosclerosis (4 biopsies) and the striped form of interstitial fibrosis (11 biopsies).",9855119_6,0,-1,0,25501,0
25510,FK506,10,11,65,70,"The serum creatinine levels of patients in the mild-type chronic FK506 nephropathy group, which included 7 episode biopsies, were statistically higher than those in the minimum-type chronic FK506-nephropathy group (P< 0.001).",9855119_7,0,-1,0,25510,0
25514,FK506,7,8,50,55,"CONCLUSIONS: This study demonstrates that chronic FK506 nephropathy consists primarily of arteriolopathy manifesting as insudative hyalinosis of the arteriolar wall, and suggests that mild-type chronic FK506 nephropathy is a condition which may lead to deterioration of renal allograft function.",9855119_8,0,-1,0,25514,0
25519,FK506,27,28,202,207,"CONCLUSIONS: This study demonstrates that chronic FK506 nephropathy consists primarily of arteriolopathy manifesting as insudative hyalinosis of the arteriolar wall, and suggests that mild-type chronic FK506 nephropathy is a condition which may lead to deterioration of renal allograft function.",9855119_8,0,-1,0,25519,0
25541,ethinyl estradiol,8,10,50,67,We used rat models of intrahepatic cholestasis by ethinyl estradiol (EE) treatment and extrahepatic cholestasis by bile duct ligation (BDL) to precisely determine the site of TJ damage.,9862868_5,0,-1,0,25541,0
25581,fenfluramine,8,9,47,59,Risk for valvular heart disease among users of fenfluramine and dexfenfluramine who underwent echocardiography before use of medication.,9867728_0,0,-1,0,25581,0
25582,dexfenfluramine,10,11,64,79,Risk for valvular heart disease among users of fenfluramine and dexfenfluramine who underwent echocardiography before use of medication.,9867728_0,0,-1,0,25582,0
25584,fenfluramine,18,19,103,115,"BACKGROUND: Because uncontrolled echocardiographic surveys suggested that up to 30% to 38% of users of fenfluramine and dexfenfluramine had valvular disease, these drugs were withdrawn from the market.",9867728_1,0,-1,0,25584,0
25585,dexfenfluramine,20,21,120,135,"BACKGROUND: Because uncontrolled echocardiographic surveys suggested that up to 30% to 38% of users of fenfluramine and dexfenfluramine had valvular disease, these drugs were withdrawn from the market.",9867728_1,0,-1,0,25585,0
25587,fenfluramine,15,16,92,104,OBJECTIVE: To determine the risk for new or worsening valvular abnormalities among users of fenfluramine or dexfenfluramine who underwent echocardiography before they began to take these medications.,9867728_2,0,-1,0,25587,0
25588,dexfenfluramine,17,18,108,123,OBJECTIVE: To determine the risk for new or worsening valvular abnormalities among users of fenfluramine or dexfenfluramine who underwent echocardiography before they began to take these medications.,9867728_2,0,-1,0,25588,0
25591,fenfluramine,6,7,31,43,PATIENTS: 46 patients who used fenfluramine or dexfenfluramine for 14 days or more and had echocardiograms obtained before therapy.,9867728_5,0,-1,0,25591,0
25592,dexfenfluramine,8,9,47,62,PATIENTS: 46 patients who used fenfluramine or dexfenfluramine for 14 days or more and had echocardiograms obtained before therapy.,9867728_5,0,-1,0,25592,0
25607,nerve growth factor,6,9,50,69,"Memory facilitation and stimulation of endogenous nerve growth factor synthesis by the acetylcholine releaser PG-9.The effects of PG-9 (3alpha-tropyl 2-(p-bromophenyl)propionate), the acetylcholine releaser, on memory processes and nerve growth factor (NGF) synthesis were evaluated.",9869257_0,0,-1,0,25607,0
25613,nerve growth factor,31,34,232,251,"Memory facilitation and stimulation of endogenous nerve growth factor synthesis by the acetylcholine releaser PG-9.The effects of PG-9 (3alpha-tropyl 2-(p-bromophenyl)propionate), the acetylcholine releaser, on memory processes and nerve growth factor (NGF) synthesis were evaluated.",9869257_0,0,-1,0,25613,0
25678,gamma-aminobutyric acid,26,28,190,213,"High doses of isoniazid increase hypotension induced by vasodilators and change the accompanying reflex tachycardia to bradycardia, an interaction attributed to decreased synthesis of brain gamma-aminobutyric acid (GABA).",9915601_1,0,-1,0,25678,0
25681,propranolol,5,6,52,63,"Isoniazid significantly increased bradycardia after propranolol, pindolol, labetalol and atenolol, as well as after clonidine, but not after hexamethonium or carbachol.",9915601_3,0,-1,0,25681,0
25682,hexamethonium,22,23,141,154,"Isoniazid significantly increased bradycardia after propranolol, pindolol, labetalol and atenolol, as well as after clonidine, but not after hexamethonium or carbachol.",9915601_3,0,-1,0,25682,0
25683,carbachol,24,25,158,167,"Isoniazid significantly increased bradycardia after propranolol, pindolol, labetalol and atenolol, as well as after clonidine, but not after hexamethonium or carbachol.",9915601_3,0,-1,0,25683,0
25685,GABAergic,9,10,65,74,These results are compatible with interference by isoniazid with GABAergic inhibition of cardiac parasympathetic tone.,9915601_5,0,-1,0,25685,0
25691,FK 506,9,11,66,72,"Mechanisms of FK 506-induced hypertension in the rat.-Tacrolimus (FK 506) is a powerful, widely used immunosuppressant.",9931093_0,0,-1,0,25691,0
25692,FK 506,4,6,24,30,The clinical utility of FK 506 is complicated by substantial hypertension and nephrotoxicity.,9931093_1,0,-1,0,25692,0
25697,FK 506,15,17,92,98,"To clarify the mechanisms of FK 506-induced hypertension, we studied the chronic effects of FK 506 on the synthesis of endothelin-1 (ET-1), the expression of mRNA of ET-1 and endothelin-converting enzyme-1 (ECE-1), the endothelial nitric oxide synthase (eNOS) activity, and the expression of mRNA of eNOS and C-type natriuretic peptide (CNP) in rat blood vessels.",9931093_2,0,-1,0,25697,0
25698,endothelin-1,21,22,119,131,"To clarify the mechanisms of FK 506-induced hypertension, we studied the chronic effects of FK 506 on the synthesis of endothelin-1 (ET-1), the expression of mRNA of ET-1 and endothelin-converting enzyme-1 (ECE-1), the endothelial nitric oxide synthase (eNOS) activity, and the expression of mRNA of eNOS and C-type natriuretic peptide (CNP) in rat blood vessels.",9931093_2,0,-1,0,25698,0
25701,endothelin-converting enzyme-1,33,35,175,205,"To clarify the mechanisms of FK 506-induced hypertension, we studied the chronic effects of FK 506 on the synthesis of endothelin-1 (ET-1), the expression of mRNA of ET-1 and endothelin-converting enzyme-1 (ECE-1), the endothelial nitric oxide synthase (eNOS) activity, and the expression of mRNA of eNOS and C-type natriuretic peptide (CNP) in rat blood vessels.",9931093_2,0,-1,0,25701,0
25706,C-type natriuretic peptide,57,60,309,335,"To clarify the mechanisms of FK 506-induced hypertension, we studied the chronic effects of FK 506 on the synthesis of endothelin-1 (ET-1), the expression of mRNA of ET-1 and endothelin-converting enzyme-1 (ECE-1), the endothelial nitric oxide synthase (eNOS) activity, and the expression of mRNA of eNOS and C-type natriuretic peptide (CNP) in rat blood vessels.",9931093_2,0,-1,0,25706,0
25711,FK 506,0,2,0,6,"FK 506, 5 mg.",9931093_4,0,-1,0,25711,0
25721,FK 506,0,2,0,6,"FK 506 decreased eNOS activity and the levels of eNOS mRNA in the aorta (48% and 55%, respectively).",9931093_8,0,-1,0,25721,0
25726,FK 506,4,6,28,34,These results indicate that FK 506 may increase blood pressure not only by increasing ET-1 production but also by decreasing NO synthesis in the vasculature.,9931093_11,0,-1,0,25726,0
25731,cytochrome c oxidase,14,17,114,134,Structural and functional impairment of mitochondria in adriamycin-induced cardiomyopathy in mice: suppression of cytochrome c oxidase II gene expression.,9952311_0,0,-1,0,25731,0
3,renal failure,12,14,106,119,22-oxacalcitriol suppresses secondary hyperparathyroidism without inducing low bone turnover in dogs with renal failure.,10027919_0,-1,1,1,3,1
7,renal failure,16,18,101,114,"BACKGROUND: Calcitriol therapy suppresses serum levels of parathyroid hormone (PTH) in patients with renal failure but has several drawbacks, including hypercalcemia and/or marked suppression of bone turnover, which may lead to adynamic bone disease.",10027919_1,-1,1,1,7,1
9,bone disease,37,39,237,249,"BACKGROUND: Calcitriol therapy suppresses serum levels of parathyroid hormone (PTH) in patients with renal failure but has several drawbacks, including hypercalcemia and/or marked suppression of bone turnover, which may lead to adynamic bone disease.",10027919_1,-1,1,1,9,1
26,renal insufficiency,17,19,94,113,"RESULTS: In Nx dogs, OCT significantly decreased serum PTH levels soon after the induction of renal insufficiency.",10027919_9,-1,1,1,26,1
42,renal insufficiency,21,23,143,162,"CONCLUSIONS: These results indicate that even though OCT does not completely prevent the occurrence of hypercalcemia in experimental dogs with renal insufficiency, it may be of use in the management of secondary hyperparathyroidism because it does not induce low bone turnover and, therefore, does not increase the risk of adynamic bone disease.",10027919_16,-1,1,1,42,1
45,bone disease,54,56,332,344,"CONCLUSIONS: These results indicate that even though OCT does not completely prevent the occurrence of hypercalcemia in experimental dogs with renal insufficiency, it may be of use in the management of secondary hyperparathyroidism because it does not induce low bone turnover and, therefore, does not increase the risk of adynamic bone disease.",10027919_16,-1,1,1,45,1
54,renal failure,13,15,94,107,"The patient was admitted with a pulmonary-renal syndrome with hemoptysis, rapidly progressive renal failure, and hypoxemia that required mechanical ventilation in the intensive care unit.",10074612_3,-1,1,1,54,1
60,junctional,4,5,17,27,The ECG showed a junctional rhythm without ventricular arrhythmia.,10074612_5,-1,1,1,60,1
62,sudden death,8,10,54,66,This study reviews the current proposed mechanisms of sudden death after a high dose of intravenous methylprednisolone (IVMP).,10074612_6,-1,1,1,62,1
82,drug withdrawal,15,17,103,118,Selegiline-induced postural hypotension in Parkinson's disease: a longitudinal study on the effects of drug withdrawal.,10091617_0,-1,1,1,82,1
128,urological,27,28,168,178,Picloxydine irrigations appeared to have a lower incidence of erosive cystitis but further studies would have to be performed before it could be recommended for use in urological procedures.,1009330_4,-1,1,1,128,1
191,neurotoxicity,10,11,53,66,Three of the cases were most likely caused by direct neurotoxicity of hyperbaric 5% lignocaine.,10225068_4,-1,1,1,191,1
194,neurotoxicity,7,8,29,42,"In the other 3 cases, direct neurotoxicity was also probable, but unfortunately radiological investigations were not done to definitely exclude a compressive aetiology.",10225068_5,-1,1,1,194,1
202,capillary leak syndrome,15,18,107,130,Systemic toxicity following administration of sirolimus (formerly rapamycin) for psoriasis: association of capillary leak syndrome with apoptosis of lesional lymphocytes.,10328196_0,-1,1,1,202,1
208,capillary leak syndrome,7,10,47,70,After 2 individuals with psoriasis developed a capillary leak syndrome following treatment with oral sirolimus lesional skin cells and activated peripheral blood cells were analyzed for induction of apoptosis.,10328196_2,-1,1,1,208,1
213,capillary leak syndrome,11,14,77,100,OBSERVATIONS: A keratome skin specimen from 1 patient with sirolimus-induced capillary leak syndrome had a 2.3-fold increase in percentage of apoptotic cells (to 48%) compared with an unaffected sirolimus-treated patient with psoriasis (21%).,10328196_3,-1,1,1,213,1
221,capillary leak syndrome,13,16,76,99,"CONCLUSIONS: Severe adverse effects of sirolimus include fever, anemia, and capillary leak syndrome.",10328196_5,-1,1,1,221,1
229,inflammatory diseases,21,23,150,171,"Because patients with severe psoriasis may develop capillary leak from various systemic therapies, clinical monitoring is advisable for patients with inflammatory diseases who are treated with immune modulators.",10328196_7,-1,1,1,229,1
272,substance-induced,14,15,88,105,This paper attempts to examine and compare prevalence rates and symptom patterns of DSM substance-induced and other mood disorders.,10365197_1,-1,1,1,272,1
290,intracerebral hemorrhage,6,8,52,76,Effect of fucoidan treatment on collagenase-induced intracerebral hemorrhage in rats.,10406016_0,-1,1,1,290,1
292,brain damage,9,11,57,69,Inflammatory cells are postulated to mediate some of the brain damage following ischemic stroke.,10406016_1,-1,1,1,292,1
293,ischemic stroke,12,14,80,95,Inflammatory cells are postulated to mediate some of the brain damage following ischemic stroke.,10406016_1,-1,1,1,293,1
294,Intracerebral hemorrhage,0,2,0,24,Intracerebral hemorrhage is associated with more inflammation than ischemic stroke.,10406016_2,-1,1,1,294,1
296,ischemic stroke,8,10,67,82,Intracerebral hemorrhage is associated with more inflammation than ischemic stroke.,10406016_2,-1,1,1,296,1
299,intracerebral hemorrhage,22,24,127,151,"We tested the sulfated polysaccharide fucoidan, which has been reported to reduce inflammatory brain damage, in a rat model of intracerebral hemorrhage induced by injection of bacterial collagenase into the caudate nucleus.",10406016_3,-1,1,1,299,1
319,intracerebral hemorrhage,12,14,97,121,Investigation of more specific anti-inflammatory agents and hemodiluting agents are warranted in intracerebral hemorrhage.,10406016_10,-1,1,1,319,1
337,aneurysmal subarachnoid hemorrhage,10,13,79,113,Effects of nonsteroidal anti-inflammatory drugs on hemostasis in patients with aneurysmal subarachnoid hemorrhage.,10414674_0,-1,1,1,337,1
341,aneurysmal subarachnoid hemorrhage,2,5,14,48,"Patients with aneurysmal subarachnoid hemorrhage (SAH) were randomized to receive either ketoprofen, 100 mg, three times a day (ketoprofen group, n = 9) or a weak NSAID, acetaminophen, 1 g, three times a day (acetaminophen group, n = 9) starting immediately after the diagnosis of aneurysmal SAH.",10414674_3,-1,1,1,341,1
350,intracranial hematoma,9,11,62,83,One patient in the ketoprofen group developed a postoperative intracranial hematoma.,10414674_9,-1,1,1,350,1
369,neuromuscular blockade,10,12,66,88,"Circumstances leading to this event and the mechanisms enabling a neuromuscular blockade to occur, following the administration of a small dose of relaxant, are discussed.",10457883_4,-1,1,1,369,1
382,genito-urinary,32,33,163,177,"The haemodynamic effects of adding 15, 20 or 25 mg of ephedrine to 200 mg of propofol were compared to control in 40 ASA 3/4 patients over 60 years presenting for genito-urinary surgery.",10520387_2,-1,1,1,382,1
390,lead-induced,8,9,50,62,Nitric oxide synthase expression in the course of lead-induced hypertension.,10523326_0,-1,1,1,390,1
393,lead-induced,33,34,190,202,"We recently showed elevated reactive oxygen species (ROS), reduced urinary excretion of NO metabolites (NOx), and increased NO sequestration as nitrotyrosine in various tissues in rats with lead-induced hypertension.",10523326_1,-1,1,1,393,1
394,lead-induced,13,14,75,87,"This study was designed to discern whether the reduction in urinary NOx in lead-induced hypertension is, in part, due to depressed NO synthase (NOS) expression.",10523326_2,-1,1,1,394,1
426,lead-induced,3,4,15,27,"In conclusion, lead-induced hypertension in this model was associated with a compensatory upregulation of renal and vascular eNOS and iNOS expression.",10523326_9,-1,1,1,426,1
428,compensatory,12,13,77,89,"In conclusion, lead-induced hypertension in this model was associated with a compensatory upregulation of renal and vascular eNOS and iNOS expression.",10523326_9,-1,1,1,428,1
438,migraine with aura,11,14,77,95,Glyceryl trinitrate induces attacks of migraine without aura in sufferers of migraine with aura.,10524660_0,-1,1,1,438,1
439,Migraine with aura,0,3,0,18,"Migraine with aura and migraine without aura have the same pain phase, thus indicating that migraine with aura and migraine without aura share a common pathway of nociception.",10524660_1,-1,1,1,439,1
441,migraine with aura,16,19,92,110,"Migraine with aura and migraine without aura have the same pain phase, thus indicating that migraine with aura and migraine without aura share a common pathway of nociception.",10524660_1,-1,1,1,441,1
445,migraine with aura,10,13,49,67,"In order to clarify whether the same is true for migraine with aura, in the present study we examined the headache response to intravenous infusion of glyceryl trinitrate (GTN) (0.5 microg/kg/min for 20 min) in 12 sufferers of migraine with aura.",10524660_3,-1,1,1,445,1
447,migraine with aura,43,46,227,245,"In order to clarify whether the same is true for migraine with aura, in the present study we examined the headache response to intravenous infusion of glyceryl trinitrate (GTN) (0.5 microg/kg/min for 20 min) in 12 sufferers of migraine with aura.",10524660_3,-1,1,1,447,1
455,migraine with aura,13,16,76,94,The results therefore suggest that NO is involved in the pain mechanisms of migraine with aura.,10524660_10,-1,1,1,455,1
458,migraine with aura,29,32,188,206,"Since cortical spreading depression has been shown to liberate NO in animals, this finding may help our understanding of the coupling between cortical spreading depression and headache in migraine with aura.",10524660_11,-1,1,1,458,1
486,Grade 3,10,12,49,56,"Six patients (12%) had World Health Organization Grade 3-4 neutropenia, 2 patients (4%) had Grade 3-4 thrombocytopenia, and 2 patients (4%) had Grade 3 neurotoxicity.",10526274_15,-1,1,1,486,1
487,Grade 3,23,25,92,99,"Six patients (12%) had World Health Organization Grade 3-4 neutropenia, 2 patients (4%) had Grade 3-4 thrombocytopenia, and 2 patients (4%) had Grade 3 neurotoxicity.",10526274_15,-1,1,1,487,1
489,Grade 3,7,9,44,51,The median age of those patients developing Grade 3-4 neutropenia was significantly higher than that of the remaining patients (75 years vs. 72 years; P = 0.047).,10526274_17,-1,1,1,489,1
507,heart failure,8,10,56,69,"Predictors of decreased renal function in patients with heart failure during angiotensin-converting enzyme inhibitor therapy: results from the studies of left ventricular dysfunction (SOLVD)BACKGROUND: Although angiotensin-converting enzyme inhibitor therapy reduces mortality rates in patients with congestive heart failure (CHF), it may also cause decreased renal function.",10539815_0,-1,1,1,507,1
509,left ventricular dysfunction,21,24,154,182,"Predictors of decreased renal function in patients with heart failure during angiotensin-converting enzyme inhibitor therapy: results from the studies of left ventricular dysfunction (SOLVD)BACKGROUND: Although angiotensin-converting enzyme inhibitor therapy reduces mortality rates in patients with congestive heart failure (CHF), it may also cause decreased renal function.",10539815_0,-1,1,1,509,1
512,congestive heart failure,37,40,300,324,"Predictors of decreased renal function in patients with heart failure during angiotensin-converting enzyme inhibitor therapy: results from the studies of left ventricular dysfunction (SOLVD)BACKGROUND: Although angiotensin-converting enzyme inhibitor therapy reduces mortality rates in patients with congestive heart failure (CHF), it may also cause decreased renal function.",10539815_0,-1,1,1,512,1
520,Left Ventricular Dysfunction,9,12,45,73,"METHOD: We analyzed data from the Studies of Left Ventricular Dysfunction (SOLVD), a randomized, double-blind, placebo-controlled trial of enalapril for the treatment of CHF.",10539815_3,-1,1,1,520,1
578,hypomania,20,21,115,124,We report a female patient with a diagnosis of a not otherwise specified psychotic disorder (DSM-IV) who developed hypomania shortly after the introduction of olanzapine treatment.,10565806_1,-1,1,1,578,1
599,side effects,15,17,108,120,These findings suggest that NRA0160 may have unique antipsychotic activities without the liability of motor side effects typical of classical antipsychotics.,10579464_9,-1,1,1,599,1
666,drug-induced,22,23,156,168,These studies were conducted to examine the differential response to a drug challenge under varied experimental test conditions routinely employed to study drug-induced behavioral and neurophysiological responses in rodents.,10683478_1,-1,1,1,666,1
678,Drug-induced,0,1,0,12,"Drug-induced gross activity counts were increased in the novel exploratory box only, while measures of stereotypic behavior were similar in both.",10683478_7,-1,1,1,678,1
693,Gerstmann syndrome,1,3,22,40,Acetazolamide-induced Gerstmann syndrome.,10692744_0,-1,1,1,693,1
695,adverse drug reaction,9,12,57,78,Acute confusion induced by acetazolamide is a well known adverse drug reaction in patients with renal impairment.,10692744_1,-1,1,1,695,1
697,Gerstmann syndrome,6,8,42,60,"We report a case of acetazolamide-induced Gerstmann syndrome in a patient with normal renal function, to highlight predisposing factors that are frequently overlooked.",10692744_2,-1,1,1,697,1
702,breast cancer,15,17,87,100,"Tamoxifen (TAM), the antiestrogenic drug most widely prescribed in the chemotherapy of breast cancer, induces changes in normal discoid shape of erythrocytes and hemolytic anemia.",10704919_1,-1,1,1,702,1
703,hemolytic anemia,27,29,162,178,"Tamoxifen (TAM), the antiestrogenic drug most widely prescribed in the chemotherapy of breast cancer, induces changes in normal discoid shape of erythrocytes and hemolytic anemia.",10704919_1,-1,1,1,703,1
705,hemolytic anemia,20,22,135,151,"This work evaluates the effects of TAM on isolated human erythrocytes, attempting to identify the underlying mechanisms on TAM-induced hemolytic anemia and the involvement of biomembranes in its cytostatic action mechanisms.",10704919_2,-1,1,1,705,1
734,hemolytic anemia,17,19,118,134,"These defects explain the abnormal erythrocyte shape and decreased mechanical stability promoted by TAM, resulting in hemolytic anemia.",10704919_14,-1,1,1,734,1
793,cardiac hypertrophy,6,8,46,65,Isoproterenol pretreatment for 15 days caused cardiac hypertrophy without affecting baseline blood pressure and heart rate.,10721819_3,-1,1,1,793,1
818,heart failure,9,11,72,85,Vasopressin in the treatment of milrinone-induced hypotension in severe heart failure.,10728962_0,-1,1,1,818,1
821,heart failure,13,15,85,98,The use of phosphodiesterase inhibitors such as milrinone in the treatment of severe heart failure is frequently restricted because they cause vasodilation and hypotension.,10728962_1,-1,1,1,821,1
872,hyperalgesia,12,13,95,107,Differential effects of systemically administered ketamine and lidocaine on dynamic and static hyperalgesia induced by intradermal capsaicin in humans.,10743446_0,-1,1,1,872,1
876,hyperalgesia,23,24,141,153,We have examined the effect of systemic administration of ketamine and lidocaine on brush-evoked (dynamic) pain and punctate-evoked (static) hyperalgesia induced by capsaicin.,10743446_1,-1,1,1,876,1
885,punctate,11,12,62,70,"The following were measured: spontaneous pain, pain evoked by punctate and brush stimuli (VAS), and areas of brush-evoked and punctate-evoked hyperalgesia.",10743446_6,-1,1,1,885,1
888,hyperalgesia,25,26,142,154,"The following were measured: spontaneous pain, pain evoked by punctate and brush stimuli (VAS), and areas of brush-evoked and punctate-evoked hyperalgesia.",10743446_6,-1,1,1,888,1
890,hyperalgesia,9,10,67,79,Ketamine reduced both the area of brush-evoked and punctate-evoked hyperalgesia significantly and it tended to reduce brush-evoked pain.,10743446_7,-1,1,1,890,1
892,hyperalgesia,6,7,46,58,Lidocaine reduced the area of punctate-evoked hyperalgesia significantly.,10743446_8,-1,1,1,892,1
898,hyperalgesia,11,12,73,85,The differential effects of ketamine and lidocaine on static and dynamic hyperalgesia suggest that the two types of hyperalgesia are mediated by separate mechanisms and have a distinct pharmacology.,10743446_10,-1,1,1,898,1
899,hyperalgesia,18,19,116,128,The differential effects of ketamine and lidocaine on static and dynamic hyperalgesia suggest that the two types of hyperalgesia are mediated by separate mechanisms and have a distinct pharmacology.,10743446_10,-1,1,1,899,1
913,neurotoxicity,5,6,38,51,"Indications for early conversion were neurotoxicity (20), (insulin-dependent) diabetes mellitus (IDDM) (5), nephrotoxicity (3), gastrointestinal (GI) toxicity (6), and cardiomyopathy (1), and for late conversion were neurotoxicity (15), IDDM (12), nephrotoxicity (3), GI toxicity (5), hepatotoxicity (6), post-transplant lmphoproliferate disease (PTLD) (2), cardiomyopathy (1), hemolytic anemia (1), and pruritus (1).",10743694_5,-1,1,1,913,1
914,insulin-dependent,11,12,59,76,"Indications for early conversion were neurotoxicity (20), (insulin-dependent) diabetes mellitus (IDDM) (5), nephrotoxicity (3), gastrointestinal (GI) toxicity (6), and cardiomyopathy (1), and for late conversion were neurotoxicity (15), IDDM (12), nephrotoxicity (3), GI toxicity (5), hepatotoxicity (6), post-transplant lmphoproliferate disease (PTLD) (2), cardiomyopathy (1), hemolytic anemia (1), and pruritus (1).",10743694_5,-1,1,1,914,1
915,diabetes mellitus,13,15,78,95,"Indications for early conversion were neurotoxicity (20), (insulin-dependent) diabetes mellitus (IDDM) (5), nephrotoxicity (3), gastrointestinal (GI) toxicity (6), and cardiomyopathy (1), and for late conversion were neurotoxicity (15), IDDM (12), nephrotoxicity (3), GI toxicity (5), hepatotoxicity (6), post-transplant lmphoproliferate disease (PTLD) (2), cardiomyopathy (1), hemolytic anemia (1), and pruritus (1).",10743694_5,-1,1,1,915,1
919,neurotoxicity,47,48,217,230,"Indications for early conversion were neurotoxicity (20), (insulin-dependent) diabetes mellitus (IDDM) (5), nephrotoxicity (3), gastrointestinal (GI) toxicity (6), and cardiomyopathy (1), and for late conversion were neurotoxicity (15), IDDM (12), nephrotoxicity (3), GI toxicity (5), hepatotoxicity (6), post-transplant lmphoproliferate disease (PTLD) (2), cardiomyopathy (1), hemolytic anemia (1), and pruritus (1).",10743694_5,-1,1,1,919,1
946,juvenile rheumatoid arthritis,3,6,25,54,Ocular manifestations of juvenile rheumatoid arthritis.,1079693_0,-1,1,1,946,1
947,juvenile rheumatoid arthritis,5,8,25,54,We followed 210 cases of juvenile rheumatoid arthritis closely for eleven years.,1079693_1,-1,1,1,947,1
963,Intracranial aneurysms,0,2,0,22,Intracranial aneurysms and cocaine abuse: analysis of prognostic indicators.,10807237_0,-1,1,1,963,1
964,cocaine abuse,3,5,27,40,Intracranial aneurysms and cocaine abuse: analysis of prognostic indicators.,10807237_0,-1,1,1,964,1
965,subarachnoid hemorrhage,5,7,26,49,OBJECTIVE: The outcome of subarachnoid hemorrhage associated with cocaine abuse is reportedly poor.,10807237_1,-1,1,1,965,1
967,cocaine abuse,9,11,66,79,OBJECTIVE: The outcome of subarachnoid hemorrhage associated with cocaine abuse is reportedly poor.,10807237_1,-1,1,1,967,1
972,cocaine abuse,18,20,103,116,This group was compared with a control group of 135 patients with ruptured aneurysms and no history of cocaine abuse.,10807237_4,-1,1,1,972,1
974,subarachnoid hemorrhage,15,17,78,101,"Age at presentation, time of ictus after intoxication, Hunt and Hess grade of subarachnoid hemorrhage, size of the aneurysm, location of the aneurysm, and the Glasgow Outcome Scale score were assessed and compared.",10807237_5,-1,1,1,974,1
979,anterior circulation,13,15,66,86,"In patients in the study group, all aneurysms were located in the anterior circulation.",10807237_7,-1,1,1,979,1
991,acute stroke,10,12,69,81,Effect of intravenous nimodipine on blood pressure and outcome after acute stroke.,10835440_0,-1,1,1,991,1
997,acute stroke,31,33,197,209,BACKGROUND AND PURPOSE: The Intravenous Nimodipine West European Stroke Trial (INWEST) found a correlation between nimodipine-induced reduction in blood pressure (BP) and an unfavorable outcome in acute stroke.,10835440_1,-1,1,1,997,1
1001,ischemic stroke,8,10,47,62,"METHODS: Patients with a clinical diagnosis of ischemic stroke (within 24 hours) were consecutively allocated to receive placebo (n=100), 1 mg/h (low-dose) nimodipine (n=101), or 2 mg/h (high-dose) nimodipine (n=94).",10835440_3,-1,1,1,1001,1
1033,acute stroke,22,24,151,163,"CONCLUSIONS: DBP, but not SBP, reduction was associated with neurological worsening after the intravenous administration of high-dose nimodipine after acute stroke.",10835440_10,-1,1,1,1033,1
1082,pyridoxine deficiency,15,17,101,122,"The fits ceased within 4 hours of administering intramuscular pyridoxine, suggesting an aetiology of pyridoxine deficiency secondary to isoniazid medication.",1085609_3,-1,1,1,1082,1
1083,of children,5,7,36,47,Ketamine sedation for the reduction of children's fractures in the emergency department.,10901305_0,-1,1,1,1083,1
1086,of children,20,22,114,125,The purpose of the present study was to examine the safety and efficacy of ketamine for sedation in the treatment of children's fractures in the emergency department.,10901305_2,-1,1,1,1086,1
1092,body weight,15,17,99,110,Ketamine hydrochloride was administered intravenously (at a dose of two milligrams per kilogram of body weight) in ninety-nine of the patients and intramuscularly (at a dose of four milligrams per kilogram of body weight) in the other fifteen.,10901305_4,-1,1,1,1092,1
1093,body weight,35,37,209,220,Ketamine hydrochloride was administered intravenously (at a dose of two milligrams per kilogram of body weight) in ninety-nine of the patients and intramuscularly (at a dose of four milligrams per kilogram of body weight) in the other fifteen.,10901305_4,-1,1,1,1093,1
1112,side effects,1,3,6,18,"Minor side effects included nausea (thirteen patients), emesis (eight of the thirteen patients with nausea), clumsiness (evident as ataxic movements in ten patients), and dysphoric reaction (one patient).",10901305_13,-1,1,1,1112,1
1115,of children,17,19,119,130,"CONCLUSIONS: Ketamine reliably, safely, and quickly provided adequate sedation to effectively facilitate the reduction of children's fractures in the emergency department at our institution.",10901305_15,-1,1,1,1115,1
1144,weight gain,3,5,13,24,"Rate of body weight gain was depressed in the P100, FR, and P10 groups compared with the S group.",10910842_6,-1,1,1,1144,1
1178,muscle atrophy,16,18,120,134,"Our results suggest that the neuromuscular dysfunction after prednisolone is dose-dependent, and derives primarily from muscle atrophy and derives less so from changes in AChR expression.",10910842_12,-1,1,1,1178,1
1182,muscle atrophy,12,14,82,96,We suggest that the observed effects are dose-dependent and derive primarily from muscle atrophy and derive less from changes in acetylcholine receptor expression.,10910842_14,-1,1,1,1182,1
1184,thrombotic microangiopathy,3,5,39,65,Cyclosporine and tacrolimus-associated thrombotic microangiopathy.,11007689_0,-1,1,1,1184,1
1185,thrombotic microangiopathy,3,5,19,45,The development of thrombotic microangiopathy (TMA) associated with the use of cyclosporine has been well documented.,11007689_1,-1,1,1,1185,1
1217,signs and symptoms,17,20,108,126,Patients who are switched from cyclosporine to tacrolimus or vice versa should be closely monitored for the signs and symptoms of recurrent TMA.,11007689_10,-1,1,1,1217,1
1242,side effects,2,4,9,21,"The main side effects of subcutaneous apomorphine treatment are related to cutaneous tolerability problems, whereas sedation and psychiatric complications play a lesser role.",11009181_7,-1,1,1,1242,1
1249,Alzheimer's disease,31,34,189,208,"OBJECTIVE: The pharmacological response to drugs that act on the cholinergic system of the iris has been used to predict deficits in central cholinergic functioning due to diseases such as Alzheimer's disease, yet correlations between central and peripheral responses have not been properly studied.",11022397_1,-1,1,1,1249,1
1315,pain syndromes,26,28,167,181,"Animal and clinical studies have suggested that N-methyl-D-aspartate (NMDA) antagonists, such as ketamine, may be effective in improving opioid analgesia in difficult pain syndromes, such as neuropathic pain.",11027905_2,-1,1,1,1315,1
1316,neuropathic pain,31,33,191,207,"Animal and clinical studies have suggested that N-methyl-D-aspartate (NMDA) antagonists, such as ketamine, may be effective in improving opioid analgesia in difficult pain syndromes, such as neuropathic pain.",11027905_2,-1,1,1,1316,1
1323,nausea and vomiting,10,13,45,64,"Pain intensity on a 0 to 10 numerical scale; nausea and vomiting, drowsiness, confusion, and dry mouth, using a scale from 0 to 3 (not at all, slight, a lot, awful); Mini-Mental State Examination (MMSE) (0-30); and arterial pressure were recorded before administration of drugs (T0) and after 30 minutes (T30), 60 minutes (T60), 120 minutes (T120), and 180 minutes (T180).",11027905_4,-1,1,1,1323,1
1339,pain syndromes,7,9,53,67,"Ketamine can improve morphine analgesia in difficult pain syndromes, such as neuropathic pain.",11027905_11,-1,1,1,1339,1
1340,neuropathic pain,12,14,77,93,"Ketamine can improve morphine analgesia in difficult pain syndromes, such as neuropathic pain.",11027905_11,-1,1,1,1340,1
1343,spinal cord injury,7,10,50,68,High-dose methylprednisolone may do more harm for spinal cord injury.,11058428_0,-1,1,1,1343,1
1355,spinal cord injury,12,15,62,80,We hypothesize that it may cause some damage to the muscle of spinal cord injury patients.,11058428_4,-1,1,1,1355,1
1360,spinal cord injury,38,41,244,262,"Further, steroid myopathy recovers naturally and the neurological improvement shown in the NASCIS may be just a recording of this natural motor recovery from the steroid myopathy, instead of any protection that methylprednisolone offers to the spinal cord injury.",11058428_5,-1,1,1,1360,1
1381,lymphoproliferative disorder,31,33,149,177,"The indications for switch were chronic CsA or Tac nephrotoxicity (12), acute CsA or Tac toxicity (3), severe facial dysmorphism (2), posttransplant lymphoproliferative disorder (PTLD) in remission (2), and hepatotoxicity in 1.",11063349_4,-1,1,1,1381,1
1462,ST,10,11,52,54,"Of the 51 patients, 7 patients showed asynergy with ST elevation.",11078231_8,-1,1,1,1462,1
1463,chest pain,8,10,27,37,"All 7 patients (13.7%) had chest pain during asynergy, and both chest pain and electrocardiographic changes were preceded by asynergy.",11078231_9,-1,1,1,1463,1
1464,chest pain,15,17,64,74,"All 7 patients (13.7%) had chest pain during asynergy, and both chest pain and electrocardiographic changes were preceded by asynergy.",11078231_9,-1,1,1,1464,1
1470,coronary artery disease,6,9,34,57,"When DSE is performed to evaluate coronary artery disease, not only fixed coronary stenosis, but also coronary spasm should be considered as a genesis of asynergy.",11078231_11,-1,1,1,1470,1
1564,disease progression,17,19,149,168,"Although responding patients were scheduled to receive consolidation radiotherapy and 24 patients received preplanned second-line chemotherapy after disease progression, the response and toxicity rates reported refer only to the chemotherapy regimen given.",11135224_5,-1,1,1,1564,1
1574,Grade 3,3,5,26,33,"World Health Organization Grade 3-4 neutropenia and thrombocytopenia occurred in 39.9% and 11.4% of patients, respectively.",11135224_10,-1,1,1,1574,1
1587,side effect,7,9,47,58,Although urinary incontinence is listed as one side effect of these drugs in their package inserts there is only one report in the literature.,11147747_2,-1,1,1,1587,1
1591,side effect,32,34,209,220,"In the present paper the authors describe 2 female patients who developed incontinence secondary to the selective serotonin reuptake inhibitors paroxetine and sertraline, as well as a third who developed this side effect on venlafaxine.",11147747_4,-1,1,1,1591,1
1599,side effect,11,13,72,83,Further research is needed to delineate the frequency of this troubling side effect and how best to treat it.,11147747_7,-1,1,1,1599,1
1619,amphetamine abuse,26,28,171,188,"Patient demographics, history of underlying drug or alcohol-related seizure disorder, estimated time from seizure to sample collection, history or suspicion of cocaine or amphetamine abuse, results of clinical urine testing for drugs of abuse, and assay results were recorded without patient identifiers.",11185967_5,-1,1,1,1619,1
1626,amphetamine abuse,19,21,110,127,Positive test results were more common in patient visits where there was a history or suspicion of cocaine or amphetamine abuse (p < 0.0005).,11185967_7,-1,1,1,1626,1
1627,drug abuse,24,26,132,142,"As a result, routine plasma screening would yield few cases of stimulant drug in which there was neither a history nor suspicion of drug abuse in this population.",11185967_9,-1,1,1,1627,1
1629,inappropriate secretion,8,10,52,75,Contribution of sodium valproate to the syndrome of inappropriate secretion of antidiuretic hormone.,11195262_0,-1,1,1,1629,1
1633,inappropriate secretion,23,25,131,154,We report the case of a 62-year-old man who was administered sodium valproate (VPA) and who subsequently developed the syndrome of inappropriate secretion of antidiuretic hormone (SIADH).,11195262_1,-1,1,1,1633,1
1641,central nervous system,20,23,107,129,We consider this episode of SIADH to be the result of a combination of factors including a weakness of the central nervous system and the long-term administration of VPA.,11195262_4,-1,1,1,1641,1
1650,central nervous system,22,25,149,171,Centrally acting alpha-2 adrenergic agonists are one of several pharmacologic agents used in the treatment of spasticity related to disorders of the central nervous system.,11198499_1,-1,1,1,1650,1
1691,nephrotic syndrome,17,19,94,112,We have studied the role of NO and its association with apoptosis in an experimental model of nephrotic syndrome induced by a single injection of adriamycin (ADR).,11208990_2,-1,1,1,1691,1
1716,tubulointerstitial,14,15,87,105,"However, in the ADR-nephropathy group, numerous apoptotic cells were identified in the tubulointerstitial areas.",11208990_12,-1,1,1,1716,1
1727,drug-induced,16,17,95,107,"Melatonin affects the circadian sleep/wake cycle, but it is not clear whether it may influence drug-induced narcosis.",11226639_1,-1,1,1,1727,1
1746,breast cancer,25,27,223,236,"Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer.",11230490_0,-1,1,1,1746,1
1753,breast cancer,39,41,298,311,"PURPOSE: To determine whether Myocet (liposome-encapsulated doxorubicin; The Liposome Company, Elan Corporation, Princeton, NJ) in combination with cyclophosphamide significantly reduces doxorubicin cardiotoxicity while providing comparable antitumor efficacy in first-line treatment of metastatic breast cancer (MBC).",11230490_1,-1,1,1,1753,1
1760,disease progression,53,55,283,302,"PATIENTS AND METHODS: Two hundred ninety-seven patients with MBC and no prior chemotherapy for metastatic disease were randomized to receive either 60 mg/m(2) of Myocet (M) or conventional doxorubicin (A), in combination with 600 mg/m(2) of cyclophosphamide (C), every 3 weeks until disease progression or unacceptable toxicity.",11230490_2,-1,1,1,1760,1
1764,congestive heart failure,19,22,145,169,"Cardiotoxicity was defined by reductions in left-ventricular ejection fraction, assessed by serial multigated radionuclide angiography scans, or congestive heart failure (CHF).",11230490_3,-1,1,1,1764,1
1845,drug-induced,9,10,61,73,CONCLUSION: Pericarditis may be the initial manifestation of drug-induced vasculitis attributable to propylthio- uracil therapy.,11250767_8,-1,1,1,1845,1
1849,solitary kidney,11,13,80,95,Repeated transient anuria following losartan administration in a patient with a solitary kidney.,11256525_0,-1,1,1,1849,1
1850,solitary kidney,11,13,60,75,We report the case of a 70-year-old hypertensive man with a solitary kidney and chronic renal insufficiency who developed two episodes of transient anuria after losartan administration.,11256525_1,-1,1,1,1850,1
1851,chronic renal insufficiency,14,17,80,107,We report the case of a 70-year-old hypertensive man with a solitary kidney and chronic renal insufficiency who developed two episodes of transient anuria after losartan administration.,11256525_1,-1,1,1,1851,1
1854,myocardial infarction,5,7,26,47,"He was hospitalized for a myocardial infarction with pulmonary edema, treated with high-dose diuretics.",11256525_2,-1,1,1,1854,1
1865,renal artery stenosis,10,13,45,66,"Ultimately, an arteriography showed a 70-80% renal artery stenosis.",11256525_7,-1,1,1,1865,1
1866,renal artery stenosis,4,7,17,38,"In this patient, renal artery stenosis combined with heart failure and diuretic therapy certainly resulted in a strong activation of the renin-angiotensin system (RAS).",11256525_8,-1,1,1,1866,1
1867,heart failure,9,11,53,66,"In this patient, renal artery stenosis combined with heart failure and diuretic therapy certainly resulted in a strong activation of the renin-angiotensin system (RAS).",11256525_8,-1,1,1,1867,1
1876,pain syndrome,2,4,30,43,Calcineurin-inhibitor induced pain syndrome (CIPS): a severe disabling complication after organ transplantation.,11263551_0,-1,1,1,1876,1
1883,bone marrow,4,6,40,51,Magnetic resonance imaging demonstrated bone marrow oedema in the painful bones.,11263551_5,-1,1,1,1883,1
1885,reflex sympathetic dystrophy,12,15,65,93,"Pain was not explained by other diseases causing foot pain, like reflex sympathetic dystrophy, polyneuropathy, Morton's neuralgia, gout, osteoporosis, avascular necrosis, intermittent claudication, orthopaedic foot deformities, stress fractures, and hyperparathyroidism.",11263551_6,-1,1,1,1885,1
1886,polyneuropathy,16,17,95,109,"Pain was not explained by other diseases causing foot pain, like reflex sympathetic dystrophy, polyneuropathy, Morton's neuralgia, gout, osteoporosis, avascular necrosis, intermittent claudication, orthopaedic foot deformities, stress fractures, and hyperparathyroidism.",11263551_6,-1,1,1,1886,1
1890,stress fractures,36,38,228,244,"Pain was not explained by other diseases causing foot pain, like reflex sympathetic dystrophy, polyneuropathy, Morton's neuralgia, gout, osteoporosis, avascular necrosis, intermittent claudication, orthopaedic foot deformities, stress fractures, and hyperparathyroidism.",11263551_6,-1,1,1,1890,1
1895,Pain Syndrome,3,5,34,47,"The Calcineurin-inhibitor Induced Pain Syndrome (CIPS) is a rare but severe side effect of cyclosporine or tacrolimus and is accurately diagnosed by its typical presentation, magnetic resonance imaging and bone scans.",11263551_8,-1,1,1,1895,1
1897,side effect,13,15,76,87,"The Calcineurin-inhibitor Induced Pain Syndrome (CIPS) is a rare but severe side effect of cyclosporine or tacrolimus and is accurately diagnosed by its typical presentation, magnetic resonance imaging and bone scans.",11263551_8,-1,1,1,1897,1
1934,congestive heart failure,3,6,25,49,Three patients developed congestive heart failure after the completion of chemotherapy.,11279304_7,-1,1,1,1934,1
1935,heart failure,7,9,51,64,Five patients were diagnosed as having subclinical heart failure after the completion of chemotherapy.,11279304_8,-1,1,1,1935,1
1937,heart failure,13,15,75,88,The plasma levels of BNP in all the patients with clinical and subclinical heart failure increased above the normal limit (40 pg/ml) before the detection of clinical or subclinical heart failure by radionuclide angiography.,11279304_9,-1,1,1,1937,1
1939,heart failure,31,33,181,194,The plasma levels of BNP in all the patients with clinical and subclinical heart failure increased above the normal limit (40 pg/ml) before the detection of clinical or subclinical heart failure by radionuclide angiography.,11279304_9,-1,1,1,1939,1
1942,heart failure,13,15,64,77,"On the other hand, BNP did not increase in the patients without heart failure given DNR, even at more than 700 mg/m(2).",11279304_10,-1,1,1,1942,1
1945,heart failure,17,19,98,111,The plasma level of ANP did not always increase in all the patients with clinical and subclinical heart failure.,11279304_11,-1,1,1,1945,1
1949,atrial fibrillation,4,6,24,43,Effects of verapamil on atrial fibrillation and its electrophysiological determinants in dogs.,11282081_0,-1,1,1,1949,1
1952,atrial fibrillation,11,13,93,112,BACKGROUND: Atrial tachycardia-induced remodeling promotes the occurrence and maintenance of atrial fibrillation (AF) and decreases L-type Ca(2+) current.,11282081_1,-1,1,1,1952,1
1992,reactivation,19,20,139,151,Epicardial mapping suggested that verapamil promoted AF by increasing the number of simultaneous wavefronts reflected by separate zones of reactivation in each cycle.,11282081_12,-1,1,1,1992,1
1998,tension-type headache,12,14,101,122,Calcitonin gene-related peptide levels during nitric oxide-induced headache in patients with chronic tension-type headache.,11284996_0,-1,1,1,1998,1
2006,tension-type headache,29,31,161,182,In the present study we aimed to investigate plasma levels of CGRP during headache induced by the NO donor glyceryl trinitrate (GTN) in 16 patients with chronic tension-type headache and 16 healthy controls.,11284996_2,-1,1,1,2006,1
2035,coronary artery disease,34,37,212,235,"CASE SUMMARY: A 68-year-old white woman with Candida glabrata isolated from a presacral abscess developed TDP eight days after commencing oral fluconazole The patient had no other risk factors for TDP, including coronary artery disease, cardiomyopathy, congestive heart failure, and electrolyte abnormalities There was a temporal association between the initiation of fluconazole and TDP.",11302406_2,-1,1,1,2035,1
2036,congestive heart failure,40,43,253,277,"CASE SUMMARY: A 68-year-old white woman with Candida glabrata isolated from a presacral abscess developed TDP eight days after commencing oral fluconazole The patient had no other risk factors for TDP, including coronary artery disease, cardiomyopathy, congestive heart failure, and electrolyte abnormalities There was a temporal association between the initiation of fluconazole and TDP.",11302406_2,-1,1,1,2036,1
2043,nonsustained ventricular tachycardia,19,22,130,166,"The TDP resolved when fluconazole was discontinued; however, the patient continued to have premature ventricular contractions and nonsustained ventricular tachycardia (NSVT) until six days after drug cessation DISCUSSION: Use of the Naranjo probability scale indicates a probable relationship between the use of fluconazole and the development of TDP.",11302406_3,-1,1,1,2043,1
2072,renal insufficiency,2,4,14,33,Patients with renal insufficiency should not be given this regimen.,1130930_4,-1,1,1,2072,1
2146,Staphylococcus aureus,13,15,73,94,"A 67-year-old man who was treated with oxacillin for one week because of Staphylococcus aureus bacteremia, developed renal failure and diffuse, symmetric, palpable purpuric lesions on his feet.",11337188_1,-1,1,1,2146,1
2147,renal failure,18,20,117,130,"A 67-year-old man who was treated with oxacillin for one week because of Staphylococcus aureus bacteremia, developed renal failure and diffuse, symmetric, palpable purpuric lesions on his feet.",11337188_1,-1,1,1,2147,1
2154,lower extremities,8,10,64,81,"Leucocytoclastic vasculitis presents as palpable purpura of the lower extremities often accompanied by abdominal pain, arthralgia, and renal involvement.",11337188_6,-1,1,1,2154,1
2155,abdominal pain,13,15,103,117,"Leucocytoclastic vasculitis presents as palpable purpura of the lower extremities often accompanied by abdominal pain, arthralgia, and renal involvement.",11337188_6,-1,1,1,2155,1
2176,manic episodes,36,38,195,209,"Patients who experienced a manic or hypomanic switch were compared with those who did not on several variables including age, sex, diagnosis (DSM-IV bipolar I vs. bipolar II), number of previous manic episodes, type of antidepressant therapy used (electroconvulsive therapy vs. antidepressant drugs and, more particularly, selective serotonin reuptake inhibitors [SSRIs]), use and type of mood stabilizers (lithium vs. anticonvulsants), and temperament of the patient, assessed during a normothymic period using the hyperthymia component of the Semi-structured Affective Temperament Interview.",11379838_3,-1,1,1,2176,1
2184,hypomania,4,5,21,30,"RESULTS: Switches to hypomania or mania occurred in 27% of all patients (N = 12) (and in 24% of the subgroup of patients treated with SSRIs [8/33]); 16% (N = 7) experienced manic episodes, and 11% (N = 5) experienced hypomanic episodes.",11379838_4,-1,1,1,2184,1
2186,manic episodes,45,47,173,187,"RESULTS: Switches to hypomania or mania occurred in 27% of all patients (N = 12) (and in 24% of the subgroup of patients treated with SSRIs [8/33]); 16% (N = 7) experienced manic episodes, and 11% (N = 5) experienced hypomanic episodes.",11379838_4,-1,1,1,2186,1
2187,hypomanic episodes,57,59,217,235,"RESULTS: Switches to hypomania or mania occurred in 27% of all patients (N = 12) (and in 24% of the subgroup of patients treated with SSRIs [8/33]); 16% (N = 7) experienced manic episodes, and 11% (N = 5) experienced hypomanic episodes.",11379838_4,-1,1,1,2187,1
2194,manic episodes,4,6,23,37,"The number of previous manic episodes did not affect the probability of switching, whereas a high score on the hyperthymia component of the Semistructured Affective Temperament Interview was associated with a greater risk of switching (p = .008).",11379838_8,-1,1,1,2194,1
2203,kidney disease,9,11,79,93,Peritubular capillary basement membrane reduplication in allografts and native kidney disease: a clinicopathologic study of 278 consecutive renal specimens.,11391224_0,-1,1,1,2203,1
2206,glomerulopathy,9,10,61,75,BACKGROUND: An association has been found between transplant glomerulopathy (TG) and reduplication of peritubular capillary basement membranes (PTCR).,11391224_1,-1,1,1,2206,1
2220,glomerulopathies,8,9,49,65,"Native kidney specimens included a wide range of glomerulopathies as well as cases of thrombotic microangiopathy, malignant hypertension, acute interstitial nephritis, and acute tubular necrosis.",11391224_5,-1,1,1,2220,1
2221,thrombotic microangiopathy,14,16,86,112,"Native kidney specimens included a wide range of glomerulopathies as well as cases of thrombotic microangiopathy, malignant hypertension, acute interstitial nephritis, and acute tubular necrosis.",11391224_5,-1,1,1,2221,1
2231,thrombotic microangiopathy,8,10,51,77,"These 13 included cases of malignant hypertension, thrombotic microangiopathy, lupus nephritis, Henoch-Schonlein nephritis, crescentic glomerulonephritis, and cocaine-related acute renal failure.",11391224_7,-1,1,1,2231,1
2233,Henoch-Schonlein,14,15,96,112,"These 13 included cases of malignant hypertension, thrombotic microangiopathy, lupus nephritis, Henoch-Schonlein nephritis, crescentic glomerulonephritis, and cocaine-related acute renal failure.",11391224_7,-1,1,1,2233,1
2237,renal failure,9,11,51,64,Mild PTCR in allografts without TG did not predict renal failure or significant proteinuria after follow-up periods of between 3 months and 1 year.,11391224_8,-1,1,1,2237,1
2245,kidney diseases,6,8,35,50,"PTCR also occurs in certain native kidney diseases, though the association is not as strong as that for TG.",11391224_10,-1,1,1,2245,1
2249,diabetes insipidus,8,10,49,67,The renal pathology in a case of lithium-induced diabetes insipidus.,1141447_0,-1,1,1,2249,1
2250,diabetes insipidus,4,6,26,44,A case of lithium-induced diabetes insipidus is reported.,1141447_1,-1,1,1,2250,1
2294,post-treatment,2,3,10,24,"Moreover, post-treatment with LR132 prevented cocaine-induced lethality in a significant proportion of animals.",11426838_6,-1,1,1,2294,1
2341,Liver disease,0,2,0,13,Liver disease caused by propylthiouracil.,1147734_0,-1,1,1,2341,1
2343,chronic active,18,20,113,127,"This report presents the clinical, laboratory, and light and electron microscopic observations on a patient with chronic active (aggressive) hepatitis caused by the administration of propylthiouracil.",1147734_1,-1,1,1,2343,1
2373,cardiac arrest,25,27,182,196,We conclude that the systemic toxicity of levobupivacaine is intermediate between that of ropivacaine and bupivacaine when administered at the same rate and that ropivacaine-induced cardiac arrest appears to be more susceptible to treatment than that induced by bupivacaine or levobupivacaine.,11524350_13,-1,1,1,2373,1
2393,ventricular tachycardia,10,12,49,72,Torsades de pointes (TDP) is a potentially fatal ventricular tachycardia associated with increases in QT interval and monophasic action potential duration (MAPD).,11569530_1,-1,1,1,2393,1
2442,cryptococcal meningitis,4,6,21,44,"DISCUSSION: AIDS and cryptococcal meningitis, both of which the patient had, can potentially cause seizures.",11573852_4,-1,1,1,2442,1
2443,alcohol abuse,6,8,29,42,The patient had a history of alcohol abuse; alcohol intake as well as withdrawal can also cause seizures.,11573852_5,-1,1,1,2443,1
2459,side effects,2,4,17,29,"Various reported side effects of fentanyl administration include chest wall rigidity, hypotension, respiratory depression, and bradycardia.",11581460_3,-1,1,1,2459,1
2461,respiratory depression,14,16,99,121,"Various reported side effects of fentanyl administration include chest wall rigidity, hypotension, respiratory depression, and bradycardia.",11581460_3,-1,1,1,2461,1
2489,lymphoblastic lymphoma,27,29,172,194,We report on two fatal cases of accidental intrathecal vincristine instillation in a 5-year old girl with recurrent acute lymphoblastic leucemia and a 57-year old man with lymphoblastic lymphoma.,11587867_1,-1,1,1,2489,1
2501,clinical course,1,3,4,19,The clinical course and histopathological results of the two cases are presented.,11587867_5,-1,1,1,2501,1
2508,of children,10,12,53,64,Current estimates suggest that between 0.4% and 8.3% of children and adolescents are affected by major depression.,11642480_1,-1,1,1,2508,1
2514,side effect,5,7,21,32,This may have been a side effect of citalopram as it remitted with redistribution of doses.,11642480_3,-1,1,1,2514,1
2519,rheumatoid arthritis,28,30,177,197,"A 34-year-old lady developed a constellation of dermatitis, fever, lymphadenopathy and hepatitis, beginning on the 17th day of a course of oral sulphasalazine for sero-negative rheumatoid arthritis.",11672959_1,-1,1,1,2519,1
2525,adverse drug reaction,30,33,224,245,"Cervical and inguinal lymph node biopsies showed the features of severe necrotising lymphadenitis, associated with erythrophagocytosis and prominent eosinophilic infiltrates, without viral inclusion bodies, suggestive of an adverse drug reaction.",11672959_2,-1,1,1,2525,1
2526,drug-induced hepatitis,5,7,24,46,"A week later, fulminant drug-induced hepatitis, associated with the presence of anti-nuclear autoantibodies (but not with other markers of autoimmunity), and accompanied by multi-organ failure and sepsis, supervened.",11672959_3,-1,1,1,2526,1
2535,tubulo-interstitial nephritis,15,17,124,153,"Post-mortem examination showed evidence of massive hepatocellular necrosis, acute hypersensitivity myocarditis, focal acute tubulo-interstitial nephritis and extensive bone marrow necrosis, with no evidence of malignancy.",11672959_5,-1,1,1,2535,1
2544,akathisia,16,17,124,133,"Intravenous administration of prochlorperazine by 15-minute infusion versus 2-minute bolus does not affect the incidence of akathisia: a prospective, randomized, controlled trial.",11679859_0,-1,1,1,2544,1
2546,akathisia,10,11,50,59,STUDY OBJECTIVE: We sought to compare the rate of akathisia after administration of intravenous prochlorperazine as a 2-minute bolus or 15-minute infusion.,11679859_1,-1,1,1,2546,1
2559,akathisia,10,11,67,76,The main outcome was the number of study participants experiencing akathisia within 60 minutes of administration.,11679859_5,-1,1,1,2559,1
2560,Akathisia,0,1,0,9,Akathisia was defined as either a spontaneous report of restlessness or agitation or a change of 2 or more in the patient-reported akathisia rating scale and a change of at least 1 in the investigator-observed akathisia rating scale.,11679859_6,-1,1,1,2560,1
2561,akathisia,22,23,131,140,Akathisia was defined as either a spontaneous report of restlessness or agitation or a change of 2 or more in the patient-reported akathisia rating scale and a change of at least 1 in the investigator-observed akathisia rating scale.,11679859_6,-1,1,1,2561,1
2562,akathisia,35,36,210,219,Akathisia was defined as either a spontaneous report of restlessness or agitation or a change of 2 or more in the patient-reported akathisia rating scale and a change of at least 1 in the investigator-observed akathisia rating scale.,11679859_6,-1,1,1,2562,1
2566,akathisia,11,12,38,47,"In the bolus group, 26.0% (13/50) had akathisia compared with 32.7% (16/49) in the infusion group (Delta=-6.7%; 95% confidence interval [CI] -24.6% to 11.2%).",11679859_11,-1,1,1,2566,1
2570,akathisia,10,11,48,57,CONCLUSION: A 50% reduction in the incidence of akathisia when prochlorperazine was administered by means of 15-minute intravenous infusion versus a 2-minute intravenous push was not detected.,11679859_14,-1,1,1,2570,1
2579,anaphylactoid reactions,16,18,115,138,"Previous studies evaluated the tolerance of nimesulide and paracetamol in subjects with cutaneous, respiratory and anaphylactoid reactions induced by nonsteroidal anti-inflammatory drugs (NSAIDs).",11694026_1,-1,1,1,2579,1
2595,chronic urticaria,10,12,50,67,"Furthermore, 18.28% of patients with a history of chronic urticaria and 11.8% of subjects with an history of NSAID-induced urticaria/angioedema or angioedema alone (with or without chronic urticaria) resulted to be intolerant to alternative drugs.",11694026_7,-1,1,1,2595,1
2597,chronic urticaria,30,32,181,198,"Furthermore, 18.28% of patients with a history of chronic urticaria and 11.8% of subjects with an history of NSAID-induced urticaria/angioedema or angioedema alone (with or without chronic urticaria) resulted to be intolerant to alternative drugs.",11694026_7,-1,1,1,2597,1
2602,chronic urticaria,18,20,106,123,"However, the risk of reaction to these alternative study drugs is statistically increased by a history of chronic urticaria and, above all, by a history of NSAID-induced angioedema.",11694026_9,-1,1,1,2602,1
2613,open-angle glaucoma,7,9,53,72,"METHODS: Forty-three Caucasian patients with primary open-angle glaucoma or ocular hypertension with a mean (+/-SD) age of 63 (+/-8) years were randomized and crossed over in a double-masked manner to 14 days of treatment with placebo (morning and evening in both eyes), timolol solution (morning and evening in both eyes), or timolol gellan (morning in both eyes with placebo in the evening).",11704023_4,-1,1,1,2613,1
2614,ocular hypertension,10,12,76,95,"METHODS: Forty-three Caucasian patients with primary open-angle glaucoma or ocular hypertension with a mean (+/-SD) age of 63 (+/-8) years were randomized and crossed over in a double-masked manner to 14 days of treatment with placebo (morning and evening in both eyes), timolol solution (morning and evening in both eyes), or timolol gellan (morning in both eyes with placebo in the evening).",11704023_4,-1,1,1,2614,1
2642,hemolytic anemia,4,6,44,60,Management strategies for ribavirin-induced hemolytic anemia in the treatment of hepatitis C: clinical and economic implications.,11705128_0,-1,1,1,2642,1
2650,chronic hepatitis,26,28,224,241,OBJECTIVES: Recently published studies have demonstrated increased efficacy and cost-effectiveness of combination therapy with interferon and alpha-2b/ribavirin compared with interferon-alpha monotherapy in the treatment of chronic hepatitis C (CHC).,11705128_1,-1,1,1,2650,1
2655,hemolytic anemia,12,14,96,112,Combination therapy is associated with a clinically important adverse effect: ribavirin-induced hemolytic anemia (RIHA).,11705128_2,-1,1,1,2655,1
2721,breast carcinoma,13,15,71,87,A Phase II trial of cisplatin plus WR-2721 (amifostine) for metastatic breast carcinoma: an Eastern Cooperative Oncology Group Study (E8188).BACKGROUND: Cisplatin has minimal antitumor activity when used as second- or third-line treatment of metastatic breast carcinoma.,11745184_0,-1,1,1,2721,1
2726,breast carcinoma,38,40,253,269,A Phase II trial of cisplatin plus WR-2721 (amifostine) for metastatic breast carcinoma: an Eastern Cooperative Oncology Group Study (E8188).BACKGROUND: Cisplatin has minimal antitumor activity when used as second- or third-line treatment of metastatic breast carcinoma.,11745184_0,-1,1,1,2726,1
2736,ototoxicity,21,22,144,155,"Although a dose-response effect has been observed with cisplatin, the dose-limiting toxicities associated with cisplatin (e.g., nephrotoxicity, ototoxicity, and neurotoxicity) have limited its use as a treatment for breast carcinoma.",11745184_2,-1,1,1,2736,1
2737,neurotoxicity,24,25,161,174,"Although a dose-response effect has been observed with cisplatin, the dose-limiting toxicities associated with cisplatin (e.g., nephrotoxicity, ototoxicity, and neurotoxicity) have limited its use as a treatment for breast carcinoma.",11745184_2,-1,1,1,2737,1
2738,breast carcinoma,34,36,216,232,"Although a dose-response effect has been observed with cisplatin, the dose-limiting toxicities associated with cisplatin (e.g., nephrotoxicity, ototoxicity, and neurotoxicity) have limited its use as a treatment for breast carcinoma.",11745184_2,-1,1,1,2738,1
2751,ototoxicity,17,18,125,136,"Early trials of cisplatin and amifostine also suggested that the incidence and severity of cisplatin-induced nephrotoxicity, ototoxicity, and neuropathy were reduced.",11745184_5,-1,1,1,2751,1
2755,breast carcinoma,20,22,128,144,"METHODS: A Phase II study of the combination of cisplatin plus amifostine was conducted in patients with progressive metastatic breast carcinoma who had received one, but not more than one, chemotherapy regimen for metastatic disease.",11745184_6,-1,1,1,2755,1
2764,disease progression,7,9,47,66,Treatment was administered every 3 weeks until disease progression.,11745184_10,-1,1,1,2764,1
2768,disease progression,10,12,49,68,Most patients (57%) stopped treatment because of disease progression.,11745184_14,-1,1,1,2768,1
2778,myocardial infarction,6,8,36,57,Oral contraceptives and the risk of myocardial infarction.,11752354_0,-1,1,1,2778,1
2780,myocardial infarction,14,16,82,103,"BACKGROUND: An association between the use of oral contraceptives and the risk of myocardial infarction has been found in some, but not all, studies.",11752354_1,-1,1,1,2780,1
2791,myocardial infarction,72,74,424,445,"We investigated this association, according to the type of progestagen included in third-generation (i.e., desogestrel or gestodene) and second-generation (i.e., levonorgestrel) oral contraceptives, the dose of estrogen, and the presence or absence of prothrombotic mutations METHODS: In a nationwide, population-based, case-control study, we identified and enrolled 248 women 18 through 49 years of age who had had a first myocardial infarction between 1990 and 1995 and 925 control women who had not had a myocardial infarction and who were matched for age, calendar year of the index event, and area of residence.",11752354_2,-1,1,1,2791,1
2792,myocardial infarction,87,89,508,529,"We investigated this association, according to the type of progestagen included in third-generation (i.e., desogestrel or gestodene) and second-generation (i.e., levonorgestrel) oral contraceptives, the dose of estrogen, and the presence or absence of prothrombotic mutations METHODS: In a nationwide, population-based, case-control study, we identified and enrolled 248 women 18 through 49 years of age who had had a first myocardial infarction between 1990 and 1995 and 925 control women who had not had a myocardial infarction and who were matched for age, calendar year of the index event, and area of residence.",11752354_2,-1,1,1,2792,1
2802,myocardial infarction,28,30,156,177,"An analysis for factor V Leiden and the G20210A mutation in the prothrombin gene was conducted in 217 patients and 763 controls RESULTS: The odds ratio for myocardial infarction among women who used any type of combined oral contraceptive, as compared with nonusers, was 2.0 (95 percent confidence interval, 1.5 to 2.8).",11752354_4,-1,1,1,2802,1
2816,myocardial infarction,50,52,257,278,"Among women who used oral contraceptives, the odds ratio was 2.1 (95 percent confidence interval, 1.5 to 3.0) for those without a prothrombotic mutation and 1.9 (95 percent confidence interval, 0.6 to 5.5) for those with a mutation CONCLUSIONS: The risk of myocardial infarction was increased among women who used second-generation oral contraceptives.",11752354_6,-1,1,1,2816,1
2821,myocardial infarction,3,5,12,33,The risk of myocardial infarction was similar among women who used oral contraceptives whether or not they had a prothrombotic mutation.,11752354_8,-1,1,1,2821,1
2828,chronic pain,18,20,115,127,"BACKGROUND: Preclinical studies of intrathecal adenosine suggest it may be effective in the treatment of acute and chronic pain in humans, and preliminary studies in volunteers and patients with a Swedish formulation of adenosine suggests it may be effective in hypersensitivity states but not with acute noxious stimulation.",11752998_1,-1,1,1,2828,1
2841,Cerebrospinal fluid,0,2,0,19,"Cerebrospinal fluid was obtained for pharmacokinetic analysis, and pain ratings in response to acute heat stimuli and areas of mechanical hyperalgesia and allodynia after intradermal capsaicin injection were determined.",11752998_4,-1,1,1,2841,1
2845,mechanical hyperalgesia,20,22,127,150,"Cerebrospinal fluid was obtained for pharmacokinetic analysis, and pain ratings in response to acute heat stimuli and areas of mechanical hyperalgesia and allodynia after intradermal capsaicin injection were determined.",11752998_4,-1,1,1,2845,1
2846,allodynia,23,24,155,164,"Cerebrospinal fluid was obtained for pharmacokinetic analysis, and pain ratings in response to acute heat stimuli and areas of mechanical hyperalgesia and allodynia after intradermal capsaicin injection were determined.",11752998_4,-1,1,1,2846,1
2850,mechanical hyperalgesia,18,20,114,137,"RESULTS: Adenosine produced no effect on pain report to acute noxious thermal or chemical stimulation but reduced mechanical hyperalgesia and allodynia from intradermal capsaicin injection for at least 24 h. In contrast, residence time of adenosine in cerebrospinal fluid was short (< 4 h).",11752998_5,-1,1,1,2850,1
2851,allodynia,21,22,142,151,"RESULTS: Adenosine produced no effect on pain report to acute noxious thermal or chemical stimulation but reduced mechanical hyperalgesia and allodynia from intradermal capsaicin injection for at least 24 h. In contrast, residence time of adenosine in cerebrospinal fluid was short (< 4 h).",11752998_5,-1,1,1,2851,1
2853,cerebrospinal fluid,39,41,252,271,"RESULTS: Adenosine produced no effect on pain report to acute noxious thermal or chemical stimulation but reduced mechanical hyperalgesia and allodynia from intradermal capsaicin injection for at least 24 h. In contrast, residence time of adenosine in cerebrospinal fluid was short (< 4 h).",11752998_5,-1,1,1,2853,1
2859,cerebrospinal fluid,27,29,176,195,The long-lasting effect is consistent with that observed in preliminary reports of patients with chronic neuropathic pain and is not due to prolonged residence of adenosine in cerebrospinal fluid.,11752998_7,-1,1,1,2859,1
2922,Epileptic seizures,0,2,0,18,Epileptic seizures following cortical application of fibrin sealants containing tranexamic acid in rats.,11807648_0,-1,1,1,2922,1
2934,epileptic seizures,8,10,39,57,"However, tAMCA has been shown to cause epileptic seizures.",11807648_4,-1,1,1,2934,1
2948,generalized seizures,8,10,44,64,"Thus, FS containing 47.5 mg/ml tAMCA evoked generalized seizures in all tested rats (n=6) while the lowest concentration of tAMCA (0.5 mg/ml) only evoked brief episodes of jerk-correlated convulsive potentials in 1 of 6 rats.",11807648_10,-1,1,1,2948,1
3001,prolactinomas,7,8,55,68,Chronically elevated prolactin levels in children with prolactinomas may be associated with arrested growth and development resulting in either delayed puberty or short stature.,11838826_2,-1,1,1,3001,1
3041,rotator cuff,20,22,128,140,CASE SUMMARY: A 70-year-old healthy woman from Iraq developed acute cholestatic hepatitis 3 weeks following repair of the right rotator cuff under general anesthesia.,11847945_2,-1,1,1,3041,1
3056,left bundle branch block,13,17,91,115,Torsade de pointes induced by metoclopramide in an elderly woman with preexisting complete left bundle branch block.,11858397_0,-1,1,1,3056,1
3062,left bundle branch block,9,13,59,83,We report on a 92-year-old woman with preexisting complete left bundle branch block who developed torsade de pointes after intravenous and oral administration of metoclopramide.,11858397_3,-1,1,1,3062,1
3075,cell death,6,8,49,59,Dopamine D2 receptor signaling controls neuronal cell death induced by muscarinic and glutamatergic drugs.,11860278_0,-1,1,1,3075,1
3079,epileptic seizures,18,20,95,113,"Dopamine (DA), through D1/D2 receptor-mediated signaling, plays a major role in the control of epileptic seizures arising in the limbic system.",11860278_1,-1,1,1,3079,1
3082,cell death,4,6,35,45,Excitotoxicity leading to neuronal cell death in the affected areas is a major consequence of seizures at the cellular level.,11860278_2,-1,1,1,3082,1
3085,cell death,19,21,111,121,"In this respect, little is known about the role of DA receptors in the occurrence of epilepsy-induced neuronal cell death.",11860278_3,-1,1,1,3085,1
3086,neurotoxicity,8,9,47,60,Here we analyze the occurrence of seizures and neurotoxicity in D2R -/- mice treated with the cholinergic agonist pilocarpine.,11860278_4,-1,1,1,3086,1
3093,neurotoxicity,22,23,129,142,"Importantly, D2R -/- mice develop seizures at doses of both drugs that are not epileptogenic for WT littermates and show greater neurotoxicity.",11860278_6,-1,1,1,3093,1
3099,neurodegeneration,7,8,55,72,"Moreover, the dopaminergic control of epilepsy-induced neurodegeneration seems to be mediated by distinct interactions of D2R signaling with these two neurotransmitters.",11860278_9,-1,1,1,3099,1
3153,heart failure,10,12,92,105,Activation of poly(ADP-ribose) polymerase contributes to development of doxorubicin-induced heart failure.,11861791_0,-1,1,1,3153,1
3181,left ventricular,6,8,36,52,"Five days after DOX administration, left ventricular performance was significantly depressed in PARP-1+/+ mice, but only to a smaller extent in PARP-1-/- ones.",11861791_6,-1,1,1,3181,1
3210,side effect,19,21,129,140,Selective distal tubular epithelial toxicity seems to be responsible for the profound potassium wasting that is a major clinical side effect of treatment with AmB. Potassium depletion also potentiates the tubular toxicity of AmB. This study was designed to assess the ability of spironolactone to reduce potassium requirements and to prevent hypokalemia in neutropenic patients on AmB treatment.,11868798_1,-1,1,1,3210,1
3214,neutropenic,53,54,357,368,Selective distal tubular epithelial toxicity seems to be responsible for the profound potassium wasting that is a major clinical side effect of treatment with AmB. Potassium depletion also potentiates the tubular toxicity of AmB. This study was designed to assess the ability of spironolactone to reduce potassium requirements and to prevent hypokalemia in neutropenic patients on AmB treatment.,11868798_1,-1,1,1,3214,1
3231,neutropenic,20,21,146,157,CONCLUSION: This study showed that spironolactone can reduce potassium requirements and prevent hypokalemia by reducing urinary potassium loss in neutropenic patients on AmB treatment.,11868798_6,-1,1,1,3231,1
3233,exencephaly,3,4,27,38,Sequential observations of exencephaly and subsequent morphological changes by mouse exo utero development system: analysis of the mechanism of transformation from exencephaly to anencephaly.,11875660_0,-1,1,1,3233,1
3235,exencephaly,22,23,164,175,Sequential observations of exencephaly and subsequent morphological changes by mouse exo utero development system: analysis of the mechanism of transformation from exencephaly to anencephaly.,11875660_0,-1,1,1,3235,1
3236,exencephaly,7,8,47,58,"Anencephaly has been suggested to develop from exencephaly; however, there is little direct experimental evidence to support this, and the mechanism of transformation remains unclear.",11875660_1,-1,1,1,3236,1
3239,exencephaly,3,4,16,27,"We observed the exencephaly induced by 5-azacytidine at embryonic day 13.5 (E13.5), let the embryos develop exo utero until E18.5, and re-observed the same embryos at E18.5.",11875660_3,-1,1,1,3239,1
3244,exencephaly,7,8,50,61,We confirmed several cases of transformation from exencephaly to anencephaly.,11875660_4,-1,1,1,3244,1
3246,exencephaly,9,10,58,69,"To analyze the transformation patterns, we classified the exencephaly by size and shape of the exencephalic tissue into several types at E13.5 and E18.5.",11875660_6,-1,1,1,3246,1
3253,exencephaly,6,7,52,63,"Microscopic observation showed the configuration of exencephaly at E13.5, frequent hemorrhaging and detachment of the neural plate from surface ectoderm in the exencephalic head at E15.5, and multiple modes of reduction in the exencephalic tissue at E18.5.",11875660_8,-1,1,1,3253,1
3267,exencephaly,43,44,308,319,"These findings suggest that overgrowth of the exencephalic neural tissue causes the altered distribution patterns of vessels, subsequent peripheral circulatory failure and/or hemorrhaging in various parts of the exencephalic head, leading to the multiple modes of tissue reduction during transformation from exencephaly to anencephaly.",11875660_10,-1,1,1,3267,1
3286,myocardial infarction,5,7,55,76,99mTc-glucarate for detection of isoproterenol-induced myocardial infarction in rats.,11897407_0,-1,1,1,3286,1
3368,cardiac arrest,15,17,106,120,"Two patients developed severe cardiac arrhythmias, including one patient who was resuscitated following a cardiac arrest.",11928786_6,-1,1,1,3368,1
3385,epithelial cell,24,26,161,176,Glomerular epithelial protein 1 (GLEPP1) is a podocyte receptor membrane protein tyrosine phosphatase located on the apical cell membrane of visceral glomerular epithelial cell and foot processes.,11961407_2,-1,1,1,3385,1
3402,glomerulosclerosis,52,53,240,258,"Tissues were analyzed at 0, 5, 7, 11, 21, 45, 80 and 126 days after PAN injection so as to include both the acute phase of proteinuria associated with foot process effacement (days 5-11) and the chronic phase of proteinuria associated with glomerulosclerosis (days 45-126).",11961407_6,-1,1,1,3402,1
3431,orofacial dyskinesia,18,20,89,109,"Reserpine (1 mg/kg), administered once every other day for 4 days, produced increases in orofacial dyskinesia, tongue protrusion and vacuous chewing in mice, which are signs indicative of tardive dyskinesia.",11999899_3,-1,1,1,3431,1
3443,oral dyskinesia,30,32,145,160,"Reserpine (1 mg/kg), administered 90 min before the test and followed by apomophine injection (0.1 mg/kg) 5 min before the test, did not produce oral dyskinesia in mice.",11999899_7,-1,1,1,3443,1
3453,abnormal movements,8,10,57,75,"These results show that reserpine produces different and abnormal movements, which are related to dose and schedule employed and can be considered as parkinsonian-like and tardive dsykinesia signs.",11999899_11,-1,1,1,3453,1
3474,side effect,12,14,77,88,"This phenomenon may be interpreted as a benign, short-term and self-limiting side effect which does not contraindicate the use of risperidone or interfere with treatment.",12013711_6,-1,1,1,3474,1
3479,aplastic anemia,7,9,67,82,Antithymocyte globulin in the treatment of D-penicillamine-induced aplastic anemia.,12041669_0,-1,1,1,3479,1
3481,aplastic anemia,8,10,58,73,A patient who received antithymocyte globulin therapy for aplastic anemia due to D-penicillamine therapy is described.,12041669_1,-1,1,1,3481,1
3483,Bone marrow,0,2,0,11,"Bone marrow recovery and peripheral blood recovery were complete 1 month and 3 months, respectively, after treatment, and blood transfusion or other therapies were not necessary in a follow-up period of more than 2 years.",12041669_2,-1,1,1,3483,1
3487,aplastic anemia,11,13,86,101,Use of antithymocyte globulin may be the optimal treatment of D-penicillamine-induced aplastic anemia.,12041669_3,-1,1,1,3487,1
3490,metabolic acidosis,9,11,58,76,Urologists should be aware that this medication can cause metabolic acidosis in patients secondary to inhibition of carbonic anhydrase.,12042105_2,-1,1,1,3490,1
3494,compensatory,15,16,89,101,"In addition, a distal tubular acidification defect may result, thus impairing the normal compensatory drop in urine pH. These factors can lead to the development of calcium phosphate nephrolithiasis.",12042105_3,-1,1,1,3494,1
3496,urologic,11,12,75,83,We report the first two cases of topiramate-induced nephrolithiasis in the urologic literature.,12042105_4,-1,1,1,3496,1
3524,chronic pain,26,28,176,188,"These findings show a significant interaction between morphine and metamizol in chronically treated rats, suggesting that this combination could be useful for the treatment of chronic pain.",12063090_10,-1,1,1,3524,1
3531,drug use,23,25,138,146,CNS toxic effects of the antineoplastic agent ifosfamide (IFX) are frequent and include a variety of neurological symptoms that can limit drug use.,12084448_1,-1,1,1,3531,1
3532,lower extremities,19,21,106,123,"We report a case of a 51-year-old man who developed severe, disabling negative myoclonus of the upper and lower extremities after the infusion of ifosfamide for plasmacytoma.",12084448_2,-1,1,1,3532,1
3552,bone marrow,13,15,102,113,Antagonism between interleukin 3 and erythropoietin in mice with azidothymidine-induced anemia and in bone marrow endothelial cells.,12090760_0,-1,1,1,3552,1
3577,bone marrow,10,12,66,77,Bovine liver erythroid cells were cultured on monolayers of human bone marrow endothelial cells previously treated with EPO and IGF-IL-3.,12090760_4,-1,1,1,3577,1
3645,virus infection,12,14,81,96,"Ribavirin is licensed in aerosol form for the treatment of respiratory syncytial virus infection, and orally in combination with interferon to treat hepatitis C. Intravenous ribavirin is the treatment of choice for infection with hemorrhagic fever viruses.",12093990_7,-1,1,1,3645,1
3647,hemorrhagic fever,35,37,230,247,"Ribavirin is licensed in aerosol form for the treatment of respiratory syncytial virus infection, and orally in combination with interferon to treat hepatitis C. Intravenous ribavirin is the treatment of choice for infection with hemorrhagic fever viruses.",12093990_7,-1,1,1,3647,1
3651,adenovirus infection,6,8,31,51,"The use of cidofovir in severe adenovirus infection has been limited by adverse effects, the most significant of which is nephrotoxicity.",12093990_9,-1,1,1,3651,1
3661,bone marrow,9,11,73,84,"Two patients developed adenovirus hemorrhagic cystitis after cardiac and bone marrow transplants, respectively.",12093990_12,-1,1,1,3661,1
3662,bone marrow,1,3,4,15,The bone marrow transplant patient also received intravenous cidofovir for progressive disseminated disease.,12093990_13,-1,1,1,3662,1
3664,DiGeorge syndrome,17,19,96,113,"An additional 3 children developed adenovirus pneumonia; 2 were neonates, 1 of whom had partial DiGeorge syndrome.",12093990_14,-1,1,1,3664,1
3674,renal failure,10,12,60,73,Use of cidofovir in 1 child was associated with progressive renal failure and neutropenia.,12093990_20,-1,1,1,3674,1
3678,bone marrow,25,27,170,181,"DISCUSSION: Our series of patients is representative of the spectrum of immunocompromised children at greatest risk for severe adenovirus disease, namely solid-organ and bone marrow transplant recipients, neonates, and children with immunodeficiency.",12093990_21,-1,1,1,3678,1
3688,adenovirus infection,22,24,136,156,"The availability of newer rapid diagnostic techniques, such as polymerase chain reaction, may make earlier, more effective treatment of adenovirus infection possible.",12093990_25,-1,1,1,3688,1
3693,cardiac arrest,2,4,18,32,Delayed asystolic cardiac arrest after diltiazem overdose; resuscitation with high dose intravenous calcium.,12101159_0,-1,1,1,3693,1
3704,tonic-clonic seizures,9,11,57,78,Eighteen hours after the overdose he had two generalised tonic-clonic seizures.,12101159_3,-1,1,1,3704,1
3705,junctional,5,6,39,49,"The patient remained unresponsive with junctional bradycardia, unrecordable blood pressure, and then became asystolic.",12101159_4,-1,1,1,3705,1
3713,cardiac arrest,8,10,42,56,It should be considered early in cases of cardiac arrest after diltiazem overdose.,12101159_8,-1,1,1,3713,1
3753,Cardiac arrest,0,2,0,14,Cardiac arrest after intravenous metoclopramide - a case of five repeated injections of metoclopramide causing five episodes of cardiac arrest.,12139551_0,-1,1,1,3753,1
3756,cardiac arrest,18,20,128,142,Cardiac arrest after intravenous metoclopramide - a case of five repeated injections of metoclopramide causing five episodes of cardiac arrest.,12139551_0,-1,1,1,3756,1
3764,cardiac arrest,6,8,33,47,We interpret this as episodes of cardiac arrest caused by metoclopramide.,12139551_6,-1,1,1,3764,1
3767,adverse drug reaction,21,24,143,164,The rapid injection via the central venous route and the concomitant tapering of dopamine infusion might have contributed in precipitating the adverse drug reaction.,12139551_7,-1,1,1,3767,1
3813,alcohol withdrawal,31,33,221,239,"BACKGROUND: The septo-hippocampal cholinergic pathway has been implicated in epileptogenesis, and genetic factors influence the response to cholinergic agents, but limited data are available on cholinergic involvement in alcohol withdrawal severity.",12198388_1,-1,1,1,3813,1
3814,alcohol withdrawal,10,12,75,93,"Thus, the relationship between cholinergic activity and responsiveness and alcohol withdrawal was investigated in a genetic animal model of ethanol withdrawal severity.",12198388_2,-1,1,1,3814,1
3823,CA1,16,17,104,107,We also used microdialysis to measure basal and potassium-stimulated acetylcholine (ACh) release in the CA1 region of the hippocampus.,12198388_5,-1,1,1,3823,1
3825,Hippocampal,0,1,0,11,Hippocampal ACh also was measured during testing for handling-induced convulsions.,12198388_7,-1,1,1,3825,1
3838,hippocampal,1,2,5,16,"When hippocampal ACh was measured during testing for handling-induced convulsions, extracellular ACh was significantly elevated (192%) in WSP mice, but was nonsignificantly elevated (59%) in WSR mice.",12198388_11,-1,1,1,3838,1
3843,postsynaptic,11,12,80,92,CONCLUSIONS: These results suggest that differences in cholinergic activity and postsynaptic sensitivity to cholinergic convulsants may be associated with ethanol withdrawal severity and implicate cholinergic mechanisms in alcohol withdrawal.,12198388_12,-1,1,1,3843,1
3847,alcohol withdrawal,28,30,223,241,CONCLUSIONS: These results suggest that differences in cholinergic activity and postsynaptic sensitivity to cholinergic convulsants may be associated with ethanol withdrawal severity and implicate cholinergic mechanisms in alcohol withdrawal.,12198388_12,-1,1,1,3847,1
3851,postsynaptic,16,17,106,118,"Specifically, WSP mice may have lower sensitivity to cholinergic convulsants compared with WSR because of postsynaptic receptor desensitization brought on by higher activity of cholinergic neurons.",12198388_13,-1,1,1,3851,1
3852,muscle pain,1,3,18,29,Capsaicin-induced muscle pain alters the excitability of the human jaw-stretch reflex.,12202650_0,-1,1,1,3852,1
3854,pathophysiology,1,2,4,19,"The pathophysiology of painful temporomandibular disorders is not fully understood, but evidence suggests that muscle pain modulates motor function in characteristic ways.",12202650_1,-1,1,1,3854,1
3856,muscle pain,15,17,111,122,"The pathophysiology of painful temporomandibular disorders is not fully understood, but evidence suggests that muscle pain modulates motor function in characteristic ways.",12202650_1,-1,1,1,3856,1
3861,masseter muscle,10,12,45,60,Capsaicin (10 micro g) was injected into the masseter muscle to induce pain in 11 healthy volunteers.,12202650_3,-1,1,1,3861,1
3871,muscle pain,8,10,59,70,Increased sensitivity of the fusimotor system during acute muscle pain could be one likely mechanism to explain the findings.,12202650_7,-1,1,1,3871,1
3881,muscle rigidity,8,10,51,66,"Haloperidol (1 mg/kg ip) induced parkinsonian-like muscle rigidity, measured as an increased resistance of a rat's hind foot to passive flexion and extension at the ankle joint.",12231232_2,-1,1,1,3881,1
3894,muscle rigidity,12,14,77,92,AIDA in doses of 7.5-15 microg/0.5 microl diminished the haloperidol-induced muscle rigidity.,12231232_4,-1,1,1,3894,1
3948,chest pain,2,4,16,26,Cocaine related chest pain: are we seeing the tip of an iceberg?The recreational use of cocaine is on the increase.,12443032_0,-1,1,1,3948,1
3951,chest pain,9,11,50,60,"In particular, the tendency of cocaine to produce chest pain ought to be in the mind of the emergency nurse when faced with a young victim of chest pain who is otherwise at low risk.",12443032_2,-1,1,1,3951,1
3952,chest pain,28,30,142,152,"In particular, the tendency of cocaine to produce chest pain ought to be in the mind of the emergency nurse when faced with a young victim of chest pain who is otherwise at low risk.",12443032_2,-1,1,1,3952,1
3954,chest pain,3,5,17,27,The mechanism of chest pain related to cocaine use is discussed and treatment dilemmas are discussed.,12443032_3,-1,1,1,3954,1
3960,renal cell carcinoma,9,12,55,75,A phase II study of thalidomide in advanced metastatic renal cell carcinoma.,12448656_0,-1,1,1,3960,1
3975,renal cell carcinoma,15,18,88,108,CONCLUSION: These results are consistent with a low level of activity of thalidomide in renal cell carcinoma.,12448656_9,-1,1,1,3975,1
3980,renal cell carcinoma,10,13,59,79,"The dose-response relationship, if any, of thalidomide for renal cell carcinoma is unclear.",12448656_11,-1,1,1,3980,1
4001,intraoperative,27,28,169,183,"Twenty-four hours later, any myalgia experienced was assessed according to a structured questionaire and graded by a four point scale by one investigator blinded to the intraoperative management.",12452237_7,-1,1,1,4001,1
4002,muscle fasciculation,4,6,26,46,The results indicate that muscle fasciculation was not found in Group PR while the patients in Group LS had a lower incidence of muscle fasciculation than those in Group PS (p < 0.001).,12452237_8,-1,1,1,4002,1
4003,muscle fasciculation,23,25,129,149,The results indicate that muscle fasciculation was not found in Group PR while the patients in Group LS had a lower incidence of muscle fasciculation than those in Group PS (p < 0.001).,12452237_8,-1,1,1,4003,1
4004,muscle fasciculation,14,16,83,103,A correlation was not found between the incidence of myalgia and the occurrence of muscle fasciculation.,12452237_10,-1,1,1,4004,1
4014,early onset,13,15,87,98,Rizatriptan is a selective 5-HT(1B/1D) receptor agonist with rapid oral absorption and early onset of action in the acute treatment of migraine.,12464714_1,-1,1,1,4014,1
4064,hippocampal,26,27,170,181,The loss of beta2 resulted in negative shifts in the voltage dependence of inactivation as well as significant decreases in sodium current density in acutely dissociated hippocampal neurons.,12481039_4,-1,1,1,4064,1
4066,optic nerve,8,10,49,60,"The integral of the compound action potential in optic nerve was significantly reduced, and the threshold for action potential generation was increased, indicating a reduction in the level of functional plasma membrane sodium channels.",12481039_5,-1,1,1,4066,1
4070,optic nerve,15,17,74,85,"In contrast, the conduction velocity, the number and size of axons in the optic nerve, and the specific localization of Na(v)1.6 channels in the nodes of Ranvier were unchanged.",12481039_6,-1,1,1,4070,1
4088,side effects,8,10,46,58,"Generally, carboplatin is said to have milder side effects than cisplatin, whose ocular and orbital toxicity are well known.",12483326_4,-1,1,1,4088,1
4096,temporal lobe,17,19,114,127,CASE: A 58-year-old man received an intracarotid injection of carboplatin for recurrent glioblastomas in his left temporal lobe.,12483326_6,-1,1,1,4096,1
4107,optic atrophy,10,12,59,72,"Finally, 6 weeks later, diffuse chorioretinal atrophy with optic atrophy occurred and the vision in his left eye was lost.",12483326_11,-1,1,1,4107,1
4111,ocular toxicity,17,19,112,127,"CONCLUSION: When performing intracarotid injection of carboplatin, we must be aware of its potentially blinding ocular toxicity.",12483326_12,-1,1,1,4111,1
4112,side effects,17,19,111,123,It is recommended that further studies and investigations are undertaken in the effort to minimize such severe side effects.,12483326_13,-1,1,1,4112,1
4113,Visual hallucinations,0,2,0,21,Visual hallucinations associated with zonisamide.,12523465_0,-1,1,1,4113,1
4118,visual hallucinations,1,3,9,30,"Although visual hallucinations have not been reported as an adverse effect of this agent, we describe three patients who experienced complex visual hallucinations and altered mental status after zonisamide treatment was begun or its dosage increased.",12523465_2,-1,1,1,4118,1
4120,visual hallucinations,22,24,141,162,"Although visual hallucinations have not been reported as an adverse effect of this agent, we describe three patients who experienced complex visual hallucinations and altered mental status after zonisamide treatment was begun or its dosage increased.",12523465_2,-1,1,1,4120,1
4123,visual hallucinations,3,5,19,40,"During monitoring, visual hallucinations did not correlate with EEG readings, nor did video recording capture any of the described events.",12523465_4,-1,1,1,4123,1
4124,visual hallucinations,6,8,37,58,None of the patients had experienced visual hallucinations before this event.,12523465_5,-1,1,1,4124,1
4133,drug-induced,8,9,51,63,"Despite the underlying diseases, the prognosis for drug-induced de novo absence seizure is good because it subsides rapidly after discontinuing the use of the offending drugs.",12536034_2,-1,1,1,4133,1
4137,absence epilepsy,16,18,133,149,The gamma-aminobutyric acid-transmitted thalamocortical circuitry accounts for a major part of the underlying neurophysiology of the absence epilepsy.,12536034_3,-1,1,1,4137,1
4138,drug-induced,1,2,8,20,"Because drug-induced de novo absence seizure is rare, pro-absence drugs can only be considered a promoting factor.",12536034_4,-1,1,1,4138,1
4143,drug-induced,3,4,19,31,The possibility of drug-induced aggravation should be considered whenever an unexpected increase in seizure frequency and/or new seizure types appear following a change in drug treatment.,12536034_6,-1,1,1,4143,1
4145,absence epilepsy,6,8,45,61,"By understanding the underlying mechanism of absence epilepsy, we can avoid the inappropriate use of anticonvulsants in children with epilepsy and prevent drug-induced absence seizures.",12536034_7,-1,1,1,4145,1
4150,liver failure,8,10,37,50,OBJECTIVE: To report a case of fatal liver failure possibly associated with concurrent use of bupropion and carbimazole.,12549952_1,-1,1,1,4150,1
4163,drug-induced acute liver injury,6,10,44,75,Liver biopsy showed evidence of nonspecific drug-induced acute liver injury.,12549952_5,-1,1,1,4163,1
4182,chronic infection,10,12,68,85,The etiology of pyeloureteritis cystica has long been attributed to chronic infection and inflammation.,1255900_1,-1,1,1,4182,1
4183,acute onset,10,12,47,58,A case is presented that is unique in that the acute onset and the rapid resolution of pyeloureteral filling defects in this patient were documented by radiography.,1255900_2,-1,1,1,4183,1
4243,renal injury,5,7,49,61,Prenatal dexamethasone programs hypertension and renal injury in the rat.,12574103_0,-1,1,1,4243,1
4246,renal injury,20,22,132,144,The purpose of the present study was to determine if prenatal dexamethasone programmed a progressive increase in blood pressure and renal injury in rats.,12574103_2,-1,1,1,4246,1
4249,body weight,16,18,106,117,"Pregnant rats were given either vehicle or 2 daily intraperitoneal injections of dexamethasone (0.2 mg/kg body weight) on gestational days 11 and 12, 13 and 14, 15 and 16, 17 and 18, or 19 and 20.",12574103_3,-1,1,1,4249,1
4259,glomerulosclerosis,16,17,98,116,"This study shows that prenatal dexamethasone in rats results in a reduction in glomerular number, glomerulosclerosis, and hypertension when administered at specific points during gestation.",12574103_8,-1,1,1,4259,1
4401,pulmonary hypertension,3,5,33,55,Octreotide-induced hypoxemia and pulmonary hypertension in premature neonates.,12596116_0,-1,1,1,4401,1
4404,enterocutaneous fistula,10,12,57,80,The authors report 2 cases of premature neonates who had enterocutaneous fistula complicating necrotizing enterocolitis.,12596116_1,-1,1,1,4404,1
4406,Pulmonary hypertension,0,2,0,22,"Pulmonary hypertension developed after administration of a somatostatin analogue, octreotide, to enhance resolution of the fistula.",12596116_2,-1,1,1,4406,1
4412,vestibulotoxicity,6,7,60,77,Protective effect of edaravone against streptomycin-induced vestibulotoxicity in the guinea pig.,12600698_0,-1,1,1,4412,1
4414,vestibulotoxicity,6,7,60,77,This study investigated alleviation of streptomycin-induced vestibulotoxicity by edaravone in guinea pigs.,12600698_1,-1,1,1,4414,1
4421,cerebral infarction,21,23,120,139,"Edaravone, a free radical scavenger, has potent free radical quenching action and is used in clinical practice to treat cerebral infarction.",12600698_2,-1,1,1,4421,1
4430,vestibulotoxicity,7,8,69,86,These results suggest that edaravone suppresses streptomycin-induced vestibulotoxicity.,12600698_6,-1,1,1,4430,1
4439,polycystic ovary syndrome,32,35,181,206,BACKGROUND: Cyproterone acetate combined with ethinyl estradiol (CPA/EE) is licensed in the UK for the treatment of women with acne and hirsutism and is also a treatment option for polycystic ovary syndrome (PCOS).,12615818_1,-1,1,1,4439,1
4476,acute renal failure,16,19,83,102,In the present work we assessed the effect of treatment of rats with gum Arabic on acute renal failure induced by gentamicin (GM) nephrotoxicity.,12617329_1,-1,1,1,4476,1
4489,kidney cortex,22,24,134,147,"Nephrotoxicity was assessed by measuring the concentrations of creatinine and urea in the plasma and reduced glutathione (GSH) in the kidney cortex, and by light microscopic examination of kidney sections.",12617329_3,-1,1,1,4489,1
4520,disease progression,13,15,81,100,This 4-week cycle was repeated until there was evidence of excessive toxicity or disease progression.,12627929_6,-1,1,1,4520,1
4526,prostate cancer,12,14,73,88,CONCLUSION: The addition of thalidomide to docetaxel in the treatment of prostate cancer significantly increases the frequency of VTE.,12627929_8,-1,1,1,4526,1
4548,adverse drug event,7,10,52,70,An objective causality assessment revealed that the adverse drug event was probably related to the use of ticlopidine.,12639165_7,-1,1,1,4548,1
4566,nephrotic syndrome,16,18,116,134,Epithelial sodium channel (ENaC) subunit mRNA and protein expression in rats with puromycin aminonucleoside-induced nephrotic syndrome.,12653683_0,-1,1,1,4566,1
4567,nephrotic syndrome,2,4,16,34,"In experimental nephrotic syndrome, urinary sodium excretion is decreased during the early phase of the disease.",12653683_1,-1,1,1,4567,1
4577,nephrotic syndrome,14,16,104,122,We examined the abundance of ENaC subunit mRNAs and proteins in puromycin aminonucleoside (PAN)-induced nephrotic syndrome.,12653683_4,-1,1,1,4577,1
4602,nephrotic syndrome,23,25,137,155,"In conclusion, ENaC mRNA expression, especially alphaENaC, is increased in the very early phase of the experimental model of PAN-induced nephrotic syndrome in rats, but appears to escape from the regulation by aldosterone after day 3.",12653683_12,-1,1,1,4602,1
4611,substance abuse,8,10,55,70,"OBJECTIVES: Given its preclinical success for treating substance abuse and the increased risk of visual field defects (VFD) associated with cumulative lifetime exposure, we explored the effects of sub-chronic low dose GVG on cocaine-induced increases in nucleus accumbens (NAcc) dopamine (DA).",12684739_3,-1,1,1,4611,1
4635,dystonia,2,3,31,39,Levodopa-induced oromandibular dystonia in progressive supranuclear palsy.,12691807_0,-1,1,1,4635,1
4636,progressive supranuclear palsy,4,7,43,73,Levodopa-induced oromandibular dystonia in progressive supranuclear palsy.,12691807_0,-1,1,1,4636,1
4640,progressive supranuclear palsy,7,10,44,74,Cranial dystonias are rare in patients with progressive supranuclear palsy (PSP).,12691807_2,-1,1,1,4640,1
4643,dystonia,12,13,88,96,"In this report we describe an unusual case of reversible levodopa-induced Oromandibular dystonia (OMD) in a PSP patient to highlight the importance of recognizing this drug related complication in the management of PSP, and discuss the possible underlying pathophysiology.",12691807_3,-1,1,1,4643,1
4646,drug related,27,29,168,180,"In this report we describe an unusual case of reversible levodopa-induced Oromandibular dystonia (OMD) in a PSP patient to highlight the importance of recognizing this drug related complication in the management of PSP, and discuss the possible underlying pathophysiology.",12691807_3,-1,1,1,4646,1
4648,pathophysiology,41,42,256,271,"In this report we describe an unusual case of reversible levodopa-induced Oromandibular dystonia (OMD) in a PSP patient to highlight the importance of recognizing this drug related complication in the management of PSP, and discuss the possible underlying pathophysiology.",12691807_3,-1,1,1,4648,1
4651,neurotoxicity,8,9,69,82,MR imaging with quantitative diffusion mapping of tacrolimus-induced neurotoxicity in organ transplant patients.,12695819_0,-1,1,1,4651,1
4656,neurologic symptoms,24,26,153,172,Our objective was to investigate brain MR imaging findings and the utility of diffusion-weighted (DW) imaging in organ transplant patients who developed neurologic symptoms during tacrolimus therapy.,12695819_1,-1,1,1,4656,1
4669,putaminal hemorrhage,21,23,75,95,"Of the 14 patients, 5 (35.7%) had white matter abnormalities, 1 (7.1%) had putaminal hemorrhage, and 8 (57.1%) had normal findings on initial MR images.",12695819_5,-1,1,1,4669,1
4676,neurotoxicity,14,15,105,118,Diffusion-weighted imaging may be useful in predicting the outcomes of the lesions of tacrolimus-induced neurotoxicity.,12695819_8,-1,1,1,4676,1
4711,intracerebral hemorrhage,9,11,64,88,Amount of bleeding and hematoma size in the collagenase-induced intracerebral hemorrhage rat model.,12716030_0,-1,1,1,4711,1
4712,intracerebral hemorrhage,4,6,23,47,The aggravated risk on intracerebral hemorrhage (ICH) with drugs used for stroke patients should be estimated carefully.,12716030_1,-1,1,1,4712,1
4728,myocardial infarction,11,13,58,79,Case report: Dexatrim (Phenylpropanolamine) as a cause of myocardial infarction.,12734532_0,-1,1,1,4728,1
4735,hemorrhagic strokes,9,11,59,78,Its use has been associated with hypertensive episodes and hemorrhagic strokes in younger women.,12734532_2,-1,1,1,4735,1
4749,systemic lupus erythematosus,9,12,63,91,Differential diagnosis of high serum creatine kinase levels in systemic lupus erythematosus.,12739036_0,-1,1,1,4749,1
4752,systemic lupus erythematosus,8,11,40,68,"Since 1989, she had been suffering from systemic lupus erythematosus (SLE) with renal involvement and undergone periods of treatment with azathioprine and cyclophosphamide.",12739036_2,-1,1,1,4752,1
4761,muscular atrophy,14,16,88,104,"The CK increase persisted, however, and she developed progressive muscular weakness and muscular atrophy.",12739036_6,-1,1,1,4761,1
4768,toxic myopathy,16,18,92,106,"Thus, muscle biopsy of the deltoid muscle was performed in order to exclude polymyositis or toxic myopathy.",12739036_9,-1,1,1,4768,1
4774,sleep deprivation,3,5,24,41,Seizure associated with sleep deprivation and sustained-release bupropion.,12745515_0,-1,1,1,4774,1
4777,generalized seizure,5,7,29,48,This case report describes a generalized seizure associated with sustained-release bupropion use and sleep deprivation.,12745515_1,-1,1,1,4777,1
4780,sleep deprivation,13,15,101,118,This case report describes a generalized seizure associated with sustained-release bupropion use and sleep deprivation.,12745515_1,-1,1,1,4780,1
4787,tonic clonic seizure,12,15,70,90,"After 5 weeks of bupropion use, the subject experienced a generalized tonic clonic seizure after staying up nearly all night packing and moving to a new residence.",12745515_3,-1,1,1,4787,1
4790,sleep deprivation,3,5,16,33,We suggest that sleep deprivation may add to the risk of bupropion-associated seizures.,12745515_5,-1,1,1,4790,1
4796,status epilepticus,11,13,93,111,Estrogens protect ovariectomized rats from hippocampal injury induced by kainic acid-induced status epilepticus (SE).,12757899_1,-1,1,1,4796,1
4803,CA1 hippocampal,6,8,37,52,The extent of silver-stained CA3 and CA1 hippocampal neurons was evaluated 2 days after SE.,12757899_5,-1,1,1,4803,1
4808,CA1,7,8,57,60,17beta-Estradiol reduced the argyrophilic neurons in the CA1 and CA3-C sectors of ovariectomized rats.,12757899_7,-1,1,1,4808,1
4816,side effect,2,4,9,20,A common side effect associated with succinylcholine is postoperative myalgia.,12760988_1,-1,1,1,4816,1
4833,of bone,7,9,50,57,"Significant disfiguring changes occur as a result of bone, cartilage, and soft tissue hypertrophy, including the thickening of the skin, coarsening of facial features, and cutis verticis gyrata.",12789195_2,-1,1,1,4833,1
4844,side effect,10,12,55,66,This is the first case report of pseudoacromegaly as a side effect of minoxidil use.,12789195_5,-1,1,1,4844,1
4846,prostate cancer,5,7,45,60,Combined androgen blockade-induced anemia in prostate cancer patients without bone involvement.,12820454_0,-1,1,1,4846,1
4848,prostate cancer,15,17,100,115,BACKGROUND: To determine the onset and extent of combined androgen blockade (CAB)-induced anemia in prostate cancer patients without bone involvement.,12820454_1,-1,1,1,4848,1
4877,prostate cancer,7,9,48,63,"The development of severe CAB-induced anemia in prostate cancer patients did not correlate with T baseline values (T < 3 ng/ml versus T > or = 3 ng/ml), with age (< 76 yrs versus > or = 76 yrs), and clinical stage (stage C versus stage D1).",12820454_12,-1,1,1,4877,1
4890,prostate cancer,15,17,96,111,CONCLUSION: Our data suggest that rHuEPO-beta correctable CAB-induced anemia occurs in 14.3% of prostate cancer patients after 6 months of therapy.,12820454_14,-1,1,1,4890,1
4893,neurotoxicity,17,18,108,121,Effect of lindane on hepatic and brain cytochrome P450s and influence of P450 modulation in lindane induced neurotoxicity.,12842176_0,-1,1,1,4893,1
4895,body weight,14,16,57,68,"Oral administration of lindane (2.5, 5, 10 and 15 mg/kg, body weight) for 5 days was found to produce a dose-dependent increase in the activity of P450 dependent 7-ethoxyresorufin-O-deethylase (EROD), 7-pentoxyresorufin-O-dealkylase (PROD) and N-nitrosodimethylamine demethylase (NDMA-d) in rat brain and liver.",12842176_1,-1,1,1,4895,1
4992,diaphragmatic hernia,24,26,136,156,"RESULTS: The literature evaluation suggested that NSAIDs induce ventricular septal defects (VSDs) and midline defects (MDs) in rats and diaphragmatic hernia (DH), MDs, and VSDs in rabbits (Cook JC et al., 2003); hence, the present study focused on these malformations, even though ASA induces several other low-incidence malformations.",12852481_8,-1,1,1,4992,1
5047,drug-related,23,24,117,129,"Thirty-nine (30%) of flumazenil-treated patients, compared with 17 (25%) of placebo-treated patients had one or more drug-related adverse experiences.",1286498_8,-1,1,1,5047,1
5050,nausea and vomiting,6,9,37,56,The most common adverse effects were nausea and vomiting in the flumazenil group and nausea and injection-site pain in the placebo group.,1286498_9,-1,1,1,5050,1
5113,Alzheimer's disease,8,11,65,84,An 82-year-old man with treatment-resistant depression and early Alzheimer's disease was started on methylphenidate.,12907924_1,-1,1,1,5113,1
5121,autoimmune hemolytic anemia,5,8,55,82,Ciprofloxacin-induced acute interstitial nephritis and autoimmune hemolytic anemia.,12911170_0,-1,1,1,5121,1
5123,side effects,6,8,47,59,Ciprofloxacin has been associated with several side effects including interstitial nephritis and hemolytic anemia.,12911170_1,-1,1,1,5123,1
5124,interstitial nephritis,9,11,70,92,Ciprofloxacin has been associated with several side effects including interstitial nephritis and hemolytic anemia.,12911170_1,-1,1,1,5124,1
5125,hemolytic anemia,12,14,97,113,Ciprofloxacin has been associated with several side effects including interstitial nephritis and hemolytic anemia.,12911170_1,-1,1,1,5125,1
5126,side effects,4,6,24,36,The combination of both side effects is extremely rare.,12911170_2,-1,1,1,5126,1
5127,interstitial nephritis,10,12,60,82,"In this report, we describe a case of ciprofloxacin-induced interstitial nephritis and autoimmune hemolytic anemia.",12911170_3,-1,1,1,5127,1
5128,autoimmune hemolytic anemia,13,16,87,114,"In this report, we describe a case of ciprofloxacin-induced interstitial nephritis and autoimmune hemolytic anemia.",12911170_3,-1,1,1,5128,1
5129,Hemolytic anemia,0,2,0,16,Hemolytic anemia improved after stopping the drug and initiation of steroid therapy.,12911170_4,-1,1,1,5129,1
5135,drug dependence,17,19,98,113,They offer protection against seizures in a range of models and seem to inhibit certain stages of drug dependence in preclinical assessments.,12921865_2,-1,1,1,5135,1
5168,renal insufficiency,15,17,90,109,"18 patients, referred to a radiocontrast study, considered at risk because of preexisting renal insufficiency, were enrolled in a prospective, randomized, controlled trial, performed at the secondary care center of a 1,100-bed private university hospital.",1300436_2,-1,1,1,5168,1
5188,Renal failure,0,2,0,13,Renal failure was associated with weight loss in the furosemide-treated group.,1300436_7,-1,1,1,5188,1
5206,myocardial infarction,6,8,34,55,"One of these patients developed a myocardial infarction before receiving any medication, shortly after the base-line values were obtained.",133615_8,-1,1,1,5206,1
5304,renal failure,35,37,208,221,"Rats with lithium-induced nephropathy were subjected to high protein (HP) feeding, uninephrectomy (NX) or a combination of these, in an attempt to induce glomerular hyperfiltration and further progression of renal failure.",1378968_1,-1,1,1,5304,1
5318,systolic hypertension,5,7,36,57,Lithium also caused proteinuria and systolic hypertension in absence of glomerulosclerosis.,1378968_6,-1,1,1,5318,1
5319,glomerulosclerosis,10,11,72,90,Lithium also caused proteinuria and systolic hypertension in absence of glomerulosclerosis.,1378968_6,-1,1,1,5319,1
5321,renal failure,6,8,40,53,HP failed to accentuante progression of renal failure and in fact tended to increase GFR and decrease plasma creatinine levels in lithium pretreated rats.,1378968_7,-1,1,1,5321,1
5352,Crohn's disease,2,5,13,28,Treatment of Crohn's disease with fusidic acid: an antibiotic with immunosuppressive properties similar to cyclosporin.,1420741_0,-1,1,1,5352,1
5360,Crohn's disease,11,14,62,77,"Because of the need for the development of new treatments for Crohn's disease, a pilot study was undertaken to estimate the pharmacodynamics and tolerability of fusidic acid treatment in chronic active, therapy-resistant patients.",1420741_2,-1,1,1,5360,1
5365,chronic active,31,33,187,201,"Because of the need for the development of new treatments for Crohn's disease, a pilot study was undertaken to estimate the pharmacodynamics and tolerability of fusidic acid treatment in chronic active, therapy-resistant patients.",1420741_2,-1,1,1,5365,1
5367,Crohn's disease,1,4,6,21,Eight Crohn's disease patients were included.,1420741_3,-1,1,1,5367,1
5371,side effects,5,7,31,43,"There were no serious clinical side effects, but dose reduction was required in two patients because of nausea.",1420741_7,-1,1,1,5371,1
5385,drug toxicity,7,9,45,58,There is evidence that cerebral reactions to drug toxicity can exhibit patterns that suggest highly selective involvement of functional subdivisions of the brain.,1423339_3,-1,1,1,5385,1
5390,side effects,8,10,55,67,Depression and sexual dysfunction have been related to side effects of topical beta-blockers.,1428568_1,-1,1,1,5390,1
5395,side effects,28,30,172,184,We performed a preliminary study in order to determine any difference between a non selective beta-blocker (timolol) and a selective beta-blocker (betaxolol) regarding CNS side effects.,1428568_2,-1,1,1,5395,1
5408,neurotoxicity,3,4,39,52,"Protection against amphetamine-induced neurotoxicity toward striatal dopamine neurons in rodents by LY274614, an excitatory amino acid antagonist.",1436384_0,-1,1,1,5408,1
5451,extravascular hemolysis,11,13,76,99,"These observations, in conjunction with clinical and laboratory evidence of extravascular hemolysis, are consistent with drug-induced hemolytic anemia, possibly involving both drug-adsorption and autoantibody formation mechanisms.",1445986_5,-1,1,1,5451,1
5462,adverse drug reactions,9,12,54,76,"This case illustrates the need for close vigilance in adverse drug reactions, particularly in the elderly.",14513889_4,-1,1,1,5462,1
5470,MPTP-induced parkinsonism,7,9,46,71,"Using macaque monkeys with different types of MPTP-induced parkinsonism, the current study evaluated the degree to which rate of symptom progression, symptom severity, and response to and duration of levodopa therapy may be involved in the development of LIDs.",14568327_3,-1,1,1,5470,1
5474,MPTP,6,7,32,36,"Monkeys with acute (short-term) MPTP exposure, rapid symptom onset and short symptom duration prior to initiation of levodopa therapy developed dyskinesia between 11 and 24 days of daily levodopa administration.",14568327_4,-1,1,1,5474,1
5477,MPTP,6,7,36,40,"In contrast, monkeys with long-term MPTP exposure, slow symptom progression and/or long symptom duration prior to initiation of levodopa therapy were more resistant to developing LIDs (e.g., dyskinesia developed no sooner than 146 days of chronic levodopa administration).",14568327_5,-1,1,1,5477,1
5484,pathophysiology,36,37,235,250,These data suggest distinct differences in the propensity to develop LIDs in monkeys with different rates of symptom progression or symptom durations prior to levodopa and demonstrate the value of these models for further studying the pathophysiology of LIDs.,14568327_7,-1,1,1,5484,1
5514,side-effect,10,11,45,56,AIM: Hemorrhagic cystitis (HC) is a limiting side-effect of chemotherapy with ifosfamide (IFS).,14633084_1,-1,1,1,5514,1
5568,dilated cardiomyopathy,1,3,11,33,Reversible dilated cardiomyopathy related to amphotericin B therapy.,14657095_0,-1,1,1,5568,1
5570,dilated cardiomyopathy,6,8,36,58,We describe a patient who developed dilated cardiomyopathy and clinical congestive heart failure after 2 months of therapy with amphotericin B (AmB) for disseminated coccidioidomycosis.,14657095_1,-1,1,1,5570,1
5571,congestive heart failure,10,13,72,96,We describe a patient who developed dilated cardiomyopathy and clinical congestive heart failure after 2 months of therapy with amphotericin B (AmB) for disseminated coccidioidomycosis.,14657095_1,-1,1,1,5571,1
5575,heart failure,4,6,40,53,His echocardiographic abnormalities and heart failure resolved after posaconazole was substituted for AmB. It is important to recognize the rare and potentially reversible toxicity of AmB.,14657095_2,-1,1,1,5575,1
5589,migraine headache,13,15,81,98,"In addition, both change and peak, showed significant positive correlations with migraine headache intensity (P<0.001).",14659530_7,-1,1,1,5589,1
5594,migraine headache,17,19,100,117,"In conclusion, the fact that plasma CGRP concentration correlates with the timing and severity of a migraine headache suggests a direct relationship between CGRP and migraine.",14659530_11,-1,1,1,5594,1
5600,granulomatosis,15,16,99,113,We report a case of intractable hemorrhagic cystitis due to cyclophosphamide therapy for Wegener's granulomatosis.,1468485_1,-1,1,1,5600,1
5606,side effect,1,3,3,14,No side effect was noted during the course of therapy.,1468485_5,-1,1,1,5606,1
5609,nonepileptic,9,10,53,65,Acute psychosis due to treatment with phenytoin in a nonepileptic patient.,14698717_0,-1,1,1,5609,1
5613,nonepileptic,4,5,14,26,The case of a nonepileptic patient who developed psychosis following phenytoin treatment for trigeminal neuralgia is described.,14698717_2,-1,1,1,5613,1
5614,trigeminal neuralgia,13,15,93,113,The case of a nonepileptic patient who developed psychosis following phenytoin treatment for trigeminal neuralgia is described.,14698717_2,-1,1,1,5614,1
5649,respiratory chain,4,6,26,43,Mitochondrial DNA and its respiratory chain products are defective in doxorubicin nephrosis.,14736955_0,-1,1,1,5649,1
5660,respiratory chain,14,16,92,109,Glomerular and tubular injury was monitored and correlated to the activity or expression of respiratory chain components.,14736955_6,-1,1,1,5660,1
5678,respiratory chain,16,18,108,125,"Among all animals, glomerular and tubular injury were inversely correlated with mtDNA levels, mtDNA-encoded respiratory chain activities and with the expression of the mtDNA-encoded respiratory chain subunit COX-I. Injury was positively correlated with superoxide production and the activities of nucleus-encoded mitochondrial or cytoplasmic enzymes.",14736955_11,-1,1,1,5678,1
5679,respiratory chain,26,28,182,199,"Among all animals, glomerular and tubular injury were inversely correlated with mtDNA levels, mtDNA-encoded respiratory chain activities and with the expression of the mtDNA-encoded respiratory chain subunit COX-I. Injury was positively correlated with superoxide production and the activities of nucleus-encoded mitochondrial or cytoplasmic enzymes.",14736955_11,-1,1,1,5679,1
5687,respiratory chain,19,21,143,160,CONCLUSIONS: These results suggest an important role for quantitative and qualitative mtDNA alterations through the reduction of mtDNA-encoded respiratory chain function and induction of superoxide in doxorubicin-induced renal lesions.,14736955_13,-1,1,1,5687,1
5711,breast cancer,7,9,42,55,Does hormone therapy for the treatment of breast cancer have a detrimental effect on memory and cognition?,14745746_0,-1,1,1,5711,1
5715,breast cancer,8,10,54,67,This pilot study examines whether hormone therapy for breast cancer affects cognition.,14745746_2,-1,1,1,5715,1
5718,breast cancer,25,27,132,145,"Patients participating in a randomised trial of anastrozole, tamoxifen alone or combined (ATAC) (n=94) and a group of women without breast cancer (n=35) completed a battery of neuropsychological measures.",14745746_3,-1,1,1,5718,1
5728,breast cancer,20,22,135,148,The results showed specific impairments in processing speed and verbal memory in women receiving hormonal therapy for the treatment of breast cancer.,14745746_6,-1,1,1,5728,1
5735,nocturnal leg cramps,12,15,75,95,"Although the United States Food and Drug Administration banned its use for nocturnal leg cramps due to lack of safety and efficacy, quinine is widely available in beverages including tonic water and bitter lemon.",14765563_1,-1,1,1,5735,1
5760,left ventricular,16,18,103,119,"Compared with wild-type mice, transgenic mice exhibited higher survival rate as well as more preserved left ventricular function and cardiac expression of alpha-sarcomeric actin.",14975762_5,-1,1,1,5760,1
5777,Ebstein's anomaly,12,15,100,117,Transient platypnea-orthodeoxia-like syndrome induced by propafenone overdose in a young woman with Ebstein's anomaly.,14976857_0,-1,1,1,5777,1
5779,Ebstein's anomaly,13,16,70,87,"In this report we describe the case of a 37-year-old white woman with Ebstein's anomaly, who developed a rare syndrome called platypnea-orthodeoxia, characterized by massive right-to-left interatrial shunting with transient profound hypoxia and cyanosis.",14976857_1,-1,1,1,5779,1
5780,platypnea-orthodeoxia,23,24,126,147,"In this report we describe the case of a 37-year-old white woman with Ebstein's anomaly, who developed a rare syndrome called platypnea-orthodeoxia, characterized by massive right-to-left interatrial shunting with transient profound hypoxia and cyanosis.",14976857_1,-1,1,1,5780,1
5781,interatrial,29,30,188,199,"In this report we describe the case of a 37-year-old white woman with Ebstein's anomaly, who developed a rare syndrome called platypnea-orthodeoxia, characterized by massive right-to-left interatrial shunting with transient profound hypoxia and cyanosis.",14976857_1,-1,1,1,5781,1
5788,right atrial,9,11,46,58,These effects gave rise to an increase in the right atrial pressure and a decrease in the left one with a consequent stretching of the foramen ovale and the creation of massive right-to-left shunting.,14976857_4,-1,1,1,5788,1
5791,interatrial,4,5,17,28,In our case this interatrial shunt was very accurately detected at bubble contrast echocardiography.,14976857_5,-1,1,1,5791,1
5811,cluster headache,23,25,179,195,Noxious chemical stimulation of rat facial mucosa increases intracranial blood flow through a trigemino-parasympathetic reflex--an experimental model for vascular dysfunctions in cluster headache.,15009014_0,-1,1,1,5811,1
5812,Cluster headache,0,2,0,16,Cluster headache is characterized by typical autonomic dysfunctions including facial and intracranial vascular disturbances.,15009014_1,-1,1,1,5812,1
5813,autonomic dysfunctions,6,8,45,67,Cluster headache is characterized by typical autonomic dysfunctions including facial and intracranial vascular disturbances.,15009014_1,-1,1,1,5813,1
5814,intracranial vascular,11,13,89,110,Cluster headache is characterized by typical autonomic dysfunctions including facial and intracranial vascular disturbances.,15009014_1,-1,1,1,5814,1
5840,cluster headache,9,11,58,74,Similar mechanisms may be involved in the pathogenesis of cluster headache.,15009014_10,-1,1,1,5840,1
5849,central nervous system,16,19,88,110,"The acute toxicity of OPs is the result of their irreversible binding with AChEs in the central nervous system (CNS), which elevates acetylcholine (ACh) levels.",15036754_2,-1,1,1,5849,1
5878,Atrial fibrillation,0,2,0,19,"Atrial fibrillation following chemotherapy for stage IIIE diffuse large B-cell gastric lymphoma in a patient with myotonic dystrophy (Steinert's disease).The authors describe the unusual association between diffuse B-cell gastric lymphoma and myotonic dystrophy, the most common form of adult muscular dystrophy, and sudden atrial fibrillation following one cycle of doxorubicin-based chemotherapy in the same patient.",15042318_0,-1,1,1,5878,1
5881,myotonic dystrophy,16,18,114,132,"Atrial fibrillation following chemotherapy for stage IIIE diffuse large B-cell gastric lymphoma in a patient with myotonic dystrophy (Steinert's disease).The authors describe the unusual association between diffuse B-cell gastric lymphoma and myotonic dystrophy, the most common form of adult muscular dystrophy, and sudden atrial fibrillation following one cycle of doxorubicin-based chemotherapy in the same patient.",15042318_0,-1,1,1,5881,1
5882,Steinert's,19,21,134,144,"Atrial fibrillation following chemotherapy for stage IIIE diffuse large B-cell gastric lymphoma in a patient with myotonic dystrophy (Steinert's disease).The authors describe the unusual association between diffuse B-cell gastric lymphoma and myotonic dystrophy, the most common form of adult muscular dystrophy, and sudden atrial fibrillation following one cycle of doxorubicin-based chemotherapy in the same patient.",15042318_0,-1,1,1,5882,1
5884,myotonic dystrophy,33,35,243,261,"Atrial fibrillation following chemotherapy for stage IIIE diffuse large B-cell gastric lymphoma in a patient with myotonic dystrophy (Steinert's disease).The authors describe the unusual association between diffuse B-cell gastric lymphoma and myotonic dystrophy, the most common form of adult muscular dystrophy, and sudden atrial fibrillation following one cycle of doxorubicin-based chemotherapy in the same patient.",15042318_0,-1,1,1,5884,1
5885,muscular dystrophy,42,44,293,311,"Atrial fibrillation following chemotherapy for stage IIIE diffuse large B-cell gastric lymphoma in a patient with myotonic dystrophy (Steinert's disease).The authors describe the unusual association between diffuse B-cell gastric lymphoma and myotonic dystrophy, the most common form of adult muscular dystrophy, and sudden atrial fibrillation following one cycle of doxorubicin-based chemotherapy in the same patient.",15042318_0,-1,1,1,5885,1
5886,atrial fibrillation,47,49,324,343,"Atrial fibrillation following chemotherapy for stage IIIE diffuse large B-cell gastric lymphoma in a patient with myotonic dystrophy (Steinert's disease).The authors describe the unusual association between diffuse B-cell gastric lymphoma and myotonic dystrophy, the most common form of adult muscular dystrophy, and sudden atrial fibrillation following one cycle of doxorubicin-based chemotherapy in the same patient.",15042318_0,-1,1,1,5886,1
5888,Atrial fibrillation,0,2,0,19,Atrial fibrillation or other cardiac arrhythmias are unusual complications in patients treated with chemotherapy.,15042318_1,-1,1,1,5888,1
5900,liver injury,24,26,162,174,OBJECTIVE: To assess lymphocyte reactivity to dilevalol and to serum containing putative ex vivo dilevalol antigens or metabolites in a case of dilevalol-induced liver injury.,1504402_1,-1,1,1,5900,1
5902,liver injury,11,13,76,88,PATIENT: A 58-year-old woman with a clinical diagnosis of dilevalol-induced liver injury.,1504402_2,-1,1,1,5902,1
5909,proliferative,2,3,14,27,A significant proliferative response to serum collected after dilevalol intake was observed in the case of the patient compared with the proliferative response to the serum collected before the drug intake.,1504402_6,-1,1,1,5909,1
5911,proliferative,21,22,137,150,A significant proliferative response to serum collected after dilevalol intake was observed in the case of the patient compared with the proliferative response to the serum collected before the drug intake.,1504402_6,-1,1,1,5911,1
5918,liver injury,28,30,216,228,"CONCLUSIONS: The methodology used allowed the detection of lymphocyte sensitization to sera containing ex vivo-prepared dilevalol antigens, suggesting the involvement of an immunologic mechanism in dilevalol-induced liver injury.",1504402_8,-1,1,1,5918,1
5921,nephrotic syndrome,12,14,102,120,Increased expression and apical targeting of renal ENaC subunits in puromycin aminonucleoside-induced nephrotic syndrome in rats.,15075188_0,-1,1,1,5921,1
5922,Nephrotic syndrome,0,2,0,18,Nephrotic syndrome is often accompanied by sodium retention and generalized edema.,15075188_1,-1,1,1,5922,1
5927,dysregulation,10,11,58,71,We hypothesized that epithelial Na channel (ENaC) subunit dysregulation may be responsible for the increased sodium retention.,15075188_3,-1,1,1,5927,1
5952,collecting duct,39,41,281,296,"Immunoperoxidase brightfield- and laser-scanning confocal fluorescence microscopy demonstrated increased targeting of alpha-ENaC, beta-ENaC, and gamma-ENaC subunits to the apical plasma membrane in the distal convoluted tubule (DCT2), connecting tubule, and cortical and medullary collecting duct segments.",15075188_8,-1,1,1,5952,1
5956,collecting duct,16,18,121,136,"Immunoelectron microscopy further revealed an increased labeling of alpha-ENaC in the apical plasma membrane of cortical collecting duct principal cells of PAN-treated rats, indicating enhanced apical targeting of alpha-ENaC subunits.",15075188_9,-1,1,1,5956,1
5973,collecting duct,24,26,147,162,"In conclusion, the increased or sustained expression of ENaC subunits combined with increased apical targeting in the DCT2, connecting tubule, and collecting duct are likely to play a role in the sodium retention associated with PAN-induced nephrotic syndrome.",15075188_12,-1,1,1,5973,1
5975,nephrotic syndrome,39,41,241,259,"In conclusion, the increased or sustained expression of ENaC subunits combined with increased apical targeting in the DCT2, connecting tubule, and collecting duct are likely to play a role in the sodium retention associated with PAN-induced nephrotic syndrome.",15075188_12,-1,1,1,5975,1
5980,compensatory,15,16,72,84,"The decreased abundance of NHE3, BSC-1, TSC, and Na-K-ATPase may play a compensatory role to promote sodium excretion.",15075188_13,-1,1,1,5980,1
5983,hyperkinesis,8,9,53,65,"A 3-year-old girl had behavioral deterioration, with hyperkinesis, irritability, and sleeping difficulties after the therapeutic administration of isoniazid.",150790_1,-1,1,1,5983,1
5992,hyperkinesis,10,11,68,80,Periodic withdrawal of pyridoxine was associated with return of the hyperkinesis.,150790_5,-1,1,1,5992,1
6004,drug-resistant,7,8,47,61,"Laitinen's procedure improved most symptoms in drug-resistant PD, which engendered wide interest in the neurosurgical community.",15096016_1,-1,1,1,6004,1
6012,bradykinesia,31,32,144,156,"According to the literature pallidotomy improves the ""on"" symptoms of PD, such as dyskinesias, as well as the ""off"" symptoms, such as rigidity, bradykinesia, and on-off fluctuations.",15096016_4,-1,1,1,6012,1
6015,bradykinesia,3,4,30,42,"Pallidal stimulation improves bradykinesia and rigidity to a minor extent; however, its strength seems to be in improving levodopa-induced dyskinesias.",15096016_5,-1,1,1,6015,1
6016,dyskinetic,9,10,59,69,"Stimulation often produces an improvement in the hyper- or dyskinetic upper limbs, but increases the ""freezing"" phenomenon in the lower limbs at the same time.",15096016_6,-1,1,1,6016,1
6018,lower limbs,22,24,130,141,"Stimulation often produces an improvement in the hyper- or dyskinetic upper limbs, but increases the ""freezing"" phenomenon in the lower limbs at the same time.",15096016_6,-1,1,1,6018,1
6024,temporal lobe epilepsy,11,14,63,85,Recurrent excitation in the dentate gyrus of a murine model of temporal lobe epilepsy.,15120741_0,-1,1,1,6024,1
6026,status epilepticus,8,10,55,73,"Similar to rats, systemic pilocarpine injection causes status epilepticus (SE) and the eventual development of spontaneous seizures and mossy fiber sprouting in C57BL/6 and CD1 mice, but the physiological correlates of these events have not been identified in mice.",15120741_1,-1,1,1,6026,1
6053,temporal lobe epilepsy,29,32,208,230,"These data support the hypothesis that SE-induced mossy fiber sprouting and synaptic reorganization are relevant characteristics of seizure development in these murine strains, resembling rat models of human temporal lobe epilepsy.",15120741_6,-1,1,1,6053,1
6054,Urinary bladder cancer,0,3,0,22,Urinary bladder cancer in Wegener's granulomatosis: risks and relation to cyclophosphamide.,15130900_0,-1,1,1,6054,1
6055,granulomatosis,6,7,36,50,Urinary bladder cancer in Wegener's granulomatosis: risks and relation to cyclophosphamide.,15130900_0,-1,1,1,6055,1
6057,bladder cancer,9,11,50,64,"OBJECTIVE: To assess and characterise the risk of bladder cancer, and its relation to cyclophosphamide, in patients with Wegener's granulomatosis.",15130900_1,-1,1,1,6057,1
6059,granulomatosis,23,24,131,145,"OBJECTIVE: To assess and characterise the risk of bladder cancer, and its relation to cyclophosphamide, in patients with Wegener's granulomatosis.",15130900_1,-1,1,1,6059,1
6060,granulomatosis,19,20,113,127,"METHODS: In the population based, nationwide Swedish Inpatient Register a cohort of 1065 patients with Wegener's granulomatosis, 1969-95, was identified.",15130900_2,-1,1,1,6060,1
6062,bladder cancer,15,17,93,107,"Through linkage with the Swedish Cancer Register, all subjects in this cohort diagnosed with bladder cancer were identified.",15130900_3,-1,1,1,6062,1
6065,bladder cancer,18,20,126,140,"Nested within the cohort, a matched case-control study was performed to estimate the association between cyclophosphamide and bladder cancer using odds ratios (ORs) as relative risk.",15130900_4,-1,1,1,6065,1
6068,bladder cancer,7,9,37,51,"In the cohort the cumulative risk of bladder cancer after Wegener's granulomatosis, and the relative prevalence of a history of bladder cancer at the time of diagnosis of Wegener's granulomatosis, were also estimated.",15130900_5,-1,1,1,6068,1
6069,granulomatosis,12,13,68,82,"In the cohort the cumulative risk of bladder cancer after Wegener's granulomatosis, and the relative prevalence of a history of bladder cancer at the time of diagnosis of Wegener's granulomatosis, were also estimated.",15130900_5,-1,1,1,6069,1
6071,bladder cancer,22,24,128,142,"In the cohort the cumulative risk of bladder cancer after Wegener's granulomatosis, and the relative prevalence of a history of bladder cancer at the time of diagnosis of Wegener's granulomatosis, were also estimated.",15130900_5,-1,1,1,6071,1
6072,granulomatosis,32,33,181,195,"In the cohort the cumulative risk of bladder cancer after Wegener's granulomatosis, and the relative prevalence of a history of bladder cancer at the time of diagnosis of Wegener's granulomatosis, were also estimated.",15130900_5,-1,1,1,6072,1
6074,bladder cancer,3,5,12,26,"The risk of bladder cancer doubled for every 10 g increment in cyclophosphamide (OR = 2.0, 95% confidence interval (CI) 0.8 to 4.9).",15130900_7,-1,1,1,6074,1
6079,bladder cancer,4,6,22,36,"The absolute risk for bladder cancer in the cohort reached 10% 16 years after diagnosis of Wegener's granulomatosis, and a history of bladder cancer was (non-significantly) twice as common as expected at the time of diagnosis of Wegener's granulomatosis.",15130900_9,-1,1,1,6079,1
6080,granulomatosis,19,20,101,115,"The absolute risk for bladder cancer in the cohort reached 10% 16 years after diagnosis of Wegener's granulomatosis, and a history of bladder cancer was (non-significantly) twice as common as expected at the time of diagnosis of Wegener's granulomatosis.",15130900_9,-1,1,1,6080,1
6081,bladder cancer,25,27,134,148,"The absolute risk for bladder cancer in the cohort reached 10% 16 years after diagnosis of Wegener's granulomatosis, and a history of bladder cancer was (non-significantly) twice as common as expected at the time of diagnosis of Wegener's granulomatosis.",15130900_9,-1,1,1,6081,1
6082,granulomatosis,44,45,239,253,"The absolute risk for bladder cancer in the cohort reached 10% 16 years after diagnosis of Wegener's granulomatosis, and a history of bladder cancer was (non-significantly) twice as common as expected at the time of diagnosis of Wegener's granulomatosis.",15130900_9,-1,1,1,6082,1
6085,bladder cancer,14,16,103,117,"CONCLUSION: The results indicate a dose-response relationship between cyclophosphamide and the risk of bladder cancer, high cumulative risks in the entire cohort, and also the possibility of risk factors operating even before Wegener's granulomatosis.",15130900_10,-1,1,1,6085,1
6087,granulomatosis,37,38,236,250,"CONCLUSION: The results indicate a dose-response relationship between cyclophosphamide and the risk of bladder cancer, high cumulative risks in the entire cohort, and also the possibility of risk factors operating even before Wegener's granulomatosis.",15130900_10,-1,1,1,6087,1
6143,diastolic dysfunction,6,8,48,69,Severe reversible left ventricular systolic and diastolic dysfunction due to accidental iatrogenic epinephrine overdose.,15188772_0,-1,1,1,6143,1
6148,myocardial stunning,15,17,101,120,"A 35-year-old woman whose cervix uteri was inadvertently injected with 8 mg of epinephrine developed myocardial stunning that was characterized by severe hemodynamic compromise, profound, albeit transient, left ventricular systolic and diastolic dysfunction, and only modestly elevated biochemical markers of myocardial necrosis.",15188772_3,-1,1,1,6148,1
6151,diastolic dysfunction,34,36,236,257,"A 35-year-old woman whose cervix uteri was inadvertently injected with 8 mg of epinephrine developed myocardial stunning that was characterized by severe hemodynamic compromise, profound, albeit transient, left ventricular systolic and diastolic dysfunction, and only modestly elevated biochemical markers of myocardial necrosis.",15188772_3,-1,1,1,6151,1
6158,myocardial infarction,8,10,74,95,Cardioprotective effect of tincture of Crataegus on isoproterenol-induced myocardial infarction in rats.,15233872_0,-1,1,1,6158,1
6165,myocardial infarction,15,17,97,118,The present study was done to investigate the protective effect of TCR on experimentally induced myocardial infarction in rats.,15233872_2,-1,1,1,6165,1
6185,rheumatoid arthritis,19,21,141,161,"We evaluated cardiovascular event data for valdecoxib, a new COX-2-specific inhibitor in approximately 8000 patients with osteoarthritis and rheumatoid arthritis treated with this agent in randomized clinical trials.",15266215_2,-1,1,1,6185,1
6192,rheumatoid arthritis,59,61,332,352,"The incidence of cardiovascular thrombotic events (cardiac, cerebrovascular and peripheral vascular, or arterial thrombotic) was determined by analyzing pooled valdecoxib (10-80 mg daily), nonselective NSAID (diclofenac 75 mg bid, ibuprofen 800 mg tid, or naproxen 500 mg bid) and placebo data from 10 randomized osteoarthritis and rheumatoid arthritis trials that were 6-52 weeks in duration.",15266215_3,-1,1,1,6192,1
6208,rheumatoid arthritis,43,45,267,287,Short- and intermediate-term treatment with therapeutic (10 or 20 mg daily) and supratherapeutic (40 or 80 mg daily) valdecoxib doses was not associated with an increased incidence of thrombotic events relative to nonselective NSAIDs or placebo in osteoarthritis and rheumatoid arthritis patients in controlled clinical trials.,15266215_9,-1,1,1,6208,1
6212,hypertrophic cardiomyopathy,10,12,77,104,The present report describes a case of eosinophilic myocarditis complicating hypertrophic cardiomyopathy.,15266362_1,-1,1,1,6212,1
6213,hypertrophic cardiomyopathy,8,10,46,73,"The 47-year-old female patient, known to have hypertrophic cardiomyopathy, was admitted with biventricular failure and managed aggressively with dobutamine infusion and other drugs while being assessed for heart transplantation.",15266362_2,-1,1,1,6213,1
6219,left ventricular dysfunction,7,10,50,78,"On transthoracic echocardiogram, she had moderate left ventricular dysfunction with regional variability and moderate mitral regurgitation.",15266362_3,-1,1,1,6219,1
6222,apical hypertrophic cardiomyopathy,8,11,45,79,The recipient's heart showed the features of apical hypertrophic cardiomyopathy and myocarditis with abundant eosinophils.,15266362_4,-1,1,1,6222,1
6227,intratympanic,4,5,25,38,Treatment of tinnitus by intratympanic instillation of lignocaine (lidocaine) 2 per cent through ventilation tubes.,1527456_0,-1,1,1,6227,1
6230,subjective tinnitus,1,3,11,30,Idiopathic subjective tinnitus (IST) is one of the most obscure otological pathologies.,1527456_1,-1,1,1,6230,1
6234,intratympanic,9,10,51,64,"This paper presents the results of treating IST by intratympanic instillation of lignocaine (lidocaine) 2 per cent through a grommet, for five weekly courses.",1527456_2,-1,1,1,6234,1
6239,side effects,6,8,36,48,"Patients should be warned about the side effects of vertigo and vomiting, which subsides gradually with every new instillation, and that the tinnitus may not disappear but will be alleviated, enabling them to cope more easily with the disease and lead a more normal life.",1527456_6,-1,1,1,6239,1
6324,breast cancer,11,13,107,120,Cardiac toxicity observed in association with high-dose cyclophosphamide-based chemotherapy for metastatic breast cancer.,15325671_0,-1,1,1,6324,1
6335,breast cancer,26,28,176,189,"STUDY DESIGN: We combined paclitaxel, melphalan and high-dose cyclophosphamide, thiotepa, and carboplatin in a triple sequential high-dose regimen for patients with metastatic breast cancer.",15325671_3,-1,1,1,6335,1
6336,breast cancer,9,11,75,88,"Analysis was performed on 61 women with chemotherapy-responsive metastatic breast cancer receiving 96-h infusional cyclophosphamide as part of a triple sequential high-dose regimen to assess association between presence of peritransplant congestive heart failure (CHF) and the following pretreatment characteristics: presence of electrocardiogram (EKG) abnormalities, age, hypertension, prior cardiac history, smoking, diabetes mellitus, prior use of anthracyclines, and left-sided chest irradiation.",15325671_4,-1,1,1,6336,1
6341,congestive heart failure,30,33,238,262,"Analysis was performed on 61 women with chemotherapy-responsive metastatic breast cancer receiving 96-h infusional cyclophosphamide as part of a triple sequential high-dose regimen to assess association between presence of peritransplant congestive heart failure (CHF) and the following pretreatment characteristics: presence of electrocardiogram (EKG) abnormalities, age, hypertension, prior cardiac history, smoking, diabetes mellitus, prior use of anthracyclines, and left-sided chest irradiation.",15325671_4,-1,1,1,6341,1
6345,diabetes mellitus,60,62,419,436,"Analysis was performed on 61 women with chemotherapy-responsive metastatic breast cancer receiving 96-h infusional cyclophosphamide as part of a triple sequential high-dose regimen to assess association between presence of peritransplant congestive heart failure (CHF) and the following pretreatment characteristics: presence of electrocardiogram (EKG) abnormalities, age, hypertension, prior cardiac history, smoking, diabetes mellitus, prior use of anthracyclines, and left-sided chest irradiation.",15325671_4,-1,1,1,6345,1
6347,left-sided,69,70,471,481,"Analysis was performed on 61 women with chemotherapy-responsive metastatic breast cancer receiving 96-h infusional cyclophosphamide as part of a triple sequential high-dose regimen to assess association between presence of peritransplant congestive heart failure (CHF) and the following pretreatment characteristics: presence of electrocardiogram (EKG) abnormalities, age, hypertension, prior cardiac history, smoking, diabetes mellitus, prior use of anthracyclines, and left-sided chest irradiation.",15325671_4,-1,1,1,6347,1
6348,grade 3,13,15,63,70,RESULTS: Six of 61 women (10%) developed clinically reversible grade 3 CHF following infusional cyclophosphamide with a median percent decline in ejection fraction of 31%.,15325671_5,-1,1,1,6348,1
6377,rest tremor,9,11,68,79,Postural tremor was measured with the arm horizontally outstretched rest tremor with the arm supported by an armrest and finally tremor was measured after holding a 2-kg weight until exhaustion.,15338796_9,-1,1,1,6377,1
6386,of children,15,17,92,103,"DISCUSSION: Quantifying tremor by using an inexpensive laser pointer is, with the exception of children (<12 years) a sensitive and reproducible method.",15338796_18,-1,1,1,6386,1
6389,side effects,4,6,30,42,Yohimbine treatment of sexual side effects induced by serotonin reuptake blockers.,1535072_0,-1,1,1,6389,1
6396,side effects,14,16,77,89,A single case report suggests that yohimbine may be used to treat the sexual side effects of clomipramine.,1535072_2,-1,1,1,6396,1
6398,side effects,10,12,61,73,This study evaluated yohimbine as a treatment for the sexual side effects caused by serotonin reuptake blockers.,1535072_3,-1,1,1,6398,1
6402,side effects,20,22,134,146,"METHOD: Six patients with either obsessive compulsive disorder, trichotillomania, anxiety, or affective disorders who suffered sexual side effects after treatment with serotonin reuptake blockers were given yohimbine on a p.r.n.",1535072_4,-1,1,1,6402,1
6412,Side effects,0,2,0,12,"Side effects of yohimbine included excessive sweating, increased anxiety, and a wound-up feeling in some patients.",1535072_9,-1,1,1,6412,1
6415,side effects,18,20,107,119,CONCLUSION: The results of this study indicate that yohimbine may be an effective treatment for the sexual side effects caused by serotonin reuptake blockers.,1535072_10,-1,1,1,6415,1
6420,bone marrow,3,5,34,45,Hemorrhagic cystitis complicating bone marrow transplantation.,1545575_0,-1,1,1,6420,1
6423,bone marrow,13,15,117,128,Hemorrhagic cystitis is a potentially serious complication of high-dose cyclophosphamide therapy administered before bone marrow transplantation.,1545575_1,-1,1,1,6423,1
6425,bone marrow,14,16,81,92,"As standard practice at our institution, patients who are scheduled to receive a bone marrow transplant are treated prophylactically with forced hydration and bladder irrigation.",1545575_2,-1,1,1,6425,1
6435,bone marrow,14,16,98,109,"In contrast, two of four consecutive patients who received mesna uroprophylaxis before allogeneic bone marrow transplantation had severe hemorrhagic cystitis for at least 2 weeks.",1545575_5,-1,1,1,6435,1
6451,endometrial hyperplasia,11,13,78,101,"Outcomes included venous thromboembolism, cataracts, gallbladder disease, and endometrial hyperplasia or cancer.",15458908_4,-1,1,1,6451,1
6464,endometrial hyperplasia,33,35,119,142,"Raloxifene did not increase risk for cataracts (RR 0.9; 95% CI 0.8-1.1), gallbladder disease (RR 1.0; 95% CI 0.7-1.3), endometrial hyperplasia (RR 1.3; 95% CI 0.4-5.1), or endometrial cancer (RR 0.9; 95% CI 0.3-2.7).",15458908_8,-1,1,1,6464,1
6466,endometrial cancer,48,50,172,190,"Raloxifene did not increase risk for cataracts (RR 0.9; 95% CI 0.8-1.1), gallbladder disease (RR 1.0; 95% CI 0.7-1.3), endometrial hyperplasia (RR 1.3; 95% CI 0.4-5.1), or endometrial cancer (RR 0.9; 95% CI 0.3-2.7).",15458908_8,-1,1,1,6466,1
6472,endometrial hyperplasia,25,27,157,180,"CONCLUSION: Raloxifene was associated with an increased risk for venous thromboembolism, but there was no increased risk for cataracts, gallbladder disease, endometrial hyperplasia, or endometrial cancer.",15458908_9,-1,1,1,6472,1
6473,endometrial cancer,29,31,185,203,"CONCLUSION: Raloxifene was associated with an increased risk for venous thromboembolism, but there was no increased risk for cataracts, gallbladder disease, endometrial hyperplasia, or endometrial cancer.",15458908_9,-1,1,1,6473,1
6483,gastrointestinal disorders,7,9,40,66,"Other possible adverse effects--such as gastrointestinal disorders, orthostatic hypotension, levodopa-induced psychosis, sleep disturbances or parasomnias, or drug interactions--also require carefully monitored individual treatment.",1549199_4,-1,1,1,6483,1
6487,parasomnias,19,20,143,154,"Other possible adverse effects--such as gastrointestinal disorders, orthostatic hypotension, levodopa-induced psychosis, sleep disturbances or parasomnias, or drug interactions--also require carefully monitored individual treatment.",1549199_4,-1,1,1,6487,1
6493,Long term,0,2,0,9,Long term audiological evaluation of beta-thalassemic patients.,15515654_0,-1,1,1,6493,1
6496,hearing loss,18,20,103,115,OBJECTIVE: The objective of this study was to identify the incidence and to monitor the progression of hearing loss in children and young adults with beta-thalassemia major.,15515654_1,-1,1,1,6496,1
6498,beta-thalassemia,26,27,150,166,OBJECTIVE: The objective of this study was to identify the incidence and to monitor the progression of hearing loss in children and young adults with beta-thalassemia major.,15515654_1,-1,1,1,6498,1
6502,sensorineural hearing loss,17,20,79,105,"RESULTS: Overall, 21 out of 104 patients (20.2%) presented with high frequency sensorineural hearing loss (SNHL), either unilateral or bilateral.",15515654_6,-1,1,1,6502,1
6504,unilateral or bilateral,25,28,121,144,"RESULTS: Overall, 21 out of 104 patients (20.2%) presented with high frequency sensorineural hearing loss (SNHL), either unilateral or bilateral.",15515654_6,-1,1,1,6504,1
6508,serum ferritin,7,9,51,65,"Patients with SNHL presented with relatively lower serum ferritin levels than those with normal hearing, however, no statistically significant difference was observed.",15515654_8,-1,1,1,6508,1
6514,hearing impairment,15,17,89,107,CONCLUSION: The findings are indicative of DFO's contributing role in the development of hearing impairment.,15515654_11,-1,1,1,6514,1
6517,hearing impairment,28,30,185,203,Regular audiologic evaluation is imperative in all thalassemic patients so that early changes may be recognized and treatment may be judiciously adjusted in order to prevent or reverse hearing impairment.,15515654_12,-1,1,1,6517,1
6521,autoimmune diseases,14,16,124,143,"Consensus statement concerning cardiotoxicity occurring during haematopoietic stem cell transplantation in the treatment of autoimmune diseases, with special reference to systemic sclerosis and multiple sclerosis.",15517007_0,-1,1,1,6521,1
6523,multiple sclerosis,24,26,194,212,"Consensus statement concerning cardiotoxicity occurring during haematopoietic stem cell transplantation in the treatment of autoimmune diseases, with special reference to systemic sclerosis and multiple sclerosis.",15517007_0,-1,1,1,6523,1
6525,autoimmune diseases,17,19,128,147,Autologous haematopoietic stem cell transplantation is now a feasible and effective treatment for selected patients with severe autoimmune diseases.,15517007_1,-1,1,1,6525,1
6538,autoimmune disease,25,27,144,162,"The object of the meeting was to analyse existing data, both published or available, in the European Group for Blood and Marrow Transplantation autoimmune disease database, and to propose a safe approach to such patients.",15517007_9,-1,1,1,6538,1
6541,cardiovascular disease,5,7,37,59,"Does supplemental vitamin C increase cardiovascular disease risk in women with diabetes?BACKGROUND: Vitamin C acts as a potent antioxidant; however, it can also be a prooxidant and glycate protein under certain circumstances in vitro.",15531665_0,-1,1,1,6541,1
6548,cardiovascular disease,16,18,97,119,OBJECTIVE: The objective was to examine the relation between vitamin C intake and mortality from cardiovascular disease.,15531665_2,-1,1,1,6548,1
6550,cardiovascular disease,14,16,82,104,"DESIGN: We studied the relation between vitamin C intake and mortality from total cardiovascular disease (n = 281), coronary artery disease (n = 175), and stroke (n = 57) in 1923 postmenopausal women who reported being diabetic at baseline.",15531665_3,-1,1,1,6550,1
6551,coronary artery disease,22,25,116,139,"DESIGN: We studied the relation between vitamin C intake and mortality from total cardiovascular disease (n = 281), coronary artery disease (n = 175), and stroke (n = 57) in 1923 postmenopausal women who reported being diabetic at baseline.",15531665_3,-1,1,1,6551,1
6553,coronary artery disease,15,18,98,121,"Diet was assessed with a food-frequency questionnaire at baseline, and subjects initially free of coronary artery disease were prospectively followed for 15 y. RESULTS: After adjustment for cardiovascular disease risk factors, type of diabetes medication used, duration of diabetes, and intakes of folate, vitamin E, and beta-carotene, the adjusted relative risks of total cardiovascular disease mortality were 1.0, 0.97, 1.11, 1.47, and 1.84 (P for trend < 0.01) across quintiles of total vitamin C intake from food and supplements.",15531665_4,-1,1,1,6553,1
6554,cardiovascular disease,29,31,190,212,"Diet was assessed with a food-frequency questionnaire at baseline, and subjects initially free of coronary artery disease were prospectively followed for 15 y. RESULTS: After adjustment for cardiovascular disease risk factors, type of diabetes medication used, duration of diabetes, and intakes of folate, vitamin E, and beta-carotene, the adjusted relative risks of total cardiovascular disease mortality were 1.0, 0.97, 1.11, 1.47, and 1.84 (P for trend < 0.01) across quintiles of total vitamin C intake from food and supplements.",15531665_4,-1,1,1,6554,1
6558,cardiovascular disease,61,63,373,395,"Diet was assessed with a food-frequency questionnaire at baseline, and subjects initially free of coronary artery disease were prospectively followed for 15 y. RESULTS: After adjustment for cardiovascular disease risk factors, type of diabetes medication used, duration of diabetes, and intakes of folate, vitamin E, and beta-carotene, the adjusted relative risks of total cardiovascular disease mortality were 1.0, 0.97, 1.11, 1.47, and 1.84 (P for trend < 0.01) across quintiles of total vitamin C intake from food and supplements.",15531665_4,-1,1,1,6558,1
6561,coronary artery disease,4,7,27,50,"Adjusted relative risks of coronary artery disease were 1.0, 0.81, 0.99, 1.26, and 1.91 (P for trend = 0.01) and of stroke were 1.0, 0.52, 1.23, 2.22, and 2.57 (P for trend < 0.01).",15531665_5,-1,1,1,6561,1
6565,cardiovascular disease,8,10,49,71,Vitamin C intake was unrelated to mortality from cardiovascular disease in the nondiabetic subjects at baseline.,15531665_7,-1,1,1,6565,1
6569,cardiovascular disease,16,18,93,115,CONCLUSION: A high vitamin C intake from supplements is associated with an increased risk of cardiovascular disease mortality in postmenopausal women with diabetes.,15531665_8,-1,1,1,6569,1
6572,optic neuropathy,11,13,89,105,Optical coherence tomography can measure axonal loss in patients with ethambutol-induced optic neuropathy.,15565293_0,-1,1,1,6572,1
6575,optic neuropathy,17,19,96,112,"PURPOSE: To map and identify the pattern, in vivo, of axonal degeneration in ethambutol-induced optic neuropathy using optical coherence tomography (OCT).",15565293_1,-1,1,1,6575,1
6580,optic neuropathy,7,9,43,59,"A serious complication of ethambutol is an optic neuropathy that impairs visual acuity, contrast sensitivity, and color vision.",15565293_3,-1,1,1,6580,1
6583,color vision,18,20,114,126,"A serious complication of ethambutol is an optic neuropathy that impairs visual acuity, contrast sensitivity, and color vision.",15565293_3,-1,1,1,6583,1
6584,toxic optic neuropathy,7,10,28,50,"However, early on, when the toxic optic neuropathy is mild and partly reversible, the funduscopic findings are often subtle and easy to miss.",15565293_4,-1,1,1,6584,1
6587,optic neuropathy,10,12,67,83,"METHODS: Three subjects with a history of ethambutol (EMB)-induced optic neuropathy of short-, intermediate-, and long-term visual deficits were administered a full neuro-ophthalmologic examination including visual acuity, color vision, contrast sensitivity, and fundus examination.",15565293_5,-1,1,1,6587,1
6593,color vision,31,33,223,235,"METHODS: Three subjects with a history of ethambutol (EMB)-induced optic neuropathy of short-, intermediate-, and long-term visual deficits were administered a full neuro-ophthalmologic examination including visual acuity, color vision, contrast sensitivity, and fundus examination.",15565293_5,-1,1,1,6593,1
6599,optic nerve,8,10,49,60,OCT interpolates data from 100 points around the optic nerve to effectively map out the RNFL.,15565293_7,-1,1,1,6599,1
6604,optic neuropathy,7,9,44,60,"In all subjects with history of EMB-induced optic neuropathy, there was a mean loss of 72% nerve fiber layer thickness in the temporal quadrant (patient A, with eventual recovery of visual acuity and fields, 58% loss; patient B, with intermediate visual deficits, 68% loss; patient C, with chronic visual deficits, 90% loss), with an average mean optic nerve thickness of 26+/-16 microm.",15565293_9,-1,1,1,6604,1
6613,optic nerve,72,74,347,358,"In all subjects with history of EMB-induced optic neuropathy, there was a mean loss of 72% nerve fiber layer thickness in the temporal quadrant (patient A, with eventual recovery of visual acuity and fields, 58% loss; patient B, with intermediate visual deficits, 68% loss; patient C, with chronic visual deficits, 90% loss), with an average mean optic nerve thickness of 26+/-16 microm.",15565293_9,-1,1,1,6613,1
6620,optic neuropathy,10,12,64,80,CONCLUSIONS: The OCT results in these patients with EMB-induced optic neuropathy show considerable loss especially of the temporal fibers.,15565293_12,-1,1,1,6620,1
6627,optic neuropathies,27,29,189,207,This is consistent with prior histopathological studies that show predominant loss of parvo-cellular axons (or small-caliber axons) within the papillo-macular bundle in toxic or hereditary optic neuropathies.,15565293_13,-1,1,1,6627,1
6629,optic neuropathies,11,13,59,77,OCT can be a valuable tool in the quantitative analysis of optic neuropathies.,15565293_14,-1,1,1,6629,1
6631,optic neuropathy,8,10,52,68,"Additionally, in terms of management of EMB-induced optic neuropathy, it is important to properly manage ethambutol dosing in patients with renal impairment and to achieve proper transition to a maintenance dose once an appropriate loading dose has been reached.",15565293_15,-1,1,1,6631,1
6650,nephrotic,7,8,45,54,"RESULTS: As anticipated, adriamycin elicited nephrotic range proteinuria, renal interstitial damage and mild focal glomerulosclerosis.",15572383_9,-1,1,1,6650,1
6652,focal glomerulosclerosis,16,18,109,133,"RESULTS: As anticipated, adriamycin elicited nephrotic range proteinuria, renal interstitial damage and mild focal glomerulosclerosis.",15572383_9,-1,1,1,6652,1
6670,renal disease,2,4,11,24,Hypoxia in renal disease with proteinuria and/or glomerular hypertension.,15579441_0,-1,1,1,6670,1
6682,nephrotic syndrome,16,18,108,126,"With this model, we were able to identify diffuse cortical hypoxia in the puromycin aminonucleoside-induced nephrotic syndrome and focal and segmental hypoxia in the remnant kidney model.",15579441_4,-1,1,1,6682,1
6693,hypoxic,22,23,160,167,"Finally, we identified the localization of proliferating cell nuclear antigen-positive, ED-1-positive, and terminal dUTP nick-end labeled-positive cells in the hypoxic cortical area in the remnant kidney model.",15579441_7,-1,1,1,6693,1
6698,chronic hepatitis,17,19,125,142,Adequate timing of ribavirin reduction in patients with hemolysis during combination therapy of interferon and ribavirin for chronic hepatitis C.BACKGROUND: Hemolytic anemia is one of the major adverse events of the combination therapy of interferon and ribavirin.,15580403_0,-1,1,1,6698,1
6699,Hemolytic anemia,21,23,157,173,Adequate timing of ribavirin reduction in patients with hemolysis during combination therapy of interferon and ribavirin for chronic hepatitis C.BACKGROUND: Hemolytic anemia is one of the major adverse events of the combination therapy of interferon and ribavirin.,15580403_0,-1,1,1,6699,1
6702,hemolytic anemia,3,5,29,45,"Because of ribavirin-related hemolytic anemia, dose reduction is a common event in this therapy.",15580403_1,-1,1,1,6702,1
6713,side effects,27,29,174,186,"However, 10 of 37 patients with reduction of ribavirin could not continue combination therapy because their <8.5 g/dl hemoglobin values decreased to or anemia-related severe side effects occurred (group B).",15580403_6,-1,1,1,6713,1
6714,group B,31,33,197,204,"However, 10 of 37 patients with reduction of ribavirin could not continue combination therapy because their <8.5 g/dl hemoglobin values decreased to or anemia-related severe side effects occurred (group B).",15580403_6,-1,1,1,6714,1
6719,group B,41,43,184,191,"We assessed the final efficacy and safety after reduction of ribavirin in groups A and B. RESULTS: A sustained virological response (SVR) was 29.6% (8/27) in group A and 10% (1/10) in group B, respectively.",15580403_7,-1,1,1,6719,1
6722,group B,23,25,86,93,"A 34.4% (12/27) of SVR + biological response in group A was higher than 10% (1/10) in group B ( P = 0.051), with slight significance.",15580403_8,-1,1,1,6722,1
6723,side effects,20,22,107,119,CONCLUSIONS: Reduction of ribavirin at hemoglobin level > or =10 g/dl is suitable in terms of efficacy and side effects.,15580403_10,-1,1,1,6723,1
6731,renal injury,21,23,140,152,"Although most cases of antibiotic induced acute interstitial nephritis are benign and self-limited, some patients are at risk for permanent renal injury.",15602202_3,-1,1,1,6731,1
6732,renal insufficiency,1,3,23,42,Spironolactone-induced renal insufficiency and hyperkalemia in patients with heart failure.,15632880_0,-1,1,1,6732,1
6733,heart failure,8,10,77,90,Spironolactone-induced renal insufficiency and hyperkalemia in patients with heart failure.,15632880_0,-1,1,1,6733,1
6735,heart failure,13,15,91,104,BACKGROUND: A previous randomized controlled trial evaluating the use of spironolactone in heart failure patients reported a low risk of hyperkalemia (2%) and renal insufficiency (0%).,15632880_1,-1,1,1,6735,1
6737,renal insufficiency,27,29,159,178,BACKGROUND: A previous randomized controlled trial evaluating the use of spironolactone in heart failure patients reported a low risk of hyperkalemia (2%) and renal insufficiency (0%).,15632880_1,-1,1,1,6737,1
6738,heart failure,3,5,23,36,"Because treatments for heart failure have changed since the benefits of spironolactone were reported, the prevalence of these complications may differ in current clinical practice.",15632880_2,-1,1,1,6738,1
6741,renal insufficiency,13,15,94,113,We therefore sought to determine the prevalence and clinical associations of hyperkalemia and renal insufficiency in heart failure patients treated with spironolactone.,15632880_3,-1,1,1,6741,1
6742,heart failure,16,18,117,130,We therefore sought to determine the prevalence and clinical associations of hyperkalemia and renal insufficiency in heart failure patients treated with spironolactone.,15632880_3,-1,1,1,6742,1
6745,heart failure,9,11,46,59,METHODS: We performed a case control study of heart failure patients treated with spironolactone in our clinical practice.,15632880_4,-1,1,1,6745,1
6748,renal insufficiency,14,16,68,87,"Cases were patients who developed hyperkalemia (K(+) >5.0 mEq/L) or renal insufficiency (Cr >or=2.5 mg/dL), and they were compared to 2 randomly selected controls per case.",15632880_5,-1,1,1,6748,1
6752,renal failure,23,25,119,132,RESULTS: Sixty-seven of 926 patients (7.2%) required discontinuation of spironolactone due to hyperkalemia (n = 33) or renal failure (n = 34).,15632880_7,-1,1,1,6752,1
6756,renal insufficiency,3,5,23,42,"Patients who developed renal insufficiency had lower baseline body weight and higher baseline serum creatinine, required higher doses of loop diuretics, and were more likely to be treated with thiazide diuretics than controls.",15632880_9,-1,1,1,6756,1
6757,body weight,8,10,62,73,"Patients who developed renal insufficiency had lower baseline body weight and higher baseline serum creatinine, required higher doses of loop diuretics, and were more likely to be treated with thiazide diuretics than controls.",15632880_9,-1,1,1,6757,1
6763,renal insufficiency,5,7,53,72,CONCLUSIONS: Spironolactone-induced hyperkalemia and renal insufficiency are more common in our clinical experience than reported previously.,15632880_10,-1,1,1,6763,1
6772,age related,20,22,105,116,"The aim of the study was to examine the influence of hyperprolactinemia, induced by haloperidol (HAL) on age related morphology and function changes of epithelial cells in rat prostate lateral lobe.",15638391_1,-1,1,1,6772,1
6837,orofacial dyskinesia,13,15,108,128,Acute reserpine and subchronic haloperidol treatments change synaptosomal brain glutamate uptake and elicit orofacial dyskinesia in rats.,15649445_0,-1,1,1,6837,1
6839,orofacial dyskinesia,3,5,35,55,Reserpine- and haloperidol-induced orofacial dyskinesia are putative animal models of tardive dyskinesia (TD) whose pathophysiology has been related to free radical generation and oxidative stress.,15649445_1,-1,1,1,6839,1
6842,pathophysiology,16,17,116,131,Reserpine- and haloperidol-induced orofacial dyskinesia are putative animal models of tardive dyskinesia (TD) whose pathophysiology has been related to free radical generation and oxidative stress.,15649445_1,-1,1,1,6842,1
6845,orofacial dyskinesia,8,10,42,62,"In the present study, the authors induced orofacial dyskinesia by acute reserpine and subchronic haloperidol administration to rats.",15649445_2,-1,1,1,6845,1
6863,spinal cord ischemia,23,26,174,194,The activation of spinal N-methyl-D-aspartate receptors may contribute to degeneration of spinal motor neurons induced by neuraxial morphine after a noninjurious interval of spinal cord ischemia.,15673851_0,-1,1,1,6863,1
6869,Spinal cord ischemia,0,3,0,20,Spinal cord ischemia was induced by aortic occlusion for 6 min with a balloon catheter.,15673851_2,-1,1,1,6869,1
6873,group C,10,12,44,51,"In a microdialysis study, 10 muL of saline (group C; n = 8) or 30 mug of morphine (group M; n = 8) was injected intrathecally (IT) 0.5 h after reflow, and 30 mug of morphine (group SM; n = 8) or 10 muL of saline (group SC; n = 8) was injected IT 0.5 h after sham operation.",15673851_3,-1,1,1,6873,1
6881,spinal cord,19,21,95,106,"Second, we investigated the effect of IT MK-801 (30 mug) on the histopathologic changes in the spinal cord after morphine-induced spastic paraparesis.",15673851_5,-1,1,1,6881,1
6883,cerebrospinal fluid,5,7,23,42,"After IT morphine, the cerebrospinal fluid (CSF) glutamate concentration was increased in group M relative to both baseline and group C (P < 0.05).",15673851_6,-1,1,1,6883,1
6884,CSF,8,9,44,47,"After IT morphine, the cerebrospinal fluid (CSF) glutamate concentration was increased in group M relative to both baseline and group C (P < 0.05).",15673851_6,-1,1,1,6884,1
6886,group C,22,24,128,135,"After IT morphine, the cerebrospinal fluid (CSF) glutamate concentration was increased in group M relative to both baseline and group C (P < 0.05).",15673851_6,-1,1,1,6886,1
6893,spinal cord ischemia,11,14,60,80,We suggest that opioids may be neurotoxic in the setting of spinal cord ischemia via NMDA receptor activation.,15673851_10,-1,1,1,6893,1
6895,low back pain,1,4,6,19,Acute low back pain during intravenous administration of amiodarone: a report of two cases.,15686794_0,-1,1,1,6895,1
6899,atrial fibrillation,10,12,89,108,Amiodarone represents an effective antiarrhythmic drug for cardioversion of recent-onset atrial fibrillation (AF) and maintenance of sinus rhythm.,15686794_1,-1,1,1,6899,1
6902,atrial fibrillation,8,10,61,80,"We briefly describe two patients suffering from recent-onset atrial fibrillation, who experienced an acute devastating low back pain a few minutes after initiation of intravenous amiodarone loading.",15686794_2,-1,1,1,6902,1
6903,low back pain,16,19,119,132,"We briefly describe two patients suffering from recent-onset atrial fibrillation, who experienced an acute devastating low back pain a few minutes after initiation of intravenous amiodarone loading.",15686794_2,-1,1,1,6903,1
6905,side effect,3,5,14,25,"Notably, this side effect has not been ever reported in the medical literature.",15686794_3,-1,1,1,6905,1
6916,post-operative,29,30,193,207,"In this study, we prospectively evaluated the incidence and clinical importance of pseudolithiasis in paediatric surgical patients receiving ceftriaxone treatment, who often had to fast in the post-operative period.",15737522_3,-1,1,1,6916,1
6925,hyperkinesia,14,15,102,114,"Quantitative drug levels in stimulant psychosis: relationship to symptom severity, catecholamines and hyperkinesia.",15764424_0,-1,1,1,6925,1
6932,hyperkinesia,13,14,100,112,Methamphetamine or amphetamine levels were related to several psychopathology scores and the global hyperkinesia rating.,15764424_2,-1,1,1,6932,1
6934,hyperkinesia,6,7,34,46,HVA levels were related to global hyperkinesia but not to psychopathology ratings.,15764424_3,-1,1,1,6934,1
6972,Drug-induced,2,3,12,24,"DISCUSSION: Drug-induced symptoms of pheochromocytoma are often associated with the use of substituted benzamide drugs, but the underlying mechanism is unknown.",15811908_5,-1,1,1,6972,1
6997,periventricular leukomalacia,23,25,154,182,"Exclusion criteria were asphyxia, malformations, major surgical interventions, small for gestational age, intraventricular haemorrhage grades III and IV, periventricular leukomalacia, and severe psychomotor retardation.",15814210_5,-1,1,1,6997,1
7022,liver toxicity,11,13,63,77,"Valproic acid I: time course of lipid peroxidation biomarkers, liver toxicity, and valproic acid metabolite levels in rats.",15858223_0,-1,1,1,7022,1
7047,Liver toxicity,0,2,0,14,Liver toxicity was evaluated based on serum levels of alpha-glutathione S-transferase (alpha-GST) and by histology.,15858223_7,-1,1,1,7047,1
7054,steatosis,30,31,187,196,"Serum alpha-GST levels were significantly elevated by day 4, which corresponded to hepatotoxicity as shown by the increasing incidence of inflammation of the liver capsule, necrosis, and steatosis throughout the study.",15858223_8,-1,1,1,7054,1
7063,steatosis,27,28,159,168,"Overall, these findings indicate that VPA treatment results in oxidative stress, as measured by levels of 15-F(2t)-IsoP, which precedes the onset of necrosis, steatosis, and elevated levels of serum alpha-GST.",15858223_10,-1,1,1,7063,1
7067,Thrombotic microangiopathy,2,4,12,38,OBJECTIVES: Thrombotic microangiopathy is a well-known problem in patients following renal transplantation.,15859940_1,-1,1,1,7067,1
7070,thrombotic microangiopathy,4,6,30,56,"In postrenal transplantation, thrombotic microangiopathy is often a reflection of hemolytic uremic syndrome.",15859940_2,-1,1,1,7070,1
7072,thrombotic microangiopathy,7,9,36,62,We aimed to determine the causes of thrombotic microangiopathy in a population of renal transplantation recipients and discuss the literature.,15859940_3,-1,1,1,7072,1
7074,thrombotic microangiopathy,9,11,53,79,"MATERIALS AND METHODS: We investigated the causes of thrombotic microangiopathy during a 1-year period, from June 2003 to June 2004, at the King Fahad National Guard Hospital in Riyadh, Saudi Arabia, by reviewing the slides of all transplant biopsies (n=25) performed during this interval.",15859940_4,-1,1,1,7074,1
7079,thrombotic microangiopathy,5,7,23,49,RESULTS: Five cases of thrombotic microangiopathy were found.,15859940_6,-1,1,1,7079,1
7084,thrombotic microangiopathy,6,8,31,57,The fifth case had features of thrombotic microangiopathy related to an antiphospholipid syndrome in a patient with systemic lupus erythematosus.,15859940_9,-1,1,1,7084,1
7085,systemic lupus erythematosus,17,20,116,144,The fifth case had features of thrombotic microangiopathy related to an antiphospholipid syndrome in a patient with systemic lupus erythematosus.,15859940_9,-1,1,1,7085,1
7090,drug-related,3,4,21,33,"Other causes include drug-related (cyclosporine, tacrolimus) toxicity, procoagulant status, and antibody-mediated rejection.",15859940_11,-1,1,1,7090,1
7094,antibody-mediated,15,16,96,113,"Other causes include drug-related (cyclosporine, tacrolimus) toxicity, procoagulant status, and antibody-mediated rejection.",15859940_11,-1,1,1,7094,1
7096,thrombotic microangiopathy,7,9,41,67,"We found that the most-frequent cause of thrombotic microangiopathy was drug related, secondary mainly to cyclosporine.",15859940_12,-1,1,1,7096,1
7097,drug related,10,12,72,84,"We found that the most-frequent cause of thrombotic microangiopathy was drug related, secondary mainly to cyclosporine.",15859940_12,-1,1,1,7097,1
7099,thrombotic microangiopathy,8,10,39,65,"In the current study, the frequency of thrombotic microangiopathy was similar to the percentage reported in the literature (20%).",15859940_13,-1,1,1,7099,1
7121,growth retardation,6,8,41,59,"RESULTS: Maternal toxicity, intrauterine growth retardation, and increase of external and skeletal variations were found in rats treated with the highest dose of piroxicam.",15863244_9,-1,1,1,7121,1
7177,foreign body,10,12,92,104,Succinylcholine-induced masseter muscle rigidity during bronchoscopic removal of a tracheal foreign body.,15893386_0,-1,1,1,7177,1
7180,malignant hyperthermia,17,19,112,134,Masseter muscle rigidity during general anesthesia is considered an early warning sign of a possible episode of malignant hyperthermia.,15893386_1,-1,1,1,7180,1
7184,foreign body,33,35,201,213,"Here, we describe a case of severe masseter muscle rigidity (jaw of steel) after succinylcholine (Sch) administration during general anesthetic management for rigid bronchoscopic removal of a tracheal foreign body.",15893386_3,-1,1,1,7184,1
7186,malignant hyperthermia,16,18,117,139,Anesthesia was continued uneventfully with propofol infusion while all facilities were available to detect and treat malignant hyperthermia.,15893386_4,-1,1,1,7186,1
7212,posttreatment,28,29,147,160,"Likewise, in vivo, B6D2F1 mice were treated with etoposide, daunorubicin, and doxorubicin, with or without dexrazoxane over a wide range of doses: posttreatment, a full hematologic evaluation was done.",15897593_4,-1,1,1,7212,1
7233,brain metastases,5,7,33,49,Clinical trials in patients with brain metastases combining dexrazoxane and high doses of etoposide is ongoing with the aim of improving efficacy without aggravating hematologic toxicity.,15897593_8,-1,1,1,7233,1
7237,side effects,12,14,85,97,"If successful, this represents an exciting mechanism for pharmacologic regulation of side effects from cytotoxic chemotherapy.",15897593_9,-1,1,1,7237,1
7239,atrial fibrillation,1,3,5,24,Lone atrial fibrillation associated with creatine monohydrate supplementation.,15899738_0,-1,1,1,7239,1
7242,Atrial fibrillation,0,2,0,19,Atrial fibrillation in young patients without structural heart disease is rare.,15899738_1,-1,1,1,7242,1
7248,atrial fibrillation,16,18,90,109,We report the case of a 30-year-old Caucasian man who came to the emergency department in atrial fibrillation with rapid ventricular response.,15899738_4,-1,1,1,7248,1
7324,retrograde amnesia,25,27,161,179,"Furthermore, patients had no recall of words repeated prior to procedural sedation in BIS ranges associated with recall after procedural sedation, suggestive of retrograde amnesia.",15930398_19,-1,1,1,7324,1
7344,memory deficits,27,29,115,130,"Both, Ro4368554 (3 and 10 mg/kg, intraperitoneally (i.p.)) and metrifonate (10 mg/kg, p.o., respectively) reversed memory deficits induced by scopolamine and TRP depletion (10 mg/kg, i.p., and 3 mg/kg, p.o., respectively).",15957009_5,-1,1,1,7344,1
7354,side-effects,12,13,81,93,"Amiodarone is an effective antiarrhythmic agent whose utility is limited by many side-effects, the most problematic being pneumonitis.",1595783_1,-1,1,1,7354,1
7356,hypersensitivity pneumonitis,22,24,155,183,The pulmonary toxicity of amiodarone is thought to result from direct injury related to the intracellular accumulation of phospholipid and T cell-mediated hypersensitivity pneumonitis.,1595783_2,-1,1,1,7356,1
7358,heart failure,11,13,62,75,"The diagnosis depends on exclusion of other entities, such as heart failure, infection, and malignancy.",1595783_4,-1,1,1,7358,1
7371,thermal hyperalgesia,22,24,135,155,"Their ester prodrugs 6 and 8 were orally active in three models of pain: reversal of formalin-induced paw licking, carrageenan-induced thermal hyperalgesia, and capsaicin-induced mechanical hyperalgesia.",15974569_2,-1,1,1,7371,1
7373,mechanical hyperalgesia,27,29,179,202,"Their ester prodrugs 6 and 8 were orally active in three models of pain: reversal of formalin-induced paw licking, carrageenan-induced thermal hyperalgesia, and capsaicin-induced mechanical hyperalgesia.",15974569_2,-1,1,1,7373,1
7383,drug-induced,3,4,13,25,Few cases of drug-induced hiccups have been reported related to macrolide antimicrobials.,15985056_8,-1,1,1,7383,1
7389,drug-induced,4,5,26,38,CONCLUSIONS: Diagnosis of drug-induced hiccups is difficult and often achieved only by a process of elimination.,15985056_11,-1,1,1,7389,1
7393,side-effect,21,22,141,152,"However, macrolide antimicrobials have been reported to be associated with hiccups and vagal mechanism could explain the development of this side-effect.",15985056_12,-1,1,1,7393,1
7420,milk-alkali syndrome,6,8,40,60,Calcium carbonate toxicity: the updated milk-alkali syndrome; report of 3 cases and review of the literature.,16006300_0,-1,1,1,7420,1
7421,milk-alkali syndrome,20,22,134,154,OBJECTIVE: To describe 3 patients with calcium carbonate-induced hypercalcemia and gain insights into the cause and management of the milk-alkali syndrome.,16006300_1,-1,1,1,7421,1
7425,milk-alkali syndrome,33,35,187,207,METHODS: We report the clinical and laboratory data in 3 patients who presented with severe hypercalcemia (corrected serum calcium > or = 14 mg/dL) and review the pertinent literature on milk-alkali syndrome.,16006300_2,-1,1,1,7425,1
7426,acute renal insufficiency,6,9,28,53,"RESULTS: The 3 patients had acute renal insufficiency, relative metabolic alkalosis, and low parathyroid hormone (PTH), PTH-related peptide, and 1,25-dihydroxyvitamin D concentrations.",16006300_3,-1,1,1,7426,1
7438,milk-alkali syndrome,20,22,121,141,"In addition to our highlighted cases, we review the history, classification, pathophysiologic features, and treatment of milk-alkali syndrome and summarize the cases reported from early 1995 to November 2003.",16006300_8,-1,1,1,7438,1
7439,Milk-alkali syndrome,2,4,12,32,CONCLUSION: Milk-alkali syndrome may be a common cause of unexplained hypercalcemia and can be precipitated by small amounts of orally ingested calcium carbonate in susceptible persons.,16006300_9,-1,1,1,7439,1
7453,myocardial infarction,19,21,116,137,"Eleven of the cocaine abusers and none of the controls had ECG evidence of significant myocardial injury defined as myocardial infarction, ischemia, and bundle branch block.",1601297_2,-1,1,1,7453,1
7454,bundle branch block,25,28,153,172,"Eleven of the cocaine abusers and none of the controls had ECG evidence of significant myocardial injury defined as myocardial infarction, ischemia, and bundle branch block.",1601297_2,-1,1,1,7454,1
7461,late-onset,5,6,26,36,We report 4 patients with late-onset LV probably due to warfarin.,16047871_3,-1,1,1,7461,1
7499,supplementary motor,2,4,8,27,rTMS of supplementary motor area modulates therapy-induced dyskinesias in Parkinson disease.,16116131_0,-1,1,1,7499,1
7500,Parkinson disease,9,11,74,91,rTMS of supplementary motor area modulates therapy-induced dyskinesias in Parkinson disease.,16116131_0,-1,1,1,7500,1
7504,supplementary motor,10,12,67,86,"Using repetitive transcranial magnetic stimulation (rTMS) over the supplementary motor area (SMA) in a group of patients with advanced Parkinson disease, the authors investigated whether modulation of SMA excitability may result in a modification of a dyskinetic state induced by continuous apomorphine infusion.",16116131_2,-1,1,1,7504,1
7505,SMA,14,15,93,96,"Using repetitive transcranial magnetic stimulation (rTMS) over the supplementary motor area (SMA) in a group of patients with advanced Parkinson disease, the authors investigated whether modulation of SMA excitability may result in a modification of a dyskinetic state induced by continuous apomorphine infusion.",16116131_2,-1,1,1,7505,1
7506,Parkinson disease,23,25,135,152,"Using repetitive transcranial magnetic stimulation (rTMS) over the supplementary motor area (SMA) in a group of patients with advanced Parkinson disease, the authors investigated whether modulation of SMA excitability may result in a modification of a dyskinetic state induced by continuous apomorphine infusion.",16116131_2,-1,1,1,7506,1
7507,SMA,32,33,201,204,"Using repetitive transcranial magnetic stimulation (rTMS) over the supplementary motor area (SMA) in a group of patients with advanced Parkinson disease, the authors investigated whether modulation of SMA excitability may result in a modification of a dyskinetic state induced by continuous apomorphine infusion.",16116131_2,-1,1,1,7507,1
7508,dyskinetic,41,42,252,262,"Using repetitive transcranial magnetic stimulation (rTMS) over the supplementary motor area (SMA) in a group of patients with advanced Parkinson disease, the authors investigated whether modulation of SMA excitability may result in a modification of a dyskinetic state induced by continuous apomorphine infusion.",16116131_2,-1,1,1,7508,1
7511,drug-induced dyskinesias,9,11,45,69,"rTMS at 1 Hz was observed to markedly reduce drug-induced dyskinesias, whereas 5-Hz rTMS induced a slight but not significant increase.",16116131_3,-1,1,1,7511,1
7516,brain tumors,2,4,16,28,Human malignant brain tumors have a poor prognosis in spite of surgery and radiation therapy.,16132524_1,-1,1,1,7516,1
7537,brain edema,16,18,93,104,"Six of the patients received more than 15 mg paclitaxel and suffered from moderate to severe brain edema, while the remaining patients received only a total of 15 mg paclitaxel.",16132524_6,-1,1,1,7537,1
7539,brain edema,5,7,21,32,"In the latter group, brain edema was markedly reduced and dealt medically.",16132524_7,-1,1,1,7539,1
7546,generalized epilepsies,10,12,76,98,Lamotrigine associated with exacerbation or de novo myoclonus in idiopathic generalized epilepsies.,16157917_0,-1,1,1,7546,1
7547,generalized epilepsies,4,6,30,52,Five patients with idiopathic generalized epilepsies (IGE) treated with lamotrigine (LTG) experienced exacerbation or de novo appearance of myoclonic jerks (MJ).,16157917_1,-1,1,1,7547,1
7552,myoclonic jerks,22,24,140,155,Five patients with idiopathic generalized epilepsies (IGE) treated with lamotrigine (LTG) experienced exacerbation or de novo appearance of myoclonic jerks (MJ).,16157917_1,-1,1,1,7552,1
7565,central nervous system,10,13,60,82,Urotensin-II (U-II) receptors are widely distributed in the central nervous system.,16160878_1,-1,1,1,7565,1
7632,osteopenia,6,7,47,57,"METHODS: Thirty-nine postmenopausal women with osteopenia or osteoporosis were included in this prospective, controlled clinical study.",16167916_1,-1,1,1,7632,1
7652,subarachnoid hemorrhage,7,9,68,91,Absence of acute cerebral vasoconstriction after cocaine-associated subarachnoid hemorrhage.,16174948_0,-1,1,1,7652,1
7659,subarachnoid hemorrhage,13,15,99,122,Information on these effects could be obtained from angiograms of patients with cocaine-associated subarachnoid hemorrhage (SAH) who underwent angiography shortly after cocaine use.,16174948_3,-1,1,1,7659,1
7669,internal carotid,14,16,93,109,"There were no significant differences between groups in the mean diameters of the intradural internal carotid, sphenoidal segment of the middle cerebral, precommunicating segment of the anterior cerebral, or basilar arteries (p greater than 0.05 for all comparisons, unpaired t-tests).",16174948_8,-1,1,1,7669,1
7678,internal carotid artery,31,34,211,234,"There also were no significant differences between groups when expressing diameters as the sum of the precommunicating segment of the anterior cerebral + sphenoidal segment of the middle cerebral + supraclinoid internal carotid artery + basilar artery divided by the diameter of the petrous internal carotid artery (p greater than 0.05, unpaired t-tests).",16174948_9,-1,1,1,7678,1
7679,basilar artery,35,37,237,251,"There also were no significant differences between groups when expressing diameters as the sum of the precommunicating segment of the anterior cerebral + sphenoidal segment of the middle cerebral + supraclinoid internal carotid artery + basilar artery divided by the diameter of the petrous internal carotid artery (p greater than 0.05, unpaired t-tests).",16174948_9,-1,1,1,7679,1
7680,internal carotid artery,44,47,291,314,"There also were no significant differences between groups when expressing diameters as the sum of the precommunicating segment of the anterior cerebral + sphenoidal segment of the middle cerebral + supraclinoid internal carotid artery + basilar artery divided by the diameter of the petrous internal carotid artery (p greater than 0.05, unpaired t-tests).",16174948_9,-1,1,1,7680,1
7717,Tic disorders,0,2,0,13,"Tic disorders can be effectively treated by atypical antipsychotics such as risperidone, olanzapine and ziprasidone.",16225977_1,-1,1,1,7717,1
7733,side effects,6,8,35,47,No more tic-like symptoms or other side effects have been reported.,16225977_8,-1,1,1,7733,1
7740,drug withdrawal,5,7,37,52,Her symptoms totally regressed after drug withdrawal and reappeared when acitretin was reintroduced.,16274958_2,-1,1,1,7740,1
7745,heart block,3,5,29,40,Chloroquine related complete heart block with blindness: case report.,1628552_0,-1,1,1,7745,1
7751,heart failure,13,15,114,127,"Ophthalmological assessment revealed features of chloroquine retinopathy, cardiac assessment revealed features of heart failure and a complete heart block with right bundle branch block pattern.",1628552_2,-1,1,1,7751,1
7752,heart block,18,20,143,154,"Ophthalmological assessment revealed features of chloroquine retinopathy, cardiac assessment revealed features of heart failure and a complete heart block with right bundle branch block pattern.",1628552_2,-1,1,1,7752,1
7753,right bundle branch block,21,25,160,185,"Ophthalmological assessment revealed features of chloroquine retinopathy, cardiac assessment revealed features of heart failure and a complete heart block with right bundle branch block pattern.",1628552_2,-1,1,1,7753,1
7754,heart block,1,3,4,15,The heart block was treated by pacemaker insertion and the heart failure resolved spontaneously following chloroquine discontinuation.,1628552_3,-1,1,1,7754,1
7755,heart failure,10,12,59,72,The heart block was treated by pacemaker insertion and the heart failure resolved spontaneously following chloroquine discontinuation.,1628552_3,-1,1,1,7755,1
7761,hearing loss,20,22,122,134,"The nitric oxide (NO) inhibitor nitro-L-arginine methyl ester (L-NAME) may act as an otoprotectant against high-frequency hearing loss caused by gentamicin, but further studies are needed to confirm this.",16298782_1,-1,1,1,7761,1
7763,ototoxicity,1,2,6,17,"Their ototoxicity is a serious health problem and, as their ototoxic mechanism involves the production of NO, we need to assess the use of NO inhibitors for the prevention of aminoglycoside-induced sensorineural hearing loss.",16298782_3,-1,1,1,7763,1
7764,health problem,5,7,31,45,"Their ototoxicity is a serious health problem and, as their ototoxic mechanism involves the production of NO, we need to assess the use of NO inhibitors for the prevention of aminoglycoside-induced sensorineural hearing loss.",16298782_3,-1,1,1,7764,1
7766,sensorineural hearing loss,33,36,198,224,"Their ototoxicity is a serious health problem and, as their ototoxic mechanism involves the production of NO, we need to assess the use of NO inhibitors for the prevention of aminoglycoside-induced sensorineural hearing loss.",16298782_3,-1,1,1,7766,1
7769,middle ear,18,20,105,115,"In this experimental study we used 30 Sprague-Dawley rats, 27 of which had gentamicin instilled into the middle ear.",16298782_4,-1,1,1,7769,1
7772,hearing loss,9,11,53,65,"Its effect was determined in terms of attenuation of hearing loss, measured by shifts in the auditory brainstem response threshold.",16298782_6,-1,1,1,7772,1
7775,hearing loss,3,5,34,46,"L-NAME reduced gentamicin-induced hearing loss in the high-frequency range, but gave no protection in the middle or low frequencies.",16298782_7,-1,1,1,7775,1
7784,heart disease,15,17,84,97,"METHODS: This was a multicenter, randomized, open-label study in adult smokers with heart disease, hypertension not controlled by medication, and/or diabetes mellitus.",16330293_4,-1,1,1,7784,1
7785,diabetes mellitus,25,27,149,166,"METHODS: This was a multicenter, randomized, open-label study in adult smokers with heart disease, hypertension not controlled by medication, and/or diabetes mellitus.",16330293_4,-1,1,1,7785,1
7806,central nervous system,7,10,51,73,Abnormal processing of somatosensory inputs in the central nervous system (central sensitization) is the mechanism accounting for the enhanced pain sensitivity in the skin surrounding tissue injury (secondary hyperalgesia).,16330766_1,-1,1,1,7806,1
7814,hyperalgesia,7,8,71,83,Secondary hyperalgesia shares clinical characteristics with neurogenic hyperalgesia in patients with neuropathic pain.,16330766_2,-1,1,1,7814,1
7815,neuropathic pain,11,13,101,117,Secondary hyperalgesia shares clinical characteristics with neurogenic hyperalgesia in patients with neuropathic pain.,16330766_2,-1,1,1,7815,1
7818,hyperalgesia,12,13,83,95,Abnormal brain responses to somatosensory stimuli have been found in patients with hyperalgesia as well as in normal subjects during experimental central sensitization.,16330766_3,-1,1,1,7818,1
7823,neuropathic pain,17,19,83,99,"The aim of this study was to assess the effects of gabapentin, a drug effective in neuropathic pain patients, on brain processing of nociceptive information in normal and central sensitization states.",16330766_4,-1,1,1,7823,1
7840,drug-induced,2,3,13,25,The observed drug-induced effects were not due to changes in the baseline fMRI signal.,16330766_8,-1,1,1,7840,1
7852,cell death,18,20,128,138,"Mitochondrial abnormalities have been associated with several aspects of epileptogenesis, such as energy generation, control of cell death, neurotransmitter synthesis, and free radical (FR) production.",16337777_1,-1,1,1,7852,1
7855,oxidative phosphorylation,13,15,86,111,Increased production of FRs may cause mtDNA damage leading to decreased activities of oxidative phosphorylation complexes containing mtDNA-encoded subunits.,16337777_2,-1,1,1,7855,1
7857,status epilepticus,12,14,73,91,"In this study, we investigated whether increased generation of FR during status epilepticus would be sufficient to provoke abnormalities in mtDNA and in the expression and activity of cytochrome c oxidase (CCO), complex IV of the respiratory chain, in the chronic phase of the pilocarpine model of temporal lobe epilepsy.",16337777_3,-1,1,1,7857,1
7862,respiratory chain,40,42,230,247,"In this study, we investigated whether increased generation of FR during status epilepticus would be sufficient to provoke abnormalities in mtDNA and in the expression and activity of cytochrome c oxidase (CCO), complex IV of the respiratory chain, in the chronic phase of the pilocarpine model of temporal lobe epilepsy.",16337777_3,-1,1,1,7862,1
7865,temporal lobe epilepsy,52,55,298,320,"In this study, we investigated whether increased generation of FR during status epilepticus would be sufficient to provoke abnormalities in mtDNA and in the expression and activity of cytochrome c oxidase (CCO), complex IV of the respiratory chain, in the chronic phase of the pilocarpine model of temporal lobe epilepsy.",16337777_3,-1,1,1,7865,1
7887,acute renal failure,9,12,62,81,"Although suprofen has been associated with the development of acute renal failure in greater than 100 subjects, the mechanism of damage remains unclear.",1636026_1,-1,1,1,7887,1
7913,CA1,5,6,38,41,Microinjection of ritanserin into the CA1 region of hippocampus improves scopolamine-induced amnesia in adult male rats.,16364460_0,-1,1,1,7913,1
7919,CA1,10,11,68,71,Rats were divided into eight groups and bilaterally cannulated into CA1 region of the hippocampus.,16364460_2,-1,1,1,7919,1
7948,CA1,9,10,61,64,Our findings show that microinjection of ritanserin into the CA1 region of the hippocampus improves the scopolamine-induced amnesia.,16364460_9,-1,1,1,7948,1
7951,renovascular hypertension,13,15,91,116,Adverse effect of the calcium channel blocker nitrendipine on nephrosclerosis in rats with renovascular hypertension.,1639466_0,-1,1,1,7951,1
7958,renovascular hypertension,43,45,274,299,"The effect of a 6-week treatment with the calcium channel blocker nitrendipine or the angiotensin converting enzyme inhibitor enalapril on blood pressure, albuminuria, renal hemodynamics, and morphology of the nonclipped kidney was studied in rats with two-kidney, one clip renovascular hypertension.",1639466_1,-1,1,1,7958,1
7959,renal artery,6,8,32,44,"Six weeks after clipping of one renal artery, hypertensive rats (178 +/- 4 mm Hg) were randomly assigned to three groups: untreated hypertensive controls (n = 8), enalapril-treated (n = 8), or nitrendipine-treated (n = 10).",1639466_2,-1,1,1,7959,1
7977,glomerulosclerosis,9,10,55,73,"Renal plasma flow increased, but albumin excretion and glomerulosclerosis did not change after enalapril treatment.",1639466_8,-1,1,1,7977,1
7983,glomerulosclerosis,2,3,13,31,"Furthermore, glomerulosclerosis index was significantly increased in the nitrendipine-treated group compared with the hypertensive controls (0.38 +/- 0.1 versus 0.13 +/- 0.04).",1639466_10,-1,1,1,7983,1
8004,coronary artery disease,5,8,23,46,We report a woman with coronary artery disease who developed a markedly prolonged QT interval and torsades de pointes (TdP) after taking ketoconazole for treatment of fungal infection.,16403073_2,-1,1,1,8004,1
8022,Turner Syndrome,6,8,41,56,PTU-associated vasculitis in a girl with Turner Syndrome and Graves' disease.,16418614_0,-1,1,1,8022,1
8025,drug-induced,4,5,14,26,"A rare cause, drug-induced vasculitis, may result from the production of antineutrophil cytoplasmic antibodies (ANCAs) in response to a medication.",16418614_2,-1,1,1,8025,1
8028,Turner syndrome,5,7,22,37,We report a girl with Turner syndrome and Graves' disease who presented with palpable purpuric lesions.,16418614_3,-1,1,1,8028,1
8036,Cerebral vasculitis,0,2,0,19,Cerebral vasculitis following oral methylphenidate intake in an adult: a case report.,16428221_0,-1,1,1,8036,1
8039,Cerebral vasculitis,0,2,0,19,"Cerebral vasculitis associated with amphetamine abuse is well documented, and in rare cases ischaemic stroke has been reported after methylphenidate intake in children.",16428221_2,-1,1,1,8039,1
8041,amphetamine abuse,4,6,36,53,"Cerebral vasculitis associated with amphetamine abuse is well documented, and in rare cases ischaemic stroke has been reported after methylphenidate intake in children.",16428221_2,-1,1,1,8041,1
8042,ischaemic stroke,14,16,92,108,"Cerebral vasculitis associated with amphetamine abuse is well documented, and in rare cases ischaemic stroke has been reported after methylphenidate intake in children.",16428221_2,-1,1,1,8042,1
8045,ischaemic strokes,20,22,128,145,We report the case of a 63-year-old female who was treated with methylphenidate due to hyperactivity and suffered from multiple ischaemic strokes.,16428221_3,-1,1,1,8045,1
8047,ischaemic strokes,12,14,83,100,We consider drug-induced cerebral vasculitis as the most likely cause of recurrent ischaemic strokes in the absence of any pathological findings during the diagnostic work-up.,16428221_4,-1,1,1,8047,1
8050,side-effect,2,3,15,26,"This potential side-effect, though very rare, represents one more reason to be very restrictive in the use of methylphenidate.",16428221_6,-1,1,1,8050,1
8055,Alzheimer's disease,33,36,203,222,"The choline acetyltransferase (ChAT) activator, which enhances cholinergic transmission via an augmentation of the enzymatic production of acetylcholine (ACh), is an important factor in the treatment of Alzheimer's disease (AD).",16428827_1,-1,1,1,8055,1
8070,body weight,6,8,38,49,"Administration of daidzein (4.5 mg/kg body weight) to mice was shown significantly to reverse scopolamine-induced amnesia, according to the results of a Y-maze test.",16428827_5,-1,1,1,8070,1
8081,overactive bladder,11,13,64,82,Urinary symptoms and quality of life changes in Thai women with overactive bladder after tolterodine treatment.,16471092_0,-1,1,1,8081,1
8085,overactive bladder,16,18,89,107,OBJECTIVES: To study the urinary symptoms and quality of life changes in Thai women with overactive bladder (OAB) after tolterodine treatment.,16471092_1,-1,1,1,8085,1
8099,side effect,3,5,16,27,The most common side effect was dry month in 5 cases (16.7%) with 2 cases reporting a moderate degree and 1 case with severe degree.,16471092_9,-1,1,1,8099,1
8132,side effects,13,15,107,119,"CONCLUSION: Pretreatment with remifentanil 1 microg/kg reduced myoclonus after etomidate induction without side effects such as sedation, apnea, nausea, or pruritus.",16563323_11,-1,1,1,8132,1
8136,memory deficits,4,6,24,39,"In recent years working memory deficits have been reported in users of MDMA (3,4-methylenedioxymethamphetamine, ecstasy).",16574712_1,-1,1,1,8136,1
8151,drug use,10,12,73,81,The latter two deficits remained significant after controlling for other drug use.,16574712_5,-1,1,1,8151,1
8195,myocardial infarction,11,13,94,115,Role of mangiferin on biochemical alterations and antioxidant status in isoproterenol-induced myocardial infarction in rats.,16584858_0,-1,1,1,8195,1
8202,myocardial infarction,25,27,154,175,"The current study dealt with the protective role of mangiferin, a polyphenol from Mangifera indica Linn. (Anacardiaceae), on isoproterenol (ISPH)-induced myocardial infarction (MI) in rats through its antioxidative mechanism.",16584858_1,-1,1,1,8202,1
8206,body weight,7,9,42,53,"Subcutaneous injection of ISPH (200 mg/kg body weight in 1 ml saline) to rats for 2 consecutive days caused myocardial damage in rat heart, which was determined by the increased activity of serum lactate dehydrogenase (LDH) and creatine phosphokinase isoenzymes (CK-MB), increased uric acid level and reduced plasma iron binding capacity.",16584858_2,-1,1,1,8206,1
8229,body weight,7,9,45,56,Upon pretreatment with mangiferin (100 mg/kg body weight suspended in 2 ml of dimethyl sulphoxide) given intraperitoneally for 28 days to MI rats protected the above-mentioned parameters to fall from the normal levels.,16584858_5,-1,1,1,8229,1
8248,myocardial infarction,23,25,189,210,"Cardiovascular risk with cyclooxygenase inhibitors: general problem with substance specific differences?Randomised clinical trials and observational studies have shown an increased risk of myocardial infarction, stroke, hypertension and heart failure during treatment with cyclooxygenase inhibitors.",16586083_0,-1,1,1,8248,1
8249,heart failure,30,32,237,250,"Cardiovascular risk with cyclooxygenase inhibitors: general problem with substance specific differences?Randomised clinical trials and observational studies have shown an increased risk of myocardial infarction, stroke, hypertension and heart failure during treatment with cyclooxygenase inhibitors.",16586083_0,-1,1,1,8249,1
8269,status epilepticus,3,5,18,36,Children who have status epilepticus have continuous or rapidly repeating seizures that may be life-threatening and may cause life-long changes in brain and behavior.,16596970_1,-1,1,1,8269,1
8270,status epilepticus,4,6,20,38,The extent to which status epilepticus causes deficits in auditory discrimination is unknown.,16596970_2,-1,1,1,8270,1
8273,status epilepticus,17,19,115,133,A naturalistic auditory location discrimination method was used to evaluate this question using an animal model of status epilepticus.,16596970_3,-1,1,1,8273,1
8278,status epilepticus,5,7,34,52,"Pilocarpine on either day induced status epilepticus; status epilepticus at P45 resulted in CA3 cell loss and spontaneous seizures, whereas P20 rats had no cell loss or spontaneous seizures.",16596970_5,-1,1,1,8278,1
8279,status epilepticus,8,10,54,72,"Pilocarpine on either day induced status epilepticus; status epilepticus at P45 resulted in CA3 cell loss and spontaneous seizures, whereas P20 rats had no cell loss or spontaneous seizures.",16596970_5,-1,1,1,8279,1
8287,status epilepticus,1,3,3,21,"In status epilepticus (P20) rats, acquisition of the sound-source location discrimination was moderately impaired.",16596970_8,-1,1,1,8287,1
8290,Status epilepticus,0,2,0,18,Status epilepticus (P45) rats failed to acquire either sound-source location or sound-silence discriminations.,16596970_9,-1,1,1,8290,1
8294,Status epilepticus,0,2,0,18,"Status epilepticus in rat causes an age-dependent, long-term impairment in auditory discrimination.",16596970_10,-1,1,1,8294,1
8298,overactive bladder,12,14,76,94,Nerve growth factor and prostaglandins in the urine of female patients with overactive bladder.,16600756_0,-1,1,1,8298,1
8332,Chronic infection,0,2,0,17,"Chronic infection with hepatitis C virus (HCV) can progress to cirrhosis, hepatocellular carcinoma, and end-stage liver disease.",16629641_1,-1,1,1,8332,1
8336,liver disease,19,21,114,127,"Chronic infection with hepatitis C virus (HCV) can progress to cirrhosis, hepatocellular carcinoma, and end-stage liver disease.",16629641_1,-1,1,1,8336,1
8342,hemolytic anemia,25,27,156,172,"Although this regimen produces sustained virologic responses (SVRs) in approximately 50% of patients, it can be associated with a potentially dose-limiting hemolytic anemia.",16629641_3,-1,1,1,8342,1
8353,hemolytic anemia,23,25,147,163,"Viramidine, a liver-targeting prodrug of ribavirin, has the potential to maintain the virologic efficacy of ribavirin while decreasing the risk of hemolytic anemia in patients with chronic hepatitis C.",16629641_8,-1,1,1,8353,1
8354,chronic hepatitis,28,30,181,198,"Viramidine, a liver-targeting prodrug of ribavirin, has the potential to maintain the virologic efficacy of ribavirin while decreasing the risk of hemolytic anemia in patients with chronic hepatitis C.",16629641_8,-1,1,1,8354,1
8361,fetal alcohol,3,5,24,37,Early identification of fetal alcohol exposure and maternal abstinence led to better infant outcomes.,16634859_2,-1,1,1,8361,1
8376,drug abuse,21,23,148,158,Analyses of covariance were used to determine whether there were differences between groups after controlling for influences of gestational age and drug abuse.,16634859_8,-1,1,1,8376,1
8387,Amphetamine abuse,0,2,0,17,Amphetamine abuse was predictive of larger cranial to body growth ratios.,16634859_12,-1,1,1,8387,1
8393,fetal alcohol,31,33,201,214,"Although the reliance on self-reported drinking is a limitation in this study, these findings support the benefits of early abstinence and the potential for ultrasound examinations in the detection of fetal alcohol effects.",16634859_14,-1,1,1,8393,1
8397,lung cancer,15,17,79,90,Phase II study of the amsacrine analogue CI-921 (NSC 343499) in non-small cell lung cancer.,1664218_0,-1,1,1,8397,1
8405,lung cancer,14,16,84,95,"It was administered by 15 min infusion to 16 evaluable patients with non-small cell lung cancer (NSCLC) (7 with no prior treatment, 9 patients in relapse following surgery/radiotherapy) at a dose (648 mg/m2 divided over 3 days, repeated every 3 weeks) determined by phase I trial.",1664218_2,-1,1,1,8405,1
8417,nausea and vomiting,7,10,30,49,Grade less than or equal to 2 nausea and vomiting occurred in 66% courses and phlebitis in the infusion arm in 37%.,1664218_6,-1,1,1,8417,1
8419,squamous cell carcinoma,3,6,15,38,1 patient with squamous cell carcinoma achieved a partial response lasting 5 months.,1664218_7,-1,1,1,8419,1
8456,optic neuropathy,1,3,22,38,Ethambutol-associated optic neuropathy.,16710500_0,-1,1,1,8456,1
8460,visual loss,25,27,148,159,"INTRODUCTION: Ethambutol is used in the treatment of tuberculosis, which is still prevalent in Southeast Asia, and can be associated with permanent visual loss.",16710500_1,-1,1,1,8460,1
8461,bitemporal hemianopia,7,9,39,60,We report 3 cases which presented with bitemporal hemianopia.,16710500_2,-1,1,1,8461,1
8463,toxic optic neuropathy,7,10,60,82,CLINICAL PICTURE: Three patients with ethambutol-associated toxic optic neuropathy are described.,16710500_3,-1,1,1,8463,1
8469,bitemporal,6,7,28,38,"The visual field loss had a bitemporal flavour, suggesting involvement of the optic chiasm.",16710500_5,-1,1,1,8469,1
8479,visual loss,8,10,59,70,CONCLUSIONS: Ethambutol usage is associated with permanent visual loss and should be avoided if possible or used with caution and proper ophthalmological follow-up.,16710500_10,-1,1,1,8479,1
8486,neuroleptic malignant syndrome,1,4,9,39,Possible neuroleptic malignant syndrome related to concomitant treatment with paroxetine and alprazolam.,16720068_0,-1,1,1,8486,1
8496,muscle rigidity,21,23,137,152,"On the 10th day of paroxetine and alprazolam treatment, the patient exhibited marked psychomotor retardation, disorientation, and severe muscle rigidity with tremors.",16720068_3,-1,1,1,8496,1
8506,neuroleptic malignant syndrome,6,9,40,70,"This patient presented with symptoms of neuroleptic malignant syndrome (NMS), thus demonstrating that NMS-like symptoms can occur after combined paroxetine and alprazolam treatment.",16720068_8,-1,1,1,8506,1
8509,adverse drug reaction,1,4,4,25,"The adverse drug reaction score obtained by the Naranjo algorithm was 6 in our case, indicating a probable relationship between the patient's NMS-like adverse symptoms and the combined treatment used in this case.",16720068_9,-1,1,1,8509,1
8533,hippocampal,6,7,46,57,These results suggest that down-regulation of hippocampal NET induced by chronic administration of desipramine may be relevant to desipramine-induced sensitization of lidocaine convulsions.,16725121_7,-1,1,1,8533,1
8542,hippocampal,7,8,60,71,Repeated administration of cocaine induces up-regulation of hippocampal NET function.,16725121_9,-1,1,1,8542,1
8553,Alzheimer's disease,19,22,118,137,METHODS: The son of an 84-year-old male discovered a newspaper report stating clinical success with plant extracts in Alzheimer's disease.,16740173_3,-1,1,1,8553,1
8566,hypersalivation,5,6,34,49,"Further signs were hyperhidrosis, hypersalivation, bronchorrhoea, and severe miosis; the electrocardiographic finding was atrio-ventricular dissociation.",16740173_11,-1,1,1,8566,1
8569,atrio-ventricular dissociation,17,19,122,152,"Further signs were hyperhidrosis, hypersalivation, bronchorrhoea, and severe miosis; the electrocardiographic finding was atrio-ventricular dissociation.",16740173_11,-1,1,1,8569,1
8578,heart failure,12,14,49,62,"On the next day he died, probably as a result of heart failure.",16740173_17,-1,1,1,8578,1
8632,side effect,14,16,83,94,Valproic acid induced encephalopathy--19 new cases in Germany from 1994 to 2003--a side effect associated to VPA-therapy not only in young children.,16787750_0,-1,1,1,8632,1
8642,hyperammonemia,23,24,162,176,"The typical signs of VPA-induced encephalopathy are impaired consciousness, sometimes marked EEG background slowing, increased seizure frequency, with or without hyperammonemia.",16787750_3,-1,1,1,8642,1
8679,Peripheral neuropathy,0,2,0,21,Peripheral neuropathy caused by high-dose cytosine arabinoside treatment in a patient with acute myeloid leukemia.,16826348_0,-1,1,1,8679,1
8681,acute myeloid leukemia,12,15,91,113,Peripheral neuropathy caused by high-dose cytosine arabinoside treatment in a patient with acute myeloid leukemia.,16826348_0,-1,1,1,8681,1
8686,acute myeloid leukemia,7,10,46,68,A 49-year-old Japanese man was diagnosed with acute myeloid leukemia.,16826348_2,-1,1,1,8686,1
8694,peripheral neuropathy,5,7,51,72,Electromyogram and nerve-conduction studies showed peripheral neuropathy in both peroneal nerves.,16826348_5,-1,1,1,8694,1
8696,bone marrow,13,15,88,99,"This neuropathy was gradually resolving; however, after the patient received allogeneic bone marrow transplantation, the symptoms worsened, with the development of graft-versus-host disease, and the symptoms subsequently responded to methylprednisolone.",16826348_6,-1,1,1,8696,1
8698,peripheral neuropathy,4,6,27,48,"Although the mechanisms of peripheral neuropathy are still unclear, high-dose cytosine arabinoside is a therapy that is potentially toxic to the peripheral nervous system, and auto/alloimmunity may play an important role in these mechanisms.",16826348_7,-1,1,1,8698,1
8705,neurotoxicity,7,8,71,84,Effect of alpha-tocopherol and deferoxamine on methamphetamine-induced neurotoxicity.,16844102_0,-1,1,1,8705,1
8715,neurotoxicity,31,32,163,176,"This study examined the effect of alpha-tocopherol (alpha-TC), a scavenger of reactive oxygen species, and deferoxamine (DFO), an iron chelator, on the MA-induced neurotoxicity.",16844102_2,-1,1,1,8715,1
8823,radiculopathy,7,8,57,70,"OBJECTIVE: Conventional treatment methods of lumbusacral radiculopathy are physical therapy, epidural steroid injections, oral medications, and spinal manipulative therapy.",16904497_1,-1,1,1,8823,1
8830,low back,7,9,44,52,CLINICAL FEATURES: A 50-year-old woman with low back and right leg pain was scheduled for epidural steroid injection.,16904497_4,-1,1,1,8830,1
8863,abdominal aorta,12,14,92,107,"Aortic atherosclerosis was diagnosed by radiographic detection of calcified deposits in the abdominal aorta, which have been shown to reflect intima atherosclerosis.",16938416_3,-1,1,1,8863,1
8875,B virus,1,3,10,17,"Hepatitis B virus (HBV) infection, which causes liver cirrhosis and hepatocellular carcinoma, remains a major health problem in Asian countries.",16960342_1,-1,1,1,8875,1
8876,liver cirrhosis,10,12,48,63,"Hepatitis B virus (HBV) infection, which causes liver cirrhosis and hepatocellular carcinoma, remains a major health problem in Asian countries.",16960342_1,-1,1,1,8876,1
8878,health problem,19,21,110,124,"Hepatitis B virus (HBV) infection, which causes liver cirrhosis and hepatocellular carcinoma, remains a major health problem in Asian countries.",16960342_1,-1,1,1,8878,1
8888,drug resistant,5,7,23,37,"During this period, no drug resistant mutant HBV emerged, and the serum HBV-DNA level was continuously suppressed.",16960342_7,-1,1,1,8888,1
8934,brain edema,8,10,42,53,AIM: Widespread use of mannitol to reduce brain edema and lower elevated ICP in brain tumor patients continues to be afflicted by the so-called rebound phenomenon.,17019386_2,-1,1,1,8934,1
8936,brain tumor,15,17,80,91,AIM: Widespread use of mannitol to reduce brain edema and lower elevated ICP in brain tumor patients continues to be afflicted by the so-called rebound phenomenon.,17019386_2,-1,1,1,8936,1
8941,brain tumor,22,24,130,141,As a contribution to this issue we decided to research the possible passage of mannitol into the brain after administration to 21 brain tumor patients.,17019386_5,-1,1,1,8941,1
8942,malignant glioma,21,23,90,106,"METHODS: Mannitol (18% solution; 1 g/kg) was administered as a bolus to patients (ten had malignant glioma, seven brain metastases and four meningioma) about 30 minutes before craniotomy.",17019386_6,-1,1,1,8942,1
8943,brain metastases,25,27,114,130,"METHODS: Mannitol (18% solution; 1 g/kg) was administered as a bolus to patients (ten had malignant glioma, seven brain metastases and four meningioma) about 30 minutes before craniotomy.",17019386_6,-1,1,1,8943,1
8952,neoplastic cells,22,24,160,176,In meningioma and metastases patients plasma concentrations of mannitol were higher than white matter concentrations except in three cases with infiltration by neoplastic cells.,17019386_9,-1,1,1,8952,1
8957,atrial fibrillation,5,7,45,64,Optimising stroke prevention in non-valvular atrial fibrillation.,17020434_0,-1,1,1,8957,1
8958,Atrial fibrillation,0,2,0,19,Atrial fibrillation is associated with substantial morbidity and mortality.,17020434_1,-1,1,1,8958,1
8974,atrial fibrillation,13,15,72,91,"Idraparinux, a Factor Xa inhibitor, is being evaluated in patients with atrial fibrillation.",17020434_6,-1,1,1,8974,1
8978,atrial fibrillation,11,13,100,119,Angiotensin-converting enzyme inhibitors and angiotensin II receptor-blocking drugs hold promise in atrial fibrillation through cardiac remodelling.,17020434_7,-1,1,1,8978,1
8984,left atrial,8,10,51,62,"Finally, percutaneous methods for the exclusion of left atrial appendage are under investigation in high-risk patients.",17020434_9,-1,1,1,8984,1
8993,akathisia,11,12,65,74,"OBJECTIVES: To evaluate extrapyramidal symptoms (EPS), including akathisia, with quetiapine in patients with bipolar mania.",17042884_1,-1,1,1,8993,1
9012,Akathisia,14,15,87,96,"Extrapyramidal symptoms were evaluated using the Simpson-Angus Scale (SAS), the Barnes Akathisia Rating Scale (BARS), adverse event reports and anticholinergic drug usage.",17042884_5,-1,1,1,9012,1
9016,akathisia,10,11,64,73,"RESULTS: The incidence of EPS-related adverse events, including akathisia, was no different with quetiapine monotherapy (12.9%) than with placebo (13.1%).",17042884_6,-1,1,1,9016,1
9032,akathisia,3,4,17,26,"The incidence of akathisia was low and similar with quetiapine monotherapy (3.3%) and placebo (6.1%), and with QTP + Li/DVP (3.6%) and PBO + Li/DVP (4.9%).",17042884_9,-1,1,1,9032,1
9044,akathisia,12,13,68,77,"Haloperidol induced a significantly higher incidence (p < 0.001) of akathisia (33.3% versus 5.9%), tremor (30.3% versus 7.8%), and extrapyramidal syndrome (35.4% versus 5.9%) than quetiapine.",17042884_11,-1,1,1,9044,1
9053,akathisia,12,13,63,72,"CONCLUSIONS: In bipolar mania, the incidence of EPS, including akathisia, with quetiapine therapy is similar to that with placebo.",17042884_14,-1,1,1,9053,1
9120,adverse cardiac event,12,15,74,95,Administration of phenytoin in the presence of hypothermia may lead to an adverse cardiac event in children.,17049862_5,-1,1,1,9120,1
9121,nonketotic hyperglycinemia,6,8,56,82,Valproate-induced chorea and encephalopathy in atypical nonketotic hyperglycinemia.,17074608_0,-1,1,1,9121,1
9122,Nonketotic hyperglycinemia,0,2,0,26,Nonketotic hyperglycinemia is a disorder of amino acid metabolism in which a defect in the glycine cleavage system leads to an accumulation of glycine in the brain and other body compartments.,17074608_1,-1,1,1,9122,1
9123,amino acid metabolism,6,9,44,65,Nonketotic hyperglycinemia is a disorder of amino acid metabolism in which a defect in the glycine cleavage system leads to an accumulation of glycine in the brain and other body compartments.,17074608_1,-1,1,1,9123,1
9126,of children,3,5,20,31,An important subset of children with nonketotic hyperglycinemia are atypical variants who present in a heterogeneous manner.,17074608_3,-1,1,1,9126,1
9127,nonketotic hyperglycinemia,6,8,37,63,An important subset of children with nonketotic hyperglycinemia are atypical variants who present in a heterogeneous manner.,17074608_3,-1,1,1,9127,1
9128,language delay,7,9,42,56,"This report describes a patient with mild language delay and mental retardation, who was found to have nonketotic hyperglycinemia following her presentation with acute encephalopathy and chorea shortly after initiation of valproate therapy.",17074608_4,-1,1,1,9128,1
9129,mental retardation,10,12,61,79,"This report describes a patient with mild language delay and mental retardation, who was found to have nonketotic hyperglycinemia following her presentation with acute encephalopathy and chorea shortly after initiation of valproate therapy.",17074608_4,-1,1,1,9129,1
9130,nonketotic hyperglycinemia,18,20,103,129,"This report describes a patient with mild language delay and mental retardation, who was found to have nonketotic hyperglycinemia following her presentation with acute encephalopathy and chorea shortly after initiation of valproate therapy.",17074608_4,-1,1,1,9130,1
9141,acute onset,5,7,32,43,She then very rapidly developed acute onset of severe facial and extremity tetany.,17111419_6,-1,1,1,9141,1
9155,cerebral ischemia,6,8,49,66,Delayed institution of hypertension during focal cerebral ischemia: effect on brain edema.,1711760_0,-1,1,1,9155,1
9156,brain edema,11,13,78,89,Delayed institution of hypertension during focal cerebral ischemia: effect on brain edema.,1711760_0,-1,1,1,9156,1
9157,induced hypertension,3,5,14,34,The effect of induced hypertension instituted after a 2-h delay following middle cerebral artery occlusion (MCAO) on brain edema formation and histochemical injury was studied.,1711760_1,-1,1,1,9157,1
9158,middle cerebral artery occlusion,11,15,74,106,The effect of induced hypertension instituted after a 2-h delay following middle cerebral artery occlusion (MCAO) on brain edema formation and histochemical injury was studied.,1711760_1,-1,1,1,9158,1
9160,brain edema,19,21,117,128,The effect of induced hypertension instituted after a 2-h delay following middle cerebral artery occlusion (MCAO) on brain edema formation and histochemical injury was studied.,1711760_1,-1,1,1,9160,1
9162,MCA,5,6,33,36,"Under isoflurane anesthesia, the MCA of 14 spontaneously hypertensive rats was occluded.",1711760_2,-1,1,1,9162,1
9199,cystic renal diseases,10,13,61,82,"Its role in the therapy of glomerulonephritis, autoimmunity, cystic renal diseases and renal cancer is under investigation.",17147461_3,-1,1,1,9199,1
9200,renal cancer,14,16,87,99,"Its role in the therapy of glomerulonephritis, autoimmunity, cystic renal diseases and renal cancer is under investigation.",17147461_3,-1,1,1,9200,1
9249,skin cancers,42,44,176,188,"The patient cohort (14 men, 11 women) was treated with SRL as conversion therapy, due to chronic allograft nephropathy (CAN) (n = 15) neoplasia (n = 8); Kaposi's sarcoma, Four skin cancers, One intestinal tumors, One renal cell carsinom) or BK virus nephropathy (n = 2).",17175308_4,-1,1,1,9249,1
9250,renal cell,50,52,217,227,"The patient cohort (14 men, 11 women) was treated with SRL as conversion therapy, due to chronic allograft nephropathy (CAN) (n = 15) neoplasia (n = 8); Kaposi's sarcoma, Four skin cancers, One intestinal tumors, One renal cell carsinom) or BK virus nephropathy (n = 2).",17175308_4,-1,1,1,9250,1
9259,nephrotic,9,10,69,78,Twenty-eight percent of patients showed increased proteinuria to the nephrotic range.,17175308_11,-1,1,1,9259,1
9261,interstitial nephritis,14,16,116,138,Biopsies performed in five patients revealed new pathological changes: One membranoproliferative glomerulopathy and interstitial nephritis.,17175308_12,-1,1,1,9261,1
9333,primary tumor,3,5,16,29,The most common primary tumor site was the head and neck.,1720453_5,-1,1,1,9333,1
9334,head and neck,8,11,43,56,The most common primary tumor site was the head and neck.,1720453_5,-1,1,1,9334,1
9346,Fanconi,30,31,168,175,Two subsets of patients were identified from this latter group: the first included four patients (5% of the total population) who developed major toxicity resulting in Fanconi's syndrome (TDFS); and the second group included five patients with elevated beta 2 microglobulinuria and low phosphate reabsorption.,1720453_8,-1,1,1,9346,1
9396,necrotizing,4,5,20,31,Statins can cause a necrotizing myopathy and hyperCKaemia which is reversible on cessation of the drug.,17241784_1,-1,1,1,9396,1
9415,temporal lobe epilepsy,10,13,68,90,"QTLs for susceptibility to pilocarpine-induced seizures, a model of temporal lobe epilepsy, have not been reported, and CSS have not previously been used to localize seizure susceptibility genes.",17242861_3,-1,1,1,9415,1
9418,B6,6,7,34,36,We report QTLs identified using a B6 (host) x A/J (donor) CSS panel to localize genes involved in susceptibility to pilocarpine-induced seizures.,17242861_4,-1,1,1,9418,1
9420,B6,9,10,49,51,"Three hundred fifty-five adult male CSS mice, 58 B6, and 39 A/J were tested for susceptibility to pilocarpine-induced seizures.",17242861_5,-1,1,1,9420,1
9423,B6,0,1,0,2,B6 mice were resistant to seizures and slower to reach stages compared to A/J mice.,17242861_7,-1,1,1,9423,1
9426,B6,18,19,104,106,"The CSS for Chromosomes 10 and 18 progressed to the most severe stages, diverging dramatically from the B6 phenotype.",17242861_8,-1,1,1,9426,1
9432,temporal lobe epilepsy,14,17,106,128,This approach provides a framework for identifying potentially novel homologous candidate genes for human temporal lobe epilepsy.,17242861_11,-1,1,1,9432,1
9437,detrusor function,7,9,49,66,"In cyclophosphamide-induced cystitis in the rat, detrusor function is impaired and the expression and effects of muscarinic receptors altered.",17244258_1,-1,1,1,9437,1
9483,cardiovascular disease,14,16,101,123,"BACKGROUND: Inhibition of cardiac sympathetic tone represents an important strategy for treatment of cardiovascular disease, including arrhythmia, coronary heart disease, and chronic heart failure.",17261653_1,-1,1,1,9483,1
9486,presynaptic,2,3,14,25,"Activation of presynaptic alpha2-adrenoceptors is the most widely accepted mechanism of action of the antisympathetic drug clonidine; however, other target proteins have been postulated to contribute to the in vivo actions of clonidine.",17261653_2,-1,1,1,9486,1
9518,Cardiac arrest,0,2,0,14,Cardiac arrest in a child with cerebral palsy undergoing sevoflurane induction of anesthesia after preoperative clonidine.,17263743_0,-1,1,1,9518,1
9519,cerebral palsy,6,8,31,45,Cardiac arrest in a child with cerebral palsy undergoing sevoflurane induction of anesthesia after preoperative clonidine.,17263743_0,-1,1,1,9519,1
9524,cerebral palsy,9,11,45,59,"We present a case of a 5-year-old child with cerebral palsy and seizure disorder, receiving clonidine for restlessness, who presented for placement of a baclofen pump.",17263743_2,-1,1,1,9524,1
9525,seizure disorder,12,14,64,80,"We present a case of a 5-year-old child with cerebral palsy and seizure disorder, receiving clonidine for restlessness, who presented for placement of a baclofen pump.",17263743_2,-1,1,1,9525,1
9530,cardiac arrest,7,9,54,68,There are no previous reports of clonidine-associated cardiac arrest in a child undergoing induction of anesthesia.,17263743_5,-1,1,1,9530,1
9538,abdominal pain,15,17,65,79,"The very next day, she presented at the emergency room (ER) with abdominal pain, nausea and vomiting.",17285209_2,-1,1,1,9538,1
9539,nausea and vomiting,18,21,81,100,"The very next day, she presented at the emergency room (ER) with abdominal pain, nausea and vomiting.",17285209_2,-1,1,1,9539,1
9561,liver injury,8,10,45,57,"This type of lesion broadens the spectrum of liver injury due to this drug combination, mainly represented by a benign cholestatic syndrome.",1728522_2,-1,1,1,9561,1
9578,conduction delay,16,18,143,159,"The second group consisted almost exclusively of elderly women who developed potentially life-threatening bradyarrhythmias or atrioventricular conduction delay, associated with either therapeutic or modestly elevated carbamazepine serum levels.",1728915_5,-1,1,1,9578,1
9657,hearing loss,22,24,145,157,"The influence of smoking during pregnancy on the developing cochlea has not been estimated, although smoking has been positively associated with hearing loss in adults.",17343925_1,-1,1,1,9657,1
9662,hearing impairment,12,14,69,87,METHODS: This study was undertaken as part of neonatal screening for hearing impairment and involved both ears of 200 newborns.,17343925_3,-1,1,1,9662,1
9684,heroin dependence,10,12,70,87,Syncope and QT prolongation among patients treated with methadone for heroin dependence in the city of Copenhagen.,17344330_0,-1,1,1,9684,1
9685,opioid use,11,13,74,84,BACKGROUND: Methadone is prescribed to heroin addicts to decrease illicit opioid use.,17344330_1,-1,1,1,9685,1
9698,Drug Addiction,5,7,23,37,"Of the patients at the Drug Addiction Service in the municipal of Copenhagen, 450 (approximately 52%) were included.",17344330_5,-1,1,1,9698,1
9718,compartment syndrome,3,5,34,54,Simvastatin-induced bilateral leg compartment syndrome and myonecrosis associated with hypothyroidism.,17344566_0,-1,1,1,9718,1
9721,compartment syndrome,12,14,93,113,A 54-year-old hypothyroid male taking thyroxine and simvastatin presented with bilateral leg compartment syndrome and myonecrosis.,17344566_1,-1,1,1,9721,1
9724,Neuroleptic malignant syndrome,0,3,0,30,Neuroleptic malignant syndrome induced by ziprasidone on the second day of treatment.,17366349_0,-1,1,1,9724,1
9726,Neuroleptic malignant syndrome,0,3,0,30,Neuroleptic malignant syndrome (NMS) is the rarest and most serious of the neuroleptic-induced movement disorders.,17366349_1,-1,1,1,9726,1
9727,movement disorders,15,17,95,113,Neuroleptic malignant syndrome (NMS) is the rarest and most serious of the neuroleptic-induced movement disorders.,17366349_1,-1,1,1,9727,1
9728,neuroleptic malignant syndrome,5,8,22,52,We describe a case of neuroleptic malignant syndrome (NMS) associated with the use of ziprasidone.,17366349_2,-1,1,1,9728,1
9734,signs and symptoms,13,16,80,98,The patient is a 24-year-old male with a history of schizophrenia who developed signs and symptoms of NMS after 2 days of treatment with an 80-mg/day dose of orally administrated ziprasidone.,17366349_4,-1,1,1,9734,1
9737,Neuroinflammation,0,1,0,17,Neuroinflammation and behavioral abnormalities after neonatal terbutaline treatment in rats: implications for autism.,17400887_0,-1,1,1,9737,1
9797,brain capillary,36,38,205,220,PURPOSE: The multidrug resistance protein 2 (MRP2) is a drug efflux transporter that is expressed predominantly at the apical domain of hepatocytes but seems also to be expressed at the apical membrane of brain capillary endothelial cells that form the blood-brain barrier (BBB).,17437408_1,-1,1,1,9797,1
9816,compensatory,15,16,85,97,"However, one drawback of such studies in genetically deficient rats is the fact that compensatory changes with upregulation of other transporters can occur.",17437408_4,-1,1,1,9816,1
9842,brain capillary,10,12,59,74,TR(-) rats exhibited a significant up-regulation of Pgp in brain capillary endothelial cells compared with wild-type controls.,17437408_8,-1,1,1,9842,1
9864,compensatory,3,4,15,27,"Because such a compensatory mechanism most likely occurs to reduce injury to the brain from cytotoxic compounds, the present data substantiate the concept that MRP2 performs a protective role in the BBB.",17437408_13,-1,1,1,9864,1
9879,XO,10,11,44,46,"2. We studied the role of xanthine oxidase (XO), which is implicated in the production of reactive oxygen species, in dexamethasone-induced hypertension (dex-HT).",17439425_2,-1,1,1,9879,1
9891,XO,16,17,89,91,"Thymus weight was used as a marker of glucocorticoid activity, and serum urate to assess XO inhibition.",17439425_5,-1,1,1,9891,1
9904,XO,19,20,142,144,"This, together with our previous findings that allopurinol failed to prevent adrenocorticotrophic hormone induced hypertension, suggests that XO activity is not a major determinant of GC-HT in the rat.",17439425_10,-1,1,1,9904,1
9906,Side effects,0,2,0,12,Side effects of postoperative administration of methylprednisolone and gentamicin into the posterior sub-Tenon's space.,17466854_0,-1,1,1,9906,1
9924,Group B,34,36,166,173,"At the end of the procedure, Group A (n = 20) had 20 mg/0.5 mL of methylprednisolone and 10 mg/0.5 mL of gentamicin injected into the posterior sub-Tenon's space and Group B (n = 20) had the same combination injected into the anterior sub-Tenon's space.",17466854_4,-1,1,1,9924,1
9929,Group B,20,22,107,114,"RESULTS: Sixty percent in Group A developed postoperative emetic symptoms, headache, or both; 1 patient in Group B developed symptoms.",17466854_7,-1,1,1,9929,1
9932,side effects,21,23,139,151,"CONCLUSIONS: The administration of methylprednisolone and gentamicin in the posterior sub-Tenon's space was related to a high incidence of side effects including nausea, vomiting, and headache.",17466854_8,-1,1,1,9932,1
10013,myocardial infarction,1,3,16,37,Cocaine-induced myocardial infarction: clinical observations and pathogenetic considerations.,1749407_0,-1,1,1,10013,1
10037,thrombotic,8,9,40,50,"Finally, the contribution of a primary, thrombotic effect of cocaine has not been excluded.",1749407_9,-1,1,1,10037,1
10039,chronic hepatitis,9,11,54,71,An extremely rare case of delusional parasitosis in a chronic hepatitis C patient during pegylated interferon alpha-2b and ribavirin treatment.,17511042_0,-1,1,1,10039,1
10041,chronic hepatitis,3,5,20,37,"During treatment of chronic hepatitis C patients with interferon and ribavirin, a lot of side effects are described.",17511042_1,-1,1,1,10041,1
10042,side effects,15,17,89,101,"During treatment of chronic hepatitis C patients with interferon and ribavirin, a lot of side effects are described.",17511042_1,-1,1,1,10042,1
10080,chronic kidney disease,21,24,144,166,Cardiac Angiography in Renally Impaired Patients (CARE) study: a randomized double-blind trial of contrast-induced nephropathy in patients with chronic kidney disease.,17562951_0,-1,1,1,10080,1
10090,chronic kidney disease,22,25,137,159,"METHODS AND RESULTS: The present study is a multicenter, randomized, double-blind comparison of iopamidol and iodixanol in patients with chronic kidney disease (estimated glomerular filtration rate, 20 to 59 mL/min) who underwent cardiac angiography or percutaneous coronary interventions.",17562951_2,-1,1,1,10090,1
10108,diabetes mellitus,9,11,46,63,"In 414 patients, contrast volume, presence of diabetes mellitus, use of N-acetylcysteine, mean baseline SCr, and estimated glomerular filtration rate were comparable in the 2 groups.",17562951_6,-1,1,1,10108,1
10127,diabetes mellitus,33,35,222,239,"CONCLUSIONS: The rate of contrast-induced nephropathy, defined by multiple end points, is not statistically different after the intraarterial administration of iopamidol or iodixanol to high-risk patients, with or without diabetes mellitus.",17562951_10,-1,1,1,10127,1
10136,cardiac arrest,24,26,126,140,"Here we report of two adult patients with a long history of epilepsy treated with PB who died suddenly: one as consequence of cardiac arrest, the other of acute bronchopneumonia.",17574447_2,-1,1,1,10136,1
10163,cognitive decline,12,14,81,98,"In the present study, we investigated whether maltolyl p-coumarate could improve cognitive decline in scopolamine-injected rats and in amyloid beta peptide(1-42)-infused rats.",17600377_2,-1,1,1,10163,1
10182,Alzheimer's disease,22,25,142,161,"Taking these in vitro and in vivo results together, our study suggests that maltolyl p-coumarate is a potentially effective candidate against Alzheimer's disease that is characterized by wide spread neuronal death and progressive decline of cognitive function.",17600377_7,-1,1,1,10182,1
10229,acute renal failure,3,6,26,45,"Severe rhabdomyolysis and acute renal failure secondary to concomitant use of simvastatin, amiodarone, and atazanavir.",17615423_0,-1,1,1,10229,1
10234,acute renal failure,21,24,132,151,"OBJECTIVE: To report a case of a severe interaction between simvastatin, amiodarone, and atazanavir resulting in rhabdomyolysis and acute renal failure.",17615423_1,-1,1,1,10234,1
10237,atrial fibrillation,12,14,82,101,"BACKGROUND: A 72-year-old white man with underlying human immunodeficiency virus, atrial fibrillation, coronary artery disease, and hyperlipidemia presented with generalized pain, fatigue, and dark orange urine for 3 days.",17615423_2,-1,1,1,10237,1
10238,coronary artery disease,15,18,103,126,"BACKGROUND: A 72-year-old white man with underlying human immunodeficiency virus, atrial fibrillation, coronary artery disease, and hyperlipidemia presented with generalized pain, fatigue, and dark orange urine for 3 days.",17615423_2,-1,1,1,10238,1
10281,leukoencephalopathy,1,2,8,27,Delayed leukoencephalopathy with stroke-like presentation in chemotherapy recipients.,17682013_0,-1,1,1,10281,1
10283,leukoencephalopathy,4,5,24,43,"BACKGROUND: A transient leukoencephalopathy mimicking cerebrovascular accident has been described as a complication of chemotherapy, most commonly in recipients of intrathecal methotrexate for childhood leukaemia.",17682013_1,-1,1,1,10283,1
10284,cerebrovascular accident,6,8,54,78,"BACKGROUND: A transient leukoencephalopathy mimicking cerebrovascular accident has been described as a complication of chemotherapy, most commonly in recipients of intrathecal methotrexate for childhood leukaemia.",17682013_1,-1,1,1,10284,1
10287,pathophysiology,7,8,54,69,Recently published neuroimaging data suggest a common pathophysiology associated with a variety of chemotherapy agents and modes of administration.,17682013_2,-1,1,1,10287,1
10296,cerebrovascular accidents,2,4,14,39,Patients with cerebrovascular accidents were excluded.,17682013_5,-1,1,1,10296,1
10297,leukoencephalopathy,8,9,43,62,"RESULTS: We identified 27 reports of toxic leukoencephalopathy in patients treated with methotrexate (intrathecal, systemic), 5-fluorouracil and its derivative carmofur, and capecitabine.",17682013_6,-1,1,1,10297,1
10307,cerebral hemispheres,21,23,138,158,"Diffusion weighted imaging (DWI) of all patients revealed well demarcated hyperintense lesions within the subcortical white matter of the cerebral hemispheres and the corpus callosum, corresponding to areas of decreased proton diffusion on apparent diffusion coefficient (ADC) maps (available in 21/27 patients).",17682013_7,-1,1,1,10307,1
10308,corpus callosum,25,27,167,182,"Diffusion weighted imaging (DWI) of all patients revealed well demarcated hyperintense lesions within the subcortical white matter of the cerebral hemispheres and the corpus callosum, corresponding to areas of decreased proton diffusion on apparent diffusion coefficient (ADC) maps (available in 21/27 patients).",17682013_7,-1,1,1,10308,1
10315,leukoencephalopathy,7,8,58,77,CONCLUSIONS: Several pathophysiological models of delayed leukoencephalopathy after exposure to intrathecal or systemic chemotherapy have been proposed.,17682013_11,-1,1,1,10315,1
10323,pulmonary hypertension,6,8,46,68,Prenatal exposure to fluoxetine induces fetal pulmonary hypertension in the rat.,17702969_0,-1,1,1,10323,1
10328,pulmonary hypertension,17,19,108,130,"The mechanism responsible for this effect is unclear and paradoxical, considering the current evidence of a pulmonary hypertension protective fluoxetine effect in adult rodents.",17702969_3,-1,1,1,10328,1
10335,pulmonary hypertension,10,12,65,87,"As compared with controls, fluoxetine exposure resulted in fetal pulmonary hypertension as evidenced by an increase in the weight ratio of the right ventricle to the left ventricle plus septum (P = 0.02) and by an increase in pulmonary arterial medial thickness (P < 0.01).",17702969_7,-1,1,1,10335,1
10337,right ventricle,23,25,143,158,"As compared with controls, fluoxetine exposure resulted in fetal pulmonary hypertension as evidenced by an increase in the weight ratio of the right ventricle to the left ventricle plus septum (P = 0.02) and by an increase in pulmonary arterial medial thickness (P < 0.01).",17702969_7,-1,1,1,10337,1
10338,left ventricle,27,29,166,180,"As compared with controls, fluoxetine exposure resulted in fetal pulmonary hypertension as evidenced by an increase in the weight ratio of the right ventricle to the left ventricle plus septum (P = 0.02) and by an increase in pulmonary arterial medial thickness (P < 0.01).",17702969_7,-1,1,1,10338,1
10346,pulmonary arterial,5,7,29,47,"In vitro, fluoxetine induced pulmonary arterial muscle contraction in fetal, but not adult, animals (P < 0.01) and reduced serotonin-induced contraction at both ages (P < 0.01).",17702969_9,-1,1,1,10346,1
10351,pulmonary hypertension,13,15,76,98,"CONCLUSIONS: In contrast to the adult, fluoxetine exposure in utero induces pulmonary hypertension in the fetal rat as a result of a developmentally regulated increase in pulmonary vascular smooth muscle proliferation.",17702969_11,-1,1,1,10351,1
10355,peripheral neuropathy,4,6,39,60,Disulfiram-induced transient optic and peripheral neuropathy: a case report.,17786501_0,-1,1,1,10355,1
10357,peripheral neuropathy,9,11,35,56,AIM: To report a case of optic and peripheral neuropathy after chronic use of disulfiram for alcohol dependence management.,17786501_1,-1,1,1,10357,1
10359,alcohol dependence,17,19,93,111,AIM: To report a case of optic and peripheral neuropathy after chronic use of disulfiram for alcohol dependence management.,17786501_1,-1,1,1,10359,1
10365,optic nerve,4,6,40,51,Fundoscopy revealed bilaterally swollen optic nerve heads.,17786501_6,-1,1,1,10365,1
10368,alcohol dependence,6,8,34,52,He had been taking disulfiram for alcohol dependence for the preceding 3 years.,17786501_8,-1,1,1,10368,1
10375,B virus,9,11,76,83,Mutations associated with lamivudine-resistance in therapy-na  ve hepatitis B virus (HBV) infected patients with and without HIV co-infection: implications for antiretroviral therapy in HBV and HIV co-infected South African patients.,17854040_0,-1,1,1,10375,1
10377,co-infection,20,21,129,141,Mutations associated with lamivudine-resistance in therapy-na  ve hepatitis B virus (HBV) infected patients with and without HIV co-infection: implications for antiretroviral therapy in HBV and HIV co-infected South African patients.,17854040_0,-1,1,1,10377,1
10383,B virus,9,11,76,83,This was an exploratory study to investigate lamivudine-resistant hepatitis B virus (HBV) strains in selected lamivudine-na  ve HBV carriers with and without human immunodeficiency virus (HIV) co-infection in South African patients.,17854040_1,-1,1,1,10383,1
10386,co-infection,31,32,193,205,This was an exploratory study to investigate lamivudine-resistant hepatitis B virus (HBV) strains in selected lamivudine-na  ve HBV carriers with and without human immunodeficiency virus (HIV) co-infection in South African patients.,17854040_1,-1,1,1,10386,1
10389,co-infection,11,12,72,84,Thirty-five lamivudine-na  ve HBV infected patients with or without HIV co-infection were studied: 15 chronic HBV mono-infected patients and 20 HBV-HIV co-infected patients.,17854040_2,-1,1,1,10389,1
10419,chronic hepatitis,10,12,72,89,HBV lamivudine-resistant strains were detected in 3 of 15 mono-infected chronic hepatitis B patients and 10 of 20 HBV-HIV co-infected patients.,17854040_7,-1,1,1,10419,1
10440,basal ganglia,7,9,59,72,"Repeated cerebral perfusion SPECT scans revealed decreased basal ganglia perfusion while the movement disorder was present, and a return to normal perfusion when the rabbit syndrome resolved.",1786266_3,-1,1,1,10440,1
10441,movement disorder,12,14,93,110,"Repeated cerebral perfusion SPECT scans revealed decreased basal ganglia perfusion while the movement disorder was present, and a return to normal perfusion when the rabbit syndrome resolved.",1786266_3,-1,1,1,10441,1
10447,side effects,8,10,51,63,"Many patients, however, develop negative long-term side effects such as premature atherosclerosis.",17879945_2,-1,1,1,10447,1
10488,adverse drug reactions,16,19,98,120,"With widespread use of antimicrobial agents, however, hepatic injury occurs frequently, and among adverse drug reactions, idiosyncratic reactions are the most serious.",17919553_2,-1,1,1,10488,1
10493,upper respiratory tract infection,11,15,61,94,He had been prescribed telithromycin 400 mg/d PO to treat an upper respiratory tract infection 7 days prior.,17919553_4,-1,1,1,10493,1
10510,adverse drug reaction,9,12,37,58,"Based on a score of 8 on the Naranjo adverse drug reaction probability scale, telithromycin was the probable cause of acute hepatitis in this patient, and pathological findings suggested drug-induced toxic hepatitis.",17919553_11,-1,1,1,10510,1
10541,hypotony,3,4,12,20,The rate of hypotony (IOP </= 5 mm Hg) following IOP-lowering surgery (42.5%) was not different from that of implanted eyes not subjected to surgery (35.4%) (P = .09).,17923537_6,-1,1,1,10541,1
10569,Dilated cardiomyopathy,2,4,12,34,"BACKGROUND: Dilated cardiomyopathy (DCM) and myocarditis occur in many HIV-infected individuals, resulting in symptomatic heart failure in up to 5% of patients.",17943461_1,-1,1,1,10569,1
10572,heart failure,18,20,122,135,"BACKGROUND: Dilated cardiomyopathy (DCM) and myocarditis occur in many HIV-infected individuals, resulting in symptomatic heart failure in up to 5% of patients.",17943461_1,-1,1,1,10572,1
10574,immunodeficiency syndrome,15,17,107,132,"Highly active antiretroviral therapy (HAART) has significantly reduced morbidity and mortality of acquired immunodeficiency syndrome (AIDS), but has resulted in an increase in cardiac and skeletal myopathies.",17943461_2,-1,1,1,10574,1
10607,rheumatoid arthritis,5,7,47,67,"Gastrointestinal tolerability of etoricoxib in rheumatoid arthritis patients: results of the etoricoxib vs diclofenac sodium gastrointestinal tolerability and effectiveness trial (EDGE-II).OBJECTIVE: A randomised, double-blind study to compare the gastrointestinal (GI) tolerability, safety and efficacy of etoricoxib and diclofenac in patients with rheumatoid arthritis (RA).",17965424_0,-1,1,1,10607,1
10616,rheumatoid arthritis,47,49,350,370,"Gastrointestinal tolerability of etoricoxib in rheumatoid arthritis patients: results of the etoricoxib vs diclofenac sodium gastrointestinal tolerability and effectiveness trial (EDGE-II).OBJECTIVE: A randomised, double-blind study to compare the gastrointestinal (GI) tolerability, safety and efficacy of etoricoxib and diclofenac in patients with rheumatoid arthritis (RA).",17965424_0,-1,1,1,10616,1
10645,renovascular,2,3,22,34,"Discontinuations from renovascular AEs, although less common than discontinuations from GI AEs, were significantly higher with etoricoxib.",17965424_11,-1,1,1,10645,1
10674,liver failure,16,18,92,105,CASE REPORT: We describe 2 patients who were regular consumers of alcohol and who developed liver failure within 3-5 days after hospitalization and stopping alcohol consumption while being treated with 4 g paracetamol/day.,18004067_2,-1,1,1,10674,1
10686,liver failure,14,16,80,93,"CONCLUSION: In patients with risk factors, e.g. regular consumption of alcohol, liver failure is possible when therapeutic doses are ingested.",18004067_5,-1,1,1,10686,1
10783,vocal fold palsy,1,4,6,22,Acute vocal fold palsy after acute disulfiram intoxication.,18023325_0,-1,1,1,10783,1
10785,vocal fold palsy,20,23,113,129,Acute peripheral neuropathy caused by a disulfiram overdose is very rare and there is no report of it leading to vocal fold palsy.,18023325_1,-1,1,1,10785,1
10786,quadriparesis,10,11,65,78,"A 49-year-old woman was transferred to our department because of quadriparesis, lancinating pain, sensory loss, and paresthesia of the distal limbs.",18023325_2,-1,1,1,10786,1
10801,vocal fold,3,5,33,43,Laryngoscopy revealed asymmetric vocal fold movements during phonation.,18023325_10,-1,1,1,10801,1
10804,laryngeal nerve,10,12,48,63,This was a case of acute palsy of the recurrent laryngeal nerve and superimposed severe acute sensorimotor axonal polyneuropathy caused by high-dose disulfiram intoxication.,18023325_12,-1,1,1,10804,1
10812,generalized seizures,10,12,68,88,FINDINGS: A 28-year-old man suffering from idiopathic epilepsy with generalized seizures was treated with LEV (3000 mg) added to valproate (VPA) (2000 mg).,18081909_2,-1,1,1,10812,1
10816,generalized tonic-clonic seizures,2,5,13,46,Frequency of generalized tonic-clonic seizures increased from one per 6 months to two per month.,18081909_3,-1,1,1,10816,1
10869,adverse drug events,16,19,124,143,"We included prospective, randomised peri-operative studies of dexmedetomidine that reported mortality, cardiac morbidity or adverse drug events.",18086064_2,-1,1,1,10869,1
10877,myocardial infarction,30,32,148,169,"Dexmedetomidine was associated with a trend towards improved cardiac outcomes; all-cause mortality (OR 0.27, 95% CI 0.01-7.13, p = 0.44), non-fatal myocardial infarction (OR 0.26, 95% CI 0.04-1.60, p = 0.14), and myocardial ischaemia (OR 0.65, 95% CI 0.26-1.63, p = 0.36).",18086064_6,-1,1,1,10877,1
10882,Myocardial infarction,0,2,0,21,Myocardial infarction in pregnancy associated with clomiphene citrate for ovulation induction: a case report.,18161408_0,-1,1,1,10882,1
10887,side effects,7,9,36,48,"It is considered safe, with minimal side effects.",18161408_2,-1,1,1,10887,1
10890,myocardial infarction,20,22,133,154,"Spontaneous coronary thrombosis or thromboembolism with subsequent clot lysis has been suggested as one of the most common causes of myocardial infarction (MI) during pregnancy, with a subsequently normal coronary angiogram.",18161408_4,-1,1,1,10890,1
10893,chest pain,19,21,118,128,CASE: A 33-year-old woman with a 5-week gestation had recently received CC for ovulation induction and presented with chest pain.,18161408_5,-1,1,1,10893,1
10894,anterior wall myocardial infarction,6,10,42,77,An electrocardiogram showed a lateral and anterior wall myocardial infarction.,18161408_6,-1,1,1,10894,1
10898,radiation injury,13,15,58,74,"At the time of admission, the patient was at high risk of radiation injury to the fetus, so a coronary angiogram was postponed until the second trimester.",18161408_8,-1,1,1,10898,1
10903,myocardial infarction,17,19,105,126,CONCLUSION: This appears to be the first reported case documenting a possible association between CC and myocardial infarction.,18161408_10,-1,1,1,10903,1
10914,pulsatile,15,16,123,132,We first tested whether chronic hyperprolactinemia inhibited two neuroendocrine parameters necessary for female fertility: pulsatile LH secretion and the estrogen-induced LH surge.,18162529_3,-1,1,1,10914,1
10940,choroid plexus,22,24,124,138,"Sulpiride induced only SOCS-1 in the medial preoptic area, where GnRH neurons are regulated, but in the arcuate nucleus and choroid plexus, PRL-R, SOCS-3, and CIS mRNA levels were also induced.",18162529_9,-1,1,1,10940,1
10949,steroid-dependent,14,15,90,107,These data show that GnRH pulse frequency is inhibited by chronic hyperprolactinemia in a steroid-dependent manner.,18162529_12,-1,1,1,10949,1
10954,left ventricular,3,5,20,36,Reverse or inverted left ventricular apical ballooning syndrome (reverse Takotsubo cardiomyopathy) in a young woman in the setting of amphetamine use.,18177388_0,-1,1,1,10954,1
10956,left ventricular,1,3,10,26,"Transient left ventricular apical ballooning syndrome was first described in Japan as ""Takotsubo cardiomyopathy."" This syndrome has been identified in many other countries.",18177388_1,-1,1,1,10956,1
10976,Renal Fanconi syndrome,0,3,0,22,Renal Fanconi syndrome and myopathy after liver transplantation: drug-related mitochondrial cytopathy?Advances in the field of transplantation provide a better quality of life and allow more favorable conditions for growth and development in children.,18186898_0,-1,1,1,10976,1
10981,adverse reactions,11,13,91,108,"However, combinations of different therapeutic regimens require consideration of potential adverse reactions.",18186898_1,-1,1,1,10981,1
10983,Wilson's disease,12,15,81,97,We describe a 15-yr-old girl who had orthotopic liver transplantation because of Wilson's disease.,18186898_2,-1,1,1,10983,1
10987,renal Fanconi syndrome,6,9,45,67,"Three yr after transplantation she developed renal Fanconi syndrome with severe metabolic acidosis, hypophosphatemia, glycosuria, and aminoaciduria.",18186898_5,-1,1,1,10987,1
10988,metabolic acidosis,11,13,80,98,"Three yr after transplantation she developed renal Fanconi syndrome with severe metabolic acidosis, hypophosphatemia, glycosuria, and aminoaciduria.",18186898_5,-1,1,1,10988,1
10989,hypophosphatemia,14,15,100,116,"Three yr after transplantation she developed renal Fanconi syndrome with severe metabolic acidosis, hypophosphatemia, glycosuria, and aminoaciduria.",18186898_5,-1,1,1,10989,1
10994,Fanconi syndrome,0,2,0,16,"Fanconi syndrome, as well as myopathy, is well recognized in patients with mitochondrial disorders and caused by depletion of mtDNA.",18186898_8,-1,1,1,10994,1
10995,mitochondrial disorders,14,16,75,98,"Fanconi syndrome, as well as myopathy, is well recognized in patients with mitochondrial disorders and caused by depletion of mtDNA.",18186898_8,-1,1,1,10995,1
11088,non-Hodgkin,10,11,81,92,"Thalidomide has limited single-agent activity in relapsed or refractory indolent non-Hodgkin lymphomas: a phase II trial of the Cancer and Leukemia Group B.Thalidomide is an immunomodulatory agent with demonstrated activity in multiple myeloma, mantle cell lymphoma and lymphoplasmacytic lymphoma.",18217897_0,-1,1,1,11088,1
11093,mantle cell lymphoma,35,38,245,265,"Thalidomide has limited single-agent activity in relapsed or refractory indolent non-Hodgkin lymphomas: a phase II trial of the Cancer and Leukemia Group B.Thalidomide is an immunomodulatory agent with demonstrated activity in multiple myeloma, mantle cell lymphoma and lymphoplasmacytic lymphoma.",18217897_0,-1,1,1,11093,1
11102,Grade 3,0,2,0,7,"Grade 3-4 adverse effects included myelosuppression, fatigue, somnolence/depressed mood, neuropathy and dyspnea.",18217897_6,-1,1,1,11102,1
11124,hyperalgesia,5,6,24,36,"To this end, persistent hyperalgesia was induced by administration of capsaicin in the tail of gonadally intact F344 rats, following which the tail was immersed in a mildly noxious thermal stimulus, and tail-withdrawal latencies measured.",18221780_3,-1,1,1,11124,1
11298,retinal vein occlusion,1,4,8,30,Central retinal vein occlusion associated with clomiphene-induced ovulation.,18343374_0,-1,1,1,11298,1
11301,retinal vein occlusion,8,11,39,61,OBJECTIVE: To report a case of central retinal vein occlusion associated with clomiphene citrate (CC).,18343374_1,-1,1,1,11301,1
11309,retinal vein occlusion,5,8,33,55,MAIN OUTCOME MEASURE(S): Central retinal vein occlusion after ovulation induction with CC.,18343374_6,-1,1,1,11309,1
11310,retinal vein occlusion,8,11,57,79,RESULT(S): A 36-year-old Chinese woman developed central retinal vein occlusion after eight courses of CC.,18343374_7,-1,1,1,11310,1
11316,retinal vein occlusion,10,13,58,80,CONCLUSION(S): This is the first reported case of central retinal vein occlusion after treatment with CC.,18343374_9,-1,1,1,11316,1
11318,side effect,19,21,114,125,"Extra caution is warranted in treating infertility patients with CC, and patients should be well informed of this side effect before commencement of therapy.",18343374_10,-1,1,1,11318,1
11321,chronic obstructive pulmonary disease,9,13,73,110,Acute bronchodilating effects of ipratropium bromide and theophylline in chronic obstructive pulmonary disease.,1835291_0,-1,1,1,11321,1
11327,chronic obstructive pulmonary disease,47,51,288,325,"The bronchodilator effects of a single dose of ipratropium bromide aerosol (36 micrograms) and short-acting theophylline tablets (dose titrated to produce serum levels of 10-20 micrograms/mL) were compared in a double-blind, placebo-controlled crossover study in 21 patients with stable, chronic obstructive pulmonary disease.",1835291_1,-1,1,1,11327,1
11335,side effects,1,3,6,18,"While side effects were rare, those experienced after theophylline use did involve the cardiovascular and gastrointestinal systems.",1835291_5,-1,1,1,11335,1
11338,chronic airflow obstruction,16,19,108,135,These results show that ipratropium is a more potent bronchodilator than oral theophylline in patients with chronic airflow obstruction.,1835291_6,-1,1,1,11338,1
11414,adverse drug reactions,6,9,46,68,BACKGROUND: Spontaneous reporting systems for adverse drug reactions (ADRs) are handicapped by under-reporting and limited detail on individual cases.,18405372_1,-1,1,1,11414,1
11418,adverse drug reactions,10,13,65,87,We report an investigation from a local surveillance for serious adverse drug reactions associated with disease modifying anti-rheumatic drugs that was triggered by the occurrence of liver failure in two of our patients.,18405372_2,-1,1,1,11418,1
11421,liver failure,26,28,183,196,We report an investigation from a local surveillance for serious adverse drug reactions associated with disease modifying anti-rheumatic drugs that was triggered by the occurrence of liver failure in two of our patients.,18405372_2,-1,1,1,11421,1
11434,interstitial nephritis,11,13,59,81,"Seven patients had a skin rash, three eosinophilia and one interstitial nephritis.",18405372_10,-1,1,1,11434,1
11448,neurotoxicity,1,2,24,37,Methamphetamine-induced neurotoxicity and microglial activation are not mediated by fractalkine receptor signaling.,18410508_0,-1,1,1,11448,1
11458,MPTP,8,9,42,46,"Because the CNS damage caused by METH and MPTP is highly selective for the DA neuronal system in mouse models of neurotoxicity, we hypothesized that the CX3CR1 plays a role in METH-induced neurotoxicity and microglial activation.",18410508_4,-1,1,1,11458,1
11461,neurotoxicity,21,22,113,126,"Because the CNS damage caused by METH and MPTP is highly selective for the DA neuronal system in mouse models of neurotoxicity, we hypothesized that the CX3CR1 plays a role in METH-induced neurotoxicity and microglial activation.",18410508_4,-1,1,1,11461,1
11464,neurotoxicity,33,34,189,202,"Because the CNS damage caused by METH and MPTP is highly selective for the DA neuronal system in mouse models of neurotoxicity, we hypothesized that the CX3CR1 plays a role in METH-induced neurotoxicity and microglial activation.",18410508_4,-1,1,1,11464,1
11469,neurotoxicity,30,31,172,185,Mice in which the CX3CR1 gene has been deleted and replaced with a cDNA encoding enhanced green fluorescent protein (eGFP) were treated with METH and examined for striatal neurotoxicity.,18410508_5,-1,1,1,11469,1
11485,neurotoxicity,12,13,76,89,We conclude from these studies that CX3CR1 signaling does not modulate METH neurotoxicity or microglial activation.,18410508_10,-1,1,1,11485,1
11507,pontine,10,11,82,89,"NIN-induced midpontine activation may correspond to activation of the dorsomedial pontine nuclei and the nucleus reticularis tegmenti pontis, structures known to participate in the generation of multidirectional saccades and smooth pursuit eye movements.",18417364_5,-1,1,1,11507,1
11510,multidirectional,27,28,195,211,"NIN-induced midpontine activation may correspond to activation of the dorsomedial pontine nuclei and the nucleus reticularis tegmenti pontis, structures known to participate in the generation of multidirectional saccades and smooth pursuit eye movements.",18417364_5,-1,1,1,11510,1
11511,smooth pursuit,30,32,225,239,"NIN-induced midpontine activation may correspond to activation of the dorsomedial pontine nuclei and the nucleus reticularis tegmenti pontis, structures known to participate in the generation of multidirectional saccades and smooth pursuit eye movements.",18417364_5,-1,1,1,11511,1
11550,Sinus node dysfunction,0,3,0,22,Sinus node dysfunction has been reported most frequently among the adverse cardiovascular effects of lithium.,18441470_1,-1,1,1,11550,1
11571,microvascular,28,29,150,163,"The aim of this study is to examine the role of gastric acid back-diffusion, mast cell histamine release, lipid peroxide (LPO) generation and mucosal microvascular permeability in modulating gastric hemorrhage and ulcer in rats with atherosclerosis induced by coadministration of vitamin D2 and cholesterol.",18442015_2,-1,1,1,11571,1
11586,microvascular,11,12,78,91,"Gastric acid back-diffusion, mucosal LPO generation, histamine concentration, microvascular permeability, luminal hemoglobin content and ulcer areas were determined.",18442015_7,-1,1,1,11586,1
11604,microvascular,19,20,142,155,"Atherosclerosis could produce gastric hemorrhagic ulcer via aggravation of gastric acid back-diffusion, LPO generation, histamine release and microvascular permeability that could be ameliorated by verapamil in rats.",18442015_12,-1,1,1,11604,1
11609,B virus,1,3,10,17,Hepatitis B virus (HBV) is one of the major causes of chronic liver disease worldwide.,18464113_1,-1,1,1,11609,1
11617,reactivation,29,30,175,187,Cancer patients who are chronic carriers of HBV have a higher hepatic complication rate while receiving cytotoxic chemotherapy (CT) and this has mainly been attributed to HBV reactivation.,18464113_2,-1,1,1,11617,1
11618,hematological malignancies,10,12,50,76,"In this study, cancer patients who have solid and hematological malignancies with chronic HBV infection received the antiviral agent lamivudine prior and during CT compared with historical control group who did not receive lamivudine.",18464113_3,-1,1,1,11618,1
11623,reactivation,15,16,90,102,"The objectives were to assess the efficacy of lamivudine in reducing the incidence of HBV reactivation, and diminishing morbidity and mortality during CT.",18464113_4,-1,1,1,11623,1
11631,reactivation,12,13,93,105,Our study suggests that prophylactic lamivudine significantly decreases the incidence of HBV reactivation and overall morbidity in cancer patients during and after immunosuppressive therapy.,18464113_14,-1,1,1,11631,1
11652,urinary bladder,17,19,113,128,A mouse inflammatory cytokine and receptor RT2 profiler array was used to determine regulated transcripts in the urinary bladder of wild type (WT) and VIP(-/-) mice with or without CYP-induced cystitis (150 mg/kg; i.p.; 48 h).,18483878_4,-1,1,1,11652,1
11675,urinary bladder,18,20,95,110,"CYP treatment significantly (p < or = 0.001) increased expression of CXCL1 and IL-1beta in the urinary bladder of WT and VIP(-/-) mice, but expression in VIP(-/-) mice with CYP treatment was significantly (p < or = 0.001) greater (4.2- to 13-fold increase) than that observed in WT urinary bladder (3.6- to 5-fold increase).",18483878_8,-1,1,1,11675,1
11680,urinary bladder,57,59,282,297,"CYP treatment significantly (p < or = 0.001) increased expression of CXCL1 and IL-1beta in the urinary bladder of WT and VIP(-/-) mice, but expression in VIP(-/-) mice with CYP treatment was significantly (p < or = 0.001) greater (4.2- to 13-fold increase) than that observed in WT urinary bladder (3.6- to 5-fold increase).",18483878_8,-1,1,1,11680,1
11730,brachial neuritis,3,5,34,51,Recovery of tacrolimus-associated brachial neuritis after conversion to everolimus in a pediatric renal transplant recipient--case report and review of the literature.,18503483_0,-1,1,1,11730,1
11737,Neurotoxicity,0,1,0,13,Neurotoxicity is a potentially serious toxic effect.,18503483_2,-1,1,1,11737,1
11743,brachial plexus,11,13,72,87,MRI demonstrated hyperintense T2 signals in the cervical cord and right brachial plexus roots indicative of both myelitis and right brachial plexitis.,18503483_5,-1,1,1,11743,1
11755,cardiac output,14,16,91,105,The resulting hypotension can be produced by a decrease in systemic vascular resistance or cardiac output through a decrease in venous return.,18513945_2,-1,1,1,11755,1
11761,compensatory,19,20,124,136,"Parturients with normal volume status, heart valves and pulmonary vasculature most often respond to this hypotension with a compensatory increase in heart rate and stroke volume.",18513945_3,-1,1,1,11761,1
11770,cardiac output,26,28,159,173,"Pulse power analysis (also called ""pulse contour analysis"") of an arterial pressure wave form allows continuous evaluation of systemic vascular resistance and cardiac output in real time, thereby elucidating the causative factors behind changes in blood pressure.",18513945_5,-1,1,1,11770,1
11779,compensatory,16,17,105,117,"Hypotension in response to oxytocin was associated with a decrease in systemic vascular resistance and a compensatory increase in stroke volume, heart rate and cardiac output.",18513945_7,-1,1,1,11779,1
11781,cardiac output,25,27,160,174,"Hypotension in response to oxytocin was associated with a decrease in systemic vascular resistance and a compensatory increase in stroke volume, heart rate and cardiac output.",18513945_7,-1,1,1,11781,1
11795,nephrotic syndrome,28,30,186,204,"We investigated the effects of antithrombin, a plasma inhibitor of coagulation factors, in rats with puromycin aminonucleoside-induced nephrosis, which is an experimental model of human nephrotic syndrome.",18541230_1,-1,1,1,11795,1
11816,nephrotic syndrome,15,17,118,136,These findings suggest that thrombin plays an important role in the pathogenesis of puromycin aminonucleoside-induced nephrotic syndrome.,18541230_8,-1,1,1,11816,1
11818,nephrotic syndrome,10,12,73,91,Treatment with antithrombin may be clinically effective in patients with nephrotic syndrome.,18541230_9,-1,1,1,11818,1
11819,nausea and vomiting,3,6,26,45,"Omitting fentanyl reduces nausea and vomiting, without increasing pain, after sevoflurane for day surgery.",18544179_0,-1,1,1,11819,1
11823,postoperative nausea and vomiting,15,19,107,140,"BACKGROUND AND OBJECTIVE: Despite advantages of induction and maintenance of anaesthesia with sevoflurane, postoperative nausea and vomiting occurs frequently.",18544179_1,-1,1,1,11823,1
11825,postoperative nausea and vomiting,11,15,72,105,METHODS: This double-blind study examined the incidence and severity of postoperative nausea and vomiting and pain in the first 24 h after sevoflurane anaesthesia in 216 adult day surgery patients.,18544179_3,-1,1,1,11825,1
11827,postoperative nausea and vomiting,12,16,70,103,"RESULTS: Omission of fentanyl did not reduce the overall incidence of postoperative nausea and vomiting, but did reduce the incidence of vomiting and/or moderate to severe nausea prior to discharge from 20% and 17% with fentanyl and fentanyl-dexamethasone, respectively, to 5% (P = 0.013).",18544179_5,-1,1,1,11827,1
11829,postoperative nausea and vomiting,11,15,72,105,Dexamethasone had no significant effect on the incidence or severity of postoperative nausea and vomiting.,18544179_7,-1,1,1,11829,1
11831,postoperative nausea and vomiting,16,20,112,145,"Combining the two fentanyl groups revealed further significant benefits from the avoidance of opioids, reducing postoperative nausea and vomiting and nausea prior to discharge from 35% and 33% to 22% and 19% (P = 0.049 and P = 0.035), respectively, while nausea in the first 24 h was decreased from 42% to 27% (P = 0.034).",18544179_8,-1,1,1,11831,1
11835,respiratory depression,13,15,102,124,"Fentanyl did reduce minor intraoperative movement but had no sevoflurane-sparing effect and increased respiratory depression, hypotension and bradycardia.",18544179_10,-1,1,1,11835,1
11836,postoperative nausea and vomiting,5,9,36,69,"CONCLUSION: As fentanyl exacerbated postoperative nausea and vomiting without an improvement in postoperative pain and also had adverse cardiorespiratory effects, it appears to be an unnecessary and possibly detrimental supplement to sevoflurane in day surgery.",18544179_11,-1,1,1,11836,1
11837,postoperative pain,13,15,96,114,"CONCLUSION: As fentanyl exacerbated postoperative nausea and vomiting without an improvement in postoperative pain and also had adverse cardiorespiratory effects, it appears to be an unnecessary and possibly detrimental supplement to sevoflurane in day surgery.",18544179_11,-1,1,1,11837,1
11851,drug withdrawal,18,20,107,122,"However, the incidence and severity of these abnormalities vary from study to study and their course after drug withdrawal has not been systematically assessed.",18560792_3,-1,1,1,11851,1
11853,drug withdrawal,17,19,118,133,OBJECTIVES: To estimate the frequency and severity of valvular heart abnormality and its possible reversibility after drug withdrawal in a case-control study.,18560792_4,-1,1,1,11853,1
11873,heart failure,26,28,142,155,"A restrictive pattern of valvular regurgitation, suggestive of the role of pergolide, was observed in 12/30 (40%) patients including two with heart failure.",18560792_12,-1,1,1,11873,1
11878,heart failure,30,32,192,205,"Pergolide was discontinued in 10 patients with valvular heart disease, resulting in a lower regurgitation grade (p=0.01) at the second transthoracic echocardiography and the two patients with heart failure returned to nearly normal clinical examination.",18560792_13,-1,1,1,11878,1
11916,heart failure,13,15,92,105,Adriamycin-induced autophagic cardiomyocyte death plays a pathogenic role in a rat model of heart failure.,18619688_0,-1,1,1,11916,1
11917,heart failure,5,7,38,51,BACKGROUND: The mechanisms underlying heart failure induced by adriamycin are very complicated and still unclear.,18619688_1,-1,1,1,11917,1
11920,heart failure,16,18,94,107,"The aim of this study was to investigate whether autophagy was involved in the progression of heart failure induced by adriamycin, so that we can develop a novel treatment strategy for heart failure.",18619688_2,-1,1,1,11920,1
11923,heart failure,32,34,185,198,"The aim of this study was to investigate whether autophagy was involved in the progression of heart failure induced by adriamycin, so that we can develop a novel treatment strategy for heart failure.",18619688_2,-1,1,1,11923,1
11927,heart failure,16,18,80,93,"METHODS: 3-methyladenine (3MA), a specific inhibitor on autophagy was used in a heart failure model of rats induced by adriamycin.",18619688_3,-1,1,1,11927,1
11960,heart failure,13,15,90,103,CONCLUSION: Autophagic cardiomyocyte death plays an important role in the pathogenesis of heart failure in rats induced by adriamycin.,18619688_10,-1,1,1,11960,1
11963,heart failure,9,11,59,72,Mitochondrial injury may be involved in the progression of heart failure caused by adriamycin via the autophagy pathway.,18619688_11,-1,1,1,11963,1
11997,inflammatory response,15,17,93,114,These findings suggest that B1R is detrimental in DOX cardiomyopathy in that it mediates the inflammatory response and apoptosis.,18627295_7,-1,1,1,11997,1
12015,focal segmental glomerulosclerosis,3,6,20,54,"Podocyte injury and focal segmental glomerulosclerosis have been related to mToR inhibition in some patients, but the pathways underlying these lesions remain hypothetic.",18631865_4,-1,1,1,12015,1
12020,epileptiform,6,7,57,69,Detailed spectral profile analysis of penicillin-induced epileptiform activity in anesthetized rats.,18657397_0,-1,1,1,12020,1
12024,epileptiform,14,15,92,104,In the present study we aimed to portray a detailed spectral analysis of penicillin-induced epileptiform activity in comparison with basal brain activity in anesthetized Wistar rats.,18657397_2,-1,1,1,12024,1
12037,epileptiform,8,9,57,69,"Basal activity, latent period and the penicillin-induced epileptiform activity periods were then analyzed using both conventional methods and spectral analysis.",18657397_5,-1,1,1,12037,1
12049,epileptiform,20,21,111,123,"Our results show that the most affected frequency bands were delta, theta, beta-2 and gamma-2 bands during the epileptiform activity and there were marked differences in terms of spectral densities between three investigated episodes (basal activity, latent period and epileptiform activity).",18657397_7,-1,1,1,12049,1
12052,epileptiform,43,44,269,281,"Our results show that the most affected frequency bands were delta, theta, beta-2 and gamma-2 bands during the epileptiform activity and there were marked differences in terms of spectral densities between three investigated episodes (basal activity, latent period and epileptiform activity).",18657397_7,-1,1,1,12052,1
12055,side effects,1,3,17,29,Neuropsychiatric side effects after the use of mefloquine.,1867351_0,-1,1,1,12055,1
12056,side effects,4,6,38,50,This study describes neuropsychiatric side effects in patients after treatment with mefloquine.,1867351_1,-1,1,1,12056,1
12059,sleep-wake,16,17,101,111,"Reactions consisted mainly of seizures, acute psychoses, anxiety neurosis, and major disturbances of sleep-wake rhythm.",1867351_2,-1,1,1,12059,1
12060,Side effects,0,2,0,12,Side effects occurred after both therapeutic and prophylactic intake and were graded from moderate to severe.,1867351_3,-1,1,1,12060,1
12063,side effects,6,8,39,51,"In a risk analysis of neuropsychiatric side effects in Germany, it is estimated that one of 8,000 mefloquine users suffers from such reactions.",1867351_4,-1,1,1,12063,1
12143,vasospasm,11,12,83,92,BACKGROUND: Papaverine hydrochloride is a direct-acting vasodilator used to manage vasospasm during various neurosurgical operations.,18726058_1,-1,1,1,12143,1
12150,microvascular,10,11,63,76,METHODS: We conducted a retrospective review of 70 consecutive microvascular decompression operations and studied those patients who received topical papaverine for vasospasm.,18726058_4,-1,1,1,12150,1
12152,vasospasm,22,23,165,174,METHODS: We conducted a retrospective review of 70 consecutive microvascular decompression operations and studied those patients who received topical papaverine for vasospasm.,18726058_4,-1,1,1,12152,1
12155,vasospasm,11,12,69,78,Topical papaverine was used as a direct therapeutic action to manage vasospasm in a total of 11 patients.,18726058_5,-1,1,1,12155,1
12168,sensorineural hearing loss,12,15,69,95,One patient showed no recovery of later waves and a delayed profound sensorineural hearing loss.,18726058_12,-1,1,1,12168,1
12172,vasospasm,8,9,53,62,CONCLUSIONS: Topical papaverine for the treatment of vasospasm was associated with the onset of a transient disturbance in neurophysiological function of the ascending auditory brainstem pathway.,18726058_14,-1,1,1,12172,1
12180,eighth nerve,19,21,129,141,The complete disappearance of BAEP waveforms with a consistent temporal delay suggests a possible adverse effect on the proximal eighth nerve.,18726058_15,-1,1,1,12180,1
12181,cranial nerve,4,6,35,48,Recommendations to avoid potential cranial nerve deficits from papaverine are provided.,18726058_16,-1,1,1,12181,1
12206,drug toxicity,17,19,130,143,"A repeat work-up revealed further elevations in aminotransferase levels, and liver biopsy revealed evidence of moderate-to-severe drug toxicity.",18752389_7,-1,1,1,12206,1
12220,liver failure,12,14,81,94,"To our knowledge, this is the first case report of simvastatin-ezetimibe-induced liver failure that resulted in liver transplantation.",18752389_11,-1,1,1,12220,1
12229,acute renal failure,3,6,24,43,Massive proteinuria and acute renal failure after oral bisphosphonate (alendronate) administration in a patient with focal segmental glomerulosclerosis.,18754075_0,-1,1,1,12229,1
12231,focal segmental glomerulosclerosis,17,20,117,151,Massive proteinuria and acute renal failure after oral bisphosphonate (alendronate) administration in a patient with focal segmental glomerulosclerosis.,18754075_0,-1,1,1,12231,1
12232,nephrotic syndrome,5,7,32,50,A 61-year-old Japanese man with nephrotic syndrome due to focal segmental glomerulosclerosis was initially responding well to steroid therapy.,18754075_1,-1,1,1,12232,1
12233,focal segmental glomerulosclerosis,9,12,58,92,A 61-year-old Japanese man with nephrotic syndrome due to focal segmental glomerulosclerosis was initially responding well to steroid therapy.,18754075_1,-1,1,1,12233,1
12236,acute renal failure,38,41,217,236,"The amount of daily urinary protein decreased from 15.6 to 2.8 g. Within 14 days of the oral bisphosphonate (alendronate sodium) administration, the amount of daily urinary protein increased rapidly up to 12.8 g with acute renal failure.",18754075_2,-1,1,1,12236,1
12243,acute renal failure,16,19,112,131,"This report demonstrates that not only intravenous, but also oral bisphosphonates can aggravate proteinuria and acute renal failure.",18754075_5,-1,1,1,12243,1
12246,nephrotic syndrome,7,9,68,86,Serum- and glucocorticoid-inducible kinase 1 in doxorubicin-induced nephrotic syndrome.,18768591_0,-1,1,1,12246,1
12257,nephrotic syndrome,18,20,106,124,The present study was performed to elucidate the role of SGK1 in the volume retention and fibrosis during nephrotic syndrome.,18768591_3,-1,1,1,12257,1
12266,nephrotic syndrome,27,29,146,164,"Doxorubicin treatment resulted in heavy proteinuria (>100 mg protein/mg crea) in 15/44 of sgk1(+/+) and 15/44 of sgk1(-/-) mice leading to severe nephrotic syndrome with ascites, lipidemia, and hypoalbuminemia in both genotypes.",18768591_5,-1,1,1,12266,1
12269,nephrotic,5,6,39,48,Plasma aldosterone levels increased in nephrotic mice of both genotypes and was followed by increased SGK1 protein expression in sgk1(+/+) mice.,18768591_6,-1,1,1,12269,1
12278,weight gain,40,42,202,213,Urinary sodium excretion reached signficantly lower values in sgk1(+/+) mice (15 +/- 5 mumol/mg crea) than in sgk1(-/-) mice (35 +/- 5 mumol/mg crea) and was associated with a significantly higher body weight gain in sgk1(+/+) compared with sgk1(-/-) mice (+6.6 +/- 0.7 vs. +4.1 +/- 0.8 g).,18768591_7,-1,1,1,12278,1
12284,nephrotic syndrome,4,6,21,39,"During the course of nephrotic syndrome, serum urea concentrations increased significantly faster in sgk1(-/-) mice than in sgk1(+/+) mice leading to uremia and a reduced median survival in sgk1(-/-) mice (29 vs. 40 days in sgk1(+/+) mice).",18768591_8,-1,1,1,12284,1
12294,nephrotic syndrome,21,23,146,164,"In conclusion, gene-targeted mice lacking SGK1 showed blunted volume retention, yet were not protected against renal fibrosis during experimental nephrotic syndrome.",18768591_9,-1,1,1,12294,1
12295,haemolytic anaemia,3,5,28,46,Severe thrombocytopenia and haemolytic anaemia associated with ciprofloxacin: a case report with fatal outcome.,18791946_0,-1,1,1,12295,1
12299,adverse reactions,1,3,15,32,Haematological adverse reactions associated with fatal outcome are rare during treatment with ciprofloxacin.,18791946_1,-1,1,1,12299,1
12302,abdominal pain,7,9,42,56,A 30-year old Caucasian man reported with abdominal pain and jaundice after 3-day administration of oral ciprofloxacin for a suspect of urinary tract infection.,18791946_2,-1,1,1,12302,1
12306,lower limbs,10,12,72,83,The patient progressively developed petechiae and purpura on thorax and lower limbs.,18791946_4,-1,1,1,12306,1
12312,microangiopathies,5,6,23,40,No thrombi or signs of microangiopathies were observed in arterial vessels.,18791946_8,-1,1,1,12312,1
12318,haemolytic anaemia,11,13,96,114,"This case report shows that ciprofloxacin may precipitate life-threatening thrombocytopenia and haemolytic anaemia, even in the early phases of treatment and without apparent previous exposures.",18791946_10,-1,1,1,12318,1
12360,neurotoxicity,6,7,52,65,Alpha-lipoic acid prevents mitochondrial damage and neurotoxicity in experimental chemotherapy neuropathy.,18809400_0,-1,1,1,12360,1
12364,neurotoxicity,11,12,92,105,"The study investigates if alpha-lipoic acid is neuroprotective against chemotherapy induced neurotoxicity, if mitochondrial damage plays a critical role in toxic neurodegenerative cascade, and if neuroprotective effects of alpha-lipoic acid depend on mitochondria protection.",18809400_1,-1,1,1,12364,1
12370,peripheral neuropathy,9,11,50,71,"We used an in vitro model of chemotherapy induced peripheral neuropathy that closely mimic the in vivo condition by exposing primary cultures of dorsal root ganglion (DRG) sensory neurons to paclitaxel and cisplatin, two widely used and highly effective chemotherapeutic drugs.",18809400_2,-1,1,1,12370,1
12391,neurotoxicity,8,9,78,91,"Alpha-lipoic acid exerts neuroprotective effects against chemotherapy induced neurotoxicity in sensory neurons: it rescues the mitochondrial toxicity and induces the expression of frataxin, an essential mitochondrial protein with anti-oxidant and chaperone properties.",18809400_5,-1,1,1,12391,1
12400,neurotoxicity,15,16,103,116,In conclusion mitochondrial toxicity is an early common event both in paclitaxel and cisplatin induced neurotoxicity.,18809400_6,-1,1,1,12400,1
12441,drug-induced,8,9,59,71,CONCLUSIONS: These data demonstrate direct and/or indirect drug-induced toxicity.,18821488_9,-1,1,1,12441,1
12479,dystonia,5,6,24,32,The major effect was on dystonia subscore.,18951540_5,-1,1,1,12479,1
12484,side effects,4,6,19,31,"Following rTMS, no side effects and no adverse effects on motor function and PD symptoms were noted.",18951540_7,-1,1,1,12484,1
12506,Grade 2,21,23,96,103,"At 550 mg/m2/d, three patients experienced nonurologic toxicity; confusion (1), nausea (1), and Grade 2 leukopenia (1).",1899352_7,-1,1,1,12506,1
12536,ventricular tachycardia,3,5,10,33,A case of ventricular tachycardia related to caffeine pretreatment.,18997632_0,-1,1,1,12536,1
12544,ventricular tachycardia,22,24,133,156,We describe a patient with no previous history of cardiac disease or arrhythmia who developed sustained bigeminy and 2 brief runs of ventricular tachycardia after caffeine administration.,18997632_3,-1,1,1,12544,1
12550,B virus,21,23,148,155,The objective of this study was to report our experience concerning the effectiveness of the prophylactic administration of lamivudine in hepatitis B virus surface antigen (HBs Ag) positive patients with rheumatologic disease.,19037603_1,-1,1,1,12550,1
12554,B virus,5,7,32,39,"Liver function tests, hepatitis B virus (HBV) serologic markers, and HBV DNA levels of the patients during follow-up were obtained from hospital file records.",19037603_3,-1,1,1,12554,1
12566,reactivation,22,23,158,170,"Prophylactic administration of lamivudine in patients who required immunosuppressive therapy seems to be safe, well tolerated and effective in preventing HBV reactivation.",19037603_13,-1,1,1,12566,1
12569,myocardial infarction,11,13,71,92,Effect of green tea and vitamin E combination in isoproterenol induced myocardial infarction in rats.,19058010_0,-1,1,1,12569,1
12574,body weight,20,22,108,119,"The present study was aimed to investigate the combined effects of green tea and vitamin E on heart weight, body weight, serum marker enzymes, lipid peroxidation, endogenous antioxidants and membrane bound ATPases in isoproterenol (ISO)-induced myocardial infarction in rats.",19058010_1,-1,1,1,12574,1
12580,myocardial infarction,39,41,245,266,"The present study was aimed to investigate the combined effects of green tea and vitamin E on heart weight, body weight, serum marker enzymes, lipid peroxidation, endogenous antioxidants and membrane bound ATPases in isoproterenol (ISO)-induced myocardial infarction in rats.",19058010_1,-1,1,1,12580,1
12588,body weight,55,57,266,277,"Adult male albino rats, treated with ISO (200 mg/kg, s.c.) for 2 days at an interval of 24 h caused a significant (P<0.05) elevation of heart weight, serum marker enzymes, lipid peroxidation and Ca+2 ATPase level whereas there was a significant (P<0.05) decrease in body weight, endogenous antioxidants, Na+/ K+ ATPase and Mg+2 ATPase levels.",19058010_2,-1,1,1,12588,1
12600,body weight,63,65,313,324,"Administration of green tea (100 mg/kg/day, p.o.) and vitamin E (100 mg/kg/day, p.o.) together for 30 consecutive days and challenged with ISO on the day 29th and 30th, showed a significant (P<0.05) decrease in heart weight, serum marker enzymes, lipid peroxidation, Ca+2 ATPase and a significant increase in the body weight, endogenous antioxidants, Na+/K+ ATPase and Mg+2 ATPase when compared with ISO treated group and green tea or vitamin E alone treated groups.",19058010_3,-1,1,1,12600,1
12611,myocardial infarction,16,18,104,125,These findings indicate the synergistic protective effect of green tea and vitamin E during ISO induced myocardial infarction in rats.,19058010_4,-1,1,1,12611,1
12620,adverse drug reactions,16,19,115,137,"While traditionally regarded as foodstuffs, consumption of fruit juices should be considered when patients develop adverse drug reactions.",19058474_3,-1,1,1,12620,1
12654,microangiopathy,18,19,144,159,Graft-versus-host disease prophylaxis with everolimus and tacrolimus is associated with a high incidence of sinusoidal obstruction syndrome and microangiopathy: results of the EVTAC trial.,19135948_0,-1,1,1,12654,1
12667,myelodysplastic syndrome,21,23,106,130,"We report on a combination of everolimus and tacrolimus in 24 patients (median age, 62 years) with either myelodysplastic syndrome (MDS; n = 17) or acute myeloid leukemia (AML; n = 7) undergoing intensive conditioning followed by HSCT from related (n = 4) or unrelated (n = 20) donors.",19135948_3,-1,1,1,12667,1
12668,acute myeloid leukemia,31,34,148,170,"We report on a combination of everolimus and tacrolimus in 24 patients (median age, 62 years) with either myelodysplastic syndrome (MDS; n = 17) or acute myeloid leukemia (AML; n = 7) undergoing intensive conditioning followed by HSCT from related (n = 4) or unrelated (n = 20) donors.",19135948_3,-1,1,1,12668,1
12675,microangiopathy,1,2,27,42,"Transplantation-associated microangiopathy (TMA) occurred in 7 patients (29%), with 2 cases of acute renal failure.",19135948_6,-1,1,1,12675,1
12677,acute renal failure,18,21,95,114,"Transplantation-associated microangiopathy (TMA) occurred in 7 patients (29%), with 2 cases of acute renal failure.",19135948_6,-1,1,1,12677,1
12691,hearing loss,1,3,10,22,"Temporary hearing loss is a known toxicity of treatment with DFMO, thus a comprehensive approach was developed to analyze serial air conduction audiograms.",19139001_2,-1,1,1,12691,1
12712,hearing loss,20,22,137,149,There was no significant difference in the proportion of subjects in the DFMO plus sulindac group who experienced clinically significant hearing loss compared with the placebo group.,19139001_9,-1,1,1,12712,1
12713,ototoxicity,5,6,35,46,"The estimated attributable risk of ototoxicity from exposure to the drug is 8.4% (95% confidence interval, -2.0% to 18.8%; P = 0.12).",19139001_10,-1,1,1,12713,1
12759,chest pain,14,16,92,102,"Although cessation of sulphasalazine treatment resulted in improvements in fever, red eyes, chest pain, titer of C-reactive protein and volume of the pleural effusions, we initiated steroid therapy, because PR3-ANCA titer rose to 320 EU, eosinophil count increased to 1,100 cells/microl, and the pleural effusion remained.",19203554_5,-1,1,1,12759,1
12789,renal injury,30,32,194,206,"In this study, the hypothesis was tested that there is a sexual dimorphism in HS-induced upregulation of intrarenal angiotensinogen mediated by testosterone that also causes increases in BP and renal injury.",19211690_4,-1,1,1,12789,1
12803,renal injury,9,11,60,72,"Testosterone replacement in castrated DS rats increased BP, renal injury, and upregulation of renal angiotensinogen associated with HS diet.",19211690_10,-1,1,1,12803,1
12808,renal injury,8,10,64,76,Testosterone contributes to the development of hypertension and renal injury in male DS rats on HS diet possibly through upregulation of the intrarenal renin-angiotensin system.,19211690_11,-1,1,1,12808,1
12847,homonymous hemianopsia,11,13,60,82,Complications were observed in two patients: one had a left homonymous hemianopsia after pallidotomy and another one developed left hemiballistic movements 3 days after subthalamotomy which partly improved within 1 month with Valproate 1000 mg/day.,19234905_10,-1,1,1,12847,1
12871,burning pain,2,4,11,23,The strong burning pain decayed exponentially within a few minutes.,19269743_7,-1,1,1,12871,1
12941,intrahepatic,14,15,99,111,"Here, we report two cases of severely immunocompromised HIV-infected patients who developed severe intrahepatic cholestasis, and in one patient lesions mimicking liver abscess formation on radiologic exams, during co-trimoxazole treatment for PCP.",19299179_3,-1,1,1,12941,1
12942,liver abscess,23,25,162,175,"Here, we report two cases of severely immunocompromised HIV-infected patients who developed severe intrahepatic cholestasis, and in one patient lesions mimicking liver abscess formation on radiologic exams, during co-trimoxazole treatment for PCP.",19299179_3,-1,1,1,12942,1
12954,hyperkinesis,26,27,194,206,The apical ballooning syndrome (ABS) is a recently described stress-mediated acute cardiac syndrome characterized by transient wall-motion abnormalities involving the apex and midventricle with hyperkinesis of the basal left ventricular (LV) segments without obstructive epicardial coronary disease.,19300240_1,-1,1,1,12954,1
12955,left ventricular,30,32,220,236,The apical ballooning syndrome (ABS) is a recently described stress-mediated acute cardiac syndrome characterized by transient wall-motion abnormalities involving the apex and midventricle with hyperkinesis of the basal left ventricular (LV) segments without obstructive epicardial coronary disease.,19300240_1,-1,1,1,12955,1
12962,chest pain,7,9,52,62,"A 79-year-old woman presented with typical ischemic chest pain, elevated cardiac enzymes with significant ST-segment abnormalities on her electrocardiogram.",19300240_5,-1,1,1,12962,1
12966,colorectal cancer,8,10,67,84,She underwent recent chemotherapy with fluorouracil for metastatic colorectal cancer.,19300240_6,-1,1,1,12966,1
12968,periapical,9,10,77,87,Echocardiography revealed a wall-motion abnormality involving the apical and periapical segments which appeared akinetic.,19300240_7,-1,1,1,12968,1
12969,akinetic,13,14,112,120,Echocardiography revealed a wall-motion abnormality involving the apical and periapical segments which appeared akinetic.,19300240_7,-1,1,1,12969,1
12984,hyperalgesia,13,14,112,124,Bradykinin receptors antagonists and nitric oxide synthase inhibitors in vincristine and streptozotocin induced hyperalgesia in chemotherapy and diabetic neuropathy rat model.,19300402_0,-1,1,1,12984,1
12985,diabetic neuropathy,17,19,145,164,Bradykinin receptors antagonists and nitric oxide synthase inhibitors in vincristine and streptozotocin induced hyperalgesia in chemotherapy and diabetic neuropathy rat model.,19300402_0,-1,1,1,12985,1
13016,hyperalgesia,23,24,136,148,It was also shown that both products of inducible NO synthase and neuronal NO synthase activation as well as bradykinin are involved in hyperalgesia produced by vincristine.,19300402_5,-1,1,1,13016,1
13027,hyperalgesia,2,3,26,38,"In streptozotocin-induced hyperalgesia, inducible NO synthase participates in pronociceptive activity of bradykinin, whereas in vincristine-induced hyperalgesia bradykinin seemed to activate neuronal NO synthase pathway.",19300402_8,-1,1,1,13027,1
13036,neuropathic pain,21,23,150,166,"Therefore, concomitant administration of small doses of bradykinin receptor antagonists and NO synthase inhibitors can be effective in alleviation of neuropathic pain, even in hospital care.",19300402_9,-1,1,1,13036,1
13038,adverse drug reaction,5,8,28,49,"Confusion, a rather serious adverse drug reaction with valproic acid: a review of the French Pharmacovigilance database.",19308880_0,-1,1,1,13038,1
13041,adverse drug reaction,5,8,30,51,INTRODUCTION: Confusion is an adverse drug reaction frequently observed with valproic acid.,19308880_1,-1,1,1,13041,1
13045,adverse drug reaction,13,16,78,99,We performed this study in order to describe the main characteristics of this adverse drug reaction.,19308880_3,-1,1,1,13045,1
13053,adverse drug reaction,18,21,107,128,"CONCLUSION: This work shows that confusion with valproic acid is a serious, rather frequent but reversible adverse drug reaction.",19308880_9,-1,1,1,13053,1
13055,intracerebral hemorrhage,13,15,100,124,Rapid reversal of anticoagulation reduces hemorrhage volume in a mouse model of warfarin-associated intracerebral hemorrhage.,19319147_0,-1,1,1,13055,1
13056,intracerebral hemorrhage,1,3,20,44,Warfarin-associated intracerebral hemorrhage (W-ICH) is a severe type of stroke.,19319147_1,-1,1,1,13056,1
13061,PCC,19,20,122,125,"Using a mouse model, we tested whether the rapid reversal of anticoagulation using human prothrombin complex concentrate (PCC) can reduce hemorrhagic blood volume.",19319147_3,-1,1,1,13061,1
13068,PCC,10,11,61,64,"First, we showed that an intravenous administration of human PCC rapidly reversed anticoagulation in mice.",19319147_5,-1,1,1,13068,1
13074,PCC,10,11,65,68,"Forty-five minutes later, the animals were randomly treated with PCC (100 U/kg) or saline i.v. (n=12 per group).",19319147_7,-1,1,1,13074,1
13083,PCC,11,12,60,63,"In contrast, such extensive lesions were never found in the PCC group.",19319147_11,-1,1,1,13083,1
13084,PCC,5,6,40,43,We provide experimental data suggesting PCC to be an effective acute treatment for W-ICH in terms of reducing hemorrhagic blood volume.,19319147_12,-1,1,1,13084,1
13108,corpus callosum,32,34,159,174,"RESULTS: Initial MRIs showed abnormal high signal intensities on DWI and FLAIR (or T2-weighted image) at the dentate nucleus (8/8), inferior colliculus (6/8), corpus callosum (2/8), pons (2/8), medulla (1/8), and bilateral cerebral white matter (1/8).",19346865_7,-1,1,1,13108,1
13184,cardiovascular disease,25,27,144,166,"BACKGROUND: Hormone therapy (HT) is widely used for controlling menopausal symptoms and has also been used for the management and prevention of cardiovascular disease, osteoporosis and dementia in older women.",19370593_1,-1,1,1,13184,1
13208,breast cancer,33,35,182,195,"In relatively healthy women, combined continuous HT significantly increased the risk of venous thrombo-embolism or coronary event (after one year's use), stroke (after three years), breast cancer and gallbladder disease.",19370593_10,-1,1,1,13208,1
13213,breast cancer,40,42,240,253,"Long-term oestrogen-only HT significantly increased the risk of venous thrombo-embolism, stroke and gallbladder disease (after one to two years, three years and seven years' use respectively), but did not significantly increase the risk of breast cancer.",19370593_11,-1,1,1,13213,1
13216,colon cancer,19,21,112,124,"The only statistically significant benefits of HT were a decreased incidence of fractures and (for combined HT) colon cancer, with long-term use.",19370593_12,-1,1,1,13216,1
13220,cardiovascular disease,3,5,17,39,"Among women with cardiovascular disease, long-term use of combined continuous HT significantly increased the risk of venous thrombo-embolism.",19370593_14,-1,1,1,13220,1
13232,chronic disease,13,15,72,87,AUTHORS' CONCLUSIONS: HT is not indicated for the routine management of chronic disease.,19370593_18,-1,1,1,13232,1
13256,myocardial infarction,8,10,71,92,Cardioprotective effect of salvianolic acid A on isoproterenol-induced myocardial infarction in rats.,19445921_0,-1,1,1,13256,1
13259,myocardial infarction,16,18,121,142,The present study was designed to evaluate the cardioprotective potential of salvianolic acid A on isoproterenol-induced myocardial infarction in rats.,19445921_1,-1,1,1,13259,1
13296,myocardial infarction,20,22,155,176,The results of our study suggest that salvianolic acid A possessing antioxidant activity has a significant protective effect against isoproterenol-induced myocardial infarction.,19445921_10,-1,1,1,13296,1
13297,neurotoxicity,8,9,73,86,Long-term glutamate supplementation failed to protect against peripheral neurotoxicity of paclitaxel.,19473225_0,-1,1,1,13297,1
13299,peripheral neuropathy,1,3,6,27,"Toxic peripheral neuropathy is still a significant limiting factor for chemotherapy with paclitaxel (PAC), although glutamate and its closely related amino acid glutamine were claimed to ameliorate PAC neurotoxicity.",19473225_1,-1,1,1,13299,1
13303,neurotoxicity,31,32,202,215,"Toxic peripheral neuropathy is still a significant limiting factor for chemotherapy with paclitaxel (PAC), although glutamate and its closely related amino acid glutamine were claimed to ameliorate PAC neurotoxicity.",19473225_1,-1,1,1,13303,1
13306,peripheral neuropathy,14,16,100,121,"This pilot trial aimed to evaluate the role of glutamate supplementation for preventing PAC-induced peripheral neuropathy in a randomized, placebo-controlled, double-blinded clinical and electro-diagnostic study.",19473225_2,-1,1,1,13306,1
13309,ovarian cancer,1,3,12,26,"Forty-three ovarian cancer patients were available for analysis following six cycles of the same PAC-containing regimen: 23 had been supplemented by glutamate all along the treatment period, at a daily dose of three times 500 mg (group G), and 20 had received a placebo (group P).",19473225_3,-1,1,1,13309,1
13316,neurotoxicity,17,18,106,119,"There was no significant difference in the frequency of signs or symptoms between the two groups although neurotoxicity symptoms presented mostly with lower scores of severity in group G. However, this difference reached statistical significance only with regard to reported pain sensation (P = 0.011).",19473225_5,-1,1,1,13316,1
13319,pain sensation,41,43,275,289,"There was no significant difference in the frequency of signs or symptoms between the two groups although neurotoxicity symptoms presented mostly with lower scores of severity in group G. However, this difference reached statistical significance only with regard to reported pain sensation (P = 0.011).",19473225_5,-1,1,1,13319,1
13322,neurotoxicity,19,20,130,143,This pilot study leads to the conclusion that glutamate supplementation at the chosen regimen fails to protect against peripheral neurotoxicity of PAC.,19473225_7,-1,1,1,13322,1
13324,chronic hepatitis,11,13,89,106,Development of ocular myasthenia during pegylated interferon and ribavirin treatment for chronic hepatitis C.A 63-year-old male experienced sudden diplopia after 9 weeks of administration of pegylated interferon (IFN) alpha-2b and ribavirin for chronic hepatitis C (CHC).,19581773_0,-1,1,1,13324,1
13327,chronic hepatitis,34,36,245,262,Development of ocular myasthenia during pegylated interferon and ribavirin treatment for chronic hepatitis C.A 63-year-old male experienced sudden diplopia after 9 weeks of administration of pegylated interferon (IFN) alpha-2b and ribavirin for chronic hepatitis C (CHC).,19581773_0,-1,1,1,13327,1
13347,memory deficits,2,4,13,28,Learning and memory deficits in ecstasy users and their neural correlates during a face-learning task.,19631624_0,-1,1,1,13347,1
13356,hippocampal,19,20,115,126,"In addition, working memory processing in ecstasy users has been shown to be associated with neural alterations in hippocampal and/or cortical regions as measured by functional magnetic resonance imaging (fMRI).",19631624_2,-1,1,1,13356,1
13362,drug use,25,27,182,190,"Using functional imaging and a face-learning task, we investigated neural correlates of encoding and recalling face-name associations in 20 recreational drug users whose predominant drug use was ecstasy and 20 controls.",19631624_3,-1,1,1,13362,1
13369,frontocortical,9,10,67,81,Deficits in learning and memory: parahippocampal hyperactivity and frontocortical hypoactivity in cannabis users.,19631624_5,-1,1,1,13369,1
13386,cingulate,23,24,142,151,"In both ecstasy and cannabis groups brain activation was decreased in the right medial frontal gyrus, left parahippocampal gyrus, left dorsal cingulate gyrus, and left caudate.",19631624_10,-1,1,1,13386,1
13392,Acute renal failure,0,3,0,19,Acute renal failure in patients with AIDS on tenofovir while receiving prolonged vancomycin course for osteomyelitis.,19642243_0,-1,1,1,13392,1
13395,Renal failure,0,2,0,13,Renal failure developed after a prolonged course of vancomycin therapy in 2 patients who were receiving tenofovir disoproxil fumarate as part of an antiretroviral regimen.,19642243_1,-1,1,1,13395,1
13400,Fanconi syndrome,8,10,52,68,Tenofovir has been implicated in the development of Fanconi syndrome and renal insufficiency because of its effects on the proximal renal tubule.,19642243_2,-1,1,1,13400,1
13401,renal insufficiency,11,13,73,92,Tenofovir has been implicated in the development of Fanconi syndrome and renal insufficiency because of its effects on the proximal renal tubule.,19642243_2,-1,1,1,13401,1
13402,renal tubule,20,22,132,144,Tenofovir has been implicated in the development of Fanconi syndrome and renal insufficiency because of its effects on the proximal renal tubule.,19642243_2,-1,1,1,13402,1
13407,renal failure,11,13,64,77,Clinicians should be aware that tenofovir may raise the risk of renal failure during prolonged administration of vancomycin.,19642243_4,-1,1,1,13407,1
13441,dystonia,2,3,26,34,Sulpiride-induced tardive dystonia.,1967484_0,-1,1,1,13441,1
13445,dystonia,9,10,64,72,We studied a 37-year-old man who developed persistent segmental dystonia within 2 months after starting sulpiride therapy.,1967484_3,-1,1,1,13445,1
13447,dystonia,10,11,68,76,We could not find any previous reports of sulpiride-induced tardive dystonia.,1967484_4,-1,1,1,13447,1
13482,side effects,16,18,125,137,The introduction of drugs that could induce hypotension with different pharmacological actions would be advantageous because side effects unique to a specific drug could be minimized by selecting appropriate therapy.,1969772_1,-1,1,1,13482,1
13543,side effects,26,28,175,187,A biodegradable polymer dextran has been utilized as a carrier for synthesis of etodolac-dextran conjugates (ED) to improve its aqueous solubility and reduce gastrointestinal side effects.,19719056_2,-1,1,1,13543,1
13576,ventricular tachycardia,17,19,114,137,"The current data showed that pilocarpine significantly delayed onset of arrhythmias, decreased the time course of ventricular tachycardia and fibrillation, reduced arrhythmia score, and increased the survival time of arrhythmic rats and guinea pigs.",19721134_3,-1,1,1,13576,1
13593,side effects,4,6,37,49,Comparative cognitive and subjective side effects of immediate-release oxycodone in healthy middle-aged and older adults.,19729346_0,-1,1,1,13593,1
13617,chronic pain,13,15,77,89,"This study suggests that for healthy older adults who are not suffering from chronic pain, neurocognitive and pharmacodynamic changes in response to a 10-mg dose of immediate-release oxycodone are similar to those observed for middle-aged adults.",19729346_6,-1,1,1,13617,1
13623,side effects,14,16,95,107,"PERSPECTIVE: Study findings indicate that the metabolism, neurocognitive effects, and physical side effects of oral oxycodone are similar for healthy middle-aged and older adults.",19729346_7,-1,1,1,13623,1
13629,side effects,24,26,141,153,"Therefore, clinicians should not avoid prescribing oral opioids to older adults based on the belief that older adults are at higher risk for side effects than younger adults.",19729346_8,-1,1,1,13629,1
13670,side-effect,32,33,214,225,"Together these findings show that the GlyT1 inhibitor, SSR103800, produces antipsychotic-like effects, which differ from those observed with compounds primarily targeting the dopaminergic system, and has a reduced side-effect potential as compared with these latter drugs.",19759529_10,-1,1,1,13670,1
13676,orofacial dyskinesia,18,20,104,124,Effect of methanolic extract of Hibiscus rosa sinensis (100-300 mg/kg) was studied on reserpine-induced orofacial dyskinesia and neurochemical alterations.,19761039_1,-1,1,1,13676,1
13698,orofacial dyskinesia,17,19,119,139,The results of the present study suggested that Hibiscus rosa sinensis had a protective role against reserpine-induced orofacial dyskinesia and oxidative stress.,19761039_7,-1,1,1,13698,1
13702,status epilepticus,9,11,76,94,Pyrrolidine dithiocarbamate protects the piriform cortex in the pilocarpine status epilepticus model.,19767176_0,-1,1,1,13702,1
13715,status epilepticus,8,10,51,69,Treatment with 150 mg/kg PDTC before and following status epilepticus significantly increased the mortality rate to 100%.,19767176_4,-1,1,1,13715,1
13719,status epilepticus,18,20,95,113,Administration of 50 mg/kg PDTC (low-dose) did not exert major effects on the development of a status epilepticus or the mortality rate.,19767176_5,-1,1,1,13719,1
13722,status epilepticus,4,6,25,43,"In vehicle-treated rats, status epilepticus caused pronounced neuronal damage in the piriform cortex comprising both pyramidal cells and interneurons.",19767176_6,-1,1,1,13722,1
13731,hippocampal,8,9,50,61,A significant decrease in neuronal density of the hippocampal hilar formation was identified in vehicle- and PDTC-treated rats following status epilepticus.,19767176_8,-1,1,1,13731,1
13735,status epilepticus,19,21,137,155,A significant decrease in neuronal density of the hippocampal hilar formation was identified in vehicle- and PDTC-treated rats following status epilepticus.,19767176_8,-1,1,1,13735,1
13743,hippocampal,32,33,207,218,These data might indicate that the generation of reactive oxygen species and activation of NF-kappaB plays a more central role in seizure-associated neuronal damage in the temporal cortex as compared to the hippocampal hilus.,19767176_10,-1,1,1,13743,1
13747,masseter spasm,4,6,26,40,Anaesthetists' nightmare: masseter spasm after induction in an undiagnosed case of myotonia congenita.,19803309_0,-1,1,1,13747,1
13748,myotonia congenita,13,15,83,101,Anaesthetists' nightmare: masseter spasm after induction in an undiagnosed case of myotonia congenita.,19803309_0,-1,1,1,13748,1
13749,myotonia congenita,6,8,33,51,"We report an undiagnosed case of myotonia congenita in a 24-year-old previously healthy primigravida, who developed life threatening masseter spasm following a standard dose of intravenous suxamethonium for induction of anaesthesia.",19803309_1,-1,1,1,13749,1
13751,masseter spasm,19,21,133,147,"We report an undiagnosed case of myotonia congenita in a 24-year-old previously healthy primigravida, who developed life threatening masseter spasm following a standard dose of intravenous suxamethonium for induction of anaesthesia.",19803309_1,-1,1,1,13751,1
13758,virus infection,19,21,115,130,We report twin neonates who were born prematurely at 32 weeks of gestation to a mother with human immunodeficiency virus infection.,19820426_1,-1,1,1,13758,1
13759,heart block,6,8,36,47,"One of the twins developed complete heart block and dilated cardiomyopathy related to lopinavir/ritonavir therapy, a boosted protease-inhibitor agent, while the other twin developed mild bradycardia.",19820426_2,-1,1,1,13759,1
13760,dilated cardiomyopathy,9,11,52,74,"One of the twins developed complete heart block and dilated cardiomyopathy related to lopinavir/ritonavir therapy, a boosted protease-inhibitor agent, while the other twin developed mild bradycardia.",19820426_2,-1,1,1,13760,1
13802,birth defects,8,10,58,71,Antibacterial medication use during pregnancy and risk of birth defects: National Birth Defects Prevention Study.,19884587_0,-1,1,1,13802,1
13803,Birth Defects,12,14,82,95,Antibacterial medication use during pregnancy and risk of birth defects: National Birth Defects Prevention Study.,19884587_0,-1,1,1,13803,1
13805,birth defects,11,13,86,99,OBJECTIVE: To estimate the association between antibacterial medications and selected birth defects.,19884587_1,-1,1,1,13805,1
13809,birth defects,27,29,157,170,"DESIGN, SETTING, AND PARTICIPANTS: Population-based, multisite, case-control study of women who had pregnancies affected by 1 of more than 30 eligible major birth defects identified via birth defect surveillance programs in 10 states (n = 13 155) and control women randomly selected from the same geographical regions (n = 4941).",19884587_2,-1,1,1,13809,1
13810,birth defect,31,33,186,198,"DESIGN, SETTING, AND PARTICIPANTS: Population-based, multisite, case-control study of women who had pregnancies affected by 1 of more than 30 eligible major birth defects identified via birth defect surveillance programs in 10 states (n = 13 155) and control women randomly selected from the same geographical regions (n = 4941).",19884587_2,-1,1,1,13810,1
13816,birth defects,17,19,105,118,MAIN OUTCOME MEASURE: Odds ratios (ORs) measuring the association between antibacterial use and selected birth defects adjusted for potential confounders.,19884587_4,-1,1,1,13816,1
13823,coarctation of the aorta,45,49,174,198,"Sulfonamides were associated with anencephaly (adjusted OR [AOR] = 3.4; 95% confidence interval [CI], 1.3-8.8), hypoplastic left heart syndrome (AOR = 3.2; 95% CI, 1.3-7.6), coarctation of the aorta (AOR = 2.7; 95% CI, 1.3-5.6), choanal atresia (AOR = 8.0; 95% CI, 2.7-23.5), transverse limb deficiency (AOR = 2.5; 95% CI, 1.0-5.9), and diaphragmatic hernia (AOR = 2.4; 95% CI, 1.1-5.4).",19884587_6,-1,1,1,13823,1
13825,choanal atresia,63,65,229,244,"Sulfonamides were associated with anencephaly (adjusted OR [AOR] = 3.4; 95% confidence interval [CI], 1.3-8.8), hypoplastic left heart syndrome (AOR = 3.2; 95% CI, 1.3-7.6), coarctation of the aorta (AOR = 2.7; 95% CI, 1.3-5.6), choanal atresia (AOR = 8.0; 95% CI, 2.7-23.5), transverse limb deficiency (AOR = 2.5; 95% CI, 1.0-5.9), and diaphragmatic hernia (AOR = 2.4; 95% CI, 1.1-5.4).",19884587_6,-1,1,1,13825,1
13829,diaphragmatic hernia,97,99,337,357,"Sulfonamides were associated with anencephaly (adjusted OR [AOR] = 3.4; 95% confidence interval [CI], 1.3-8.8), hypoplastic left heart syndrome (AOR = 3.2; 95% CI, 1.3-7.6), coarctation of the aorta (AOR = 2.7; 95% CI, 1.3-5.6), choanal atresia (AOR = 8.0; 95% CI, 2.7-23.5), transverse limb deficiency (AOR = 2.5; 95% CI, 1.0-5.9), and diaphragmatic hernia (AOR = 2.4; 95% CI, 1.1-5.4).",19884587_6,-1,1,1,13829,1
13837,atrial septal defects,39,42,161,182,"Nitrofurantoins were associated with anophthalmia or microphthalmos (AOR = 3.7; 95% CI, 1.1-12.2), hypoplastic left heart syndrome (AOR = 4.2; 95% CI, 1.9-9.1), atrial septal defects (AOR = 1.9; 95% CI, 1.1-3.4), and cleft lip with cleft palate (AOR = 2.1; 95% CI, 1.2-3.9).",19884587_7,-1,1,1,13837,1
13839,cleft palate,60,62,232,244,"Nitrofurantoins were associated with anophthalmia or microphthalmos (AOR = 3.7; 95% CI, 1.1-12.2), hypoplastic left heart syndrome (AOR = 4.2; 95% CI, 1.9-9.1), atrial septal defects (AOR = 1.9; 95% CI, 1.1-3.4), and cleft lip with cleft palate (AOR = 2.1; 95% CI, 1.2-3.9).",19884587_7,-1,1,1,13839,1
13848,birth defects,23,25,147,160,"CONCLUSIONS: Reassuringly, penicillins, erythromycins, and cephalosporins, although used commonly by pregnant women, were not associated with many birth defects.",19884587_9,-1,1,1,13848,1
13850,birth defects,7,9,62,75,"Sulfonamides and nitrofurantoins were associated with several birth defects, indicating a need for additional scrutiny.",19884587_10,-1,1,1,13850,1
13855,B virus,16,18,116,123,Differential impact of immune escape mutations G145R and P120T on the replication of lamivudine-resistant hepatitis B virus e antigen-positive and -negative strains.,19889778_0,-1,1,1,13855,1
13858,B virus,6,8,40,47,"Immune escape variants of the hepatitis B virus (HBV) represent an emerging clinical challenge, because they can be associated with vaccine escape, HBV reactivation, and failure of diagnostic tests.",19889778_1,-1,1,1,13858,1
13863,reactivation,27,28,152,164,"Immune escape variants of the hepatitis B virus (HBV) represent an emerging clinical challenge, because they can be associated with vaccine escape, HBV reactivation, and failure of diagnostic tests.",19889778_1,-1,1,1,13863,1
13872,treatment-associated,33,34,214,234,"We therefore systematically analyzed the functional impact of the most prevalent immune escape variants, the sG145R and sP120T mutants, on the viral replication efficacy and antiviral drug susceptibility of common treatment-associated mutants with resistance to lamivudine (LAM) and/or HBeAg negativity.",19889778_3,-1,1,1,13872,1
13909,blood vessel,3,5,20,32,Dynamic response of blood vessel in acute renal failure.,19893084_0,-1,1,1,13909,1
13910,acute renal failure,6,9,36,55,Dynamic response of blood vessel in acute renal failure.,19893084_0,-1,1,1,13910,1
13911,acute renal failure,7,10,40,59,"In this study we postulated that during acute renal failure induced by gentamicin the transient or dynamic response of blood vessels could be affected, and that antioxidants can prevent the changes in dynamic responses of blood vessels.",19893084_1,-1,1,1,13911,1
13917,blood vessel,6,8,28,40,"The new approach to ex vivo blood vessel experiments in which not only the end points of vessels response within the time interval is considered, but also dynamics of this response, was used in this paper.",19893084_2,-1,1,1,13917,1
13972,cognitive dysfunction,18,20,115,136,BACKGROUND: Hypotension and a resultant decrease in cerebral blood flow have been implicated in the development of cognitive dysfunction.,19923525_1,-1,1,1,13972,1
14036,Hemolytic anemia,0,2,0,16,Hemolytic anemia associated with the use of omeprazole.,1992636_0,-1,1,1,14036,1
14043,adverse reaction,9,11,49,65,We report the first case of a serious short-term adverse reaction with the use of omeprazole: hemolytic anemia.,1992636_4,-1,1,1,14043,1
14044,hemolytic anemia,17,19,94,110,We report the first case of a serious short-term adverse reaction with the use of omeprazole: hemolytic anemia.,1992636_4,-1,1,1,14044,1
14045,shortness of breath,8,11,46,65,"The patient developed weakness, lethargy, and shortness of breath 2 days after starting therapy with omeprazole.",1992636_5,-1,1,1,14045,1
14050,hemolytic anemia,9,11,55,71,"The mechanism by which omeprazole caused the patient's hemolytic anemia is uncertain, but physicians should be alerted to this possible adverse effect.",1992636_8,-1,1,1,14050,1
14059,central nervous system,11,14,78,100,Metabotropic glutamate (mGlu) receptors modulate synaptic transmission in the central nervous system and represent promising therapeutic targets for symptomatic treatment of Parkinson's disease (PD).,19940105_1,-1,1,1,14059,1
14064,basal ganglia,14,16,87,100,"Among the eight mGlu receptor subtypes, mGlu7 receptor is prominently expressed in the basal ganglia, but its role in restoring motor function in animal models of PD is not known.",19940105_2,-1,1,1,14064,1
14098,renal cell carcinoma,5,8,32,52,A 65-year-old man with advanced renal cell carcinoma was admitted due to continuing chest pain at rest.,19944333_1,-1,1,1,14098,1
14099,chest pain,13,15,84,94,A 65-year-old man with advanced renal cell carcinoma was admitted due to continuing chest pain at rest.,19944333_1,-1,1,1,14099,1
14101,myocardial infarction,5,7,39,60,He was diagnosed with non-ST-elevation myocardial infarction by laboratory data and electrocardiogram.,19944333_3,-1,1,1,14101,1
14163,frontal lobe,5,7,40,52,Phenylephrine but not ephedrine reduces frontal lobe oxygenation following anesthesia-induced hypotension.,19957053_0,-1,1,1,14163,1
14167,frontal lobe,9,11,57,69,We describe the effect of phenylephrine and ephedrine on frontal lobe oxygenation (S(c)O(2)) following anesthesia-induced hypotension.,19957053_2,-1,1,1,14167,1
14173,cardiac output,14,16,42,56,"Heart rate (HR), MAP, stroke volume (SV), cardiac output (CO), and frontal lobe oxygenation (S(c)O(2)) were registered.",19957053_4,-1,1,1,14173,1
14174,frontal lobe,21,23,67,79,"Heart rate (HR), MAP, stroke volume (SV), cardiac output (CO), and frontal lobe oxygenation (S(c)O(2)) were registered.",19957053_4,-1,1,1,14174,1
14193,frontal lobe,22,24,151,163,CONCLUSIONS: The utilization of phenylephrine to correct hypotension induced by anesthesia has a negative impact on S(c)O(2) while ephedrine maintains frontal lobe oxygenation potentially related to an increase in CO.,19957053_9,-1,1,1,14193,1
14198,convulsive seizures,17,19,100,119,"BACKGROUND: In 2 separate centers, we observed a notable increase in the incidence of postoperative convulsive seizures from 1.3% to 3.8% in patients having undergone major cardiac surgical procedures.",19996135_1,-1,1,1,14198,1
14239,intraoperative,40,41,219,233,"The patient required massive transfusion support (55 units of red blood cells, 42 units of fresh-frozen plasma, 40 units of cryoprecipitate, 40 units of platelets, and three doses of recombinant Factor VIIa) for severe intraoperative and postoperative bleeding.",20003049_3,-1,1,1,14239,1
14252,clinical course,14,16,107,122,CONCLUSIONS: Correlation of plasma argatroban concentration versus the patient's coagulation variables and clinical course suggest that prolonged elevated levels of plasma argatroban may have contributed to the patient's extended coagulopathy.,20003049_6,-1,1,1,14252,1
14269,ventricular tachycardia,20,22,122,145,"Although most patients were receiving several drugs, Mellaril (thioridazine) appeared to be responsible for five cases of ventricular tachycardia, one of which was fatal in a 35 year old woman.",2004_2,-1,1,1,14269,1
14270,Supraventricular tachycardia,0,2,0,28,Supraventricular tachycardia developed in one patient receiving Thorazine (chlorpromazine).,2004_3,-1,1,1,14270,1
14272,left bundle branch block,11,15,65,89,Aventyl (nortriptyline) and Elavil (amitriptyline) each produced left bundle branch block in a 73 year old woman.,2004_4,-1,1,1,14272,1
14282,tachyarrhythmias,1,2,4,20,The tachyarrhythmias generally subsided within 48 hours after administration of the drugs was stopped.,2004_7,-1,1,1,14282,1
14283,heart disease,18,20,92,105,Five of the eight patients were 50 years of age or younger; only one clearly had antecedent heart disease.,2004_8,-1,1,1,14283,1
14285,heart disease,10,12,69,82,Major cardiac arrhythmias are a potential hazard in patients without heart disease who are receiving customary therapeutic doses of psychotropic drugs.,2004_9,-1,1,1,14285,1
14303,bone marrow,9,11,47,58,"Despite the anaemia, the number of splenic and bone marrow BFU-e in AZT treated mice increased up to five-fold over levels observed in infected untreated animals after 15 d of treatment.",2004015_5,-1,1,1,14303,1
14305,bone marrow,5,7,32,43,"Colony formation by splenic and bone marrow BFUe was stimulated at lower concentrations of EPO in mice receiving AZT for 15 d than for infected, untreated mice.",2004015_6,-1,1,1,14305,1
14309,bone marrow,9,11,43,54,"By day 30, sensitivity of both splenic and bone marrow BFU-e of treated animals returned to that observed from cells of infected untreated animals.",2004015_7,-1,1,1,14309,1
14325,intraoperative,6,7,41,55,OBJECTIVE: To determine whether limiting intraoperative sedation depth during spinal anesthesia for hip fracture repair in elderly patients can decrease the prevalence of postoperative delirium.,20042557_1,-1,1,1,14325,1
14362,side-effect,38,39,205,216,"OBJECTIVE: To determine the safety and efficacy of adjunctive bupropion sustained-release (SR) on male sexual dysfunction (SD) induced by a selective serotonin reuptake inhibitor (SSRI), as SD is a common side-effect of SSRIs and the most effective treatments have yet to be determined.",20067456_1,-1,1,1,14362,1
14392,hippocampal,6,7,45,56,Prevention of seizures and reorganization of hippocampal functions by transplantation of bone marrow cells in the acute phase of experimental epilepsy.,20080419_0,-1,1,1,14392,1
14400,status epilepticus,19,21,126,144,BMCs obtained from green fluorescent protein (GFP) transgenic mice or rats were transplanted intravenously after induction of status epilepticus (SE).,20080419_2,-1,1,1,14400,1
14410,hippocampal,3,4,15,26,The density of hippocampal neurons in the brains of animals treated with BMCs was markedly preserved.,20080419_6,-1,1,1,14410,1
14412,hippocampal,1,2,3,14,"At hippocampal Schaeffer collateral-CA1 synapses, long-term potentiation was preserved in BMC-transplanted rats compared to epileptic controls.",20080419_7,-1,1,1,14412,1
14419,hippocampal,24,25,146,157,"In conclusion, treatment with BMCs can prevent the development of chronic seizures, reduce neuronal loss, and influence the reorganization of the hippocampal neuronal network.",20080419_9,-1,1,1,14419,1
14423,daytime sleepiness,19,21,112,130,OBJECTIVE: The purpose of the present study was to determine the effect of morning-dosed modafinil on sleep and daytime sleepiness in chronic cocaine users.,20080983_1,-1,1,1,14423,1
14442,REM sleep,19,21,120,129,The effect of modafinil interacted with the abstinence week and was associated with longer total sleep time and shorter REM sleep latency in the third week of abstinence.,20080983_8,-1,1,1,14442,1
14454,daytime sleepiness,25,27,159,177,"Modafinil was associated with increased daytime sleep latency, as measured by the Multiple Sleep Latency Test, and a nearly significant decrease in subjective daytime sleepiness.",20080983_10,-1,1,1,14454,1
14458,daytime sleepiness,14,16,108,126,"CONCLUSIONS: Morning-dosed modafinil promotes nocturnal sleep, normalizes sleep architecture, and decreases daytime sleepiness in abstinent cocaine users.",20080983_11,-1,1,1,14458,1
14460,cocaine dependence,9,11,50,68,These effects may be relevant in the treatment of cocaine dependence.,20080983_12,-1,1,1,14460,1
14485,airway obstruction,28,30,121,139,Mild hypoxia (SO2<90%) was the most common event (11 patients); 3 patients (2%) presented transient hypoxia due to upper airway obstruction by probe introduction and 8 (5.8%) due to hypoxia caused by MZ use.,20084309_9,-1,1,1,14485,1
14503,chest pain,20,22,142,152,The effects of intracoronary administration of methylergonovine were studied in 21 patients with variant angina and 22 patients with atypical chest pain and in others without angina pectoris (control group).,2008831_1,-1,1,1,14503,1
14504,angina pectoris,26,28,175,190,The effects of intracoronary administration of methylergonovine were studied in 21 patients with variant angina and 22 patients with atypical chest pain and in others without angina pectoris (control group).,2008831_1,-1,1,1,14504,1
14512,ST,6,7,38,40,In the control group neither ischemic ST change nor localized spasm occurred.,2008831_4,-1,1,1,14512,1
14562,diabetic nephropathy,7,9,54,74,The protective role of Nrf2 in streptozotocin-induced diabetic nephropathy.,20103708_0,-1,1,1,14562,1
14563,Diabetic nephropathy,2,4,11,31,"OBJECTIVE: Diabetic nephropathy is one of the major causes of renal failure, which is accompanied by the production of reactive oxygen species (ROS).",20103708_1,-1,1,1,14563,1
14564,renal failure,11,13,62,75,"OBJECTIVE: Diabetic nephropathy is one of the major causes of renal failure, which is accompanied by the production of reactive oxygen species (ROS).",20103708_1,-1,1,1,14564,1
14569,diabetic nephropathy,13,15,77,97,"Here, we report our findings demonstrating a protective role of Nrf2 against diabetic nephropathy.",20103708_3,-1,1,1,14569,1
14573,diabetic nephropathy,13,15,76,96,"RESEARCH DESIGN AND METHODS: We explore the protective role of Nrf2 against diabetic nephropathy using human kidney biopsy tissues from diabetic nephropathy patients, a streptozotocin-induced diabetic nephropathy model in Nrf2(-/-) mice, and cultured human mesangial cells.",20103708_4,-1,1,1,14573,1
14575,diabetic nephropathy,21,23,136,156,"RESEARCH DESIGN AND METHODS: We explore the protective role of Nrf2 against diabetic nephropathy using human kidney biopsy tissues from diabetic nephropathy patients, a streptozotocin-induced diabetic nephropathy model in Nrf2(-/-) mice, and cultured human mesangial cells.",20103708_4,-1,1,1,14575,1
14576,diabetic nephropathy,27,29,192,212,"RESEARCH DESIGN AND METHODS: We explore the protective role of Nrf2 against diabetic nephropathy using human kidney biopsy tissues from diabetic nephropathy patients, a streptozotocin-induced diabetic nephropathy model in Nrf2(-/-) mice, and cultured human mesangial cells.",20103708_4,-1,1,1,14576,1
14580,diabetic nephropathy,6,8,32,52,RESULTS: The glomeruli of human diabetic nephropathy patients were under oxidative stress and had elevated Nrf2 levels.,20103708_5,-1,1,1,14580,1
14588,renal injury,19,21,115,127,This is evident by Nrf2(-/-) mice having higher ROS production and suffering from greater oxidative DNA damage and renal injury compared with Nrf2(+/+) mice.,20103708_7,-1,1,1,14588,1
14594,diabetic nephropathy,16,18,106,126,"Mechanistic studies in both in vivo and in vitro systems showed that the Nrf2-mediated protection against diabetic nephropathy is, at least, partially through inhibition of transforming growth factor-beta1 (TGF-beta1) and reduction of extracellular matrix production.",20103708_8,-1,1,1,14594,1
14611,diabetic nephropathy,12,14,70,90,"CONCLUSIONS: This work clearly indicates a protective role of Nrf2 in diabetic nephropathy, suggesting that dietary or therapeutic activation of Nrf2 could be used as a strategy to prevent or slow down the progression of diabetic nephropathy.",20103708_11,-1,1,1,14611,1
14614,diabetic nephropathy,37,39,221,241,"CONCLUSIONS: This work clearly indicates a protective role of Nrf2 in diabetic nephropathy, suggesting that dietary or therapeutic activation of Nrf2 could be used as a strategy to prevent or slow down the progression of diabetic nephropathy.",20103708_11,-1,1,1,14614,1
14626,acute renal failure,5,8,54,73,Metformin treatment fully blocked gentamicin-mediated acute renal failure.,20164825_4,-1,1,1,14626,1
14660,group B,21,23,99,106,"The 80 patients in the study consecutively received either iopromide (group A, n = 40) or iohexol (group B, n = 40).",20195852_3,-1,1,1,14660,1
14664,renal failure,2,4,8,21,"Risk of renal failure, Injury to the kidney, Failure of kidney function, Loss of kidney function, and End-stage renal damage (RIFLE criteria) were used to define CIN and its incidence in the study population.",20195852_6,-1,1,1,14664,1
14673,renal injury,27,29,114,126,"Accordingly, among the 15 CIN patients (18.75%), 7.5% of the patients in group A had increased risk and 3.75% had renal injury, whereas 5% of group B had increased risk and 2.5% had renal injury.",20195852_7,-1,1,1,14673,1
14674,group B,34,36,142,149,"Accordingly, among the 15 CIN patients (18.75%), 7.5% of the patients in group A had increased risk and 3.75% had renal injury, whereas 5% of group B had increased risk and 2.5% had renal injury.",20195852_7,-1,1,1,14674,1
14675,renal injury,43,45,182,194,"Accordingly, among the 15 CIN patients (18.75%), 7.5% of the patients in group A had increased risk and 3.75% had renal injury, whereas 5% of group B had increased risk and 2.5% had renal injury.",20195852_7,-1,1,1,14675,1
14689,drug-induced,12,13,89,101,Antituberculosis therapy (ATT)-associated acute liver failure (ATT-ALF) is the commonest drug-induced ALF in South Asia.,20196116_1,-1,1,1,14689,1
14694,clinical course,8,10,57,72,"The current study prospectively evaluated the magnitude, clinical course, outcome, and prognostic factors in ATT-ALF.",20196116_3,-1,1,1,14694,1
14700,virus infection,11,13,53,68,Another 15 (1.2%) had ATT and simultaneous hepatitis virus infection.,20196116_5,-1,1,1,14700,1
14707,cerebral edema,6,8,45,59,"At presentation, advanced encephalopathy and cerebral edema were present in 51 (76%) and 29 (41.4%) patients, respectively.",20196116_10,-1,1,1,14707,1
14709,acute renal failure,8,11,49,68,"Gastrointestinal bleed, seizures, infection, and acute renal failure were documented in seven (10%), five (7.1%), 26 (37.1%), and seven (10%) patients, respectively.",20196116_11,-1,1,1,14709,1
14737,PAH,21,22,121,124,"Glomerular filtration rate (GFR) and effective renal plasma flow (ERPF) were measured by inulin and para-aminohippurate (PAH) clearance, respectively.",2021202_2,-1,1,1,14737,1
14749,compensatory,4,5,23,35,We conclude that renal compensatory mechanisms are preserved during isoflurane-induced hypotension and that renal function and hemodynamics quickly return to normal when normotension is resumed.,2021202_8,-1,1,1,14749,1
14755,congestive heart failure,20,23,122,146,Design and analysis of the HYPREN-trial: safety of enalapril and prazosin in the initial treatment phase of patients with congestive heart failure.,2024540_0,-1,1,1,14755,1
14758,congestive heart failure,18,21,120,144,"Since the introduction of angiotensin converting enzyme (ACE) inhibitors into the adjunctive treatment of patients with congestive heart failure, cases of severe hypotension, especially on the first day of treatment, have occasionally been reported.",2024540_1,-1,1,1,14758,1
14766,cocaine abuse,10,12,60,73,Many authors described the effects on the fetus of maternal cocaine abuse during pregnancy.,20304337_1,-1,1,1,14766,1
14767,fetal anomalies,15,17,89,104,Vasoconstriction appears to be the common mechanism of action leading to a wide range of fetal anomalies.,20304337_2,-1,1,1,14767,1
14768,cranial-nerve,7,8,37,50,"We report on an infant with multiple cranial-nerve involvement attributable to brainstem dysgenesis, born to a cocaine-addicted mother.",20304337_3,-1,1,1,14768,1
14858,telangiectasia,4,5,29,43,Skin biopsy specimens showed telangiectasia and noncaseating epithelioid granulomatous tissue formation in the papillary to mid dermis.,20466178_2,-1,1,1,14858,1
14859,epithelioid,7,8,61,72,Skin biopsy specimens showed telangiectasia and noncaseating epithelioid granulomatous tissue formation in the papillary to mid dermis.,20466178_2,-1,1,1,14859,1
14867,Central nervous system,0,3,0,22,Central nervous system complications during treatment of acute lymphoblastic leukemia in a single pediatric institution.,20470218_0,-1,1,1,14867,1
14868,acute lymphoblastic leukemia,7,10,57,85,Central nervous system complications during treatment of acute lymphoblastic leukemia in a single pediatric institution.,20470218_0,-1,1,1,14868,1
14869,Central nervous system,0,3,0,22,Central nervous system (CNS) complications during treatment of childhood acute lymphoblastic leukemia (ALL) remain a challenging clinical problem.,20470218_1,-1,1,1,14869,1
14882,leukoencephalopathy syndrome,5,7,48,76,"CNS complications included posterior reversible leukoencephalopathy syndrome (n = 10), stroke (n = 5), temporal lobe epilepsy (n = 2), high-dose methotrexate toxicity (n = 2), syndrome of inappropriate antidiuretic hormone secretion (n = 1), and other unclassified events (n = 7).",20470218_6,-1,1,1,14882,1
14883,temporal lobe epilepsy,20,23,103,125,"CNS complications included posterior reversible leukoencephalopathy syndrome (n = 10), stroke (n = 5), temporal lobe epilepsy (n = 2), high-dose methotrexate toxicity (n = 2), syndrome of inappropriate antidiuretic hormone secretion (n = 1), and other unclassified events (n = 7).",20470218_6,-1,1,1,14883,1
14898,drug toxicity,23,25,129,142,Nuclear factor kappa B (NFkappaB) is a sensor of oxidative stress and participates in memory formation that could be involved in drug toxicity and addiction mechanisms.,20477932_2,-1,1,1,14898,1
14905,cocaine addiction,33,35,194,211,"Therefore NFkappaB activity, oxidative stress, neuronal nitric oxide synthase (nNOS) activity, spatial learning and memory as well as the effect of topiramate, a previously proposed therapy for cocaine addiction, were evaluated in an experimental model of cocaine administration in rats.",20477932_3,-1,1,1,14905,1
14927,acute renal injury,11,14,74,92,The nephroprotective effect of coenzyme Q10 was investigated in mice with acute renal injury induced by a single i.p.,20510337_1,-1,1,1,14927,1
14964,liver disease,12,14,82,95,"A 67-year-old patient, with primary polymyositis and without previous evidence of liver disease, developed clinical and biochemical features of severe cholestasis 3 months after initiation of azathioprine therapy.",2051906_2,-1,1,1,14964,1
15005,weight change,14,16,74,87,"Across all groups, no more than 5% of patients had clinically significant weight change.",20520283_7,-1,1,1,15005,1
15024,side effects,3,5,16,28,The most common side effects attributable to the AraG included Grade 2 and 3 sensory and motor neuropathy and musculoskeletal pain.,20528871_2,-1,1,1,15024,1
15026,Grade 2,10,12,63,70,The most common side effects attributable to the AraG included Grade 2 and 3 sensory and motor neuropathy and musculoskeletal pain.,20528871_2,-1,1,1,15026,1
15027,motor neuropathy,16,18,89,105,The most common side effects attributable to the AraG included Grade 2 and 3 sensory and motor neuropathy and musculoskeletal pain.,20528871_2,-1,1,1,15027,1
15040,neurotoxicity,9,10,73,86,Dopamine is not essential for the development of methamphetamine-induced neurotoxicity.,20533999_0,-1,1,1,15040,1
15049,neurotoxicity,20,21,158,171,Here we show that the recently reported ability of L-dihydroxyphenylalanine to reverse the protective effect of alpha-methyl-para-tyrosine on METH-induced DA neurotoxicity is also confounded by drug effects on body temperature.,20533999_3,-1,1,1,15049,1
15054,neurotoxicity,16,17,91,104,"Further, we show that mice genetically engineered to be deficient in brain DA develop METH neurotoxicity, as long as the thermic effects of METH are preserved.",20533999_4,-1,1,1,15054,1
15067,kidney injury,21,23,127,140,"Acute normal tissue toxicities (i.e., leukopenia and thrombocytopenia) and late normal tissue toxicities (i.e., myocardial and kidney injury) were evaluated by functional/physiological assays and by morphological techniques.",2054792_3,-1,1,1,15067,1
15071,side effects,18,20,115,127,Whole body hyperthermia (120 min at 41.5 degrees C) enhanced both Adriamycin-mediated antitumor activity and toxic side effects.,2054792_4,-1,1,1,15071,1
15078,tachyarrhythmia,2,3,26,41,Swallowing-induced atrial tachyarrhythmia triggered by salbutamol: case report and review of the literature.,20552622_0,-1,1,1,15078,1
15083,tachyarrhythmia,6,7,41,56,"On electrocardiogram, episodes of atrial tachyarrhythmia were recorded immediately after swallowing; 24-hour Holter monitoring recorded several events.",20552622_2,-1,1,1,15083,1
15087,tachyarrhythmia,4,5,38,53,DISCUSSION: Swallowing-induced atrial tachyarrhythmia (SIAT) is a rare phenomenon.,20552622_6,-1,1,1,15087,1
15111,body weight,11,13,58,69,"2. Diabetes of 2 months duration resulted in decreases in body weight and increases in fluid consumption, urine volume, frequency of micturition, and average volume per micturition; effects which were prevented by insulin treatment.",2055425_2,-1,1,1,15111,1
15118,body weight,10,12,60,71,"Diabetes of 4 months duration also resulted in decreases in body weight, and increases in fluid consumption, urine volume, frequency of micturition, and average volume per micturition, effects which were reversed by insulin treatment for the final 2 months of the study.",2055425_5,-1,1,1,15118,1
15200,drug-induced,15,16,98,110,"BACKGROUND: Current animal models of obsessive-compulsive disorder (OCD) typically involve acute, drug-induced symptom provocation or a genetic association with stereotypies or anxiety.",20619828_1,-1,1,1,15200,1
15237,Thoracic aorta,2,4,9,23,METHODS: Thoracic aorta of male Sprague-Dawley rats was exposed to 0.5M CaCl(2) or normal saline (NaCl).,20621845_2,-1,1,1,15237,1
15276,vascular remodeling,35,37,202,221,"CONCLUSION: This study establishes a TAA model by periarterial CaCl(2) exposure in rats, and demonstrates a significant elevation of expression of MMP-2, MMP-9, ADAM10 and ADAM17 in the pathogenesis of vascular remodeling.",20621845_9,-1,1,1,15276,1
15288,congestive heart failure,1,4,7,31,Severe congestive heart failure patient on amiodarone presenting with myxedemic coma: a case report.,20635749_0,-1,1,1,15288,1
15291,congestive heart failure,17,20,111,135,This is a case report of myxedema coma secondary to amiodarone-induced hypothyroidism in a patient with severe congestive heart failure (CHF).,20635749_1,-1,1,1,15291,1
15294,long term,17,19,101,110,To our knowledge and after reviewing the literature there is one case report of myxedema coma during long term amiodarone therapy.,20635749_2,-1,1,1,15294,1
15310,cognitive dysfunction,2,4,21,42,Curcumin ameliorates cognitive dysfunction and oxidative damage in phenobarbitone and carbamazepine administered rats.,20667451_0,-1,1,1,15310,1
15359,Alzheimer's disease,15,18,102,121,"Effects of active constituents of Crocus sativus L., crocin on streptozocin-induced model of sporadic Alzheimer's disease in male rats.",20683499_0,-1,1,1,15359,1
15365,Alzheimer's disease,11,14,56,75,"In the present study, the effect of crocins on sporadic Alzheimer's disease induced by intracerebroventricular (icv) streptozocin (STZ) in male rats was investigated.",20683499_2,-1,1,1,15365,1
15374,Alzheimer's disease,1,4,3,22,"In Alzheimer's disease groups, rats were injected with STZ-icv bilaterally (3 mg/kg) in first day and 3 days later, a similar STZ-icv application was repeated.",20683499_4,-1,1,1,15374,1
15400,neurodegenerative diseases,32,34,191,217,"CONCLUSION: Therefore, these results demonstrate the effectiveness of crocin (30 mg/kg) in antagonizing the cognitive deficits caused by STZ-icv in rats and its potential in the treatment of neurodegenerative diseases such as Alzheimer's disease.",20683499_10,-1,1,1,15400,1
15401,Alzheimer's disease,36,39,226,245,"CONCLUSION: Therefore, these results demonstrate the effectiveness of crocin (30 mg/kg) in antagonizing the cognitive deficits caused by STZ-icv in rats and its potential in the treatment of neurodegenerative diseases such as Alzheimer's disease.",20683499_10,-1,1,1,15401,1
15444,pathophysiology,26,27,168,183,"These animal models were considered to reflect the positive symptoms of schizophrenia, and the above evidence suggests that altered 5-HT6 receptors are involved in the pathophysiology of psychotic disorders.",20705401_4,-1,1,1,15444,1
15473,pathophysiology,10,11,51,66,CONCLUSION: HTR6 may play an important role in the pathophysiology of METH-induced psychosis in the Japanese population.,20705401_12,-1,1,1,15473,1
15495,kidney disease,29,31,164,178,"WHAT THE READER WILL GAIN: The reader will gain better insight into the safety of capecitabine in special populations such as patients with advanced age, renal and kidney disease.",20722491_3,-1,1,1,15495,1
15503,renal cell,22,24,142,152,"It has shown promising results alone or in combination with other chemotherapeutic agents in colorectal, breast, pancreaticobiliary, gastric, renal cell and head and neck cancers.",20722491_6,-1,1,1,15503,1
15513,pathophysiology,12,13,82,97,The glutamatergic N-methyl-D-aspartate (NMDA) receptor has been implicated in the pathophysiology of schizophrenia.,20727411_1,-1,1,1,15513,1
15540,pathophysiology,15,16,94,109,Our results provide further support for the hypothesis of an NMDA receptor dysfunction in the pathophysiology of schizophrenia.,20727411_11,-1,1,1,15540,1
15547,acute liver injury,10,13,77,95,"METHODS: We followed up all transplant-free survivors of paracetamol-induced acute liver injury, hospitalized in a Danish national referral centre during 1984-2004.",20735774_3,-1,1,1,15547,1
15552,liver injury,16,18,107,119,We compared age-specific mortality rates from 1 year post-discharge through 2008 between those in whom the liver injury led to an acute liver failure and those in whom it did not.,20735774_4,-1,1,1,15552,1
15555,liver injury,15,17,109,121,"On average, age-specific mortality rates were slightly higher for the 101 patients whose paracetamol-induced liver injury had caused an acute liver failure (adjusted mortality rate ratio = 1.70, 95% CI 1.02-2.85), but the association was age-dependent, and no survivors of acute liver failure died of liver disease, whereas suicides were frequent in both groups.",20735774_6,-1,1,1,15555,1
15560,liver disease,54,56,301,314,"On average, age-specific mortality rates were slightly higher for the 101 patients whose paracetamol-induced liver injury had caused an acute liver failure (adjusted mortality rate ratio = 1.70, 95% CI 1.02-2.85), but the association was age-dependent, and no survivors of acute liver failure died of liver disease, whereas suicides were frequent in both groups.",20735774_6,-1,1,1,15560,1
15563,substance abuse,17,19,113,128,"More likely, the elevated mortality rate ratio resulted from incomplete adjustment for the greater prevalence of substance abuse among survivors of acute liver failure.",20735774_8,-1,1,1,15563,1
15567,liver failure,10,12,56,69,"Clinical follow-up may be justified by the cause of the liver failure, but not by the liver failure itself.",20735774_10,-1,1,1,15567,1
15568,liver failure,17,19,86,99,"Clinical follow-up may be justified by the cause of the liver failure, but not by the liver failure itself.",20735774_10,-1,1,1,15568,1
15573,pulsatile,6,7,51,60,"Although preclinical and clinical findings suggest pulsatile stimulation of striatal postsynaptic receptors as a key mechanism underlying levodopa-induced dyskinesias, their pathogenesis is still unclear.",20880751_3,-1,1,1,15573,1
15574,postsynaptic,10,11,85,97,"Although preclinical and clinical findings suggest pulsatile stimulation of striatal postsynaptic receptors as a key mechanism underlying levodopa-induced dyskinesias, their pathogenesis is still unclear.",20880751_3,-1,1,1,15574,1
15578,dyskinetic,31,32,218,228,"In recent years, evidence from animal models of Parkinson's disease has provided important information to understand the effect of specific receptor and post-receptor molecular mechanisms underlying the development of dyskinetic movements.",20880751_4,-1,1,1,15578,1
15581,presynaptic,16,17,104,115,"Recent preclinical and clinical data from promising lines of research focus on the differential role of presynaptic versus postsynaptic mechanisms, dopamine receptor subtypes, ionotropic and metabotropic glutamate receptors, and non-dopaminergic neurotransmitter systems in the pathophysiology of levodopa-induced dyskinesias.",20880751_5,-1,1,1,15581,1
15582,postsynaptic,18,19,123,135,"Recent preclinical and clinical data from promising lines of research focus on the differential role of presynaptic versus postsynaptic mechanisms, dopamine receptor subtypes, ionotropic and metabotropic glutamate receptors, and non-dopaminergic neurotransmitter systems in the pathophysiology of levodopa-induced dyskinesias.",20880751_5,-1,1,1,15582,1
15586,pathophysiology,37,38,278,293,"Recent preclinical and clinical data from promising lines of research focus on the differential role of presynaptic versus postsynaptic mechanisms, dopamine receptor subtypes, ionotropic and metabotropic glutamate receptors, and non-dopaminergic neurotransmitter systems in the pathophysiology of levodopa-induced dyskinesias.",20880751_5,-1,1,1,15586,1
15617,organic mental disorders,1,4,17,41,Carmofur-induced organic mental disorders.,2096243_0,-1,1,1,15617,1
15620,leukoencephalopathy,18,19,122,141,Organic mental disorder was observed in a 29-year-old female in the prognostic period after the onset of carmofur-induced leukoencephalopathy.,2096243_1,-1,1,1,15620,1
15625,periventricular,4,5,20,35,Brain CT revealed a periventricular low density area in the frontal white matter and moderate dilatation of the lateral ventricles especially at the bilateral anterior horns.,2096243_3,-1,1,1,15625,1
15629,leukoencephalopathy,3,4,31,50,"Consequently, carmofur-induced leukoencephalopathy may uncommonly result in organic personality syndrome in the residual state.",2096243_4,-1,1,1,15629,1
15632,frontal lobe,10,12,53,65,It may be attributed to the structural damage to the frontal lobe.,2096243_5,-1,1,1,15632,1
15654,drug-induced,70,71,373,385,"Compound 1 is a potent A(2A)/A(1) receptor antagonist in vitro (A(2A) K(i) = 4.1 nM; A(1) K(i) = 17.0 nM) that has excellent activity, after oral administration, across a number of animal models of Parkinson's disease including mouse and rat models of haloperidol-induced catalepsy, mouse model of reserpine-induced akinesia, rat 6-hydroxydopamine (6-OHDA) lesion model of drug-induced rotation, and MPTP-treated non-human primate model.",20973483_3,-1,1,1,15654,1
15686,hippocampal,3,4,15,26,Effects of the hippocampal deep brain stimulation on cortical epileptic discharges in penicillin - induced epilepsy model in rats.,21294084_0,-1,1,1,15686,1
15690,hippocampal,9,10,58,69,"AIM: Experimental and clinical studies have revealed that hippocampal DBS can control epileptic activity, but the mechanism of action is obscure and optimal stimulation parameters are not clearly defined.",21294084_1,-1,1,1,15690,1
15692,hippocampal,10,11,54,65,The aim was to evaluate the effects of high frequency hippocampal stimulation on cortical epileptic activity in penicillin-induced epilepsy model.,21294084_2,-1,1,1,15692,1
15696,hippocampal,5,6,18,29,"In group-1 (n=10) hippocampal DBS was off and in the group-2 (n=10) hippocampal DBS was on (185 Hz, 0.5V, 1V, 2V, and 5V for 60 sec) following penicillin G injection intracortically.",21294084_4,-1,1,1,15696,1
15698,hippocampal,16,17,68,79,"In group-1 (n=10) hippocampal DBS was off and in the group-2 (n=10) hippocampal DBS was on (185 Hz, 0.5V, 1V, 2V, and 5V for 60 sec) following penicillin G injection intracortically.",21294084_4,-1,1,1,15698,1
15704,hippocampal,4,5,21,32,In the control group hippocampal DBS was on following 8  l saline injection intracortically.,21294084_5,-1,1,1,15704,1
15708,hippocampal,4,5,24,35,RESULTS: High frequency hippocampal DBS suppressed the acute penicillin-induced cortical epileptic activity independent from stimulus intensity.,21294084_7,-1,1,1,15708,1
15711,hippocampal,5,6,22,33,"In the control group, hippocampal stimulation alone lead only to diffuse slowing of cerebral bioelectrical activity at 5V stimulation.",21294084_8,-1,1,1,15711,1
15716,hippocampal,12,13,75,86,These results are important in terms of defining the optimal parameters of hippocampal DBS in patients with epilepsy.,21294084_10,-1,1,1,15716,1
15734,histiocytic,18,19,90,101,"CCNU was used most commonly in the treatment of lymphoma, mast cell tumour, brain tumour, histiocytic tumours and epitheliotropic lymphoma.",21418164_3,-1,1,1,15734,1
15743,peripheral neuropathy,3,5,24,45,Perhexiline maleate and peripheral neuropathy.,220563_0,-1,1,1,15743,1
15744,Peripheral neuropathy,0,2,0,21,"Peripheral neuropathy has been noted as a complication of therapy with perhexiline maleate, a drug widely used in France (and in clinical trials in the United States) for the prophylactic treatment of angina pectoris.",220563_1,-1,1,1,15744,1
15749,angina pectoris,35,37,201,216,"Peripheral neuropathy has been noted as a complication of therapy with perhexiline maleate, a drug widely used in France (and in clinical trials in the United States) for the prophylactic treatment of angina pectoris.",220563_1,-1,1,1,15749,1
15752,demyelinating disorder,22,24,142,164,"In 24 patients with this complication, the marked slowing of motor nerve conduction velocity and the electromyographic changes imply mainly a demyelinating disorder.",220563_2,-1,1,1,15752,1
15755,vein thrombosis,1,3,8,23,Central vein thrombosis and topical dipivalyl epinephrine.,2220369_0,-1,1,1,15755,1
15757,vein thrombosis,11,13,64,79,A report is given on an 83-year-old female who acquired central vein thrombosis in her seeing eye one day after having started topical medication with dipivalyl epinephrine for advanced glaucoma discovered in the other eye.,2220369_1,-1,1,1,15757,1
15783,mucositis,17,18,101,110,"Less frequent toxic effects included thrombocytopenia, anemia, nausea, mild alopecia, phlebitis, and mucositis.",2224762_8,-1,1,1,15783,1
15805,basal cell carcinoma,9,12,56,76,"Activity was noted in mesothelioma, leiomyosarcoma, and basal cell carcinoma.",2224762_14,-1,1,1,15805,1
15824,hearing loss,10,12,79,91,Auditory toxicity was characterized by a mid- to high-frequency neurosensorial hearing loss and the lesion was of the cochlear type.,2234245_5,-1,1,1,15824,1
15827,hearing loss,24,26,145,157,"Desferrioxamine withdrawal resulted in a complete recovery of visual function in 1 patient and partial recovery in 3, and a complete reversal of hearing loss in 3 patients and partial recovery in 3.",2234245_6,-1,1,1,15827,1
15874,vitamin B6,19,21,119,129,The first patient died without a diagnosis; the second patient had a dramatic recovery following the administration of vitamin B6.,2265898_2,-1,1,1,15874,1
15878,Duchenne,7,8,46,54,"Randomized, double-blind trial of mazindol in Duchenne dystrophy.",2266990_0,-1,1,1,15878,1
15880,Duchenne,15,16,87,95,There is evidence that growth hormone may be related to the progression of weakness in Duchenne dystrophy.,2266990_1,-1,1,1,15880,1
15884,Duchenne,20,21,117,125,"We conducted a 12-month controlled trial of mazindol, a putative growth hormone secretion inhibitor, in 83 boys with Duchenne dystrophy.",2266990_2,-1,1,1,15884,1
15890,Side effects,0,2,0,12,"Side effects attributable to mazindol included decreased appetite (36%), dry mouth (10%), behavioral change (22%), and gastrointestinal symptoms (18%); mazindol dosage was reduced in 43% of patients.",2266990_6,-1,1,1,15890,1
15899,postabsorptive,13,14,81,95,"The effect of mazindol on GH secretion was estimated indirectly by comparing the postabsorptive IGF-I levels obtained following 3, 6, 9, and 12 months in the mazindol treated to those in the placebo groups.",2266990_7,-1,1,1,15899,1
15907,Duchenne,9,10,55,63,Mazindol doses not slow the progression of weakness in Duchenne dystrophy.,2266990_9,-1,1,1,15907,1
15944,Neurotoxicity,0,1,0,13,Neurotoxicity of halogenated hydroxyquinolines: clinical analysis of cases reported outside Japan.,230316_0,-1,1,1,15944,1
15951,optic atrophy,13,15,74,87,"The most common manifestation, observed in 15 further cases, was isolated optic atrophy.",230316_5,-1,1,1,15951,1
15953,myelopathy,8,9,41,51,"In the remaining cases, a combination of myelopathy, visual disturbance, and peripheral neuropathy was the most common manifestation.",230316_7,-1,1,1,15953,1
15955,peripheral neuropathy,14,16,77,98,"In the remaining cases, a combination of myelopathy, visual disturbance, and peripheral neuropathy was the most common manifestation.",230316_7,-1,1,1,15955,1
15956,myelopathy,1,2,9,19,"Isolated myelopathy or peripheral neuropathy, or these manifestations occurring together, were infrequent.",230316_8,-1,1,1,15956,1
15957,peripheral neuropathy,3,5,23,44,"Isolated myelopathy or peripheral neuropathy, or these manifestations occurring together, were infrequent.",230316_8,-1,1,1,15957,1
15958,toxic encephalopathy,7,9,40,60,"The onset of all manifestations (except toxic encephalopathy) was usually subacute, with subsequent partial recovery.",230316_9,-1,1,1,15958,1
15960,side effects,6,8,38,50,Older subjects tended to display more side effects.,230316_10,-1,1,1,15960,1
15971,clinical course,3,5,14,29,The patient's clinical course is described and correlated with initial urodynamic studies while on prazosin and subsequent studies while taking verapamil.,2304736_4,-1,1,1,15971,1
15980,Myocardial infarction,0,2,0,21,Myocardial infarction following sublingual administration of isosorbide dinitrate.,2312209_0,-1,1,1,15980,1
15983,myocardial infarction,9,11,63,84,A 78-year-old with healed septal necrosis suffered a recurrent myocardial infarction of the anterior wall following the administration of isosorbide dinitrate 5 mg sublingually.,2312209_1,-1,1,1,15983,1
15984,anterior wall,13,15,92,105,A 78-year-old with healed septal necrosis suffered a recurrent myocardial infarction of the anterior wall following the administration of isosorbide dinitrate 5 mg sublingually.,2312209_1,-1,1,1,15984,1
15990,pathophysiology,28,29,203,218,"After detailing the course of events, we discuss the role of paradoxical coronary spasm and hypotension-mediated myocardial ischemia occurring downstream to significant coronary arterial stenosis in the pathophysiology of acute coronary insufficiency.",2312209_2,-1,1,1,15990,1
15994,breast cancer,9,11,66,79,Lethal anuria complicating high dose ifosfamide chemotherapy in a breast cancer patient with an impaired renal function.,2320800_0,-1,1,1,15994,1
15996,breast cancer,5,7,37,50,"A sixty-year-old woman with advanced breast cancer, previously treated with cisplatin, developed an irreversible lethal renal failure with anuria, the day after 5 g/m2 bolus ifosfamide.",2320800_1,-1,1,1,15996,1
15999,renal failure,17,19,120,133,"A sixty-year-old woman with advanced breast cancer, previously treated with cisplatin, developed an irreversible lethal renal failure with anuria, the day after 5 g/m2 bolus ifosfamide.",2320800_1,-1,1,1,15999,1
16003,renal failure,7,9,47,60,"A prerenal component could have contributed to renal failure because of a transient hypotension, due to an increasing ascitis, occurring just before anuria.",2320800_3,-1,1,1,16003,1
16041,hyperalgesia,4,5,37,49,"Conversely, prostaglandin E2-induced hyperalgesia was blocked by AH6809 (greater than or equal to 500 ng) but not by the substance P antagonist.",2322844_6,-1,1,1,16041,1
16048,hyperalgesia,11,12,80,92,"These results demonstrate that both prostaglandin D2 and prostaglandin E2 exert hyperalgesia in the spinal cord, but in different ways.",2322844_8,-1,1,1,16048,1
16049,spinal cord,14,16,100,111,"These results demonstrate that both prostaglandin D2 and prostaglandin E2 exert hyperalgesia in the spinal cord, but in different ways.",2322844_8,-1,1,1,16049,1
16051,localized scleroderma,5,7,36,57,D-penicillamine in the treatment of localized scleroderma.,2334179_0,-1,1,1,16051,1
16052,Localized scleroderma,0,2,0,21,Localized scleroderma has no recognized internal organ involvement but may be disfiguring and disabling when the cutaneous lesions are extensive or affect children.,2334179_1,-1,1,1,16052,1
16055,localized scleroderma,8,10,45,66,There is no accepted or proven treatment for localized scleroderma.,2334179_2,-1,1,1,16055,1
16057,localized scleroderma,9,11,51,72,"Case reports of 11 patients with severe, extensive localized scleroderma who were treated with D-penicillamine are summarized in this article.",2334179_3,-1,1,1,16057,1
16070,nephrotic syndrome,2,4,23,41,D-Penicillamine caused nephrotic syndrome in 1 patient and milder reversible proteinuria in 3 other patients; none developed renal insufficiency.,2334179_8,-1,1,1,16070,1
16071,renal insufficiency,18,20,125,144,D-Penicillamine caused nephrotic syndrome in 1 patient and milder reversible proteinuria in 3 other patients; none developed renal insufficiency.,2334179_8,-1,1,1,16071,1
16073,localized scleroderma,12,14,76,97,These data suggest that D-penicillamine may be effective in severe cases of localized scleroderma.,2334179_9,-1,1,1,16073,1
16085,tachyarrhythmias,7,8,37,53,There was also a higher incidence of tachyarrhythmias (P less than 0.05) and ventricular ectopic beats (P less than 0.05) in the morphine infusion group.,2334618_6,-1,1,1,16085,1
16089,transverse sinus thrombosis,11,14,73,100,We describe a 42-year-old woman who developed superior sagittal and left transverse sinus thrombosis associated with prolonged epsilon-aminocaproic acid therapy for menorrhagia.,2339463_1,-1,1,1,16089,1
16101,head trauma,15,17,82,93,Two elderly patients with a history of either cerebral vascular accident (CVA) or head trauma and no evidence of renal disease developed seizures while receiving maximum doses of imipenem/cilastatin.,2343592_1,-1,1,1,16101,1
16102,renal disease,21,23,113,126,Two elderly patients with a history of either cerebral vascular accident (CVA) or head trauma and no evidence of renal disease developed seizures while receiving maximum doses of imipenem/cilastatin.,2343592_1,-1,1,1,16102,1
16110,respiratory failure,11,13,89,108,Effects of aminophylline on the threshold for initiating ventricular fibrillation during respiratory failure.,234669_0,-1,1,1,16110,1
16112,respiratory failure,9,11,70,89,Cardiac arrhythmias have frequently been reported in association with respiratory failure.,234669_1,-1,1,1,16112,1
16116,respiratory failure,14,16,106,125,The possible additive role of pharmacologic agents in precipitating cardiac disturbances in patients with respiratory failure has only recently been emphasized.,234669_2,-1,1,1,16116,1
16120,respiratory failure,15,17,117,136,The effects of aminophylline on the ventricular fibrillation threshold during normal acid-base conditions and during respiratory failure were studied in anesthetized open chest dogs.,234669_3,-1,1,1,16120,1
16128,respiratory failure,1,3,5,24,"When respiratory failure was produced by hypoventilation (pH 7.05 to 7.25; PC02 70 to 100 mm Hg: P02 20 to 40 mm Hg), infusion of aminophylline resulted in an even greater decrease in ventricular fibrillation threshold to 60 percent of the control level.",234669_6,-1,1,1,16128,1
16129,hypoventilation,6,7,41,56,"When respiratory failure was produced by hypoventilation (pH 7.05 to 7.25; PC02 70 to 100 mm Hg: P02 20 to 40 mm Hg), infusion of aminophylline resulted in an even greater decrease in ventricular fibrillation threshold to 60 percent of the control level.",234669_6,-1,1,1,16129,1
16134,respiratory failure,17,19,125,144,"These experiments suggest that although many factors may contribute to the increased incidence of ventricular arrhythmias in respiratory failure, pharmacologic agents, particularly aminophylline, may play a significant role.",234669_7,-1,1,1,16134,1
16162,malignant neoplasms,14,16,67,86,"The leading causes of death were pneumonia and bronchitis (44.1%), malignant neoplasms (11.6%), heart diseases (4.1%), cerebral infarction (3.7%) and septicaemia (3.3%).",2355241_2,-1,1,1,16162,1
16163,heart diseases,21,23,96,110,"The leading causes of death were pneumonia and bronchitis (44.1%), malignant neoplasms (11.6%), heart diseases (4.1%), cerebral infarction (3.7%) and septicaemia (3.3%).",2355241_2,-1,1,1,16163,1
16164,cerebral infarction,28,30,119,138,"The leading causes of death were pneumonia and bronchitis (44.1%), malignant neoplasms (11.6%), heart diseases (4.1%), cerebral infarction (3.7%) and septicaemia (3.3%).",2355241_2,-1,1,1,16164,1
16180,Myasthenia gravis,0,2,0,17,Myasthenia gravis presenting as weakness after magnesium administration.,2385256_0,-1,1,1,16180,1
16182,neuromuscular disease,9,11,46,67,We studied a patient with no prior history of neuromuscular disease who became virtually quadriplegic after parenteral magnesium administration for preeclampsia.,2385256_1,-1,1,1,16182,1
16192,myasthenia gravis,12,14,92,109,"Although paralysis after magnesium administration has been described in patients with known myasthenia gravis, it has not previously been reported to be the initial or only manifestation of the disease.",2385256_7,-1,1,1,16192,1
16223,spinal cord,34,36,233,244,Previous experiments in this laboratory have shown that microinjection of methyldopa onto the ventrolateral cells of the B3 serotonin neurons in the medulla elicits a hypotensive response mediated by a projection descending into the spinal cord.,2422478_1,-1,1,1,16223,1
16235,spinal cord,19,21,125,136,"However, intraspinal injection of 5,7-DHT to produce a more selective lesion of only descending serotonin projections in the spinal cord did not affect this hypotension.",2422478_4,-1,1,1,16235,1
16251,side-effects,3,4,19,31,"On two paradoxical side-effects of prednisolone in rats, ribosomal RNA biosyntheses, and a mechanism of action.",2425813_0,-1,1,1,16251,1
16279,central nervous system,17,20,103,125,"This pharmacological profile is similar to those of mexiletine and tocainide, and all three drugs have central nervous system (CNS) stimulant action.",2435991_4,-1,1,1,16279,1
16281,sinus node,7,9,50,60,"Because cibenzoline had only weak hypotensive and sinus node depressive effects and was found to be orally active when given to coronary ligation arrhythmia dogs, its clinical usefulness is expected.",2435991_5,-1,1,1,16281,1
16332,hemorrhagic fever,10,12,71,88,Tolerance and antiviral effect of ribavirin in patients with Argentine hemorrhagic fever.,2445283_0,-1,1,1,16332,1
16334,hemorrhagic fever,13,15,85,102,Tolerance and antiviral effect of ribavirin was studied in 6 patients with Argentine hemorrhagic fever (AHF) of more than 8 days of evolution.,2445283_1,-1,1,1,16334,1
16352,ST,26,27,179,181,We prospectively performed continuous ambulatory ECG monitoring on 25 patients undergoing 5-FU infusion for treatment of solid tumors in order to assess the incidence of ischemic ST changes.,2466960_2,-1,1,1,16352,1
16359,ST,3,4,22,24,"However, asymptomatic ST changes (greater than or equal to 1 mm ST deviation) were common: six of 25 patients (24%) had ST changes before 5-FU infusion v 17 (68%) during 5-FU infusion (P less than .002).",2466960_5,-1,1,1,16359,1
16360,ST,13,14,64,66,"However, asymptomatic ST changes (greater than or equal to 1 mm ST deviation) were common: six of 25 patients (24%) had ST changes before 5-FU infusion v 17 (68%) during 5-FU infusion (P less than .002).",2466960_5,-1,1,1,16360,1
16361,ST,28,29,120,122,"However, asymptomatic ST changes (greater than or equal to 1 mm ST deviation) were common: six of 25 patients (24%) had ST changes before 5-FU infusion v 17 (68%) during 5-FU infusion (P less than .002).",2466960_5,-1,1,1,16361,1
16373,coronary artery disease,9,12,55,78,ECG changes were more common among patients with known coronary artery disease.,2466960_8,-1,1,1,16373,1
16374,sudden death,5,7,24,36,"There were two cases of sudden death, both of which occurred at the end of the chemotherapy course.",2466960_9,-1,1,1,16374,1
16379,coronary artery disease,24,27,161,184,"We conclude that 5-FU infusion is associated with a significant increase in silent ST segment deviation suggestive of ischemia, particularly among patients with coronary artery disease.",2466960_10,-1,1,1,16379,1
16386,central nervous system,10,13,58,80,Evidence is accumulating that lindane can be toxic to the central nervous system and may be associated with aplastic anaemia.,2476560_2,-1,1,1,16386,1
16388,aplastic anaemia,18,20,108,124,Evidence is accumulating that lindane can be toxic to the central nervous system and may be associated with aplastic anaemia.,2476560_2,-1,1,1,16388,1
16429,side effects,19,21,106,118,The BALB/C mouse was the most sensitive strain and could serve as the strain of choice for evaluating the side effects of amantadine.,2484011_11,-1,1,1,16429,1
16458,frontotemporal,19,20,125,139,Source of pain and primitive dysfunction in migraine: an identical site?Twenty common migraine patients received a one sided frontotemporal application of nitroglycerin (10 patients) or placebo ointment (10 patients) in a double blind study.,2515254_0,-1,1,1,16458,1
16461,early onset,8,10,52,63,"Subsequently 20 migraine patients, who developed an early onset attack with frontotemporal nitroglycerin, received the drug in a second induction test at other body areas.",2515254_2,-1,1,1,16461,1
16468,frontotemporal,22,23,139,153,"Thus the migraine-inducing effect of nitroglycerin seems to depend on direct stimulation of the habitual site of pain, suggesting that the frontotemporal region is of crucial importance in the development of a migraine crisis.",2515254_4,-1,1,1,16468,1
16470,CNS origin,6,8,30,40,This is not consistent with a CNS origin of migraine attack.,2515254_5,-1,1,1,16470,1
16473,renal failure,14,16,104,117,"Hypersensitivity to carbamazepine presenting with a leukemoid reaction, eosinophilia, erythroderma, and renal failure.",2522601_0,-1,1,1,16473,1
16477,renal failure,24,26,164,177,"We report a patient in whom hypersensitivity to carbamazepine presented with generalized erythroderma, a severe leukemoid reaction, eosinophilia, hyponatremia, and renal failure.",2522601_1,-1,1,1,16477,1
16480,side effects,9,11,62,74,"Nature, time course and dose dependence of zidovudine-related side effects: results from the Multicenter Canadian Azidothymidine Trial.To characterize the nature, time course and dose dependency of zidovudine-related side effects, we undertook a multicenter, prospective, dose-range finding study.",2528969_0,-1,1,1,16480,1
16483,side effects,32,34,217,229,"Nature, time course and dose dependence of zidovudine-related side effects: results from the Multicenter Canadian Azidothymidine Trial.To characterize the nature, time course and dose dependency of zidovudine-related side effects, we undertook a multicenter, prospective, dose-range finding study.",2528969_0,-1,1,1,16483,1
16511,Bone marrow,0,2,0,11,Bone marrow changes occurred rapidly as demonstrated by megaloblastosis in 95% of 65 specimens at week 18.(ABSTRACT TRUNCATED AT 250 WORDS),2528969_11,-1,1,1,16511,1
16515,B virus,10,12,78,85,"National project on the prevention of mother-to-infant infection by hepatitis B virus in Japan.In Japan, a nationwide prevention program against mother-to-infant infection by hepatitis B virus (HBV) started in 1985.",2533791_0,-1,1,1,16515,1
16518,B virus,27,29,185,192,"National project on the prevention of mother-to-infant infection by hepatitis B virus in Japan.In Japan, a nationwide prevention program against mother-to-infant infection by hepatitis B virus (HBV) started in 1985.",2533791_0,-1,1,1,16518,1
16537,akathisia,1,2,19,28,Fluoxetine-induced akathisia: clinical and theoretical implications.,2549018_0,-1,1,1,16537,1
16540,akathisia,15,16,116,125,Five patients receiving fluoxetine for the treatment of obsessive compulsive disorder or major depression developed akathisia.,2549018_1,-1,1,1,16540,1
16543,akathisia,27,28,194,203,"The typical fluoxetine-induced symptoms of restlessness, constant pacing, purposeless movements of the feet and legs, and marked anxiety were indistinguishable from those of neuroleptic-induced akathisia.",2549018_2,-1,1,1,16543,1
16544,akathisia,6,7,55,64,"Three patients who had experienced neuroleptic-induced akathisia in the past reported that the symptoms of fluoxetine-induced akathisia were identical, although somewhat milder.",2549018_3,-1,1,1,16544,1
16545,akathisia,16,17,126,135,"Three patients who had experienced neuroleptic-induced akathisia in the past reported that the symptoms of fluoxetine-induced akathisia were identical, although somewhat milder.",2549018_3,-1,1,1,16545,1
16546,Akathisia,0,1,0,9,"Akathisia appeared to be a common side effect of fluoxetine and generally responded well to treatment with the beta-adrenergic antagonist propranolol, dose reduction, or both.",2549018_4,-1,1,1,16546,1
16547,side effect,6,8,34,45,"Akathisia appeared to be a common side effect of fluoxetine and generally responded well to treatment with the beta-adrenergic antagonist propranolol, dose reduction, or both.",2549018_4,-1,1,1,16547,1
16550,akathisia,5,6,44,53,"The authors suggest that fluoxetine-induced akathisia may be caused by serotonergically mediated inhibition of dopaminergic neurotransmission and that the pathophysiology of fluoxetine-induced akathisia and tricyclic antidepressant-induced ""jitteriness"" may be identical.",2549018_5,-1,1,1,16550,1
16553,pathophysiology,19,20,155,170,"The authors suggest that fluoxetine-induced akathisia may be caused by serotonergically mediated inhibition of dopaminergic neurotransmission and that the pathophysiology of fluoxetine-induced akathisia and tricyclic antidepressant-induced ""jitteriness"" may be identical.",2549018_5,-1,1,1,16553,1
16554,akathisia,22,23,193,202,"The authors suggest that fluoxetine-induced akathisia may be caused by serotonergically mediated inhibition of dopaminergic neurotransmission and that the pathophysiology of fluoxetine-induced akathisia and tricyclic antidepressant-induced ""jitteriness"" may be identical.",2549018_5,-1,1,1,16554,1
16571,hyperalgesia,20,21,141,153,"Intradermal injection of mu, but not delta or kappa opioid-agonists, however, produced dose-dependent inhibition of prostaglandin E2-induced hyperalgesia.",2557556_2,-1,1,1,16571,1
16574,hyperalgesia,8,9,37,49,"Morphine did not, however, alter the hyperalgesia induced by 8-bromo cyclic adenosine monophosphate.",2557556_4,-1,1,1,16574,1
16610,renal injury,21,23,106,118,Groups 3 and 4 were studied at four and at six months to assess the effect of enalapril on progression of renal injury in adriamycin nephrosis.,2559236_6,-1,1,1,16610,1
16629,muscular rigidity,9,11,87,104,Involvement of locus coeruleus and noradrenergic neurotransmission in fentanyl-induced muscular rigidity in the rat.,2564649_0,-1,1,1,16629,1
16630,muscular rigidity,1,3,8,25,"Whereas muscular rigidity is a well-known side effect that is associated with high-dose fentanyl anesthesia, a paucity of information exists with regard to its underlying mechanism(s).",2564649_1,-1,1,1,16630,1
16631,side effect,6,8,42,53,"Whereas muscular rigidity is a well-known side effect that is associated with high-dose fentanyl anesthesia, a paucity of information exists with regard to its underlying mechanism(s).",2564649_1,-1,1,1,16631,1
16642,muscular rigidity,3,5,16,33,"Such an induced muscular rigidity by the narcotic agent was significantly antagonized or even reduced by prior electrolytic lesions of the locus coeruleus or pretreatment with the alpha-adrenoceptor blocker, prazosin.",2564649_4,-1,1,1,16642,1
16648,pontine,11,12,69,76,"Microinjection of fentanyl (2.5 micrograms/50 nl) directly into this pontine nucleus, on the other hand, elicited discernible electromyographic excitation.",2564649_5,-1,1,1,16648,1
16650,muscular rigidity,7,9,39,56,It is speculated that the induction of muscular rigidity by fentanyl may involve the coerulospinal noradrenergic fibers to the spinal motoneurons.,2564649_6,-1,1,1,16650,1
16655,muscle rigidity,10,12,87,102,"Dexmedetomidine, acting through central alpha-2 adrenoceptors, prevents opiate-induced muscle rigidity in the rat.",2569282_0,-1,1,1,16655,1
16659,muscle flaccidity,13,15,95,112,The highly-selective alpha-2 adrenergic agonist dexmedetomidine (D-MED) is capable of inducing muscle flaccidity and anesthesia in rats and dogs.,2569282_1,-1,1,1,16659,1
16660,muscle rigidity,2,4,20,35,Intense generalized muscle rigidity is an undesirable side effect of potent opiate agonists.,2569282_2,-1,1,1,16660,1
16661,side effect,7,9,54,65,Intense generalized muscle rigidity is an undesirable side effect of potent opiate agonists.,2569282_2,-1,1,1,16661,1
16663,opiate-induced,4,5,31,45,"Although the neurochemistry of opiate-induced rigidity has yet to be fully elucidated, recent work suggests a role for a central adrenergic mechanism.",2569282_3,-1,1,1,16663,1
16665,muscle rigidity,14,16,82,97,"In the present study, the authors determined if treatment with D-MED prevents the muscle rigidity caused by high-dose alfentanil anesthesia in the rat.",2569282_4,-1,1,1,16665,1
16689,muscle rigidity,6,8,48,63,"In contrast, D-MED prevented alfentanil-induced muscle rigidity in a dose-dependent fashion.",2569282_9,-1,1,1,16689,1
16696,akinetic,7,8,42,50,"The high-dose D-MED animals were flaccid, akinetic, and lacked a startle response during the entire experimental period.(ABSTRACT TRUNCATED AT 250 WORDS)",2569282_11,-1,1,1,16696,1
16819,renal disease,19,21,119,132,"Possible risk factors included young age, concurrent use of other analgesic agents (especially ibuprofen), preexisting renal disease, a history of kidney stones, a history of gout, a recent increase in activity, a recent increase in sun exposure, and residence in the Sunbelt.",2598570_5,-1,1,1,16819,1
16839,Chronic active hepatitis,0,3,0,24,Chronic active hepatitis associated with diclofenac sodium therapy.,2611118_0,-1,1,1,16839,1
16850,chronic active hepatitis,4,7,32,56,"The patient described developed chronic active hepatitis after six months therapy with diclofenac sodium which progressed despite the withdrawal of the drug, a finding not previously reported.",2611118_3,-1,1,1,16850,1
16869,renal insufficiency,14,16,86,105,Effects of an inhibitor of angiotensin converting enzyme (Captopril) on pulmonary and renal insufficiency due to intravascular coagulation in the rat.,2670794_0,-1,1,1,16869,1
16874,renal insufficiency,26,28,161,180,Induction of intravascular coagulation and inhibition of fibrinolysis by injection of thrombin and tranexamic acid (AMCA) in the rat gives rise to pulmonary and renal insufficiency resembling that occurring after trauma or sepsis in man.,2670794_1,-1,1,1,16874,1
16877,renal insufficiency,22,24,114,133,"Injection of Captopril (1 mg/kg), an inhibitor of angiotensin converting enzyme (ACE), reduced both pulmonary and renal insufficiency in this rat model.",2670794_2,-1,1,1,16877,1
16898,Intracranial aneurysms,0,2,0,22,Intracranial aneurysms or arteriovenous malformations were present in 17 of 32 patients studied angiographically or at autopsy; cerebral vasculitis was present in two patients.,2673163_4,-1,1,1,16898,1
16899,arteriovenous malformations,3,5,26,53,Intracranial aneurysms or arteriovenous malformations were present in 17 of 32 patients studied angiographically or at autopsy; cerebral vasculitis was present in two patients.,2673163_4,-1,1,1,16899,1
16901,cerebral vasculitis,18,20,128,147,Intracranial aneurysms or arteriovenous malformations were present in 17 of 32 patients studied angiographically or at autopsy; cerebral vasculitis was present in two patients.,2673163_4,-1,1,1,16901,1
16902,Cerebral infarction,0,2,0,19,"Cerebral infarction occurred in 10 patients (22%), intracerebral hemorrhage in 22 (49%), and subarachnoid hemorrhage in 13 (29%).",2673163_5,-1,1,1,16902,1
16903,intracerebral hemorrhage,11,13,51,75,"Cerebral infarction occurred in 10 patients (22%), intracerebral hemorrhage in 22 (49%), and subarachnoid hemorrhage in 13 (29%).",2673163_5,-1,1,1,16903,1
16904,subarachnoid hemorrhage,21,23,93,116,"Cerebral infarction occurred in 10 patients (22%), intracerebral hemorrhage in 22 (49%), and subarachnoid hemorrhage in 13 (29%).",2673163_5,-1,1,1,16904,1
16912,intracranial aneurysms,53,55,282,304,"These data indicate that (1) the apparent incidence of stroke related to cocaine use is increasing; (2) cocaine-associated stroke occurs primarily in young adults; (3) stroke may follow any route of cocaine administration; (4) stroke after cocaine use is frequently associated with intracranial aneurysms and arteriovenous malformations; and (5) in cocaine-associated stroke, the frequency of intracranial hemorrhage exceeds that of cerebral infarction.",2673163_6,-1,1,1,16912,1
16913,arteriovenous malformations,56,58,309,336,"These data indicate that (1) the apparent incidence of stroke related to cocaine use is increasing; (2) cocaine-associated stroke occurs primarily in young adults; (3) stroke may follow any route of cocaine administration; (4) stroke after cocaine use is frequently associated with intracranial aneurysms and arteriovenous malformations; and (5) in cocaine-associated stroke, the frequency of intracranial hemorrhage exceeds that of cerebral infarction.",2673163_6,-1,1,1,16913,1
16914,intracranial hemorrhage,70,72,393,416,"These data indicate that (1) the apparent incidence of stroke related to cocaine use is increasing; (2) cocaine-associated stroke occurs primarily in young adults; (3) stroke may follow any route of cocaine administration; (4) stroke after cocaine use is frequently associated with intracranial aneurysms and arteriovenous malformations; and (5) in cocaine-associated stroke, the frequency of intracranial hemorrhage exceeds that of cerebral infarction.",2673163_6,-1,1,1,16914,1
16915,cerebral infarction,75,77,433,452,"These data indicate that (1) the apparent incidence of stroke related to cocaine use is increasing; (2) cocaine-associated stroke occurs primarily in young adults; (3) stroke may follow any route of cocaine administration; (4) stroke after cocaine use is frequently associated with intracranial aneurysms and arteriovenous malformations; and (5) in cocaine-associated stroke, the frequency of intracranial hemorrhage exceeds that of cerebral infarction.",2673163_6,-1,1,1,16915,1
16921,drug-induced,11,12,75,87,Each patient was subjected to an identical anesthetic protocol and similar drug-induced reductions in mean arterial blood pressure (BP) (50 to 55 mmHg).,2696505_2,-1,1,1,16921,1
16928,cardiac output,18,20,103,117,Nitroprusside infusion was associated with a significant (p less than 0.05) increase in heart rate and cardiac output; rebound hypertension was observed in three patients after discontinuation of nitroprusside.,2696505_3,-1,1,1,16928,1
16936,diabetes mellitus,4,6,41,58,"Because rats with streptozotocin-induced diabetes mellitus (DM) have a high solute diuresis (glycosuria of 10 to 12 g/day), we have suggested that this may in part be responsible for their resistance to gentamicin-induced acute renal failure (ARF).",2709684_1,-1,1,1,16936,1
16937,acute renal failure,38,41,222,241,"Because rats with streptozotocin-induced diabetes mellitus (DM) have a high solute diuresis (glycosuria of 10 to 12 g/day), we have suggested that this may in part be responsible for their resistance to gentamicin-induced acute renal failure (ARF).",2709684_1,-1,1,1,16937,1
17006,cardiac output,18,20,88,102,"We studied the effects of 1 week of oral hydrocortisone (200 mg/day) on blood pressure, cardiac output, total peripheral resistance, forearm vascular resistance, and norepinephrine spillover to plasma in eight healthy male volunteers.",2722224_2,-1,1,1,17006,1
17012,SED,18,19,111,114,"Although diastolic blood pressure remained unchanged, systolic blood pressure increased from 119 to 135 mm Hg (SED +/- 3.4, p less than 0.01), associated with an increased cardiac output (5.85-7.73 l/min, SED +/- 0.46, p less than 0.01).",2722224_3,-1,1,1,17012,1
17015,cardiac output,33,35,172,186,"Although diastolic blood pressure remained unchanged, systolic blood pressure increased from 119 to 135 mm Hg (SED +/- 3.4, p less than 0.01), associated with an increased cardiac output (5.85-7.73 l/min, SED +/- 0.46, p less than 0.01).",2722224_3,-1,1,1,17015,1
17016,SED,41,42,205,208,"Although diastolic blood pressure remained unchanged, systolic blood pressure increased from 119 to 135 mm Hg (SED +/- 3.4, p less than 0.01), associated with an increased cardiac output (5.85-7.73 l/min, SED +/- 0.46, p less than 0.01).",2722224_3,-1,1,1,17016,1
17019,SED,12,13,73,76,"Total peripheral vascular resistance fell from 15.1 to 12.2 mm Hg/l/min (SED +/- 1.03, p less than 0.05).",2722224_4,-1,1,1,17019,1
17026,SED,42,43,246,249,"Resting forearm vascular resistance remained unchanged, but the reflex response to the cold pressor test was accentuated, the rise in resistance increasing from 10.5 mm Hg/ml/100 ml/min (R units) before treatment to 32.6 R units after treatment (SED +/- 6.4, p less than 0.025).",2722224_5,-1,1,1,17026,1
17033,SED,48,49,275,278,"The rise in forearm vascular resistance accompanying intra-arterial norepinephrine (25, 50, and 100 ng/min) was also significantly greater after hydrocortisone, increasing from an average of 14.9 +/- 2.4 R units before treatment to 35.1 +/- 5.5 R units after hydrocortisone (SED +/- 6.0, p less than 0.05).",2722224_6,-1,1,1,17033,1
17036,nervous system,16,18,132,146,Measurement of resting norepinephrine spillover rate to plasma and norepinephrine uptake indicated that overall resting sympathetic nervous system activity was not increased.,2722224_8,-1,1,1,17036,1
17039,cardiac output,13,15,87,101,The rise in resting blood pressure with hydrocortisone is associated with an increased cardiac output (presumably due to increased blood volume).(ABSTRACT TRUNCATED AT 250 WORDS),2722224_9,-1,1,1,17039,1
17041,Neuromuscular blockade,0,2,0,22,Neuromuscular blockade with magnesium sulfate and nifedipine.,2750819_0,-1,1,1,17041,1
17044,neuromuscular blockade,8,10,59,81,A patient who received tocolysis with nifedipine developed neuromuscular blockade after 500 mg of magnesium sulfate was administered.,2750819_1,-1,1,1,17044,1
17072,side effects,12,14,75,87,"The possible utility of chronic CBZ in preventing the development of toxic side effects in human cocaine users is suggested by these data, but remains to be directly evaluated.",2790457_9,-1,1,1,17072,1
17151,movement disorder,1,3,4,21,"The movement disorder investigated in these studies has some features in common with human idiopathic dystonia, and information obtained in these studies may be of potential clinical benefit.",2840807_1,-1,1,1,17151,1
17165,movement disorder,75,77,410,427,"However, it is not certain as to the following: (a) what receptors were stimulated by the ACTH N-terminal fragments at the LC that resulted in this disorder; (b) whether NE, released onto Purkinje cell synapses located at terminals of the ceruleo-cerebellar pathway, did indeed cause the long-term depression at Purkinje cell synapses (previously described by others) that resulted in the long duration of the movement disorder; (c) whether the inhibition of inhibitory Purkinje cells resulted in disinhibition or increased excitability of the unilateral cerebellar fastigial or interpositus nuclei, the output targets of the Purkinje cell axons, that may have been an important contributing factor to this disorder.",2840807_3,-1,1,1,17165,1
17197,tachyarrhythmia,9,10,75,90,Flestolol effectively reduced heart rate in patients with supraventricular tachyarrhythmia.,2870085_9,-1,1,1,17197,1
17198,unstable angina,3,5,17,32,"In patients with unstable angina, flestolol infusion was found to be safe and effective in controlling chest pain.",2870085_10,-1,1,1,17198,1
17200,chest pain,17,19,103,113,"In patients with unstable angina, flestolol infusion was found to be safe and effective in controlling chest pain.",2870085_10,-1,1,1,17200,1
17235,prolactinomas,10,11,91,104,"Immunohistochemical, electron microscopic and morphometric studies of estrogen-induced rat prolactinomas after bromocriptine treatment.",2887062_0,-1,1,1,17235,1
17239,prolactinoma,7,8,43,55,"To clarify the effects of bromocriptine on prolactinoma cells in vivo, immunohistochemical, ultrastructural and morphometrical analyses were applied to estrogen-induced rat prolactinoma cells 1 h and 6 h after injection of bromocriptine (3 mg/kg of body weight).",2887062_1,-1,1,1,17239,1
17245,prolactinoma,23,24,173,185,"To clarify the effects of bromocriptine on prolactinoma cells in vivo, immunohistochemical, ultrastructural and morphometrical analyses were applied to estrogen-induced rat prolactinoma cells 1 h and 6 h after injection of bromocriptine (3 mg/kg of body weight).",2887062_1,-1,1,1,17245,1
17247,body weight,38,40,249,260,"To clarify the effects of bromocriptine on prolactinoma cells in vivo, immunohistochemical, ultrastructural and morphometrical analyses were applied to estrogen-induced rat prolactinoma cells 1 h and 6 h after injection of bromocriptine (3 mg/kg of body weight).",2887062_1,-1,1,1,17247,1
17253,prolactinoma,20,21,148,160,"Electron microscopy disclosed many secretory granules, slightly distorted rough endoplasmic reticulum, and partially dilated Golgi cisternae in the prolactinoma cells.",2887062_3,-1,1,1,17253,1
17264,prolactinoma,1,2,4,16,"The prolactinoma cells at this time were well granulated, with vesiculated rough endoplasmic reticulum and markedly dilated Golgi cisternae.",2887062_7,-1,1,1,17264,1
17273,prolactinoma,23,24,177,189,"Electron microscopical immunohistochemistry revealed positive reaction products noted on the secretory granules, Golgi cisternae, and endoplasmic reticulum of the untreated rat prolactinoma cells.",2887062_8,-1,1,1,17273,1
17291,brain stem,35,37,206,216,"25 mg/kg, i.v. thiopental produced anesthesia without altering respiratory rate, increased GABA, decreased glutamate, and had no effect on aspartate or glycine levels compared to controls in rat cortex and brain stem.",2893236_3,-1,1,1,17291,1
17296,brain stem,22,24,130,140,"50 mg/kg, i.v. thiopental produced respiratory arrest with further increase in GABA and decrease in glutamate again in cortex and brain stem without affecting any of the amino acids studied in four regions of rat brain.",2893236_5,-1,1,1,17296,1
17300,brain stem,20,22,106,116,"Naloxone (2.5 mg/kg, i.v.) reversed respiratory paralysis, glutamate and GABA levels to control values in brain stem and cortex with no changes in caudate or cerebellum.",2893236_6,-1,1,1,17300,1
17327,central nervous system,14,17,120,142,The data indicate that diazepam acts through the benzodiazepine-GABA-chloride channel macromolecular complex within the central nervous system to facilitate reflex bradycardia mediated through baroreceptor reflexes in response to an acute increase in arterial pressure.,2894433_6,-1,1,1,17327,1
17332,lupus erythematosus,1,3,22,41,Sulfasalazine-induced lupus erythematosus.,2894766_0,-1,1,1,17332,1
17378,postsynaptic,4,5,23,35,"However, inhibition of postsynaptic 5-HT receptors neither inhibited nor potentiated reversal of catalepsy and leaves open the question as to the site or mechanism for this effect.",2907585_5,-1,1,1,17378,1
17410,weight gain,32,34,183,194,"In the course of developing this model, a common vehicle, propylene glycol, by itself in high doses, was found to exhibit protective properties against induced seizures and inhibited weight gain.",2924746_4,-1,1,1,17410,1
17419,weight gain,30,32,182,193,Oral administration of CBZ as an aqueous suspension every 8 h at a dose of 250 mg/kg was continuously protective against HFDE-induced seizures and was minimally toxic as measured by weight gain over 8 weeks of treatment.,2924746_6,-1,1,1,17419,1
17427,side effect,12,14,61,72,"To our knowledge, this has not previously been reported as a side effect of preoperative dipyridamole therapy, although dipyridamole-induced myocardial ischemia has been demonstrated to occur in animals and humans with coronary artery disease.",2950248_2,-1,1,1,17427,1
17430,coronary artery disease,33,36,219,242,"To our knowledge, this has not previously been reported as a side effect of preoperative dipyridamole therapy, although dipyridamole-induced myocardial ischemia has been demonstrated to occur in animals and humans with coronary artery disease.",2950248_2,-1,1,1,17430,1
17482,nephrogenic diabetes insipidus,16,19,100,130,It has been suggested that adenylate cyclase inhibition may be important in the development of both nephrogenic diabetes insipidus and hypothyroidism during lithium treatment.,3001299_1,-1,1,1,17482,1
17492,Remodelling,0,1,0,11,Remodelling of nerve structure in experimental isoniazid neuropathy in the rat.,3015327_0,-1,1,1,17492,1
17588,side effects,4,6,22,34,There were no serious side effects in any of the treatment groups.,3057041_12,-1,1,1,17588,1
17590,altered taste,2,4,15,28,Drowsiness and altered taste perception were increased significantly over placebo only in the high-dose azelastine group.,3057041_13,-1,1,1,17590,1
17594,renal insufficiency,3,5,35,54,Reversibility of captopril-induced renal insufficiency after prolonged use in an unusual case of renovascular hypertension.,3070035_0,-1,1,1,17594,1
17595,renovascular hypertension,13,15,97,122,Reversibility of captopril-induced renal insufficiency after prolonged use in an unusual case of renovascular hypertension.,3070035_0,-1,1,1,17595,1
17596,renal artery,10,12,57,69,"We report a case of severe hypertension with an occluded renal artery to a solitary kidney, who developed sudden deterioration of renal function following treatment with captopril.",3070035_1,-1,1,1,17596,1
17597,solitary kidney,14,16,75,90,"We report a case of severe hypertension with an occluded renal artery to a solitary kidney, who developed sudden deterioration of renal function following treatment with captopril.",3070035_1,-1,1,1,17597,1
17602,renal failure,5,7,50,63,This indicates reversibility in captopril-induced renal failure even after its prolonged use and suggests that no organic damage occurs to glomerular arterioles following chronic ACE inhibition.,3070035_3,-1,1,1,17602,1
17632,rheumatoid arthritis,7,9,44,64,Toxicity due to remission inducing drugs in rheumatoid arthritis.,3084782_0,-1,1,1,17632,1
17635,rheumatoid arthritis,3,5,26,46,Twenty-five patients with rheumatoid arthritis (RA) who developed toxicity while taking remission inducing drugs and 30 without toxicity were studied for possible associations with class I and II HLA antigens.,3084782_2,-1,1,1,17635,1
17688,long term,14,16,101,110,Clinical and biochemical monitoring at regular intervals for evidence of hepatitis is advised during long term treatment with ketoconazole to prevent possible serious hepatic injury.,3101906_14,-1,1,1,17688,1
17696,viral infection,6,8,35,50,"There was no serologic evidence of viral infection, and a liver biopsy sample showed a histologic pattern consistent with drug-induced hepatitis.",3107448_4,-1,1,1,17696,1
17700,drug-induced hepatitis,20,22,122,144,"There was no serologic evidence of viral infection, and a liver biopsy sample showed a histologic pattern consistent with drug-induced hepatitis.",3107448_4,-1,1,1,17700,1
17706,microangiopathic hemolytic anemia,3,6,15,48,"It consists of microangiopathic hemolytic anemia, thrombocytopenia and progressive renal failure associated with mitomycin C treatment and affects about 10% of patients treated with this agent.",3108839_2,-1,1,1,17706,1
17707,renal failure,10,12,83,96,"It consists of microangiopathic hemolytic anemia, thrombocytopenia and progressive renal failure associated with mitomycin C treatment and affects about 10% of patients treated with this agent.",3108839_2,-1,1,1,17707,1
17711,renal failure,1,3,4,17,The renal failure usually develops about 8-10 mth after start of mitomycin C treatment and the mortality is approximately 60% from renal failure or pulmonary edema.,3108839_3,-1,1,1,17711,1
17713,renal failure,24,26,131,144,The renal failure usually develops about 8-10 mth after start of mitomycin C treatment and the mortality is approximately 60% from renal failure or pulmonary edema.,3108839_3,-1,1,1,17713,1
17718,subendothelial,17,18,106,120,"Renal lesions are similar to those seen in idiopathic HUS and include arteriolar fibrin thrombi, expanded subendothelial zones in glomerular capillary walls, ischemic wrinkling of glomerular basement membranes and mesangiolysis.",3108839_4,-1,1,1,17718,1
17723,clinical course,3,5,16,31,We describe the clinical course and pathological findings in a 65 yr-old man with gastric adenocarcinoma who developed renal failure and thrombocytopenia while on treatment with mitomycin C and died in pulmonary edema.,3108839_6,-1,1,1,17723,1
17725,renal failure,18,20,119,132,We describe the clinical course and pathological findings in a 65 yr-old man with gastric adenocarcinoma who developed renal failure and thrombocytopenia while on treatment with mitomycin C and died in pulmonary edema.,3108839_6,-1,1,1,17725,1
17730,muscle rigidity,4,6,52,67,Ketanserin pretreatment reverses alfentanil-induced muscle rigidity.,3115150_0,-1,1,1,17730,1
17734,muscle rigidity,16,18,128,143,"Systemic pretreatment with ketanserin, a relatively specific type-2 serotonin receptor antagonist, significantly attenuated the muscle rigidity produced in rats by the potent short-acting opiate agonist alfentanil.",3115150_1,-1,1,1,17734,1
17753,muscle rigidity,11,13,63,78,"These results, in combination with previous work, suggest that muscle rigidity, a clinically relevant side-effect of parenteral narcotic administration, may be partly mediated via serotonergic pathways.",3115150_7,-1,1,1,17753,1
17754,side-effect,17,18,102,113,"These results, in combination with previous work, suggest that muscle rigidity, a clinically relevant side-effect of parenteral narcotic administration, may be partly mediated via serotonergic pathways.",3115150_7,-1,1,1,17754,1
17757,opiate-induced,11,12,87,101,"Pretreatment with type-2 serotonin antagonists may be clinically useful in attenuating opiate-induced rigidity, although further studies will be necessary to assess the interaction of possibly enhanced CNS, cardiovascular, and respiratory depression.",3115150_8,-1,1,1,17757,1
17758,respiratory depression,32,34,227,249,"Pretreatment with type-2 serotonin antagonists may be clinically useful in attenuating opiate-induced rigidity, although further studies will be necessary to assess the interaction of possibly enhanced CNS, cardiovascular, and respiratory depression.",3115150_8,-1,1,1,17758,1
17827,squamous cell papilloma,40,43,231,254,"In groups given 2% BHA, although marked hyperplastic changes of the forestomach epithelium were observed in all animals, co-administration of 0.25% RA significantly (P less than 0.05) increased the incidence of forestomach tumors (squamous cell papilloma and carcinoma) to 60% (9/15, 2 rats with carcinoma) from 15% (3/20, one rat with carcinoma) in the group given RA-free water.",3131282_3,-1,1,1,17827,1
17844,side effect,8,10,53,64,Data on dose dependency or incidence concerning this side effect were not known.,3137399_1,-1,1,1,17844,1
17852,cardiac failure,5,7,30,45,One of the patients developed cardiac failure after 30 mg m-2 MMC and only 150 mg m-2 doxorubicin.,3137399_6,-1,1,1,17852,1
17854,cardiac failure,1,3,4,19,The cardiac failure was predicted by a drop in EF determined during a cold pressor test.,3137399_7,-1,1,1,17854,1
17864,myocardial infarction,7,9,44,65,Verapamil withdrawal as a possible cause of myocardial infarction in a hypertensive woman with a normal coronary angiogram.,3173179_0,-1,1,1,17864,1
17870,myocardial infarction,6,8,26,47,We report a case in which myocardial infarction coincided with the introduction of captopril and the withdrawal of verapamil in a previously asymptomatic woman with severe hypertension.,3173179_3,-1,1,1,17870,1
17904,cardiovascular disease,7,9,42,64,"In the pre-treatment evaluation, signs of cardiovascular disease were found in 33 patients (43%).",3187073_6,-1,1,1,17904,1
17908,cardiovascular disease,12,14,73,95,The incidence of cardiotoxicity was not higher in patients with signs of cardiovascular disease than in those without in the pre-treatment evaluation.,3187073_9,-1,1,1,17908,1
17911,chest pain,7,9,45,55,"The most common signs of cardiotoxicity were chest pain, ST-T wave changes and atrial fibrillation.",3187073_10,-1,1,1,17911,1
17913,atrial fibrillation,14,16,79,98,"The most common signs of cardiotoxicity were chest pain, ST-T wave changes and atrial fibrillation.",3187073_10,-1,1,1,17913,1
17915,sudden death,10,12,65,77,This was followed by ventricular fibrillation in one patient and sudden death in another.,3187073_11,-1,1,1,17915,1
17917,chest pain,21,23,131,141,It is concluded that patients on 5-FU treatment should be under close supervision and that the treatment should be discontinued if chest pain or tachyarrhythmia is observed.,3187073_12,-1,1,1,17917,1
17918,tachyarrhythmia,24,25,145,160,It is concluded that patients on 5-FU treatment should be under close supervision and that the treatment should be discontinued if chest pain or tachyarrhythmia is observed.,3187073_12,-1,1,1,17918,1
17919,gestational trophoblastic disease,4,7,27,60,Death from chemotherapy in gestational trophoblastic disease.,3192036_0,-1,1,1,17919,1
17941,acute onset,14,16,80,91,"In view of the close time association between the start of chemotherapy and the acute onset of massive embolism other explanations, such as spontaneous necrosis, must be considered less likely.",3192036_7,-1,1,1,17941,1
17988,cardiac output,28,30,156,170,"Before nitroprusside infusion, 5 cm H2O CPAP significantly, P less than .05, decreased arterial blood pressure, but did not significantly alter heart rate, cardiac output, systemic vascular resistance, or QS/QT.",322550_2,-1,1,1,17988,1
17995,cardiac output,22,24,154,168,Ten cm H2O CPAP before nitroprusside infusion produced a further decrease in arterial blood pressure and significantly increased heart rate and decreased cardiac output and QS/QT.,322550_3,-1,1,1,17995,1
18001,cardiac output,22,24,151,165,"Nitroprusside caused significant decreases in arterial blood pressure and systemic vascular resistance and increases in heart rate, but did not change cardiac output or QS/QT.",322550_4,-1,1,1,18001,1
18008,cardiac output,11,13,59,73,"However, 10 cm H2O CPAP decreased arterial blood pressure, cardiac output, and QS/QT.",322550_6,-1,1,1,18008,1
18012,cardiac output,22,24,129,143,These data indicate that nitroprusside infusion rates that decrease mean arterial blood pressure by 40-50 per cent do not change cardiac output or QS/QT.,322550_7,-1,1,1,18012,1
18019,cardiac output,37,39,213,227,"During nitroprusside infusion low levels of CPAP do not markedly alter cardiovascular dynamics, but high levels of CPAP (10 cm H2O), while decreasing QS/QT, produce marked decreases in arterial blood pressure and cardiac output.",322550_8,-1,1,1,18019,1
18029,vasospasm,5,6,22,31,"A rare case of morbid vasospasm, together with striking angiographic findings, is described secondary to the ingestion of methysergide by a 48-year-old woman.",3300918_1,-1,1,1,18029,1
18032,migraine headache,33,35,183,200,"A discussion of the history of ergot includes its original discovery, the epidemics of gangrene that it has caused through the ages and its past and present role in the management of migraine headache.",3300918_3,-1,1,1,18032,1
18061,side effect,28,30,196,207,We think that even these lower dosages of cyclosporine can cause chronic nephrotoxicity and that further modification of the immunosuppressive regimen is required to completely abolish this toxic side effect.,3311455_7,-1,1,1,18061,1
18072,cardiac output,4,6,35,49,During HEM-induced hypotension the cardiac output was significantly lower and systemic vascular resistance higher compared with that in the SNP group.,3341566_3,-1,1,1,18072,1
18092,Ventricular tachyarrhythmias,0,2,0,28,Ventricular tachyarrhythmias during cesarean section after ritodrine therapy: interaction with anesthetics.,3358181_0,-1,1,1,18092,1
18127,metabolic acidosis,3,5,29,47,"Paracetamol-associated coma, metabolic acidosis, renal and hepatic failure.",3403780_0,-1,1,1,18127,1
18129,metabolic acidosis,3,5,10,28,"A case of metabolic acidosis, acute renal failure and hepatic failure following paracetamol ingestion is presented.",3403780_1,-1,1,1,18129,1
18130,acute renal failure,6,9,30,49,"A case of metabolic acidosis, acute renal failure and hepatic failure following paracetamol ingestion is presented.",3403780_1,-1,1,1,18130,1
18137,rheumatoid arthritis,13,15,94,114,"The relationship of arthritis and sexual dysfunction was investigated among 169 patients with rheumatoid arthritis, osteoarthritis and spondyloarthropathy, 130 of whom were pair-matched to controls.",3409645_1,-1,1,1,18137,1
18147,co-morbidity,16,17,96,108,Impotence was more common among male patients than controls and was found to be associated with co-morbidity and the taking of methotrexate.,3409645_4,-1,1,1,18147,1
18158,fulminant hepatitis,2,4,41,60,Quinidine phenylethylbarbiturate-induced fulminant hepatitis in a pregnant woman.,3411101_0,-1,1,1,18158,1
18160,fulminant hepatitis,11,13,64,83,We report the case of a 19-year-old Laotian patient affected by fulminant hepatitis during the third trimester of her pregnancy after a 1-month administration of quinidine phenylethylbarbiturate.,3411101_2,-1,1,1,18160,1
18165,fulminant hepatitis,8,10,66,85,Quinidine itself or phenylethylbarbiturate may be responsible for fulminant hepatitis in this patient.,3411101_5,-1,1,1,18165,1
18170,cancer of,16,18,120,129,"Does paracetamol cause urothelial cancer or renal papillary necrosis?The risk of developing renal papillary necrosis or cancer of the renal pelvis, ureter or bladder associated with consumption of either phenacetin or paracetamol was calculated from data acquired by questionnaire from 381 cases and 808 controls.",3412544_0,-1,1,1,18170,1
18175,cancer of,21,23,130,139,"The risk of renal papillary necrosis was increased nearly 20-fold by consumption of phenacetin, which also increased the risk for cancer of the renal pelvis and bladder but not for ureteric cancer.",3412544_1,-1,1,1,18175,1
18180,cancer of the ureter,32,36,199,219,"By contrast, we were unable to substantiate an increased risk from paracetamol consumption for renal papillary necrosis or any of these cancers although there was a suggestion of an association with cancer of the ureter.",3412544_2,-1,1,1,18180,1
18182,exercise-induced,10,11,74,90,Mechanisms of myocardial ischemia induced by epinephrine: comparison with exercise-induced ischemia.,3413271_0,-1,1,1,18182,1
18184,coronary artery disease,13,16,87,110,The role of epinephrine in eliciting myocardial ischemia was examined in patients with coronary artery disease.,3413271_1,-1,1,1,18184,1
18199,hemolytic anemia,3,5,30,46,Dapsone-associated Heinz body hemolytic anemia in a Cambodian woman with hemoglobin E trait.,3425586_0,-1,1,1,18199,1
18202,hemolytic anemia,16,18,82,98,A Cambodian woman with hemoglobin E trait (AE) and leprosy developed a Heinz body hemolytic anemia while taking a dose of dapsone (50 mg/day) not usually associated with clinical hemolysis.,3425586_1,-1,1,1,18202,1
18222,hemolytic anemia,25,27,128,144,"Thus, AE RBCs appear to have an increased sensitivity to oxidant stress both in vitro and in vivo, since dapsone does not cause hemolytic anemia at this dose in hematologically normal individuals.",3425586_6,-1,1,1,18222,1
18251,breast cancer,13,15,66,79,"In early clinical studies with CB 3717, activity has been seen in breast cancer, ovarian cancer, hepatoma, and mesothelioma.",3431591_4,-1,1,1,18251,1
18252,ovarian cancer,16,18,81,95,"In early clinical studies with CB 3717, activity has been seen in breast cancer, ovarian cancer, hepatoma, and mesothelioma.",3431591_4,-1,1,1,18252,1
18256,renal tubule,13,15,73,85,This latter effect is thought to be due to drug precipitation within the renal tubule as a result of the poor solubility of CB 3717 under acidic conditions.,3431591_6,-1,1,1,18256,1
18266,side effects,8,10,55,67,Hepatotoxicity and malaise are again the most frequent side effects.,3431591_9,-1,1,1,18266,1
18274,needle-stick,4,5,23,35,Type B hepatitis after needle-stick exposure: prevention with hepatitis B immune globulin.,343678_0,-1,1,1,18274,1
18283,needle-stick,33,34,190,202,"Hepatitis B immune globulin (HBIG) and immune serum globulin (ISG) were examined in a randomized, double-blind trial to assess their relative efficacies in preventing type B hepatitis after needle-stick exposure to hepatitis B surface antigen (HBsAG)-positive donors.",343678_2,-1,1,1,18283,1
18313,coronary artery disease,5,8,37,60,A 47-year-old patient suffering from coronary artery disease was admitted to the CCU in shock with III.,3437726_1,-1,1,1,18313,1
18332,adverse drug reactions,26,29,187,209,"Therefore, patients belonging to the poor-metabolizer phenotype of sparteine/debrisoquine polymorphism in drug metabolism, which constitutes 6.4% of the German population, may experience adverse drug reactions when treated with standard doses of one of these drugs alone.",3437726_9,-1,1,1,18332,1
18336,prostate cancer,3,5,28,43,Production of autochthonous prostate cancer in Lobund-Wistar rats by treatments with N-nitroso-N-methylurea and testosterone.,3461217_0,-1,1,1,18336,1
18350,prostate cancer,19,21,96,111,"In L-W rats, TP acted as a tumor enhancement agent, with primary emphasis on the development of prostate cancer.",3461217_4,-1,1,1,18350,1
18362,extrapyramidal,6,7,41,55,Nine patients exhibited mild to moderate extrapyramidal concomitant symptoms; no other side effects were observed.,347884_6,-1,1,1,18362,1
18363,side effects,12,14,87,99,Nine patients exhibited mild to moderate extrapyramidal concomitant symptoms; no other side effects were observed.,347884_6,-1,1,1,18363,1
18373,side effects,7,9,45,57,No differences were observed with respect to side effects and general tolerability.,347884_10,-1,1,1,18373,1
18381,hypereosinophilia,13,14,92,109,Jaundice occurred after administration of troleandomycin for 7 days and was associated with hypereosinophilia.,3496378_2,-1,1,1,18381,1
18389,neurotoxicity,4,5,27,40,Serial studies of auditory neurotoxicity in patients receiving deferoxamine therapy.,3503576_0,-1,1,1,18389,1
18391,neurotoxicity,3,4,20,33,Visual and auditory neurotoxicity was previously documented in 42 of 89 patients with transfusion-dependent anemia who were receiving iron chelation therapy with daily subcutaneous deferoxamine.,3503576_1,-1,1,1,18391,1
18403,ototoxicity,29,30,242,253,"Auditory deterioration and improvement, demonstrated serially in individual patients receiving and not receiving deferoxamine, respectively, provided convincing evidence for a cause-and-effect relation between deferoxamine administration and ototoxicity.",3503576_6,-1,1,1,18403,1
18408,hearing loss,5,7,26,38,"In those with symptoms of hearing loss, the drug should be stopped for four weeks, and when the audiogram is stable or improved, therapy should be restarted at 10 to 25 mg/kg per dose.",3503576_11,-1,1,1,18408,1
18411,serum ferritin,20,22,131,145,Serial audiograms should be performed every six months in those without problems and more frequently in young patients with normal serum ferritin values and in those with auditory dysfunction.,3503576_12,-1,1,1,18411,1
18412,auditory dysfunction,27,29,171,191,Serial audiograms should be performed every six months in those without problems and more frequently in young patients with normal serum ferritin values and in those with auditory dysfunction.,3503576_12,-1,1,1,18412,1
18422,Ototoxicity,0,1,0,11,Ototoxicity occurred in four (9.5%) of 42 netilmicin and piperacillin and in 12 (22%) of 54 tobramycin and piperacillin-treated patients.,3535719_4,-1,1,1,18422,1
18432,ototoxicity,4,5,43,54,We conclude that aminoglycoside-associated ototoxicity was less severe and more often reversible with netilmicin than with tobramycin.,3535719_7,-1,1,1,18432,1
18440,juvenile rheumatoid arthritis,5,8,33,62,Flurbiprofen in the treatment of juvenile rheumatoid arthritis.,3560095_0,-1,1,1,18440,1
18441,juvenile rheumatoid arthritis,3,6,26,55,"Thirty-four patients with juvenile rheumatoid arthritis, who were treated with flurbiprofen at a maximum dose of 4 mg/kg/day, had statistically significant decreases from baseline in 6 arthritis indices after 12 weeks of treatment.",3560095_1,-1,1,1,18441,1
18447,side effect,4,6,29,40,"The most frequently observed side effect was fecal occult blood (25% of patients); however, there was no other evidence of gastrointestinal (GI) bleeding in these patients.",3560095_3,-1,1,1,18447,1
18450,abdominal pain,12,14,80,94,One patient was prematurely discontinued from the study for severe headache and abdominal pain.,3560095_4,-1,1,1,18450,1
18451,side effects,1,3,5,17,Most side effects were mild and related to the GI tract.,3560095_5,-1,1,1,18451,1
18469,vasospasm,1,2,8,17,Intense vasospasm with threatened gangrene arose in the arm used for the infusion.,3564823_3,-1,1,1,18469,1
18471,vasospasm,24,25,161,170,"Since the cranial condition precluded use of more usual methods, lidocaine was given intra-arterially, with careful cardiovascular monitoring, to counteract the vasospasm.",3564823_4,-1,1,1,18471,1
18557,Reye syndrome,3,5,20,33,"Twenty-six cases of Reye syndrome from The Children's Hospital, Camperdown, Australia, occurring between 1973 and 1982 were reviewed.",3670965_1,-1,1,1,18557,1
18562,Reye syndrome,20,22,110,123,"Of these, 20 cases met the US Public Health Service Centers for Disease Control criteria for the diagnosis of Reye syndrome.",3670965_2,-1,1,1,18562,1
18564,Reye syndrome,6,8,44,57,Pathologic confirmation of the diagnosis of Reye syndrome was accomplished in 90% of the cases.,3670965_4,-1,1,1,18564,1
18565,Reye syndrome,3,5,17,30,"The incidence of Reye syndrome in New South Wales, Australia, is estimated from this study to be approximately nine cases per 1 million children compared with recent US data of ten to 20 cases per 1 million children and three to seven cases per 1 million children in Great Britain.",3670965_5,-1,1,1,18565,1
18568,Reye syndrome,4,6,24,37,The mortality for these Reye syndrome cases in Australia was 45% as compared with a 32% case-fatality rate in the United States.,3670965_6,-1,1,1,18568,1
18572,Reye syndrome,0,2,0,13,"Reye syndrome may be disappearing from Australia despite a total lack of association with salicylates or aspirin ingestion, since there were no cases found at The Children's Hospital in 1983, 1984, or 1985.",3670965_8,-1,1,1,18572,1
18576,cerebral aneurysms,14,16,110,128,Cerebral blood flow and metabolism during isoflurane-induced hypotension in patients subjected to surgery for cerebral aneurysms.,3676049_0,-1,1,1,18576,1
18580,cerebral aneurysm,24,26,168,185,Cerebral blood flow and cerebral metabolic rate for oxygen were measured during isoflurane-induced hypotension in 10 patients subjected to craniotomy for clipping of a cerebral aneurysm.,3676049_1,-1,1,1,18580,1
18581,subarachnoid,11,12,54,66,Flow and metabolism were measured 5-13 days after the subarachnoid haemorrhage by a modification of the classical Kety-Schmidt technique using xenon-133 i.v.,3676049_2,-1,1,1,18581,1
18629,Nonketotic,0,1,0,10,Nonketotic lactic acidosis was present in one and ketosis without a known serum lactate level was present in the other.,3703509_4,-1,1,1,18629,1
18631,Respiratory failure,0,2,0,19,Respiratory failure rapidly ensued and both patients expired in spite of efforts at resuscitation.,3703509_5,-1,1,1,18631,1
18660,spinal cord,2,4,10,21,"Brain and spinal cord NTE activities were measured in Long-Evans male rats 1 hr post-exposure to various dosages of Mipafox (ip, 1-15 mg/kg).",3714122_2,-1,1,1,18660,1
18669,spinal cord,18,20,90,101,Those dosages (greater than or equal to 10 mg/kg) that inhibited mean NTE activity in the spinal cord greater than or equal to 73% and brain greater than or equal to 67% of control values produced severe (greater than or equal to 3) cervical cord pathology in 85% of the rats.,3714122_4,-1,1,1,18669,1
18674,spinal cord,21,23,101,112,"In contrast, dosages of Mipafox (less than or equal to 5 mg/kg) which inhibited mean NTE activity in spinal cord less than or equal to 61% and brain less than or equal to 60% produced this degree of cord damage in only 9% of the animals.",3714122_5,-1,1,1,18674,1
18678,spinal cord,13,15,78,89,These data indicate that a critical percentage of NTE inhibition in brain and spinal cord sampled shortly after Mipafox exposure can predict neuropathic damage in rats several weeks later.,3714122_6,-1,1,1,18678,1
18681,Allergic reaction,0,2,0,17,Allergic reaction to 5-fluorouracil infusion.,3719553_0,-1,1,1,18681,1
18683,allergic reaction,1,3,3,20,"An allergic reaction consisting of angioneurotic edema secondary to continuous infusion 5-fluorouracil occurred in a patient with recurrent carcinoma of the oral cavity, cirrhosis, and cisplatin-induced impaired renal function.",3719553_1,-1,1,1,18683,1
18691,allergic reaction,12,14,89,106,Oral diphenhydramine and prednisone were ineffective in preventing the recurrence of the allergic reaction.,3719553_3,-1,1,1,18691,1
18693,disease progression,13,15,100,119,Discontinuance of effective chemotherapy in this patient during partial remission resulted in fatal disease progression.,3719553_4,-1,1,1,18693,1
18697,coronary artery disease,7,10,31,54,"If this were so, patients with coronary artery disease might be especially susceptible.",3732088_2,-1,1,1,18697,1
18700,coronary artery disease,15,18,109,132,"Thus, myocardial electrical excitability was measured in patients with mild essential hypertension and known coronary artery disease after 8 weeks of treatment with a potassium-conserving diuretic (amiloride) and a similar period on a potassium-losing diuretic (chlorthalidone) in a randomised study.",3732088_3,-1,1,1,18700,1
18706,bodyweight,8,9,48,58,"Blood pressure and volume states as assessed by bodyweight, plasma renin and noradrenaline (norepinephrine) concentrations were similar on the 2 regimens.",3732088_5,-1,1,1,18706,1
18722,Myasthenia gravis,0,2,0,17,Myasthenia gravis caused by penicillamine and chloroquine therapy for rheumatoid arthritis.,3750012_0,-1,1,1,18722,1
18723,rheumatoid arthritis,9,11,70,90,Myasthenia gravis caused by penicillamine and chloroquine therapy for rheumatoid arthritis.,3750012_0,-1,1,1,18723,1
18724,myasthenia gravis,11,13,71,88,We have described a unique patient who had reversible and dose-related myasthenia gravis after penicillamine and chloroquine therapy for rheumatoid arthritis.,3750012_1,-1,1,1,18724,1
18725,rheumatoid arthritis,19,21,137,157,We have described a unique patient who had reversible and dose-related myasthenia gravis after penicillamine and chloroquine therapy for rheumatoid arthritis.,3750012_1,-1,1,1,18725,1
18754,side effect,17,19,112,123,This antidyskinetic drug is widely used in clinical psychiatric practice and physicians should be aware of this side effect.,3769769_4,-1,1,1,18754,1
18755,Post-operative,0,1,0,14,Post-operative rigidity after fentanyl administration.,3780697_0,-1,1,1,18755,1
18757,respiratory failure,7,9,48,67,A case of thoraco-abdominal rigidity leading to respiratory failure is described in the post-operative period in an elderly patient who received a moderate dose of fentanyl.,3780697_1,-1,1,1,18757,1
18758,post-operative,13,14,88,102,A case of thoraco-abdominal rigidity leading to respiratory failure is described in the post-operative period in an elderly patient who received a moderate dose of fentanyl.,3780697_1,-1,1,1,18758,1
18765,preneoplastic,16,17,80,93,"After the end of the treatment, the number and the size of induced PAS positive preneoplastic foci was significantly reduced when PB was given simultaneously with DEN for 4 and 6 weeks.",3780814_3,-1,1,1,18765,1
18767,micronuclei,7,8,45,56,The mitotic inhibition and the production of micronuclei normally observed after partial hepatectomy in DEN treated rats were also significantly decreased in DEN + PB treated rats.,3780814_4,-1,1,1,18767,1
18770,muscular rigidity,10,12,57,74,On the mechanisms of the development of tolerance to the muscular rigidity produced by morphine in rats.,3780846_0,-1,1,1,18770,1
18771,muscular rigidity,6,8,36,53,The development of tolerance to the muscular rigidity produced by morphine was studied in rats.,3780846_1,-1,1,1,18771,1
18776,akinetic,47,48,255,263,Rats treated for 11 days with morphine and withdrawn for 36-40 h showed differences in the development of tolerance: about half of the animals showed a rigidity after the test dose of morphine that was not significantly less than in the controls and were akinetic (A group).,3780846_3,-1,1,1,18776,1
18778,akinetic,24,25,132,140,"The other rats showed a strong decrease in the rigidity and the occurrence of stereotyped (S) licking and/or gnawing in presence of akinetic or hyperkinetic (K) behaviour (AS/KS group), suggesting signs of dopaminergic activation.",3780846_4,-1,1,1,18778,1
18779,hyperkinetic,26,27,144,156,"The other rats showed a strong decrease in the rigidity and the occurrence of stereotyped (S) licking and/or gnawing in presence of akinetic or hyperkinetic (K) behaviour (AS/KS group), suggesting signs of dopaminergic activation.",3780846_4,-1,1,1,18779,1
18796,signs and symptoms,2,5,13,31,"The clinical signs and symptoms, typical laboratory features, and complications of rhabdomyolysis are presented.",3782049_2,-1,1,1,18796,1
18801,acute renal failure,14,17,100,119,The case of a schizophrenic patient is reported to illustrate massive rhabdomyolysis and subsequent acute renal failure following molindone administration.,3782049_3,-1,1,1,18801,1
18804,radial nerve,4,6,30,42,Compression neuropathy of the radial nerve due to pentazocine-induced fibrous myopathy.,3800626_0,-1,1,1,18804,1
18807,side effect,7,9,41,52,"Fibrous myopathy is a common, well-known side effect of repeated pentazocine injection.",3800626_1,-1,1,1,18807,1
18815,wrist drop,21,23,153,163,"In a 37-year-old woman with documented pentazocine-induced fibrous myopathy of triceps and deltoid muscles bilaterally and a three-week history of right wrist drop, electrodiagnostic examination showed a severe but partial lesion of the right radial nerve distal to the branches to the triceps, in addition to the fibrous myopathy.",3800626_3,-1,1,1,18815,1
18817,radial nerve,35,37,243,255,"In a 37-year-old woman with documented pentazocine-induced fibrous myopathy of triceps and deltoid muscles bilaterally and a three-week history of right wrist drop, electrodiagnostic examination showed a severe but partial lesion of the right radial nerve distal to the branches to the triceps, in addition to the fibrous myopathy.",3800626_3,-1,1,1,18817,1
18819,radial nerve,4,6,27,39,Surgery revealed the right radial nerve to be severely compressed by the densely fibrotic lateral head of the triceps.,3800626_4,-1,1,1,18819,1
18822,acute renal failure,2,5,21,40,Recurrent reversible acute renal failure from amphotericin.,3827439_0,-1,1,1,18822,1
18823,cryptogenic,3,4,15,26,A patient with cryptogenic cirrhosis and disseminated sporotrichosis developed acute renal failure immediately following the administration of amphotericin B on four separate occasions.,3827439_1,-1,1,1,18823,1
18824,acute renal failure,9,12,79,98,A patient with cryptogenic cirrhosis and disseminated sporotrichosis developed acute renal failure immediately following the administration of amphotericin B on four separate occasions.,3827439_1,-1,1,1,18824,1
18826,renal failure,4,6,22,35,The abruptness of the renal failure and its reversibility within days suggests that there was a functional component to the renal dysfunction.,3827439_2,-1,1,1,18826,1
18830,acute renal failure,22,25,147,166,"We propose that amphotericin, in the setting of reduced effective arterial volume, may activate tubuloglomerular feedback, thereby contributing to acute renal failure.",3827439_3,-1,1,1,18830,1
18831,Cerebral infarction,0,2,0,19,Cerebral infarction with a single oral dose of phenylpropanolamine.,3828020_0,-1,1,1,18831,1
18837,intracerebral hemorrhage,11,13,64,88,"Its prolonged use or overuse has been associated with seizures, intracerebral hemorrhage, neuropsychiatric symptoms, and nonhemorrhagic cerebral infarction.",3828020_2,-1,1,1,18837,1
18839,cerebral infarction,19,21,136,155,"Its prolonged use or overuse has been associated with seizures, intracerebral hemorrhage, neuropsychiatric symptoms, and nonhemorrhagic cerebral infarction.",3828020_2,-1,1,1,18839,1
18840,cerebral infarction,11,13,51,70,We report the case of a young woman who suffered a cerebral infarction after taking a single oral dose of PPA.,3828020_3,-1,1,1,18840,1
18843,optic neuropathy,1,3,10,26,Bilateral optic neuropathy due to combined ethambutol and isoniazid treatment.,384871_0,-1,1,1,18843,1
18847,retrobulbar,2,3,12,23,A bilateral retrobulbar neuropathy with an unusual central bitemporal hemianopic scotoma was found.,384871_2,-1,1,1,18847,1
18848,bitemporal,8,9,59,69,A bilateral retrobulbar neuropathy with an unusual central bitemporal hemianopic scotoma was found.,384871_2,-1,1,1,18848,1
18853,optic nerve,3,5,15,26,The hazards of optic nerve toxicity due to ethambutol are known.,384871_5,-1,1,1,18853,1
18858,acute lymphoblastic leukemia,3,6,21,49,Twenty children with acute lymphoblastic leukemia who developed meningeal disease were treated with a high-dose intravenous methotrexate regimen that was designed to achieve and maintain CSF methotrexate concentrations of 10(-5) mol/L without the need for concomitant intrathecal dosing.,3856631_1,-1,1,1,18858,1
18875,mucositis,16,17,116,125,"The most common toxicities encountered were transient serum transaminase and bilirubin elevations, neutropenia, and mucositis.",3856631_5,-1,1,1,18875,1
18876,focal seizures,3,5,16,30,One patient had focal seizures and transient hemiparesis but recovered completely.,3856631_6,-1,1,1,18876,1
18877,hemiparesis,7,8,45,56,One patient had focal seizures and transient hemiparesis but recovered completely.,3856631_6,-1,1,1,18877,1
18880,acute lymphoblastic leukemia,16,19,119,147,High-dose intravenous methotrexate is an effective treatment for the induction of remission after meningeal relapse in acute lymphoblastic leukemia.,3856631_7,-1,1,1,18880,1
18889,side effects,1,3,7,19,"Severe side effects in terms of mental confusion and progressive hyperbilirubinemia, however, point to an enhancement not only of antineoplastic effects but also of toxicity in normal tissues.",3865016_3,-1,1,1,18889,1
18897,adverse reactions,4,6,23,40,A prospective study of adverse reactions associated with vancomycin therapy.,3934126_0,-1,1,1,18897,1
18903,adverse reactions,8,10,45,62,Drugs were ceased in six patients because of adverse reactions; in three of these vancomycin was considered the likely cause.,3934126_3,-1,1,1,18903,1
18909,ototoxicity,11,12,93,104,Thrombophlebitis occurred only with infusion through peripheral cannulae; nephrotoxicity and ototoxicity were confined to patients receiving an aminoglycoside plus vancomycin.,3934126_5,-1,1,1,18909,1
18966,chest pain,15,17,86,96,We report a case of a patient with colon carcinoma and liver metastasis who presented chest pain after 5-fluorouracil (5-FU) administration.,3952818_2,-1,1,1,18966,1
18971,chest pain,14,16,97,107,"Clinical electrocardiographic evolution was similar to that observed in Prinzmetal's angina, and chest pain promptly resolved with nifedipine.",3952818_3,-1,1,1,18971,1
19004,tachyarrhythmias,12,13,85,101,Amiodarone has proved very effective in the treatment of otherwise resistant cardiac tachyarrhythmias.,3962737_1,-1,1,1,19004,1
19005,side-effects,14,15,68,80,"The use of amiodarone has, however, been limited due to its serious side-effects.",3962737_2,-1,1,1,19005,1
19010,steatosis,16,17,100,109,"It is concluded that solid evidence exists of hepatic injury due to amiodarone treatment, including steatosis, alterations resembling alcoholic hepatitis, cholestatic hepatitis and micronodular cirrhosis of the liver.",3962737_4,-1,1,1,19010,1
19011,alcoholic hepatitis,20,22,134,153,"It is concluded that solid evidence exists of hepatic injury due to amiodarone treatment, including steatosis, alterations resembling alcoholic hepatitis, cholestatic hepatitis and micronodular cirrhosis of the liver.",3962737_4,-1,1,1,19011,1
19023,prostate cancer,17,19,99,114,"Conventional LW rats, implanted with testosterone at age 4 months, developed a higher incidence of prostate cancer after an average interval of 14 months: 24% had developed gross tumors, and 40% when it included microscopic tumors.",3969369_2,-1,1,1,19023,1
19027,prostate cancer,27,29,154,169,"Preliminary results indicate that testosterone-treated LW rats that were fed the same diet, which was supplemented with corn oil up to 20% fat, developed prostate cancer after intervals of 6-12 months.",3969369_3,-1,1,1,19027,1
19028,prostate cancer,10,12,52,67,Aged GF Sprague-Dawley (SD) rats have not developed prostate cancer spontaneously.,3969369_4,-1,1,1,19028,1
19033,prostate cancer,14,16,112,127,Experimental designs should consider genetic susceptibility as a basic prerequisite for studies on experimental prostate cancer.,3969369_6,-1,1,1,19033,1
19034,rheumatoid arthritis,6,8,40,60,Incidence of neoplasms in patients with rheumatoid arthritis exposed to different treatment regimens.,3970039_0,-1,1,1,19034,1
19037,rheumatoid arthritis,16,18,101,121,Immunosuppressive drugs have been used during the last 30 years in treatment of patients with severe rheumatoid arthritis.,3970039_1,-1,1,1,19037,1
19042,adverse reactions,1,3,6,23,"Since adverse reactions are frequent, less than 50 percent of patients are able to continue a particular drug for more than one year.",3970039_4,-1,1,1,19042,1
19046,acute nonlymphocytic leukemia,12,15,81,110,"Patients treated with alkylating agents have an increased risk of development of acute nonlymphocytic leukemia, and both alkylating agents and azathioprine are associated with the development of non-Hodgkin's lymphoma.",3970039_6,-1,1,1,19046,1
19049,non-Hodgkin's lymphoma,28,31,195,217,"Patients treated with alkylating agents have an increased risk of development of acute nonlymphocytic leukemia, and both alkylating agents and azathioprine are associated with the development of non-Hodgkin's lymphoma.",3970039_6,-1,1,1,19049,1
19051,rheumatoid arthritis,9,11,59,79,There have been several long-term studies of patients with rheumatoid arthritis treated with azathioprine and cyclophosphamide and the incidence of most of the common cancers is not increased.,3970039_8,-1,1,1,19051,1
19054,rheumatoid arthritis,9,11,53,73,"Data on the possible increased risk of malignancy in rheumatoid arthritis are still being collected, and until further information is available, the use of immunosuppressive drugs, particularly alkylating agents, in the treatment of rheumatoid arthritis should be reserved for patients with severe progressive disease or life-threatening complications.",3970039_9,-1,1,1,19054,1
19057,rheumatoid arthritis,37,39,233,253,"Data on the possible increased risk of malignancy in rheumatoid arthritis are still being collected, and until further information is available, the use of immunosuppressive drugs, particularly alkylating agents, in the treatment of rheumatoid arthritis should be reserved for patients with severe progressive disease or life-threatening complications.",3970039_9,-1,1,1,19057,1
19063,left ventricular,15,17,103,119,"Time course alterations of QTC interval due to hypaque 76.Sequential measurement of QT interval during left ventricular angiography was made 30 seconds and one, three, five and ten minutes after injection of hypaque 76.",3973521_0,-1,1,1,19063,1
19068,cardiac output,18,20,122,136,Significant QTC prolongation occurred in 30 seconds to one minute in association with marked hypotension and elevation of cardiac output.,3973521_2,-1,1,1,19068,1
19070,nerve palsy,6,8,62,73,Warfarin-induced iliopsoas hemorrhage with subsequent femoral nerve palsy.,3985451_0,-1,1,1,19070,1
19074,nerve entrapment,8,10,64,80,"Surgical exploration revealed an iliopsoas hematoma and femoral nerve entrapment, resulting in a femoral nerve palsy and partial loss of quadriceps functions.",3985451_2,-1,1,1,19074,1
19075,nerve palsy,15,17,105,116,"Surgical exploration revealed an iliopsoas hematoma and femoral nerve entrapment, resulting in a femoral nerve palsy and partial loss of quadriceps functions.",3985451_2,-1,1,1,19075,1
19078,nerve palsy,2,4,30,41,"Anticoagulant-induced femoral nerve palsy represents the most common form of warfarin-induced peripheral neuropathy; it is characterized by severe pain in the inguinal region, varying degrees of motor and sensory impairment, and flexure contracture of the involved extremity.",3985451_3,-1,1,1,19078,1
19079,peripheral neuropathy,11,13,94,115,"Anticoagulant-induced femoral nerve palsy represents the most common form of warfarin-induced peripheral neuropathy; it is characterized by severe pain in the inguinal region, varying degrees of motor and sensory impairment, and flexure contracture of the involved extremity.",3985451_3,-1,1,1,19079,1
19083,pericardial effusion,4,6,29,49,Pneumonitis with pleural and pericardial effusion and neuropathy during amiodarone therapy.,3997294_0,-1,1,1,19083,1
19089,pericardial effusions,6,8,38,59,"He developed pneumonitis, pleural and pericardial effusions, and a predominantly proximal motor neuropathy.",3997294_2,-1,1,1,19089,1
19090,motor neuropathy,13,15,90,106,"He developed pneumonitis, pleural and pericardial effusions, and a predominantly proximal motor neuropathy.",3997294_2,-1,1,1,19090,1
19096,supraventricular tachycardia,20,22,154,182,"We observed sinoatrial block due to chronic amiodarone administration in a 5-year-old boy with primary cardiomyopathy, Wolff-Parkinson-White syndrome and supraventricular tachycardia.",4008111_1,-1,1,1,19096,1
19117,retrobulbar,33,34,213,224,"Local anesthetics that are commonly used in ophthalmic surgery (0.75% bupivacaine hydrochloride, 2.0% mepivacaine hydrochloride, and 2.0% lidocaine hydrochloride plus 1:100,000 epinephrine) were injected into the retrobulbar area of rat eyes.",4038130_2,-1,1,1,19117,1
19132,acute renal failure,12,15,66,85,The clinical and autopsy findings in a premature baby who died of acute renal failure after therapy with gentamicin (5 mg/kg/day) and penicillin are presented.,4069770_1,-1,1,1,19132,1
19140,renal insufficiency,1,3,21,40,Indomethacin-induced renal insufficiency: recurrence on rechallenge.,4071154_0,-1,1,1,19140,1
19145,drug withdrawal,6,8,46,61,"Prompt restoration of renal function followed drug withdrawal, while re-exposure to a single dose of indomethacin caused recurrence of acute reversible oliguria.",4071154_2,-1,1,1,19145,1
19154,compensatory,7,8,64,76,"Since nonsteroidal anti-inflammatory agents interfere with this compensatory mechanism and may cause acute renal failure, they should be used with caution in such patients.",4071154_4,-1,1,1,19154,1
19155,acute renal failure,12,15,101,120,"Since nonsteroidal anti-inflammatory agents interfere with this compensatory mechanism and may cause acute renal failure, they should be used with caution in such patients.",4071154_4,-1,1,1,19155,1
19177,liver disease,3,5,21,34,Twelve patients with liver disease related to methyldopa were seen between 1967 and 1977.,424937_1,-1,1,1,19177,1
19180,abdominal pain,22,24,133,147,"Jaundice with tender hepatomegaly, usually preceded by symptoms of malaise, anorexia, nausea and vomiting, and associated with upper abdominal pain, was an invariable finding in all patients.",424937_3,-1,1,1,19180,1
19188,massive hepatic necrosis,29,32,217,241,"Biochemical liver function tests indicated hepatocellular necrosis and correlated with histopathological evidence of hepatic injury, the spectrum of which ranged from fatty change and focal hepatocellular necrosis to massive hepatic necrosis.",424937_4,-1,1,1,19188,1
19190,chronic active hepatitis,9,12,59,83,Most patients showed moderate to severe acute hepatitis or chronic active hepatitis with associated cholestasis.,424937_5,-1,1,1,19190,1
19193,fulminant hepatitis,7,9,46,65,The remaining patient in the series developed fulminant hepatitis when the drug was accidentally recommenced 1 year after a prior episode of methyldopa-induced hepatitis.,424937_8,-1,1,1,19193,1
19198,hemiparesis,1,2,10,21,Transient hemiparesis: a rare manifestation of diphenylhydantoin toxicity.,430165_0,-1,1,1,19198,1
19199,side effects,3,5,17,29,"Among the common side effects of diphenylhydantoin (DPH) overdose, the most frequently encountered neurological signs are those of cerebellar dysfunction.",430165_2,-1,1,1,19199,1
19203,neurological manifestations,5,7,23,50,"Very rarely, the toxic neurological manifestations of this drug are of cerebral origin.",430165_3,-1,1,1,19203,1
19205,hemiparesis,7,8,52,63,Two patients are presented who suffered progressive hemiparesis due to DPH overdose.,430165_4,-1,1,1,19205,1
19217,ulnar nerve,16,18,103,114,The infusion was discontinued either when there was no muscular response to tetanic stimulation of the ulnar nerve or when Sch 120 mg was exceeded.,435349_3,-1,1,1,19217,1
19227,involuntary movements,3,5,29,50,Tiapride in levodopa-induced involuntary movements.,458486_0,-1,1,1,19227,1
19233,involuntary movements,15,17,115,136,"Tiapride, a substituted benzamide derivative closely related to metoclopramide, reduced levodopa-induced peak dose involuntary movements in 16 patients with idiopathic Parkinson's disease.",458486_1,-1,1,1,19233,1
19242,portal fibrosis,8,10,46,61,Minimal cholestasis was seen in two cases and portal fibrosis of a reversible degree in eight.,4812392_3,-1,1,1,19242,1
19267,primary tumors,9,11,75,89,The possibility that the intraarterial lesions might represent independent primary tumors is considered.,567256_3,-1,1,1,19267,1
19272,arterial occlusion,5,7,32,50,"Characteristic of the entity is arterial occlusion by platelet-fibrin thrombi with distal ischemia occurring four to twenty days after the initiation of heparin therapy, preceded by profound thrombocytopenia with platelet counts in the range of 30,000 to 40,000 per cubic millimeter.",591536_2,-1,1,1,19272,1
19290,neuromuscular block,15,17,98,117,It is longer acting than physostigmine and is used in anaesthesia to reverse the non-depolarizing neuromuscular block.,603022_1,-1,1,1,19290,1
19319,Adverse reactions,0,2,0,17,Adverse reactions to bendrofluazide and propranolol for the treatment of mild hypertension.,6115999_0,-1,1,1,19319,1
19334,adverse reactions,1,3,6,23,"Other adverse reactions significantly linked with active drugs include impaired glucose tolerance in men and women and gout in men, associated with bendrofluazide treatment, and Raynaud's phenomenon and dyspnoea in men and women taking propranolol.",6115999_6,-1,1,1,19334,1
19338,Raynaud's phenomenon,27,30,178,198,"Other adverse reactions significantly linked with active drugs include impaired glucose tolerance in men and women and gout in men, associated with bendrofluazide treatment, and Raynaud's phenomenon and dyspnoea in men and women taking propranolol.",6115999_6,-1,1,1,19338,1
19350,myoclonic jerks,8,10,72,87,"Serotonergic drugs, benzodiazepines and baclofen block muscimol-induced myoclonic jerks in a strain of mice.",6118280_0,-1,1,1,19350,1
19353,myoclonic jerks,7,9,38,53,"In male Swiss mice, muscimol produced myoclonic jerks.",6118280_1,-1,1,1,19353,1
19363,myoclonic jerks,30,32,136,151,"Of the benzodiazepines, clonazepam (0.1-0.3 mg/kg) was found to be several fold more potent than diazepam (0.3-3 mg/kg) in blocking the myoclonic jerks.",6118280_6,-1,1,1,19363,1
19375,cardiac failure,8,10,63,78,"Three patients with ischaemic heart disease developed profound cardiac failure, hypotension and bradycardia during combined therapy with verapamil and beta-adrenergic blocking drugs.",6127992_1,-1,1,1,19375,1
19380,left ventricular,1,3,9,25,"Baseline left ventricular function, assessed by cardiac catheterisation or nuclear angiography, was normal in two patients and only mildly reduced in the other.",6127992_3,-1,1,1,19380,1
19390,congenital anomalies,24,26,157,177,"Three infants, born of two mothers with inflammatory bowel disease who received treatment with sulphasalazine throughout pregnancy, were found to have major congenital anomalies.",6133211_1,-1,1,1,19390,1
19393,coarctation of the aorta,19,23,91,115,"In the singleton pregnancy, the mother had ulcerative colitis, and the infant, a male, had coarctation of the aorta and a ventricular septal defect.",6133211_2,-1,1,1,19393,1
19396,Crohn's disease,8,11,38,53,"In the twin pregnancy, the mother had Crohn's disease.",6133211_3,-1,1,1,19396,1
19398,polycystic kidney,12,14,53,70,"The first twin, a female, had a left Potter-type IIa polycystic kidney and a rudimentary left uterine cornu.",6133211_4,-1,1,1,19398,1
19400,hypoplastic,15,16,63,74,"The second twin, a male, had some features of Potter's facies, hypoplastic lungs, absent kidneys and ureters, and talipes equinovarus.",6133211_5,-1,1,1,19400,1
19411,systemic mastocytosis,9,11,66,87,"Nineteen patients had Zollinger-Ellison syndrome, one patient had systemic mastocytosis, and two patients had idiopathic hypersecretion.",6150641_2,-1,1,1,19411,1
19431,motor seizures,14,16,97,111,"In one patient, enflurane administered during a donor nephrectomy resulted in unexpected partial motor seizures.",6153967_2,-1,1,1,19431,1
19433,generalized seizures,9,11,54,74,"Two other patients suffered from partial, complex and generalized seizures uncontrolled by medication.",6153967_4,-1,1,1,19433,1
19440,Thrombotic microangiopathy,0,2,0,26,Thrombotic microangiopathy and renal failure associated with antineoplastic chemotherapy.,6203452_0,-1,1,1,19440,1
19441,renal failure,3,5,31,44,Thrombotic microangiopathy and renal failure associated with antineoplastic chemotherapy.,6203452_0,-1,1,1,19441,1
19444,thrombotic microangiopathy,5,7,39,65,"Five patients with carcinoma developed thrombotic microangiopathy (characterized by renal insufficiency, microangiopathic hemolytic anemia, and usually thrombocytopenia) after treatment with cisplatin, bleomycin, and a vinca alkaloid.",6203452_1,-1,1,1,19444,1
19445,renal insufficiency,10,12,84,103,"Five patients with carcinoma developed thrombotic microangiopathy (characterized by renal insufficiency, microangiopathic hemolytic anemia, and usually thrombocytopenia) after treatment with cisplatin, bleomycin, and a vinca alkaloid.",6203452_1,-1,1,1,19445,1
19446,microangiopathic hemolytic anemia,13,16,105,138,"Five patients with carcinoma developed thrombotic microangiopathy (characterized by renal insufficiency, microangiopathic hemolytic anemia, and usually thrombocytopenia) after treatment with cisplatin, bleomycin, and a vinca alkaloid.",6203452_1,-1,1,1,19446,1
19449,thrombotic thrombocytopenic purpura,3,6,16,51,"One patient had thrombotic thrombocytopenic purpura, three the hemolytic-uremic syndrome, and one an apparent forme fruste of one of these disorders.",6203452_2,-1,1,1,19449,1
19451,forme fruste,16,18,110,122,"One patient had thrombotic thrombocytopenic purpura, three the hemolytic-uremic syndrome, and one an apparent forme fruste of one of these disorders.",6203452_2,-1,1,1,19451,1
19456,tumor-free,4,5,25,35,"Because each patient was tumor-free or had only a small tumor at the onset of this syndrome, the thrombotic microangiopathy may have been induced by chemotherapy.",6203452_4,-1,1,1,19456,1
19457,thrombotic microangiopathy,19,21,97,123,"Because each patient was tumor-free or had only a small tumor at the onset of this syndrome, the thrombotic microangiopathy may have been induced by chemotherapy.",6203452_4,-1,1,1,19457,1
19460,renal failure,24,26,145,158,"Diagnosis of this potentially fatal complication may be delayed or missed if renal tissue or the peripheral blood smear is not examined, because renal failure may be ascribed to cisplatin nephrotoxicity and the anemia and thrombocytopenia to drug-induced bone marrow suppression.",6203452_5,-1,1,1,19460,1
19463,cardiac hypertrophy,3,5,37,56,Development of isoproterenol-induced cardiac hypertrophy.,6203632_0,-1,1,1,19463,1
19464,cardiac hypertrophy,3,5,19,38,The development of cardiac hypertrophy was studied in adult female Wistar rats following daily subcutaneous injections of isoproterenol (ISO) (0.3 mg/kg body weight).,6203632_1,-1,1,1,19464,1
19468,body weight,24,26,153,164,The development of cardiac hypertrophy was studied in adult female Wistar rats following daily subcutaneous injections of isoproterenol (ISO) (0.3 mg/kg body weight).,6203632_1,-1,1,1,19468,1
19475,hypertrophic,16,17,75,87,Ventricular DNA content was unchanged during the early stage (1-4 days) of hypertrophic growth but increased to a new steady-state level 19% above the controls after 8 days of treatment.,6203632_7,-1,1,1,19475,1
19494,myocardial infarction,26,28,178,199,The antiarrhythmic effects of the sustained release form of mexiletine (Mexitil-Perlongets) were evaluated in a double-blind placebo trial in 630 patients with recent documented myocardial infarction.,6209318_2,-1,1,1,19494,1
19507,side effects,2,4,22,34,"Previously recognized side effects, particularly tremor and gastrointestinal problems, were more frequent in the mexiletine group than in the placebo group.",6209318_8,-1,1,1,19507,1
19510,side effects,1,3,9,21,Multiple side effects of penicillamine therapy in one patient with rheumatoid arthritis.,6216862_0,-1,1,1,19510,1
19511,rheumatoid arthritis,10,12,67,87,Multiple side effects of penicillamine therapy in one patient with rheumatoid arthritis.,6216862_0,-1,1,1,19511,1
19513,systemic lupus erythematosus,5,8,26,54,"Skin rashes, proteinuria, systemic lupus erythematosus, polymyositis and myasthenia gravis have all been recorded as complications of penicillamine therapy in patients with rheumatoid arthritis.",6216862_1,-1,1,1,19513,1
19514,myasthenia gravis,11,13,73,90,"Skin rashes, proteinuria, systemic lupus erythematosus, polymyositis and myasthenia gravis have all been recorded as complications of penicillamine therapy in patients with rheumatoid arthritis.",6216862_1,-1,1,1,19514,1
19515,rheumatoid arthritis,25,27,173,193,"Skin rashes, proteinuria, systemic lupus erythematosus, polymyositis and myasthenia gravis have all been recorded as complications of penicillamine therapy in patients with rheumatoid arthritis.",6216862_1,-1,1,1,19515,1
19517,side effect,15,17,93,104,"The skin lesion resembled elastosis perforans serpiginosa, which has been reported as a rare side effect in patients with Wilson's disease but not in patients with rheumatoid arthritis treated with penicillamine.",6216862_3,-1,1,1,19517,1
19518,Wilson's disease,20,23,122,138,"The skin lesion resembled elastosis perforans serpiginosa, which has been reported as a rare side effect in patients with Wilson's disease but not in patients with rheumatoid arthritis treated with penicillamine.",6216862_3,-1,1,1,19518,1
19519,rheumatoid arthritis,28,30,164,184,"The skin lesion resembled elastosis perforans serpiginosa, which has been reported as a rare side effect in patients with Wilson's disease but not in patients with rheumatoid arthritis treated with penicillamine.",6216862_3,-1,1,1,19519,1
19522,myocardial infarction,9,11,63,84,Changes in heart size during long-term timolol treatment after myocardial infarction.,6229975_0,-1,1,1,19522,1
19524,myocardial infarction,10,12,62,83,"The effect of long-term timolol treatment on heart size after myocardial infarction was evaluated by X-ray in a double-blind study including 241 patients (placebo 126, timolol 115).",6229975_1,-1,1,1,19524,1
19529,compensatory,10,11,69,81,These differences may be caused by timolol-induced bradycardia and a compensatory increase in end-diastolic volume.,6229975_4,-1,1,1,19529,1
19589,motor neuropathy,20,22,109,125,"Guillain-Barr   syndrome was the commonest identifiable cause (15.6%), accounting for half of the cases with motor neuropathy.",6287825_4,-1,1,1,19589,1
19590,Peripheral neuropathy,0,2,0,21,Peripheral neuropathy due to nutritional deficiency of thiamine and riboflavin was common (10.1%) and presented mainly as sensory and sensori-motor neuropathy.,6287825_5,-1,1,1,19590,1
19593,Diabetes mellitus,0,2,0,17,Diabetes mellitus was the major cause of autonomic neuropathy.,6287825_6,-1,1,1,19593,1
19594,autonomic neuropathy,7,9,41,61,Diabetes mellitus was the major cause of autonomic neuropathy.,6287825_6,-1,1,1,19594,1
19595,drug-induced,7,8,41,53,Isoniazid was the most frequent agent in drug-induced neuropathy.,6287825_7,-1,1,1,19595,1
19596,cranial neuropathy,11,13,44,62,Migraine (20%) was not an uncommon cause of cranial neuropathy although malignancies arising from the reticuloendothelial system or related structures of the head and neck were more frequent (26%).,6287825_8,-1,1,1,19596,1
19598,head and neck,25,28,158,171,Migraine (20%) was not an uncommon cause of cranial neuropathy although malignancies arising from the reticuloendothelial system or related structures of the head and neck were more frequent (26%).,6287825_8,-1,1,1,19598,1
19603,Wilms tumor,3,5,18,29,Two children with Wilms tumor of the left kidney experienced severe anthracycline cardiomyopathy after irradiation to the tumor bed and conventional dosage of doxorubicin.,6292680_1,-1,1,1,19603,1
19607,Wilms tumor,14,16,79,90,The cardiomyopathy is attributed 1) to the fact that radiation fields for left Wilms tumor include the lower portion of the heart and 2) to the interaction of doxorubicin and irradiation on cardiac muscle.,6292680_2,-1,1,1,19607,1
19611,Wilms tumor,12,14,81,92,It is recommended that doxorubicin dosage be sharply restricted in children with Wilms tumor of the left kidney who receive postoperative irradiation.,6292680_3,-1,1,1,19611,1
19614,extrapyramidal,5,6,29,43,Effects of calcitonin on rat extrapyramidal motor system: behavioral and biochemical data.,6293644_0,-1,1,1,19614,1
19618,extrapyramidal,14,15,97,111,"injection of human and salmon calcitonin on biochemical and behavioral parameters related to the extrapyramidal motor system, were investigated in male rats.",6293644_2,-1,1,1,19618,1
19658,respiratory depression,9,11,83,105,"Moreover, naloxazone significantly attenuated the morphine-induced hypotension and respiratory depression, whereas morphine-induced bradycardia was less affected.",6308526_3,-1,1,1,19658,1
19663,hyperammonemia,5,6,31,45,Modification of drug action by hyperammonemia.,6323692_0,-1,1,1,19663,1
19671,hyperammonemia,2,3,6,20,"Thus, hyperammonemia is capable of altering drug action and must be considered along with impaired drug metabolism in enhanced drug responses associated with liver disease.",6323692_2,-1,1,1,19671,1
19676,liver disease,24,26,158,171,"Thus, hyperammonemia is capable of altering drug action and must be considered along with impaired drug metabolism in enhanced drug responses associated with liver disease.",6323692_2,-1,1,1,19676,1
19695,hyperammonemia,4,5,22,36,The data suggest that hyperammonemia exerts a calcium channel blocking action which enhances the effects of central nervous system depressants and certain opioid analgesics.,6323692_8,-1,1,1,19695,1
19698,central nervous system,16,19,108,130,The data suggest that hyperammonemia exerts a calcium channel blocking action which enhances the effects of central nervous system depressants and certain opioid analgesics.,6323692_8,-1,1,1,19698,1
19701,choreic,13,14,86,93,"Levodopa-induced dyskinesia of the limbs in thirteen cases of Parkinsonism, which was choreic, ballistic or dystonic in type, was alleviated almost completely by stereotaxic surgery using a microelectrode technique for the ventralis oralis anterior and posterior nuclei of the thalamus, but much less by the ventralis intermedius nucleus.",6381653_1,-1,1,1,19701,1
19708,thalamic,5,6,43,51,Control of levodopa-induced dyskinesias by thalamic lesions in the course of routine treatment of Parkinsonism is discussed.,6381653_2,-1,1,1,19708,1
19718,side effects,4,6,25,37,"The overall incidence of side effects and the frequency and severity of blurred vision, dry mouth, and drowsiness were significantly less with dothiepin than with amitriptyline.",6386793_3,-1,1,1,19718,1
19727,side effects,13,15,86,98,Dothiepin thus was found to be an effective antidepressant drug associated with fewer side effects than amitriptyline in the treatment of depressed outpatients.,6386793_6,-1,1,1,19727,1
19752,lung cancer,19,21,149,160,Treatment of ifosfamide-induced urothelial toxicity by oral administration of sodium 2-mercaptoethane sulphonate (MESNA) to patients with inoperable lung cancer.,6402369_0,-1,1,1,19752,1
19761,lung cancer,35,37,218,229,The protective effect of oral administration of the thiol compound sodium 2-mercaptoethane sulphonate (MESNA) against urothelial toxicity induced by ifosfamide (IF) was tested in a group of 45 patients with inoperable lung cancer under treatment with IF (2250 mg/m2 on days 2-5) as part of a polychemotherapy regimen repeated in a 4-week cycle.,6402369_1,-1,1,1,19761,1
19789,Myoclonic,0,1,0,9,"Myoclonic, atonic, and absence seizures following institution of carbamazepine therapy in children.",6415512_0,-1,1,1,19789,1
19790,absence seizures,5,7,23,39,"Myoclonic, atonic, and absence seizures following institution of carbamazepine therapy in children.",6415512_0,-1,1,1,19790,1
19796,myoclonic,25,26,137,146,"Five children, aged 3 to 11 years, treated with carbamazepine for epilepsy, had an acute aberrant reaction characterized by the onset of myoclonic, atypical absence and/or atonic (minor motor) seizures within a few days.",6415512_1,-1,1,1,19796,1
19798,motor seizures,22,24,124,138,"When the carbamazepine was discontinued, two of the children returned to their former state very quickly, two had the minor motor seizures resolve in 3 and 6 months, and one had the seizures persist.",6415512_2,-1,1,1,19798,1
19799,ceroid lipofuscinosis,12,14,65,86,The child in whom the seizures persisted was later found to have ceroid lipofuscinosis.,6415512_3,-1,1,1,19799,1
19839,side effect,3,5,17,28,Proteinuria is a side effect of captopril treatment in hypertensive patients.,6454943_1,-1,1,1,19839,1
19849,body weight,24,26,160,171,"Captopril had little or no demonstrable effects on serum electrolyte concentrations, excretion of urine, sodium and potassium, endogenous creatinine clearance, body weight, and food and water consumption.",6454943_5,-1,1,1,19849,1
19870,heart block,1,3,9,20,Complete heart block following a single dose of trazodone.,6496797_0,-1,1,1,19870,1
19872,heart block,15,17,96,107,"Forty minutes after receiving a single starting dose of trazodone, a patient developed complete heart block.",6496797_1,-1,1,1,19872,1
19873,cardiac conduction,16,18,89,107,"The case illustrates that, despite the results of earlier studies, trazodone's effect on cardiac conduction may be severe in individuals at risk for conduction delay.",6496797_2,-1,1,1,19873,1
19874,conduction delay,26,28,149,165,"The case illustrates that, despite the results of earlier studies, trazodone's effect on cardiac conduction may be severe in individuals at risk for conduction delay.",6496797_2,-1,1,1,19874,1
19879,clinical course,4,6,22,37,There was a fulminant clinical course from start of symptoms until death.,6503301_2,-1,1,1,19879,1
19880,venous congestion,11,13,57,74,At autopsy the liver was enlarged and firm with signs of venous congestion.,6503301_3,-1,1,1,19880,1
19887,movement disorders,3,5,16,34,Known causes of movement disorders were eliminated after evaluation.,6504332_2,-1,1,1,19887,1
19889,movement disorders,13,15,81,99,Phenobarbital should be added to the list of anticonvulsant drugs that can cause movement disorders.,6504332_4,-1,1,1,19889,1
19890,Ebstein's anomaly,4,7,30,47,Maternal lithium and neonatal Ebstein's anomaly: evaluation with cross-sectional echocardiography.,6518066_0,-1,1,1,19890,1
19893,Ebstein's anomaly,4,7,15,32,"In one infant, Ebstein's anomaly of the tricuspid valve was identified.",6518066_2,-1,1,1,19893,1
19896,Ebstein's anomaly,14,17,103,120,In the other infant cross-sectional echocardiography provided reassurance that the infant did not have Ebstein's anomaly.,6518066_3,-1,1,1,19896,1
19903,myocardial infarction,8,10,50,71,Effects of training on the extent of experimental myocardial infarction in aging rats.,6534871_0,-1,1,1,19903,1
19905,myocardial infarction,9,11,65,86,"The effects of exercise on the severity of isoproterenol-induced myocardial infarction were studied in female albino rats of 20,40,60 and 80 weeks of age.",6534871_1,-1,1,1,19905,1
19915,myocardial infarction,3,5,21,42,Studies dealing with myocardial infarction are more informative when dealt with age.,6534871_7,-1,1,1,19915,1
19941,pineal gland,18,20,99,111,"Serotonin and N-acetyl serotonin which augmented ketamine DOC, did not do so in the absence of the pineal gland, whereas melatonin potentiated the ketamine DOC in both the intact and pinealectomized chick.",6540303_4,-1,1,1,19941,1
19943,circadian rhythm,10,12,64,80,"Ketamine was more potent in the hypophysectomized chick and the circadian rhythm noted in the intact chick was absent; furthermore, melatonin did not augment the ketamine DOC whereas dopamine continued to do so.",6540303_5,-1,1,1,19943,1
19984,ventricular tachycardias,28,30,206,230,"Sublingual absorption of the quaternary ammonium antiarrhythmic agent, UM-272.UM-272 (N,N-dimethylpropranolol), a quaternary antiarrhythmic agent, was administered sublingually to dogs with ouabain-induced ventricular tachycardias.",6634932_0,-1,1,1,19984,1
19989,ventricular tachycardia,3,5,28,51,Sublingual UM-272 converted ventricular tachycardia to sinus rhythm in all 5 dogs.,6634932_2,-1,1,1,19989,1
19996,ventricular tachycardia,9,11,68,91,Long-term efficacy and toxicity of high-dose amiodarone therapy for ventricular tachycardia or ventricular fibrillation.,6637851_0,-1,1,1,19996,1
19998,ventricular tachycardia,11,13,75,98,"Amiodarone was administered to 154 patients who had sustained, symptomatic ventricular tachycardia (VT) (n = 118) or a cardiac arrest (n = 36) and who were refractory to conventional antiarrhythmic drugs.",6637851_1,-1,1,1,19998,1
19999,cardiac arrest,23,25,119,133,"Amiodarone was administered to 154 patients who had sustained, symptomatic ventricular tachycardia (VT) (n = 118) or a cardiac arrest (n = 36) and who were refractory to conventional antiarrhythmic drugs.",6637851_1,-1,1,1,19999,1
20009,adverse drug reactions,3,6,12,34,One or more adverse drug reactions occurred in 51% of patients.,6637851_5,-1,1,1,20009,1
20011,adverse reactions,4,6,28,45,"The most common symptomatic adverse reactions were tremor or ataxia (35%), nausea and anorexia (8%), visual halos or blurring (6%), thyroid function abnormalities (6%) and pulmonary interstitial infiltrates (5%).",6637851_7,-1,1,1,20011,1
20027,bladder tumors,20,22,114,128,Adriamycin (50 mg/50 ml) was administered intravesically within 24 h after transurethral resection of TA-T1 (O-A) bladder tumors.,6640832_2,-1,1,1,20027,1
20033,tumor-free,15,16,77,87,"In patients that were free of recurrence during the first year, 80% remained tumor-free during the 2- to 3-year follow-up period.",6640832_11,-1,1,1,20033,1
20060,subendothelial,13,14,96,110,"In experimental animals excess deposition of collagen and glycoaminoglycans was observed in the subendothelial and medial layer of the aortic wall, together with prominent basal membrane substance around aortic smooth muscle cells.",6666578_7,-1,1,1,20060,1
20085,necrotizing,3,4,10,21,A case of necrotizing myopathy due to a short epsilon-aminocaproic acid (EACA) treatment in a 72 year-old patient with subarachnoid haemorrhage (SAH) is described.,6674249_1,-1,1,1,20085,1
20089,subarachnoid,21,22,119,131,A case of necrotizing myopathy due to a short epsilon-aminocaproic acid (EACA) treatment in a 72 year-old patient with subarachnoid haemorrhage (SAH) is described.,6674249_1,-1,1,1,20089,1
20094,urinary bladder,9,11,107,122,Effect of aspirin on N-[4-(5-nitro-2-furyl)-2-thiazolyl]-formamide-induced epithelial proliferation in the urinary bladder and forestomach of the rat.,6692345_0,-1,1,1,20094,1
20121,Cerebral hemorrhage,0,2,0,19,Cerebral hemorrhage associated with phenylpropanolamine in combination with caffeine.,6695415_0,-1,1,1,20121,1
20125,side effects,13,15,74,86,Phenylpropanolamine (PPA) is a drug that has been associated with serious side effects including stroke.,6695415_1,-1,1,1,20125,1
20128,Subarachnoid,0,1,0,12,Subarachnoid and cerebral hemorrhage was noted in 18% of the hypertensive rats.,6695415_4,-1,1,1,20128,1
20129,cerebral hemorrhage,2,4,17,36,Subarachnoid and cerebral hemorrhage was noted in 18% of the hypertensive rats.,6695415_4,-1,1,1,20129,1
20134,cerebral hemorrhage,8,10,52,71,These results suggest that PPA/caffeine can lead to cerebral hemorrhage in previously hypertensive animals when administered in greater than the allowed dosage.,6695415_6,-1,1,1,20134,1
20139,rheumatoid arthritis,4,6,23,43,"A 31-year-old man with rheumatoid arthritis, who had previously been treated with sulindac, fenoprofen calcium, high dose salicylates and gold salts, developed renal papillary necrosis (RPN) 4 months after institution of naproxen therapy.",6699841_1,-1,1,1,20139,1
20150,drug use,8,10,59,67,We review previous reports linking RPN to antiinflammatory drug use and discuss possible advantages of sulindac in patients who have experienced renal toxicity from other antiinflammatory agents.,6699841_4,-1,1,1,20150,1
20154,involuntary movements,1,3,9,30,"Abnormal involuntary movements appeared in the mouth, tongue, neck and abdomen of a 64-year-old male patient after he took metoclopramide for gastrointestinal disorder in a regimen of 30 mg per day for a total of about 260 days.",6727060_1,-1,1,1,20154,1
20156,gastrointestinal disorder,23,25,142,167,"Abnormal involuntary movements appeared in the mouth, tongue, neck and abdomen of a 64-year-old male patient after he took metoclopramide for gastrointestinal disorder in a regimen of 30 mg per day for a total of about 260 days.",6727060_1,-1,1,1,20156,1
20158,abnormal movements,8,10,61,79,"When the metoclopramide administration was discontinued, the abnormal movements gradually improved to a considerable extent.",6727060_3,-1,1,1,20158,1
20186,obstructive sleep apnea syndrome,3,7,17,49,Induction of the obstructive sleep apnea syndrome in a woman by exogenous androgen administration.,6732043_0,-1,1,1,20186,1
20189,obstructive sleep apnea,27,30,179,202,We documented airway occlusion during sleep and an abnormally high supraglottic resistance while awake in a 54-yr-old woman who had developed physical changes and the syndrome of obstructive sleep apnea while being administered exogenous androgens.,6732043_1,-1,1,1,20189,1
20195,obstructive sleep apnea,7,10,49,72,A rechallenge with androgen produced symptoms of obstructive sleep apnea that abated upon withdrawal of the hormone.,6732043_3,-1,1,1,20195,1
20196,sleep apnea,12,14,73,84,Previous reports have favored a role of androgens in the pathogenesis of sleep apnea.,6732043_4,-1,1,1,20196,1
20199,obstructive sleep apnea syndrome,3,7,19,51,Development of the obstructive sleep apnea syndrome must be considered a possible side effect of androgen therapy.,6732043_7,-1,1,1,20199,1
20200,side effect,12,14,82,93,Development of the obstructive sleep apnea syndrome must be considered a possible side effect of androgen therapy.,6732043_7,-1,1,1,20200,1
20203,malignant gliomas,6,8,50,67,Intra-arterial BCNU chemotherapy for treatment of malignant gliomas of the central nervous system.,6747681_0,-1,1,1,20203,1
20204,central nervous system,10,13,75,97,Intra-arterial BCNU chemotherapy for treatment of malignant gliomas of the central nervous system.,6747681_0,-1,1,1,20204,1
20209,malignant gliomas,26,28,211,228,"Because of the rapid systemic clearance of BCNU (1,3-bis-(2-chloroethyl)-1-nitrosourea), intra-arterial administration should provide a substantial advantage over intravenous administration for the treatment of malignant gliomas.",6747681_1,-1,1,1,20209,1
20213,internal carotid,18,20,109,125,"Thirty-six patients were treated with BCNU every 6 to 8 weeks, either by transfemoral catheterization of the internal carotid or vertebral artery or through a fully implantable intracarotid drug delivery system, beginning with a dose of 200 mg/sq m body surface area.",6747681_2,-1,1,1,20213,1
20214,vertebral artery,21,23,129,145,"Thirty-six patients were treated with BCNU every 6 to 8 weeks, either by transfemoral catheterization of the internal carotid or vertebral artery or through a fully implantable intracarotid drug delivery system, beginning with a dose of 200 mg/sq m body surface area.",6747681_2,-1,1,1,20214,1
20218,Grade III,3,5,21,30,Twelve patients with Grade III or IV astrocytomas were treated after partial resection of the tumor without prior radiation therapy.,6747681_3,-1,1,1,20218,1
20219,astrocytomas,7,8,37,49,Twelve patients with Grade III or IV astrocytomas were treated after partial resection of the tumor without prior radiation therapy.,6747681_3,-1,1,1,20219,1
20225,astrocytomas,8,9,50,62,"Twenty-four patients with recurrent Grade I to IV astrocytomas, whose resection and irradiation therapy had failed, received two to eight courses of intra-arterial BCNU therapy.",6747681_7,-1,1,1,20225,1
20232,visual loss,3,5,17,28,The frequency of visual loss decreased after the concentration of the ethanol diluent was lowered.,6747681_11,-1,1,1,20232,1
20240,congestive heart failure,6,9,30,54,8 of the 10 monkeys developed congestive heart failure at an average cumulative adriamycin dose (310 mg/m2) well below that considered the safe upper limit (550 mg/m2) in man.,6769133_1,-1,1,1,20240,1
20243,acute myeloblastic leukemia,6,9,30,57,1 of the 10 monkeys developed acute myeloblastic leukemia after receiving 324 mg/m2 of adriamycin; the 10th monkey is alive and well 26 months after the last dose of drug.,6769133_3,-1,1,1,20243,1
20249,diabetic autonomic,7,9,56,74,"Provocation of postural hypotension by nitroglycerin in diabetic autonomic neuropathy?The effect of nitroglycerin on heart rate and systolic blood pressure was compared in 5 normal subjects, 12 diabetic subjects without autonomic neuropathy, and 5 diabetic subjects with autonomic neuropathy.",6773726_0,-1,1,1,20249,1
20253,autonomic neuropathy,31,33,220,240,"Provocation of postural hypotension by nitroglycerin in diabetic autonomic neuropathy?The effect of nitroglycerin on heart rate and systolic blood pressure was compared in 5 normal subjects, 12 diabetic subjects without autonomic neuropathy, and 5 diabetic subjects with autonomic neuropathy.",6773726_0,-1,1,1,20253,1
20254,autonomic neuropathy,39,41,271,291,"Provocation of postural hypotension by nitroglycerin in diabetic autonomic neuropathy?The effect of nitroglycerin on heart rate and systolic blood pressure was compared in 5 normal subjects, 12 diabetic subjects without autonomic neuropathy, and 5 diabetic subjects with autonomic neuropathy.",6773726_0,-1,1,1,20254,1
20258,autonomic neuropathy,29,31,181,201,"The magnitude and time course of the increase in heart rate and the decrease in systolic blood pressure after nitroglycerin were similar in the normal and diabetic subjects without autonomic neuropathy, whereas a lesser increase in heart rate and a greater decrease in systolic blood pressure occurred in the diabetic subjects with autonomic neuropathy.",6773726_1,-1,1,1,20258,1
20262,autonomic neuropathy,53,55,332,352,"The magnitude and time course of the increase in heart rate and the decrease in systolic blood pressure after nitroglycerin were similar in the normal and diabetic subjects without autonomic neuropathy, whereas a lesser increase in heart rate and a greater decrease in systolic blood pressure occurred in the diabetic subjects with autonomic neuropathy.",6773726_1,-1,1,1,20262,1
20264,autonomic neuropathy,20,22,140,160,"It is therefore suggested that caution should be exercised when prescribing vasodilator drugs in diabetic patients, particularly those with autonomic neuropathy.",6773726_2,-1,1,1,20264,1
20270,congestive heart failure,10,13,64,88,"A newborn with massive tricuspid regurgitation, atrial flutter, congestive heart failure, and a high serum lithium level is described.",6794356_1,-1,1,1,20270,1
20279,early pregnancy,17,19,108,123,Lithium carbonate may be a factor in the increasing incidence of congenital heart disease when taken during early pregnancy.,6794356_4,-1,1,1,20279,1
20325,Pituitary tumors,0,2,0,16,"Pituitary tumors were induced in F344 female rats by chronic treatment with diethylstilbestrol (DES, 8-10 mg) implanted subcutaneously in silastic capsules.",6888657_1,-1,1,1,20325,1
20384,central nervous system,18,21,108,130,These results further support the view that calcium ions in excess have an atropine-like action also in the central nervous system.,6892185_6,-1,1,1,20384,1
20454,kidney disease,34,36,164,178,There was only one case of dementia possibly due to cimetidine (with a drug level of 1.9 microgram/ml 6 hr after a dose) in a group of 13 patients without liver or kidney disease who had cimetidine levels above 1.25 microgram/ml.,7053303_6,-1,1,1,20454,1
20459,acute lymphocytic leukemia,13,16,94,120,Clinically reversible veno-occlusive disease of the liver developed in a 23-year-old man with acute lymphocytic leukemia after 10 months of maintenance therapy with 6-thioguanine.,7053705_1,-1,1,1,20459,1
20467,optic neuropathy,1,3,23,39,Chlorpropamide-induced optic neuropathy.,7059267_0,-1,1,1,20467,1
20468,adult-onset,4,5,25,36,A 65-year-old woman with adult-onset diabetes treated with chlorpropamide (Diabenese) had a toxic optic neuropathy that resolved with discontinuation of chlorpropamide therapy.,7059267_1,-1,1,1,20468,1
20472,toxic optic neuropathy,14,17,92,114,A 65-year-old woman with adult-onset diabetes treated with chlorpropamide (Diabenese) had a toxic optic neuropathy that resolved with discontinuation of chlorpropamide therapy.,7059267_1,-1,1,1,20472,1
20474,Visual loss,0,2,0,11,"Visual loss occurs in diabetics for a variety of reasons, and accurate diagnosis is necessary to institute appropriate therapy.",7059267_2,-1,1,1,20474,1
20477,visual loss,15,17,105,116,The possibility of a drug-induced optic neuropathy should be considered in the differential diagnosis of visual loss in diabetics.,7059267_3,-1,1,1,20477,1
20479,nephrotic syndrome,10,12,69,87,Plasma and urinary lipids and lipoproteins during the development of nephrotic syndrome induced in the rat by puromycin aminonucleoside.,7066357_0,-1,1,1,20479,1
20482,nephrotic syndrome,14,16,95,113,"This study was undertaken to ascertain whether the alterations of plasma lipoproteins found in nephrotic syndrome induced by puromycin aminonucleoside were due to nephrotic syndrome per se, or, at least in part, to the aminonucleoside.",7066357_1,-1,1,1,20482,1
20484,nephrotic syndrome,23,25,163,181,"This study was undertaken to ascertain whether the alterations of plasma lipoproteins found in nephrotic syndrome induced by puromycin aminonucleoside were due to nephrotic syndrome per se, or, at least in part, to the aminonucleoside.",7066357_1,-1,1,1,20484,1
20488,nephrotic syndrome,34,36,210,228,The purpose of the present study was to investigate the changes in plasma and urinary lipoproteins during the administration of puromycin aminonucleoside (20 mg/kg for 7 days) and the subsequent development of nephrotic syndrome.,7066357_2,-1,1,1,20488,1
20492,nephrotic,28,29,147,156,"Since massive albuminuria occurred after 6 days of treatment, the time-course study was divided into two stages: pre-nephrotic stage (day 1-5) and nephrotic stage (day 6-11).",7066357_3,-1,1,1,20492,1
20498,nephrotic,4,5,20,29,"At the beginning of nephrotic stage (day 6) the concentration of plasma albumin dropped to a very low level, while that of apolipoprotein A-I increased abruptly (4-fold increase) and continued to rise, although less steeply, in the following days.",7066357_6,-1,1,1,20498,1
20506,nephrotic,12,13,78,87,"In the pre-nephrotic stage lipoproteinuria was negligible, while in the early nephrotic stage the urinary loss of plasma lipoproteins consisted mainly of HDL.",7066357_10,-1,1,1,20506,1
20511,nephrotic,14,15,73,82,It is likely that the early and striking increase of plasma HDL found in nephrotic rats is related to a direct effect of the drug on HDL metabolism.,7066357_12,-1,1,1,20511,1
20513,aplastic anemia,1,3,6,21,Fatal aplastic anemia following topical administration of ophthalmic chloramphenicol.,7072798_0,-1,1,1,20513,1
20517,aplastic anemia,5,7,28,43,A 73-year-old woman died of aplastic anemia less than two months after undergoing cataract extraction and beginning topical therapy with chloramphenicol.,7072798_1,-1,1,1,20517,1
20519,aplastic anemia,4,6,19,34,The pattern of the aplastic anemia was associated with an idiosyncratic response to chloramphenicol.,7072798_3,-1,1,1,20519,1
20522,aplastic anemia,7,9,36,51,"This was the second report of fatal aplastic anemia after topical treatment with chloramphenicol for ocular conditions, although two cases of reversible bone marrow hypoplasia have also been reported.",7072798_4,-1,1,1,20522,1
20525,ocular toxicity,5,7,29,44,"Any other suspected cases of ocular toxicity associated with topically applied chloramphenicol should be reported to the National Registry of Drug-Induced Ocular Side Effects, Oregon Health Sciences University, Portland, OR 97201.",7072798_5,-1,1,1,20525,1
20527,Drug-Induced,20,21,142,154,"Any other suspected cases of ocular toxicity associated with topically applied chloramphenicol should be reported to the National Registry of Drug-Induced Ocular Side Effects, Oregon Health Sciences University, Portland, OR 97201.",7072798_5,-1,1,1,20527,1
20528,Side Effects,22,24,162,174,"Any other suspected cases of ocular toxicity associated with topically applied chloramphenicol should be reported to the National Registry of Drug-Induced Ocular Side Effects, Oregon Health Sciences University, Portland, OR 97201.",7072798_5,-1,1,1,20528,1
20574,Akathisia,0,1,0,9,"Akathisia was controlled by the benzodiazepine lorazepam in 14 out of 16 patients, while prophylactic antiparkinsonians were ineffective.",7161250_5,-1,1,1,20574,1
20590,cardiopulmonary arrest,8,10,60,82,"Convulsions always preceded death, except after precipitous cardiopulmonary arrest from extreme doses.",7189975_4,-1,1,1,20590,1
20598,REM sleep deprivation,0,3,0,21,REM sleep deprivation changes behavioral response to catecholaminergic and serotonergic receptor activation in rats.,7197363_0,-1,1,1,20598,1
20603,REM sleep deprivation,3,6,15,36,The effects of REM sleep deprivation (REMD) on apomorphine-induced aggressiveness and quipazine-induced head twitches in rats were determined.,7197363_1,-1,1,1,20603,1
20615,subarachnoid,3,4,22,34,"Neurologic effects of subarachnoid administration of 2-chloroprocaine-CE, bupivacaine, and low pH normal saline in dogs.",7199841_0,-1,1,1,20615,1
20617,subarachnoid,13,14,84,96,The purpose of this study was to evaluate the neurologic consequences of deliberate subarachnoid injection of large volumes of 2-chloroprocaine-CE in experimental animals.,7199841_1,-1,1,1,20617,1
20619,neurotoxicity,16,17,84,97,The possible role of low pH as well as total volume as potential factors in causing neurotoxicity was evaluated.,7199841_2,-1,1,1,20619,1
20620,subarachnoid,10,11,52,64,"The 65 dogs in the study received injections in the subarachnoid space as follows: 6 to 8 ml of bupivacaine (N = 15), 2-chloroprocaine-CE (N = 20), low pH normal saline (pH 3.0) (N = 20), or normal saline (N = 10).",7199841_3,-1,1,1,20620,1
20624,subarachnoid,6,7,32,44,Of the 20 animals that received subarachnoid injection of 2-chloroprocaine-CE seven (35%) developed hind-limb paralysis.,7199841_4,-1,1,1,20624,1
20630,subarachnoid,21,22,121,133,"Of the 15 spinal cords of the animals that received 2-chloroprocaine-CE, 13 showed subpial necrosis; the nerve roots and subarachnoid vessels were normal.",7199841_6,-1,1,1,20630,1
20642,ventricular tachycardia,23,25,161,184,"In four patients, polymorphous ventricular tachycardia appeared after intravenous administration of 200 to 400 mg of procainamide for the treatment of sustained ventricular tachycardia.",7234705_2,-1,1,1,20642,1
20667,body weight,36,38,186,197,"The optimal rat size to begin phenobarbitone was determined as 100 g, and this size as a group had a mean maximum relative liver weight increase 47% greater than normal rats of the same body weight.",7248170_3,-1,1,1,20667,1
20669,aplastic anemia,1,3,6,21,Fatal aplastic anemia due to indomethacin--lymphocyte transformation tests in vitro.,7263204_0,-1,1,1,20669,1
20671,aplastic anemia,10,12,65,80,"Although indomethacin has been implicated as a possible cause of aplastic anemia on the basis of a few clinical observations, its role has not been definitely established.",7263204_1,-1,1,1,20671,1
20673,aplastic anemia,4,6,16,31,A case of fatal aplastic anemia is described in which no drugs other than allopurinol and indomethacin were given.,7263204_2,-1,1,1,20673,1
20677,aplastic anemia,19,21,134,149,A positive lymphocyte transformation test with indomethacin in vitro further substantiates the potential role of this drug in causing aplastic anemia in a susceptible patient.,7263204_4,-1,1,1,20677,1
20701,myocardial disease,30,32,199,217,The cardiomyopathy (CM) produced by the anticancer drug doxorubicin (DXR) (Adriamycin) provides a unique opportunity to analyze dose-effect and structure-function relationships during development of myocardial disease.,7282516_1,-1,1,1,20701,1
20721,ventricular tachycardia,1,3,8,31,Variant ventricular tachycardia in desipramine toxicity.,7292072_0,-1,1,1,20721,1
20722,ventricular tachycardia,6,8,28,51,We report a case of variant ventricular tachycardia induced by desipramine toxicity.,7292072_1,-1,1,1,20722,1
20728,ventricular tachycardia,3,5,23,46,Recognition of variant ventricular tachycardia is important because therapy differs from that of classic ventricular tachycardia.,7292072_3,-1,1,1,20728,1
20729,ventricular tachycardia,14,16,105,128,Recognition of variant ventricular tachycardia is important because therapy differs from that of classic ventricular tachycardia.,7292072_3,-1,1,1,20729,1
20732,Cerebral edema,0,2,0,14,Cerebral edema may complicate the course of fulminant hepatic failure.,7337133_1,-1,1,1,20732,1
20735,signs and symptoms,12,15,86,104,"We present a patient with fatal acetaminophen-induced fulminant hepatic failure, with signs and symptoms of cerebral edema, unresponsive to conventional medical therapy.",7337133_3,-1,1,1,20735,1
20736,cerebral edema,16,18,108,122,"We present a patient with fatal acetaminophen-induced fulminant hepatic failure, with signs and symptoms of cerebral edema, unresponsive to conventional medical therapy.",7337133_3,-1,1,1,20736,1
20767,longterm,12,13,71,79,Various data suggest that male patients who have received digoxin on a longterm basis have increased levels of serum estrogen and decreased levels of plasma testosterone and luteinizing hormone (LH).,7416947_1,-1,1,1,20767,1
20773,rheumatic heart disease,32,35,164,187,The patients of the study and control group (without digoxin) were of similar cardiac functional capacity and age (25-40 years) and were randomly selected from the rheumatic heart disease patients.,7416947_3,-1,1,1,20773,1
20793,ototoxicity,8,9,66,77,Gentamicin sulfate and tobramycin sulfate continue to demonstrate ototoxicity and nephrotoxicity in both animal and clinical studies.,7420681_3,-1,1,1,20793,1
20800,renal failure,40,42,255,268,"In this study, 62 patients with confirmed initial normal renal function and treated with 2 to 5 mg/kg/day of gentamicin sulfate or tobramycin sulfate for a minimum of seven days were followed up prospectively for the development of aminoglycoside-related renal failure, defined as at least a one-third reduction in renal function.",7420681_4,-1,1,1,20800,1
20802,renal failure,9,11,42,55,"In these 62 patients, no other causes for renal failure could be identified.",7420681_5,-1,1,1,20802,1
20805,renal failure,24,26,112,125,Five of 33 (15%) of the tobramycin-treated patients and 16 of 29 (55.2%) of the gentamicin-treated patients had renal failure.,7420681_6,-1,1,1,20805,1
20807,renal failure,6,8,37,50,"Thus, gentamicin was associated with renal failure more than three times as often as was tobramycin.",7420681_7,-1,1,1,20807,1
20808,Endometrial carcinoma,0,2,0,21,Endometrial carcinoma after Hodgkin disease in childhood.,7421734_0,-1,1,1,20808,1
20809,Hodgkin disease,3,5,28,43,Endometrial carcinoma after Hodgkin disease in childhood.,7421734_0,-1,1,1,20809,1
20810,endometrial carcinoma,5,7,41,62,A 34-year-old patient developed metastic endometrial carcinoma after Hodgkin disease in childhood.,7421734_1,-1,1,1,20810,1
20811,Hodgkin disease,8,10,69,84,A 34-year-old patient developed metastic endometrial carcinoma after Hodgkin disease in childhood.,7421734_1,-1,1,1,20811,1
20812,ovarian failure,2,4,8,23,"She had ovarian failure after abdominal irradiation and chemotherapy for Hodgkin disease, and received exogenous estrogens, a treatment implicated in the development of endometrial cancer in menopausal women.",7421734_2,-1,1,1,20812,1
20814,Hodgkin disease,10,12,73,88,"She had ovarian failure after abdominal irradiation and chemotherapy for Hodgkin disease, and received exogenous estrogens, a treatment implicated in the development of endometrial cancer in menopausal women.",7421734_2,-1,1,1,20814,1
20815,endometrial cancer,25,27,169,187,"She had ovarian failure after abdominal irradiation and chemotherapy for Hodgkin disease, and received exogenous estrogens, a treatment implicated in the development of endometrial cancer in menopausal women.",7421734_2,-1,1,1,20815,1
20816,ovarian failure,6,8,41,56,Young women on replacement estrogens for ovarian failure after cancer therapy may also have increased risk of endometrial carcinoma and should be examined periodically.,7421734_3,-1,1,1,20816,1
20817,endometrial carcinoma,17,19,110,131,Young women on replacement estrogens for ovarian failure after cancer therapy may also have increased risk of endometrial carcinoma and should be examined periodically.,7421734_3,-1,1,1,20817,1
20896,pathophysiology,4,5,28,43,Potential mechanisms of the pathophysiology are briefly discussed.,7468724_3,-1,1,1,20896,1
20897,Toxic hepatitis,0,2,0,15,Toxic hepatitis induced by antithyroid drugs: four cases including one with cross-reactivity between carbimazole and benzylthiouracil.,7504976_0,-1,1,1,20897,1
20907,toxic hepatitis,11,13,51,66,RESULTS: Four patients (1.7%) were identified with toxic hepatitis which could reasonably be attributed to the use of antithyroid agent.,7504976_3,-1,1,1,20907,1
20917,Toxic hepatitis,2,4,12,27,"CONCLUSION: Toxic hepatitis is a potential adverse effect of antithyroid drugs which warrants, as for haematological disturbances, a pre-therapeutic determination and a careful follow-up of relevant biological markers.",7504976_9,-1,1,1,20917,1
21011,Acute renal failure,0,3,0,19,Acute renal failure in high dose carboplatin chemotherapy.,7565311_0,-1,1,1,21011,1
21014,acute renal failure,6,9,39,58,Carboplatin has been reported to cause acute renal failure when administered in high doses to adult patients.,7565311_1,-1,1,1,21014,1
21019,Acute renal failure,0,3,0,19,Acute renal failure developed followed by a slow partial recovery of renal function.,7565311_3,-1,1,1,21019,1
21094,lower limbs,8,10,43,54,He was admitted with acute myopathy of the lower limbs which resolved in a few days after pravastatin discontinuation.,7604176_5,-1,1,1,21094,1
21102,toxic myopathy,8,10,59,73,"While lovastatin and simvastatin have been associated with toxic myopathy, pravastatin-associated myopathy could represent a distinct, inflammatory entity.",7604176_8,-1,1,1,21102,1
21119,myocardial infarction,1,3,18,39,Etoposide-related myocardial infarction.,7619765_0,-1,1,1,21119,1
21120,myocardial infarction,4,6,20,41,"The occurrence of a myocardial infarction is reported after chemotherapy containing etoposide, in a man with no risk factors for coronary heart disease.",7619765_1,-1,1,1,21120,1
21176,centrilobular,19,20,136,149,Enflurane administration resulted in neoantigens detected in both the microsomal and cytosolic fraction of liver homogenates and in the centrilobular region of the liver.,7647582_6,-1,1,1,21176,1
21188,myasthenia gravis,28,30,186,203,"A patient developed a severe cholinergic syndrome from the use of echothiophate iodide ophthalmic drops, presented with profound muscle weakness and was initially given the diagnosis of myasthenia gravis.",7650771_1,-1,1,1,21188,1
21196,respiratory depression,11,13,80,102,Flumazenil is a benzodiazepine receptor antagonist used to reverse sedation and respiratory depression induced by benzodiazepines.,7651879_1,-1,1,1,21196,1
21200,generalized tonic-clonic seizure,6,9,30,62,We report the occurrence of a generalized tonic-clonic seizure in a pediatric patient following the administration of flumazenil.,7651879_5,-1,1,1,21200,1
21204,bone marrow,11,13,79,90,Phase I trial of 13-cis-retinoic acid in children with neuroblastoma following bone marrow transplantation.,7707116_0,-1,1,1,21204,1
21213,bone marrow,31,33,206,217,"This phase I trial was designed to determine the maximal-tolerated dosage (MTD), toxicities, and pharmacokinetics of cis-RA administered on an intermittent schedule in children with neuroblastoma following bone marrow transplantation (BMT).",7707116_3,-1,1,1,21213,1
21241,cerebral ischemia,12,14,89,106,"Time dependence of plasma malondialdehyde, oxypurines, and nucleosides during incomplete cerebral ischemia in the rat.",7710775_0,-1,1,1,21241,1
21242,cerebral ischemia,1,3,11,28,Incomplete cerebral ischemia (30 min) was induced in the rat by bilaterally clamping the common carotid arteries.,7710775_1,-1,1,1,21242,1
21243,common carotid,16,18,89,103,Incomplete cerebral ischemia (30 min) was induced in the rat by bilaterally clamping the common carotid arteries.,7710775_1,-1,1,1,21243,1
21316,detrusor,30,31,183,191,"The present results thus suggest that intra-arterial PGE2, given near the bladder, may initiate micturition in the normal rat chiefly by directly contracting the smooth muscle of the detrusor.",7752389_4,-1,1,1,21316,1
21328,urinary tract,22,24,140,153,"Prostanoids may, via release of tachykinins, contribute to both urge and bladder hyperactivity seen in inflammatory conditions of the lower urinary tract.",7752389_7,-1,1,1,21328,1
21330,heart block,5,7,42,53,Refractory cardiogenic shock and complete heart block after verapamil SR and metoprolol treatment.,7785794_0,-1,1,1,21330,1
21333,heart block,6,8,55,66,A seventy-eight-year-old woman presented with complete heart block and refractory hypotension two days after a therapeutic dose of sustained-release verapamil with concomitant use of metoprolol.,7785794_2,-1,1,1,21333,1
21337,heart block,8,10,58,69,"The patient continued to remain hypotensive with complete heart block, even with multiple uses of intravenous atropine as well as high doses of pressor agents such as dopamine and dobutamine.",7785794_3,-1,1,1,21337,1
21343,heart block,16,18,104,115,"However, shortly after the use of intravenous calcium chloride, the refractory hypotension and complete heart block resolved.",7785794_4,-1,1,1,21343,1
21359,Group B,47,49,273,280,"METHODS: Forty-five hospitalized elderly patients (> 65 years old) who required therapy with nonsteroidal antiinflammatory drugs (NSAID) were randomly assigned to receive either indomethacin, 150 mg/day (Group A), or indomethacin 150 mg/day plus misoprostol at 0.6 mg/day (Group B).",7791169_2,-1,1,1,21359,1
21368,Group B,48,50,219,226,"RESULTS: Forty-two patients completed the study, 22 in Group A and 20 in Group B. BUN and creatinine increased by > 50% of baseline levels in 54 and 45% of Group A patients, respectively, compared to only 20 and 10% of Group B patients (p < 0.05).",7791169_5,-1,1,1,21368,1
21371,Group B,25,27,96,103,"Potassium (K) increment of 0.6 mEq/l or more was observed in 50% of Group A, but in only 15% of Group B patients (p < 0.05).",7791169_6,-1,1,1,21371,1
21373,Group B,24,26,96,103,"The mean increments in BUN, creatinine, and K were reduced by 63, 80, and 42%, respectively, in Group B patients compared to Group A. Response to treatment did not differ significantly between the 2 groups.",7791169_7,-1,1,1,21373,1
21380,side-effects,2,3,11,23,Safety and side-effects of alprazolam.,7802851_0,-1,1,1,21380,1
21384,side-effect,14,15,83,94,"The efficacy of alprazolam and placebo in panic disorder with agoraphobia, and the side-effect and adverse effect profiles of both drug groups were measured.",7802851_3,-1,1,1,21384,1
21391,adverse reactions,9,11,67,84,"Compared with placebo subjects, alprazolam patients developed more adverse reactions (21% v. 0%) of depression, enuresis, disinhibition and aggression; and more side-effects, particularly sedation, irritability, impaired memory, weight loss and ataxia.",7802851_8,-1,1,1,21391,1
21393,side-effects,29,30,161,173,"Compared with placebo subjects, alprazolam patients developed more adverse reactions (21% v. 0%) of depression, enuresis, disinhibition and aggression; and more side-effects, particularly sedation, irritability, impaired memory, weight loss and ataxia.",7802851_8,-1,1,1,21393,1
21396,Side-effects,0,1,0,12,Side-effects tended to diminish during treatment but remained significant at week 8.,7802851_9,-1,1,1,21396,1
21398,side-effects,4,5,31,43,CONCLUSIONS: Alprazolam caused side-effects and adverse effects during treatment but many patients were willing to accept these.,7802851_11,-1,1,1,21398,1
21428,heart failure,11,13,67,80,"A hemodynamic, volumetric, and metabolic study in patients without heart failure.",783197_1,-1,1,1,21428,1
21434,body weight,9,11,48,59,"We assessed the effects of ouabain (0.015 mg/kg body weight) on hemodynamic, volumetric, and metabolic parameters in 11 patients with severe chronic coronary artery disease without clinical congestive heart failure.",783197_3,-1,1,1,21434,1
21436,congestive heart failure,31,34,190,214,"We assessed the effects of ouabain (0.015 mg/kg body weight) on hemodynamic, volumetric, and metabolic parameters in 11 patients with severe chronic coronary artery disease without clinical congestive heart failure.",783197_3,-1,1,1,21436,1
21438,Left ventricular,0,2,0,16,"Left ventricular end-diastolic pressure and left ventricular end-diastolic volume fell in each patient given ouabain, even though they were initially elevated in only two patients.",783197_5,-1,1,1,21438,1
21439,left ventricular,5,7,44,60,"Left ventricular end-diastolic pressure and left ventricular end-diastolic volume fell in each patient given ouabain, even though they were initially elevated in only two patients.",783197_5,-1,1,1,21439,1
21441,Left ventricular,0,2,0,16,Left ventricular end-diastolic pressure fell from 11.5+/-1.4 (mean+/-SE) to 5.6+/-0.9 mm Hg (P less than 0.001) and left ventricular end-diastolic volume fell from 100+/-17 to 82+/-12 ml/m2 (P less than 0.01) 1 h after ouabain infusion was completed.,783197_6,-1,1,1,21441,1
21443,left ventricular,21,23,116,132,Left ventricular end-diastolic pressure fell from 11.5+/-1.4 (mean+/-SE) to 5.6+/-0.9 mm Hg (P less than 0.001) and left ventricular end-diastolic volume fell from 100+/-17 to 82+/-12 ml/m2 (P less than 0.01) 1 h after ouabain infusion was completed.,783197_6,-1,1,1,21443,1
21460,compensatory,2,3,14,26,"Nevertheless, compensatory mechanisms prevent a deterioration of resting myocardial metabolism.",783197_12,-1,1,1,21460,1
21466,proliferative,9,10,54,67,This case study reveals an unusual finding of rapidly proliferative crescentic glomerulonephritis in a patient treated with rifampin who had no other identifiable causes for developing this disease.,7834920_1,-1,1,1,21466,1
21469,renal failure,22,24,148,161,This patient underwent a 10-month regimen of rifampin and isoniazid for pulmonary tuberculosis and was discovered to have developed signs of severe renal failure five weeks after completion of therapy.,7834920_2,-1,1,1,21469,1
21475,ocular hypertension,1,3,22,41,Dexamethasone-induced ocular hypertension in perfusion-cultured human eyes.,7843916_0,-1,1,1,21475,1
21477,ocular hypertension,10,12,70,89,PURPOSE: Glucocorticoid administration can lead to the development of ocular hypertension and corticosteroid glaucoma in a subset of the population through a decrease in the aqueous humor outflow facility.,7843916_1,-1,1,1,21477,1
21507,ocular hypertension,15,17,104,123,"CONCLUSION: Dexamethasone treatment of isolated, perfusion-cultured human eyes led to the generation of ocular hypertension in approximately 30% of the dexamethasone-treated eyes.",7843916_12,-1,1,1,21507,1
21512,open angle glaucoma,18,21,135,154,Steroid treatment resulted in morphologic changes in the trabecular meshwork similar to those reported for corticosteroid glaucoma and open angle glaucoma.,7843916_13,-1,1,1,21512,1
21515,primary open angle glaucoma,19,23,116,143,This system may provide an acute model in which to study the pathogenic mechanisms involved in steroid glaucoma and primary open angle glaucoma.,7843916_14,-1,1,1,21515,1
21526,neurologic symptoms,3,5,19,38,"He developed acute neurologic symptoms of mental confusion, disorientation and irritability, and then lapsed into a deep coma, lasting for approximately 40 hours during the first dose (day 2) of 5-fluorouracil and folinic acid infusion.",7858459_2,-1,1,1,21526,1
21536,neurotoxicity,12,13,72,85,"Because folinic acid was unlikely to be associated with this condition, neurotoxicity due to high-dose 5-fluorouracil was highly suspected.",7858459_4,-1,1,1,21536,1
21542,dehydrogenase deficiency,23,25,160,184,"The pathogenesis of 5-fluorouracil neurotoxicity may be due to a Krebs cycle blockade by fluoroacetate and fluorocitrate, thiamine deficiency, or dihydrouracil dehydrogenase deficiency.",7858459_5,-1,1,1,21542,1
21560,brachial plexus,5,7,50,65,Auditory disturbance associated with interscalene brachial plexus block.,7880714_0,-1,1,1,21560,1
21563,brachial plexus,18,20,116,131,We performed an audiometric study in 20 patients who underwent surgery of the shoulder region under an interscalene brachial plexus block (IBPB).,7880714_1,-1,1,1,21563,1
21568,hearing impairment,3,5,17,35,"In four patients hearing impairment on the side of the block was demonstrated after operation, in three measurements on the day of surgery and in one on the following day.",7880714_4,-1,1,1,21568,1
21572,auditory dysfunction,4,6,25,45,"IBPB may cause transient auditory dysfunction in the ipsilateral ear, possibly via an effect on sympathetic innervation.",7880714_8,-1,1,1,21572,1
21603,gall stones,33,35,218,229,"Because knowledge of stone composition is essential for studies of their pathogenesis, treatment, and prevention, this was investigated by direct and indirect methods in 14 octreotide treated acromegalic patients with gall stones.",7890216_2,-1,1,1,21603,1
21604,gall stones,3,5,21,32,"Chemical analysis of gall stones retrieved at cholecystectomy from two patients, showed that they contained 71% and 87% cholesterol by weight.",7890216_3,-1,1,1,21604,1
21606,gall bladder,11,13,67,79,"In the remaining 12 patients, localised computed tomography of the gall bladder showed that eight had stones with maximum attenuation scores of < 100 Hounsfield units (values of < 100 HU predict cholesterol rich, dissolvable stones).",7890216_4,-1,1,1,21606,1
21614,microcrystal,32,33,157,169,"All six patients had supersaturated bile (mean (SEM) cholesterol saturation index of 1.19 (0.08) (range 1.01-1.53)) and all had abnormally rapid cholesterol microcrystal nucleation times (< 4 days (range 1-4)), whilst in four, the bile contained cholesterol microcrystals immediately after sampling.",7890216_6,-1,1,1,21614,1
21621,gall stone,27,29,115,125,"After one year of treatment, five of the remaining nine patients showed either partial (n = 3) or complete (n = 2) gall stone dissolution, suggesting that their stones were cholesterol rich.",7890216_8,-1,1,1,21621,1
21622,gall stone,14,16,68,78,"This corresponds, by actuarial (life table) analysis, to a combined gall stone dissolution rate of 58.3 (15.9%).",7890216_9,-1,1,1,21622,1
21624,gall stones,5,7,34,45,"In conclusion, octreotide induced gall stones are generally small, multiple, and cholesterol rich although, in common with spontaneous gall stone disease, at presentation some patients will have a blocked cystic duct and some gall stones containing calcium.",7890216_10,-1,1,1,21624,1
21627,gall stones,38,40,226,237,"In conclusion, octreotide induced gall stones are generally small, multiple, and cholesterol rich although, in common with spontaneous gall stone disease, at presentation some patients will have a blocked cystic duct and some gall stones containing calcium.",7890216_10,-1,1,1,21627,1
21650,abdominal pain,4,6,22,36,"Diarrhea, flatulence, abdominal pain, and weight loss were common for combination recipients.(ABSTRACT TRUNCATED AT 250 WORDS)",7905523_8,-1,1,1,21650,1
21672,neuromuscular junction,12,14,63,85,The weakness in these patients is due to pathology at both the neuromuscular junction (most likely due to ND-NMBA) and muscle (most likely due to corticosteroids).,7910951_8,-1,1,1,21672,1
21683,congestive heart failure,7,10,59,83,Medications were discontinued when erythema multiforme and congestive heart failure caused by myocarditis occurred.,7919560_3,-1,1,1,21683,1
21710,REM sleep,14,16,102,111,During the night clomipramine ingestion altered the complete sleep architecture in that it suppressed REM sleep and the sleep cycles and induced increased wakefulness.,7930386_6,-1,1,1,21710,1
21719,REM sleep,3,5,16,25,"The presence of REM sleep was shown not to be a determining factor either for secretory pulse amplitude and frequency, as, for both, mean nocturnal values were similar with and without prior clomipramine ingestion.",7930386_8,-1,1,1,21719,1
21732,adverse reactions,5,7,23,40,"There were 13 cases of adverse reactions (0.34%), ten of which were mild reactions such as nausea, exanthema, urtication, itchiness, and urgency to defecate, and did not require treatment.",7977601_7,-1,1,1,21732,1
21734,adverse reactions,7,9,42,59,CONCLUSIONS: A comparison of frequency of adverse reactions to indocyanine green with the previously reported frequency of such reactions to fluorescein sodium indicated that indocyanine green is a safe as fluorescein for use in angiography.,7977601_10,-1,1,1,21734,1
21740,chest pain,17,19,91,101,"A 72-year-old woman was admitted to the hospital with ""flash"" pulmonary edema, preceded by chest pain, requiring intubation.",7988234_1,-1,1,1,21740,1
21743,coronary artery disease,4,7,29,52,"Her medical history included coronary artery disease with previous myocardial infarctions, hypertension, and diabetes mellitus.",7988234_2,-1,1,1,21743,1
21744,myocardial infarctions,9,11,67,89,"Her medical history included coronary artery disease with previous myocardial infarctions, hypertension, and diabetes mellitus.",7988234_2,-1,1,1,21744,1
21745,diabetes mellitus,15,17,109,126,"Her medical history included coronary artery disease with previous myocardial infarctions, hypertension, and diabetes mellitus.",7988234_2,-1,1,1,21745,1
21843,allergic reactions,1,3,10,28,Immediate allergic reactions to amoxicillin.,8092427_0,-1,1,1,21843,1
21844,allergic reactions,7,9,41,59,A large group of patients with suspected allergic reactions to beta-lactam antibiotics was evaluated.,8092427_1,-1,1,1,21844,1
21881,allergic reaction,19,21,100,117,"Challenge tests with AX were performed in 23 subjects (43%) to establish the diagnosis of immediate allergic reaction to AX, and in 15 cases (28%) both skin test and RAST for AX were negative.",8092427_13,-1,1,1,21881,1
21894,myocardial infarctions,5,7,35,57,"Ten patients with acute transmural myocardial infarctions received intravenous nitroglycerin, sufficient to reduce mean arterial pressure from 107 +/- 6 to 85 +/- 6 mm Hg (P less than 0.001), for 60 minutes.",809711_3,-1,1,1,21894,1
21898,Left ventricular,0,2,0,16,Left ventricular filling pressure decreased from 19 +/- 2 to 11 +/- 2 mm Hg (P less than 0.001).,809711_4,-1,1,1,21898,1
21907,left ventricular,30,32,160,176,"Subsequent addition of phenylephrine infusion, sufficient to re-elevate mean arterial pressure to 106 +/- 4 mm Hg (P less than 0.001) for 30 minutes, increased left ventricular filling pressure to 17 +/- 2 mm Hg (P less than 0.05) and also significantly increased sigmaST (P less than 0.05).",809711_6,-1,1,1,21907,1
21913,MPTP,11,12,65,69,A group of four monkeys was rendered parkinsonian with the toxin MPTP.,8106150_1,-1,1,1,21913,1
21918,dyskinetic,22,23,135,145,A series of agents acting primarily on neurotransmitters other than dopamine were then tested in combination with L-DOPA to see if the dyskinetic movements would be modified.,8106150_4,-1,1,1,21918,1
21923,dyskinetic,20,21,119,129,"Several drugs, including clonidine, physostigmine, methysergide, 5-MDOT, propranolol, and MK-801, markedly reduced the dyskinetic movements but at the cost of a return of parkinsonian symptomatology.",8106150_5,-1,1,1,21923,1
21926,dyskinetic,8,9,60,70,"However, yohimbine and meperidine reduced predominantly the dyskinetic movements.",8106150_6,-1,1,1,21926,1
21930,neurotoxicity,3,4,38,51,Hallucinations and ifosfamide-induced neurotoxicity.,8111719_0,-1,1,1,21930,1
21931,neurotoxicity,8,9,51,64,BACKGROUND: Hallucinations as a symptom of central neurotoxicity are a known but poorly described side effect of ifosfamide.,8111719_1,-1,1,1,21931,1
21932,side effect,15,17,98,109,BACKGROUND: Hallucinations as a symptom of central neurotoxicity are a known but poorly described side effect of ifosfamide.,8111719_1,-1,1,1,21932,1
21936,bone marrow,10,12,66,77,All patients were receiving high-dose ifosfamide as part of their bone marrow transplant procedure.,8111719_4,-1,1,1,21936,1
21938,neurotoxicity,11,12,70,83,CONCLUSIONS: Hallucinations may be the sole or first manifestation of neurotoxicity.,8111719_7,-1,1,1,21938,1
21940,neurotoxicity,17,18,119,132,"The clinician should be alerted for possible ifosfamide-induced hallucinations, which may occur without other signs of neurotoxicity. ""Eyes-closed"" hallucinatory experiences appear to be an unusual feature of this presentation.",8111719_9,-1,1,1,21940,1
21946,periodic paralysis,11,13,86,104,We studied 20 patients receiving long-term carbonic anhydrase inhibitor treatment for periodic paralysis and myotonia.,8170551_2,-1,1,1,21946,1
21972,telangiectasia,3,4,43,57,Photodistributed nifedipine-induced facial telangiectasia.,8251368_0,-1,1,1,21972,1
21974,telangiectasia,14,15,95,109,"Five months after starting nifedipine (Adalat), two patients developed photodistributed facial telangiectasia, which became more noticeable with time.",8251368_1,-1,1,1,21974,1
21977,telangiectasia,14,15,84,98,"One commenced the closely related drug amlodipine 3 years later, with recurrence of telangiectasia.",8251368_4,-1,1,1,21977,1
21979,telangiectasia,4,5,29,43,The photodistribution of the telangiectasia suggests a significant drug/light interaction.,8251368_5,-1,1,1,21979,1
21982,rheumatoid arthritis,8,10,79,99,Penicillamine-induced rapidly progressive glomerulonephritis in a patient with rheumatoid arthritis.,8267029_0,-1,1,1,21982,1
21983,rheumatoid arthritis,4,6,25,45,A 67-year-old woman with rheumatoid arthritis presented rapidly progressive glomerulonephritis (RPGN) after 5 months of D-penicillamine (250 mg/day) treatment.,8267029_1,-1,1,1,21983,1
22002,primary biliary cirrhosis,8,11,41,66,A case of polymyositis in a patient with primary biliary cirrhosis treated with D-penicillamine.,8268147_0,-1,1,1,22002,1
22007,Polymyositis/dermatomyositis,0,1,0,28,"Polymyositis/dermatomyositis can develop as one of the autoimmune complications of D-penicillamine treatment, but its exact pathogenesis remains unclear.",8268147_2,-1,1,1,22007,1
22010,primary biliary cirrhosis,5,8,25,50,"We report a patient with primary biliary cirrhosis, who developed polymyositis while receiving D-penicillamine therapy.",8268147_3,-1,1,1,22010,1
22012,clinical course,4,6,25,40,We described the special clinical course of the patient.,8268147_4,-1,1,1,22012,1
22015,polymyositis/dermatomyositis,15,16,125,153,Patients receiving D-penicillamine therapy should be followed carefully for the development of autoimmune complications like polymyositis/dermatomyositis.,8268147_5,-1,1,1,22015,1
22016,Hyperalgesia,0,1,0,12,Hyperalgesia and myoclonus in terminal cancer patients treated with continuous intravenous morphine.,8278214_0,-1,1,1,22016,1
22020,hyperalgesia,18,19,118,130,Eight cancer patients in the terminal stages of the disease treated with high doses of intravenous morphine developed hyperalgesia.,8278214_1,-1,1,1,22020,1
22022,hyperalgesia,4,5,34,46,Five patients developed universal hyperalgesia and hyperesthesia which in 2 cases were accompanied by myoclonus.,8278214_3,-1,1,1,22022,1
22023,hyperesthesia,6,7,51,64,Five patients developed universal hyperalgesia and hyperesthesia which in 2 cases were accompanied by myoclonus.,8278214_3,-1,1,1,22023,1
22094,nephrotic syndromes,3,5,18,37,"The appearance of nephrotic syndromes such as proteinuria, hypoalbuminemia, hypercholesterolemia and increase in blood nitrogen urea, induced in rats by injection of puromycin aminonucleoside was markedly inhibited by oral administration of Dup 753 (losartan), a novel angiotensin II receptor antagonist, at a dose of 1 or 2 mg/kg per day.",8319760_1,-1,1,1,22094,1
22107,cochlear hearing loss,8,11,63,84,Neuroplasticity of the adult primate auditory cortex following cochlear hearing loss.,8372922_0,-1,1,1,22107,1
22115,cochlear hearing loss,16,19,101,122,The purpose of this study was to determine if changes occur in this tonotopic organization following cochlear hearing loss.,8372922_3,-1,1,1,22115,1
22129,cochlear hearing loss,15,18,91,112,The region of cortex that represents the low frequencies was not obviously affected by the cochlear hearing loss.,8372922_10,-1,1,1,22129,1
22131,Non-Hodgkin's Lymphoma,3,6,20,42,Forty patients with Non-Hodgkin's Lymphoma treated with vincristine between 1984 and 1990 (cumulative dose 12 mg in 18-24 weeks) were investigated in order to evaluate the long term effects of vincristine on the peripheral nervous system.,8384253_1,-1,1,1,22131,1
22134,long term,31,33,172,181,Forty patients with Non-Hodgkin's Lymphoma treated with vincristine between 1984 and 1990 (cumulative dose 12 mg in 18-24 weeks) were investigated in order to evaluate the long term effects of vincristine on the peripheral nervous system.,8384253_1,-1,1,1,22134,1
22142,signs and symptoms,4,7,26,44,In these patients sensory signs and symptoms predominated.,8384253_6,-1,1,1,22142,1
22145,long term,8,10,56,65,Neuropathic complaints were not very troublesome on the long term.,8384253_11,-1,1,1,22145,1
22146,signs and symptoms,11,14,72,90,It is concluded that with the above mentioned vincristine dose schedule signs and symptoms of vincristine neuropathy are reversible for a great deal and prognosis is fairly good.,8384253_12,-1,1,1,22146,1
22185,Adverse reactions,0,2,0,17,Adverse reactions possibly attributable to didanosine were common.,8387218_7,-1,1,1,22185,1
22186,side-effect,3,4,16,27,"The most common side-effect was diarrhoea, which resulted in cessation of therapy in 19 individuals.",8387218_8,-1,1,1,22186,1
22187,Peripheral neuropathy,0,2,0,21,Peripheral neuropathy occurred in 12 patients and pancreatitis in six.,8387218_9,-1,1,1,22187,1
22189,abdominal pain,8,10,59,73,Thirteen patients developed a raised serum amylase without abdominal pain.,8387218_10,-1,1,1,22189,1
22224,status epilepticus,11,13,90,108,Infarcts in substantia nigra pars reticulata were evoked by prolonged pilocarpine-induced status epilepticus.,8410052_3,-1,1,1,22224,1
22242,hippocampal,10,11,78,89,"Sprague-Dawley rats were injected intraperitoneally with pilocarpine, and the hippocampal formation was studied histologically at 1, 2, 4, and 8 week intervals after pilocarpine-induced seizures.",8410199_2,-1,1,1,22242,1
22253,fibrillary,18,19,142,152,"Additional neuronanatomical studies, including cresyl violet staining, neuronal degeneration methods, and histochemical localization of glial fibrillary acidic protein, suggested that the decrease in the number of GAD mRNA-containing neurons was related to neuronal loss rather than to a decrease in GAD mRNA levels.",8410199_4,-1,1,1,22253,1
22280,liver dysfunction,7,9,36,53,"These 6 patients had both renal and liver dysfunction (P less than 0.05), as well as cimetidine trough-concentrations of more than 1.25 microgram/ml (P less than 0.05).",84204_2,-1,1,1,22280,1
22285,cerebrospinal fluid,1,3,4,23,The cerebrospinal fluid: serum ratio of cimetidine concentrations was 0.24:1 and indicates that cimetidine passes the blood-brain barrier; it also raises the possibility that M.S. changes are due to blockade of histamine H2-receptors in the central nervous system.,84204_4,-1,1,1,22285,1
22290,central nervous system,37,40,241,263,The cerebrospinal fluid: serum ratio of cimetidine concentrations was 0.24:1 and indicates that cimetidine passes the blood-brain barrier; it also raises the possibility that M.S. changes are due to blockade of histamine H2-receptors in the central nervous system.,84204_4,-1,1,1,22290,1
22354,Sinus arrest,0,2,0,12,Sinus arrest associated with continuous-infusion cimetidine.,8437969_0,-1,1,1,22354,1
22359,sinus arrest,18,20,114,126,"A 40-year-old man with leukemia and no history of cardiac disease developed recurrent, brief episodes of apparent sinus arrest while receiving continuous-infusion cimetidine 50 mg/hour.",8437969_2,-1,1,1,22359,1
22363,sinus arrest,7,9,35,47,This is the first reported case of sinus arrest associated with continuous-infusion cimetidine.,8437969_4,-1,1,1,22363,1
22365,rheumatoid arthritis,3,5,17,37,Apparent cure of rheumatoid arthritis by bone marrow transplantation.,8441146_0,-1,1,1,22365,1
22366,bone marrow,6,8,41,52,Apparent cure of rheumatoid arthritis by bone marrow transplantation.,8441146_0,-1,1,1,22366,1
22368,bone marrow,19,21,115,126,We describe the induction of sustained remissions and possible cure of severe erosive rheumatoid arthritis (RA) by bone marrow transplantation (BMT) in 2 patients.,8441146_1,-1,1,1,22368,1
22371,aplastic anemia,6,8,29,44,BMT was used to treat severe aplastic anemia which was caused by gold in one case and D-penicillamine in the other.,8441146_2,-1,1,1,22371,1
22382,ventricular tachycardia,6,8,41,64,Case report: pentamidine and polymorphic ventricular tachycardia revisited.,8475949_0,-1,1,1,22382,1
22385,ventricular tachyarrhythmias,6,8,49,77,"Pentamidine isethionate has been associated with ventricular tachyarrhythmias, including torsade de pointes.",8475949_1,-1,1,1,22385,1
22393,side effects,7,9,34,46,"In these patients, no other acute side effects of pentamidine were observed.",8475949_5,-1,1,1,22393,1
22432,muscle spasms,13,15,93,106,"While severe hypokalemia may cause muscle weakness, severe hypomagnesemia is associated with muscle spasms and tetany which cannot be corrected by potassium and calcium supplementation alone (1,2).",8492347_2,-1,1,1,22432,1
22440,acute renal failure,6,9,40,59,Five patients with cancer who developed acute renal failure that followed treatment with ciprofloxacin are described and an additional 15 cases reported in the literature are reviewed.,8494478_2,-1,1,1,22440,1
22443,interstitial nephritis,1,3,9,31,Allergic interstitial nephritis is believed to be the underlying pathological-process.,8494478_4,-1,1,1,22443,1
22449,acute renal failure,19,22,155,174,An improvement in renal function that followed the discontinuation of the offending antibiotic supports the presumptive diagnosis of ciprofloxacin-induced acute renal failure.,8494478_6,-1,1,1,22449,1
22470,visual hallucinations,1,3,26,47,Clarithromycin-associated visual hallucinations in a patient with chronic renal failure on continuous ambulatory peritoneal dialysis.,8546130_0,-1,1,1,22470,1
22472,Visual hallucinations,0,2,0,21,Visual hallucinations are a rare event in chronic renal failure and not related to uremia per se.,8546130_1,-1,1,1,22472,1
22474,visual hallucinations,5,7,32,53,"Unreported in the literature is visual hallucinations occurring in association with the new macrolide antibiotic, clarithromycin.",8546130_2,-1,1,1,22474,1
22484,side effect,34,36,223,234,"The combination of a relatively high dose of clarithromycin in face of chronic renal failure in a functionally anephric patient, with underlying aluminum intoxication, may have facilitated the appearance of this neurotoxic side effect.",8546130_4,-1,1,1,22484,1
22490,preneoplastic,4,5,26,39,Changes in peroxisomes in preneoplastic liver and hepatoma of mice induced by alpha-benzene hexachloride.,85485_0,-1,1,1,22490,1
22510,squamous cell,7,9,44,57,Phase II trial of vinorelbine in metastatic squamous cell esophageal carcinoma.,8558192_0,-1,1,1,22510,1
22518,squamous cell,36,38,230,243,European Organization for Research and Treatment of Cancer Gastrointestinal Treat Cancer Cooperative Group.PURPOSE: To evaluate the response rate and toxic effects of vinorelbine (VNB) administered as a single agent in metastatic squamous cell esophageal carcinoma. PATIENTS AND METHODS: Forty-six eligible patients with measurable lesions were included and were stratified according to previous chemotherapy.,8558192_1,-1,1,1,22518,1
22532,grade 3,5,7,24,31,At least one episode of grade 3 or 4 granulocytopenia was seen in 59% of patients.,8558192_10,-1,1,1,22532,1
22533,grade 2,1,3,2,9,"A grade 2 or 3 infection occurred in 16% of patients, but no toxic deaths occurred.",8558192_11,-1,1,1,22533,1
22535,side effects,1,3,6,18,"Other side effects were rare, and peripheral neurotoxicity has been minor (26% grade 1).",8558192_12,-1,1,1,22535,1
22536,neurotoxicity,8,9,45,58,"Other side effects were rare, and peripheral neurotoxicity has been minor (26% grade 1).",8558192_12,-1,1,1,22536,1
22537,grade 1,15,17,79,86,"Other side effects were rare, and peripheral neurotoxicity has been minor (26% grade 1).",8558192_12,-1,1,1,22537,1
22540,squamous cell carcinoma,14,17,85,108,CONCLUSION: These data indicate that VNB is an active agent in metastatic esophageal squamous cell carcinoma.,8558192_13,-1,1,1,22540,1
22544,nervous system,4,6,32,46,Contribution of the sympathetic nervous system to salt-sensitivity in lifetime captopril-treated spontaneously hypertensive rats.,8586822_0,-1,1,1,22544,1
22549,nervous system,20,22,125,139,"OBJECTIVE: To test the hypothesis that, in lifetime captopril-treated spontaneously hypertensive rats (SHR), the sympathetic nervous system contributes importantly to the hypertensive effect of dietary sodium chloride supplementation.",8586822_1,-1,1,1,22549,1
22560,central nervous system,3,6,16,38,Infusion of the central nervous system alpha2-adrenergic receptor agonist clonidine also resulted in a greater reduction in MAP in both groups of SHR that were fed the high (compared with the basal) sodium chloride diet.,8586822_6,-1,1,1,22560,1
22566,nervous system,12,14,81,95,"CONCLUSIONS: In both lifetime captopril-treated and control SHR, the sympathetic nervous system contributes to the pressor effects of a high sodium chloride diet.",8586822_7,-1,1,1,22566,1
22568,adverse reactions,2,4,14,31,Evaluation of adverse reactions of aponidine hydrochloride ophthalmic solution.,8590259_0,-1,1,1,22568,1
22571,adverse reactions,4,6,31,48,We prospectively evaluated the adverse reactions of apraclonidine in 20 normal volunteers by instilling a single drop of 1% apraclonidine in their right eyes.,8590259_1,-1,1,1,22571,1
22595,corneal abrasion,34,36,195,211,"While the elevations of the upper lid margin in most subjects were not more than 2 mm and did not cause noticeable change in appearance, one subject suffered from mechanical entropion and marked corneal abrasion 3 hours after instillation of the medication.",8590259_8,-1,1,1,22595,1
22606,Group C,2,4,12,19,"Patients in Group C received 2 ml normal saline, Group L, 2 ml, lidocaine 2% (40 mg) and Group T, 2 ml thiopentone 2.5% (50 mg).",8595686_3,-1,1,1,22606,1
22618,Group C,41,43,164,171,Loss of consciousness occurred in 60-90 sec. Visual analogue scores (mean +/- SD) during induction were lower in Groups L (3.3 +/- 2.5) and T (4.1 +/- 2.7) than in Group C (5.6 +/- 2.3); P = 0.0031.,8595686_5,-1,1,1,22618,1
22621,Group C,20,22,82,89,The incidence of venous discomfort was lower in Group L (76.6%; P < 0.05) than in Group C (100%) but not different from Group T (90%).,8595686_6,-1,1,1,22621,1
22702,disease progression,22,24,145,164,"We suspect that the potential for caffeine to stabilize high resistance states in susceptible persons suggests that its use may facilitate their disease progression, as well as hinder accurate diagnosis and treatment.",8607407_11,-1,1,1,22702,1
22719,side effects,17,19,85,97,Three subjects (2 on sertraline and 1 on placebo) withdrew from the study because of side effects.,8617710_8,-1,1,1,22719,1
22720,side effects,6,8,36,48,Ten subjects in each group reported side effects related to treatment.,8617710_9,-1,1,1,22720,1
22721,side effect,1,3,4,15,The side effect profiles of sertraline and of placebo were similar.,8617710_10,-1,1,1,22721,1
22737,internal carotid artery thrombosis,6,10,41,75,Coexistence of cerebral venous sinus and internal carotid artery thrombosis associated with exogenous sex hormones.,8638876_0,-1,1,1,22737,1
22741,nausea and vomiting,8,11,61,80,"A forty-six year-old premenopausal woman developed headache, nausea and vomiting, left hemiparesis and seizure two days after parenteral use of progesterone and estradiol.",8638876_2,-1,1,1,22741,1
22742,hemiparesis,13,14,87,98,"A forty-six year-old premenopausal woman developed headache, nausea and vomiting, left hemiparesis and seizure two days after parenteral use of progesterone and estradiol.",8638876_2,-1,1,1,22742,1
22744,Diabetes mellitus,0,2,0,17,Diabetes mellitus (DM) was found during admission.,8638876_3,-1,1,1,22744,1
22746,frontal lobe,9,11,62,74,Computed tomography showed a hemorrhagic infarct in the right frontal lobe and increased density in the superior sagittal sinus (SSS).,8638876_4,-1,1,1,22746,1
22747,sagittal sinus,17,19,113,127,Computed tomography showed a hemorrhagic infarct in the right frontal lobe and increased density in the superior sagittal sinus (SSS).,8638876_4,-1,1,1,22747,1
22749,internal carotid artery,8,11,53,76,Left carotid angiography found occlusion of the left internal carotid artery (ICA).,8638876_5,-1,1,1,22749,1
22753,venous sinus thrombosis,15,18,91,114,"Right carotid angiograms failed to show the SSS and inferior sagittal sinus, suggestive of venous sinus thrombosis.",8638876_6,-1,1,1,22753,1
22754,cerebral artery,3,5,19,34,Coexistence of the cerebral artery and the venous sinus occlusion has been described infrequently.,8638876_7,-1,1,1,22754,1
22759,lung cancer,6,8,51,62,Chemotherapy of advanced inoperable non-small cell lung cancer with paclitaxel: a phase II trial.,8643966_0,-1,1,1,22759,1
22766,breast carcinoma,25,27,168,184,"Paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) has demonstrated significant antineoplastic activity against different tumor types, notably ovarian and breast carcinoma.",8643966_1,-1,1,1,22766,1
22771,lung cancer,18,20,120,131,Two phase II trials of 24-hour paclitaxel infusions in chemotherapy-naive patients with stage IIIB or IV non-small cell lung cancer (NSCLC) reported response rates of 21% and 24%.,8643966_2,-1,1,1,22771,1
22786,disease progression,28,30,106,125,"Of 50 patients evaluable for response, 12 (24%) had partial remission, 26 (52%) had no change, and 12 had disease progression (24%).",8643966_8,-1,1,1,22786,1
22787,grade 3,13,15,66,73,"Hematologic toxicities were mild: only one patient (2%) developed grade 3 or 4 neutropenia, while 29% had grade 1 or 2.",8643966_9,-1,1,1,22787,1
22788,grade 1,23,25,106,113,"Hematologic toxicities were mild: only one patient (2%) developed grade 3 or 4 neutropenia, while 29% had grade 1 or 2.",8643966_9,-1,1,1,22788,1
22789,Grade 1,0,2,0,7,Grade 1 or 2 polyneuropathy affected 56% of patients while only one (2%) experienced severe polyneuropathy.,8643966_10,-1,1,1,22789,1
22790,polyneuropathy,4,5,13,27,Grade 1 or 2 polyneuropathy affected 56% of patients while only one (2%) experienced severe polyneuropathy.,8643966_10,-1,1,1,22790,1
22791,polyneuropathy,19,20,92,106,Grade 1 or 2 polyneuropathy affected 56% of patients while only one (2%) experienced severe polyneuropathy.,8643966_10,-1,1,1,22791,1
22792,grade 1,2,4,11,18,"Similarly, grade 1 or 2 myalgia/arthralgia was observed in 63.2% of patients, but only 14.3% experienced grade 3 or 4.",8643966_11,-1,1,1,22792,1
22794,grade 3,20,22,105,112,"Similarly, grade 1 or 2 myalgia/arthralgia was observed in 63.2% of patients, but only 14.3% experienced grade 3 or 4.",8643966_11,-1,1,1,22794,1
22795,Nausea and vomiting,0,3,0,19,"Nausea and vomiting were infrequent, with 14% of patients experiencing grade 1 or 2 and only 2% experiencing grade 3 or 4.",8643966_12,-1,1,1,22795,1
22796,grade 1,12,14,71,78,"Nausea and vomiting were infrequent, with 14% of patients experiencing grade 1 or 2 and only 2% experiencing grade 3 or 4.",8643966_12,-1,1,1,22796,1
22797,grade 3,21,23,109,116,"Nausea and vomiting were infrequent, with 14% of patients experiencing grade 1 or 2 and only 2% experiencing grade 3 or 4.",8643966_12,-1,1,1,22797,1
22821,head and neck cancer,32,36,193,213,"Preliminary results of an Eastern Cooperative Oncology Group study of single-agent paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) reported a 37% response rate in patients with head and neck cancer, and the paclitaxel/cisplatin combination has been used successfully and has significantly improved median response duration in ovarian cancer patients.",8643971_2,-1,1,1,22821,1
22824,ovarian cancer,53,55,342,356,"Preliminary results of an Eastern Cooperative Oncology Group study of single-agent paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) reported a 37% response rate in patients with head and neck cancer, and the paclitaxel/cisplatin combination has been used successfully and has significantly improved median response duration in ovarian cancer patients.",8643971_2,-1,1,1,22824,1
22855,grade 1,23,25,133,140,"Alopecia, paresthesias, and arthralgias/myalgias have occurred frequently, but with one exception (a grade 3 myalgia) they have been grade 1 or 2.",8643971_16,-1,1,1,22855,1
22858,head and neck cancer,9,13,84,104,Paclitaxel/cisplatin is an effective first-line regimen for locoregionally advanced head and neck cancer and continued study is warranted.,8643971_18,-1,1,1,22858,1
22864,ovarian cancer,10,12,77,91,Paclitaxel combined with carboplatin in the first-line treatment of advanced ovarian cancer.,8643973_0,-1,1,1,22864,1
22871,ovarian cancer,41,43,235,249,"In a phase I study to determine the maximum tolerated dose of paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) given as a 3-hour infusion in combination with carboplatin administered every 21 days to women with advanced ovarian cancer, paclitaxel doses were escalated as follows: level 1, 135 mg/m2; level 2, 160 mg/m2; level 3, 185 mg/m2; and level 4,210 mg/m2.",8643973_1,-1,1,1,22871,1
22883,Neurotoxicity,0,1,0,13,Neurotoxicity was largely moderate.,8643973_6,-1,1,1,22883,1
22884,complete or partial,21,24,88,107,"So far, 14 patients are evaluable for response; of these, eight (57%) showed objective (complete or partial) response and disease stabilized in six patients.",8643973_7,-1,1,1,22884,1
22886,disease progression,3,5,15,34,No patient had disease progression.,8643973_8,-1,1,1,22886,1
22904,dystonia,9,10,68,76,"Ballistic and choreic dyskinesia were markedly ameliorated, whereas dystonia was not.",8649546_3,-1,1,1,22904,1
22920,body weight,8,10,43,54,This was associated with a similar loss in body weight.,8665051_4,-1,1,1,22920,1
22936,type IIb,12,14,76,84,"ATPase staining of the diaphragm, scalenus medius, and gastrocnemius showed type IIb fiber atrophy in the steroid groups and also diaphragmatic type IIa atrophy with T, whereas histologic examinations revealed a normal muscular pattern with absence of necrosis.",8665051_10,-1,1,1,22936,1
22937,diaphragmatic,22,23,130,143,"ATPase staining of the diaphragm, scalenus medius, and gastrocnemius showed type IIb fiber atrophy in the steroid groups and also diaphragmatic type IIa atrophy with T, whereas histologic examinations revealed a normal muscular pattern with absence of necrosis.",8665051_10,-1,1,1,22937,1
22938,type IIa,23,25,144,152,"ATPase staining of the diaphragm, scalenus medius, and gastrocnemius showed type IIb fiber atrophy in the steroid groups and also diaphragmatic type IIa atrophy with T, whereas histologic examinations revealed a normal muscular pattern with absence of necrosis.",8665051_10,-1,1,1,22938,1
22942,muscle atrophy,24,26,81,95,"Finally, a pair-fed (PF) study, performed in 18 rats (C, T, and PF), showed that muscle atrophy was considerably less pronounced in PF animals than in T-treated animals.",8665051_11,-1,1,1,22942,1
22948,type IIb,30,32,174,182,"We conclude that (1) short-term treatment with massive doses of steroids induced severe respiratory and limb muscle wasting; (2) both types of steroids induced predominantly type IIb atrophy, resulting in the expected alterations in diaphragm contractile properties; (3) neither steroid caused muscle necrosis; (4) type IIb atrophy was not caused by acute nutritional deprivation alone.",8665051_12,-1,1,1,22948,1
22951,muscle necrosis,50,52,294,309,"We conclude that (1) short-term treatment with massive doses of steroids induced severe respiratory and limb muscle wasting; (2) both types of steroids induced predominantly type IIb atrophy, resulting in the expected alterations in diaphragm contractile properties; (3) neither steroid caused muscle necrosis; (4) type IIb atrophy was not caused by acute nutritional deprivation alone.",8665051_12,-1,1,1,22951,1
22952,type IIb,56,58,315,323,"We conclude that (1) short-term treatment with massive doses of steroids induced severe respiratory and limb muscle wasting; (2) both types of steroids induced predominantly type IIb atrophy, resulting in the expected alterations in diaphragm contractile properties; (3) neither steroid caused muscle necrosis; (4) type IIb atrophy was not caused by acute nutritional deprivation alone.",8665051_12,-1,1,1,22952,1
23004,allergic reactions,3,5,18,36,Other symptoms of allergic reactions were not clinically detectable.,8682684_5,-1,1,1,23004,1
23008,back pain,2,4,8,17,Leg and back pain after spinal anaesthesia involving hyperbaric 5% lignocaine.,8686832_0,-1,1,1,23008,1
23016,back pain,2,4,11,20,Leg and/or back pain is associated with the intrathecal use of hyperbaric 5% lignocaine.,8686832_5,-1,1,1,23016,1
23025,diabetic nephropathy,15,17,127,147,Reduction of heparan sulphate-associated anionic sites in the glomerular basement membrane of rats with streptozotocin-induced diabetic nephropathy.,8690168_0,-1,1,1,23025,1
23075,extracerebral,14,15,68,81,L-Dopa (5 mg/kg i.v.) decreased blood pressure and heart rate after extracerebral decarboxylase inhibition with MK-486 (25 mg/kg i.v.) in anesthetize MAO-inhibited dogs.,869641_1,-1,1,1,23075,1
23099,carotid sinus,16,18,105,118,"Furthermore, the effects are mediated through dopamine rather than norepinephrine and do not require the carotid sinus baroreceptors.",869641_9,-1,1,1,23099,1
23100,Microangiopathic hemolytic anemia,0,3,0,33,Microangiopathic hemolytic anemia complicating FK506 (tacrolimus) therapy.,8701950_0,-1,1,1,23100,1
23103,microangiopathic hemolytic anemia,5,8,26,59,We describe 3 episodes of microangiopathic hemolytic anemia (MAHA) in 2 solid organ recipients under FK506 (tacrolimus) therapy.,8701950_1,-1,1,1,23103,1
23238,liver injury,36,38,239,251,"Recently, we demonstrated the hepatoprotective effects of nicotinic acid amide, a selective inhibitor of poly(ADP-ribose) polymerase (PARP; EC 2.4.2.30) on mice suffering from acetaminophen (AAP)-hepatitis, suggesting that the AAP-induced liver injury involves a step which depends on adenoribosylation.",8742498_1,-1,1,1,23238,1
23245,Liver injuries,0,2,0,14,Liver injuries were quantified as serum activities of glutamate-oxaloacetate transaminase (GOT) and glutamate-pyruvate transaminase (GPT).,8742498_3,-1,1,1,23245,1
23280,side effects,26,28,148,160,"Although much has been written about the management of the more common adverse effects of lithium, such as polyuria and tremor, more subtle lithium side effects such as cognitive deficits, loss of creativity, and functional impairments remain understudied.",8752018_2,-1,1,1,23280,1
23303,chronic pain,16,18,115,127,This drug was initiated in association with paroxetine and dosulepine hydrochloride in a tetraparetic patient with chronic pain.,8766220_2,-1,1,1,23303,1
23307,long term,5,7,30,39,"The case report questions the long term use of pain killers combined with psycho-active drugs in chronic non malignant pain, especially if pain is under control.",8766220_4,-1,1,1,23307,1
23357,cerebral hypoxia,9,11,58,74,Alpha and beta coma in drug intoxication uncomplicated by cerebral hypoxia.,88336_0,-1,1,1,23357,1
23359,hypoxic,16,17,93,100,"Four patients who were rendered comatose or stuporous by drug intoxication, but who were not hypoxic, are described.",88336_1,-1,1,1,23359,1
23374,brain stem,13,15,97,107,The similarities between the effects of structural lesions and pharmacological depression of the brain stem reticular formation are discussed.,88336_6,-1,1,1,23374,1
23402,drug-related,3,4,17,29,"The incidence of drug-related dependent edema was somewhat higher in the amlodipine group, particularly at a dose of 10 mg per day (2.4% for 80 mg valsartan; 3.6% for 5 mg amlodipine; 0% for valsartan plus 5 mg amlodipine; 14.3% for 10 mg amlodipine).",8841157_12,-1,1,1,23402,1
23409,side effects,17,19,96,108,"The results also show valsartan to be well tolerated and suggest that it is not associated with side effects characteristic of this comparator class, dihydropyridine calcium antagonists.",8841157_14,-1,1,1,23409,1
23416,drug-induced,8,9,52,64,Cocaine-induced paranoia (CIP) remains an important drug-induced model of idiopathic paranoia for which no psychophysiologic marker has yet emerged.,8854309_1,-1,1,1,23416,1
23427,cerebellar atrophy,14,16,88,106,The aim of this study was to evaluate the relationship between phenytoin medication and cerebellar atrophy in patients who had experienced clinical intoxication.,8864707_1,-1,1,1,23427,1
23443,cerebellar atrophy,10,12,69,87,We conclude that phenytoin overdosage does not necessarily result in cerebellar atrophy and it is unlikely that phenytoin medication was the only cause of cerebellar atrophy in the remaining patients.,8864707_10,-1,1,1,23443,1
23444,cerebellar atrophy,24,26,155,173,We conclude that phenytoin overdosage does not necessarily result in cerebellar atrophy and it is unlikely that phenytoin medication was the only cause of cerebellar atrophy in the remaining patients.,8864707_10,-1,1,1,23444,1
23449,muscle rigidity,17,19,117,132,"Excessive stimulation of serotonin 5HT1A receptors causes a syndrome of serotonin excess that consists of shivering, muscle rigidity, salivation, confusion, agitation and hyperthermia.",8888541_1,-1,1,1,23449,1
23456,myoclonic jerks,19,21,101,116,"He was brought directly to a hospital where he was found to be agitated and confused with shivering, myoclonic jerks, rigidity, salivation and diaphoresis.",8888541_7,-1,1,1,23456,1
23463,muscle rigidity,33,35,171,186,"Vital signs were: blood pressure 120/67 mm Hg, heart rate 127/min, respiratory rate 28/min, and temperature 97 F. After 180 mg of diazepam i.v. he remained tremulous with muscle rigidity and clenched jaws.",8888541_9,-1,1,1,23463,1
23464,hypoventilation,9,10,54,69,"He was intubated for airway protection and because of hypoventilation, and was paralyzed to control muscle rigidity.",8888541_10,-1,1,1,23464,1
23465,muscle rigidity,16,18,100,115,"He was intubated for airway protection and because of hypoventilation, and was paralyzed to control muscle rigidity.",8888541_10,-1,1,1,23465,1
23466,non-immune,6,7,41,51,His subsequent course was remarkable for non-immune thrombocytopenia which resolved.,8888541_11,-1,1,1,23466,1
23487,microangiopathic hemolytic anemia,27,30,169,202,"Therefore, in adult patients affected by HUS, dialysis should not be discontinued prematurely; moreover, bilateral nephrectomy, for treatment of severe hypertension and microangiopathic hemolytic anemia, should be performed with caution.",891050_4,-1,1,1,23487,1
23489,bladder cancer,2,4,28,42,Cyclophosphamide associated bladder cancer--a highly aggressive disease: analysis of 12 cases.,8911359_0,-1,1,1,23489,1
23495,bladder cancer,22,24,117,131,MATERIALS AND METHODS: The medical records of 6 men and 6 women (mean age 55 years) with cyclophosphamide associated bladder cancer were reviewed.,8911359_2,-1,1,1,23495,1
23496,grade 3,5,7,25,32,RESULTS: All tumors were grade 3 or 4 transitional cell carcinoma.,8911359_3,-1,1,1,23496,1
23502,bladder tumor,4,6,41,54,CONCLUSIONS: Cyclophosphamide associated bladder tumor is an aggressive disease.,8911359_7,-1,1,1,23502,1
23505,bladder tumors,12,14,81,95,"However, long-term survival is possible when radical cystectomy is performed for bladder tumors with any sign of invasion and for recurrent high grade disease, even when noninvasive.",8911359_8,-1,1,1,23505,1
23549,hyperammonemia,9,10,53,67,"The possible influence of the hepatic damage, mainly hyperammonemia, upon the development of valproate encephalopathy is discussed.",8919272_15,-1,1,1,23549,1
23555,allergic reaction,17,19,95,112,We present a case of paramedic misjudgment in the execution of a protocol for the treatment of allergic reaction in a case of pulmonary edema with wheezing.,8953972_1,-1,1,1,23555,1
23557,sudden onset,1,3,4,16,"The sudden onset of respiratory distress, rash, and a history of a new medicine led the two paramedics on the scene to administer subcutaneous epinephrine.",8953972_2,-1,1,1,23557,1
23558,respiratory distress,4,6,20,40,"The sudden onset of respiratory distress, rash, and a history of a new medicine led the two paramedics on the scene to administer subcutaneous epinephrine.",8953972_2,-1,1,1,23558,1
23559,cardiac arrest,3,5,20,34,"Subsequently, acute cardiac arrest and fatal subarachnoid hemorrhage occurred.",8953972_3,-1,1,1,23559,1
23560,subarachnoid hemorrhage,7,9,45,68,"Subsequently, acute cardiac arrest and fatal subarachnoid hemorrhage occurred.",8953972_3,-1,1,1,23560,1
23561,cardiac arrest,6,8,33,47,"Epinephrine has a proven role in cardiac arrest in prehospital care; however, use by paramedics in patients with suspected allergic reaction and severe hypertension should be viewed with caution.",8953972_4,-1,1,1,23561,1
23563,allergic reaction,21,23,123,140,"Epinephrine has a proven role in cardiac arrest in prehospital care; however, use by paramedics in patients with suspected allergic reaction and severe hypertension should be viewed with caution.",8953972_4,-1,1,1,23563,1
23613,mucositis,2,3,21,30,Thrombocytopenia and mucositis were the major toxicities.,8958188_6,-1,1,1,23613,1
23622,cocaine-related,5,6,23,38,"From a registry of all cocaine-related deaths in Dade County, Florida, from 1969-1990, 58 EDDs were compared with 125 victims of accidental cocaine overdose without excited delirium.",8988571_2,-1,1,1,23622,1
23634,sudden death,37,39,250,262,"The epidemiologic findings are most consistent with the hypothesis that chronic cocaine use disrupts dopaminergic function and, when coupled with recent cocaine use, may precipitate agitation, delirium, aberrant thermoregulation, rhabdomyolysis, and sudden death.",8988571_6,-1,1,1,23634,1
23636,sensorineural hearing loss,3,6,16,42,Risk factors of sensorineural hearing loss in preterm infants.,8996652_0,-1,1,1,23636,1
23639,sensorineural hearing loss,28,31,145,171,"Among 547 preterm infants of < or = 34 weeks gestation born between 1987 and 1991, 8 children (1.46%) developed severe progressive and bilateral sensorineural hearing loss.",8996652_1,-1,1,1,23639,1
23641,hearing loss,6,8,39,51,Perinatal risk factors of infants with hearing loss were compared with those of two control groups matched for gestation and birth weight and for perinatal complications.,8996652_2,-1,1,1,23641,1
23645,hearing loss,6,8,48,60,Our observations demonstrated an association of hearing loss with a higher incidence of perinatal complications.,8996652_3,-1,1,1,23645,1
23647,Ototoxicity,0,1,0,11,"Ototoxicity appeared closely related to a prolonged administration and higher total dose of ototoxic drugs, particularly aminoglycosides and furosemide.",8996652_4,-1,1,1,23647,1
23653,hearing loss,17,19,120,132,"Finally, we strongly recommend to prospectively and regularly perform audiologic assessment in sick preterm children as hearing loss is of delayed onset and in most cases bilateral and severe.",8996652_5,-1,1,1,23653,1
23663,movement disorders,14,16,80,98,Pemoline has not been commonly associated in the literature as a cause of acute movement disorders.,9022662_2,-1,1,1,23663,1
23675,movement disorders,7,9,38,56,The children gave no history of prior movement disorders and there was no family history of movement disorders.,9022662_8,-1,1,1,23675,1
23677,movement disorders,16,18,92,110,The children gave no history of prior movement disorders and there was no family history of movement disorders.,9022662_8,-1,1,1,23677,1
23683,movement disorder,4,6,32,49,CONCLUSION: Pemoline associated movement disorder has been rarely reported in the acute toxicology literature.,9022662_12,-1,1,1,23683,1
23693,generalized seizure,14,16,89,108,"After the ingestion of 26 venlafaxine 50-mg tablets, the patient experienced a witnessed generalized seizure.",9034419_3,-1,1,1,23693,1
23697,generalized seizure,19,21,105,124,"DISCUSSION: To our knowledge, this is the first reported case of venlafaxine overdose that resulted in a generalized seizure.",9034419_5,-1,1,1,23697,1
23702,generalized seizure,14,16,85,104,CONCLUSIONS: The venlafaxine overdose in our patient resulted in a single episode of generalized seizure but elicited no further sequelae.,9034419_7,-1,1,1,23702,1
23706,optic nerve,15,17,112,123,Effect of myopic excimer laser photorefractive keratectomy on the electrophysiologic function of the retina and optic nerve.,9041081_0,-1,1,1,23706,1
23710,optic nerve,19,21,115,126,PURPOSE: To assess by electrophysiologic testing the effect of photorefractive keratectomy (PRK) on the retina and optic nerve.,9041081_1,-1,1,1,23710,1
23732,bacterial infections,15,17,98,118,Defects in superoxide and hydrogen peroxide production may be implicated in the high incidence of bacterial infections in patients with acute liver failure (ALF).,9061311_1,-1,1,1,23732,1
23792,cell death,19,21,112,122,These data suggest that CS intervenes in a critical cellular event that is an important common pathway to toxic cell death.,9067481_6,-1,1,1,23792,1
23806,group B,29,31,144,151,"The patients were randomly allocated to one of three groups; those in group A (n = 10) were subjected to controlled hypotension alone, those in group B (n = 10) to haemodilution alone and those in group C (n = 10) to both controlled hypotension and haemodilution.",9088814_2,-1,1,1,23806,1
23808,group C,42,44,197,204,"The patients were randomly allocated to one of three groups; those in group A (n = 10) were subjected to controlled hypotension alone, those in group B (n = 10) to haemodilution alone and those in group C (n = 10) to both controlled hypotension and haemodilution.",9088814_2,-1,1,1,23808,1
23830,group C,19,21,109,116,"AKBR and biological hepatic function tests showed no change throughout the time course in groups A and B. In group C, AKBR showed a significant decrease at 120 min (-40%) and at 180 min (-49%) after the start of hypotension and at 60 min (-32%) after recovery of normotension, and SGOT, SGPT, LDH and total bilirubin showed significant increases after operation.",9088814_6,-1,1,1,23830,1
23891,ventricular septal rupture,4,7,28,54,Two cases of postinfarction ventricular septal rupture in patients on long-term steroid therapy are presented and the favourable outcome in both cases described.,9105126_1,-1,1,1,23891,1
23893,septal rupture,9,11,77,91,A possible association between steroid therapy and subsequent postinfarction septal rupture is discussed.,9105126_2,-1,1,1,23893,1
23897,status epilepticus,11,13,94,112,Neuroactive steroids protect against pilocarpine- and kainic acid-induced limbic seizures and status epilepticus in mice.,9121607_0,-1,1,1,23897,1
23912,motor seizures,28,30,190,204,"Steroids with the 3-hydroxy group in the alpha-position and 5-H in the alpha- or beta-configurations were highly effective in protecting against pilocarpine (416 mg/kg, s.c.)-induced limbic motor seizures and status epilepticus (ED50 values, 7.0-18.7 mg/kg, i.p.).",9121607_2,-1,1,1,23912,1
23913,status epilepticus,31,33,209,227,"Steroids with the 3-hydroxy group in the alpha-position and 5-H in the alpha- or beta-configurations were highly effective in protecting against pilocarpine (416 mg/kg, s.c.)-induced limbic motor seizures and status epilepticus (ED50 values, 7.0-18.7 mg/kg, i.p.).",9121607_2,-1,1,1,23913,1
23933,status epilepticus,27,29,156,174,"However, when a second dose of the steroid was administered 1 hr after the first dose, complete protection from the kainic acid-induced limbic seizures and status epilepticus was obtained.",9121607_6,-1,1,1,23933,1
23939,status epilepticus,17,19,131,149,"We conclude that neuroactive steroids are highly effective in protecting against pilocarpine- and kainic acid-induced seizures and status epilepticus in mice, and may be of utility in the treatment of some forms of status epilepticus in humans.",9121607_8,-1,1,1,23939,1
23940,status epilepticus,34,36,215,233,"We conclude that neuroactive steroids are highly effective in protecting against pilocarpine- and kainic acid-induced seizures and status epilepticus in mice, and may be of utility in the treatment of some forms of status epilepticus in humans.",9121607_8,-1,1,1,23940,1
23946,nephrotic syndrome,15,17,107,125,Plasma concentration and urine excretion of the renin-angiotensin system proteins are altered in rats with nephrotic syndrome (NS).,9154656_1,-1,1,1,23946,1
23951,extrahepatic,27,28,158,170,"In this work the messenger ribonucleic acid (mRNA) levels of angiotensinogen (Ao) were analyzed with the slot-blot hybridization technique in liver and other extrahepatic tissues: kidney, heart, brain, and adrenal gland from control, nephrotic, and pair-fed (PF) rats.",9154656_2,-1,1,1,23951,1
23952,adrenal gland,37,39,206,219,"In this work the messenger ribonucleic acid (mRNA) levels of angiotensinogen (Ao) were analyzed with the slot-blot hybridization technique in liver and other extrahepatic tissues: kidney, heart, brain, and adrenal gland from control, nephrotic, and pair-fed (PF) rats.",9154656_2,-1,1,1,23952,1
23953,nephrotic,42,43,234,243,"In this work the messenger ribonucleic acid (mRNA) levels of angiotensinogen (Ao) were analyzed with the slot-blot hybridization technique in liver and other extrahepatic tissues: kidney, heart, brain, and adrenal gland from control, nephrotic, and pair-fed (PF) rats.",9154656_2,-1,1,1,23953,1
23960,extrahepatic,13,14,61,73,"Furthermore, the Ao mRNA levels did not change in any of the extrahepatic tissues studied on day 6, nor did its hepatic levels at days 1, 3, 5, or 7 after PAN injection.",9154656_5,-1,1,1,23960,1
23962,extrahepatic,7,8,40,52,These data suggest that the hepatic and extrahepatic Ao mRNA levels are unaltered during the development of the acute NS induced by PAN.,9154656_6,-1,1,1,23962,1
23965,Neuroleptic malignant syndrome,0,3,0,30,Neuroleptic malignant syndrome with risperidone.,9165568_0,-1,1,1,23965,1
23967,Neuroleptic malignant syndrome,0,3,0,30,Neuroleptic malignant syndrome is thought to be a result of dopamine D2 receptor blockade in the striatum of the basal ganglia.,9165568_1,-1,1,1,23967,1
23969,basal ganglia,19,21,113,126,Neuroleptic malignant syndrome is thought to be a result of dopamine D2 receptor blockade in the striatum of the basal ganglia.,9165568_1,-1,1,1,23969,1
23976,neuroleptic malignant syndrome,14,17,84,114,"With this low frequency of extrapyramidal symptoms, it was thought the frequency of neuroleptic malignant syndrome might also be lowered.",9165568_4,-1,1,1,23976,1
23977,neuroleptic malignant syndrome,4,7,30,60,A 73-year-old woman developed neuroleptic malignant syndrome after monotherapy with risperidone.,9165568_5,-1,1,1,23977,1
23985,neuroleptic malignant syndrome,17,20,122,152,It appears that the protection from extrapyramidal side effects observed with risperidone does not ensure protection from neuroleptic malignant syndrome.,9165568_7,-1,1,1,23985,1
23986,side effects,4,6,19,31,The site of common side effects of sumatriptan.,9195768_0,-1,1,1,23986,1
23992,side effects,4,6,22,34,"In these individuals, side effects are most likely generated superficially in the skin.",9195768_4,-1,1,1,23992,1
23995,endophthalmitis,11,12,98,113,"BACKGROUND: Although intravitreal aminoglycosides have substantially improved visual prognosis in endophthalmitis, macular infarction may impair full visual recovery.",9199746_1,-1,1,1,23995,1
23999,endophthalmitis,20,21,149,164,METHODS: We present a case of presumed amikacin retinal toxicity following treatment with amikacin and vancomycin for alpha-haemolytic streptococcal endophthalmitis.,9199746_2,-1,1,1,23999,1
24000,Endophthalmitis,2,3,9,24,RESULTS: Endophthalmitis resolved with improvement in visual acuity to 6/24 at three months.,9199746_3,-1,1,1,24000,1
24003,macular,4,5,41,48,Fundus fluorescein angiography confirmed macular capillary closure and telangiectasis.,9199746_4,-1,1,1,24003,1
24004,telangiectasis,8,9,71,85,Fundus fluorescein angiography confirmed macular capillary closure and telangiectasis.,9199746_4,-1,1,1,24004,1
24012,akathisia,12,13,81,90,"It is known that beta-adrenoceptor antagonists are effective in the treatment of akathisia, one of the extrapyramidal side effects that occur during neuroleptic treatment.",9201797_1,-1,1,1,24012,1
24015,akathisia,20,21,161,170,"Neuroleptic-induced catalepsy, a model of neuroleptic-induced extrapyramidal side effects, was considered suitable as a model for predicting neuroleptic-induced akathisia in humans, although neuroleptic-induced catalepsy was not considered a specific test for neuroleptic-induced akathisia.",9201797_2,-1,1,1,24015,1
24016,akathisia,35,36,280,289,"Neuroleptic-induced catalepsy, a model of neuroleptic-induced extrapyramidal side effects, was considered suitable as a model for predicting neuroleptic-induced akathisia in humans, although neuroleptic-induced catalepsy was not considered a specific test for neuroleptic-induced akathisia.",9201797_2,-1,1,1,24016,1
24045,akathisia,24,25,185,194,These results strongly suggest that carteolol improves haloperidol-induced catalepsy via its beta-adrenoceptor antagonistic activity and is expected to be effective in the treatment of akathisia without attenuating neuroleptic-induced antipsychotic effects due to its postsynaptic dopamine receptor antagonistic activity.,9201797_10,-1,1,1,24045,1
24049,Granulosa cell tumor,0,3,0,20,Granulosa cell tumor of the ovary associated with antecedent tamoxifen use.,9205462_0,-1,1,1,24049,1
24053,breast carcinoma,15,17,108,124,CASE: A 52-year-old postmenopausal woman was treated with tamoxifen for stage II estrogen receptor-positive breast carcinoma.,9205462_3,-1,1,1,24053,1
24056,granulosa cell tumor,19,22,104,124,"After an additional 17 months of elevated serum transaminases, the patient was found to have a stage Ic granulosa cell tumor of the ovary.",9205462_5,-1,1,1,24056,1
24057,liver dysfunction,5,7,44,61,CONCLUSION: Patients with tamoxifen-induced liver dysfunction may be at increased risk for granulosa cell tumors because of alterations in tamoxifen metabolism.,9205462_6,-1,1,1,24057,1
24058,granulosa cell tumors,13,16,91,112,CONCLUSION: Patients with tamoxifen-induced liver dysfunction may be at increased risk for granulosa cell tumors because of alterations in tamoxifen metabolism.,9205462_6,-1,1,1,24058,1
24060,myelodysplasia,10,11,62,76,Lifetime treatment of mice with azidothymidine (AZT) produces myelodysplasia.,9209318_0,-1,1,1,24060,1
24062,long term,10,12,56,65,AZT has induced a macrocytic anemia in AIDS patients on long term AZT therapy.,9209318_1,-1,1,1,24062,1
24069,myelodysplastic syndrome,14,16,99,123,Histological examination on 9 of 10 mice with such thrombocytopenia showed changes compatible with myelodysplastic syndrome (MDS).,9209318_5,-1,1,1,24069,1
24071,myelodysplasia,6,7,37,51,"There were two cases of hypocellular myelodysplasia, two cases of hypersegmented myelodysplastic granulocytosis, two cases of hypercellular marrow with abnormal megakaryocytes with bizarre nuclei, one case of megakaryocytic myelosis associated with a hyperplastic marrow, dysmyelopoiesis and a hypocellular marrow and two cases of myelodysplasia with dyserythropoiesis, hemosiderosis and a hypocellular marrow.",9209318_7,-1,1,1,24071,1
24073,myelodysplastic,12,13,81,96,"There were two cases of hypocellular myelodysplasia, two cases of hypersegmented myelodysplastic granulocytosis, two cases of hypercellular marrow with abnormal megakaryocytes with bizarre nuclei, one case of megakaryocytic myelosis associated with a hyperplastic marrow, dysmyelopoiesis and a hypocellular marrow and two cases of myelodysplasia with dyserythropoiesis, hemosiderosis and a hypocellular marrow.",9209318_7,-1,1,1,24073,1
24081,myelodysplasia,47,48,331,345,"There were two cases of hypocellular myelodysplasia, two cases of hypersegmented myelodysplastic granulocytosis, two cases of hypercellular marrow with abnormal megakaryocytes with bizarre nuclei, one case of megakaryocytic myelosis associated with a hyperplastic marrow, dysmyelopoiesis and a hypocellular marrow and two cases of myelodysplasia with dyserythropoiesis, hemosiderosis and a hypocellular marrow.",9209318_7,-1,1,1,24081,1
24086,myelodysplastic syndrome,26,28,167,191,"Above mentioned AZT incorporation may have induced an ineffective hemopoiesis in the primitive hemopoietic progenitor cells, which is known to be seen commonly in the myelodysplastic syndrome.",9209318_8,-1,1,1,24086,1
24102,pituitary tumors,16,18,118,134,Over expression of vascular endothelial growth factor and its receptor during the development of estrogen-induced rat pituitary tumors may mediate estrogen-initiated tumor angiogenesis.,9214597_0,-1,1,1,24102,1
24144,nephrogenic diabetes insipidus,1,4,11,41,Persistent nephrogenic diabetes insipidus following lithium therapy.,9226773_0,-1,1,1,24144,1
24147,head injury,14,16,92,103,We report the case of a patient who developed severe hypernatraemic dehydration following a head injury.,9226773_1,-1,1,1,24147,1
24149,nephrogenic diabetes insipidus,10,13,67,97,"Ten years previously he had been diagnosed to have lithium-induced nephrogenic diabetes insipidus, and lithium therapy had been discontinued.",9226773_2,-1,1,1,24149,1
24152,nephrogenic diabetes insipidus,28,31,191,221,"He remained thirsty and polyuric despite cessation of lithium and investigations on admission showed him to have normal osmoregulated thirst and vasopressin secretion, with clear evidence of nephrogenic diabetes insipidus.",9226773_3,-1,1,1,24152,1
24153,nephrogenic diabetes insipidus,2,5,16,46,Lithium induced nephrogenic diabetes insipidus is considered to be reversible on cessation of therapy but polyuria persisted in this patient for ten years after lithium was stopped.,9226773_4,-1,1,1,24153,1
24155,nephrogenic diabetes insipidus,15,18,110,140,We discuss the possible renal mechanisms and the implications for management of patients with lithium-induced nephrogenic diabetes insipidus.,9226773_5,-1,1,1,24155,1
24177,Alzheimer's disease,14,17,76,95,The findings suggest that NIK-247 may be a useful drug for the treatment of Alzheimer's disease.,9228650_9,-1,1,1,24177,1
24178,cardiovascular disease,6,8,40,62,The role of nicotine in smoking-related cardiovascular disease.,9245658_0,-1,1,1,24178,1
24179,nervous system,4,6,35,49,Nicotine activates the sympathetic nervous system and in this way could contribute to cardiovascular disease.,9245658_1,-1,1,1,24179,1
24180,cardiovascular disease,13,15,86,108,Nicotine activates the sympathetic nervous system and in this way could contribute to cardiovascular disease.,9245658_1,-1,1,1,24180,1
24188,carbon monoxide,39,41,261,276,"Almost certainly, nicotine via its hemodynamic effects contributes to acute cardiovascular events, although current evidence suggests that the effects of nicotine are much less important than are the prothrombotic effects of cigarette smoking or the effects of carbon monoxide.",9245658_3,-1,1,1,24188,1
24200,idiopathic dilated cardiomyopathy,18,21,165,198,Iatrogenically induced intractable atrioventricular reentrant tachycardia after verapamil and catheter ablation in a patient with Wolff-Parkinson-White syndrome and idiopathic dilated cardiomyopathy.,9249847_0,-1,1,1,24200,1
24201,idiopathic dilated cardiomyopathy,7,10,35,68,"In a patient with WPW syndrome and idiopathic dilated cardiomyopathy, intractable atrioventricular reentrant tachycardia (AVRT) was iatrogenically induced.",9249847_1,-1,1,1,24201,1
24206,preexcitation,2,3,12,25,"QRS without preexcitation, caused by junctional escape beats after verapamil or unidirectional antegrade block of accessory pathway after catheter ablation, established frequent AVRT attack.",9249847_2,-1,1,1,24206,1
24207,junctional,6,7,37,47,"QRS without preexcitation, caused by junctional escape beats after verapamil or unidirectional antegrade block of accessory pathway after catheter ablation, established frequent AVRT attack.",9249847_2,-1,1,1,24207,1
24208,accessory pathway,16,18,114,131,"QRS without preexcitation, caused by junctional escape beats after verapamil or unidirectional antegrade block of accessory pathway after catheter ablation, established frequent AVRT attack.",9249847_2,-1,1,1,24208,1
24232,dyskinetic,24,25,225,235,"We therefore conducted the present acute dose-response study in four 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-exposed cynomolgus monkeys primed to exhibit levodopa-induced dyskinesias to evaluate the locomotor and dyskinetic effects on challenge with four doses (from 0.03 to 1.0 mg/kg) of A-86929 ([-]-[5aR,11bS]-4,5,5a,6,7,11b-hexahydro-2-propyl-3-thia-5-+ ++azacyclopent-1- ena[c]phenathrene-9-10-diol), a selective and full DA D1-like receptor agonist with an intermediate duration of action.",9270571_3,-1,1,1,24232,1
24242,MPTP-induced parkinsonism,9,11,66,91,"Acute administration of A-86929 was as efficacious in alleviating MPTP-induced parkinsonism as levodopa and LY-171555, but was less likely to reproduce the levodopa-induced dyskinesias in these animals than with either LY-171555 or subsequent challenge of levodopa.",9270571_5,-1,1,1,24242,1
24250,basal ganglia,28,30,171,184,Selective stimulation of the DA D1 receptor may provide better integration of neural inputs transmitted to the internal segment of the globus pallidus (referred to as the basal ganglia output) compared with levodopa and selective DA D2 receptor agonist.,9270571_6,-1,1,1,24250,1
24256,liver disease,2,4,12,25,Epidemic of liver disease caused by hydrochlorofluorocarbons used as ozone-sparing substitutes of chlorofluorocarbons.,9284778_0,-1,1,1,24256,1
24261,liver disease,5,7,31,44,"We investigated an epidemic of liver disease in nine industrial workers who had had repeated accidental exposure to a mixture of 1,1-dichloro-2,2,2-trifluoroethane (HCFC 123) and 1-chloro-1,2,2,2-tetrafluoroethane (HCFC 124).",9284778_3,-1,1,1,24261,1
24268,liver disease,13,15,65,78,We aimed to test whether HCFCs 123 and 124 can result in serious liver disease.,9284778_6,-1,1,1,24268,1
24279,centrilobular,26,27,172,185,FINDINGS: The liver biopsy sample showed hepatocellular necrosis which was prominent in perivenular zone three and extended focally from portal tracts to portal tracts and centrilobular areas (bridging necrosis).,9284778_9,-1,1,1,24279,1
24285,liver injury,16,18,93,105,INTERPRETATION: Repeated exposure of human beings to HCFCs 123 and 124 can result in serious liver injury in a large proportion of the exposed population.,9284778_12,-1,1,1,24285,1
24289,Bile duct,0,2,0,9,Bile duct hamartoma occurring in association with long-term treatment with danazol.,9293063_0,-1,1,1,24289,1
24291,bile duct,5,7,20,29,We report a case of bile duct hamartoma which developed in a patient who had been on long-term danazol treatment.,9293063_1,-1,1,1,24291,1
24301,temporal lobe epilepsy,7,10,60,82,Neuropeptide-Y immunoreactivity in the pilocarpine model of temporal lobe epilepsy.,9305828_0,-1,1,1,24301,1
24306,hippocampal,14,15,75,86,Neuropeptide-Y (NPY) is expressed by granule cells and mossy fibres of the hippocampal dentate gyrus during experimental temporal lobe epilepsy (TLE).,9305828_1,-1,1,1,24306,1
24308,temporal lobe epilepsy,19,22,121,143,Neuropeptide-Y (NPY) is expressed by granule cells and mossy fibres of the hippocampal dentate gyrus during experimental temporal lobe epilepsy (TLE).,9305828_1,-1,1,1,24308,1
24313,hippocampal,21,22,156,167,This expression may represent an endogenous damping mechanism since NPY has been shown to block seizure-like events following high-frequency stimulation in hippocampal slices.,9305828_2,-1,1,1,24313,1
24315,status epilepticus,15,17,80,98,The pilocarpine (PILO) model of epilepsy is characterized by an acute period of status epilepticus followed by spontaneous recurrent seizures and related brain damage.,9305828_3,-1,1,1,24315,1
24317,brain damage,24,26,154,166,The pilocarpine (PILO) model of epilepsy is characterized by an acute period of status epilepticus followed by spontaneous recurrent seizures and related brain damage.,9305828_3,-1,1,1,24317,1
24349,drug withdrawal,15,17,99,114,"METHODS: Forty patients with Parkinson's disease underwent serial, detailed assessments both after drug withdrawal (""off"" period) and while taking their optimal medical regimens (""on"" period).",9321531_2,-1,1,1,24349,1
24363,bradykinesia,13,14,96,108,"The improvements in dyskinesias and the total scores for off-period parkinsonism, contralateral bradykinesia, and rigidity were sustained in the 11 patients examined at two years.",9321531_5,-1,1,1,24363,1
24372,ventricular tachycardia,1,3,23,46,Clarithromycin-induced ventricular tachycardia.,9326871_0,-1,1,1,24372,1
24411,pituitary tumors,1,3,4,20,Two pituitary tumors were discovered after testosterone determination.,9334596_11,-1,1,1,24411,1
24416,vasculogenic,58,59,339,351,"Most of the other low testosterone levels seemed to result from nonorganic hypothalamic dysfunction because of normal serum luteinizing hormone and prolactin and to have only a small role in erectile dysfunction (definite improvement in only 16 of 44 [36%] after androgen therapy, normal morning or nocturnal erections in 30% and definite vasculogenic contributions in 42%).",9334596_12,-1,1,1,24416,1
24419,prolactinoma,2,3,7,19,Only 1 prolactinoma was discovered.,9334596_16,-1,1,1,24419,1
24420,prolactinomas,7,8,28,41,"in 1.86% of 1,821 patients, prolactinomas in 7, 0.38%).",9334596_18,-1,1,1,24420,1
24427,pituitary tumors,21,23,130,146,"However, cost-effective screening strategies recommended so far missed 40 to 50% of cases improved with endocrine therapy and the pituitary tumors.",9334596_23,-1,1,1,24427,1
24462,breast cancer,5,7,43,56,Treatment of previously treated metastatic breast cancer by mitoxantrone and 48-hour continuous infusion of high-dose 5-FU and leucovorin (MFL): low palliative benefit and high treatment-related toxicity.,9390208_0,-1,1,1,24462,1
24468,treatment-related,26,27,177,194,Treatment of previously treated metastatic breast cancer by mitoxantrone and 48-hour continuous infusion of high-dose 5-FU and leucovorin (MFL): low palliative benefit and high treatment-related toxicity.,9390208_0,-1,1,1,24468,1
24469,breast cancer,4,6,32,45,"For previously treated advanced breast cancer, there is no standard second-line therapy.",9390208_1,-1,1,1,24469,1
24477,breast cancer,15,17,107,120,"From October 1993 to November 1995, we treated 13 patients with previously chemotherapy-treated metastatic breast cancer by mitoxantrone, 12 mg/m2, on day 1 and continuous infusion of 5-FU, 3000 mg/m2, together with leucovorin, 300 mg/m2, for 48 h from day 1 to 2.",9390208_3,-1,1,1,24477,1
24495,treatment-related,14,15,68,85,Eight patients were dead in the last follow-up; two of them died of treatment-related toxicity.,9390208_16,-1,1,1,24495,1
24498,breast cancer,5,7,34,47,Administration of this regimen to breast cancer patients who have been treated by chemotherapy and those with impaired heart function requires careful attention.,9390208_18,-1,1,1,24498,1
24500,aplastic anemia,1,3,20,35,Ticlopidine-induced aplastic anemia: report of three Chinese patients and review of the literature.,9401499_0,-1,1,1,24500,1
24501,aplastic anemia,9,11,63,78,"In this study, three Chinese patients with ticlopidine-induced aplastic anemia were reported and another 13 patients in the English literature were reviewed.",9401499_1,-1,1,1,24501,1
24508,aplastic anemia,3,5,34,49,Treatment for ticlopidine-induced aplastic anemia with colony-stimulating factors seemed to have little effect.,9401499_7,-1,1,1,24508,1
24514,diabetes insipidus,16,18,119,137,Upregulation of the expression of vasopressin gene in the paraventricular and supraoptic nuclei of the lithium-induced diabetes insipidus rat.,9406968_0,-1,1,1,24514,1
24534,diabetes insipidus,36,38,220,238,These results suggest that dehydration and/or the activation of visceral afferent inputs may contribute to the elevation of plasma AVP and the upregulation of AVP gene expression in the PVN and the SON of the Li-induced diabetes insipidus rat.,9406968_6,-1,1,1,24534,1
24550,common bile duct,35,38,178,194,"RESULTS: Prostigmine-morphine provocation caused significant increases in the time to peak activity (Tmax) over the hepatic hilum (HH: 34.33 +/- 5.05 vs. 22.77 +/- 3.26) and the common bile duct (CBD: 60.44 +/- 5.99 vs. 40.0 +/- 2.88) and in the half-time of excretion (T1/2) over the liver parenchyma (LP: 120.04 +/- 16.01 vs. 27.37 +/- 2.19), HH (117.61 +/- 14.71 vs. 31.85 +/- 3.99) and CBD (158.11 +/- 9.18 vs. 40.1 +/- 6.24), indicating a complete spasm at the level of the sphincter of Oddi.",9431903_4,-1,1,1,24550,1
24661,rheumatoid arthritis,3,5,19,39,Four patients with rheumatoid arthritis developed heavy proteinuria after five to 12 months of treatment with D-penicillamine.,950631_1,-1,1,1,24661,1
24670,epithelial cell,12,14,88,103,"Electron microscopy, however, revealed subepithelial electron-dense deposits, fusion of epithelial cell foot processes, and evidence of mesangial cell hyperactivity.",950631_3,-1,1,1,24670,1
24675,membranous glomerulonephritis,8,10,44,73,"The findings were similar to those in early membranous glomerulonephritis, differences being observed however in the results of staining for the early-acting complement components C1q and C4.",950631_5,-1,1,1,24675,1
24679,cranial pain,1,3,13,25,Experimental cranial pain elicited by capsaicin: a PET study.,9514561_0,-1,1,1,24679,1
24681,brain stem,22,24,122,132,"Using a positron emission tomography (PET) study it was shown recently that in migraine without aura certain areas in the brain stem were activated during the headache state, but not in the headache free interval.",9514561_1,-1,1,1,24681,1
24682,brain stem,5,7,27,37,It was suggested that this brain stem activation is inherent to the migraine attack itself and represents the so called 'migraine generator'.,9514561_2,-1,1,1,24682,1
24686,trigeminal nerve,24,26,148,164,A small amount of capsaicin was administered subcutaneously in the right forehead to evoke a burning painful sensation in the first division of the trigeminal nerve.,9514561_4,-1,1,1,24686,1
24690,cingulate,19,20,103,112,"Increases of regional cerebral blood flow (rCBF) were found bilaterally in the insula, in the anterior cingulate cortex, the cavernous sinus and the cerebellum.",9514561_5,-1,1,1,24690,1
24691,cavernous sinus,23,25,125,140,"Increases of regional cerebral blood flow (rCBF) were found bilaterally in the insula, in the anterior cingulate cortex, the cavernous sinus and the cerebellum.",9514561_5,-1,1,1,24691,1
24693,brain stem,14,16,85,95,Using the same stereotactic space limits as in the above mentioned migraine study no brain stem activation was found in the acute pain state compared to the pain free state.,9514561_6,-1,1,1,24693,1
24696,cavernous sinus,9,11,48,63,"The increase of activation in the region of the cavernous sinus however, suggests that this structure is more likely to be involved in trigeminal transmitted pain as such, rather than in a specific type of headache as was suggested for cluster headache.",9514561_7,-1,1,1,24696,1
24698,cluster headache,42,44,236,252,"The increase of activation in the region of the cavernous sinus however, suggests that this structure is more likely to be involved in trigeminal transmitted pain as such, rather than in a specific type of headache as was suggested for cluster headache.",9514561_7,-1,1,1,24698,1
24700,hearing loss,7,9,46,58,The effect of different anaesthetic agents in hearing loss following spinal anaesthesia.,9522143_0,-1,1,1,24700,1
24702,hearing loss,3,5,13,25,The cause of hearing loss after spinal anaesthesia is unknown.,9522143_1,-1,1,1,24702,1
24706,hearing loss,9,11,43,55,The aim of this study was to describe this hearing loss and to investigate other factors influencing the degree of hearing loss.,9522143_3,-1,1,1,24706,1
24707,hearing loss,20,22,115,127,The aim of this study was to describe this hearing loss and to investigate other factors influencing the degree of hearing loss.,9522143_3,-1,1,1,24707,1
24711,hearing loss,8,10,54,66,Patients given prilocaine were more likely to develop hearing loss (10 out of 22) than those given bupivacaine (4 out of 22) (P < 0.05).,9522143_5,-1,1,1,24711,1
24713,hearing loss,2,4,12,24,The average hearing loss for speech frequencies was about 10 dB after prilocaine and 15 dB after bupivacaine.,9522143_6,-1,1,1,24713,1
24731,side effect,23,25,148,159,Prospective multicentre studies with a large population and a long follow-up should be performed in order to evaluate the incidence of this unusual side effect.,9522152_4,-1,1,1,24731,1
24737,neurologic symptoms,1,3,10,29,Transient neurologic symptoms after spinal anesthesia: a lower incidence with prilocaine and bupivacaine than with lidocaine.,9523805_0,-1,1,1,24737,1
24741,neurologic symptoms,7,9,52,71,BACKGROUND: Recent evidence suggests that transient neurologic symptoms (TNSs) frequently follow lidocaine spinal anesthesia but are infrequent with bupivacaine.,9523805_1,-1,1,1,24741,1
24801,motility disorders,19,21,112,130,"Cisapride, a cytochrome P450 3A4 (CYP3A4) substrate, is widely prescribed for the treatment of gastrointestinal motility disorders.",9545159_1,-1,1,1,24801,1
24805,sudden cardiac death,10,13,54,74,"Prolongation of QT interval, torsades de pointes, and sudden cardiac death have been reported after concomitant administration with erythromycin or azole antifungal agents, but not with other CYP3A4 inhibitors.",9545159_2,-1,1,1,24805,1
24832,supplementary motor,30,32,215,234,"The dyskinetic parkinsonian patients exhibited a pattern of response which was markedly different from those of the normal subjects and non-dyskinetic parkinsonian patients, with a significant overactivation in the supplementary motor area and the ipsi- and contralateral primary motor areas.",9549528_4,-1,1,1,24832,1
24835,hyperkinetic,9,10,57,69,"These results are compatible with the hypothesis that an hyperkinetic abnormal involuntary movement, like L-dopa-induced peak dose dyskinesia, is due to a disinhibition of the primary and associated motor cortex secondary to an excessive outflow of the pallidothalamocortical motor loop.",9549528_5,-1,1,1,24835,1
24836,involuntary movement,11,13,79,99,"These results are compatible with the hypothesis that an hyperkinetic abnormal involuntary movement, like L-dopa-induced peak dose dyskinesia, is due to a disinhibition of the primary and associated motor cortex secondary to an excessive outflow of the pallidothalamocortical motor loop.",9549528_5,-1,1,1,24836,1
24850,signs and symptoms,8,11,47,65,Clinical response was assessed on the basis of signs and symptoms and sinus radiograph or computed tomography results.,9564988_4,-1,1,1,24850,1
24856,Haemophilus influenzae,7,9,40,62,"RESULTS: The most common pathogens were Haemophilus influenzae, Streptococcus pneumoniae, Staphylococcus aureus, and Moraxella catarrhalis.",9564988_6,-1,1,1,24856,1
24857,Streptococcus pneumoniae,10,12,64,88,"RESULTS: The most common pathogens were Haemophilus influenzae, Streptococcus pneumoniae, Staphylococcus aureus, and Moraxella catarrhalis.",9564988_6,-1,1,1,24857,1
24858,Staphylococcus aureus,13,15,90,111,"RESULTS: The most common pathogens were Haemophilus influenzae, Streptococcus pneumoniae, Staphylococcus aureus, and Moraxella catarrhalis.",9564988_6,-1,1,1,24858,1
24859,Moraxella,17,18,117,126,"RESULTS: The most common pathogens were Haemophilus influenzae, Streptococcus pneumoniae, Staphylococcus aureus, and Moraxella catarrhalis.",9564988_6,-1,1,1,24859,1
24876,endometrial carcinoma,3,5,20,41,Iatrogenic risks of endometrial carcinoma after treatment for breast cancer in a large French case-control study.,9579567_0,-1,1,1,24876,1
24877,breast cancer,8,10,62,75,Iatrogenic risks of endometrial carcinoma after treatment for breast cancer in a large French case-control study.,9579567_0,-1,1,1,24877,1
24879,breast cancer,19,21,104,117,"F  d  ration Nationale des Centres de Lutte Contre le Cancer (FNCLCC).Since tamoxifen is widely used in breast cancer treatment and has been proposed for the prevention of breast cancer, its endometrial iatrogenic effects must be carefully examined.",9579567_1,-1,1,1,24879,1
24880,breast cancer,30,32,172,185,"F  d  ration Nationale des Centres de Lutte Contre le Cancer (FNCLCC).Since tamoxifen is widely used in breast cancer treatment and has been proposed for the prevention of breast cancer, its endometrial iatrogenic effects must be carefully examined.",9579567_1,-1,1,1,24880,1
24881,endometrial cancer,6,8,45,63,We have investigated the association between endometrial cancer and tamoxifen use or other treatments in women treated for breast cancer in a case-control study.,9579567_2,-1,1,1,24881,1
24882,breast cancer,18,20,123,136,We have investigated the association between endometrial cancer and tamoxifen use or other treatments in women treated for breast cancer in a case-control study.,9579567_2,-1,1,1,24882,1
24884,endometrial cancer,2,4,9,27,"Cases of endometrial cancer diagnosed after breast cancer (n = 135) and 467 controls matched for age, year of diagnosis of breast cancer and hospital and survival time with an intact uterus were included.",9579567_3,-1,1,1,24884,1
24885,breast cancer,6,8,44,57,"Cases of endometrial cancer diagnosed after breast cancer (n = 135) and 467 controls matched for age, year of diagnosis of breast cancer and hospital and survival time with an intact uterus were included.",9579567_3,-1,1,1,24885,1
24886,breast cancer,24,26,123,136,"Cases of endometrial cancer diagnosed after breast cancer (n = 135) and 467 controls matched for age, year of diagnosis of breast cancer and hospital and survival time with an intact uterus were included.",9579567_3,-1,1,1,24886,1
24889,endometrial cancer,11,13,72,90,"Women who had received tamoxifen were significantly more likely to have endometrial cancer diagnosed than those who had not (crude relative risk = 4.9, p = 0.0001).",9579567_4,-1,1,1,24889,1
24899,endometrial cancer,3,5,14,32,Women who had endometrial cancer and had received tamoxifen had more advanced disease and poorer prognosis than those with endometrial cancer who had not received this treatment.,9579567_8,-1,1,1,24899,1
24901,endometrial cancer,19,21,123,141,Women who had endometrial cancer and had received tamoxifen had more advanced disease and poorer prognosis than those with endometrial cancer who had not received this treatment.,9579567_8,-1,1,1,24901,1
24902,endometrial cancer,9,11,50,68,"Our results suggest a causal role of tamoxifen in endometrial cancer, particularly when used as currently proposed for breast cancer prevention.",9579567_9,-1,1,1,24902,1
24903,breast cancer,19,21,119,132,"Our results suggest a causal role of tamoxifen in endometrial cancer, particularly when used as currently proposed for breast cancer prevention.",9579567_9,-1,1,1,24903,1
24906,breast cancer,11,13,74,87,Pelvic radiotherapy may be an additional iatrogenic factor for women with breast cancer.,9579567_10,-1,1,1,24906,1
24907,Endometrial cancers,0,2,0,19,Endometrial cancers diagnosed in women treated with tamoxifen have poorer prognosis.,9579567_11,-1,1,1,24907,1
24909,breast cancer,5,7,32,45,Women who receive tamoxifen for breast cancer should be offered gynaecological surveillance during and after treatment.,9579567_12,-1,1,1,24909,1
24912,breast cancer,14,16,92,105,A long-term evaluation of the risk-benefit ratio of tamoxifen as a preventive treatment for breast cancer is clearly warranted.,9579567_13,-1,1,1,24912,1
24914,cardiac arrest,1,3,22,36,Suxamethonium-induced cardiac arrest and death following 5 days of immobilization.,9587734_0,-1,1,1,24914,1
24915,cardiac arrest,7,9,39,53,The present report describes a case of cardiac arrest and subsequent death as a result of hyperkalaemia following the use of suxamethonium in a 23-year-old Malawian woman.,9587734_1,-1,1,1,24915,1
24920,cardiac arrest,9,11,64,78,"Forty seconds after injection of suxamethonium, bradycardia and cardiac arrest occurred.",9587734_3,-1,1,1,24920,1
24921,L-1,11,12,59,62,The serum level of potassium was observed to be 8.4 mequiv L-1.,9587734_5,-1,1,1,24921,1
24932,autoimmune hemolytic anemia,3,6,17,44,"Acute hepatitis, autoimmune hemolytic anemia, and erythroblastocytopenia induced by ceftriaxone.",9625142_0,-1,1,1,24932,1
24936,autoimmune hemolytic anemia,31,34,208,235,"Although the transaminases gradually returned to baseline after withholding the beta lactam antibiotic, there was a gradual increase in serum bilirubin and a decrease in hemoglobin concentration caused by an autoimmune hemolytic anemia and erythroblastocytopenia.",9625142_2,-1,1,1,24936,1
24938,side effects,10,12,57,69,Despite the widespread use of these agents this triad of side effects has not previously been reported in connection with beta lactam antibiotics.,9625142_4,-1,1,1,24938,1
24943,muscle tone,20,22,129,140,Contribution of the glycine site of NMDA receptors in rostral and intermediate-caudal parts of the striatum to the regulation of muscle tone in rats.,9630698_0,-1,1,1,24943,1
24945,muscle tone,25,27,135,146,The aim of the present study was to assess the contribution of the glycine site of NMDA receptors in the striatum to the regulation of muscle tone.,9630698_1,-1,1,1,24945,1
24946,Muscle tone,0,2,0,11,"Muscle tone was examined using a combined mechanoand electromyographic method, which measured simultaneously the muscle resistance (MMG) of the rat's hind foot to passive extension and flexion in the ankle joint and the electromyographic activity (EMG) of the antagonistic muscles of that joint: gastrocnemius and tibialis anterior.",9630698_2,-1,1,1,24946,1
24955,Muscle rigidity,0,2,0,15,Muscle rigidity was induced by haloperidol (2.5 mg/kg i.p.).,9630698_3,-1,1,1,24955,1
24960,muscle rigidity,35,37,220,235,"5,7-dichlorokynurenic acid (5,7-DCKA), a selective glycine site antagonist, injected in doses of 2.5 and 4.5 microg/0.5 microl bilaterally, into the rostral region of the striatum, decreased both the haloperidol-induced muscle rigidity (MMG) and the enhanced electromyographic activity (EMG).",9630698_4,-1,1,1,24960,1
24966,muscle tone,28,30,178,189,"5,7-DCKA injected bilaterally in a dose of 4.5 microg/0.5 microl into the intermediate-caudal region of the striatum of rats not pretreated with haloperidol had no effect on the muscle tone.",9630698_5,-1,1,1,24966,1
24983,Neurotoxicity,0,1,0,13,"Neurotoxicity was assessed for behavioral (tail-flick test), neurophysiological (nerve conduction velocity in the tail nerve), morphological, morphometrical and analytical effects.",9636837_4,-1,1,1,24983,1
24990,neurotoxicity,7,8,64,77,RESULTS: CBDCA administration induced dose-dependent peripheral neurotoxicity.,9636837_5,-1,1,1,24990,1
25005,neurotoxicity,31,32,167,180,"CONCLUSIONS: CBDCA is neurotoxic in our model, and the type of pathological changes it induces are so closely similar to those caused by CDDP that it is probable that neurotoxicity is induced in the two drugs by the same mechanism.",9636837_9,-1,1,1,25005,1
25010,drug abuse,8,10,61,71,Eating disorders and the associated behavioural problems and drug abuse are uncommon in pregnancy.,9653867_1,-1,1,1,25010,1
25056,bowel syndrome,14,16,101,115,Effects of cisapride on symptoms and postcibal small-bowel motor function in patients with irritable bowel syndrome.,9669632_0,-1,1,1,25056,1
25057,bowel syndrome,3,5,22,36,BACKGROUND: Irritable bowel syndrome is a common cause of abdominal pain and discomfort and may be related to disordered gastrointestinal motility.,9669632_1,-1,1,1,25057,1
25058,abdominal pain,10,12,58,72,BACKGROUND: Irritable bowel syndrome is a common cause of abdominal pain and discomfort and may be related to disordered gastrointestinal motility.,9669632_1,-1,1,1,25058,1
25063,bowel syndrome,26,28,156,170,"Our aim was to assess the effects of long-term treatment with a prokinetic agent, cisapride, on postprandial jejunal motility and symptoms in the irritable bowel syndrome (IBS).",9669632_2,-1,1,1,25063,1
25068,jejunal,22,23,132,139,"METHODS: Thirty-eight patients with IBS (constipation-predominant, n = 17; diarrhoea-predominant, n = 21) underwent 24-h ambulatory jejunal manometry before and after 12 week's treatment [cisapride, 5 mg three times daily (n = 19) or placebo (n = 19)].",9669632_3,-1,1,1,25068,1
25115,jejunal,4,5,30,37,CONCLUSION: Cisapride affects jejunal contraction characteristics and some symptoms in IBS.,9669632_10,-1,1,1,25115,1
25117,breast cancer,2,4,14,27,Prevention of breast cancer with tamoxifen: preliminary findings from the Italian randomised trial among hysterectomised women.,9672273_0,-1,1,1,25117,1
25122,breast cancer,9,11,62,75,"BACKGROUND: Tamoxifen is a candidate chemopreventive agent in breast cancer, although the drug may be associated with the development of endometrial cancer.",9672273_2,-1,1,1,25122,1
25124,endometrial cancer,22,24,137,155,"BACKGROUND: Tamoxifen is a candidate chemopreventive agent in breast cancer, although the drug may be associated with the development of endometrial cancer.",9672273_2,-1,1,1,25124,1
25129,breast cancer,28,30,147,160,"METHODS: In October, 1992, we started a double-blind placebo-controlled, randomised trial of tamoxifen in women (mainly in Italy) who did not have breast cancer and who had had a hysterectomy.",9672273_4,-1,1,1,25129,1
25133,breast cancer,10,12,60,73,The primary endpoints are the occurrence of and deaths from breast cancer.,9672273_9,-1,1,1,25133,1
25136,breast cancer,3,5,12,25,41 cases of breast cancer occurred so far; there have been no deaths from breast cancer.,9672273_12,-1,1,1,25136,1
25137,breast cancer,15,17,74,87,41 cases of breast cancer occurred so far; there have been no deaths from breast cancer.,9672273_12,-1,1,1,25137,1
25140,breast cancer,7,9,50,63,"There is a statistically significant reduction of breast cancer among women receiving tamoxifen who also used hormone-replacement therapy during the trial: among 390 women on such therapy and allocated to placebo, we found eight cases of breast cancer compared with one case among 362 women allocated to tamoxifen.",9672273_14,-1,1,1,25140,1
25142,breast cancer,38,40,238,251,"There is a statistically significant reduction of breast cancer among women receiving tamoxifen who also used hormone-replacement therapy during the trial: among 390 women on such therapy and allocated to placebo, we found eight cases of breast cancer compared with one case among 362 women allocated to tamoxifen.",9672273_14,-1,1,1,25142,1
25148,breast cancer,19,21,115,128,"INTERPRETATION: Although this preliminary analysis has low power, in this cohort of women at low-to-normal risk of breast cancer, the postulated protective effects of tamoxifen are not yet apparent.",9672273_16,-1,1,1,25148,1
25151,breast cancer,5,7,26,39,There were no deaths from breast cancer recorded in women in the study.,9672273_18,-1,1,1,25151,1
25154,postoperative pain,9,11,77,95,Pethidine-associated seizure in a healthy adolescent receiving pethidine for postoperative pain control.,9672936_0,-1,1,1,25154,1
25157,PCA,15,16,113,116,A healthy 17-year-old male received standard intermittent doses of pethidine via a patient-controlled analgesia (PCA) pump for management of postoperative pain control.,9672936_1,-1,1,1,25157,1
25158,postoperative pain,21,23,141,159,A healthy 17-year-old male received standard intermittent doses of pethidine via a patient-controlled analgesia (PCA) pump for management of postoperative pain control.,9672936_1,-1,1,1,25158,1
25163,central nervous system,15,18,109,131,Both plasma pethidine and norpethidine were elevated in the range associated with clinical manifestations of central nervous system excitation.,9672936_3,-1,1,1,25163,1
25171,PCA,6,7,33,36,The routine use of pethidine via PCA even for a brief postoperative analgesia should be reconsidered.,9672936_6,-1,1,1,25171,1
25177,atrial fibrillation,8,10,46,65,"An increase in blood pressure, accompanied by atrial fibrillation, agitation, incomprehensible shouts and loss of consciousness, was observed in an elderly, ASA classification group II, cardiovascularly medicated male, 12 min after performance of axillary block with mepivacaine 850 mg containing adrenaline 0.225 mg, for correction of Dupuytren's contracture.",9698967_1,-1,1,1,25177,1
25183,Dupuytren's contracture,54,57,336,359,"An increase in blood pressure, accompanied by atrial fibrillation, agitation, incomprehensible shouts and loss of consciousness, was observed in an elderly, ASA classification group II, cardiovascularly medicated male, 12 min after performance of axillary block with mepivacaine 850 mg containing adrenaline 0.225 mg, for correction of Dupuytren's contracture.",9698967_1,-1,1,1,25183,1
25186,atrial fibrillation,12,14,83,102,The block was successful and surgery was conducted as scheduled despite persisting atrial fibrillation.,9698967_3,-1,1,1,25186,1
25193,bile duct,3,5,38,47,Drug-associated acute-onset vanishing bile duct and Stevens-Johnson syndromes in a child.,9721172_0,-1,1,1,25193,1
25194,Stevens-Johnson syndromes,6,8,52,77,Drug-associated acute-onset vanishing bile duct and Stevens-Johnson syndromes in a child.,9721172_0,-1,1,1,25194,1
25196,Stevens-Johnson syndrome,0,2,0,24,"Stevens-Johnson syndrome is a well-recognized immune complex-mediated hypersensitivity reaction that affects all age groups, is drug or infection induced, and has classic systemic, mucosal, and dermatologic manifestations.",9721172_3,-1,1,1,25196,1
25198,hypersensitivity reaction,7,9,70,95,"Stevens-Johnson syndrome is a well-recognized immune complex-mediated hypersensitivity reaction that affects all age groups, is drug or infection induced, and has classic systemic, mucosal, and dermatologic manifestations.",9721172_3,-1,1,1,25198,1
25203,Stevens-Johnson syndrome,18,20,119,143,"A previously healthy child who developed acute, severe, rapidly progressive vanishing bile duct syndrome shortly after Stevens-Johnson syndrome is described; this was temporally associated with ibuprofen use.",9721172_4,-1,1,1,25203,1
25209,drug-related,4,5,26,38,This case documents acute drug-related vanishing bile duct syndrome in the pediatric age group and suggests shared immune mechanisms in the pathogenesis of both Stevens-Johnson syndrome and vanishing bile duct syndrome.,9721172_6,-1,1,1,25209,1
25213,Stevens-Johnson syndrome,24,26,161,185,This case documents acute drug-related vanishing bile duct syndrome in the pediatric age group and suggests shared immune mechanisms in the pathogenesis of both Stevens-Johnson syndrome and vanishing bile duct syndrome.,9721172_6,-1,1,1,25213,1
25215,primary pulmonary hypertension,3,6,18,48,High incidence of primary pulmonary hypertension associated with appetite suppressants in Belgium.,9727773_0,-1,1,1,25215,1
25218,Primary pulmonary hypertension,0,3,0,30,"Primary pulmonary hypertension is a rare, progressive and incurable disease, which has been associated with the intake of appetite suppressant drugs.",9727773_1,-1,1,1,25218,1
25222,primary pulmonary hypertension,3,6,26,56,Thirty-five patients with primary pulmonary hypertension and 85 matched controls were recruited over 32 months (1992-1994) in Belgium.,9727773_3,-1,1,1,25222,1
25231,primary pulmonary hypertension,6,9,31,61,"In 8 patients the diagnosis of primary pulmonary hypertension was uncertain, 5 of them had taken appetite suppressants.",9727773_7,-1,1,1,25231,1
25238,primary pulmonary hypertension,16,19,106,136,A policy of unrestricted prescription of appetite suppressants may lead to a high incidence of associated primary pulmonary hypertension.,9727773_9,-1,1,1,25238,1
25243,absence seizures,8,10,61,77,Inappropriate use of carbamazepine and vigabatrin in typical absence seizures.,9746003_0,-1,1,1,25243,1
25246,absence seizures,7,9,60,76,Carbamazepine and vigabatrin are contraindicated in typical absence seizures.,9746003_1,-1,1,1,25246,1
25247,of children,4,6,28,39,"Of 18 consecutive referrals of children with resistant typical absences only, eight were erroneously treated with carbamazepine either as monotherapy or as an add-on.",9746003_2,-1,1,1,25247,1
25254,myoclonic jerks,15,17,103,118,"Frequency of absences increased in four children treated with carbamazepine and two of these developed myoclonic jerks, which resolved on withdrawal of carbamazepine.",9746003_4,-1,1,1,25254,1
25261,hyperkinesias,1,2,13,26,Choreatiform hyperkinesias are known to be occasional movement abnormalities during intoxications with cocaine but not opiates.,9754849_1,-1,1,1,25261,1
25273,side effects,43,45,297,309,Epileptogenic activity of folic acid after drug induces SLE (folic acid and epilepsy)OBJECTIVE: To study the effect of folic acid-containing multivitamin supplementation in epileptic women before and during pregnancy in order to determine the rate of structural birth defects and epilepsy-related side effects.,9758264_0,-1,1,1,25273,1
25279,side effects,20,22,148,160,"RESULTS: Of 60 epileptic women with periconceptional folic acid (0.8 mg)-containing multivitamin supplementation, no one developed epilepsy-related side effects during the periconception period.",9758264_2,-1,1,1,25279,1
25286,status epilepticus,2,4,14,32,She developed status epilepticus and later symptoms of systemic lupus erythematodes.,9758264_6,-1,1,1,25286,1
25290,autoimmune disease,7,9,46,64,"CONCLUSIONS: The epileptic pregnant patient's autoimmune disease (probably drug-induced lupus) could damage the blood-brain barrier, therefore the therapeutic dose (> or =1 mg) of folic acid triggered a cluster of seizures.",9758264_8,-1,1,1,25290,1
25291,drug-induced,11,12,75,87,"CONCLUSIONS: The epileptic pregnant patient's autoimmune disease (probably drug-induced lupus) could damage the blood-brain barrier, therefore the therapeutic dose (> or =1 mg) of folic acid triggered a cluster of seizures.",9758264_8,-1,1,1,25291,1
25298,autoimmune disease,21,23,97,115,"Physiological dose (<1 mg) of folic acid both in healthy and 60 epileptic women, all without any autoimmune disease, did not increase the risk for epileptic seizures.",9758264_9,-1,1,1,25298,1
25299,epileptic seizures,30,32,147,165,"Physiological dose (<1 mg) of folic acid both in healthy and 60 epileptic women, all without any autoimmune disease, did not increase the risk for epileptic seizures.",9758264_9,-1,1,1,25299,1
25309,side effect,1,3,4,15,The side effect profiles of the atypical antipsychotics are more advantageous than those of the conventional neuroleptics.,9766615_4,-1,1,1,25309,1
25312,central nervous system,6,9,49,71,"Conventional agents are associated with unwanted central nervous system effects, including extrapyramidal symptoms (EPS), tardive dyskinesia, sedation, and possible impairment of some cognitive measures, as well as cardiac effects, orthostatic hypotension, hepatic changes, anticholinergic side effects, sexual dysfunction, and weight gain.",9766615_5,-1,1,1,25312,1
25321,weight gain,51,53,328,339,"Conventional agents are associated with unwanted central nervous system effects, including extrapyramidal symptoms (EPS), tardive dyskinesia, sedation, and possible impairment of some cognitive measures, as well as cardiac effects, orthostatic hypotension, hepatic changes, anticholinergic side effects, sexual dysfunction, and weight gain.",9766615_5,-1,1,1,25321,1
25325,weight gain,26,28,154,165,"The newer atypical agents have a lower risk of EPS, but are associated in varying degrees with sedation, cardiovascular effects, anticholinergic effects, weight gain, sexual dysfunction, hepatic effects, lowered seizure threshold (primarily clozapine), and agranulocytosis (clozapine only).",9766615_6,-1,1,1,25325,1
25330,side effects,21,23,143,155,"Since the incidence and severity of specific adverse effects differ among the various atypicals, the clinician should carefully consider which side effects are most likely to lead to the individual's dissatisfaction and noncompliance before choosing an antipsychotic for a particular patient.",9766615_7,-1,1,1,25330,1
25332,ischemic stroke,10,12,68,83,The association of cocaine and amphetamine use with hemorrhagic and ischemic stroke is based almost solely on data from case series.,9799166_1,-1,1,1,25332,1
25356,Alzheimer's disease,14,17,112,131,"A randomized, placebo-controlled dose-comparison trial of haloperidol for psychosis and disruptive behaviors in Alzheimer's disease.",9812111_0,-1,1,1,25356,1
25357,side effects,13,15,66,78,OBJECTIVE: The goal of this study was to compare the efficacy and side effects of two doses of haloperidol and placebo in the treatment of psychosis and disruptive behaviors in patients with Alzheimer's disease.,9812111_1,-1,1,1,25357,1
25359,Alzheimer's disease,33,36,191,210,OBJECTIVE: The goal of this study was to compare the efficacy and side effects of two doses of haloperidol and placebo in the treatment of psychosis and disruptive behaviors in patients with Alzheimer's disease.,9812111_1,-1,1,1,25359,1
25367,Alzheimer's disease,45,48,213,232,"METHOD: In a 6-week random-assignment, double-blind, placebo-controlled trial (phase A), haloperidol, 2-3 mg/day (standard dose), and haloperidol, 0.50-0.75 mg/day (low dose), were compared in 71 outpatients with Alzheimer's disease.",9812111_2,-1,1,1,25367,1
25377,psychomotor agitation,35,37,221,242,"RESULTS: For the 60 patients who completed phase A, standard-dose haloperidol was efficacious and superior to both low-dose haloperidol and placebo for scores on the Brief Psychiatric Rating Scale psychosis factor and on psychomotor agitation.",9812111_4,-1,1,1,25377,1
25387,side effects,13,15,79,91,Low-dose haloperidol did not differ from placebo on any measure of efficacy or side effects.,9812111_7,-1,1,1,25387,1
25394,Alzheimer's disease,15,18,101,120,The narrow therapeutic window observed with haloperidol may also apply to other neuroleptics used in Alzheimer's disease patients with psychosis and disruptive behaviors.,9812111_10,-1,1,1,25394,1
25396,Acute renal failure,0,3,0,19,Acute renal failure subsequent to the administration of rifampicin.,982002_0,-1,1,1,25396,1
25400,acute renal failure,16,19,72,91,A clinical presentation is made of a 2-3 year follow-up of six cases of acute renal failure that have been reported earlier.,982002_2,-1,1,1,25400,1
25503,arteriolopathy,15,16,91,105,"Chronic FK506 nephropathy consisted of rough and foamy tubular vacuolization (5 biopsies), arteriolopathy (angiodegeneration of the arteriolar wall; 20 biopsies), focal segmental glomerulosclerosis (4 biopsies) and the striped form of interstitial fibrosis (11 biopsies).",9855119_6,-1,1,1,25503,1
25506,focal segmental glomerulosclerosis,27,30,163,197,"Chronic FK506 nephropathy consisted of rough and foamy tubular vacuolization (5 biopsies), arteriolopathy (angiodegeneration of the arteriolar wall; 20 biopsies), focal segmental glomerulosclerosis (4 biopsies) and the striped form of interstitial fibrosis (11 biopsies).",9855119_6,-1,1,1,25506,1
25515,arteriolopathy,12,13,90,104,"CONCLUSIONS: This study demonstrates that chronic FK506 nephropathy consists primarily of arteriolopathy manifesting as insudative hyalinosis of the arteriolar wall, and suggests that mild-type chronic FK506 nephropathy is a condition which may lead to deterioration of renal allograft function.",9855119_8,-1,1,1,25515,1
25516,hyalinosis,16,17,131,141,"CONCLUSIONS: This study demonstrates that chronic FK506 nephropathy consists primarily of arteriolopathy manifesting as insudative hyalinosis of the arteriolar wall, and suggests that mild-type chronic FK506 nephropathy is a condition which may lead to deterioration of renal allograft function.",9855119_8,-1,1,1,25516,1
25523,intrahepatic,12,13,87,99,Different lobular distributions of altered hepatocyte tight junctions in rat models of intrahepatic and extrahepatic cholestasis.,9862868_0,-1,1,1,25523,1
25524,extrahepatic,14,15,104,116,Different lobular distributions of altered hepatocyte tight junctions in rat models of intrahepatic and extrahepatic cholestasis.,9862868_0,-1,1,1,25524,1
25540,intrahepatic,5,6,22,34,We used rat models of intrahepatic cholestasis by ethinyl estradiol (EE) treatment and extrahepatic cholestasis by bile duct ligation (BDL) to precisely determine the site of TJ damage.,9862868_5,-1,1,1,25540,1
25542,extrahepatic,15,16,87,99,We used rat models of intrahepatic cholestasis by ethinyl estradiol (EE) treatment and extrahepatic cholestasis by bile duct ligation (BDL) to precisely determine the site of TJ damage.,9862868_5,-1,1,1,25542,1
25543,bile duct,18,20,115,124,We used rat models of intrahepatic cholestasis by ethinyl estradiol (EE) treatment and extrahepatic cholestasis by bile duct ligation (BDL) to precisely determine the site of TJ damage.,9862868_5,-1,1,1,25543,1
25601,bicuspid aortic valve,3,6,17,38,One had baseline bicuspid aortic valve and mild aortic regurgitation that progressed to moderate regurgitation.,9867728_9,-1,1,1,25601,1
25650,body weight,14,16,66,77,"RESULTS: The two groups were comparable with respect to sex, age, body weight and renal function.",9875685_6,-1,1,1,25650,1
25687,ambiguus,11,12,70,78,"Such interference could be exerted centrally, possibly at the nucleus ambiguus, or peripherally at the sinus node.",9915601_6,-1,1,1,25687,1
25688,sinus node,17,19,103,113,"Such interference could be exerted centrally, possibly at the nucleus ambiguus, or peripherally at the sinus node.",9915601_6,-1,1,1,25688,1
16,Nx,8,9,48,50,"METHODS: Sixty dogs were either nephrectomized (Nx, N = 38) or sham-operated (Sham, N = 22).",10027919_4,-1,-1,2,16,-1
19,Nx,12,13,73,75,"Fourteen weeks after the start of phosphate supplementation, half of the Nx and Sham dogs received doses of OCT (three times per week); the other half were given vehicle for 60 weeks.",10027919_6,-1,-1,2,19,-1
23,crossover period,37,39,204,220,"Biochemical and hormonal indices of calcium and bone metabolism were measured throughout the study, and bone biopsies were done at baseline, 60 weeks after OCT or vehicle treatment, and at the end of the crossover period.",10027919_8,-1,-1,2,23,-1
24,Nx,3,4,12,14,"RESULTS: In Nx dogs, OCT significantly decreased serum PTH levels soon after the induction of renal insufficiency.",10027919_9,-1,-1,2,24,-1
30,Nx,20,21,112,114,"Serum PTH levels rose thereafter, but the rise was less pronounced compared with baseline than the rise seen in Nx control.",10027919_11,-1,-1,2,30,-1
34,Nx,1,2,3,5,"In Nx dogs, OCT reversed abnormal bone formation, such as woven osteoid and fibrosis, but did not significantly alter the level of bone turnover.",10027919_14,-1,-1,2,34,-1
40,Nx,22,23,108,110,"In addition, OCT improved mineralization lag time, (that is, the rate at which osteoid mineralizes) in both Nx and Sham dogs.",10027919_15,-1,-1,2,40,-1
50,electrocardiographic (ECG,23,26,163,188,"We report a case of hypotension, bradycardia, and asystole after intravenous administration of high-dose methylprednisolone in a 73-year-old patient who underwent electrocardiographic (ECG) monitoring throughout the episode.",10074612_1,-1,-1,2,50,-1
67,risk factors,8,10,61,73,"Rapid infusion and underlying cardiac disease were important risk factors in the case reported here, and the authors discount ventricular arrhythmia as the main mechanism.",10074612_8,-1,-1,2,67,-1
77,activation tasks,4,6,27,43,"These results suggest that activation tasks such as ""speaking aloud"" could be used for objective assessment of dyskinesia severity.",10091616_3,-1,-1,2,77,-1
80,longitudinal study,9,11,66,84,Selegiline-induced postural hypotension in Parkinson's disease: a longitudinal study on the effects of drug withdrawal.,10091617_0,-1,-1,2,80,-1
81,effects of,13,15,92,102,Selegiline-induced postural hypotension in Parkinson's disease: a longitudinal study on the effects of drug withdrawal.,10091617_0,-1,-1,2,81,-1
88,associated with,11,13,63,78,"Recently, we found that therapy with selegiline and L-dopa was associated with selective systolic orthostatic hypotension which was abolished by withdrawal of selegiline.",10091617_2,-1,-1,2,88,-1
94,consequences of,26,28,149,164,The aims of this study were to confirm our previous findings in a separate cohort of patients and to determine the time course of the cardiovascular consequences of stopping selegiline in the expectation that this might shed light on the mechanisms by which the drug causes orthostatic hypotension.,10091617_4,-1,-1,2,94,-1
109,consistent with,12,14,97,112,Stopping selegiline also significantly reduced the supine systolic and diastolic blood pressures consistent with a previously undescribed supine pressor action.,10091617_9,-1,-1,2,109,-1
112,associated with,15,17,99,114,CONCLUSION: This study confirms our previous finding that selegiline in combination with L-dopa is associated with selective orthostatic hypotension.,10091617_10,-1,-1,2,112,-1
124,associated with,9,11,77,92,A high percentage of kanamycin-colistin and povidone-iodine irrigations were associated with erosive cystitis and suggested a possible complication with human usage.,1009330_3,-1,-1,2,124,-1
140,in vitro,34,36,204,212,"The present study was undertaken to investigate the effects of TET and FAN on the experimental thrombosis induced by collagen plus epinephrine (EP) in mice, and platelet aggregation and blood coagulation in vitro.",10193204_2,-1,-1,2,140,-1
141,in vivo study,2,5,7,20,"In the in vivo study, the administration (50 mg/kg, i.p.) of TET and FAN in mice showed the inhibition of thrombosis by 55% and 35%, respectively, while acetylsalicylic acid (ASA, 50 mg/kg, i.p.), a positive control, showed only 30% inhibition.",10193204_3,-1,-1,2,141,-1
146,dependently,21,22,120,131,"In the vitro human platelet aggregations induced by the agonists used in tests, TET and FAN showed the inhibitions dose dependently.",10193204_4,-1,-1,2,146,-1
151,human-citrated plasma,36,38,194,215,"In addition, neither TET nor FAN showed any anticoagulation activities in the measurement of the activated partial thromboplastin time (APTT), prothrombin time (PT) and thrombin time (TT) using human-citrated plasma.",10193204_5,-1,-1,2,151,-1
156,tubular damage?BACKGROUND,6,8,51,76,"Urine N-acetyl-beta-D-glucosaminidase--a marker of tubular damage?BACKGROUND: Although an indicator of renal tubular dysfunction, an increased urinary N-acetyl-beta-D-glucosaminidase (NAG) activity might reflect increased lysosomal activity in renal tubular cells.",10193809_0,-1,-1,2,156,-1
164,urine samples,15,17,96,109,"Total protein, albumin, NAG activity and protein electrophoretic pattern were assessed in daily urine samples for 33 days.",10193809_2,-1,-1,2,164,-1
166,urine volume,5,7,35,47,"RESULTS: Following intravenous PAN urine volume and urine NAG activity increased significantly by day two, but returned to normal by day four. After day four all treated animals exhibited a marked rise in urine albumin, total protein excretion and NAG activity.",10193809_4,-1,-1,2,166,-1
167,urine albumin,36,38,205,218,"RESULTS: Following intravenous PAN urine volume and urine NAG activity increased significantly by day two, but returned to normal by day four. After day four all treated animals exhibited a marked rise in urine albumin, total protein excretion and NAG activity.",10193809_4,-1,-1,2,167,-1
168,molecular weight,9,11,65,81,Electrophoresis showed a generalised increase in middle and high molecular weight urine proteins from day four onwards.,10193809_5,-1,-1,2,168,-1
171,isoenzyme pattern,9,11,44,61,Peak urine NAG activity and a change in NAG isoenzyme pattern coincided with both the peak proteinuria and the reduction in intracellular protein and NAG droplets (day six onwards).,10193809_7,-1,-1,2,171,-1
172,peak proteinuria,15,17,86,102,Peak urine NAG activity and a change in NAG isoenzyme pattern coincided with both the peak proteinuria and the reduction in intracellular protein and NAG droplets (day six onwards).,10193809_7,-1,-1,2,172,-1
173,animal model,3,5,18,30,"CONCLUSIONS: This animal model demonstrates that an increase in lysosomal turnover and hence urine NAG activity, occurs when increased protein is presented to the tubular cells.",10193809_8,-1,-1,2,173,-1
180,1997.Six,29,30,179,187,Cauda equina syndrome after spinal anaesthesia with hyperbaric 5% lignocaine: a review of six cases of cauda equina syndrome reported to the Swedish Pharmaceutical Insurance 1993-1997.Six cases of cauda equina syndrome with varying severity were reported to the Swedish Pharmaceutical Insurance during the period 1993-1997.,10225068_0,-1,-1,2,180,-1
203,lesional lymphocytes,21,23,149,169,Systemic toxicity following administration of sirolimus (formerly rapamycin) for psoriasis: association of capillary leak syndrome with apoptosis of lesional lymphocytes.,10328196_0,-1,-1,2,203,-1
207,T-cell,14,15,94,100,BACKGROUND: Sirolimus (formerly rapamycin) is an immunosuppressive agent that interferes with T-cell activation.,10328196_1,0,1,2,207,-1
210,peripheral blood cells,20,23,145,167,After 2 individuals with psoriasis developed a capillary leak syndrome following treatment with oral sirolimus lesional skin cells and activated peripheral blood cells were analyzed for induction of apoptosis.,10328196_2,-1,-1,2,210,-1
216,peripheral blood T cells,1,5,10,34,"Activated peripheral blood T cells from patients with psoriasis tended to exhibit greater spontaneous or dexamethasone-induced apoptosis than did normal T cells, particularly in the presence of sirolimus.",10328196_4,-1,-1,2,216,-1
217,T cells,20,22,153,160,"Activated peripheral blood T cells from patients with psoriasis tended to exhibit greater spontaneous or dexamethasone-induced apoptosis than did normal T cells, particularly in the presence of sirolimus.",10328196_4,-1,-1,2,217,-1
223,lesional leukocytes,10,12,62,81,"These symptoms may be the result of drug-induced apoptosis of lesional leukocytes, especially activated T lymphocytes, and possibly release of inflammatory mediators.",10328196_6,-1,-1,2,223,-1
224,T lymphocytes,15,17,104,117,"These symptoms may be the result of drug-induced apoptosis of lesional leukocytes, especially activated T lymphocytes, and possibly release of inflammatory mediators.",10328196_6,-1,-1,2,224,-1
227,systemic therapies,11,13,79,97,"Because patients with severe psoriasis may develop capillary leak from various systemic therapies, clinical monitoring is advisable for patients with inflammatory diseases who are treated with immune modulators.",10328196_7,-1,-1,2,227,-1
230,treated with,25,27,180,192,"Because patients with severe psoriasis may develop capillary leak from various systemic therapies, clinical monitoring is advisable for patients with inflammatory diseases who are treated with immune modulators.",10328196_7,-1,-1,2,230,-1
236,lithium therapy,9,11,53,68,"These were evaluated with respect to the duration of lithium therapy, age, sex, and family history (whether or not the patient had a first-degree relative with thyroid disease).",10354657_2,-1,-1,2,236,-1
239,Prospective study,2,4,8,25,DESIGN: Prospective study.,10354657_3,-1,-1,2,239,-1
243,lithium maintenance therapy,18,21,93,120,PATIENTS: One hundred and one patients (28 men and 73 women) with bipolar disorder receiving lithium maintenance therapy ranging from 1 year's to 32 years' duration.,10354657_5,-1,-1,2,243,-1
244,control group,1,3,4,17,The control group consisted of 82 patients with no psychiatric or endocrinological diagnoses from the hospital's out-patient clinics.,10354657_6,-1,-1,2,244,-1
248,Laboratory analyses,3,5,18,37,"OUTCOME MEASURES: Laboratory analyses of calcium, magnesium and thyroid-stimulating hormone levels performed before beginning lithium therapy and at biannual follow-up.",10354657_7,-1,-1,2,248,-1
250,lithium therapy,16,18,126,141,"OUTCOME MEASURES: Laboratory analyses of calcium, magnesium and thyroid-stimulating hormone levels performed before beginning lithium therapy and at biannual follow-up.",10354657_7,-1,-1,2,250,-1
255,lithium therapy,20,22,137,152,All patients having first-degree relatives affected by thyroid illness had accelerated onset of hypothyroidism (3.7 years after onset of lithium therapy) compared with patients without a family history (8.6 years after onset of lithium therapy).,10354657_9,-1,-1,2,255,-1
258,Magnesium levels,0,2,0,16,Magnesium levels in patients on lithium treatment were unchanged from baseline levels.,10354657_11,-1,-1,2,258,-1
262,associated with,11,13,75,90,"Thus, lithium treatment counteracted the decrease in plasma calcium levels associated with aging.",10354657_13,-1,-1,2,262,-1
264,risk factor,7,9,43,54,CONCLUSIONS: Familial thyroid illness is a risk factor for hypothyroidism and hypercalcemia during lithium therapy.,10354657_14,-1,-1,2,264,-1
267,prevalence rates,4,6,31,47,Cocaine-induced mood disorder: prevalence rates and psychiatric symptoms in an outpatient cocaine-dependent sample.,10365197_0,-1,-1,2,267,-1
271,DSM,13,14,84,87,This paper attempts to examine and compare prevalence rates and symptom patterns of DSM substance-induced and other mood disorders.,10365197_1,-1,-1,2,271,-1
276,CIMD,8,9,70,74,"243 cocaine-dependent outpatients with cocaine-induced mood disorder (CIMD), other mood disorders, or no mood disorder were compared on measures of psychiatric symptoms.",10365197_2,-1,-1,2,276,-1
284,CIMD,2,3,14,18,Patients with CIMD had symptom severity levels between those of patients with and without a mood disorder.,10365197_5,-1,-1,2,284,-1
287,DSM-IV,8,9,49,55,"These findings suggest some validity for the new DSM-IV diagnosis of CIMD, but also suggest that it requires further specification and replication.",10365197_6,-1,-1,2,287,-1
291,Inflammatory cells,0,2,0,18,Inflammatory cells are postulated to mediate some of the brain damage following ischemic stroke.,10406016_1,-1,-1,2,291,-1
295,associated with,3,5,28,43,Intracerebral hemorrhage is associated with more inflammation than ischemic stroke.,10406016_2,-1,-1,2,295,-1
302,treated with,2,4,10,22,Rats were treated with seven day intravenous infusion of fucoidan (30 micrograms h-1) or vehicle.,10406016_4,-1,-1,2,302,-1
304,in vivo,4,6,26,33,The hematoma was assessed in vivo by magnetic resonance imaging.,10406016_5,-1,-1,2,304,-1
305,magnetic resonance imaging,7,10,37,63,The hematoma was assessed in vivo by magnetic resonance imaging.,10406016_5,-1,-1,2,305,-1
309,Fucoidan-treated,0,1,0,16,"Fucoidan-treated rats exhibited evidence of impaired blood clotting and hemodilution, had larger hematomas, and tended to have less inflammation in the vicinity of the hematoma after three days.",10406016_7,-1,-1,2,309,-1
314,passive avoidance test,21,24,141,163,They showed significantly more rapid improvement of motor function in the first week following hemorrhage and better memory retention in the passive avoidance test.,10406016_8,-1,-1,2,314,-1
321,associated with,4,6,31,46,Severe immune hemolytic anemia associated with prophylactic use of cefotetan in obstetric and gynecologic procedures.,10411803_0,-1,-1,2,321,-1
327,associated with,10,12,84,99,"Second- and third-generation cephalosporins, especially cefotetan, are increasingly associated with severe, sometimes fatal immune hemolytic anemia.",10411803_1,-1,-1,2,327,-1
343,SAH,59,60,292,295,"Patients with aneurysmal subarachnoid hemorrhage (SAH) were randomized to receive either ketoprofen, 100 mg, three times a day (ketoprofen group, n = 9) or a weak NSAID, acetaminophen, 1 g, three times a day (acetaminophen group, n = 9) starting immediately after the diagnosis of aneurysmal SAH.",10414674_3,-1,-1,2,343,-1
344,Test blood samples,0,3,0,18,"Test blood samples were taken before treatment and surgery as well as on the first, third, and fifth postoperative mornings.",10414674_5,-1,-1,2,344,-1
355,platelet function,5,7,42,59,Ketoprofen but not acetaminophen impaired platelet function in patients with SAH.,10414674_11,-1,-1,2,355,-1
358,risk factor,16,18,93,104,"If ketoprofen is used before surgery on cerebral artery aneurysms, it may pose an additional risk factor for hemorrhage.",10414674_12,-1,-1,2,358,-1
362,recovery room,6,8,32,45,A case of recurarization in the recovery room is reported.,10457883_1,-1,-1,2,362,-1
364,intravenous line,5,7,34,50,Accumulation of atracurium in the intravenous line led to recurarization after flushing the line in the recovery room.,10457883_2,-1,-1,2,364,-1
374,ASA groups 3,13,16,88,100,The haemodynamic effects of propofol in combination with ephedrine in elderly patients (ASA groups 3 and 4).The marked vasodilator and negative inotropic effects of propofol are disadvantages in frail elderly patients.,10520387_0,-1,-1,2,374,-1
381,ASA,24,25,117,120,"The haemodynamic effects of adding 15, 20 or 25 mg of ephedrine to 200 mg of propofol were compared to control in 40 ASA 3/4 patients over 60 years presenting for genito-urinary surgery.",10520387_2,-1,-1,2,381,-1
386,associated with,4,6,28,43,"However, marked tachycardia associated with the use of ephedrine in combination with propofol occurred in the majority of patients, occasionally reaching high levels in individual patients.",10520387_4,-1,-1,2,386,-1
397,lead-treated group,8,10,53,71,"Male Sprague-Dawley rats were randomly assigned to a lead-treated group (given lead acetate, 100 ppm, in drinking water and regular rat chow), a group given lead and vitamin E-fortified chow, or a normal control group given either regular food and water or vitamin E-fortified food for 12 weeks.",10523326_3,-1,-1,2,397,-1
413,eNOS,30,31,173,177,"The lead-treated group exhibited a rise in blood pressure and plasma MDA concentration, a fall in urinary NOx excretion, and a paradoxical rise in vascular and renal tissue eNOS and iNOS expression.",10523326_5,-1,-1,2,413,-1
414,iNOS,32,33,182,186,"The lead-treated group exhibited a rise in blood pressure and plasma MDA concentration, a fall in urinary NOx excretion, and a paradoxical rise in vascular and renal tissue eNOS and iNOS expression.",10523326_5,-1,-1,2,414,-1
418,iNOS,28,29,189,193,"Vitamin E supplementation ameliorated hypertension, lowered plasma MDA concentration, and raised urinary NOx excretion while significantly lowering vascular, but not renal, tissue eNOS and iNOS expression.",10523326_6,-1,-1,2,418,-1
420,no effect,4,6,30,39,"Vitamin E supplementation had no effect on either blood pressure, plasma MDA, or NOS expression in the control group.",10523326_7,-1,-1,2,420,-1
422,MDA,12,13,73,76,"Vitamin E supplementation had no effect on either blood pressure, plasma MDA, or NOS expression in the control group.",10523326_7,-1,-1,2,422,-1
423,control group,19,21,103,116,"Vitamin E supplementation had no effect on either blood pressure, plasma MDA, or NOS expression in the control group.",10523326_7,-1,-1,2,423,-1
425,cell-free preparations,13,15,84,106,The study also revealed significant inhibition of NOS enzymatic activity by lead in cell-free preparations.,10523326_8,-1,-1,2,425,-1
427,associated with,9,11,59,74,"In conclusion, lead-induced hypertension in this model was associated with a compensatory upregulation of renal and vascular eNOS and iNOS expression.",10523326_9,-1,-1,2,427,-1
429,upregulation,13,14,90,102,"In conclusion, lead-induced hypertension in this model was associated with a compensatory upregulation of renal and vascular eNOS and iNOS expression.",10523326_9,-1,-1,2,429,-1
432,ROS-mediated,8,9,25,37,"This is, in part, due to ROS-mediated NO inactivation, lead-associated inhibition of NOS activity, and perhaps stimulatory actions of increased shear stress associated with hypertension.",10523326_10,-1,-1,2,432,-1
433,lead-associated inhibition,12,14,55,81,"This is, in part, due to ROS-mediated NO inactivation, lead-associated inhibition of NOS activity, and perhaps stimulatory actions of increased shear stress associated with hypertension.",10523326_10,-1,-1,2,433,-1
440,pain phase,10,12,59,69,"Migraine with aura and migraine without aura have the same pain phase, thus indicating that migraine with aura and migraine without aura share a common pathway of nociception.",10524660_1,-1,-1,2,440,-1
444,pain mechanisms,20,22,112,127,"In recent years, increasing evidence has suggested that the messenger molecule nitric oxide (NO) is involved in pain mechanisms of migraine without aura.",10524660_2,-1,-1,2,444,-1
453,diagnostic criteria,13,15,71,90,At this time the induced headache in 6 of 12 migraineurs fulfilled the diagnostic criteria for migraine without aura of the International Headache Society.,10524660_9,-1,-1,2,453,-1
454,pain mechanisms,10,12,57,72,The results therefore suggest that NO is involved in the pain mechanisms of migraine with aura.,10524660_10,-1,-1,2,454,-1
463,Oncopaz Cooperative Group,0,3,0,25,Oncopaz Cooperative Group.,10526274_1,-1,-1,2,463,-1
466,single agent therapy,4,7,29,49,"Recent reports indicate that single agent therapy with vinorelbine (VNB) or gemcitabine (GEM) may obtain a response rate of 20-30% in elderly patients, with acceptable toxicity and improvement in symptoms and quality of life.",10526274_3,-1,-1,2,466,-1
477,VNB,4,5,27,30,"Treatment was comprised of VNB, 25 mg/m(2), plus GEM, 1000 mg/m(2), both on Days 1, 8, and 15 every 28 days.",10526274_7,-1,-1,2,477,-1
479,sixty-five courses,4,6,21,39,"RESULTS: One hundred sixty-five courses were administered, with a median of 3.",10526274_9,-1,-1,2,479,-1
480,response rate,2,4,12,25,"The overall response rate was 26% (95% confidence interval, 15-41%).",10526274_11,-1,-1,2,480,-1
481,confidence interval,10,12,39,58,"The overall response rate was 26% (95% confidence interval, 15-41%).",10526274_11,-1,-1,2,481,-1
483,partial response,19,21,80,96,Two patients attained a complete response (4%) and 11 patients (22%) achieved a partial response.,10526274_12,-1,-1,2,483,-1
484,Eastern Cooperative Oncology Group,0,4,0,34,"Eastern Cooperative Oncology Group performance status improved in 35% of those patients with an initial value > 0, whereas relief of at least 1 symptom without worsening of other symptoms was noted in 27 patients (55%).",10526274_13,-1,-1,2,484,-1
485,1-year survival,10,12,52,67,The median time to progression was 16 weeks and the 1-year survival rate was 33%. Toxicity was mild.,10526274_14,-1,-1,2,485,-1
491,age group,1,3,5,14,This age group had an increased risk of myelosuppression.,10526274_19,-1,-1,2,491,-1
511,mortality rates,32,34,267,282,"Predictors of decreased renal function in patients with heart failure during angiotensin-converting enzyme inhibitor therapy: results from the studies of left ventricular dysfunction (SOLVD)BACKGROUND: Although angiotensin-converting enzyme inhibitor therapy reduces mortality rates in patients with congestive heart failure (CHF), it may also cause decreased renal function.",10539815_0,-1,-1,2,511,-1
513,CHF,41,42,326,329,"Predictors of decreased renal function in patients with heart failure during angiotensin-converting enzyme inhibitor therapy: results from the studies of left ventricular dysfunction (SOLVD)BACKGROUND: Although angiotensin-converting enzyme inhibitor therapy reduces mortality rates in patients with congestive heart failure (CHF), it may also cause decreased renal function.",10539815_0,-1,-1,2,513,-1
515,clinical predictors,5,7,32,51,OBJECTIVE: To quantify specific clinical predictors of reduction in renal function in patients with CHF who are prescribed angiotensin-converting enzyme inhibitor therapy.,10539815_2,-1,-1,2,515,-1
523,placebo-controlled trial,21,23,111,135,"METHOD: We analyzed data from the Studies of Left Ventricular Dysfunction (SOLVD), a randomized, double-blind, placebo-controlled trial of enalapril for the treatment of CHF.",10539815_3,-1,-1,2,523,-1
524,CHF,29,30,170,173,"METHOD: We analyzed data from the Studies of Left Ventricular Dysfunction (SOLVD), a randomized, double-blind, placebo-controlled trial of enalapril for the treatment of CHF.",10539815_3,-1,-1,2,524,-1
529,ejection fraction,17,19,118,135,"We used time-to-event analysis to identify potential predictors of decrease in renal function including age, baseline ejection fraction, baseline creatinine, low systolic blood pressure (<100 mm Hg), history of hypertension, diabetes, and use of antiplatelet, diuretic, and beta-blocker therapy.",10539815_6,-1,-1,2,529,-1
539,associated with,20,22,114,129,"By multivariate analysis, in both the placebo and enalapril groups older age, diuretic therapy, and diabetes were associated with decreased renal function, whereas beta-blocker therapy and higher ejection fraction were renoprotective.",10539815_8,-1,-1,2,539,-1
545,associated with,3,5,14,29,"Older age was associated with a greater risk of developing decreased renal function in both groups, but significantly more so in the enalapril group (enalapril: risk ratio [RR] 1.42 per 10 years, 95% confidence interval [CI] 1.32-1.52 with enalapril; placebo: RR 1.18, 95% CI 1.12-1.25).",10539815_9,-1,-1,2,545,-1
550,confidence interval,40,42,200,219,"Older age was associated with a greater risk of developing decreased renal function in both groups, but significantly more so in the enalapril group (enalapril: risk ratio [RR] 1.42 per 10 years, 95% confidence interval [CI] 1.32-1.52 with enalapril; placebo: RR 1.18, 95% CI 1.12-1.25).",10539815_9,-1,-1,2,550,-1
552,associated with,4,6,30,45,"Diuretic therapy was likewise associated with a greater risk of decreased renal function in the enalapril group (RR 1.89, 95% CI 1.70-2.08) than in the placebo group (RR 1.35, 95% CI 1.09-1.66).",10539815_10,-1,-1,2,552,-1
565,Enalapril use,2,4,13,26,CONCLUSIONS: Enalapril use caused a 33% increase in the risk of decreased renal function in patients with CHF.,10539815_13,-1,-1,2,565,-1
573,ejection fraction,4,6,32,49,beta-Blocker therapy and higher ejection fraction were renoprotective in all patients regardless of therapy.,10539815_16,-1,-1,2,573,-1
584,Ki values,39,41,198,207,"NRA0160, 5 - [2- ( 4- ( 3 - fluorobenzylidene) piperidin-1-yl) ethyl] - 4 -(4-fluorophenyl) thiazole-2-carboxamide, has a high affinity for human cloned dopamine D4.2, D4.4 and D4.7 receptors, with Ki values of 0.5, 0.9 and 2.7 nM, respectively.",10579464_1,-1,-1,2,584,-1
592,dose given,24,26,150,160,"NRA0160 and clozapine antagonized MAP-induced stereotyped behavior in mice, although their effects did not exceed 50% inhibition, even at the highest dose given.",10579464_5,-1,-1,2,592,-1
594,prepulse inhibition,8,10,63,82,NRA0160 and clozapine significantly reversed the disruption of prepulse inhibition (PPI) in rats produced by apomorphine.,10579464_7,-1,-1,2,594,-1
603,gamma-carboxylation,34,35,242,261,"Warfarin-induced artery calcification is accelerated by growth and vitamin D.The present studies demonstrate that growth and vitamin D treatment enhance the extent of artery calcification in rats given sufficient doses of Warfarin to inhibit gamma-carboxylation of matrix Gla protein, a calcification inhibitor known to be expressed by smooth muscle cells and macrophages in the artery wall.",10669626_0,-1,-1,2,603,-1
608,Warfarin-treated,17,18,107,123,The first series of experiments examined the influence of age and growth status on artery calcification in Warfarin-treated rats.,10669626_1,-1,-1,2,608,-1
619,ad libitum-fed rats,18,21,122,141,"Concurrent treatment of both dietary groups with Warfarin produced massive focal calcification of the artery media in the ad libitum-fed rats but no detectable artery calcification in the restricted-diet, growth-inhibited group.",10669626_5,-1,-1,2,619,-1
622,growth-inhibited group,30,32,205,227,"Concurrent treatment of both dietary groups with Warfarin produced massive focal calcification of the artery media in the ad libitum-fed rats but no detectable artery calcification in the restricted-diet, growth-inhibited group.",10669626_5,-1,-1,2,622,-1
625,serum phosphate,27,29,177,192,"Although the explanation for the association between artery calcification and growth status cannot be determined from the present study, there was a relationship between higher serum phosphate and susceptibility to artery calcification, with 30% higher levels of serum phosphate in young, ad libitum-fed rats compared with either of the groups that was resistant to Warfarin-induced artery calcification, ie, the 10-month-old rats and the restricted-diet, growth-inhibited young rats.",10669626_6,-1,-1,2,625,-1
627,serum phosphate,41,43,263,278,"Although the explanation for the association between artery calcification and growth status cannot be determined from the present study, there was a relationship between higher serum phosphate and susceptibility to artery calcification, with 30% higher levels of serum phosphate in young, ad libitum-fed rats compared with either of the groups that was resistant to Warfarin-induced artery calcification, ie, the 10-month-old rats and the restricted-diet, growth-inhibited young rats.",10669626_6,-1,-1,2,627,-1
628,ad libitum-fed rats,46,49,289,308,"Although the explanation for the association between artery calcification and growth status cannot be determined from the present study, there was a relationship between higher serum phosphate and susceptibility to artery calcification, with 30% higher levels of serum phosphate in young, ad libitum-fed rats compared with either of the groups that was resistant to Warfarin-induced artery calcification, ie, the 10-month-old rats and the restricted-diet, growth-inhibited young rats.",10669626_6,-1,-1,2,628,-1
630,restricted-diet,70,71,439,454,"Although the explanation for the association between artery calcification and growth status cannot be determined from the present study, there was a relationship between higher serum phosphate and susceptibility to artery calcification, with 30% higher levels of serum phosphate in young, ad libitum-fed rats compared with either of the groups that was resistant to Warfarin-induced artery calcification, ie, the 10-month-old rats and the restricted-diet, growth-inhibited young rats.",10669626_6,-1,-1,2,630,-1
633,serum phosphate,15,17,124,139,This observation suggests that increased susceptibility to Warfarin-induced artery calcification could be related to higher serum phosphate levels.,10669626_7,-1,-1,2,633,-1
642,treatment times,21,23,114,129,"High doses of the vitamin K antagonist Warfarin are also known to cause calcification of the artery media, but at treatment times of 2 weeks or longer yet not at 1 week.",10669626_10,-1,-1,2,642,-1
643,vitamin D-treated,29,31,194,211,"In the current study, we investigated the synergy between these 2 treatments and found that concurrent Warfarin administration dramatically increased the extent of calcification in the media of vitamin D-treated rats at 3 and 4 days.",10669626_11,-1,-1,2,643,-1
647,serum calcium,26,28,141,154,"There was a close parallel between the effect of vitamin D dose on artery calcification and the effect of vitamin D dose on the elevation of serum calcium, which suggests that vitamin D may induce artery calcification through its effect on serum calcium.",10669626_12,-1,-1,2,647,-1
650,serum calcium,42,44,240,253,"There was a close parallel between the effect of vitamin D dose on artery calcification and the effect of vitamin D dose on the elevation of serum calcium, which suggests that vitamin D may induce artery calcification through its effect on serum calcium.",10669626_12,-1,-1,2,650,-1
651,no effect,4,6,31,40,"Because Warfarin treatment had no effect on the elevation in serum calcium produced by vitamin D, the synergy between Warfarin and vitamin D is probably best explained by the hypothesis that Warfarin inhibits the activity of matrix Gla protein as a calcification inhibitor.",10669626_13,-1,-1,2,651,-1
652,serum calcium,10,12,61,74,"Because Warfarin treatment had no effect on the elevation in serum calcium produced by vitamin D, the synergy between Warfarin and vitamin D is probably best explained by the hypothesis that Warfarin inhibits the activity of matrix Gla protein as a calcification inhibitor.",10669626_13,-1,-1,2,652,-1
656,treated with,15,17,85,97,"High levels of matrix Gla protein are found at sites of artery calcification in rats treated with vitamin D plus Warfarin, and chemical analysis showed that the protein that accumulated was indeed not gamma-carboxylated.",10669626_14,-1,-1,2,656,-1
660,calcification sites,31,33,217,236,"These observations indicate that although the gamma-carboxyglutamate residues of matrix Gla protein are apparently required for its function as a calcification inhibitor, they are not required for its accumulation at calcification sites.",10669626_15,-1,-1,2,660,-1
661,Test conditions,0,2,0,15,Test conditions influence the response to a drug challenge in rodents.,10683478_0,-1,-1,2,661,-1
663,differential response,7,9,44,65,These studies were conducted to examine the differential response to a drug challenge under varied experimental test conditions routinely employed to study drug-induced behavioral and neurophysiological responses in rodents.,10683478_1,-1,-1,2,663,-1
665,experimental test,15,17,99,116,These studies were conducted to examine the differential response to a drug challenge under varied experimental test conditions routinely employed to study drug-induced behavioral and neurophysiological responses in rodents.,10683478_1,-1,-1,2,665,-1
669,biphasic,12,13,70,78,"Apomorphine, a nonselective dopamine agonist, was selected due to its biphasic behavioral effects, its ability to induce hypothermia, and to produce distinct changes to dopamine turnover in the rodent brain.",10683478_2,-1,-1,2,669,-1
671,critically depends,15,17,119,137,From such experiments there is evidence that characterization and detection of apomorphine-induced activity in rodents critically depends upon the test conditions employed.,10683478_3,-1,-1,2,671,-1
673,test conditions,16,18,110,125,"In rats, detection of apomorphine-induced hyperactivity was facilitated by a period of acclimatization to the test conditions.",10683478_4,-1,-1,2,673,-1
674,test conditions,2,4,10,25,"Moreover, test conditions can impact upon other physiological responses to apomorphine such as drug-induced hypothermia.",10683478_5,-1,-1,2,674,-1
675,physiological responses,8,10,48,71,"Moreover, test conditions can impact upon other physiological responses to apomorphine such as drug-induced hypothermia.",10683478_5,-1,-1,2,675,-1
677,home test cage,19,22,136,150,"In mice, apomorphine produced qualitatively different responses under novel conditions when compared to those behaviors elicited in the home test cage.",10683478_6,-1,-1,2,677,-1
679,exploratory box,9,11,63,78,"Drug-induced gross activity counts were increased in the novel exploratory box only, while measures of stereotypic behavior were similar in both.",10683478_7,-1,-1,2,679,-1
682,exploratory box,11,13,76,91,"By contrast, apomorphine-induced locomotion was more prominent in the novel exploratory box.",10683478_8,-1,-1,2,682,-1
686,exposed to,20,22,87,97,Dopamine turnover ratios (DOPAC:DA and HVA:DA) were found to be lower in those animals exposed to the exploratory box when compared to their home cage counterparts.,10683478_9,-1,-1,2,686,-1
687,exploratory box,23,25,102,117,Dopamine turnover ratios (DOPAC:DA and HVA:DA) were found to be lower in those animals exposed to the exploratory box when compared to their home cage counterparts.,10683478_9,-1,-1,2,687,-1
689,apomorphine-induced reductions,2,4,9,39,"However, apomorphine-induced reductions in striatal dopamine turnover were detected in both novel and home cage environments.",10683478_10,-1,-1,2,689,-1
692,psychopharmacological challenge tests,12,15,90,127,The implications of these findings are discussed with particular emphasis upon conducting psychopharmacological challenge tests in rodents.,10683478_11,-1,-1,2,692,-1
699,predisposing factors,18,20,115,135,"We report a case of acetazolamide-induced Gerstmann syndrome in a patient with normal renal function, to highlight predisposing factors that are frequently overlooked.",10692744_2,-1,-1,2,699,-1
700,membrane structure,12,14,81,99,Hemolysis of human erythrocytes induced by tamoxifen is related to disruption of membrane structure.,10704919_0,-1,-1,2,700,-1
708,osmotic fragility curves,11,14,69,93,"Despite inducing extensive erythrocyte lysis, TAM does not shift the osmotic fragility curves of erythrocytes.",10704919_5,-1,-1,2,708,-1
716,peroxidation,9,10,51,63,"Furthermore, it was observed that TAM inhibits the peroxidation of human erythrocytes induced by AAPH, thus ruling out TAM-induced cell oxidative stress.",10704919_8,-1,-1,2,716,-1
718,TAM-induced cell,20,22,119,135,"Furthermore, it was observed that TAM inhibits the peroxidation of human erythrocytes induced by AAPH, thus ruling out TAM-induced cell oxidative stress.",10704919_8,-1,-1,2,718,-1
721,colloid-osmotic type mechanism,20,23,97,127,"Hemolysis caused by TAM was not preceded by the leakage of K(+) from the cells, also excluding a colloid-osmotic type mechanism of hemolysis, according to the effects on osmotic fragility curves.",10704919_9,-1,-1,2,721,-1
722,osmotic fragility curves,31,34,170,194,"Hemolysis caused by TAM was not preceded by the leakage of K(+) from the cells, also excluding a colloid-osmotic type mechanism of hemolysis, according to the effects on osmotic fragility curves.",10704919_9,-1,-1,2,722,-1
727,model membranes,12,14,87,102,Either alpha-T or alpha-TAc increases membrane packing and prevents TAM partition into model membranes.,10704919_11,-1,-1,2,727,-1
728,condensed membranes,18,20,119,138,These effects suggest that the protection from hemolysis by tocopherols is related to a decreased TAM incorporation in condensed membranes and the structural damage of the erythrocyte membrane is consequently avoided.,10704919_12,-1,-1,2,728,-1
730,erythrocyte membrane,26,28,172,192,These effects suggest that the protection from hemolysis by tocopherols is related to a decreased TAM incorporation in condensed membranes and the structural damage of the erythrocyte membrane is consequently avoided.,10704919_12,-1,-1,2,730,-1
731,red cell membrane,10,13,75,92,"Therefore, TAM-induced hemolysis results from a structural perturbation of red cell membrane, leading to changes in the framework of the erythrocyte membrane and its cytoskeleton caused by its high partition in the membrane.",10704919_13,-1,-1,2,731,-1
732,erythrocyte membrane,22,24,137,157,"Therefore, TAM-induced hemolysis results from a structural perturbation of red cell membrane, leading to changes in the framework of the erythrocyte membrane and its cytoskeleton caused by its high partition in the membrane.",10704919_13,-1,-1,2,732,-1
733,mechanical stability,9,11,67,87,"These defects explain the abnormal erythrocyte shape and decreased mechanical stability promoted by TAM, resulting in hemolytic anemia.",10704919_14,-1,-1,2,733,-1
737,anticancer action,30,32,192,209,"Additionally, since membrane leakage is a final stage of cytotoxicity, the disruption of the structural characteristics of biomembranes by TAM may contribute to the multiple mechanisms of its anticancer action.",10704919_15,-1,-1,2,737,-1
744,transmembraneous transport,8,10,49,75,"To assess the molecular basis of disturbances in transmembraneous transport of Na+, we studied the response of cardiac (Na,K)-ATPase to NO-deficient hypertension induced in rats by NO-synthase inhibition with 40 mg/kg/day N(G)-nitro-L-arginine methyl ester (L-NAME) for 4 four weeks.",10706004_4,-1,-1,2,744,-1
752,4-week,1,2,6,12,"After 4-week administration of L-NAME, the systolic blood pressure (SBP) increased by 36%.",10706004_5,-1,-1,2,752,-1
756,SBP,8,9,47,50,"Two weeks after terminating the treatment, the SBP recovered to control value.",10706004_6,-1,-1,2,756,-1
757,control value,11,13,64,77,"Two weeks after terminating the treatment, the SBP recovered to control value.",10706004_6,-1,-1,2,757,-1
761,Vmax values,16,18,79,90,"When activating the (Na,K)-ATPase with its substrate ATP, no changes in Km and Vmax values were observed in NO-deficient rats.",10706004_7,-1,-1,2,761,-1
762,NO-deficient,21,22,108,120,"When activating the (Na,K)-ATPase with its substrate ATP, no changes in Km and Vmax values were observed in NO-deficient rats.",10706004_7,-1,-1,2,762,-1
764,Vmax,6,7,32,36,"During activation with Na+, the Vmax remained unchanged, however the K(Na) increased by 50%, indicating a profound decrease in the affinity of the Na+-binding site in NO-deficient rats.",10706004_8,-1,-1,2,764,-1
771,Km value,27,29,152,160,"After recovery from hypertension, the activity of (Na,K)-ATPase increased, due to higher affinity of the ATP-binding site, as revealed from the lowered Km value for ATP.",10706004_9,-1,-1,2,771,-1
772,K(Na) value,1,4,4,15,The K(Na) value for Na+ returned to control value.,10706004_10,-1,-1,2,772,-1
774,control value,8,10,36,49,The K(Na) value for Na+ returned to control value.,10706004_10,-1,-1,2,774,-1
776,depressed Na+-extrusion,9,11,75,98,"Inhibition of NO-synthase induced a reversible hypertension accompanied by depressed Na+-extrusion from cardiac cells as a consequence of deteriorated Na+-binding properties of the (Na,K)-ATPase.",10706004_11,-1,-1,2,776,-1
778,consequence of,16,18,123,137,"Inhibition of NO-synthase induced a reversible hypertension accompanied by depressed Na+-extrusion from cardiac cells as a consequence of deteriorated Na+-binding properties of the (Na,K)-ATPase.",10706004_11,-1,-1,2,778,-1
782,control values,6,8,36,50,"After recovery of blood pressure to control values, the extrusion of Na+ from cardiac cells was normalized, as revealed by restoration of the (Na,K)-ATPase activity.",10706004_12,-1,-1,2,782,-1
784,cardiac cells,14,16,78,91,"After recovery of blood pressure to control values, the extrusion of Na+ from cardiac cells was normalized, as revealed by restoration of the (Na,K)-ATPase activity.",10706004_12,-1,-1,2,784,-1
787,pretreatment,3,4,21,33,Effects of long-term pretreatment with isoproterenol on bromocriptine-induced tachycardia in conscious rats.,10721819_0,-1,-1,2,787,-1
789,pretreatment,32,33,194,206,"It has been shown that bromocriptine-induced tachycardia, which persisted after adrenalectomy, is (i) mediated by central dopamine D2 receptor activation and (ii) reduced by 5-day isoproterenol pretreatment, supporting therefore the hypothesis that this effect is dependent on sympathetic outflow to the heart.",10721819_1,-1,-1,2,789,-1
792,pretreatment,1,2,14,26,Isoproterenol pretreatment for 15 days caused cardiac hypertrophy without affecting baseline blood pressure and heart rate.,10721819_3,-1,-1,2,792,-1
804,perfused heart preparations,2,5,12,39,"In isolated perfused heart preparations from isoproterenol-pretreated rats, the isoproterenol-induced maximal increase in left ventricular systolic pressure was significantly reduced, compared with saline-pretreated rats (the EC50 of the isoproterenol-induced increase in left ventricular systolic pressure was enhanced approximately 22-fold).",10721819_8,-1,-1,2,804,-1
830,controlled conditions,1,3,6,27,"Under controlled conditions, infant rats emit ultrasonic vocalizations during extreme cold exposure and after administration of the alpha(2) adrenoceptor agonist, clonidine.",10737864_1,-1,-1,2,830,-1
833,ultrasound production,11,13,72,93,"Previous investigations have determined that, in response to clonidine, ultrasound production increases through the 2nd-week postpartum and decreases thereafter.",10737864_2,-1,-1,2,833,-1
835,developmental effects,26,28,188,209,"Given that sympathetic neural dominance exhibits a similar developmental pattern, and given that clonidine induces sympathetic withdrawal and bradycardia, we hypothesized that clonidine's developmental effects on cardiac rate and ultrasound production would mirror each other.",10737864_3,-1,-1,2,835,-1
842,ultrasound production,10,12,64,85,This experiment is discussed with regard to the hypothesis that ultrasound production is the acoustic by-product of a physiological maneuver that compensates for clonidine's detrimental effects on cardiovascular function.,10737864_6,-1,-1,2,842,-1
843,detrimental effects,25,27,174,193,This experiment is discussed with regard to the hypothesis that ultrasound production is the acoustic by-product of a physiological maneuver that compensates for clonidine's detrimental effects on cardiovascular function.,10737864_6,-1,-1,2,843,-1
845,Recurrent use of,0,3,0,16,Recurrent use of newer oral contraceptives and the risk of venous thromboembolism.,10739826_0,-1,-1,2,845,-1
848,epidemiological studies,1,3,4,27,"The epidemiological studies that assessed the risk of venous thromboembolism (VTE) associated with newer oral contraceptives (OC) did not distinguish between patterns of OC use, namely first-time users, repeaters and switchers.",10739826_1,-1,-1,2,848,-1
855,Transnational case-control study,3,6,12,44,"Data from a Transnational case-control study were used to assess the risk of VTE for the latter patterns of use, while accounting for duration of use.",10739826_2,-1,-1,2,855,-1
857,VTE,10,11,40,43,"Over the period 1993-1996, 551 cases of VTE were identified in Germany and the UK along with 2066 controls.",10739826_3,-1,-1,2,857,-1
858,switching patterns,19,21,101,119,Totals of 128 cases and 650 controls were analysed for repeat use and 135 cases and 622 controls for switching patterns.,10739826_4,-1,-1,2,858,-1
859,VTE,5,6,27,30,"The adjusted rate ratio of VTE for repeat users of third generation OC was 0.6 (95% CI:0.3-1.2) relative to repeat users of second generation pills, whereas it was 1.3 (95% CI:0.7-2.4) for switchers from second to third generation pills relative to switchers from third to second generation pills.",10739826_5,-1,-1,2,859,-1
866,associated with,9,11,56,71,We conclude that second and third generation agents are associated with equivalent risks of VTE when the same agent is used repeatedly after interruption periods or when users are switched between the two generations of pills.,10739826_6,-1,-1,2,866,-1
868,OC,11,12,67,69,These analyses suggest that the higher risk observed for the newer OC in other studies may be the result of inadequate comparisons of pill users with different patterns of pill use.,10739826_7,-1,-1,2,868,-1
870,Differential effects,0,2,0,20,Differential effects of systemically administered ketamine and lidocaine on dynamic and static hyperalgesia induced by intradermal capsaicin in humans.,10743446_0,-1,-1,2,870,-1
871,systemically,3,4,24,36,Differential effects of systemically administered ketamine and lidocaine on dynamic and static hyperalgesia induced by intradermal capsaicin in humans.,10743446_0,-1,-1,2,871,-1
873,systemic administration,6,8,31,54,We have examined the effect of systemic administration of ketamine and lidocaine on brush-evoked (dynamic) pain and punctate-evoked (static) hyperalgesia induced by capsaicin.,10743446_1,-1,-1,2,873,-1
878,placebo-controlled,6,7,31,49,"In a randomized, double-blind, placebo-controlled, crossover study, we studied 12 volunteers in three experiments.",10743446_2,-1,-1,2,878,-1
879,crossover study,8,10,51,66,"In a randomized, double-blind, placebo-controlled, crossover study, we studied 12 volunteers in three experiments.",10743446_2,-1,-1,2,879,-1
881,kg-1,7,8,35,39,"infusion of ketamine (bolus 0.1 mg kg-1 over 10 min followed by infusion of 7 micrograms kg-1 min-1), lidocaine 5 mg kg-1 or saline for 50 min.",10743446_4,-1,-1,2,881,-1
882,kg-1 min-1,17,19,89,99,"infusion of ketamine (bolus 0.1 mg kg-1 over 10 min followed by infusion of 7 micrograms kg-1 min-1), lidocaine 5 mg kg-1 or saline for 50 min.",10743446_4,-1,-1,2,882,-1
886,brush stimuli,13,15,75,88,"The following were measured: spontaneous pain, pain evoked by punctate and brush stimuli (VAS), and areas of brush-evoked and punctate-evoked hyperalgesia.",10743446_6,-1,-1,2,886,-1
895,no effect,11,13,59,68,It tended to reduce VAS scores of spontaneous pain but had no effect on evoked pain.,10743446_9,-1,-1,2,895,-1
897,differential effects,1,3,4,24,The differential effects of ketamine and lidocaine on static and dynamic hyperalgesia suggest that the two types of hyperalgesia are mediated by separate mechanisms and have a distinct pharmacology.,10743446_10,-1,-1,2,897,-1
900,tacrolimus-related adverse effects,2,5,13,47,Treatment of tacrolimus-related adverse effects by conversion to cyclosporine in liver transplant recipients.,10743694_0,-1,-1,2,900,-1
912,blood level,35,37,235,246,"Of 388 liver recipients who received tacrolimus as primary immunosuppression, 70 required conversion to CyA. We recorded indication for conversion, whether conversion was early or late after transplantation, tacrolimus dose and trough blood level at conversion, and incidence of rejection after conversion.",10743694_3,-1,-1,2,912,-1
916,nephrotoxicity (3,22,25,108,125,"Indications for early conversion were neurotoxicity (20), (insulin-dependent) diabetes mellitus (IDDM) (5), nephrotoxicity (3), gastrointestinal (GI) toxicity (6), and cardiomyopathy (1), and for late conversion were neurotoxicity (15), IDDM (12), nephrotoxicity (3), GI toxicity (5), hepatotoxicity (6), post-transplant lmphoproliferate disease (PTLD) (2), cardiomyopathy (1), hemolytic anemia (1), and pruritus (1).",10743694_5,-1,-1,2,916,-1
920,nephrotoxicity (3,57,60,248,265,"Indications for early conversion were neurotoxicity (20), (insulin-dependent) diabetes mellitus (IDDM) (5), nephrotoxicity (3), gastrointestinal (GI) toxicity (6), and cardiomyopathy (1), and for late conversion were neurotoxicity (15), IDDM (12), nephrotoxicity (3), GI toxicity (5), hepatotoxicity (6), post-transplant lmphoproliferate disease (PTLD) (2), cardiomyopathy (1), hemolytic anemia (1), and pruritus (1).",10743694_5,-1,-1,2,920,-1
929,improvement/resolution,10,11,47,69,"Among late-conversion patients, 37 (90.2%) had improvement/resolution; in 4 (9.8%), adverse effects persisted.",10743694_7,-1,-1,2,929,-1
931,rejection rate,2,4,12,26,The overall rejection rate was 30%.,10743694_8,-1,-1,2,931,-1
932,/- 362,13,15,66,72,"Sixty-two patients (88.6%) are alive with functioning grafts 686 +/- 362 days (range, 154-1433 days) after conversion.",10743694_9,-1,-1,2,932,-1
936,Wistar rats,12,14,92,103,Development of apomorphine-induced aggressive behavior: comparison of adult male and female Wistar rats.,10791295_0,-1,-1,2,936,-1
937,apomorphine-induced,3,4,19,38,The development of apomorphine-induced (1.0 mg/kg s.c. once daily) aggressive behavior of adult male and female Wistar rats obtained from the same breeder was studied in two consecutive sets.,10791295_1,-1,-1,2,937,-1
939,Wistar rats,19,21,112,123,The development of apomorphine-induced (1.0 mg/kg s.c. once daily) aggressive behavior of adult male and female Wistar rats obtained from the same breeder was studied in two consecutive sets.,10791295_1,-1,-1,2,939,-1
944,validation criteria,27,29,182,201,"In conclusion, the present study demonstrates gender differences in the development of the apomorphine-induced aggressive behavior and indicates that the female rats do not fill the validation criteria for use in this method.",10791295_4,-1,-1,2,944,-1
959,Systemically,0,1,0,12,Systemically administered corticosteroids were used in 75 of 210 cases; a significant number of posterior subcapsular cataracts was found.,1079693_12,-1,-1,2,959,-1
968,statistical model,13,15,62,79,"However, no study in the literature has reported the use of a statistical model to analyze the variables that influence outcome.",10807237_2,-1,-1,2,968,-1
970,control group,6,8,31,44,This group was compared with a control group of 135 patients with ruptured aneurysms and no history of cocaine abuse.,10807237_4,-1,-1,2,970,-1
976,study group,6,8,29,40,RESULTS: The patients in the study group were significantly younger than the patients in the control group (P < 0.002).,10807237_6,-1,-1,2,976,-1
977,control group,16,18,93,106,RESULTS: The patients in the study group were significantly younger than the patients in the control group (P < 0.002).,10807237_6,-1,-1,2,977,-1
978,study group,4,6,19,30,"In patients in the study group, all aneurysms were located in the anterior circulation.",10807237_7,-1,-1,2,978,-1
980,control group,11,13,63,76,The majority of these aneurysms were smaller than those of the control group (8 +/- 6.08 mm versus 11 +/- 5.4 mm; P = 0.05).,10807237_8,-1,-1,2,980,-1
981,/-,16,17,81,83,The majority of these aneurysms were smaller than those of the control group (8 +/- 6.08 mm versus 11 +/- 5.4 mm; P = 0.05).,10807237_8,0,1,2,981,-1
982,/-,22,23,103,105,The majority of these aneurysms were smaller than those of the control group (8 +/- 6.08 mm versus 11 +/- 5.4 mm; P = 0.05).,10807237_8,0,1,2,982,-1
993,INWEST,12,13,79,85,BACKGROUND AND PURPOSE: The Intravenous Nimodipine West European Stroke Trial (INWEST) found a correlation between nimodipine-induced reduction in blood pressure (BP) and an unfavorable outcome in acute stroke.,10835440_1,-1,-1,2,993,-1
994,nimodipine-induced reduction,18,20,115,143,BACKGROUND AND PURPOSE: The Intravenous Nimodipine West European Stroke Trial (INWEST) found a correlation between nimodipine-induced reduction in blood pressure (BP) and an unfavorable outcome in acute stroke.,10835440_1,-1,-1,2,994,-1
996,BP,24,25,163,165,BACKGROUND AND PURPOSE: The Intravenous Nimodipine West European Stroke Trial (INWEST) found a correlation between nimodipine-induced reduction in blood pressure (BP) and an unfavorable outcome in acute stroke.,10835440_1,-1,-1,2,996,-1
998,prognostic variables,11,13,70,90,We sought to confirm this correlation with and without adjustment for prognostic variables and to investigate outcome in subgroups with increasing levels of BP reduction.,10835440_2,-1,-1,2,998,-1
1006,BP,4,5,32,34,The correlation between average BP change during the first 2 days and the outcome at day 21 was analyzed.,10835440_4,-1,-1,2,1006,-1
1010,statistically significant,5,7,35,60,Nimodipine treatment resulted in a statistically significant reduction in systolic BP (SBP) and diastolic BP (DBP) from baseline compared with placebo during the first few days.,10835440_6,-1,-1,2,1010,-1
1011,systolic BP,9,11,74,85,Nimodipine treatment resulted in a statistically significant reduction in systolic BP (SBP) and diastolic BP (DBP) from baseline compared with placebo during the first few days.,10835440_6,-1,-1,2,1011,-1
1013,diastolic BP,15,17,96,108,Nimodipine treatment resulted in a statistically significant reduction in systolic BP (SBP) and diastolic BP (DBP) from baseline compared with placebo during the first few days.,10835440_6,-1,-1,2,1013,-1
1014,DBP,18,19,110,113,Nimodipine treatment resulted in a statistically significant reduction in systolic BP (SBP) and diastolic BP (DBP) from baseline compared with placebo during the first few days.,10835440_6,-1,-1,2,1014,-1
1019,beta=0.49,23,24,149,158,"In multivariate analysis, a significant correlation between DBP reduction and worsening of the neurological score was found for the high-dose group (beta=0.49, P=0. 048).",10835440_7,-1,-1,2,1019,-1
1020,P=0,25,26,160,163,"In multivariate analysis, a significant correlation between DBP reduction and worsening of the neurological score was found for the high-dose group (beta=0.49, P=0. 048).",10835440_7,-1,-1,2,1020,-1
1021,DBP,3,4,16,19,"Patients with a DBP reduction of > or =20% in the high-dose group had a significantly increased adjusted OR for the compound outcome variable death or dependency (Barthel Index <60) (n/N=25/26, OR 10. 16, 95% CI 1.02 to 101.74) and death alone (n/N=9/26, OR 4.336, 95% CI 1.131 16.619) compared with all placebo patients (n/N=62/92 and 14/92, respectively).",10835440_8,-1,-1,2,1021,-1
1023,Barthel Index,30,32,163,176,"Patients with a DBP reduction of > or =20% in the high-dose group had a significantly increased adjusted OR for the compound outcome variable death or dependency (Barthel Index <60) (n/N=25/26, OR 10. 16, 95% CI 1.02 to 101.74) and death alone (n/N=9/26, OR 4.336, 95% CI 1.131 16.619) compared with all placebo patients (n/N=62/92 and 14/92, respectively).",10835440_8,-1,-1,2,1023,-1
1024,n/N=9/26,54,55,245,253,"Patients with a DBP reduction of > or =20% in the high-dose group had a significantly increased adjusted OR for the compound outcome variable death or dependency (Barthel Index <60) (n/N=25/26, OR 10. 16, 95% CI 1.02 to 101.74) and death alone (n/N=9/26, OR 4.336, 95% CI 1.131 16.619) compared with all placebo patients (n/N=62/92 and 14/92, respectively).",10835440_8,-1,-1,2,1024,-1
1025,n/N=62/92,71,72,322,331,"Patients with a DBP reduction of > or =20% in the high-dose group had a significantly increased adjusted OR for the compound outcome variable death or dependency (Barthel Index <60) (n/N=25/26, OR 10. 16, 95% CI 1.02 to 101.74) and death alone (n/N=9/26, OR 4.336, 95% CI 1.131 16.619) compared with all placebo patients (n/N=62/92 and 14/92, respectively).",10835440_8,-1,-1,2,1025,-1
1026,SBP,5,6,33,36,There was no correlation between SBP change and outcome.,10835440_9,-1,-1,2,1026,-1
1027,DBP,2,3,13,16,"CONCLUSIONS: DBP, but not SBP, reduction was associated with neurological worsening after the intravenous administration of high-dose nimodipine after acute stroke.",10835440_10,-1,-1,2,1027,-1
1029,associated with,10,12,45,60,"CONCLUSIONS: DBP, but not SBP, reduction was associated with neurological worsening after the intravenous administration of high-dose nimodipine after acute stroke.",10835440_10,-1,-1,2,1029,-1
1031,intravenous administration,16,18,94,120,"CONCLUSIONS: DBP, but not SBP, reduction was associated with neurological worsening after the intravenous administration of high-dose nimodipine after acute stroke.",10835440_10,-1,-1,2,1031,-1
1039,behavioral approach,7,9,67,86,Cyclophosphamide-induced cystitis in freely-moving conscious rats: behavioral approach to a new model of visceral pain.,10840460_0,-1,-1,2,1039,-1
1042,behavioral approach,13,15,61,80,PURPOSE: To develop a model of visceral pain in rats using a behavioral approach.,10840460_1,-1,-1,2,1042,-1
1046,toxic effects,11,13,61,74,"Cyclophosphamide (CP), an antitumoral agent known to produce toxic effects on the bladder wall through its main toxic metabolite acrolein, was used to induce cystitis.",10840460_2,-1,-1,2,1046,-1
1049,effects of,1,3,4,14,The effects of morphine (0.5 to 4 mg./kg.,10840460_5,-1,-1,2,1049,-1
1056,intravesical route,2,4,7,25,"by the intravesical route, and acrolein at doses of 0.5 mg.",10840460_11,-1,-1,2,1056,-1
1057,intravesical route,2,4,7,25,by the intravesical route and of 5 mg./kg.,10840460_12,-1,-1,2,1057,-1
1058,mg./kg,7,8,35,41,by the intravesical route and of 5 mg./kg.,10840460_12,-1,-1,2,1058,-1
1060,dose-relatedly,5,6,17,31,"i.v. RESULTS: CP dose-relatedly induced marked behavioral modifications in male rats: breathing rate decrease, closing of the eyes and occurrence of specific postures.",10840460_13,-1,-1,2,1060,-1
1061,breathing rate,14,16,86,100,"i.v. RESULTS: CP dose-relatedly induced marked behavioral modifications in male rats: breathing rate decrease, closing of the eyes and occurrence of specific postures.",10840460_13,-1,-1,2,1061,-1
1062,dose-dependently,1,2,9,25,Morphine dose-dependently reversed these behavioral disorders.,10840460_14,-1,-1,2,1062,-1
1064,behavioral score,15,17,64,80,A dose of 0.5 mg./kg. produced a reduction of almost 50% of the behavioral score induced by CP 200 mg./kg.,10840460_15,-1,-1,2,1064,-1
1074,mg./kg,4,5,23,29,"Conversely, acrolein 5 mg./kg.",10840460_24,-1,-1,2,1074,-1
1075,experimental model,9,11,55,73,"CONCLUSIONS: Overall, these results indicate that this experimental model of CP-induced cystitis may be an interesting new behavioral model of inflammatory visceral pain, allowing a better understanding of these painful syndromes and thus a better therapeutic approach to them.",10840460_26,-1,-1,2,1075,-1
1098,Eastern Ontario Pain Scale,21,25,128,154,Any pain during the reduction was rated by the orthopaedic surgeon treating the patient according to the Children's Hospital of Eastern Ontario Pain Scale (CHEOPS).,10901305_6,-1,-1,2,1098,-1
1099,average time,3,5,13,25,"RESULTS: The average time from intravenous administration of ketamine to manipulation of the fracture or dislocation was one minute and thirty-six seconds (range, twenty seconds to five minutes), and the average time from intramuscular administration to manipulation was four minutes and forty-two seconds (range, sixty seconds to fifteen minutes).",10901305_7,-1,-1,2,1099,-1
1100,intravenous administration,6,8,31,57,"RESULTS: The average time from intravenous administration of ketamine to manipulation of the fracture or dislocation was one minute and thirty-six seconds (range, twenty seconds to five minutes), and the average time from intramuscular administration to manipulation was four minutes and forty-two seconds (range, sixty seconds to fifteen minutes).",10901305_7,-1,-1,2,1100,-1
1101,average time,35,37,204,216,"RESULTS: The average time from intravenous administration of ketamine to manipulation of the fracture or dislocation was one minute and thirty-six seconds (range, twenty seconds to five minutes), and the average time from intramuscular administration to manipulation was four minutes and forty-two seconds (range, sixty seconds to fifteen minutes).",10901305_7,-1,-1,2,1101,-1
1102,average score,1,3,4,17,"The average score according to the Children's Hospital of Eastern Ontario Pain Scale was 6.4 points (range, 5 to 10 points), reflecting minimal or no pain during fracture reduction.",10901305_8,-1,-1,2,1102,-1
1104,Eastern Ontario Pain Scale,10,14,58,84,"The average score according to the Children's Hospital of Eastern Ontario Pain Scale was 6.4 points (range, 5 to 10 points), reflecting minimal or no pain during fracture reduction.",10901305_8,-1,-1,2,1104,-1
1108,Ninety-nine percent (sixty-eight,0,4,0,32,Ninety-nine percent (sixty-eight) of the sixty-nine parents present during the reduction were pleased with the sedation and would allow it to be used again in a similar situation.,10901305_10,-1,-1,2,1108,-1
1109,sixty-nine parents,7,9,41,59,Ninety-nine percent (sixty-eight) of the sixty-nine parents present during the reduction were pleased with the sedation and would allow it to be used again in a similar situation.,10901305_10,-1,-1,2,1109,-1
1122,effects of,3,5,20,30,"We investigated the effects of moderate and large doses of prednisolone on muscle function and pharmacology, and their relationship to changes in muscle size and acetylcholine receptor (AChR) expression.",10910842_2,-1,-1,2,1122,-1
1127,Sprague-Dawley rats,5,7,32,51,"With institutional approval, 35 Sprague-Dawley rats were randomly allocated to receive daily subcutaneous doses of 10 mg/kg prednisolone (P10 group), 100 mg/kg prednisolone (P100 group), or an equal volume of saline (S group) for 7 days.",10910842_3,-1,-1,2,1127,-1
1136,peak twitch tensions,6,9,27,47,"On Day 8, the nerve-evoked peak twitch tensions, tetanic tensions, and fatigability, and the dose-response curves of d-tubocurarine in the tibialis cranialis muscle were measured in vivo and related to muscle mass or expression of AChRs.",10910842_5,-1,-1,2,1136,-1
1137,tetanic tensions,10,12,49,65,"On Day 8, the nerve-evoked peak twitch tensions, tetanic tensions, and fatigability, and the dose-response curves of d-tubocurarine in the tibialis cranialis muscle were measured in vivo and related to muscle mass or expression of AChRs.",10910842_5,-1,-1,2,1137,-1
1141,in vivo,29,31,179,186,"On Day 8, the nerve-evoked peak twitch tensions, tetanic tensions, and fatigability, and the dose-response curves of d-tubocurarine in the tibialis cranialis muscle were measured in vivo and related to muscle mass or expression of AChRs.",10910842_5,-1,-1,2,1141,-1
1143,AChRs,39,40,231,236,"On Day 8, the nerve-evoked peak twitch tensions, tetanic tensions, and fatigability, and the dose-response curves of d-tubocurarine in the tibialis cranialis muscle were measured in vivo and related to muscle mass or expression of AChRs.",10910842_5,-1,-1,2,1143,-1
1150,P10,12,13,63,66,Tibialis muscle mass was smaller in the P100 group than in the P10 or S groups.,10910842_7,-1,-1,2,1150,-1
1162,P10,18,19,95,98,The 50% effective dose of d-tubocurarine (microg/kg) in the tibialis muscle was smaller in the P10 (33.6 +/- 5.4) than in the S (61.9 +/- 5.0) or the P100 (71.3 +/- 9.6) groups.,10910842_9,-1,-1,2,1162,-1
1167,AChR,0,1,0,4,AChR expression was less in the P10 group than in the S group.,10910842_10,-1,-1,2,1167,-1
1177,dose-dependent,10,11,77,91,"Our results suggest that the neuromuscular dysfunction after prednisolone is dose-dependent, and derives primarily from muscle atrophy and derives less so from changes in AChR expression.",10910842_12,-1,-1,2,1177,-1
1179,AChR,25,26,171,175,"Our results suggest that the neuromuscular dysfunction after prednisolone is dose-dependent, and derives primarily from muscle atrophy and derives less so from changes in AChR expression.",10910842_12,-1,-1,2,1179,-1
1186,TMA,6,7,47,50,The development of thrombotic microangiopathy (TMA) associated with the use of cyclosporine has been well documented.,11007689_1,-1,-1,2,1186,-1
1187,associated with,8,10,52,67,The development of thrombotic microangiopathy (TMA) associated with the use of cyclosporine has been well documented.,11007689_1,-1,-1,2,1187,-1
1190,plasma exchange,13,15,102,117,"Treatments have included discontinuation or reduction of cyclosporine dose with or without concurrent plasma exchange, plasma infusion, anticoagulation, and intravenous immunoglobulin G infusion.",11007689_2,-1,-1,2,1190,-1
1191,plasma infusion,16,18,119,134,"Treatments have included discontinuation or reduction of cyclosporine dose with or without concurrent plasma exchange, plasma infusion, anticoagulation, and intravenous immunoglobulin G infusion.",11007689_2,-1,-1,2,1191,-1
1219,underutilized therapy,3,5,16,37,Apomorphine: an underutilized therapy for Parkinson's disease.,11009181_0,-1,-1,2,1219,-1
1222,drug ever,5,7,39,48,Apomorphine was the first dopaminergic drug ever used to treat symptoms of Parkinson's disease.,11009181_1,-1,-1,2,1222,-1
1226,subcutaneous administration,21,23,137,164,"While powerful antiparkinsonian effects had been observed as early as 1951, the potential of treating fluctuating Parkinson's disease by subcutaneous administration of apomorphine has only recently become the subject of systematic study.",11009181_2,-1,-1,2,1226,-1
1234,Continuous subcutaneous apomorphine infusions,0,4,0,45,"Continuous subcutaneous apomorphine infusions can reduce daily off-time by more than 50% in this group of patients, which appears to be a stronger effect than that generally seen with add-on therapy with oral dopamine agonists or COMT inhibitors.",11009181_4,-1,-1,2,1234,-1
1235,off-time,7,8,63,71,"Continuous subcutaneous apomorphine infusions can reduce daily off-time by more than 50% in this group of patients, which appears to be a stronger effect than that generally seen with add-on therapy with oral dopamine agonists or COMT inhibitors.",11009181_4,-1,-1,2,1235,-1
1239,monotherapy,9,10,56,67,"In addition, there is convincing clinical evidence that monotherapy with continuous subcutaneous apomorphine infusions is associated with marked reductions of preexisting levodopa-induced dyskinesias.",11009181_6,-1,-1,2,1239,-1
1241,associated with,16,18,122,137,"In addition, there is convincing clinical evidence that monotherapy with continuous subcutaneous apomorphine infusions is associated with marked reductions of preexisting levodopa-induced dyskinesias.",11009181_6,-1,-1,2,1241,-1
1248,pharmacological response,3,5,15,39,"OBJECTIVE: The pharmacological response to drugs that act on the cholinergic system of the iris has been used to predict deficits in central cholinergic functioning due to diseases such as Alzheimer's disease, yet correlations between central and peripheral responses have not been properly studied.",11022397_1,-1,-1,2,1248,-1
1256,Randomized double-blind controlled trial,2,6,8,48,DESIGN: Randomized double-blind controlled trial.,11022397_4,-1,-1,2,1256,-1
1258,computerized infrared pupillometer,8,11,52,86,INTERVENTIONS: Pupil diameter was monitored using a computerized infrared pupillometer over 4 hours.,11022397_6,-1,-1,2,1258,-1
1265,randomized order,7,9,30,46,All eye drops were given in a randomized order.,11022397_10,-1,-1,2,1265,-1
1268,Buschke Selective Reminding Test,31,35,161,193,"In 2 separate sessions, a single dose of scopolamine (0.5 mg, intravenously) or placebo was administered, and the effects on word recall were measured using the Buschke Selective Reminding Test over 2 hours.",11022397_11,-1,-1,2,1268,-1
1270,time points,6,8,32,43,OUTCOME MEASURES: Pupil size at time points after administration of tropicamide and pilocarpine; scopolamine-induced impairment in word recall.,11022397_12,-1,-1,2,1270,-1
1274,young volunteers,10,12,65,81,RESULTS: There was no significant difference between elderly and young volunteers in pupillary response to tropicamide at any time point (p > 0.05).,11022397_13,-1,-1,2,1274,-1
1277,time point,19,21,126,136,RESULTS: There was no significant difference between elderly and young volunteers in pupillary response to tropicamide at any time point (p > 0.05).,11022397_13,-1,-1,2,1277,-1
1278,elderly group,1,3,4,17,"The elderly group had a significantly greater pilocarpine-induced net decrease in pupil size 85, 125, 165 and 215 minutes after administration, compared with the young group (p < 0.05).",11022397_14,-1,-1,2,1278,-1
1279,pilocarpine-induced net decrease,7,10,46,78,"The elderly group had a significantly greater pilocarpine-induced net decrease in pupil size 85, 125, 165 and 215 minutes after administration, compared with the young group (p < 0.05).",11022397_14,-1,-1,2,1279,-1
1281,young group,27,29,162,173,"The elderly group had a significantly greater pilocarpine-induced net decrease in pupil size 85, 125, 165 and 215 minutes after administration, compared with the young group (p < 0.05).",11022397_14,-1,-1,2,1281,-1
1282,young group,3,5,18,29,"Compared with the young group, the elderly group had greater scopolamine-induced impairment in word recall 60, 90 and 120 minutes after administration (p < 0.05).",11022397_15,-1,-1,2,1282,-1
1283,elderly group,7,9,35,48,"Compared with the young group, the elderly group had greater scopolamine-induced impairment in word recall 60, 90 and 120 minutes after administration (p < 0.05).",11022397_15,-1,-1,2,1283,-1
1306,control subjects,13,15,84,100,"Results showed that MM individuals were significantly less tolerant of CP pain than control subjects, replicating previous work.",11027904_4,-1,-1,2,1306,-1
1308,pain-intolerant,9,10,55,70,These data indicate that MM opioid abusers represent a pain-intolerant subset of clinical patients.,11027904_6,-1,-1,2,1308,-1
1309,double-blind,17,18,107,119,"Analgesic effect of intravenous ketamine in cancer patients on morphine therapy: a randomized, controlled, double-blind, crossover, double-dose study.",11027905_0,-1,-1,2,1309,-1
1320,double-dose study,35,37,185,202,"A slow bolus of subhypnotic doses of ketamine (0.25 mg/kg or 0.50 mg/kg) was given to 10 cancer patients whose pain was unrelieved by morphine in a randomized, double-blind, crossover, double-dose study.",11027905_3,-1,-1,2,1320,-1
1322,numerical scale,7,9,28,43,"Pain intensity on a 0 to 10 numerical scale; nausea and vomiting, drowsiness, confusion, and dry mouth, using a scale from 0 to 3 (not at all, slight, a lot, awful); Mini-Mental State Examination (MMSE) (0-30); and arterial pressure were recorded before administration of drugs (T0) and after 30 minutes (T30), 60 minutes (T60), 120 minutes (T120), and 180 minutes (T180).",11027905_4,-1,-1,2,1322,-1
1325,Mini-Mental State Examination (MMSE),42,48,166,202,"Pain intensity on a 0 to 10 numerical scale; nausea and vomiting, drowsiness, confusion, and dry mouth, using a scale from 0 to 3 (not at all, slight, a lot, awful); Mini-Mental State Examination (MMSE) (0-30); and arterial pressure were recorded before administration of drugs (T0) and after 30 minutes (T30), 60 minutes (T60), 120 minutes (T120), and 180 minutes (T180).",11027905_4,-1,-1,2,1325,-1
1327,T0,64,65,279,281,"Pain intensity on a 0 to 10 numerical scale; nausea and vomiting, drowsiness, confusion, and dry mouth, using a scale from 0 to 3 (not at all, slight, a lot, awful); Mini-Mental State Examination (MMSE) (0-30); and arterial pressure were recorded before administration of drugs (T0) and after 30 minutes (T30), 60 minutes (T60), 120 minutes (T120), and 180 minutes (T180).",11027905_4,-1,-1,2,1327,-1
1328,T30,71,72,305,308,"Pain intensity on a 0 to 10 numerical scale; nausea and vomiting, drowsiness, confusion, and dry mouth, using a scale from 0 to 3 (not at all, slight, a lot, awful); Mini-Mental State Examination (MMSE) (0-30); and arterial pressure were recorded before administration of drugs (T0) and after 30 minutes (T30), 60 minutes (T60), 120 minutes (T120), and 180 minutes (T180).",11027905_4,-1,-1,2,1328,-1
1329,T60,77,78,323,326,"Pain intensity on a 0 to 10 numerical scale; nausea and vomiting, drowsiness, confusion, and dry mouth, using a scale from 0 to 3 (not at all, slight, a lot, awful); Mini-Mental State Examination (MMSE) (0-30); and arterial pressure were recorded before administration of drugs (T0) and after 30 minutes (T30), 60 minutes (T60), 120 minutes (T120), and 180 minutes (T180).",11027905_4,-1,-1,2,1329,-1
1331,T180,90,91,366,370,"Pain intensity on a 0 to 10 numerical scale; nausea and vomiting, drowsiness, confusion, and dry mouth, using a scale from 0 to 3 (not at all, slight, a lot, awful); Mini-Mental State Examination (MMSE) (0-30); and arterial pressure were recorded before administration of drugs (T0) and after 30 minutes (T30), 60 minutes (T60), 120 minutes (T120), and 180 minutes (T180).",11027905_4,-1,-1,2,1331,-1
1334,treated with,7,9,42,54,This effect was more relevant in patients treated with higher doses.,11027905_6,-1,-1,2,1334,-1
1336,treated with,8,10,62,74,Significant increases in drowsiness were reported in patients treated with ketamine in both groups and were more marked with ketamine 0.50 mg/kg.,11027905_9,-1,-1,2,1336,-1
1337,MMSE,4,5,28,32,A significant difference in MMSE was observed at T30 in patients who received 0.50 mg/kg of ketamine.,11027905_10,-1,-1,2,1337,-1
1338,T30,8,9,49,52,A significant difference in MMSE was observed at T30 in patients who received 0.50 mg/kg of ketamine.,11027905_10,-1,-1,2,1338,-1
1345,NASCIS,10,11,58,64,"Because of the National Acute Spinal Cord Injury Studies (NASCIS), high-dose methylprednisolone became the standard of care for the acute spinal cord injury.",11058428_1,-1,-1,2,1345,-1
1347,standard of care,17,20,107,123,"Because of the National Acute Spinal Cord Injury Studies (NASCIS), high-dose methylprednisolone became the standard of care for the acute spinal cord injury.",11058428_1,-1,-1,2,1347,-1
1357,NASCIS,13,14,91,97,"Further, steroid myopathy recovers naturally and the neurological improvement shown in the NASCIS may be just a recording of this natural motor recovery from the steroid myopathy, instead of any protection that methylprednisolone offers to the spinal cord injury.",11058428_5,-1,-1,2,1357,-1
1382,PTLD,34,35,179,183,"The indications for switch were chronic CsA or Tac nephrotoxicity (12), acute CsA or Tac toxicity (3), severe facial dysmorphism (2), posttransplant lymphoproliferative disorder (PTLD) in remission (2), and hepatotoxicity in 1.",11063349_4,-1,-1,2,1382,-1
1397,drug levels,7,9,42,53,"However, when converting patients to RAPA drug levels should be monitored to avoid over-immunosuppression and adequate antiviral and Pneumocystis carinii pneumonia prophylaxis should be given.",11063349_14,-1,-1,2,1397,-1
1413,Humphrey Visual Field Analyzer,11,15,66,96,METHODS: The central and peripheral fields were examined with the Humphrey Visual Field Analyzer.,11077455_4,-1,-1,2,1413,-1
1418,VERIS system,18,20,128,140,"Full visual electrophysiology, including flash electroretinography (ERG), pattern electroretinography, multifocal ERG using the VERIS system, electro-oculography, and flash and pattern visual evoked potentials, was undertaken.",11077455_5,-1,-1,2,1418,-1
1424,electrophysiological responses,1,3,5,35,Most electrophysiological responses were usually just within normal limits; two patients had subnormal Arden electro-oculography indices; and one patient showed an abnormally delayed photopic b wave.,11077455_8,-1,-1,2,1424,-1
1427,oscillatory potentials,16,18,95,117,"However, five patients showed delayed 30-Hz flicker b waves, and seven patients showed delayed oscillatory potentials.",11077455_9,-1,-1,2,1427,-1
1440,DSE,4,5,36,39,Dobutamine stress echocardiography (DSE) is a useful and safe provocation test for myocardial ischemia.,11078231_1,-1,-1,2,1440,-1
1441,provocation test,11,13,62,78,Dobutamine stress echocardiography (DSE) is a useful and safe provocation test for myocardial ischemia.,11078231_1,-1,-1,2,1441,-1
1449,DSE,2,3,13,16,We performed DSE on 51 patients with coronary spastic angina but without significant fixed coronary artery stenosis.,11078231_4,-1,-1,2,1449,-1
1456,intracoronary injection,5,7,30,53,"Coronary spasm was induced by intracoronary injection of acetylcholine, and no fixed coronary artery stenosis was documented on angiograms in all patients.",11078231_6,-1,-1,2,1456,-1
1458,DSE,0,1,0,3,"DSE was performed with intravenous dobutamine infusion with an incremental doses of 5, 10, 20, 30, and 40 microg/kg/min every 5 minutes.",11078231_7,-1,-1,2,1458,-1
1461,microg/kg/min,22,23,106,119,"DSE was performed with intravenous dobutamine infusion with an incremental doses of 5, 10, 20, 30, and 40 microg/kg/min every 5 minutes.",11078231_7,-1,-1,2,1461,-1
1469,DSE,1,2,5,8,"When DSE is performed to evaluate coronary artery disease, not only fixed coronary stenosis, but also coronary spasm should be considered as a genesis of asynergy.",11078231_11,-1,-1,2,1469,-1
1484,placebo-controlled trial,6,8,34,58,"DESIGN: Randomized, double-blind, placebo-controlled trial.",11079278_2,-1,-1,2,1484,-1
1487,stress tests,5,7,44,56,INTERVENTION: Patients underwent dobutamine stress tests per standard protocol.,11079278_5,-1,-1,2,1487,-1
1488,standard protocol,8,10,61,78,INTERVENTION: Patients underwent dobutamine stress tests per standard protocol.,11079278_5,-1,-1,2,1488,-1
1495,stress scores,14,16,81,94,"MEASUREMENTS AND MAIN RESULTS: Metoprolol reduced maximum heart rate 31%, summed stress scores 29%, and summed difference scores 43% versus control.",11079278_8,-1,-1,2,1495,-1
1504,functional somatotopy,2,4,12,33,Evidence of functional somatotopy in GPi from results of pallidotomy.,11099450_0,-1,-1,2,1504,-1
1512,timed tests,20,22,152,163,"We found significant positive correlations between the preoperative levodopa responsiveness of motor signs and the levodopa responsiveness of scores in timed tests (Core Assessment Program for Intracerebral Transplantations) in the contralateral limbs and the improvement in these scores after surgery, whereas there was no correlation with the improvement in LID.",11099450_2,-1,-1,2,1512,-1
1513,Core Assessment Program,23,26,165,188,"We found significant positive correlations between the preoperative levodopa responsiveness of motor signs and the levodopa responsiveness of scores in timed tests (Core Assessment Program for Intracerebral Transplantations) in the contralateral limbs and the improvement in these scores after surgery, whereas there was no correlation with the improvement in LID.",11099450_2,-1,-1,2,1513,-1
1521,differential predictive value,1,4,4,33,The differential predictive value of levodopa responsiveness for the outcome of parkinsonian 'off' signs and LID and the different correlations of ventral lesion volume with dyskinesias and parkinsonian 'off' signs indicate that different anatomical or pathophysiological substrates may be responsible for the generation of parkinsonian 'off' signs and dyskinesias.,11099450_5,-1,-1,2,1521,-1
1529,somatotopy,11,12,72,82,"We suggest that our observations are additional proof of the functional somatotopy of the systems within the GPi that mediate parkinsonism and dyskinesias, especially along the dorsoventral trajectory used in pallidotomy.",11099450_7,-1,-1,2,1529,-1
1544,NSCLC,18,19,133,138,BACKGROUND: Cisplatin-based chemotherapy combinations improve quality of life and survival in advanced nonsmall cell lung carcinoma (NSCLC).,11135224_1,-1,-1,2,1544,-1
1546,response rate,13,15,71,84,"METHODS: The objective of this study was to determine the feasibility, response rate, and toxicity of a paclitaxel, cisplatin, and gemcitabine combination to treat metastatic NSCLC.",11135224_3,-1,-1,2,1546,-1
1551,chemotherapy-naive,2,3,24,42,"Thirty-five consecutive chemotherapy-naive patients with Stage IV NSCLC and an Eastern Cooperative Oncology Group performance status of 0-2 were treated with a combination of paclitaxel (135 mg/m(2) given intravenously in 3 hours) on Day 1, cisplatin (120 mg/m(2) given intravenously in 6 hours) on Day 1, and gemcitabine (800 mg/m(2) given intravenously in 30 minutes) on Days 1 and 8, every 4 weeks.",11135224_4,-1,-1,2,1551,-1
1552,Stage IV,5,7,57,65,"Thirty-five consecutive chemotherapy-naive patients with Stage IV NSCLC and an Eastern Cooperative Oncology Group performance status of 0-2 were treated with a combination of paclitaxel (135 mg/m(2) given intravenously in 3 hours) on Day 1, cisplatin (120 mg/m(2) given intravenously in 6 hours) on Day 1, and gemcitabine (800 mg/m(2) given intravenously in 30 minutes) on Days 1 and 8, every 4 weeks.",11135224_4,-1,-1,2,1552,-1
1554,Eastern Cooperative Oncology Group,10,14,79,113,"Thirty-five consecutive chemotherapy-naive patients with Stage IV NSCLC and an Eastern Cooperative Oncology Group performance status of 0-2 were treated with a combination of paclitaxel (135 mg/m(2) given intravenously in 3 hours) on Day 1, cisplatin (120 mg/m(2) given intravenously in 6 hours) on Day 1, and gemcitabine (800 mg/m(2) given intravenously in 30 minutes) on Days 1 and 8, every 4 weeks.",11135224_4,-1,-1,2,1554,-1
1557,Day 1,38,40,234,239,"Thirty-five consecutive chemotherapy-naive patients with Stage IV NSCLC and an Eastern Cooperative Oncology Group performance status of 0-2 were treated with a combination of paclitaxel (135 mg/m(2) given intravenously in 3 hours) on Day 1, cisplatin (120 mg/m(2) given intravenously in 6 hours) on Day 1, and gemcitabine (800 mg/m(2) given intravenously in 30 minutes) on Days 1 and 8, every 4 weeks.",11135224_4,-1,-1,2,1557,-1
1559,Day 1,53,55,299,304,"Thirty-five consecutive chemotherapy-naive patients with Stage IV NSCLC and an Eastern Cooperative Oncology Group performance status of 0-2 were treated with a combination of paclitaxel (135 mg/m(2) given intravenously in 3 hours) on Day 1, cisplatin (120 mg/m(2) given intravenously in 6 hours) on Day 1, and gemcitabine (800 mg/m(2) given intravenously in 30 minutes) on Days 1 and 8, every 4 weeks.",11135224_4,-1,-1,2,1559,-1
1561,Days 1,69,71,373,379,"Thirty-five consecutive chemotherapy-naive patients with Stage IV NSCLC and an Eastern Cooperative Oncology Group performance status of 0-2 were treated with a combination of paclitaxel (135 mg/m(2) given intravenously in 3 hours) on Day 1, cisplatin (120 mg/m(2) given intravenously in 6 hours) on Day 1, and gemcitabine (800 mg/m(2) given intravenously in 30 minutes) on Days 1 and 8, every 4 weeks.",11135224_4,-1,-1,2,1561,-1
1565,examinable,12,13,62,72,RESULTS: All the patients were examined for toxicity; 34 were examinable for response.,11135224_6,-1,-1,2,1565,-1
1566,objective response,1,3,3,21,"An objective response was observed in 73.5% of the patients (95% confidence interval [CI], 55.6-87.1%), including 4 complete responses (11.7%).",11135224_7,-1,-1,2,1566,-1
1567,confidence interval,14,16,65,84,"An objective response was observed in 73.5% of the patients (95% confidence interval [CI], 55.6-87.1%), including 4 complete responses (11.7%).",11135224_7,-1,-1,2,1567,-1
1569,response rate,6,8,45,58,"According to intention-to-treat, the overall response rate was 71.4% (95% CI, 53. 7-85.4%).",11135224_8,-1,-1,2,1569,-1
1577,survival time,21,23,110,123,"After a median follow-up of 22 months, the median progression free survival rate was 7 months, and the median survival time was 16 months.",11135224_13,-1,-1,2,1577,-1
1581,NSCLC,20,21,127,132,"CONCLUSIONS: The combination of paclitaxel, cisplatin, and gemcitabine is well tolerated and shows high activity in metastatic NSCLC.",11135224_14,-1,-1,2,1581,-1
1596,secondary to,5,7,41,53,Animal studies suggest that incontinence secondary to serotonergic antidepressants could be mediated by the 5HT4 receptors found on the bladder.,11147747_6,-1,-1,2,1596,-1
1600,differential sensitivity,4,6,32,56,Acute cocaine-induced seizures: differential sensitivity of six inbred mouse strains.,11166519_0,-1,-1,2,1600,-1
1602,Seizure end points,0,3,0,18,"Seizure end points included latency to forelimb or hindlimb clonus, latency to clonic running seizure and latency to jumping bouncing seizure.",11166519_3,-1,-1,2,1602,-1
1603,A/J,9,10,61,64,A range of strain specific sensitivities was documented with A/J and SJL mice being most sensitive and C57BL/6J most resistant.,11166519_4,-1,-1,2,1603,-1
1604,SJL mice,11,13,69,77,A range of strain specific sensitivities was documented with A/J and SJL mice being most sensitive and C57BL/6J most resistant.,11166519_4,-1,-1,2,1604,-1
1605,DBA/2J,0,1,0,6,"DBA/2J, BALB/cByJ and NZW/LacJ strains exhibited intermediate sensitivity.",11166519_5,-1,-1,2,1605,-1
1606,BALB/cByJ,2,3,8,17,"DBA/2J, BALB/cByJ and NZW/LacJ strains exhibited intermediate sensitivity.",11166519_5,-1,-1,2,1606,-1
1607,SJL,5,6,28,31,"EEG recordings were made in SJL, A/J and C57BL/6J mice revealing a close correspondence between electrical activity and behavior.",11166519_6,-1,-1,2,1607,-1
1608,A/J,7,8,33,36,"EEG recordings were made in SJL, A/J and C57BL/6J mice revealing a close correspondence between electrical activity and behavior.",11166519_6,-1,-1,2,1608,-1
1611,prospective study,3,5,14,31,METHODS: This prospective study evaluated consecutive eligible seizure patients who had a plasma sample collected as part of their clinical evaluation.,11185967_2,-1,-1,2,1611,-1
1621,plasma samples,15,17,50,64,"RESULTS: Fourteen of 248 (5.6%, 95% CI 2.7%-8.5%) plasma samples were positive by immunoassay testing for benzoylecgonine and no samples (0%, 95% CI 0-1.2%) were positive for amphetamine.",11185967_6,-1,-1,2,1621,-1
1622,immunoassay testing,20,22,82,101,"RESULTS: Fourteen of 248 (5.6%, 95% CI 2.7%-8.5%) plasma samples were positive by immunoassay testing for benzoylecgonine and no samples (0%, 95% CI 0-1.2%) were positive for amphetamine.",11185967_6,-1,-1,2,1622,-1
1624,Positive test,0,2,0,13,Positive test results were more common in patient visits where there was a history or suspicion of cocaine or amphetamine abuse (p < 0.0005).,11185967_7,-1,-1,2,1624,-1
1644,treated with,9,11,64,76,Hypotension following the initiation of tizanidine in a patient treated with an angiotensin converting enzyme inhibitor for chronic hypertension.,11198499_0,-1,-1,2,1644,-1
1651,adverse cardiorespiratory effects,9,12,52,85,"In addition to their effects on spasticity, certain adverse cardiorespiratory effects have been reported.",11198499_2,-1,-1,2,1651,-1
1652,treated with,2,4,19,31,Adults chronically treated with angiotensin converting enzyme inhibitors may have a limited ability to respond to hypotension when the sympathetic response is simultaneously blocked.,11198499_3,-1,-1,2,1652,-1
1655,treated with,7,9,50,62,"The authors present a 10-year-old boy chronically treated with lisinopril, an angiotensin converting enzyme inhibitor, to control hypertension who developed hypotension following the addition of tizanidine, an alpha-2 agonist, for the treatment of spasticity.",11198499_4,-1,-1,2,1655,-1
1663,mouse lines,1,3,4,15,Two mouse lines selected for differential sensitivities to beta-carboline-induced seizures are also differentially sensitive to various pharmacological effects of other GABA(A) receptor ligands.,11206082_0,-1,-1,2,1663,-1
1664,differential sensitivities,5,7,29,55,Two mouse lines selected for differential sensitivities to beta-carboline-induced seizures are also differentially sensitive to various pharmacological effects of other GABA(A) receptor ligands.,11206082_0,-1,-1,2,1664,-1
1668,mouse lines,1,3,4,15,Two mouse lines were selectively bred according to their sensitivity (BS line) or resistance (BR line) to seizures induced by a single i.p.,11206082_1,-1,-1,2,1668,-1
1677,plus-maze test,7,9,58,72,"We measured diazepam-induced anxiolysis with the elevated plus-maze test, diazepam-induced sedation by recording the vigilance states, and picrotoxin- and pentylenetetrazol-induced seizures after i.p. injections.",11206082_4,-1,-1,2,1677,-1
1679,vigilance states,15,17,117,133,"We measured diazepam-induced anxiolysis with the elevated plus-maze test, diazepam-induced sedation by recording the vigilance states, and picrotoxin- and pentylenetetrazol-induced seizures after i.p. injections.",11206082_4,-1,-1,2,1679,-1
1680,i.p. injections,24,27,196,211,"We measured diazepam-induced anxiolysis with the elevated plus-maze test, diazepam-induced sedation by recording the vigilance states, and picrotoxin- and pentylenetetrazol-induced seizures after i.p. injections.",11206082_4,-1,-1,2,1680,-1
1681,differential sensitivities,6,8,37,63,"Results presented here show that the differential sensitivities of BS and BR lines to beta-CCM can be extended to diazepam, picrotoxin, and pentylenetetrazol, suggesting a genetic selection of a general sensitivity and resistance to several ligands of the GABA(A) receptor.",11206082_5,-1,-1,2,1681,-1
1690,experimental model,14,16,72,90,We have studied the role of NO and its association with apoptosis in an experimental model of nephrotic syndrome induced by a single injection of adriamycin (ADR).,11208990_2,-1,-1,2,1690,-1
1694,NO pathway,6,8,31,41,METHODS: The alteration in the NO pathway was assessed by measuring nitrite levels in serum/urine and by evaluating the changes in vascular reactivity of the isolated perfused rat kidney (IPRK) system.,11208990_3,-1,-1,2,1694,-1
1695,serum/urine,15,16,86,97,METHODS: The alteration in the NO pathway was assessed by measuring nitrite levels in serum/urine and by evaluating the changes in vascular reactivity of the isolated perfused rat kidney (IPRK) system.,11208990_3,-1,-1,2,1695,-1
1697,control groups,4,6,26,40,Rats were stratified into control groups and ADR-induced nephropathy groups.,11208990_4,-1,-1,2,1697,-1
1699,group 1,8,10,41,48,"These two groups were then divided into: group 1, animals receiving saline; and group 2, animals receiving aminoguanidine (AG) which is a specific inhibitor of inducible-NO synthase.",11208990_5,-1,-1,2,1699,-1
1700,group 2,16,18,80,87,"These two groups were then divided into: group 1, animals receiving saline; and group 2, animals receiving aminoguanidine (AG) which is a specific inhibitor of inducible-NO synthase.",11208990_5,-1,-1,2,1700,-1
1703,biochemical analysis,11,13,61,81,"On day 21, rats were sacrificed after obtaining material for biochemical analysis.",11208990_6,-1,-1,2,1703,-1
1707,focal areas,13,15,88,99,RESULTS: Histopathological examination of the kidneys of rats treated with ADR revealed focal areas of mesangial proliferation and mild tubulointerstitial inflammation.,11208990_7,-1,-1,2,1707,-1
1710,treatment groups,12,14,83,99,They also had significantly higher levels of proteinuria compared with control and treatment groups (P < 0.05).,11208990_8,-1,-1,2,1710,-1
1714,ADR-nephropathy,4,5,16,31,"However, in the ADR-nephropathy group, numerous apoptotic cells were identified in the tubulointerstitial areas.",11208990_12,-1,-1,2,1714,-1
1717,Double staining,0,2,0,15,"Double staining revealed numerous interstitial apoptotic cells to stain for ED1, a marker for monocytes/macrophages.",11208990_13,-1,-1,2,1717,-1
1731,dose-effect,13,14,84,95,"Melatonin pre-treatment affected in a dual manner barbiturate narcosis, however, no dose-effect correlation was found.",11226639_3,-1,-1,2,1731,-1
1734,paradoxical increase,14,16,63,83,"In contrast, the highest dose of melatonin (50 mg/kg) caused a paradoxical increase in the latency and produced a sustained reduction of the duration of narcosis, and a reduction in mortality rate.",11226639_5,-1,-1,2,1734,-1
1738,dual action,3,5,10,21,"Thus, the dual action of melatonin on pharmacological narcosis seems to be specific for the barbiturate mechanism of action.",11226639_7,-1,-1,2,1738,-1
1740,mechanism of action,17,20,104,123,"Thus, the dual action of melatonin on pharmacological narcosis seems to be specific for the barbiturate mechanism of action.",11226639_7,-1,-1,2,1740,-1
1745,multicenter trial,21,23,191,208,"Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer.",11230490_0,-1,-1,2,1745,-1
1747,Myocet,5,6,30,36,"PURPOSE: To determine whether Myocet (liposome-encapsulated doxorubicin; The Liposome Company, Elan Corporation, Princeton, NJ) in combination with cyclophosphamide significantly reduces doxorubicin cardiotoxicity while providing comparable antitumor efficacy in first-line treatment of metastatic breast cancer (MBC).",11230490_1,-1,-1,2,1747,-1
1749,Elan Corporation,14,16,95,111,"PURPOSE: To determine whether Myocet (liposome-encapsulated doxorubicin; The Liposome Company, Elan Corporation, Princeton, NJ) in combination with cyclophosphamide significantly reduces doxorubicin cardiotoxicity while providing comparable antitumor efficacy in first-line treatment of metastatic breast cancer (MBC).",11230490_1,-1,-1,2,1749,-1
1766,World Health Organization criteria,10,14,67,101,"Antitumor efficacy was assessed by objective tumor response rates (World Health Organization criteria), time to progression, and survival.",11230490_4,-1,-1,2,1766,-1
1768,CHF,15,16,72,75,RESULTS: Six percent of MC patients versus 21% (including five cases of CHF) of AC patients developed cardiotoxicity (P =.0002).,11230490_5,-1,-1,2,1768,-1
1770,hazard ratio,25,27,116,128,"Median cumulative doxorubicin dose at onset was more than 2,220 mg/m(2) for MC versus 480 mg/m(2) for AC (P =.0001, hazard ratio, 5.04).",11230490_6,-1,-1,2,1770,-1
1771,response rates,10,12,61,75,"Antitumor efficacy of MC versus AC was comparable: objective response rates, 43% versus 43%; median time to progression, 5.1% versus 5.5 months; median time to treatment failure, 4.6 versus 4.4 months; and median survival, 19 versus 16 months.",11230490_8,-1,-1,2,1771,-1
1774,Myocet,2,3,12,18,"CONCLUSION: Myocet improves the therapeutic index of doxorubicin by significantly reducing cardiotoxicity and grade 4 neutropenia and provides comparable antitumor efficacy, when used in combination with cyclophosphamide as first-line therapy for MBC.",11230490_9,-1,-1,2,1774,-1
1794,anemia-induced reduction,3,5,28,52,Erythropoietin restores the anemia-induced reduction in cyclophosphamide cytotoxicity in rat tumors.,11245434_0,-1,-1,2,1794,-1
1801,long-lasting reduction,18,20,85,107,Anemia was induced using a single dose of carboplatin (50 mg/kg i.v.) resulting in a long-lasting reduction (30%) of the hemoglobin concentration.,11245434_2,-1,-1,2,1801,-1
1806,DS-sarcoma,8,9,47,57,"Four days after carboplatin treatment, tumors (DS-sarcoma of the rat) were implanted s.c. onto the hind food dorsum.",11245434_5,-1,-1,2,1806,-1
1809,rHuEPO treatment,3,5,24,40,Neither carboplatin nor rHuEPO treatment influenced tumor growth rate per se.,11245434_6,-1,-1,2,1809,-1
1810,treated with,3,5,17,29,"When tumors were treated with a single dose of cyclophosphamide (60 mg/kg i.p.) 5 days after implantation, a growth delay with a subsequent regrowth of the tumors was observed.",11245434_7,-1,-1,2,1810,-1
1829,treated with,13,15,74,86,"METHODS: We present the first case report of a woman with hyperthyroidism treated with propylthiouracil in whom a syndrome of pericarditis, fever, and glomerulonephritis developed.",11250767_2,-1,-1,2,1829,-1
1831,immunologic studies,3,5,22,41,"Serologic testing and immunologic studies were done, and a pericardial biopsy was performed.",11250767_3,-1,-1,2,1831,-1
1837,MPO,16,17,142,145,Serologic evaluation revealed the presence of perinuclear-staining antineutrophil cytoplasmic autoantibodies (pANCA) against myeloperoxidase (MPO).,11250767_5,-1,-1,2,1837,-1
1839,treated with,8,10,52,64,"Propylthiouracil therapy was withdrawn, and she was treated with a 1-month course of prednisone, which alleviated her symptoms.",11250767_6,-1,-1,2,1839,-1
1843,associated with,13,15,100,115,A literature review revealed no prior reports of pericarditis in anti-MPO pANCA-positive vasculitis associated with propylthio- uracil therapy.,11250767_7,-1,-1,2,1843,-1
1871,glomerular filtration pressure,16,19,104,134,"Under such conditions, angiotensin II receptor blockade by losartan probably induced a critical fall in glomerular filtration pressure.",11256525_9,-1,-1,2,1871,-1
1904,secondary to,3,5,31,43,Fatal haemorrhagic myocarditis secondary to cyclophosphamide therapy.,11271907_0,-1,-1,2,1904,-1
1908,ultrasound features,4,6,20,39,We believe that the ultrasound features of this disorder have not been previously reported.,11271907_3,-1,-1,2,1908,-1
1923,treated with,31,33,206,218,We measured the plasma level of brain natriuretic peptide (BNP) to determine whether BNP might serve as a simple diagnostic indicator of anthracycline-induced cardiotoxicity in patients with acute leukemia treated with a daunorubicin (DNR)-containing regimen.,11279304_3,-1,-1,2,1923,-1
1926,treated with,6,8,43,55,Thirteen patients with acute leukemia were treated with a DNR-containing regimen.,11279304_4,-1,-1,2,1926,-1
1938,normal limit,18,20,109,121,The plasma levels of BNP in all the patients with clinical and subclinical heart failure increased above the normal limit (40 pg/ml) before the detection of clinical or subclinical heart failure by radionuclide angiography.,11279304_9,-1,-1,2,1938,-1
1941,BNP,5,6,19,22,"On the other hand, BNP did not increase in the patients without heart failure given DNR, even at more than 700 mg/m(2).",11279304_10,-1,-1,2,1941,-1
1946,BNP,5,6,39,42,These preliminary results suggest that BNP may be useful as an early and sensitive indicator of anthracycline-induced cardiotoxicity.,11279304_12,-1,-1,2,1946,-1
1948,Effects of,0,2,0,10,Effects of verapamil on atrial fibrillation and its electrophysiological determinants in dogs.,11282081_0,-1,-1,2,1948,-1
1950,electrophysiological determinants,8,10,52,85,Effects of verapamil on atrial fibrillation and its electrophysiological determinants in dogs.,11282081_0,-1,-1,2,1950,-1
1953,AF,14,15,114,116,BACKGROUND: Atrial tachycardia-induced remodeling promotes the occurrence and maintenance of atrial fibrillation (AF) and decreases L-type Ca(2+) current.,11282081_1,-1,-1,2,1953,-1
1955,clinical suggestion,4,6,16,35,"There is also a clinical suggestion that acute L-type Ca(2) channel blockade can promote AF, consistent with an AF promoting effect of Ca(2+) channel inhibition.",11282081_2,-1,-1,2,1955,-1
1958,consistent with,17,19,93,108,"There is also a clinical suggestion that acute L-type Ca(2) channel blockade can promote AF, consistent with an AF promoting effect of Ca(2+) channel inhibition.",11282081_2,-1,-1,2,1958,-1
1966,epicardial electrodes,4,6,28,49,Epicardial mapping with 240 epicardial electrodes was used to evaluate activation during AF.,11282081_5,-1,-1,2,1966,-1
1967,AF,12,13,89,91,Epicardial mapping with 240 epicardial electrodes was used to evaluate activation during AF.,11282081_5,-1,-1,2,1967,-1
1969,mean duration,11,13,63,76,"RESULTS: Verapamil caused AF promotion in six dogs, increasing mean duration of AF induced by burst pacing, from 8+/-4 s (mean+/-S.E.) to 95+/-39 s (P<0.01 vs. control) at a loading dose of 0.1 mg/kg and 228+/-101 s (P<0.0005 vs. control) at a dose of 0.2 mg/kg.",11282081_6,-1,-1,2,1969,-1
1975,control conditions,12,14,96,114,Underlying electrophysiological mechanisms were studied in detail in five additional dogs under control conditions and in the presence of the higher dose of verapamil.,11282081_7,-1,-1,2,1975,-1
1976,refractory period,8,10,57,74,"In these experiments, verapamil shortened mean effective refractory period (ERP) from 122+/-5 to 114+/-4 ms (P<0.02) at a cycle length of 300 ms, decreased ERP heterogeneity (from 15+/-1 to 10+/-1%, P<0.05), heterogeneously accelerated atrial conduction and decreased the cycle length of AF (94+/-4 to 84+/-3 ms, P<0.005).",11282081_8,-1,-1,2,1976,-1
1977,ERP,11,12,76,79,"In these experiments, verapamil shortened mean effective refractory period (ERP) from 122+/-5 to 114+/-4 ms (P<0.02) at a cycle length of 300 ms, decreased ERP heterogeneity (from 15+/-1 to 10+/-1%, P<0.05), heterogeneously accelerated atrial conduction and decreased the cycle length of AF (94+/-4 to 84+/-3 ms, P<0.005).",11282081_8,-1,-1,2,1977,-1
1979,ERP,30,31,156,159,"In these experiments, verapamil shortened mean effective refractory period (ERP) from 122+/-5 to 114+/-4 ms (P<0.02) at a cycle length of 300 ms, decreased ERP heterogeneity (from 15+/-1 to 10+/-1%, P<0.05), heterogeneously accelerated atrial conduction and decreased the cycle length of AF (94+/-4 to 84+/-3 ms, P<0.005).",11282081_8,-1,-1,2,1979,-1
1982,cycle length of AF,49,53,272,290,"In these experiments, verapamil shortened mean effective refractory period (ERP) from 122+/-5 to 114+/-4 ms (P<0.02) at a cycle length of 300 ms, decreased ERP heterogeneity (from 15+/-1 to 10+/-1%, P<0.05), heterogeneously accelerated atrial conduction and decreased the cycle length of AF (94+/-4 to 84+/-3 ms, P<0.005).",11282081_8,-1,-1,2,1982,-1
1983,ERP,4,5,25,28,"Diltiazem did not affect ERP, AF cycle length or AF duration, but produced conduction acceleration similar to that caused by verapamil (n=5).",11282081_9,-1,-1,2,1983,-1
2000,associated with,17,19,89,104,It has been proposed that nitric oxide (NO) induced headache in primary headaches may be associated with release of calcitonin gene-related peptide (CGRP).,11284996_1,-1,-1,2,2000,-1
2007,healthy controls,33,35,190,206,In the present study we aimed to investigate plasma levels of CGRP during headache induced by the NO donor glyceryl trinitrate (GTN) in 16 patients with chronic tension-type headache and 16 healthy controls.,11284996_2,-1,-1,2,2007,-1
2010,Blood samples,0,2,0,13,"Blood samples were collected at baseline, 10, 20 and 60 min after start of infusion.",11284996_4,-1,-1,2,2010,-1
2012,area under,6,8,36,46,There was no difference between the area under the CGRP curve (AUCCGRP) on GTN vs. placebo day in either patients (P=0.65) or controls (P=0.48).,11284996_6,-1,-1,2,2012,-1
2017,GTN,5,6,28,31,The AUCCGRP recorded on the GTN day did not differ between patients and controls (P=0.36).,11284996_7,-1,-1,2,2017,-1
2021,associated with,10,12,70,85,The present study indicates that NO-induced immediate headache is not associated with release of CGRP.,11284996_9,-1,-1,2,2021,-1
2023,torsade de pointes,1,4,20,38,Fluconazole-induced torsade de pointes.,11302406_0,-1,-1,2,2023,-1
2024,torsade de pointes,8,11,55,73,OBJECTIVE: To present a case of fluconazole-associated torsade de pointes (TDP) and discuss fluconazole's role in causing TDP.,11302406_1,-1,-1,2,2024,-1
2027,TDP,21,22,122,125,OBJECTIVE: To present a case of fluconazole-associated torsade de pointes (TDP) and discuss fluconazole's role in causing TDP.,11302406_1,-1,-1,2,2027,-1
2029,white woman,5,7,28,39,"CASE SUMMARY: A 68-year-old white woman with Candida glabrata isolated from a presacral abscess developed TDP eight days after commencing oral fluconazole The patient had no other risk factors for TDP, including coronary artery disease, cardiomyopathy, congestive heart failure, and electrolyte abnormalities There was a temporal association between the initiation of fluconazole and TDP.",11302406_2,-1,-1,2,2029,-1
2033,risk factors,28,30,180,192,"CASE SUMMARY: A 68-year-old white woman with Candida glabrata isolated from a presacral abscess developed TDP eight days after commencing oral fluconazole The patient had no other risk factors for TDP, including coronary artery disease, cardiomyopathy, congestive heart failure, and electrolyte abnormalities There was a temporal association between the initiation of fluconazole and TDP.",11302406_2,-1,-1,2,2033,-1
2044,NSVT,23,24,168,172,"The TDP resolved when fluconazole was discontinued; however, the patient continued to have premature ventricular contractions and nonsustained ventricular tachycardia (NSVT) until six days after drug cessation DISCUSSION: Use of the Naranjo probability scale indicates a probable relationship between the use of fluconazole and the development of TDP.",11302406_3,-1,-1,2,2044,-1
2050,QT,13,14,74,76,"In our patient, there was no other etiology identified that could explain QT prolongation or TDP The complete disappearance of NSVT and premature ventricular contractions followed by normalization of QT interval after the drug was stopped strongly suggests fluconazole as the etiology.",11302406_5,-1,-1,2,2050,-1
2052,NSVT,21,22,127,131,"In our patient, there was no other etiology identified that could explain QT prolongation or TDP The complete disappearance of NSVT and premature ventricular contractions followed by normalization of QT interval after the drug was stopped strongly suggests fluconazole as the etiology.",11302406_5,-1,-1,2,2052,-1
2058,QT interval,19,21,107,118,"CONCLUSIONS: Clinicians should be aware that fluconazole, even at low doses, may cause prolongation of the QT interval, leading to TDP.",11302406_6,-1,-1,2,2058,-1
2059,TDP,24,25,131,134,"CONCLUSIONS: Clinicians should be aware that fluconazole, even at low doses, may cause prolongation of the QT interval, leading to TDP.",11302406_6,-1,-1,2,2059,-1
2073,In vivo,0,2,0,7,"In vivo protection of dna damage associated apoptotic and necrotic cell deaths during acetaminophen-induced nephrotoxicity, amiodarone-induced lung toxicity and doxorubicin-induced cardiotoxicity by a novel IH636 grape seed proanthocyanidin extract.",11334364_0,-1,-1,2,2073,-1
2080,IH636 grape,25,27,207,218,"In vivo protection of dna damage associated apoptotic and necrotic cell deaths during acetaminophen-induced nephrotoxicity, amiodarone-induced lung toxicity and doxorubicin-induced cardiotoxicity by a novel IH636 grape seed proanthocyanidin extract.",11334364_0,-1,-1,2,2080,-1
2082,seed extract,1,3,6,18,"Grape seed extract, primarily a mixture of proanthocyanidins, has been shown to modulate a wide-range of biological, pharmacological and toxicological effects which are mainly cytoprotective.",11334364_1,-1,-1,2,2082,-1
2084,toxicological effects,22,24,137,158,"Grape seed extract, primarily a mixture of proanthocyanidins, has been shown to modulate a wide-range of biological, pharmacological and toxicological effects which are mainly cytoprotective.",11334364_1,-1,-1,2,2084,-1
2102,mg/Kg/day,18,19,75,84,injections of organ specific three drugs (AAP: 500 mg/Kg for 24 h; AMI: 50 mg/Kg/day for four days; DOX: 20 mg/Kg for 48 h).,11334364_5,-1,-1,2,2102,-1
2104,serum chemistry,6,8,41,56,"Parameters of study included analysis of serum chemistry (ALT, BUN and CPK), and orderly fragmentation of genomic DNA (both endonuclease-dependent and independent) in addition to microscopic evaluation of damage and/or protection in corresponding PAS stained tissues.",11334364_6,-1,-1,2,2104,-1
2108,endonuclease-dependent,24,25,124,146,"Parameters of study included analysis of serum chemistry (ALT, BUN and CPK), and orderly fragmentation of genomic DNA (both endonuclease-dependent and independent) in addition to microscopic evaluation of damage and/or protection in corresponding PAS stained tissues.",11334364_6,-1,-1,2,2108,-1
2110,GSPE preexposure,3,5,22,38,"Results indicate that GSPE preexposure prior to AAP, AMI and DOX, provided near complete protection in terms of serum chemistry changes (ALT, BUN and CPK), and significantly reduced DNA fragmentation.",11334364_7,-1,-1,2,2110,-1
2118,GSPE preexposure,30,32,193,209,"Histopathological examination of kidney, heart and lung sections revealed moderate to massive tissue damage with a variety of morphological aberrations by all the three drugs in the absence of GSPE preexposure than in its presence.",11334364_8,-1,-1,2,2118,-1
2130,biotransformation,7,8,31,48,"Since AAP, AMI and DOX undergo biotransformation and are known to produce damaging radicals in vivo, the protection by GSPE may be linked to both inhibition of metabolism and/or detoxification of cytotoxic radicals.",11334364_12,-1,-1,2,2130,-1
2132,in vivo,15,17,92,99,"Since AAP, AMI and DOX undergo biotransformation and are known to produce damaging radicals in vivo, the protection by GSPE may be linked to both inhibition of metabolism and/or detoxification of cytotoxic radicals.",11334364_12,-1,-1,2,2132,-1
2137,apoptotic death,11,13,65,80,"Additionally, this may have been the first report on AMI-induced apoptotic death in the lung tissue.",11334364_14,-1,-1,2,2137,-1
2142,in vivo,31,33,219,226,"Taken together, these events undoubtedly establish GSPE's abundant bioavailability, and the power to defend multiple target organs from toxic assaults induced by structurally diverse and functionally different entities in vivo.",11334364_15,-1,-1,2,2142,-1
2144,associated with,3,5,38,53,Cutaneous leucocytoclastic vasculitis associated with oxacillin.,11337188_0,-1,-1,2,2144,-1
2145,treated with,5,7,26,38,"A 67-year-old man who was treated with oxacillin for one week because of Staphylococcus aureus bacteremia, developed renal failure and diffuse, symmetric, palpable purpuric lesions on his feet.",11337188_1,-1,-1,2,2145,-1
2151,treated with,6,8,43,55,Oxacillin was discontinued and patient was treated with corticosteroids.,11337188_4,-1,-1,2,2151,-1
2157,Etiologic factors,0,2,0,17,"Etiologic factors or associated disorders include infections, medications, collagen vascular disease and neoplasia.",11337188_7,-1,-1,2,2157,-1
2160,etiologic factor,8,10,33,49,"However, in half of the cases no etiologic factor is identified.",11337188_8,-1,-1,2,2160,-1
2162,corticosteroid therapy,8,10,43,65,"Usually it is a self-limited disorder, but corticosteroid therapy may be needed in life-threatening cases since early treatment with corticosteroids in severe cases can prevent complications.",11337188_9,-1,-1,2,2162,-1
2165,risk factors,8,10,68,80,Antidepressant-induced mania in bipolar patients: identification of risk factors.,11379838_0,-1,-1,2,2165,-1
2166,associated with,10,12,64,79,BACKGROUND: Concerns about possible risks of switching to mania associated with antidepressants continue to interfere with the establishment of an optimal treatment paradigm for bipolar depression.,11379838_1,-1,-1,2,2166,-1
2167,interfere with,15,17,108,122,BACKGROUND: Concerns about possible risks of switching to mania associated with antidepressants continue to interfere with the establishment of an optimal treatment paradigm for bipolar depression.,11379838_1,-1,-1,2,2167,-1
2169,DSM-IV criteria,8,10,44,59,METHOD: The response of 44 patients meeting DSM-IV criteria for bipolar disorder to naturalistic treatment was assessed for at least 6 weeks using the Montgomery-Asberg Depression Rating Scale and the Bech-Rafaelson Mania Rating Scale.,11379838_2,-1,-1,2,2169,-1
2172,Montgomery-Asberg,25,26,151,168,METHOD: The response of 44 patients meeting DSM-IV criteria for bipolar disorder to naturalistic treatment was assessed for at least 6 weeks using the Montgomery-Asberg Depression Rating Scale and the Bech-Rafaelson Mania Rating Scale.,11379838_2,-1,-1,2,2172,-1
2185,treated with,29,31,121,133,"RESULTS: Switches to hypomania or mania occurred in 27% of all patients (N = 12) (and in 24% of the subgroup of patients treated with SSRIs [8/33]); 16% (N = 7) experienced manic episodes, and 11% (N = 5) experienced hypomanic episodes.",11379838_4,-1,-1,2,2185,-1
2188,bipolar I,6,8,21,30,"Sex, age, diagnosis (bipolar I vs. bipolar II), and additional treatment did not affect the risk of switching.",11379838_5,-1,-1,2,2188,-1
2189,bipolar II,9,11,35,45,"Sex, age, diagnosis (bipolar I vs. bipolar II), and additional treatment did not affect the risk of switching.",11379838_5,-1,-1,2,2189,-1
2193,treated with,22,24,109,121,"In contrast, mood switches were less frequent in patients receiving lithium (15%, 4/26) than in patients not treated with lithium (44%, 8/18; p = .04).",11379838_7,-1,-1,2,2193,-1
2197,associated with,29,31,191,206,"The number of previous manic episodes did not affect the probability of switching, whereas a high score on the hyperthymia component of the Semistructured Affective Temperament Interview was associated with a greater risk of switching (p = .008).",11379838_8,-1,-1,2,2197,-1
2199,associated with,7,9,44,59,CONCLUSION: The frequency of mood switching associated with acute antidepressant therapy may be reduced by lithium treatment.,11379838_9,-1,-1,2,2199,-1
2207,TG,11,12,77,79,BACKGROUND: An association has been found between transplant glomerulopathy (TG) and reduplication of peritubular capillary basement membranes (PTCR).,11391224_1,-1,-1,2,2207,-1
2208,peritubular capillary basement membranes,16,20,102,142,BACKGROUND: An association has been found between transplant glomerulopathy (TG) and reduplication of peritubular capillary basement membranes (PTCR).,11391224_1,-1,-1,2,2208,-1
2209,PTCR,21,22,144,148,BACKGROUND: An association has been found between transplant glomerulopathy (TG) and reduplication of peritubular capillary basement membranes (PTCR).,11391224_1,-1,-1,2,2209,-1
2210,prospective study,13,15,82,99,"Although such an association is of practical and theoretical importance, only one prospective study has tried to confirm it.",11391224_2,-1,-1,2,2210,-1
2215,TG,6,7,37,39,"In addition to renal allografts with TG, we also examined grafts with acute rejection, recurrent glomerulonephritis, chronic allograft nephropathy and stable grafts (""protocol biopsies"").",11391224_4,-1,-1,2,2215,-1
2225,PTCR,4,5,18,22,"RESULTS: We found PTCR in 14 of 15 cases of TG, in 7 transplant biopsy specimens without TG, and in 13 of 143 native kidney biopsy specimens.",11391224_6,-1,-1,2,2225,-1
2228,TG,19,20,89,91,"RESULTS: We found PTCR in 14 of 15 cases of TG, in 7 transplant biopsy specimens without TG, and in 13 of 143 native kidney biopsy specimens.",11391224_6,-1,-1,2,2228,-1
2236,TG,5,6,32,34,Mild PTCR in allografts without TG did not predict renal failure or significant proteinuria after follow-up periods of between 3 months and 1 year.,11391224_8,-1,-1,2,2236,-1
2238,significant proteinuria,12,14,68,91,Mild PTCR in allografts without TG did not predict renal failure or significant proteinuria after follow-up periods of between 3 months and 1 year.,11391224_8,-1,-1,2,2238,-1
2241,PTCR,24,25,143,147,"CONCLUSIONS: We conclude that in transplants, there is a strong association between well-developed PTCR and TG, while the significance of mild PTCR and its predictive value in the absence of TG is unclear.",11391224_9,-1,-1,2,2241,-1
2242,predictive value,27,29,156,172,"CONCLUSIONS: We conclude that in transplants, there is a strong association between well-developed PTCR and TG, while the significance of mild PTCR and its predictive value in the absence of TG is unclear.",11391224_9,-1,-1,2,2242,-1
2243,TG,33,34,191,193,"CONCLUSIONS: We conclude that in transplants, there is a strong association between well-developed PTCR and TG, while the significance of mild PTCR and its predictive value in the absence of TG is unclear.",11391224_9,-1,-1,2,2243,-1
2246,TG,19,20,104,106,"PTCR also occurs in certain native kidney diseases, though the association is not as strong as that for TG.",11391224_10,-1,-1,2,2246,-1
2252,cells lining,9,11,60,72,At necropsy microscopy shoed unique and extensive damage to cells lining the distal nephron.,1141447_2,-1,-1,2,2252,-1
2259,natural energy,19,21,142,156,"We describe a 25-year-old woman with pre-existing mitral valve prolapse who developed intractable ventricular fibrillation after consuming a ""natural energy"" guarana health drink containing a high concentration of caffeine.",11419773_1,-1,-1,2,2259,-1
2266,Cocaine's,0,2,0,9,Cocaine's ability to interact with sigma receptors suggests that these proteins mediate some of its behavioral effects.,11426838_1,-1,-1,2,2266,-1
2268,behavioral effects,16,18,100,118,Cocaine's ability to interact with sigma receptors suggests that these proteins mediate some of its behavioral effects.,11426838_1,-1,-1,2,2268,-1
2270,Swiss Webster mice,13,16,89,107,"Therefore, three novel sigma receptor ligands with antagonist activity were evaluated in Swiss Webster mice: BD1018 (3S-1-[2-(3,4-dichlorophenyl)ethyl]-1,4-diazabicyclo[4.3.0]nonane), BD1063 (1-[2-(3,4-dichlorophenyl)ethyl]-4-methylpiperazine), and LR132 (1R,2S-(+)-cis-N-[2-(3,4-dichlorophenyl)ethyl]-2-(1-pyrrolidinyl)cyclohexylamine).",11426838_2,-1,-1,2,2270,-1
2283,Competition binding assays,0,3,0,26,Competition binding assays demonstrated that all three compounds have high affinities for sigma1 receptors.,11426838_3,-1,-1,2,2283,-1
2302,no significant,7,9,36,50,"At doses where alone, they produced no significant effects on locomotion, BD1018, BD1063 and LR132 significantly attenuated the locomotor stimulatory effects of cocaine.",11426838_8,-1,-1,2,2302,-1
2318,associated with,5,7,32,47,This drug occasionally has been associated with acute interstitial nephritis in native kidneys.,11431197_2,-1,-1,2,2318,-1
2323,exposure to,26,28,177,188,We report a case of ranitidine-induced acute interstitial nephritis in a recipient of a cadaveric renal allograft presenting with acute allograft dysfunction within 48 hours of exposure to the drug.,11431197_4,-1,-1,2,2323,-1
2325,pathognomonic features,4,6,27,49,"The biopsy specimen showed pathognomonic features, including eosinophilic infiltration of the interstitial compartment.",11431197_5,-1,-1,2,2325,-1
2328,associated with,2,4,21,36,Cholestatic jaundice associated with the use of metformin.,11467664_0,-1,-1,2,2328,-1
2331,abdominal CT,5,7,28,40,Ultrasound of the liver and abdominal CT were normal.,11467664_2,-1,-1,2,2331,-1
2357,resuscitation sequence,11,13,60,82,"When asystole was recorded, drug infusion was stopped and a resuscitation sequence was begun.",11524350_6,-1,-1,2,2357,-1
2380,pharmacological profile,16,18,100,123,"The underlying mechanism of withdrawal-emergent RS in the present case may have been related to the pharmacological profile of risperidone, a serotonin-dopamine antagonist, suggesting the pathophysiologic influence of the serotonin system in the development of RS.",11532387_5,-1,-1,2,2380,-1
2384,Pharmacokinetic/pharmacodynamic assessment,0,2,0,42,"Pharmacokinetic/pharmacodynamic assessment of the effects of E4031, cisapride, terfenadine and terodiline on monophasic action potential duration in dog.1.",11569530_0,-1,-1,2,2384,-1
2392,TDP,4,5,21,24,Torsades de pointes (TDP) is a potentially fatal ventricular tachycardia associated with increases in QT interval and monophasic action potential duration (MAPD).,11569530_1,-1,-1,2,2392,-1
2394,associated with,12,14,73,88,Torsades de pointes (TDP) is a potentially fatal ventricular tachycardia associated with increases in QT interval and monophasic action potential duration (MAPD).,11569530_1,-1,-1,2,2394,-1
2395,QT interval,16,18,102,113,Torsades de pointes (TDP) is a potentially fatal ventricular tachycardia associated with increases in QT interval and monophasic action potential duration (MAPD).,11569530_1,-1,-1,2,2395,-1
2397,MAPD,24,25,156,160,Torsades de pointes (TDP) is a potentially fatal ventricular tachycardia associated with increases in QT interval and monophasic action potential duration (MAPD).,11569530_1,-1,-1,2,2397,-1
2401,TDP,6,7,36,39,The potential of compounds to cause TDP was evaluated by monitoring their effects on MAPD in dog.,11569530_4,-1,-1,2,2401,-1
2402,MAPD,14,15,85,89,The potential of compounds to cause TDP was evaluated by monitoring their effects on MAPD in dog.,11569530_4,-1,-1,2,2402,-1
2403,QT interval,5,7,33,44,"Four compounds known to increase QT interval and cause TDP were investigated: terfenadine, terodiline, cisapride and E4031.",11569530_5,-1,-1,2,2403,-1
2404,TDP,9,10,55,58,"Four compounds known to increase QT interval and cause TDP were investigated: terfenadine, terodiline, cisapride and E4031.",11569530_5,-1,-1,2,2404,-1
2412,drug exposures,28,30,170,184,"On the basis that only free drug in the systemic circulation will elicit a pharmacological response target, free concentrations in plasma were selected to mimic the free drug exposures in man.",11569530_6,-1,-1,2,2412,-1
2415,MAPD,27,28,192,196,Infusion regimens were designed that rapidly achieved and maintained target-free concentrations of these drugs in plasma and data on the relationship between free concentration and changes in MAPD were obtained for these compounds.,11569530_7,-1,-1,2,2415,-1
2421,QT,42,43,193,195,"These data indicate that the free ED50 in plasma for terfenadine (1.9 nM), terodiline (76 nM), cisapride (11 nM) and E4031 (1.9 nM) closely correlate with the free concentration in man causing QT effects.",11569530_9,-1,-1,2,2421,-1
2430,drug concentrations,24,26,153,172,These data underline the need to maximize the therapeutic ratio with respect to TDP in potential development candidates and the importance of using free drug concentrations in pharmacokinetic/pharmacodynamic studies.,11569530_11,-1,-1,2,2430,-1
2431,pharmacokinetic/pharmacodynamic studies,27,29,176,215,These data underline the need to maximize the therapeutic ratio with respect to TDP in potential development candidates and the importance of using free drug concentrations in pharmacokinetic/pharmacodynamic studies.,11569530_11,-1,-1,2,2431,-1
2432,AIDS.OBJECTIVE,7,8,50,64,Amphotericin B-induced seizures in a patient with AIDS.OBJECTIVE: To report a case of multiple episodes of seizure activity in an AIDS patent following amphotericin B infusion.,11573852_0,-1,-1,2,2432,-1
2440,drug concentrations,30,32,197,216,"CASE SUMMARY: A 46-year-old African-American man experienced recurrent grand mal seizures during intravenous infusion of amphotericin B, then petit mal seizures as the infusion was stopped and the drug concentrations decreased with time.",11573852_1,-1,-1,2,2440,-1
2448,associated with,8,10,38,53,"To date, only three cases of seizures associated with amphotericin B have been reported in the literature, but healthcare providers should be aware of the potential for this rare adverse effect.",11573852_10,-1,-1,2,2448,-1
2452,case reports,15,17,89,101,Bladder retention of urine as a result of continuous intravenous infusion of fentanyl: 2 case reports.,11581460_0,-1,-1,2,2452,-1
2471,associated with,16,18,111,126,"Although these drugs are highly effective and represent the mainstay of transplant immunosuppression, they are associated with acute and chronic nephrotoxicity.",11583940_2,-1,-1,2,2471,-1
2498,exposed to,24,26,173,183,"Histological and immunohistochemical investigations (HE-LFB, CD-68, Neurofilament) revealed degeneration of myelin and axons as well as pseudocystic transformation in areas exposed to vincristine, accompanied by secondary changes with numerous prominent macrophages.",11587867_4,-1,-1,2,2498,-1
2510,favorable response,3,5,12,30,We report a favorable response to treatment with citalopram by a 15-year-old boy with major depression who exhibited palpebral twitching during his first 2 weeks of treatment.,11642480_2,-1,-1,2,2510,-1
2521,associated with,14,16,99,114,"Cervical and inguinal lymph node biopsies showed the features of severe necrotising lymphadenitis, associated with erythrophagocytosis and prominent eosinophilic infiltrates, without viral inclusion bodies, suggestive of an adverse drug reaction.",11672959_2,-1,-1,2,2521,-1
2527,associated with,8,10,48,63,"A week later, fulminant drug-induced hepatitis, associated with the presence of anti-nuclear autoantibodies (but not with other markers of autoimmunity), and accompanied by multi-organ failure and sepsis, supervened.",11672959_3,-1,-1,2,2527,-1
2531,drug therapy,11,13,65,77,She subsequently died some 5 weeks after the commencement of her drug therapy.,11672959_4,-1,-1,2,2531,-1
2545,controlled trial,23,25,162,178,"Intravenous administration of prochlorperazine by 15-minute infusion versus 2-minute bolus does not affect the incidence of akathisia: a prospective, randomized, controlled trial.",11679859_0,-1,-1,2,2545,-1
2549,double-blind study,9,11,49,67,"METHODS: We conducted a prospective, randomized, double-blind study in the emergency department of a central-city teaching hospital.",11679859_2,-1,-1,2,2549,-1
2552,treated with,6,8,32,44,"Patients aged 18 years or older treated with prochlorperazine for headache, nausea, or vomiting were eligible for inclusion.",11679859_3,-1,-1,2,2552,-1
2553,Study participants,0,2,0,18,Study participants were randomized to receive 10 mg of prochlorperazine administered intravenously by means of 2-minute push (bolus group) or 10 mg diluted in 50 mL of normal saline solution administered by means of intravenous infusion during a 15-minute period (infusion group).,11679859_4,-1,-1,2,2553,-1
2557,15-minute period,40,42,246,262,Study participants were randomized to receive 10 mg of prochlorperazine administered intravenously by means of 2-minute push (bolus group) or 10 mg diluted in 50 mL of normal saline solution administered by means of intravenous infusion during a 15-minute period (infusion group).,11679859_4,-1,-1,2,2557,-1
2564,study participants,7,9,37,55,Seventy-three percent (73/99) of the study participants were treated for headache and 70% (70/99) for nausea.,11679859_10,-1,-1,2,2564,-1
2568,confidence interval,29,31,116,135,"In the bolus group, 26.0% (13/50) had akathisia compared with 32.7% (16/49) in the infusion group (Delta=-6.7%; 95% confidence interval [CI] -24.6% to 11.2%).",11679859_11,-1,-1,2,2568,-1
2569,infusion groups,6,8,37,52,The difference between the bolus and infusion groups in the percentage of participants who saw a 50% reduction in their headache intensity within 30 minutes was 11.8% (95% CI -9.6% to 33.3%).,11679859_12,-1,-1,2,2569,-1
2572,statistical comparisons,27,29,162,185,"The efficacy of prochlorperazine in the treatment of headache and nausea likewise did not appear to be affected by the rate of administration, although no formal statistical comparisons were made.",11679859_15,-1,-1,2,2572,-1
2573,Tolerability,0,1,0,12,Tolerability of nimesulide and paracetamol in patients with NSAID-induced urticaria/angioedema.,11694026_0,-1,-1,2,2573,-1
2581,tolerability,5,6,30,42,In this study we investigated tolerability and reliability of nimesulide and paracetamol in a very large number of patients with an exclusive well-documented history of NSAID-induced urticaria/angioedema.,11694026_2,-1,-1,2,2581,-1
2593,positive test,14,16,62,75,"Of the 715 patients tested with nimesulide 62 (8.6%) showed a positive test, while of 114 subjects submitted to the challenge with paracetamol, 13 (9.6%) did not tolerate this drug.",11694026_6,-1,-1,2,2593,-1
2605,24-hour heart rate response,11,15,72,99,Comparison of aqueous and gellan ophthalmic timolol with placebo on the 24-hour heart rate response in patients on treatment for glaucoma.,11704023_0,-1,-1,2,2605,-1
2606,routine therapy,6,8,43,58,PURPOSE: Topical beta-blocker treatment is routine therapy in the management of patients with glaucoma.,11704023_1,-1,-1,2,2606,-1
2615,(+,15,17,108,110,"METHODS: Forty-three Caucasian patients with primary open-angle glaucoma or ocular hypertension with a mean (+/-SD) age of 63 (+/-8) years were randomized and crossed over in a double-masked manner to 14 days of treatment with placebo (morning and evening in both eyes), timolol solution (morning and evening in both eyes), or timolol gellan (morning in both eyes with placebo in the evening).",11704023_4,0,1,2,2615,-1
2621,24-hour period,18,20,96,110,"On the 13th day of each period, heart rate was recorded continuously during a typical, ambulant 24-hour period.",11704023_5,-1,-1,2,2621,-1
2633,statistically significant,31,33,189,214,"During the night, the mean 12-hour heart rate on placebo and timolol gellan were both significantly less than on timolol solution; the difference between solution and gellan treatments was statistically significant (P = .01).",11704023_8,-1,-1,2,2633,-1
2638,data quantify,1,3,6,19,These data quantify the modest bradycardia associated with ophthalmic beta-blocker therapy in a typical patient population on therapy for glaucoma.,11704023_11,-1,-1,2,2638,-1
2639,associated with,6,8,43,58,These data quantify the modest bradycardia associated with ophthalmic beta-blocker therapy in a typical patient population on therapy for glaucoma.,11704023_11,-1,-1,2,2639,-1
2641,patient population,14,16,104,122,These data quantify the modest bradycardia associated with ophthalmic beta-blocker therapy in a typical patient population on therapy for glaucoma.,11704023_11,-1,-1,2,2641,-1
2644,economic implications,15,17,107,128,Management strategies for ribavirin-induced hemolytic anemia in the treatment of hepatitis C: clinical and economic implications.,11705128_0,-1,-1,2,2644,-1
2645,published studies,3,5,21,38,OBJECTIVES: Recently published studies have demonstrated increased efficacy and cost-effectiveness of combination therapy with interferon and alpha-2b/ribavirin compared with interferon-alpha monotherapy in the treatment of chronic hepatitis C (CHC).,11705128_1,-1,-1,2,2645,-1
2653,associated with,3,5,23,38,Combination therapy is associated with a clinically important adverse effect: ribavirin-induced hemolytic anemia (RIHA).,11705128_2,-1,-1,2,2653,-1
2659,CHC,19,20,116,119,The objective of this study was to evaluate the direct health-care costs and management of RIHA during treatment of CHC in a clinical trial setting.,11705128_3,-1,-1,2,2659,-1
2660,clinical trial setting,22,25,125,147,The objective of this study was to evaluate the direct health-care costs and management of RIHA during treatment of CHC in a clinical trial setting.,11705128_3,-1,-1,2,2660,-1
2663,Decision-analytic techniques,0,2,0,28,Decision-analytic techniques were used to estimate the cost of treating RIHA.,11705128_5,-1,-1,2,2663,-1
2665,sensitivity analyses,4,6,32,52,Uncertainty was evaluated using sensitivity analyses.,11705128_6,-1,-1,2,2665,-1
2667,treated with,26,28,119,131,"RESULTS: RIHA, defined as a reduction in hemoglobin to less than 100 g/L, occurs in approximately 7% to 9% of patients treated with combination therapy.",11705128_7,-1,-1,2,2667,-1
2675,one-way sensitivity analyses,4,7,19,47,The results of the one-way sensitivity analyses ranged from  57 to  317.,11705128_10,-1,-1,2,2675,-1
2685,plasma lactate,7,9,67,81,Combined antiretroviral therapy causes cardiomyopathy and elevates plasma lactate in transgenic AIDS mice.,11706060_0,-1,-1,2,2685,-1
2686,transgenic AIDS,10,12,85,100,Combined antiretroviral therapy causes cardiomyopathy and elevates plasma lactate in transgenic AIDS mice.,11706060_0,-1,-1,2,2686,-1
2690,in vivo,6,8,45,52,"To determine mitochondrial events from HAART in vivo, 8-week-old hemizygous transgenic AIDS mice (NL4-3Delta gag/pol; TG) and wild-type FVB/n littermates were treated with the HAART combination of zidovudine, lamivudine, and indinavir or vehicle control for 10 days or 35 days.",11706060_2,-1,-1,2,2690,-1
2691,hemizygous transgenic AIDS mice,10,14,65,96,"To determine mitochondrial events from HAART in vivo, 8-week-old hemizygous transgenic AIDS mice (NL4-3Delta gag/pol; TG) and wild-type FVB/n littermates were treated with the HAART combination of zidovudine, lamivudine, and indinavir or vehicle control for 10 days or 35 days.",11706060_2,-1,-1,2,2691,-1
2694,wild-type FVB/n littermates,23,26,126,153,"To determine mitochondrial events from HAART in vivo, 8-week-old hemizygous transgenic AIDS mice (NL4-3Delta gag/pol; TG) and wild-type FVB/n littermates were treated with the HAART combination of zidovudine, lamivudine, and indinavir or vehicle control for 10 days or 35 days.",11706060_2,-1,-1,2,2694,-1
2696,quantitation,10,11,68,80,"At termination of the experiments, mice underwent echocardiography, quantitation of abundance of molecular markers of CM (ventricular mRNA encoding atrial natriuretic factor [ANF] and sarcoplasmic calcium ATPase [SERCA2]), and determination of plasma LA.",11706060_3,-1,-1,2,2696,-1
2703,semiquantitatively,5,6,45,63,Myocardial histologic features were analyzed semiquantitatively and results were confirmed by transmission electron microscopy.,11706060_4,-1,-1,2,2703,-1
2704,transmission electron microscopy,11,14,94,126,Myocardial histologic features were analyzed semiquantitatively and results were confirmed by transmission electron microscopy.,11706060_4,-1,-1,2,2704,-1
2707,Molecularly,0,1,0,11,"Molecularly, ANF mRNA increased 250% and SERCA2 mRNA decreased 57%.",11706060_6,-1,-1,2,2707,-1
2709,SERCA2,8,9,41,47,"Molecularly, ANF mRNA increased 250% and SERCA2 mRNA decreased 57%.",11706060_6,-1,-1,2,2709,-1
2710,/-,8,9,37,39,"Biochemically, LA was elevated (8.5 +/- 2.0 mM).",11706060_7,0,1,2,2710,-1
2712,No changes,0,2,0,10,No changes were found in other cohorts.,11706060_10,-1,-1,2,2712,-1
2716,transgenic mice,13,15,84,99,Results show that cumulative HAART caused mitochondrial CM with elevated LA in AIDS transgenic mice.,11706060_12,-1,-1,2,2716,-1
2717,Phase II trial,1,4,2,16,A Phase II trial of cisplatin plus WR-2721 (amifostine) for metastatic breast carcinoma: an Eastern Cooperative Oncology Group Study (E8188).BACKGROUND: Cisplatin has minimal antitumor activity when used as second- or third-line treatment of metastatic breast carcinoma.,11745184_0,-1,-1,2,2717,-1
2722,Eastern Cooperative Oncology Group Study,17,22,92,132,A Phase II trial of cisplatin plus WR-2721 (amifostine) for metastatic breast carcinoma: an Eastern Cooperative Oncology Group Study (E8188).BACKGROUND: Cisplatin has minimal antitumor activity when used as second- or third-line treatment of metastatic breast carcinoma.,11745184_0,-1,-1,2,2722,-1
2725,third-line treatment,34,36,218,238,A Phase II trial of cisplatin plus WR-2721 (amifostine) for metastatic breast carcinoma: an Eastern Cooperative Oncology Group Study (E8188).BACKGROUND: Cisplatin has minimal antitumor activity when used as second- or third-line treatment of metastatic breast carcinoma.,11745184_0,-1,-1,2,2725,-1
2728,response rate,5,7,35,48,Older reports suggest an objective response rate of 8% when 60-120 mg/m2 of cisplatin is administered every 3-4 weeks.,11745184_1,-1,-1,2,2728,-1
2730,dose-response effect,2,4,11,31,"Although a dose-response effect has been observed with cisplatin, the dose-limiting toxicities associated with cisplatin (e.g., nephrotoxicity, ototoxicity, and neurotoxicity) have limited its use as a treatment for breast carcinoma.",11745184_2,-1,-1,2,2730,-1
2741,military personnel,8,10,57,75,WR-2721 or amifostine initially was developed to protect military personnel in the event of nuclear war.,11745184_3,-1,-1,2,2741,-1
2747,Early trials,0,2,0,12,"Early trials of cisplatin and amifostine also suggested that the incidence and severity of cisplatin-induced nephrotoxicity, ototoxicity, and neuropathy were reduced.",11745184_5,-1,-1,2,2747,-1
2752,Phase II study,3,6,11,25,"METHODS: A Phase II study of the combination of cisplatin plus amifostine was conducted in patients with progressive metastatic breast carcinoma who had received one, but not more than one, chemotherapy regimen for metastatic disease.",11745184_6,-1,-1,2,2752,-1
2756,chemotherapy regimen,33,35,190,210,"METHODS: A Phase II study of the combination of cisplatin plus amifostine was conducted in patients with progressive metastatic breast carcinoma who had received one, but not more than one, chemotherapy regimen for metastatic disease.",11745184_6,-1,-1,2,2756,-1
2765,partial responses,1,3,4,21,Six partial responses were observed for an overall response rate of 16%.,11745184_13,-1,-1,2,2765,-1
2766,response rate,8,10,51,64,Six partial responses were observed for an overall response rate of 16%.,11745184_13,-1,-1,2,2766,-1
2767,stopped treatment,6,8,20,37,Most patients (57%) stopped treatment because of disease progression.,11745184_14,-1,-1,2,2767,-1
2772,response rate,15,17,94,107,CONCLUSIONS: The combination of cisplatin and amifostine in this study resulted in an overall response rate of 16%.,11745184_17,-1,-1,2,2772,-1
2773,tumor-protective effect,2,4,10,33,Neither a tumor-protective effect nor reduced toxicity to normal tissues was observed with the addition of amifostine to cisplatin in this trial.,11745184_18,-1,-1,2,2773,-1
2790,case-control study,52,54,320,338,"We investigated this association, according to the type of progestagen included in third-generation (i.e., desogestrel or gestodene) and second-generation (i.e., levonorgestrel) oral contraceptives, the dose of estrogen, and the presence or absence of prothrombotic mutations METHODS: In a nationwide, population-based, case-control study, we identified and enrolled 248 women 18 through 49 years of age who had had a first myocardial infarction between 1990 and 1995 and 925 control women who had not had a myocardial infarction and who were matched for age, calendar year of the index event, and area of residence.",11752354_2,-1,-1,2,2790,-1
2796,oral-contraceptive use,4,6,33,55,Subjects supplied information on oral-contraceptive use and major cardiovascular risk factors.,11752354_3,-1,-1,2,2796,-1
2799,G20210A,8,9,40,47,"An analysis for factor V Leiden and the G20210A mutation in the prothrombin gene was conducted in 217 patients and 763 controls RESULTS: The odds ratio for myocardial infarction among women who used any type of combined oral contraceptive, as compared with nonusers, was 2.0 (95 percent confidence interval, 1.5 to 2.8).",11752354_4,-1,-1,2,2799,-1
2800,prothrombin gene,12,14,64,80,"An analysis for factor V Leiden and the G20210A mutation in the prothrombin gene was conducted in 217 patients and 763 controls RESULTS: The odds ratio for myocardial infarction among women who used any type of combined oral contraceptive, as compared with nonusers, was 2.0 (95 percent confidence interval, 1.5 to 2.8).",11752354_4,-1,-1,2,2800,-1
2804,nonusers,44,45,257,265,"An analysis for factor V Leiden and the G20210A mutation in the prothrombin gene was conducted in 217 patients and 763 controls RESULTS: The odds ratio for myocardial infarction among women who used any type of combined oral contraceptive, as compared with nonusers, was 2.0 (95 percent confidence interval, 1.5 to 2.8).",11752354_4,-1,-1,2,2804,-1
2805,confidence interval,51,53,287,306,"An analysis for factor V Leiden and the G20210A mutation in the prothrombin gene was conducted in 217 patients and 763 controls RESULTS: The odds ratio for myocardial infarction among women who used any type of combined oral contraceptive, as compared with nonusers, was 2.0 (95 percent confidence interval, 1.5 to 2.8).",11752354_4,-1,-1,2,2805,-1
2807,confidence interval,9,11,44,63,"The adjusted odds ratio was 2.5 (95 percent confidence interval, 1.5 to 4.1) among women who used second-generation oral contraceptives and 1.3 (95 percent confidence interval, 0.7 to 2.5) among those who used third-generation oral contraceptives.",11752354_5,-1,-1,2,2807,-1
2809,confidence interval,28,30,156,175,"The adjusted odds ratio was 2.5 (95 percent confidence interval, 1.5 to 4.1) among women who used second-generation oral contraceptives and 1.3 (95 percent confidence interval, 0.7 to 2.5) among those who used third-generation oral contraceptives.",11752354_5,-1,-1,2,2809,-1
2813,confidence interval,15,17,77,96,"Among women who used oral contraceptives, the odds ratio was 2.1 (95 percent confidence interval, 1.5 to 3.0) for those without a prothrombotic mutation and 1.9 (95 percent confidence interval, 0.6 to 5.5) for those with a mutation CONCLUSIONS: The risk of myocardial infarction was increased among women who used second-generation oral contraceptives.",11752354_6,-1,-1,2,2813,-1
2815,confidence interval,33,35,173,192,"Among women who used oral contraceptives, the odds ratio was 2.1 (95 percent confidence interval, 1.5 to 3.0) for those without a prothrombotic mutation and 1.9 (95 percent confidence interval, 0.6 to 5.5) for those with a mutation CONCLUSIONS: The risk of myocardial infarction was increased among women who used second-generation oral contraceptives.",11752354_6,-1,-1,2,2815,-1
2826,Preclinical studies,2,4,12,31,"BACKGROUND: Preclinical studies of intrathecal adenosine suggest it may be effective in the treatment of acute and chronic pain in humans, and preliminary studies in volunteers and patients with a Swedish formulation of adenosine suggests it may be effective in hypersensitivity states but not with acute noxious stimulation.",11752998_1,-1,-1,2,2826,-1
2827,intrathecal adenosine,5,7,35,56,"BACKGROUND: Preclinical studies of intrathecal adenosine suggest it may be effective in the treatment of acute and chronic pain in humans, and preliminary studies in volunteers and patients with a Swedish formulation of adenosine suggests it may be effective in hypersensitivity states but not with acute noxious stimulation.",11752998_1,-1,-1,2,2827,-1
2829,preliminary studies,24,26,143,162,"BACKGROUND: Preclinical studies of intrathecal adenosine suggest it may be effective in the treatment of acute and chronic pain in humans, and preliminary studies in volunteers and patients with a Swedish formulation of adenosine suggests it may be effective in hypersensitivity states but not with acute noxious stimulation.",11752998_1,-1,-1,2,2829,-1
2837,dose-escalating trial,28,30,175,196,"METHODS: Following Food and Drug Administration and institutional review board approval and written informed consent, 65 volunteers were studied in two trials: an open-label, dose-escalating trial with intrathecal adenosine doses of 0.25-2.0 mg and a double-blind, placebo-controlled trial of adenosine, 2 mg.",11752998_3,-1,-1,2,2837,-1
2838,intrathecal adenosine doses,31,34,202,229,"METHODS: Following Food and Drug Administration and institutional review board approval and written informed consent, 65 volunteers were studied in two trials: an open-label, dose-escalating trial with intrathecal adenosine doses of 0.25-2.0 mg and a double-blind, placebo-controlled trial of adenosine, 2 mg.",11752998_3,-1,-1,2,2838,-1
2840,placebo-controlled trial,43,45,265,289,"METHODS: Following Food and Drug Administration and institutional review board approval and written informed consent, 65 volunteers were studied in two trials: an open-label, dose-escalating trial with intrathecal adenosine doses of 0.25-2.0 mg and a double-blind, placebo-controlled trial of adenosine, 2 mg.",11752998_3,-1,-1,2,2840,-1
2842,pharmacokinetic analysis,5,7,37,61,"Cerebrospinal fluid was obtained for pharmacokinetic analysis, and pain ratings in response to acute heat stimuli and areas of mechanical hyperalgesia and allodynia after intradermal capsaicin injection were determined.",11752998_4,-1,-1,2,2842,-1
2847,no effect,4,6,28,37,"RESULTS: Adenosine produced no effect on pain report to acute noxious thermal or chemical stimulation but reduced mechanical hyperalgesia and allodynia from intradermal capsaicin injection for at least 24 h. In contrast, residence time of adenosine in cerebrospinal fluid was short (< 4 h).",11752998_5,-1,-1,2,2847,-1
2852,residence time,34,36,221,235,"RESULTS: Adenosine produced no effect on pain report to acute noxious thermal or chemical stimulation but reduced mechanical hyperalgesia and allodynia from intradermal capsaicin injection for at least 24 h. In contrast, residence time of adenosine in cerebrospinal fluid was short (< 4 h).",11752998_5,-1,-1,2,2852,-1
2854,intrathecal adenosine,8,10,56,77,"CONCLUSIONS: These results show selective inhibition by intrathecal adenosine of hypersensitivity, presumed to reflect central sensitization in humans after peripheral capsaicin injection.",11752998_6,-1,-1,2,2854,-1
2855,long-lasting effect,1,3,4,23,The long-lasting effect is consistent with that observed in preliminary reports of patients with chronic neuropathic pain and is not due to prolonged residence of adenosine in cerebrospinal fluid.,11752998_7,-1,-1,2,2855,-1
2856,consistent with,4,6,27,42,The long-lasting effect is consistent with that observed in preliminary reports of patients with chronic neuropathic pain and is not due to prolonged residence of adenosine in cerebrospinal fluid.,11752998_7,-1,-1,2,2856,-1
2857,preliminary reports,9,11,60,79,The long-lasting effect is consistent with that observed in preliminary reports of patients with chronic neuropathic pain and is not due to prolonged residence of adenosine in cerebrospinal fluid.,11752998_7,-1,-1,2,2857,-1
2861,ESRD,4,5,25,29,End-stage renal disease (ESRD) after orthotopic liver transplantation (OLTX) using calcineurin-based immunotherapy: risk of development and treatment.,11773892_0,-1,-1,2,2861,-1
2868,OLTX,7,8,47,51,Their use in orthotopic liver transplantation (OLTX) has dramatically improved success rates.,11773892_2,-1,-1,2,2868,-1
2869,success rates,12,14,79,92,Their use in orthotopic liver transplantation (OLTX) has dramatically improved success rates.,11773892_2,-1,-1,2,2869,-1
2870,OLTX,15,16,80,84,"Recently, however, we have had an increase of patients who are presenting after OLTX with end-stage renal disease (ESRD).",11773892_3,-1,-1,2,2870,-1
2872,ESRD,21,22,115,119,"Recently, however, we have had an increase of patients who are presenting after OLTX with end-stage renal disease (ESRD).",11773892_3,-1,-1,2,2872,-1
2876,CRF,15,16,97,100,This retrospective study examines the incidence and treatment of ESRD and chronic renal failure (CRF) in OLTX patients.,11773892_4,-1,-1,2,2876,-1
2878,OLTX,5,6,31,35,METHODS: Patients receiving an OLTX only from June 1985 through December of 1994 who survived 6 months postoperatively were studied (n=834).,11773892_5,-1,-1,2,2878,-1
2884,laboratory variables,5,7,38,58,"Groups were compared for preoperative laboratory variables, diagnosis, postoperative variables, survival, type of ESRD therapy, and survival from onset of ESRD.",11773892_8,-1,-1,2,2884,-1
2887,OLTX,6,7,27,31,"RESULTS: At 13 years after OLTX, the incidence of severe renal dysfunction was 18.1% (CRF 8.6% and ESRD 9.5%).",11773892_9,-1,-1,2,2887,-1
2889,CRF,18,19,86,89,"RESULTS: At 13 years after OLTX, the incidence of severe renal dysfunction was 18.1% (CRF 8.6% and ESRD 9.5%).",11773892_9,-1,-1,2,2889,-1
2890,ESRD,22,23,99,103,"RESULTS: At 13 years after OLTX, the incidence of severe renal dysfunction was 18.1% (CRF 8.6% and ESRD 9.5%).",11773892_9,-1,-1,2,2890,-1
2891,control patients,2,4,14,30,"Compared with control patients, CRF and ESRD patients had higher preoperative serum creatinine levels, a greater percentage of patients with hepatorenal syndrome, higher percentage requirement for dialysis in the first 3 months postoperatively, and a higher 1-year serum creatinine.",11773892_10,-1,-1,2,2891,-1
2892,CRF,5,6,32,35,"Compared with control patients, CRF and ESRD patients had higher preoperative serum creatinine levels, a greater percentage of patients with hepatorenal syndrome, higher percentage requirement for dialysis in the first 3 months postoperatively, and a higher 1-year serum creatinine.",11773892_10,-1,-1,2,2892,-1
2896,serum creatinine,41,43,265,281,"Compared with control patients, CRF and ESRD patients had higher preoperative serum creatinine levels, a greater percentage of patients with hepatorenal syndrome, higher percentage requirement for dialysis in the first 3 months postoperatively, and a higher 1-year serum creatinine.",11773892_10,-1,-1,2,2896,-1
2899,risk factors,33,35,234,246,"Multivariate stepwise logistic regression analysis using preoperative and postoperative variables identified that an increase of serum creatinine compared with average at 1 year, 3 months, and 4 weeks postoperatively were independent risk factors for the development of CRF or ESRD with odds ratios of 2.6, 2.2, and 1.6, respectively.",11773892_11,-1,-1,2,2899,-1
2900,CRF,39,40,270,273,"Multivariate stepwise logistic regression analysis using preoperative and postoperative variables identified that an increase of serum creatinine compared with average at 1 year, 3 months, and 4 weeks postoperatively were independent risk factors for the development of CRF or ESRD with odds ratios of 2.6, 2.2, and 1.6, respectively.",11773892_11,-1,-1,2,2900,-1
2901,ESRD,41,42,277,281,"Multivariate stepwise logistic regression analysis using preoperative and postoperative variables identified that an increase of serum creatinine compared with average at 1 year, 3 months, and 4 weeks postoperatively were independent risk factors for the development of CRF or ESRD with odds ratios of 2.6, 2.2, and 1.6, respectively.",11773892_11,-1,-1,2,2901,-1
2902,odds ratios,43,45,287,298,"Multivariate stepwise logistic regression analysis using preoperative and postoperative variables identified that an increase of serum creatinine compared with average at 1 year, 3 months, and 4 weeks postoperatively were independent risk factors for the development of CRF or ESRD with odds ratios of 2.6, 2.2, and 1.6, respectively.",11773892_11,-1,-1,2,2902,-1
2905,ESRD,26,27,138,142,"Overall survival from the time of OLTX was not significantly different among groups, but by year 13, the survival of the patients who had ESRD was only 28.2% compared with 54.6% in the control group.",11773892_12,-1,-1,2,2905,-1
2910,post-OLTX,9,10,49,58,CONCLUSIONS: Patients who are more than 10 years post-OLTX have CRF and ESRD at a high rate.,11773892_14,-1,-1,2,2910,-1
2911,CRF,11,12,64,67,CONCLUSIONS: Patients who are more than 10 years post-OLTX have CRF and ESRD at a high rate.,11773892_14,-1,-1,2,2911,-1
2913,high rate,16,18,82,91,CONCLUSIONS: Patients who are more than 10 years post-OLTX have CRF and ESRD at a high rate.,11773892_14,-1,-1,2,2913,-1
2915,treated with,11,13,75,87,"The development of ESRD decreases survival, particularly in those patients treated with dialysis only.",11773892_15,-1,-1,2,2915,-1
2920,CRF,18,19,115,118,"However, an increase of serum creatinine at various times postoperatively is more predictive of the development of CRF or ESRD.",11773892_17,-1,-1,2,2920,-1
2923,cortical application,3,5,29,49,Epileptic seizures following cortical application of fibrin sealants containing tranexamic acid in rats.,11807648_0,-1,-1,2,2923,-1
2936,convulsive action,8,10,45,62,We wanted to study whether tAMCA retains its convulsive action if incorporated into a FS.,11807648_5,-1,-1,2,2936,-1
2944,associated with,11,13,73,88,FINDINGS: FS containing tAMCA caused paroxysmal brain activity which was associated with distinct convulsive behaviours.,11807648_8,-1,-1,2,2944,-1
2953,paroxysmal activity,10,12,55,74,"In contrast, FS containing aprotinin did not evoke any paroxysmal activity.",11807648_11,-1,-1,2,2953,-1
2955,convulsive action,6,8,44,61,INTERPRETATION: Tranexamic acid retains its convulsive action within FS.,11807648_12,-1,-1,2,2955,-1
2956,tAMCA,6,7,27,32,"Thus, use of FS containing tAMCA for surgery within or close to the CNS may pose a substantial risk to the patient.",11807648_13,-1,-1,2,2956,-1
2957,substantial risk,18,20,83,99,"Thus, use of FS containing tAMCA for surgery within or close to the CNS may pose a substantial risk to the patient.",11807648_13,-1,-1,2,2957,-1
2967,cardiovascular surgery programs,9,12,50,81,SETTING: Three large urban hospitals (with active cardiovascular surgery programs).,11827497_5,-1,-1,2,2967,-1
2970,Platelet counts,2,4,14,29,"MEASUREMENTS: Platelet counts, onset of objectively determined thromboembolism, results of heparin-induced platelet factor 4 antibody tests, and outcomes.",11827497_7,-1,-1,2,2970,-1
2973,exposure--,11,13,77,87,"RESULTS: Patients went home after hospitalizations that had included heparin exposure--in most cases, with no thrombocytopenia recognized--only to return to the hospital (median, day 14) with thromboembolic complications.",11827497_8,-1,-1,2,2973,-1
2977,Platelet counts,0,2,0,15,Platelet counts were mildly decreased in all but 2 patients on second presentation.,11827497_10,-1,-1,2,2977,-1
2978,patients',12,14,77,86,"On readmission, 11 patients received therapeutic heparin, which worsened the patients' clinical condition and, in all 11 cases, decreased the platelet count (mean at readmission, 143 x 10(9) cells/L; mean nadir after heparin re-exposure, 39 x 10(9) cells/L).",11827497_11,-1,-1,2,2978,-1
2980,platelet count,25,27,142,156,"On readmission, 11 patients received therapeutic heparin, which worsened the patients' clinical condition and, in all 11 cases, decreased the platelet count (mean at readmission, 143 x 10(9) cells/L; mean nadir after heparin re-exposure, 39 x 10(9) cells/L).",11827497_11,-1,-1,2,2980,-1
2982,serologic tests,2,4,11,26,Results of serologic tests for heparin-induced antibodies were positive in all patients.,11827497_12,-1,-1,2,2982,-1
2983,heparin-induced antibodies,5,7,31,57,Results of serologic tests for heparin-induced antibodies were positive in all patients.,11827497_12,-1,-1,2,2983,-1
2984,thrombolytic drugs (3,10,14,73,94,"Subsequent treatments included alternative anticoagulants (11 patients), thrombolytic drugs (3 patients), inferior vena cava filters (3 patients) and, eventually, warfarin (11 patients).",11827497_13,-1,-1,2,2984,-1
2985,inferior vena cava filters,17,21,106,132,"Subsequent treatments included alternative anticoagulants (11 patients), thrombolytic drugs (3 patients), inferior vena cava filters (3 patients) and, eventually, warfarin (11 patients).",11827497_13,-1,-1,2,2985,-1
2997,associated with,18,20,107,122,"BACKGROUND: Risperidone, a potent antagonist of both serotonergic (5HT2A) and dopaminergic D2 receptors is associated with hyperprolactinemia in adults and children.",11838826_1,-1,-1,2,2997,-1
3000,prolactin levels,2,4,21,37,Chronically elevated prolactin levels in children with prolactinomas may be associated with arrested growth and development resulting in either delayed puberty or short stature.,11838826_2,-1,-1,2,3000,-1
3002,associated with,10,12,76,91,Chronically elevated prolactin levels in children with prolactinomas may be associated with arrested growth and development resulting in either delayed puberty or short stature.,11838826_2,-1,-1,2,3002,-1
3019,mean dose,53,55,274,283,"RESULTS: Four males (age 6-11 years) with Diagnostic and Statistical Manual of Mental Disorders (fourth edition) bipolar disorder or psychoses, with risperidone-induced elevations in serum prolactin levels (57.5-129 ng/mL, normal 5-15 ng/mL), were treated with cabergoline (mean dose 2.13 +/- 0.09 mg/week).",11838826_6,-1,-1,2,3019,-1
3020,/-,57,58,290,292,"RESULTS: Four males (age 6-11 years) with Diagnostic and Statistical Manual of Mental Disorders (fourth edition) bipolar disorder or psychoses, with risperidone-induced elevations in serum prolactin levels (57.5-129 ng/mL, normal 5-15 ng/mL), were treated with cabergoline (mean dose 2.13 +/- 0.09 mg/week).",11838826_6,0,1,2,3020,-1
3022,/-,13,14,72,74,"When serum prolactin levels normalized in all four subjects (mean 11.2 +/- 10.9 ng/mL), the cabergoline dose was reduced to 1 mg/week in three of four subjects.",11838826_7,0,1,2,3022,-1
3024,mg/week,25,26,126,133,"When serum prolactin levels normalized in all four subjects (mean 11.2 +/- 10.9 ng/mL), the cabergoline dose was reduced to 1 mg/week in three of four subjects.",11838826_7,-1,-1,2,3024,-1
3026,/-,10,11,57,59,"The mean duration of therapy with cabergoline was 523.5 +/- 129.7 days, and the mean duration of therapy with risperidone was 788.5 +/- 162.5 days.",11838826_8,0,1,2,3026,-1
3028,/-,25,26,133,135,"The mean duration of therapy with cabergoline was 523.5 +/- 129.7 days, and the mean duration of therapy with risperidone was 788.5 +/- 162.5 days.",11838826_8,0,1,2,3028,-1
3035,exposure to,4,6,34,45,Acute cholestatic hepatitis after exposure to isoflurane.,11847945_0,-1,-1,2,3035,-1
3037,exposure to,11,13,69,80,OBJECTIVE: To report a case of acute cholestatic hepatitis following exposure to the inhalational anesthetic isoflurane.,11847945_1,-1,-1,2,3037,-1
3045,peak concentration,7,9,47,65,The alanine aminotransferase was elevated to a peak concentration of 1533 U/L and the serum bilirubin reached a peak of 17.0 mg/dL. There was slow improvement over 4 months.,11847945_5,-1,-1,2,3045,-1
3046,U/L,11,12,74,77,The alanine aminotransferase was elevated to a peak concentration of 1533 U/L and the serum bilirubin reached a peak of 17.0 mg/dL. There was slow improvement over 4 months.,11847945_5,-1,-1,2,3046,-1
3052,mortality rate,18,20,116,130,"DISCUSSION: The clinical and histologic picture of this case resembles halothane hepatitis, which has a significant mortality rate.",11847945_7,-1,-1,2,3052,-1
3054,Torsade de pointes,0,3,0,18,Torsade de pointes induced by metoclopramide in an elderly woman with preexisting complete left bundle branch block.,11858397_0,-1,-1,2,3054,-1
3057,torsade de pointes,14,17,77,95,There is a growing list of drugs implicated in acquired long QT syndrome and torsade de pointes.,11858397_1,-1,-1,2,3057,-1
3071,torsade de pointes,8,11,61,79,This is the first documentation that metoclopramide provokes torsade de pointes clinically.,11858397_6,-1,-1,2,3071,-1
3073,torsade de pointes,11,14,68,86,Metoclopramide should be used cautiously in patients with a risk of torsade de pointes.,11858397_7,-1,-1,2,3073,-1
3078,receptor-mediated signaling,7,9,29,56,"Dopamine (DA), through D1/D2 receptor-mediated signaling, plays a major role in the control of epileptic seizures arising in the limbic system.",11860278_1,-1,-1,2,3078,-1
3083,cellular level,18,20,110,124,Excitotoxicity leading to neuronal cell death in the affected areas is a major consequence of seizures at the cellular level.,11860278_2,-1,-1,2,3083,-1
3092,WT littermates,17,19,97,111,"Importantly, D2R -/- mice develop seizures at doses of both drugs that are not epileptogenic for WT littermates and show greater neurotoxicity.",11860278_6,-1,-1,2,3092,-1
3095,WT,13,14,89,91,"However, pilocarpine-induced seizures result in a more widespread neuronal death in both WT and D2R -/- brains in comparison to KA.",11860278_7,-1,-1,2,3095,-1
3106,learning studies,21,23,135,151,"Pregnenolone sulphate (PREGS) has generated interest as one of the most potent memory-enhancing neurosteroids to be examined in rodent learning studies, with particular importance in the ageing process.",11860495_1,-1,-1,2,3106,-1
3111,PREGS,6,7,41,46,This hypothesis stems from findings that PREGS is a potent positive modulator of N-methyl-d-aspartate receptors (NMDARs) and a negative modulator of gamma-aminobutyric acid(A) receptors (GABA(A)Rs).,11860495_3,-1,-1,2,3111,-1
3118,PREGS,2,3,10,15,"Moreover, PREGS is able to reverse the amnesic-like effects of NMDAR and GABA(A)R ligands.",11860495_4,-1,-1,2,3118,-1
3119,amnesic-like effects,8,10,39,59,"Moreover, PREGS is able to reverse the amnesic-like effects of NMDAR and GABA(A)R ligands.",11860495_4,-1,-1,2,3119,-1
3122,memory-altering,12,13,71,86,"To investigate this hypothesis, the present study in rats examined the memory-altering abilities of structural analogs of PREGS, which differ in their modulation of NMDAR and/or GABA(A)R function.",11860495_5,-1,-1,2,3122,-1
3125,GABA(A)R function,28,30,178,195,"To investigate this hypothesis, the present study in rats examined the memory-altering abilities of structural analogs of PREGS, which differ in their modulation of NMDAR and/or GABA(A)R function.",11860495_5,-1,-1,2,3125,-1
3137,memory-enhancing effects,1,3,4,28,The memory-enhancing effects of PREGS and its analogs were tested in the passive avoidance task using the model of scopolamine-induced amnesia.,11860495_7,-1,-1,2,3137,-1
3146,memory-enhancing effects,31,33,211,235,"The results show that, unlike PREGS, 11-ketopregnenolone sulphate and epipregnanolone sulphate failed to block the effect of scopolamine, suggesting that altering the modulation of NMDA receptors diminishes the memory-enhancing effects of PREGS.",11860495_9,-1,-1,2,3146,-1
3150,neuropharmacological site,5,7,31,56,These results identify a novel neuropharmacological site for the modulation of memory processes by neuroactive steroids.,11860495_11,-1,-1,2,3150,-1
3167,dual approach,2,4,8,21,"Using a dual approach of PARP-1 suppression, by genetic deletion or pharmacological inhibition with the phenanthridinone PARP inhibitor PJ34, we now demonstrate the role of PARP in the development of cardiac dysfunction induced by DOX.",11861791_4,-1,-1,2,3167,-1
3177,PARP-1+/+,0,1,0,9,PARP-1+/+ and PARP-1-/- mice received a single injection of DOX (25 mg/kg i.p).,11861791_5,-1,-1,2,3177,-1
3178,PARP-1-/- mice,2,4,14,28,PARP-1+/+ and PARP-1-/- mice received a single injection of DOX (25 mg/kg i.p).,11861791_5,-1,-1,2,3178,-1
3183,PARP-1+/+ mice,13,15,96,110,"Five days after DOX administration, left ventricular performance was significantly depressed in PARP-1+/+ mice, but only to a smaller extent in PARP-1-/- ones.",11861791_6,-1,-1,2,3183,-1
3184,PARP-1-/-,23,24,144,153,"Five days after DOX administration, left ventricular performance was significantly depressed in PARP-1+/+ mice, but only to a smaller extent in PARP-1-/- ones.",11861791_6,-1,-1,2,3184,-1
3186,treated with,7,9,50,62,Similar experiments were conducted in BALB/c mice treated with PJ34 or vehicle.,11861791_7,-1,-1,2,3186,-1
3195,PARP,2,3,6,10,"Thus, PARP activation contributes to the cardiotoxicity of DOX.",11861791_10,-1,-1,2,3195,-1
3201,associated with,13,15,101,116,PARP inhibitors may exert protective effects against the development of severe cardiac complications associated with the DOX treatment.,11861791_11,-1,-1,2,3201,-1
3209,profound potassium,11,13,77,95,Selective distal tubular epithelial toxicity seems to be responsible for the profound potassium wasting that is a major clinical side effect of treatment with AmB. Potassium depletion also potentiates the tubular toxicity of AmB. This study was designed to assess the ability of spironolactone to reduce potassium requirements and to prevent hypokalemia in neutropenic patients on AmB treatment.,11868798_1,-1,-1,2,3209,-1
3211,AmB.,24,25,159,163,Selective distal tubular epithelial toxicity seems to be responsible for the profound potassium wasting that is a major clinical side effect of treatment with AmB. Potassium depletion also potentiates the tubular toxicity of AmB. This study was designed to assess the ability of spironolactone to reduce potassium requirements and to prevent hypokalemia in neutropenic patients on AmB treatment.,11868798_1,-1,-1,2,3211,-1
3213,AmB.,33,34,225,229,Selective distal tubular epithelial toxicity seems to be responsible for the profound potassium wasting that is a major clinical side effect of treatment with AmB. Potassium depletion also potentiates the tubular toxicity of AmB. This study was designed to assess the ability of spironolactone to reduce potassium requirements and to prevent hypokalemia in neutropenic patients on AmB treatment.,11868798_1,-1,-1,2,3213,-1
3215,AmB,56,57,381,384,Selective distal tubular epithelial toxicity seems to be responsible for the profound potassium wasting that is a major clinical side effect of treatment with AmB. Potassium depletion also potentiates the tubular toxicity of AmB. This study was designed to assess the ability of spironolactone to reduce potassium requirements and to prevent hypokalemia in neutropenic patients on AmB treatment.,11868798_1,-1,-1,2,3215,-1
3224,plasma potassium,14,16,120,136,Those patients receiving AmB and spironolactone required significantly less potassium supplementation to maintain their plasma potassium within the normal range (P = 0.022).,11868798_4,-1,-1,2,3224,-1
3225,normal range,18,20,148,160,Those patients receiving AmB and spironolactone required significantly less potassium supplementation to maintain their plasma potassium within the normal range (P = 0.022).,11868798_4,-1,-1,2,3225,-1
3232,AmB,23,24,170,173,CONCLUSION: This study showed that spironolactone can reduce potassium requirements and prevent hypokalemia by reducing urinary potassium loss in neutropenic patients on AmB treatment.,11868798_6,-1,-1,2,3232,-1
3251,E13.5,32,33,197,202,"It was found that the transformation of exencephalic tissue was not simply size-dependent, and all cases of anencephaly at E18.5 resulted from embryos with a large amount of exencephalic tissue at E13.5.",11875660_7,-1,-1,2,3251,-1
3256,surface ectoderm,19,21,136,152,"Microscopic observation showed the configuration of exencephaly at E13.5, frequent hemorrhaging and detachment of the neural plate from surface ectoderm in the exencephalic head at E15.5, and multiple modes of reduction in the exencephalic tissue at E18.5.",11875660_8,-1,-1,2,3256,-1
3271,uni-,7,8,49,53,Erectile function was assessed 6 weeks following uni- and bilateral injections of 6-hydroxydopamine in the substantia nigra nucleus of the brain.,11890511_1,-1,-1,2,3271,-1
3274,uni-,15,16,90,94,Behavioral apomorphine-induced penile erections were reduced (5/8) and increased (3/8) in uni- and bilateral lesioned animals.,11890511_2,-1,-1,2,3274,-1
3282,associated with,7,9,46,61,Lesions of the substantia nigra are therefore associated with erectile dysfunction in rats and may serve as a model to study erectile dysfunction in Parkinson's disease.,11890511_6,-1,-1,2,3282,-1
3298,biodistribution,2,3,8,23,The rat biodistribution studies showed a rapid blood clearance via the kidneys.,11897407_6,-1,-1,2,3298,-1
3299,blood clearance,7,9,47,62,The rat biodistribution studies showed a rapid blood clearance via the kidneys.,11897407_6,-1,-1,2,3299,-1
3300,standardised heart uptake value,6,10,56,87,Thirty minutes after 99mTc-glucarate administration the standardised heart uptake value S(h)UV was 4.7 in infarcted rat heart which is six times more than in normal rats.,11897407_7,-1,-1,2,3300,-1
3303,gamma camera,4,6,20,32,ROIs drawn over the gamma camera images showed a ratio of 4.4.,11897407_8,-1,-1,2,3303,-1
3305,contrast images,7,9,42,57,"The high image quality suggests that high contrast images can be obtained in humans and the 96 h stability makes it an ideal agent to detect, in patients, early cardiac infarction.",11897407_9,-1,-1,2,3305,-1
3329,healthy controls,39,41,189,205,"We studied two groups of Parkinson's disease patients with (Parkinson's disease + LID, n = 23) and without levodopa-induced dyskinesias (Parkinson's disease - LID, n = 10), and age-matched healthy controls.",11912119_2,-1,-1,2,3329,-1
3332,grip-lift paradigm,19,21,99,117,"The motor score of the Unified Parkinson's Disease Rating Scale, a dyskinesia score and force in a grip-lift paradigm were assessed ON and OFF levodopa.",11912119_3,-1,-1,2,3332,-1
3336,peak grip force,3,6,19,34,An overshooting of peak grip force by 51% (P < 0.05) and of static grip force by 45% (P < 0.01) was observed in the ON- compared with the OFF-drug condition.,11912119_6,-1,-1,2,3336,-1
3337,static grip force,16,19,60,77,An overshooting of peak grip force by 51% (P < 0.05) and of static grip force by 45% (P < 0.01) was observed in the ON- compared with the OFF-drug condition.,11912119_6,-1,-1,2,3337,-1
3338,ON-,31,32,116,119,An overshooting of peak grip force by 51% (P < 0.05) and of static grip force by 45% (P < 0.01) was observed in the ON- compared with the OFF-drug condition.,11912119_6,-1,-1,2,3338,-1
3339,OFF-drug,35,36,138,146,An overshooting of peak grip force by 51% (P < 0.05) and of static grip force by 45% (P < 0.01) was observed in the ON- compared with the OFF-drug condition.,11912119_6,-1,-1,2,3339,-1
3341,Peak grip force,0,3,0,15,"Peak grip force in ON-state was 140% (P < 0.05) higher in Parkinson's disease + LID than in Parkinson's disease - LID, while static grip force was increased by 138% (P < 0.01) between groups.",11912119_8,-1,-1,2,3341,-1
3346,grip force,8,10,63,73,"Severity of peak-dose dyskinesias was strongly correlated with grip force in ON-state (r = 0.79 with peak force, P < 0.01).",11912119_9,-1,-1,2,3346,-1
3347,ON-state,11,12,77,85,"Severity of peak-dose dyskinesias was strongly correlated with grip force in ON-state (r = 0.79 with peak force, P < 0.01).",11912119_9,-1,-1,2,3347,-1
3349,peak force,17,19,101,111,"Severity of peak-dose dyskinesias was strongly correlated with grip force in ON-state (r = 0.79 with peak force, P < 0.01).",11912119_9,-1,-1,2,3349,-1
3354,ON-drug,14,15,88,95,A close relationship was seen between the overshooting of forces and dyskinesias in the ON-drug condition.,11912119_12,-1,-1,2,3354,-1
3355,grip force,6,8,31,41,We postulate that both LID and grip force excess share common pathophysiological mechanisms related to motor fluctuations.,11912119_13,-1,-1,2,3355,-1
3366,National Poisons Information Centre,18,22,93,128,"In the initial 6 months since it's introduction, 12 overdose cases have been reported to The National Poisons Information Centre.",11928786_3,-1,-1,2,3366,-1
3372,treated with,3,5,24,36,Recurrent seizures were treated with diazepam and broad complex tachycardia was successfully treated with adenosine.,11928786_9,-1,-1,2,3372,-1
3387,podocyte,12,13,71,79,This receptor plays a role in regulating the structure and function of podocyte foot process.,11961407_3,-1,-1,2,3387,-1
3392,Western blot,28,30,171,183,"To better understand the utility of GLEPP1 as a marker of glomerular injury, the amount and distribution of GLEPP1 protein and mRNA were examined by immunohistochemistry, Western blot and RNase protection assay in a model of podocyte injury in the rat.",11961407_4,-1,-1,2,3392,-1
3396,mg/100g BW,16,19,122,132,"Puromycin aminonucleoside nephrosis was induced by single intraperitoneal injection of puromycin aminonucleoside (PAN, 20 mg/100g BW).",11961407_5,-1,-1,2,3396,-1
3398,associated with,33,35,135,150,"Tissues were analyzed at 0, 5, 7, 11, 21, 45, 80 and 126 days after PAN injection so as to include both the acute phase of proteinuria associated with foot process effacement (days 5-11) and the chronic phase of proteinuria associated with glomerulosclerosis (days 45-126).",11961407_6,-1,-1,2,3398,-1
3401,associated with,50,52,224,239,"Tissues were analyzed at 0, 5, 7, 11, 21, 45, 80 and 126 days after PAN injection so as to include both the acute phase of proteinuria associated with foot process effacement (days 5-11) and the chronic phase of proteinuria associated with glomerulosclerosis (days 45-126).",11961407_6,-1,-1,2,3401,-1
3404,normal range,12,14,56,68,"At day 5, GLEPP1 protein and mRNA were reduced from the normal range (265.2 +/- 79.6 x 10(6) moles/glomerulus and 100%) to 15% of normal (41.8 +/- 4.8 x 10(6) moles/glomerulus, p < 0.005).",11961407_7,-1,-1,2,3404,-1
3405,/- 79.6 x,17,20,77,86,"At day 5, GLEPP1 protein and mRNA were reduced from the normal range (265.2 +/- 79.6 x 10(6) moles/glomerulus and 100%) to 15% of normal (41.8 +/- 4.8 x 10(6) moles/glomerulus, p < 0.005).",11961407_7,-1,-1,2,3405,-1
3406,/-,35,36,144,146,"At day 5, GLEPP1 protein and mRNA were reduced from the normal range (265.2 +/- 79.6 x 10(6) moles/glomerulus and 100%) to 15% of normal (41.8 +/- 4.8 x 10(6) moles/glomerulus, p < 0.005).",11961407_7,0,1,2,3406,-1
3407,/-,14,15,83,85,This occurred in association with an increase in urinary protein content from 1.8 +/- 1 to 99.0 +/- 61 mg/day (p < 0.001).,11961407_8,0,1,2,3407,-1
3408,/-,19,20,97,99,This occurred in association with an increase in urinary protein content from 1.8 +/- 1 to 99.0 +/- 61 mg/day (p < 0.001).,11961407_8,0,1,2,3408,-1
3409,mg/day,21,22,103,109,This occurred in association with an increase in urinary protein content from 1.8 +/- 1 to 99.0 +/- 61 mg/day (p < 0.001).,11961407_8,-1,-1,2,3409,-1
3421,reserpine-treated mice,5,7,32,54,Behavioral effects of MK-801 on reserpine-treated mice.,11999899_0,-1,-1,2,3421,-1
3436,observation test,11,13,51,67,"MK-801 (0.1 mg/kg), administered 30 min before the observation test, prevented the vacuous chewing movements, tongue protrusions and catalepsy induced by reserpine.",11999899_5,-1,-1,2,3436,-1
3440,reserpine-treated mice,11,13,71,93,"However, MK-801 injection produced a significant increase of tremor in reserpine-treated mice.",11999899_6,-1,-1,2,3440,-1
3444,control mice,14,16,83,95,"On the other hand, reserpine induced increases in tremor and catalepsy compared to control mice.",11999899_8,-1,-1,2,3444,-1
3448,observation test,11,13,54,70,"Pretreatment with reserpine (1 mg/kg) 24 h before the observation test produced increases in vacuous chewing movements and tongue protrusion, as well as increases in tremor and catalepsy, whereas MK-801 (0.1 mg/kg) injection 90 min before the test reversed the effects of reserpine.",11999899_10,-1,-1,2,3448,-1
3476,interfere with,23,25,145,159,"This phenomenon may be interpreted as a benign, short-term and self-limiting side effect which does not contraindicate the use of risperidone or interfere with treatment.",12013711_6,-1,-1,2,3476,-1
3491,secondary to,13,15,89,101,Urologists should be aware that this medication can cause metabolic acidosis in patients secondary to inhibition of carbonic anhydrase.,12042105_2,-1,-1,2,3491,-1
3501,constipating effects,6,8,44,64,This work evaluates the antinociceptive and constipating effects of the combination of 3.2 mg/kg s.c.,12063090_1,-1,-1,2,3501,-1
3507,charcoal meal test,23,26,148,166,"On the 13th day, antinociceptive effects were assessed using a model of inflammatory nociception, pain-induced functional impairment model, and the charcoal meal test was used to evaluate the intestinal transit.",12063090_4,-1,-1,2,3507,-1
3511,139+/-36 units area,26,29,179,198,Simultaneous administration of morphine with metamizol resulted in a markedly antinociceptive potentiation and an increasing of the duration of action after a single (298+/-7 vs. 139+/-36 units area (ua); P<0.001) and repeated administration (280+/-17 vs. 131+/-22 ua; P<0.001).,12063090_5,-1,-1,2,3511,-1
3519,constipating effects,31,33,186,206,"In independent groups, morphine inhibited the intestinal transit in 48+/-4% and 38+/-4% after acute and chronic treatment, respectively, suggesting that tolerance did not develop to the constipating effects.",12063090_8,-1,-1,2,3519,-1
3547,imaging studies,18,20,114,129,"In the patient described, the presence of asterixis during infusion of ifosfamide, normal laboratory findings and imaging studies and the resolution of symptoms following the discontinuation of the drug suggest that negative myoclonus is associated with the use of IFX.",12084448_7,-1,-1,2,3547,-1
3548,associated with,36,38,238,253,"In the patient described, the presence of asterixis during infusion of ifosfamide, normal laboratory findings and imaging studies and the resolution of symptoms following the discontinuation of the drug suggest that negative myoclonus is associated with the use of IFX.",12084448_7,-1,-1,2,3548,-1
3561,hematopoietic cell,17,19,91,109,"Although interleukin 3 (IL-3) and erythropoietin (EPO) are known to act synergistically on hematopoietic cell proliferation in vitro, injection of IGF-IL-3 and EPO in AZT-treated mice resulted in a reduction of red cells and an increase of plasma EPO levels as compared to animals treated with IGF-IL-3 or EPO alone.",12090760_2,-1,-1,2,3561,-1
3562,in vitro,20,22,124,132,"Although interleukin 3 (IL-3) and erythropoietin (EPO) are known to act synergistically on hematopoietic cell proliferation in vitro, injection of IGF-IL-3 and EPO in AZT-treated mice resulted in a reduction of red cells and an increase of plasma EPO levels as compared to animals treated with IGF-IL-3 or EPO alone.",12090760_2,-1,-1,2,3562,-1
3565,AZT-treated mice,29,31,167,183,"Although interleukin 3 (IL-3) and erythropoietin (EPO) are known to act synergistically on hematopoietic cell proliferation in vitro, injection of IGF-IL-3 and EPO in AZT-treated mice resulted in a reduction of red cells and an increase of plasma EPO levels as compared to animals treated with IGF-IL-3 or EPO alone.",12090760_2,-1,-1,2,3565,-1
3566,red cells,36,38,211,220,"Although interleukin 3 (IL-3) and erythropoietin (EPO) are known to act synergistically on hematopoietic cell proliferation in vitro, injection of IGF-IL-3 and EPO in AZT-treated mice resulted in a reduction of red cells and an increase of plasma EPO levels as compared to animals treated with IGF-IL-3 or EPO alone.",12090760_2,-1,-1,2,3566,-1
3574,erythroid cells,13,15,73,88,We tested the hypothesis that the antagonistic effect of IL-3 and EPO on erythroid cells may be mediated by endothelial cells.,12090760_3,-1,-1,2,3574,-1
3575,endothelial cells,19,21,108,125,We tested the hypothesis that the antagonistic effect of IL-3 and EPO on erythroid cells may be mediated by endothelial cells.,12090760_3,-1,-1,2,3575,-1
3576,liver erythroid cells,1,4,7,28,Bovine liver erythroid cells were cultured on monolayers of human bone marrow endothelial cells previously treated with EPO and IGF-IL-3.,12090760_4,-1,-1,2,3576,-1
3582,endothelial cells,12,14,85,102,There was a significant reduction of thymidine incorporation into both erythroid and endothelial cells in cultures pre-treated with IGF-IL-3 and EPO.,12090760_5,-1,-1,2,3582,-1
3587,ultrafiltration,6,7,51,66,Endothelial cell culture supernatants separated by ultrafiltration and ultracentrifugation from cells treated with EPO and IL-3 significantly reduced thymidine incorporation into erythroid cells as compared to identical fractions obtained from the media of cells cultured with EPO alone.,12090760_6,-1,-1,2,3587,-1
3591,erythroid cells,21,23,179,194,Endothelial cell culture supernatants separated by ultrafiltration and ultracentrifugation from cells treated with EPO and IL-3 significantly reduced thymidine incorporation into erythroid cells as compared to identical fractions obtained from the media of cells cultured with EPO alone.,12090760_6,-1,-1,2,3591,-1
3593,endothelial cells,4,6,27,44,These results suggest that endothelial cells treated simultaneously with EPO and IL-3 have a negative effect on erythroid cell production.,12090760_7,-1,-1,2,3593,-1
3596,cell production,18,20,122,137,These results suggest that endothelial cells treated simultaneously with EPO and IL-3 have a negative effect on erythroid cell production.,12090760_7,-1,-1,2,3596,-1
3602,north Uganda,31,33,204,216,"Ketamine in war/tropical surgery (a final tribute to the racemic mixture).A technique of continuous intravenous anaesthesia with ketamine was used successfully during the Somalia civil war in 1994 and in north Uganda in 1999 for 64 operations in 62 patients, aged from 6 weeks to 70 years, undergoing limb and abdominal surgery including caesarian sections and interventions in neonates.",12091028_0,-1,-1,2,3602,-1
3605,sophisticated equipment,12,14,65,88,Operations lasting up to 2h could be performed in the absence of sophisticated equipment such as pulse oximeters or ventilators in patients on spontaneous ventilation breathing air/oxygen only.,12091028_1,-1,-1,2,3605,-1
3606,pulse oximeters,16,18,97,112,Operations lasting up to 2h could be performed in the absence of sophisticated equipment such as pulse oximeters or ventilators in patients on spontaneous ventilation breathing air/oxygen only.,12091028_1,-1,-1,2,3606,-1
3607,spontaneous ventilation breathing air/oxygen,23,27,143,187,Operations lasting up to 2h could be performed in the absence of sophisticated equipment such as pulse oximeters or ventilators in patients on spontaneous ventilation breathing air/oxygen only.,12091028_1,-1,-1,2,3607,-1
3617,anaesthetic blocks,1,3,6,24,Local anaesthetic blocks were useful in decreasing the requirement for postoperative analgesia.,12091028_5,-1,-1,2,3617,-1
3621,chronotropic effects,23,25,142,162,"An antisialogue was usually unnecessary in operations lasting up to 2 h, glycopyrrolate being the best choice for its lowest psychotropic and chronotropic effects, especially in a hot climate.",12091028_6,-1,-1,2,3621,-1
3630,association with,11,13,74,90,"The incidence of severe adenovirus disease in pediatrics is increasing in association with growing numbers of immunocompromised children, where case fatality rates as high as 50% to 80% have been reported.",12093990_2,-1,-1,2,3630,-1
3632,case fatality rates,20,23,144,163,"The incidence of severe adenovirus disease in pediatrics is increasing in association with growing numbers of immunocompromised children, where case fatality rates as high as 50% to 80% have been reported.",12093990_2,-1,-1,2,3632,-1
3635,controlled trials,24,26,150,167,"There are no approved antiviral agents with proven efficacy for the treatment of severe adenovirus disease, nor are there any prospective randomized, controlled trials of potentially useful anti-adenovirus therapies.",12093990_3,-1,-1,2,3635,-1
3639,case reports,15,17,92,104,Apparent clinical success in the treatment of severe adenovirus disease is limited to a few case reports and small series.,12093990_4,-1,-1,2,3639,-1
3640,small series,18,20,109,121,Apparent clinical success in the treatment of severe adenovirus disease is limited to a few case reports and small series.,12093990_4,-1,-1,2,3640,-1
3644,in vitro,22,24,145,153,"Ribavirin, a guanosine analogue, has broad antiviral activity against both RNA and DNA viruses, including documented activity against adenovirus in vitro.",12093990_6,-1,-1,2,3644,-1
3656,DESIGN/METHODS,0,1,0,14,DESIGN/METHODS: We retrospectively reviewed the medical records of 5 children treated with intravenous ribavirin for documented severe adenovirus disease.,12093990_11,-1,-1,2,3656,-1
3658,treated with,11,13,78,90,DESIGN/METHODS: We retrospectively reviewed the medical records of 5 children treated with intravenous ribavirin for documented severe adenovirus disease.,12093990_11,-1,-1,2,3658,-1
3666,compassionate-use protocol,6,8,44,70,Intravenous ribavirin was administered on a compassionate-use protocol.,12093990_16,-1,-1,2,3666,-1
3680,polymerase chain reaction,5,8,28,53,"Early identification, eg by polymerase chain reaction of those patients at risk of disseminated adenovirus disease may permit earlier antiviral treatment and better evaluation of therapeutic response.",12093990_23,-1,-1,2,3680,-1
3682,antiviral treatment,20,22,134,153,"Early identification, eg by polymerase chain reaction of those patients at risk of disseminated adenovirus disease may permit earlier antiviral treatment and better evaluation of therapeutic response.",12093990_23,-1,-1,2,3682,-1
3683,therapeutic response,26,28,179,199,"Early identification, eg by polymerase chain reaction of those patients at risk of disseminated adenovirus disease may permit earlier antiviral treatment and better evaluation of therapeutic response.",12093990_23,-1,-1,2,3683,-1
3685,treated with,10,12,62,74,CONCLUSIONS: Two of 5 children with severe adenovirus disease treated with intravenous ribavirin recovered.,12093990_24,-1,-1,2,3685,-1
3686,diagnostic techniques,5,7,32,53,"The availability of newer rapid diagnostic techniques, such as polymerase chain reaction, may make earlier, more effective treatment of adenovirus infection possible.",12093990_25,-1,-1,2,3686,-1
3687,polymerase chain reaction,10,13,63,88,"The availability of newer rapid diagnostic techniques, such as polymerase chain reaction, may make earlier, more effective treatment of adenovirus infection possible.",12093990_25,-1,-1,2,3687,-1
3690,multicenter clinical trial,19,22,118,144,"Given the seriousness and increasing prevalence of adenovirus disease in certain hosts, especially children, a large, multicenter clinical trial of potentially useful anti-adenoviral therapies, such as intravenous ribavirin, is clearly required to demonstrate the most effective and least toxic therapy.",12093990_26,-1,-1,2,3690,-1
3700,treated with,13,15,81,93,He initially presented to hospital after six hours with mild hypotension and was treated with activated charcoal and intravenous fluids.,12101159_2,-1,-1,2,3700,-1
3703,Eighteen hours,0,2,0,14,Eighteen hours after the overdose he had two generalised tonic-clonic seizures.,12101159_3,-1,-1,2,3703,-1
3711,intravenous calcium therapy,11,14,60,87,"This case suggests there is a role for aggressive high dose intravenous calcium therapy in severe diltiazem overdose, particularly with the onset of asystole.",12101159_7,-1,-1,2,3711,-1
3718,OAC,8,9,52,55,"BACKGROUND: The interruption of oral anticoagulant (OAC) administration is sometimes indicated in patients with mechanical heart valves, mainly before noncardiac surgery, non-surgical interventions, and pregnancy.",12109865_1,-1,-1,2,3718,-1
3723,UH,3,4,24,26,Unfractionated heparin (UH) is currently the substitute for selected patients.,12109865_2,-1,-1,2,3723,-1
3726,theoretical advantages,6,8,43,65,"Low-molecular-weight heparin (LMWH) offers theoretical advantages over UH, but is not currently considered in clinical guidelines as an alternative to UH in patients with prosthetic valves.",12109865_3,-1,-1,2,3726,-1
3727,UH,9,10,71,73,"Low-molecular-weight heparin (LMWH) offers theoretical advantages over UH, but is not currently considered in clinical guidelines as an alternative to UH in patients with prosthetic valves.",12109865_3,-1,-1,2,3727,-1
3728,clinical guidelines,17,19,110,129,"Low-molecular-weight heparin (LMWH) offers theoretical advantages over UH, but is not currently considered in clinical guidelines as an alternative to UH in patients with prosthetic valves.",12109865_3,-1,-1,2,3728,-1
3732,patient population,23,25,110,128,HYPOTHESIS: The aim of the present study was to review the data accumulated so far on the use of LMWH in this patient population and to discuss its applicability in common practice.,12109865_4,-1,-1,2,3732,-1
3736,case reports,8,10,41,53,RESULTS: There were eight series and six case reports.,12109865_6,-1,-1,2,3736,-1
3742,OAC,48,49,239,242,"After excluding case reports, the following groups were constructed: (a) short-term administration, after valve insertion (n = 212); (b) short-term, perioperative (noncardiac)/periprocedural (n = 114); (c) long-term, due to intolerance to OAC (n = 16); (d) long-term, in pregnancy (n = 10).",12109865_9,-1,-1,2,3742,-1
3743,incidence rate,1,3,4,18,"The incidence rate of thromboembolism was 0.9% for all the studies and 0.5, 0, 20, and 0% in groups a, b, c, and d, respectively; for hemorrhage, the overall rate was 3.4% (3.8, 2.6, 10, and 0% for the respective groups).",12109865_10,-1,-1,2,3743,-1
3744,overall rate,39,41,150,162,"The incidence rate of thromboembolism was 0.9% for all the studies and 0.5, 0, 20, and 0% in groups a, b, c, and d, respectively; for hemorrhage, the overall rate was 3.4% (3.8, 2.6, 10, and 0% for the respective groups).",12109865_10,-1,-1,2,3744,-1
3746,LMWH therapy,10,12,66,78,"CONCLUSIONS: In patients with mechanical heart valves, short-term LMWH therapy compares favorably with UH.",12109865_11,-1,-1,2,3746,-1
3747,UH,15,16,103,105,"CONCLUSIONS: In patients with mechanical heart valves, short-term LMWH therapy compares favorably with UH.",12109865_11,-1,-1,2,3747,-1
3748,mid-,2,3,8,12,Data on mid- and long-term LMWH administration in these patients are sparse.,12109865_12,-1,-1,2,3748,-1
3750,randomized studies,1,3,8,26,Further randomized studies are needed to confirm the safety and precise indications for the use of LMWH in patients with mechanical heart valves.,12109865_13,-1,-1,2,3750,-1
3777,immunohistochemically,13,14,85,106,"Arteritis induced in rats by vasodilators, fenoldopam and theophylline, was examined immunohistochemically for expressions of inducible type of nitric oxide synthase (iNOS), basic fibroblast growth factor (bFGF) and tumor growth factor-beta1 (TGF-beta1).",12180796_1,-1,-1,2,3777,-1
3785,intravenous infusion,8,10,50,70,Rats were administered fenoldopam for 24 hours by intravenous infusion with or without following repeated daily oral administrations of theophylline.,12180796_2,-1,-1,2,3785,-1
3789,post-fenoldopam-infusion,18,19,122,146,"Irrespective of theophylline administration, iNOS antigens were remarkably abundant in ED-1-positive cells on day 5 and 8 post-fenoldopam-infusion (DPI); bFGF antigens were remarkably abundant in ED-1-positive cells on 1 and 3 DPI; TGF-beta1 antigens were observed in ED-1-positive cells on and after 5 DPI.",12180796_3,-1,-1,2,3789,-1
3797,peak expression,5,7,31,46,"These results suggest that the peak expression of iNOS antigen was followed by that of bFGF antigen, and bFGF may have a suppressive effect on iNOS expression in these rat arteritis models.",12180796_4,-1,-1,2,3797,-1
3802,arteritis models,31,33,172,188,"These results suggest that the peak expression of iNOS antigen was followed by that of bFGF antigen, and bFGF may have a suppressive effect on iNOS expression in these rat arteritis models.",12180796_4,-1,-1,2,3802,-1
3804,iNOS,15,16,80,84,"On the other hand, TGF-beta1 was not considered to have a suppressive effect on iNOS expression in these models.",12180796_5,-1,-1,2,3804,-1
3805,hippocampal acetylcholine,3,5,25,50,The relationship between hippocampal acetylcholine release and cholinergic convulsant sensitivity in withdrawal seizure-prone and withdrawal seizure-resistant selected mouse lines.,12198388_0,-1,-1,2,3805,-1
3809,mouse lines,17,19,168,179,The relationship between hippocampal acetylcholine release and cholinergic convulsant sensitivity in withdrawal seizure-prone and withdrawal seizure-resistant selected mouse lines.,12198388_0,-1,-1,2,3809,-1
3811,genetic factors,13,15,98,113,"BACKGROUND: The septo-hippocampal cholinergic pathway has been implicated in epileptogenesis, and genetic factors influence the response to cholinergic agents, but limited data are available on cholinergic involvement in alcohol withdrawal severity.",12198388_1,-1,-1,2,3811,-1
3815,genetic animal model,16,19,116,136,"Thus, the relationship between cholinergic activity and responsiveness and alcohol withdrawal was investigated in a genetic animal model of ethanol withdrawal severity.",12198388_2,-1,-1,2,3815,-1
3824,reverse dialysis twice,4,7,25,47,"Potassium was applied by reverse dialysis twice, separated by 75 min.",12198388_6,-1,-1,2,3824,-1
3827,WSR,19,20,131,134,"RESULTS: Sensitivity to several convulsion endpoints induced by nicotine, carbachol, and neostigmine were significantly greater in WSR versus WSP mice.",12198388_8,-1,-1,2,3827,-1
3828,WSP,21,22,142,145,"RESULTS: Sensitivity to several convulsion endpoints induced by nicotine, carbachol, and neostigmine were significantly greater in WSR versus WSP mice.",12198388_8,-1,-1,2,3828,-1
3829,microdialysis,1,2,3,16,"In microdialysis experiments, the lines did not differ in basal release of ACh, and 50 mM KCl increased ACh output in both lines of mice.",12198388_9,-1,-1,2,3829,-1
3836,WSP,19,20,102,105,"However, the increase in release of ACh produced by the first application of KCl was 2-fold higher in WSP versus WSR mice.",12198388_10,-1,-1,2,3836,-1
3837,WSR,21,22,113,116,"However, the increase in release of ACh produced by the first application of KCl was 2-fold higher in WSP versus WSR mice.",12198388_10,-1,-1,2,3837,-1
3840,extracellular ACh,11,13,83,100,"When hippocampal ACh was measured during testing for handling-induced convulsions, extracellular ACh was significantly elevated (192%) in WSP mice, but was nonsignificantly elevated (59%) in WSR mice.",12198388_11,-1,-1,2,3840,-1
3841,WSP,21,22,138,141,"When hippocampal ACh was measured during testing for handling-induced convulsions, extracellular ACh was significantly elevated (192%) in WSP mice, but was nonsignificantly elevated (59%) in WSR mice.",12198388_11,-1,-1,2,3841,-1
3842,WSR,33,34,191,194,"When hippocampal ACh was measured during testing for handling-induced convulsions, extracellular ACh was significantly elevated (192%) in WSP mice, but was nonsignificantly elevated (59%) in WSR mice.",12198388_11,-1,-1,2,3842,-1
3845,associated with,18,20,139,154,CONCLUSIONS: These results suggest that differences in cholinergic activity and postsynaptic sensitivity to cholinergic convulsants may be associated with ethanol withdrawal severity and implicate cholinergic mechanisms in alcohol withdrawal.,12198388_12,-1,-1,2,3845,-1
3850,WSR,13,14,91,94,"Specifically, WSP mice may have lower sensitivity to cholinergic convulsants compared with WSR because of postsynaptic receptor desensitization brought on by higher activity of cholinergic neurons.",12198388_13,-1,-1,2,3850,-1
3863,Short-latency reflex responses,0,3,0,30,"Short-latency reflex responses were evoked in the masseter and temporalis muscles by a stretch device with different velocities and displacements before, during, and after the pain.",12202650_4,-1,-1,2,3863,-1
3865,stretch device,13,15,87,101,"Short-latency reflex responses were evoked in the masseter and temporalis muscles by a stretch device with different velocities and displacements before, during, and after the pain.",12202650_4,-1,-1,2,3865,-1
3868,faster stretches,13,15,82,98,"The normalized reflex amplitude was significantly higher during pain, but only at faster stretches in the painful muscle.",12202650_6,-1,-1,2,3868,-1
3891,haloperidol-treated animals,44,46,280,307,"(RS)-1-aminoindan-1,5-dicarboxylic acid (AIDA; 0.5-15 microg/0.5 microl), a potent and selective mGluR1 antagonist, or (2R,4R)-4-aminopyrrolidine-2,4-dicarboxylate (2R,4R-APDC; 7.5-15 microg/0.5 microl), a selective group II agonist, was injected bilaterally into the striatum of haloperidol-treated animals.",12231232_3,-1,-1,2,3891,-1
3902,microinjected,5,6,35,48,Effects of 5-HT1B receptor ligands microinjected into the accumbal shell or core on the cocaine-induced locomotor hyperactivity in rats.,12369736_0,-1,-1,2,3902,-1
3906,microinjected,13,14,80,93,The present study was designed to examine the effect of 5-HT1B receptor ligands microinjected into the subregions of the nucleus accumbens (the shell and the core) on the locomotor hyperactivity induced by cocaine in rats.,12369736_1,-1,-1,2,3906,-1
3907,subregions,16,17,103,113,The present study was designed to examine the effect of 5-HT1B receptor ligands microinjected into the subregions of the nucleus accumbens (the shell and the core) on the locomotor hyperactivity induced by cocaine in rats.,12369736_1,-1,-1,2,3907,-1
3921,Systemic cocaine,0,2,0,16,Systemic cocaine (10 mg/kg) significantly increased the locomotor activity of rats.,12369736_4,-1,-1,2,3921,-1
3922,locomotor activity,9,11,56,74,Systemic cocaine (10 mg/kg) significantly increased the locomotor activity of rats.,12369736_4,-1,-1,2,3922,-1
3931,locomotor response,25,27,117,135,"When injected into the accumbens shell (but not the core) before cocaine, CP 93129 (0.1-10 microg/side) enhanced the locomotor response to cocaine; the maximum effect being observed after 10 microg/side of the agonist.",12369736_7,-1,-1,2,3931,-1
3939,microinjected,13,14,98,111,"Our findings indicate that cocaine induced hyperlocomotion is modified by 5-HT1B receptor ligands microinjected into the accumbens shell, but not core, this modification consisting in inhibitory and facilitatory effects of the 5-HT1B receptor antagonist (GR 55562) and agonist (CP 93129), respectively.",12369736_9,-1,-1,2,3939,-1
3949,iceberg?The,12,13,56,67,Cocaine related chest pain: are we seeing the tip of an iceberg?The recreational use of cocaine is on the increase.,12443032_0,-1,-1,2,3949,-1
3953,low risk,34,36,173,181,"In particular, the tendency of cocaine to produce chest pain ought to be in the mind of the emergency nurse when faced with a young victim of chest pain who is otherwise at low risk.",12443032_2,-1,-1,2,3953,-1
3956,treatment dilemmas,12,14,68,86,The mechanism of chest pain related to cocaine use is discussed and treatment dilemmas are discussed.,12443032_3,-1,-1,2,3956,-1
3958,cocaine users,10,12,59,72,"Finally, moral issues relating to the testing of potential cocaine users will be addressed.",12443032_4,-1,-1,2,3958,-1
3959,phase II study,1,4,2,16,A phase II study of thalidomide in advanced metastatic renal cell carcinoma.,12448656_0,-1,-1,2,3959,-1
3964,intra-patient dose,15,17,83,101,PATIENTS AND METHODS: 29 patients were enrolled on a study of thalidomide using an intra-patient dose escalation schedule.,12448656_2,-1,-1,2,3964,-1
3970,minor response,30,32,158,172,"RESULTS: 24 patients were evaluable for response with one partial response of 11 months duration of a patient with hepatic and pulmonary metastases (4%), one minor response, and 2 patients stable for over 6 months.",12448656_6,-1,-1,2,3970,-1
3973,consistent with,5,7,30,45,CONCLUSION: These results are consistent with a low level of activity of thalidomide in renal cell carcinoma.,12448656_9,-1,-1,2,3973,-1
3976,mg/day,5,6,33,39,"Administration of doses over 800 mg/day was difficult to achieve in this patient population, however lower doses were practical.",12448656_10,-1,-1,2,3976,-1
3977,patient population,12,14,73,91,"Administration of doses over 800 mg/day was difficult to achieve in this patient population, however lower doses were practical.",12448656_10,-1,-1,2,3977,-1
3979,dose-response relationship,1,3,4,30,"The dose-response relationship, if any, of thalidomide for renal cell carcinoma is unclear.",12448656_11,-1,-1,2,3979,-1
3981,myalgia?This study,6,8,59,77,Can lidocaine reduce succinylcholine induced postoperative myalgia?This study was undertaken to determine the effect of lidocaine pretreatment on reduction of succinylcholine-induced myalgia in patients undergoing general anesthesia for gynecological surgery.,12452237_0,-1,-1,2,3981,-1
3986,randomized manner,19,21,106,123,"One hundred and thirty-five patients were assigned to one of three groups in a prospective, double blind, randomized manner.",12452237_1,-1,-1,2,3986,-1
3991,pulse oximetry,25,27,139,153,"Morphine 0.1 mg x kg(-1) iv was given for premedication and all patients were monitored with a noninvasive blood pressure monitor, ECG and pulse oximetry.",12452237_3,-1,-1,2,3991,-1
3994,Group PR,22,24,113,121,"Anesthesia was induced with 5 mg.kg(-1) thiopental iv. followed by succinylcholine (Group PS, LS) or rocuronium (Group PR) for tracheal intubation.",12452237_4,-1,-1,2,3994,-1
3996,drug administered,29,31,172,189,"Following administration of these agents, the presence, and degree of fasciculation were assessed visually on a four point scale by one investigator who was blinded to the drug administered.",12452237_5,-1,-1,2,3996,-1
3999,Twenty-four hours,0,2,0,17,"Twenty-four hours later, any myalgia experienced was assessed according to a structured questionaire and graded by a four point scale by one investigator blinded to the intraoperative management.",12452237_7,-1,-1,2,3999,-1
4000,structured questionaire,12,14,77,100,"Twenty-four hours later, any myalgia experienced was assessed according to a structured questionaire and graded by a four point scale by one investigator blinded to the intraoperative management.",12452237_7,-1,-1,2,4000,-1
4008,Crossover comparison,0,2,0,20,Crossover comparison of efficacy and preference for rizatriptan 10 mg versus ergotamine/caffeine in migraine.,12464714_0,-1,-1,2,4008,-1
4023,co-primary endpoint,1,3,4,23,The co-primary endpoint of being pain free at 2 h was also in favor of rizatriptan.,12464714_5,-1,-1,2,4023,-1
4026,pain free 2,5,8,36,47,"Forty-nine percent of patients were pain free 2 h after rizatriptan, compared with 24.3% treated with ergotamine/caffeine (p < or = 0.001), rizatriptan being superior within 1 h of treatment.",12464714_6,-1,-1,2,4026,-1
4054,cell systems,15,17,108,120,"Sodium channel beta-subunits modulate channel gating, assembly, and cell surface expression in heterologous cell systems.",12481039_1,-1,-1,2,4054,-1
4057,in vivo,24,26,138,145,"We generated beta2(-/-) mice to investigate the role of beta2 in control of sodium channel density, localization, and function in neurons in vivo.",12481039_2,-1,-1,2,4057,-1
4063,negative shifts,6,8,30,45,The loss of beta2 resulted in negative shifts in the voltage dependence of inactivation as well as significant decreases in sodium current density in acutely dissociated hippocampal neurons.,12481039_4,-1,-1,2,4063,-1
4065,compound action,4,6,20,35,"The integral of the compound action potential in optic nerve was significantly reduced, and the threshold for action potential generation was increased, indicating a reduction in the level of functional plasma membrane sodium channels.",12481039_5,-1,-1,2,4065,-1
4067,action potential generation,18,21,110,137,"The integral of the compound action potential in optic nerve was significantly reduced, and the threshold for action potential generation was increased, indicating a reduction in the level of functional plasma membrane sodium channels.",12481039_5,-1,-1,2,4067,-1
4072,Ranvier,29,30,154,161,"In contrast, the conduction velocity, the number and size of axons in the optic nerve, and the specific localization of Na(v)1.6 channels in the nodes of Ranvier were unchanged.",12481039_6,-1,-1,2,4072,-1
4076,in vivo,20,22,133,140,Our observations show that beta2-subunits play an important role in the regulation of sodium channel density and function in neurons in vivo and are required for normal action potential generation and control of excitability.,12481039_8,-1,-1,2,4076,-1
4077,normal action,26,28,162,175,Our observations show that beta2-subunits play an important role in the regulation of sodium channel density and function in neurons in vivo and are required for normal action potential generation and control of excitability.,12481039_8,-1,-1,2,4077,-1
4094,intracarotid injection,7,9,36,58,CASE: A 58-year-old man received an intracarotid injection of carboplatin for recurrent glioblastomas in his left temporal lobe.,12483326_6,-1,-1,2,4094,-1
4100,treated with,4,6,16,28,RESULTS: He was treated with intravenous administration of corticosteroids and glycerin for 6 days after the injection.,12483326_9,-1,-1,2,4100,-1
4101,intravenous administration,6,8,29,55,RESULTS: He was treated with intravenous administration of corticosteroids and glycerin for 6 days after the injection.,12483326_9,-1,-1,2,4101,-1
4114,associated with,2,4,22,37,Visual hallucinations associated with zonisamide.,12523465_0,-1,-1,2,4114,-1
4127,associated with,12,14,70,85,"Until then, clinicians need to be aware of this possible complication associated with zonisamide.",12523465_9,-1,-1,2,4127,-1
4140,pro-absence,9,10,54,65,"Because drug-induced de novo absence seizure is rare, pro-absence drugs can only be considered a promoting factor.",12536034_4,-1,-1,2,4140,-1
4151,associated with,11,13,60,75,OBJECTIVE: To report a case of fatal liver failure possibly associated with concurrent use of bupropion and carbimazole.,12549952_1,-1,-1,2,4151,-1
4169,Naranjo probability scale,15,18,95,120,"The likelihood that bupropion induced hepatotoxicity in our patient was possible, based on the Naranjo probability scale.",12549952_8,-1,-1,2,4169,-1
4176,hepatotoxic drugs,20,22,132,149,CONCLUSIONS: Clinicians should be aware of the possibility of acute liver insult induced by bupropion given concurrently with other hepatotoxic drugs.,12549952_10,-1,-1,2,4176,-1
4178,associated with,3,5,30,45,Pyeloureteral filling defects associated with systemic anticoagulation: a case report.,1255900_0,-1,-1,2,4178,-1
4189,Nephrotoxic effects,0,2,0,19,Nephrotoxic effects in high-risk patients undergoing angiography.,12571256_0,-1,-1,2,4189,-1
4195,multicenter study,11,13,63,80,"METHODS: We conducted a randomized, double-blind, prospective, multicenter study comparing the nephrotoxic effects of an iso-osmolar, dimeric, nonionic contrast medium, iodixanol, with those of a low-osmolar, nonionic, monomeric contrast medium, iohexol.",12571256_3,-1,-1,2,4195,-1
4196,nephrotoxic effects,15,17,95,114,"METHODS: We conducted a randomized, double-blind, prospective, multicenter study comparing the nephrotoxic effects of an iso-osmolar, dimeric, nonionic contrast medium, iodixanol, with those of a low-osmolar, nonionic, monomeric contrast medium, iohexol.",12571256_3,-1,-1,2,4196,-1
4207,peak increase,6,8,30,43,The primary end point was the peak increase from base line in the creatinine concentration during the three days after angiography.,12571256_5,-1,-1,2,4207,-1
4208,base line,9,11,49,58,The primary end point was the peak increase from base line in the creatinine concentration during the three days after angiography.,12571256_5,-1,-1,2,4208,-1
4214,significantly less,6,8,48,66,RESULTS: The creatinine concentration increased significantly less in patients who received iodixanol.,12571256_7,-1,-1,2,4214,-1
4216,peak increase,9,11,30,43,"From day 0 to day 3, the mean peak increase in creatinine was 0.13 mg per deciliter in the iodixanol group and 0.55 mg per deciliter in the iohexol group (P=0.001; the increase with iodixanol minus the increase with iohexol, -0.42 mg per deciliter [95 percent confidence interval, -0.73 to -0.22]).",12571256_8,-1,-1,2,4216,-1
4222,confidence interval,51,53,260,279,"From day 0 to day 3, the mean peak increase in creatinine was 0.13 mg per deciliter in the iodixanol group and 0.55 mg per deciliter in the iohexol group (P=0.001; the increase with iodixanol minus the increase with iohexol, -0.42 mg per deciliter [95 percent confidence interval, -0.73 to -0.22]).",12571256_8,-1,-1,2,4222,-1
4229,confidence interval,62,64,295,314,"Two of the 64 patients in the iodixanol group (3 percent) had an increase in the creatinine concentration of 0.5 mg per deciliter or more, as compared with 17 of the 65 patients in the iohexol group (26 percent) (P=0.002; odds ratio for such an increase in the iodixanol group, 0.09 [95 percent confidence interval, 0.02 to 0.41]).",12571256_9,-1,-1,2,4229,-1
4238,confidence interval,54,56,276,295,"The mean change in the creatinine concentration from day 0 to day 7 was 0.07 mg per deciliter in the iodixanol group and 0.24 mg per deciliter in the iohexol group (P=0.003; value in the iodixanol group minus the value in the iohexol group, -0.17 mg per deciliter [95 percent confidence interval, -0.34 to -0.07]).",12571256_11,-1,-1,2,4238,-1
4248,intraperitoneal,9,10,51,66,"Pregnant rats were given either vehicle or 2 daily intraperitoneal injections of dexamethasone (0.2 mg/kg body weight) on gestational days 11 and 12, 13 and 14, 15 and 16, 17 and 18, or 19 and 20.",12574103_3,-1,-1,2,4248,-1
4250,gestational days,20,22,122,138,"Pregnant rats were given either vehicle or 2 daily intraperitoneal injections of dexamethasone (0.2 mg/kg body weight) on gestational days 11 and 12, 13 and 14, 15 and 16, 17 and 18, or 19 and 20.",12574103_3,-1,-1,2,4250,-1
4252,Six-,0,1,0,4,Six- to 9-month old rats receiving prenatal dexamethasone on days 17 and 18 of gestation had a 17% reduction in glomeruli (23 380+/-587) compared with control rats (P<0.05).,12574103_5,-1,-1,2,4252,-1
4253,control rats,28,30,151,163,Six- to 9-month old rats receiving prenatal dexamethasone on days 17 and 18 of gestation had a 17% reduction in glomeruli (23 380+/-587) compared with control rats (P<0.05).,12574103_5,-1,-1,2,4253,-1
4254,blood pressures,24,26,117,132,"Male rats that received prenatal dexamethasone on days 15 and 16, 17 and 18, and 13 and 14 of gestation had elevated blood pressures at 6 months of age; the latter group did not have a reduction in glomerular number.",12574103_6,-1,-1,2,4254,-1
4257,control rats,17,19,110,122,Adult rats given dexamethasone on days 15 and 16 of gestation had more glomeruli with glomerulosclerosis than control rats.,12574103_7,-1,-1,2,4257,-1
4272,nephrotoxic effects,13,15,78,97,"These are nephrotoxic, but SRL seems to act differently displaying only minor nephrotoxic effects, although this question is still open.",12584269_2,-1,-1,2,4272,-1
4273,treatment protocols,4,6,15,34,In a number of treatment protocols where SRL was combined with a calcineurin inhibitor indications of a synergistic nephrotoxic effect were described.,12584269_3,-1,-1,2,4273,-1
4276,synergistic nephrotoxic effect,17,20,104,134,In a number of treatment protocols where SRL was combined with a calcineurin inhibitor indications of a synergistic nephrotoxic effect were described.,12584269_3,-1,-1,2,4276,-1
4278,Sprague-Dawley rats,21,23,121,140,"The aim of this study was to examine further the renal function, including morphological analysis of the kidneys of male Sprague-Dawley rats treated with either cyclosporine A (CsA), tacrolimus (FK506) or SRL as monotherapies or in different combinations.",12584269_4,-1,-1,2,4278,-1
4279,treated with,23,25,141,153,"The aim of this study was to examine further the renal function, including morphological analysis of the kidneys of male Sprague-Dawley rats treated with either cyclosporine A (CsA), tacrolimus (FK506) or SRL as monotherapies or in different combinations.",12584269_4,-1,-1,2,4279,-1
4281,CsA,29,30,177,180,"The aim of this study was to examine further the renal function, including morphological analysis of the kidneys of male Sprague-Dawley rats treated with either cyclosporine A (CsA), tacrolimus (FK506) or SRL as monotherapies or in different combinations.",12584269_4,-1,-1,2,4281,-1
4286,CsA,9,10,34,37,"METHODS: For a period of 2 weeks, CsA 15 mg/kg/day (given orally), FK506 3.0 mg/kg/day (given orally) or SRL 0.4 mg/kg/day (given intraperitoneally) was administered once a day as these doses have earlier been found to achieve a significant immunosuppressive effect in Sprague-Dawley rats.",12584269_5,-1,-1,2,4286,-1
4292,rat',5,7,31,35,"In the 'conscious catheterized rat' model, the glomerular filtration rate (GFR) was measured as the clearance of Cr(EDTA).",12584269_6,-1,-1,2,4292,-1
4293,glomerular filtration rate,10,13,47,73,"In the 'conscious catheterized rat' model, the glomerular filtration rate (GFR) was measured as the clearance of Cr(EDTA).",12584269_6,-1,-1,2,4293,-1
4296,semi-quantitative scoring system,8,11,53,85,"The morphological analysis of the kidneys included a semi-quantitative scoring system analysing the degree of striped fibrosis, subcapsular fibrosis and the number of basophilic tubules, plus an additional stereological analysis of the total grade of fibrosis in the cortex stained with Sirius Red.",12584269_7,-1,-1,2,4296,-1
4300,CsA,2,3,9,12,"RESULTS: CsA, FK506 and SRL all significantly decreased the GFR.",12584269_8,-1,-1,2,4300,-1
4308,treated with,23,25,129,141,"A further deterioration was seen when CsA was combined with either FK506 or SRL, whereas the GFR remained unchanged in the group treated with FK506 plus SRL when compared with treatment with any of the single substances.",12584269_9,-1,-1,2,4308,-1
4312,semi-quantitative scoring,1,3,4,29,The semi-quantitative scoring was significantly worst in the group treated with CsA plus SRL (P<0.001 compared with controls) and the analysis of the total grade of fibrosis also showed the highest proportion in the same group and was significantly different from controls (P<0.02).,12584269_11,-1,-1,2,4312,-1
4313,treated with,9,11,67,79,The semi-quantitative scoring was significantly worst in the group treated with CsA plus SRL (P<0.001 compared with controls) and the analysis of the total grade of fibrosis also showed the highest proportion in the same group and was significantly different from controls (P<0.02).,12584269_11,-1,-1,2,4313,-1
4314,CsA,11,12,80,83,The semi-quantitative scoring was significantly worst in the group treated with CsA plus SRL (P<0.001 compared with controls) and the analysis of the total grade of fibrosis also showed the highest proportion in the same group and was significantly different from controls (P<0.02).,12584269_11,-1,-1,2,4314,-1
4318,marginally higher,8,10,45,62,The FK506 plus SRL combination showed only a marginally higher degree of fibrosis as compared with controls (P=0.05).,12584269_12,-1,-1,2,4318,-1
4319,synergistic nephrotoxic effect,7,10,42,72,"CONCLUSION: This rat study demonstrated a synergistic nephrotoxic effect of CsA plus SRL, whereas FK506 plus SRL was better tolerated.",12584269_13,-1,-1,2,4319,-1
4320,CsA,11,12,76,79,"CONCLUSION: This rat study demonstrated a synergistic nephrotoxic effect of CsA plus SRL, whereas FK506 plus SRL was better tolerated.",12584269_13,-1,-1,2,4320,-1
4328,Cardiac troponins I,2,5,12,31,BACKGROUND: Cardiac troponins I (cTnI) and T (cTnT) have been shown to be highly sensitive and specific markers of myocardial cell injury.,12589964_1,-1,-1,2,4328,-1
4329,cTnI,6,7,33,37,BACKGROUND: Cardiac troponins I (cTnI) and T (cTnT) have been shown to be highly sensitive and specific markers of myocardial cell injury.,12589964_1,-1,-1,2,4329,-1
4330,T (cTnT,9,12,43,50,BACKGROUND: Cardiac troponins I (cTnI) and T (cTnT) have been shown to be highly sensitive and specific markers of myocardial cell injury.,12589964_1,-1,-1,2,4330,-1
4331,diagnostic value,3,5,20,36,"We investigated the diagnostic value of cTnI and cTnT for the diagnosis of myocardial damage in a rat model of doxorubicin (DOX)-induced cardiomyopathy, and we examined the relationship between serial cTnI and cTnT with the development of cardiac disorders monitored by echocardiography and histological examinations in this model.",12589964_2,-1,-1,2,4331,-1
4332,cTnI,6,7,40,44,"We investigated the diagnostic value of cTnI and cTnT for the diagnosis of myocardial damage in a rat model of doxorubicin (DOX)-induced cardiomyopathy, and we examined the relationship between serial cTnI and cTnT with the development of cardiac disorders monitored by echocardiography and histological examinations in this model.",12589964_2,-1,-1,2,4332,-1
4333,cTnT,8,9,49,53,"We investigated the diagnostic value of cTnI and cTnT for the diagnosis of myocardial damage in a rat model of doxorubicin (DOX)-induced cardiomyopathy, and we examined the relationship between serial cTnI and cTnT with the development of cardiac disorders monitored by echocardiography and histological examinations in this model.",12589964_2,-1,-1,2,4333,-1
4336,cTnT,33,34,210,214,"We investigated the diagnostic value of cTnI and cTnT for the diagnosis of myocardial damage in a rat model of doxorubicin (DOX)-induced cardiomyopathy, and we examined the relationship between serial cTnI and cTnT with the development of cardiac disorders monitored by echocardiography and histological examinations in this model.",12589964_2,-1,-1,2,4336,-1
4341,control group,6,8,30,43,Ten rats received saline as a control group.,12589964_4,-1,-1,2,4341,-1
4342,cTnI,0,1,0,4,"cTnI was measured with Access(R) (ng/ml) and a research immunoassay (pg/ml), and compared with cTnT, CK-MB mass and CK.",12589964_5,-1,-1,2,4342,-1
4344,research immunoassay,11,13,47,67,"cTnI was measured with Access(R) (ng/ml) and a research immunoassay (pg/ml), and compared with cTnT, CK-MB mass and CK.",12589964_5,-1,-1,2,4344,-1
4346,CK-MB,22,23,101,106,"cTnI was measured with Access(R) (ng/ml) and a research immunoassay (pg/ml), and compared with cTnT, CK-MB mass and CK.",12589964_5,-1,-1,2,4346,-1
4347,CK,25,26,116,118,"cTnI was measured with Access(R) (ng/ml) and a research immunoassay (pg/ml), and compared with cTnT, CK-MB mass and CK.",12589964_5,-1,-1,2,4347,-1
4353,DOX-rats,4,5,27,35,Histology was performed in DOX-rats at 6 and 9 weeks after the last DOX dose and in all controls.,12589964_7,-1,-1,2,4353,-1
4356,9-week,14,15,82,88,RESULTS: Eighteen of the DOX rats died prematurely of general toxicity during the 9-week period.,12589964_8,-1,-1,2,4356,-1
4359,LV FS,15,17,90,95,"End-diastolic (ED) and end-systolic (ES) LV diameters/BW significantly increased, whereas LV FS was decreased after 9 weeks in the DOX group (p<0.001).",12589964_9,-1,-1,2,4359,-1
4366,cTnT,4,5,22,26,A significant rise in cTnT was found in DOX rats after cumulative doses of 7.5 and 12 mg/kg in comparison with baseline (p<0.05).,12589964_14,-1,-1,2,4366,-1
4368,cTnT,0,1,0,4,cTnT found in rats after 12 mg/kg were significantly greater than that found after 7.5 mg/kg DOX.,12589964_15,-1,-1,2,4368,-1
4374,CK-MB,5,6,14,19,"cTnI (ng/ml), CK-MB mass and CK remained unchanged in DOX rats compared with controls.",12589964_17,-1,-1,2,4374,-1
4377,cTnT,9,10,68,72,Analysis of data revealed a significant correlation between maximal cTnT and ED and ES LV diameters/BW (r=0.81 and 0.65; p<0.0001).,12589964_19,-1,-1,2,4377,-1
4378,ES LV diameters/BW,13,16,84,102,Analysis of data revealed a significant correlation between maximal cTnT and ED and ES LV diameters/BW (r=0.81 and 0.65; p<0.0001).,12589964_19,-1,-1,2,4378,-1
4379,cTnT,7,8,56,60,"A significant relationship was observed between maximal cTnT and the extent of myocardial morphological changes, and between LV diameters/BW and histological findings.",12589964_20,-1,-1,2,4379,-1
4380,LV diameters/BW,18,20,125,140,"A significant relationship was observed between maximal cTnT and the extent of myocardial morphological changes, and between LV diameters/BW and histological findings.",12589964_20,-1,-1,2,4380,-1
4383,cTnT,12,13,65,69,"CONCLUSIONS: Among markers of ischemic injury after DOX in rats, cTnT showed the greatest ability to detect myocardial damage assessed by echocardiographic detection and histological changes.",12589964_21,-1,-1,2,4383,-1
4413,guinea pig,9,11,85,95,Protective effect of edaravone against streptomycin-induced vestibulotoxicity in the guinea pig.,12600698_0,-1,-1,2,4413,-1
4416,guinea pigs,10,12,94,105,This study investigated alleviation of streptomycin-induced vestibulotoxicity by edaravone in guinea pigs.,12600698_1,-1,-1,2,4416,-1
4435,case-control study,21,23,143,161,The risk of venous thromboembolism in women prescribed cyproterone acetate in combination with ethinyl estradiol: a nested cohort analysis and case-control study.,12615818_0,-1,-1,2,4435,-1
4449,cohort analysis,11,13,69,84,"METHODS: Using the General Practice Research Database we conducted a cohort analysis and case-control study nested within a population of women aged between 15 and 39 years with acne, hirsutism or PCOS to estimate the risk of VTE associated with CPA/EE.",12615818_4,-1,-1,2,4449,-1
4450,case-control study,14,16,89,107,"METHODS: Using the General Practice Research Database we conducted a cohort analysis and case-control study nested within a population of women aged between 15 and 39 years with acne, hirsutism or PCOS to estimate the risk of VTE associated with CPA/EE.",12615818_4,-1,-1,2,4450,-1
4452,VTE,39,40,226,229,"METHODS: Using the General Practice Research Database we conducted a cohort analysis and case-control study nested within a population of women aged between 15 and 39 years with acne, hirsutism or PCOS to estimate the risk of VTE associated with CPA/EE.",12615818_4,-1,-1,2,4452,-1
4453,associated with,40,42,230,245,"METHODS: Using the General Practice Research Database we conducted a cohort analysis and case-control study nested within a population of women aged between 15 and 39 years with acne, hirsutism or PCOS to estimate the risk of VTE associated with CPA/EE.",12615818_4,-1,-1,2,4453,-1
4454,CPA/EE,42,43,246,252,"METHODS: Using the General Practice Research Database we conducted a cohort analysis and case-control study nested within a population of women aged between 15 and 39 years with acne, hirsutism or PCOS to estimate the risk of VTE associated with CPA/EE.",12615818_4,-1,-1,2,4454,-1
4456,incidence rate,4,6,26,40,RESULTS: The age-adjusted incidence rate ratio for CPA/EE versus conventional COCs was 2.20 [95% confidence interval (CI) 1.35-3.58].,12615818_5,-1,-1,2,4456,-1
4459,confidence interval,17,19,97,116,RESULTS: The age-adjusted incidence rate ratio for CPA/EE versus conventional COCs was 2.20 [95% confidence interval (CI) 1.35-3.58].,12615818_5,-1,-1,2,4459,-1
4462,case-control analysis,22,24,126,147,"Using as the reference group women who were not using oral contraception, had no recent pregnancy or menopausal symptoms, the case-control analysis gave an adjusted odds ratio (OR(adj)) of 7.44 (95% CI 3.67-15.08) for CPA/EE use compared with an OR(adj) of 2.58 (95% CI 1.60-4.18) for use of conventional COCs.",12615818_6,-1,-1,2,4462,-1
4465,CPA/EE use,44,46,218,228,"Using as the reference group women who were not using oral contraception, had no recent pregnancy or menopausal symptoms, the case-control analysis gave an adjusted odds ratio (OR(adj)) of 7.44 (95% CI 3.67-15.08) for CPA/EE use compared with an OR(adj) of 2.58 (95% CI 1.60-4.18) for use of conventional COCs.",12615818_6,-1,-1,2,4465,-1
4466,OR(adj,49,50,246,252,"Using as the reference group women who were not using oral contraception, had no recent pregnancy or menopausal symptoms, the case-control analysis gave an adjusted odds ratio (OR(adj)) of 7.44 (95% CI 3.67-15.08) for CPA/EE use compared with an OR(adj) of 2.58 (95% CI 1.60-4.18) for use of conventional COCs.",12615818_6,-1,-1,2,4466,-1
4468,VTE,9,10,55,58,"CONCLUSIONS: We have demonstrated an increased risk of VTE associated with the use of CPA/EE in women with acne, hirsutism or PCOS although residual confounding by indication cannot be excluded.",12615818_7,-1,-1,2,4468,-1
4469,associated with,10,12,59,74,"CONCLUSIONS: We have demonstrated an increased risk of VTE associated with the use of CPA/EE in women with acne, hirsutism or PCOS although residual confounding by indication cannot be excluded.",12615818_7,-1,-1,2,4469,-1
4474,preliminary study,14,16,80,97,The effect of treatment with gum Arabic on gentamicin nephrotoxicity in rats: a preliminary study.,12617329_0,-1,-1,2,4474,-1
4478,treated with,2,4,10,22,"Rats were treated with the vehicle (2 mL/kg of distilled water and 5% w/v cellulose, 10 days), gum Arabic (2 mL/kg of a 10% w/v aqueous suspension of gum Arabic powder, orally for 10 days), or gum Arabic concomitantly with GM (80mg/kg/day intramuscularly, during the last six days of the treatment period).",12617329_2,-1,-1,2,4478,-1
4479,mL/kg,8,9,38,43,"Rats were treated with the vehicle (2 mL/kg of distilled water and 5% w/v cellulose, 10 days), gum Arabic (2 mL/kg of a 10% w/v aqueous suspension of gum Arabic powder, orally for 10 days), or gum Arabic concomitantly with GM (80mg/kg/day intramuscularly, during the last six days of the treatment period).",12617329_2,-1,-1,2,4479,-1
4482,mL/kg,26,27,109,114,"Rats were treated with the vehicle (2 mL/kg of distilled water and 5% w/v cellulose, 10 days), gum Arabic (2 mL/kg of a 10% w/v aqueous suspension of gum Arabic powder, orally for 10 days), or gum Arabic concomitantly with GM (80mg/kg/day intramuscularly, during the last six days of the treatment period).",12617329_2,-1,-1,2,4482,-1
4493,treated with,36,38,201,213,"The results indicated that concomitant treatment with gum Arabic and GM significantly increased creatinine and urea by about 183 and 239%, respectively (compared to 432 and 346%, respectively, in rats treated with cellulose and GM), and decreased that of cortical GSH by 21% (compared to 27% in the cellulose plus GM group) The GM-induced proximal tubular necrosis appeared to be slightly less severe in rats given GM together with gum Arabic than in those given GM and cellulose.",12617329_4,-1,-1,2,4493,-1
4498,biochemical indices,19,21,113,132,It could be inferred that gum Arabic treatment has induced a modest amelioration of some of the histological and biochemical indices of GM nephrotoxicity.,12617329_5,-1,-1,2,4498,-1
4500,renal functional aspects,11,14,61,85,"Further work is warranted on the effect of the treatments on renal functional aspects in models of chronic renal failure, and on the mechanism(s) involved.",12617329_6,-1,-1,2,4500,-1
4502,mechanism(s),24,26,133,145,"Further work is warranted on the effect of the treatments on renal functional aspects in models of chronic renal failure, and on the mechanism(s) involved.",12617329_6,-1,-1,2,4502,-1
4509,treated with,22,24,147,159,STUDY OBJECTIVE: To evaluate the frequency of venous thromboembolism (VTE) in patients with advanced androgen-independent prostate cancer who were treated with docetaxel alone or in combination with thalidomide.,12627929_1,-1,-1,2,4509,-1
4512,randomized phase II trial,6,10,36,61,DESIGN: Retrospective analysis of a randomized phase II trial.,12627929_2,-1,-1,2,4512,-1
4513,National Institutes of Health clinical research center,2,9,9,63,SETTING: National Institutes of Health clinical research center.,12627929_3,-1,-1,2,4513,-1
4516,mg/m2/week,9,10,68,78,"INTERVENTION: Each patient received either intravenous docetaxel 30 mg/m2/week for 3 consecutive weeks, followed by 1 week off, or the combination of continuous oral thalidomide 200 mg every evening plus the same docetaxel regimen.",12627929_5,-1,-1,2,4516,-1
4519,4-week cycle,1,3,5,17,This 4-week cycle was repeated until there was evidence of excessive toxicity or disease progression.,12627929_6,-1,-1,2,4519,-1
4531,published cases,25,27,166,181,"OBJECTIVE: To report 2 cases of ticlopidine-induced cholestatic hepatitis, investigate its mechanism, and compare the observed main characteristics with those of the published cases.",12639165_1,-1,-1,2,4531,-1
4535,T-cell,0,1,0,6,"T-cell stimulation by therapeutic concentration of ticlopidine was demonstrated in vitro in the patients, but not in healthy controls.",12639165_3,0,1,2,4535,-1
4538,in vitro,9,11,80,88,"T-cell stimulation by therapeutic concentration of ticlopidine was demonstrated in vitro in the patients, but not in healthy controls.",12639165_3,-1,-1,2,4538,-1
4539,healthy controls,18,20,117,133,"T-cell stimulation by therapeutic concentration of ticlopidine was demonstrated in vitro in the patients, but not in healthy controls.",12639165_3,-1,-1,2,4539,-1
4542,English literature,23,25,144,162,DISCUSSION: Cholestatic hepatitis is a rare complication of the antiplatelet agent ticlopidine; several cases have been reported but few in the English literature.,12639165_4,-1,-1,2,4542,-1
4551,Immune mechanisms,0,2,0,17,"Immune mechanisms may be involved in the drug's hepatotoxicity, as suggested by the T-cell stimulation study reported here.",12639165_9,-1,-1,2,4551,-1
4552,drug's,7,9,41,47,"Immune mechanisms may be involved in the drug's hepatotoxicity, as suggested by the T-cell stimulation study reported here.",12639165_9,-1,-1,2,4552,-1
4554,T-cell,15,16,84,90,"Immune mechanisms may be involved in the drug's hepatotoxicity, as suggested by the T-cell stimulation study reported here.",12639165_9,0,1,2,4554,-1
4556,adverse effect,7,9,45,59,CONCLUSIONS: Cholestatic hepatitis is a rare adverse effect of ticlopidine that may be immune mediated.,12639165_10,-1,-1,2,4556,-1
4560,blood cell,14,16,94,104,Patients receiving the drug should be monitored with liver function tests along with complete blood cell counts.,12639165_11,-1,-1,2,4560,-1
4568,early phase,12,14,85,96,"In experimental nephrotic syndrome, urinary sodium excretion is decreased during the early phase of the disease.",12653683_1,-1,-1,2,4568,-1
4569,molecular mechanism(s),1,4,4,26,The molecular mechanism(s) leading to salt retention has not been completely elucidated.,12653683_2,-1,-1,2,4569,-1
4571,rate-limiting constituent,1,3,4,29,The rate-limiting constituent of collecting duct sodium transport is the epithelial sodium channel (ENaC).,12653683_3,-1,-1,2,4571,-1
4572,collecting duct sodium,4,7,33,55,The rate-limiting constituent of collecting duct sodium transport is the epithelial sodium channel (ENaC).,12653683_3,-1,-1,2,4572,-1
4581,treated with,19,21,136,148,"The time courses of urinary sodium excretion, plasma aldosterone concentration and proteinuria were studied in male Sprague-Dawley rats treated with a single dose of either PAN or vehicle.",12653683_5,-1,-1,2,4581,-1
4586,real-time quantitative TaqMan PCR,18,22,110,143,"The relative amounts of alphaENaC, betaENaC and gammaENaC mRNAs were determined in kidneys from these rats by real-time quantitative TaqMan PCR, and the amounts of proteins by Western blot.",12653683_6,-1,-1,2,4586,-1
4587,Western blot,29,31,176,188,"The relative amounts of alphaENaC, betaENaC and gammaENaC mRNAs were determined in kidneys from these rats by real-time quantitative TaqMan PCR, and the amounts of proteins by Western blot.",12653683_6,-1,-1,2,4587,-1
4588,up-regulation,2,3,14,27,A significant up-regulation of alphaENaC and betaENaC mRNA abundance on days 1 and 2 preceded sodium retention on days 2 and 3.,12653683_9,-1,-1,2,4588,-1
4591,down-regulation,2,3,12,27,"Conversely, down-regulation of alphaENaC, betaENaC and gammaENaC mRNA expression on day 3 occurred in the presence of high aldosterone concentrations, and was followed by a return of sodium excretion to control values.",12653683_10,-1,-1,2,4591,-1
4595,return of,28,30,173,182,"Conversely, down-regulation of alphaENaC, betaENaC and gammaENaC mRNA expression on day 3 occurred in the presence of high aldosterone concentrations, and was followed by a return of sodium excretion to control values.",12653683_10,-1,-1,2,4595,-1
4596,control values,33,35,203,217,"Conversely, down-regulation of alphaENaC, betaENaC and gammaENaC mRNA expression on day 3 occurred in the presence of high aldosterone concentrations, and was followed by a return of sodium excretion to control values.",12653683_10,-1,-1,2,4596,-1
4601,experimental model,19,21,103,121,"In conclusion, ENaC mRNA expression, especially alphaENaC, is increased in the very early phase of the experimental model of PAN-induced nephrotic syndrome in rats, but appears to escape from the regulation by aldosterone after day 3.",12653683_12,-1,-1,2,4601,-1
4606,nucleus accumbens dopamine,12,15,89,115,Sub-chronic low dose gamma-vinyl GABA (vigabatrin) inhibits cocaine-induced increases in nucleus accumbens dopamine.,12684739_0,-1,-1,2,4606,-1
4608,non-receptor,1,2,5,17,This non-receptor mediated inhibition requires de novo synthesis for restoration of functional GABA catabolism.,12684739_2,-1,-1,2,4608,-1
4610,preclinical success,4,6,22,41,"OBJECTIVES: Given its preclinical success for treating substance abuse and the increased risk of visual field defects (VFD) associated with cumulative lifetime exposure, we explored the effects of sub-chronic low dose GVG on cocaine-induced increases in nucleus accumbens (NAcc) dopamine (DA).",12684739_3,-1,-1,2,4610,-1
4613,VFD,19,20,119,122,"OBJECTIVES: Given its preclinical success for treating substance abuse and the increased risk of visual field defects (VFD) associated with cumulative lifetime exposure, we explored the effects of sub-chronic low dose GVG on cocaine-induced increases in nucleus accumbens (NAcc) dopamine (DA).",12684739_3,-1,-1,2,4613,-1
4614,associated with,21,23,124,139,"OBJECTIVES: Given its preclinical success for treating substance abuse and the increased risk of visual field defects (VFD) associated with cumulative lifetime exposure, we explored the effects of sub-chronic low dose GVG on cocaine-induced increases in nucleus accumbens (NAcc) dopamine (DA).",12684739_3,-1,-1,2,4614,-1
4620,in vivo,3,5,15,22,"METHODS: Using in vivo microdialysis, we compared acute exposure (450 mg/kg) to an identical sub-chronic exposure (150 mg/kg per day for 3 days), followed by 1- or 3-day washout.",12684739_4,-1,-1,2,4620,-1
4622,acute exposure,9,11,50,64,"METHODS: Using in vivo microdialysis, we compared acute exposure (450 mg/kg) to an identical sub-chronic exposure (150 mg/kg per day for 3 days), followed by 1- or 3-day washout.",12684739_4,-1,-1,2,4622,-1
4623,sub-chronic exposure,18,20,93,113,"METHODS: Using in vivo microdialysis, we compared acute exposure (450 mg/kg) to an identical sub-chronic exposure (150 mg/kg per day for 3 days), followed by 1- or 3-day washout.",12684739_4,-1,-1,2,4623,-1
4625,washout period,19,21,82,96,"Finally, we examined the low dose of 150 mg/kg (50 mg/kg per day) using a similar washout period.",12684739_5,-1,-1,2,4625,-1
4627,GVG,3,4,21,24,"RESULTS: Sub-chronic GVG exposure inhibited the effect of cocaine for 3 days, which exceeded in magnitude and duration the identical acute dose.",12684739_6,-1,-1,2,4627,-1
4632,cumulative exposures,19,21,140,160,"CONCLUSIONS: Sub-chronic low dose GVG potentiates and extends the inhibition of cocaine-induced increases in dopamine, effectively reducing cumulative exposures and the risk for VFDS.",12684739_7,-1,-1,2,4632,-1
4641,PSP,11,12,76,79,Cranial dystonias are rare in patients with progressive supranuclear palsy (PSP).,12691807_2,-1,-1,2,4641,-1
4645,PSP,18,19,108,111,"In this report we describe an unusual case of reversible levodopa-induced Oromandibular dystonia (OMD) in a PSP patient to highlight the importance of recognizing this drug related complication in the management of PSP, and discuss the possible underlying pathophysiology.",12691807_3,-1,-1,2,4645,-1
4647,PSP,34,35,215,218,"In this report we describe an unusual case of reversible levodopa-induced Oromandibular dystonia (OMD) in a PSP patient to highlight the importance of recognizing this drug related complication in the management of PSP, and discuss the possible underlying pathophysiology.",12691807_3,-1,-1,2,4647,-1
4650,quantitative diffusion mapping,3,6,16,46,MR imaging with quantitative diffusion mapping of tacrolimus-induced neurotoxicity in organ transplant patients.,12695819_0,-1,-1,2,4650,-1
4653,brain MR imaging,5,8,33,49,Our objective was to investigate brain MR imaging findings and the utility of diffusion-weighted (DW) imaging in organ transplant patients who developed neurologic symptoms during tacrolimus therapy.,12695819_1,-1,-1,2,4653,-1
4654,diffusion-weighted (DW) imaging,13,18,78,109,Our objective was to investigate brain MR imaging findings and the utility of diffusion-weighted (DW) imaging in organ transplant patients who developed neurologic symptoms during tacrolimus therapy.,12695819_1,-1,-1,2,4654,-1
4658,Brain MR studies,0,3,0,16,"Brain MR studies, including DW imaging, were prospectively performed in 14 organ transplant patients receiving tacrolimus who developed neurologic complications.",12695819_2,-1,-1,2,4658,-1
4659,DW imaging,5,7,28,38,"Brain MR studies, including DW imaging, were prospectively performed in 14 organ transplant patients receiving tacrolimus who developed neurologic complications.",12695819_2,-1,-1,2,4659,-1
4663,MR study,9,11,53,61,"In each patient who had abnormalities on the initial MR study, a follow-up MR study was performed 1 month later.",12695819_3,-1,-1,2,4663,-1
4664,MR study,14,16,75,83,"In each patient who had abnormalities on the initial MR study, a follow-up MR study was performed 1 month later.",12695819_3,-1,-1,2,4664,-1
4665,Apparent diffusion coefficient,0,3,0,30,Apparent diffusion coefficient (ADC) values on the initial MR study were correlated with reversibility of the lesions.,12695819_4,-1,-1,2,4665,-1
4667,MR study,10,12,59,67,Apparent diffusion coefficient (ADC) values on the initial MR study were correlated with reversibility of the lesions.,12695819_4,-1,-1,2,4667,-1
4673,MR images,23,25,121,130,"Among the 5 patients with white matter abnormalities, 4 patients (80.0%) showed higher than normal ADC values on initial MR images, and all showed complete resolution on follow-up images.",12695819_6,-1,-1,2,4673,-1
4684,mmol/d,22,23,110,116,Hydrocortisone acetate (50 mg) was given orally every 6 hours for 24 hours after a 5-day fixed-salt diet (150 mmol/d).,12707296_4,-1,-1,2,4684,-1
4685,Crossover studies,0,2,0,17,Crossover studies were performed 2 weeks apart.,12707296_5,-1,-1,2,4685,-1
4686,peripheral blood mononuclear cells,9,13,58,92,Thirty milliliters of blood was obtained for isolation of peripheral blood mononuclear cells after each treatment period.,12707296_6,-1,-1,2,4686,-1
4688,mononuclear cells,5,7,34,51,"L-arginine uptake was assessed in mononuclear cells incubated with L-arginine (1 to 300 micromol/L), incorporating 100 nmol/L [3H]-l-arginine for a period of 5 minutes at 37 degrees C. Forearm [3H]-L-arginine extraction was calculated after infusion of [3H]-L-arginine into the brachial artery at a rate of 100 nCi/min for 80 minutes.",12707296_7,-1,-1,2,4688,-1
4692,C. Forearm,30,32,182,192,"L-arginine uptake was assessed in mononuclear cells incubated with L-arginine (1 to 300 micromol/L), incorporating 100 nmol/L [3H]-l-arginine for a period of 5 minutes at 37 degrees C. Forearm [3H]-L-arginine extraction was calculated after infusion of [3H]-L-arginine into the brachial artery at a rate of 100 nCi/min for 80 minutes.",12707296_7,-1,-1,2,4692,-1
4697,venous samples,2,4,13,27,Deep forearm venous samples were collected for determination of L-arginine extraction.,12707296_8,-1,-1,2,4697,-1
4699,active phase,8,10,68,80,"Plasma cortisol concentrations were significantly raised during the active phase (323+/-43 to 1082+/-245 mmol/L, P<0.05).",12707296_9,-1,-1,2,4699,-1
4702,mononuclear cells,4,6,34,51,"Neither L-arginine transport into mononuclear cells (placebo vs active, 26.3+/-3.6 vs 29.0+/-2.1 pmol/10 000 cells per 5 minutes, respectively, at an l-arginine concentration of 300 micromol/L) nor L-arginine extraction in the forearm (at 80 minutes, placebo vs active, 1 868 904+/-434 962 vs 2 013 910+/-770 619 disintegrations per minute) was affected by cortisol treatment; ie, that L-arginine uptake is not affected by short-term cortisol treatment.",12707296_11,-1,-1,2,4702,-1
4708,associated with,10,12,70,85,We conclude that cortisol-induced increases in blood pressure are not associated with abnormalities in the l-arginine transport system.,12707296_12,-1,-1,2,4708,-1
4710,collagenase-induced,8,9,44,63,Amount of bleeding and hematoma size in the collagenase-induced intracerebral hemorrhage rat model.,12716030_0,-1,-1,2,4710,-1
4714,quantification methods,4,6,35,57,We therefore established sensitive quantification methods and provided a rat ICH model for detection of ICH deterioration.,12716030_2,-1,-1,2,4714,-1
4715,ICH model,10,12,77,86,We therefore established sensitive quantification methods and provided a rat ICH model for detection of ICH deterioration.,12716030_2,-1,-1,2,4715,-1
4717,ICH,1,2,3,6,"In ICH intrastriatally induced by 0.014-unit, 0.070-unit, and 0.350-unit collagenase, the amount of bleeding was measured using a hemoglobin assay developed in the present study and was compared with the morphologically determined hematoma volume.",12716030_3,-1,-1,2,4717,-1
4719,ICH,21,22,144,147,"The blood amounts and hematoma volumes were significantly correlated, and the hematoma induced by 0.014-unit collagenase was adequate to detect ICH deterioration.",12716030_4,-1,-1,2,4719,-1
4729,PPA,2,3,21,24,Phenylpropanolamine (PPA) is a sympathetic amine used in over-the-counter cold remedies and weight-control preparations worldwide.,12734532_1,-1,-1,2,4729,-1
4733,associated with,4,6,17,32,Its use has been associated with hypertensive episodes and hemorrhagic strokes in younger women.,12734532_2,-1,-1,2,4733,-1
4736,Several reports,0,2,0,15,"Several reports have linked the abuse of PPA with myocardial injury, especially when overdose is involved.",12734532_3,-1,-1,2,4736,-1
4742,PPA,10,11,44,47,"In addition, we review the 7 other cases of PPA related myocardial injury that have been reported so far.",12734532_5,-1,-1,2,4742,-1
4745,associated with,11,13,70,85,"Physicians and patients should be alert to the potential cardiac risk associated with the use of PPA, even at doses generally considered to be safe.",12734532_6,-1,-1,2,4745,-1
4746,PPA,16,17,97,100,"Physicians and patients should be alert to the potential cardiac risk associated with the use of PPA, even at doses generally considered to be safe.",12734532_6,-1,-1,2,4746,-1
4758,treated with,8,10,44,56,"Myositis was suspected, and the patient was treated with steroids.",12739036_5,-1,-1,2,4758,-1
4759,CK,1,2,4,6,"The CK increase persisted, however, and she developed progressive muscular weakness and muscular atrophy.",12739036_6,-1,-1,2,4759,-1
4762,Routine controls,0,2,0,16,"Routine controls revealed markedly elevated CK levels of 1,700 U/l.",12739036_7,-1,-1,2,4762,-1
4763,CK,5,6,44,46,"Routine controls revealed markedly elevated CK levels of 1,700 U/l.",12739036_7,-1,-1,2,4763,-1
4764,U/l,9,10,63,66,"Routine controls revealed markedly elevated CK levels of 1,700 U/l.",12739036_7,-1,-1,2,4764,-1
4782,investigational,16,17,94,109,"The subject, a 31-year-old female smoker, was participating in a clinical trial evaluating an investigational medication for smoking cessation that used sustained-release bupropion as an active control.",12745515_2,-1,-1,2,4782,-1
4785,active control,27,29,187,201,"The subject, a 31-year-old female smoker, was participating in a clinical trial evaluating an investigational medication for smoking cessation that used sustained-release bupropion as an active control.",12745515_2,-1,-1,2,4785,-1
4789,risk factors,5,7,25,37,The patient had no other risk factors for seizures.,12745515_4,-1,-1,2,4789,-1
4792,ovariectomized female,6,8,56,77,Estradiol reduces seizure-induced hippocampal injury in ovariectomized female but not in male rats.,12757899_0,-1,-1,2,4792,-1
4798,ovariectomized female,10,12,62,83,We compared the effects of 17beta-estradiol in adult male and ovariectomized female rats subjected to lithium-pilocarpine-induced SE.,12757899_2,-1,-1,2,4798,-1
4802,silver-stained CA3,3,5,14,32,The extent of silver-stained CA3 and CA1 hippocampal neurons was evaluated 2 days after SE.,12757899_5,-1,-1,2,4802,-1
4810,ovariectomized rats,12,14,82,101,17beta-Estradiol reduced the argyrophilic neurons in the CA1 and CA3-C sectors of ovariectomized rats.,12757899_7,-1,-1,2,4810,-1
4811,total damage score,6,9,34,52,"In males, estradiol increased the total damage score.",12757899_8,-1,-1,2,4811,-1
4813,sex-related differences,17,19,103,126,These findings suggest that the effects of estradiol on seizure threshold and damage may be altered by sex-related differences in the hormonal environment.,12757899_9,-1,-1,2,4813,-1
4814,hormonal environment,21,23,134,154,These findings suggest that the effects of estradiol on seizure threshold and damage may be altered by sex-related differences in the hormonal environment.,12757899_9,-1,-1,2,4814,-1
4817,associated with,4,6,21,36,A common side effect associated with succinylcholine is postoperative myalgia.,12760988_1,-1,-1,2,4817,-1
4819,saline group,29,31,181,193,"Incidence and severity of myalgia did not differ significantly between the two groups: 15 patients in the dexamethasone group complained of myalgia compared with 18 patients in the saline group, and severe myalgia was reported by five patients and three patients, respectively (not significant).",12760988_5,-1,-1,2,4819,-1
4845,minoxidil use,13,15,70,83,This is the first case report of pseudoacromegaly as a side effect of minoxidil use.,12789195_5,-1,-1,2,4845,-1
4851,T3N0M0,16,17,103,109,PATIENTS AND METHODS: Forty-two patients with biopsy-proven prostatic adenocarcinoma [26 with stage C (T3N0M0) and 16 with stage D1 (T3N1M0)] were included in this study.,12820454_2,-1,-1,2,4851,-1
4852,stage D1,21,23,123,131,PATIENTS AND METHODS: Forty-two patients with biopsy-proven prostatic adenocarcinoma [26 with stage C (T3N0M0) and 16 with stage D1 (T3N1M0)] were included in this study.,12820454_2,-1,-1,2,4852,-1
4861,upper limits,22,24,120,132,"Patients with stage D2-3 disease, abnormal hemoglobin level or renal and liver function tests that were higher than the upper limits were excluded from the study.",12820454_5,-1,-1,2,4861,-1
4869,mean value,12,14,61,71,"At six months post-CAB, patients with severe anemia had a Hb mean value of 10.2 +/- 0.1 g/dl (X +/- SE), whereas the other patients had mild anemia with Hb mean value of 13.2 +/- 0.17 (X +/- SE).",12820454_10,-1,-1,2,4869,-1
4870,/- 0.1 g/dl,17,20,81,92,"At six months post-CAB, patients with severe anemia had a Hb mean value of 10.2 +/- 0.1 g/dl (X +/- SE), whereas the other patients had mild anemia with Hb mean value of 13.2 +/- 0.17 (X +/- SE).",12820454_10,-1,-1,2,4870,-1
4871,X +/- SE,21,25,94,102,"At six months post-CAB, patients with severe anemia had a Hb mean value of 10.2 +/- 0.1 g/dl (X +/- SE), whereas the other patients had mild anemia with Hb mean value of 13.2 +/- 0.17 (X +/- SE).",12820454_10,-1,-1,2,4871,-1
4872,mean value,36,38,156,166,"At six months post-CAB, patients with severe anemia had a Hb mean value of 10.2 +/- 0.1 g/dl (X +/- SE), whereas the other patients had mild anemia with Hb mean value of 13.2 +/- 0.17 (X +/- SE).",12820454_10,-1,-1,2,4872,-1
4873,/-,41,42,176,178,"At six months post-CAB, patients with severe anemia had a Hb mean value of 10.2 +/- 0.1 g/dl (X +/- SE), whereas the other patients had mild anemia with Hb mean value of 13.2 +/- 0.17 (X +/- SE).",12820454_10,0,1,2,4873,-1
4874,X +/- SE,44,48,185,193,"At six months post-CAB, patients with severe anemia had a Hb mean value of 10.2 +/- 0.1 g/dl (X +/- SE), whereas the other patients had mild anemia with Hb mean value of 13.2 +/- 0.17 (X +/- SE).",12820454_10,-1,-1,2,4874,-1
4875,post-CAB,8,9,45,53,The development of severe anemia at 6 months post-CAB was predictable by the reduction of Hb baseline value of more than 2.5 g/dl after 3 months of CAB (p = 0.01).,12820454_11,-1,-1,2,4875,-1
4878,T baseline values,14,17,96,113,"The development of severe CAB-induced anemia in prostate cancer patients did not correlate with T baseline values (T < 3 ng/ml versus T > or = 3 ng/ml), with age (< 76 yrs versus > or = 76 yrs), and clinical stage (stage C versus stage D1).",12820454_12,-1,-1,2,4878,-1
4881,stage D1,52,54,230,238,"The development of severe CAB-induced anemia in prostate cancer patients did not correlate with T baseline values (T < 3 ng/ml versus T > or = 3 ng/ml), with age (< 76 yrs versus > or = 76 yrs), and clinical stage (stage C versus stage D1).",12820454_12,-1,-1,2,4881,-1
4883,subcutaneous injections,9,11,61,84,Severe and clinically evident anemia was easily corrected by subcutaneous injections (3 times/week for 1 month) of recombinant erythropoietin (rHuEPO-beta).,12820454_13,-1,-1,2,4883,-1
4885,times/week,13,14,88,98,Severe and clinically evident anemia was easily corrected by subcutaneous injections (3 times/week for 1 month) of recombinant erythropoietin (rHuEPO-beta).,12820454_13,-1,-1,2,4885,-1
4894,Oral administration,0,2,0,19,"Oral administration of lindane (2.5, 5, 10 and 15 mg/kg, body weight) for 5 days was found to produce a dose-dependent increase in the activity of P450 dependent 7-ethoxyresorufin-O-deethylase (EROD), 7-pentoxyresorufin-O-dealkylase (PROD) and N-nitrosodimethylamine demethylase (NDMA-d) in rat brain and liver.",12842176_1,-1,-1,2,4894,-1
4906,liver microsomes,21,23,127,143,"As observed with different doses, the magnitude of induction in the activity of P450 monooxygenases was several fold higher in liver microsomes when compared with the brain.",12842176_3,-1,-1,2,4906,-1
4907,Western blotting studies,0,3,0,24,"Western blotting studies have indicated that the increase in the P450 enzymes could be due to the increase in the expression of P450 1A1/1A2, 2B1/2B2 and 2E1 isoenzymes.",12842176_4,-1,-1,2,4907,-1
4912,In vitro studies,0,3,0,16,"In vitro studies using organic inhibitors specific for individual P450 isoenzymes and antibody inhibition experiments have further demonstrated that the increase in the activity of PROD, EROD and NDMA-d are due to the increase in the levels of P450 2B1/2B2, 1A1/1A2 and 2E1 isoenzymes, respectively.",12842176_5,-1,-1,2,4912,-1
4921,Induction studies,0,2,0,17,"Induction studies have further shown that while pretreatment of 3-methylcholanthrene (MC), an inducer of P4501A1/1A2, did not produce any significant effect in the incidence of lindane induced convulsions, pretreatment with phenobarbital (PB), an inducer of P450 2B1/2B2 or ethanol, an inducer of P450 2E1 catalysed reactions, significantly increased the incidence of lindane induced convulsions.",12842176_6,-1,-1,2,4921,-1
4922,pretreatment,7,8,48,60,"Induction studies have further shown that while pretreatment of 3-methylcholanthrene (MC), an inducer of P4501A1/1A2, did not produce any significant effect in the incidence of lindane induced convulsions, pretreatment with phenobarbital (PB), an inducer of P450 2B1/2B2 or ethanol, an inducer of P450 2E1 catalysed reactions, significantly increased the incidence of lindane induced convulsions.",12842176_6,-1,-1,2,4922,-1
4928,P450-mediated metabolism,4,6,20,44,"Similarly, when the P450-mediated metabolism of lindane was blocked by cobalt chloride incidence of convulsions was increased in animals treated with lindane indicating that lindane per se or its metabolites formed by PB or ethanol inducible P450 isoenzymes are involved in its neurobehavioral toxicity.",12842176_7,-1,-1,2,4928,-1
4930,treated with,20,22,137,149,"Similarly, when the P450-mediated metabolism of lindane was blocked by cobalt chloride incidence of convulsions was increased in animals treated with lindane indicating that lindane per se or its metabolites formed by PB or ethanol inducible P450 isoenzymes are involved in its neurobehavioral toxicity.",12842176_7,-1,-1,2,4930,-1
4931,inducible,36,37,232,241,"Similarly, when the P450-mediated metabolism of lindane was blocked by cobalt chloride incidence of convulsions was increased in animals treated with lindane indicating that lindane per se or its metabolites formed by PB or ethanol inducible P450 isoenzymes are involved in its neurobehavioral toxicity.",12842176_7,-1,-1,2,4931,-1
4945,Danish National Register of Patients,4,9,18,54,"METHODS: From the Danish National Register of Patients (NRP), 1996 to 1998, the records of 1.1 million Danish women, ages 15 to 44 years, were searched for evidence of VTE.",12851669_2,-1,-1,2,4945,-1
4946,NRP,10,11,56,59,"METHODS: From the Danish National Register of Patients (NRP), 1996 to 1998, the records of 1.1 million Danish women, ages 15 to 44 years, were searched for evidence of VTE.",12851669_2,-1,-1,2,4946,-1
4947,Danish women,22,24,103,115,"METHODS: From the Danish National Register of Patients (NRP), 1996 to 1998, the records of 1.1 million Danish women, ages 15 to 44 years, were searched for evidence of VTE.",12851669_2,-1,-1,2,4947,-1
4948,VTE,36,37,168,171,"METHODS: From the Danish National Register of Patients (NRP), 1996 to 1998, the records of 1.1 million Danish women, ages 15 to 44 years, were searched for evidence of VTE.",12851669_2,-1,-1,2,4948,-1
4949,COC,0,1,0,3,COC use was ascertained through mailed questionnaires.,12851669_3,-1,-1,2,4949,-1
4950,COCs,3,4,20,24,Sales statistics of COCs and CPA/EE were provided through Danish Drug Statistics.,12851669_4,-1,-1,2,4950,-1
4952,Danish Drug Statistics,9,12,58,80,Sales statistics of COCs and CPA/EE were provided through Danish Drug Statistics.,12851669_4,-1,-1,2,4952,-1
4954,VTE,17,18,78,81,"RESULTS: During the time frame of the study, 330 women were found to have had VTE while on COCs.",12851669_5,-1,-1,2,4954,-1
4955,COCs,20,21,91,95,"RESULTS: During the time frame of the study, 330 women were found to have had VTE while on COCs.",12851669_5,-1,-1,2,4955,-1
4958,CPA/EE,3,4,15,21,Eleven were on CPA/EE.,12851669_7,-1,-1,2,4958,-1
4959,VTE,5,6,35,38,"The corresponding absolute risk of VTE was 3.4 (range, 3.1-3.8) per 10 000 women years among the women on COCs, 4.2 (range, 3.2-5.2) per 10 000 women years among women on levonorgestrel-containing COCs, and 3.1 (range, 1.3-4.9) per 10 000 women years among the women on CPA/EE.",12851669_8,-1,-1,2,4959,-1
4967,CPA/EE,22,23,122,128,CONCLUSION: Our results suggest the absolute risk of VTE among Danish women on COCs is similar to that among women taking CPA/EE.,12851669_9,-1,-1,2,4967,-1
4974,Wistar rats,23,25,141,152,"Aspirin (acetylsalicylic acid [ASA]), an irreversible cyclooxygenase 1 and 2 inhibitor, induces developmental anomalies when administered to Wistar rats on gestational day (GD) 9, 10, or 11 (Kimmel CA, Wilson JG, Schumacher HJ.",12852481_2,-1,-1,2,4974,-1
4976,Kimmel CA,38,40,191,200,"Aspirin (acetylsalicylic acid [ASA]), an irreversible cyclooxygenase 1 and 2 inhibitor, induces developmental anomalies when administered to Wistar rats on gestational day (GD) 9, 10, or 11 (Kimmel CA, Wilson JG, Schumacher HJ.",12852481_2,-1,-1,2,4976,-1
4977,HJ,45,46,224,226,"Aspirin (acetylsalicylic acid [ASA]), an irreversible cyclooxygenase 1 and 2 inhibitor, induces developmental anomalies when administered to Wistar rats on gestational day (GD) 9, 10, or 11 (Kimmel CA, Wilson JG, Schumacher HJ.",12852481_2,-1,-1,2,4977,-1
4978,ASA,4,5,23,26,There are no published ASA studies using the multiple dosing paradigm of GDs 6 to 17.,12852481_4,-1,-1,2,4978,-1
4984,ASA,63,64,383,386,"Objectives of the current study were to compare results between Sprague-Dawley (SD) and Wistar strains when ASA is administered on GD 9, 10, or 11; to compare the malformation patterns following single and multiple dosings during organogenesis in SD rats; and to test the hypothesis that maternal gastrointestinal toxicity confounds the detection of low incidence malformations with ASA when a multiple dosing paradigm is used.",12852481_5,-1,-1,2,4984,-1
4987,multiple dose study,72,75,214,233,"METHODS: ASA was administered as a single dose on GD 9 (0, 250, 500, or 625 mg/kg), 10 (0, 500, 625, or 750 mg/kg), or 11 (0, 500, 750, or 1000 mg/kg) and from GD 6 to GD 17 (0, 50, 125, or 250 mg/kg a day) in the multiple dose study to SD rats.",12852481_6,-1,-1,2,4987,-1
4990,VSDs,13,14,92,96,"RESULTS: The literature evaluation suggested that NSAIDs induce ventricular septal defects (VSDs) and midline defects (MDs) in rats and diaphragmatic hernia (DH), MDs, and VSDs in rabbits (Cook JC et al., 2003); hence, the present study focused on these malformations, even though ASA induces several other low-incidence malformations.",12852481_8,-1,-1,2,4990,-1
4993,DH,27,28,158,160,"RESULTS: The literature evaluation suggested that NSAIDs induce ventricular septal defects (VSDs) and midline defects (MDs) in rats and diaphragmatic hernia (DH), MDs, and VSDs in rabbits (Cook JC et al., 2003); hence, the present study focused on these malformations, even though ASA induces several other low-incidence malformations.",12852481_8,-1,-1,2,4993,-1
4994,VSDs,33,34,172,176,"RESULTS: The literature evaluation suggested that NSAIDs induce ventricular septal defects (VSDs) and midline defects (MDs) in rats and diaphragmatic hernia (DH), MDs, and VSDs in rabbits (Cook JC et al., 2003); hence, the present study focused on these malformations, even though ASA induces several other low-incidence malformations.",12852481_8,-1,-1,2,4994,-1
4996,ASA,57,58,281,284,"RESULTS: The literature evaluation suggested that NSAIDs induce ventricular septal defects (VSDs) and midline defects (MDs) in rats and diaphragmatic hernia (DH), MDs, and VSDs in rabbits (Cook JC et al., 2003); hence, the present study focused on these malformations, even though ASA induces several other low-incidence malformations.",12852481_8,-1,-1,2,4996,-1
4998,single dose studies,1,4,3,22,"In single dose studies, DH, MD, and VSD were induced on GDs 9 and 10.",12852481_9,-1,-1,2,4998,-1
5000,VSD,10,11,36,39,"In single dose studies, DH, MD, and VSD were induced on GDs 9 and 10.",12852481_9,-1,-1,2,5000,-1
5005,VSD,21,22,101,104,"In contrast, DH and MD were noted in the multiple dose study design only in the high-dose group, and VSD was noted across all dose groups.",12852481_11,-1,-1,2,5005,-1
5006,dose groups,26,28,126,137,"In contrast, DH and MD were noted in the multiple dose study design only in the high-dose group, and VSD was noted across all dose groups.",12852481_11,-1,-1,2,5006,-1
5008,Wistar,9,10,71,77,CONCLUSIONS: High concordance in major developmental anomalies between Wistar and SD rats were noted with the exception of VSD in the SD rats and hydrocephalus in the Wistar rats.,12852481_12,-1,-1,2,5008,-1
5009,VSD,19,20,123,126,CONCLUSIONS: High concordance in major developmental anomalies between Wistar and SD rats were noted with the exception of VSD in the SD rats and hydrocephalus in the Wistar rats.,12852481_12,-1,-1,2,5009,-1
5010,Wistar rats,28,30,167,178,CONCLUSIONS: High concordance in major developmental anomalies between Wistar and SD rats were noted with the exception of VSD in the SD rats and hydrocephalus in the Wistar rats.,12852481_12,-1,-1,2,5010,-1
5015,single dose studies,29,32,163,182,"It was also evident that, by titrating the dose to achieve a maximum tolerated dose, malformations that normally occur at low incidence, as reported from previous single dose studies, could also be induced with ASA given at multiple doses.",12852481_14,-1,-1,2,5015,-1
5016,ASA,38,39,211,214,"It was also evident that, by titrating the dose to achieve a maximum tolerated dose, malformations that normally occur at low incidence, as reported from previous single dose studies, could also be induced with ASA given at multiple doses.",12852481_14,-1,-1,2,5016,-1
5022,double-blind multicenter study,19,22,133,163,Reversal of central benzodiazepine effects by flumazenil after intravenous conscious sedation with diazepam and opioids: report of a double-blind multicenter study.,1286498_0,-1,-1,2,5022,-1
5033,treated with,8,10,57,69,The group assessable for efficacy comprised 122 patients treated with flumazenil and 64 patients given placebo.,1286498_3,-1,-1,2,5033,-1
5035,flumazenil-treated patients,9,11,30,57,"After 5 minutes, 80/115 (70%) flumazenil-treated patients, compared with 21/63 (33%) placebo-treated patients, were completely awake and alert, as indicated by a score of 5 on the Observer's Assessment of Alertness/Sedation Scale.",1286498_4,-1,-1,2,5035,-1
5036,placebo-treated,19,20,85,100,"After 5 minutes, 80/115 (70%) flumazenil-treated patients, compared with 21/63 (33%) placebo-treated patients, were completely awake and alert, as indicated by a score of 5 on the Observer's Assessment of Alertness/Sedation Scale.",1286498_4,-1,-1,2,5036,-1
5038,Alertness/Sedation Scale,41,43,205,229,"After 5 minutes, 80/115 (70%) flumazenil-treated patients, compared with 21/63 (33%) placebo-treated patients, were completely awake and alert, as indicated by a score of 5 on the Observer's Assessment of Alertness/Sedation Scale.",1286498_4,-1,-1,2,5038,-1
5039,5-minute assessment,15,17,79,98,Ninety-five percent of patients in each group who attained a score of 5 at the 5-minute assessment showed no loss of alertness throughout the 180-minute assessment period.,1286498_5,-1,-1,2,5039,-1
5040,Flumazenil-treated,0,1,0,18,Flumazenil-treated patients also performed significantly better on the Finger-to-Nose Test and the recall of pictures shown at the 5-minute assessment.,1286498_6,-1,-1,2,5040,-1
5042,5-minute assessment,18,20,131,150,Flumazenil-treated patients also performed significantly better on the Finger-to-Nose Test and the recall of pictures shown at the 5-minute assessment.,1286498_6,-1,-1,2,5042,-1
5045,flumazenil-treated patients,6,8,21,48,"Thirty-nine (30%) of flumazenil-treated patients, compared with 17 (25%) of placebo-treated patients had one or more drug-related adverse experiences.",1286498_8,-1,-1,2,5045,-1
5046,placebo-treated,17,18,76,91,"Thirty-nine (30%) of flumazenil-treated patients, compared with 17 (25%) of placebo-treated patients had one or more drug-related adverse experiences.",1286498_8,-1,-1,2,5046,-1
5056,risk factors,8,10,62,74,Delirium during clozapine treatment: incidence and associated risk factors.,12905102_0,-1,-1,2,5056,-1
5057,risk factors,4,6,26,38,BACKGROUND: Incidence and risk factors for delirium during clozapine treatment require further clarification.,12905102_1,-1,-1,2,5057,-1
5060,treated with,13,15,92,104,"METHODS: We used computerized pharmacy records to identify all adult psychiatric inpatients treated with clozapine (1995-96), reviewed their medical records to score incidence and severity of delirium, and tested associations with potential risk factors.",12905102_2,-1,-1,2,5060,-1
5062,risk factors,39,41,241,253,"METHODS: We used computerized pharmacy records to identify all adult psychiatric inpatients treated with clozapine (1995-96), reviewed their medical records to score incidence and severity of delirium, and tested associations with potential risk factors.",12905102_2,-1,-1,2,5062,-1
5063,/-,18,19,65,67,"RESULTS: Subjects (n = 139) were 72 women and 67 men, aged 40.8 +/- 12.1 years, hospitalized for 24.9 +/- 23.3 days, and given clozapine, gradually increased to an average daily dose of 282 +/- 203 mg (3.45 +/- 2.45 mg/kg) for 18.9 +/- 16.4 days.",12905102_3,0,1,2,5063,-1
5064,/-,26,27,103,105,"RESULTS: Subjects (n = 139) were 72 women and 67 men, aged 40.8 +/- 12.1 years, hospitalized for 24.9 +/- 23.3 days, and given clozapine, gradually increased to an average daily dose of 282 +/- 203 mg (3.45 +/- 2.45 mg/kg) for 18.9 +/- 16.4 days.",12905102_3,0,1,2,5064,-1
5065,/-,44,45,191,193,"RESULTS: Subjects (n = 139) were 72 women and 67 men, aged 40.8 +/- 12.1 years, hospitalized for 24.9 +/- 23.3 days, and given clozapine, gradually increased to an average daily dose of 282 +/- 203 mg (3.45 +/- 2.45 mg/kg) for 18.9 +/- 16.4 days.",12905102_3,0,1,2,5065,-1
5067,/-,57,58,233,235,"RESULTS: Subjects (n = 139) were 72 women and 67 men, aged 40.8 +/- 12.1 years, hospitalized for 24.9 +/- 23.3 days, and given clozapine, gradually increased to an average daily dose of 282 +/- 203 mg (3.45 +/- 2.45 mg/kg) for 18.9 +/- 16.4 days.",12905102_3,0,1,2,5067,-1
5068,cases/person-years,12,13,56,74,"Delirium was diagnosed in 14 (10.1 % incidence, or 1.48 cases/person-years of exposure); 71.4 % of cases were moderate or severe.",12905102_4,-1,-1,2,5068,-1
5069,Associated factors,0,2,0,18,"Associated factors were co-treatment with other centrally antimuscarinic agents, poor clinical outcome, older age, and longer hospitalization (by 17.5 days, increasing cost); sex, diagnosis or medical co-morbidity, and daily clozapine dose, which fell with age, were unrelated.",12905102_5,-1,-1,2,5069,-1
5076,fell with,42,44,247,256,"Associated factors were co-treatment with other centrally antimuscarinic agents, poor clinical outcome, older age, and longer hospitalization (by 17.5 days, increasing cost); sex, diagnosis or medical co-morbidity, and daily clozapine dose, which fell with age, were unrelated.",12905102_5,-1,-1,2,5076,-1
5077,clozapine-treated inpatients,9,11,43,71,"CONCLUSIONS: Delirium was found in 10 % of clozapine-treated inpatients, particularly in older patients exposed to other central anticholinergics.",12905102_6,-1,-1,2,5077,-1
5078,associated with,10,12,74,89,"Delirium was inconsistently recognized clinically in milder cases and was associated with increased length-of-stay and higher costs, and inferior clinical outcome.",12905102_7,-1,-1,2,5078,-1
5086,associated with,15,17,120,135,"Neuroprotective action of MPEP, a selective mGluR5 antagonist, in methamphetamine-induced dopaminergic neurotoxicity is associated with a decrease in dopamine outflow and inhibition of hyperthermia in rats.",12907309_0,-1,-1,2,5086,-1
5106,MPEP,3,4,28,32,"Neuroprotection rendered by MPEP may be associated with the reduction of the methamphetamine-induced dopamine efflux in the striatum due to the blockade of extrastriatal mGluR5, and with a decrease in hyperthermia.",12907309_8,-1,-1,2,5106,-1
5107,associated with,6,8,40,55,"Neuroprotection rendered by MPEP may be associated with the reduction of the methamphetamine-induced dopamine efflux in the striatum due to the blockade of extrastriatal mGluR5, and with a decrease in hyperthermia.",12907309_8,-1,-1,2,5107,-1
5136,preclinical assessments,20,22,117,140,They offer protection against seizures in a range of models and seem to inhibit certain stages of drug dependence in preclinical assessments.,12921865_2,-1,-1,2,5136,-1
5141,cocaine engendered,35,37,233,251,The present study was designed to evaluate two endogenous and one synthetic neuroactive steroid that positively modulate the gamma-aminobutyric acid (GABA(A)) receptor against the increase in sensitivity to the convulsant effects of cocaine engendered by repeated cocaine administration (seizure kindling).,12921865_3,-1,-1,2,5141,-1
5159,associated with,12,14,89,104,"Allopregnanolone and pregnanolone, but not ganaxolone, also reduced cumulative lethality associated with kindling.",12921865_7,-1,-1,2,5159,-1
5162,effects of,28,30,193,203,These findings demonstrate that some neuroactive steroids attenuate convulsant and sensitizing properties of cocaine and add to a growing literature on their potential use in the modulation of effects of drugs of abuse.,12921865_8,-1,-1,2,5162,-1
5163,deleterious effect,1,3,10,28,Potential deleterious effect of furosemide in radiocontrast nephropathy.,1300436_0,-1,-1,2,5163,-1
5169,controlled trial,26,28,155,171,"18 patients, referred to a radiocontrast study, considered at risk because of preexisting renal insufficiency, were enrolled in a prospective, randomized, controlled trial, performed at the secondary care center of a 1,100-bed private university hospital.",1300436_2,-1,-1,2,5169,-1
5172,treatment group,6,8,27,42,"In addition to fluids, the treatment group received furosemide (mean dose 110 mg) intravenously 30 min prior to the injection of contrast material.",1300436_3,-1,-1,2,5172,-1
5175,control group,1,3,4,17,The control group received fluids (mean 3 liters).,1300436_4,-1,-1,2,5175,-1
5180,pretreated,7,8,55,65,"Renal function significantly deteriorated in the group pretreated with furosemide (p < 0.005 by ANOVA), with a rise in serum creatinine from 145 +/- 13 to 182 +/- 16 mumol/l at 24 h, while no change occurred in the control group (from 141 +/- 6 to 142 +/- 7 mumol/l).",1300436_6,-1,-1,2,5180,-1
5182,/-,27,28,146,148,"Renal function significantly deteriorated in the group pretreated with furosemide (p < 0.005 by ANOVA), with a rise in serum creatinine from 145 +/- 13 to 182 +/- 16 mumol/l at 24 h, while no change occurred in the control group (from 141 +/- 6 to 142 +/- 7 mumol/l).",1300436_6,0,1,2,5182,-1
5183,/-,32,33,160,162,"Renal function significantly deteriorated in the group pretreated with furosemide (p < 0.005 by ANOVA), with a rise in serum creatinine from 145 +/- 13 to 182 +/- 16 mumol/l at 24 h, while no change occurred in the control group (from 141 +/- 6 to 142 +/- 7 mumol/l).",1300436_6,0,1,2,5183,-1
5186,/-,51,52,240,242,"Renal function significantly deteriorated in the group pretreated with furosemide (p < 0.005 by ANOVA), with a rise in serum creatinine from 145 +/- 13 to 182 +/- 16 mumol/l at 24 h, while no change occurred in the control group (from 141 +/- 6 to 142 +/- 7 mumol/l).",1300436_6,0,1,2,5186,-1
5187,/-,56,57,253,255,"Renal function significantly deteriorated in the group pretreated with furosemide (p < 0.005 by ANOVA), with a rise in serum creatinine from 145 +/- 13 to 182 +/- 16 mumol/l at 24 h, while no change occurred in the control group (from 141 +/- 6 to 142 +/- 7 mumol/l).",1300436_6,0,1,2,5187,-1
5197,pretreatment,11,12,88,100,Thromboembolic and other complications of oral contraceptive therapy in relationship to pretreatment levels of blood coagulation factors: summary report of a ten-year study.,133615_2,-1,-1,2,5197,-1
5198,blood coagulation factors,14,17,111,136,Thromboembolic and other complications of oral contraceptive therapy in relationship to pretreatment levels of blood coagulation factors: summary report of a ten-year study.,133615_2,-1,-1,2,5198,-1
5199,ten-year study,22,24,158,172,Thromboembolic and other complications of oral contraceptive therapy in relationship to pretreatment levels of blood coagulation factors: summary report of a ten-year study.,133615_2,-1,-1,2,5199,-1
5200,ten-year period,2,4,9,24,"During a ten-year period, 348 women were studied for a total of 5,877 patient months in four separate studies relating oral contraceptives to changes in hematologic parameters.",133615_3,-1,-1,2,5200,-1
5207,base-line values,16,18,107,123,"One of these patients developed a myocardial infarction before receiving any medication, shortly after the base-line values were obtained.",133615_8,-1,-1,2,5207,-1
5209,possiblility,4,5,31,43,Previous studies suggested the possiblility of increased propensity for thromboembolic episodes in patients possessing the A antigen.,133615_12,-1,-1,2,5209,-1
5212,work-ups,7,8,44,52,It appears from these data that hematologic work-ups may be useful in women who are about to start long-term oral contraceptive therapy.,133615_13,-1,-1,2,5212,-1
5216,hypertensive rats.1,12,14,126,145,Orthostatic hypotension occurs following alpha 2-adrenoceptor blockade in chronic prazosin-pretreated conscious spontaneously hypertensive rats.1.,1355091_0,-1,-1,2,5216,-1
5220,SHR,27,28,208,211,Studies were performed to evaluate whether chronic prazosin treatment alters the alpha 2-adrenoceptor function for orthostatic control of arterial blood pressure in conscious spontaneously hypertensive rats (SHR).,1355091_1,-1,-1,2,5220,-1
5221,Conscious SHR,2,4,3,16,2. Conscious SHR (male 300-350 g) were subjected to 90 degrees head-up tilts for 60 s following acute administration of prazosin (0.1 mg kg-1 i.p.) or rauwolscine (3 mg kg-1 i.v.).,1355091_2,-1,-1,2,5221,-1
5229,tilt period,22,24,121,132,Orthostatic hypotension was determined by the average decrease (%) in mean arterial pressure (MAP femoral) over the 60-s tilt period.,1355091_3,-1,-1,2,5229,-1
5231,conscious SHR,4,6,17,30,The basal MAP of conscious SHR was reduced to a similar extent by prazosin (-23%(-)-26% MAP) and rauwolscine (-16%(-)-33% MAP).,1355091_4,-1,-1,2,5231,-1
5235,SHR,10,11,65,68,"However, the head-up tilt induced orthostatic hypotension in the SHR treated with prazosin (-16% MAP, n = 6), but not in the SHR treated with rauwolscine (less than +2% MAP, n = 6).",1355091_5,-1,-1,2,5235,-1
5237,SHR,28,29,125,128,"However, the head-up tilt induced orthostatic hypotension in the SHR treated with prazosin (-16% MAP, n = 6), but not in the SHR treated with rauwolscine (less than +2% MAP, n = 6).",1355091_5,-1,-1,2,5237,-1
5240,Conscious SHR,2,4,3,16,3. Conscious SHR were treated for 4 days with prazosin at 2 mg kg-1 day-1 i.p. for chronic alpha 1-adrenoceptor blockade.,1355091_6,-1,-1,2,5240,-1
5241,kg-1,14,15,63,67,3. Conscious SHR were treated for 4 days with prazosin at 2 mg kg-1 day-1 i.p. for chronic alpha 1-adrenoceptor blockade.,1355091_6,-1,-1,2,5241,-1
5245,untreated SHR,15,17,80,93,MAP in conscious SHR after chronic prazosin treatment was 14% lower than in the untreated SHR (n = 8).,1355091_7,-1,-1,2,5245,-1
5251,kg-1,8,9,48,52,"Conversely, administration of rauwolscine (3 mg kg-1 i.v.) in chronic prazosin treated SHR decreased the basal MAP by 12-31% (n = 4), and subsequent tilts induced further drops of MAP by 19-23% in these rats.",1355091_9,-1,-1,2,5251,-1
5253,basal MAP,19,21,105,114,"Conversely, administration of rauwolscine (3 mg kg-1 i.v.) in chronic prazosin treated SHR decreased the basal MAP by 12-31% (n = 4), and subsequent tilts induced further drops of MAP by 19-23% in these rats.",1355091_9,-1,-1,2,5253,-1
5255,kg-1,17,18,97,101,"4. The pressor responses and bradycardia to the alpha 1-agonist cirazoline (0.6 and 2 micrograms kg-1 i.v.), the alpha 2-agonist Abbott-53693 (1 and 3 micrograms kg-1 i.v.), and noradrenaline (0.1 and 1.0 micrograms kg-1 i.v.) were determined in conscious SHR with and without chronic prazosin pretreatment.",1355091_10,-1,-1,2,5255,-1
5260,conscious SHR,50,52,246,259,"4. The pressor responses and bradycardia to the alpha 1-agonist cirazoline (0.6 and 2 micrograms kg-1 i.v.), the alpha 2-agonist Abbott-53693 (1 and 3 micrograms kg-1 i.v.), and noradrenaline (0.1 and 1.0 micrograms kg-1 i.v.) were determined in conscious SHR with and without chronic prazosin pretreatment.",1355091_10,-1,-1,2,5260,-1
5261,pretreatment,57,58,294,306,"4. The pressor responses and bradycardia to the alpha 1-agonist cirazoline (0.6 and 2 micrograms kg-1 i.v.), the alpha 2-agonist Abbott-53693 (1 and 3 micrograms kg-1 i.v.), and noradrenaline (0.1 and 1.0 micrograms kg-1 i.v.) were determined in conscious SHR with and without chronic prazosin pretreatment.",1355091_10,-1,-1,2,5261,-1
5264,untreated SHR,24,26,129,142,Both the pressor and bradycardia effects of cirazoline were abolished in chronic prazosin treated SHR (n = 4) as compared to the untreated SHR (n = 4).,1355091_11,-1,-1,2,5264,-1
5267,SHR,25,26,139,142,"On the other hand, the pressor effects of Abbott-53693 were similar in both groups of SHR, but the accompanying bradycardia was greater in SHR with chronic prazosin treatment than without such treatment.",1355091_12,-1,-1,2,5267,-1
5271,SHR.(ABSTRACT,36,37,235,248,"Furthermore, the bradycardia that accompanied the noradrenaline-induced pressor effect in SHR was similar with and without chronic prazosin treatment despite a 47-71% reduction of the pressor effect in chronic alpha 1-receptor blocked SHR.(ABSTRACT TRUNCATED AT 400 WORDS)",1355091_13,-1,-1,2,5271,-1
5273,morphine-induced increase,5,7,32,57,Effect of humoral modulators of morphine-induced increase in locomotor activity of mice.,137340_0,-1,-1,2,5273,-1
5274,locomotor activity,8,10,61,79,Effect of humoral modulators of morphine-induced increase in locomotor activity of mice.,137340_0,-1,-1,2,5274,-1
5277,locomotor activity,10,12,69,87,The effect of humoral modulators on the morphine-induced increase in locomotor activity of mice was studied.,137340_1,-1,-1,2,5277,-1
5279,morphine-HC1,7,8,47,59,The subcutaneous administration of 10 mg/kg of morphine-HC1 produced a marked increase in locomotor activity in mice.,137340_2,-1,-1,2,5279,-1
5280,locomotor activity,13,15,90,108,The subcutaneous administration of 10 mg/kg of morphine-HC1 produced a marked increase in locomotor activity in mice.,137340_2,-1,-1,2,5280,-1
5283,blood-brain barrier,13,15,78,97,"In contrast, both methscopolamine and neostigmine, which do not penetrate the blood-brain barrier, had no effect on the hyperactivity produced by morphine.",137340_4,-1,-1,2,5283,-1
5284,no effect,17,19,103,112,"In contrast, both methscopolamine and neostigmine, which do not penetrate the blood-brain barrier, had no effect on the hyperactivity produced by morphine.",137340_4,-1,-1,2,5284,-1
5288,activity-increasing effects,24,26,140,167,"Pretreatment of mice with alpha-methyltyrosine (20 mg/kg i.p., one hour), an inhibitor of tyrosine hydroxylase, significantly decreased the activity-increasing effects of morphine.",137340_5,-1,-1,2,5288,-1
5292,activity-increasing effects,5,7,28,55,The study suggests that the activity-increasing effects of morphine are mediated by the release of catecholamines from adrenergic neurons in the brain. And the results are consistent with the hypothesis that morphine acts by retarding the release of acetylcholine at some central cholinergic synapses.,137340_7,-1,-1,2,5292,-1
5293,consistent with,27,29,172,187,The study suggests that the activity-increasing effects of morphine are mediated by the release of catecholamines from adrenergic neurons in the brain. And the results are consistent with the hypothesis that morphine acts by retarding the release of acetylcholine at some central cholinergic synapses.,137340_7,-1,-1,2,5293,-1
5294,activity-increasing effects,9,11,54,81,It is also suggested from collected evidence that the activity-increasing effects of morphine in mice are mediated by mechanisms different from those which mediate the activity-increasing effects of morphine in rats.,137340_8,-1,-1,2,5294,-1
5295,activity-increasing effects,25,27,168,195,It is also suggested from collected evidence that the activity-increasing effects of morphine in mice are mediated by mechanisms different from those which mediate the activity-increasing effects of morphine in rats.,137340_8,-1,-1,2,5295,-1
5302,NX,16,17,99,101,"Rats with lithium-induced nephropathy were subjected to high protein (HP) feeding, uninephrectomy (NX) or a combination of these, in an attempt to induce glomerular hyperfiltration and further progression of renal failure.",1378968_1,-1,-1,2,5302,-1
5307,normal diet,20,22,110,121,"Newborn female Wistar rats were fed a lithium-containing diet (50 mmol/kg) for 8 weeks and then randomized to normal diet, HP diet (40 vs. 19%), NX or HP+NX for another 8 weeks.",1378968_2,-1,-1,2,5307,-1
5312,non-lithium-treated groups,6,8,42,68,"When comparing all lithium treated versus non-lithium-treated groups, lithium caused a reduction in glomerular filtration rate (GFR) without significant changes in effective renal plasma flow (as determined by a marker secreted into the proximal tubules) or lithium clearance.",1378968_4,-1,-1,2,5312,-1
5313,glomerular filtration rate,14,17,100,126,"When comparing all lithium treated versus non-lithium-treated groups, lithium caused a reduction in glomerular filtration rate (GFR) without significant changes in effective renal plasma flow (as determined by a marker secreted into the proximal tubules) or lithium clearance.",1378968_4,-1,-1,2,5313,-1
5315,renal plasma flow,25,28,174,191,"When comparing all lithium treated versus non-lithium-treated groups, lithium caused a reduction in glomerular filtration rate (GFR) without significant changes in effective renal plasma flow (as determined by a marker secreted into the proximal tubules) or lithium clearance.",1378968_4,-1,-1,2,5315,-1
5320,accentuante,3,4,13,24,HP failed to accentuante progression of renal failure and in fact tended to increase GFR and decrease plasma creatinine levels in lithium pretreated rats.,1378968_7,-1,-1,2,5320,-1
5328,NX+HP,0,1,0,5,NX+HP caused a further rise in blood pressure in Li-pretreated rats.,1378968_9,-1,-1,2,5328,-1
5333,associated with,17,19,97,112,"The results indicate that Li-induced nephropathy, even when the GFR is only modestly reduced, is associated with proteinuria and arterial systolic hypertension.",1378968_10,-1,-1,2,5333,-1
5337,renal plasma flow,20,23,114,131,"In this model of chronic renal failure the decline in GFR is not accompanied by a corresponding fall in effective renal plasma flow, which may be the functional expression of the formation of nonfiltrating atubular glomeruli.",1378968_11,-1,-1,2,5337,-1
5338,nonfiltrating,34,35,192,205,"In this model of chronic renal failure the decline in GFR is not accompanied by a corresponding fall in effective renal plasma flow, which may be the functional expression of the formation of nonfiltrating atubular glomeruli.",1378968_11,-1,-1,2,5338,-1
5344,associated with,2,4,26,41,Hemolytic-uremic syndrome associated with ingestion of quinine.,1415380_0,-1,-1,2,5344,-1
5346,plasma exchange,5,7,30,45,"Treatment has included use of plasma exchange, prednisone, aspirin, and dipyridamole.",1415380_4,-1,-1,2,5346,-1
5349,pharmacological treatment,6,8,31,56,"However, it is unclear whether pharmacological treatment or spontaneous resolution is responsible for the improvement.",1415380_6,-1,-1,2,5349,-1
5357,T-cell,6,7,35,41,Fusidic acid is an antibiotic with T-cell specific immunosuppressive effects similar to those of cyclosporin.,1420741_1,0,1,2,5357,-1
5361,pilot study,16,18,81,92,"Because of the need for the development of new treatments for Crohn's disease, a pilot study was undertaken to estimate the pharmacodynamics and tolerability of fusidic acid treatment in chronic active, therapy-resistant patients.",1420741_2,-1,-1,2,5361,-1
5369,grading score,10,12,69,82,The disease activity was primarily measured by a modified individual grading score.,1420741_5,-1,-1,2,5369,-1
5374,pilot study,4,6,20,31,The results of this pilot study suggest that fusidic acid may be of benefit in selected chronic active Crohn's disease patients in whom conventional treatment is ineffective.,1420741_10,-1,-1,2,5374,-1
5377,scientific rationale,6,8,31,51,"Because there seems to exist a scientific rationale for the use of fusidic acid at the cytokine level in inflammatory bowel disease, we suggest that the role of this treatment should be further investigated.",1420741_11,-1,-1,2,5377,-1
5380,associated with,2,4,18,33,Amnestic syndrome associated with propranolol toxicity: a case report.,1423339_0,-1,-1,2,5380,-1
5392,preliminary study,3,5,15,32,We performed a preliminary study in order to determine any difference between a non selective beta-blocker (timolol) and a selective beta-blocker (betaxolol) regarding CNS side effects.,1428568_2,-1,-1,2,5392,-1
5397,treated with,4,6,40,52,"Eight glaucomatous patients chronically treated with timolol 0.5%/12h, suffering from depression diagnosed through DMS-III-R criteria, were included in the study.",1428568_3,-1,-1,2,5397,-1
5398,DMS-III-R criteria,14,16,115,133,"Eight glaucomatous patients chronically treated with timolol 0.5%/12h, suffering from depression diagnosed through DMS-III-R criteria, were included in the study.",1428568_3,-1,-1,2,5398,-1
5401,Zung-Conde scales,13,15,79,96,"During the six-month follow up, depression was quantified through the Beck and Zung-Conde scales every two months.",1428568_4,-1,-1,2,5401,-1
5402,double blind cross-over study,2,6,5,34,"In a double blind cross-over study with control group, the patients under timolol treatment presented higher depression values measured through the Beck and the Zung-Conde scales (p < 0.001 vs control).",1428568_5,-1,-1,2,5402,-1
5403,control group,7,9,40,53,"In a double blind cross-over study with control group, the patients under timolol treatment presented higher depression values measured through the Beck and the Zung-Conde scales (p < 0.001 vs control).",1428568_5,-1,-1,2,5403,-1
5404,depression values,17,19,109,126,"In a double blind cross-over study with control group, the patients under timolol treatment presented higher depression values measured through the Beck and the Zung-Conde scales (p < 0.001 vs control).",1428568_5,-1,-1,2,5404,-1
5405,Zung-Conde scales,25,27,161,178,"In a double blind cross-over study with control group, the patients under timolol treatment presented higher depression values measured through the Beck and the Zung-Conde scales (p < 0.001 vs control).",1428568_5,-1,-1,2,5405,-1
5407,depression-inducer,10,11,56,74,These results suggest that betaxolol could be less of a depression-inducer than timolol in predisposed patients.,1428568_6,-1,-1,2,5407,-1
5412,LY274614,0,1,0,8,"LY274614, 3SR,4aRS,6SR,8aRS-6-[phosphonomethyl]decahydr oisoquinoline-3- carboxylic acid, has been described as a potent antagonist of the N-methyl-D-aspartate (NMDA) subtype of glutamate receptor.",1436384_1,-1,-1,2,5412,-1
5417,iprindole-treated,16,17,101,118,Here its ability to antagonize the prolonged depletion of dopamine in the striatum by amphetamine in iprindole-treated rats is reported.,1436384_2,-1,-1,2,5417,-1
5428,dose-dependent,6,7,38,52,"The protective effect of LY274614 was dose-dependent, being maximum at 10-40 mgkg (i.p.).",1436384_5,-1,-1,2,5428,-1
5434,dose-dependently,20,21,128,144,"The prolonged depletion of dopamine in the striatum in mice, given multiple injections of methamphetamine, was also antagonized dose-dependently and completely by LY274614.",1436384_8,-1,-1,2,5434,-1
5440,in vivo,31,33,226,233,The data strengthen the evidence that the neurotoxic effect of amphetamine and related compounds toward nigrostriatal dopamine neurons involves NMDA receptors and that LY274614 is an NMDA receptor antagonist with long-lasting in vivo effects in rats.,1436384_9,-1,-1,2,5440,-1
5443,drug-adsorption mechanism,6,8,33,58,Immune hemolytic anemia due to a drug-adsorption mechanism has been described primarily in patients receiving penicillins and first-generation cephalosporins.,1445986_1,-1,-1,2,5443,-1
5446,patient's,6,8,52,61,Cefotetan-dependent antibodies were detected in the patient's serum and in an eluate prepared from his red blood cells.,1445986_3,-1,-1,2,5446,-1
5447,red blood cells,16,19,103,118,Cefotetan-dependent antibodies were detected in the patient's serum and in an eluate prepared from his red blood cells.,1445986_3,-1,-1,2,5447,-1
5448,red blood cells,6,9,36,51,"The eluate also reacted weakly with red blood cells in the absence of cefotetan, suggesting the concomitant formation of warm-reactive autoantibodies.",1445986_4,-1,-1,2,5448,-1
5452,consistent with,15,17,105,120,"These observations, in conjunction with clinical and laboratory evidence of extravascular hemolysis, are consistent with drug-induced hemolytic anemia, possibly involving both drug-adsorption and autoantibody formation mechanisms.",1445986_5,-1,-1,2,5452,-1
5467,risk factors,5,7,30,42,"Due to the interdependence of risk factors in clinical populations, it is difficult to independently examine factors that may influence the development of LIDs.",14568327_2,-1,-1,2,5467,-1
5468,clinical populations,8,10,46,66,"Due to the interdependence of risk factors in clinical populations, it is difficult to independently examine factors that may influence the development of LIDs.",14568327_2,-1,-1,2,5468,-1
5473,response to,27,29,172,183,"Using macaque monkeys with different types of MPTP-induced parkinsonism, the current study evaluated the degree to which rate of symptom progression, symptom severity, and response to and duration of levodopa therapy may be involved in the development of LIDs.",14568327_3,-1,-1,2,5473,-1
5491,locomotor activity,6,8,35,53,"After a 30-min baseline measure of locomotor activity (day 0), animals were maintained on a cyclic diet of 12-h deprivation followed by 12-h access to 10% sucrose solution and chow pellets (12 h access starting 4 h after onset of the dark period) for 21 days.",14596845_3,-1,-1,2,5491,-1
5493,12-h deprivation,21,23,107,123,"After a 30-min baseline measure of locomotor activity (day 0), animals were maintained on a cyclic diet of 12-h deprivation followed by 12-h access to 10% sucrose solution and chow pellets (12 h access starting 4 h after onset of the dark period) for 21 days.",14596845_3,-1,-1,2,5493,-1
5497,ad libitum chow,10,13,49,64,"Beginning on day 22, all rats were maintained on ad libitum chow.",14596845_5,-1,-1,2,5497,-1
5501,control groups,18,20,120,134,"The animals that had experienced cyclic sucrose and chow were hyperactive in response to amphetamine compared with four control groups (ad libitum 10% sucrose and chow followed by amphetamine injection, cyclic chow followed by amphetamine injection, ad libitum chow with amphetamine, or cyclic 10% sucrose and chow with a saline injection).",14596845_7,-1,-1,2,5501,-1
5505,saline injection,55,57,322,338,"The animals that had experienced cyclic sucrose and chow were hyperactive in response to amphetamine compared with four control groups (ad libitum 10% sucrose and chow followed by amphetamine injection, cyclic chow followed by amphetamine injection, ad libitum chow with amphetamine, or cyclic 10% sucrose and chow with a saline injection).",14596845_7,-1,-1,2,5505,-1
5508,chow produces,17,19,106,119,"These results suggest that a diet comprised of alternating deprivation and access to a sugar solution and chow produces bingeing on sugar that leads to a long lasting state of increased sensitivity to amphetamine, possibly due to a lasting alteration in the dopamine system.",14596845_8,-1,-1,2,5508,-1
5516,IFS,16,17,90,93,AIM: Hemorrhagic cystitis (HC) is a limiting side-effect of chemotherapy with ifosfamide (IFS).,14633084_1,-1,-1,2,5516,-1
5519,HC,21,22,130,132,"In the study presented here, we investigated the use of dexamethasone in combination with mesna for the prevention of IFS-induced HC.",14633084_2,-1,-1,2,5519,-1
5532,IFS,13,14,88,91,"In addition, it almost abolished the macroscopic and microscopic alterations induced by IFS.",14633084_7,-1,-1,2,5532,-1
5537,HC,12,13,90,92,CONCLUSION: Dexamethasone in combination with mesna was efficient in blocking IFS-induced HC.,14633084_9,-1,-1,2,5537,-1
5540,HC,23,24,125,127,"However, the replacement of last two doses of mesna with saline or all of the mesna doses with dexamethasone did not prevent HC.",14633084_10,-1,-1,2,5540,-1
5544,associated with,2,4,17,32,Erythema nodosum associated with all- trans-retinoic acid (ATRA) for acute promyelocytic leukemia (APL) is very rare.,14648024_1,-1,-1,2,5544,-1
5553,D11,11,12,89,92,"Fever and subsequent multiple painful erythematous nodules over extremities developed on D11, D16, D17, and D19, respectively, after ATRA therapy.",14648024_3,-1,-1,2,5553,-1
5554,D16,13,14,94,97,"Fever and subsequent multiple painful erythematous nodules over extremities developed on D11, D16, D17, and D19, respectively, after ATRA therapy.",14648024_3,-1,-1,2,5554,-1
5555,D17,15,16,99,102,"Fever and subsequent multiple painful erythematous nodules over extremities developed on D11, D16, D17, and D19, respectively, after ATRA therapy.",14648024_3,-1,-1,2,5555,-1
5556,D19,18,19,108,111,"Fever and subsequent multiple painful erythematous nodules over extremities developed on D11, D16, D17, and D19, respectively, after ATRA therapy.",14648024_3,-1,-1,2,5556,-1
5557,ATRA therapy,23,25,133,145,"Fever and subsequent multiple painful erythematous nodules over extremities developed on D11, D16, D17, and D19, respectively, after ATRA therapy.",14648024_3,-1,-1,2,5557,-1
5559,consistent with,8,10,44,59,The skin biopsy taken from each patient was consistent with erythema nodosum.,14648024_4,-1,-1,2,5559,-1
5564,ATRA,8,9,63,67,All patients achieved complete remission without withdrawal of ATRA.,14648024_7,-1,-1,2,5564,-1
5577,AmB.,12,13,102,106,His echocardiographic abnormalities and heart failure resolved after posaconazole was substituted for AmB. It is important to recognize the rare and potentially reversible toxicity of AmB.,14657095_2,-1,-1,2,5577,-1
5587,time schedule,14,16,69,82,In those subjects who had no migraine attack (11 subjects) a similar time schedule was used.,14659530_5,-1,-1,2,5587,-1
5604,absolute pressure,7,9,37,54,"We then used hyperbaric oxygen at an absolute pressure of 2 atm, 5 days a week for 8 consecutive weeks.",1468485_3,-1,-1,2,5604,-1
5632,pharmacodynamic nature,10,12,55,77,"However, only two first combinations occurred to be of pharmacodynamic nature.",14704468_3,-1,-1,2,5632,-1
5655,treated with,4,6,19,31,METHODS: Rats were treated with intravenous doxorubicin (1 mg kg(-1) week(-1)) for 7 weeks and were sacrificed either 1 week ('short-term') or 30 weeks ('long-term') following the last dose.,14736955_3,-1,-1,2,5655,-1
5661,mitochondrial DNA,7,9,40,57,"Finally, we quantified both nuclear and mitochondrial DNA (mtDNA) as well as superoxide production and the 4834 base pair 'common' mtDNA deletion.",14736955_7,-1,-1,2,5661,-1
5663,superoxide production,15,17,77,98,"Finally, we quantified both nuclear and mitochondrial DNA (mtDNA) as well as superoxide production and the 4834 base pair 'common' mtDNA deletion.",14736955_7,-1,-1,2,5663,-1
5664,base pair,20,22,112,121,"Finally, we quantified both nuclear and mitochondrial DNA (mtDNA) as well as superoxide production and the 4834 base pair 'common' mtDNA deletion.",14736955_7,-1,-1,2,5664,-1
5673,short-term',2,4,4,15,"In 'short-term' rats, there were fewer tubular lesions, but similar numbers of glomerular lesions activity.",14736955_10,-1,-1,2,5673,-1
5682,cytoplasmic enzymes,44,46,330,349,"Among all animals, glomerular and tubular injury were inversely correlated with mtDNA levels, mtDNA-encoded respiratory chain activities and with the expression of the mtDNA-encoded respiratory chain subunit COX-I. Injury was positively correlated with superoxide production and the activities of nucleus-encoded mitochondrial or cytoplasmic enzymes.",14736955_11,-1,-1,2,5682,-1
5683,long-term' group,4,7,18,34,Kidneys from the 'long-term' group showed more mtDNA deletions than in 'short-term' animals and these were not observed in the other groups.,14736955_12,-1,-1,2,5683,-1
5684,mtDNA,9,10,47,52,Kidneys from the 'long-term' group showed more mtDNA deletions than in 'short-term' animals and these were not observed in the other groups.,14736955_12,-1,-1,2,5684,-1
5685,short-term',14,16,72,83,Kidneys from the 'long-term' group showed more mtDNA deletions than in 'short-term' animals and these were not observed in the other groups.,14736955_12,-1,-1,2,5685,-1
5690,crossover study,5,7,34,49,"A randomized, placebo-controlled, crossover study of ephedrine for SSRI-induced female sexual dysfunction.",14742097_0,-1,-1,2,5690,-1
5699,double-blind,17,18,124,136,"Nineteen sexually dysfunctional women receiving either fluoxetine, sertraline, or paroxetine participated in an eight-week, double-blind, placebo-controlled, cross-over study of the effects of ephedrine (50 mg) on self-report measures of sexual desire, arousal, orgasm, and sexual satisfaction.",14742097_2,-1,-1,2,5699,-1
5700,placebo-controlled,19,20,138,156,"Nineteen sexually dysfunctional women receiving either fluoxetine, sertraline, or paroxetine participated in an eight-week, double-blind, placebo-controlled, cross-over study of the effects of ephedrine (50 mg) on self-report measures of sexual desire, arousal, orgasm, and sexual satisfaction.",14742097_2,-1,-1,2,5700,-1
5701,cross-over study,21,23,158,174,"Nineteen sexually dysfunctional women receiving either fluoxetine, sertraline, or paroxetine participated in an eight-week, double-blind, placebo-controlled, cross-over study of the effects of ephedrine (50 mg) on self-report measures of sexual desire, arousal, orgasm, and sexual satisfaction.",14742097_2,-1,-1,2,5701,-1
5710,placebo-controlled trials,7,9,54,79,These findings highlight the importance of conducting placebo-controlled trials for this condition.,14742097_4,-1,-1,2,5710,-1
5712,detrimental effect,11,13,63,81,Does hormone therapy for the treatment of breast cancer have a detrimental effect on memory and cognition?,14745746_0,-1,-1,2,5712,-1
5713,pilot study,1,3,2,13,A pilot study.,14745746_1,-1,-1,2,5713,-1
5714,pilot study,1,3,5,16,This pilot study examines whether hormone therapy for breast cancer affects cognition.,14745746_2,-1,-1,2,5714,-1
5720,control group,3,5,18,31,"Compared with the control group, the patients were impaired on a processing speed task (p=0.032) and on a measure of immediate verbal memory (p=0.026) after controlling for the use of hormone replacement therapy in both groups.",14745746_4,-1,-1,2,5720,-1
5727,hormonal therapy,14,16,97,113,The results showed specific impairments in processing speed and verbal memory in women receiving hormonal therapy for the treatment of breast cancer.,14745746_6,-1,-1,2,5727,-1
5731,preventative setting,13,15,69,89,In view of the increased use of hormone therapies in an adjuvant and preventative setting their impact on cognitive functioning should be investigated more thoroughly.,14745746_8,-1,-1,2,5731,-1
5736,tonic water,30,32,183,194,"Although the United States Food and Drug Administration banned its use for nocturnal leg cramps due to lack of safety and efficacy, quinine is widely available in beverages including tonic water and bitter lemon.",14765563_1,-1,-1,2,5736,-1
5738,anecdotal reports,1,3,9,26,"Numerous anecdotal reports suggest that products containing quinine may produce neurological complications, including confusion, altered mental status, seizures, and coma, particularly in older women.",14765563_2,-1,-1,2,5738,-1
5744,in vivo,8,10,60,67,Expression of p300 protects cardiac myocytes from apoptosis in vivo.,14975762_0,-1,-1,2,5744,-1
5746,cardiac-specific,7,8,50,66,Doxorubicin is an anti-tumor agent that represses cardiac-specific gene expression and induces myocardial cell apoptosis.,14975762_1,-1,-1,2,5746,-1
5747,gene expression,8,10,67,82,Doxorubicin is an anti-tumor agent that represses cardiac-specific gene expression and induces myocardial cell apoptosis.,14975762_1,-1,-1,2,5747,-1
5759,survival rate,9,11,63,76,"Compared with wild-type mice, transgenic mice exhibited higher survival rate as well as more preserved left ventricular function and cardiac expression of alpha-sarcomeric actin.",14975762_5,-1,-1,2,5759,-1
5761,cardiac expression,20,22,133,151,"Compared with wild-type mice, transgenic mice exhibited higher survival rate as well as more preserved left ventricular function and cardiac expression of alpha-sarcomeric actin.",14975762_5,-1,-1,2,5761,-1
5764,transgenic mice,11,13,75,90,Doxorubicin induced myocardial cell apoptosis in wild-type mice but not in transgenic mice.,14975762_6,-1,-1,2,5764,-1
5766,cardiac level,5,7,33,46,"Expression of p300 increased the cardiac level of bcl-2 and mdm-2, but not that of p53 or other members of the bcl-2 family.",14975762_7,-1,-1,2,5766,-1
5771,overexpression,4,5,32,46,These findings demonstrate that overexpression of p300 protects cardiac myocytes from doxorubicin-induced apoptosis and reduces the extent of acute heart failure in adult mice in vivo.,14975762_8,-1,-1,2,5771,-1
5775,in vivo,24,26,176,183,These findings demonstrate that overexpression of p300 protects cardiac myocytes from doxorubicin-induced apoptosis and reduces the extent of acute heart failure in adult mice in vivo.,14975762_8,-1,-1,2,5775,-1
5778,white woman,10,12,53,64,"In this report we describe the case of a 37-year-old white woman with Ebstein's anomaly, who developed a rare syndrome called platypnea-orthodeoxia, characterized by massive right-to-left interatrial shunting with transient profound hypoxia and cyanosis.",14976857_1,-1,-1,2,5778,-1
5782,ovale,8,9,41,46,"This shunt of blood via a patent foramen ovale occurred in the presence of a normal pulmonary artery pressure, and was probably precipitated by a propafenone overdose.",14976857_2,-1,-1,2,5782,-1
5787,peripheral vasodilatory effect,19,22,110,140,"This drug caused biventricular dysfunction, due to its negative inotropic effect, and hypotension, due to its peripheral vasodilatory effect.",14976857_3,-1,-1,2,5787,-1
5809,experimental model,17,19,131,149,Noxious chemical stimulation of rat facial mucosa increases intracranial blood flow through a trigemino-parasympathetic reflex--an experimental model for vascular dysfunctions in cluster headache.,15009014_0,-1,-1,2,5809,-1
5816,experimental model,1,3,3,21,An experimental model was developed in the rat to measure changes in lacrimation and intracranial blood flow following noxious chemical stimulation of facial mucosa.,15009014_3,-1,-1,2,5816,-1
5822,laser Doppler flowmetry,17,20,101,124,Blood flow was monitored in arteries of the exposed cranial dura mater and the parietal cortex using laser Doppler flowmetry.,15009014_4,-1,-1,2,5822,-1
5839,blood flow responses,1,4,4,24,The blood flow responses seem to be mediated by the release of acetylcholine and VIP within the meninges.,15009014_9,-1,-1,2,5839,-1
5847,BChEs,26,27,173,178,"Such organophosphorus (OP) compounds as diisopropylfluorophosphate (DFP), sarin and soman are potent inhibitors of acetylcholinesterases (AChEs) and butyrylcholinesterases (BChEs).",15036754_1,-1,-1,2,5847,-1
5852,Han-Wistar,27,28,155,165,The protective action of subcutaneously (SC) administered antidotes or their combinations in DFP (2.0 mg/kg BW) intoxication was studied in 9-10-weeks-old Han-Wistar male rats.,15036754_3,-1,-1,2,5852,-1
5869,treated with,2,4,9,21,The rats treated with DFP-atropine showed severe typical OP-induced toxicity signs.,15036754_7,-1,-1,2,5869,-1
5879,stage IIIE,5,7,47,57,"Atrial fibrillation following chemotherapy for stage IIIE diffuse large B-cell gastric lymphoma in a patient with myotonic dystrophy (Steinert's disease).The authors describe the unusual association between diffuse B-cell gastric lymphoma and myotonic dystrophy, the most common form of adult muscular dystrophy, and sudden atrial fibrillation following one cycle of doxorubicin-based chemotherapy in the same patient.",15042318_0,-1,-1,2,5879,-1
5887,doxorubicin-based chemotherapy,53,55,367,397,"Atrial fibrillation following chemotherapy for stage IIIE diffuse large B-cell gastric lymphoma in a patient with myotonic dystrophy (Steinert's disease).The authors describe the unusual association between diffuse B-cell gastric lymphoma and myotonic dystrophy, the most common form of adult muscular dystrophy, and sudden atrial fibrillation following one cycle of doxorubicin-based chemotherapy in the same patient.",15042318_0,-1,-1,2,5887,-1
5890,treated with,11,13,87,99,Atrial fibrillation or other cardiac arrhythmias are unusual complications in patients treated with chemotherapy.,15042318_1,-1,-1,2,5890,-1
5892,associated with,4,6,35,50,The cardiac toxicity intrinsically associated with the aggressive chemotherapy employed could function as a triggering factor for the arrhythmia in the predisposed myocardium of this patient.,15042318_2,-1,-1,2,5892,-1
5893,aggressive chemotherapy,7,9,55,78,The cardiac toxicity intrinsically associated with the aggressive chemotherapy employed could function as a triggering factor for the arrhythmia in the predisposed myocardium of this patient.,15042318_2,-1,-1,2,5893,-1
5896,lymphocyte reactivity,4,6,21,42,OBJECTIVE: To assess lymphocyte reactivity to dilevalol and to serum containing putative ex vivo dilevalol antigens or metabolites in a case of dilevalol-induced liver injury.,1504402_1,-1,-1,2,5896,-1
5903,Peripheral blood mononuclear cells,2,6,9,43,METHODS: Peripheral blood mononuclear cells collected from the patient were cultured in the presence of a solution of dilevalol and also with sera collected from a volunteer before and after dilevalol intake.,1504402_3,-1,-1,2,5903,-1
5906,healthy subject,9,11,57,72,A similar protocol was performed with lymphocytes from a healthy subject.,1504402_4,-1,-1,2,5906,-1
5913,No reactivity,0,2,0,13,No reactivity was found when lymphocytes from the healthy subject were tested under similar conditions.,1504402_7,-1,-1,2,5913,-1
5914,healthy subject,8,10,50,65,No reactivity was found when lymphocytes from the healthy subject were tested under similar conditions.,1504402_7,-1,-1,2,5914,-1
5915,lymphocyte sensitization,9,11,59,83,"CONCLUSIONS: The methodology used allowed the detection of lymphocyte sensitization to sera containing ex vivo-prepared dilevalol antigens, suggesting the involvement of an immunologic mechanism in dilevalol-induced liver injury.",1504402_8,-1,-1,2,5915,-1
5916,vivo-prepared,15,16,106,119,"CONCLUSIONS: The methodology used allowed the detection of lymphocyte sensitization to sera containing ex vivo-prepared dilevalol antigens, suggesting the involvement of an immunologic mechanism in dilevalol-induced liver injury.",1504402_8,-1,-1,2,5916,-1
5924,molecular basis,3,5,13,28,"However, the molecular basis for the decreased renal sodium excretion remains undefined.",15075188_2,-1,-1,2,5924,-1
5928,experimental group,1,3,3,21,"An experimental group of rats was treated with puromycin aminonucleoside (PAN; 180 mg/kg iv), whereas the control group received only vehicle.",15075188_4,-1,-1,2,5928,-1
5929,treated with,6,8,34,46,"An experimental group of rats was treated with puromycin aminonucleoside (PAN; 180 mg/kg iv), whereas the control group received only vehicle.",15075188_4,-1,-1,2,5929,-1
5931,control group,20,22,106,119,"An experimental group of rats was treated with puromycin aminonucleoside (PAN; 180 mg/kg iv), whereas the control group received only vehicle.",15075188_4,-1,-1,2,5931,-1
5936,inner stripe,11,13,71,83,The protein abundance of alpha-ENaC and beta-ENaC was increased in the inner stripe of the outer medulla (ISOM) and in the inner medulla (IM) but was not altered in the cortex.,15075188_6,-1,-1,2,5936,-1
5942,ISOM,8,9,50,54,"gamma-ENaC abundance was increased in the cortex, ISOM, and IM.",15075188_7,-1,-1,2,5942,-1
5945,laser-scanning confocal fluorescence microscopy,3,7,34,81,"Immunoperoxidase brightfield- and laser-scanning confocal fluorescence microscopy demonstrated increased targeting of alpha-ENaC, beta-ENaC, and gamma-ENaC subunits to the apical plasma membrane in the distal convoluted tubule (DCT2), connecting tubule, and cortical and medullary collecting duct segments.",15075188_8,-1,-1,2,5945,-1
5957,PAN-treated,21,22,156,167,"Immunoelectron microscopy further revealed an increased labeling of alpha-ENaC in the apical plasma membrane of cortical collecting duct principal cells of PAN-treated rats, indicating enhanced apical targeting of alpha-ENaC subunits.",15075188_9,-1,-1,2,5957,-1
5959,type 3,10,12,60,66,"In contrast, the protein abundances of Na(+)/H(+) exchanger type 3 (NHE3), Na(+)-K(+)-2Cl(-) cotransporter (BSC-1), and thiazide-sensitive Na(+)-Cl(-) cotransporter (TSC) were decreased.",15075188_10,0,1,2,5959,-1
5964,TSC,29,30,166,169,"In contrast, the protein abundances of Na(+)/H(+) exchanger type 3 (NHE3), Na(+)-K(+)-2Cl(-) cotransporter (BSC-1), and thiazide-sensitive Na(+)-Cl(-) cotransporter (TSC) were decreased.",15075188_10,-1,-1,2,5964,-1
5970,apical targeting,14,16,94,110,"In conclusion, the increased or sustained expression of ENaC subunits combined with increased apical targeting in the DCT2, connecting tubule, and collecting duct are likely to play a role in the sodium retention associated with PAN-induced nephrotic syndrome.",15075188_12,-1,-1,2,5970,-1
5971,DCT2,18,19,118,122,"In conclusion, the increased or sustained expression of ENaC subunits combined with increased apical targeting in the DCT2, connecting tubule, and collecting duct are likely to play a role in the sodium retention associated with PAN-induced nephrotic syndrome.",15075188_12,-1,-1,2,5971,-1
5977,BSC-1,6,7,33,38,"The decreased abundance of NHE3, BSC-1, TSC, and Na-K-ATPase may play a compensatory role to promote sodium excretion.",15075188_13,-1,-1,2,5977,-1
5978,TSC,8,9,40,43,"The decreased abundance of NHE3, BSC-1, TSC, and Na-K-ATPase may play a compensatory role to promote sodium excretion.",15075188_13,-1,-1,2,5978,-1
5988,no effect,3,5,14,23,"A placebo had no effect, but niacinamide was as effective as pyridoxine.",150790_4,-1,-1,2,5988,-1
5990,associated with,5,7,38,53,Periodic withdrawal of pyridoxine was associated with return of the hyperkinesis.,150790_5,-1,-1,2,5990,-1
6001,posteroventral pallidotomy,26,28,160,186,Pallidal stimulation: an alternative to pallidotomy?A resurgence of interest in the surgical treatment of Parkinson's disease (PD) came with the rediscovery of posteroventral pallidotomy by Laitinen in 1985.,15096016_0,-1,-1,2,6001,-1
6009,success rates,22,24,163,176,"Another lesioning procedure, ventrolateral thalamotomy, has become a powerful alternative to stimulate the nucleus ventralis intermedius, producing high long-term success rates and low morbidity rates.",15096016_2,-1,-1,2,6009,-1
6017,"""freezing""",16,19,101,111,"Stimulation often produces an improvement in the hyper- or dyskinetic upper limbs, but increases the ""freezing"" phenomenon in the lower limbs at the same time.",15096016_6,-1,-1,2,6017,-1
6028,C57BL/6,25,26,161,168,"Similar to rats, systemic pilocarpine injection causes status epilepticus (SE) and the eventual development of spontaneous seizures and mossy fiber sprouting in C57BL/6 and CD1 mice, but the physiological correlates of these events have not been identified in mice.",15120741_1,-1,-1,2,6028,-1
6029,CD1 mice,27,29,173,181,"Similar to rats, systemic pilocarpine injection causes status epilepticus (SE) and the eventual development of spontaneous seizures and mossy fiber sprouting in C57BL/6 and CD1 mice, but the physiological correlates of these events have not been identified in mice.",15120741_1,-1,-1,2,6029,-1
6030,Population responses,0,2,0,20,Population responses in granule cells of the dentate gyrus were examined in transverse slices of the ventral hippocampus from pilocarpine-treated and untreated mice.,15120741_2,-1,-1,2,6030,-1
6031,granule cells,3,5,24,37,Population responses in granule cells of the dentate gyrus were examined in transverse slices of the ventral hippocampus from pilocarpine-treated and untreated mice.,15120741_2,-1,-1,2,6031,-1
6035,untreated mice,21,23,150,164,Population responses in granule cells of the dentate gyrus were examined in transverse slices of the ventral hippocampus from pilocarpine-treated and untreated mice.,15120741_2,-1,-1,2,6035,-1
6039,granule cells,28,30,191,204,"In Mg(2+)-free bathing medium containing bicuculline, conditions designed to increase excitability in the slices, electrical stimulation of the hilus resulted in a single population spike in granule cells from control mice and pilocarpine-treated mice that did not experience SE.",15120741_3,-1,-1,2,6039,-1
6040,control mice,31,33,210,222,"In Mg(2+)-free bathing medium containing bicuculline, conditions designed to increase excitability in the slices, electrical stimulation of the hilus resulted in a single population spike in granule cells from control mice and pilocarpine-treated mice that did not experience SE.",15120741_3,-1,-1,2,6040,-1
6041,pilocarpine-treated mice,34,36,227,251,"In Mg(2+)-free bathing medium containing bicuculline, conditions designed to increase excitability in the slices, electrical stimulation of the hilus resulted in a single population spike in granule cells from control mice and pilocarpine-treated mice that did not experience SE.",15120741_3,-1,-1,2,6041,-1
6042,SE survivors,1,3,3,15,"In SE survivors, similar stimulation resulted in a population spike followed, at a variable latency, by negative DC shifts and repetitive afterdischarges of 3-60 s duration, which were blocked by ionotropic glutamate receptor antagonists.",15120741_4,-1,-1,2,6042,-1
6043,variable latency,15,17,83,99,"In SE survivors, similar stimulation resulted in a population spike followed, at a variable latency, by negative DC shifts and repetitive afterdischarges of 3-60 s duration, which were blocked by ionotropic glutamate receptor antagonists.",15120741_4,-1,-1,2,6043,-1
6047,photostimulation,2,3,16,32,Focal glutamate photostimulation of the granule cell layer at sites distant from the recording pipette resulted in population responses of 1-30 s duration in slices from SE survivors but not other groups.,15120741_5,-1,-1,2,6047,-1
6049,population responses,17,19,115,135,Focal glutamate photostimulation of the granule cell layer at sites distant from the recording pipette resulted in population responses of 1-30 s duration in slices from SE survivors but not other groups.,15120741_5,-1,-1,2,6049,-1
6050,SE survivors,28,30,170,182,Focal glutamate photostimulation of the granule cell layer at sites distant from the recording pipette resulted in population responses of 1-30 s duration in slices from SE survivors but not other groups.,15120741_5,-1,-1,2,6050,-1
6063,case-control study,7,9,36,54,"Nested within the cohort, a matched case-control study was performed to estimate the association between cyclophosphamide and bladder cancer using odds ratios (ORs) as relative risk.",15130900_4,-1,-1,2,6063,-1
6067,relative risk,27,29,168,181,"Nested within the cohort, a matched case-control study was performed to estimate the association between cyclophosphamide and bladder cancer using odds ratios (ORs) as relative risk.",15130900_4,-1,-1,2,6067,-1
6070,relative prevalence,16,18,92,111,"In the cohort the cumulative risk of bladder cancer after Wegener's granulomatosis, and the relative prevalence of a history of bladder cancer at the time of diagnosis of Wegener's granulomatosis, were also estimated.",15130900_5,-1,-1,2,6070,-1
6076,confidence interval,20,22,95,114,"The risk of bladder cancer doubled for every 10 g increment in cyclophosphamide (OR = 2.0, 95% confidence interval (CI) 0.8 to 4.9).",15130900_7,-1,-1,2,6076,-1
6077,associated with,7,9,42,57,"Treatment duration longer than 1 year was associated with an eightfold increased risk (OR = 7.7, 95% CI 0.9 to 69).",15130900_8,-1,-1,2,6077,-1
6083,dose-response,6,7,35,48,"CONCLUSION: The results indicate a dose-response relationship between cyclophosphamide and the risk of bladder cancer, high cumulative risks in the entire cohort, and also the possibility of risk factors operating even before Wegener's granulomatosis.",15130900_10,-1,-1,2,6083,-1
6086,risk factors,30,32,191,203,"CONCLUSION: The results indicate a dose-response relationship between cyclophosphamide and the risk of bladder cancer, high cumulative risks in the entire cohort, and also the possibility of risk factors operating even before Wegener's granulomatosis.",15130900_10,-1,-1,2,6086,-1
6088,Differential modulation,0,2,0,23,Differential modulation by estrogen of alpha2-adrenergic and I1-imidazoline receptor-mediated hypotension in female rats.,15145918_0,-1,-1,2,6088,-1
6090,I1-imidazoline receptor-mediated,7,9,61,93,Differential modulation by estrogen of alpha2-adrenergic and I1-imidazoline receptor-mediated hypotension in female rats.,15145918_0,-1,-1,2,6090,-1
6105,Ovx,46,47,310,313,"Changes evoked by a single intraperitoneal injection of rilmenidine (600 microg/kg) or alpha-methyldopa (100 mg/kg), selective I1- and alpha2-receptor agonists, respectively, in blood pressure, hemodynamic variability, and locomotor activity were assessed in radiotelemetered sham-operated and ovariectomized (Ovx) Sprague-Dawley female rats with or without 12-wk estrogen replacement.",15145918_3,-1,-1,2,6105,-1
6111,beat-to-beat intervals,29,31,190,212,Three time domain indexes of hemodynamic variability were employed: the standard deviation of mean arterial pressure as a measure of blood pressure variability and the standard deviation of beat-to-beat intervals (SDRR) and the root mean square of successive differences in R-wave-to-R-wave intervals as measures of heart rate variability.,15145918_4,-1,-1,2,6111,-1
6112,SDRR,32,33,214,218,Three time domain indexes of hemodynamic variability were employed: the standard deviation of mean arterial pressure as a measure of blood pressure variability and the standard deviation of beat-to-beat intervals (SDRR) and the root mean square of successive differences in R-wave-to-R-wave intervals as measures of heart rate variability.,15145918_4,-1,-1,2,6112,-1
6113,root mean square,36,39,228,244,Three time domain indexes of hemodynamic variability were employed: the standard deviation of mean arterial pressure as a measure of blood pressure variability and the standard deviation of beat-to-beat intervals (SDRR) and the root mean square of successive differences in R-wave-to-R-wave intervals as measures of heart rate variability.,15145918_4,-1,-1,2,6113,-1
6114,R-wave-to-R-wave,43,44,274,290,Three time domain indexes of hemodynamic variability were employed: the standard deviation of mean arterial pressure as a measure of blood pressure variability and the standard deviation of beat-to-beat intervals (SDRR) and the root mean square of successive differences in R-wave-to-R-wave intervals as measures of heart rate variability.,15145918_4,-1,-1,2,6114,-1
6119,associated with,18,20,117,132,"In sham-operated rats, rilmenidine or alpha-methyldopa elicited similar hypotension that lasted at least 5 h and was associated with reductions in standard deviation of mean arterial pressure.",15145918_5,-1,-1,2,6119,-1
6122,SDRR,0,1,0,4,SDRR was reduced only by alpha-methyldopa.,15145918_6,-1,-1,2,6122,-1
6125,hypotensive response,4,6,31,51,"Ovx significantly enhanced the hypotensive response to alpha-methyldopa, in contrast to no effect on rilmenidine hypotension.",15145918_7,-1,-1,2,6125,-1
6129,Ovx,5,6,45,48,The enhanced alpha-methyldopa hypotension in Ovx rats was paralleled with further reduction in SDRR and a reduced locomotor activity.,15145918_8,-1,-1,2,6129,-1
6131,locomotor activity,17,19,114,132,The enhanced alpha-methyldopa hypotension in Ovx rats was paralleled with further reduction in SDRR and a reduced locomotor activity.,15145918_8,-1,-1,2,6131,-1
6134,microg/day,8,9,65,75,"Estrogen replacement (17beta-estradiol subcutaneous pellet, 14.2 microg/day, 12 wk) of Ovx rats restored the hemodynamic and locomotor effects of alpha-methyldopa to sham-operated levels.",15145918_9,-1,-1,2,6134,-1
6138,sham-operated levels,25,27,166,186,"Estrogen replacement (17beta-estradiol subcutaneous pellet, 14.2 microg/day, 12 wk) of Ovx rats restored the hemodynamic and locomotor effects of alpha-methyldopa to sham-operated levels.",15145918_9,-1,-1,2,6138,-1
6160,alcoholic extract,8,10,32,49,"Tincture of Crataegus (TCR), an alcoholic extract of the berries of hawthorn (Crataegus oxycantha), is used in herbal and homeopathic medicine.",15233872_1,-1,-1,2,6160,-1
6161,Crataegus oxycantha,16,18,78,97,"Tincture of Crataegus (TCR), an alcoholic extract of the berries of hawthorn (Crataegus oxycantha), is used in herbal and homeopathic medicine.",15233872_1,-1,-1,2,6161,-1
6166,Pretreatment,0,1,0,12,"Pretreatment of TCR, at a dose of 0.5 mL/100 g bodyweight per day, orally for 30 days, prevented the increase in lipid peroxidation and activity of marker enzymes observed in isoproterenol-induced rats (85 mg kg(-1) s. c. for 2 days at an interval of 24 h).",15233872_3,-1,-1,2,6166,-1
6169,isoproterenol-induced rats,33,35,175,201,"Pretreatment of TCR, at a dose of 0.5 mL/100 g bodyweight per day, orally for 30 days, prevented the increase in lipid peroxidation and activity of marker enzymes observed in isoproterenol-induced rats (85 mg kg(-1) s. c. for 2 days at an interval of 24 h).",15233872_3,-1,-1,2,6169,-1
6171,isoproterenol-induced decrease,3,5,18,48,TCR prevented the isoproterenol-induced decrease in antioxidant enzymes in the heart and increased the rate of ADP-stimulated oxygen uptake and respiratory coupling ratio.,15233872_4,-1,-1,2,6171,-1
6172,ADP-stimulated,16,17,111,125,TCR prevented the isoproterenol-induced decrease in antioxidant enzymes in the heart and increased the rate of ADP-stimulated oxygen uptake and respiratory coupling ratio.,15233872_4,-1,-1,2,6172,-1
6173,respiratory coupling ratio,20,23,144,170,TCR prevented the isoproterenol-induced decrease in antioxidant enzymes in the heart and increased the rate of ADP-stimulated oxygen uptake and respiratory coupling ratio.,15233872_4,-1,-1,2,6173,-1
6186,treated with,21,23,162,174,"We evaluated cardiovascular event data for valdecoxib, a new COX-2-specific inhibitor in approximately 8000 patients with osteoarthritis and rheumatoid arthritis treated with this agent in randomized clinical trials.",15266215_2,-1,-1,2,6186,-1
6193,incidence rates,1,3,4,19,The incidence rates of events were determined in all patients (n = 7934) and in users of low-dose (< or =325 mg daily) aspirin (n = 1051) and nonusers of aspirin (n = 6883).,15266215_4,-1,-1,2,6193,-1
6200,treatment groups,13,15,63,79,The rates of events in users of aspirin were similar for all 3 treatment groups and across valdecoxib doses.,15266215_8,-1,-1,2,6200,-1
6205,associated with,26,28,142,157,Short- and intermediate-term treatment with therapeutic (10 or 20 mg daily) and supratherapeutic (40 or 80 mg daily) valdecoxib doses was not associated with an increased incidence of thrombotic events relative to nonselective NSAIDs or placebo in osteoarthritis and rheumatoid arthritis patients in controlled clinical trials.,15266215_9,-1,-1,2,6205,-1
6214,admitted with,12,14,79,92,"The 47-year-old female patient, known to have hypertrophic cardiomyopathy, was admitted with biventricular failure and managed aggressively with dobutamine infusion and other drugs while being assessed for heart transplantation.",15266362_2,-1,-1,2,6214,-1
6231,IST,4,5,32,35,Idiopathic subjective tinnitus (IST) is one of the most obscure otological pathologies.,1527456_1,-1,-1,2,6231,-1
6233,IST,7,8,44,47,"This paper presents the results of treating IST by intratympanic instillation of lignocaine (lidocaine) 2 per cent through a grommet, for five weekly courses.",1527456_2,-1,-1,2,6233,-1
6236,therapeutic trial,8,10,68,85,"Fifty-two patients suffering from intractable tinnitus entered this therapeutic trial, but only nine finished all five courses.",1527456_3,-1,-1,2,6236,-1
6238,treated by,11,13,68,78,"We suggest this mode of treatment for patients that were previously treated by drugs, acupuncture and biofeedback, with disappointing results.",1527456_5,-1,-1,2,6238,-1
6269,mitral cell layer,30,33,180,197,"Using in situ hybridization probes for the alpha3 and alpha5 subunits, we showed that alpha5 mRNA levels are unchanged, whereas alpha3 mRNA levels are selectively decreased in the mitral cell layer of the olfactory bulb, and the inferior and the superior colliculus of beta4 -/- brains.",15275829_6,-1,-1,2,6269,-1
6275,wild-type,13,14,87,96,alpha3 +/- mice were partially resistant to nicotine-induced seizures when compared to wild-type littermates.,15275829_7,-1,-1,2,6275,-1
6276,littermates,14,15,97,108,alpha3 +/- mice were partially resistant to nicotine-induced seizures when compared to wild-type littermates.,15275829_7,-1,-1,2,6276,-1
6280,/- brains,14,16,76,85,mRNA levels for the alpha5 and the beta4 subunits were unchanged in alpha3 +/- brains.,15275829_8,-1,-1,2,6280,-1
6289,time period,36,38,230,241,"The annual incidence of warfarin-related bleeding at Brigham and Women's Hospital increased from 0.97/1,000 patient admissions in the first time period (January 1995 to October 1998) to 1.19/1,000 patient admissions in the second time period (November 1998 to August 2002) of this study.",15276120_1,-1,-1,2,6289,-1
6291,time period,22,24,122,133,"The proportion of patients with major and intracranial bleeding increased from 20.2% and 1.9%, respectively, in the first time period, to 33.3% and 7.8%, respectively, in the second.",15276120_2,-1,-1,2,6291,-1
6296,/-,12,13,49,51,"The convulsive threshold (mean +/- SD) was 41.4 +/- 6.5 mg. l(-1) with lidocaine infusion (6 mg.kg(-1).min(-1)), increasing significantly to 66.6 +/- 10.9 mg. l(-1) when the end-tidal concentration of sevoflurane was 0.8%.",15278670_2,0,1,2,6296,-1
6300,/-,7,8,30,32,"However, the threshold (61.6 +/- 8.7 mg. l(-1)) during 1.6% sevoflurane was not significant from that during 0.8% sevoflurane, indicating a celling effect.",15278670_3,0,1,2,6300,-1
6303,celling effect,30,32,140,154,"However, the threshold (61.6 +/- 8.7 mg. l(-1)) during 1.6% sevoflurane was not significant from that during 0.8% sevoflurane, indicating a celling effect.",15278670_3,-1,-1,2,6303,-1
6310,mmHg,19,20,129,133,"However, there was no significant difference in the lidocaine concentrations measured when the systolic blood pressure became 70 mmHg.",15278670_6,-1,-1,2,6310,-1
6318,statistically significant,32,34,125,150,Apamin (10 ng) had a tendency to decrease the convulsive threshold (21.6 +/- 2.2 to 19.9 +/- 2.5 mg. l(-1)) but this was not statistically significant.,15278670_8,-1,-1,2,6318,-1
6320,convulsive effect,7,9,45,62,It is suggested that sevoflurane reduces the convulsive effect of lidocaine toxicity but carries some risk due to circulatory depression.,15278670_9,-1,-1,2,6320,-1
6328,nonhematological,5,6,19,35,"In high doses, its nonhematological dose-limiting toxicity is cardiomyopathy.",15325671_2,-1,-1,2,6328,-1
6329,dose-limiting,6,7,36,49,"In high doses, its nonhematological dose-limiting toxicity is cardiomyopathy.",15325671_2,-1,-1,2,6329,-1
6342,CHF,34,35,264,267,"Analysis was performed on 61 women with chemotherapy-responsive metastatic breast cancer receiving 96-h infusional cyclophosphamide as part of a triple sequential high-dose regimen to assess association between presence of peritransplant congestive heart failure (CHF) and the following pretreatment characteristics: presence of electrocardiogram (EKG) abnormalities, age, hypertension, prior cardiac history, smoking, diabetes mellitus, prior use of anthracyclines, and left-sided chest irradiation.",15325671_4,-1,-1,2,6342,-1
6349,CHF,15,16,71,74,RESULTS: Six of 61 women (10%) developed clinically reversible grade 3 CHF following infusional cyclophosphamide with a median percent decline in ejection fraction of 31%.,15325671_5,-1,-1,2,6349,-1
6351,ejection fraction,25,27,146,163,RESULTS: Six of 61 women (10%) developed clinically reversible grade 3 CHF following infusional cyclophosphamide with a median percent decline in ejection fraction of 31%.,15325671_5,-1,-1,2,6351,-1
6354,CHF,7,8,48,51,"Older age was significantly correlated with the CHF development; with median ages for the entire group and for patients developing CHF of 45 and 59, respectively.",15325671_7,-1,-1,2,6354,-1
6355,entire group,15,17,90,102,"Older age was significantly correlated with the CHF development; with median ages for the entire group and for patients developing CHF of 45 and 59, respectively.",15325671_7,-1,-1,2,6355,-1
6356,CHF,21,22,131,134,"Older age was significantly correlated with the CHF development; with median ages for the entire group and for patients developing CHF of 45 and 59, respectively.",15325671_7,-1,-1,2,6356,-1
6357,No association,0,2,0,14,No association was found with other pretreatment characteristics.,15325671_8,-1,-1,2,6357,-1
6366,low-priced method,15,17,86,103,"OBJECTIVE: To study tremor side effects of salbutamol an easily applicable, quick and low-priced method is needed.",15338796_1,-1,-1,2,6366,-1
6367,pen-shaped laser pointer,8,11,45,69,"A new method using a commercially available, pen-shaped laser pointer was developed.",15338796_2,-1,-1,2,6367,-1
6368,reference values,11,13,64,80,"Aim of the study was to determine sensitivity, reproducibility, reference values and the agreement with a questionnaire.",15338796_3,-1,-1,2,6368,-1
6369,laser pointer technique,7,10,37,60,METHODS: Tremor was measured using a laser pointer technique.,15338796_4,-1,-1,2,6369,-1
6373,concentric circles,14,16,68,86,"Subjects were asked to aim at the centre of a target, subdivided in concentric circles, from 5 m distance.",15338796_6,-1,-1,2,6373,-1
6374,millimetres radius,12,14,69,87,The circle in which the participant succeeded to aim was recorded in millimetres radius.,15338796_7,-1,-1,2,6374,-1
6375,reference values,8,10,55,71,"In another series of measurements, reproducibility and reference values of the tremor was assessed in 65 healthy subjects in three sessions, at 9 a.m., 4 p.m. and 9 a.m., respectively, 1 week later.",15338796_8,-1,-1,2,6375,-1
6379,healthy subjects,9,11,58,74,Inter-observer variability was measured in a series of 10 healthy subjects.,15338796_10,-1,-1,2,6379,-1
6381,dose-dependent,11,12,77,91,RESULTS: Salbutamol significantly increased tremor severity in patients in a dose-dependent way.,15338796_12,-1,-1,2,6381,-1
6384,no significant,3,5,23,37,Postural tremor showed no significant difference between the first and third session (P = 0.07).,15338796_15,-1,-1,2,6384,-1
6387,reproducible method,25,27,132,151,"DISCUSSION: Quantifying tremor by using an inexpensive laser pointer is, with the exception of children (<12 years) a sensitive and reproducible method.",15338796_18,-1,-1,2,6387,-1
6424,standard practice,1,3,3,20,"As standard practice at our institution, patients who are scheduled to receive a bone marrow transplant are treated prophylactically with forced hydration and bladder irrigation.",1545575_2,-1,-1,2,6424,-1
6426,prophylactically,19,20,116,132,"As standard practice at our institution, patients who are scheduled to receive a bone marrow transplant are treated prophylactically with forced hydration and bladder irrigation.",1545575_2,-1,-1,2,6426,-1
6427,feasibility trial,14,16,81,98,"In an attempt to obviate the inconvenience of bladder irrigation, we conducted a feasibility trial of uroprophylaxis with mesna, which neutralizes the hepatic metabolite of cyclophosphamide that causes hemorrhagic cystitis.",1545575_3,-1,-1,2,6427,-1
6440,associated with,4,6,27,42,Safety and adverse effects associated with raloxifene: multiple outcomes of raloxifene evaluation.,15458908_0,-1,-1,2,6440,-1
6447,double-blind trial,14,16,84,102,"METHODS: The Multiple Outcomes of Raloxifene Evaluation, a multicenter, randomized, double-blind trial, enrolled 7,705 postmenopausal women with osteoporosis.",15458908_2,-1,-1,2,6447,-1
6453,associated with,12,14,62,77,"RESULTS: During a mean follow-up of 3.3 years, raloxifene was associated with an increased risk for venous thromboembolism (relative risk [RR] 2.1; 95% confidence interval [CI] 1.2-3.8).",15458908_5,-1,-1,2,6453,-1
6455,relative risk,21,23,124,137,"RESULTS: During a mean follow-up of 3.3 years, raloxifene was associated with an increased risk for venous thromboembolism (relative risk [RR] 2.1; 95% confidence interval [CI] 1.2-3.8).",15458908_5,-1,-1,2,6455,-1
6457,confidence interval,30,32,152,171,"RESULTS: During a mean follow-up of 3.3 years, raloxifene was associated with an increased risk for venous thromboembolism (relative risk [RR] 2.1; 95% confidence interval [CI] 1.2-3.8).",15458908_5,-1,-1,2,6457,-1
6469,associated with,4,6,27,42,"CONCLUSION: Raloxifene was associated with an increased risk for venous thromboembolism, but there was no increased risk for cataracts, gallbladder disease, endometrial hyperplasia, or endometrial cancer.",15458908_9,-1,-1,2,6469,-1
6474,LEVEL OF,0,2,0,8,LEVEL OF EVIDENCE: I,15458908_10,-1,-1,2,6474,-1
6476,general rule,27,29,167,179,"While there is no single correct starting dose for levodopa therapy, many individuals can be started on either the 25/100 or controlled-release formula, following the general rule not to attempt to titrate carbidopa-levodopa to the point of ""normality,"" which can lead to toxicity.",1549199_1,-1,-1,2,6476,-1
6480,standard approach,19,21,119,136,The physician should also determine the proper use of any adjunctive medications; such combined therapy has become the standard approach to treatment.,1549199_2,-1,-1,2,6480,-1
6495,beta-thalassemic,5,6,37,53,Long term audiological evaluation of beta-thalassemic patients.,15515654_0,-1,-1,2,6495,-1
6499,transfusion-chelation program,6,8,31,60,All patients were on a regular transfusion-chelation program maintaining a mean hemoglobin level of 9.5 gr/dl.,15515654_3,-1,-1,2,6499,-1
6507,SNHL,2,3,14,18,"Patients with SNHL presented with relatively lower serum ferritin levels than those with normal hearing, however, no statistically significant difference was observed.",15515654_8,-1,-1,2,6507,-1
6510,statistically significant,19,21,117,142,"Patients with SNHL presented with relatively lower serum ferritin levels than those with normal hearing, however, no statistically significant difference was observed.",15515654_8,-1,-1,2,6510,-1
6512,DFO,6,7,37,40,Subjects with SNHL were submitted to DFO reduction or temporary withdrawal.,15515654_9,-1,-1,2,6512,-1
6513,DFO's,7,9,43,48,CONCLUSION: The findings are indicative of DFO's contributing role in the development of hearing impairment.,15515654_11,-1,-1,2,6513,-1
6526,phase I,12,14,70,77,"Worldwide, over 650 patients have been transplanted in the context of phase I and II clinical trials.",15517007_2,-1,-1,2,6526,-1
6527,clinical trials,16,18,85,100,"Worldwide, over 650 patients have been transplanted in the context of phase I and II clinical trials.",15517007_2,-1,-1,2,6527,-1
6536,European Group,18,20,92,106,"The object of the meeting was to analyse existing data, both published or available, in the European Group for Blood and Marrow Transplantation autoimmune disease database, and to propose a safe approach to such patients.",15517007_9,-1,-1,2,6536,-1
6542,diabetes?BACKGROUND,11,12,79,98,"Does supplemental vitamin C increase cardiovascular disease risk in women with diabetes?BACKGROUND: Vitamin C acts as a potent antioxidant; however, it can also be a prooxidant and glycate protein under certain circumstances in vitro.",15531665_0,-1,-1,2,6542,-1
6545,in vitro,35,37,225,233,"Does supplemental vitamin C increase cardiovascular disease risk in women with diabetes?BACKGROUND: Vitamin C acts as a potent antioxidant; however, it can also be a prooxidant and glycate protein under certain circumstances in vitro.",15531665_0,-1,-1,2,6545,-1
6552,food-frequency questionnaire,5,7,25,53,"Diet was assessed with a food-frequency questionnaire at baseline, and subjects initially free of coronary artery disease were prospectively followed for 15 y. RESULTS: After adjustment for cardiovascular disease risk factors, type of diabetes medication used, duration of diabetes, and intakes of folate, vitamin E, and beta-carotene, the adjusted relative risks of total cardiovascular disease mortality were 1.0, 0.97, 1.11, 1.47, and 1.84 (P for trend < 0.01) across quintiles of total vitamin C intake from food and supplements.",15531665_4,-1,-1,2,6552,-1
6568,associated with,10,12,56,71,CONCLUSION: A high vitamin C intake from supplements is associated with an increased risk of cardiovascular disease mortality in postmenopausal women with diabetes.,15531665_8,-1,-1,2,6568,-1
6573,in vivo,9,11,42,49,"PURPOSE: To map and identify the pattern, in vivo, of axonal degeneration in ethambutol-induced optic neuropathy using optical coherence tomography (OCT).",15565293_1,-1,-1,2,6573,-1
6576,optical coherence tomography,20,23,119,147,"PURPOSE: To map and identify the pattern, in vivo, of axonal degeneration in ethambutol-induced optic neuropathy using optical coherence tomography (OCT).",15565293_1,-1,-1,2,6576,-1
6588,short-,13,14,87,93,"METHODS: Three subjects with a history of ethambutol (EMB)-induced optic neuropathy of short-, intermediate-, and long-term visual deficits were administered a full neuro-ophthalmologic examination including visual acuity, color vision, contrast sensitivity, and fundus examination.",15565293_5,-1,-1,2,6588,-1
6589,intermediate-,15,16,95,108,"METHODS: Three subjects with a history of ethambutol (EMB)-induced optic neuropathy of short-, intermediate-, and long-term visual deficits were administered a full neuro-ophthalmologic examination including visual acuity, color vision, contrast sensitivity, and fundus examination.",15565293_5,-1,-1,2,6589,-1
6598,analysis protocol,31,33,142,159,"In addition, OCT (OCT 3000, Humphrey-Zeiss, Dublin, CA) was performed on both eyes of each subject using the retinal nerve fiber layer (RNFL) analysis protocol.",15565293_6,-1,-1,2,6598,-1
6622,consistent with,2,4,8,23,This is consistent with prior histopathological studies that show predominant loss of parvo-cellular axons (or small-caliber axons) within the papillo-macular bundle in toxic or hereditary optic neuropathies.,15565293_13,-1,-1,2,6622,-1
6624,parvo-cellular,12,13,86,100,This is consistent with prior histopathological studies that show predominant loss of parvo-cellular axons (or small-caliber axons) within the papillo-macular bundle in toxic or hereditary optic neuropathies.,15565293_13,-1,-1,2,6624,-1
6625,small-caliber,16,17,111,124,This is consistent with prior histopathological studies that show predominant loss of parvo-cellular axons (or small-caliber axons) within the papillo-macular bundle in toxic or hereditary optic neuropathies.,15565293_13,-1,-1,2,6625,-1
6628,quantitative analysis,8,10,34,55,OCT can be a valuable tool in the quantitative analysis of optic neuropathies.,15565293_14,-1,-1,2,6628,-1
6635,renal ACE,3,5,26,35,Individual differences in renal ACE activity in healthy rats predict susceptibility to adriamycin-induced renal damage.,15572383_0,-1,-1,2,6635,-1
6638,associated with,23,25,114,129,"BACKGROUND: In man, differences in angiotensin-converting enzyme (ACE) levels, related to ACE (I/D) genotype, are associated with renal prognosis.",15572383_1,-1,-1,2,6638,-1
6639,renal ACE,8,10,58,67,This raises the hypothesis that individual differences in renal ACE activity are involved in renal susceptibility to inflicted damage.,15572383_2,-1,-1,2,6639,-1
6643,Renal ACE activity,2,5,9,27,METHODS: Renal ACE activity (Hip-His-Leu cleavage by cortical homogenates) was determined by renal biopsy in 27 adult male Wistar rats.,15572383_4,-1,-1,2,6643,-1
6644,Hip-His-Leu,6,7,29,40,METHODS: Renal ACE activity (Hip-His-Leu cleavage by cortical homogenates) was determined by renal biopsy in 27 adult male Wistar rats.,15572383_4,-1,-1,2,6644,-1
6645,cortical homogenates,9,11,53,73,METHODS: Renal ACE activity (Hip-His-Leu cleavage by cortical homogenates) was determined by renal biopsy in 27 adult male Wistar rats.,15572383_4,-1,-1,2,6645,-1
6647,Wistar rats,21,23,123,134,METHODS: Renal ACE activity (Hip-His-Leu cleavage by cortical homogenates) was determined by renal biopsy in 27 adult male Wistar rats.,15572383_4,-1,-1,2,6647,-1
6657,interstitial collagen III,45,48,232,257,"Baseline renal ACE positively correlated with the relative rise in proteinuria after adriamycin (r = 0.62, P<0.01), renal interstitial alpha-smooth muscle actin (r = 0.49, P<0.05), interstitial macrophage influx (r = 0.56, P<0.05), interstitial collagen III (r = 0.53, P<0.05), glomerular alpha-smooth muscle actin (r = 0.74, P<0.01) and glomerular desmin (r = 0.48, P<0.05).",15572383_10,-1,-1,2,6657,-1
6662,renal ACE,1,3,9,18,"Baseline renal ACE did not correlate with focal glomerulosclerosis (r = 0.22, NS).",15572383_11,-1,-1,2,6662,-1
6663,focal glomerulosclerosis (r,7,11,42,69,"Baseline renal ACE did not correlate with focal glomerulosclerosis (r = 0.22, NS).",15572383_11,-1,-1,2,6663,-1
6664,predictive values,4,6,16,33,"In controls, no predictive values for renal parameters were observed.",15572383_12,-1,-1,2,6664,-1
6665,renal parameters,7,9,38,54,"In controls, no predictive values for renal parameters were observed.",15572383_12,-1,-1,2,6665,-1
6667,renal ACE,7,9,49,58,This supports the assumption that differences in renal ACE activity predispose to a less favourable course of renal damage.,15572383_14,-1,-1,2,6667,-1
6673,cellular level,12,14,79,93,"Despite the increasing need to identify and quantify tissue oxygenation at the cellular level, relatively few methods have been available.",15579441_1,-1,-1,2,6673,-1
6677,hypoxia-sensing transgenic,29,31,191,217,"In this study, we developed a new hypoxia-responsive reporter vector using a hypoxia-responsive element of the 5' vascular endothelial growth factor untranslated region and generated a novel hypoxia-sensing transgenic rat.",15579441_2,-1,-1,2,6677,-1
6678,animal model,4,6,21,33,We then applied this animal model to the detection of tubulointerstitial hypoxia in the diseased kidney.,15579441_3,-1,-1,2,6678,-1
6684,hypoxia-responsive,3,4,18,36,"Expression of the hypoxia-responsive transgene increased throughout the observation period, reaching 2.2-fold at 2 weeks in the puromycin aminonucleoside model and 2.6-fold at 4 weeks in the remnant kidney model, whereas that of vascular endothelial growth factor showed a mild decrease, reflecting distinct behaviors of the two genes.",15579441_5,-1,-1,2,6684,-1
6686,kidney model,29,31,199,211,"Expression of the hypoxia-responsive transgene increased throughout the observation period, reaching 2.2-fold at 2 weeks in the puromycin aminonucleoside model and 2.6-fold at 4 weeks in the remnant kidney model, whereas that of vascular endothelial growth factor showed a mild decrease, reflecting distinct behaviors of the two genes.",15579441_5,-1,-1,2,6686,-1
6689,proliferating cell nuclear antigen-positive,7,11,43,86,"Finally, we identified the localization of proliferating cell nuclear antigen-positive, ED-1-positive, and terminal dUTP nick-end labeled-positive cells in the hypoxic cortical area in the remnant kidney model.",15579441_7,-1,-1,2,6689,-1
6692,labeled-positive cells,18,20,130,152,"Finally, we identified the localization of proliferating cell nuclear antigen-positive, ED-1-positive, and terminal dUTP nick-end labeled-positive cells in the hypoxic cortical area in the remnant kidney model.",15579441_7,-1,-1,2,6692,-1
6701,combination therapy,32,34,216,235,Adequate timing of ribavirin reduction in patients with hemolysis during combination therapy of interferon and ribavirin for chronic hepatitis C.BACKGROUND: Hemolytic anemia is one of the major adverse events of the combination therapy of interferon and ribavirin.,15580403_0,-1,-1,2,6701,-1
6705,HCV-genotype,8,9,46,58,"METHODS: Thirty-seven of 160 patients who had HCV-genotype 1b, had high virus load, and received 24-week combination therapy developed anemia with hemoglobin level <10 g/dl or anemia-related signs during therapy.",15580403_3,-1,-1,2,6705,-1
6716,B. RESULTS,15,17,87,97,"We assessed the final efficacy and safety after reduction of ribavirin in groups A and B. RESULTS: A sustained virological response (SVR) was 29.6% (8/27) in group A and 10% (1/10) in group B, respectively.",15580403_7,-1,-1,2,6716,-1
6717,virological response,20,22,111,131,"We assessed the final efficacy and safety after reduction of ribavirin in groups A and B. RESULTS: A sustained virological response (SVR) was 29.6% (8/27) in group A and 10% (1/10) in group B, respectively.",15580403_7,-1,-1,2,6717,-1
6725,azithromycin-induced,8,9,47,67,"A 14-year-old girl is reported with recurrent, azithromycin-induced, acute interstitial nephritis.",15602202_1,-1,-1,2,6725,-1
6727,treated with,14,16,74,86,"The second episode was more severe than the first; and although both were treated with intensive corticosteroid therapy, renal function remained impaired.",15602202_2,-1,-1,2,6727,-1
6734,randomized controlled trial,4,7,23,50,BACKGROUND: A previous randomized controlled trial evaluating the use of spironolactone in heart failure patients reported a low risk of hyperkalemia (2%) and renal insufficiency (0%).,15632880_1,-1,-1,2,6734,-1
6736,low risk,18,20,125,133,BACKGROUND: A previous randomized controlled trial evaluating the use of spironolactone in heart failure patients reported a low risk of hyperkalemia (2%) and renal insufficiency (0%).,15632880_1,-1,-1,2,6736,-1
6746,treated with,12,14,69,81,METHODS: We performed a case control study of heart failure patients treated with spironolactone in our clinical practice.,15632880_4,-1,-1,2,6746,-1
6751,time periods,12,14,87,99,"Clinical characteristics, medications, and serum chemistries at baseline and follow-up time periods were compared.",15632880_6,-1,-1,2,6751,-1
6753,serum potassium levels,16,19,101,123,"Patients who developed hyperkalemia were older and more likely to have diabetes, had higher baseline serum potassium levels and lower baseline potassium supplement doses, and were more likely to be treated with beta-blockers than controls (n = 134).",15632880_8,-1,-1,2,6753,-1
6754,treated with,32,34,198,210,"Patients who developed hyperkalemia were older and more likely to have diabetes, had higher baseline serum potassium levels and lower baseline potassium supplement doses, and were more likely to be treated with beta-blockers than controls (n = 134).",15632880_8,-1,-1,2,6754,-1
6760,treated with,29,31,180,192,"Patients who developed renal insufficiency had lower baseline body weight and higher baseline serum creatinine, required higher doses of loop diuretics, and were more likely to be treated with thiazide diuretics than controls.",15632880_9,-1,-1,2,6760,-1
6767,epithelial cells,3,5,17,33,Aging process of epithelial cells of the rat prostate lateral lobe in experimental hyperprolactinemia induced by haloperidol.,15638391_0,-1,-1,2,6767,-1
6773,epithelial cells,27,29,152,168,"The aim of the study was to examine the influence of hyperprolactinemia, induced by haloperidol (HAL) on age related morphology and function changes of epithelial cells in rat prostate lateral lobe.",15638391_1,-1,-1,2,6773,-1
6778,electron microscopy,7,9,46,65,Tissue sections were evaluated with light and electron microscopy.,15638391_4,-1,-1,2,6778,-1
6779,Immunohistochemical reactions,0,2,0,29,Immunohistochemical reactions for Anti-Proliferating Cell Nuclear Antigen (PCNA) were performed.,15638391_5,-1,-1,2,6779,-1
6781,PCNA,8,9,75,79,Immunohistochemical reactions for Anti-Proliferating Cell Nuclear Antigen (PCNA) were performed.,15638391_5,-1,-1,2,6781,-1
6782,experimental group,4,6,15,33,"In rats of the experimental group, the mean concentration of: PRL was more than twice higher, whereas T concentration was almost twice lower than that in the control group.",15638391_6,-1,-1,2,6782,-1
6785,control group,30,32,158,171,"In rats of the experimental group, the mean concentration of: PRL was more than twice higher, whereas T concentration was almost twice lower than that in the control group.",15638391_6,-1,-1,2,6785,-1
6788,associated with,15,17,106,121,"Light microscopy visualized the following: hypertrophy and epithelium hyperplasia of the glandular ducts, associated with increased PCNA expression.",15638391_7,-1,-1,2,6788,-1
6789,PCNA,18,19,132,136,"Light microscopy visualized the following: hypertrophy and epithelium hyperplasia of the glandular ducts, associated with increased PCNA expression.",15638391_7,-1,-1,2,6789,-1
6794,thallium-201 single-photon emission tomography,18,22,136,182,Relation of perfusion defects observed with myocardial contrast echocardiography to the severity of coronary stenosis: correlation with thallium-201 single-photon emission tomography.,1564236_0,-1,-1,2,6794,-1
6805,dual-perfusion technique,21,23,123,147,The perfusion defect produced in 16 open chest dogs was compared with the anatomic area at risk measured by the postmortem dual-perfusion technique and with thallium-201 single-photon emission tomography (SPECT).,1564236_3,-1,-1,2,6805,-1
6806,thallium-201 single-photon emission tomography,25,29,157,203,The perfusion defect produced in 16 open chest dogs was compared with the anatomic area at risk measured by the postmortem dual-perfusion technique and with thallium-201 single-photon emission tomography (SPECT).,1564236_3,-1,-1,2,6806,-1
6807,SPECT,30,31,205,210,The perfusion defect produced in 16 open chest dogs was compared with the anatomic area at risk measured by the postmortem dual-perfusion technique and with thallium-201 single-photon emission tomography (SPECT).,1564236_3,-1,-1,2,6807,-1
6820,Thallium-201,0,1,0,12,Thallium-201 SPECT demonstrated a perfusion defect in all 14 dogs analyzed during dipyridamole-induced hyperemia; the size of the perfusion defect correlated with the anatomic area at risk (r = 0.58; p less than 0.03) and with the perfusion defect by contrast echocardiography (r = 0.58; p less than 0.03).,1564236_9,-1,-1,2,6820,-1
6821,SPECT,1,2,13,18,Thallium-201 SPECT demonstrated a perfusion defect in all 14 dogs analyzed during dipyridamole-induced hyperemia; the size of the perfusion defect correlated with the anatomic area at risk (r = 0.58; p less than 0.03) and with the perfusion defect by contrast echocardiography (r = 0.58; p less than 0.03).,1564236_9,-1,-1,2,6821,-1
6828,quantitate,11,12,72,82,"Thus, myocardial contrast echocardiography can be used to visualize and quantitate the amount of jeopardized myocardium during moderate to severe degrees of coronary stenosis.",1564236_10,-1,-1,2,6828,-1
6840,animal models,7,9,69,82,Reserpine- and haloperidol-induced orofacial dyskinesia are putative animal models of tardive dyskinesia (TD) whose pathophysiology has been related to free radical generation and oxidative stress.,15649445_1,-1,-1,2,6840,-1
6843,radical generation,22,24,157,175,Reserpine- and haloperidol-induced orofacial dyskinesia are putative animal models of tardive dyskinesia (TD) whose pathophysiology has been related to free radical generation and oxidative stress.,15649445_1,-1,-1,2,6843,-1
6872,microdialysis study,2,4,5,24,"In a microdialysis study, 10 muL of saline (group C; n = 8) or 30 mug of morphine (group M; n = 8) was injected intrathecally (IT) 0.5 h after reflow, and 30 mug of morphine (group SM; n = 8) or 10 muL of saline (group SC; n = 8) was injected IT 0.5 h after sham operation.",15673851_3,-1,-1,2,6872,-1
6896,intravenous administration,5,7,27,53,Acute low back pain during intravenous administration of amiodarone: a report of two cases.,15686794_0,-1,-1,2,6896,-1
6907,parenteral administration,11,13,72,97,Clinicians should be aware of this reaction since prompt termination of parenteral administration leads to complete resolution.,15686794_4,-1,-1,2,6907,-1
6920,no significant,9,11,68,82,"Comparison of the patients with or without pseudolithiasis revealed no significant difference with respect to age, sex, duration of the treatment and starvation variables.",15737522_5,-1,-1,2,6920,-1
6923,Quantitative drug levels,0,3,0,24,"Quantitative drug levels in stimulant psychosis: relationship to symptom severity, catecholamines and hyperkinesia.",15764424_0,-1,-1,2,6923,-1
6926,drug levels,7,9,59,70,"To examine the relationship between quantitative stimulant drug levels, catecholamines, and psychotic symptoms, nineteen patients in a psychiatric emergency service with a diagnosis of amphetamine- or cocaine-induced psychosis were interviewed, and plasma and urine were collected for quantitative assays of stimulant drug and catecholamine metabolite levels.",15764424_1,-1,-1,2,6926,-1
6931,quantitative assays,41,43,285,304,"To examine the relationship between quantitative stimulant drug levels, catecholamines, and psychotic symptoms, nineteen patients in a psychiatric emergency service with a diagnosis of amphetamine- or cocaine-induced psychosis were interviewed, and plasma and urine were collected for quantitative assays of stimulant drug and catecholamine metabolite levels.",15764424_1,-1,-1,2,6931,-1
6945,toxic effects,24,26,155,168,"Formation of coronary aneurysm is a rare complication of stenting with bare metal stents, but based on experimental studies drug-eluting stents may induce toxic effects on the vessel wall with incomplete stent apposition, aneurysm formation and with the potential of stent thrombosis or vessel rupture.",15804801_1,-1,-1,2,6945,-1
6953,routine control,11,13,64,79,The patient was asymptomatic and the aneurysm was detected in a routine control.,15804801_3,-1,-1,2,6953,-1
6956,treated with,4,6,29,41,The patient was successfully treated with a graft stent.,15804801_5,-1,-1,2,6956,-1
6960,treated with,11,13,70,82,OBJECTIVE: To describe the unmasking of pheochromocytoma in a patient treated with amisulpride and tiapride.,15811908_1,-1,-1,2,6960,-1
6973,associated with,8,10,64,79,"DISCUSSION: Drug-induced symptoms of pheochromocytoma are often associated with the use of substituted benzamide drugs, but the underlying mechanism is unknown.",15811908_5,-1,-1,2,6973,-1
6975,Naranjo probability scale,7,10,24,49,"In our case, use of the Naranjo probability scale indicated a possible relationship between the hypertensive crisis and amisulpride and tiapride therapy.",15811908_6,-1,-1,2,6975,-1
6993,Exclusion criteria,0,2,0,18,"Exclusion criteria were asphyxia, malformations, major surgical interventions, small for gestational age, intraventricular haemorrhage grades III and IV, periventricular leukomalacia, and severe psychomotor retardation.",15814210_5,-1,-1,2,6993,-1
7002,Kaufman Assessment Battery,21,24,145,171,Each child was examined by a neuropediatrician for minor neurological dysfunctions and tested by a psychologist for cognitive development with a Kaufman Assessment Battery for Children and a Draw-a-Man Test.,15814210_6,-1,-1,2,7002,-1
7003,Draw-a-Man Test,28,30,191,206,Each child was examined by a neuropediatrician for minor neurological dysfunctions and tested by a psychologist for cognitive development with a Kaufman Assessment Battery for Children and a Draw-a-Man Test.,15814210_6,-1,-1,2,7003,-1
7004,demographic data,5,7,29,45,"There were no differences in demographic data, growth, and socio-economic status between the two groups.",15814210_7,-1,-1,2,7004,-1
7008,control group,12,14,76,89,Fine motor skills and gross motor function were significantly better in the control group (p<0.01).,15814210_8,-1,-1,2,7008,-1
7009,Draw-a-Man Test,2,4,7,22,"In the Draw-a-Man Test, the control group showed better results (p<0.001).",15814210_9,-1,-1,2,7009,-1
7010,control group,6,8,28,41,"In the Draw-a-Man Test, the control group showed better results (p<0.001).",15814210_9,-1,-1,2,7010,-1
7012,Kaufman Assessment Battery,14,17,80,106,"There were no differences in development of speech, social development, and the Kaufman Assessment Battery for Children.",15814210_10,-1,-1,2,7012,-1
7016,follow-up studies,2,4,18,35,Further long-term follow-up studies will be necessary to fully evaluate the impact of dexamethasone on neurological and cognitive development.,15814210_13,-1,-1,2,7016,-1
7028,associated with,19,21,84,99,"A single dose of valproic acid (VPA), which is a widely used antiepileptic drug, is associated with oxidative stress in rats, as recently demonstrated by elevated levels of 15-F(2t)-isoprostane (15-F(2t)-IsoP).",15858223_1,-1,-1,2,7028,-1
7031,VPA-associated,9,10,63,77,"To determine whether there was a temporal relationship between VPA-associated oxidative stress and hepatotoxicity, adult male Sprague-Dawley rats were treated ip with VPA (500 mg/kg) or 0.9% saline (vehicle) once daily for 2, 4, 7, 10, or 14 days.",15858223_2,-1,-1,2,7031,-1
7034,Sprague-Dawley rats,17,19,126,145,"To determine whether there was a temporal relationship between VPA-associated oxidative stress and hepatotoxicity, adult male Sprague-Dawley rats were treated ip with VPA (500 mg/kg) or 0.9% saline (vehicle) once daily for 2, 4, 7, 10, or 14 days.",15858223_2,-1,-1,2,7034,-1
7037,liver levels,8,10,56,68,"Oxidative stress was assessed by determining plasma and liver levels of 15-F(2t)-IsoP, lipid hydroperoxides (LPO), and thiobarbituric acid reactive substances (TBARs).",15858223_3,-1,-1,2,7037,-1
7045,Liver LPO,0,2,0,9,"Liver LPO levels were not elevated until day 7 of treatment (1.8-fold versus control, p < 0.05).",15858223_5,-1,-1,2,7045,-1
7046,TBARs,3,4,17,22,"Liver and plasma TBARs were not increased until 14 days (2-fold vs. control, p < 0.05).",15858223_6,-1,-1,2,7046,-1
7048,serum levels,6,8,38,50,Liver toxicity was evaluated based on serum levels of alpha-glutathione S-transferase (alpha-GST) and by histology.,15858223_7,-1,-1,2,7048,-1
7051,Serum alpha-GST levels,0,3,0,22,"Serum alpha-GST levels were significantly elevated by day 4, which corresponded to hepatotoxicity as shown by the increasing incidence of inflammation of the liver capsule, necrosis, and steatosis throughout the study.",15858223_8,-1,-1,2,7051,-1
7055,liver levels,1,3,4,16,"The liver levels of beta-oxidation metabolites of VPA were decreased by day 14, while the levels of 4-ene-VPA and (E)-2,4-diene-VPA were not elevated throughout the study.",15858223_9,-1,-1,2,7055,-1
7056,beta-oxidation,4,5,20,34,"The liver levels of beta-oxidation metabolites of VPA were decreased by day 14, while the levels of 4-ene-VPA and (E)-2,4-diene-VPA were not elevated throughout the study.",15858223_9,-1,-1,2,7056,-1
7064,serum alpha-GST,33,35,193,208,"Overall, these findings indicate that VPA treatment results in oxidative stress, as measured by levels of 15-F(2t)-IsoP, which precedes the onset of necrosis, steatosis, and elevated levels of serum alpha-GST.",15858223_10,-1,-1,2,7064,-1
7076,Saudi Arabia,33,35,186,198,"MATERIALS AND METHODS: We investigated the causes of thrombotic microangiopathy during a 1-year period, from June 2003 to June 2004, at the King Fahad National Guard Hospital in Riyadh, Saudi Arabia, by reviewing the slides of all transplant biopsies (n=25) performed during this interval.",15859940_4,-1,-1,2,7076,-1
7102,CRL:(WI)WUBR,11,12,99,111,Comparison of developmental toxicity of selective and non-selective cyclooxygenase-2 inhibitors in CRL:(WI)WUBR Wistar rats--DFU and piroxicam study.,15863244_0,-1,-1,2,7102,-1
7106,developmental toxicity,9,11,46,68,"The aim of the experiment was to evaluate the developmental toxicity of the non-selective (piroxicam) and selective (DFU; 5,5-dimethyl-3-(3-fluorophenyl)-4-(4-methylsulphonyl) phenyl-2(5H)-furanon) COX-2 inhibitors.",15863244_3,-1,-1,2,7106,-1
7111,pregnant rats,11,13,59,72,"METHODS: Drugs were separately, orally once daily dosed to pregnant rats from day 8 to 21 (GD1=plug day).",15863244_4,-1,-1,2,7111,-1
7112,GD1=plug day,19,21,91,103,"METHODS: Drugs were separately, orally once daily dosed to pregnant rats from day 8 to 21 (GD1=plug day).",15863244_4,-1,-1,2,7112,-1
7128,teratogenicity,2,3,8,22,Lack of teratogenicity was found in piroxicam and DFU-exposed groups.,15863244_11,-1,-1,2,7128,-1
7129,DFU-exposed,8,9,50,61,Lack of teratogenicity was found in piroxicam and DFU-exposed groups.,15863244_11,-1,-1,2,7129,-1
7130,exposure to,1,3,9,20,Prenatal exposure to non-selective COX inhibitors increases the risk of VSD and MD when compared to historic control but not with selective COX-2 inhibitors.,15863244_12,-1,-1,2,7130,-1
7133,VSD,10,11,72,75,Prenatal exposure to non-selective COX inhibitors increases the risk of VSD and MD when compared to historic control but not with selective COX-2 inhibitors.,15863244_12,-1,-1,2,7133,-1
7142,historic control,25,27,165,181,Prenatal exposure to selective COX-2 inhibitors does not increase the risk of ventricular septal and midline defects in rat when compared to non-selective drugs and historic control.,15863244_15,-1,-1,2,7142,-1
7144,rubella prevention,6,8,40,58,Assessment of perinatal hepatitis B and rubella prevention in New Hampshire delivery hospitals.,15867025_0,-1,-1,2,7144,-1
7145,New Hampshire,9,11,62,75,Assessment of perinatal hepatitis B and rubella prevention in New Hampshire delivery hospitals.,15867025_0,-1,-1,2,7145,-1
7147,rubella prevention,12,14,84,102,OBJECTIVE: To evaluate current performance on recommended perinatal hepatitis B and rubella prevention practices in New Hampshire.,15867025_1,-1,-1,2,7147,-1
7148,New Hampshire,16,18,116,129,OBJECTIVE: To evaluate current performance on recommended perinatal hepatitis B and rubella prevention practices in New Hampshire.,15867025_1,-1,-1,2,7148,-1
7150,birth cohort,14,16,86,98,METHODS: Data were extracted from 2021 paired mother-infant records for the year 2000 birth cohort in New Hampshire's 25 delivery hospitals.,15867025_2,-1,-1,2,7150,-1
7155,hepatitis B surface,39,42,229,248,"Assessment was done on the following: prenatal screening for hepatitis B and rubella, administration of the hepatitis B vaccine birth dose to all infants, administration of hepatitis B immune globulin to infants who were born to hepatitis B surface antigen-positive mothers, rubella immunity, and administration of in-hospital postpartum rubella vaccine to rubella nonimmune women.",15867025_3,-1,-1,2,7155,-1
7157,rubella immunity,45,47,275,291,"Assessment was done on the following: prenatal screening for hepatitis B and rubella, administration of the hepatitis B vaccine birth dose to all infants, administration of hepatitis B immune globulin to infants who were born to hepatitis B surface antigen-positive mothers, rubella immunity, and administration of in-hospital postpartum rubella vaccine to rubella nonimmune women.",15867025_3,-1,-1,2,7157,-1
7159,rubella nonimmune,56,58,357,374,"Assessment was done on the following: prenatal screening for hepatitis B and rubella, administration of the hepatitis B vaccine birth dose to all infants, administration of hepatitis B immune globulin to infants who were born to hepatitis B surface antigen-positive mothers, rubella immunity, and administration of in-hospital postpartum rubella vaccine to rubella nonimmune women.",15867025_3,-1,-1,2,7159,-1
7160,Prenatal screening rates,2,5,9,33,RESULTS: Prenatal screening rates for hepatitis B (98.8%) and rubella (99.4%) were high.,15867025_4,-1,-1,2,7160,-1
7163,hepatitis B surface,6,9,29,48,All infants who were born to hepatitis B surface antigen-positive mothers also received hepatitis B immune globulin.,15867025_6,-1,-1,2,7163,-1
7164,antigen-positive mothers,9,11,49,73,All infants who were born to hepatitis B surface antigen-positive mothers also received hepatitis B immune globulin.,15867025_6,-1,-1,2,7164,-1
7171,study documents,3,5,17,32,CONCLUSION: This study documents good compliance in New Hampshire's birthing hospitals with national guidelines for perinatal hepatitis B and rubella prevention and highlights potential areas for improvement.,15867025_11,-1,-1,2,7171,-1
7172,New Hampshire's,8,11,52,67,CONCLUSION: This study documents good compliance in New Hampshire's birthing hospitals with national guidelines for perinatal hepatitis B and rubella prevention and highlights potential areas for improvement.,15867025_11,-1,-1,2,7172,-1
7173,national guidelines,14,16,92,111,CONCLUSION: This study documents good compliance in New Hampshire's birthing hospitals with national guidelines for perinatal hepatitis B and rubella prevention and highlights potential areas for improvement.,15867025_11,-1,-1,2,7173,-1
7175,rubella prevention,21,23,142,160,CONCLUSION: This study documents good compliance in New Hampshire's birthing hospitals with national guidelines for perinatal hepatitis B and rubella prevention and highlights potential areas for improvement.,15867025_11,-1,-1,2,7175,-1
7201,blood progenitor cells,32,35,233,255,"EXPERIMENTAL DESIGN: Because of their widespread use, the hematologic toxicity following coadministration of dexrazoxane and these three structurally different DNA cleavage enhancers was investigated: Sensitivity of human and murine blood progenitor cells to etoposide, daunorubicin, and doxorubicin +/- dexrazoxane was determined in granulocyte-macrophage colony forming assays.",15897593_3,-1,-1,2,7201,-1
7205,granulocyte-macrophage,48,49,334,356,"EXPERIMENTAL DESIGN: Because of their widespread use, the hematologic toxicity following coadministration of dexrazoxane and these three structurally different DNA cleavage enhancers was investigated: Sensitivity of human and murine blood progenitor cells to etoposide, daunorubicin, and doxorubicin +/- dexrazoxane was determined in granulocyte-macrophage colony forming assays.",15897593_3,-1,-1,2,7205,-1
7206,in vivo,2,4,10,17,"Likewise, in vivo, B6D2F1 mice were treated with etoposide, daunorubicin, and doxorubicin, with or without dexrazoxane over a wide range of doses: posttreatment, a full hematologic evaluation was done.",15897593_4,-1,-1,2,7206,-1
7220,colony assay,24,26,175,187,"RESULTS: Nontoxic doses of dexrazoxane reduced myelosuppression and weight loss from daunorubicin and etoposide in mice and antagonized their antiproliferative effects in the colony assay; however, dexrazoxane neither reduced myelosuppression, weight loss, nor the in vitro cytotoxicity from doxorubicin.",15897593_5,-1,-1,2,7220,-1
7224,in vitro,39,41,265,273,"RESULTS: Nontoxic doses of dexrazoxane reduced myelosuppression and weight loss from daunorubicin and etoposide in mice and antagonized their antiproliferative effects in the colony assay; however, dexrazoxane neither reduced myelosuppression, weight loss, nor the in vitro cytotoxicity from doxorubicin.",15897593_5,-1,-1,2,7224,-1
7226,hematologic activity,12,14,91,111,"CONCLUSION: Although our findings support the observation that dexrazoxane reduces neither hematologic activity nor antitumor activity from doxorubicin clinically, the potent antagonism of daunorubicin activity raises concern; a possible interference with anticancer efficacy certainly would call for renewed attention.",15897593_6,-1,-1,2,7226,-1
7229,anticancer efficacy,34,36,256,275,"CONCLUSION: Although our findings support the observation that dexrazoxane reduces neither hematologic activity nor antitumor activity from doxorubicin clinically, the potent antagonism of daunorubicin activity raises concern; a possible interference with anticancer efficacy certainly would call for renewed attention.",15897593_6,-1,-1,2,7229,-1
7236,pharmacologic regulation,9,11,57,81,"If successful, this represents an exciting mechanism for pharmacologic regulation of side effects from cytotoxic chemotherapy.",15897593_9,-1,-1,2,7236,-1
7240,associated with,3,5,25,40,Lone atrial fibrillation associated with creatine monohydrate supplementation.,15899738_0,-1,-1,2,7240,-1
7263,follow-up plans,16,18,88,103,"When discharged less than 24 hours later, he was receiving metoprolol and aspirin, with follow-up plans for echocardiography and nuclear imaging to assess perfusion.",15899738_9,-1,-1,2,7263,-1
7266,animal products,19,21,101,116,"Vegetarians may also take creatine to replace what they are not consuming from meat, fish, and other animal products.",15899738_11,-1,-1,2,7266,-1
7267,anecdotal reports,1,3,9,26,Previous anecdotal reports have linked creatine to the development of arrhythmia.,15899738_12,-1,-1,2,7267,-1
7272,associated with,10,12,55,70,"In addition, it is important to report adverse effects associated with frequently consumed supplements and herbal products to the Food and Drug Administration and in the literature.",15899738_14,-1,-1,2,7272,-1
7277,t1/2,3,4,15,19,"The half-life (t1/2) of cocaine is relatively short, but some of the consequences of its use, such as seizures and strokes, can occur hours after exposure.",1592014_1,-1,-1,2,7277,-1
7282,locomotor activity,15,17,84,102,"Treated rats were then evaluated for incidence, latency, and seizure pattern or for locomotor activity in animals without seizures.",1592014_5,-1,-1,2,7282,-1
7287,locomotor activity,10,12,67,85,BE-Injected rats that did not have seizures had significantly more locomotor activity than cocaine-injected animals without seizures.,1592014_9,-1,-1,2,7287,-1
7288,cocaine-injected animals,13,15,91,115,BE-Injected rats that did not have seizures had significantly more locomotor activity than cocaine-injected animals without seizures.,1592014_9,-1,-1,2,7288,-1
7289,cocaine-,3,4,17,25,"The finding that cocaine- and BE-induced seizures differ in several respects suggests more than one mechanism for cocaine-induced seizures and emphasizes the importance of a cocaine metabolite, BE.",1592014_10,-1,-1,2,7289,-1
7298,single-intervention study,7,9,33,58,"METHODS: This was a prospective, single-intervention study of consenting adult patients undergoing procedural sedation with propofol between December 28, 2002, and October 31, 2003.",15930398_2,-1,-1,2,7298,-1
7302,1-minute,1,2,3,11,"At 1-minute intervals during the procedural sedation, until the patient regained baseline mental status at the end of the procedure, a word from a standardized list was read aloud, and the patient was asked to immediately repeat the word to the investigator.",15930398_4,-1,-1,2,7302,-1
7304,standardized list,26,28,147,164,"At 1-minute intervals during the procedural sedation, until the patient regained baseline mental status at the end of the procedure, a word from a standardized list was read aloud, and the patient was asked to immediately repeat the word to the investigator.",15930398_4,-1,-1,2,7304,-1
7305,read aloud,29,31,169,179,"At 1-minute intervals during the procedural sedation, until the patient regained baseline mental status at the end of the procedure, a word from a standardized list was read aloud, and the patient was asked to immediately repeat the word to the investigator.",15930398_4,-1,-1,2,7305,-1
7306,patient's,12,14,52,61,The BIS score at the time the word was read and the patient's ability to repeat the word were recorded.,15930398_5,-1,-1,2,7306,-1
7307,data analysis,13,15,87,100,RESULTS: Seventy-five consenting patients were enrolled; one patient was excluded from data analysis for a protocol violation.,15930398_7,-1,-1,2,7307,-1
7309,procedural sedations,8,10,48,68,No serious adverse events were noted during the procedural sedations.,15930398_8,-1,-1,2,7309,-1
7310,(+,2,4,9,11,The mean (+/-standard deviation) time of data collection was 16.4 minutes (+/-7.1; range 5 to 34 minutes).,15930398_9,0,1,2,7310,-1
7313,preprocedure,4,5,18,30,The mean initial (preprocedure) BIS score was 97.1 (+/-2.3; range 92 to 99).,15930398_10,-1,-1,2,7313,-1
7314,BIS score,6,8,32,41,The mean initial (preprocedure) BIS score was 97.1 (+/-2.3; range 92 to 99).,15930398_10,-1,-1,2,7314,-1
7317,(+,12,14,79,81,The mean lowest BIS score occurring during these procedural sedations was 66.9 (+/-14.4; range 33 to 91).,15930398_11,0,1,2,7317,-1
7318,words read,15,17,92,102,The mean lowest BIS score corresponding to the ability of the patient to immediately repeat words read from the list was 77.1 (95% CI = 74.3 to 80.0).,15930398_12,-1,-1,2,7318,-1
7322,associated with,16,18,97,112,"Furthermore, patients had no recall of words repeated prior to procedural sedation in BIS ranges associated with recall after procedural sedation, suggestive of retrograde amnesia.",15930398_19,-1,-1,2,7322,-1
7329,serotonin type 6,2,5,15,31,Antagonists at serotonin type 6 (5-HT(6)) receptors show activity in models of learning and memory.,15957009_1,-1,-1,2,7329,-1
7330,mechanism(s),3,5,24,36,"Although the underlying mechanism(s) are not well understood, these effects may involve an increase in acetylcholine (ACh) levels.",15957009_2,-1,-1,2,7330,-1
7331,cognitive-enhancing,7,8,45,64,"The present study sought to characterize the cognitive-enhancing effects of the 5-HT(6) antagonist Ro4368554 (3-benzenesulfonyl-7-(4-methyl-piperazin-1-yl)1H-indole) in a rat object recognition task employing a cholinergic (scopolamine pretreatment) and a serotonergic- (tryptophan (TRP) depletion) deficient model, and compared its pattern of action with that of the acetylcholinesterase inhibitor metrifonate.",15957009_3,-1,-1,2,7331,-1
7342,intraperitoneally,9,10,33,50,"Both, Ro4368554 (3 and 10 mg/kg, intraperitoneally (i.p.)) and metrifonate (10 mg/kg, p.o., respectively) reversed memory deficits induced by scopolamine and TRP depletion (10 mg/kg, i.p., and 3 mg/kg, p.o., respectively).",15957009_5,-1,-1,2,7342,-1
7374,azithromycin-associated hiccups,1,3,9,40,Possible azithromycin-associated hiccups.,15985056_0,-1,-1,2,7374,-1
7375,associated by,9,11,50,63,OBJECTIVE: To report a case of persistent hiccups associated by azithromycin therapy.,15985056_1,-1,-1,2,7375,-1
7379,associated with,7,9,60,75,DISCUSSION: Pharmacotherapeutic agents have been uncommonly associated with hiccups.,15985056_6,-1,-1,2,7379,-1
7385,Naranjo adverse effect reaction probability scale,2,8,10,59,"Using the Naranjo adverse effect reaction probability scale this event could be classified as possible (score 5 points), mostly because of the close temporal sequence, previous reports on this reaction with other macrolides and the absence of any alternative explanation for hiccups.",15985056_9,-1,-1,2,7385,-1
7386,temporal sequence,26,28,149,166,"Using the Naranjo adverse effect reaction probability scale this event could be classified as possible (score 5 points), mostly because of the close temporal sequence, previous reports on this reaction with other macrolides and the absence of any alternative explanation for hiccups.",15985056_9,-1,-1,2,7386,-1
7388,vagal mechanism,5,7,25,40,Our hypothesis is that a vagal mechanism mediated by azithromycin could be the pathogenesis of hiccups in our patient.,15985056_10,-1,-1,2,7388,-1
7391,associated with,9,11,59,74,"However, macrolide antimicrobials have been reported to be associated with hiccups and vagal mechanism could explain the development of this side-effect.",15985056_12,-1,-1,2,7391,-1
7397,cocaine continues,4,6,19,36,The illicit use of cocaine continues in epidemic proportions and treatment for cocaine overdose remains elusive.,16005948_1,-1,-1,2,7397,-1
7399,protein-based technology,1,3,8,32,"Current protein-based technology offers a new therapeutic venue by which antibodies bind the drug in the blood stream, inactivating its toxic effects.",16005948_2,-1,-1,2,7399,-1
7401,toxic effects,21,23,136,149,"Current protein-based technology offers a new therapeutic venue by which antibodies bind the drug in the blood stream, inactivating its toxic effects.",16005948_2,-1,-1,2,7401,-1
7407,photocell cages,10,12,70,85,Swiss albino mice prepared with intrajugular catheters were tested in photocell cages after administration of 93 mg/kg (LD50) of cocaine and GNC92H2 infusions ranging from 30 to 190 mg/kg.,16005948_4,-1,-1,2,7407,-1
7415,post-cocaine,6,7,42,54,"Importantly, GNC92H2 prevented death even post-cocaine injection.",16005948_7,-1,-1,2,7415,-1
7423,corrected serum calcium,18,21,107,130,METHODS: We report the clinical and laboratory data in 3 patients who presented with severe hypercalcemia (corrected serum calcium > or = 14 mg/dL) and review the pertinent literature on milk-alkali syndrome.,16006300_2,-1,-1,2,7423,-1
7444,associated with,3,5,25,40,"Pamidronate treatment is associated with considerable risk for hypocalcemia, even in cases of initially severe hypercalcemia.",16006300_11,-1,-1,2,7444,-1
7448,electrocardiograms (,1,3,4,24,The electrocardiograms (ECG) of 99 cocaine-abusing patients were compared with the ECGs of 50 schizophrenic controls.,1601297_1,-1,-1,2,7448,-1
7450,schizophrenic controls,16,18,94,116,The electrocardiograms (ECG) of 99 cocaine-abusing patients were compared with the ECGs of 50 schizophrenic controls.,1601297_1,-1,-1,2,7450,-1
7458,associated with,2,4,15,30,Skin reactions associated with oral coumarin-derived anticoagulants are an uncommon occurrence.,16047871_1,-1,-1,2,7458,-1
7465,rechallenge,7,8,24,35,"In 2 of the 4 patients, rechallenge with warfarin led to recurrence of the lesions.",16047871_6,-1,-1,2,7465,-1
7467,associated with,7,9,40,55,LV may be a late-onset adverse reaction associated with warfarin therapy.,16047871_7,-1,-1,2,7467,-1
7469,associated with,6,8,46,61,A variety of abnormal sensory/motor behaviors associated with electrical discharges recorded from the bilateral brainstem were induced in adult WKY rats by mechanical (electrode implants) and DC electrical current stimulations and by acute and chronic administration of cocaine.,1610717_1,-1,-1,2,7469,-1
7472,WKY,19,20,144,147,A variety of abnormal sensory/motor behaviors associated with electrical discharges recorded from the bilateral brainstem were induced in adult WKY rats by mechanical (electrode implants) and DC electrical current stimulations and by acute and chronic administration of cocaine.,1610717_1,-1,-1,2,7472,-1
7473,electrode implants,24,26,168,186,A variety of abnormal sensory/motor behaviors associated with electrical discharges recorded from the bilateral brainstem were induced in adult WKY rats by mechanical (electrode implants) and DC electrical current stimulations and by acute and chronic administration of cocaine.,1610717_1,-1,-1,2,7473,-1
7477,acute experiment,10,12,54,70,Cocaine (40 mg/kg) was injected subcutaneously for an acute experiment and subsequent 20 mg/kg doses twice daily for 3 days in a chronic study.,1610717_3,-1,-1,2,7477,-1
7478,chronic study,24,26,129,142,Cocaine (40 mg/kg) was injected subcutaneously for an acute experiment and subsequent 20 mg/kg doses twice daily for 3 days in a chronic study.,1610717_3,-1,-1,2,7478,-1
7480,perturbated,14,15,107,118,"Cocaine generated more abnormal behaviors in the brainstem perturbation group, especially the electrically perturbated subjects.",1610717_4,-1,-1,2,7480,-1
7483,beating drum,13,15,84,96,"The abnormal behaviors were yawning, retrocollis, hyperactivity, hypersensitivity, ""beating drum"" behavior, squealing, head bobbing, circling, sniffing, abnormal posturing, and facial twitching.",1610717_5,-1,-1,2,7483,-1
7486,power frequency spectra,3,6,14,37,Shifts in the power frequency spectra of the discharge patterns were noted between quiet and pacing behavioral states.,1610717_6,-1,-1,2,7486,-1
7487,discharge patterns,8,10,45,63,Shifts in the power frequency spectra of the discharge patterns were noted between quiet and pacing behavioral states.,1610717_6,-1,-1,2,7487,-1
7489,spectral frequency,19,21,124,142,"Hypersensitivity to various auditory, tactile, and visual stimulation was present and shifts in the brainstem ambient power spectral frequency occurred in response to tactile stimulation.",1610717_7,-1,-1,2,7489,-1
7491,discharge system,6,8,34,50,Cocaine was found to activate the discharge system and thus induce abnormal behaviors that are generated at the discharge site and at distant sites to which the discharge propagates.,1610717_9,-1,-1,2,7491,-1
7493,discharge site,18,20,112,126,Cocaine was found to activate the discharge system and thus induce abnormal behaviors that are generated at the discharge site and at distant sites to which the discharge propagates.,1610717_9,-1,-1,2,7493,-1
7494,distant sites,22,24,134,147,Cocaine was found to activate the discharge system and thus induce abnormal behaviors that are generated at the discharge site and at distant sites to which the discharge propagates.,1610717_9,-1,-1,2,7494,-1
7498,rTMS,0,1,0,4,rTMS of supplementary motor area modulates therapy-induced dyskinesias in Parkinson disease.,16116131_0,-1,-1,2,7498,-1
7503,rTMS,6,7,52,56,"Using repetitive transcranial magnetic stimulation (rTMS) over the supplementary motor area (SMA) in a group of patients with advanced Parkinson disease, the authors investigated whether modulation of SMA excitability may result in a modification of a dyskinetic state induced by continuous apomorphine infusion.",16116131_2,-1,-1,2,7503,-1
7518,radiation therapy,13,15,75,92,Human malignant brain tumors have a poor prognosis in spite of surgery and radiation therapy.,16132524_1,-1,-1,2,7518,-1
7519,biocontinuous,5,6,31,44,"Cubic phases consist of curved biocontinuous lipid bilayers, separating two congruent networks of water channels.",16132524_2,-1,-1,2,7519,-1
7520,lipid bilayers,6,8,45,59,"Cubic phases consist of curved biocontinuous lipid bilayers, separating two congruent networks of water channels.",16132524_2,-1,-1,2,7520,-1
7521,water channels,14,16,98,112,"Cubic phases consist of curved biocontinuous lipid bilayers, separating two congruent networks of water channels.",16132524_2,-1,-1,2,7521,-1
7523,gel-like matrix,9,11,40,55,"Used as a host for cytotoxic drugs, the gel-like matrix can easily be applied to the walls of a surgical resection cavity.",16132524_3,-1,-1,2,7523,-1
7529,liquid crystalline,24,26,170,188,"For human glioblastoma recurrences, the feasibility, safety, and short-term effects of a surgical intracavitary application of paclitaxel and carboplatin encapsulated by liquid crystalline cubic phases are examined in a pilot study.",16132524_4,-1,-1,2,7529,-1
7530,pilot study,32,34,220,231,"For human glioblastoma recurrences, the feasibility, safety, and short-term effects of a surgical intracavitary application of paclitaxel and carboplatin encapsulated by liquid crystalline cubic phases are examined in a pilot study.",16132524_4,-1,-1,2,7530,-1
7541,cubic phases,6,8,59,71,"Intracavitary chemotherapy in recurrent glioblastoma using cubic phases is feasible and safe, yet the clinical benefit remains to be examined in a clinical phase II study.",16132524_8,-1,-1,2,7541,-1
7542,clinical phase II study,23,27,147,170,"Intracavitary chemotherapy in recurrent glioblastoma using cubic phases is feasible and safe, yet the clinical benefit remains to be examined in a clinical phase II study.",16132524_8,-1,-1,2,7542,-1
7548,treated with,9,11,59,71,Five patients with idiopathic generalized epilepsies (IGE) treated with lamotrigine (LTG) experienced exacerbation or de novo appearance of myoclonic jerks (MJ).,16157917_1,-1,-1,2,7548,-1
7553,MJ,25,26,157,159,Five patients with idiopathic generalized epilepsies (IGE) treated with lamotrigine (LTG) experienced exacerbation or de novo appearance of myoclonic jerks (MJ).,16157917_1,-1,-1,2,7553,-1
7554,LTG,4,5,19,22,"In three patients, LTG exacerbated MJ in a dose-dependent manner with early aggravation during titration.",16157917_2,-1,-1,2,7554,-1
7555,MJ,6,7,35,37,"In three patients, LTG exacerbated MJ in a dose-dependent manner with early aggravation during titration.",16157917_2,-1,-1,2,7555,-1
7556,dose-dependent,9,10,43,57,"In three patients, LTG exacerbated MJ in a dose-dependent manner with early aggravation during titration.",16157917_2,-1,-1,2,7556,-1
7559,LTG,4,5,17,20,"In two patients, LTG exacerbated MJ in a delayed but more severe manner, with myoclonic status that only ceased after LTG withdrawal.",16157917_4,-1,-1,2,7559,-1
7567,i.c.v,2,3,25,30,Intracerebroventricular (i.c.v.) injection of U-II causes hypertension and bradycardia and stimulates prolactin and thyrotropin secretion.,16160878_2,-1,-1,2,7567,-1
7570,centrally administered,6,8,35,57,"However, the behavioral effects of centrally administered U-II have received little attention.",16160878_3,-1,-1,2,7570,-1
7572,effects of,8,10,36,46,"In the present study, we tested the effects of i.c.v.",16160878_4,-1,-1,2,7572,-1
7573,i.c.v,10,11,47,52,"In the present study, we tested the effects of i.c.v.",16160878_4,-1,-1,2,7573,-1
7580,dose-dependent,18,19,75,89,"Administration of graded doses of U-II (1-10,000 ng/mouse) provoked: (1) a dose-dependent reduction in the number of head dips in the hole-board test; (2) a dose-dependent reduction in the number of entries in the white chamber in the black-and-white compartment test, and in the number of entries in the central platform and open arms in the plus-maze test; and (3) a dose-dependent increase in the duration of immobility in the forced-swimming test and tail suspension test.",16160878_6,-1,-1,2,7580,-1
7582,hole-board test,28,30,134,149,"Administration of graded doses of U-II (1-10,000 ng/mouse) provoked: (1) a dose-dependent reduction in the number of head dips in the hole-board test; (2) a dose-dependent reduction in the number of entries in the white chamber in the black-and-white compartment test, and in the number of entries in the central platform and open arms in the plus-maze test; and (3) a dose-dependent increase in the duration of immobility in the forced-swimming test and tail suspension test.",16160878_6,-1,-1,2,7582,-1
7583,dose-dependent,35,36,157,171,"Administration of graded doses of U-II (1-10,000 ng/mouse) provoked: (1) a dose-dependent reduction in the number of head dips in the hole-board test; (2) a dose-dependent reduction in the number of entries in the white chamber in the black-and-white compartment test, and in the number of entries in the central platform and open arms in the plus-maze test; and (3) a dose-dependent increase in the duration of immobility in the forced-swimming test and tail suspension test.",16160878_6,-1,-1,2,7583,-1
7586,plus-maze test,67,69,343,357,"Administration of graded doses of U-II (1-10,000 ng/mouse) provoked: (1) a dose-dependent reduction in the number of head dips in the hole-board test; (2) a dose-dependent reduction in the number of entries in the white chamber in the black-and-white compartment test, and in the number of entries in the central platform and open arms in the plus-maze test; and (3) a dose-dependent increase in the duration of immobility in the forced-swimming test and tail suspension test.",16160878_6,-1,-1,2,7586,-1
7588,dose-dependent,75,76,369,383,"Administration of graded doses of U-II (1-10,000 ng/mouse) provoked: (1) a dose-dependent reduction in the number of head dips in the hole-board test; (2) a dose-dependent reduction in the number of entries in the white chamber in the black-and-white compartment test, and in the number of entries in the central platform and open arms in the plus-maze test; and (3) a dose-dependent increase in the duration of immobility in the forced-swimming test and tail suspension test.",16160878_6,-1,-1,2,7588,-1
7594,ng/mouse,18,19,108,116,"Intracerebroventricular injection of U-II also caused an increase in: food intake at doses of 100 and 1,000 ng/mouse, water intake at doses of 100-10,000 ng/mouse, and horizontal locomotion activity at a dose of 10,000 ng/mouse.",16160878_7,-1,-1,2,7594,-1
7596,ng/mouse,28,29,154,162,"Intracerebroventricular injection of U-II also caused an increase in: food intake at doses of 100 and 1,000 ng/mouse, water intake at doses of 100-10,000 ng/mouse, and horizontal locomotion activity at a dose of 10,000 ng/mouse.",16160878_7,-1,-1,2,7596,-1
7599,central administration,6,8,27,49,"Whatever was the dose, the central administration of U-II had no effect on body temperature, nociception, apomorphine-induced penile erection and climbing behavior, and stress-induced plasma corticosterone level.",16160878_8,-1,-1,2,7599,-1
7609,ng/mouse,19,20,103,111,"Taken together, the present study demonstrates that the central injection of U-II at doses of 1-10,000 ng/mouse induces anxiogenic- and depressant-like effects in mouse.",16160878_9,-1,-1,2,7609,-1
7616,food reinforcement,10,12,58,76,Rats were trained to approach a shelf where they received food reinforcement.,1616457_2,-1,-1,2,7616,-1
7617,normal state,21,23,105,117,In Group 1 the rats were trained under the influence of pentobarbital to run to the same shelf as in the normal state.,1616457_3,-1,-1,2,7617,-1
7620,Groups 1,12,14,87,95,Differences in the parameters of training under the influence of pentobarbital between Groups 1 and 2 were revealed.,1616457_6,-1,-1,2,7620,-1
7633,controlled clinical study,15,18,109,134,"METHODS: Thirty-nine postmenopausal women with osteopenia or osteoporosis were included in this prospective, controlled clinical study.",16167916_1,-1,-1,2,7633,-1
7635,Age-matched controls,0,2,0,20,Age-matched controls (n = 14) were given only calcium.,16167916_3,-1,-1,2,7635,-1
7639,Wilcoxon's test,6,9,43,58,Variations of individuals were assessed by Wilcoxon's test.,16167916_5,-1,-1,2,7639,-1
7642,associated with,8,10,50,65,"RESULTS: Three months of raloxifene treatment was associated with a significant decrease in the plasma TAFI antigen concentrations (16% change, P < 0.01), and a significant increase in tPA antigen concentrations (25% change, P < 0.05).",16167916_7,-1,-1,2,7642,-1
7654,associated with,6,8,35,50,"INTRODUCTION: Cocaine use has been associated with neurovascular complications, including arterial vasoconstriction and vasculitis.",16174948_1,-1,-1,2,7654,-1
7657,angiographic effects,7,9,34,54,"However, there are few studies of angiographic effects of cocaine on human cerebral arteries.",16174948_2,-1,-1,2,7657,-1
7660,SAH,16,17,124,127,Information on these effects could be obtained from angiograms of patients with cocaine-associated subarachnoid hemorrhage (SAH) who underwent angiography shortly after cocaine use.,16174948_3,-1,-1,2,7660,-1
7662,SAH,6,7,35,38,METHODS: We screened patients with SAH retrospectively and identified those with positive urine toxicology for cocaine or its metabolites.,16174948_4,-1,-1,2,7662,-1
7665,SAH,17,18,135,138,Quantitative arterial diameter measurements from angiograms of these patients were compared to measurements from control patients with SAH who were matched for factors known to influence arterial diameter.,16174948_5,-1,-1,2,7665,-1
7674,unpaired t-tests,43,45,267,283,"There were no significant differences between groups in the mean diameters of the intradural internal carotid, sphenoidal segment of the middle cerebral, precommunicating segment of the anterior cerebral, or basilar arteries (p greater than 0.05 for all comparisons, unpaired t-tests).",16174948_8,-1,-1,2,7674,-1
7681,unpaired t-tests,53,55,337,353,"There also were no significant differences between groups when expressing diameters as the sum of the precommunicating segment of the anterior cerebral + sphenoidal segment of the middle cerebral + supraclinoid internal carotid artery + basilar artery divided by the diameter of the petrous internal carotid artery (p greater than 0.05, unpaired t-tests).",16174948_9,-1,-1,2,7681,-1
7688,SAH,30,31,220,223,CONCLUSION: No quantitative evidence for narrowing of large cerebral arteries or qualitative angiographic evidence for distal narrowing or vasculitis could be found in patients who underwent angiography after aneurysmal SAH associated with cocaine use.,16174948_11,-1,-1,2,7688,-1
7689,associated with,31,33,224,239,CONCLUSION: No quantitative evidence for narrowing of large cerebral arteries or qualitative angiographic evidence for distal narrowing or vasculitis could be found in patients who underwent angiography after aneurysmal SAH associated with cocaine use.,16174948_11,-1,-1,2,7689,-1
7692,triphasic waves,4,6,29,44,The EEG shows characteristic triphasic waves in most patients with this complication.,16181582_4,-1,-1,2,7692,-1
7693,kinase-related pathways,6,8,46,69,Methamphetamine causes alterations in the MAP kinase-related pathways in the brains of mice that display increased aggressiveness.,16192988_0,-1,-1,2,7693,-1
7696,CD-1,19,20,115,119,"Herein, we report that multiple (but not single) injections of METH significantly increased aggressiveness in male CD-1 mice.",16192988_2,-1,-1,2,7696,-1
7698,antibody microarrays,5,7,37,57,Analysis of protein expression using antibody microarrays and Western blotting revealed differential changes in MAP kinase-related pathways after multiple and single METH injections.,16192988_4,-1,-1,2,7698,-1
7699,Western blotting,8,10,62,78,Analysis of protein expression using antibody microarrays and Western blotting revealed differential changes in MAP kinase-related pathways after multiple and single METH injections.,16192988_4,-1,-1,2,7699,-1
7700,differential changes,11,13,88,108,Analysis of protein expression using antibody microarrays and Western blotting revealed differential changes in MAP kinase-related pathways after multiple and single METH injections.,16192988_4,-1,-1,2,7700,-1
7701,kinase-related pathways,15,17,116,139,Analysis of protein expression using antibody microarrays and Western blotting revealed differential changes in MAP kinase-related pathways after multiple and single METH injections.,16192988_4,-1,-1,2,7701,-1
7702,statistically significant,2,4,11,36,"There were statistically significant (p<0.05) decreases in MEK1, Erk2p, GSK3alpha, 14-3-3e, and MEK7 in the striata of mice after multiple injections of METH.",16192988_5,-1,-1,2,7702,-1
7710,statistically significant,8,10,35,60,"In the frontal cortex, there was a statistically significant decrease in GSK3alpha after multiple (but not single) injections of METH.",16192988_7,-1,-1,2,7710,-1
7712,kinase-related pathways,7,9,47,70,These findings suggest that alterations in MAP kinase-related pathways in the prefronto-striatal circuitries might be involved in the manifestation of aggressive behaviors in mice.,16192988_8,-1,-1,2,7712,-1
7743,pharmacological effect,7,9,34,56,This effect may be related to the pharmacological effect of this drug on mucous membranes.,16274958_4,-1,-1,2,7743,-1
7757,gentamicin ototoxicity,8,10,61,83,Nitro-L-arginine methyl ester: a potential protector against gentamicin ototoxicity.,16298782_0,-1,-1,2,7757,-1
7767,experimental study,2,4,8,26,"In this experimental study we used 30 Sprague-Dawley rats, 27 of which had gentamicin instilled into the middle ear.",16298782_4,-1,-1,2,7767,-1
7768,Sprague-Dawley rats,7,9,38,57,"In this experimental study we used 30 Sprague-Dawley rats, 27 of which had gentamicin instilled into the middle ear.",16298782_4,-1,-1,2,7768,-1
7776,high-frequency,7,8,54,68,"L-NAME reduced gentamicin-induced hearing loss in the high-frequency range, but gave no protection in the middle or low frequencies.",16298782_7,-1,-1,2,7776,-1
7778,12-week,21,22,127,134,"Safety profile of a nicotine lozenge compared with that of nicotine gum in adult smokers with underlying medical conditions: a 12-week, randomized, open-label study.",16330293_0,-1,-1,2,7778,-1
7779,open-label study,25,27,148,164,"Safety profile of a nicotine lozenge compared with that of nicotine gum in adult smokers with underlying medical conditions: a 12-week, randomized, open-label study.",16330293_0,-1,-1,2,7779,-1
7783,open-label study,9,11,45,61,"METHODS: This was a multicenter, randomized, open-label study in adult smokers with heart disease, hypertension not controlled by medication, and/or diabetes mellitus.",16330293_4,-1,-1,2,7783,-1
7786,safety population,23,25,124,141,"RESULTS: Nine hundred one patients were randomized to treatment, 447 who received the lozenge and 454 who received the gum (safety population).",16330293_7,-1,-1,2,7786,-1
7787,Patients',0,2,0,9,"Patients' mean age was 53.9 years, their mean weight was 193.9 pounds, and they smoked a mean of 25.2 cigarettes per day at baseline.",16330293_9,-1,-1,2,7787,-1
7790,evaluable population,33,35,157,177,"Five hundred fifty-three patients, 264 taking the lozenge and 289 taking the gum, used the study product for > or =4 days per week during the first 2 weeks (evaluable population).",16330293_10,-1,-1,2,7790,-1
7792,product use,17,19,88,99,"The incidence of adverse events in the 2 groups was similar during the first 2 weeks of product use (evaluation population: 55.3% lozenge, 54.7% gum), as well as during the entire study (safety population: 63.8% and 58.6%, respectively).",16330293_12,-1,-1,2,7792,-1
7793,evaluation population,20,22,101,122,"The incidence of adverse events in the 2 groups was similar during the first 2 weeks of product use (evaluation population: 55.3% lozenge, 54.7% gum), as well as during the entire study (safety population: 63.8% and 58.6%, respectively).",16330293_12,-1,-1,2,7793,-1
7794,safety population,40,42,187,204,"The incidence of adverse events in the 2 groups was similar during the first 2 weeks of product use (evaluation population: 55.3% lozenge, 54.7% gum), as well as during the entire study (safety population: 63.8% and 58.6%, respectively).",16330293_12,-1,-1,2,7794,-1
7802,safety profiles,12,14,75,90,CONCLUSION: The 4-mg nicotine lozenge and 4-mg nicotine gum had comparable safety profiles in these patients with label-restricted medical conditions.,16330293_18,-1,-1,2,7802,-1
7825,nociceptive information,25,27,133,156,"The aim of this study was to assess the effects of gabapentin, a drug effective in neuropathic pain patients, on brain processing of nociceptive information in normal and central sensitization states.",16330766_4,-1,-1,2,7825,-1
7830,brain activity,18,20,121,135,"Using functional magnetic resonance imaging (fMRI) in normal volunteers, we studied the gabapentin-induced modulation of brain activity in response to nociceptive mechanical stimulation of normal skin and capsaicin-induced secondary hyperalgesia.",16330766_5,-1,-1,2,7830,-1
7847,experimental model,6,8,50,68,Investigation of mitochondrial involvement in the experimental model of epilepsy induced by pilocarpine.,16337777_0,-1,-1,2,7847,-1
7849,associated with,4,6,38,53,"Mitochondrial abnormalities have been associated with several aspects of epileptogenesis, such as energy generation, control of cell death, neurotransmitter synthesis, and free radical (FR) production.",16337777_1,-1,-1,2,7849,-1
7851,energy generation,13,15,98,115,"Mitochondrial abnormalities have been associated with several aspects of epileptogenesis, such as energy generation, control of cell death, neurotransmitter synthesis, and free radical (FR) production.",16337777_1,-1,-1,2,7851,-1
7860,CCO,33,34,206,209,"In this study, we investigated whether increased generation of FR during status epilepticus would be sufficient to provoke abnormalities in mtDNA and in the expression and activity of cytochrome c oxidase (CCO), complex IV of the respiratory chain, in the chronic phase of the pilocarpine model of temporal lobe epilepsy.",16337777_3,-1,-1,2,7860,-1
7861,complex IV,36,38,212,222,"In this study, we investigated whether increased generation of FR during status epilepticus would be sufficient to provoke abnormalities in mtDNA and in the expression and activity of cytochrome c oxidase (CCO), complex IV of the respiratory chain, in the chronic phase of the pilocarpine model of temporal lobe epilepsy.",16337777_3,-1,-1,2,7861,-1
7863,chronic phase,45,47,256,269,"In this study, we investigated whether increased generation of FR during status epilepticus would be sufficient to provoke abnormalities in mtDNA and in the expression and activity of cytochrome c oxidase (CCO), complex IV of the respiratory chain, in the chronic phase of the pilocarpine model of temporal lobe epilepsy.",16337777_3,-1,-1,2,7863,-1
7864,pilocarpine model,49,51,277,294,"In this study, we investigated whether increased generation of FR during status epilepticus would be sufficient to provoke abnormalities in mtDNA and in the expression and activity of cytochrome c oxidase (CCO), complex IV of the respiratory chain, in the chronic phase of the pilocarpine model of temporal lobe epilepsy.",16337777_3,-1,-1,2,7864,-1
7867,experimental groups,23,25,129,148,DNA analysis revealed low amounts of a 4.8 kb mtDNA deletion but with no differences in frequency or quantity in the control and experimental groups.,16337777_4,-1,-1,2,7867,-1
7868,mtDNA-encoded subunit of CCO,12,16,71,99,We did not find abnormalities in the expression and distribution of an mtDNA-encoded subunit of CCO (CCO-I) or a relative decrease in CCO-I when compared with nuclear-encoded subunits (CCO-IV and SDH-fp).,16337777_5,-1,-1,2,7868,-1
7875,CCO,3,4,18,21,No abnormality in CCO activity was observed through histochemistry.,16337777_6,-1,-1,2,7875,-1
7876,histochemistry,8,9,52,66,No abnormality in CCO activity was observed through histochemistry.,16337777_6,-1,-1,2,7876,-1
7878,published studies,9,11,75,92,"Although evidences of mitochondrial abnormalities were found in previously published studies, our results do not suggest that the FRs, generated during the acute phase, determined important abnormalities in mtDNA, in expression of CCO-I, and in CCO activity.",16337777_7,-1,-1,2,7878,-1
7882,CCO,40,41,245,248,"Although evidences of mitochondrial abnormalities were found in previously published studies, our results do not suggest that the FRs, generated during the acute phase, determined important abnormalities in mtDNA, in expression of CCO-I, and in CCO activity.",16337777_7,-1,-1,2,7882,-1
7886,associated with,4,6,27,42,"Although suprofen has been associated with the development of acute renal failure in greater than 100 subjects, the mechanism of damage remains unclear.",1636026_1,-1,-1,2,7886,-1
7888,nephrotoxic effects,2,4,11,30,The direct nephrotoxic effects of a single dose of 15 mg of suprofen were compared in the recirculating isolated rat kidney perfused with cell-free buffer with or without the addition of 5 mg/dL of uric acid.,1636026_2,-1,-1,2,7888,-1
7893,urinary flow rates,14,17,88,106,"There were no significant differences in renal sodium excretion, oxygen consumption, or urinary flow rates in kidneys perfused with suprofen compared with the drug-free control groups.",1636026_3,-1,-1,2,7893,-1
7895,drug-free control groups,25,28,159,183,"There were no significant differences in renal sodium excretion, oxygen consumption, or urinary flow rates in kidneys perfused with suprofen compared with the drug-free control groups.",1636026_3,-1,-1,2,7895,-1
7896,glomerular filtration rate,7,10,38,64,"In contrast, a significant decline in glomerular filtration rate was found after the introduction of suprofen to the kidney perfused with uric acid; no changes were found with suprofen in the absence of uric acid.",1636026_4,-1,-1,2,7896,-1
7903,drug-free controls,20,22,115,133,"A significant decrease in the baseline excretion rate of uric acid was found in rats given suprofen, compared with drug-free controls.",1636026_5,-1,-1,2,7903,-1
7904,fractional excretion,3,5,13,33,"However, the fractional excretion of uric acid was unchanged between the groups over the experimental period.",1636026_6,-1,-1,2,7904,-1
7917,Morris water maze,16,19,114,131,The effect of ritanserin (5-HT2 antagonist) on scopolamine (muscarinic cholinergic antagonist)-induced amnesia in Morris water maze (MWM) was investigated.,16364460_1,-1,-1,2,7917,-1
7918,MWM,20,21,133,136,The effect of ritanserin (5-HT2 antagonist) on scopolamine (muscarinic cholinergic antagonist)-induced amnesia in Morris water maze (MWM) was investigated.,16364460_1,-1,-1,2,7918,-1
7924,saline/side,21,22,112,123,"One week later, they received repeatedly vehicles (saline, DMSO, saline+DMSO), scopolamine (2 microg/0.5 microl saline/side; 30 min before training), ritanserin (2, 4 and 8 microg/0.5 microl DMSO/side; 20 min before training) and scopolamine (2 microg/0.5 microl; 30 min before ritanserin injection)+ritanserin (4 microg/0.5 microl DMSO) through cannulae each day.",16364460_3,-1,-1,2,7924,-1
7927,DMSO/side,38,39,191,200,"One week later, they received repeatedly vehicles (saline, DMSO, saline+DMSO), scopolamine (2 microg/0.5 microl saline/side; 30 min before training), ritanserin (2, 4 and 8 microg/0.5 microl DMSO/side; 20 min before training) and scopolamine (2 microg/0.5 microl; 30 min before ritanserin injection)+ritanserin (4 microg/0.5 microl DMSO) through cannulae each day.",16364460_3,-1,-1,2,7927,-1
7934,trial/day,9,10,49,58,Animals were tested for four consecutive days (4 trial/day) in MWM during which the position of hidden platform was unchanged.,16364460_4,-1,-1,2,7934,-1
7935,MWM,12,13,63,66,Animals were tested for four consecutive days (4 trial/day) in MWM during which the position of hidden platform was unchanged.,16364460_4,-1,-1,2,7935,-1
7936,hidden platform,18,20,96,111,Animals were tested for four consecutive days (4 trial/day) in MWM during which the position of hidden platform was unchanged.,16364460_4,-1,-1,2,7936,-1
7937,water surface,11,13,54,67,"In the fifth day, the platform was elevated above the water surface in another position to evaluate the function of motor, motivational and visual systems.",16364460_5,-1,-1,2,7937,-1
7941,Ritanserin-treated rats,0,2,0,23,Ritanserin-treated rats (4 microg/0.5 microl/side) showed a significant decrease in the mentioned parameters as compared to DMSO-treated group.,16364460_7,-1,-1,2,7941,-1
7944,co-administration,5,6,36,53,"However, scopolamine and ritanserin co-administration resulted in a significant decrease in escape latencies and traveled distances as compared to the scopolamine-treated rats.",16364460_8,-1,-1,2,7944,-1
7945,scopolamine-treated,21,22,151,170,"However, scopolamine and ritanserin co-administration resulted in a significant decrease in escape latencies and traveled distances as compared to the scopolamine-treated rats.",16364460_8,-1,-1,2,7945,-1
7960,hypertensive rats,9,11,46,63,"Six weeks after clipping of one renal artery, hypertensive rats (178 +/- 4 mm Hg) were randomly assigned to three groups: untreated hypertensive controls (n = 8), enalapril-treated (n = 8), or nitrendipine-treated (n = 10).",1639466_2,-1,-1,2,7960,-1
7961,/- 4 mm Hg,14,18,70,80,"Six weeks after clipping of one renal artery, hypertensive rats (178 +/- 4 mm Hg) were randomly assigned to three groups: untreated hypertensive controls (n = 8), enalapril-treated (n = 8), or nitrendipine-treated (n = 10).",1639466_2,-1,-1,2,7961,-1
7962,untreated hypertensive controls,26,29,122,153,"Six weeks after clipping of one renal artery, hypertensive rats (178 +/- 4 mm Hg) were randomly assigned to three groups: untreated hypertensive controls (n = 8), enalapril-treated (n = 8), or nitrendipine-treated (n = 10).",1639466_2,-1,-1,2,7962,-1
7966,normotensive controls,4,6,29,50,"Sham-operated rats served as normotensive controls (128 +/- 3 mm Hg, n = 8).",1639466_3,-1,-1,2,7966,-1
7967,/- 3 mm Hg,9,13,57,67,"Sham-operated rats served as normotensive controls (128 +/- 3 mm Hg, n = 8).",1639466_3,-1,-1,2,7967,-1
7969,glomerular filtration rate,9,12,48,74,"After 6 weeks of treatment, renal hemodynamics (glomerular filtration rate and renal plasma flow) were measured in the anesthetized rats.",1639466_4,-1,-1,2,7969,-1
7970,renal plasma flow,13,16,79,96,"After 6 weeks of treatment, renal hemodynamics (glomerular filtration rate and renal plasma flow) were measured in the anesthetized rats.",1639466_4,-1,-1,2,7970,-1
7975,glomerular filtration rate,6,9,26,52,"After 6 weeks of therapy, glomerular filtration rate was not different among the studied groups.",1639466_7,-1,-1,2,7975,-1
7976,Renal plasma flow,0,3,0,17,"Renal plasma flow increased, but albumin excretion and glomerulosclerosis did not change after enalapril treatment.",1639466_8,-1,-1,2,7976,-1
7980,/-,18,19,107,109,"In contrast, in the nitrendipine-treated group albuminuria increased from 12.8 +/- 2 progressively to 163 +/- 55 compared with 19.2 +/- 9 mg/24 hr in the hypertensive controls.",1639466_9,0,1,2,7980,-1
7981,/- 9 mg/24,24,27,133,143,"In contrast, in the nitrendipine-treated group albuminuria increased from 12.8 +/- 2 progressively to 163 +/- 55 compared with 19.2 +/- 9 mg/24 hr in the hypertensive controls.",1639466_9,-1,-1,2,7981,-1
7982,hypertensive controls,30,32,154,175,"In contrast, in the nitrendipine-treated group albuminuria increased from 12.8 +/- 2 progressively to 163 +/- 55 compared with 19.2 +/- 9 mg/24 hr in the hypertensive controls.",1639466_9,-1,-1,2,7982,-1
7985,hypertensive controls,14,16,118,139,"Furthermore, glomerulosclerosis index was significantly increased in the nitrendipine-treated group compared with the hypertensive controls (0.38 +/- 0.1 versus 0.13 +/- 0.04).",1639466_10,-1,-1,2,7985,-1
7986,/-,19,20,147,149,"Furthermore, glomerulosclerosis index was significantly increased in the nitrendipine-treated group compared with the hypertensive controls (0.38 +/- 0.1 versus 0.13 +/- 0.04).",1639466_10,0,1,2,7986,-1
7987,/-,24,25,167,169,"Furthermore, glomerulosclerosis index was significantly increased in the nitrendipine-treated group compared with the hypertensive controls (0.38 +/- 0.1 versus 0.13 +/- 0.04).",1639466_10,0,1,2,7987,-1
7990,/-,14,15,81,83,"In addition, glomerular size was higher in the nitrendipine-treated group (14.9 +/- 0.17 10(-3) mm2) but lower in the enalapril-treated group (11.5 +/- 0.15 10(-3) mm2) compared with the hypertensive controls (12.1 +/- 0.17 10(-3) mm2).(ABSTRACT TRUNCATED AT 250 WORDS)",1639466_11,0,1,2,7990,-1
7991,mm2,18,19,96,99,"In addition, glomerular size was higher in the nitrendipine-treated group (14.9 +/- 0.17 10(-3) mm2) but lower in the enalapril-treated group (11.5 +/- 0.15 10(-3) mm2) compared with the hypertensive controls (12.1 +/- 0.17 10(-3) mm2).(ABSTRACT TRUNCATED AT 250 WORDS)",1639466_11,-1,-1,2,7991,-1
7994,mm2,33,34,164,167,"In addition, glomerular size was higher in the nitrendipine-treated group (14.9 +/- 0.17 10(-3) mm2) but lower in the enalapril-treated group (11.5 +/- 0.15 10(-3) mm2) compared with the hypertensive controls (12.1 +/- 0.17 10(-3) mm2).(ABSTRACT TRUNCATED AT 250 WORDS)",1639466_11,-1,-1,2,7994,-1
7995,hypertensive controls,38,40,187,208,"In addition, glomerular size was higher in the nitrendipine-treated group (14.9 +/- 0.17 10(-3) mm2) but lower in the enalapril-treated group (11.5 +/- 0.15 10(-3) mm2) compared with the hypertensive controls (12.1 +/- 0.17 10(-3) mm2).(ABSTRACT TRUNCATED AT 250 WORDS)",1639466_11,-1,-1,2,7995,-1
7996,/-,43,44,216,218,"In addition, glomerular size was higher in the nitrendipine-treated group (14.9 +/- 0.17 10(-3) mm2) but lower in the enalapril-treated group (11.5 +/- 0.15 10(-3) mm2) compared with the hypertensive controls (12.1 +/- 0.17 10(-3) mm2).(ABSTRACT TRUNCATED AT 250 WORDS)",1639466_11,0,1,2,7996,-1
7999,QT,9,10,68,70,Ketoconazole induced torsades de pointes without concomitant use of QT interval-prolonging drug.,16403073_0,-1,-1,2,7999,-1
8003,QT,11,12,73,75,Ketoconazole is not known to be proarrhythmic without concomitant use of QT interval-prolonging drugs.,16403073_1,-1,-1,2,8003,-1
8005,QT interval,13,15,82,93,We report a woman with coronary artery disease who developed a markedly prolonged QT interval and torsades de pointes (TdP) after taking ketoconazole for treatment of fungal infection.,16403073_2,-1,-1,2,8005,-1
8017,QT interval,17,19,97,108,"We postulate that by virtue of its direct blocking action on IKr, ketoconazole alone may prolong QT interval and induce TdP. This calls for attention when ketoconazole is administered to patients with risk factors for acquired long QT syndrome.",16403073_5,-1,-1,2,8017,-1
8034,radioablation,6,7,56,69,"Subsequent treatment of persistent hyperthyroidism with radioablation did not result in an exacerbation of the vasculitis, a complication described in prior case reports.",16418614_5,-1,-1,2,8034,-1
8043,methylphenidate intake,20,22,133,155,"Cerebral vasculitis associated with amphetamine abuse is well documented, and in rare cases ischaemic stroke has been reported after methylphenidate intake in children.",16428221_2,-1,-1,2,8043,-1
8052,MC-IXC cells,5,7,50,62,Daidzein activates choline acetyltransferase from MC-IXC cells and improves drug-induced amnesia.,16428827_0,-1,-1,2,8052,-1
8056,Methanolic extracts,0,2,0,19,Methanolic extracts from Pueraria thunbergiana exhibited an activation effect (46%) on ChAT in vitro.,16428827_2,-1,-1,2,8056,-1
8057,Pueraria thunbergiana,3,5,25,46,Methanolic extracts from Pueraria thunbergiana exhibited an activation effect (46%) on ChAT in vitro.,16428827_2,-1,-1,2,8057,-1
8059,in vitro,15,17,92,100,Methanolic extracts from Pueraria thunbergiana exhibited an activation effect (46%) on ChAT in vitro.,16428827_2,-1,-1,2,8059,-1
8060,Pueraria thunbergiana,5,7,32,53,"Via the sequential isolation of Pueraria thunbergiana, the active component was ultimately identified as daidzein (4',7-dihydroxy-isoflavone).",16428827_3,-1,-1,2,8060,-1
8068,in vivo tests,24,27,159,172,"In order to investigate the effects of daidzein from Pueraria thunbergiana on scopolamine-induced impairments of learning and memory, we conducted a series of in vivo tests.",16428827_4,-1,-1,2,8068,-1
8072,Y-maze tests,10,12,72,84,Injections of scopolamine into mice resulted in impaired performance on Y-maze tests (a 37% decreases in alternation behavior).,16428827_6,-1,-1,2,8072,-1
8074,treated with,6,8,25,37,"By way of contrast, mice treated with daidzein prior to the scopolamine injections were noticeably protected from this performance impairment (an approximately 12%-21% decrease in alternation behavior).",16428827_7,-1,-1,2,8074,-1
8088,OAB,16,17,73,76,"MATERIAL AND METHOD: Thirty women (aged 30-77 years) diagnosed as having OAB at the Gynecology Clinic, King Chulalongkorn Memorial Hospital from January to April 2004 were included in the present study.",16471092_2,-1,-1,2,8088,-1
8090,King Chulalongkorn Memorial Hospital,22,26,103,139,"MATERIAL AND METHOD: Thirty women (aged 30-77 years) diagnosed as having OAB at the Gynecology Clinic, King Chulalongkorn Memorial Hospital from January to April 2004 were included in the present study.",16471092_2,-1,-1,2,8090,-1
8092,diary variables,8,10,48,63,"After 8 weeks treatment, changes in micturition diary variables and tolerability were determined.",16471092_4,-1,-1,2,8092,-1
8093,tolerability,11,12,68,80,"After 8 weeks treatment, changes in micturition diary variables and tolerability were determined.",16471092_4,-1,-1,2,8093,-1
8095,/-,2,3,3,5,7 +/- 5. 3 to 6. 7 +/- 2.4 times per day.,16471092_7,0,1,2,8095,-1
8096,/-,11,12,20,22,7 +/- 5. 3 to 6. 7 +/- 2.4 times per day.,16471092_7,0,1,2,8096,-1
8097,/-,9,10,52,54,The number of nocturia episodes decreased from 5.4 +/- 4.2 to 1.1 +/- 1.0 times per night.,16471092_8,0,1,2,8097,-1
8098,/-,14,15,67,69,The number of nocturia episodes decreased from 5.4 +/- 4.2 to 1.1 +/- 1.0 times per night.,16471092_8,0,1,2,8098,-1
8109,OAB,18,19,107,110,CONCLUSION: Tolterodine was well tolerated and its effects improved the quality of life in Thai women with OAB.,16471092_12,-1,-1,2,8109,-1
8111,pretreatment,1,2,13,25,Remifentanil pretreatment reduces myoclonus after etomidate.,16563323_0,-1,-1,2,8111,-1
8117,double-blind study,7,9,31,49,"DESIGN: This was a randomized, double-blind study.",16563323_2,-1,-1,2,8117,-1
8119,randomized double-blinded fashion,8,11,46,79,PATIENTS: Sixty patients were pretreated in a randomized double-blinded fashion with remifentanil 1 microg/kg or placebo.,16563323_4,-1,-1,2,8119,-1
8127,associated with,8,10,41,56,"In the placebo group, male patients were associated with significantly increased incidence of myoclonus after etomidate administration.",16563323_10,-1,-1,2,8127,-1
8140,non-ecstasy user controls,7,10,47,72,"Fifteen polydrug ecstasy users and 15 polydrug non-ecstasy user controls completed a general drug use questionnaire, the Brixton Spatial Anticipation task (set shifting), Backward Digit Span procedure (memory updating), Inhibition of Return (inhibition), an emotional intelligence scale, the Tromso Social Intelligence Scale and the Dysexecutive Questionnaire (DEX).",16574712_3,-1,-1,2,8140,-1
8141,general drug use questionnaire,12,16,85,115,"Fifteen polydrug ecstasy users and 15 polydrug non-ecstasy user controls completed a general drug use questionnaire, the Brixton Spatial Anticipation task (set shifting), Backward Digit Span procedure (memory updating), Inhibition of Return (inhibition), an emotional intelligence scale, the Tromso Social Intelligence Scale and the Dysexecutive Questionnaire (DEX).",16574712_3,-1,-1,2,8141,-1
8142,Brixton Spatial Anticipation task,18,22,121,154,"Fifteen polydrug ecstasy users and 15 polydrug non-ecstasy user controls completed a general drug use questionnaire, the Brixton Spatial Anticipation task (set shifting), Backward Digit Span procedure (memory updating), Inhibition of Return (inhibition), an emotional intelligence scale, the Tromso Social Intelligence Scale and the Dysexecutive Questionnaire (DEX).",16574712_3,-1,-1,2,8142,-1
8145,Return (,38,40,234,242,"Fifteen polydrug ecstasy users and 15 polydrug non-ecstasy user controls completed a general drug use questionnaire, the Brixton Spatial Anticipation task (set shifting), Backward Digit Span procedure (memory updating), Inhibition of Return (inhibition), an emotional intelligence scale, the Tromso Social Intelligence Scale and the Dysexecutive Questionnaire (DEX).",16574712_3,-1,-1,2,8145,-1
8146,emotional intelligence scale,44,47,258,286,"Fifteen polydrug ecstasy users and 15 polydrug non-ecstasy user controls completed a general drug use questionnaire, the Brixton Spatial Anticipation task (set shifting), Backward Digit Span procedure (memory updating), Inhibition of Return (inhibition), an emotional intelligence scale, the Tromso Social Intelligence Scale and the Dysexecutive Questionnaire (DEX).",16574712_3,-1,-1,2,8146,-1
8147,Tromso Social Intelligence Scale,49,53,292,324,"Fifteen polydrug ecstasy users and 15 polydrug non-ecstasy user controls completed a general drug use questionnaire, the Brixton Spatial Anticipation task (set shifting), Backward Digit Span procedure (memory updating), Inhibition of Return (inhibition), an emotional intelligence scale, the Tromso Social Intelligence Scale and the Dysexecutive Questionnaire (DEX).",16574712_3,-1,-1,2,8147,-1
8148,Dysexecutive Questionnaire,55,57,333,359,"Fifteen polydrug ecstasy users and 15 polydrug non-ecstasy user controls completed a general drug use questionnaire, the Brixton Spatial Anticipation task (set shifting), Backward Digit Span procedure (memory updating), Inhibition of Return (inhibition), an emotional intelligence scale, the Tromso Social Intelligence Scale and the Dysexecutive Questionnaire (DEX).",16574712_3,-1,-1,2,8148,-1
8150,MDMA-free polydrug controls,2,5,14,41,"Compared with MDMA-free polydrug controls, MDMA polydrug users showed impairments in set shifting and memory updating, and also in social and emotional judgement processes.",16574712_4,-1,-1,2,8150,-1
8154,recreational ecstasy use,20,23,126,150,These data lend further support to the proposal that cognitive processes mediated by the prefrontal cortex may be impaired by recreational ecstasy use.,16574712_6,-1,-1,2,8154,-1
8157,promoter gene,5,7,42,55,Memory function and serotonin transporter promoter gene polymorphism in ecstasy (MDMA) users.,16574713_0,-1,-1,2,8157,-1
8165,covariance effect,23,25,142,159,Because 5-HT transporters play a key element in the regulation of synaptic 5-HT transmission it may be important to control for the potential covariance effect of a polymorphism in the 5-HT transporter promoter gene region (5-HTTLPR) when studying the effects of MDMA as well as cognitive functioning.,16574713_2,-1,-1,2,8165,-1
8167,promoter gene region,32,35,202,222,Because 5-HT transporters play a key element in the regulation of synaptic 5-HT transmission it may be important to control for the potential covariance effect of a polymorphism in the 5-HT transporter promoter gene region (5-HTTLPR) when studying the effects of MDMA as well as cognitive functioning.,16574713_2,-1,-1,2,8167,-1
8170,effects of,9,11,44,54,"The aim of the study was to investigate the effects of moderate and heavy MDMA use on cognitive function, as well as the effects of long-term abstention from MDMA, in subjects genotyped for 5-HTTLPR.",16574713_3,-1,-1,2,8170,-1
8172,genotyped,33,34,176,185,"The aim of the study was to investigate the effects of moderate and heavy MDMA use on cognitive function, as well as the effects of long-term abstention from MDMA, in subjects genotyped for 5-HTTLPR.",16574713_3,-1,-1,2,8172,-1
8174,ex-MDMA+ users,23,25,100,114,"Fifteen moderate MDMA users (<55 lifetime tablets), 22 heavy MDMA+ users (>55 lifetime tablets), 16 ex-MDMA+ users (last tablet > 1 year ago) and 13 controls were compared on a battery of neuropsychological tests.",16574713_5,-1,-1,2,8174,-1
8177,genotyped,7,8,44,53,DNA from peripheral nuclear blood cells was genotyped for 5-HTTLPR using standard polymerase chain reaction methods.,16574713_6,-1,-1,2,8177,-1
8179,standard polymerase chain reaction methods,11,16,73,115,DNA from peripheral nuclear blood cells was genotyped for 5-HTTLPR using standard polymerase chain reaction methods.,16574713_6,-1,-1,2,8179,-1
8181,reaction times,19,21,92,106,A significant group effect was observed only on memory function tasks (p = 0.04) but not on reaction times (p = 0.61) or attention/executive functioning (p = 0.59).,16574713_7,-1,-1,2,8181,-1
8183,ex-MDMA+ users,2,4,10,24,Heavy and ex-MDMA+ users performed significantly poorer on memory tasks than controls.,16574713_8,-1,-1,2,8183,-1
8184,memory tasks,8,10,59,71,Heavy and ex-MDMA+ users performed significantly poorer on memory tasks than controls.,16574713_8,-1,-1,2,8184,-1
8186,No significant,0,2,0,14,No significant effect of 5-HTTLPR or gender was observed.,16574713_10,-1,-1,2,8186,-1
8188,associated with,16,18,77,92,"While the use of MDMA in quantities that may be considered ""moderate"" is not associated with impaired memory functioning, heavy use of MDMA use may lead to long lasting memory impairments.",16574713_11,-1,-1,2,8188,-1
8191,No effect,0,2,0,9,No effect of 5-HTTLPR or gender on memory function or MDMA use was observed.,16574713_12,-1,-1,2,8191,-1
8213,iron binding,56,58,316,328,"Subcutaneous injection of ISPH (200 mg/kg body weight in 1 ml saline) to rats for 2 consecutive days caused myocardial damage in rat heart, which was determined by the increased activity of serum lactate dehydrogenase (LDH) and creatine phosphokinase isoenzymes (CK-MB), increased uric acid level and reduced plasma iron binding capacity.",16584858_2,-1,-1,2,8213,-1
8216,macroscopic enzyme mapping assay,17,21,101,133,The protective role of mangiferin was analyzed by triphenyl tetrazolium chloride (TTC) test used for macroscopic enzyme mapping assay of the ischemic myocardium.,16584858_3,-1,-1,2,8216,-1
8218,heart tissue antioxidant,1,4,4,28,"The heart tissue antioxidant enzymes such as superoxide dismutase, catalase, glutathione peroxidase, glutathione transferase and glutathione reductase activities, non-enzymic antioxidants such as cerruloplasmin, Vitamin C, Vitamin E and glutathione levels were altered in MI rats.",16584858_4,-1,-1,2,8218,-1
8231,intraperitoneally,18,19,105,122,Upon pretreatment with mangiferin (100 mg/kg body weight suspended in 2 ml of dimethyl sulphoxide) given intraperitoneally for 28 days to MI rats protected the above-mentioned parameters to fall from the normal levels.,16584858_5,-1,-1,2,8231,-1
8232,above-mentioned parameters,27,29,160,186,Upon pretreatment with mangiferin (100 mg/kg body weight suspended in 2 ml of dimethyl sulphoxide) given intraperitoneally for 28 days to MI rats protected the above-mentioned parameters to fall from the normal levels.,16584858_5,-1,-1,2,8232,-1
8233,normal levels,33,35,204,217,Upon pretreatment with mangiferin (100 mg/kg body weight suspended in 2 ml of dimethyl sulphoxide) given intraperitoneally for 28 days to MI rats protected the above-mentioned parameters to fall from the normal levels.,16584858_5,-1,-1,2,8233,-1
8240,defense system,26,28,168,182,"From the present study it is concluded that mangiferin exerts a beneficial effect against ISPH-induced MI due to its antioxidant potential, which regulated the tissues defense system against cardiac damage.",16584858_7,-1,-1,2,8240,-1
8245,differences?Randomised,11,12,92,114,"Cardiovascular risk with cyclooxygenase inhibitors: general problem with substance specific differences?Randomised clinical trials and observational studies have shown an increased risk of myocardial infarction, stroke, hypertension and heart failure during treatment with cyclooxygenase inhibitors.",16586083_0,-1,-1,2,8245,-1
8246,clinical trials,12,14,115,130,"Cardiovascular risk with cyclooxygenase inhibitors: general problem with substance specific differences?Randomised clinical trials and observational studies have shown an increased risk of myocardial infarction, stroke, hypertension and heart failure during treatment with cyclooxygenase inhibitors.",16586083_0,-1,-1,2,8246,-1
8247,observational studies,15,17,135,156,"Cardiovascular risk with cyclooxygenase inhibitors: general problem with substance specific differences?Randomised clinical trials and observational studies have shown an increased risk of myocardial infarction, stroke, hypertension and heart failure during treatment with cyclooxygenase inhibitors.",16586083_0,-1,-1,2,8247,-1
8252,risk factors,14,16,98,110,"Adverse cardiovascular effects occurred mainly, but not exclusively, in patients with concomitant risk factors.",16586083_1,-1,-1,2,8252,-1
8258,daily dose,11,13,74,84,The incidence of cardiovascular adverse events tends to increase with the daily dose and total exposure time.,16586083_3,-1,-1,2,8258,-1
8259,total exposure time,14,17,89,108,The incidence of cardiovascular adverse events tends to increase with the daily dose and total exposure time.,16586083_3,-1,-1,2,8259,-1
8260,substance-specific differences,10,12,88,118,"A comparison of individual selective and unselective cyclooxygenase inhibitors suggests substance-specific differences, which may depend on differences in pharmacokinetic parameters or inhibitory potency and may be contributed by prostaglandin-independent effects.",16586083_4,-1,-1,2,8260,-1
8272,animal model,14,16,99,111,A naturalistic auditory location discrimination method was used to evaluate this question using an animal model of status epilepticus.,16596970_3,-1,-1,2,8272,-1
8282,P20,22,23,140,143,"Pilocarpine on either day induced status epilepticus; status epilepticus at P45 resulted in CA3 cell loss and spontaneous seizures, whereas P20 rats had no cell loss or spontaneous seizures.",16596970_5,-1,-1,2,8282,-1
8284,sound-source,5,6,30,42,Mature rats were trained with sound-source location and sound-silence discriminations.,16596970_6,-1,-1,2,8284,-1
8285,sound-silence discriminations,8,10,56,85,Mature rats were trained with sound-source location and sound-silence discriminations.,16596970_6,-1,-1,2,8285,-1
8288,P20,4,5,23,26,"In status epilepticus (P20) rats, acquisition of the sound-source location discrimination was moderately impaired.",16596970_8,-1,-1,2,8288,-1
8292,sound-source location,10,12,55,76,Status epilepticus (P45) rats failed to acquire either sound-source location or sound-silence discriminations.,16596970_9,-1,-1,2,8292,-1
8293,sound-silence discriminations,13,15,80,109,Status epilepticus (P45) rats failed to acquire either sound-source location or sound-silence discriminations.,16596970_9,-1,-1,2,8293,-1
8302,study groups,5,7,27,39,MATERIALS AND METHODS: The study groups included 65 women with OAB and 20 without bladder symptoms who served as controls.,16600756_3,-1,-1,2,8302,-1
8303,OAB,11,12,63,66,MATERIALS AND METHODS: The study groups included 65 women with OAB and 20 without bladder symptoms who served as controls.,16600756_3,-1,-1,2,8303,-1
8306,urodynamic studies,11,13,69,87,"Evaluation included patient history, urinalysis, a voiding diary and urodynamic studies.",16600756_4,-1,-1,2,8306,-1
8307,Urine samples,0,2,0,13,Urine samples were collected.,16600756_5,-1,-1,2,8307,-1
8317,OAB,14,15,87,90,"RESULTS: Urinary NGF, PGE2 and PGF2alpha were significantly increased in patients with OAB compared with controls (p <0.05).",16600756_8,-1,-1,2,8317,-1
8322,cystometric capacity,17,19,104,124,In patients with OAB urinary PGE2 positively correlated with volume at first desire to void and maximum cystometric capacity (p <0.05).,16600756_10,-1,-1,2,8322,-1
8328,OAB,12,13,68,71,CONCLUSIONS: NGF and PGs have important roles in the development of OAB symptoms in female patients.,16600756_12,-1,-1,2,8328,-1
8329,Urinary levels,0,2,0,14,Urinary levels of these factors may be used as markers to evaluate OAB symptoms.,16600756_13,-1,-1,2,8329,-1
8330,OAB,12,13,67,70,Urinary levels of these factors may be used as markers to evaluate OAB symptoms.,16600756_13,-1,-1,2,8330,-1
8339,virologic responses,5,7,41,60,"Although this regimen produces sustained virologic responses (SVRs) in approximately 50% of patients, it can be associated with a potentially dose-limiting hemolytic anemia.",16629641_3,-1,-1,2,8339,-1
8340,associated with,20,22,112,127,"Although this regimen produces sustained virologic responses (SVRs) in approximately 50% of patients, it can be associated with a potentially dose-limiting hemolytic anemia.",16629641_3,-1,-1,2,8340,-1
8341,dose-limiting,24,25,142,155,"Although this regimen produces sustained virologic responses (SVRs) in approximately 50% of patients, it can be associated with a potentially dose-limiting hemolytic anemia.",16629641_3,-1,-1,2,8341,-1
8365,alcohol intervention study,22,25,149,175,METHODS: We obtained fetal ultrasound measures from routine ultrasound examinations for 167 pregnant hazardous drinkers who were enrolled in a brief alcohol intervention study.,16634859_4,-1,-1,2,8365,-1
8366,fetal measures,1,3,4,18,The fetal measures for women who quit after learning of their pregnancies were compared with measures for women who continued some drinking throughout the course of their pregnancies.,16634859_5,-1,-1,2,8366,-1
8368,associated with,6,8,44,59,"Because intensity of alcohol consumption is associated with poorer fetal outcomes, separate analyses were conducted for the heavy (average of >or=5 drinks per drinking day) alcohol consumers.",16634859_6,-1,-1,2,8368,-1
8371,Fetal measures,0,2,0,14,"Fetal measures from the heavy-exposed fetuses were also compared with measures from a nondrinking group that was representative of normal, uncomplicated pregnancies from our clinics.",16634859_7,-1,-1,2,8371,-1
8373,nondrinking group,13,15,86,103,"Fetal measures from the heavy-exposed fetuses were also compared with measures from a nondrinking group that was representative of normal, uncomplicated pregnancies from our clinics.",16634859_7,-1,-1,2,8373,-1
8377,pregnant drinkers,6,8,28,45,RESULTS: Nearly half of the pregnant drinkers abstained after learning of their pregnancies.,16634859_9,-1,-1,2,8377,-1
8380,non-alcohol-exposed group,19,21,126,151,"When women reportedly quit drinking early in their pregnancies, fetal growth measures were not significantly different from a non-alcohol-exposed group, regardless of prior drinking patterns.",16634859_10,-1,-1,2,8380,-1
8383,heavy drinkers,7,9,60,74,Any alcohol consumption postpregnancy recognition among the heavy drinkers resulted in reduced cerebellar growth as well as decreased cranial to body growth in comparison with women who either quit drinking or who were nondrinkers.,16634859_11,-1,-1,2,8383,-1
8389,biometric measurements,5,7,34,56,CONCLUSIONS: Alterations in fetal biometric measurements were observed among the heavy drinkers only when they continued drinking after becoming aware of their pregnancies.,16634859_13,-1,-1,2,8389,-1
8390,heavy drinkers,11,13,81,95,CONCLUSIONS: Alterations in fetal biometric measurements were observed among the heavy drinkers only when they continued drinking after becoming aware of their pregnancies.,16634859_13,-1,-1,2,8390,-1
8394,Phase II study,0,3,0,14,Phase II study of the amsacrine analogue CI-921 (NSC 343499) in non-small cell lung cancer.,1664218_0,-1,-1,2,8394,-1
8398,CI-921,0,1,0,6,"CI-921 (NSC 343499; 9-[[2-methoxy-4-[(methylsulphonyl)amino]phenyl]amino] -N,5-dimethyl- 4-acridinecarboxamide) is a topoisomerase II poison with high experimental antitumour activity.",1664218_1,-1,-1,2,8398,-1
8406,NSCLC,17,18,97,102,"It was administered by 15 min infusion to 16 evaluable patients with non-small cell lung cancer (NSCLC) (7 with no prior treatment, 9 patients in relapse following surgery/radiotherapy) at a dose (648 mg/m2 divided over 3 days, repeated every 3 weeks) determined by phase I trial.",1664218_2,-1,-1,2,8406,-1
8408,phase I trial,51,54,266,279,"It was administered by 15 min infusion to 16 evaluable patients with non-small cell lung cancer (NSCLC) (7 with no prior treatment, 9 patients in relapse following surgery/radiotherapy) at a dose (648 mg/m2 divided over 3 days, repeated every 3 weeks) determined by phase I trial.",1664218_2,-1,-1,2,8408,-1
8413,large cell undifferentiated carcinoma (1,26,32,126,166,"The histology comprised squamous carcinoma (11), adenocarcinoma (1), mixed histology (2), bronchio-alveolar carcinoma (1) and large cell undifferentiated carcinoma (1).",1664218_4,-1,-1,2,8413,-1
8418,infusion arm,19,21,95,107,Grade less than or equal to 2 nausea and vomiting occurred in 66% courses and phlebitis in the infusion arm in 37%.,1664218_6,-1,-1,2,8418,-1
8420,response lasting,9,11,58,74,1 patient with squamous cell carcinoma achieved a partial response lasting 5 months.,1664218_7,-1,-1,2,8420,-1
8430,genotyped,6,7,37,46,"METHODS: Seventeen subjects who were genotyped as CYP2D6 extensive metabolizers were enrolled in this randomized, open-label, crossover study to receive a single oral dose of desipramine (50 mg) on two separate occasions, once alone and once after multiple doses of cinacalcet (90 mg for 7 days).",16680561_3,-1,-1,2,8430,-1
8431,CYP2D6,8,9,50,56,"METHODS: Seventeen subjects who were genotyped as CYP2D6 extensive metabolizers were enrolled in this randomized, open-label, crossover study to receive a single oral dose of desipramine (50 mg) on two separate occasions, once alone and once after multiple doses of cinacalcet (90 mg for 7 days).",16680561_3,-1,-1,2,8431,-1
8432,metabolizers,10,11,67,79,"METHODS: Seventeen subjects who were genotyped as CYP2D6 extensive metabolizers were enrolled in this randomized, open-label, crossover study to receive a single oral dose of desipramine (50 mg) on two separate occasions, once alone and once after multiple doses of cinacalcet (90 mg for 7 days).",16680561_3,-1,-1,2,8432,-1
8434,crossover study,19,21,126,141,"METHODS: Seventeen subjects who were genotyped as CYP2D6 extensive metabolizers were enrolled in this randomized, open-label, crossover study to receive a single oral dose of desipramine (50 mg) on two separate occasions, once alone and once after multiple doses of cinacalcet (90 mg for 7 days).",16680561_3,-1,-1,2,8434,-1
8438,Blood samples,0,2,0,13,Blood samples were obtained predose and up to 72 h postdose.,16680561_4,-1,-1,2,8438,-1
8439,predose,4,5,28,35,Blood samples were obtained predose and up to 72 h postdose.,16680561_4,-1,-1,2,8439,-1
8441,treatment arms,6,8,42,56,RESULTS: Fourteen subjects completed both treatment arms.,16680561_5,-1,-1,2,8441,-1
8445,t (max,1,4,4,10,The t (max) was similar between the regimens.,16680561_8,-1,-1,2,8445,-1
8449,treated with,38,40,228,240,"Fewer subjects reported adverse events following treatment with desipramine alone than when receiving desipramine with cinacalcet (33 versus 86%), the most frequent of which (nausea and headache) have been reported for patients treated with either desipramine or cinacalcet.",16680561_9,-1,-1,2,8449,-1
8452,CYP2D6,12,13,77,83,CONCLUSION: This study demonstrates that cinacalcet is a strong inhibitor of CYP2D6.,16680561_10,-1,-1,2,8452,-1
8455,CYP2D6,27,28,180,186,"These data suggest that during concomitant treatment with cinacalcet, dose adjustment may be necessary for drugs that demonstrate a narrow therapeutic index and are metabolized by CYP2D6.",16680561_11,-1,-1,2,8455,-1
8459,associated with,22,24,122,137,"INTRODUCTION: Ethambutol is used in the treatment of tuberculosis, which is still prevalent in Southeast Asia, and can be associated with permanent visual loss.",16710500_1,-1,-1,2,8459,-1
8466,Ishihara,13,14,65,73,"All 3 patients had loss of central visual acuity, colour vision (Ishihara) and visual field.",16710500_4,-1,-1,2,8466,-1
8478,associated with,5,7,33,48,CONCLUSIONS: Ethambutol usage is associated with permanent visual loss and should be avoided if possible or used with caution and proper ophthalmological follow-up.,16710500_10,-1,-1,2,8478,-1
8480,ophthalmological,22,23,137,153,CONCLUSIONS: Ethambutol usage is associated with permanent visual loss and should be avoided if possible or used with caution and proper ophthalmological follow-up.,16710500_10,-1,-1,2,8480,-1
8504,patient's,9,11,44,53,"7 days later, the fever disappeared and the patient's serum CPK levels were normalized (175 IU/L).",16720068_7,-1,-1,2,8504,-1
8507,NMS-like,16,17,102,110,"This patient presented with symptoms of neuroleptic malignant syndrome (NMS), thus demonstrating that NMS-like symptoms can occur after combined paroxetine and alprazolam treatment.",16720068_8,-1,-1,2,8507,-1
8511,patient's,22,24,132,141,"The adverse drug reaction score obtained by the Naranjo algorithm was 6 in our case, indicating a probable relationship between the patient's NMS-like adverse symptoms and the combined treatment used in this case.",16720068_9,-1,-1,2,8511,-1
8513,combined treatment,29,31,176,194,"The adverse drug reaction score obtained by the Naranjo algorithm was 6 in our case, indicating a probable relationship between the patient's NMS-like adverse symptoms and the combined treatment used in this case.",16720068_9,-1,-1,2,8513,-1
8514,environmental aspects,5,7,35,56,The involvement of physiologic and environmental aspects specific to this patient was suspected.,16720068_10,-1,-1,2,8514,-1
8515,Several risk factors,0,3,0,20,"Several risk factors for NMS should be noted in elderly depressive patients whose symptoms often include dehydration, agitation, malnutrition, and exhaustion.",16720068_11,-1,-1,2,8515,-1
8517,therapeutic intervention,1,3,8,32,Careful therapeutic intervention is necessary in cases involving elderly patients who suffer from depression.,16720068_12,-1,-1,2,8517,-1
8519,chronic administration,7,9,66,88,Down-regulation of norepinephrine transporter function induced by chronic administration of desipramine linking to the alteration of sensitivity of local-anesthetics-induced convulsions and the counteraction by co-administration with local anesthetics.,16725121_0,-1,-1,2,8519,-1
8531,convulsive activity,9,11,72,91,Co-administration of lidocaine with desipramine reversed the changes of convulsive activity of lidocaine and cocaine induced by repeated administration of desipramine.,16725121_6,-1,-1,2,8531,-1
8534,chronic administration,10,12,73,95,These results suggest that down-regulation of hippocampal NET induced by chronic administration of desipramine may be relevant to desipramine-induced sensitization of lidocaine convulsions.,16725121_7,-1,-1,2,8534,-1
8535,desipramine-induced sensitization,18,20,130,163,These results suggest that down-regulation of hippocampal NET induced by chronic administration of desipramine may be relevant to desipramine-induced sensitization of lidocaine convulsions.,16725121_7,-1,-1,2,8535,-1
8540,down-regulation,11,12,83,98,Inhibition of Na(+) channels by local anesthetics may regulate desipramine-induced down-regulation of NET function.,16725121_8,-1,-1,2,8540,-1
8541,up-regulation,5,6,43,56,Repeated administration of cocaine induces up-regulation of hippocampal NET function.,16725121_9,-1,-1,2,8541,-1
8550,newspaper report,10,12,53,69,METHODS: The son of an 84-year-old male discovered a newspaper report stating clinical success with plant extracts in Alzheimer's disease.,16740173_3,-1,-1,2,8550,-1
8554,mode of,1,3,4,11,"The mode of action was said to be comparable to that of the synthetic compound 'carbamylcholin'; that is, carbachol.",16740173_4,-1,-1,2,8554,-1
8560,HPLC-mass spectrometry,17,19,98,120,Carbachol concentrations in serum and urine on day 1 and 2 of hospital admission were analysed by HPLC-mass spectrometry.,16740173_6,-1,-1,2,8560,-1
8561,oral administration,4,6,23,42,"RESULTS: Minutes after oral administration, the patient developed nausea, sweating and hypotension, and finally collapsed.",16740173_7,-1,-1,2,8561,-1
8565,bradyarrhythmic patient,10,12,56,79,"On hospital admission, blood pressure of the intubated, bradyarrhythmic patient was 100/65 mmHg.",16740173_10,-1,-1,2,8565,-1
8579,Serum samples,0,2,0,13,"Serum samples from the first and second days contained 3.6 and 1.9 mg/l carbachol, respectively.",16740173_18,-1,-1,2,8579,-1
8581,urine concentrations,2,4,18,38,The corresponding urine concentrations amounted to 374 and 554 mg/l.,16740173_19,-1,-1,2,8581,-1
8582,media report,7,9,37,49,"CONCLUSION: This case started with a media report in a popular newspaper, initiated by published, peer-reviewed research on herbals, and involved human failure in a case history, medical examination and clinical treatment.",16740173_20,-1,-1,2,8582,-1
8583,peer-reviewed research,18,20,98,120,"CONCLUSION: This case started with a media report in a popular newspaper, initiated by published, peer-reviewed research on herbals, and involved human failure in a case history, medical examination and clinical treatment.",16740173_20,-1,-1,2,8583,-1
8588,analytical method,6,8,23,40,"For the first time, an analytical method for the determination of carbachol in plasma and urine has been developed.",16740173_21,-1,-1,2,8588,-1
8592,intensivists,5,6,28,40,"Especially in old patients, intensivists should consider intoxications (with cholinergics) as a cause of acute cardiovascular failure.",16740173_23,-1,-1,2,8592,-1
8605,behavioral models,11,13,79,96,Elevated plus maze and passive avoidance apparatus served as the exteroceptive behavioral models for testing memory.,16755009_3,-1,-1,2,8605,-1
8609,behavioral models,10,12,79,96,"Diazepam-, scopolamine- and ageing-induced amnesia served as the interoceptive behavioral models.",16755009_4,-1,-1,2,8609,-1
8611,memory scores,14,16,61,74,"DCE (200, 400 mg/kg, p.o.) showed significant improvement in memory scores of young and aged mice.",16755009_5,-1,-1,2,8611,-1
8616,memory scores,5,7,39,52,"Similarly, significant improvements in memory scores were observed using passive avoidance apparatus and aged mice.",16755009_7,-1,-1,2,8616,-1
8617,passive avoidance apparatus,10,13,73,100,"Similarly, significant improvements in memory scores were observed using passive avoidance apparatus and aged mice.",16755009_7,-1,-1,2,8617,-1
8619,DCE,2,3,13,16,"Furthermore, DCE reversed the amnesia induced by scopolamine (0.4 mg/kg, i.p.) and diazepam (1 mg/kg, i.p.).",16755009_8,-1,-1,2,8619,-1
8623,cholesterol levels,19,21,111,129,"Daucus carota extract (200, 400 mg/kg, p.o.) reduced significantly the brain acetylcholinesterase activity and cholesterol levels in young and aged mice.",16755009_9,-1,-1,2,8623,-1
8626,total cholesterol,6,8,36,53,"There was a remarkable reduction in total cholesterol level as well, to the extent of 23% in young and 21% in aged animals with this dose of DCE.",16755009_11,-1,-1,2,8626,-1
8628,DCE,2,3,11,14,"Therefore, DCE may prove to be a useful remedy for the management of cognitive dysfunctions on account of its multifarious beneficial effects such as, memory improving property, cholesterol lowering property and anticholinesterase activity.",16755009_12,-1,-1,2,8628,-1
8630,cholesterol lowering property,30,33,178,207,"Therefore, DCE may prove to be a useful remedy for the management of cognitive dysfunctions on account of its multifarious beneficial effects such as, memory improving property, cholesterol lowering property and anticholinesterase activity.",16755009_12,-1,-1,2,8630,-1
8633,associated to,16,18,95,108,Valproic acid induced encephalopathy--19 new cases in Germany from 1994 to 2003--a side effect associated to VPA-therapy not only in young children.,16787750_0,-1,-1,2,8633,-1
8643,causative effect,6,8,27,43,"There is still no proof of causative effect of VPA in patients with encephalopathy, but only of an association with an assumed causal relation.",16787750_4,-1,-1,2,8643,-1
8647,Sprague-Dawley rats,17,19,112,131,"To assess the antioxidant effects of atorvastatin (atorva) on dexamethasone (dex)-induced hypertension, 60 male Sprague-Dawley rats were treated with atorva 30 mg/kg/day or tap water for 15 days.",16820346_1,-1,-1,2,8647,-1
8653,SBP,6,7,39,42,"Dex increased systolic blood pressure (SBP) from 109 +/- 1.8 to 135 +/- 0.6 mmHg and plasma superoxide (5711 +/- 284.9 saline, 7931 +/- 392.8 U/ml dex, P < 0.001).",16820346_2,-1,-1,2,8653,-1
8654,/-,11,12,54,56,"Dex increased systolic blood pressure (SBP) from 109 +/- 1.8 to 135 +/- 0.6 mmHg and plasma superoxide (5711 +/- 284.9 saline, 7931 +/- 392.8 U/ml dex, P < 0.001).",16820346_2,0,1,2,8654,-1
8655,/- 0.6 mmHg,16,19,69,80,"Dex increased systolic blood pressure (SBP) from 109 +/- 1.8 to 135 +/- 0.6 mmHg and plasma superoxide (5711 +/- 284.9 saline, 7931 +/- 392.8 U/ml dex, P < 0.001).",16820346_2,-1,-1,2,8655,-1
8659,prevention study,2,4,8,24,"In this prevention study, SBP in the atorva + dex group was increased from 115 +/- 0.4 to 124 +/- 1.5 mmHg, but this was significantly lower than in the dex-only group (P' < 0.05).",16820346_3,-1,-1,2,8659,-1
8660,SBP,5,6,26,29,"In this prevention study, SBP in the atorva + dex group was increased from 115 +/- 0.4 to 124 +/- 1.5 mmHg, but this was significantly lower than in the dex-only group (P' < 0.05).",16820346_3,-1,-1,2,8660,-1
8662,/-,17,18,80,82,"In this prevention study, SBP in the atorva + dex group was increased from 115 +/- 0.4 to 124 +/- 1.5 mmHg, but this was significantly lower than in the dex-only group (P' < 0.05).",16820346_3,0,1,2,8662,-1
8663,/-,22,23,95,97,"In this prevention study, SBP in the atorva + dex group was increased from 115 +/- 0.4 to 124 +/- 1.5 mmHg, but this was significantly lower than in the dex-only group (P' < 0.05).",16820346_3,0,1,2,8663,-1
8664,dex-only,34,35,153,161,"In this prevention study, SBP in the atorva + dex group was increased from 115 +/- 0.4 to 124 +/- 1.5 mmHg, but this was significantly lower than in the dex-only group (P' < 0.05).",16820346_3,-1,-1,2,8664,-1
8666,/- 0.6 mmHg,7,10,47,58,"Atorva reversed dex-induced hypertension (129 +/- 0.6 mmHg, vs. 135 +/- 0.6 mmHg P' < 0.05) and decreased plasma superoxide (7931 +/- 392.8 dex, 1187 +/- 441.2 atorva + dex, P < 0.0001).",16820346_4,-1,-1,2,8666,-1
8667,/- 0.6 mmHg,14,17,69,80,"Atorva reversed dex-induced hypertension (129 +/- 0.6 mmHg, vs. 135 +/- 0.6 mmHg P' < 0.05) and decreased plasma superoxide (7931 +/- 392.8 dex, 1187 +/- 441.2 atorva + dex, P < 0.0001).",16820346_4,-1,-1,2,8667,-1
8668,plasma superoxide,24,26,106,123,"Atorva reversed dex-induced hypertension (129 +/- 0.6 mmHg, vs. 135 +/- 0.6 mmHg P' < 0.05) and decreased plasma superoxide (7931 +/- 392.8 dex, 1187 +/- 441.2 atorva + dex, P < 0.0001).",16820346_4,-1,-1,2,8668,-1
8670,/-,35,36,151,153,"Atorva reversed dex-induced hypertension (129 +/- 0.6 mmHg, vs. 135 +/- 0.6 mmHg P' < 0.05) and decreased plasma superoxide (7931 +/- 392.8 dex, 1187 +/- 441.2 atorva + dex, P < 0.0001).",16820346_4,0,1,2,8670,-1
8674,dex-treated,8,9,46,57,"Plasma nitrate/nitrite (NOx) was decreased in dex-treated rats compared to saline-treated rats (11.2 +/- 1.08 microm, 15.3 +/- 1.17 microm, respectively, P < 0.05).",16820346_5,-1,-1,2,8674,-1
8675,saline-treated rats,12,14,75,94,"Plasma nitrate/nitrite (NOx) was decreased in dex-treated rats compared to saline-treated rats (11.2 +/- 1.08 microm, 15.3 +/- 1.17 microm, respectively, P < 0.05).",16820346_5,-1,-1,2,8675,-1
8676,/-,17,18,102,104,"Plasma nitrate/nitrite (NOx) was decreased in dex-treated rats compared to saline-treated rats (11.2 +/- 1.08 microm, 15.3 +/- 1.17 microm, respectively, P < 0.05).",16820346_5,0,1,2,8676,-1
8677,/-,23,24,124,126,"Plasma nitrate/nitrite (NOx) was decreased in dex-treated rats compared to saline-treated rats (11.2 +/- 1.08 microm, 15.3 +/- 1.17 microm, respectively, P < 0.05).",16820346_5,0,1,2,8677,-1
8689,g/m2,25,26,133,137,"After he achieved complete remission, he received high-dose cytosine arabinoside treatment (2 g/m2 twice a day for 5 days; total, 20 g/m2) as consolidation therapy.",16826348_3,-1,-1,2,8689,-1
8693,nerve-conduction studies,2,4,19,43,Electromyogram and nerve-conduction studies showed peripheral neuropathy in both peroneal nerves.,16826348_5,-1,-1,2,8693,-1
8707,associated with,8,10,74,89,Methamphetamine (MA)-induced dopaminergic neurotoxicity is believed to be associated with the increased formation of free radicals.,16844102_1,-1,-1,2,8707,-1
8716,treated with,3,5,15,27,"Male rats were treated with MA (10 mg/kg, every 2 h for four injections).",16844102_3,-1,-1,2,8716,-1
8718,intraperitoneally,9,10,44,61,The rat received either alpha-TC (20 mg/kg) intraperitoneally for 3 days and 30 min prior to MA administration or DFO (50 mg/kg) subcutaneously 30 min before MA administration.,16844102_4,-1,-1,2,8718,-1
8722,pretreatment,26,27,162,174,"The concentrations of dopamine (DA), serotonin and their metabolites decreased significantly after MA administration, which was inhibited by the alpha-TC and DFO pretreatment.",16844102_5,-1,-1,2,8722,-1
8725,locomotor activity,14,16,90,108,alpha-TC and DFO attenuated the MA-induced hyperthermia as well as the alterations in the locomotor activity.,16844102_6,-1,-1,2,8725,-1
8728,MA-treated,16,17,102,112,The level of lipid peroxidation was higher and the reduced glutathione concentration was lower in the MA-treated rats.,16844102_7,-1,-1,2,8728,-1
8738,preventability,9,10,49,63,"PURPOSE: To evaluate the frequency, severity and preventability of warfarin-induced cerebral haemorrhages due to warfarin and warfarin-drug interactions in patients living in the county of Osterg  tland, Sweden. METHODS: All patients with a diagnosed cerebral haemorrhage at three hospitals during the period 2000-2002 were identified.",16858720_1,-1,-1,2,8738,-1
8740,warfarin-drug interactions,18,20,126,152,"PURPOSE: To evaluate the frequency, severity and preventability of warfarin-induced cerebral haemorrhages due to warfarin and warfarin-drug interactions in patients living in the county of Osterg  tland, Sweden. METHODS: All patients with a diagnosed cerebral haemorrhage at three hospitals during the period 2000-2002 were identified.",16858720_1,-1,-1,2,8740,-1
8741,Osterg  tland,27,30,189,202,"PURPOSE: To evaluate the frequency, severity and preventability of warfarin-induced cerebral haemorrhages due to warfarin and warfarin-drug interactions in patients living in the county of Osterg  tland, Sweden. METHODS: All patients with a diagnosed cerebral haemorrhage at three hospitals during the period 2000-2002 were identified.",16858720_1,-1,-1,2,8741,-1
8748,"1.7/100,000 treatment",5,7,27,48,"This imply an incidence of 1.7/100,000 treatment years.",16858720_5,-1,-1,2,8748,-1
8754,fatality rate,13,15,93,106,CONCLUSIONS: Warfarin-induced cerebral haemorrhages are a major clinical problem with a high fatality rate.,16858720_8,-1,-1,2,8754,-1
8755,warfarin-drug interaction,9,11,42,67,Almost half of the cases was related to a warfarin-drug interaction.,16858720_9,-1,-1,2,8755,-1
8767,RAMH,2,3,27,31,"(R)-alpha-methylhistamine (RAMH) (5 microg i.c.v.) and thioperamide (THP) (15 mg/kg i.p.), per se did not cause catalepsy.",16867021_4,-1,-1,2,8767,-1
8768,i.c.v,7,8,43,48,"(R)-alpha-methylhistamine (RAMH) (5 microg i.c.v.) and thioperamide (THP) (15 mg/kg i.p.), per se did not cause catalepsy.",16867021_4,-1,-1,2,8768,-1
8771,THP,2,3,18,21,"Administration of THP (3.75, 7.5 and 15 mg/kg i.p.) 1 h prior to haloperidol resulted in a dose-dependent increase in the catalepsy times (P < 0.05).",16867021_5,-1,-1,2,8771,-1
8775,THP,11,12,73,76,"However, pretreatment with RAMH significantly reversed such an effect of THP (15 mg/kg i.p.).",16867021_6,-1,-1,2,8775,-1
8779,THP,16,17,100,103,"RAMH per se showed significant reduction in locomotor time, distance traveled and average speed but THP (15 mg/kg i.p.) per se had no effect on these parameters.",16867021_7,-1,-1,2,8779,-1
8780,no effect,26,28,131,140,"RAMH per se showed significant reduction in locomotor time, distance traveled and average speed but THP (15 mg/kg i.p.) per se had no effect on these parameters.",16867021_7,-1,-1,2,8780,-1
8782,THP,4,5,38,41,"On amphetamine-induced hyperactivity, THP (3.75 and 7.5 mg/kg i.p.) reduced locomotor time, distance traveled and average speed (P < 0.05).",16867021_8,-1,-1,2,8782,-1
8787,i.c.v,6,7,33,38,Pretreatment with RAMH (5 microg i.c.v.) could partially reverse such effects of THP (3.75 mg/kg i.p.).,16867021_9,-1,-1,2,8787,-1
8789,THP,11,12,77,80,Climbing behavior induced by apomorphine was reduced in animals treated with THP.,16867021_10,-1,-1,2,8789,-1
8791,THP,0,1,0,3,"THP exhibited an antipsychotic-like profile by potentiating haloperidol-induced catalepsy, reducing amphetamine-induced hyperactivity and reducing apomorphine-induced climbing in mice.",16867021_12,-1,-1,2,8791,-1
8795,THP,3,4,16,19,Such effects of THP were reversed by RAMH indicating the involvement of histamine H(3)-receptors.,16867021_13,-1,-1,2,8795,-1
8800,mice.1,12,13,72,78,Blockade of both D-1 and D-2 dopamine receptors may induce catalepsy in mice.1.,1687392_0,-1,-1,2,8800,-1
8807,dose-dependent,7,8,45,59,The effect of fluphenazine and sulpiride was dose-dependent.,1687392_3,-1,-1,2,8807,-1
8822,Conventional treatment methods,2,5,11,41,"OBJECTIVE: Conventional treatment methods of lumbusacral radiculopathy are physical therapy, epidural steroid injections, oral medications, and spinal manipulative therapy.",16904497_1,-1,-1,2,8822,-1
8826,spinal manipulative therapy,20,23,144,171,"OBJECTIVE: Conventional treatment methods of lumbusacral radiculopathy are physical therapy, epidural steroid injections, oral medications, and spinal manipulative therapy.",16904497_1,-1,-1,2,8826,-1
8833,Touhy needle,6,8,38,50,INTERVENTION AND OUTCOME: An 18-gauge Touhy needle was inserted until loss of resistance occurred at the L4-5 level.,16904497_5,-1,-1,2,8833,-1
8837,radiographic imaging,12,14,74,94,Spread of the contrast medium within the epidural space was determined by radiographic imaging.,16904497_6,-1,-1,2,8837,-1
8847,pinprick test,8,10,42,55,There was a decrease in the perception of pinprick test.,16904497_11,-1,-1,2,8847,-1
8848,Deep-tendon reflexes,0,2,0,20,Deep-tendon reflexes were decreased especially in the right leg.,16904497_12,-1,-1,2,8848,-1
8853,Foley catheter,12,14,66,80,She had a gradual return of motor function and ability of feeling Foley catheter.,16904497_15,-1,-1,2,8853,-1
8854,associated with,3,5,26,41,CONCLUSION: Complications associated with epidural steroid injections are rare.,16904497_17,-1,-1,2,8854,-1
8858,associated with,3,5,26,41,High-dose testosterone is associated with atherosclerosis in postmenopausal women.,16938416_0,-1,-1,2,8858,-1
8859,population-based study,4,6,14,36,"METHODS: In a population-based study in 513 naturally postmenopausal women aged 54-67 years, we studied the association between self-reported intramuscularly administered high-dose estrogen-testosterone therapy (estradiol- and testosterone esters) and aortic atherosclerosis.",16938416_2,-1,-1,2,8859,-1
8862,calcified deposits,8,10,66,84,"Aortic atherosclerosis was diagnosed by radiographic detection of calcified deposits in the abdominal aorta, which have been shown to reflect intima atherosclerosis.",16938416_3,-1,-1,2,8862,-1
8864,never users,6,8,41,52,Hormone therapy users were compared with never users.,16938416_4,-1,-1,2,8864,-1
8866,cholesterol level,9,11,67,84,"The association remained after additional adjustment for diabetes, cholesterol level, systolic blood pressure, or alcohol use.",16938416_7,-1,-1,2,8866,-1
8869,No association,0,2,0,14,No association was found for hormone use less than 1 year.,16938416_8,-1,-1,2,8869,-1
8879,Asian countries,22,24,128,143,"Hepatitis B virus (HBV) infection, which causes liver cirrhosis and hepatocellular carcinoma, remains a major health problem in Asian countries.",16960342_1,-1,-1,2,8879,-1
8889,HBV,8,9,45,48,"During this period, no drug resistant mutant HBV emerged, and the serum HBV-DNA level was continuously suppressed.",16960342_7,-1,-1,2,8889,-1
8891,virological responses,1,3,6,27,These virological responses were also maintained even after the antiviral therapy was discontinued.,16960342_8,-1,-1,2,8891,-1
8909,pentobarbital-anesthetized dogs,24,26,137,168,"Digitalis arrhythmia, which is suppressed by Na channel blockers, was induced by intermittent intravenous (i.v.) injection of ouabain in pentobarbital-anesthetized dogs.",1700207_2,-1,-1,2,8909,-1
8916,/-,15,16,123,125,"The minimum effective plasma concentrations of (+)-cibenzoline for digitalis- and adrenaline-induced arrhythmias were 1.4 +/- 0.4 and 2.0 +/- 0.6 micrograms/ml, respectively (mean +/- SD, n = 6).",1700207_6,0,1,2,8916,-1
8917,/-,20,21,139,141,"The minimum effective plasma concentrations of (+)-cibenzoline for digitalis- and adrenaline-induced arrhythmias were 1.4 +/- 0.4 and 2.0 +/- 0.6 micrograms/ml, respectively (mean +/- SD, n = 6).",1700207_6,0,1,2,8917,-1
8918,/- SD,28,30,181,186,"The minimum effective plasma concentrations of (+)-cibenzoline for digitalis- and adrenaline-induced arrhythmias were 1.4 +/- 0.4 and 2.0 +/- 0.6 micrograms/ml, respectively (mean +/- SD, n = 6).",1700207_6,-1,-1,2,8918,-1
8925,/-,15,16,123,125,"The minimum effective plasma concentrations of (-)-cibenzoline for digitalis- and adrenaline-induced arrhythmia were 0.06 +/- 0.04 and 0.7 +/- 0.1 micrograms/ml, respectively (mean +/- SD, n = 6).",1700207_8,0,1,2,8925,-1
8926,/-,20,21,140,142,"The minimum effective plasma concentrations of (-)-cibenzoline for digitalis- and adrenaline-induced arrhythmia were 0.06 +/- 0.04 and 0.7 +/- 0.1 micrograms/ml, respectively (mean +/- SD, n = 6).",1700207_8,0,1,2,8926,-1
8927,/- SD,28,30,182,187,"The minimum effective plasma concentrations of (-)-cibenzoline for digitalis- and adrenaline-induced arrhythmia were 0.06 +/- 0.04 and 0.7 +/- 0.1 micrograms/ml, respectively (mean +/- SD, n = 6).",1700207_8,-1,-1,2,8927,-1
8932,Ca channels,30,32,183,194,"The stronger antiarrhythmic effect of (-)-cibenzoline indicates that (-)-isomer may have an effect nearly 5-20 times stronger in suppressing Na channels, but effects of both drugs on Ca channels may be almost equipotent.",1700207_9,-1,-1,2,8932,-1
8938,BBB,10,11,65,68,Leakage of mannitol into the brain parenchyma through an altered BBB and secondary reversal of osmotic gradient is considered the major cause of rebound .,17019386_3,-1,-1,2,8938,-1
8939,secondary reversal,12,14,73,91,Leakage of mannitol into the brain parenchyma through an altered BBB and secondary reversal of osmotic gradient is considered the major cause of rebound .,17019386_3,-1,-1,2,8939,-1
8940,osmotic gradient,15,17,95,111,Leakage of mannitol into the brain parenchyma through an altered BBB and secondary reversal of osmotic gradient is considered the major cause of rebound .,17019386_3,-1,-1,2,8940,-1
8945,venous blood sample,21,24,107,126,"During resection, a sample of the surrounding edematous white matter was taken at the same time as a 10 ml venous blood sample.",17019386_7,-1,-1,2,8945,-1
8954,BBB,21,22,113,116,"CONCLUSIONS: The results of our study show that even after a single bolus, mannitol may leak through the altered BBB near gliomas, reversing the initial plasma-to-blood osmotic gradient, aggravating peritumoral edema and promoting rebound of ICP.",17019386_10,-1,-1,2,8954,-1
8955,plasma-to-blood osmotic gradient,28,31,153,185,"CONCLUSIONS: The results of our study show that even after a single bolus, mannitol may leak through the altered BBB near gliomas, reversing the initial plasma-to-blood osmotic gradient, aggravating peritumoral edema and promoting rebound of ICP.",17019386_10,-1,-1,2,8955,-1
8956,ICP,39,40,242,245,"CONCLUSIONS: The results of our study show that even after a single bolus, mannitol may leak through the altered BBB near gliomas, reversing the initial plasma-to-blood osmotic gradient, aggravating peritumoral edema and promoting rebound of ICP.",17019386_10,-1,-1,2,8956,-1
8959,associated with,3,5,23,38,Atrial fibrillation is associated with substantial morbidity and mortality.,17020434_1,-1,-1,2,8959,-1
8965,ACTIVE-W,1,2,4,12,The ACTIVE-W (Atrial Fibrillation Clopidogrel Trial with Irbesartan for Prevention of Vascular Events) study has demonstrated that warfarin is superior to platelet therapy (clopidogrel plus aspirin) in the prevention af embolic events.,17020434_5,-1,-1,2,8965,-1
8980,Preliminary studies,0,2,0,19,Preliminary studies suggest that statins could interfere with the risk of recurrence after electrical cardioversion.,17020434_8,-1,-1,2,8980,-1
8981,interfere with,6,8,47,61,Preliminary studies suggest that statins could interfere with the risk of recurrence after electrical cardioversion.,17020434_8,-1,-1,2,8981,-1
8983,percutaneous methods,2,4,9,29,"Finally, percutaneous methods for the exclusion of left atrial appendage are under investigation in high-risk patients.",17020434_9,-1,-1,2,8983,-1
8985,Placebo-level,0,1,0,13,Placebo-level incidence of extrapyramidal symptoms (EPS) with quetiapine in controlled studies of patients with bipolar mania.,17042884_0,-1,-1,2,8985,-1
8989,controlled studies,11,13,76,94,Placebo-level incidence of extrapyramidal symptoms (EPS) with quetiapine in controlled studies of patients with bipolar mania.,17042884_0,-1,-1,2,8989,-1
8992,EPS,7,8,49,52,"OBJECTIVES: To evaluate extrapyramidal symptoms (EPS), including akathisia, with quetiapine in patients with bipolar mania.",17042884_1,-1,-1,2,8992,-1
8996,double-blind,12,13,70,82,"METHODS: Data were analyzed from four similarly designed, randomized, double-blind, 3- to 12-week studies.",17042884_2,-1,-1,2,8996,-1
8997,12-week studies,16,18,90,105,"METHODS: Data were analyzed from four similarly designed, randomized, double-blind, 3- to 12-week studies.",17042884_2,-1,-1,2,8997,-1
9001,active controls,31,33,154,169,"Two studies evaluated quetiapine monotherapy (up to 800 mg/day) (n = 209) versus placebo (n = 198), with lithium or haloperidol monotherapy as respective active controls.",17042884_3,-1,-1,2,9001,-1
9005,QTP,21,22,114,117,"Two studies evaluated quetiapine (up to 800 mg/day) in combination with a mood stabilizer (lithium or divalproex, QTP + Li/DVP) (n = 196) compared to placebo and mood stabilizer (PBO + Li/DVP) (n = 203).",17042884_4,-1,-1,2,9005,-1
9006,Li/DVP,23,24,120,126,"Two studies evaluated quetiapine (up to 800 mg/day) in combination with a mood stabilizer (lithium or divalproex, QTP + Li/DVP) (n = 196) compared to placebo and mood stabilizer (PBO + Li/DVP) (n = 203).",17042884_4,-1,-1,2,9006,-1
9011,Simpson-Angus Scale,6,8,49,68,"Extrapyramidal symptoms were evaluated using the Simpson-Angus Scale (SAS), the Barnes Akathisia Rating Scale (BARS), adverse event reports and anticholinergic drug usage.",17042884_5,-1,-1,2,9011,-1
9026,treated with,11,13,60,72,"Adverse events related to EPS occurred in 59.6% of patients treated with haloperidol (n = 99) monotherapy, whereas 26.5% of patients treated with lithium (n = 98) monotherapy experienced adverse events related to EPS.",17042884_8,-1,-1,2,9026,-1
9028,treated with,26,28,133,145,"Adverse events related to EPS occurred in 59.6% of patients treated with haloperidol (n = 99) monotherapy, whereas 26.5% of patients treated with lithium (n = 98) monotherapy experienced adverse events related to EPS.",17042884_8,-1,-1,2,9028,-1
9035,QTP,24,25,111,114,"The incidence of akathisia was low and similar with quetiapine monotherapy (3.3%) and placebo (6.1%), and with QTP + Li/DVP (3.6%) and PBO + Li/DVP (4.9%).",17042884_9,-1,-1,2,9035,-1
9037,PBO,32,33,135,138,"The incidence of akathisia was low and similar with quetiapine monotherapy (3.3%) and placebo (6.1%), and with QTP + Li/DVP (3.6%) and PBO + Li/DVP (4.9%).",17042884_9,-1,-1,2,9037,-1
9039,associated with,2,4,12,27,"Lithium was associated with a significantly higher incidence (p < 0.05) of tremor (18.4%) than quetiapine (5.6%); cerebellar tremor, which is a known adverse effect of lithium, may have contributed to the elevated rate of tremor in patients receiving lithium therapy.",17042884_10,-1,-1,2,9039,-1
9049,BARS scores,12,14,83,94,No significant differences were observed between quetiapine and placebo on SAS and BARS scores.,17042884_12,-1,-1,2,9049,-1
9052,EPS,9,10,48,51,"CONCLUSIONS: In bipolar mania, the incidence of EPS, including akathisia, with quetiapine therapy is similar to that with placebo.",17042884_14,-1,-1,2,9052,-1
9057,rat.1,9,10,82,87,Anti-oxidant effects of atorvastatin in dexamethasone-induced hypertension in the rat.1.,17042910_0,-1,-1,2,9057,-1
9059,associated with,8,10,85,100,Dexamethasone (Dex)-induced hypertension is characterized by endothelial dysfunction associated with nitric oxide (NO) deficiency and increased superoxide (O2-) production.,17042910_1,-1,-1,2,9059,-1
9071,treated with,11,13,30,42,2. Male SD rats (n = 30) were treated with Ato (50 mg/kg per day in drinking water) or tap water for 15 days.,17042910_4,-1,-1,2,9071,-1
9075,Ato-treated,18,19,81,92,"Dexamethasone (10 microg/kg per day, s.c.) or saline was started after 4 days in Ato-treated and non-treated rats and continued for 11-13 days.",17042910_5,-1,-1,2,9075,-1
9076,non-treated,20,21,97,108,"Dexamethasone (10 microg/kg per day, s.c.) or saline was started after 4 days in Ato-treated and non-treated rats and continued for 11-13 days.",17042910_5,-1,-1,2,9076,-1
9078,SBP,4,5,25,28,Systolic blood pressure (SBP) was measured on alternate days using the tail-cuff method.,17042910_6,-1,-1,2,9078,-1
9079,alternate days,9,11,46,60,Systolic blood pressure (SBP) was measured on alternate days using the tail-cuff method.,17042910_6,-1,-1,2,9079,-1
9080,tail-cuff method,13,15,71,87,Systolic blood pressure (SBP) was measured on alternate days using the tail-cuff method.,17042910_6,-1,-1,2,9080,-1
9082,acetylcholine-induced vasorelaxation,5,7,37,73,Endothelial function was assessed by acetylcholine-induced vasorelaxation and phenylephrine-induced vasoconstriction in aortic segments.,17042910_7,-1,-1,2,9082,-1
9085,eNOS,1,2,9,13,Vascular eNOS mRNA was assessed by semi-quantitative reverse transcription-polymerase chain reaction.,17042910_8,-1,-1,2,9085,-1
9086,semi-quantitative reverse transcription-polymerase chain reaction,6,11,35,100,Vascular eNOS mRNA was assessed by semi-quantitative reverse transcription-polymerase chain reaction.,17042910_8,-1,-1,2,9086,-1
9087,treated with,2,4,8,20,"In rats treated with Dex alone, SBP was increased from 109 +/- 2 to 133 +/- 2 mmHg on Days 4 and Day 14, respectively (P < 0.001).",17042910_10,-1,-1,2,9087,-1
9091,/- 2 mmHg,18,21,73,82,"In rats treated with Dex alone, SBP was increased from 109 +/- 2 to 133 +/- 2 mmHg on Days 4 and Day 14, respectively (P < 0.001).",17042910_10,-1,-1,2,9091,-1
9092,Days 4,22,24,86,92,"In rats treated with Dex alone, SBP was increased from 109 +/- 2 to 133 +/- 2 mmHg on Days 4 and Day 14, respectively (P < 0.001).",17042910_10,-1,-1,2,9092,-1
9095,SBP,7,8,24,27,"In the Ato + Dex group, SBP was increased from 113 +/- 2 to 119 +/- 2 mmHg on Days 4 to 14, respectively (P < 0.001), but was significantly lower than SBP in the group treated with Dex alone (P < 0.05).",17042910_11,-1,-1,2,9095,-1
9097,/- 2 mmHg,18,21,65,74,"In the Ato + Dex group, SBP was increased from 113 +/- 2 to 119 +/- 2 mmHg on Days 4 to 14, respectively (P < 0.001), but was significantly lower than SBP in the group treated with Dex alone (P < 0.05).",17042910_11,-1,-1,2,9097,-1
9099,treated with,43,45,168,180,"In the Ato + Dex group, SBP was increased from 113 +/- 2 to 119 +/- 2 mmHg on Days 4 to 14, respectively (P < 0.001), but was significantly lower than SBP in the group treated with Dex alone (P < 0.05).",17042910_11,-1,-1,2,9099,-1
9108,treated with,15,17,86,98,Aortic superoxide production was lower in the Dex + Ato group compared with the group treated with Dex alone (P < 0.0001).,17042910_13,-1,-1,2,9108,-1
9112,Dex-treated SD,14,16,99,113,"Treatment with Ato improved endothelial function, reduced superoxide production and reduced SBP in Dex-treated SD rats.",17042910_15,-1,-1,2,9112,-1
9113,child?A,7,8,50,57,Is phenytoin administration safe in a hypothermic child?A male neonate with a Chiari malformation and a leaking myelomeningocoele underwent ventriculoperitoneal shunt insertion followed by repair of myelomeningocoele.,17049862_0,-1,-1,2,9113,-1
9134,platelet donation,6,8,57,74,Severe citrate toxicity complicating volunteer apheresis platelet donation.,17111419_0,-1,-1,2,9134,-1
9135,donor apheresis,10,12,61,76,We report a case of severe citrate toxicity during volunteer donor apheresis platelet collection.,17111419_1,-1,-1,2,9135,-1
9136,platelet collection,12,14,77,96,We report a case of severe citrate toxicity during volunteer donor apheresis platelet collection.,17111419_1,-1,-1,2,9136,-1
9137,first-time apheresis platelet donor,7,11,36,71,"The donor was a 40-year-old female, first-time apheresis platelet donor.",17111419_2,-1,-1,2,9137,-1
9144,consistent with,3,5,15,30,The events are consistent with a severe reaction to calcium chelation by sodium citrate anticoagulant resulting in symptomatic systemic hypocalcemia.,17111419_8,-1,-1,2,9144,-1
9163,control group,2,4,7,20,"In the control group (n = 7), the mean arterial pressure (MAP) was not manipulated.",1711760_3,-1,-1,2,9163,-1
9165,hypertensive group,2,4,7,25,"In the hypertensive group (n = 7), the MAP was elevated by 25-30 mm Hg beginning 2 h after MCAO.",1711760_4,-1,-1,2,9165,-1
9167,MCAO,3,4,17,21,"Four hours after MCAO, the rats were killed and the brains harvested.",1711760_5,-1,-1,2,9167,-1
9168,coronal planes,5,7,32,46,The brains were sectioned along coronal planes spanning the distribution of ischemia produced by MCAO.,1711760_6,-1,-1,2,9168,-1
9169,MCAO,14,15,97,101,The brains were sectioned along coronal planes spanning the distribution of ischemia produced by MCAO.,1711760_6,-1,-1,2,9169,-1
9177,hypertensive group,21,23,106,124,"In the periphery of the ischemic territory, SG in the cortex was greater (less edema accumulation) in the hypertensive group (1.041 +/- 0.001 vs 1.039 +/- 0.001, P less than 0.05).",1711760_10,-1,-1,2,9177,-1
9178,/-,26,27,133,135,"In the periphery of the ischemic territory, SG in the cortex was greater (less edema accumulation) in the hypertensive group (1.041 +/- 0.001 vs 1.039 +/- 0.001, P less than 0.05).",1711760_10,0,1,2,9178,-1
9179,/-,31,32,152,154,"In the periphery of the ischemic territory, SG in the cortex was greater (less edema accumulation) in the hypertensive group (1.041 +/- 0.001 vs 1.039 +/- 0.001, P less than 0.05).",1711760_10,0,1,2,9179,-1
9181,hypertensive group,21,23,110,128,"The area of histochemical injury (as a percent of the cross-sectional area of the hemisphere) was less in the hypertensive group (33 +/- 3% vs 21 +/- 2%, P less than 0.05).",1711760_11,-1,-1,2,9181,-1
9182,/-,26,27,134,136,"The area of histochemical injury (as a percent of the cross-sectional area of the hemisphere) was less in the hypertensive group (33 +/- 3% vs 21 +/- 2%, P less than 0.05).",1711760_11,0,1,2,9182,-1
9183,/-,32,33,147,149,"The area of histochemical injury (as a percent of the cross-sectional area of the hemisphere) was less in the hypertensive group (33 +/- 3% vs 21 +/- 2%, P less than 0.05).",1711760_11,0,1,2,9183,-1
9196,therapeutic advance,4,6,29,48,Sirolimus represents a major therapeutic advance in the prevention of acute renal allograft rejection and chronic allograft nephropathy.,17147461_2,-1,-1,2,9196,-1
9207,associated with,13,15,79,94,"However, clinical reports suggest that, under some circumstances, sirolimus is associated with proteinuria and acute renal dysfunction.",17147461_5,-1,-1,2,9207,-1
9209,risk factor,2,4,9,20,A common risk factor appears to be presence of pre-existing chronic renal damage.,17147461_6,-1,-1,2,9209,-1
9211,sirolimus-associated proteinuria,3,5,18,50,The mechanisms of sirolimus-associated proteinuria are multifactorial and may be due to an increase in glomerular capillary pressure following calcineurin inhibitor withdrawal.,17147461_7,-1,-1,2,9211,-1
9217,associated with,4,6,28,43,The acute renal dysfunction associated with sirolimus (such as in delayed graft function) may be due to suppression of compensatory renal cell proliferation and survival/repair processes.,17147461_9,-1,-1,2,9217,-1
9220,compensatory renal cell,21,24,119,142,The acute renal dysfunction associated with sirolimus (such as in delayed graft function) may be due to suppression of compensatory renal cell proliferation and survival/repair processes.,17147461_9,-1,-1,2,9220,-1
9221,survival/repair processes,26,28,161,186,The acute renal dysfunction associated with sirolimus (such as in delayed graft function) may be due to suppression of compensatory renal cell proliferation and survival/repair processes.,17147461_9,-1,-1,2,9221,-1
9226,patient populations,32,34,193,212,"Although these adverse effects occur in some patients, their occurrence could be minimised by knowledge of the molecular effects of sirolimus on the kidney, the use of sirolimus in appropriate patient populations, close monitoring of proteinuria and renal function, use of angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers if proteinuria occurs and withdrawal if needed.",17147461_10,-1,-1,2,9226,-1
9230,renal allograft studies,4,7,30,53,Further long-term analysis of renal allograft studies using sirolimus as de novo immunosuppression along with clinical and laboratory studies will refine these issues in the future.,17147461_11,-1,-1,2,9230,-1
9233,laboratory studies,17,19,123,141,Further long-term analysis of renal allograft studies using sirolimus as de novo immunosuppression along with clinical and laboratory studies will refine these issues in the future.,17147461_11,-1,-1,2,9233,-1
9239,consequence of,9,11,50,64,"More recently, proteinuria has been reported as a consequence of sirolimus therapy, although the mechanism has remained unclear.",17175308_2,-1,-1,2,9239,-1
9243,patient cohort,1,3,4,18,"The patient cohort (14 men, 11 women) was treated with SRL as conversion therapy, due to chronic allograft nephropathy (CAN) (n = 15) neoplasia (n = 8); Kaposi's sarcoma, Four skin cancers, One intestinal tumors, One renal cell carsinom) or BK virus nephropathy (n = 2).",17175308_4,-1,-1,2,9243,-1
9253,/-,9,10,33,35,SRL was started at a mean of 78 +/- 42 (15 to 163) months after transplantation.,17175308_5,0,1,2,9253,-1
9254,Mean follow-up,0,2,0,14,Mean follow-up on SRL therapy was 20 +/- 12 (6 to 43) months.,17175308_6,-1,-1,2,9254,-1
9256,/-,8,9,38,40,Mean follow-up on SRL therapy was 20 +/- 12 (6 to 43) months.,17175308_6,0,1,2,9256,-1
9257,g/d,9,10,44,47,Proteinuria increased from 0.445 (0 to 1.5) g/d before conversion to 3.2 g/dL (0.2 to 12) after conversion (P = 0.001).,17175308_7,-1,-1,2,9257,-1
9264,/-,10,11,60,62,Serum creatinine values did not change significantly: 1.98 +/-,17175308_14,0,1,2,9264,-1
9266,/-,8,9,39,41,0.8 mg/dL before SRL therapy and 2.53 +/- 1.9 mg/dL at last follow-up (P = .14).,17175308_15,0,1,2,9266,-1
9268,g/d,16,17,80,83,Mean urinary protein of patients who returned to dialysis was 1.26 (0.5 to 3.5) g/d before and 4.7 (3 to 12) g/d after conversion (P = .01).,17175308_18,-1,-1,2,9268,-1
9270,g/d,25,26,109,112,Mean urinary protein of patients who returned to dialysis was 1.26 (0.5 to 3.5) g/d before and 4.7 (3 to 12) g/d after conversion (P = .01).,17175308_18,-1,-1,2,9270,-1
9271,serum creatinine,1,3,5,21,"Mean serum creatinine level before conversion was 2.21 mg/dL and thereafter, 4.93 mg/dL (P = .02).",17175308_19,-1,-1,2,9271,-1
9283,PCPA-treated rats,8,10,27,44,"At puberty (P40), half the PCPA-treated rats and half the saline-treated rats began treatment with testosterone (T, 5 mg/kg, 5 days/week).",17194457_3,-1,-1,2,9283,-1
9284,saline-treated,13,14,58,72,"At puberty (P40), half the PCPA-treated rats and half the saline-treated rats began treatment with testosterone (T, 5 mg/kg, 5 days/week).",17194457_3,-1,-1,2,9284,-1
9289,Brain levels,0,2,0,12,"Brain levels of 5-HT and its metabolite, 5-hydroxyindoleacetic acid (5-HIAA), were determined using HPLC.",17194457_6,-1,-1,2,9289,-1
9293,HPLC,17,18,100,104,"Brain levels of 5-HT and its metabolite, 5-hydroxyindoleacetic acid (5-HIAA), were determined using HPLC.",17194457_6,-1,-1,2,9293,-1
9306,no effect,14,16,109,118,"Chronic exposure to PCPA alone significantly decreased locomotor activity and increased irritability but had no effect on sexual behavior, partner preference, or aggression.",17194457_9,-1,-1,2,9306,-1
9309,no effect,3,5,12,21,"T alone had no effect on locomotion, irritability, or sexual behavior but increased partner preference and aggression.",17194457_10,-1,-1,2,9309,-1
9315,central 5-HT,15,17,75,87,"Based on these data, it can be speculated that pubertal AAS users with low central 5-HT may be especially prone to exhibit aggressive behavior.",17194457_12,-1,-1,2,9315,-1
9320,Oncology report,19,21,141,156,Long-term follow-up of ifosfamide renal toxicity in children treated for malignant mesenchymal tumors: an International Society of Pediatric Oncology report.,1720453_0,-1,-1,2,9320,-1
9327,Total cumulative doses,0,3,0,22,"Total cumulative doses were 36 or 60 g/m2 of ifosfamide (six or 10 cycles of ifosfamide, vincristine, and dactinomycin [IVA]).",1720453_2,-1,-1,2,9327,-1
9328,g/m2,7,8,37,41,"Total cumulative doses were 36 or 60 g/m2 of ifosfamide (six or 10 cycles of ifosfamide, vincristine, and dactinomycin [IVA]).",1720453_2,-1,-1,2,9328,-1
9336,urinary electrolytes,8,10,56,76,"Renal function was investigated by measuring plasma and urinary electrolytes, glucosuria, proteinuria, aminoaciduria, urinary pH, osmolarity, creatinine clearance, phosphate tubular reabsorption, beta 2 microglobulinuria, and lysozymuria.",1720453_6,-1,-1,2,9336,-1
9342,lysozymuria,34,35,226,237,"Renal function was investigated by measuring plasma and urinary electrolytes, glucosuria, proteinuria, aminoaciduria, urinary pH, osmolarity, creatinine clearance, phosphate tubular reabsorption, beta 2 microglobulinuria, and lysozymuria.",1720453_6,-1,-1,2,9342,-1
9345,total population,21,23,108,124,Two subsets of patients were identified from this latter group: the first included four patients (5% of the total population) who developed major toxicity resulting in Fanconi's syndrome (TDFS); and the second group included five patients with elevated beta 2 microglobulinuria and low phosphate reabsorption.,1720453_8,-1,-1,2,9345,-1
9347,TDFS,34,35,188,192,Two subsets of patients were identified from this latter group: the first included four patients (5% of the total population) who developed major toxicity resulting in Fanconi's syndrome (TDFS); and the second group included five patients with elevated beta 2 microglobulinuria and low phosphate reabsorption.,1720453_8,-1,-1,2,9347,-1
9363,Earlier studies,0,2,0,15,"Earlier studies have demonstrated that antagonism of sigma1 receptors attenuates the convulsive, lethal, locomotor stimulatory and rewarding actions of cocaine in mice.",17241657_1,-1,-1,2,9363,-1
9374,behavioral studies,22,24,182,200,"To begin addressing this need, we characterized UMB24 (1-(2-phenethyl)-4-(2-pyridyl)-piperazine) and (+/-)-SM 21 (3alpha-tropanyl-2-(4-chorophenoxy)butyrate) in receptor binding and behavioral studies.",17241657_3,-1,-1,2,9374,-1
9375,Receptor binding studies,0,3,0,24,Receptor binding studies confirmed that UMB24 and (+/-)-SM 21 display preferential affinity for sigma2 over sigma1 receptors.,17241657_4,-1,-1,2,9375,-1
9378,display preferential,9,11,62,82,Receptor binding studies confirmed that UMB24 and (+/-)-SM 21 display preferential affinity for sigma2 over sigma1 receptors.,17241657_4,-1,-1,2,9378,-1
9387,(+/-)-SM,4,5,25,33,"When administered alone, (+/-)-SM 21 produced no significant effects compared to control injections of saline, but UMB24 had locomotor depressant actions.",17241657_6,-1,-1,2,9387,-1
9388,no significant,7,9,46,60,"When administered alone, (+/-)-SM 21 produced no significant effects compared to control injections of saline, but UMB24 had locomotor depressant actions.",17241657_6,-1,-1,2,9388,-1
9392,up-regulation,3,4,26,39,Progressive myopathy with up-regulation of MHC-I associated with statin therapy.,17241784_0,-1,-1,2,9392,-1
9399,multifocal,7,8,34,44,In all cases there was diffuse or multifocal up-regulation of MHC-I expression even in non-necrotic fibres.,17241784_5,-1,-1,2,9399,-1
9400,up-regulation,8,9,45,58,In all cases there was diffuse or multifocal up-regulation of MHC-I expression even in non-necrotic fibres.,17241784_5,-1,-1,2,9400,-1
9402,non-necrotic fibres,14,16,87,106,In all cases there was diffuse or multifocal up-regulation of MHC-I expression even in non-necrotic fibres.,17241784_5,-1,-1,2,9402,-1
9407,up-regulation,22,23,145,158,The mechanism of this myopathy is uncertain but may involve the induction by statins of an endoplasmic reticulum stress response with associated up-regulation of MHC-I expression and antigen presentation by muscle fibres.,17241784_8,-1,-1,2,9407,-1
9411,susceptibility loci,8,10,59,78,Use of chromosome substitution strains to identify seizure susceptibility loci in mice.,17242861_0,-1,-1,2,9411,-1
9412,quantitative trait loci,38,41,198,221,"Chromosome substitution strains (CSS), in which a single chromosome from one inbred strain (donor) has been transferred onto a second strain (host) by repeated backcrossing, may be used to identify quantitative trait loci (QTLs) that contribute to seizure susceptibility.",17242861_2,-1,-1,2,9412,-1
9414,QTLs,0,1,0,4,"QTLs for susceptibility to pilocarpine-induced seizures, a model of temporal lobe epilepsy, have not been reported, and CSS have not previously been used to localize seizure susceptibility genes.",17242861_3,-1,-1,2,9414,-1
9416,susceptibility genes,29,31,174,194,"QTLs for susceptibility to pilocarpine-induced seizures, a model of temporal lobe epilepsy, have not been reported, and CSS have not previously been used to localize seizure susceptibility genes.",17242861_3,-1,-1,2,9416,-1
9419,localize genes,18,20,71,85,We report QTLs identified using a B6 (host) x A/J (donor) CSS panel to localize genes involved in susceptibility to pilocarpine-induced seizures.,17242861_4,-1,-1,2,9419,-1
9421,A/J,13,14,60,63,"Three hundred fifty-five adult male CSS mice, 58 B6, and 39 A/J were tested for susceptibility to pilocarpine-induced seizures.",17242861_5,-1,-1,2,9421,-1
9422,Highest stage,0,2,0,13,Highest stage reached and latency to each stage were recorded for all mice.,17242861_6,-1,-1,2,9422,-1
9425,Chromosomes 10,3,5,12,26,"The CSS for Chromosomes 10 and 18 progressed to the most severe stages, diverging dramatically from the B6 phenotype.",17242861_8,-1,-1,2,9425,-1
9427,CSS10,8,9,56,61,Latencies to stages were also significantly shorter for CSS10 and CSS18 mice.,17242861_9,-1,-1,2,9427,-1
9428,CSS18,10,11,66,71,Latencies to stages were also significantly shorter for CSS10 and CSS18 mice.,17242861_9,-1,-1,2,9428,-1
9429,susceptibility loci,4,6,29,48,CSS mapping suggests seizure susceptibility loci on mouse Chromosomes 10 and 18.,17242861_10,-1,-1,2,9429,-1
9431,homologous candidate genes,9,12,69,95,This approach provides a framework for identifying potentially novel homologous candidate genes for human temporal lobe epilepsy.,17242861_11,-1,-1,2,9431,-1
9433,In vitro,0,2,0,8,In vitro characterization of parasympathetic and sympathetic responses in cyclophosphamide-induced cystitis in the rat.,17244258_0,-1,-1,2,9433,-1
9434,sympathetic responses,6,8,49,70,In vitro characterization of parasympathetic and sympathetic responses in cyclophosphamide-induced cystitis in the rat.,17244258_0,-1,-1,2,9434,-1
9440,urinary strip preparations,2,5,13,39,"Responses of urinary strip preparations from control and cyclophosphamide-pretreated rats to electrical field stimulation and to agonists were assessed in the absence and presence of muscarinic, adrenergic and purinergic receptor antagonists.",17244258_3,-1,-1,2,9440,-1
9445,electrical field stimulation,18,21,104,132,"Generally, atropine reduced contractions, but in contrast to controls, it also reduced responses to low electrical field stimulation intensity (1-5 Hz) in inflamed preparations.",17244258_4,-1,-1,2,9445,-1
9447,purinoceptor desensitization,4,6,15,43,"In both types, purinoceptor desensitization with alpha,beta-methylene adenosine-5'-triphosphate (alpha,beta-meATP) caused further reductions at low frequencies (<10 Hz).",17244258_5,-1,-1,2,9447,-1
9456,stimulation-evoked contractile response,37,40,246,285,"The muscarinic receptor antagonists atropine, 4-diphenylacetoxy-N-methylpiperidine (4-DAMP) ('M(1)/M(3)/M(5)-selective'), methoctramine ('M(2)-selective') and pirenzepine ('M(1)-selective') antagonized the tonic component of the electrical field stimulation-evoked contractile response more potently than the phasic component.",17244258_6,-1,-1,2,9456,-1
9459,tonic contractions,3,5,21,39,4-DAMP inhibited the tonic contractions in controls more potently than methoctramine and pirenzepine.,17244258_7,-1,-1,2,9459,-1
9470,tonic responses,13,15,80,95,"In contrast to controls, methoctramine increased -- instead of decreased -- the tonic responses at high frequencies.",17244258_9,-1,-1,2,9470,-1
9472,control strips,13,15,73,87,"While contractions to carbachol and ATP were the same in inflamed and in control strips when related to a reference potassium response, isoprenaline-induced relaxations were smaller in inflamed strips.",17244258_10,-1,-1,2,9472,-1
9473,potassium response,20,22,116,134,"While contractions to carbachol and ATP were the same in inflamed and in control strips when related to a reference potassium response, isoprenaline-induced relaxations were smaller in inflamed strips.",17244258_10,-1,-1,2,9473,-1
9475,functional responses,9,11,54,74,"Thus, in cystitis substantial changes of the efferent functional responses occur.",17244258_11,-1,-1,2,9475,-1
9478,effects by,7,9,73,83,"While postjunctional beta-adrenoceptor-mediated relaxations are reduced, effects by prejunctional inhibitory muscarinic receptors may be increased.",17244258_12,-1,-1,2,9478,-1
9489,in vivo,30,32,207,214,"Activation of presynaptic alpha2-adrenoceptors is the most widely accepted mechanism of action of the antisympathetic drug clonidine; however, other target proteins have been postulated to contribute to the in vivo actions of clonidine.",17261653_2,-1,-1,2,9489,-1
9492,targeted deletion,21,23,146,163,"METHODS AND RESULTS: To test whether clonidine elicits pharmacological effects independent of alpha2-adrenoceptors, we have generated mice with a targeted deletion of all 3 alpha2-adrenoceptor subtypes (alpha2ABC-/-).",17261653_3,-1,-1,2,9492,-1
9494,subtypes,27,28,193,201,"METHODS AND RESULTS: To test whether clonidine elicits pharmacological effects independent of alpha2-adrenoceptors, we have generated mice with a targeted deletion of all 3 alpha2-adrenoceptor subtypes (alpha2ABC-/-).",17261653_3,-1,-1,2,9494,-1
9495,Alpha2ABC-/- mice,0,2,0,17,"Alpha2ABC-/- mice were completely unresponsive to the analgesic and hypnotic effects of clonidine; however, clonidine significantly lowered heart rate in alpha2ABC-/- mice by up to 150 bpm.",17261653_4,-1,-1,2,9495,-1
9499,wild-type,24,25,129,138,Clonidine-induced bradycardia in conscious alpha2ABC-/- mice was 32.3% (10 microg/kg) and 26.6% (100 microg/kg) of the effect in wild-type mice.,17261653_5,-1,-1,2,9499,-1
9500,bradycardic effect,2,4,10,28,A similar bradycardic effect of clonidine was observed in isolated spontaneously beating right atria from alpha2ABC-knockout and wild-type mice.,17261653_6,-1,-1,2,9500,-1
9501,spontaneously beating,10,12,67,88,A similar bradycardic effect of clonidine was observed in isolated spontaneously beating right atria from alpha2ABC-knockout and wild-type mice.,17261653_6,-1,-1,2,9501,-1
9502,wild-type,17,18,129,138,A similar bradycardic effect of clonidine was observed in isolated spontaneously beating right atria from alpha2ABC-knockout and wild-type mice.,17261653_6,-1,-1,2,9502,-1
9507,HEK293 cells,31,33,217,229,Clonidine inhibited the native pacemaker current (I(f)) in isolated sinoatrial node pacemaker cells and the I(f)-generating hyperpolarization-activated cyclic nucleotide-gated (HCN) 2 and HCN4 channels in transfected HEK293 cells.,17261653_7,-1,-1,2,9507,-1
9508,consequence of,2,4,5,19,"As a consequence of blocking I(f), clonidine reduced the slope of the diastolic depolarization and the frequency of pacemaker potentials in sinoatrial node cells from wild-type and alpha2ABC-knockout mice.",17261653_8,-1,-1,2,9508,-1
9510,sinoatrial node cells,23,26,140,161,"As a consequence of blocking I(f), clonidine reduced the slope of the diastolic depolarization and the frequency of pacemaker potentials in sinoatrial node cells from wild-type and alpha2ABC-knockout mice.",17261653_8,-1,-1,2,9510,-1
9511,wild-type,27,28,167,176,"As a consequence of blocking I(f), clonidine reduced the slope of the diastolic depolarization and the frequency of pacemaker potentials in sinoatrial node cells from wild-type and alpha2ABC-knockout mice.",17261653_8,-1,-1,2,9511,-1
9513,bradycardic effects,12,14,84,103,"CONCLUSIONS: Direct inhibition of cardiac HCN pacemaker channels contributes to the bradycardic effects of clonidine gene-targeted mice in vivo, and thus, clonidine-like drugs represent novel structures for future HCN channel inhibitors.",17261653_9,-1,-1,2,9513,-1
9514,gene-targeted mice,16,18,117,135,"CONCLUSIONS: Direct inhibition of cardiac HCN pacemaker channels contributes to the bradycardic effects of clonidine gene-targeted mice in vivo, and thus, clonidine-like drugs represent novel structures for future HCN channel inhibitors.",17261653_9,-1,-1,2,9514,-1
9515,in vivo,18,20,136,143,"CONCLUSIONS: Direct inhibition of cardiac HCN pacemaker channels contributes to the bradycardic effects of clonidine gene-targeted mice in vivo, and thus, clonidine-like drugs represent novel structures for future HCN channel inhibitors.",17261653_9,-1,-1,2,9515,-1
9528,patient's,9,11,52,61,"Without the knowledge of the medical personnel, the patient's mother administered three doses of clonidine during the evening before and morning of surgery to reduce anxiety.",17263743_3,-1,-1,2,9528,-1
9543,normal range,12,14,66,78,"Physical exam, complete metabolic panel, and hemogram were in the normal range.",17285209_3,-1,-1,2,9543,-1
9560,lesion broadens,3,5,13,28,"This type of lesion broadens the spectrum of liver injury due to this drug combination, mainly represented by a benign cholestatic syndrome.",1728522_2,-1,-1,2,9560,-1
9574,patient group,1,3,4,17,One patient group developed sinus tachycardias in the setting of a massive carbamazepine overdose.,1728915_4,-1,-1,2,9574,-1
9579,associated with,19,21,161,176,"The second group consisted almost exclusively of elderly women who developed potentially life-threatening bradyarrhythmias or atrioventricular conduction delay, associated with either therapeutic or modestly elevated carbamazepine serum levels.",1728915_5,-1,-1,2,9579,-1
9589,screening test,6,8,46,60,"To develop a more sensitive echocardiographic screening test for cardiac damage due to doxorubicin, a cohort study was performed using dobutamine infusion to differentiate asymptomatic long-term survivors of childhood cancer treated with doxorubicin from healthy control subjects.",1732369_2,-1,-1,2,9589,-1
9591,cohort study,16,18,102,114,"To develop a more sensitive echocardiographic screening test for cardiac damage due to doxorubicin, a cohort study was performed using dobutamine infusion to differentiate asymptomatic long-term survivors of childhood cancer treated with doxorubicin from healthy control subjects.",1732369_2,-1,-1,2,9591,-1
9594,treated with,31,33,225,237,"To develop a more sensitive echocardiographic screening test for cardiac damage due to doxorubicin, a cohort study was performed using dobutamine infusion to differentiate asymptomatic long-term survivors of childhood cancer treated with doxorubicin from healthy control subjects.",1732369_2,-1,-1,2,9594,-1
9595,healthy control subjects,35,38,255,279,"To develop a more sensitive echocardiographic screening test for cardiac damage due to doxorubicin, a cohort study was performed using dobutamine infusion to differentiate asymptomatic long-term survivors of childhood cancer treated with doxorubicin from healthy control subjects.",1732369_2,-1,-1,2,9595,-1
9597,experimental group,4,6,32,50,Echocardiographic data from the experimental group of 21 patients (mean age 16 +/- 5 years) treated from 1.6 to 14.3 years (median 5.3) before this study with 27 to 532 mg/m2 of doxorubicin (mean 196) were compared with echocardiographic data from 12 normal age-matched control subjects.,1732369_3,-1,-1,2,9597,-1
9598,/- 5 years,14,17,80,90,Echocardiographic data from the experimental group of 21 patients (mean age 16 +/- 5 years) treated from 1.6 to 14.3 years (median 5.3) before this study with 27 to 532 mg/m2 of doxorubicin (mean 196) were compared with echocardiographic data from 12 normal age-matched control subjects.,1732369_3,-1,-1,2,9598,-1
9602,Doppler studies,1,3,18,33,Echocardiographic Doppler studies were performed before infusion and after 15 min of infusion at each rate.,1732369_5,-1,-1,2,9602,-1
9605,incidence rate,17,19,102,116,Dobutamine infusion at 10 micrograms/kg per min was discontinued after six studies secondary to a 50% incidence rate of adverse symptoms.,1732369_6,-1,-1,2,9605,-1
9607,control subjects,10,12,62,78,"The most important findings were that compared with values in control subjects, end-systolic left ventricular posterior wall dimension and percent of left ventricular posterior wall thickening in doxorubicin-treated patients were decreased at baseline study and these findings were more clearly delineated with dobutamine stimulation.",1732369_7,-1,-1,2,9607,-1
9610,doxorubicin-treated,28,29,196,215,"The most important findings were that compared with values in control subjects, end-systolic left ventricular posterior wall dimension and percent of left ventricular posterior wall thickening in doxorubicin-treated patients were decreased at baseline study and these findings were more clearly delineated with dobutamine stimulation.",1732369_7,-1,-1,2,9610,-1
9611,baseline study,33,35,243,257,"The most important findings were that compared with values in control subjects, end-systolic left ventricular posterior wall dimension and percent of left ventricular posterior wall thickening in doxorubicin-treated patients were decreased at baseline study and these findings were more clearly delineated with dobutamine stimulation.",1732369_7,-1,-1,2,9611,-1
9614,doxorubicin-treated group,10,12,75,100,End-systolic left ventricular posterior wall dimension at baseline for the doxorubicin-treated group was 11 +/- 1.9 mm versus 13.1 +/- 1.5 mm for control subjects (p less than 0.01).,1732369_8,-1,-1,2,9614,-1
9615,/-,15,16,109,111,End-systolic left ventricular posterior wall dimension at baseline for the doxorubicin-treated group was 11 +/- 1.9 mm versus 13.1 +/- 1.5 mm for control subjects (p less than 0.01).,1732369_8,0,1,2,9615,-1
9617,control subjects,25,27,146,162,End-systolic left ventricular posterior wall dimension at baseline for the doxorubicin-treated group was 11 +/- 1.9 mm versus 13.1 +/- 1.5 mm for control subjects (p less than 0.01).,1732369_8,-1,-1,2,9617,-1
9620,doxorubicin-treated group,15,17,114,139,End-systolic left ventricular posterior wall dimension at the 5-micrograms/kg per min dobutamine infusion for the doxorubicin-treated group was 14.1 +/- 2.4 mm versus 19.3 +/- 2.6 mm for control subjects (p less than 0.01).(ABSTRACT TRUNCATED AT 250 WORDS),1732369_9,-1,-1,2,9620,-1
9623,control subjects,30,32,187,203,End-systolic left ventricular posterior wall dimension at the 5-micrograms/kg per min dobutamine infusion for the doxorubicin-treated group was 14.1 +/- 2.4 mm versus 19.3 +/- 2.6 mm for control subjects (p less than 0.01).(ABSTRACT TRUNCATED AT 250 WORDS),1732369_9,-1,-1,2,9623,-1
9629,dose-dependently,23,24,160,176,"Using a rat model of adriamycin-induced cardiomyopathy, we tested the hypothesis that abnormal cardiac adrenergic neuron activity may appear and be exacerbated dose-dependently in adriamycin cardiomyopathy.",1732442_2,-1,-1,2,9629,-1
9634,treatment groups,13,15,76,92,"There were no abnormalities or only isolated degeneration in the 1- or 2-wk treatment groups, isolated or scattered degeneration in half of the 3-wk group, frequent scattered degeneration in the 4-wk group, scattered or focal degeneration in the 5-wk group, and extensive degeneration in the 8-wk group.",1732442_4,-1,-1,2,9634,-1
9637,intravenous injection,7,9,49,70,Myocardial accumulation of [125I]MIBG 4 hr after intravenous injection did not differ between the controls and the groups treated 3 wk or less.,1732442_5,-1,-1,2,9637,-1
9638,treated 3,18,20,122,131,Myocardial accumulation of [125I]MIBG 4 hr after intravenous injection did not differ between the controls and the groups treated 3 wk or less.,1732442_5,-1,-1,2,9638,-1
9647,dose-dependent,11,12,69,83,"Thus, MIBG accumulation in the myocardium decreased in an adriamycin dose-dependent manner.",1732442_9,-1,-1,2,9647,-1
9653,newborns?OBJECTIVE,20,21,141,159,Influence of smoking on developing cochlea. Does smoking during pregnancy affect the amplitudes of transient evoked otoacoustic emissions in newborns?OBJECTIVE: Maternal tobacco smoking has negative effects on fetal growth.,17343925_0,-1,-1,2,9653,-1
9656,associated with,20,22,129,144,"The influence of smoking during pregnancy on the developing cochlea has not been estimated, although smoking has been positively associated with hearing loss in adults.",17343925_1,-1,-1,2,9656,-1
9663,control group,15,17,89,102,"Newborns whose mothers reported smoking during pregnancy (n=200 ears) were compared to a control group of newborns (n=200 ears), whose mothers were non-smokers.",17343925_4,-1,-1,2,9663,-1
9666,exposed neonates,3,5,12,28,"RESULTS: In exposed neonates, TEOAEs mean response (across frequency) and mean amplitude at 4000Hz was significantly lower than in non-exposed neonates.",17343925_6,-1,-1,2,9666,-1
9667,TEOAEs mean response,6,9,30,50,"RESULTS: In exposed neonates, TEOAEs mean response (across frequency) and mean amplitude at 4000Hz was significantly lower than in non-exposed neonates.",17343925_6,-1,-1,2,9667,-1
9668,mean amplitude,14,16,74,88,"RESULTS: In exposed neonates, TEOAEs mean response (across frequency) and mean amplitude at 4000Hz was significantly lower than in non-exposed neonates.",17343925_6,-1,-1,2,9668,-1
9669,non-exposed neonates,23,25,131,151,"RESULTS: In exposed neonates, TEOAEs mean response (across frequency) and mean amplitude at 4000Hz was significantly lower than in non-exposed neonates.",17343925_6,-1,-1,2,9669,-1
9670,no significant,7,9,57,71,Comparisons between exposed newborns' subgroups revealed no significant differences.,17343925_7,-1,-1,2,9670,-1
9671,control group,7,9,39,52,"However, by comparing each subgroup to control group, we found statistically significant decreases of TEOAEs amplitudes at 4000Hz for all three groups.",17343925_8,-1,-1,2,9671,-1
9672,statistically significant,12,14,63,88,"However, by comparing each subgroup to control group, we found statistically significant decreases of TEOAEs amplitudes at 4000Hz for all three groups.",17343925_8,-1,-1,2,9672,-1
9674,TEOAEs responses,1,3,5,21,Mean TEOAEs responses of highly exposed newborns were also significantly lower in comparison to our control group.,17343925_9,-1,-1,2,9674,-1
9675,control group,15,17,100,113,Mean TEOAEs responses of highly exposed newborns were also significantly lower in comparison to our control group.,17343925_9,-1,-1,2,9675,-1
9676,In utero,2,4,12,20,"CONCLUSION: In utero, exposure to tobacco smoking seems to have a small impact on outer hair cells.",17343925_10,-1,-1,2,9676,-1
9683,treated with,6,8,43,55,Syncope and QT prolongation among patients treated with methadone for heroin dependence in the city of Copenhagen.,17344330_0,-1,-1,2,9683,-1
9686,QT interval,3,5,20,31,Prolongation of the QT interval in the ECG of patients with torsade de pointes (TdP) has been reported in methadone users.,17344330_2,-1,-1,2,9686,-1
9687,torsade de pointes,11,14,60,78,Prolongation of the QT interval in the ECG of patients with torsade de pointes (TdP) has been reported in methadone users.,17344330_2,-1,-1,2,9687,-1
9691,TdP,28,29,177,180,"As heroin addicts sometimes faint while using illicit drugs, doctors might attribute too many episodes of syncope to illicit drug use and thereby underestimate the incidence of TdP in this special population, and the high mortality in this population may, in part, be caused by the proarrhythmic effect of methadone.",17344330_3,-1,-1,2,9691,-1
9692,special population,31,33,189,207,"As heroin addicts sometimes faint while using illicit drugs, doctors might attribute too many episodes of syncope to illicit drug use and thereby underestimate the incidence of TdP in this special population, and the high mortality in this population may, in part, be caused by the proarrhythmic effect of methadone.",17344330_3,-1,-1,2,9692,-1
9694,cross-sectional study interview,4,7,17,48,"METHODS: In this cross-sectional study interview, ECGs and blood samples were collected in a population of adult heroin addicts treated with methadone or buprenorphine on a daily basis.",17344330_4,-1,-1,2,9694,-1
9695,blood samples,10,12,59,72,"METHODS: In this cross-sectional study interview, ECGs and blood samples were collected in a population of adult heroin addicts treated with methadone or buprenorphine on a daily basis.",17344330_4,-1,-1,2,9695,-1
9696,treated with,21,23,128,140,"METHODS: In this cross-sectional study interview, ECGs and blood samples were collected in a population of adult heroin addicts treated with methadone or buprenorphine on a daily basis.",17344330_4,-1,-1,2,9696,-1
9699,QT interval,1,3,4,15,The QT interval was estimated from 12 lead ECGs.,17344330_6,-1,-1,2,9699,-1
9701,QT,6,7,40,42,"The association between opioid dose and QT, and methadone dose and reporting of syncope was assessed using multivariate linear regression and logistic regression, respectively.",17344330_8,-1,-1,2,9701,-1
9702,multivariate linear regression,18,21,107,137,"The association between opioid dose and QT, and methadone dose and reporting of syncope was assessed using multivariate linear regression and logistic regression, respectively.",17344330_8,-1,-1,2,9702,-1
9703,logistic regression,22,24,142,161,"The association between opioid dose and QT, and methadone dose and reporting of syncope was assessed using multivariate linear regression and logistic regression, respectively.",17344330_8,-1,-1,2,9703,-1
9705,associated with,5,7,28,43,RESULTS: Methadone dose was associated with longer QT interval of 0.140 ms/mg (p = 0.002).,17344330_9,-1,-1,2,9705,-1
9706,QT interval,8,10,51,62,RESULTS: Methadone dose was associated with longer QT interval of 0.140 ms/mg (p = 0.002).,17344330_9,-1,-1,2,9706,-1
9708,QTc,5,6,41,44,No association between buprenorphine and QTc was found.,17344330_10,-1,-1,2,9708,-1
9709,treated with,3,5,19,31,"Among the subjects treated with methadone, 28% men and 32% women had prolonged QTc interval.",17344330_11,-1,-1,2,9709,-1
9710,QTc interval,16,18,79,91,"Among the subjects treated with methadone, 28% men and 32% women had prolonged QTc interval.",17344330_11,-1,-1,2,9710,-1
9711,treated with,4,6,21,33,None of the subjects treated with buprenorphine had QTc interval >0.440 s((1/2)).,17344330_12,-1,-1,2,9711,-1
9713,QTc interval,8,10,52,64,None of the subjects treated with buprenorphine had QTc interval >0.440 s((1/2)).,17344330_12,-1,-1,2,9713,-1
9714,associated with,7,9,34,49,A 50 mg higher methadone dose was associated with a 1.2 (95% CI 1.1 to 1.4) times higher odds for syncope.,17344330_13,-1,-1,2,9714,-1
9715,associated with,4,6,26,41,CONCLUSIONS: Methadone is associated with QT prolongation and higher reporting of syncope in a population of heroin addicts.,17344330_14,-1,-1,2,9715,-1
9722,fasciotomies,1,2,7,19,Urgent fasciotomies were performed and the patient made an uneventful recovery with the withdrawal of simvastatin.,17344566_2,-1,-1,2,9722,-1
9729,associated with,11,13,59,74,We describe a case of neuroleptic malignant syndrome (NMS) associated with the use of ziprasidone.,17366349_2,-1,-1,2,9729,-1
9731,associated with,6,8,55,70,"Although conventional neuroleptics are more frequently associated with NMS, atypical antipsychotic drugs like ziprasidone may also be a cause.",17366349_3,-1,-1,2,9731,-1
9743,genetic influences,3,5,15,33,"In addition to genetic influences, recent studies suggest that prenatal drug or chemical exposures are risk factors for autism.",17400887_2,-1,-1,2,9743,-1
9745,risk factors,16,18,103,115,"In addition to genetic influences, recent studies suggest that prenatal drug or chemical exposures are risk factors for autism.",17400887_2,-1,-1,2,9745,-1
9749,associated with,13,15,81,96,"Terbutaline, a beta2-adrenoceptor agonist used to arrest preterm labor, has been associated with increased concordance for autism in dizygotic twins.",17400887_3,-1,-1,2,9749,-1
9753,microglial activation,7,9,41,62,We studied the effects of terbutaline on microglial activation in different brain regions and behavioral outcomes in developing rats.,17400887_4,-1,-1,2,9753,-1
9756,PN,14,15,72,74,Newborn rats were given terbutaline (10 mg/kg) daily on postnatal days (PN) 2 to 5 or PN 11 to 14 and examined 24 h after the last dose and at PN 30.,17400887_5,-1,-1,2,9756,-1
9757,PN,20,21,86,88,Newborn rats were given terbutaline (10 mg/kg) daily on postnatal days (PN) 2 to 5 or PN 11 to 14 and examined 24 h after the last dose and at PN 30.,17400887_5,-1,-1,2,9757,-1
9758,PN,34,35,143,145,Newborn rats were given terbutaline (10 mg/kg) daily on postnatal days (PN) 2 to 5 or PN 11 to 14 and examined 24 h after the last dose and at PN 30.,17400887_5,-1,-1,2,9758,-1
9759,Immunohistochemical studies,0,2,0,27,"Immunohistochemical studies showed that administration of terbutaline on PN 2 to 5 produced a robust increase in microglial activation on PN 30 in the cerebral cortex, as well as in cerebellar and cerebrocortical white matter.",17400887_6,-1,-1,2,9759,-1
9767,PN,10,11,63,65,None of these effects occurred in animals given terbutaline on PN 11 to 14.,17400887_7,-1,-1,2,9767,-1
9769,treated with,5,7,29,41,"In behavioral tests, animals treated with terbutaline on PN 2 to 5 showed consistent patterns of hyper-reactivity to novelty and aversive stimuli when assessed in a novel open field, as well as in the acoustic startle response test.",17400887_8,-1,-1,2,9769,-1
9771,PN,9,10,57,59,"In behavioral tests, animals treated with terbutaline on PN 2 to 5 showed consistent patterns of hyper-reactivity to novelty and aversive stimuli when assessed in a novel open field, as well as in the acoustic startle response test.",17400887_8,-1,-1,2,9771,-1
9773,aversive stimuli,21,23,129,145,"In behavioral tests, animals treated with terbutaline on PN 2 to 5 showed consistent patterns of hyper-reactivity to novelty and aversive stimuli when assessed in a novel open field, as well as in the acoustic startle response test.",17400887_8,-1,-1,2,9773,-1
9775,acoustic startle response test,36,40,201,231,"In behavioral tests, animals treated with terbutaline on PN 2 to 5 showed consistent patterns of hyper-reactivity to novelty and aversive stimuli when assessed in a novel open field, as well as in the acoustic startle response test.",17400887_8,-1,-1,2,9775,-1
9777,overstimulation,5,6,46,61,"Our findings indicate that beta2-adrenoceptor overstimulation during an early critical period results in microglial activation associated with innate neuroinflammatory pathways and behavioral abnormalities, similar to those described in autism.",17400887_9,-1,-1,2,9777,-1
9779,associated with,15,17,127,142,"Our findings indicate that beta2-adrenoceptor overstimulation during an early critical period results in microglial activation associated with innate neuroinflammatory pathways and behavioral abnormalities, similar to those described in autism.",17400887_9,-1,-1,2,9779,-1
9780,innate neuroinflammatory pathways,17,20,143,176,"Our findings indicate that beta2-adrenoceptor overstimulation during an early critical period results in microglial activation associated with innate neuroinflammatory pathways and behavioral abnormalities, similar to those described in autism.",17400887_9,-1,-1,2,9780,-1
9782,animal model,5,7,29,41,This study provides a useful animal model for understanding the neuropathological processes underlying autism spectrum disorders.,17400887_10,-1,-1,2,9782,-1
9786,brain expression,2,4,16,32,Upregulation of brain expression of P-glycoprotein in MRP2-deficient TR(-) rats resembles seizure-induced up-regulation of this drug efflux transporter in normal rats.,17437408_0,-1,-1,2,9786,-1
9790,up-regulation,13,14,106,119,Upregulation of brain expression of P-glycoprotein in MRP2-deficient TR(-) rats resembles seizure-induced up-regulation of this drug efflux transporter in normal rats.,17437408_0,-1,-1,2,9790,-1
9794,apical domain,21,23,119,132,PURPOSE: The multidrug resistance protein 2 (MRP2) is a drug efflux transporter that is expressed predominantly at the apical domain of hepatocytes but seems also to be expressed at the apical membrane of brain capillary endothelial cells that form the blood-brain barrier (BBB).,17437408_1,-1,-1,2,9794,-1
9796,apical membrane,33,35,186,201,PURPOSE: The multidrug resistance protein 2 (MRP2) is a drug efflux transporter that is expressed predominantly at the apical domain of hepatocytes but seems also to be expressed at the apical membrane of brain capillary endothelial cells that form the blood-brain barrier (BBB).,17437408_1,-1,-1,2,9796,-1
9801,transport-deficient (TR(-)),5,10,22,49,"MRP2 is absent in the transport-deficient (TR(-)) Wistar rat mutant, so that this rat strain was very helpful in defining substrates of MRP2 by comparing tissue concentrations or functional activities of compounds in MRP2-deficient rats with those in transport-competent Wistar rats.",17437408_2,-1,-1,2,9801,-1
9802,Wistar rat mutant,10,13,50,67,"MRP2 is absent in the transport-deficient (TR(-)) Wistar rat mutant, so that this rat strain was very helpful in defining substrates of MRP2 by comparing tissue concentrations or functional activities of compounds in MRP2-deficient rats with those in transport-competent Wistar rats.",17437408_2,-1,-1,2,9802,-1
9804,tissue concentrations,29,31,154,175,"MRP2 is absent in the transport-deficient (TR(-)) Wistar rat mutant, so that this rat strain was very helpful in defining substrates of MRP2 by comparing tissue concentrations or functional activities of compounds in MRP2-deficient rats with those in transport-competent Wistar rats.",17437408_2,-1,-1,2,9804,-1
9805,functional activities,32,34,179,200,"MRP2 is absent in the transport-deficient (TR(-)) Wistar rat mutant, so that this rat strain was very helpful in defining substrates of MRP2 by comparing tissue concentrations or functional activities of compounds in MRP2-deficient rats with those in transport-competent Wistar rats.",17437408_2,-1,-1,2,9805,-1
9806,MRP2-deficient,37,38,217,231,"MRP2 is absent in the transport-deficient (TR(-)) Wistar rat mutant, so that this rat strain was very helpful in defining substrates of MRP2 by comparing tissue concentrations or functional activities of compounds in MRP2-deficient rats with those in transport-competent Wistar rats.",17437408_2,-1,-1,2,9806,-1
9807,transport-competent,42,43,251,270,"MRP2 is absent in the transport-deficient (TR(-)) Wistar rat mutant, so that this rat strain was very helpful in defining substrates of MRP2 by comparing tissue concentrations or functional activities of compounds in MRP2-deficient rats with those in transport-competent Wistar rats.",17437408_2,-1,-1,2,9807,-1
9808,Wistar rats,43,45,271,282,"MRP2 is absent in the transport-deficient (TR(-)) Wistar rat mutant, so that this rat strain was very helpful in defining substrates of MRP2 by comparing tissue concentrations or functional activities of compounds in MRP2-deficient rats with those in transport-competent Wistar rats.",17437408_2,-1,-1,2,9808,-1
9814,BBB,32,33,170,173,"By using this strategy to study the involvement of MRP2 in brain access of antiepileptic drugs (AEDs), we recently reported that phenytoin is a substrate for MRP2 in the BBB.",17437408_3,-1,-1,2,9814,-1
9817,upregulation,18,19,111,123,"However, one drawback of such studies in genetically deficient rats is the fact that compensatory changes with upregulation of other transporters can occur.",17437408_4,-1,-1,2,9817,-1
9818,brain expression,6,8,30,46,"This prompted us to study the brain expression of P-glycoprotein (Pgp), a major drug efflux transporter in many tissues, including the BBB, in TR(-) rats compared with nonmutant (wild-type) Wistar rats.",17437408_5,-1,-1,2,9818,-1
9824,nonmutant,33,34,168,177,"This prompted us to study the brain expression of P-glycoprotein (Pgp), a major drug efflux transporter in many tissues, including the BBB, in TR(-) rats compared with nonmutant (wild-type) Wistar rats.",17437408_5,-1,-1,2,9824,-1
9825,wild-type,35,36,179,188,"This prompted us to study the brain expression of P-glycoprotein (Pgp), a major drug efflux transporter in many tissues, including the BBB, in TR(-) rats compared with nonmutant (wild-type) Wistar rats.",17437408_5,-1,-1,2,9825,-1
9831,Wistar rats,19,21,93,104,"METHODS: The expression of MRP2 and Pgp in brain and liver sections of TR(-) rats and normal Wistar rats was determined with immunohistochemistry, by using a novel, highly selective monoclonal MRP2 antibody and the monoclonal Pgp antibody C219, respectively.",17437408_6,-1,-1,2,9831,-1
9834,Immunofluorescence staining,2,4,9,36,"RESULTS: Immunofluorescence staining with the MRP2 antibody was found to label a high number of microvessels throughout the brain in normal Wistar rats, whereas such labeling was absent in TR(-) rats.",17437408_7,-1,-1,2,9834,-1
9836,microvessels,16,17,96,108,"RESULTS: Immunofluorescence staining with the MRP2 antibody was found to label a high number of microvessels throughout the brain in normal Wistar rats, whereas such labeling was absent in TR(-) rats.",17437408_7,-1,-1,2,9836,-1
9837,Wistar rats,22,24,140,151,"RESULTS: Immunofluorescence staining with the MRP2 antibody was found to label a high number of microvessels throughout the brain in normal Wistar rats, whereas such labeling was absent in TR(-) rats.",17437408_7,-1,-1,2,9837,-1
9840,up-regulation,6,7,35,48,TR(-) rats exhibited a significant up-regulation of Pgp in brain capillary endothelial cells compared with wild-type controls.,17437408_8,-1,-1,2,9840,-1
9843,endothelial cells,12,14,75,92,TR(-) rats exhibited a significant up-regulation of Pgp in brain capillary endothelial cells compared with wild-type controls.,17437408_8,-1,-1,2,9843,-1
9844,wild-type controls,16,18,107,125,TR(-) rats exhibited a significant up-regulation of Pgp in brain capillary endothelial cells compared with wild-type controls.,17437408_8,-1,-1,2,9844,-1
9845,upregulation,3,4,16,28,No such obvious upregulation of Pgp was observed in liver sections.,17437408_9,-1,-1,2,9845,-1
9848,overexpression,2,3,13,27,A comparable overexpression of Pgp in the BBB was obtained after pilocarpine-induced seizures in wild-type Wistar rats.,17437408_10,-1,-1,2,9848,-1
9851,wild-type,14,15,97,106,A comparable overexpression of Pgp in the BBB was obtained after pilocarpine-induced seizures in wild-type Wistar rats.,17437408_10,-1,-1,2,9851,-1
9852,Wistar rats,15,17,107,118,A comparable overexpression of Pgp in the BBB was obtained after pilocarpine-induced seizures in wild-type Wistar rats.,17437408_10,-1,-1,2,9852,-1
9863,BBB,23,24,124,127,CONCLUSIONS: The data on TR(-) rats indicate that Pgp plays an important role in the compensation of MRP2 deficiency in the BBB.,17437408_12,-1,-1,2,9863,-1
9867,BBB,32,33,199,202,"Because such a compensatory mechanism most likely occurs to reduce injury to the brain from cytotoxic compounds, the present data substantiate the concept that MRP2 performs a protective role in the BBB.",17437408_13,-1,-1,2,9867,-1
9871,BBB,22,23,124,127,"Furthermore, our data suggest that TR(-) rats are an interesting tool to study consequences of overexpression of Pgp in the BBB on access of drugs in the brain, without the need of inducing seizures or other Pgp-enhancing events for this purpose.",17437408_14,-1,-1,2,9871,-1
9874,rats.1,8,9,66,72,Role of xanthine oxidase in dexamethasone-induced hypertension in rats.1.,17439425_0,-1,-1,2,9874,-1
9876,GC-HT,3,4,37,42,Glucocorticoid-induced hypertension (GC-HT) in the rat is associated with nitric oxide-redox imbalance.,17439425_1,-1,-1,2,9876,-1
9877,associated with,9,11,58,73,Glucocorticoid-induced hypertension (GC-HT) in the rat is associated with nitric oxide-redox imbalance.,17439425_1,-1,-1,2,9877,-1
9878,nitric oxide-redox imbalance,11,14,74,102,Glucocorticoid-induced hypertension (GC-HT) in the rat is associated with nitric oxide-redox imbalance.,17439425_1,-1,-1,2,9878,-1
9883,treatment groups,11,13,67,83,"3. Thirty male Sprague-Dawley rats were divided randomly into four treatment groups: saline, dexamethasone (dex), allopurinol plus saline, and allopurinol plus dex.",17439425_3,-1,-1,2,9883,-1
9888,SBP,6,7,29,32,4. Systolic blood pressures (SBP) and bodyweights were recorded each alternate day.,17439425_4,-1,-1,2,9888,-1
9895,/- 3 mmHg,11,14,34,43,"Dex increased SBP (110 +/- 2-126 +/- 3 mmHg; P < 0.001) and decreased thymus (P < 0.001) and bodyweights (P"" < 0.01).",17439425_7,-1,-1,2,9895,-1
9897,/-,7,8,43,45,Allopurinol decreased serum urate from 76 +/- 5 to 30 +/- 3 micromol/L (P < 0.001) in saline and from 84 +/- 13 to 28 +/- 2 micromol/L in dex-treated (P < 0.01) groups.,17439425_8,0,1,2,9897,-1
9901,dex-treated,35,36,138,149,Allopurinol decreased serum urate from 76 +/- 5 to 30 +/- 3 micromol/L (P < 0.001) in saline and from 84 +/- 13 to 28 +/- 2 micromol/L in dex-treated (P < 0.01) groups.,17439425_8,-1,-1,2,9901,-1
9902,dex-HT,6,7,31,37,6. Allopurinol did not prevent dex-HT.,17439425_9,-1,-1,2,9902,-1
9915,prospective study,5,7,37,54,METHODS: A double-blind double-armed prospective study comprised 40 patients who had uneventful sutureless phacoemulsification under sub-Tenon's local infiltration of 3 mL of plain lignocaine.,17466854_3,-1,-1,2,9915,-1
9917,sub-Tenon's,16,18,133,144,METHODS: A double-blind double-armed prospective study comprised 40 patients who had uneventful sutureless phacoemulsification under sub-Tenon's local infiltration of 3 mL of plain lignocaine.,17466854_3,-1,-1,2,9917,-1
9926,chi-square test,1,3,2,17,A chi-square test was used to assess the statistical significance of results.,17466854_6,-1,-1,2,9926,-1
9927,statistical significance,8,10,41,65,A chi-square test was used to assess the statistical significance of results.,17466854_6,-1,-1,2,9927,-1
9945,Perls' iron staining,37,41,226,246,"To demonstrate the relationship between peripheral iron overload and dopaminergic neuron loss in rat substantia nigra (SN), in the present study we used fast cyclic voltammetry, tyrosine hydroxylase (TH) immunohistochemistry, Perls' iron staining, and high performance liquid chromatography-electrochemical detection to study the degeneration of dopaminergic neurons and increased iron content in the SN of iron dextran overloaded animals.",17490790_2,-1,-1,2,9945,-1
9946,chromatography-electrochemical detection,46,48,276,316,"To demonstrate the relationship between peripheral iron overload and dopaminergic neuron loss in rat substantia nigra (SN), in the present study we used fast cyclic voltammetry, tyrosine hydroxylase (TH) immunohistochemistry, Perls' iron staining, and high performance liquid chromatography-electrochemical detection to study the degeneration of dopaminergic neurons and increased iron content in the SN of iron dextran overloaded animals.",17490790_2,-1,-1,2,9946,-1
9948,iron content,57,59,381,393,"To demonstrate the relationship between peripheral iron overload and dopaminergic neuron loss in rat substantia nigra (SN), in the present study we used fast cyclic voltammetry, tyrosine hydroxylase (TH) immunohistochemistry, Perls' iron staining, and high performance liquid chromatography-electrochemical detection to study the degeneration of dopaminergic neurons and increased iron content in the SN of iron dextran overloaded animals.",17490790_2,-1,-1,2,9948,-1
9951,iron staining positive cells,10,14,72,100,The findings showed that peripheral iron dextran overload increased the iron staining positive cells and reduced the number of TH-immunoreactive neurons in the SN.,17490790_3,-1,-1,2,9951,-1
9954,chronic overload group,7,10,41,63,Even more dramatic changes were found in chronic overload group.,17490790_5,-1,-1,2,9954,-1
9956,iron level,10,12,68,78,"These results suggest that peripheral iron dextran can increase the iron level in the SN, where excessive iron causes the degeneration of dopaminergic neurons.",17490790_6,-1,-1,2,9956,-1
9967,chronic periadolescent,24,26,127,149,"We investigated the effect of an early stress, in the form of maternal deprivation, combined with a later stress, simulated by chronic periadolescent corticosterone treatment, on behaviour in rats.",17490864_2,-1,-1,2,9967,-1
9968,prepulse inhibition,7,9,54,73,"Acute treatment with apomorphine caused disruption of prepulse inhibition (PPI) in controls and in rats that had undergone either maternal deprivation or corticosterone treatment, but was surprisingly absent in rats that had undergone the combined early and late stress.",17490864_3,-1,-1,2,9968,-1
9971,PPI,4,5,46,49,"Amphetamine treatment significantly disrupted PPI in both non-deprived groups, but was absent in both maternally deprived groups.",17490864_4,-1,-1,2,9971,-1
9972,non-deprived groups,7,9,58,77,"Amphetamine treatment significantly disrupted PPI in both non-deprived groups, but was absent in both maternally deprived groups.",17490864_4,-1,-1,2,9972,-1
9984,cardiac performance,7,9,42,61,Assessment of a new non-invasive index of cardiac performance for detection of dobutamine-induced myocardial ischemia.,17491223_0,-1,-1,2,9984,-1
9987,diagnostic value,6,8,32,48,"OBJECTIVES: To assess the added diagnostic value of a new cardiac performance index (dP/dtejc) measurement, based on brachial artery flow changes, as compared to standard 12-lead ECG, for detecting dobutamine-induced myocardial ischemia, using Tc99m-Sestamibi single-photon emission computed tomography as the gold standard of comparison to assess the presence or absence of ischemia.",17491223_2,-1,-1,2,9987,-1
9988,cardiac performance index,11,14,58,83,"OBJECTIVES: To assess the added diagnostic value of a new cardiac performance index (dP/dtejc) measurement, based on brachial artery flow changes, as compared to standard 12-lead ECG, for detecting dobutamine-induced myocardial ischemia, using Tc99m-Sestamibi single-photon emission computed tomography as the gold standard of comparison to assess the presence or absence of ischemia.",17491223_2,-1,-1,2,9988,-1
9989,dP/dtejc,15,16,85,93,"OBJECTIVES: To assess the added diagnostic value of a new cardiac performance index (dP/dtejc) measurement, based on brachial artery flow changes, as compared to standard 12-lead ECG, for detecting dobutamine-induced myocardial ischemia, using Tc99m-Sestamibi single-photon emission computed tomography as the gold standard of comparison to assess the presence or absence of ischemia.",17491223_2,-1,-1,2,9989,-1
9995,study group,3,5,13,24,METHODS: The study group comprised 40 patients undergoing Sestamibi-SPECT/dobutamine stress test.,17491223_3,-1,-1,2,9995,-1
9998,dP/dtejc,7,8,53,61,Simultaneous measurements of ECG and brachial artery dP/dtejc were performed at each dobutamine level.,17491223_4,-1,-1,2,9998,-1
10000,SPECT,14,15,85,90,In 19 of the 40 patients perfusion defects compatible with ischemia were detected on SPECT.,17491223_5,-1,-1,2,10000,-1
10001,dP/dtejc,3,4,16,24,The increase in dP/dtejc during infusion of dobutamine in this group was severely impaired as compared to the non-ischemic group.,17491223_6,-1,-1,2,10001,-1
10003,non-ischemic group,18,20,110,128,The increase in dP/dtejc during infusion of dobutamine in this group was severely impaired as compared to the non-ischemic group.,17491223_6,-1,-1,2,10003,-1
10005,ECG-enhanced,11,12,62,74,"dP/dtejc outcome was combined with the ECG results, giving an ECG-enhanced value, and compared to ECG alone.",17491223_7,-1,-1,2,10005,-1
10006,positive predictive value,13,16,64,89,"RESULTS: The sensitivity improved dramatically from 16% to 79%, positive predictive value increased from 60% to 68% and negative predictive value from 54% to 78%, and specificity decreased from 90% to 67%.",17491223_8,-1,-1,2,10006,-1
10008,dP/dtejc,13,14,72,80,"CONCLUSIONS: If ECG alone is used for specificity, the combination with dP/dtejc improved the sensitivity of the test and could be a cost-savings alternative to cardiac imaging or perfusion studies to detect myocardial ischemia, especially in patients unable to exercise.",17491223_9,-1,-1,2,10008,-1
10009,cost-savings,24,25,133,145,"CONCLUSIONS: If ECG alone is used for specificity, the combination with dP/dtejc improved the sensitivity of the test and could be a cost-savings alternative to cardiac imaging or perfusion studies to detect myocardial ischemia, especially in patients unable to exercise.",17491223_9,-1,-1,2,10009,-1
10015,pathogenetic considerations,7,9,65,92,Cocaine-induced myocardial infarction: clinical observations and pathogenetic considerations.,1749407_0,-1,-1,2,10015,-1
10019,associated with,22,24,157,172,"In individuals with preexisting, high-grade coronary arterial narrowing, acute myocardial infarction may result from an increase in myocardial oxygen demand associated with cocaine-induced increase in rate-pressure product.",1749407_2,-1,-1,2,10019,-1
10020,cocaine-induced increase,24,26,173,197,"In individuals with preexisting, high-grade coronary arterial narrowing, acute myocardial infarction may result from an increase in myocardial oxygen demand associated with cocaine-induced increase in rate-pressure product.",1749407_2,-1,-1,2,10020,-1
10021,rate-pressure product,27,29,201,222,"In individuals with preexisting, high-grade coronary arterial narrowing, acute myocardial infarction may result from an increase in myocardial oxygen demand associated with cocaine-induced increase in rate-pressure product.",1749407_2,-1,-1,2,10021,-1
10030,consistent with,5,7,43,58,"Diffuse intramural vasoconstriction is not consistent with reports of segmental, discrete infarction.",1749407_6,-1,-1,2,10030,-1
10032,in vivo,2,4,16,23,"Whereas certain in vivo data suggest that these effects are alpha-mediated, other in vitro data suggest the opposite.",1749407_7,-1,-1,2,10032,-1
10033,in vitro,13,15,82,90,"Whereas certain in vivo data suggest that these effects are alpha-mediated, other in vitro data suggest the opposite.",1749407_7,-1,-1,2,10033,-1
10050,viral response,5,7,29,43,She had a complete sustained viral response.,17511042_9,-1,-1,2,10050,-1
10051,Proteomic analysis,0,2,0,18,Proteomic analysis of striatal proteins in the rat model of L-DOPA-induced dyskinesia.,17532790_0,-1,-1,2,10051,-1
10057,striatal samples,15,17,84,100,"In the present study, we investigated the changes occurring at the protein level in striatal samples obtained from the unilaterally 6-hydroxydopamine-lesion rat model of PD treated with saline, L-DOPA or bromocriptine using two-dimensional difference gel electrophoresis and mass spectrometry (MS).",17532790_3,-1,-1,2,10057,-1
10058,treated with,26,28,173,185,"In the present study, we investigated the changes occurring at the protein level in striatal samples obtained from the unilaterally 6-hydroxydopamine-lesion rat model of PD treated with saline, L-DOPA or bromocriptine using two-dimensional difference gel electrophoresis and mass spectrometry (MS).",17532790_3,-1,-1,2,10058,-1
10062,treated with,1,3,5,17,Rats treated with L-DOPA were allocated to two groups based on the presence or absence of LID.,17532790_4,-1,-1,2,10062,-1
10063,statistical difference,6,8,34,56,"Among the 2000 spots compared for statistical difference, 67 spots were significantly changed in abundance and identified using matrix-assisted laser desorption/ionization time-of-flight MS, atmospheric pressure matrix-assisted laser desorption/ionization and HPLC coupled tandem MS (LC/MS/MS).",17532790_5,-1,-1,2,10063,-1
10064,matrix-assisted laser desorption/ionization time-of-flight MS,19,24,128,189,"Among the 2000 spots compared for statistical difference, 67 spots were significantly changed in abundance and identified using matrix-assisted laser desorption/ionization time-of-flight MS, atmospheric pressure matrix-assisted laser desorption/ionization and HPLC coupled tandem MS (LC/MS/MS).",17532790_5,-1,-1,2,10064,-1
10066,HPLC,31,32,260,264,"Among the 2000 spots compared for statistical difference, 67 spots were significantly changed in abundance and identified using matrix-assisted laser desorption/ionization time-of-flight MS, atmospheric pressure matrix-assisted laser desorption/ionization and HPLC coupled tandem MS (LC/MS/MS).",17532790_5,-1,-1,2,10066,-1
10067,LC/MS/MS,36,37,284,292,"Among the 2000 spots compared for statistical difference, 67 spots were significantly changed in abundance and identified using matrix-assisted laser desorption/ionization time-of-flight MS, atmospheric pressure matrix-assisted laser desorption/ionization and HPLC coupled tandem MS (LC/MS/MS).",17532790_5,-1,-1,2,10067,-1
10073,Complementary techniques,0,2,0,24,Complementary techniques such as western immunoblotting and immunohistochemistry were performed to investigate the validity of the data obtained using the proteomic approach.,17532790_7,-1,-1,2,10073,-1
10075,proteomic approach,20,22,155,173,Complementary techniques such as western immunoblotting and immunohistochemistry were performed to investigate the validity of the data obtained using the proteomic approach.,17532790_7,-1,-1,2,10075,-1
10078,randomized double-blind trial,12,15,65,94,Cardiac Angiography in Renally Impaired Patients (CARE) study: a randomized double-blind trial of contrast-induced nephropathy in patients with chronic kidney disease.,17562951_0,-1,-1,2,10078,-1
10086,multicenter,9,10,44,55,"METHODS AND RESULTS: The present study is a multicenter, randomized, double-blind comparison of iopamidol and iodixanol in patients with chronic kidney disease (estimated glomerular filtration rate, 20 to 59 mL/min) who underwent cardiac angiography or percutaneous coronary interventions.",17562951_2,-1,-1,2,10086,-1
10087,double-blind,13,14,69,81,"METHODS AND RESULTS: The present study is a multicenter, randomized, double-blind comparison of iopamidol and iodixanol in patients with chronic kidney disease (estimated glomerular filtration rate, 20 to 59 mL/min) who underwent cardiac angiography or percutaneous coronary interventions.",17562951_2,-1,-1,2,10087,-1
10091,glomerular filtration rate,27,30,171,197,"METHODS AND RESULTS: The present study is a multicenter, randomized, double-blind comparison of iopamidol and iodixanol in patients with chronic kidney disease (estimated glomerular filtration rate, 20 to 59 mL/min) who underwent cardiac angiography or percutaneous coronary interventions.",17562951_2,-1,-1,2,10091,-1
10095,SCr,3,4,18,21,Serum creatinine (SCr) levels and estimated glomerular filtration rate were assessed at baseline and 2 to 5 days after receiving medications.,17562951_3,-1,-1,2,10095,-1
10096,glomerular filtration rate,8,11,44,70,Serum creatinine (SCr) levels and estimated glomerular filtration rate were assessed at baseline and 2 to 5 days after receiving medications.,17562951_3,-1,-1,2,10096,-1
10099,SCr,6,7,35,38,The primary outcome was a postdose SCr increase > or = 0.5 mg/dL (44.2 micromol/L) over baseline.,17562951_4,-1,-1,2,10099,-1
10100,Secondary outcomes,0,2,0,18,"Secondary outcomes were a postdose SCr increase > or = 25%, a postdose estimated glomerular filtration rate decrease of > or = 25%, and the mean peak change in SCr.",17562951_5,-1,-1,2,10100,-1
10102,SCr,5,6,35,38,"Secondary outcomes were a postdose SCr increase > or = 25%, a postdose estimated glomerular filtration rate decrease of > or = 25%, and the mean peak change in SCr.",17562951_5,-1,-1,2,10102,-1
10104,glomerular filtration rate,16,19,81,107,"Secondary outcomes were a postdose SCr increase > or = 25%, a postdose estimated glomerular filtration rate decrease of > or = 25%, and the mean peak change in SCr.",17562951_5,-1,-1,2,10104,-1
10105,peak change,30,32,145,156,"Secondary outcomes were a postdose SCr increase > or = 25%, a postdose estimated glomerular filtration rate decrease of > or = 25%, and the mean peak change in SCr.",17562951_5,-1,-1,2,10105,-1
10106,SCr,33,34,160,163,"Secondary outcomes were a postdose SCr increase > or = 25%, a postdose estimated glomerular filtration rate decrease of > or = 25%, and the mean peak change in SCr.",17562951_5,-1,-1,2,10106,-1
10111,glomerular filtration rate,22,25,123,149,"In 414 patients, contrast volume, presence of diabetes mellitus, use of N-acetylcysteine, mean baseline SCr, and estimated glomerular filtration rate were comparable in the 2 groups.",17562951_6,-1,-1,2,10111,-1
10112,SCr,0,1,0,3,"SCr increases > or = 0.5 mg/dL occurred in 4.4% (9 of 204 patients) after iopamidol and 6.7% (14 of 210 patients) after iodixanol (P=0.39), whereas rates of SCr increases > or = 25% were 9.8% and 12.4%, respectively (P=0.44).",17562951_7,-1,-1,2,10112,-1
10116,SCr,5,6,27,30,"In patients with diabetes, SCr increases > or = 0.5 mg/dL were 5.1% (4 of 78 patients) with iopamidol and 13.0% (12 of 92 patients) with iodixanol (P=0.11), whereas SCr increases > or = 25% were 10.3% and 15.2%, respectively (P=0.37).",17562951_8,-1,-1,2,10116,-1
10119,SCr,39,40,165,168,"In patients with diabetes, SCr increases > or = 0.5 mg/dL were 5.1% (4 of 78 patients) with iopamidol and 13.0% (12 of 92 patients) with iodixanol (P=0.11), whereas SCr increases > or = 25% were 10.3% and 15.2%, respectively (P=0.37).",17562951_8,-1,-1,2,10119,-1
10128,clinically significant,13,15,69,91,Any true difference between the agents is small and not likely to be clinically significant.,17562951_11,-1,-1,2,10128,-1
10130,PB-related,16,17,81,91,"Phenobarbital (PB) has a reputation for safety, and it is commonly believed that PB-related increases in serum aminotransferase levels do not indicate or predict the development of significant chronic liver disease.",17574447_1,-1,-1,2,10130,-1
10134,treated with,13,15,69,81,"Here we report of two adult patients with a long history of epilepsy treated with PB who died suddenly: one as consequence of cardiac arrest, the other of acute bronchopneumonia.",17574447_2,-1,-1,2,10134,-1
10135,consequence of,22,24,111,125,"Here we report of two adult patients with a long history of epilepsy treated with PB who died suddenly: one as consequence of cardiac arrest, the other of acute bronchopneumonia.",17574447_2,-1,-1,2,10135,-1
10140,monocyte cells,19,21,127,141,"At autopsy, analysis of liver parenchyma revealed rich portal inflammatory infiltrate, which consisted of mixed eosinophil and monocyte cells, associated with several foci of necrosis surrounded by a hard ring of non-specific granulomatous tissue.",17574447_3,-1,-1,2,10140,-1
10141,associated with,22,24,143,158,"At autopsy, analysis of liver parenchyma revealed rich portal inflammatory infiltrate, which consisted of mixed eosinophil and monocyte cells, associated with several foci of necrosis surrounded by a hard ring of non-specific granulomatous tissue.",17574447_3,-1,-1,2,10141,-1
10146,associated with,7,9,39,54,"Our findings illustrate that PB may be associated with chronic liver damage, which may lead to more serious and deleterious consequences.",17574447_5,-1,-1,2,10146,-1
10154,in vitro,14,16,104,112,"A novel compound, maltolyl p-coumarate, attenuates cognitive deficits and shows neuroprotective effects in vitro and in vivo dementia models.",17600377_0,-1,-1,2,10154,-1
10155,in vivo,17,19,117,124,"A novel compound, maltolyl p-coumarate, attenuates cognitive deficits and shows neuroprotective effects in vitro and in vivo dementia models.",17600377_0,-1,-1,2,10155,-1
10159,esterification,22,23,146,160,"To develop a novel and effective drug that could enhance cognitive function and neuroprotection, we newly synthesized maltolyl p-coumarate by the esterification of maltol and p-coumaric acid.",17600377_1,-1,-1,2,10159,-1
10167,passive avoidance test,13,16,88,110,Maltolyl p-coumarate was found to attenuate cognitive deficits in both rat models using passive avoidance test and to reduce apoptotic cell death observed in the hippocampus of the amyloid beta peptide(1-42)-infused rats.,17600377_3,-1,-1,2,10167,-1
10171,in vitro,9,11,69,77,We also examined the neuroprotective effects of maltolyl p-coumarate in vitro using SH-SY5Y cells.,17600377_4,-1,-1,2,10171,-1
10172,SH-SY5Y cells,12,14,84,97,We also examined the neuroprotective effects of maltolyl p-coumarate in vitro using SH-SY5Y cells.,17600377_4,-1,-1,2,10172,-1
10179,in vitro,2,4,13,21,"Taking these in vitro and in vivo results together, our study suggests that maltolyl p-coumarate is a potentially effective candidate against Alzheimer's disease that is characterized by wide spread neuronal death and progressive decline of cognitive function.",17600377_7,-1,-1,2,10179,-1
10180,in vivo,5,7,26,33,"Taking these in vitro and in vivo results together, our study suggests that maltolyl p-coumarate is a potentially effective candidate against Alzheimer's disease that is characterized by wide spread neuronal death and progressive decline of cognitive function.",17600377_7,-1,-1,2,10180,-1
10197,pretreatment,1,2,19,31,Lipopolysaccharide pretreatment did not affect the basal body temperature or methamphetamine-elicited hyperthermia three days later.,17608141_3,-1,-1,2,10197,-1
10207,infusion-produced,12,13,94,111,"Moreover, systemic lipopolysaccharide pretreatment (1 mg/kg) attenuated local methamphetamine infusion-produced dopamine and 3,4-dihydroxyphenylacetic acid depletions in the striatum, indicating that the protective effect of lipopolysaccharide is less likely due to interrupted peripheral distribution or metabolism of methamphetamine.",17608141_6,-1,-1,2,10207,-1
10213,pretreatment,9,10,68,80,We concluded a critical time window for systemic lipopolysaccharide pretreatment in exerting effective protection against methamphetamine-induced nigrostriatal dopamine neurotoxicity.,17608141_7,-1,-1,2,10213,-1
10217,associated with,2,4,18,33,Acute myocarditis associated with clozapine.,17612891_0,-1,-1,2,10217,-1
10219,associated with,7,9,39,54,"OBJECTIVE: A case of acute myocarditis associated with the commencement of clozapine is described, highlighting the onset, course and possible contributing factors.",17612891_1,-1,-1,2,10219,-1
10220,raise awareness,6,8,27,42,There is an urgent need to raise awareness about this potentially fatal complication of clozapine use.,17612891_2,-1,-1,2,10220,-1
10224,associated with,8,10,68,83,CONCLUSIONS: Myocarditis is an increasingly recognized complication associated with the use of clozapine.,17612891_7,-1,-1,2,10224,-1
10226,raise awareness,19,21,117,132,"Considering that clozapine remains the gold standard in treatment of resistant psychosis, there is an urgent need to raise awareness among medical and paramedical staff involved in the care of these patients.",17612891_9,-1,-1,2,10226,-1
10227,paramedical staff,24,26,151,168,"Considering that clozapine remains the gold standard in treatment of resistant psychosis, there is an urgent need to raise awareness among medical and paramedical staff involved in the care of these patients.",17612891_9,-1,-1,2,10227,-1
10230,use of,9,11,71,77,"Severe rhabdomyolysis and acute renal failure secondary to concomitant use of simvastatin, amiodarone, and atazanavir.",17615423_0,-1,-1,2,10230,-1
10248,human immunodeficiency virus medications,8,12,43,83,"Simvastatin, amiodarone, and the patient's human immunodeficiency virus medications were all temporarily discontinued and the patient was given forced alkaline diuresis and started on dialysis.",17615423_5,-1,-1,2,10248,-1
10250,patient's,4,6,20,29,Nine days later the patient's creatine kinase had dropped to 1695 U/L and creatinine was 3.3 mg/dL. The patient was discharged and continued outpatient dialysis for 1 month until his renal function recovered.,17615423_6,-1,-1,2,10250,-1
10252,U/L,12,13,66,69,Nine days later the patient's creatine kinase had dropped to 1695 U/L and creatinine was 3.3 mg/dL. The patient was discharged and continued outpatient dialysis for 1 month until his renal function recovered.,17615423_6,-1,-1,2,10252,-1
10259,Pharmacokinetic differences,2,4,13,40,CONCLUSIONS: Pharmacokinetic differences in statins are an important consideration for assessing the risk of potential drug interactions.,17615423_10,-1,-1,2,10259,-1
10263,lowest risk,20,22,128,139,"In patients requiring the concurrent use of statins and CYP3A4 inhibitors, pravastatin, fluvastatin, and rosuvastatin carry the lowest risk of drug interactions; atorvastatin carries moderate risk, whereas simvastatin and lovastatin have the highest risk and should be avoided in patients taking concomitant CYP3A4 inhibitors.",17615423_11,-1,-1,2,10263,-1
10267,case series,6,8,47,58,Interaction between warfarin and levofloxacin: case series.,17639754_0,-1,-1,2,10267,-1
10274,prospective studies,2,4,12,31,"While small prospective studies have not revealed any significant drug-drug interaction between warfarin and levofloxacin, several case reports have indicated that levofloxacin may significantly potentiate the anticoagulation effect of warfarin.",17639754_3,-1,-1,2,10274,-1
10277,case reports,17,19,131,143,"While small prospective studies have not revealed any significant drug-drug interaction between warfarin and levofloxacin, several case reports have indicated that levofloxacin may significantly potentiate the anticoagulation effect of warfarin.",17639754_3,-1,-1,2,10277,-1
10288,associated with,8,10,70,85,Recently published neuroimaging data suggest a common pathophysiology associated with a variety of chemotherapy agents and modes of administration.,17682013_2,-1,-1,2,10288,-1
10294,intrathecal chemotherapy,23,25,156,180,METHODS: We reviewed the medical literature for single reports and case series of patients presenting with stroke-like episodes while receiving systemic or intrathecal chemotherapy.,17682013_3,-1,-1,2,10294,-1
10295,neuroimaging data,6,8,44,61,We only included studies providing detailed neuroimaging data.,17682013_4,-1,-1,2,10295,-1
10298,treated with,11,13,75,87,"RESULTS: We identified 27 reports of toxic leukoencephalopathy in patients treated with methotrexate (intrathecal, systemic), 5-fluorouracil and its derivative carmofur, and capecitabine.",17682013_6,-1,-1,2,10298,-1
10303,Diffusion weighted imaging,0,3,0,26,"Diffusion weighted imaging (DWI) of all patients revealed well demarcated hyperintense lesions within the subcortical white matter of the cerebral hemispheres and the corpus callosum, corresponding to areas of decreased proton diffusion on apparent diffusion coefficient (ADC) maps (available in 21/27 patients).",17682013_7,-1,-1,2,10303,-1
10310,apparent diffusion coefficient,36,39,240,270,"Diffusion weighted imaging (DWI) of all patients revealed well demarcated hyperintense lesions within the subcortical white matter of the cerebral hemispheres and the corpus callosum, corresponding to areas of decreased proton diffusion on apparent diffusion coefficient (ADC) maps (available in 21/27 patients).",17682013_7,-1,-1,2,10310,-1
10312,ADC,14,15,84,87,Complete resolution of symptoms within 1-4 days was accompanied by normalisation of ADC abnormalities.,17682013_9,-1,-1,2,10312,-1
10316,exposure to,9,11,84,95,CONCLUSIONS: Several pathophysiological models of delayed leukoencephalopathy after exposure to intrathecal or systemic chemotherapy have been proposed.,17682013_11,-1,-1,2,10316,-1
10318,systemic chemotherapy,13,15,111,132,CONCLUSIONS: Several pathophysiological models of delayed leukoencephalopathy after exposure to intrathecal or systemic chemotherapy have been proposed.,17682013_11,-1,-1,2,10318,-1
10319,DWI,0,1,0,3,DWI findings in this cohort are indicative of cytotoxic oedema within cerebral white matter and lend support to an at least partially reversible metabolic derangement as the basis for this syndrome.,17682013_12,-1,-1,2,10319,-1
10322,exposure to,1,3,9,20,Prenatal exposure to fluoxetine induces fetal pulmonary hypertension in the rat.,17702969_0,-1,-1,2,10322,-1
10329,pulmonary vascular smooth muscle,10,14,59,91,OBJECTIVES: To evaluate the fluoxetine effect on fetal rat pulmonary vascular smooth muscle mechanical properties and cell proliferation rate.,17702969_4,-1,-1,2,10329,-1
10330,mechanical properties,14,16,92,113,OBJECTIVES: To evaluate the fluoxetine effect on fetal rat pulmonary vascular smooth muscle mechanical properties and cell proliferation rate.,17702969_4,-1,-1,2,10330,-1
10331,cell proliferation rate,17,20,118,141,OBJECTIVES: To evaluate the fluoxetine effect on fetal rat pulmonary vascular smooth muscle mechanical properties and cell proliferation rate.,17702969_4,-1,-1,2,10331,-1
10333,treated with,5,7,28,40,METHODS: Pregnant rats were treated with fluoxetine (10 mg/kg) from Day 11 through Day 21 of gestation.,17702969_5,-1,-1,2,10333,-1
10336,weight ratio,19,21,123,135,"As compared with controls, fluoxetine exposure resulted in fetal pulmonary hypertension as evidenced by an increase in the weight ratio of the right ventricle to the left ventricle plus septum (P = 0.02) and by an increase in pulmonary arterial medial thickness (P < 0.01).",17702969_7,-1,-1,2,10336,-1
10340,experimental animals,5,7,40,60,"Postnatal mortality was increased among experimental animals, and arterial oxygen saturation was 96 +/- 1% in 1-day-old control animals and significantly lower (P < 0.01) in fluoxetine-exposed pups (79 +/- 2%).",17702969_8,-1,-1,2,10340,-1
10341,/-,15,16,101,103,"Postnatal mortality was increased among experimental animals, and arterial oxygen saturation was 96 +/- 1% in 1-day-old control animals and significantly lower (P < 0.01) in fluoxetine-exposed pups (79 +/- 2%).",17702969_8,0,1,2,10341,-1
10342,control animals,20,22,120,135,"Postnatal mortality was increased among experimental animals, and arterial oxygen saturation was 96 +/- 1% in 1-day-old control animals and significantly lower (P < 0.01) in fluoxetine-exposed pups (79 +/- 2%).",17702969_8,-1,-1,2,10342,-1
10345,In vitro,0,2,0,8,"In vitro, fluoxetine induced pulmonary arterial muscle contraction in fetal, but not adult, animals (P < 0.01) and reduced serotonin-induced contraction at both ages (P < 0.01).",17702969_9,-1,-1,2,10345,-1
10348,exposure to,3,5,15,26,"After in utero exposure to a low fluoxetine concentration the pulmonary arterial smooth muscle cell proliferation rate was significantly increased in fetal, but not adult, cells (P < 0.01).",17702969_10,-1,-1,2,10348,-1
10349,pulmonary arterial smooth muscle,10,14,62,94,"After in utero exposure to a low fluoxetine concentration the pulmonary arterial smooth muscle cell proliferation rate was significantly increased in fetal, but not adult, cells (P < 0.01).",17702969_10,-1,-1,2,10349,-1
10353,pulmonary vascular smooth muscle,28,32,171,203,"CONCLUSIONS: In contrast to the adult, fluoxetine exposure in utero induces pulmonary hypertension in the fetal rat as a result of a developmentally regulated increase in pulmonary vascular smooth muscle proliferation.",17702969_11,-1,-1,2,10353,-1
10358,chronic use of,12,15,63,77,AIM: To report a case of optic and peripheral neuropathy after chronic use of disulfiram for alcohol dependence management.,17786501_1,-1,-1,2,10358,-1
10373,associated with,1,3,10,25,Mutations associated with lamivudine-resistance in therapy-na  ve hepatitis B virus (HBV) infected patients with and without HIV co-infection: implications for antiretroviral therapy in HBV and HIV co-infected South African patients.,17854040_0,-1,-1,2,10373,-1
10374,lamivudine-resistance,3,4,26,47,Mutations associated with lamivudine-resistance in therapy-na  ve hepatitis B virus (HBV) infected patients with and without HIV co-infection: implications for antiretroviral therapy in HBV and HIV co-infected South African patients.,17854040_0,-1,-1,2,10374,-1
10376,HBV,12,13,85,88,Mutations associated with lamivudine-resistance in therapy-na  ve hepatitis B virus (HBV) infected patients with and without HIV co-infection: implications for antiretroviral therapy in HBV and HIV co-infected South African patients.,17854040_0,-1,-1,2,10376,-1
10379,HBV,27,28,186,189,Mutations associated with lamivudine-resistance in therapy-na  ve hepatitis B virus (HBV) infected patients with and without HIV co-infection: implications for antiretroviral therapy in HBV and HIV co-infected South African patients.,17854040_0,-1,-1,2,10379,-1
10381,South African,31,33,210,223,Mutations associated with lamivudine-resistance in therapy-na  ve hepatitis B virus (HBV) infected patients with and without HIV co-infection: implications for antiretroviral therapy in HBV and HIV co-infected South African patients.,17854040_0,-1,-1,2,10381,-1
10382,exploratory study,3,5,12,29,This was an exploratory study to investigate lamivudine-resistant hepatitis B virus (HBV) strains in selected lamivudine-na  ve HBV carriers with and without human immunodeficiency virus (HIV) co-infection in South African patients.,17854040_1,-1,-1,2,10382,-1
10384,HBV,20,21,128,131,This was an exploratory study to investigate lamivudine-resistant hepatitis B virus (HBV) strains in selected lamivudine-na  ve HBV carriers with and without human immunodeficiency virus (HIV) co-infection in South African patients.,17854040_1,-1,-1,2,10384,-1
10388,HBV,4,5,30,33,Thirty-five lamivudine-na  ve HBV infected patients with or without HIV co-infection were studied: 15 chronic HBV mono-infected patients and 20 HBV-HIV co-infected patients.,17854040_2,-1,-1,2,10388,-1
10390,chronic HBV,16,18,102,113,Thirty-five lamivudine-na  ve HBV infected patients with or without HIV co-infection were studied: 15 chronic HBV mono-infected patients and 20 HBV-HIV co-infected patients.,17854040_2,-1,-1,2,10390,-1
10392,HBV-HIV,22,23,144,151,Thirty-five lamivudine-na  ve HBV infected patients with or without HIV co-infection were studied: 15 chronic HBV mono-infected patients and 20 HBV-HIV co-infected patients.,17854040_2,-1,-1,2,10392,-1
10394,HBV,9,10,56,59,The latter group was further sub-divided into 13 occult HBV (HBsAg-negative) and 7 overt HBV (HBsAg- positive) patients.,17854040_3,-1,-1,2,10394,-1
10395,HBsAg-negative,11,12,61,75,The latter group was further sub-divided into 13 occult HBV (HBsAg-negative) and 7 overt HBV (HBsAg- positive) patients.,17854040_3,-1,-1,2,10395,-1
10396,HBsAg- positive,18,20,94,109,The latter group was further sub-divided into 13 occult HBV (HBsAg-negative) and 7 overt HBV (HBsAg- positive) patients.,17854040_3,-1,-1,2,10396,-1
10403,Abbott Laboratories,20,22,109,128,"HBsAg, anti-HBs, anti-HBc, and anti-HIV 1/2 were determined as part of routine diagnosis using Axsym assays (Abbott Laboratories, North Chicago, IL).",17854040_4,-1,-1,2,10403,-1
10404,North Chicago,23,25,130,143,"HBsAg, anti-HBs, anti-HBc, and anti-HIV 1/2 were determined as part of routine diagnosis using Axsym assays (Abbott Laboratories, North Chicago, IL).",17854040_4,-1,-1,2,10404,-1
10405,Serum samples,0,2,0,13,"Serum samples were PCR amplified with HBV reverse transcriptase (RT) primers, followed by direct sequencing across the tyrosine-methionine-aspartate-aspartate (YMDD) motif of the major catalytic region in the C domain of the HBV RT enzyme.",17854040_5,-1,-1,2,10405,-1
10406,PCR,3,4,19,22,"Serum samples were PCR amplified with HBV reverse transcriptase (RT) primers, followed by direct sequencing across the tyrosine-methionine-aspartate-aspartate (YMDD) motif of the major catalytic region in the C domain of the HBV RT enzyme.",17854040_5,-1,-1,2,10406,-1
10409,catalytic region,28,30,185,201,"Serum samples were PCR amplified with HBV reverse transcriptase (RT) primers, followed by direct sequencing across the tyrosine-methionine-aspartate-aspartate (YMDD) motif of the major catalytic region in the C domain of the HBV RT enzyme.",17854040_5,-1,-1,2,10409,-1
10410,C domain,32,34,209,217,"Serum samples were PCR amplified with HBV reverse transcriptase (RT) primers, followed by direct sequencing across the tyrosine-methionine-aspartate-aspartate (YMDD) motif of the major catalytic region in the C domain of the HBV RT enzyme.",17854040_5,-1,-1,2,10410,-1
10412,HBV,0,1,0,3,"HBV viral load was performed with Amplicor HBV Monitor test v2.0 (Roche Diagnostics, Penzberg, Germany).",17854040_6,-1,-1,2,10412,-1
10414,Amplicor HBV Monitor test v2.0,6,11,34,64,"HBV viral load was performed with Amplicor HBV Monitor test v2.0 (Roche Diagnostics, Penzberg, Germany).",17854040_6,-1,-1,2,10414,-1
10417,HBV,0,1,0,3,HBV lamivudine-resistant strains were detected in 3 of 15 mono-infected chronic hepatitis B patients and 10 of 20 HBV-HIV co-infected patients.,17854040_7,-1,-1,2,10417,-1
10422,HBV-HIV,20,21,118,125,"To the best of our knowledge, this constitutes the first report of HBV lamivudine-resistant strains in therapy-na  ve HBV-HIV co-infected patients.",17854040_8,-1,-1,2,10422,-1
10424,HBV,1,2,4,7,"The HBV viral loads for mono-infected and co-infected patients ranged from 3.32 x 10(2) to 3.82 x 10(7) and <200 to 4.40 x 10(3) copies/ml, respectively.",17854040_9,-1,-1,2,10424,-1
10425,viral loads,2,4,8,19,"The HBV viral loads for mono-infected and co-infected patients ranged from 3.32 x 10(2) to 3.82 x 10(7) and <200 to 4.40 x 10(3) copies/ml, respectively.",17854040_9,-1,-1,2,10425,-1
10428,antiviral mutations,8,10,48,67,"It remains to be seen whether such pre-existing antiviral mutations could result in widespread emergence of HBV resistant strains when lamivudine-containing highly active antiretroviral (ARV) treatment (HAART) regimens become widely applied in South Africa, as this is likely to have potential implications in the management of HBV-HIV co-infected patients.",17854040_10,-1,-1,2,10428,-1
10429,HBV,16,17,108,111,"It remains to be seen whether such pre-existing antiviral mutations could result in widespread emergence of HBV resistant strains when lamivudine-containing highly active antiretroviral (ARV) treatment (HAART) regimens become widely applied in South Africa, as this is likely to have potential implications in the management of HBV-HIV co-infected patients.",17854040_10,-1,-1,2,10429,-1
10433,HBV-HIV,51,52,328,335,"It remains to be seen whether such pre-existing antiviral mutations could result in widespread emergence of HBV resistant strains when lamivudine-containing highly active antiretroviral (ARV) treatment (HAART) regimens become widely applied in South Africa, as this is likely to have potential implications in the management of HBV-HIV co-infected patients.",17854040_10,-1,-1,2,10433,-1
10437,associated with,8,10,53,68,The rabbit syndrome is an extrapyramidal side effect associated with chronic neuroleptic therapy.,1786266_1,-1,-1,2,10437,-1
10438,treated with,6,8,34,46,"Its occurrence in a patient being treated with imipramine is described, representing the first reported case of this syndrome in conjunction with antidepressants.",1786266_2,-1,-1,2,10438,-1
10449,male mice,12,14,103,112,We have previously demonstrated that ritonavir treatment increases atherosclerotic lesion formation in male mice to a greater extent than in female mice.,17879945_3,-1,-1,2,10449,-1
10453,molecular mechanisms,9,11,47,67,"In the present study, we have investigated the molecular mechanisms by which female hormones influence cholesterol metabolism in macrophages in response to the HIV protease inhibitor ritonavir.",17879945_5,-1,-1,2,10453,-1
10456,human monocyte cell line,4,8,21,45,"We have utilized the human monocyte cell line, THP-1 as a model to address this question.",17879945_6,-1,-1,2,10456,-1
10457,THP-1,9,10,47,52,"We have utilized the human monocyte cell line, THP-1 as a model to address this question.",17879945_6,-1,-1,2,10457,-1
10458,PMA,11,12,56,59,"Briefly, cells were differentiated for 72 h with 100 nM PMA to obtain a macrophage-like phenotype in the presence or absence of 1 nM 17beta-estradiol (E2), 100 nM progesterone or vehicle (0.01% ethanol).",17879945_7,-1,-1,2,10458,-1
10459,macrophage-like phenotype,15,17,72,97,"Briefly, cells were differentiated for 72 h with 100 nM PMA to obtain a macrophage-like phenotype in the presence or absence of 1 nM 17beta-estradiol (E2), 100 nM progesterone or vehicle (0.01% ethanol).",17879945_7,-1,-1,2,10459,-1
10462,treated with,3,5,16,28,"Cells were then treated with 30 ng/ml ritonavir or vehicle in the presence of aggregated LDL for 24 h. Cell extracts were harvested, and lipid or total RNA was isolated.",17879945_8,-1,-1,2,10462,-1
10463,Cell extracts,19,21,103,116,"Cells were then treated with 30 ng/ml ritonavir or vehicle in the presence of aggregated LDL for 24 h. Cell extracts were harvested, and lipid or total RNA was isolated.",17879945_8,-1,-1,2,10463,-1
10467,ritonavir treatment,10,12,77,96,E2 decreased the accumulation of cholesteryl esters in macrophages following ritonavir treatment.,17879945_9,-1,-1,2,10467,-1
10470,ritonavir treatment,2,4,14,33,"Additionally, ritonavir treatment selectively increased the relative levels of PPARgamma mRNA, a transcription factor responsible for the regulation of CD36 mRNA expression.",17879945_11,-1,-1,2,10470,-1
10476,fluorescent immunocytochemistry,13,15,75,106,"E2 did, however, significantly suppress CD36 protein levels as measured by fluorescent immunocytochemistry.",17879945_13,-1,-1,2,10476,-1
10481,ritonavir treatment,26,28,188,207,This data suggests that E2 modifies the expression of CD36 at the level of protein expression in monocyte-derived macrophages resulting in reduced cholesteryl ester accumulation following ritonavir treatment.,17879945_14,-1,-1,2,10481,-1
10483,exposure to,4,6,29,40,Acute hepatitis attack after exposure to telithromycin.,17919553_0,-1,-1,2,10483,-1
10494,laboratory tests,1,3,10,26,"Admission laboratory tests were as follows: alanine aminotransferase, 67 U/L (reference range, 10-37 U/L); aspartate aminotransferase, 98 U/L (10-40 U/L); alkaline phosphatase, 513 U/L (0-270 U/L); gamma-glutamyltransferase, 32 U/L (7-49 U/L); amylase, 46 U/L (0-220 U/L); total bilirubin, 20.1 mg/dL (0.2-1.0 mg/dL); direct bilirubin, 14.8 mg/dL (0-0.3 mg/dL); and albumin, 4.7 mg/dL (3.5-5.4 mg/dL).",17919553_5,-1,-1,2,10494,-1
10496,U/L,11,12,73,76,"Admission laboratory tests were as follows: alanine aminotransferase, 67 U/L (reference range, 10-37 U/L); aspartate aminotransferase, 98 U/L (10-40 U/L); alkaline phosphatase, 513 U/L (0-270 U/L); gamma-glutamyltransferase, 32 U/L (7-49 U/L); amylase, 46 U/L (0-220 U/L); total bilirubin, 20.1 mg/dL (0.2-1.0 mg/dL); direct bilirubin, 14.8 mg/dL (0-0.3 mg/dL); and albumin, 4.7 mg/dL (3.5-5.4 mg/dL).",17919553_5,-1,-1,2,10496,-1
10497,reference range,13,15,78,93,"Admission laboratory tests were as follows: alanine aminotransferase, 67 U/L (reference range, 10-37 U/L); aspartate aminotransferase, 98 U/L (10-40 U/L); alkaline phosphatase, 513 U/L (0-270 U/L); gamma-glutamyltransferase, 32 U/L (7-49 U/L); amylase, 46 U/L (0-220 U/L); total bilirubin, 20.1 mg/dL (0.2-1.0 mg/dL); direct bilirubin, 14.8 mg/dL (0-0.3 mg/dL); and albumin, 4.7 mg/dL (3.5-5.4 mg/dL).",17919553_5,-1,-1,2,10497,-1
10508,associated with,3,5,12,27,It has been associated with infrequent and usually reversible severe hepatic dysfunction.,17919553_10,-1,-1,2,10508,-1
10517,associated with,11,13,62,77,CONCLUSION: Here we report a case of acute hepatitis probably associated with the administration of telithromycin.,17919553_13,-1,-1,2,10517,-1
10520,treated with,6,8,46,58,Intraocular pressure in patients with uveitis treated with fluocinolone acetonide implants.,17923537_0,-1,-1,2,10520,-1
10526,multicenter,6,7,27,38,"DESIGN: Pooled data from 3 multicenter, double-masked, randomized, controlled, phase 2b/3 clinical trials evaluating the safety and efficacy of the 0.59-mg or 2.1-mg FA intravitreal implant or standard therapy were analyzed.",17923537_2,-1,-1,2,10526,-1
10527,double-masked,8,9,40,53,"DESIGN: Pooled data from 3 multicenter, double-masked, randomized, controlled, phase 2b/3 clinical trials evaluating the safety and efficacy of the 0.59-mg or 2.1-mg FA intravitreal implant or standard therapy were analyzed.",17923537_2,-1,-1,2,10527,-1
10528,phase 2b/3 clinical trials,14,18,79,105,"DESIGN: Pooled data from 3 multicenter, double-masked, randomized, controlled, phase 2b/3 clinical trials evaluating the safety and efficacy of the 0.59-mg or 2.1-mg FA intravitreal implant or standard therapy were analyzed.",17923537_2,-1,-1,2,10528,-1
10531,3-year,4,5,20,26,"RESULTS: During the 3-year follow-up, 71.0% of implanted eyes had an IOP increase of 10 mm Hg or more than baseline and 55.1%, 24.7%, and 6.2% of eyes reached an IOP of 30 mm Hg or more, 40 mm Hg or more, and 50 mm Hg or more, respectively.",17923537_3,-1,-1,2,10531,-1
10532,implanted eyes,10,12,47,61,"RESULTS: During the 3-year follow-up, 71.0% of implanted eyes had an IOP increase of 10 mm Hg or more than baseline and 55.1%, 24.7%, and 6.2% of eyes reached an IOP of 30 mm Hg or more, 40 mm Hg or more, and 50 mm Hg or more, respectively.",17923537_3,-1,-1,2,10532,-1
10539,postoperative IOP,8,10,67,84,Intraocular pressure-lowering surgeries were considered a success (postoperative IOP of 6-21 mm Hg with or without additional IOP-lowering medication) in 85.1% of eyes at 1 year.,17923537_5,-1,-1,2,10539,-1
10542,IOP-lowering surgery,13,15,49,69,The rate of hypotony (IOP </= 5 mm Hg) following IOP-lowering surgery (42.5%) was not different from that of implanted eyes not subjected to surgery (35.4%) (P = .09).,17923537_6,-1,-1,2,10542,-1
10544,Elevated IOP,2,4,12,24,CONCLUSION: Elevated IOP is a significant complication with the FA intravitreal implant but may be controlled with medication and surgery.,17923537_7,-1,-1,2,10544,-1
10546,injection duration,12,14,59,77,AIM: This study was carried out to determine the effect of injection duration on bruising and pain following the administration of the subcutaneous injection of heparin.,17931375_1,-1,-1,2,10546,-1
10547,subcutaneous injection,23,25,135,157,AIM: This study was carried out to determine the effect of injection duration on bruising and pain following the administration of the subcutaneous injection of heparin.,17931375_1,-1,-1,2,10547,-1
10548,subcutaneous injection,12,14,82,104,"BACKGROUND: Although different methods to prevent bruising and pain following the subcutaneous injection of heparin have been widely studied and described, the effect of injection duration on the occurrence of bruising and pain is little documented.",17931375_2,-1,-1,2,10548,-1
10549,injection duration,26,28,170,188,"BACKGROUND: Although different methods to prevent bruising and pain following the subcutaneous injection of heparin have been widely studied and described, the effect of injection duration on the occurrence of bruising and pain is little documented.",17931375_2,-1,-1,2,10549,-1
10550,quasi-experimental research,9,11,51,78,"DESIGN: This study was designed as within-subject, quasi-experimental research.",17931375_3,-1,-1,2,10550,-1
10553,Injections areas,0,2,0,16,Injections areas were assessed for the presence of bruising at 48 and 72 hours after each injection.,17931375_6,-1,-1,2,10553,-1
10554,millimetric,13,14,88,99,Dimensions of the bruising on the heparin applied areas were measured using transparent millimetric measuring paper.,17931375_7,-1,-1,2,10554,-1
10556,stop-watch,15,16,71,81,The visual analog scale (VAS) was used to measure pain intensity and a stop-watch was used to time the pain period.,17931375_8,-1,-1,2,10556,-1
10557,pain period,21,23,103,114,The visual analog scale (VAS) was used to measure pain intensity and a stop-watch was used to time the pain period.,17931375_8,-1,-1,2,10557,-1
10558,chi-square test,4,6,25,40,"Data were analysed using chi-square test, Mann-Whitney U, Wilcoxon signed ranks tests and correlation.",17931375_9,-1,-1,2,10558,-1
10559,Mann-Whitney U,7,9,42,56,"Data were analysed using chi-square test, Mann-Whitney U, Wilcoxon signed ranks tests and correlation.",17931375_9,-1,-1,2,10559,-1
10560,Wilcoxon signed ranks tests,10,14,58,85,"Data were analysed using chi-square test, Mann-Whitney U, Wilcoxon signed ranks tests and correlation.",17931375_9,-1,-1,2,10560,-1
10564,10-second injection,16,18,111,130,Pain intensity and pain period were statistically significantly lower for the 30-second injection than for the 10-second injection.,17931375_12,-1,-1,2,10564,-1
10566,subcutaneous administration,17,19,104,131,CONCLUSIONS: It was determined that injection duration had an effect on bruising and pain following the subcutaneous administration of heparin.,17931375_13,-1,-1,2,10566,-1
10568,Myocardial Fas,0,2,0,14,Myocardial Fas ligand expression increases susceptibility to AZT-induced cardiomyopathy.,17943461_0,-1,-1,2,10568,-1
10577,Fas-dependent cell-death pathway,20,23,134,166,"METHODS AND RESULTS: In order to investigate whether the HAART component zidovudine (3'-azido-2',3'-deoxythymidine; AZT) triggers the Fas-dependent cell-death pathway and cause cytoskeletal disruption in a murine model of DCM, 8-week-old transgenic (expressing Fas ligand in the myocardium: FasL Tg) and non-transgenic (NTg) mice received water ad libitum containing different concentrations of AZT (0, 0.07, 0.2, and 0.7 mg/ml).",17943461_3,-1,-1,2,10577,-1
10579,DCM,32,33,222,225,"METHODS AND RESULTS: In order to investigate whether the HAART component zidovudine (3'-azido-2',3'-deoxythymidine; AZT) triggers the Fas-dependent cell-death pathway and cause cytoskeletal disruption in a murine model of DCM, 8-week-old transgenic (expressing Fas ligand in the myocardium: FasL Tg) and non-transgenic (NTg) mice received water ad libitum containing different concentrations of AZT (0, 0.07, 0.2, and 0.7 mg/ml).",17943461_3,-1,-1,2,10579,-1
10580,transgenic,35,36,238,248,"METHODS AND RESULTS: In order to investigate whether the HAART component zidovudine (3'-azido-2',3'-deoxythymidine; AZT) triggers the Fas-dependent cell-death pathway and cause cytoskeletal disruption in a murine model of DCM, 8-week-old transgenic (expressing Fas ligand in the myocardium: FasL Tg) and non-transgenic (NTg) mice received water ad libitum containing different concentrations of AZT (0, 0.07, 0.2, and 0.7 mg/ml).",17943461_3,-1,-1,2,10580,-1
10582,non-transgenic (NTg) mice,48,53,304,329,"METHODS AND RESULTS: In order to investigate whether the HAART component zidovudine (3'-azido-2',3'-deoxythymidine; AZT) triggers the Fas-dependent cell-death pathway and cause cytoskeletal disruption in a murine model of DCM, 8-week-old transgenic (expressing Fas ligand in the myocardium: FasL Tg) and non-transgenic (NTg) mice received water ad libitum containing different concentrations of AZT (0, 0.07, 0.2, and 0.7 mg/ml).",17943461_3,-1,-1,2,10582,-1
10586,immunohistochemical methods,17,19,116,143,"After 6 weeks, cardiac function was assessed by echocardiography and morphology was assessed by histopathologic and immunohistochemical methods.",17943461_4,-1,-1,2,10586,-1
10588,FasL Tg mice,3,6,18,30,NTg and untreated FasL Tg mice showed little or no change in cardiac structure or function.,17943461_5,-1,-1,2,10588,-1
10589,no change,9,11,48,57,NTg and untreated FasL Tg mice showed little or no change in cardiac structure or function.,17943461_5,-1,-1,2,10589,-1
10591,AZT-treated,3,4,13,24,"In contrast, AZT-treated FasL Tg mice developed cardiac dilation and depressed cardiac function in a dose-dependent manner, with concomitant inflammatory infiltration of both ventricles.",17943461_6,-1,-1,2,10591,-1
10594,dose-dependent,16,17,101,115,"In contrast, AZT-treated FasL Tg mice developed cardiac dilation and depressed cardiac function in a dose-dependent manner, with concomitant inflammatory infiltration of both ventricles.",17943461_6,-1,-1,2,10594,-1
10595,associated with,3,5,19,34,"These changes were associated with an increased sarcolemmal expression of Fas and FasL, as well as increased activation of caspase 3, translocation of calpain 1 to the sarcolemma and sarcomere, and increased numbers of cells undergoing apoptosis.",17943461_7,-1,-1,2,10595,-1
10599,associated with,2,4,11,26,"These were associated with changes in dystrophin and cardiac troponin I localization, as well as loss of sarcolemmal integrity.",17943461_8,-1,-1,2,10599,-1
10602,HIV-positive,14,15,78,90,"CONCLUSIONS: The expression of Fas ligand in the myocardium, as identified in HIV-positive patients, might increase the susceptibility to HAART-induced cardiomyopathy due to activation of apoptotic pathways, resulting in cardiac dilation and dysfunction.",17943461_9,-1,-1,2,10602,-1
10612,double-blind study,26,28,214,232,"Gastrointestinal tolerability of etoricoxib in rheumatoid arthritis patients: results of the etoricoxib vs diclofenac sodium gastrointestinal tolerability and effectiveness trial (EDGE-II).OBJECTIVE: A randomised, double-blind study to compare the gastrointestinal (GI) tolerability, safety and efficacy of etoricoxib and diclofenac in patients with rheumatoid arthritis (RA).",17965424_0,-1,-1,2,10612,-1
10613,gastrointestinal (GI) tolerability,31,36,248,282,"Gastrointestinal tolerability of etoricoxib in rheumatoid arthritis patients: results of the etoricoxib vs diclofenac sodium gastrointestinal tolerability and effectiveness trial (EDGE-II).OBJECTIVE: A randomised, double-blind study to compare the gastrointestinal (GI) tolerability, safety and efficacy of etoricoxib and diclofenac in patients with rheumatoid arthritis (RA).",17965424_0,-1,-1,2,10613,-1
10633,hazard ratio,26,28,162,174,"The cumulative discontinuation rate due to GI AEs was significantly lower with etoricoxib than diclofenac (5.2 vs 8.5 events per 100 patient-years, respectively; hazard ratio 0.62 (95% CI: 0.47, 0.81; p<or=0.001)).",17965424_7,-1,-1,2,10633,-1
10635,AEs,8,9,78,81,The incidence of discontinuations for hypertension-related and oedema-related AEs were significantly higher with etoricoxib (2.5% and 1.1% respectively) compared with diclofenac (1.5% and 0.4% respectively; p<0.001 for hypertension and p<0.01 for oedema).,17965424_8,-1,-1,2,10635,-1
10642,discontinuing treatment,11,13,74,97,CONCLUSIONS: Etoricoxib 90 mg demonstrated a significantly lower risk for discontinuing treatment due to GI AEs compared with diclofenac 150 mg.,17965424_10,-1,-1,2,10642,-1
10646,AEs,12,13,91,94,"Discontinuations from renovascular AEs, although less common than discontinuations from GI AEs, were significantly higher with etoricoxib.",17965424_11,-1,-1,2,10646,-1
10648,Anxiogenic potential,0,2,0,20,Anxiogenic potential of ciprofloxacin and norfloxacin in rats.,17975693_0,-1,-1,2,10648,-1
10650,anxiogenic effects,4,6,27,45,"INTRODUCTION: The possible anxiogenic effects of fluoroquinolones, namely ciprofloxacin and norfloxacin, were investigated in adult Charles Foster albino rats of either sex, weighing 150-200 g. METHODS: The drugs were given orally, in doses of 50 mg/kg for five consecutive days and the experiments were performed on the fifth day.",17975693_1,-1,-1,2,10650,-1
10653,albino rats,20,22,147,158,"INTRODUCTION: The possible anxiogenic effects of fluoroquinolones, namely ciprofloxacin and norfloxacin, were investigated in adult Charles Foster albino rats of either sex, weighing 150-200 g. METHODS: The drugs were given orally, in doses of 50 mg/kg for five consecutive days and the experiments were performed on the fifth day.",17975693_1,-1,-1,2,10653,-1
10660,norfloxacin-treated rats,8,10,54,78,RESULTS: The results indicate that ciprofloxacin- and norfloxacin-treated rats showed anxious behaviour in comparison to control rats in all the parameters studied.,17975693_3,-1,-1,2,10660,-1
10663,norfloxacin-treated,4,5,28,47,"However, ciprofloxacin- and norfloxacin-treated rats did not differ significantly from each other in various behavioural parameters.",17975693_4,-1,-1,2,10663,-1
10664,anxiogenic potential,10,12,83,103,CONCLUSION: The present experimental findings substantiate the clinically observed anxiogenic potential of ciprofloxacin and norfloxacin.,17975693_5,-1,-1,2,10664,-1
10676,treated with,31,33,189,201,CASE REPORT: We describe 2 patients who were regular consumers of alcohol and who developed liver failure within 3-5 days after hospitalization and stopping alcohol consumption while being treated with 4 g paracetamol/day.,18004067_2,-1,-1,2,10676,-1
10677,paracetamol/day,35,36,206,221,CASE REPORT: We describe 2 patients who were regular consumers of alcohol and who developed liver failure within 3-5 days after hospitalization and stopping alcohol consumption while being treated with 4 g paracetamol/day.,18004067_2,-1,-1,2,10677,-1
10679,toxic range,14,16,75,86,A paracetamol serum level obtained in one of these patients was not in the toxic range.,18004067_3,-1,-1,2,10679,-1
10680,risk factors,1,3,9,21,Possible risk factors for the development of hepatotoxicity in patients treated with therapeutic doses of paracetamol are discussed.,18004067_4,-1,-1,2,10680,-1
10682,treated with,10,12,72,84,Possible risk factors for the development of hepatotoxicity in patients treated with therapeutic doses of paracetamol are discussed.,18004067_4,-1,-1,2,10682,-1
10685,risk factors,5,7,29,41,"CONCLUSION: In patients with risk factors, e.g. regular consumption of alcohol, liver failure is possible when therapeutic doses are ingested.",18004067_5,-1,-1,2,10685,-1
10690,treated with,25,27,150,162,We propose that the paracetamol dose should not exceed 2 g/day in such patients and that their liver function should be monitored closely while being treated with paracetamol.,18004067_6,-1,-1,2,10690,-1
10699,clinical setting,19,21,131,147,We hypothesized that propofol infusion pain might be prevented by infusing remifentanil before starting the propofol infusion in a clinical setting where target-controlled infusions (TCI) of both drugs were used.,18006530_2,-1,-1,2,10699,-1
10700,target-controlled infusions,22,24,154,181,We hypothesized that propofol infusion pain might be prevented by infusing remifentanil before starting the propofol infusion in a clinical setting where target-controlled infusions (TCI) of both drugs were used.,18006530_2,-1,-1,2,10700,-1
10703,placebo-controlled trial,7,9,41,65,"A prospective, randomized, double-blind, placebo-controlled trial was performed to determine the effect-site concentration (Ce) of remifentanil to prevent the pain without producing complications.",18006530_3,-1,-1,2,10703,-1
10717,Groups R4,10,12,58,67,"RESULTS: The incidence of pain was significantly lower in Groups R4 and R6 than in the control and R2 groups (12/32 and 6/31 vs 26/31 and 25/32, respectively, P<0.001).",18006530_7,-1,-1,2,10717,-1
10718,R6,13,14,72,74,"RESULTS: The incidence of pain was significantly lower in Groups R4 and R6 than in the control and R2 groups (12/32 and 6/31 vs 26/31 and 25/32, respectively, P<0.001).",18006530_7,-1,-1,2,10718,-1
10720,Groups R4,5,7,24,33,Pain was less severe in Groups R4 and R6 than in the control and R2 groups (P<0.001).,18006530_8,-1,-1,2,10720,-1
10723,Groups R4,12,14,72,81,"However, both incidence and severity of pain were not different between Groups R4 and R6.",18006530_9,-1,-1,2,10723,-1
10724,R6,15,16,86,88,"However, both incidence and severity of pain were not different between Groups R4 and R6.",18006530_9,-1,-1,2,10724,-1
10734,non-randomised clinical study,18,21,118,147,"Associations between use of benzodiazepines or related drugs and health, physical abilities and cognitive function: a non-randomised clinical study in the elderly.",18020536_0,-1,-1,2,10734,-1
10738,non-randomised clinical study,3,6,11,40,METHODS: A non-randomised clinical study of patients aged > or =65 years admitted to acute hospital wards during 1 month.,18020536_2,-1,-1,2,10738,-1
10741,/-,14,15,57,59,164 patients (mean age +/- standard deviation [SD] 81.6 +/- 6.8 years) were admitted.,18020536_3,0,1,2,10741,-1
10742,BZDs/RDs,2,3,9,17,"had used BZDs/RDs before admission, and the remainder (n = 86) were non-users.",18020536_5,-1,-1,2,10742,-1
10743,non-users,15,16,68,77,"had used BZDs/RDs before admission, and the remainder (n = 86) were non-users.",18020536_5,-1,-1,2,10743,-1
10745,Mini-Mental State Examination (,6,10,38,69,Cognitive ability was assessed by the Mini-Mental State Examination (MMSE).,18020536_6,-1,-1,2,10745,-1
10747,MMSE sum points,6,9,26,41,Patients scoring > or =20 MMSE sum points were interviewed (n = 79) and questioned regarding symptoms and functional abilities during the week prior to admission.,18020536_7,-1,-1,2,10747,-1
10749,BZDs/RDs,4,5,15,23,"Data on use of BZDs/RDs before admission, current medications and discharge diagnoses were collected from medical records.",18020536_8,-1,-1,2,10749,-1
10755,non-users,13,14,89,98,"Health, physical abilities and cognitive function were compared between BZD/RD users and non-users, and adjustments were made for confounding variables.",18020536_9,-1,-1,2,10755,-1
10756,confounding variables,20,22,130,151,"Health, physical abilities and cognitive function were compared between BZD/RD users and non-users, and adjustments were made for confounding variables.",18020536_9,-1,-1,2,10756,-1
10758,/-,5,6,19,21,RESULTS: The mean +/- SD duration of BZD/RD use was 7 +/- 7 years (range 1-31).,18020536_11,0,1,2,10758,-1
10759,BZD/RD,9,10,37,43,RESULTS: The mean +/- SD duration of BZD/RD use was 7 +/- 7 years (range 1-31).,18020536_11,-1,-1,2,10759,-1
10760,/- 7 years,14,17,55,65,RESULTS: The mean +/- SD duration of BZD/RD use was 7 +/- 7 years (range 1-31).,18020536_11,-1,-1,2,10760,-1
10761,BZDs/RDs,3,4,13,21,Two or three BZDs/RDs were concomitantly taken by 26% of users (n = 20).,18020536_12,-1,-1,2,10761,-1
10762,associated with,6,8,33,48,"Long-term use of these drugs was associated with female sex and use of a higher number of drugs with effects on the CNS, which tended to be related to diagnosed dementia.",18020536_13,-1,-1,2,10762,-1
10766,associated with,13,15,77,92,"After adjustment for these variables as confounders, use of BZDs/RDs was not associated with cognitive function as measured by the MMSE.",18020536_14,-1,-1,2,10766,-1
10768,MMSE,21,22,131,135,"After adjustment for these variables as confounders, use of BZDs/RDs was not associated with cognitive function as measured by the MMSE.",18020536_14,-1,-1,2,10768,-1
10769,BZDs/RDs,4,5,16,24,"However, use of BZDs/RDs was associated with dizziness, inability to sleep after awaking at night and tiredness in the mornings during the week prior to admission and with stronger depressive symptoms measured at the beginning of the hospital stay.",18020536_15,-1,-1,2,10769,-1
10774,associated with,6,8,29,44,Use of BZDs/RDs tended to be associated with a reduced ability to walk and shorter night-time sleep during the week prior to admission.,18020536_16,-1,-1,2,10774,-1
10775,MMSE sum score,11,14,75,89,A higher residual serum concentration of temazepam correlated with a lower MMSE sum score after adjustment for confounding variables.,18020536_17,-1,-1,2,10775,-1
10776,confounding variables,17,19,111,132,A higher residual serum concentration of temazepam correlated with a lower MMSE sum score after adjustment for confounding variables.,18020536_17,-1,-1,2,10776,-1
10777,BZD/RD,11,12,64,70,CONCLUSIONS: Long-term use and concomitant use of more than one BZD/RD were common in elderly patients hospitalised because of acute illnesses.,18020536_18,-1,-1,2,10777,-1
10779,associated with,3,5,18,33,Long-term use was associated with daytime and night-time symptoms indicative of poorer health and potentially caused by the adverse effects of these drugs.,18020536_19,-1,-1,2,10779,-1
10789,Co.,0,1,0,3,"Co., Ansan, Korea) in a suicide attempt.",18023325_4,-1,-1,2,10789,-1
10795,consistent with,5,7,29,44,A nerve conduction study was consistent with severe sensorimotor axonal polyneuropathy.,18023325_8,-1,-1,2,10795,-1
10798,thyroarytenoid muscle,3,5,28,49,Laryngeal electromyography (thyroarytenoid muscle) showed ample denervation potentials.,18023325_9,-1,-1,2,10798,-1
10813,treated with,13,15,93,105,FINDINGS: A 28-year-old man suffering from idiopathic epilepsy with generalized seizures was treated with LEV (3000 mg) added to valproate (VPA) (2000 mg).,18081909_2,-1,-1,2,10813,-1
10830,cocaine's,4,6,32,41,"While the mechanisms underlying cocaine's rewarding effects have been studied extensively, less attention has been paid to the unpleasant behavioral states induced by cocaine, such as anxiety.",18083142_2,-1,-1,2,10830,-1
10832,EPM,33,34,166,169,"METHODS: In this study, we evaluated the performance of dopamine beta-hydroxylase knockout (Dbh -/-) mice, which lack norepinephrine (NE), in the elevated plus maze (EPM) to examine the contribution of noradrenergic signaling to cocaine-induced anxiety.",18083142_3,-1,-1,2,10832,-1
10835,dose-dependently,6,7,31,47,"RESULTS: We found that cocaine dose-dependently increased anxiety-like behavior in control (Dbh +/-) mice, as measured by a decrease in open arm exploration.",18083142_4,-1,-1,2,10835,-1
10840,anxiogenic effects,17,19,97,115,The Dbh -/- mice had normal baseline performance in the EPM but were completely resistant to the anxiogenic effects of cocaine.,18083142_5,-1,-1,2,10840,-1
10842,Dbh,6,7,47,50,"Cocaine-induced anxiety was also attenuated in Dbh +/- mice following administration of disulfiram, a dopamine beta-hydroxylase (DBH) inhibitor.",18083142_6,-1,-1,2,10842,-1
10848,wild-type,26,27,199,208,"In experiments using specific adrenergic antagonists, we found that pretreatment with the beta-adrenergic receptor antagonist propranolol blocked cocaine-induced anxiety-like behavior in Dbh +/- and wild-type C57BL6/J mice, while the alpha(1) antagonist prazosin and the alpha(2) antagonist yohimbine had no effect.",18083142_7,-1,-1,2,10848,-1
10859,meta-analysis,9,10,66,79,Dexmedetomidine and cardiac protection for non-cardiac surgery: a meta-analysis of randomised controlled trials.,18086064_0,-1,-1,2,10859,-1
10860,randomised controlled trials,11,14,83,111,Dexmedetomidine and cardiac protection for non-cardiac surgery: a meta-analysis of randomised controlled trials.,18086064_0,-1,-1,2,10860,-1
10866,randomised peri-operative studies,4,7,25,58,"We included prospective, randomised peri-operative studies of dexmedetomidine that reported mortality, cardiac morbidity or adverse drug events.",18086064_2,-1,-1,2,10866,-1
10872,reference lists,1,3,4,19,The reference lists of identified papers were examined for further trials.,18086064_4,-1,-1,2,10872,-1
10873,meta-analysis,10,11,51,64,"Of 425 studies identified, 20 were included in the meta-analysis (840 patients).",18086064_5,-1,-1,2,10873,-1
10875,associated with,2,4,20,35,"Dexmedetomidine was associated with a trend towards improved cardiac outcomes; all-cause mortality (OR 0.27, 95% CI 0.01-7.13, p = 0.44), non-fatal myocardial infarction (OR 0.26, 95% CI 0.04-1.60, p = 0.14), and myocardial ischaemia (OR 0.65, 95% CI 0.26-1.63, p = 0.36).",18086064_6,-1,-1,2,10875,-1
10880,randomised placebo-controlled trial,1,4,2,37,A randomised placebo-controlled trial of dexmedetomidine is warranted.,18086064_9,-1,-1,2,10880,-1
10883,associated with,4,6,35,50,Myocardial infarction in pregnancy associated with clomiphene citrate for ovulation induction: a case report.,18161408_0,-1,-1,2,10883,-1
10895,Cardiac enzymes,0,2,0,15,Cardiac enzymes showed a peak rise in troponin I to 9.10 ng/mL. An initial exercise stress test was normal.,18161408_7,-1,-1,2,10895,-1
10900,second trimester,27,29,137,153,"At the time of admission, the patient was at high risk of radiation injury to the fetus, so a coronary angiogram was postponed until the second trimester.",18161408_8,-1,-1,2,10900,-1
10902,case documenting,9,11,50,66,CONCLUSION: This appears to be the first reported case documenting a possible association between CC and myocardial infarction.,18161408_10,-1,-1,2,10902,-1
10911,central prolactin actions,1,4,9,34,"Although central prolactin actions are thought to contribute to this, the mechanisms are poorly understood.",18162529_2,-1,-1,2,10911,-1
10916,LH surge,21,23,171,179,We first tested whether chronic hyperprolactinemia inhibited two neuroendocrine parameters necessary for female fertility: pulsatile LH secretion and the estrogen-induced LH surge.,18162529_3,-1,-1,2,10916,-1
10919,pulse frequency,14,16,98,113,"Chronic hyperprolactinemia induced by the dopamine antagonist sulpiride caused a 40% reduction LH pulse frequency in ovariectomized rats, but only in the presence of chronic low levels of estradiol.",18162529_4,-1,-1,2,10919,-1
10920,ovariectomized rats,17,19,117,136,"Chronic hyperprolactinemia induced by the dopamine antagonist sulpiride caused a 40% reduction LH pulse frequency in ovariectomized rats, but only in the presence of chronic low levels of estradiol.",18162529_4,-1,-1,2,10920,-1
10927,prolactin's signaling pathway,19,23,109,138,Estradiol is known to influence expression of the long form of prolactin receptors (PRL-R) and components of prolactin's signaling pathway.,18162529_6,-1,-1,2,10927,-1
10931,cytokine signaling,8,10,44,62,"Lastly, we measured PRL-R and suppressor of cytokine signaling (SOCS-1 and -3 and CIS, which reflect the level of prolactin signaling) mRNAs in response to sulpiride and estradiol.",18162529_8,-1,-1,2,10931,-1
10934,prolactin signaling,22,24,114,133,"Lastly, we measured PRL-R and suppressor of cytokine signaling (SOCS-1 and -3 and CIS, which reflect the level of prolactin signaling) mRNAs in response to sulpiride and estradiol.",18162529_8,-1,-1,2,10934,-1
10943,SOCS-3,5,6,36,42,Estradiol enhanced these effects on SOCS-3 and CIS.,18162529_10,-1,-1,2,10943,-1
10947,pulse frequency,5,7,26,41,These data show that GnRH pulse frequency is inhibited by chronic hyperprolactinemia in a steroid-dependent manner.,18162529_12,-1,-1,2,10947,-1
10951,brain region-specific regulation,7,10,55,87,They also provide evidence for estradiol-dependent and brain region-specific regulation of PRL-R expression and signaling responses by prolactin.,18162529_13,-1,-1,2,10951,-1
10953,signaling responses,14,16,112,131,They also provide evidence for estradiol-dependent and brain region-specific regulation of PRL-R expression and signaling responses by prolactin.,18162529_13,-1,-1,2,10953,-1
10958,reverse type,6,8,25,37,"One of the rarest is the reverse type of this syndrome, with hyperdynamic apex and complete akinesia of the base (as opposed to the classic apical ballooning).",18177388_3,-1,-1,2,10958,-1
10964,16-week multicenter,4,6,13,32,"METHOD: In a 16-week multicenter, double-blind trial, 122 children with ADHD were randomly assigned to clonidine (n = 31), methylphenidate (n = 29), clonidine and methylphenidate (n = 32), or placebo (n = 30).",18182964_3,-1,-1,2,10964,-1
10965,double-blind trial,7,9,34,52,"METHOD: In a 16-week multicenter, double-blind trial, 122 children with ADHD were randomly assigned to clonidine (n = 31), methylphenidate (n = 29), clonidine and methylphenidate (n = 32), or placebo (n = 30).",18182964_3,-1,-1,2,10965,-1
10968,treated with,10,12,62,74,"RESULTS: There were more incidents of bradycardia in subjects treated with clonidine compared with those not treated with clonidine (17.5% versus 3.4%; p =.02), but no other significant group differences regarding electrocardiogram and other cardiovascular outcomes.",18182964_6,-1,-1,2,10968,-1
10973,associated with,25,27,115,130,Moderate or severe adverse events were more common in subjects on clonidine (79.4% versus 49.2%; p =.0006) but not associated with higher rates of early study withdrawal.,18182964_8,-1,-1,2,10973,-1
10975,childhood ADHD,16,18,95,109,"CONCLUSIONS: Clonidine, used alone or with methylphenidate, appears safe and well tolerated in childhood ADHD.",18182964_10,-1,-1,2,10975,-1
11021,double-blind study,16,18,85,103,"METHODS: This comparative, Phase III, 12-week, multicenter, prospective, randomized, double-blind study was conducted in Indian patients aged 18 to 65 years with established stage II hypertension.",18201582_2,-1,-1,2,11021,-1
11023,treated with,2,4,14,26,Patients were treated with oral FDC of T+A or A QD before breakfast for 12 weeks; blood pressure (BP) and heart rate were measured in the sitting position.,18201582_3,-1,-1,2,11023,-1
11025,T+A,7,8,39,42,Patients were treated with oral FDC of T+A or A QD before breakfast for 12 weeks; blood pressure (BP) and heart rate were measured in the sitting position.,18201582_3,-1,-1,2,11025,-1
11026,QD,10,11,48,50,Patients were treated with oral FDC of T+A or A QD before breakfast for 12 weeks; blood pressure (BP) and heart rate were measured in the sitting position.,18201582_3,-1,-1,2,11026,-1
11028,BP,20,21,98,100,Patients were treated with oral FDC of T+A or A QD before breakfast for 12 weeks; blood pressure (BP) and heart rate were measured in the sitting position.,18201582_3,-1,-1,2,11028,-1
11031,Primary efficacy,0,2,0,16,"Primary efficacy end points were reduction in clinical systolic BP (SBP)/ diastolic BP (DBP) from baseline to study end and number of responders (ie, patients who achieved target SBP/ DBP <130/<80 mm Hg) at end of study.",18201582_4,-1,-1,2,11031,-1
11033,clinical systolic BP,7,10,46,66,"Primary efficacy end points were reduction in clinical systolic BP (SBP)/ diastolic BP (DBP) from baseline to study end and number of responders (ie, patients who achieved target SBP/ DBP <130/<80 mm Hg) at end of study.",18201582_4,-1,-1,2,11033,-1
11034,diastolic BP,11,13,74,86,"Primary efficacy end points were reduction in clinical systolic BP (SBP)/ diastolic BP (DBP) from baseline to study end and number of responders (ie, patients who achieved target SBP/ DBP <130/<80 mm Hg) at end of study.",18201582_4,-1,-1,2,11034,-1
11035,DBP,14,15,88,91,"Primary efficacy end points were reduction in clinical systolic BP (SBP)/ diastolic BP (DBP) from baseline to study end and number of responders (ie, patients who achieved target SBP/ DBP <130/<80 mm Hg) at end of study.",18201582_4,-1,-1,2,11035,-1
11036,DBP,33,34,184,187,"Primary efficacy end points were reduction in clinical systolic BP (SBP)/ diastolic BP (DBP) from baseline to study end and number of responders (ie, patients who achieved target SBP/ DBP <130/<80 mm Hg) at end of study.",18201582_4,-1,-1,2,11036,-1
11044,statistically significant,4,6,14,39,"At study end, statistically significant percentage reductions from baseline within groups and between groups were observed in SBP (T+A [-27.4%]; A [-16.6%]) and DBP (T+A [-20.1%]; A [-13.3%]) (all, P < 0.05).",18201582_7,-1,-1,2,11044,-1
11045,SBP,18,19,126,129,"At study end, statistically significant percentage reductions from baseline within groups and between groups were observed in SBP (T+A [-27.4%]; A [-16.6%]) and DBP (T+A [-20.1%]; A [-13.3%]) (all, P < 0.05).",18201582_7,-1,-1,2,11045,-1
11046,T+A,20,21,131,134,"At study end, statistically significant percentage reductions from baseline within groups and between groups were observed in SBP (T+A [-27.4%]; A [-16.6%]) and DBP (T+A [-20.1%]; A [-13.3%]) (all, P < 0.05).",18201582_7,-1,-1,2,11046,-1
11047,DBP,33,34,161,164,"At study end, statistically significant percentage reductions from baseline within groups and between groups were observed in SBP (T+A [-27.4%]; A [-16.6%]) and DBP (T+A [-20.1%]; A [-13.3%]) (all, P < 0.05).",18201582_7,-1,-1,2,11047,-1
11048,T+A,35,36,166,169,"At study end, statistically significant percentage reductions from baseline within groups and between groups were observed in SBP (T+A [-27.4%]; A [-16.6%]) and DBP (T+A [-20.1%]; A [-13.3%]) (all, P < 0.05).",18201582_7,-1,-1,2,11048,-1
11049,Response rates,0,2,0,14,Response rates were 87.3% (89/102) in the T+A group and 69.3% (70/101) in the A group (P < 0.05).,18201582_8,-1,-1,2,11049,-1
11053,treatment groups,12,14,81,97,"The prevalences of adverse events were not significantly different between the 2 treatment groups (T+A, 16.0% [17/106]; A, 15.4% [16/104]).",18201582_9,-1,-1,2,11053,-1
11059,statistical significance,59,61,256,280,"Peripheral edema was reported in 8.5% patients (9/106) in the T+A group compared with 13.5% (14/104) in the A group, and cough was reported in 3.8% patients (4/106) in the T+A group and 1.0% (1/104) patients in the A group; these differences did not reach statistical significance.",18201582_10,-1,-1,2,11059,-1
11061,FDC,12,13,73,76,"CONCLUSIONS: Among these Indian patients with stage II hypertension, the FDC of T+A was found to be significantly more effective, with regard to BP reductions, than A, and both treatments were well tolerated.",18201582_12,-1,-1,2,11061,-1
11064,optical density,1,3,7,22,Higher optical density of an antigen assay predicts thrombosis in patients with heparin-induced thrombocytopenia.,18208574_0,-1,-1,2,11064,-1
11065,antigen assay,5,7,29,42,Higher optical density of an antigen assay predicts thrombosis in patients with heparin-induced thrombocytopenia.,18208574_0,-1,-1,2,11065,-1
11067,optical density,4,6,25,40,OBJECTIVES: To correlate optical density and percent inhibition of a two-step heparin-induced thrombocytopenia (HIT) antigen assay with thrombosis; the assay utilizes reaction inhibition characteristics of a high heparin concentration.,18208574_1,-1,-1,2,11067,-1
11068,platelet count,12,14,62,76,"PATIENTS AND METHODS: Patients with more than 50% decrease in platelet count or thrombocytopenia (<150 x 10(9)/L) after exposure to heparin, who had a positive two-step antigen assay [optical density (OD) >0.4 and >50 inhibition with high concentration of heparin] were included in the study.",18208574_2,-1,-1,2,11068,-1
11069,exposure to,23,25,120,131,"PATIENTS AND METHODS: Patients with more than 50% decrease in platelet count or thrombocytopenia (<150 x 10(9)/L) after exposure to heparin, who had a positive two-step antigen assay [optical density (OD) >0.4 and >50 inhibition with high concentration of heparin] were included in the study.",18208574_2,-1,-1,2,11069,-1
11070,two-step antigen assay,31,34,160,182,"PATIENTS AND METHODS: Patients with more than 50% decrease in platelet count or thrombocytopenia (<150 x 10(9)/L) after exposure to heparin, who had a positive two-step antigen assay [optical density (OD) >0.4 and >50 inhibition with high concentration of heparin] were included in the study.",18208574_2,-1,-1,2,11070,-1
11071,optical density,35,37,184,199,"PATIENTS AND METHODS: Patients with more than 50% decrease in platelet count or thrombocytopenia (<150 x 10(9)/L) after exposure to heparin, who had a positive two-step antigen assay [optical density (OD) >0.4 and >50 inhibition with high concentration of heparin] were included in the study.",18208574_2,-1,-1,2,11071,-1
11072,isolated-HIT,14,15,73,85,RESULTS: Forty of 94 HIT patients had thrombosis at diagnosis; 54/94 had isolated-HIT without thrombosis.,18208574_3,-1,-1,2,11072,-1
11073,isolated-HIT,3,4,13,25,"Eight of the isolated-HIT patients developed thrombosis within the next 30 d; thus, a total of 48 patients had thrombosis at day 30.",18208574_4,-1,-1,2,11073,-1
11074,isolated-HIT,17,18,107,119,At diagnosis there was no significant difference in OD between HIT patients with thrombosis and those with isolated-HIT.,18208574_5,-1,-1,2,11074,-1
11075,/-,18,19,84,86,"However, OD was significantly higher in all patients with thrombosis (n = 48, 1.34 +/- 0.89), including isolated-HIT patients who later developed thrombosis within 30 d (n = 8, 1.84 +/- 0.64) as compared to isolated-HIT patients who did not develop thrombosis (0.96 +/- 0.75; P = 0.011 and P = 0.008).",18208574_6,0,1,2,11075,-1
11076,isolated-HIT patients,23,25,104,125,"However, OD was significantly higher in all patients with thrombosis (n = 48, 1.34 +/- 0.89), including isolated-HIT patients who later developed thrombosis within 30 d (n = 8, 1.84 +/- 0.64) as compared to isolated-HIT patients who did not develop thrombosis (0.96 +/- 0.75; P = 0.011 and P = 0.008).",18208574_6,-1,-1,2,11076,-1
11077,/-,39,40,183,185,"However, OD was significantly higher in all patients with thrombosis (n = 48, 1.34 +/- 0.89), including isolated-HIT patients who later developed thrombosis within 30 d (n = 8, 1.84 +/- 0.64) as compared to isolated-HIT patients who did not develop thrombosis (0.96 +/- 0.75; P = 0.011 and P = 0.008).",18208574_6,0,1,2,11077,-1
11078,isolated-HIT,45,46,207,219,"However, OD was significantly higher in all patients with thrombosis (n = 48, 1.34 +/- 0.89), including isolated-HIT patients who later developed thrombosis within 30 d (n = 8, 1.84 +/- 0.64) as compared to isolated-HIT patients who did not develop thrombosis (0.96 +/- 0.75; P = 0.011 and P = 0.008).",18208574_6,-1,-1,2,11078,-1
11079,/-,55,56,267,269,"However, OD was significantly higher in all patients with thrombosis (n = 48, 1.34 +/- 0.89), including isolated-HIT patients who later developed thrombosis within 30 d (n = 8, 1.84 +/- 0.64) as compared to isolated-HIT patients who did not develop thrombosis (0.96 +/- 0.75; P = 0.011 and P = 0.008).",18208574_6,0,1,2,11079,-1
11081,isolated-HIT group,12,14,72,90,The Receiver Operative Characteristic Curve showed that OD >1.27 in the isolated-HIT group had a significantly higher chance of developing thrombosis by day 30.,18208574_7,-1,-1,2,11081,-1
11082,percent inhibition,8,10,54,72,None of these groups showed significant difference in percent inhibition.,18208574_8,-1,-1,2,11082,-1
11083,Multivariate analysis,0,2,0,21,Multivariate analysis showed a 2.8-fold increased risk of thrombosis in females.,18208574_9,-1,-1,2,11083,-1
11085,associated with,5,7,25,40,"CONCLUSION: Higher OD is associated with significant risk of subsequent thrombosis in patients with isolated-HIT; percent inhibition, however, was not predictive.",18208574_11,-1,-1,2,11085,-1
11095,tumour milieu,10,12,53,66,"Its activity is believed to be due modulation of the tumour milieu, including downregulation of angiogenesis and inflammatory cytokines.",18217897_1,-1,-1,2,11095,-1
11096,downregulation,14,15,78,92,"Its activity is believed to be due modulation of the tumour milieu, including downregulation of angiogenesis and inflammatory cytokines.",18217897_1,-1,-1,2,11096,-1
11100,response rate,19,21,112,125,"Of 24 evaluable patients, two achieved a complete remission and one achieved a partial remission for an overall response rate of 12.5% (95% confidence interval: 2.6-32.4%).",18217897_4,-1,-1,2,11100,-1
11101,confidence interval,27,29,140,159,"Of 24 evaluable patients, two achieved a complete remission and one achieved a partial remission for an overall response rate of 12.5% (95% confidence interval: 2.6-32.4%).",18217897_4,-1,-1,2,11101,-1
11107,response rate,7,9,47,60,"Our results failed to demonstrate an important response rate to single agent thalidomide in indolent lymphomas and contrast with the higher activity level reported with the second generation immunomodulatory agent, lenalidomide.",18217897_8,-1,-1,2,11107,-1
11120,acute pain models,20,23,124,141,"The purpose of this investigation was to extend these findings to a persistent pain model which could be distinguished from acute pain models on the basis of the nociceptive fibers activated, neurochemical substrates, and duration of the nociceptive stimulus.",18221780_2,-1,-1,2,11120,-1
11121,nociceptive fibers,28,30,162,180,"The purpose of this investigation was to extend these findings to a persistent pain model which could be distinguished from acute pain models on the basis of the nociceptive fibers activated, neurochemical substrates, and duration of the nociceptive stimulus.",18221780_2,-1,-1,2,11121,-1
11123,nociceptive stimulus,39,41,238,258,"The purpose of this investigation was to extend these findings to a persistent pain model which could be distinguished from acute pain models on the basis of the nociceptive fibers activated, neurochemical substrates, and duration of the nociceptive stimulus.",18221780_2,-1,-1,2,11123,-1
11130,warm water,15,17,80,90,"For comparison, tests were conducted in two acute pain models, the hotplate and warm water tail-withdrawal procedures.",18221780_4,-1,-1,2,11130,-1
11135,dose-and time-dependent manner,21,24,142,172,"In males, the non-competitive NMDA antagonist dextromethorphan enhanced the antihyperalgesic effect of low to moderate doses of morphine in a dose-and time-dependent manner.",18221780_5,-1,-1,2,11135,-1
11136,pretreatment,4,5,21,33,"Across the doses and pretreatment times examined, enhancement was not observed in females.",18221780_6,-1,-1,2,11136,-1
11140,sexually-dimorphic interaction,4,6,29,59,These findings demonstrate a sexually-dimorphic interaction between NMDA antagonists and morphine in a persistent pain model that can be distinguished from those observed in acute pain models.,18221780_8,-1,-1,2,11140,-1
11145,associated with,3,5,25,40,Increased mental slowing associated with the APOE epsilon4 allele after trihexyphenidyl oral anticholinergic challenge in healthy elderly.,18239197_0,-1,-1,2,11145,-1
11162,placebo-controlled,8,9,37,55,"This was a randomized, double blind, placebo-controlled, three-way, crossover experimental design.",18239197_3,-1,-1,2,11162,-1
11163,crossover experimental design,12,15,68,97,"This was a randomized, double blind, placebo-controlled, three-way, crossover experimental design.",18239197_3,-1,-1,2,11163,-1
11166,Lader's,2,4,9,16,"Bond and Lader's visual analog scales and alternate versions of the Buschke Selective Reminding Test were administered in a repeated measures design at baseline, 1, 2.5, and 5 hours postdrug administration.",18239197_5,-1,-1,2,11166,-1
11178,Buschke Selective Reminding Test,27,31,183,215,Drug effects as determined by difference scores between 2.0 mg trihexyphenidyl and placebo on ratings of mental slowness significantly correlated with total and delayed recall on the Buschke Selective Reminding Test in carriers of the APOE epsilon4 allele only.,18239197_7,-1,-1,2,11178,-1
11183,associated with,9,11,55,70,CONCLUSION: The epsilon4 allele in healthy elderly was associated with increased subjective mental slowing after trihexyphenidyl anticholinergic challenge.,18239197_9,-1,-1,2,11183,-1
11193,nephrotoxic effects,12,14,59,78,"The novel immunosuppressive (IS) drug sirolmus (Srl) lacks nephrotoxic effects; however, proteinuria associated with Srl has been reported following renal transplantation.",18261172_2,-1,-1,2,11193,-1
11194,associated with,18,20,101,116,"The novel immunosuppressive (IS) drug sirolmus (Srl) lacks nephrotoxic effects; however, proteinuria associated with Srl has been reported following renal transplantation.",18261172_2,-1,-1,2,11194,-1
11198,associated with,8,10,57,72,"In cardiac transplantation, the incidence of proteinuria associated with Srl is unknown.",18261172_3,-1,-1,2,11198,-1
11204,preswitch,15,16,78,87,Proteinuria increased significantly from a median of 0.13 g/day (range 0-5.7) preswitch to 0.23 g/day (0-9.88) at 24 months postswitch (p = 0.0024).,18261172_6,-1,-1,2,11204,-1
11205,postswitch,27,28,124,134,Proteinuria increased significantly from a median of 0.13 g/day (range 0-5.7) preswitch to 0.23 g/day (0-9.88) at 24 months postswitch (p = 0.0024).,18261172_6,-1,-1,2,11205,-1
11207,postswitch,22,23,102,112,"Before the switch, 11.5% of patients had high-grade proteinuria (>1.0 g/day); this increased to 22.9% postswitch (p = 0.006).",18261172_7,-1,-1,2,11207,-1
11214,adverse effect,18,20,100,114,"Thus, proteinuria may develop in cardiac transplant patients after switch to Srl, which may have an adverse effect on renal function in these patients.",18261172_10,-1,-1,2,11214,-1
11226,Rg1,11,12,55,58,The aim of this study was to investigate the effect of Rg1 on learning impairment by chronic morphine administration and the mechanism responsible for this effect.,18308784_3,-1,-1,2,11226,-1
11232,Morris water maze,7,10,46,63,Spatial learning capacity was assessed in the Morris water maze.,18308784_5,-1,-1,2,11232,-1
11233,treated with,5,7,29,41,The results showed that rats treated with Morphine/Rg1 decreased escape latency and increased the time spent in platform quadrant and entering frequency.,18308784_6,-1,-1,2,11233,-1
11234,Morphine/Rg1,7,8,42,54,The results showed that rats treated with Morphine/Rg1 decreased escape latency and increased the time spent in platform quadrant and entering frequency.,18308784_6,-1,-1,2,11234,-1
11235,platform quadrant,17,19,112,129,The results showed that rats treated with Morphine/Rg1 decreased escape latency and increased the time spent in platform quadrant and entering frequency.,18308784_6,-1,-1,2,11235,-1
11237,in vivo,7,9,65,72,"By implantation of electrodes and electrophysiological recording in vivo, the results showed that Rg1 restored the long-term potentiation (LTP) impaired by morphine in both freely moving and anaesthetised rats.",18308784_7,-1,-1,2,11237,-1
11239,long-term potentiation (LTP,17,21,115,142,"By implantation of electrodes and electrophysiological recording in vivo, the results showed that Rg1 restored the long-term potentiation (LTP) impaired by morphine in both freely moving and anaesthetised rats.",18308784_7,-1,-1,2,11239,-1
11241,in vitro,3,5,35,43,"The electrophysiological recording in vitro showed that Rg1 restored the LTP in slices from the rats treated with morphine, but not changed LTP in the slices from normal saline- or morphine/Rg1-treated rats; this restoration could be inhibited by N-methyl-D-aspartate (NMDA) receptor antagonist MK801.",18308784_8,-1,-1,2,11241,-1
11246,morphine/Rg1-treated,31,32,181,201,"The electrophysiological recording in vitro showed that Rg1 restored the LTP in slices from the rats treated with morphine, but not changed LTP in the slices from normal saline- or morphine/Rg1-treated rats; this restoration could be inhibited by N-methyl-D-aspartate (NMDA) receptor antagonist MK801.",18308784_8,-1,-1,2,11246,-1
11251,morphine-inhibited LTP,19,21,136,158,We conclude that Rg1 may significantly improve the spatial learning capacity impaired by chonic morphine administration and restore the morphine-inhibited LTP.,18308784_9,-1,-1,2,11251,-1
11252,NMDA receptor dependent,3,6,15,38,This effect is NMDA receptor dependent.,18308784_10,-1,-1,2,11252,-1
11263,exposure of,6,8,46,57,Previous studies have suggested that repeated exposure of rats to the drug or to the experimental environment is necessary to observe nicotine-induced locomotor stimulation.,1833784_1,-1,-1,2,11263,-1
11264,experimental environment,15,17,85,109,Previous studies have suggested that repeated exposure of rats to the drug or to the experimental environment is necessary to observe nicotine-induced locomotor stimulation.,1833784_1,-1,-1,2,11264,-1
11265,experimental environment,10,12,52,76,In the present study the role of habituation to the experimental environment on the stimulant effect of nicotine in rats was examined.,1833784_2,-1,-1,2,11265,-1
11270,Sprague-Dawley rats,6,8,40,59,Locomotor activity was assessed in male Sprague-Dawley rats tested in photocell cages.,1833784_4,-1,-1,2,11270,-1
11271,photocell cages,10,12,70,85,Locomotor activity was assessed in male Sprague-Dawley rats tested in photocell cages.,1833784_4,-1,-1,2,11271,-1
11272,locomotor activity,10,12,54,72,"Nicotine (1.0 mg/kg) caused a significant increase in locomotor activity in rats that were habituated to the test environment, but had only a weak and delayed stimulant action in rats that were unfamiliar with the test environment.",1833784_5,-1,-1,2,11272,-1
11273,test environment,19,21,109,125,"Nicotine (1.0 mg/kg) caused a significant increase in locomotor activity in rats that were habituated to the test environment, but had only a weak and delayed stimulant action in rats that were unfamiliar with the test environment.",1833784_5,-1,-1,2,11273,-1
11274,test environment,38,40,214,230,"Nicotine (1.0 mg/kg) caused a significant increase in locomotor activity in rats that were habituated to the test environment, but had only a weak and delayed stimulant action in rats that were unfamiliar with the test environment.",1833784_5,-1,-1,2,11274,-1
11293,test environment,16,18,112,128,The results indicate that acute nicotine injection induces a pronounced hyperactivity in rats habituated to the test environment.,1833784_9,-1,-1,2,11293,-1
11294,central nicotine receptors,7,10,37,63,"The effect appears to be mediated by central nicotine receptors, possibly located on dopaminergic neurons, and also requires the activation of both D1 and D2 dopamine receptors.",1833784_10,-1,-1,2,11294,-1
11299,associated with,4,6,31,46,Central retinal vein occlusion associated with clomiphene-induced ovulation.,18343374_0,-1,-1,2,11299,-1
11302,associated with,11,13,62,77,OBJECTIVE: To report a case of central retinal vein occlusion associated with clomiphene citrate (CC).,18343374_1,-1,-1,2,11302,-1
11308,CC therapy,5,7,46,56,INTERVENTION(S): Ophthalmic examination after CC therapy.,18343374_5,-1,-1,2,11308,-1
11315,CONCLUSION(S,0,1,0,12,CONCLUSION(S): This is the first reported case of central retinal vein occlusion after treatment with CC.,18343374_9,-1,-1,2,11315,-1
11319,Acute bronchodilating effects,0,3,0,29,Acute bronchodilating effects of ipratropium bromide and theophylline in chronic obstructive pulmonary disease.,1835291_0,-1,-1,2,11319,-1
11326,placebo-controlled crossover study,38,41,225,259,"The bronchodilator effects of a single dose of ipratropium bromide aerosol (36 micrograms) and short-acting theophylline tablets (dose titrated to produce serum levels of 10-20 micrograms/mL) were compared in a double-blind, placebo-controlled crossover study in 21 patients with stable, chronic obstructive pulmonary disease.",1835291_1,-1,-1,2,11326,-1
11328,peak forced expiratory volume,1,5,5,34,"Mean peak forced expiratory volume in 1 second (FEV1) increases over baseline and the proportion of patients attaining at least a 15% increase in the FEV1 (responders) were 31% and 90%, respectively, for ipratropium and 17% and 50%, respectively, for theophylline.",1835291_2,-1,-1,2,11328,-1
11329,FEV1,9,10,48,52,"Mean peak forced expiratory volume in 1 second (FEV1) increases over baseline and the proportion of patients attaining at least a 15% increase in the FEV1 (responders) were 31% and 90%, respectively, for ipratropium and 17% and 50%, respectively, for theophylline.",1835291_2,-1,-1,2,11329,-1
11330,FEV1,28,29,150,154,"Mean peak forced expiratory volume in 1 second (FEV1) increases over baseline and the proportion of patients attaining at least a 15% increase in the FEV1 (responders) were 31% and 90%, respectively, for ipratropium and 17% and 50%, respectively, for theophylline.",1835291_2,-1,-1,2,11330,-1
11332,FEV1,2,3,12,16,The average FEV1 increases during the 6-hour observation period were 18% for ipratropium and 8% for theophylline.,1835291_3,-1,-1,2,11332,-1
11344,extended-interval,2,3,14,31,"Strategies of extended-interval and conventional dosing have been utilized extensively in the general medical population; however, data are lacking to support a dosing strategy in the hematology/oncology population.",18356633_2,-1,-1,2,11344,-1
11349,open-label trial,15,17,118,134,"To evaluate amikacin-associated nephrotoxicity in an adult hematology/oncology population, a prospective, randomized, open-label trial was conducted at a university-affiliated medical center.",18356633_3,-1,-1,2,11349,-1
11360,extended-interval groups,10,12,74,98,"The occurrence of nephrotoxicity was similar between the conventional and extended-interval groups, at 10% and 5%, respectively (P = 1.00).",18356633_6,-1,-1,2,11360,-1
11363,positive culture,8,10,45,61,"Six patients in the conventional group had a positive culture, compared with none in the extended-interval group (P = 0.002).",18356633_7,-1,-1,2,11363,-1
11364,extended-interval group,16,18,89,112,"Six patients in the conventional group had a positive culture, compared with none in the extended-interval group (P = 0.002).",18356633_7,-1,-1,2,11364,-1
11367,risk factors,16,18,102,114,"The occurrence of nephrotoxicity was similar between the two dosing regimens, but the distribution of risk factors was variable between the two groups.",18356633_8,-1,-1,2,11367,-1
11370,MRI.OBJECTIVE,9,10,61,74,High dose dexmedetomidine as the sole sedative for pediatric MRI.OBJECTIVE: This large-scale retrospective review evaluates the sedation profile of dexmedetomidine.,18363626_0,-1,-1,2,11370,-1
11373,hemodynamic responses,5,7,22,43,"AIM: To determine the hemodynamic responses, efficacy and adverse events associated with the use of high dose dexmedetomidine as the sole sedative for magnetic resonance imaging (MRI) studies.",18363626_1,-1,-1,2,11373,-1
11375,associated with,12,14,73,88,"AIM: To determine the hemodynamic responses, efficacy and adverse events associated with the use of high dose dexmedetomidine as the sole sedative for magnetic resonance imaging (MRI) studies.",18363626_1,-1,-1,2,11375,-1
11382,METHODS/MATERIALS,0,1,0,17,"METHODS/MATERIALS: As part of the ongoing Quality Assurance process, data on all sedations are reviewed monthly and protocols modified as needed.",18363626_4,-1,-1,2,11382,-1
11383,Assurance process,8,10,50,67,"METHODS/MATERIALS: As part of the ongoing Quality Assurance process, data on all sedations are reviewed monthly and protocols modified as needed.",18363626_4,-1,-1,2,11383,-1
11387,imaging study,16,18,108,121,"The current sedation protocol progressively increased the rate of successful sedation (able to complete the imaging study) when using dexmedetomidine alone from 91.8% to 97.6% (P = 0.009), reducing the requirement for adjuvant pentobarbital in the event of sedation failure with dexmedetomidine alone and decreased the mean recovery time by 10 min (P < 0.001).",18363626_7,-1,-1,2,11387,-1
11392,associated with,4,6,38,53,"Although dexmedetomidine sedation was associated with a 16% incidence of bradycardia, all concomitant mean arterial blood pressures were within 20% of age-adjusted normal range and oxygen saturations were 95% or higher.",18363626_8,-1,-1,2,11392,-1
11397,MRI studies,11,13,83,94,CONCLUSION: Dexmedetomidine in high doses provides adequate sedation for pediatric MRI studies.,18363626_9,-1,-1,2,11397,-1
11400,associated with,7,9,42,57,"While use of high dose dexmedetomidine is associated with decreases in heart rate and blood pressure outside the established 'awake' norms, this deviation is generally within 20% of norms, and is not associated with adverse sequelae.",18363626_10,-1,-1,2,11400,-1
11403,associated with,37,39,200,215,"While use of high dose dexmedetomidine is associated with decreases in heart rate and blood pressure outside the established 'awake' norms, this deviation is generally within 20% of norms, and is not associated with adverse sequelae.",18363626_10,-1,-1,2,11403,-1
11407,associated with,1,3,15,30,Hepatotoxicity associated with sulfasalazine in inflammatory arthritis: A case series from a local surveillance of serious adverse events.,18405372_0,-1,-1,2,11407,-1
11410,case series,9,11,74,85,Hepatotoxicity associated with sulfasalazine in inflammatory arthritis: A case series from a local surveillance of serious adverse events.,18405372_0,-1,-1,2,11410,-1
11419,associated with,13,15,88,103,We report an investigation from a local surveillance for serious adverse drug reactions associated with disease modifying anti-rheumatic drugs that was triggered by the occurrence of liver failure in two of our patients.,18405372_2,-1,-1,2,11419,-1
11422,ADR,3,4,17,20,METHODS: Serious ADR reports have been solicited from local clinicians by regular postcards over the past seven years.,18405372_3,-1,-1,2,11422,-1
11426,ADR,15,16,85,88,"Patients', who had hepatotoxicity on sulfasalazine and met a definition of a serious ADR, were identified.",18405372_4,-1,-1,2,11426,-1
11428,causality assessment,15,17,99,119,Two clinicians reviewed structured case reports and assessed causality by consensus and by using a causality assessment instrument.,18405372_5,-1,-1,2,11428,-1
11437,Liver enzymes,0,2,0,13,Liver enzymes showed a hepatocellular pattern in four cases and a mixed pattern in six.,18405372_12,-1,-1,2,11437,-1
11438,hepatocellular pattern,4,6,23,45,Liver enzymes showed a hepatocellular pattern in four cases and a mixed pattern in six.,18405372_12,-1,-1,2,11438,-1
11439,mixed pattern,11,13,66,79,Liver enzymes showed a hepatocellular pattern in four cases and a mixed pattern in six.,18405372_12,-1,-1,2,11439,-1
11444,associated with,4,6,35,50,CONCLUSION: Serious hepatotoxicity associated with sulfasalazine appears to be under-appreciated and intensive monitoring and vigilance in the first 6 weeks of treatment is especially important.,18405372_15,-1,-1,2,11444,-1
11446,under-appreciated,10,11,79,96,CONCLUSION: Serious hepatotoxicity associated with sulfasalazine appears to be under-appreciated and intensive monitoring and vigilance in the first 6 weeks of treatment is especially important.,18405372_15,-1,-1,2,11446,-1
11453,Cardona,0,1,0,7,Cardona et al. [Nat. Neurosci.,18410508_2,-1,-1,2,11453,-1
11459,DA neuronal system,14,17,75,93,"Because the CNS damage caused by METH and MPTP is highly selective for the DA neuronal system in mouse models of neurotoxicity, we hypothesized that the CX3CR1 plays a role in METH-induced neurotoxicity and microglial activation.",18410508_4,-1,-1,2,11459,-1
11460,mouse models,18,20,97,109,"Because the CNS damage caused by METH and MPTP is highly selective for the DA neuronal system in mouse models of neurotoxicity, we hypothesized that the CX3CR1 plays a role in METH-induced neurotoxicity and microglial activation.",18410508_4,-1,-1,2,11460,-1
11466,CX3CR1 gene,4,6,18,29,Mice in which the CX3CR1 gene has been deleted and replaced with a cDNA encoding enhanced green fluorescent protein (eGFP) were treated with METH and examined for striatal neurotoxicity.,18410508_5,-1,-1,2,11466,-1
11468,treated with,23,25,128,140,Mice in which the CX3CR1 gene has been deleted and replaced with a cDNA encoding enhanced green fluorescent protein (eGFP) were treated with METH and examined for striatal neurotoxicity.,18410508_5,-1,-1,2,11468,-1
11473,knockout mice,14,16,89,102,"METH depleted DA, caused microglial activation, and increased body temperature in CX3CR1 knockout mice to the same extent and over the same time course seen in wild-type controls.",18410508_6,-1,-1,2,11473,-1
11475,wild-type controls,28,30,160,178,"METH depleted DA, caused microglial activation, and increased body temperature in CX3CR1 knockout mice to the same extent and over the same time course seen in wild-type controls.",18410508_6,-1,-1,2,11475,-1
11488,activation cascade,12,14,81,99,"Furthermore, it appears that striatal-resident microglia respond to METH with an activation cascade and then return to a surveying state without undergoing apoptosis or migration.",18410508_11,-1,-1,2,11488,-1
11489,surveying state,19,21,121,136,"Furthermore, it appears that striatal-resident microglia respond to METH with an activation cascade and then return to a surveying state without undergoing apoptosis or migration.",18410508_11,-1,-1,2,11489,-1
11492,pathomechanism,1,2,4,18,The pathomechanism of nicotine-induced nystagmus (NIN) is unknown.,18417364_1,-1,-1,2,11492,-1
11498,magnetic resonance imaging,10,13,74,100,Eight healthy volunteers inhaled nicotine in darkness during a functional magnetic resonance imaging (fMRI) experiment; eye movements were registered using video-oculography.,18417364_3,-1,-1,2,11498,-1
11529,hippocampal glutamate,15,17,123,144,In vivo microdialysis demonstrated that an intraperitoneal administration of pilocarpine induced a pronounced increment of hippocampal glutamate and aspartate whereas no significant change was observed on the level of glycine and GABA.,18439803_3,-1,-1,2,11529,-1
11534,pilocarpine-evoked,20,21,96,114,Pretreatment with either VPU (50 and 100 mg/kg) or VPA (300 and 600 mg/kg) completely abolished pilocarpine-evoked increases in extracellular glutamate and aspartate.,18439803_4,-1,-1,2,11534,-1
11537,drastic reduction,21,23,118,135,"In addition, a statistically significant reduction was also observed on the level of GABA and glycine but less than a drastic reduction of glutamate and aspartate level.",18439803_5,-1,-1,2,11537,-1
11549,lithium therapy,5,7,45,60,Complete atrioventricular block secondary to lithium therapy.,18441470_0,-1,-1,2,11549,-1
11553,secondary to,15,17,90,102,"In the present case, complete atrioventricular (AV) block with syncopal attacks developed secondary to lithium therapy, necessitating permanent pacemaker implantation.",18441470_2,-1,-1,2,11553,-1
11555,Serum lithium levels,0,3,0,20,Serum lithium levels remained under or within the therapeutic range during the syncopal attacks.,18441470_3,-1,-1,2,11555,-1
11556,therapeutic range,8,10,50,67,Serum lithium levels remained under or within the therapeutic range during the syncopal attacks.,18441470_3,-1,-1,2,11556,-1
11565,gastric acid,11,13,48,60,"The aim of this study is to examine the role of gastric acid back-diffusion, mast cell histamine release, lipid peroxide (LPO) generation and mucosal microvascular permeability in modulating gastric hemorrhage and ulcer in rats with atherosclerosis induced by coadministration of vitamin D2 and cholesterol.",18442015_2,-1,-1,2,11565,-1
11566,back-diffusion,13,14,61,75,"The aim of this study is to examine the role of gastric acid back-diffusion, mast cell histamine release, lipid peroxide (LPO) generation and mucosal microvascular permeability in modulating gastric hemorrhage and ulcer in rats with atherosclerosis induced by coadministration of vitamin D2 and cholesterol.",18442015_2,-1,-1,2,11566,-1
11568,histamine release,17,19,87,104,"The aim of this study is to examine the role of gastric acid back-diffusion, mast cell histamine release, lipid peroxide (LPO) generation and mucosal microvascular permeability in modulating gastric hemorrhage and ulcer in rats with atherosclerosis induced by coadministration of vitamin D2 and cholesterol.",18442015_2,-1,-1,2,11568,-1
11573,coadministration,42,43,260,276,"The aim of this study is to examine the role of gastric acid back-diffusion, mast cell histamine release, lipid peroxide (LPO) generation and mucosal microvascular permeability in modulating gastric hemorrhage and ulcer in rats with atherosclerosis induced by coadministration of vitamin D2 and cholesterol.",18442015_2,-1,-1,2,11573,-1
11583,simulated gastric juice,13,16,71,94,"After gastric surgery, rat stomachs were irrigated for 3 h with either simulated gastric juice or normal saline.",18442015_6,-1,-1,2,11583,-1
11585,LPO,5,6,37,40,"Gastric acid back-diffusion, mucosal LPO generation, histamine concentration, microvascular permeability, luminal hemoglobin content and ulcer areas were determined.",18442015_7,-1,-1,2,11585,-1
11588,serum calcium,6,8,45,58,"Elevated atherosclerotic parameters, such as serum calcium, total cholesterol and low-density lipoprotein concentration were obtained in atherosclerotic rats.",18442015_8,-1,-1,2,11588,-1
11592,ulcerogenic factors,6,8,49,68,"Severe gastric ulcers accompanied with increased ulcerogenic factors, including gastric acid back-diffusion, histamine release, LPO generation and luminal hemoglobin content were also observed in these rats.",18442015_9,-1,-1,2,11592,-1
11594,histamine release,14,16,109,126,"Severe gastric ulcers accompanied with increased ulcerogenic factors, including gastric acid back-diffusion, histamine release, LPO generation and luminal hemoglobin content were also observed in these rats.",18442015_9,-1,-1,2,11594,-1
11610,HBV,4,5,19,22,Hepatitis B virus (HBV) is one of the major causes of chronic liver disease worldwide.,18464113_1,-1,-1,2,11610,-1
11612,chronic carriers,4,6,24,40,Cancer patients who are chronic carriers of HBV have a higher hepatic complication rate while receiving cytotoxic chemotherapy (CT) and this has mainly been attributed to HBV reactivation.,18464113_2,-1,-1,2,11612,-1
11613,HBV,7,8,44,47,Cancer patients who are chronic carriers of HBV have a higher hepatic complication rate while receiving cytotoxic chemotherapy (CT) and this has mainly been attributed to HBV reactivation.,18464113_2,-1,-1,2,11613,-1
11616,HBV,28,29,171,174,Cancer patients who are chronic carriers of HBV have a higher hepatic complication rate while receiving cytotoxic chemotherapy (CT) and this has mainly been attributed to HBV reactivation.,18464113_2,-1,-1,2,11616,-1
11621,historical control group,27,30,178,202,"In this study, cancer patients who have solid and hematological malignancies with chronic HBV infection received the antiviral agent lamivudine prior and during CT compared with historical control group who did not receive lamivudine.",18464113_3,-1,-1,2,11621,-1
11622,HBV,14,15,86,89,"The objectives were to assess the efficacy of lamivudine in reducing the incidence of HBV reactivation, and diminishing morbidity and mortality during CT.",18464113_4,-1,-1,2,11622,-1
11625,historical controls,1,3,4,23,The historical controls consisted of 50 consecutive patients who underwent CT without prophylactic lamivudine.,18464113_7,-1,-1,2,11625,-1
11626,control group,2,4,7,20,"Of our control group (n= 50), 21 patients (42%) were established hepatitis.",18464113_10,-1,-1,2,11626,-1
11627,ALT values,4,6,23,33,Comparison of the mean ALT values revealed significantly higher mean alanine aminotransferase (ALT) values in the control group than the prophylactic lamivudine group; 154:64 (p < 0.32).,18464113_13,-1,-1,2,11627,-1
11629,control group,18,20,114,127,Comparison of the mean ALT values revealed significantly higher mean alanine aminotransferase (ALT) values in the control group than the prophylactic lamivudine group; 154:64 (p < 0.32).,18464113_13,-1,-1,2,11629,-1
11630,HBV,11,12,89,92,Our study suggests that prophylactic lamivudine significantly decreases the incidence of HBV reactivation and overall morbidity in cancer patients during and after immunosuppressive therapy.,18464113_14,-1,-1,2,11630,-1
11644,micturition pathways,11,13,79,99,VIP(-/-) mice exhibit altered bladder function and neurochemical properties in micturition pathways after cyclophosphamide (CYP)-induced cystitis.,18483878_2,-1,-1,2,11644,-1
11647,VIP's,1,3,6,11,"Given VIP's role as an anti-inflammatory mediator, we hypothesized that VIP(-/-) mice would exhibit enhanced inflammatory mediator expression after cystitis.",18483878_3,-1,-1,2,11647,-1
11653,wild type,20,22,132,141,A mouse inflammatory cytokine and receptor RT2 profiler array was used to determine regulated transcripts in the urinary bladder of wild type (WT) and VIP(-/-) mice with or without CYP-induced cystitis (150 mg/kg; i.p.; 48 h).,18483878_4,-1,-1,2,11653,-1
11668,Several regulated genes,0,3,0,23,Several regulated genes were validated using enzyme-linked immunoassays including IL-1beta and CXCL1.,18483878_7,-1,-1,2,11668,-1
11669,enzyme-linked immunoassays,6,8,45,71,Several regulated genes were validated using enzyme-linked immunoassays including IL-1beta and CXCL1.,18483878_7,-1,-1,2,11669,-1
11684,WT,20,21,126,128,"The data suggest that in VIP(-/-) mice with bladder inflammation, inflammatory mediators are increased above that observed in WT with CYP.",18483878_9,-1,-1,2,11684,-1
11689,micturition pathways,22,24,153,173,This shift in balance may contribute to increased bladder dysfunction in VIP(-/-) mice with bladder inflammation and altered neurochemical expression in micturition pathways.,18483878_10,-1,-1,2,11689,-1
11694,genetic control,9,11,71,86,The metabolism of the cardioselective beta-blocker metoprolol is under genetic control of the debrisoquine/sparteine type.,1848636_1,-1,-1,2,11694,-1
11696,poor metabolizers,10,12,49,66,"The two metabolic phenotypes, extensive (EM) and poor metabolizers (PM), show different stereoselective metabolism, resulting in apparently higher beta-1 adrenoceptor antagonistic potency of racemic metoprolol in EMs.",1848636_2,-1,-1,2,11696,-1
11697,stereoselective metabolism,18,20,88,114,"The two metabolic phenotypes, extensive (EM) and poor metabolizers (PM), show different stereoselective metabolism, resulting in apparently higher beta-1 adrenoceptor antagonistic potency of racemic metoprolol in EMs.",1848636_2,-1,-1,2,11697,-1
11702,drug effect,1,3,4,15,The drug effect studied was the antagonism by metoprolol of terbutaline-induced hypokalemia.,1848636_4,-1,-1,2,11702,-1
11704,pharmacokinetic pharmacodynamic modeling,2,5,9,49,"By using pharmacokinetic pharmacodynamic modeling the pharmacodynamics of racemic metoprolol and the active S-isomer, were quantitated in EMs and PMs in terms of IC50 values, representing metoprolol plasma concentrations resulting in half-maximum receptor occupancy.",1848636_5,-1,-1,2,11704,-1
11708,quantitated,16,17,123,134,"By using pharmacokinetic pharmacodynamic modeling the pharmacodynamics of racemic metoprolol and the active S-isomer, were quantitated in EMs and PMs in terms of IC50 values, representing metoprolol plasma concentrations resulting in half-maximum receptor occupancy.",1848636_5,-1,-1,2,11708,-1
11713,Blood samples,0,2,0,13,"Blood samples for the analysis of plasma potassium, terbutaline, metoprolol (racemic, R- and S-isomer), and alpha-hydroxymetoprolol concentrations were taken at regular time intervals, during 8 hr after metoprolol.",1848636_8,-1,-1,2,11713,-1
11720,time intervals,27,29,169,183,"Blood samples for the analysis of plasma potassium, terbutaline, metoprolol (racemic, R- and S-isomer), and alpha-hydroxymetoprolol concentrations were taken at regular time intervals, during 8 hr after metoprolol.",1848636_8,-1,-1,2,11720,-1
11722,time curve,13,15,85,95,"In PMs, metoprolol increased the terbutaline area under the plasma concentration vs. time curve (+67%).",1848636_9,-1,-1,2,11722,-1
11728,/- 7 ng.ml-1,18,21,100,112,"There was a difference in metoprolol potency with higher racemic metoprolol IC50 values in PMs (72 +/- 7 ng.ml-1) than EMs (42 +/- 8 ng.ml-1, P less than .001).(ABSTRACT TRUNCATED AT 250 WORDS)",1848636_11,-1,-1,2,11728,-1
11729,/- 8 ng.ml-1,27,30,128,140,"There was a difference in metoprolol potency with higher racemic metoprolol IC50 values in PMs (72 +/- 7 ng.ml-1) than EMs (42 +/- 8 ng.ml-1, P less than .001).(ABSTRACT TRUNCATED AT 250 WORDS)",1848636_11,-1,-1,2,11729,-1
11740,BN,12,13,88,90,"Here, we describe an eight-and-a-half-yr-old male renal transplant recipient with right BN.",18503483_4,-1,-1,2,11740,-1
11771,real time,29,31,177,186,"Pulse power analysis (also called ""pulse contour analysis"") of an arterial pressure wave form allows continuous evaluation of systemic vascular resistance and cardiac output in real time, thereby elucidating the causative factors behind changes in blood pressure.",18513945_5,-1,-1,2,11771,-1
11772,causative factors,35,37,212,229,"Pulse power analysis (also called ""pulse contour analysis"") of an arterial pressure wave form allows continuous evaluation of systemic vascular resistance and cardiac output in real time, thereby elucidating the causative factors behind changes in blood pressure.",18513945_5,-1,-1,2,11772,-1
11777,associated with,6,8,40,55,"Hypotension in response to oxytocin was associated with a decrease in systemic vascular resistance and a compensatory increase in stroke volume, heart rate and cardiac output.",18513945_7,-1,-1,2,11777,-1
11794,experimental model,24,26,158,176,"We investigated the effects of antithrombin, a plasma inhibitor of coagulation factors, in rats with puromycin aminonucleoside-induced nephrosis, which is an experimental model of human nephrotic syndrome.",18541230_1,-1,-1,2,11794,-1
11805,proteinaceous casts,8,10,67,86,"Histopathological examination revealed severe renal damage such as proteinaceous casts in tubuli and tubular expansion in the kidney of control rats, while an improvement of the damage was seen in antithrombin-treated rats.",18541230_5,-1,-1,2,11805,-1
11807,control rats,19,21,136,148,"Histopathological examination revealed severe renal damage such as proteinaceous casts in tubuli and tubular expansion in the kidney of control rats, while an improvement of the damage was seen in antithrombin-treated rats.",18541230_5,-1,-1,2,11807,-1
11808,antithrombin-treated,31,32,197,217,"Histopathological examination revealed severe renal damage such as proteinaceous casts in tubuli and tubular expansion in the kidney of control rats, while an improvement of the damage was seen in antithrombin-treated rats.",18541230_5,-1,-1,2,11808,-1
11813,aminonucleoside-induced,3,4,23,46,"Furthermore, puromycin aminonucleoside-induced increases in renal cytokine content were also decreased.",18541230_7,-1,-1,2,11813,-1
11814,renal cytokine,6,8,60,74,"Furthermore, puromycin aminonucleoside-induced increases in renal cytokine content were also decreased.",18541230_7,-1,-1,2,11814,-1
11839,detrimental supplement,30,32,208,230,"CONCLUSION: As fentanyl exacerbated postoperative nausea and vomiting without an improvement in postoperative pain and also had adverse cardiorespiratory effects, it appears to be an unnecessary and possibly detrimental supplement to sevoflurane in day surgery.",18544179_11,-1,-1,2,11839,-1
11844,treated with,9,11,60,72,Valvular heart disease in patients with Parkinson's disease treated with pergolide.,18560792_0,-1,-1,2,11844,-1
11854,case-control study,21,23,139,157,OBJECTIVES: To estimate the frequency and severity of valvular heart abnormality and its possible reversibility after drug withdrawal in a case-control study.,18560792_4,-1,-1,2,11854,-1
11855,Amiens area,7,9,32,43,METHODS: All PD patients in the Amiens area treated with pergolide were invited to attend a cardiologic assessment including transthoracic echocardiography.,18560792_5,-1,-1,2,11855,-1
11856,treated with,9,11,44,56,METHODS: All PD patients in the Amiens area treated with pergolide were invited to attend a cardiologic assessment including transthoracic echocardiography.,18560792_5,-1,-1,2,11856,-1
11860,median interval,6,8,41,56,A second echocardiography was performed (median interval: 13 months) after pergolide withdrawal (n=10 patients).,18560792_7,-1,-1,2,11860,-1
11862,sex-matched,4,5,23,34,Controls were age- and sex-matched non-PD patients referred to the cardiology department.,18560792_8,-1,-1,2,11862,-1
11867,n=2.4+/-0.7,6,7,31,42,"The number of affected valves (n=2.4+/-0.7) and the sum of regurgitation grades (n=2.8+/-1.09) were higher (p=0.008 and p=0.006, respectively) in the pergolide group.",18560792_10,-1,-1,2,11867,-1
11881,treated with,13,15,89,101,This study supports the high frequency of restrictive valve regurgitation in PD patients treated with pergolide and reveals that a significant improvement is usual when the treatment is converted to non-ergot dopamine agonists.,18560792_14,-1,-1,2,11881,-1
11891,adverse immune-mediated reaction,7,10,45,77,"Heparin-induced thrombocytopenia (HIT) is an adverse immune-mediated reaction to heparin, resulting in platelet count decreases of more than 50%.",18589141_2,-1,-1,2,11891,-1
11892,platelet count,15,17,103,117,"Heparin-induced thrombocytopenia (HIT) is an adverse immune-mediated reaction to heparin, resulting in platelet count decreases of more than 50%.",18589141_2,-1,-1,2,11892,-1
11897,IU/kg/h,5,6,20,27,"We started LMWH (25 IU/kg/h) on postoperative day (POD) 1, switching to UFH (5000 U/d) on POD 2 or 3.",18589141_5,-1,-1,2,11897,-1
11899,U/d,20,21,82,85,"We started LMWH (25 IU/kg/h) on postoperative day (POD) 1, switching to UFH (5000 U/d) on POD 2 or 3.",18589141_5,-1,-1,2,11899,-1
11901,clotting time,10,12,55,68,The dose of UFH was changed according to the activated clotting time level.,18589141_6,-1,-1,2,11901,-1
11902,Platelet count,0,2,0,14,Platelet count was measured daily for 3 weeks.,18589141_8,-1,-1,2,11902,-1
11903,average platelet counts,3,6,13,36,"RESULTS: The average platelet counts preoperatively, and on POD 7, 14, and 21 were 65, 88, 149, and 169 x 10(9)/L, respectively.",18589141_9,-1,-1,2,11903,-1
11904,preoperatively,6,7,37,51,"RESULTS: The average platelet counts preoperatively, and on POD 7, 14, and 21 were 65, 88, 149, and 169 x 10(9)/L, respectively.",18589141_9,-1,-1,2,11904,-1
11906,antibody-negative,18,19,104,121,"Two patients developed hepatic artery thrombosis on POD 11 and 19, respectively, although they were HIT antibody-negative and their platelet counts were stable.",18589141_10,-1,-1,2,11906,-1
11907,platelet counts,21,23,132,147,"Two patients developed hepatic artery thrombosis on POD 11 and 19, respectively, although they were HIT antibody-negative and their platelet counts were stable.",18589141_10,-1,-1,2,11907,-1
11908,platelet count,6,8,25,39,"In 2 other patients, the platelet count decreased suddenly from 107 x 10(9)/L on POD 4 to 65 x 10(9)/L on POD 6 and from 76 x 10(9)/L on POD 7 to 33 x 10(9)/L on POD 9, respectively.",18589141_11,-1,-1,2,11908,-1
11910,antibody-positive,4,5,22,39,"The percentage of HIT antibody-positive patients was 0.5% preoperatively, 5.6% on POD 7, and 5.6% on POD 14.",18589141_13,-1,-1,2,11910,-1
11911,preoperatively,9,10,58,72,"The percentage of HIT antibody-positive patients was 0.5% preoperatively, 5.6% on POD 7, and 5.6% on POD 14.",18589141_13,-1,-1,2,11911,-1
11913,UFH-related,5,6,40,51,None of the subjects/patients developed UFH-related HIT.,18589141_14,-1,-1,2,11913,-1
11915,pathogenic role,6,8,58,73,Adriamycin-induced autophagic cardiomyocyte death plays a pathogenic role in a rat model of heart failure.,18619688_0,-1,-1,2,11915,-1
11935,mitochondrial,12,13,62,75,"We then examined the morphology, expression of beclin 1 gene, mitochondrial permeability transition (MPT), and Na+-K+ ATPase activity in vivo.",18619688_5,0,1,2,11935,-1
11936,MPT,16,17,101,104,"We then examined the morphology, expression of beclin 1 gene, mitochondrial permeability transition (MPT), and Na+-K+ ATPase activity in vivo.",18619688_5,-1,-1,2,11936,-1
11939,in vivo,23,25,134,141,"We then examined the morphology, expression of beclin 1 gene, mitochondrial permeability transition (MPT), and Na+-K+ ATPase activity in vivo.",18619688_5,-1,-1,2,11939,-1
11942,autophagic,12,13,86,96,"We also assessed cell viability, mitochondrial membrane potential changes and counted autophagic vacuoles in cultured cardiomyocytes.",18619688_6,-1,-1,2,11942,-1
11944,autophagy,8,9,43,52,"In addition, we analyzed the expression of autophagy associated gene, beclin 1 using RT-PCR and Western blotting in an animal model.",18619688_7,-1,-1,2,11944,-1
11948,Western blotting,17,19,96,112,"In addition, we analyzed the expression of autophagy associated gene, beclin 1 using RT-PCR and Western blotting in an animal model.",18619688_7,-1,-1,2,11948,-1
11965,autophagy pathway,16,18,102,119,Mitochondrial injury may be involved in the progression of heart failure caused by adriamycin via the autophagy pathway.,18619688_11,-1,-1,2,11965,-1
11975,knockout mice,23,25,123,136,"To elucidate the possible role of the kinin B1 receptor (B1R) during the development of DOX cardiomyopathy, we studied B1R knockout mice (B1R(-/-)) by investigating cardiac inflammation and apoptosis after induction of DOX-induced cardiomyopathy.",18627295_2,-1,-1,2,11975,-1
11980,pressure-volume loops,8,10,56,77,DOX control mice showed cardiac dysfunction measured by pressure-volume loops in vivo.,18627295_3,-1,-1,2,11980,-1
11981,in vivo,10,12,78,85,DOX control mice showed cardiac dysfunction measured by pressure-volume loops in vivo.,18627295_3,-1,-1,2,11981,-1
11982,associated with,2,4,9,24,"This was associated with a reduced activation state of AKT, as well as an increased bax/bcl2 ratio in Western blots, indicating cardiac apoptosis.",18627295_4,-1,-1,2,11982,-1
11983,activation state,6,8,35,51,"This was associated with a reduced activation state of AKT, as well as an increased bax/bcl2 ratio in Western blots, indicating cardiac apoptosis.",18627295_4,-1,-1,2,11983,-1
11985,Western blots,19,21,102,115,"This was associated with a reduced activation state of AKT, as well as an increased bax/bcl2 ratio in Western blots, indicating cardiac apoptosis.",18627295_4,-1,-1,2,11985,-1
11988,DOX B1R(-/-) mice,1,5,3,20,"In DOX B1R(-/-) mice, cardiac dysfunction was improved compared to DOX control mice, which was associated with normalization of the bax/bcl-2 ratio and interleukin 6, as well as AKT activation state.",18627295_6,-1,-1,2,11988,-1
11991,associated with,18,20,95,110,"In DOX B1R(-/-) mice, cardiac dysfunction was improved compared to DOX control mice, which was associated with normalization of the bax/bcl-2 ratio and interleukin 6, as well as AKT activation state.",18627295_6,-1,-1,2,11991,-1
11995,activation state,33,35,182,198,"In DOX B1R(-/-) mice, cardiac dysfunction was improved compared to DOX control mice, which was associated with normalization of the bax/bcl-2 ratio and interleukin 6, as well as AKT activation state.",18627295_6,-1,-1,2,11995,-1
12000,inhibitors-induced proteinuria,1,3,5,35,"mToR inhibitors-induced proteinuria: mechanisms, significance, and management.",18631865_0,-1,-1,2,12000,-1
12010,consequence of,9,11,51,65,Whether proteinuria was due to sirolimus or only a consequence of calcineurin inhibitors withdrawal remained unsolved until high range proteinuria has been observed during sirolimus therapy in islet transplantation and in patients who received sirolimus de novo.,18631865_3,-1,-1,2,12010,-1
12018,blockade-induced proteinuria,11,13,71,99,We discuss herein the possible mechanisms and the significance of mToR blockade-induced proteinuria.,18631865_5,-1,-1,2,12018,-1
12021,Penicillin model,0,2,0,16,Penicillin model is a widely used experimental model for epilepsy research.,18657397_1,-1,-1,2,12021,-1
12022,experimental model,6,8,34,52,Penicillin model is a widely used experimental model for epilepsy research.,18657397_1,-1,-1,2,12022,-1
12023,spectral analysis,10,12,52,69,In the present study we aimed to portray a detailed spectral analysis of penicillin-induced epileptiform activity in comparison with basal brain activity in anesthetized Wistar rats.,18657397_2,-1,-1,2,12023,-1
12025,basal brain activity,19,22,133,153,In the present study we aimed to portray a detailed spectral analysis of penicillin-induced epileptiform activity in comparison with basal brain activity in anesthetized Wistar rats.,18657397_2,-1,-1,2,12025,-1
12026,Wistar rats,24,26,170,181,In the present study we aimed to portray a detailed spectral analysis of penicillin-induced epileptiform activity in comparison with basal brain activity in anesthetized Wistar rats.,18657397_2,-1,-1,2,12026,-1
12029,electrocorticogram,13,14,74,92,Male Wistar rats were anesthetized with i.p. urethane and connected to an electrocorticogram setup.,18657397_3,-1,-1,2,12029,-1
12038,conventional methods,16,18,117,137,"Basal activity, latent period and the penicillin-induced epileptiform activity periods were then analyzed using both conventional methods and spectral analysis.",18657397_5,-1,-1,2,12038,-1
12039,spectral analysis,19,21,142,159,"Basal activity, latent period and the penicillin-induced epileptiform activity periods were then analyzed using both conventional methods and spectral analysis.",18657397_5,-1,-1,2,12039,-1
12042,frequency bands,11,13,79,94,"Spectral analyses were conducted by dividing the whole spectrum into different frequency bands including delta, theta (slow and fast), alpha-sigma, beta (1 and 2) and gamma (1 and 2) bands.",18657397_6,-1,-1,2,12042,-1
12046,frequency bands,7,9,40,55,"Our results show that the most affected frequency bands were delta, theta, beta-2 and gamma-2 bands during the epileptiform activity and there were marked differences in terms of spectral densities between three investigated episodes (basal activity, latent period and epileptiform activity).",18657397_7,-1,-1,2,12046,-1
12050,spectral densities,30,32,179,197,"Our results show that the most affected frequency bands were delta, theta, beta-2 and gamma-2 bands during the epileptiform activity and there were marked differences in terms of spectral densities between three investigated episodes (basal activity, latent period and epileptiform activity).",18657397_7,-1,-1,2,12050,-1
12053,experimental models,11,13,66,85,Our results may help to analyze novel data obtained using similar experimental models and the simple analysis method described here can be used in similar studies to investigate the basic neuronal mechanism of this or other types of experimental epilepsies.,18657397_8,-1,-1,2,12053,-1
12054,simple analysis method,15,18,94,116,Our results may help to analyze novel data obtained using similar experimental models and the simple analysis method described here can be used in similar studies to investigate the basic neuronal mechanism of this or other types of experimental epilepsies.,18657397_8,-1,-1,2,12054,-1
12065,therapeutic users,8,10,51,68,"The incidence calculation revealed that one of 215 therapeutic users had reactions, compared with one of 13,000 in the prophylaxis group, making the risk of neuropsychiatric reactions after mefloquine treatment 60 times higher than after prophylaxis.",1867351_5,-1,-1,2,12065,-1
12079,upregulated,21,22,156,167,"This cardioprotection is accompanied by decreased cardiac oxidative stress and triglycerides and increased cardiac fatty-acid oxidation, ATP synthesis, and upregulated JAK/STAT3 pathway.",18674790_3,-1,-1,2,12079,-1
12081,high fat diet,15,18,90,103,"In the current study, we investigated whether a physiological intervention by feeding 40% high fat diet (HFD), which induces obesity in male Sprague-Dawley rats (250-275 g), sensitizes to doxorubicin-induced cardiotoxicity.",18674790_4,-1,-1,2,12081,-1
12082,HFD,19,20,105,108,"In the current study, we investigated whether a physiological intervention by feeding 40% high fat diet (HFD), which induces obesity in male Sprague-Dawley rats (250-275 g), sensitizes to doxorubicin-induced cardiotoxicity.",18674790_4,-1,-1,2,12082,-1
12083,male Sprague-Dawley rats,26,29,136,160,"In the current study, we investigated whether a physiological intervention by feeding 40% high fat diet (HFD), which induces obesity in male Sprague-Dawley rats (250-275 g), sensitizes to doxorubicin-induced cardiotoxicity.",18674790_4,-1,-1,2,12083,-1
12092,no change,4,6,44,53,Doxorubicin toxicokinetics studies revealed no change in accumulation of doxorubicin and doxorubicinol (toxic metabolite) in the normal diet-fed (ND) and OB hearts.,18674790_6,-1,-1,2,12092,-1
12095,normal diet-fed,18,20,129,144,Doxorubicin toxicokinetics studies revealed no change in accumulation of doxorubicin and doxorubicinol (toxic metabolite) in the normal diet-fed (ND) and OB hearts.,18674790_6,-1,-1,2,12095,-1
12096,Mechanistic studies,0,2,0,19,"Mechanistic studies revealed that OB rats are sensitized due to: (1) higher oxyradical stress leading to upregulation of uncoupling proteins 2 and 3, (2) downregulation of cardiac peroxisome proliferators activated receptor-alpha, (3) decreased plasma adiponectin levels, (4) decreased cardiac fatty-acid oxidation (666.9+/-14.0 nmol/min/g heart in ND versus 400.2+/-11.8 nmol/min/g heart in OB), (5) decreased mitochondrial AMP-alpha2 protein kinase, and (6) 86% drop in cardiac ATP levels accompanied by decreased ATP/ADP ratio after doxorubicin administration.",18674790_7,-1,-1,2,12096,-1
12099,upregulation,19,20,105,117,"Mechanistic studies revealed that OB rats are sensitized due to: (1) higher oxyradical stress leading to upregulation of uncoupling proteins 2 and 3, (2) downregulation of cardiac peroxisome proliferators activated receptor-alpha, (3) decreased plasma adiponectin levels, (4) decreased cardiac fatty-acid oxidation (666.9+/-14.0 nmol/min/g heart in ND versus 400.2+/-11.8 nmol/min/g heart in OB), (5) decreased mitochondrial AMP-alpha2 protein kinase, and (6) 86% drop in cardiac ATP levels accompanied by decreased ATP/ADP ratio after doxorubicin administration.",18674790_7,-1,-1,2,12099,-1
12100,downregulation,30,31,154,168,"Mechanistic studies revealed that OB rats are sensitized due to: (1) higher oxyradical stress leading to upregulation of uncoupling proteins 2 and 3, (2) downregulation of cardiac peroxisome proliferators activated receptor-alpha, (3) decreased plasma adiponectin levels, (4) decreased cardiac fatty-acid oxidation (666.9+/-14.0 nmol/min/g heart in ND versus 400.2+/-11.8 nmol/min/g heart in OB), (5) decreased mitochondrial AMP-alpha2 protein kinase, and (6) 86% drop in cardiac ATP levels accompanied by decreased ATP/ADP ratio after doxorubicin administration.",18674790_7,-1,-1,2,12100,-1
12103,plasma adiponectin,42,44,245,263,"Mechanistic studies revealed that OB rats are sensitized due to: (1) higher oxyradical stress leading to upregulation of uncoupling proteins 2 and 3, (2) downregulation of cardiac peroxisome proliferators activated receptor-alpha, (3) decreased plasma adiponectin levels, (4) decreased cardiac fatty-acid oxidation (666.9+/-14.0 nmol/min/g heart in ND versus 400.2+/-11.8 nmol/min/g heart in OB), (5) decreased mitochondrial AMP-alpha2 protein kinase, and (6) 86% drop in cardiac ATP levels accompanied by decreased ATP/ADP ratio after doxorubicin administration.",18674790_7,-1,-1,2,12103,-1
12106,mitochondrial,71,72,411,424,"Mechanistic studies revealed that OB rats are sensitized due to: (1) higher oxyradical stress leading to upregulation of uncoupling proteins 2 and 3, (2) downregulation of cardiac peroxisome proliferators activated receptor-alpha, (3) decreased plasma adiponectin levels, (4) decreased cardiac fatty-acid oxidation (666.9+/-14.0 nmol/min/g heart in ND versus 400.2+/-11.8 nmol/min/g heart in OB), (5) decreased mitochondrial AMP-alpha2 protein kinase, and (6) 86% drop in cardiac ATP levels accompanied by decreased ATP/ADP ratio after doxorubicin administration.",18674790_7,0,1,2,12106,-1
12111,downregulated,7,8,61,74,Decreased cardiac erythropoietin and increased SOCS3 further downregulated the cardioprotective JAK/STAT3 pathway.,18674790_8,-1,-1,2,12111,-1
12117,mitochondrial ATP,16,18,138,155,"In conclusion, HFD-induced obese rats are highly sensitized to doxorubicin-induced cardiotoxicity by substantially downregulating cardiac mitochondrial ATP generation, increasing oxidative stress and downregulating the JAK/STAT3 pathway.",18674790_9,-1,-1,2,12117,-1
12119,downregulating,24,25,200,214,"In conclusion, HFD-induced obese rats are highly sensitized to doxorubicin-induced cardiotoxicity by substantially downregulating cardiac mitochondrial ATP generation, increasing oxidative stress and downregulating the JAK/STAT3 pathway.",18674790_9,-1,-1,2,12119,-1
12124,animal model,9,11,40,52,The goal of these studies was to use an animal model to examine the effects of prenatal protein deprivation on behaviors and receptor binding with relevance to schizophrenia.,18703024_2,-1,-1,2,12124,-1
12125,receptor binding,22,24,125,141,The goal of these studies was to use an animal model to examine the effects of prenatal protein deprivation on behaviors and receptor binding with relevance to schizophrenia.,18703024_2,-1,-1,2,12125,-1
12126,stereotypic response,14,16,80,100,We report that prenatally protein deprived (PD) female rats showed an increased stereotypic response to apomorphine and an increased locomotor response to amphetamine in adulthood.,18703024_3,-1,-1,2,12126,-1
12127,locomotor response,21,23,133,151,We report that prenatally protein deprived (PD) female rats showed an increased stereotypic response to apomorphine and an increased locomotor response to amphetamine in adulthood.,18703024_3,-1,-1,2,12127,-1
12147,adverse effect,11,13,84,98,This study supports previous reports and provides neurophysiological evidence of an adverse effect on the auditory nerve.,18726058_3,-1,-1,2,12147,-1
12159,BAEPs,5,6,38,43,Brainstem auditory evoked potentials (BAEPs) were routinely used to monitor cochlear nerve function during these operations.,18726058_7,-1,-1,2,12159,-1
12173,associated with,10,12,67,82,CONCLUSIONS: Topical papaverine for the treatment of vasospasm was associated with the onset of a transient disturbance in neurophysiological function of the ascending auditory brainstem pathway.,18726058_14,-1,-1,2,12173,-1
12179,adverse effect,14,16,98,112,The complete disappearance of BAEP waveforms with a consistent temporal delay suggests a possible adverse effect on the proximal eighth nerve.,18726058_15,-1,-1,2,12179,-1
12191,Hispanic woman,4,6,26,40,We describe a 70-year-old Hispanic woman who developed fulminant hepatic failure necessitating liver transplantation 10 weeks after conversion from simvastatin 40 mg/day to simvastatin 10 mg-ezetimibe 40 mg/day.,18752389_3,-1,-1,2,12191,-1
12197,lipid panel,3,5,14,25,The patient's lipid panel had been maintained with simvastatin for 18 months before the conversion without evidence of hepatotoxicity.,18752389_4,-1,-1,2,12197,-1
12241,normal range,9,11,60,72,"Urinary volume and serum creatinine levels recovered to the normal range, with urinary protein disappearing completely within 40 days.",18754075_4,-1,-1,2,12241,-1
12244,Serum-,0,1,0,6,Serum- and glucocorticoid-inducible kinase 1 in doxorubicin-induced nephrotic syndrome.,18768591_0,-1,-1,2,12244,-1
12258,gene-targeted mice lacking,15,18,76,102,"To this end, doxorubicin (15 mug/g body wt) was injected intravenously into gene-targeted mice lacking SGK1 (sgk1(-/-)) and their wild-type littermates (sgk1(+/+)).",18768591_4,-1,-1,2,12258,-1
12261,wild-type littermates,25,27,130,151,"To this end, doxorubicin (15 mug/g body wt) was injected intravenously into gene-targeted mice lacking SGK1 (sgk1(-/-)) and their wild-type littermates (sgk1(+/+)).",18768591_4,-1,-1,2,12261,-1
12263,heavy proteinuria,4,6,34,51,"Doxorubicin treatment resulted in heavy proteinuria (>100 mg protein/mg crea) in 15/44 of sgk1(+/+) and 15/44 of sgk1(-/-) mice leading to severe nephrotic syndrome with ascites, lipidemia, and hypoalbuminemia in both genotypes.",18768591_5,-1,-1,2,12263,-1
12271,sgk1(+/+) mice,19,22,129,143,Plasma aldosterone levels increased in nephrotic mice of both genotypes and was followed by increased SGK1 protein expression in sgk1(+/+) mice.,18768591_6,-1,-1,2,12271,-1
12273,sgk1(+/+) mice,8,11,62,76,Urinary sodium excretion reached signficantly lower values in sgk1(+/+) mice (15 +/- 5 mumol/mg crea) than in sgk1(-/-) mice (35 +/- 5 mumol/mg crea) and was associated with a significantly higher body weight gain in sgk1(+/+) compared with sgk1(-/-) mice (+6.6 +/- 0.7 vs. +4.1 +/- 0.8 g).,18768591_7,-1,-1,2,12273,-1
12277,associated with,34,36,158,173,Urinary sodium excretion reached signficantly lower values in sgk1(+/+) mice (15 +/- 5 mumol/mg crea) than in sgk1(-/-) mice (35 +/- 5 mumol/mg crea) and was associated with a significantly higher body weight gain in sgk1(+/+) compared with sgk1(-/-) mice (+6.6 +/- 0.7 vs. +4.1 +/- 0.8 g).,18768591_7,-1,-1,2,12277,-1
12285,significantly faster,11,13,77,97,"During the course of nephrotic syndrome, serum urea concentrations increased significantly faster in sgk1(-/-) mice than in sgk1(+/+) mice leading to uremia and a reduced median survival in sgk1(-/-) mice (29 vs. 40 days in sgk1(+/+) mice).",18768591_8,-1,-1,2,12285,-1
12289,sgk1(+/+) mice,40,43,224,238,"During the course of nephrotic syndrome, serum urea concentrations increased significantly faster in sgk1(-/-) mice than in sgk1(+/+) mice leading to uremia and a reduced median survival in sgk1(-/-) mice (29 vs. 40 days in sgk1(+/+) mice).",18768591_8,-1,-1,2,12289,-1
12290,gene-targeted mice lacking,3,6,15,41,"In conclusion, gene-targeted mice lacking SGK1 showed blunted volume retention, yet were not protected against renal fibrosis during experimental nephrotic syndrome.",18768591_9,-1,-1,2,12290,-1
12296,associated with,5,7,47,62,Severe thrombocytopenia and haemolytic anaemia associated with ciprofloxacin: a case report with fatal outcome.,18791946_0,-1,-1,2,12296,-1
12307,supportive interventions,3,5,28,52,"Despite pharmacological and supportive interventions, laboratory parameters worsened and the patient died 17 hours after admission.",18791946_5,-1,-1,2,12307,-1
12315,bacterial growth,8,10,42,58,Blood and urine cultures did not show any bacterial growth.,18791946_9,-1,-1,2,12315,-1
12319,early phases,17,19,128,140,"This case report shows that ciprofloxacin may precipitate life-threatening thrombocytopenia and haemolytic anaemia, even in the early phases of treatment and without apparent previous exposures.",18791946_10,-1,-1,2,12319,-1
12330,contractile machinery,22,24,145,166,"Taking into account that the sarcolemmal integrity is stabilized by the dystrophin-glycoprotein complex (DGC) that connects actin and laminin in contractile machinery and extracellular matrix and by integrins, this study tests the hypothesis that isoproterenol affects sarcolemmal stability through changes in the DGC and integrins.",18808529_3,-1,-1,2,12330,-1
12338,subcutaneous administration,11,13,72,99,We found different sensitivity of the DGC and integrin to isoproterenol subcutaneous administration.,18808529_4,-1,-1,2,12338,-1
12339,Immunofluorescent staining,0,2,0,26,Immunofluorescent staining revealed that dystrophin is the most sensitive among the structures connecting the actin in the cardiomyocyte cytoskeleton and the extracellular matrix.,18808529_5,-1,-1,2,12339,-1
12342,extracellular matrix,21,23,158,178,Immunofluorescent staining revealed that dystrophin is the most sensitive among the structures connecting the actin in the cardiomyocyte cytoskeleton and the extracellular matrix.,18808529_5,-1,-1,2,12342,-1
12353,extracellular matrix,29,31,179,199,"In conclusion, administration of isoproterenol to rats results in primary loss of dystrophin, the most sensitive among the structural proteins that form the DGC that connects the extracellular matrix and the cytoskeleton in cardiomyocyte.",18808529_8,-1,-1,2,12353,-1
12369,in vitro model,3,6,11,25,"We used an in vitro model of chemotherapy induced peripheral neuropathy that closely mimic the in vivo condition by exposing primary cultures of dorsal root ganglion (DRG) sensory neurons to paclitaxel and cisplatin, two widely used and highly effective chemotherapeutic drugs.",18809400_2,-1,-1,2,12369,-1
12371,in vivo,15,17,95,102,"We used an in vitro model of chemotherapy induced peripheral neuropathy that closely mimic the in vivo condition by exposing primary cultures of dorsal root ganglion (DRG) sensory neurons to paclitaxel and cisplatin, two widely used and highly effective chemotherapeutic drugs.",18809400_2,-1,-1,2,12371,-1
12372,primary cultures,20,22,125,141,"We used an in vitro model of chemotherapy induced peripheral neuropathy that closely mimic the in vivo condition by exposing primary cultures of dorsal root ganglion (DRG) sensory neurons to paclitaxel and cisplatin, two widely used and highly effective chemotherapeutic drugs.",18809400_2,-1,-1,2,12372,-1
12382,exposure to,24,26,182,193,This approach allowed investigating the efficacy of alpha-lipoic acid in preventing axonal damage and apoptosis and the function and ultrastructural morphology of mitochondria after exposure to toxic agents and alpha-lipoic acid.,18809400_3,-1,-1,2,12382,-1
12388,autophagic vacuoles,20,22,145,164,Our results demonstrate that both cisplatin and paclitaxel cause early mitochondrial impairment with loss of membrane potential and induction of autophagic vacuoles in neurons.,18809400_4,-1,-1,2,12388,-1
12404,mitochondrial,9,10,72,85,"Alpha-lipoic acid protects sensory neurons through its anti-oxidant and mitochondrial regulatory functions, possibly inducing the expression of frataxin.",18809400_7,0,1,2,12404,-1
12408,clinical trials,23,25,179,194,These findings suggest that alpha-lipoic acid might reduce the risk of developing peripheral nerve toxicity in patients undergoing chemotherapy and encourage further confirmatory clinical trials.,18809400_8,-1,-1,2,12408,-1
12412,MHb,19,20,219,222,Toxicity in rhesus monkeys following administration of the 8-aminoquinoline 8-[(4-amino-l-methylbutyl)amino]- 5-(l-hexyloxy)-6-methoxy-4-methylquinoline (WR242511).INTRODUCTION: Many substances that form methemoglobin (MHb) effectively counter cyanide (CN) toxicity.,18821488_0,-1,-1,2,12412,-1
12414,MHb,1,2,9,12,"Although MHb formers are generally applied as treatments for CN poisoning, it has been proposed that a stable, long-acting MHb former could serve as a CN pretreatment.",18821488_1,-1,-1,2,12414,-1
12417,CN,27,28,151,153,"Although MHb formers are generally applied as treatments for CN poisoning, it has been proposed that a stable, long-acting MHb former could serve as a CN pretreatment.",18821488_1,-1,-1,2,12417,-1
12418,pretreatment,28,29,154,166,"Although MHb formers are generally applied as treatments for CN poisoning, it has been proposed that a stable, long-acting MHb former could serve as a CN pretreatment.",18821488_1,-1,-1,2,12418,-1
12421,beagle dogs,16,18,101,112,"Using this rationale, the 8-aminoquinoline WR242511, a potent long-lasting MHb former in rodents and beagle dogs, was studied in the rhesus monkey for advanced development as a potential CN pretreatment.",18821488_2,-1,-1,2,12421,-1
12430,MHb,3,4,18,21,Health status and MHb levels were monitored following exposure.,18821488_4,-1,-1,2,12430,-1
12434,MHb,24,25,162,165,"RESULTS: The selected doses of WR242511, which produced significant methemoglobinemia in beagle dogs in earlier studies conducted elsewhere, produced very little MHb (mean < 2.0%) in the rhesus monkey.",18821488_5,-1,-1,2,12434,-1
12440,orally-treated,19,20,116,130,"Histopathology analyses in the 2 animals that died revealed liver and kidney toxicity, with greater severity in the orally-treated animal.",18821488_8,-1,-1,2,12440,-1
12443,pretreatment,11,12,57,69,It is concluded that WR242511 should not be pursued as a pretreatment for CN poisoning unless the anti-CN characteristics of this compound can be successfully dissociated from those producing undesirable toxicity.,18821488_10,-1,-1,2,12443,-1
12444,CN,13,14,74,76,It is concluded that WR242511 should not be pursued as a pretreatment for CN poisoning unless the anti-CN characteristics of this compound can be successfully dissociated from those producing undesirable toxicity.,18821488_10,-1,-1,2,12444,-1
12445,Etiologic factors,0,2,0,17,Etiologic factors in the pathogenesis of liver tumors associated with oral contraceptives.,188339_0,-1,-1,2,12445,-1
12447,associated with,8,10,54,69,Etiologic factors in the pathogenesis of liver tumors associated with oral contraceptives.,188339_0,-1,-1,2,12447,-1
12452,Associated with,5,7,30,45,"The Registry for Liver Tumors Associated with Oral Contraceptives at the University of California, Irvine, has clearly identified 27 cases.",188339_2,-1,-1,2,12452,-1
12459,uninterrupted usage,6,8,60,79,Significant statistical etiologic factors include prolonged uninterrupted usage of oral contraceptive steroids.,188339_5,-1,-1,2,12459,-1
12467,crossover study,6,8,41,56,"In a placebo-controlled, single-blinded, crossover study, we assessed the effect of ""real"" repetitive transcranial magnetic stimulation (rTMS) versus ""sham"" rTMS (placebo) on peak dose dyskinesias in patients with Parkinson's disease (PD).",18951540_1,-1,-1,2,12467,-1
12470,rTMS,28,29,157,161,"In a placebo-controlled, single-blinded, crossover study, we assessed the effect of ""real"" repetitive transcranial magnetic stimulation (rTMS) versus ""sham"" rTMS (placebo) on peak dose dyskinesias in patients with Parkinson's disease (PD).",18951540_1,-1,-1,2,12470,-1
12474,real stimuli,29,31,149,161,"Ten patients with PD and prominent dyskinesias had rTMS (1,800 pulses; 1 Hz rate) delivered over the motor cortex for 4 consecutive days twice, once real stimuli and once sham stimulation were used; evaluations were done at the baseline and 1 day after the end of each of the treatment series.",18951540_2,-1,-1,2,12474,-1
12476,real rTMS,5,7,35,44,Direct comparison between sham and real rTMS effects showed no significant difference in clinician-assessed dyskinesia severity.,18951540_3,-1,-1,2,12476,-1
12477,no significant,9,11,60,74,Direct comparison between sham and real rTMS effects showed no significant difference in clinician-assessed dyskinesia severity.,18951540_3,-1,-1,2,12477,-1
12480,subscore,6,7,33,41,The major effect was on dystonia subscore.,18951540_5,-1,-1,2,12480,-1
12482,real rTMS,33,35,205,214,"Similarly, in patient diaries, although both treatments caused reduction in subjective dyskinesia scores during the days of intervention, the effect was sustained for 3 days after the intervention for the real rTMS only.",18951540_6,-1,-1,2,12482,-1
12483,rTMS,1,2,10,14,"Following rTMS, no side effects and no adverse effects on motor function and PD symptoms were noted.",18951540_7,-1,-1,2,12483,-1
12487,low-frequency,15,16,116,129,The results suggest the existence of residual beneficial clinical aftereffects of consecutive daily applications of low-frequency rTMS on dyskinesias in PD.,18951540_8,-1,-1,2,12487,-1
12492,phase I trial,1,4,2,15,A phase I trial of a 14-day cycle.,1899352_1,-1,-1,2,12492,-1
12499,mg/m2/d,16,17,67,74,"Dose escalations proceeded from 200 to 300, 400, 450, 500, and 550 mg/m2/d.",1899352_4,-1,-1,2,12499,-1
12500,mg/m2/d,13,14,77,84,"Four patients developed transient microscopic hematuria at 400, 450, and 500 mg/m2/d.",1899352_5,-1,-1,2,12500,-1
12502,mg/m2/d,2,3,7,14,"At 550 mg/m2/d, three patients experienced nonurologic toxicity; confusion (1), nausea (1), and Grade 2 leukopenia (1).",1899352_7,-1,-1,2,12502,-1
12509,mg/m2/d,5,6,28,35,"The recommended dose of 500 mg/m2/d delivers a total dose of 7 g/m2 per cycle, which is comparable to that delivered in clinical practice for bolus or short-term infusion.",1899352_8,-1,-1,2,12509,-1
12517,infusion schedule,2,4,15,32,The protracted infusion schedule for ifosfamide permits convenient outpatient administration without Mesna and reduces the drug cost of clinical usage of this agent by up to  890 per cycle.,1899352_11,-1,-1,2,12517,-1
12521,clinical usage,18,20,136,150,The protracted infusion schedule for ifosfamide permits convenient outpatient administration without Mesna and reduces the drug cost of clinical usage of this agent by up to  890 per cycle.,1899352_11,-1,-1,2,12521,-1
12526,clinical effectiveness,29,31,184,206,"Clinical activity was demonstrated in a single patient, but a comparative trial of standard bolus schedules with the protracted infusion schedule will be necessary to determine if the clinical effectiveness of the drug is maintained.",1899352_12,-1,-1,2,12526,-1
12531,Emergency Department (,13,16,71,93,"A 45-year-old man, an admitted frequent cocaine user, presented to the Emergency Department (ED) on two separate occasions with a history of priapism after cocaine use.",18996674_2,-1,-1,2,12531,-1
12533,management options,1,3,4,22,"The management options in the ED, as exemplified by four individual case reports, in particular the use of a minimally invasive method of intracorporal epinephrine instillation, are discussed.",18996674_3,-1,-1,2,12533,-1
12534,case reports,12,14,68,80,"The management options in the ED, as exemplified by four individual case reports, in particular the use of a minimally invasive method of intracorporal epinephrine instillation, are discussed.",18996674_3,-1,-1,2,12534,-1
12535,minimally invasive method,21,24,109,134,"The management options in the ED, as exemplified by four individual case reports, in particular the use of a minimally invasive method of intracorporal epinephrine instillation, are discussed.",18996674_3,-1,-1,2,12535,-1
12537,pretreatment,8,9,54,66,A case of ventricular tachycardia related to caffeine pretreatment.,18997632_0,-1,-1,2,12537,-1
12539,electroconvulsive therapy practice,7,10,55,89,"Suboptimal seizure duration is commonly encountered in electroconvulsive therapy practice, especially in older patients with higher seizure thresholds.",18997632_1,-1,-1,2,12539,-1
12540,occasional reports,21,23,138,156,Intravenous caffeine is commonly used to improve seizure duration and quality in such patients and is generally well tolerated aside from occasional reports of relatively benign ventricular ectopy.,18997632_2,-1,-1,2,12540,-1
12546,Prophylactic use,0,2,0,16,Prophylactic use of lamivudine with chronic immunosuppressive therapy for rheumatologic disorders.,19037603_0,-1,-1,2,12546,-1
12547,chronic immunosuppressive therapy,5,8,36,69,Prophylactic use of lamivudine with chronic immunosuppressive therapy for rheumatologic disorders.,19037603_0,-1,-1,2,12547,-1
12560,HBV,3,4,17,20,In four patients HBV DNA levels were higher than normal at baseline.,19037603_8,-1,-1,2,12560,-1
12561,clinical sings,6,8,37,51,None of the patients had significant clinical sings of HBV activation.,19037603_11,-1,-1,2,12561,-1
12562,HBV,9,10,55,58,None of the patients had significant clinical sings of HBV activation.,19037603_11,-1,-1,2,12562,-1
12565,HBV,21,22,154,157,"Prophylactic administration of lamivudine in patients who required immunosuppressive therapy seems to be safe, well tolerated and effective in preventing HBV reactivation.",19037603_13,-1,-1,2,12565,-1
12581,albino rats,2,4,11,22,"Adult male albino rats, treated with ISO (200 mg/kg, s.c.) for 2 days at an interval of 24 h caused a significant (P<0.05) elevation of heart weight, serum marker enzymes, lipid peroxidation and Ca+2 ATPase level whereas there was a significant (P<0.05) decrease in body weight, endogenous antioxidants, Na+/ K+ ATPase and Mg+2 ATPase levels.",19058010_2,-1,-1,2,12581,-1
12582,treated with,5,7,24,36,"Adult male albino rats, treated with ISO (200 mg/kg, s.c.) for 2 days at an interval of 24 h caused a significant (P<0.05) elevation of heart weight, serum marker enzymes, lipid peroxidation and Ca+2 ATPase level whereas there was a significant (P<0.05) decrease in body weight, endogenous antioxidants, Na+/ K+ ATPase and Mg+2 ATPase levels.",19058010_2,-1,-1,2,12582,-1
12618,fruit juices,14,16,87,99,"We propose that naturally occurring compounds such as flavonoids, which are present in fruit juices, may increase the potency of warfarin by competing for the enzymes that normally inactivate warfarin.",19058474_2,-1,-1,2,12618,-1
12638,convulsing mice,28,30,145,160,RESULTS: The results showed that IP administration of bupropion HCl 120 mg/kg by bolus injection induced convulsions in 6 out of 10 mice (60% of convulsing mice) in group 1.,19105845_7,-1,-1,2,12638,-1
12639,group 1,32,34,165,172,RESULTS: The results showed that IP administration of bupropion HCl 120 mg/kg by bolus injection induced convulsions in 6 out of 10 mice (60% of convulsing mice) in group 1.,19105845_7,-1,-1,2,12639,-1
12641,infusion time,5,7,43,56,Logistic regression analysis revealed that infusion time was significant (p = 0.0004; odds ratio = 0.974) and increasing the IP infusion time of bupropion HCl 120 mg/kg was associated with a 91% reduced odds of convulsions at infusion times of 15 to 90 min compared to bolus injection.,19105845_8,-1,-1,2,12641,-1
12644,associated with,31,33,173,188,Logistic regression analysis revealed that infusion time was significant (p = 0.0004; odds ratio = 0.974) and increasing the IP infusion time of bupropion HCl 120 mg/kg was associated with a 91% reduced odds of convulsions at infusion times of 15 to 90 min compared to bolus injection.,19105845_8,-1,-1,2,12644,-1
12645,bolus injection,50,52,269,284,Logistic regression analysis revealed that infusion time was significant (p = 0.0004; odds ratio = 0.974) and increasing the IP infusion time of bupropion HCl 120 mg/kg was associated with a 91% reduced odds of convulsions at infusion times of 15 to 90 min compared to bolus injection.,19105845_8,-1,-1,2,12645,-1
12646,infusion time,3,5,20,33,Further increase in infusion time resulted in further reduction in the odds of convulsions to 99.8% reduction at 240 min.,19105845_9,-1,-1,2,12646,-1
12649,prospective study,29,31,171,188,"CONCLUSION: In conclusion, the demonstration of an inverse relationship between infusion time of a fixed and convulsive dose of bupropion and the risk of convulsions in a prospective study is novel.",19105845_10,-1,-1,2,12649,-1
12652,associated with,8,10,72,87,Graft-versus-host disease prophylaxis with everolimus and tacrolimus is associated with a high incidence of sinusoidal obstruction syndrome and microangiopathy: results of the EVTAC trial.,19135948_0,-1,-1,2,12652,-1
12655,EVTAC trial,23,25,176,187,Graft-versus-host disease prophylaxis with everolimus and tacrolimus is associated with a high incidence of sinusoidal obstruction syndrome and microangiopathy: results of the EVTAC trial.,19135948_0,-1,-1,2,12655,-1
12658,GVHD,14,15,110,114,A calcineurin inhibitor combined with methotrexate is the standard prophylaxis for graft-versus-host disease (GVHD) after allogeneic hematopoietic stem cell transplantation (HSCT).,19135948_1,-1,-1,2,12658,-1
12660,HSCT,23,24,174,178,A calcineurin inhibitor combined with methotrexate is the standard prophylaxis for graft-versus-host disease (GVHD) after allogeneic hematopoietic stem cell transplantation (HSCT).,19135948_1,-1,-1,2,12660,-1
12669,AML,35,36,172,175,"We report on a combination of everolimus and tacrolimus in 24 patients (median age, 62 years) with either myelodysplastic syndrome (MDS; n = 17) or acute myeloid leukemia (AML; n = 7) undergoing intensive conditioning followed by HSCT from related (n = 4) or unrelated (n = 20) donors.",19135948_3,-1,-1,2,12669,-1
12673,acute grade II-IV GVHD,7,11,30,52,"Nine patients (37%) developed acute grade II-IV GVHD, and 11 of 17 evaluable patients (64%) developed chronic extensive GVHD.",19135948_5,-1,-1,2,12673,-1
12674,chronic extensive GVHD,23,26,102,124,"Nine patients (37%) developed acute grade II-IV GVHD, and 11 of 17 evaluable patients (64%) developed chronic extensive GVHD.",19135948_5,-1,-1,2,12674,-1
12676,TMA,3,4,44,47,"Transplantation-associated microangiopathy (TMA) occurred in 7 patients (29%), with 2 cases of acute renal failure.",19135948_6,-1,-1,2,12676,-1
12679,survival rate,11,13,57,70,"With a median follow-up of 26 months, the 2-year overall survival rate was 47%.",19135948_8,-1,-1,2,12679,-1
12681,acute GVHD,13,15,84,94,"Although this new combination appears to be effective as a prophylactic regimen for acute GVHD, the incidence of TMA and SOS is considerably higher than seen with other regimens.",19135948_9,-1,-1,2,12681,-1
12685,phase III clinical trial,8,12,58,82,Longitudinal assessment of air conduction audiograms in a phase III clinical trial of difluoromethylornithine and sulindac for prevention of sporadic colorectal adenomas.,19139001_0,-1,-1,2,12685,-1
12693,comprehensive approach,14,16,74,96,"Temporary hearing loss is a known toxicity of treatment with DFMO, thus a comprehensive approach was developed to analyze serial air conduction audiograms.",19139001_2,-1,-1,2,12693,-1
12695,generalized estimating equation method,1,5,4,42,The generalized estimating equation method estimated the mean difference between treatment arms with regard to change in air conduction pure tone thresholds while accounting for within-subject correlation due to repeated measurements at frequencies.,19139001_3,-1,-1,2,12695,-1
12700,confidence interval,29,31,161,180,"Based on 290 subjects, there was an average difference of 0.50 dB between subjects treated with DFMO plus sulindac compared with those treated with placebo (95% confidence interval, -0.64 to 1.63 dB; P = 0.39), adjusted for baseline values, age, and frequencies.",19139001_4,-1,-1,2,12700,-1
12701,baseline values,44,46,224,239,"Based on 290 subjects, there was an average difference of 0.50 dB between subjects treated with DFMO plus sulindac compared with those treated with placebo (95% confidence interval, -0.64 to 1.63 dB; P = 0.39), adjusted for baseline values, age, and frequencies.",19139001_4,-1,-1,2,12701,-1
12702,speech range,3,5,14,26,"In the normal speech range of 500 to 3,000 Hz, an estimated difference of 0.99 dB (-0.17 to 2.14 dB; P = 0.09) was detected.",19139001_5,-1,-1,2,12702,-1
12703,Dose intensity,0,2,0,14,Dose intensity did not add information to models.,19139001_6,-1,-1,2,12703,-1
12708,treatment arms,34,36,176,190,Follow-up air conduction done at least 6 months after end of treatment showed an adjusted mean difference in hearing thresholds of 1.08 dB (-0.81 to 2.96 dB; P = 0.26) between treatment arms.,19139001_8,-1,-1,2,12708,-1
12714,exposure to,7,9,52,63,"The estimated attributable risk of ototoxicity from exposure to the drug is 8.4% (95% confidence interval, -2.0% to 18.8%; P = 0.12).",19139001_10,-1,-1,2,12714,-1
12715,confidence interval,17,19,86,105,"The estimated attributable risk of ototoxicity from exposure to the drug is 8.4% (95% confidence interval, -2.0% to 18.8%; P = 0.12).",19139001_10,-1,-1,2,12715,-1
12716,treated with,12,14,59,71,There is a <2 dB difference in mean threshold for patients treated with DFMO plus sulindac compared with those treated with placebo.,19139001_11,-1,-1,2,12716,-1
12726,interstitial matrix,10,12,57,76,"There was no evidence of repair to the damaged medullary interstitial matrix, or proliferation of remaining undamaged type 1 medullary interstitial cells after the recovery period following analgesic treatment.",1919871_3,-1,-1,2,12726,-1
12727,type 1,18,20,118,124,"There was no evidence of repair to the damaged medullary interstitial matrix, or proliferation of remaining undamaged type 1 medullary interstitial cells after the recovery period following analgesic treatment.",1919871_3,0,1,2,12727,-1
12728,interstitial cells,21,23,135,153,"There was no evidence of repair to the damaged medullary interstitial matrix, or proliferation of remaining undamaged type 1 medullary interstitial cells after the recovery period following analgesic treatment.",1919871_3,-1,-1,2,12728,-1
12730,early stages,2,4,11,23,"During the early stages of analgesic treatment, the changes in urinary concentrating ability were reversible, but after prolonged analgesic treatment, maximum urinary concentrating ability failed to recover.",1919871_5,-1,-1,2,12730,-1
12731,urinary concentrating ability,11,14,63,92,"During the early stages of analgesic treatment, the changes in urinary concentrating ability were reversible, but after prolonged analgesic treatment, maximum urinary concentrating ability failed to recover.",1919871_5,-1,-1,2,12731,-1
12732,interstitial matrix,18,20,122,141,This study shows that prolonged analgesic treatment in Fischer 344 rats causes progressive and irreversible damage to the interstitial matrix and type 1 interstitial cells leading to RPN.,1919871_6,-1,-1,2,12732,-1
12733,type 1,21,23,146,152,This study shows that prolonged analgesic treatment in Fischer 344 rats causes progressive and irreversible damage to the interstitial matrix and type 1 interstitial cells leading to RPN.,1919871_6,0,1,2,12733,-1
12734,interstitial cells,23,25,153,171,This study shows that prolonged analgesic treatment in Fischer 344 rats causes progressive and irreversible damage to the interstitial matrix and type 1 interstitial cells leading to RPN.,1919871_6,-1,-1,2,12734,-1
12736,early stages,10,12,74,86,The associated urinary concentrating defect is reversible only during the early stages of structural damage to the inner medulla.,1919871_7,-1,-1,2,12736,-1
12752,normal range less,20,23,112,129,"Proteinase 3-antineutrophil cytoplasmic antibody (PR3-ANCA) titer was elevated at 183 ELISA units (EU) in sera (normal range less than 10 EU), myeloperoxidase-ANCA was negative.",19203554_3,-1,-1,2,12752,-1
12762,cells/microl,46,47,274,286,"Although cessation of sulphasalazine treatment resulted in improvements in fever, red eyes, chest pain, titer of C-reactive protein and volume of the pleural effusions, we initiated steroid therapy, because PR3-ANCA titer rose to 320 EU, eosinophil count increased to 1,100 cells/microl, and the pleural effusion remained.",19203554_5,-1,-1,2,12762,-1
12769,upregulation,3,4,40,52,Testosterone-dependent hypertension and upregulation of intrarenal angiotensinogen in Dahl salt-sensitive rats.,19211690_0,-1,-1,2,12769,-1
12773,BP,3,4,16,18,Blood pressure (BP) is more salt sensitive in men than in premenopausal women.,19211690_1,-1,-1,2,12773,-1
12774,salt sensitive,7,9,28,42,Blood pressure (BP) is more salt sensitive in men than in premenopausal women.,19211690_1,-1,-1,2,12774,-1
12775,Dahl salt-sensitive rats,1,4,3,27,"In Dahl salt-sensitive rats (DS), high-salt (HS) diet increases BP more in males than females.",19211690_2,-1,-1,2,12775,-1
12777,BP,14,15,64,66,"In Dahl salt-sensitive rats (DS), high-salt (HS) diet increases BP more in males than females.",19211690_2,-1,-1,2,12777,-1
12781,intrarenal levels,26,28,160,177,"In contrast to the systemic renin-angiotensin system, which is suppressed in response to HS in male DS, intrarenal angiotensinogen expression is increased, and intrarenal levels of ANG II are not suppressed.",19211690_3,-1,-1,2,12781,-1
12783,sexual dimorphism,12,14,57,74,"In this study, the hypothesis was tested that there is a sexual dimorphism in HS-induced upregulation of intrarenal angiotensinogen mediated by testosterone that also causes increases in BP and renal injury.",19211690_4,-1,-1,2,12783,-1
12785,upregulation,16,17,89,101,"In this study, the hypothesis was tested that there is a sexual dimorphism in HS-induced upregulation of intrarenal angiotensinogen mediated by testosterone that also causes increases in BP and renal injury.",19211690_4,-1,-1,2,12785,-1
12788,BP,28,29,187,189,"In this study, the hypothesis was tested that there is a sexual dimorphism in HS-induced upregulation of intrarenal angiotensinogen mediated by testosterone that also causes increases in BP and renal injury.",19211690_4,-1,-1,2,12788,-1
12792,angiotensinogen mRNA,15,17,65,85,"On a low-salt (LS) diet, male DS had higher levels of intrarenal angiotensinogen mRNA than females.",19211690_5,-1,-1,2,12792,-1
12794,renal cortical angiotensinogen mRNA,6,10,27,62,"HS diet for 4 wk increased renal cortical angiotensinogen mRNA and protein only in male DS, which was prevented by castration.",19211690_6,-1,-1,2,12794,-1
12795,no effect,5,7,29,38,Ovariectomy of female DS had no effect on intrarenal angiotensinogen expression on either diet.,19211690_7,-1,-1,2,12795,-1
12802,BP,7,8,56,58,"Testosterone replacement in castrated DS rats increased BP, renal injury, and upregulation of renal angiotensinogen associated with HS diet.",19211690_10,-1,-1,2,12802,-1
12804,upregulation,13,14,78,90,"Testosterone replacement in castrated DS rats increased BP, renal injury, and upregulation of renal angiotensinogen associated with HS diet.",19211690_10,-1,-1,2,12804,-1
12810,upregulation,19,20,121,133,Testosterone contributes to the development of hypertension and renal injury in male DS rats on HS diet possibly through upregulation of the intrarenal renin-angiotensin system.,19211690_11,-1,-1,2,12810,-1
12816,double-blind pilot study,5,8,27,51,"A prospective, randomized, double-blind pilot study to compare the results of stereotactic unilateral pallidotomy and subthalamotomy in advanced idiopathic Parkinson's disease (PD) refractory to medical treatment was designed.",19234905_1,-1,-1,2,12816,-1
12821,/-,9,10,42,44,"Ten consecutive patients (mean age, 58.4 +/- 6.8 years; 7 men, 3 women) with similar characteristics at the duration of disease (mean disease time, 8.4 +/- 3.5 years), disabling motor fluctuations (Hoehn _ Yahr stage 3-5 in off-drug phases) and levodopa-induced dyskinesias were selected.",19234905_2,0,1,2,12821,-1
12824,Yahr stage,45,47,206,216,"Ten consecutive patients (mean age, 58.4 +/- 6.8 years; 7 men, 3 women) with similar characteristics at the duration of disease (mean disease time, 8.4 +/- 3.5 years), disabling motor fluctuations (Hoehn _ Yahr stage 3-5 in off-drug phases) and levodopa-induced dyskinesias were selected.",19234905_2,-1,-1,2,12824,-1
12825,off-drug phases,51,53,224,239,"Ten consecutive patients (mean age, 58.4 +/- 6.8 years; 7 men, 3 women) with similar characteristics at the duration of disease (mean disease time, 8.4 +/- 3.5 years), disabling motor fluctuations (Hoehn _ Yahr stage 3-5 in off-drug phases) and levodopa-induced dyskinesias were selected.",19234905_2,-1,-1,2,12825,-1
12829,STN,20,21,104,107,Six patients were operated on in the globus pallidus interna (GPi) and four in the subthalamic nucleus (STN).,19234905_4,-1,-1,2,12829,-1
12835,daily living (ADL) score,24,30,144,168,"Clinical evaluation included the use of the Unified Parkinson's Disease Rating Scale (UPDRS), Hoehn_Yahr score and Schwab England activities of daily living (ADL) score in 'on'- and 'off'-drug conditions before surgery and 6 months after surgery.",19234905_5,-1,-1,2,12835,-1
12836,on'-,32,33,173,177,"Clinical evaluation included the use of the Unified Parkinson's Disease Rating Scale (UPDRS), Hoehn_Yahr score and Schwab England activities of daily living (ADL) score in 'on'- and 'off'-drug conditions before surgery and 6 months after surgery.",19234905_5,-1,-1,2,12836,-1
12838,statistically significant,2,4,10,35,There was statistically significant improvement in all contralateral major parkinsonian motor signs in all patients followed for 6 months.,19234905_6,-1,-1,2,12838,-1
12841,STN,9,10,66,69,Levodopa equivalent daily intake was significantly reduced in the STN group.,19234905_7,-1,-1,2,12841,-1
12842,UPDRS,2,3,11,16,"Changes in UPDRS, Hoehn _ Yahr and Schwab England ADL scores were similar in both groups.",19234905_8,-1,-1,2,12842,-1
12843,Hoehn,4,5,18,23,"Changes in UPDRS, Hoehn _ Yahr and Schwab England ADL scores were similar in both groups.",19234905_8,-1,-1,2,12843,-1
12845,Schwab England,8,10,35,49,"Changes in UPDRS, Hoehn _ Yahr and Schwab England ADL scores were similar in both groups.",19234905_8,-1,-1,2,12845,-1
12852,mg/day,35,36,241,247,Complications were observed in two patients: one had a left homonymous hemianopsia after pallidotomy and another one developed left hemiballistic movements 3 days after subthalamotomy which partly improved within 1 month with Valproate 1000 mg/day.,19234905_10,-1,-1,2,12852,-1
12853,STN,11,12,66,69,The findings of this study suggest that lesions of the unilateral STN and GPi are equally effective treatment for patients with advanced PD refractory to medical treatment.,19234905_11,-1,-1,2,12853,-1
12857,sensory-discriminative components,4,6,29,62,Explicit episodic memory for sensory-discriminative components of capsaicin-induced pain: immediate and delayed ratings.,19269743_0,-1,-1,2,12857,-1
12863,sensory features,8,10,60,76,Systematic investigations of the human capacity to remember sensory features of experimental pain are sparse.,19269743_2,-1,-1,2,12863,-1
12869,computerized visual analogue scale,6,10,34,68,"Pain rating was performed using a computerized visual analogue scale (0-100) digitized at 1/s, either immediately online or one hour or one day after injection.",19269743_4,-1,-1,2,12869,-1
12870,dose-dependent,5,6,39,53,Capsaicin injection reliably induced a dose-dependent flare (p<0.001) without any difference within or across sessions.,19269743_6,-1,-1,2,12870,-1
12873,first-time,21,22,133,143,"Subjects were able to reliably discriminate pain magnitude and duration across capsaicin doses (both p<0.001), regardless of whether first-time ratings were requested immediately, after one hour or after one day.",19269743_8,-1,-1,2,12873,-1
12874,first-time,10,11,60,70,Correlation with rating recall after one week was best when first-time ratings were requested as late as one day after injection (R(2)=0.79) indicating that both rating retrievals utilized similar memory traces.,19269743_10,-1,-1,2,12874,-1
12875,R(2)=0.79,22,23,130,139,Correlation with rating recall after one week was best when first-time ratings were requested as late as one day after injection (R(2)=0.79) indicating that both rating retrievals utilized similar memory traces.,19269743_10,-1,-1,2,12875,-1
12876,rating retrievals,27,29,162,179,Correlation with rating recall after one week was best when first-time ratings were requested as late as one day after injection (R(2)=0.79) indicating that both rating retrievals utilized similar memory traces.,19269743_10,-1,-1,2,12876,-1
12878,interim stage,13,15,79,92,"The data further suggest that the consolidation of this memory is an important interim stage, and may take up to one day.",19269743_12,-1,-1,2,12878,-1
12879,DSMM XI study,0,3,0,13,DSMM XI study: dose definition for intravenous cyclophosphamide in combination with bortezomib/dexamethasone for remission induction in patients with newly diagnosed myeloma.,19274460_0,-1,-1,2,12879,-1
12880,dose definition,4,6,15,30,DSMM XI study: dose definition for intravenous cyclophosphamide in combination with bortezomib/dexamethasone for remission induction in patients with newly diagnosed myeloma.,19274460_0,-1,-1,2,12880,-1
12883,remission induction,14,16,113,132,DSMM XI study: dose definition for intravenous cyclophosphamide in combination with bortezomib/dexamethasone for remission induction in patients with newly diagnosed myeloma.,19274460_0,-1,-1,2,12883,-1
12888,induction treatment,19,21,136,155,A clinical trial was initiated to evaluate the recommended dose of cyclophosphamide in combination with bortezomib and dexamethasone as induction treatment before stem cell transplantation for younger patients with newly diagnosed multiple myeloma (MM).,19274460_1,-1,-1,2,12888,-1
12892,treated with,3,5,21,33,"Thirty patients were treated with three 21-day cycles of bortezomib 1.3 mg/m(2) on days 1, 4, 8, and 11 plus dexamethasone 40 mg on the day of bortezomib injection and the day after plus cyclophosphamide at 900, 1,200, or 1,500 mg/m(2) on day 1.",19274460_2,-1,-1,2,12892,-1
12898,partial response,13,15,56,72,"At this dose level, 92% of patients achieved at least a partial response.",19274460_4,-1,-1,2,12898,-1
12899,response rate,2,4,12,25,"The overall response rate [complete response (CR) plus partial response (PR)] across all dose levels was 77%, with a 10% CR rate.",19274460_5,-1,-1,2,12899,-1
12900,complete response (,5,8,27,46,"The overall response rate [complete response (CR) plus partial response (PR)] across all dose levels was 77%, with a 10% CR rate.",19274460_5,-1,-1,2,12900,-1
12913,treated with,13,15,83,95,"To our knowledge, this is the first reported case of captopril-induced hypotension treated with naloxone.",1928887_4,-1,-1,2,12913,-1
12914,microplate method,6,8,41,58,Identification of a simple and sensitive microplate method for the detection of oversulfated chondroitin sulfate in heparin products.,19289093_0,-1,-1,2,12914,-1
12921,hypotensive response,28,30,167,187,"Recently, a number of commercial lots of heparin products were found to be contaminated with an oversulfated chondroitin sulfate (OSCS) derivative that could elicit a hypotensive response in pigs following a single high-dose infusion.",19289093_2,-1,-1,2,12921,-1
12925,effect level,3,5,16,28,"The no observed effect level (NOEL) for this contaminant appears to be approximately 1mg/kg, corresponding to a contamination level of approximately 3%.",19289093_4,-1,-1,2,12925,-1
12926,OSCS,4,5,26,30,"We also demonstrated that OSCS can be identified in heparin products using a simple, inexpensive, commercially available heparin enzyme immunoassay (EIA) kit that has a limit of detection of approximately 0.1%, well below the NOEL.",19289093_5,-1,-1,2,12926,-1
12928,limit of detection,29,32,169,187,"We also demonstrated that OSCS can be identified in heparin products using a simple, inexpensive, commercially available heparin enzyme immunoassay (EIA) kit that has a limit of detection of approximately 0.1%, well below the NOEL.",19289093_5,-1,-1,2,12928,-1
12945,patient 1,1,3,8,17,"Whereas patient 1 showed lesions of up to 1 cm readily detectable on magnetic resonance imaging under prolonged co-trimoxazole treatment, therapy of patient 2 was switched early.",19299179_4,-1,-1,2,12945,-1
12946,magnetic resonance imaging,13,16,69,95,"Whereas patient 1 showed lesions of up to 1 cm readily detectable on magnetic resonance imaging under prolonged co-trimoxazole treatment, therapy of patient 2 was switched early.",19299179_4,-1,-1,2,12946,-1
12948,patient 2,23,25,149,158,"Whereas patient 1 showed lesions of up to 1 cm readily detectable on magnetic resonance imaging under prolonged co-trimoxazole treatment, therapy of patient 2 was switched early.",19299179_4,-1,-1,2,12948,-1
12960,secondary to,8,10,37,49,"However, there are no reports of ABS secondary to chemotherapeutic agents.",19300240_3,-1,-1,2,12960,-1
12974,Pathogenetic mechanisms,0,2,0,23,"Pathogenetic mechanisms of cardiac complications in cancer patients undergoing chemotherapy include coronary vasospasm, endothelial damage and consequent thrombus formation.",19300240_12,-1,-1,2,12974,-1
12978,supraphysiologic,5,6,21,37,"In our patient, both supraphysiologic levels of plasma catecholamines and stress related neuropeptides caused by cancer diagnosis as well as chemotherapy may have contributed the development of ABS.",19300240_13,-1,-1,2,12978,-1
13000,mechanical stimuli,10,12,62,80,METHODS: The changes in pain thresholds were determined using mechanical stimuli--the modification of the classic paw withdrawal test described by Randall-Selitto.,19300402_2,-1,-1,2,13000,-1
13012,inducible,8,9,40,49,It was also shown that both products of inducible NO synthase and neuronal NO synthase activation as well as bradykinin are involved in hyperalgesia produced by vincristine.,19300402_5,-1,-1,2,13012,-1
13025,nociceptive stimuli,17,19,102,121,CONCLUSIONS: Results of these studies suggest that B1 and B2 receptors are engaged in transmission of nociceptive stimuli in both diabetic and toxic neuropathy.,19300402_7,-1,-1,2,13025,-1
13044,systematic study,10,12,57,73,Some case reports are published in the literature but no systematic study from a sample of patients has been published.,19308880_2,-1,-1,2,13044,-1
13046,French Pharmacovigilance database,4,7,19,52,"METHODS: Using the French Pharmacovigilance database, we selected the cases of confusion reported since 1985 with valproic acid.",19308880_4,-1,-1,2,13046,-1
13050,outcome favourable,17,19,64,82,"It was ""serious"" for almost 2/3 of the patients (62.5%) and its outcome favourable in most of the cases (82%).",19308880_7,-1,-1,2,13050,-1
13051,ADR,4,5,23,26,The occurrence of this ADR was more frequent in patients aged between 61 and 80 years.,19308880_8,-1,-1,2,13051,-1
13057,W-ICH,4,5,46,51,Warfarin-associated intracerebral hemorrhage (W-ICH) is a severe type of stroke.,19319147_1,-1,-1,2,13057,-1
13058,W-ICH,9,10,51,56,There is no consensus on the optimal treatment for W-ICH.,19319147_2,-1,-1,2,13058,-1
13059,mouse model,2,4,8,19,"Using a mouse model, we tested whether the rapid reversal of anticoagulation using human prothrombin complex concentrate (PCC) can reduce hemorrhagic blood volume.",19319147_3,-1,-1,2,13059,-1
13060,human prothrombin complex concentrate,14,18,83,120,"Using a mouse model, we tested whether the rapid reversal of anticoagulation using human prothrombin complex concentrate (PCC) can reduce hemorrhagic blood volume.",19319147_3,-1,-1,2,13060,-1
13064,treated with,4,6,20,32,"Male CD-1 mice were treated with warfarin (2 mg/kg over 24 h), resulting in a mean (+/-s.d.) International Normalized Ratio of 3.5+/-0.9.",19319147_4,-1,-1,2,13064,-1
13065,(+,19,21,83,85,"Male CD-1 mice were treated with warfarin (2 mg/kg over 24 h), resulting in a mean (+/-s.d.) International Normalized Ratio of 3.5+/-0.9.",19319147_4,0,1,2,13065,-1
13066,International Normalized Ratio,24,27,93,123,"Male CD-1 mice were treated with warfarin (2 mg/kg over 24 h), resulting in a mean (+/-s.d.) International Normalized Ratio of 3.5+/-0.9.",19319147_4,-1,-1,2,13066,-1
13067,intravenous administration,6,8,25,51,"First, we showed that an intravenous administration of human PCC rapidly reversed anticoagulation in mice.",19319147_5,-1,-1,2,13067,-1
13069,reversed anticoagulation,12,14,73,97,"First, we showed that an intravenous administration of human PCC rapidly reversed anticoagulation in mice.",19319147_5,-1,-1,2,13069,-1
13072,Forty-five minutes,0,2,0,18,"Forty-five minutes later, the animals were randomly treated with PCC (100 U/kg) or saline i.v. (n=12 per group).",19319147_7,-1,-1,2,13072,-1
13073,treated with,8,10,52,64,"Forty-five minutes later, the animals were randomly treated with PCC (100 U/kg) or saline i.v. (n=12 per group).",19319147_7,-1,-1,2,13073,-1
13079,saline controls,16,18,102,117,"The mean hemorrhagic blood volume was reduced in PCC-treated animals (6.5+/-3.1 microL) compared with saline controls (15.3+/-11.2 microL, P=0.015).",19319147_9,-1,-1,2,13079,-1
13081,saline group,2,4,7,19,"In the saline group, 45% of the mice developed large hematomas (i.e., >15 microL).",19319147_10,-1,-1,2,13081,-1
13085,acute treatment,10,12,63,78,We provide experimental data suggesting PCC to be an effective acute treatment for W-ICH in terms of reducing hemorrhagic blood volume.,19319147_12,-1,-1,2,13085,-1
13088,W-ICH,15,16,98,103,Future studies are needed to assess the therapeutic potential emerging from our finding for human W-ICH.,19319147_13,-1,-1,2,13088,-1
13091,diffusion-weighted,12,13,110,128,Reversible inferior colliculus lesion in metronidazole-induced encephalopathy: magnetic resonance findings on diffusion-weighted and fluid attenuated inversion recovery imaging.,19346865_0,-1,-1,2,13091,-1
13093,diffusion-weighted imaging,18,20,126,152,"OBJECTIVE: This is to present reversible inferior colliculus lesions in metronidazole-induced encephalopathy, to focus on the diffusion-weighted imaging (DWI) and fluid attenuated inversion recovery (FLAIR) imaging.",19346865_1,-1,-1,2,13093,-1
13098,apparent diffusion coefficient,20,23,109,139,"Initial brain magnetic resonance imaging (MRI) were obtained after the hospitalization, including DWI (8/8), apparent diffusion coefficient (ADC) map (4/8), FLAIR (7/8), and T2-weighted image (8/8).",19346865_4,-1,-1,2,13098,-1
13099,T2-weighted image,37,39,174,191,"Initial brain magnetic resonance imaging (MRI) were obtained after the hospitalization, including DWI (8/8), apparent diffusion coefficient (ADC) map (4/8), FLAIR (7/8), and T2-weighted image (8/8).",19346865_4,-1,-1,2,13099,-1
13100,retrospectively evaluated,7,9,44,69,"Findings of initial and follow-up MRIs were retrospectively evaluated by 2 neuroradiologists by consensus, to analyze the presence of abnormal signal intensities, their locations, and signal changes on follow-up images.",19346865_6,-1,-1,2,13100,-1
13101,neuroradiologists,11,12,75,92,"Findings of initial and follow-up MRIs were retrospectively evaluated by 2 neuroradiologists by consensus, to analyze the presence of abnormal signal intensities, their locations, and signal changes on follow-up images.",19346865_6,-1,-1,2,13101,-1
13102,signal intensities,21,23,143,161,"Findings of initial and follow-up MRIs were retrospectively evaluated by 2 neuroradiologists by consensus, to analyze the presence of abnormal signal intensities, their locations, and signal changes on follow-up images.",19346865_6,-1,-1,2,13102,-1
13105,T2-weighted image,15,17,83,100,"RESULTS: Initial MRIs showed abnormal high signal intensities on DWI and FLAIR (or T2-weighted image) at the dentate nucleus (8/8), inferior colliculus (6/8), corpus callosum (2/8), pons (2/8), medulla (1/8), and bilateral cerebral white matter (1/8).",19346865_7,-1,-1,2,13105,-1
13110,High-signal,0,1,0,11,"High-signal intensity lesions on DWI tended to show low signal intensity on ADC map (3/4), but in one patient, high signal intensity was shown at bilateral dentate nuclei on not only DWI but also ADC map.",19346865_8,-1,-1,2,13110,-1
13113,signal intensity,9,11,56,72,"High-signal intensity lesions on DWI tended to show low signal intensity on ADC map (3/4), but in one patient, high signal intensity was shown at bilateral dentate nuclei on not only DWI but also ADC map.",19346865_8,-1,-1,2,13113,-1
13114,ADC,12,13,76,79,"High-signal intensity lesions on DWI tended to show low signal intensity on ADC map (3/4), but in one patient, high signal intensity was shown at bilateral dentate nuclei on not only DWI but also ADC map.",19346865_8,-1,-1,2,13114,-1
13115,signal intensity,24,26,116,132,"High-signal intensity lesions on DWI tended to show low signal intensity on ADC map (3/4), but in one patient, high signal intensity was shown at bilateral dentate nuclei on not only DWI but also ADC map.",19346865_8,-1,-1,2,13115,-1
13118,ADC,38,39,196,199,"High-signal intensity lesions on DWI tended to show low signal intensity on ADC map (3/4), but in one patient, high signal intensity was shown at bilateral dentate nuclei on not only DWI but also ADC map.",19346865_8,-1,-1,2,13118,-1
13134,associated with,9,11,75,90,We have encountered several patients who developed substantial proteinuria associated with sirolimus use.,19356053_3,-1,-1,2,13134,-1
13139,Washington Hospital Center,17,20,112,138,METHODS: We analyzed the clinical and laboratory information available for all 119 patients transplanted at the Washington Hospital Center between 1999-2003 for whom sirolimus was a component of their immunosuppressant regimen.,19356053_5,-1,-1,2,13139,-1
13142,urine samples,12,14,72,85,"In these patients, the magnitude of proteinuria was assessed on morning urine samples by turbidometric measurement or random urine protein:creatinine ratios, an estimate of grams of proteinuria/day.",19356053_6,-1,-1,2,13142,-1
13145,proteinuria/day,30,31,182,197,"In these patients, the magnitude of proteinuria was assessed on morning urine samples by turbidometric measurement or random urine protein:creatinine ratios, an estimate of grams of proteinuria/day.",19356053_6,-1,-1,2,13145,-1
13152,clinical variables,13,15,99,117,Proteinuria correlated most strongly with sirolimus therapy when compared to other demographic and clinical variables.,19356053_11,-1,-1,2,13152,-1
13155,pre-existing proteinuria,6,8,45,69,CONCLUSIONS: Sirolimus induces or aggravates pre-existing proteinuria in an unpredictable subset of renal allograft recipients.,19356053_13,-1,-1,2,13155,-1
13162,passive avoidance test,12,15,87,109,The anti-dementia effects of s-limonene and s-perillyl alcohol were observed using the passive avoidance test (PA) and the open field habituation test (OFH).,19356307_1,-1,-1,2,13162,-1
13163,open field habituation test,20,24,123,150,The anti-dementia effects of s-limonene and s-perillyl alcohol were observed using the passive avoidance test (PA) and the open field habituation test (OFH).,19356307_1,-1,-1,2,13163,-1
13169,OFH,36,37,235,238,"These lemon essential oils showed strong ability to improve memory impaired by scopolamine; however, s-perillyl alcohol relieved the deficit of associative memory in PA only, and did not improve non-associative memory significantly in OFH.",19356307_2,-1,-1,2,13169,-1
13171,test day,10,12,72,80,"Analysis of neurotransmitter concentration in some brain regions on the test day showed that dopamine concentration of the vehicle/scopolamine group was significantly lower than that of the vehicle/vehicle group, but this phenomenon was reversed when s-limonene or s-perillyl alcohol were administered before the injection of scopolamine.",19356307_3,-1,-1,2,13171,-1
13178,in vitro,15,17,115,123,"Simultaneously, we found that these two lemon essential oil components could inhibit acetylcholinesterase activity in vitro using the Ellman method.",19356307_4,-1,-1,2,13178,-1
13186,Cochrane review,8,10,43,58,This is an updated version of the original Cochrane review first published in 2005.,19370593_2,-1,-1,2,13186,-1
13191,Trials Register of the,12,16,71,93,"SEARCH STRATEGY: We searched the following databases to November 2007: Trials Register of the Cochrane Menstrual Disorders and Subfertility Group, Cochrane Central Register of Controlled Trials, MEDLINE, EMBASE, Biological Abstracts.",19370593_4,-1,-1,2,13191,-1
13193,Subfertility Group,20,22,127,145,"SEARCH STRATEGY: We searched the following databases to November 2007: Trials Register of the Cochrane Menstrual Disorders and Subfertility Group, Cochrane Central Register of Controlled Trials, MEDLINE, EMBASE, Biological Abstracts.",19370593_4,-1,-1,2,13193,-1
13194,Cochrane Central Register of Controlled Trials,23,29,147,193,"SEARCH STRATEGY: We searched the following databases to November 2007: Trials Register of the Cochrane Menstrual Disorders and Subfertility Group, Cochrane Central Register of Controlled Trials, MEDLINE, EMBASE, Biological Abstracts.",19370593_4,-1,-1,2,13194,-1
13195,EMBASE,32,33,204,210,"SEARCH STRATEGY: We searched the following databases to November 2007: Trials Register of the Cochrane Menstrual Disorders and Subfertility Group, Cochrane Central Register of Controlled Trials, MEDLINE, EMBASE, Biological Abstracts.",19370593_4,-1,-1,2,13195,-1
13197,SELECTION CRITERIA,0,2,0,18,"SELECTION CRITERIA: Randomised double-blind trials of HT versus placebo, taken for at least one year by perimenopausal or postmenopausal women.",19370593_6,-1,-1,2,13197,-1
13198,Randomised double-blind trials,3,6,20,50,"SELECTION CRITERIA: Randomised double-blind trials of HT versus placebo, taken for at least one year by perimenopausal or postmenopausal women.",19370593_6,-1,-1,2,13198,-1
13201,HT,0,1,0,2,"HT included oestrogens, with or without progestogens, via oral, transdermal, subcutaneous or transnasal routes.",19370593_7,-1,-1,2,13201,-1
13202,transnasal routes,16,18,93,110,"HT included oestrogens, with or without progestogens, via oral, transdermal, subcutaneous or transnasal routes.",19370593_7,-1,-1,2,13202,-1
13204,Nineteen trials,3,5,14,29,"MAIN RESULTS: Nineteen trials involving 41,904 women were included.",19370593_9,-1,-1,2,13204,-1
13205,HT,7,8,49,51,"In relatively healthy women, combined continuous HT significantly increased the risk of venous thrombo-embolism or coronary event (after one year's use), stroke (after three years), breast cancer and gallbladder disease.",19370593_10,-1,-1,2,13205,-1
13210,HT,2,3,25,27,"Long-term oestrogen-only HT significantly increased the risk of venous thrombo-embolism, stroke and gallbladder disease (after one to two years, three years and seven years' use respectively), but did not significantly increase the risk of breast cancer.",19370593_11,-1,-1,2,13210,-1
13214,statistically significant,2,4,9,34,"The only statistically significant benefits of HT were a decreased incidence of fractures and (for combined HT) colon cancer, with long-term use.",19370593_12,-1,-1,2,13214,-1
13215,HT,6,7,47,49,"The only statistically significant benefits of HT were a decreased incidence of fractures and (for combined HT) colon cancer, with long-term use.",19370593_12,-1,-1,2,13215,-1
13219,statistically significant,27,29,144,169,"Among women aged over 65 who were relatively healthy (i.e. generally fit, without overt disease) and taking continuous combined HT, there was a statistically significant increase in the incidence of dementia.",19370593_13,-1,-1,2,13219,-1
13221,HT,11,12,78,80,"Among women with cardiovascular disease, long-term use of combined continuous HT significantly increased the risk of venous thrombo-embolism.",19370593_14,-1,-1,2,13221,-1
13223,analysed subgroups,2,4,10,28,"One trial analysed subgroups of 2839 relatively healthy 50 to 59 year old women taking combined continuous HT and 1637 taking oestrogen-only HT, versus similar-sized placebo groups.",19370593_15,-1,-1,2,13223,-1
13229,younger women,13,15,76,89,"However, this study was not powered to detect differences between groups of younger women.",19370593_17,-1,-1,2,13229,-1
13231,HT,4,5,22,24,AUTHORS' CONCLUSIONS: HT is not indicated for the routine management of chronic disease.,19370593_18,-1,-1,2,13231,-1
13235,younger women,24,26,138,151,"We need more evidence on the safety of HT for menopausal symptom control, though short-term use appears to be relatively safe for healthy younger women.",19370593_19,-1,-1,2,13235,-1
13236,Attentional modulation,0,2,0,22,Attentional modulation of perceived pain intensity in capsaicin-induced secondary hyperalgesia.,19387625_0,-1,-1,2,13236,-1
13244,distracted away,15,17,100,115,Here we show that perceived pain intensity in secondary hyperalgesia is decreased when attention is distracted away from the painful pinprick stimulus with a visual task.,19387625_3,-1,-1,2,13244,-1
13245,painful pinprick stimulus,19,22,125,150,Here we show that perceived pain intensity in secondary hyperalgesia is decreased when attention is distracted away from the painful pinprick stimulus with a visual task.,19387625_3,-1,-1,2,13245,-1
13247,attentional modulation,9,11,48,70,"Furthermore, it was found that the magnitude of attentional modulation in secondary hyperalgesia is very similar to that of capsaicin-untreated, control condition.",19387625_4,-1,-1,2,13247,-1
13249,capsaicin-untreated,20,21,124,143,"Furthermore, it was found that the magnitude of attentional modulation in secondary hyperalgesia is very similar to that of capsaicin-untreated, control condition.",19387625_4,-1,-1,2,13249,-1
13250,control condition,22,24,145,162,"Furthermore, it was found that the magnitude of attentional modulation in secondary hyperalgesia is very similar to that of capsaicin-untreated, control condition.",19387625_4,-1,-1,2,13250,-1
13251,attentional modulation,10,12,69,91,"Our findings, showing no interaction between capsaicin treatment and attentional modulation suggest that capsaicin-induced secondary hyperalgesia and attention might affect mechanical pain through independent mechanisms.",19387625_5,-1,-1,2,13251,-1
13261,Cardiac marker,0,2,0,14,Cardiac marker enzymes and antioxidative parameters in serum and heart tissues were measured.,19445921_3,-1,-1,2,13261,-1
13268,Isoproterenol-treated rats,0,2,0,26,"Isoproterenol-treated rats showed significant increases in the levels of lactate dehydrogenase, aspartate transaminase, creatine kinase and malondialdehyde and significant decreases in the activities of superoxide dismutase, catalase and glutathione peroxidase in serum and heart.",19445921_5,-1,-1,2,13268,-1
13276,minimum rate,13,15,83,95,"These rats also showed declines in left ventricular systolic pressure, maximum and minimum rate of developed left ventricular pressure, and elevation of left ventricular end-diastolic pressure and ST-segment.",19445921_6,-1,-1,2,13276,-1
13281,respiratory control ratio,9,12,78,103,"In addition, mitochondrial respiratory dysfunction characterized by decreased respiratory control ratio and ADP/O was observed in isoproterenol-treated rats.",19445921_7,-1,-1,2,13281,-1
13283,isoproterenol-treated rats,17,19,130,156,"In addition, mitochondrial respiratory dysfunction characterized by decreased respiratory control ratio and ADP/O was observed in isoproterenol-treated rats.",19445921_7,-1,-1,2,13283,-1
13307,placebo-controlled,20,21,139,157,"This pilot trial aimed to evaluate the role of glutamate supplementation for preventing PAC-induced peripheral neuropathy in a randomized, placebo-controlled, double-blinded clinical and electro-diagnostic study.",19473225_2,-1,-1,2,13307,-1
13317,group G.,27,29,179,187,"There was no significant difference in the frequency of signs or symptoms between the two groups although neurotoxicity symptoms presented mostly with lower scores of severity in group G. However, this difference reached statistical significance only with regard to reported pain sensation (P = 0.011).",19473225_5,-1,-1,2,13317,-1
13318,statistical significance,34,36,221,245,"There was no significant difference in the frequency of signs or symptoms between the two groups although neurotoxicity symptoms presented mostly with lower scores of severity in group G. However, this difference reached statistical significance only with regard to reported pain sensation (P = 0.011).",19473225_5,-1,-1,2,13318,-1
13341,associated with,3,5,22,37,"The ocular myasthenia associated with combination therapy of pegylated IFN alpha-2b and ribavirin for CHC is very rarely reported; therefore, we present this case with a review of the various eye complications of IFN therapy.",19581773_5,-1,-1,2,13341,-1
13348,ecstasy users,5,7,32,45,Learning and memory deficits in ecstasy users and their neural correlates during a face-learning task.,19631624_0,-1,-1,2,13348,-1
13353,ecstasy users,7,9,42,55,"In addition, working memory processing in ecstasy users has been shown to be associated with neural alterations in hippocampal and/or cortical regions as measured by functional magnetic resonance imaging (fMRI).",19631624_2,-1,-1,2,13353,-1
13354,associated with,14,16,77,92,"In addition, working memory processing in ecstasy users has been shown to be associated with neural alterations in hippocampal and/or cortical regions as measured by functional magnetic resonance imaging (fMRI).",19631624_2,-1,-1,2,13354,-1
13358,magnetic resonance imaging,27,30,177,203,"In addition, working memory processing in ecstasy users has been shown to be associated with neural alterations in hippocampal and/or cortical regions as measured by functional magnetic resonance imaging (fMRI).",19631624_2,-1,-1,2,13358,-1
13363,confounding effects,4,6,25,44,"To address the potential confounding effects of the cannabis use of the ecstasy using group, a second analysis included 14 previously tested cannabis users (Nestor, L., Roberts, G., Garavan, H., Hester, R., 2008.",19631624_4,-1,-1,2,13363,-1
13365,cannabis users,23,25,141,155,"To address the potential confounding effects of the cannabis use of the ecstasy using group, a second analysis included 14 previously tested cannabis users (Nestor, L., Roberts, G., Garavan, H., Hester, R., 2008.",19631624_4,-1,-1,2,13365,-1
13367,Hester,38,39,195,201,"To address the potential confounding effects of the cannabis use of the ecstasy using group, a second analysis included 14 previously tested cannabis users (Nestor, L., Roberts, G., Garavan, H., Hester, R., 2008.",19631624_4,-1,-1,2,13367,-1
13370,cannabis users,12,14,98,112,Deficits in learning and memory: parahippocampal hyperactivity and frontocortical hypoactivity in cannabis users.,19631624_5,-1,-1,2,13370,-1
13372,cannabis users,13,15,92,106,Ecstasy users performed significantly worse in learning and memory compared to controls and cannabis users.,19631624_7,-1,-1,2,13372,-1
13382,cannabis groups,4,6,20,35,"In both ecstasy and cannabis groups brain activation was decreased in the right medial frontal gyrus, left parahippocampal gyrus, left dorsal cingulate gyrus, and left caudate.",19631624_10,-1,-1,2,13382,-1
13404,coadministration,8,9,60,76,Vancomycin nephrotoxicity is infrequent but may result from coadministration with a nephrotoxic agent.,19642243_3,-1,-1,2,13404,-1
13405,nephrotoxic agent,11,13,84,101,Vancomycin nephrotoxicity is infrequent but may result from coadministration with a nephrotoxic agent.,19642243_3,-1,-1,2,13405,-1
13409,case reports,10,12,82,94,Disulfiram-like syndrome after hydrogen cyanamide professional skin exposure: two case reports in France.,19657887_0,-1,-1,2,13409,-1
13416,occupational exposure to,15,18,92,116,The purpose of this report is to describe two cases of a disulfiram-like syndrome following occupational exposure to hydrogen cyanamide.,19657887_3,-1,-1,2,13416,-1
13418,Dormex,9,10,51,57,"The first case involved a 59-year-old man who used Dormex, which contains hydrogen cyanamide, without protection after consuming a large amount of alcohol during a meal.",19657887_4,-1,-1,2,13418,-1
13421,contact with,10,12,69,81,The second case occurred in a 55-year-old farmer following cutaneous contact with Dormex.,19657887_7,-1,-1,2,13421,-1
13436,rechallenge,18,19,102,113,"We report a case of reversible olfactory disorder related to pyrazinamide in a woman, with a positive rechallenge.",19674115_3,-1,-1,2,13436,-1
13439,rechallenge,10,11,85,96,Dysosmia disappeared completely after pyrazinamide withdrawal and recurred after its rechallenge.,19674115_5,-1,-1,2,13439,-1
13448,mPGES-1,2,3,13,20,Mice lacking mPGES-1 are resistant to lithium-induced polyuria.,19692487_0,-1,-1,2,13448,-1
13457,mPGES-1 +/+ mice,12,16,60,76,A 2-wk administration of LiCl (4 mmol.kg(-1).day(-1) ip) in mPGES-1 +/+ mice led to a marked polyuria with hyposmotic urine.,19692487_4,-1,-1,2,13457,-1
13459,associated with,2,4,9,24,This was associated with elevated renal mPGES-1 protein expression and increased urine PGE(2) excretion.,19692487_5,-1,-1,2,13459,-1
13463,Immunoblotting,0,1,0,14,"Immunoblotting, immunohistochemistry, and quantitative (q) RT-PCR consistently detected a significant decrease in aquaporin-2 (AQP2) protein expression in both the renal cortex and medulla of lithium-treated +/+ mice.",19692487_7,-1,-1,2,13463,-1
13472,dowregulation,4,5,17,30,"In contrast, the dowregulation of renal medullary NKCC2 expression was significantly attenuated in the -/- mice.",19692487_11,-1,-1,2,13472,-1
13481,pharmacological actions,10,12,71,94,The introduction of drugs that could induce hypotension with different pharmacological actions would be advantageous because side effects unique to a specific drug could be minimized by selecting appropriate therapy.,1969772_1,-1,-1,2,13481,-1
13495,electromagnetic flow probe,18,21,119,145,"Systemic aortic blood pressure and renal blood flow were measured continuously with a carotid arterial catheter and an electromagnetic flow probe respectively, in order to compare the cardiovascular and renal vascular effects of fenoldopam and sodium nitroprusside in ten dogs under halothane general anaesthesia.",1969772_5,-1,-1,2,13495,-1
13496,renal vascular effects,30,33,203,225,"Systemic aortic blood pressure and renal blood flow were measured continuously with a carotid arterial catheter and an electromagnetic flow probe respectively, in order to compare the cardiovascular and renal vascular effects of fenoldopam and sodium nitroprusside in ten dogs under halothane general anaesthesia.",1969772_5,-1,-1,2,13496,-1
13501,/-,7,8,41,43,Mean arterial pressure was decreased 30 +/- 8 per cent from control with infusion of fenoldopam (3.4 +/- 2.0 micrograms.kg-1.min-1) and 34 +/- 4 per cent with infusion of sodium nitroprusside (5.9 micrograms.kg-1.min-1) (NS).,1969772_6,0,1,2,13501,-1
13503,/-,20,21,102,104,Mean arterial pressure was decreased 30 +/- 8 per cent from control with infusion of fenoldopam (3.4 +/- 2.0 micrograms.kg-1.min-1) and 34 +/- 4 per cent with infusion of sodium nitroprusside (5.9 micrograms.kg-1.min-1) (NS).,1969772_6,0,1,2,13503,-1
13504,micrograms.kg-1.min-1,22,23,109,130,Mean arterial pressure was decreased 30 +/- 8 per cent from control with infusion of fenoldopam (3.4 +/- 2.0 micrograms.kg-1.min-1) and 34 +/- 4 per cent with infusion of sodium nitroprusside (5.9 micrograms.kg-1.min-1) (NS).,1969772_6,-1,-1,2,13504,-1
13505,/- 4 per,27,30,140,148,Mean arterial pressure was decreased 30 +/- 8 per cent from control with infusion of fenoldopam (3.4 +/- 2.0 micrograms.kg-1.min-1) and 34 +/- 4 per cent with infusion of sodium nitroprusside (5.9 micrograms.kg-1.min-1) (NS).,1969772_6,-1,-1,2,13505,-1
13511,/-,20,21,107,109,Renal blood flow (RBF) increased during fenoldopam-induced hypotension 11 +/- 7 per cent and decreased 21 +/- 8 per cent during sodium nitroprusside-induced hypotension (P less than 0.01).,1969772_7,0,1,2,13511,-1
13519,associated with,1,3,9,24,Seizures associated with levofloxacin: case presentation and literature review.,19707748_0,-1,-1,2,13519,-1
13527,Cochrane,10,11,71,79,"METHODS: Several biomedical databases were searched including MEDLINE, Cochrane and Ovid.",19707748_2,-1,-1,2,13527,-1
13538,in vitro,5,7,40,48,"Dextran-etodolac conjugates: synthesis, in vitro and in vivo evaluation.",19719056_0,-1,-1,2,13538,-1
13539,in vivo,8,10,53,60,"Dextran-etodolac conjugates: synthesis, in vitro and in vivo evaluation.",19719056_0,-1,-1,2,13539,-1
13547,molecular weights,22,24,139,156,"An activated moiety, i.e. N-acylimidazole derivative of etodolac (EAI), was condensed with the polysaccharide polymer dextran of different molecular weights (40000, 60000, 110000 and 200000).",19719056_3,-1,-1,2,13547,-1
13548,ester bonding,6,8,40,53,IR spectral data confirmed formation of ester bonding in the conjugates.,19719056_4,-1,-1,2,13548,-1
13549,UV-spectrophotometric analysis,5,7,36,66,Etodolac contents were evaluated by UV-spectrophotometric analysis.,19719056_5,-1,-1,2,13549,-1
13550,molecular weights,1,3,4,21,The molecular weights were determined by measuring viscosity using the Mark-Howink-Sakurada equation.,19719056_6,-1,-1,2,13550,-1
13551,Mark-Howink-Sakurada equation,10,12,71,100,The molecular weights were determined by measuring viscosity using the Mark-Howink-Sakurada equation.,19719056_6,-1,-1,2,13551,-1
13554,first-order,33,34,145,156,"At pH 9, a higher rate of etodolac release from ED was observed as compared to aqueous buffer of pH 7.4 and 80% human plasma (pH 7.4), following first-order kinetics.",19719056_8,-1,-1,2,13554,-1
13558,writhing model,11,13,91,105,"Acute analgesic and antiinflammatory activities were ascertained using acetic acid induced writhing model (mice) and carrageenan-induced rat paw edema model, respectively.",19719056_10,-1,-1,2,13558,-1
13565,ionic mechanisms,5,7,39,55,The antiarrhythmic effect and possible ionic mechanisms of pilocarpine on animal models.,19721134_0,-1,-1,2,13565,-1
13568,ionic mechanism,14,16,90,105,"This study was designed to evaluate the effects of pilocarpine and explore the underlying ionic mechanism, using both aconitine-induced rat and ouabain-induced guinea pig arrhythmia models.",19721134_1,-1,-1,2,13568,-1
13570,ouabain-induced guinea,22,24,144,166,"This study was designed to evaluate the effects of pilocarpine and explore the underlying ionic mechanism, using both aconitine-induced rat and ouabain-induced guinea pig arrhythmia models.",19721134_1,-1,-1,2,13570,-1
13574,myocytes,15,16,108,116,Confocal microscopy was used to measure intracellular free-calcium concentrations ([Ca(2+)](i)) in isolated myocytes.,19721134_2,-1,-1,2,13574,-1
13577,survival time,29,31,200,213,"The current data showed that pilocarpine significantly delayed onset of arrhythmias, decreased the time course of ventricular tachycardia and fibrillation, reduced arrhythmia score, and increased the survival time of arrhythmic rats and guinea pigs.",19721134_3,-1,-1,2,13577,-1
13578,guinea pigs,35,37,237,248,"The current data showed that pilocarpine significantly delayed onset of arrhythmias, decreased the time course of ventricular tachycardia and fibrillation, reduced arrhythmia score, and increased the survival time of arrhythmic rats and guinea pigs.",19721134_3,-1,-1,2,13578,-1
13590,cardiac M(3)-mAChR.,23,25,160,179,These data suggest that pilocarpine produced antiarrhythmic actions on arrhythmic rat and guinea pig models induced by aconitine or ouabain via stimulating the cardiac M(3)-mAChR. The mechanism may be related to the improvement of Ca(2+) handling.,19721134_6,-1,-1,2,13590,-1
13600,Seventy-one participants,0,2,0,24,"Seventy-one participants completed 2 separate study days and were blind to medication condition (placebo, 10-mg oxycodone).",19729346_2,-1,-1,2,13600,-1
13601,medication condition,11,13,75,95,"Seventy-one participants completed 2 separate study days and were blind to medication condition (placebo, 10-mg oxycodone).",19729346_2,-1,-1,2,13601,-1
13606,physiological effects,22,24,116,137,"Plasma oxycodone concentration peaked between 60 and 90 minutes postdose (P < .01) and pupil size, an indication of physiological effects of the medication, peaked at approximately 90 to 120 minutes postdose (P < .01).",19729346_3,-1,-1,2,13606,-1
13611,age groups,25,27,153,163,"Significant declines in simple and sustained attention, working memory, and verbal memory were observed at 1 hour postdose compared to baseline for both age groups with a trend toward return to baseline by 5 hours postdose.",19729346_4,-1,-1,2,13611,-1
13613,cognitive measures,3,5,15,33,"For almost all cognitive measures, there were no medication by age-interaction effects, which indicates that the 2 age groups exhibited similar responses to the medication challenge.",19729346_5,-1,-1,2,13613,-1
13614,age-interaction effects,11,13,63,86,"For almost all cognitive measures, there were no medication by age-interaction effects, which indicates that the 2 age groups exhibited similar responses to the medication challenge.",19729346_5,-1,-1,2,13614,-1
13615,age groups,19,21,115,125,"For almost all cognitive measures, there were no medication by age-interaction effects, which indicates that the 2 age groups exhibited similar responses to the medication challenge.",19729346_5,-1,-1,2,13615,-1
13632,antipsychotic-like profile,10,12,80,106,The glycine transporter-1 inhibitor SSR103800 displays a selective and specific antipsychotic-like profile in normal and transgenic mice.,19759529_0,-1,-1,2,13632,-1
13634,associated with,4,6,33,48,Schizophrenia has been initially associated with dysfunction in dopamine neurotransmission.,19759529_1,-1,-1,2,13634,-1
13644,NMDA receptor function,16,19,100,122,"Among them are glycine transporter-1 (GlyT1) inhibitors such as SSR103800, which indirectly enhance NMDA receptor function by increasing the glycine (a co-agonist for the NMDA receptor) levels in the synapse.",19759529_4,-1,-1,2,13644,-1
13660,DAT(-/-),18,20,124,132,"In contrast, SSR103800 failed to affect hyperactivity induced by amphetamine or naturally observed in dopamine transporter (DAT(-/-)) knockout mice (10-30 mg/kg p.o.).",19759529_7,-1,-1,2,13660,-1
13665,bar test,15,17,84,92,"However, unlike these latter, SSR103800 did not produce catalepsy (retention on the bar test) up to 30 mg/kg p.o.",19759529_9,-1,-1,2,13665,-1
13668,antipsychotic-like effects,12,14,75,101,"Together these findings show that the GlyT1 inhibitor, SSR103800, produces antipsychotic-like effects, which differ from those observed with compounds primarily targeting the dopaminergic system, and has a reduced side-effect potential as compared with these latter drugs.",19759529_10,-1,-1,2,13668,-1
13672,sinensis,4,5,24,32,Effect of Hibiscus rosa sinensis on reserpine-induced neurobehavioral and biochemical alterations in rats.,19761039_0,-1,-1,2,13672,-1
13678,treated with,3,5,14,26,"The rats were treated with intraperitoneal reserpine (1 mg/kg, ip) for 3 days every other day.",19761039_2,-1,-1,2,13678,-1
13684,coadministration,13,14,105,121,"Reserpine treated rats significantly developed vacuous chewing movements and tongue protrusions however, coadministration of Hibiscus rosa sinensis roots extract (100, 200 and 300 mg/kg, per orally) attenuated the effects.",19761039_4,-1,-1,2,13684,-1
13688,lipid peroxidation,11,13,92,110,"Biochemical analysis of brain revealed that the reserpine treatment significantly increased lipid peroxidation and decreased levels of superoxide dismutase (SOD), catalase (CAT) and glutathione reductase (GSH), an index of oxidative stress process.",19761039_5,-1,-1,2,13688,-1
13696,Hibiscus rosa,8,10,48,61,The results of the present study suggested that Hibiscus rosa sinensis had a protective role against reserpine-induced orofacial dyskinesia and oxidative stress.,19761039_7,-1,-1,2,13696,-1
13704,PDTC,3,4,29,33,Pyrrolidine dithiocarbamate (PDTC) has a dual mechanism of action as an antioxidant and an inhibitor of the transcription factor kappa-beta.,19767176_1,-1,-1,2,13704,-1
13705,mechanism of action,8,11,46,65,Pyrrolidine dithiocarbamate (PDTC) has a dual mechanism of action as an antioxidant and an inhibitor of the transcription factor kappa-beta.,19767176_1,-1,-1,2,13705,-1
13710,PDTC,3,4,14,18,The effect of PDTC on status epilepticus-associated cell loss in the hippocampus and piriform cortex was evaluated in the rat fractionated pilocarpine model.,19767176_3,-1,-1,2,13710,-1
13714,PDTC,4,5,25,29,Treatment with 150 mg/kg PDTC before and following status epilepticus significantly increased the mortality rate to 100%.,19767176_4,-1,-1,2,13714,-1
13716,mortality rate,13,15,98,112,Treatment with 150 mg/kg PDTC before and following status epilepticus significantly increased the mortality rate to 100%.,19767176_4,-1,-1,2,13716,-1
13717,PDTC,4,5,27,31,Administration of 50 mg/kg PDTC (low-dose) did not exert major effects on the development of a status epilepticus or the mortality rate.,19767176_5,-1,-1,2,13717,-1
13720,mortality rate,22,24,121,135,Administration of 50 mg/kg PDTC (low-dose) did not exert major effects on the development of a status epilepticus or the mortality rate.,19767176_5,-1,-1,2,13720,-1
13725,pyramidal cells,16,18,117,132,"In vehicle-treated rats, status epilepticus caused pronounced neuronal damage in the piriform cortex comprising both pyramidal cells and interneurons.",19767176_6,-1,-1,2,13725,-1
13730,neuronal density,4,6,26,42,A significant decrease in neuronal density of the hippocampal hilar formation was identified in vehicle- and PDTC-treated rats following status epilepticus.,19767176_8,-1,-1,2,13730,-1
13734,PDTC-treated,16,17,109,121,A significant decrease in neuronal density of the hippocampal hilar formation was identified in vehicle- and PDTC-treated rats following status epilepticus.,19767176_8,-1,-1,2,13734,-1
13746,Anaesthetists' nightmare,0,3,0,24,Anaesthetists' nightmare: masseter spasm after induction in an undiagnosed case of myotonia congenita.,19803309_0,-1,-1,2,13746,-1
13777,effects of,2,4,9,19,"When the effects of IV drugs are inadequate in patients receiving CVVHDF, interference with adjacent catheters resulting in elimination of the drug by CVVHDF should be suspected.",19843802_6,-1,-1,2,13777,-1
13783,multiple doses,28,30,179,193,OBJECTIVE: This study was designed to determine whether patients maintained on a regimen of lithium on a once-per-day schedule have lower urine volumes than do patients receiving multiple doses per day.,1987816_1,-1,-1,2,13783,-1
13784,cross-sectional study,5,7,19,40,METHOD: This was a cross-sectional study of 85 patients from a lithium clinic who received different dose schedules.,1987816_2,-1,-1,2,13784,-1
13785,lithium clinic,12,14,63,77,METHOD: This was a cross-sectional study of 85 patients from a lithium clinic who received different dose schedules.,1987816_2,-1,-1,2,13785,-1
13788,urine volume,15,17,95,107,"Patients were admitted to the hospital for measurement of lithium level, creatinine clearance, urine volume, and maximum osmolality.",1987816_3,-1,-1,2,13788,-1
13790,Multiple daily,2,4,9,23,RESULTS: Multiple daily doses of lithium were associated with higher urine volumes.,1987816_4,-1,-1,2,13790,-1
13791,associated with,8,10,46,61,RESULTS: Multiple daily doses of lithium were associated with higher urine volumes.,1987816_4,-1,-1,2,13791,-1
13800,renal effects,12,14,73,86,Lithium-induced polyuria seems to be related to extrarenal as well as to renal effects.,1987816_7,-1,-1,2,13800,-1
13808,case-control study,11,13,64,82,"DESIGN, SETTING, AND PARTICIPANTS: Population-based, multisite, case-control study of women who had pregnancies affected by 1 of more than 30 eligible major birth defects identified via birth defect surveillance programs in 10 states (n = 13 155) and control women randomly selected from the same geographical regions (n = 4941).",19884587_2,-1,-1,2,13808,-1
13818,associated with,2,4,18,33,"Sulfonamides were associated with anencephaly (adjusted OR [AOR] = 3.4; 95% confidence interval [CI], 1.3-8.8), hypoplastic left heart syndrome (AOR = 3.2; 95% CI, 1.3-7.6), coarctation of the aorta (AOR = 2.7; 95% CI, 1.3-5.6), choanal atresia (AOR = 8.0; 95% CI, 2.7-23.5), transverse limb deficiency (AOR = 2.5; 95% CI, 1.0-5.9), and diaphragmatic hernia (AOR = 2.4; 95% CI, 1.1-5.4).",19884587_6,-1,-1,2,13818,-1
13820,confidence interval,16,18,76,95,"Sulfonamides were associated with anencephaly (adjusted OR [AOR] = 3.4; 95% confidence interval [CI], 1.3-8.8), hypoplastic left heart syndrome (AOR = 3.2; 95% CI, 1.3-7.6), coarctation of the aorta (AOR = 2.7; 95% CI, 1.3-5.6), choanal atresia (AOR = 8.0; 95% CI, 2.7-23.5), transverse limb deficiency (AOR = 2.5; 95% CI, 1.0-5.9), and diaphragmatic hernia (AOR = 2.4; 95% CI, 1.1-5.4).",19884587_6,-1,-1,2,13820,-1
13822,AOR,32,33,145,148,"Sulfonamides were associated with anencephaly (adjusted OR [AOR] = 3.4; 95% confidence interval [CI], 1.3-8.8), hypoplastic left heart syndrome (AOR = 3.2; 95% CI, 1.3-7.6), coarctation of the aorta (AOR = 2.7; 95% CI, 1.3-5.6), choanal atresia (AOR = 8.0; 95% CI, 2.7-23.5), transverse limb deficiency (AOR = 2.5; 95% CI, 1.0-5.9), and diaphragmatic hernia (AOR = 2.4; 95% CI, 1.1-5.4).",19884587_6,-1,-1,2,13822,-1
13824,AOR,50,51,200,203,"Sulfonamides were associated with anencephaly (adjusted OR [AOR] = 3.4; 95% confidence interval [CI], 1.3-8.8), hypoplastic left heart syndrome (AOR = 3.2; 95% CI, 1.3-7.6), coarctation of the aorta (AOR = 2.7; 95% CI, 1.3-5.6), choanal atresia (AOR = 8.0; 95% CI, 2.7-23.5), transverse limb deficiency (AOR = 2.5; 95% CI, 1.0-5.9), and diaphragmatic hernia (AOR = 2.4; 95% CI, 1.1-5.4).",19884587_6,-1,-1,2,13824,-1
13826,AOR,66,67,246,249,"Sulfonamides were associated with anencephaly (adjusted OR [AOR] = 3.4; 95% confidence interval [CI], 1.3-8.8), hypoplastic left heart syndrome (AOR = 3.2; 95% CI, 1.3-7.6), coarctation of the aorta (AOR = 2.7; 95% CI, 1.3-5.6), choanal atresia (AOR = 8.0; 95% CI, 2.7-23.5), transverse limb deficiency (AOR = 2.5; 95% CI, 1.0-5.9), and diaphragmatic hernia (AOR = 2.4; 95% CI, 1.1-5.4).",19884587_6,-1,-1,2,13826,-1
13828,AOR,83,84,304,307,"Sulfonamides were associated with anencephaly (adjusted OR [AOR] = 3.4; 95% confidence interval [CI], 1.3-8.8), hypoplastic left heart syndrome (AOR = 3.2; 95% CI, 1.3-7.6), coarctation of the aorta (AOR = 2.7; 95% CI, 1.3-5.6), choanal atresia (AOR = 8.0; 95% CI, 2.7-23.5), transverse limb deficiency (AOR = 2.5; 95% CI, 1.0-5.9), and diaphragmatic hernia (AOR = 2.4; 95% CI, 1.1-5.4).",19884587_6,-1,-1,2,13828,-1
13830,AOR,100,101,359,362,"Sulfonamides were associated with anencephaly (adjusted OR [AOR] = 3.4; 95% confidence interval [CI], 1.3-8.8), hypoplastic left heart syndrome (AOR = 3.2; 95% CI, 1.3-7.6), coarctation of the aorta (AOR = 2.7; 95% CI, 1.3-5.6), choanal atresia (AOR = 8.0; 95% CI, 2.7-23.5), transverse limb deficiency (AOR = 2.5; 95% CI, 1.0-5.9), and diaphragmatic hernia (AOR = 2.4; 95% CI, 1.1-5.4).",19884587_6,-1,-1,2,13830,-1
13831,associated with,2,4,21,36,"Nitrofurantoins were associated with anophthalmia or microphthalmos (AOR = 3.7; 95% CI, 1.1-12.2), hypoplastic left heart syndrome (AOR = 4.2; 95% CI, 1.9-9.1), atrial septal defects (AOR = 1.9; 95% CI, 1.1-3.4), and cleft lip with cleft palate (AOR = 2.1; 95% CI, 1.2-3.9).",19884587_7,-1,-1,2,13831,-1
13834,AOR,8,9,69,72,"Nitrofurantoins were associated with anophthalmia or microphthalmos (AOR = 3.7; 95% CI, 1.1-12.2), hypoplastic left heart syndrome (AOR = 4.2; 95% CI, 1.9-9.1), atrial septal defects (AOR = 1.9; 95% CI, 1.1-3.4), and cleft lip with cleft palate (AOR = 2.1; 95% CI, 1.2-3.9).",19884587_7,-1,-1,2,13834,-1
13836,AOR,26,27,132,135,"Nitrofurantoins were associated with anophthalmia or microphthalmos (AOR = 3.7; 95% CI, 1.1-12.2), hypoplastic left heart syndrome (AOR = 4.2; 95% CI, 1.9-9.1), atrial septal defects (AOR = 1.9; 95% CI, 1.1-3.4), and cleft lip with cleft palate (AOR = 2.1; 95% CI, 1.2-3.9).",19884587_7,-1,-1,2,13836,-1
13838,AOR,43,44,184,187,"Nitrofurantoins were associated with anophthalmia or microphthalmos (AOR = 3.7; 95% CI, 1.1-12.2), hypoplastic left heart syndrome (AOR = 4.2; 95% CI, 1.9-9.1), atrial septal defects (AOR = 1.9; 95% CI, 1.1-3.4), and cleft lip with cleft palate (AOR = 2.1; 95% CI, 1.2-3.9).",19884587_7,-1,-1,2,13838,-1
13840,AOR,63,64,246,249,"Nitrofurantoins were associated with anophthalmia or microphthalmos (AOR = 3.7; 95% CI, 1.1-12.2), hypoplastic left heart syndrome (AOR = 4.2; 95% CI, 1.9-9.1), atrial septal defects (AOR = 1.9; 95% CI, 1.1-3.4), and cleft lip with cleft palate (AOR = 2.1; 95% CI, 1.2-3.9).",19884587_7,-1,-1,2,13840,-1
13847,associated with,20,22,126,141,"CONCLUSIONS: Reassuringly, penicillins, erythromycins, and cephalosporins, although used commonly by pregnant women, were not associated with many birth defects.",19884587_9,-1,-1,2,13847,-1
13849,associated with,4,6,38,53,"Sulfonamides and nitrofurantoins were associated with several birth defects, indicating a need for additional scrutiny.",19884587_10,-1,-1,2,13849,-1
13851,Differential impact,0,2,0,19,Differential impact of immune escape mutations G145R and P120T on the replication of lamivudine-resistant hepatitis B virus e antigen-positive and -negative strains.,19889778_0,-1,-1,2,13851,-1
13852,immune escape mutations,3,6,23,46,Differential impact of immune escape mutations G145R and P120T on the replication of lamivudine-resistant hepatitis B virus e antigen-positive and -negative strains.,19889778_0,-1,-1,2,13852,-1
13856,antigen-positive,19,20,126,142,Differential impact of immune escape mutations G145R and P120T on the replication of lamivudine-resistant hepatitis B virus e antigen-positive and -negative strains.,19889778_0,-1,-1,2,13856,-1
13857,Immune escape variants,0,3,0,22,"Immune escape variants of the hepatitis B virus (HBV) represent an emerging clinical challenge, because they can be associated with vaccine escape, HBV reactivation, and failure of diagnostic tests.",19889778_1,-1,-1,2,13857,-1
13860,associated with,21,23,116,131,"Immune escape variants of the hepatitis B virus (HBV) represent an emerging clinical challenge, because they can be associated with vaccine escape, HBV reactivation, and failure of diagnostic tests.",19889778_1,-1,-1,2,13860,-1
13861,vaccine escape,23,25,132,146,"Immune escape variants of the hepatitis B virus (HBV) represent an emerging clinical challenge, because they can be associated with vaccine escape, HBV reactivation, and failure of diagnostic tests.",19889778_1,-1,-1,2,13861,-1
13862,HBV,26,27,148,151,"Immune escape variants of the hepatitis B virus (HBV) represent an emerging clinical challenge, because they can be associated with vaccine escape, HBV reactivation, and failure of diagnostic tests.",19889778_1,-1,-1,2,13862,-1
13864,diagnostic tests,32,34,181,197,"Immune escape variants of the hepatitis B virus (HBV) represent an emerging clinical challenge, because they can be associated with vaccine escape, HBV reactivation, and failure of diagnostic tests.",19889778_1,-1,-1,2,13864,-1
13865,immune escape mutants,7,10,48,69,Recent data suggest a preferential selection of immune escape mutants in distinct peripheral blood leukocyte compartments of infected individuals.,19889778_2,-1,-1,2,13865,-1
13867,immune escape,11,13,81,94,"We therefore systematically analyzed the functional impact of the most prevalent immune escape variants, the sG145R and sP120T mutants, on the viral replication efficacy and antiviral drug susceptibility of common treatment-associated mutants with resistance to lamivudine (LAM) and/or HBeAg negativity.",19889778_3,-1,-1,2,13867,-1
13874,HBV,1,2,22,25,Replication-competent HBV strains with sG145R or sP120T and LAM resistance (rtM204I or rtL180M/rtM204V) were generated on an HBeAg-positive and an HBeAg-negative background with precore (PC) and basal core promoter (BCP) mutants.,19889778_4,-1,-1,2,13874,-1
13881,precore,26,27,178,185,Replication-competent HBV strains with sG145R or sP120T and LAM resistance (rtM204I or rtL180M/rtM204V) were generated on an HBeAg-positive and an HBeAg-negative background with precore (PC) and basal core promoter (BCP) mutants.,19889778_4,-1,-1,2,13881,-1
13882,basal core promoter,31,34,195,214,Replication-competent HBV strains with sG145R or sP120T and LAM resistance (rtM204I or rtL180M/rtM204V) were generated on an HBeAg-positive and an HBeAg-negative background with precore (PC) and basal core promoter (BCP) mutants.,19889778_4,-1,-1,2,13882,-1
13885,LAM-resistant,17,18,108,121,"The sG145R mutation strongly reduced HBsAg levels and was able to fully restore the impaired replication of LAM-resistant HBV mutants to the levels of wild-type HBV, and PC or BCP mutations further enhanced viral replication.",19889778_5,-1,-1,2,13885,-1
13888,BCP mutations,30,32,176,189,"The sG145R mutation strongly reduced HBsAg levels and was able to fully restore the impaired replication of LAM-resistant HBV mutants to the levels of wild-type HBV, and PC or BCP mutations further enhanced viral replication.",19889778_5,-1,-1,2,13888,-1
13892,LAM-resistant,17,18,102,115,"Although the sP120T substitution also impaired HBsAg secretion, it did not enhance the replication of LAM-resistant clones.",19889778_6,-1,-1,2,13892,-1
13894,PC/BCP,9,10,57,63,"However, the concomitant occurrence of HBeAg negativity (PC/BCP), sP120T, and LAM resistance resulted in the restoration of replication to levels of wild-type HBV.",19889778_7,-1,-1,2,13894,-1
13896,wild-type,27,28,149,158,"However, the concomitant occurrence of HBeAg negativity (PC/BCP), sP120T, and LAM resistance resulted in the restoration of replication to levels of wild-type HBV.",19889778_7,-1,-1,2,13896,-1
13903,in vitro,24,26,172,180,"In all clones with combined immune escape and LAM resistance mutations, the nucleotide analogues adefovir and tenofovir remained effective in suppressing viral replication in vitro.",19889778_8,-1,-1,2,13903,-1
13904,immune escape variants,7,10,49,71,"These findings reveal the differential impact of immune escape variants on the replication and drug susceptibility of complex HBV mutants, supporting the need of close surveillance and treatment adjustment in response to the selection of distinct mutational patterns.",19889778_9,-1,-1,2,13904,-1
13906,HBV,18,19,126,129,"These findings reveal the differential impact of immune escape variants on the replication and drug susceptibility of complex HBV mutants, supporting the need of close surveillance and treatment adjustment in response to the selection of distinct mutational patterns.",19889778_9,-1,-1,2,13906,-1
13908,Dynamic response,0,2,0,16,Dynamic response of blood vessel in acute renal failure.,19893084_0,-1,-1,2,13908,-1
13912,dynamic response,16,18,99,115,"In this study we postulated that during acute renal failure induced by gentamicin the transient or dynamic response of blood vessels could be affected, and that antioxidants can prevent the changes in dynamic responses of blood vessels.",19893084_1,-1,-1,2,13912,-1
13914,dynamic responses,33,35,201,218,"In this study we postulated that during acute renal failure induced by gentamicin the transient or dynamic response of blood vessels could be affected, and that antioxidants can prevent the changes in dynamic responses of blood vessels.",19893084_1,-1,-1,2,13914,-1
13916,ex vivo,4,6,20,27,"The new approach to ex vivo blood vessel experiments in which not only the end points of vessels response within the time interval is considered, but also dynamics of this response, was used in this paper.",19893084_2,-1,-1,2,13916,-1
13919,time interval,21,23,117,130,"The new approach to ex vivo blood vessel experiments in which not only the end points of vessels response within the time interval is considered, but also dynamics of this response, was used in this paper.",19893084_2,-1,-1,2,13919,-1
13920,dynamic response,6,8,38,54,Our results confirm the alteration in dynamic response of blood vessels during the change of pressure in gentamicin-treated animals.,19893084_3,-1,-1,2,13920,-1
13922,gentamicin-treated,17,18,105,123,Our results confirm the alteration in dynamic response of blood vessels during the change of pressure in gentamicin-treated animals.,19893084_3,-1,-1,2,13922,-1
13924,gentamicin-treated animals,8,10,54,80,The beneficial effects of vitamin C administration to gentamicin-treated animals are also confirmed through: lower level of blood urea and creatinine and higher level of potassium.,19893084_4,-1,-1,2,13924,-1
13927,dynamic responses,2,4,13,30,The pressure dynamic responses of isolated blood vessels show a faster pressure change in gentamicin-treated animals (8.07 +/- 1.7 s vs. 5.64 +/- 0.18 s).,19893084_5,-1,-1,2,13927,-1
13930,gentamicin-treated animals,14,16,90,116,The pressure dynamic responses of isolated blood vessels show a faster pressure change in gentamicin-treated animals (8.07 +/- 1.7 s vs. 5.64 +/- 0.18 s).,19893084_5,-1,-1,2,13930,-1
13931,/-,19,20,124,126,The pressure dynamic responses of isolated blood vessels show a faster pressure change in gentamicin-treated animals (8.07 +/- 1.7 s vs. 5.64 +/- 0.18 s).,19893084_5,0,1,2,13931,-1
13932,/-,25,26,143,145,The pressure dynamic responses of isolated blood vessels show a faster pressure change in gentamicin-treated animals (8.07 +/- 1.7 s vs. 5.64 +/- 0.18 s).,19893084_5,0,1,2,13932,-1
13935,control values,11,13,73,87,Vitamin C administration induced slowdown of pressure change back to the control values.,19893084_6,-1,-1,2,13935,-1
13938,dynamic response,20,22,142,158,"The pressure dynamic properties, quantitatively defined by comparative pressure dynamic and total pressure dynamic, confirm the alteration in dynamic response of blood vessels during the change of pressure in gentamicin-treated animals and beneficial effects of vitamin C administration.",19893084_7,-1,-1,2,13938,-1
13940,gentamicin-treated animals,31,33,209,235,"The pressure dynamic properties, quantitatively defined by comparative pressure dynamic and total pressure dynamic, confirm the alteration in dynamic response of blood vessels during the change of pressure in gentamicin-treated animals and beneficial effects of vitamin C administration.",19893084_7,-1,-1,2,13940,-1
13967,blood concentration,6,8,42,61,"In patients receiving tacrolimus therapy, blood concentration should be carefully controlled and extreme attention paid to cardiac involvement.",19917396_9,-1,-1,2,13967,-1
13975,onset of,12,14,68,76,We tested the hypothesis that nimodipine (NIMO) administered at the onset of nitroglycerin (NTG)-induced hypotension would preserve long-term associative memory.,19923525_2,-1,-1,2,13975,-1
13980,suspended platform,14,16,68,86,"For PA training, latencies (seconds) were recorded for entry from a suspended platform into a Plexiglas tube where a shock was automatically delivered.",19923525_4,-1,-1,2,13980,-1
13981,Plexiglas tube,18,20,94,108,"For PA training, latencies (seconds) were recorded for entry from a suspended platform into a Plexiglas tube where a shock was automatically delivered.",19923525_4,-1,-1,2,13981,-1
13982,automatically delivered,24,26,127,150,"For PA training, latencies (seconds) were recorded for entry from a suspended platform into a Plexiglas tube where a shock was automatically delivered.",19923525_4,-1,-1,2,13982,-1
13983,testing trial,8,10,41,54,Latencies were recorded 48 h later for a testing trial.,19923525_5,-1,-1,2,13983,-1
13985,NTG,29,30,103,106,"Ninety-six Swiss-Webster mice (30-35 g, 6-8 wk), were randomized into 6 groups 1) saline (control), 2) NTG immediately after learning, 3) NTG 3 h after learning, 4) NTG and NIMO, 5) vehicle, and 6) NIMO alone.",19923525_6,-1,-1,2,13985,-1
13986,NTG,36,37,138,141,"Ninety-six Swiss-Webster mice (30-35 g, 6-8 wk), were randomized into 6 groups 1) saline (control), 2) NTG immediately after learning, 3) NTG 3 h after learning, 4) NTG and NIMO, 5) vehicle, and 6) NIMO alone.",19923525_6,-1,-1,2,13986,-1
13992,training latencies,6,8,38,56,RESULTS: All groups exhibited similar training latencies (17.0 +/- 4.6 s).,19923525_8,-1,-1,2,13992,-1
13993,/-,11,12,64,66,RESULTS: All groups exhibited similar training latencies (17.0 +/- 4.6 s).,19923525_8,0,1,2,13993,-1
13995,latency time,10,12,72,84,"Mice subjected to hypotensive episodes showed a significant decrease in latency time (178 +/- 156 s) compared with those injected with saline, NTG + NIMO, or delayed NTG (580 +/- 81 s, 557 +/- 67 s, and 493 +/- 146 s, respectively).",19923525_9,-1,-1,2,13995,-1
13996,/- 156,15,17,91,97,"Mice subjected to hypotensive episodes showed a significant decrease in latency time (178 +/- 156 s) compared with those injected with saline, NTG + NIMO, or delayed NTG (580 +/- 81 s, 557 +/- 67 s, and 493 +/- 146 s, respectively).",19923525_9,-1,-1,2,13996,-1
13997,NTG,26,27,143,146,"Mice subjected to hypotensive episodes showed a significant decrease in latency time (178 +/- 156 s) compared with those injected with saline, NTG + NIMO, or delayed NTG (580 +/- 81 s, 557 +/- 67 s, and 493 +/- 146 s, respectively).",19923525_9,-1,-1,2,13997,-1
14000,/-,36,37,176,178,"Mice subjected to hypotensive episodes showed a significant decrease in latency time (178 +/- 156 s) compared with those injected with saline, NTG + NIMO, or delayed NTG (580 +/- 81 s, 557 +/- 67 s, and 493 +/- 146 s, respectively).",19923525_9,0,1,2,14000,-1
14001,/-,42,43,190,192,"Mice subjected to hypotensive episodes showed a significant decrease in latency time (178 +/- 156 s) compared with those injected with saline, NTG + NIMO, or delayed NTG (580 +/- 81 s, 557 +/- 67 s, and 493 +/- 146 s, respectively).",19923525_9,0,1,2,14001,-1
14002,/-,49,50,208,210,"Mice subjected to hypotensive episodes showed a significant decrease in latency time (178 +/- 156 s) compared with those injected with saline, NTG + NIMO, or delayed NTG (580 +/- 81 s, 557 +/- 67 s, and 493 +/- 146 s, respectively).",19923525_9,0,1,2,14002,-1
14003,Kruskal-Wallis 1-way analysis of,1,5,2,34,A Kruskal-Wallis 1-way analysis of variance indicated a significant difference among the 4 treatment groups (H = 15.34; P < 0.001).,19923525_10,-1,-1,2,14003,-1
14004,treatment groups,13,15,91,107,A Kruskal-Wallis 1-way analysis of variance indicated a significant difference among the 4 treatment groups (H = 15.34; P < 0.001).,19923525_10,-1,-1,2,14004,-1
14005,behavioral studies,9,11,45,63,"In a separate group of mice not subjected to behavioral studies, the same dose of NTG (n = 3) and NTG + NIMO (n = 3) caused mean arterial blood pressure to decrease from 85.9 +/- 3.8 mm Hg sem to 31.6 +/- 0.8 mm Hg sem and from 86.2 +/- 3.7 mm Hg sem to 32.6 +/- 0.2 mm Hg sem, respectively.",19923525_11,-1,-1,2,14005,-1
14013,/-,66,67,260,262,"In a separate group of mice not subjected to behavioral studies, the same dose of NTG (n = 3) and NTG + NIMO (n = 3) caused mean arterial blood pressure to decrease from 85.9 +/- 3.8 mm Hg sem to 31.6 +/- 0.8 mm Hg sem and from 86.2 +/- 3.7 mm Hg sem to 32.6 +/- 0.2 mm Hg sem, respectively.",19923525_11,0,1,2,14013,-1
14015,treated with,6,8,37,49,Mean arterial blood pressure in mice treated with NIMO alone decreased from 88.1 +/- 3.8 mm Hg to 80.0 +/- 2.9 mm Hg.,19923525_12,-1,-1,2,14015,-1
14017,/-,14,15,82,84,Mean arterial blood pressure in mice treated with NIMO alone decreased from 88.1 +/- 3.8 mm Hg to 80.0 +/- 2.9 mm Hg.,19923525_12,0,1,2,14017,-1
14020,statistically significant,4,6,30,55,The intergroup difference was statistically significant (P < 0.05).,19923525_13,-1,-1,2,14020,-1
14021,/-,6,7,29,31,"PbtO(2) decreased from 51.7 +/- 4.5 mm Hg sem to 33.8 +/- 5.2 mm Hg sem in the NTG group and from 38.6 +/- 6.1 mm Hg sem to 25.4 +/- 2.0 mm Hg sem in the NTG + NIMO groups, respectively.",19923525_14,0,1,2,14021,-1
14022,/-,14,15,55,57,"PbtO(2) decreased from 51.7 +/- 4.5 mm Hg sem to 33.8 +/- 5.2 mm Hg sem in the NTG group and from 38.6 +/- 6.1 mm Hg sem to 25.4 +/- 2.0 mm Hg sem in the NTG + NIMO groups, respectively.",19923525_14,0,1,2,14022,-1
14025,/-,35,36,130,132,"PbtO(2) decreased from 51.7 +/- 4.5 mm Hg sem to 33.8 +/- 5.2 mm Hg sem in the NTG group and from 38.6 +/- 6.1 mm Hg sem to 25.4 +/- 2.0 mm Hg sem in the NTG + NIMO groups, respectively.",19923525_14,0,1,2,14025,-1
14029,NTG,11,12,57,60,"CONCLUSION: In a PA retention paradigm, the injection of NTG immediately after learning produced a significant impairment of long-term associative memory in mice, whereas delayed induced hypotension had no effect.",19923525_16,-1,-1,2,14029,-1
14030,no effect,31,33,203,212,"CONCLUSION: In a PA retention paradigm, the injection of NTG immediately after learning produced a significant impairment of long-term associative memory in mice, whereas delayed induced hypotension had no effect.",19923525_16,-1,-1,2,14030,-1
14035,PbtO(2) indices,25,28,159,174,"The observed effect of NIMO may have been attributable to the preservation of calcium homeostasis during hypotension, because there were no differences in the PbtO(2) indices among groups.",19923525_18,-1,-1,2,14035,-1
14037,associated with,2,4,17,32,Hemolytic anemia associated with the use of omeprazole.,1992636_0,-1,-1,2,14037,-1
14038,secretory process,14,16,74,91,Omeprazole is the first drug designed to block the final step in the acid secretory process within the parietal cell.,1992636_1,-1,-1,2,14038,-1
14042,controlled studies,10,12,68,86,"Although clinical experience with omeprazole is still limited, many controlled studies have established the short-term safety of this drug.",1992636_3,-1,-1,2,14042,-1
14047,Coombs antiglobulin test,25,28,123,147,"Two weeks after the initiation of therapy, her hematocrit had decreased from 44.1% to 20.4%, and she had a positive direct Coombs antiglobulin test and an elevated indirect bilirubin.",1992636_6,-1,-1,2,14047,-1
14058,synaptic transmission,7,9,49,70,Metabotropic glutamate (mGlu) receptors modulate synaptic transmission in the central nervous system and represent promising therapeutic targets for symptomatic treatment of Parkinson's disease (PD).,19940105_1,-1,-1,2,14058,-1
14066,animal models,25,27,146,159,"Among the eight mGlu receptor subtypes, mGlu7 receptor is prominently expressed in the basal ganglia, but its role in restoring motor function in animal models of PD is not known.",19940105_2,-1,-1,2,14066,-1
14072,intrastriatal administration,11,13,37,65,"Here, we show that oral (5 mg/kg) or intrastriatal administration (0.1 and 0.5 nmol) of AMN082 reverses haloperidol-induced catalepsy in rats.",19940105_4,-1,-1,2,14072,-1
14079,reaction time,22,24,127,140,"In a more complex task commonly used to evaluate major akinetic symptoms of PD patients, 5 mg/kg AMN082 reverses the increased reaction time to respond to a cue of bilateral 6-OHDA-lesioned rats.",19940105_6,-1,-1,2,14079,-1
14082,receptor-dependent,13,14,85,103,"In addition, AMN082 reduces the duration of haloperidol-induced catalepsy in a mGlu7 receptor-dependent manner in wild-type but not mGlu7 receptor knockout mice.",19940105_7,-1,-1,2,14082,-1
14087,no effect,13,15,51,60,Higher doses of AMN082 (10 and 20 mg/kg p.o.) have no effect on the same models of PD.,19940105_8,-1,-1,2,14087,-1
14090,associated with,12,14,92,107,Overall these findings suggest that mGlu7 receptor activation can reverse motor dysfunction associated with reduced dopamine activity.,19940105_9,-1,-1,2,14090,-1
14106,provocative test,7,9,39,55,Coronary artery spasm was induced by a provocative test.,19944333_6,-1,-1,2,14106,-1
14117,Rho/ROCK pathway,6,8,23,39,"On the other hand, the Rho/ROCK pathway has an important role in the pathogenesis of coronary artery spasm.",19944333_11,-1,-1,2,14117,-1
14120,Rho/ROCK pathway,9,11,45,61,Our report may show an adverse effect on the Rho/ROCK pathway by sorafenib use.,19944333_12,-1,-1,2,14120,-1
14124,BBB.The,19,20,106,113,A novel animal model to evaluate the ability of a drug delivery system to promote the passage through the BBB.The purpose of this investigation was to explore the potentiality of a novel animal model to be used for the in vivo evaluation of the ability of a drug delivery system to promote the passage through the blood-brain barrier (BBB) and/or to improve the brain localization of a bioactive compound.,19944736_0,-1,-1,2,14124,-1
14129,BBB,59,60,335,338,A novel animal model to evaluate the ability of a drug delivery system to promote the passage through the BBB.The purpose of this investigation was to explore the potentiality of a novel animal model to be used for the in vivo evaluation of the ability of a drug delivery system to promote the passage through the blood-brain barrier (BBB) and/or to improve the brain localization of a bioactive compound.,19944736_0,-1,-1,2,14129,-1
14133,colloidal drug delivery system,12,16,74,104,"A Tween 80-coated poly-L-lactid acid nanoparticles was used as a model of colloidal drug delivery system, able to trespass the BBB.",19944736_1,-1,-1,2,14133,-1
14134,BBB,21,22,127,130,"A Tween 80-coated poly-L-lactid acid nanoparticles was used as a model of colloidal drug delivery system, able to trespass the BBB.",19944736_1,-1,-1,2,14134,-1
14136,LiCl,4,5,25,29,"Tacrine, administered in LiCl pre-treated rats, induces electrocorticographic seizures and delayed hippocampal damage.",19944736_2,-1,-1,2,14136,-1
14139,toxic effects,1,3,4,17,"The toxic effects of tacrine-loaded poly-L-lactid acid nanoparticles (5mg/kg), a saline solution of tacrine (5mg/kg) and an empty colloidal nanoparticle suspension were compared following i.p.",19944736_3,-1,-1,2,14139,-1
14145,LiCl-pre-treated Wistar rats,2,5,18,46,administration in LiCl-pre-treated Wistar rats.,19944736_4,-1,-1,2,14145,-1
14146,treated with,3,5,16,28,"All the animals treated with tacrine-loaded nanoparticles showed an earlier outcome of CNS adverse symptoms, i.e. epileptic onset, with respect to those animals treated with the free compound (10 min vs. 22 min respectively).",19944736_5,-1,-1,2,14146,-1
14150,treated with,25,27,161,173,"All the animals treated with tacrine-loaded nanoparticles showed an earlier outcome of CNS adverse symptoms, i.e. epileptic onset, with respect to those animals treated with the free compound (10 min vs. 22 min respectively).",19944736_5,-1,-1,2,14150,-1
14153,neuronal cells,9,11,75,89,"In addition, tacrine-loaded nanoparticles administration induced damage of neuronal cells in CA1 field of the hippocampus in all treated animals, while the saline solution of tacrine only in 60% of animals.",19944736_6,-1,-1,2,14153,-1
14160,drug delivery system,36,39,228,248,"In conclusion, the evaluation of time-to-onset of symptoms and the severity of neurodegenerative processes induced by the tacrine-lithium model of epilepsy in the rat, could be used to evaluate preliminarily the capability of a drug delivery system to trespass (or not) the BBB in vivo.",19944736_8,-1,-1,2,14160,-1
14162,in vivo,47,49,278,285,"In conclusion, the evaluation of time-to-onset of symptoms and the severity of neurodegenerative processes induced by the tacrine-lithium model of epilepsy in the rat, could be used to evaluate preliminarily the capability of a drug delivery system to trespass (or not) the BBB in vivo.",19944736_8,-1,-1,2,14162,-1
14172,SV,11,12,37,39,"Heart rate (HR), MAP, stroke volume (SV), cardiac output (CO), and frontal lobe oxygenation (S(c)O(2)) were registered.",19957053_4,-1,-1,2,14172,-1
14176,SV,15,16,72,74,"RESULTS: Induction of anesthesia was followed by a decrease in MAP, HR, SV, and CO concomitant with an elevation in S(c)O(2).",19957053_5,-1,-1,2,14176,-1
14178,/-,10,11,58,60,"After administration of phenylephrine, MAP increased (51 +/- 12 to 81 +/- 13 mmHg; P < 0.001; mean +/- SD).",19957053_6,0,1,2,14178,-1
14179,/- 13 mmHg,15,18,71,81,"After administration of phenylephrine, MAP increased (51 +/- 12 to 81 +/- 13 mmHg; P < 0.001; mean +/- SD).",19957053_6,-1,-1,2,14179,-1
14180,/- SD,25,27,100,105,"After administration of phenylephrine, MAP increased (51 +/- 12 to 81 +/- 13 mmHg; P < 0.001; mean +/- SD).",19957053_6,-1,-1,2,14180,-1
14181,/-,9,10,25,27,"However, a 14% (from 70 +/- 8% to 60 +/- 7%) reduction in S(c)O(2) (P < 0.05) followed with no change in CO (3.7 +/- 1.1 to 3.4 +/- 0.9 l min(-1)).",19957053_7,0,1,2,14181,-1
14182,/-,15,16,38,40,"However, a 14% (from 70 +/- 8% to 60 +/- 7%) reduction in S(c)O(2) (P < 0.05) followed with no change in CO (3.7 +/- 1.1 to 3.4 +/- 0.9 l min(-1)).",19957053_7,0,1,2,14182,-1
14183,S(c)O(2),21,23,58,66,"However, a 14% (from 70 +/- 8% to 60 +/- 7%) reduction in S(c)O(2) (P < 0.05) followed with no change in CO (3.7 +/- 1.1 to 3.4 +/- 0.9 l min(-1)).",19957053_7,-1,-1,2,14183,-1
14184,no change,30,32,92,101,"However, a 14% (from 70 +/- 8% to 60 +/- 7%) reduction in S(c)O(2) (P < 0.05) followed with no change in CO (3.7 +/- 1.1 to 3.4 +/- 0.9 l min(-1)).",19957053_7,-1,-1,2,14184,-1
14186,/-,42,43,129,131,"However, a 14% (from 70 +/- 8% to 60 +/- 7%) reduction in S(c)O(2) (P < 0.05) followed with no change in CO (3.7 +/- 1.1 to 3.4 +/- 0.9 l min(-1)).",19957053_7,0,1,2,14186,-1
14187,/-,14,15,70,72,"The administration of ephedrine led to a similar increase in MAP (53 +/- 9 to 79 +/- 8 mmHg; P < 0.001), restored CO (3.2 +/- 1.2 to 5.0 +/- 1.3 l min(-1)), and preserved S(c)O(2).",19957053_8,0,1,2,14187,-1
14188,/- 8 mmHg,19,22,82,91,"The administration of ephedrine led to a similar increase in MAP (53 +/- 9 to 79 +/- 8 mmHg; P < 0.001), restored CO (3.2 +/- 1.2 to 5.0 +/- 1.3 l min(-1)), and preserved S(c)O(2).",19957053_8,-1,-1,2,14188,-1
14192,S(c)O(2,17,18,116,123,CONCLUSIONS: The utilization of phenylephrine to correct hypotension induced by anesthesia has a negative impact on S(c)O(2) while ephedrine maintains frontal lobe oxygenation potentially related to an increase in CO.,19957053_9,-1,-1,2,14192,-1
14195,associated with,4,6,29,44,High-dose tranexamic Acid is associated with nonischemic clinical seizures in cardiac surgical patients.,19996135_0,-1,-1,2,14195,-1
14209,brain imaging studies,19,22,129,150,"Electroencephalographic activity was recorded in 11 of these patients, and all patients had a formal neurological evaluation and brain imaging studies.",19996135_5,-1,-1,2,14209,-1
14222,associated with,23,25,155,170,CONCLUSION: Our results suggest that use of high-dose TXA in older patients in conjunction with cardiopulmonary bypass and open-chamber cardiac surgery is associated with clinical seizures in susceptible patients.,19996135_11,-1,-1,2,14222,-1
14228,HITT,30,31,189,193,BACKGROUND: Direct thrombin inhibitors (DTIs) provide an alternative method of anticoagulation for patients with a history of heparin-induced thrombocytopenia (HIT) or HIT with thrombosis (HITT) undergoing cardiopulmonary bypass (CPB).,20003049_1,-1,-1,2,14228,-1
14230,CPB,36,37,230,233,BACKGROUND: Direct thrombin inhibitors (DTIs) provide an alternative method of anticoagulation for patients with a history of heparin-induced thrombocytopenia (HIT) or HIT with thrombosis (HITT) undergoing cardiopulmonary bypass (CPB).,20003049_1,-1,-1,2,14230,-1
14235,red blood cells,10,13,62,77,"The patient required massive transfusion support (55 units of red blood cells, 42 units of fresh-frozen plasma, 40 units of cryoprecipitate, 40 units of platelets, and three doses of recombinant Factor VIIa) for severe intraoperative and postoperative bleeding.",20003049_3,-1,-1,2,14235,-1
14236,fresh-frozen,17,18,91,103,"The patient required massive transfusion support (55 units of red blood cells, 42 units of fresh-frozen plasma, 40 units of cryoprecipitate, 40 units of platelets, and three doses of recombinant Factor VIIa) for severe intraoperative and postoperative bleeding.",20003049_3,-1,-1,2,14236,-1
14238,recombinant Factor VIIa,34,37,183,206,"The patient required massive transfusion support (55 units of red blood cells, 42 units of fresh-frozen plasma, 40 units of cryoprecipitate, 40 units of platelets, and three doses of recombinant Factor VIIa) for severe intraoperative and postoperative bleeding.",20003049_3,-1,-1,2,14238,-1
14241,Plasma samples,5,7,26,40,STUDY DESIGN AND METHODS: Plasma samples from before and after CPB were analyzed postoperatively for argatroban concentration using a modified ecarin clotting time (ECT) assay.,20003049_4,-1,-1,2,14241,-1
14242,CPB,11,12,63,66,STUDY DESIGN AND METHODS: Plasma samples from before and after CPB were analyzed postoperatively for argatroban concentration using a modified ecarin clotting time (ECT) assay.,20003049_4,-1,-1,2,14242,-1
14248,published elimination t(1/2,38,41,194,221,"RESULTS: Unexpectedly high concentrations of argatroban were measured in these samples (range, 0-32 microg/mL), and a prolonged plasma argatroban half life (t(1/2)) of 514 minutes was observed (published elimination t(1/2) is 39-51 minutes [< or = 181 minutes with hepatic impairment]).",20003049_5,-1,-1,2,14248,-1
14258,surgical teams,8,10,42,56,"Because DTIs do not have reversal agents, surgical teams and transfusion services should remain aware of the possibility of massive transfusion events during anticoagulation with these agents.",20003049_7,-1,-1,2,14258,-1
14259,transfusion services,11,13,61,81,"Because DTIs do not have reversal agents, surgical teams and transfusion services should remain aware of the possibility of massive transfusion events during anticoagulation with these agents.",20003049_7,-1,-1,2,14259,-1
14261,CPB,14,15,86,89,This is the first report to measure plasma argatroban concentration in the context of CPB and extended coagulopathy.,20003049_8,-1,-1,2,14261,-1
14276,intravenous administration,5,7,41,67,The ventricular arrhythmias responded to intravenous administration of lidocaine and to direct current electric shock; ventricular pacing was required in some instances and intravenous administration of propranolol combined with ventricular pacing in one.,2004_6,-1,-1,2,14276,-1
14293,C57BL/6 mice,12,14,57,69,"We have used a murine model of AIDS, infection of female C57BL/6 mice with LP-BM5 murine leukaemia (MuLV) virus, to determine if AZT-induced anaemia is due, in part, to decreased responsiveness of erythropoietic precursors (BFU-e) to erythropoietin (EPO).",2004015_2,-1,-1,2,14293,-1
14295,MuLV,19,20,100,104,"We have used a murine model of AIDS, infection of female C57BL/6 mice with LP-BM5 murine leukaemia (MuLV) virus, to determine if AZT-induced anaemia is due, in part, to decreased responsiveness of erythropoietic precursors (BFU-e) to erythropoietin (EPO).",2004015_2,-1,-1,2,14295,-1
14300,early stage,3,5,12,23,Mice in the early stage of LP-BM5 MuLV disease were given AZT in their drinking water at 1.0 and 2.5 mg/ml.,2004015_3,-1,-1,2,14300,-1
14302,dose-dependent,9,10,42,56,"AZT produced anaemia in both groups, in a dose-dependent fashion.",2004015_4,-1,-1,2,14302,-1
14330,double-blind,7,8,37,49,"PATIENTS AND METHODS: We performed a double-blind, randomized controlled trial at an academic medical center of elderly patients (>or=65 years) without preoperative delirium or severe dementia who underwent hip fracture repair under spinal anesthesia with propofol sedation.",20042557_2,-1,-1,2,14330,-1
14331,randomized controlled trial,9,12,51,78,"PATIENTS AND METHODS: We performed a double-blind, randomized controlled trial at an academic medical center of elderly patients (>or=65 years) without preoperative delirium or severe dementia who underwent hip fracture repair under spinal anesthesia with propofol sedation.",20042557_2,-1,-1,2,14331,-1
14337,bispectral index,9,11,76,92,"Sedation depth was titrated using processed electroencephalography with the bispectral index (BIS), and patients were randomized to receive either deep (BIS, approximately 50) or light (BIS, >or=80) sedation.",20042557_3,-1,-1,2,14337,-1
14342,light sedation group,10,13,72,92,"The prevalence of postoperative delirium was significantly lower in the light sedation group (11/57 [19%] vs 23/57 [40%] in the deep sedation group; P=.02), indicating that 1 incident of delirium will be prevented for every 4.7 patients treated with light sedation.",20042557_6,-1,-1,2,14342,-1
14343,deep sedation group,27,30,128,147,"The prevalence of postoperative delirium was significantly lower in the light sedation group (11/57 [19%] vs 23/57 [40%] in the deep sedation group; P=.02), indicating that 1 incident of delirium will be prevented for every 4.7 patients treated with light sedation.",20042557_6,-1,-1,2,14343,-1
14344,treated with,47,49,237,249,"The prevalence of postoperative delirium was significantly lower in the light sedation group (11/57 [19%] vs 23/57 [40%] in the deep sedation group; P=.02), indicating that 1 incident of delirium will be prevented for every 4.7 patients treated with light sedation.",20042557_6,-1,-1,2,14344,-1
14345,/- SD,3,5,10,15,The mean +/- SD number of days of delirium during hospitalization was lower in the light sedation group than in the deep sedation group (0.5+/-1.5 days vs 1.4+/-4.0 days; P=.01).,20042557_7,-1,-1,2,14345,-1
14347,deep sedation group,22,25,116,135,The mean +/- SD number of days of delirium during hospitalization was lower in the light sedation group than in the deep sedation group (0.5+/-1.5 days vs 1.4+/-4.0 days; P=.01).,20042557_7,-1,-1,2,14347,-1
14357,double-blind placebo-controlled,19,21,122,153,The effects of the adjunctive bupropion on male sexual dysfunction induced by a selective serotonin reuptake inhibitor: a double-blind placebo-controlled and randomized study.,20067456_0,-1,-1,2,14357,-1
14358,randomized study,22,24,158,174,The effects of the adjunctive bupropion on male sexual dysfunction induced by a selective serotonin reuptake inhibitor: a double-blind placebo-controlled and randomized study.,20067456_0,-1,-1,2,14358,-1
14363,randomized sample,5,7,26,43,PATIENTS AND METHODS: The randomized sample consisted of 234 euthymic men who were receiving some type of SSRI.,20067456_2,-1,-1,2,14363,-1
14367,CGI-SF,10,11,77,83,"Efficacy was evaluated using the Clinical Global Impression-Sexual Function (CGI-SF; the primary outcome measure), the International Index of Erectile Function (IIEF), Arizona Sexual Experience Scale (ASEX), and Erectile Dysfunction Inventory of Treatment Satisfaction (EDITS) (secondary outcome measures).",20067456_4,-1,-1,2,14367,-1
14368,International Index of,19,22,119,141,"Efficacy was evaluated using the Clinical Global Impression-Sexual Function (CGI-SF; the primary outcome measure), the International Index of Erectile Function (IIEF), Arizona Sexual Experience Scale (ASEX), and Erectile Dysfunction Inventory of Treatment Satisfaction (EDITS) (secondary outcome measures).",20067456_4,-1,-1,2,14368,-1
14371,Arizona Sexual Experience Scale,28,32,168,199,"Efficacy was evaluated using the Clinical Global Impression-Sexual Function (CGI-SF; the primary outcome measure), the International Index of Erectile Function (IIEF), Arizona Sexual Experience Scale (ASEX), and Erectile Dysfunction Inventory of Treatment Satisfaction (EDITS) (secondary outcome measures).",20067456_4,-1,-1,2,14371,-1
14375,secondary outcome measures,47,50,278,304,"Efficacy was evaluated using the Clinical Global Impression-Sexual Function (CGI-SF; the primary outcome measure), the International Index of Erectile Function (IIEF), Arizona Sexual Experience Scale (ASEX), and Erectile Dysfunction Inventory of Treatment Satisfaction (EDITS) (secondary outcome measures).",20067456_4,-1,-1,2,14375,-1
14378,placebo group,38,40,164,177,"RESULTS: After 12 weeks of treatment, the mean (sd) scores for CGI-SF were significantly lower, i.e. better, in patients on bupropion SR, at 2.4 (1.2), than in the placebo group, at 3.9 (1.1) (P= 0.01).",20067456_6,-1,-1,2,14378,-1
14380,total IIEF score,10,13,61,77,"Men who received bupropion had a significant increase in the total IIEF score (54.4% vs 1.2%; P= 0.003), and in the five different domains of the IIEF.",20067456_7,-1,-1,2,14380,-1
14382,Total ASEX scores,0,3,0,17,"Total ASEX scores were significantly lower, i.e. better, among men who received bupropion than placebo, at 15.5 (4.3) vs 21.5 (4.7) (P= 0.002).",20067456_8,-1,-1,2,14382,-1
14385,placebo group,18,20,76,89,The EDITS scores were 67.4 (10.2) for the bupropion and 36.3 (11.7) for the placebo group (P= 0.001).,20067456_9,-1,-1,2,14385,-1
14386,ASEX,1,2,4,8,The ASEX score and CGI-SF score were correlated (P= 0.003).,20067456_10,-1,-1,2,14386,-1
14387,CGI-SF,4,5,19,25,The ASEX score and CGI-SF score were correlated (P= 0.003).,20067456_10,-1,-1,2,14387,-1
14388,linear regression analyses,1,4,3,29,"In linear regression analyses the CGI-SF score was not affected significantly by the duration of SD, type of SSRI used and age.",20067456_11,-1,-1,2,14388,-1
14389,CGI-SF,5,6,34,40,"In linear regression analyses the CGI-SF score was not affected significantly by the duration of SD, type of SSRI used and age.",20067456_11,-1,-1,2,14389,-1
14396,BMCs,15,16,91,95,"In this study, we investigated the therapeutic potential of bone marrow mononuclear cells (BMCs) in a model of epilepsy induced by pilocarpine in rats.",20080419_1,-1,-1,2,14396,-1
14397,BMCs,0,1,0,4,BMCs obtained from green fluorescent protein (GFP) transgenic mice or rats were transplanted intravenously after induction of status epilepticus (SE).,20080419_2,-1,-1,2,14397,-1
14399,transgenic mice,9,11,51,66,BMCs obtained from green fluorescent protein (GFP) transgenic mice or rats were transplanted intravenously after induction of status epilepticus (SE).,20080419_2,-1,-1,2,14399,-1
14401,saline-treated epileptic control group,6,10,23,61,"All of the rats in the saline-treated epileptic control group developed SRS, whereas none of the BMC-treated epileptic animals had seizures in the short term (15 days after transplantation), regardless of the BMC source.",20080419_4,-1,-1,2,14401,-1
14402,BMC-treated,17,18,97,108,"All of the rats in the saline-treated epileptic control group developed SRS, whereas none of the BMC-treated epileptic animals had seizures in the short term (15 days after transplantation), regardless of the BMC source.",20080419_4,-1,-1,2,14402,-1
14403,epileptic animals,18,20,109,126,"All of the rats in the saline-treated epileptic control group developed SRS, whereas none of the BMC-treated epileptic animals had seizures in the short term (15 days after transplantation), regardless of the BMC source.",20080419_4,-1,-1,2,14403,-1
14406,chronic phase,3,5,19,32,"Over the long-term chronic phase (120 days after transplantation), only 25% of BMC-treated epileptic animals had seizures, but with a lower frequency and duration compared to the epileptic control group.",20080419_5,-1,-1,2,14406,-1
14407,BMC-treated,16,17,79,90,"Over the long-term chronic phase (120 days after transplantation), only 25% of BMC-treated epileptic animals had seizures, but with a lower frequency and duration compared to the epileptic control group.",20080419_5,-1,-1,2,14407,-1
14409,epileptic control group,32,35,179,202,"Over the long-term chronic phase (120 days after transplantation), only 25% of BMC-treated epileptic animals had seizures, but with a lower frequency and duration compared to the epileptic control group.",20080419_5,-1,-1,2,14409,-1
14413,collateral-CA1,3,4,25,39,"At hippocampal Schaeffer collateral-CA1 synapses, long-term potentiation was preserved in BMC-transplanted rats compared to epileptic controls.",20080419_7,-1,-1,2,14413,-1
14415,epileptic controls,15,17,124,142,"At hippocampal Schaeffer collateral-CA1 synapses, long-term potentiation was preserved in BMC-transplanted rats compared to epileptic controls.",20080419_7,-1,-1,2,14415,-1
14416,donor-derived GFP(+) cells,1,5,4,30,The donor-derived GFP(+) cells were rarely found in the brains of transplanted epileptic rats.,20080419_8,-1,-1,2,14416,-1
14425,cocaine-dependent participants,3,5,15,45,"METHOD: Twenty cocaine-dependent participants were randomly assigned to receive modafinil, 400 mg (N=10), or placebo (N=10) every morning at 7:30 a.m. for 16 days in an inpatient, double-blind randomized trial.",20080983_2,-1,-1,2,14425,-1
14427,double-blind randomized trial,35,38,180,209,"METHOD: Twenty cocaine-dependent participants were randomly assigned to receive modafinil, 400 mg (N=10), or placebo (N=10) every morning at 7:30 a.m. for 16 days in an inpatient, double-blind randomized trial.",20080983_2,-1,-1,2,14427,-1
14432,associated with,7,9,49,64,RESULTS: Progressive abstinence from cocaine was associated with worsening of all measured polysomnographic sleep outcomes.,20080983_6,-1,-1,2,14432,-1
14437,cocaine-dependent participants,15,17,105,135,"Compared with placebo, modafinil decreased nighttime sleep latency and increased slow-wave sleep time in cocaine-dependent participants.",20080983_7,-1,-1,2,14437,-1
14440,associated with,11,13,68,83,The effect of modafinil interacted with the abstinence week and was associated with longer total sleep time and shorter REM sleep latency in the third week of abstinence.,20080983_8,-1,-1,2,14440,-1
14447,healthy participants,16,18,97,117,"Comparison of slow-wave sleep time, total sleep time, and sleep latency in cocaine-dependent and healthy participants revealed a normalizing effect of modafinil in cocaine-dependent participants.",20080983_9,-1,-1,2,14447,-1
14451,associated with,2,4,14,29,"Modafinil was associated with increased daytime sleep latency, as measured by the Multiple Sleep Latency Test, and a nearly significant decrease in subjective daytime sleepiness.",20080983_10,-1,-1,2,14451,-1
14459,cocaine users,18,20,140,153,"CONCLUSIONS: Morning-dosed modafinil promotes nocturnal sleep, normalizes sleep architecture, and decreases daytime sleepiness in abstinent cocaine users.",20080983_11,-1,-1,2,14459,-1
14463,semi-invasive tool,5,7,21,39,BACKGROUND: TEE is a semi-invasive tool broadly used and its utilization associated to sedatives drugs might to affect the procedure safety.,20084309_1,-1,-1,2,14463,-1
14464,associated to,12,14,73,86,BACKGROUND: TEE is a semi-invasive tool broadly used and its utilization associated to sedatives drugs might to affect the procedure safety.,20084309_1,-1,-1,2,14464,-1
14466,associated to,8,10,44,57,OBJECTIVE: to analyze aspects of TEE safety associated to the use of Midazolan (MZ) and Flumazenil (FL) and the influence of the clinical variables on the event rate.,20084309_2,-1,-1,2,14466,-1
14470,clinical variables,27,29,129,147,OBJECTIVE: to analyze aspects of TEE safety associated to the use of Midazolan (MZ) and Flumazenil (FL) and the influence of the clinical variables on the event rate.,20084309_2,-1,-1,2,14470,-1
14471,prospective study,2,4,8,25,METHOD: prospective study with 137 patients that underwent TEE with MZ associated to moderate sedation.,20084309_3,-1,-1,2,14471,-1
14472,MZ,11,12,68,70,METHOD: prospective study with 137 patients that underwent TEE with MZ associated to moderate sedation.,20084309_3,-1,-1,2,14472,-1
14473,associated to,12,14,71,84,METHOD: prospective study with 137 patients that underwent TEE with MZ associated to moderate sedation.,20084309_3,-1,-1,2,14473,-1
14476,Uni-,0,1,0,4,"Uni- and multivariate analyses were used to test the influence of the clinical variables: age, sex, stroke, myocardiopathy (MP), duration of the test, mitral regurgitation (MR) and the MZ dose.",20084309_5,-1,-1,2,14476,-1
14477,multivariate analyses,2,4,9,30,"Uni- and multivariate analyses were used to test the influence of the clinical variables: age, sex, stroke, myocardiopathy (MP), duration of the test, mitral regurgitation (MR) and the MZ dose.",20084309_5,-1,-1,2,14477,-1
14478,clinical variables,12,14,70,88,"Uni- and multivariate analyses were used to test the influence of the clinical variables: age, sex, stroke, myocardiopathy (MP), duration of the test, mitral regurgitation (MR) and the MZ dose.",20084309_5,-1,-1,2,14478,-1
14481,mean doses,1,3,4,14,"The mean doses of MZ and FL were 4.3+/-1.9 mg and 0.28+/-0.2 mg, respectively.",20084309_7,-1,-1,2,14481,-1
14483,mean ejection fraction,7,10,40,62,"The duration of the examination and the mean ejection fraction (EF) were 16.4+/-6.1 minutes and 60+/-9%, respectively.",20084309_8,-1,-1,2,14483,-1
14484,EF,11,12,64,66,"The duration of the examination and the mean ejection fraction (EF) were 16.4+/-6.1 minutes and 60+/-9%, respectively.",20084309_8,-1,-1,2,14484,-1
14486,probe introduction,31,33,143,161,Mild hypoxia (SO2<90%) was the most common event (11 patients); 3 patients (2%) presented transient hypoxia due to upper airway obstruction by probe introduction and 8 (5.8%) due to hypoxia caused by MZ use.,20084309_9,-1,-1,2,14486,-1
14487,MZ,44,45,200,202,Mild hypoxia (SO2<90%) was the most common event (11 patients); 3 patients (2%) presented transient hypoxia due to upper airway obstruction by probe introduction and 8 (5.8%) due to hypoxia caused by MZ use.,20084309_9,-1,-1,2,14487,-1
14489,SAP<90mmHg,3,4,23,33,Transient hypotension (SAP<90mmHg) occurred in 1 patient (0.7%).,20084309_10,-1,-1,2,14489,-1
14492,associated with,24,26,94,109,"The multivariate analysis showed that severe MR, MP (EF<45%) and high doses of MZ (>5mg) were associated with events (p<0.001).",20084309_11,-1,-1,2,14492,-1
14494,associated with,26,28,96,111,"The EF was 40%, in the group with MP and 44% in the group with severe MR and it can be a factor associated with clinical events in the last group.",20084309_12,-1,-1,2,14494,-1
14496,low rate,7,9,41,49,CONCLUSION: TEE with sedation presents a low rate of events.,20084309_13,-1,-1,2,14496,-1
14497,intracoronary administration,3,5,17,45,Effect of direct intracoronary administration of methylergonovine in patients with and without variant angina.,2008831_0,-1,-1,2,14497,-1
14500,intracoronary administration,3,5,15,43,The effects of intracoronary administration of methylergonovine were studied in 21 patients with variant angina and 22 patients with atypical chest pain and in others without angina pectoris (control group).,2008831_1,-1,-1,2,14500,-1
14505,control group,29,31,192,205,The effects of intracoronary administration of methylergonovine were studied in 21 patients with variant angina and 22 patients with atypical chest pain and in others without angina pectoris (control group).,2008831_1,-1,-1,2,14505,-1
14511,control group,2,4,7,20,In the control group neither ischemic ST change nor localized spasm occurred.,2008831_4,-1,-1,2,14511,-1
14518,provocation tests,5,7,33,50,"These results suggest that spasm provocation tests, which use an intracoronary injection of a relatively low dose of methylergonovine, have a high sensitivity in variant angina and the vasoreactivity of the right coronary artery may be greater than that of the other coronary arteries.",2008831_7,-1,-1,2,14518,-1
14532,associated with,25,27,122,137,"AIM: The aim of the documentation of this clinical case is to make clinicians aware of ""meth mouth"" and the medical risks associated with this serious condition.",20098969_1,-1,-1,2,14532,-1
14577,Nrf2(-/-) mice,31,34,222,236,"RESEARCH DESIGN AND METHODS: We explore the protective role of Nrf2 against diabetic nephropathy using human kidney biopsy tissues from diabetic nephropathy patients, a streptozotocin-induced diabetic nephropathy model in Nrf2(-/-) mice, and cultured human mesangial cells.",20103708_4,-1,-1,2,14577,-1
14578,cultured human,36,38,242,256,"RESEARCH DESIGN AND METHODS: We explore the protective role of Nrf2 against diabetic nephropathy using human kidney biopsy tissues from diabetic nephropathy patients, a streptozotocin-induced diabetic nephropathy model in Nrf2(-/-) mice, and cultured human mesangial cells.",20103708_4,-1,-1,2,14578,-1
14586,Nrf2(-/-) mice,4,7,19,33,This is evident by Nrf2(-/-) mice having higher ROS production and suffering from greater oxidative DNA damage and renal injury compared with Nrf2(+/+) mice.,20103708_7,-1,-1,2,14586,-1
14589,Nrf2(+/+) mice,23,26,142,156,This is evident by Nrf2(-/-) mice having higher ROS production and suffering from greater oxidative DNA damage and renal injury compared with Nrf2(+/+) mice.,20103708_7,-1,-1,2,14589,-1
14590,Mechanistic studies,0,2,0,19,"Mechanistic studies in both in vivo and in vitro systems showed that the Nrf2-mediated protection against diabetic nephropathy is, at least, partially through inhibition of transforming growth factor-beta1 (TGF-beta1) and reduction of extracellular matrix production.",20103708_8,-1,-1,2,14590,-1
14591,in vivo,4,6,28,35,"Mechanistic studies in both in vivo and in vitro systems showed that the Nrf2-mediated protection against diabetic nephropathy is, at least, partially through inhibition of transforming growth factor-beta1 (TGF-beta1) and reduction of extracellular matrix production.",20103708_8,-1,-1,2,14591,-1
14592,in vitro systems,7,10,40,56,"Mechanistic studies in both in vivo and in vitro systems showed that the Nrf2-mediated protection against diabetic nephropathy is, at least, partially through inhibition of transforming growth factor-beta1 (TGF-beta1) and reduction of extracellular matrix production.",20103708_8,-1,-1,2,14592,-1
14601,overexpression,4,5,27,41,"Furthermore, activation or overexpression of Nrf2 inhibited the promoter activity of TGF-beta1 in a dose-dependent manner, whereas knockdown of Nrf2 by siRNA enhanced TGF-beta1 transcription and fibronectin production.",20103708_10,-1,-1,2,14601,-1
14605,dose-dependent,15,16,100,114,"Furthermore, activation or overexpression of Nrf2 inhibited the promoter activity of TGF-beta1 in a dose-dependent manner, whereas knockdown of Nrf2 by siRNA enhanced TGF-beta1 transcription and fibronectin production.",20103708_10,-1,-1,2,14605,-1
14612,therapeutic activation,19,21,119,141,"CONCLUSIONS: This work clearly indicates a protective role of Nrf2 in diabetic nephropathy, suggesting that dietary or therapeutic activation of Nrf2 could be used as a strategy to prevent or slow down the progression of diabetic nephropathy.",20103708_11,-1,-1,2,14612,-1
14616,mitochondria-dependent pathway,7,9,68,98,Metformin prevents experimental gentamicin-induced nephropathy by a mitochondria-dependent pathway.,20164825_0,-1,-1,2,14616,-1
14619,endothelial cells,12,14,86,103,The antidiabetic drug metformin can diminish apoptosis induced by oxidative stress in endothelial cells and prevent vascular dysfunction even in nondiabetic patients.,20164825_1,-1,-1,2,14619,-1
14623,respiration intensity,3,5,24,45,"Mitochondrial analysis, respiration intensity, levels of reactive oxygen species, permeability transition, and cytochrome c release were assessed 3 and 6 days after gentamicin administration.",20164825_3,-1,-1,2,14623,-1
14624,permeability transition,12,14,82,105,"Mitochondrial analysis, respiration intensity, levels of reactive oxygen species, permeability transition, and cytochrome c release were assessed 3 and 6 days after gentamicin administration.",20164825_3,-1,-1,2,14624,-1
14630,in vivo,1,3,6,13,These in vivo markers of kidney dysfunction and their correction by metformin were complemented by in vitro studies of mitochondrial function.,20164825_7,-1,-1,2,14630,-1
14632,in vitro studies,15,18,99,115,These in vivo markers of kidney dysfunction and their correction by metformin were complemented by in vitro studies of mitochondrial function.,20164825_7,-1,-1,2,14632,-1
14634,respiratory components,6,8,44,66,"We found that gentamicin treatment depleted respiratory components (cytochrome c, NADH), probably due to the opening of mitochondrial transition pores.",20164825_8,-1,-1,2,14634,-1
14637,mitochondrial,21,22,120,133,"We found that gentamicin treatment depleted respiratory components (cytochrome c, NADH), probably due to the opening of mitochondrial transition pores.",20164825_8,0,1,2,14637,-1
14638,electron transfer chain,14,17,78,101,"These injuries, partly mediated by a rise in reactive oxygen species from the electron transfer chain, were significantly decreased by metformin.",20164825_9,-1,-1,2,14638,-1
14639,pleiotropic,6,7,30,41,"Thus, our study suggests that pleiotropic effects of metformin can lessen gentamicin nephrotoxicity and improve mitochondrial homeostasis.",20164825_10,-1,-1,2,14639,-1
14644,prospective study,16,18,111,128,Risk of nephropathy after consumption of nonionic contrast media by children undergoing cardiac angiography: a prospective study.,20195852_0,-1,-1,2,14644,-1
14649,predisposing factors,32,34,210,230,"Despite increasing reports on nonionic contrast media-induced nephropathy (CIN) in hospitalized adult patients during cardiac procedures, the studies in pediatrics are limited, with even less focus on possible predisposing factors and preventive measures for patients undergoing cardiac angiography.",20195852_1,-1,-1,2,14649,-1
14652,prospective study,1,3,5,22,"This prospective study determined the incidence of CIN for two nonionic contrast media (CM), iopromide and iohexol, among 80 patients younger than 18 years and compared the rates for this complication in relation to the type and dosage of CM and the presence of cyanosis.",20195852_2,-1,-1,2,14652,-1
14662,baseline values,23,25,95,110,"Serum sodium (Na), potassium (K), and creatinine (Cr) were measured 24 h before angiography as baseline values, then measured again at 12-, 24-, and 48-h intervals after CM use.",20195852_4,-1,-1,2,14662,-1
14663,Urine samples,0,2,0,13,Urine samples for Na and Cr also were checked at the same intervals.,20195852_5,-1,-1,2,14663,-1
14669,CIN,32,33,162,165,"Risk of renal failure, Injury to the kidney, Failure of kidney function, Loss of kidney function, and End-stage renal damage (RIFLE criteria) were used to define CIN and its incidence in the study population.",20195852_6,-1,-1,2,14669,-1
14670,study population,38,40,191,207,"Risk of renal failure, Injury to the kidney, Failure of kidney function, Loss of kidney function, and End-stage renal damage (RIFLE criteria) were used to define CIN and its incidence in the study population.",20195852_6,-1,-1,2,14670,-1
14671,CIN,5,6,26,29,"Accordingly, among the 15 CIN patients (18.75%), 7.5% of the patients in group A had increased risk and 3.75% had renal injury, whereas 5% of group B had increased risk and 2.5% had renal injury.",20195852_7,-1,-1,2,14671,-1
14678,CIN,5,6,27,30,"Among the 15 patients with CIN, 6 had cyanotic congenital heart diseases, but the incidence did not differ significantly from that for the noncyanotic patients (p = 0.243).",20195852_9,-1,-1,2,14678,-1
14682,CIN,4,5,28,31,"Although clinically silent, CIN is not rare in pediatrics.",20195852_10,-1,-1,2,14682,-1
14691,South Asia,15,17,109,119,Antituberculosis therapy (ATT)-associated acute liver failure (ATT-ALF) is the commonest drug-induced ALF in South Asia.,20196116_1,-1,-1,2,14691,-1
14692,Prospective studies,0,2,0,19,Prospective studies on ATT-ALF are lacking.,20196116_2,-1,-1,2,14692,-1
14696,ATT-ALF,17,18,109,116,"The current study prospectively evaluated the magnitude, clinical course, outcome, and prognostic factors in ATT-ALF.",20196116_3,-1,-1,2,14696,-1
14697,ALF,9,10,52,55,"From January 1986 to January 2009, 1223 consecutive ALF patients were evaluated: ATT alone was the cause in 70 (5.7%) patients.",20196116_4,-1,-1,2,14697,-1
14699,ATT,7,8,22,25,Another 15 (1.2%) had ATT and simultaneous hepatitis virus infection.,20196116_5,-1,-1,2,14699,-1
14702,ATT-ALF,0,1,0,7,"ATT-ALF patients were younger (32.87 [+/-15.8] years), and 49 (70%) of them were women.",20196116_7,-1,-1,2,14702,-1
14706,ALF,6,7,34,37,The median duration of ATT before ALF was 30 (7-350) days.,20196116_9,-1,-1,2,14706,-1
14711,HEV,6,7,33,36,"Compared with hepatitis E virus (HEV) and non-A non-E-induced ALF, ATT-ALF patients had nearly similar presentations except for older age and less elevation of liver enzymes.",20196116_12,-1,-1,2,14711,-1
14712,non-A,9,10,42,47,"Compared with hepatitis E virus (HEV) and non-A non-E-induced ALF, ATT-ALF patients had nearly similar presentations except for older age and less elevation of liver enzymes.",20196116_12,-1,-1,2,14712,-1
14713,ALF,11,12,62,65,"Compared with hepatitis E virus (HEV) and non-A non-E-induced ALF, ATT-ALF patients had nearly similar presentations except for older age and less elevation of liver enzymes.",20196116_12,-1,-1,2,14713,-1
14717,mortality rate,1,3,4,18,"The mortality rate among patients with ATT-ALF was high (67.1%, n = 47), and only 23 (32.9%) patients recovered with medical treatment.",20196116_13,-1,-1,2,14717,-1
14718,ATT-ALF,6,7,39,46,"The mortality rate among patients with ATT-ALF was high (67.1%, n = 47), and only 23 (32.9%) patients recovered with medical treatment.",20196116_13,-1,-1,2,14718,-1
14721,prothrombin time,18,20,109,125,"In multivariate analysis, three factors independently predicted mortality: serum bilirubin (>or=10.8 mg/dL), prothrombin time (PT) prolongation (>or=26 seconds), and grade III/IV encephalopathy at presentation.",20196116_14,-1,-1,2,14721,-1
14724,mortality rate,15,17,73,87,CONCLUSION: ATT-ALF constituted 5.7% of ALF at our center and had a high mortality rate.,20196116_15,-1,-1,2,14724,-1
14725,mortality rate,2,4,12,26,"Because the mortality rate is so high, determining which factors are predictors is less important.",20196116_16,-1,-1,2,14725,-1
14726,ATT,7,8,43,46,"A high proportion of patients had consumed ATT empirically, which could have been prevented.",20196116_17,-1,-1,2,14726,-1
14731,renal blood flow,9,12,72,88,The effect of isoflurane-induced hypotension on glomerular function and renal blood flow was investigated in 20 human subjects.,2021202_1,-1,-1,2,14731,-1
14732,Glomerular filtration rate,0,3,0,26,"Glomerular filtration rate (GFR) and effective renal plasma flow (ERPF) were measured by inulin and para-aminohippurate (PAH) clearance, respectively.",2021202_2,-1,-1,2,14732,-1
14734,renal plasma flow,8,11,47,64,"Glomerular filtration rate (GFR) and effective renal plasma flow (ERPF) were measured by inulin and para-aminohippurate (PAH) clearance, respectively.",2021202_2,-1,-1,2,14734,-1
14739,/-,6,7,35,37,Hypotension was induced for 236.9 +/- 15.1 min by increasing the isoflurane inspired concentration to maintain a mean arterial pressure of 59.8 +/- 0.4 mmHg.,2021202_4,0,1,2,14739,-1
14742,/-,24,25,145,147,Hypotension was induced for 236.9 +/- 15.1 min by increasing the isoflurane inspired concentration to maintain a mean arterial pressure of 59.8 +/- 0.4 mmHg.,2021202_4,0,1,2,14742,-1
14753,HYPREN-trial,5,6,27,39,Design and analysis of the HYPREN-trial: safety of enalapril and prazosin in the initial treatment phase of patients with congestive heart failure.,2024540_0,-1,-1,2,14753,-1
14754,treatment phase,15,17,89,104,Design and analysis of the HYPREN-trial: safety of enalapril and prazosin in the initial treatment phase of patients with congestive heart failure.,2024540_0,-1,-1,2,14754,-1
14762,Trial medication,0,2,0,16,Trial medication was 2.5 mg enalapril or 0.5 prazosin.,2024540_3,-1,-1,2,14762,-1
14763,class II,13,15,80,88,Subjects were 1210 inpatients with New York Heart Association (NYHA) functional class II and III.,2024540_4,0,1,2,14763,-1
14778,BMD,22,23,148,151,OBJECTIVE: The aim of the present study was to investigate the effect of risperidone-induced hyperprolactinemia on trabecular bone mineral density (BMD) in children and adolescents.,20331935_1,-1,-1,2,14778,-1
14780,naturalistic setting,13,15,76,96,"METHOD: Medically healthy 7- to 17-year-old males chronically treated, in a naturalistic setting, with risperidone were recruited for this cross-sectional study through child psychiatry outpatient clinics between November 2005 and June 2007.",20331935_2,-1,-1,2,14780,-1
14782,cross-sectional study,22,24,139,160,"METHOD: Medically healthy 7- to 17-year-old males chronically treated, in a naturalistic setting, with risperidone were recruited for this cross-sectional study through child psychiatry outpatient clinics between November 2005 and June 2007.",20331935_2,-1,-1,2,14782,-1
14789,Volumetric BMD,0,2,0,14,"Volumetric BMD of the ultradistal radius was measured using peripheral quantitative computed tomography, and areal BMD of the lumbar spine was estimated using dual-energy x-ray absorptiometry.",20331935_5,-1,-1,2,14789,-1
14792,areal BMD,15,17,109,118,"Volumetric BMD of the ultradistal radius was measured using peripheral quantitative computed tomography, and areal BMD of the lumbar spine was estimated using dual-energy x-ray absorptiometry.",20331935_5,-1,-1,2,14792,-1
14794,dual-energy x-ray absorptiometry,24,27,159,191,"Volumetric BMD of the ultradistal radius was measured using peripheral quantitative computed tomography, and areal BMD of the lumbar spine was estimated using dual-energy x-ray absorptiometry.",20331935_5,-1,-1,2,14794,-1
14796,treated with,16,18,67,79,RESULTS: Hyperprolactinemia was present in 49% of 83 boys (n = 41) treated with risperidone for a mean of 2.9 years.,20331935_6,-1,-1,2,14796,-1
14800,bone mineral content,3,6,13,33,"As expected, bone mineral content and BMD increased with sexual maturity.",20331935_8,-1,-1,2,14800,-1
14801,BMD,7,8,38,41,"As expected, bone mineral content and BMD increased with sexual maturity.",20331935_8,-1,-1,2,14801,-1
14804,z scores,12,14,71,79,"After adjusting for the stage of sexual development and height and BMI z scores, serum prolactin was negatively associated with trabecular volumetric BMD at the ultradistal radius (P < .03).",20331935_9,-1,-1,2,14804,-1
14806,associated with,19,21,112,127,"After adjusting for the stage of sexual development and height and BMI z scores, serum prolactin was negatively associated with trabecular volumetric BMD at the ultradistal radius (P < .03).",20331935_9,-1,-1,2,14806,-1
14810,associated with,19,21,120,135,"Controlling for relevant covariates, we also found treatment with selective serotonin reuptake inhibitors (SSRIs) to be associated with lower trabecular BMD at the radius (P = .03) and BMD z score at the lumbar spine (P < .05).",20331935_10,-1,-1,2,14810,-1
14815,non-Hispanic white,11,13,70,88,These findings became more marked when the analysis was restricted to non-Hispanic white patients.,20331935_11,-1,-1,2,14815,-1
14819,BMD,16,17,112,115,CONCLUSIONS: This is the first study to link risperidone-induced hyperprolactinemia and SSRI treatment to lower BMD in children and adolescents.,20331935_13,-1,-1,2,14819,-1
14823,fracture rate,20,22,135,148,Future research should evaluate the longitudinal course of this adverse event to determine its temporal stability and whether a higher fracture rate ensues.,20331935_14,-1,-1,2,14823,-1
14827,light-enhanced startle paradigm,5,8,30,61,"RATIONALE AND OBJECTIVES: The light-enhanced startle paradigm (LES) is suggested to model anxiety, because of the non-specific cue and the long-term effect.",20394767_1,-1,-1,2,14827,-1
14831,pharmacological profiles,3,5,13,37,"However, the pharmacological profiles of these two paradigms are very similar.",20394767_3,-1,-1,2,14831,-1
14844,mCPP,10,11,49,53,"RESULTS: None of the drugs enhanced LES, whereas mCPP increased percentage FPS and yohimbine increased absolute FPS values.",20394767_6,-1,-1,2,14844,-1
14847,startle amplitude,5,7,42,59,"Furthermore, yohimbine increased baseline startle amplitude in the LES, while mCPP suppressed baseline startle in both the LES and FPS and PTZ suppressed baseline startle in the FPS.",20394767_7,-1,-1,2,14847,-1
14850,pharmacological differentiation,4,6,14,45,"Thus, a clear pharmacological differentiation was found between LES and FPS.",20394767_9,-1,-1,2,14850,-1
14852,associated with,2,4,23,38,Rosaceiform dermatitis associated with topical tacrolimus treatment.,20466178_0,-1,-1,2,14852,-1
14861,Continuous topical use of,0,4,0,25,"Continuous topical use of immunomodulators such as tacrolimus or pimecrolimus should be regarded as a potential cause of rosaceiform dermatitis, although many cases have not been reported.",20466178_3,-1,-1,2,14861,-1
14865,cause of,16,18,112,120,"Continuous topical use of immunomodulators such as tacrolimus or pimecrolimus should be regarded as a potential cause of rosaceiform dermatitis, although many cases have not been reported.",20466178_3,-1,-1,2,14865,-1
14875,Exclusion criteria,0,2,0,18,"Exclusion criteria included CNS leukemic infiltration at diagnosis, therapy-related peripheral neuropathy, late-onset encephalopathy, or long-term neurocognitive defects.",20470218_4,-1,-1,2,14875,-1
14881,front-line protocol,27,29,141,160,"During a 9-year period, we retrospectively collected 27 neurological events (11%) in as many patients, from 253 children enrolled in the ALL front-line protocol.",20470218_5,-1,-1,2,14881,-1
14892,oxidative status,18,20,132,148,Different mechanisms have been suggested for cocaine toxicity including an increase in oxidative stress but the association between oxidative status in the brain and cocaine induced-behaviour is poorly understood.,20477932_1,-1,-1,2,14892,-1
14906,experimental model,40,42,234,252,"Therefore NFkappaB activity, oxidative stress, neuronal nitric oxide synthase (nNOS) activity, spatial learning and memory as well as the effect of topiramate, a previously proposed therapy for cocaine addiction, were evaluated in an experimental model of cocaine administration in rats.",20477932_3,-1,-1,2,14906,-1
14919,nitrosative stress,12,14,80,98,These results provide evidence for a possible mechanistic role of oxidative and nitrosative stress and NFkappaB in the alterations induced by cocaine.,20477932_7,-1,-1,2,14919,-1
14939,lipid peroxidation,21,23,160,178,"Coenzyme Q10 significantly compensated deficits in the antioxidant defense mechanisms (reduced glutathione level and superoxide dismutase activity), suppressed lipid peroxidation, decreased the elevations of tumor necrosis factor-alpha, nitric oxide and platinum ion concentration, and attenuated the reductions of selenium and zinc ions in renal tissue resulted from cisplatin administration.",20510337_5,-1,-1,2,14939,-1
14950,cisplatin-induced overexpression,9,11,84,116,"Immunohistochemical analysis revealed that coenzyme Q10 significantly decreased the cisplatin-induced overexpression of inducible nitric oxide synthase, nuclear factor-kappaB, caspase-3 and p53 in renal tissue.",20510337_7,-1,-1,2,14950,-1
14970,associated with,14,16,99,114,It is believed that this is the first reported case of reversible azathioprine-induced cholestasis associated with histological evidence of bile duct injury.,2051906_5,-1,-1,2,14970,-1
14973,placebo- and haloperidol-controlled trial,7,11,38,79,Efficacy and safety of asenapine in a placebo- and haloperidol-controlled trial in patients with acute exacerbation of schizophrenia.,20520283_0,-1,-1,2,14973,-1
14977,associated with,22,24,136,151,Asenapine is approved by the Food and Drugs Administration in adults for acute treatment of schizophrenia or of manic or mixed episodes associated with bipolar I disorder with or without psychotic features.,20520283_1,-1,-1,2,14977,-1
14986,mixed model,51,53,267,278,"With last observations carried forward (LOCF), mean Positive and Negative Syndrome Scale total score reductions from baseline to endpoint were significantly greater with asenapine at 5 mg BID (-16.2) and haloperidol (-15.4) than placebo (-10.7; both P < 0.05); using mixed model for repeated measures (MMRM), changes at day 42 were significantly greater with asenapine at 5 and 10 mg BID (-21.3 and -19.4, respectively) and haloperidol (-20.0) than placebo (-14.6; all P < 0.05).",20520283_3,-1,-1,2,14986,-1
14987,MMRM,57,58,302,306,"With last observations carried forward (LOCF), mean Positive and Negative Syndrome Scale total score reductions from baseline to endpoint were significantly greater with asenapine at 5 mg BID (-16.2) and haloperidol (-15.4) than placebo (-10.7; both P < 0.05); using mixed model for repeated measures (MMRM), changes at day 42 were significantly greater with asenapine at 5 and 10 mg BID (-21.3 and -19.4, respectively) and haloperidol (-20.0) than placebo (-14.6; all P < 0.05).",20520283_3,-1,-1,2,14987,-1
14993,MMRM,35,36,199,203,"On the Positive and Negative Syndrome Scale positive subscale, all treatments were superior to placebo with LOCF and MMRM; asenapine at 5 mg BID was superior to placebo on the negative subscale with MMRM and on the general psychopathology subscale with LOCF and MMRM.",20520283_4,-1,-1,2,14993,-1
14995,MMRM,45,46,262,266,"On the Positive and Negative Syndrome Scale positive subscale, all treatments were superior to placebo with LOCF and MMRM; asenapine at 5 mg BID was superior to placebo on the negative subscale with MMRM and on the general psychopathology subscale with LOCF and MMRM.",20520283_4,-1,-1,2,14995,-1
15030,platelet recovery,17,19,112,129,"Haematological toxicity was greater for the combination than AraG alone, although median time to neutrophil and platelet recovery was consistent with other salvage therapies.",20528871_3,-1,-1,2,15030,-1
15031,consistent with,20,22,134,149,"Haematological toxicity was greater for the combination than AraG alone, although median time to neutrophil and platelet recovery was consistent with other salvage therapies.",20528871_3,-1,-1,2,15031,-1
15042,interfere with,21,23,140,154,"It is widely believed that dopamine (DA) mediates methamphetamine (METH)-induced toxicity to brain dopaminergic neurons, because drugs that interfere with DA neurotransmission decrease toxicity, whereas drugs that increase DA neurotransmission enhance toxicity.",20533999_1,-1,-1,2,15042,-1
15050,drug effects,25,27,194,206,Here we show that the recently reported ability of L-dihydroxyphenylalanine to reverse the protective effect of alpha-methyl-para-tyrosine on METH-induced DA neurotoxicity is also confounded by drug effects on body temperature.,20533999_3,-1,-1,2,15050,-1
15052,genetically engineered,6,8,27,49,"Further, we show that mice genetically engineered to be deficient in brain DA develop METH neurotoxicity, as long as the thermic effects of METH are preserved.",20533999_4,-1,-1,2,15052,-1
15061,Thermal enhancement,0,2,0,19,Thermal enhancement of Adriamycin-mediated antitumor activity and normal tissue toxicities by whole body hyperthermia were compared using a F344 rat model.,2054792_1,-1,-1,2,15061,-1
15064,F344 rat model,18,21,140,154,Thermal enhancement of Adriamycin-mediated antitumor activity and normal tissue toxicities by whole body hyperthermia were compared using a F344 rat model.,2054792_1,-1,-1,2,15064,-1
15068,functional/physiological assays,27,29,160,191,"Acute normal tissue toxicities (i.e., leukopenia and thrombocytopenia) and late normal tissue toxicities (i.e., myocardial and kidney injury) were evaluated by functional/physiological assays and by morphological techniques.",2054792_3,-1,-1,2,15068,-1
15069,degrees C,8,10,41,50,Whole body hyperthermia (120 min at 41.5 degrees C) enhanced both Adriamycin-mediated antitumor activity and toxic side effects.,2054792_4,-1,-1,2,15069,-1
15072,thermal enhancement,1,3,4,23,The thermal enhancement ratio calculated for antitumor activity was 1.6.,2054792_5,-1,-1,2,15072,-1
15074,Thermal enhancement,0,2,0,19,"Thermal enhancement ratios estimated for ""acute"" hematological changes were 1.3, whereas those estimated for ""late"" damage (based on morphological cardiac and renal lesions) varied between 2.4 and 4.3.",2054792_6,-1,-1,2,15074,-1
15077,therapeutic gain,21,23,143,159,"Thus, while whole body hyperthermia enhances Adriamycin-mediated antitumor effect, normal tissue toxicity is also increased, and the potential therapeutic gain of the combined modality treatment is eroded.",2054792_7,-1,-1,2,15077,-1
15079,triggered by,3,5,42,54,Swallowing-induced atrial tachyarrhythmia triggered by salbutamol: case report and review of the literature.,20552622_0,-1,-1,2,15079,-1
15094,treatment possibilities,18,20,122,145,"It discusses demographics, clinical characteristics and types of arrhythmia, postulated mechanisms of SIAT, and different treatment possibilities such as medications, surgery, and radiofrequency catheter ablation (RFCA).",20552622_9,-1,-1,2,15094,-1
15105,mellitus.1,19,20,137,147,The ability of insulin treatment to reverse or prevent the changes in urinary bladder function caused by streptozotocin-induced diabetes mellitus.1.,2055425_0,-1,-1,2,15105,-1
15107,in vivo,6,8,36,43,The effects of insulin treatment on in vivo and in vitro urinary bladder function in streptozotocin-diabetic rats were investigated.,2055425_1,-1,-1,2,15107,-1
15108,in vitro,9,11,48,56,The effects of insulin treatment on in vivo and in vitro urinary bladder function in streptozotocin-diabetic rats were investigated.,2055425_1,-1,-1,2,15108,-1
15110,streptozotocin-diabetic rats,15,17,85,113,The effects of insulin treatment on in vivo and in vitro urinary bladder function in streptozotocin-diabetic rats were investigated.,2055425_1,-1,-1,2,15110,-1
15113,average volume,27,29,150,164,"2. Diabetes of 2 months duration resulted in decreases in body weight and increases in fluid consumption, urine volume, frequency of micturition, and average volume per micturition; effects which were prevented by insulin treatment.",2055425_2,-1,-1,2,15113,-1
15114,contractile responses,9,11,53,74,"3. Insulin treatment also prevented the increases in contractile responses of bladder body strips from diabetic rats to nerve stimulation, ATP, and bethanechol.",2055425_3,-1,-1,2,15114,-1
15115,bladder body strips,12,15,78,97,"3. Insulin treatment also prevented the increases in contractile responses of bladder body strips from diabetic rats to nerve stimulation, ATP, and bethanechol.",2055425_3,-1,-1,2,15115,-1
15120,average volume,27,29,153,167,"Diabetes of 4 months duration also resulted in decreases in body weight, and increases in fluid consumption, urine volume, frequency of micturition, and average volume per micturition, effects which were reversed by insulin treatment for the final 2 months of the study.",2055425_5,-1,-1,2,15120,-1
15121,contractile responses,6,8,44,65,"Insulin treatment reversed the increases in contractile responses of bladder body strips from diabetic rats to nerve stimulation, ATP, and bethanechol.",2055425_7,-1,-1,2,15121,-1
15122,bladder body strips,9,12,69,88,"Insulin treatment reversed the increases in contractile responses of bladder body strips from diabetic rats to nerve stimulation, ATP, and bethanechol.",2055425_7,-1,-1,2,15122,-1
15139,systemically,25,26,179,191,The present study examined the influence of excitatory amino acid-mediated mechanisms in the IC on the catalepsy induced by the dopamine receptor blocker haloperidol administered systemically (1 or 0.5 mg/kg) in rats.,20558148_4,-1,-1,2,15139,-1
15141,intracollicular,6,7,56,71,"Haloperidol-induced catalepsy was challenged with prior intracollicular microinjections of glutamate NMDA receptor antagonists, MK-801 (15 or 30 mmol/0.5 microl) and AP7 (10 or 20 nmol/0.5 microl), or of the NMDA receptor agonist N-methyl-d-aspartate (NMDA, 20 or 30 nmol/0.5 microl).",20558148_5,-1,-1,2,15141,-1
15142,microinjections,7,8,72,87,"Haloperidol-induced catalepsy was challenged with prior intracollicular microinjections of glutamate NMDA receptor antagonists, MK-801 (15 or 30 mmol/0.5 microl) and AP7 (10 or 20 nmol/0.5 microl), or of the NMDA receptor agonist N-methyl-d-aspartate (NMDA, 20 or 30 nmol/0.5 microl).",20558148_5,-1,-1,2,15142,-1
15155,systemic injections,12,14,85,104,"The results showed that intracollicular microinjection of MK-801 and AP7 previous to systemic injections of haloperidol significantly attenuated the catalepsy, as indicated by a reduced latency to step down from a horizontal bar.",20558148_6,-1,-1,2,15155,-1
15160,glutamate-mediated mechanisms,4,6,28,57,These findings suggest that glutamate-mediated mechanisms in the neural circuits at the IC level influence haloperidol-induced catalepsy and participate in the regulation of motor activity.,20558148_8,-1,-1,2,15160,-1
15164,glomerular barrier,12,14,81,99,"Permeability, ultrastructural changes, and distribution of novel proteins in the glomerular barrier in early puromycin aminonucleoside nephrosis.",20588063_0,-1,-1,2,15164,-1
15166,BACKGROUND/AIMS,0,1,0,15,BACKGROUND/AIMS: It is still unclear what happens in the glomerulus when proteinuria starts.,20588063_1,-1,-1,2,15166,-1
15169,podocyte-associated molecules,23,25,149,178,"Using puromycin aminonucleoside nephrosis (PAN) rats, we studied early ultrastructural and permeability changes in relation to the expression of the podocyte-associated molecules nephrin, a-actinin, dendrin, and plekhh2, the last two of which were only recently discovered in podocytes.",20588063_2,-1,-1,2,15169,-1
15175,immune stainings,3,5,15,31,"METHODS: Using immune stainings, semiquantitative measurement was performed under the electron microscope.",20588063_3,-1,-1,2,15175,-1
15176,semiquantitative measurement,6,8,33,61,"METHODS: Using immune stainings, semiquantitative measurement was performed under the electron microscope.",20588063_3,-1,-1,2,15176,-1
15177,electron microscope,12,14,86,105,"METHODS: Using immune stainings, semiquantitative measurement was performed under the electron microscope.",20588063_3,-1,-1,2,15177,-1
15192,podocyte,13,14,80,88,"This was preceded by altered nephrin expression, supporting its pivotal role in podocyte morphology.",20588063_13,-1,-1,2,15192,-1
15197,animal models,3,5,20,33,"BACKGROUND: Current animal models of obsessive-compulsive disorder (OCD) typically involve acute, drug-induced symptom provocation or a genetic association with stereotypies or anxiety.",20619828_1,-1,-1,2,15197,-1
15203,OCD-like behaviors,7,9,50,68,None of these current models demonstrate multiple OCD-like behaviors.,20619828_2,-1,-1,2,15203,-1
15204,treated with,5,7,28,40,METHODS: Neonatal rats were treated with the tricyclic antidepressant clomipramine or vehicle between days 9 and 16 twice daily and behaviorally tested in adulthood.,20619828_3,-1,-1,2,15204,-1
15206,behaviorally tested,21,23,132,151,METHODS: Neonatal rats were treated with the tricyclic antidepressant clomipramine or vehicle between days 9 and 16 twice daily and behaviorally tested in adulthood.,20619828_3,-1,-1,2,15206,-1
15213,consistent with,10,12,66,81,CONCLUSIONS: This is the first demonstration of multiple symptoms consistent with an OCD-like profile in animals.,20619828_6,-1,-1,2,15213,-1
15214,OCD-like profile,13,15,85,101,CONCLUSIONS: This is the first demonstration of multiple symptoms consistent with an OCD-like profile in animals.,20619828_6,-1,-1,2,15214,-1
15216,OCD,17,18,119,122,"Moreover, these behaviors are accompanied by biochemical changes in brain regions previously identified as relevant to OCD.",20619828_7,-1,-1,2,15216,-1
15217,OCD,4,5,20,23,"This novel model of OCD demonstrates that drug exposure during a sensitive period can program disease-like systems permanently, which could have implications for current and future therapeutic strategies for this and other psychiatric disorders.",20619828_8,-1,-1,2,15217,-1
15219,disease-like systems,15,17,94,114,"This novel model of OCD demonstrates that drug exposure during a sensitive period can program disease-like systems permanently, which could have implications for current and future therapeutic strategies for this and other psychiatric disorders.",20619828_8,-1,-1,2,15219,-1
15225,MMP-9,8,9,39,44,"Elevation of ADAM10, ADAM17, MMP-2 and MMP-9 expression with media degeneration features CaCl2-induced thoracic aortic aneurysm in a rat model.",20621845_0,-1,-1,2,15225,-1
15242,CaCl(2)-treated,8,9,44,59,"After 12weeks, animals were euthanized, and CaCl(2)-treated, CaCl(2)-untreated (n=12) and NaCl-treated aortic segments (n=12) were collected for histological and molecular assessments.",20621845_3,-1,-1,2,15242,-1
15245,molecular assessments,26,28,162,183,"After 12weeks, animals were euthanized, and CaCl(2)-treated, CaCl(2)-untreated (n=12) and NaCl-treated aortic segments (n=12) were collected for histological and molecular assessments.",20621845_3,-1,-1,2,15245,-1
15247,semi-quantitatively analyzed,5,7,29,57,MMP-TIMP and ADAM mRNAs were semi-quantitatively analyzed and protein expressions were determined by immunohistochemistry.,20621845_4,-1,-1,2,15247,-1
15248,CaCl(2)-treated,7,8,50,65,"RESULTS: Despite similar external diameters among CaCl(2)-treated, non-CaCl(2)-treated and NaCl-treated segments, aneurymal alteration (n=6, 50%), media degeneration with regional disruption, fragmentation of elastic fiber, and increased collagen deposition (n=12, 100%) were demonstrated in CaCl(2)-treated segments.",20621845_5,-1,-1,2,15248,-1
15249,non-CaCl(2)-treated,9,10,67,86,"RESULTS: Despite similar external diameters among CaCl(2)-treated, non-CaCl(2)-treated and NaCl-treated segments, aneurymal alteration (n=6, 50%), media degeneration with regional disruption, fragmentation of elastic fiber, and increased collagen deposition (n=12, 100%) were demonstrated in CaCl(2)-treated segments.",20621845_5,-1,-1,2,15249,-1
15250,NaCl-treated,11,12,91,103,"RESULTS: Despite similar external diameters among CaCl(2)-treated, non-CaCl(2)-treated and NaCl-treated segments, aneurymal alteration (n=6, 50%), media degeneration with regional disruption, fragmentation of elastic fiber, and increased collagen deposition (n=12, 100%) were demonstrated in CaCl(2)-treated segments.",20621845_5,-1,-1,2,15250,-1
15253,elastic fiber,31,33,209,222,"RESULTS: Despite similar external diameters among CaCl(2)-treated, non-CaCl(2)-treated and NaCl-treated segments, aneurymal alteration (n=6, 50%), media degeneration with regional disruption, fragmentation of elastic fiber, and increased collagen deposition (n=12, 100%) were demonstrated in CaCl(2)-treated segments.",20621845_5,-1,-1,2,15253,-1
15254,CaCl(2)-treated,47,48,292,307,"RESULTS: Despite similar external diameters among CaCl(2)-treated, non-CaCl(2)-treated and NaCl-treated segments, aneurymal alteration (n=6, 50%), media degeneration with regional disruption, fragmentation of elastic fiber, and increased collagen deposition (n=12, 100%) were demonstrated in CaCl(2)-treated segments.",20621845_5,-1,-1,2,15254,-1
15256,MMP-9,2,3,7,12,"MMP-2, MMP-9, ADAM-10 and ADAM-17 mRNA levels were increased in CaCl(2)-treated segments (all p<0.01), with trends of elevation in CaCl(2)-untreated segments, as compared with NaCl-treated segments.",20621845_6,-1,-1,2,15256,-1
15259,CaCl(2)-treated,12,13,64,79,"MMP-2, MMP-9, ADAM-10 and ADAM-17 mRNA levels were increased in CaCl(2)-treated segments (all p<0.01), with trends of elevation in CaCl(2)-untreated segments, as compared with NaCl-treated segments.",20621845_6,-1,-1,2,15259,-1
15261,NaCl-treated,30,31,176,188,"MMP-2, MMP-9, ADAM-10 and ADAM-17 mRNA levels were increased in CaCl(2)-treated segments (all p<0.01), with trends of elevation in CaCl(2)-untreated segments, as compared with NaCl-treated segments.",20621845_6,-1,-1,2,15261,-1
15263,MMP-9,8,9,77,82,"Immunohistochemistry displayed significantly increased expressions of MMP-2, MMP-9, ADAM-10 and ADAM-17 (all p<0.01) in intima and media for CaCl(2)-treated segments.",20621845_7,-1,-1,2,15263,-1
15266,CaCl(2)-treated,22,23,141,156,"Immunohistochemistry displayed significantly increased expressions of MMP-2, MMP-9, ADAM-10 and ADAM-17 (all p<0.01) in intima and media for CaCl(2)-treated segments.",20621845_7,-1,-1,2,15266,-1
15268,tissue levels,3,5,14,27,TIMP mRNA and tissue levels did not differ obviously among the three aortic segments.,20621845_8,-1,-1,2,15268,-1
15271,CaCl(2) exposure,10,13,63,79,"CONCLUSION: This study establishes a TAA model by periarterial CaCl(2) exposure in rats, and demonstrates a significant elevation of expression of MMP-2, MMP-9, ADAM10 and ADAM17 in the pathogenesis of vascular remodeling.",20621845_9,-1,-1,2,15271,-1
15278,electroconvulsive therapy,8,10,61,86,Suxamethonium induced prolonged apnea in a patient receiving electroconvulsive therapy.,20633755_0,-1,-1,2,15278,-1
15281,enzyme gets,9,11,78,89,Suxamethonium causes prolonged apnea in patients in whom pseudocholinesterase enzyme gets deactivated by organophosphorus (OP) poisons.,20633755_1,-1,-1,2,15281,-1
15284,electroconvulsive therapy,14,16,81,106,"Here, we present a similar incident in a severely depressed patient who received electroconvulsive therapy (ECT).",20633755_2,-1,-1,2,15284,-1
15296,treated with,3,5,17,29,The condition is treated with intravenous thyroxine (T4) or intravenous tri-iodo-thyronine (T3).,20635749_4,-1,-1,2,15296,-1
15301,follow up,19,21,124,133,"Patients with CHF on amiodarone may suffer serious morbidity and mortality from hypothyroidism, and thus may deserve closer follow up for thyroid stimulating hormone (TSH) levels.",20635749_5,-1,-1,2,15301,-1
15304,CHF,15,16,104,107,This case report carries an important clinical application given the frequent usage of amiodarone among CHF patients.,20635749_6,-1,-1,2,15304,-1
15317,free radical generation,3,6,16,39,The increase in free radical generation has been implicated as one of the important mechanisms of cognitive impairment by antiepileptic drugs.,20667451_2,-1,-1,2,15317,-1
15326,Pharmacokinetic interactions,0,2,0,28,Pharmacokinetic interactions of curcumin with phenobarbitone and carbamazepine were also studied.,20667451_5,-1,-1,2,15326,-1
15330,Wistar rats,8,10,57,68,Vehicle/drugs were administered daily for 21days to male Wistar rats.,20667451_6,-1,-1,2,15330,-1
15348,treated with,20,22,139,151,These results show that curcumin has beneficial effect in mitigating the deterioration of cognitive functions and oxidative damage in rats treated with phenobarbitone and carbamazepine without significantly altering their serum concentrations.,20667451_12,-1,-1,2,15348,-1
15353,associated with,24,26,175,190,The findings suggest that curcumin can be considered as a potential safe and effective adjuvant to phenobarbitone and carbamazepine therapy in preventing cognitive impairment associated with these drugs.,20667451_13,-1,-1,2,15353,-1
15358,streptozocin-induced model,11,13,63,89,"Effects of active constituents of Crocus sativus L., crocin on streptozocin-induced model of sporadic Alzheimer's disease in male rats.",20683499_0,-1,-1,2,15358,-1
15362,Crocus sativus L. extract,17,21,104,129,"BACKGROUND: The involvement of water-soluble carotenoids, crocins, as the main and active components of Crocus sativus L. extract in learning and memory processes has been proposed.",20683499_1,-1,-1,2,15362,-1
15375,STZ-icv,10,11,55,62,"In Alzheimer's disease groups, rats were injected with STZ-icv bilaterally (3 mg/kg) in first day and 3 days later, a similar STZ-icv application was repeated.",20683499_4,-1,-1,2,15375,-1
15377,STZ-icv,26,27,126,133,"In Alzheimer's disease groups, rats were injected with STZ-icv bilaterally (3 mg/kg) in first day and 3 days later, a similar STZ-icv application was repeated.",20683499_4,-1,-1,2,15377,-1
15386,Y-maze task,20,22,130,141,"However, the learning and memory performance was assessed using passive avoidance paradigm, and for spatial cognition evaluation, Y-maze task was used.",20683499_7,-1,-1,2,15386,-1
15388,STZ-injected,11,12,57,69,RESULTS: It was found out that crocin (30 mg/kg)-treated STZ-injected rats show higher correct choices and lower errors in Y-maze than vehicle-treated STZ-injected rats.,20683499_8,-1,-1,2,15388,-1
15389,lower errors,18,20,107,119,RESULTS: It was found out that crocin (30 mg/kg)-treated STZ-injected rats show higher correct choices and lower errors in Y-maze than vehicle-treated STZ-injected rats.,20683499_8,-1,-1,2,15389,-1
15391,vehicle-treated,23,24,135,150,RESULTS: It was found out that crocin (30 mg/kg)-treated STZ-injected rats show higher correct choices and lower errors in Y-maze than vehicle-treated STZ-injected rats.,20683499_8,-1,-1,2,15391,-1
15392,STZ-injected,24,25,151,163,RESULTS: It was found out that crocin (30 mg/kg)-treated STZ-injected rats show higher correct choices and lower errors in Y-maze than vehicle-treated STZ-injected rats.,20683499_8,-1,-1,2,15392,-1
15396,passive avoidance test,20,23,137,159,"In addition, crocin in the mentioned dose could significantly attenuated learning and memory impairment in treated STZ-injected group in passive avoidance test.",20683499_9,-1,-1,2,15396,-1
15402,anemia?BACKGROUND/AIMS,11,12,77,99,Can angiogenesis be a target of treatment for ribavirin associated hemolytic anemia?BACKGROUND/AIMS: Recently ribavirin has been found to inhibit angiogenesis and a number of angiogenesis inhibitors such as sunitinib and sorafenib have been found to cause acute hemolysis.,20698227_0,-1,-1,2,15402,-1
15412,serum levels,6,8,33,45,"In contrast with the literature, serum levels of angiogenesis factors did not change significantly by pegylated interferon and ribavirin therapy.",20698227_6,-1,-1,2,15412,-1
15417,associated with,6,8,42,57,Previous reports have suggested that pain associated with the injection of lidocaine is related to the acidic pH of the solution.,2070391_1,-1,-1,2,15417,-1
15419,randomized study,29,31,169,185,"To determine if the addition of a buffering solution to adjust the pH of lidocaine into the physiologic range would reduce pain during injection, we performed a blinded randomized study in patients undergoing cardiac catheterization.",2070391_2,-1,-1,2,15419,-1
15423,mean pain score,1,4,4,19,"The mean pain score for buffered lidocaine was significantly lower than the mean score for standard lidocaine (2.7 +/- 1.9 vs. 3.8 +/- 2.2, P = 0.03).",2070391_4,-1,-1,2,15423,-1
15424,mean score,12,14,76,86,"The mean pain score for buffered lidocaine was significantly lower than the mean score for standard lidocaine (2.7 +/- 1.9 vs. 3.8 +/- 2.2, P = 0.03).",2070391_4,-1,-1,2,15424,-1
15425,/-,20,21,116,118,"The mean pain score for buffered lidocaine was significantly lower than the mean score for standard lidocaine (2.7 +/- 1.9 vs. 3.8 +/- 2.2, P = 0.03).",2070391_4,0,1,2,15425,-1
15426,/-,25,26,132,134,"The mean pain score for buffered lidocaine was significantly lower than the mean score for standard lidocaine (2.7 +/- 1.9 vs. 3.8 +/- 2.2, P = 0.03).",2070391_4,0,1,2,15426,-1
15427,associated with,5,7,29,44,Serotonin 6 receptor gene is associated with methamphetamine-induced psychosis in a Japanese population.,20705401_0,-1,-1,2,15427,-1
15429,Japanese population,11,13,84,103,Serotonin 6 receptor gene is associated with methamphetamine-induced psychosis in a Japanese population.,20705401_0,-1,-1,2,15429,-1
15432,susceptibility factor,11,13,77,98,BACKGROUND: Altered serotonergic neural transmission is hypothesized to be a susceptibility factor for psychotic disorders such as schizophrenia.,20705401_1,-1,-1,2,15432,-1
15441,animal study,20,22,137,149,"In addition, the disrupted prepulse inhibition induced by d-amphetamine or phencyclidine was restored by 5-HT6 receptor antagonist in an animal study using rats.",20705401_3,-1,-1,2,15441,-1
15447,HTR6,14,15,74,78,"Therefore, we conducted an analysis of the association of the 5-HT6 gene (HTR6) with METH-induced psychosis.",20705401_6,-1,-1,2,15447,-1
15455,case-control samples,25,27,139,159,"METHOD: Using five tagging SNPs (rs6693503, rs1805054, rs4912138, rs3790757 and rs9659997), we conducted a genetic association analysis of case-control samples (197 METH-induced psychosis patients and 337 controls) in the Japanese population.",20705401_7,-1,-1,2,15455,-1
15457,Japanese population,38,40,222,241,"METHOD: Using five tagging SNPs (rs6693503, rs1805054, rs4912138, rs3790757 and rs9659997), we conducted a genetic association analysis of case-control samples (197 METH-induced psychosis patients and 337 controls) in the Japanese population.",20705401_7,-1,-1,2,15457,-1
15458,control subjects,6,8,23,39,The age and sex of the control subjects did not differ from those of the methamphetamine dependence patients.,20705401_8,-1,-1,2,15458,-1
15460,associated with,4,6,23,38,RESULTS: rs6693503 was associated with METH-induced psychosis patients in the allele/genotype-wise analysis.,20705401_9,-1,-1,2,15460,-1
15462,allele/genotype-wise analysis,11,13,78,107,RESULTS: rs6693503 was associated with METH-induced psychosis patients in the allele/genotype-wise analysis.,20705401_9,-1,-1,2,15462,-1
15464,haplotype-wise analysis,2,4,7,30,"In the haplotype-wise analysis, we detected an association between two markers (rs6693503 and rs1805054) and three markers (rs6693503, rs1805054 and rs4912138) in HTR6 and METH-induced psychosis patients, respectively.",20705401_11,-1,-1,2,15464,-1
15470,HTR6,28,29,163,167,"In the haplotype-wise analysis, we detected an association between two markers (rs6693503 and rs1805054) and three markers (rs6693503, rs1805054 and rs4912138) in HTR6 and METH-induced psychosis patients, respectively.",20705401_11,-1,-1,2,15470,-1
15472,HTR6,2,3,12,16,CONCLUSION: HTR6 may play an important role in the pathophysiology of METH-induced psychosis in the Japanese population.,20705401_12,-1,-1,2,15472,-1
15475,Japanese population,16,18,100,119,CONCLUSION: HTR6 may play an important role in the pathophysiology of METH-induced psychosis in the Japanese population.,20705401_12,-1,-1,2,15475,-1
15484,mnemonic tests,21,23,87,101,"Before and 0.5, 1, 2, 3, and 6 h after injection the subjects were given attention and mnemonic tests.",2071257_4,-1,-1,2,15484,-1
15493,special populations,18,20,98,117,"WHAT THE READER WILL GAIN: The reader will gain better insight into the safety of capecitabine in special populations such as patients with advanced age, renal and kidney disease.",20722491_3,-1,-1,2,15493,-1
15500,safety/efficacy profile,27,29,151,174,TAKE HOME MESSAGE: Capecitabine is an oral prodrug of 5-FU and was developed to fulfill the need for a more convenient therapy and provide an improved safety/efficacy profile.,20722491_5,-1,-1,2,15500,-1
15521,double-blind study design,6,9,42,67,"In a counterbalanced, placebo-controlled, double-blind study design, healthy subjects were administered a continuous subanesthetic S-ketamine infusion while differences in BOLD responses measured with fMRI were detected.",20727411_4,-1,-1,2,15521,-1
15522,healthy subjects,10,12,69,85,"In a counterbalanced, placebo-controlled, double-blind study design, healthy subjects were administered a continuous subanesthetic S-ketamine infusion while differences in BOLD responses measured with fMRI were detected.",20727411_4,-1,-1,2,15522,-1
15525,scanning period,2,4,11,26,"During the scanning period, subjects performed continuous overt verbal fluency tasks (phonological, lexical and semantic).",20727411_5,-1,-1,2,15525,-1
15526,verbal fluency tasks,9,12,64,84,"During the scanning period, subjects performed continuous overt verbal fluency tasks (phonological, lexical and semantic).",20727411_5,-1,-1,2,15526,-1
15529,t-tests,1,2,9,16,"Post-hoc t-tests revealed significant differences between placebo and ketamine for the amounts of words generated during lexical and semantic verbal fluency, while the phonological domain remained unaffected.",20727411_8,-1,-1,2,15529,-1
15543,transplant-free survivors,5,7,30,55,BACKGROUND: The prognosis for transplant-free survivors of paracetamol-induced acute liver failure remains unknown.,20735774_1,-1,-1,2,15543,-1
15548,Danish national referral centre,17,21,115,146,"METHODS: We followed up all transplant-free survivors of paracetamol-induced acute liver injury, hospitalized in a Danish national referral centre during 1984-2004.",20735774_3,-1,-1,2,15548,-1
15550,mortality rates,3,5,25,40,We compared age-specific mortality rates from 1 year post-discharge through 2008 between those in whom the liver injury led to an acute liver failure and those in whom it did not.,20735774_4,-1,-1,2,15550,-1
15554,mortality rates,4,6,25,40,"On average, age-specific mortality rates were slightly higher for the 101 patients whose paracetamol-induced liver injury had caused an acute liver failure (adjusted mortality rate ratio = 1.70, 95% CI 1.02-2.85), but the association was age-dependent, and no survivors of acute liver failure died of liver disease, whereas suicides were frequent in both groups.",20735774_6,-1,-1,2,15554,-1
15557,mortality rate ratio,25,28,166,186,"On average, age-specific mortality rates were slightly higher for the 101 patients whose paracetamol-induced liver injury had caused an acute liver failure (adjusted mortality rate ratio = 1.70, 95% CI 1.02-2.85), but the association was age-dependent, and no survivors of acute liver failure died of liver disease, whereas suicides were frequent in both groups.",20735774_6,-1,-1,2,15557,-1
15562,mortality rate ratio,5,8,26,46,"More likely, the elevated mortality rate ratio resulted from incomplete adjustment for the greater prevalence of substance abuse among survivors of acute liver failure.",20735774_8,-1,-1,2,15562,-1
15575,animal models,6,8,31,44,"In recent years, evidence from animal models of Parkinson's disease has provided important information to understand the effect of specific receptor and post-receptor molecular mechanisms underlying the development of dyskinetic movements.",20880751_4,-1,-1,2,15575,-1
15577,post-receptor molecular mechanisms,24,27,153,187,"In recent years, evidence from animal models of Parkinson's disease has provided important information to understand the effect of specific receptor and post-receptor molecular mechanisms underlying the development of dyskinetic movements.",20880751_4,-1,-1,2,15577,-1
15580,research focus,9,11,61,75,"Recent preclinical and clinical data from promising lines of research focus on the differential role of presynaptic versus postsynaptic mechanisms, dopamine receptor subtypes, ionotropic and metabotropic glutamate receptors, and non-dopaminergic neurotransmitter systems in the pathophysiology of levodopa-induced dyskinesias.",20880751_5,-1,-1,2,15580,-1
15590,electrophysiological studies,11,13,94,122,Effects of pallidal neurotensin on haloperidol-induced parkinsonian catalepsy: behavioral and electrophysiological studies.,20882060_0,-1,-1,2,15590,-1
15612,electrophysiological effects,12,14,87,115,The neurotensin type-1 receptor antagonist SR48692 blocked both the behavioral and the electrophysiological effects induced by neurotensin.,20882060_7,-1,-1,2,15612,-1
15619,prognostic period,11,13,68,85,Organic mental disorder was observed in a 29-year-old female in the prognostic period after the onset of carmofur-induced leukoencephalopathy.,2096243_1,-1,-1,2,15619,-1
15622,DSM-III-R.,27,28,176,186,"Symptoms such as euphoria, emotional lability and puerile attitude noted in the patient were diagnosed as organic personality syndrome according to the criteria defined in the DSM-III-R. It is referred to as a frontal lobe syndrome.",2096243_2,-1,-1,2,15622,-1
15626,low density area,5,8,36,52,Brain CT revealed a periventricular low density area in the frontal white matter and moderate dilatation of the lateral ventricles especially at the bilateral anterior horns.,2096243_3,-1,-1,2,15626,-1
15635,animal models,11,13,75,88,In vivo characterization of a dual adenosine A2A/A1 receptor antagonist in animal models of Parkinson's disease.,20973483_0,-1,-1,2,15635,-1
15639,animal models,14,16,91,104,The in vivo characterization of a dual adenosine A(2A)/A(1) receptor antagonist in several animal models of Parkinson's disease is described.,20973483_1,-1,-1,2,15639,-1
15641,scale-up syntheses,2,4,14,32,"Discovery and scale-up syntheses of compound 1 are described in detail, highlighting optimization steps that increased the overall yield of 1 from 10.0% to 30.5%.",20973483_2,-1,-1,2,15641,-1
15642,compound 1,5,7,36,46,"Discovery and scale-up syntheses of compound 1 are described in detail, highlighting optimization steps that increased the overall yield of 1 from 10.0% to 30.5%.",20973483_2,-1,-1,2,15642,-1
15646,oral administration,34,36,141,160,"Compound 1 is a potent A(2A)/A(1) receptor antagonist in vitro (A(2A) K(i) = 4.1 nM; A(1) K(i) = 17.0 nM) that has excellent activity, after oral administration, across a number of animal models of Parkinson's disease including mouse and rat models of haloperidol-induced catalepsy, mouse model of reserpine-induced akinesia, rat 6-hydroxydopamine (6-OHDA) lesion model of drug-induced rotation, and MPTP-treated non-human primate model.",20973483_3,-1,-1,2,15646,-1
15647,animal models,41,43,181,194,"Compound 1 is a potent A(2A)/A(1) receptor antagonist in vitro (A(2A) K(i) = 4.1 nM; A(1) K(i) = 17.0 nM) that has excellent activity, after oral administration, across a number of animal models of Parkinson's disease including mouse and rat models of haloperidol-induced catalepsy, mouse model of reserpine-induced akinesia, rat 6-hydroxydopamine (6-OHDA) lesion model of drug-induced rotation, and MPTP-treated non-human primate model.",20973483_3,-1,-1,2,15647,-1
15649,mouse model,56,58,283,294,"Compound 1 is a potent A(2A)/A(1) receptor antagonist in vitro (A(2A) K(i) = 4.1 nM; A(1) K(i) = 17.0 nM) that has excellent activity, after oral administration, across a number of animal models of Parkinson's disease including mouse and rat models of haloperidol-induced catalepsy, mouse model of reserpine-induced akinesia, rat 6-hydroxydopamine (6-OHDA) lesion model of drug-induced rotation, and MPTP-treated non-human primate model.",20973483_3,-1,-1,2,15649,-1
15655,MPTP-treated non-human primate model,74,78,400,436,"Compound 1 is a potent A(2A)/A(1) receptor antagonist in vitro (A(2A) K(i) = 4.1 nM; A(1) K(i) = 17.0 nM) that has excellent activity, after oral administration, across a number of animal models of Parkinson's disease including mouse and rat models of haloperidol-induced catalepsy, mouse model of reserpine-induced akinesia, rat 6-hydroxydopamine (6-OHDA) lesion model of drug-induced rotation, and MPTP-treated non-human primate model.",20973483_3,-1,-1,2,15655,-1
15660,duration of action,1,4,4,22,"The duration of action may be prolonged in patients with genetic variants of the butyrylcholinesterase enzyme (BChE), the most common being the K- and the A-variants.",21029050_2,-1,-1,2,15660,-1
15661,genetic variants,10,12,57,73,"The duration of action may be prolonged in patients with genetic variants of the butyrylcholinesterase enzyme (BChE), the most common being the K- and the A-variants.",21029050_2,-1,-1,2,15661,-1
15666,clinical significance,9,11,39,60,The aim of the study was to assess the clinical significance of genetic variants in butyrylcholinesterase gene (BCHE) in patients with a suspected prolonged duration of action of succinylcholine after ECT.,21029050_3,-1,-1,2,15666,-1
15667,genetic variants,12,14,64,80,The aim of the study was to assess the clinical significance of genetic variants in butyrylcholinesterase gene (BCHE) in patients with a suspected prolonged duration of action of succinylcholine after ECT.,21029050_3,-1,-1,2,15667,-1
15671,BCHE genotype,7,9,40,53,"We determined the BChE activity and the BCHE genotype using molecular genetic methods, the duration of apnea, time to sufficient spontaneous ventilation and whether neuromuscular monitoring was used.",21029050_5,-1,-1,2,15671,-1
15672,molecular genetic methods,10,13,60,85,"We determined the BChE activity and the BCHE genotype using molecular genetic methods, the duration of apnea, time to sufficient spontaneous ventilation and whether neuromuscular monitoring was used.",21029050_5,-1,-1,2,15672,-1
15675,published data,7,9,40,54,The duration of apnea was compared with published data on normal subjects.,21029050_6,-1,-1,2,15675,-1
15677,BCHE gene,11,13,53,62,"RESULTS: in 11 patients, mutations were found in the BCHE gene, the K-variant being the most frequent.",21029050_7,-1,-1,2,15677,-1
15678,K-variant,15,16,68,77,"RESULTS: in 11 patients, mutations were found in the BCHE gene, the K-variant being the most frequent.",21029050_7,-1,-1,2,15678,-1
15680,recovery phase,6,8,33,47,Severe distress was noted in the recovery phase in two patients.,21029050_9,-1,-1,2,15680,-1
15682,duration of action,9,12,51,69,"CONCLUSION: eleven of 13 patients with a prolonged duration of action of succinylcholine had mutations in BCHE, indicating that this is the possible reason for a prolonged period of apnea.",21029050_11,-1,-1,2,15682,-1
15694,Sprague-Dawley rats,5,7,34,53,MATERIAL AND METHODS: Twenty-five Sprague-Dawley rats were implanted DBS electrodes.,21294084_3,-1,-1,2,15694,-1
15695,group-1,1,2,3,10,"In group-1 (n=10) hippocampal DBS was off and in the group-2 (n=10) hippocampal DBS was on (185 Hz, 0.5V, 1V, 2V, and 5V for 60 sec) following penicillin G injection intracortically.",21294084_4,-1,-1,2,15695,-1
15697,group-2,12,13,53,60,"In group-1 (n=10) hippocampal DBS was off and in the group-2 (n=10) hippocampal DBS was on (185 Hz, 0.5V, 1V, 2V, and 5V for 60 sec) following penicillin G injection intracortically.",21294084_4,-1,-1,2,15697,-1
15703,control group,2,4,7,20,In the control group hippocampal DBS was on following 8  l saline injection intracortically.,21294084_5,-1,-1,2,15703,-1
15705,saline injection,12,14,59,75,In the control group hippocampal DBS was on following 8  l saline injection intracortically.,21294084_5,-1,-1,2,15705,-1
15710,control group,2,4,7,20,"In the control group, hippocampal stimulation alone lead only to diffuse slowing of cerebral bioelectrical activity at 5V stimulation.",21294084_8,-1,-1,2,15710,-1
15712,cerebral bioelectrical activity,14,17,84,115,"In the control group, hippocampal stimulation alone lead only to diffuse slowing of cerebral bioelectrical activity at 5V stimulation.",21294084_8,-1,-1,2,15712,-1
15713,5V stimulation,18,20,119,133,"In the control group, hippocampal stimulation alone lead only to diffuse slowing of cerebral bioelectrical activity at 5V stimulation.",21294084_8,-1,-1,2,15713,-1
15718,retrospective study,9,11,37,56,"CCNU (lomustine) toxicity in dogs: a retrospective study (2002-07).OBJECTIVE: To describe the incidence of haematological, renal, hepatic and gastrointestinal toxicities in tumour-bearing dogs receiving 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU).",21418164_0,-1,-1,2,15718,-1
15726,Melbourne Veterinary Specialist Centre,15,19,75,113,DESIGN: The medical records of 206 dogs that were treated with CCNU at the Melbourne Veterinary Specialist Centre between February 2002 and December 2007 were retrospectively evaluated.,21418164_1,-1,-1,2,15726,-1
15727,retrospectively evaluated,26,28,159,184,DESIGN: The medical records of 206 dogs that were treated with CCNU at the Melbourne Veterinary Specialist Centre between February 2002 and December 2007 were retrospectively evaluated.,21418164_1,-1,-1,2,15727,-1
15728,treated with,6,8,25,37,"RESULTS: Of the 206 dogs treated with CCNU, 185 met the inclusion criteria for at least one class of toxicity.",21418164_2,-1,-1,2,15728,-1
15730,inclusion criteria,13,15,56,74,"RESULTS: Of the 206 dogs treated with CCNU, 185 met the inclusion criteria for at least one class of toxicity.",21418164_2,-1,-1,2,15730,-1
15746,clinical trials,23,25,129,144,"Peripheral neuropathy has been noted as a complication of therapy with perhexiline maleate, a drug widely used in France (and in clinical trials in the United States) for the prophylactic treatment of angina pectoris.",220563_1,-1,-1,2,15746,-1
15754,lipid storage,21,23,122,135,"The underlying mechanism causing the neuropathy is not yet fully known, although some evidence indicates that it may be a lipid storage process.",220563_5,-1,-1,2,15754,-1
15764,phase I study,1,4,2,15,A phase I study of 4'-0-tetrahydropyranyladriamycin.,2224762_0,-1,-1,2,15764,-1
15767,Phase I study,1,4,2,15,A Phase I study of intravenous (IV) bolus 4'-0-tetrahydropyranyladriamycin (Pirarubicin) was done in 55 patients in good performance status with refractory tumors.,2224762_2,-1,-1,2,15767,-1
15771,good risk,6,8,38,47,"Twenty-six had minimal prior therapy (good risk), 23 had extensive prior therapy (poor risk), and six had renal and/or hepatic dysfunction.",2224762_3,-1,-1,2,15771,-1
15778,dose-limiting toxic effect,1,4,4,30,The dose-limiting toxic effect was transient noncumulative granulocytopenia.,2224762_6,-1,-1,2,15778,-1
15786,Pharmacokinetic analyses,0,2,0,24,"Pharmacokinetic analyses in 21 patients revealed Pirarubicin plasma T 1/2 alpha (+/- SE) of 2.5 +/- 0.85 minutes, T beta 1/2 of 25.6 +/- 6.5 minutes, and T 1/2 gamma of 23.6 +/- 7.6 hours.",2224762_10,-1,-1,2,15786,-1
15788,(+,11,13,80,82,"Pharmacokinetic analyses in 21 patients revealed Pirarubicin plasma T 1/2 alpha (+/- SE) of 2.5 +/- 0.85 minutes, T beta 1/2 of 25.6 +/- 6.5 minutes, and T 1/2 gamma of 23.6 +/- 7.6 hours.",2224762_10,0,1,2,15788,-1
15792,T 1/2 gamma,34,37,154,165,"Pharmacokinetic analyses in 21 patients revealed Pirarubicin plasma T 1/2 alpha (+/- SE) of 2.5 +/- 0.85 minutes, T beta 1/2 of 25.6 +/- 6.5 minutes, and T 1/2 gamma of 23.6 +/- 7.6 hours.",2224762_10,-1,-1,2,15792,-1
15794,area under the curve,1,5,4,24,"The area under the curve was 537 +/- 149 ng/ml x hours, volume of distribution (Vd) 3504 +/- 644 l/m2, and total clearance (ClT) was 204 + 39.3 l/hour/m2.",2224762_11,-1,-1,2,15794,-1
15795,/-,8,9,34,36,"The area under the curve was 537 +/- 149 ng/ml x hours, volume of distribution (Vd) 3504 +/- 644 l/m2, and total clearance (ClT) was 204 + 39.3 l/hour/m2.",2224762_11,0,1,2,15795,-1
15796,volume of distribution,14,17,56,78,"The area under the curve was 537 +/- 149 ng/ml x hours, volume of distribution (Vd) 3504 +/- 644 l/m2, and total clearance (ClT) was 204 + 39.3 l/hour/m2.",2224762_11,-1,-1,2,15796,-1
15797,/-,22,23,90,92,"The area under the curve was 537 +/- 149 ng/ml x hours, volume of distribution (Vd) 3504 +/- 644 l/m2, and total clearance (ClT) was 204 + 39.3 l/hour/m2.",2224762_11,0,1,2,15797,-1
15798,l/m2,24,25,97,101,"The area under the curve was 537 +/- 149 ng/ml x hours, volume of distribution (Vd) 3504 +/- 644 l/m2, and total clearance (ClT) was 204 + 39.3 l/hour/m2.",2224762_11,-1,-1,2,15798,-1
15799,total clearance,27,29,107,122,"The area under the curve was 537 +/- 149 ng/ml x hours, volume of distribution (Vd) 3504 +/- 644 l/m2, and total clearance (ClT) was 204 + 39.3 l/hour/m2.",2224762_11,-1,-1,2,15799,-1
15800,ClT,30,31,124,127,"The area under the curve was 537 +/- 149 ng/ml x hours, volume of distribution (Vd) 3504 +/- 644 l/m2, and total clearance (ClT) was 204 + 39.3 l/hour/m2.",2224762_11,-1,-1,2,15800,-1
15812,hemodialyzed patients,7,9,38,59,During an 18-month period of study 41 hemodialyzed patients receiving desferrioxamine (10-40 mg/kg BW/3 times weekly) for the first time were monitored for detection of audiovisual toxicity.,2234245_1,-1,-1,2,15812,-1
15820,associated with,15,17,103,118,"Visual toxicity was of retinal origin and was characterized by a tritan-type dyschromatopsy, sometimes associated with a loss of visual acuity and pigmentary retinal deposits.",2234245_4,-1,-1,2,15820,-1
15823,high-frequency,8,9,49,63,Auditory toxicity was characterized by a mid- to high-frequency neurosensorial hearing loss and the lesion was of the cochlear type.,2234245_5,-1,-1,2,15823,-1
15830,aluminium serum levels,19,22,132,154,This toxicity appeared in patients receiving the higher doses of desferrioxamine or coincided with the normalization of ferritin or aluminium serum levels.,2234245_7,-1,-1,2,15830,-1
15833,hemodialyzed patients,7,9,57,78,Periodical audiovisual monitoring should be performed on hemodialyzed patients receiving the drug in order to detect adverse effects as early as possible.,2234245_9,-1,-1,2,15833,-1
15839,in vitro,14,16,86,94,"Increased extracellular concentrations of uridine (Urd) have been reported to reduce, in vitro, azidothymidine (AZT)-induced inhibition of human granulocyte-macrophage progenitor cells without impairment of its antihuman immunodeficiency virus (HIV) activity.",2257294_1,-1,-1,2,15839,-1
15844,chronic Urd administration,7,10,51,77,"Because of the clinical toxicities associated with chronic Urd administration, the ability of benzylacyclouridine (BAU) to effect, in vivo, AZT-induced anemia and leukopenia was assessed.",2257294_2,-1,-1,2,15844,-1
15850,in vivo,7,9,40,47,"This agent inhibits Urd catabolism and, in vivo, increases the plasma concentration of Urd in a dose-dependent manner, without Urd-related toxicity.",2257294_3,-1,-1,2,15850,-1
15862,In vitro,0,2,0,8,"In vitro, at a concentration of 100 mumol/L, BAU possesses minimal anti-HIV activity and has no effect on the ability of AZT to reverse the HIV-induced cytopathic effect in MT4 cells.",2257294_6,-1,-1,2,15862,-1
15865,no effect,17,19,93,102,"In vitro, at a concentration of 100 mumol/L, BAU possesses minimal anti-HIV activity and has no effect on the ability of AZT to reverse the HIV-induced cytopathic effect in MT4 cells.",2257294_6,-1,-1,2,15865,-1
15867,cytopathic effect,28,30,152,169,"In vitro, at a concentration of 100 mumol/L, BAU possesses minimal anti-HIV activity and has no effect on the ability of AZT to reverse the HIV-induced cytopathic effect in MT4 cells.",2257294_6,-1,-1,2,15867,-1
15868,MT4 cells,31,33,173,182,"In vitro, at a concentration of 100 mumol/L, BAU possesses minimal anti-HIV activity and has no effect on the ability of AZT to reverse the HIV-induced cytopathic effect in MT4 cells.",2257294_6,-1,-1,2,15868,-1
15876,double-blind trial,2,4,12,30,"Randomized, double-blind trial of mazindol in Duchenne dystrophy.",2266990_0,-1,-1,2,15876,-1
15881,12-month controlled trial,3,6,15,40,"We conducted a 12-month controlled trial of mazindol, a putative growth hormone secretion inhibitor, in 83 boys with Duchenne dystrophy.",2266990_2,-1,-1,2,15881,-1
15898,GH secretion,5,7,26,38,"The effect of mazindol on GH secretion was estimated indirectly by comparing the postabsorptive IGF-I levels obtained following 3, 6, 9, and 12 months in the mazindol treated to those in the placebo groups.",2266990_7,-1,-1,2,15898,-1
15902,mazindol-treated,1,2,9,25,"Although mazindol-treated patients gained less weight and height than placebo-treated patients, no significant effect on IGF-I levels was observed.",2266990_8,-1,-1,2,15902,-1
15904,placebo-treated,9,10,70,85,"Although mazindol-treated patients gained less weight and height than placebo-treated patients, no significant effect on IGF-I levels was observed.",2266990_8,-1,-1,2,15904,-1
15909,pre-test,5,6,36,44,Facilitation of memory retrieval by pre-test morphine and its state dependency in the step-through type passive avoidance learning test in mice.,2273650_0,-1,-1,2,15909,-1
15910,step-through type,13,15,86,103,Facilitation of memory retrieval by pre-test morphine and its state dependency in the step-through type passive avoidance learning test in mice.,2273650_0,-1,-1,2,15910,-1
15912,test trial,15,17,100,110,"Amnesia produced by scopolamine and cycloheximide were reversed by morphine given 30 min before the test trial (pre-test), and pre-test morphine also facilitated the memory retrieval in the animals administered naloxone during the training trial.",2273650_1,-1,-1,2,15912,-1
15913,pre-test,18,19,112,120,"Amnesia produced by scopolamine and cycloheximide were reversed by morphine given 30 min before the test trial (pre-test), and pre-test morphine also facilitated the memory retrieval in the animals administered naloxone during the training trial.",2273650_1,-1,-1,2,15913,-1
15914,pre-test,22,23,127,135,"Amnesia produced by scopolamine and cycloheximide were reversed by morphine given 30 min before the test trial (pre-test), and pre-test morphine also facilitated the memory retrieval in the animals administered naloxone during the training trial.",2273650_1,-1,-1,2,15914,-1
15917,pre-test,2,3,11,19,"Similarly, pre-test scopolamine partially reversed the scopolamine-induced amnesia, but not significantly; and pre-test cycloheximide failed to reverse the cycloheximide-induced amnesia.",2273650_2,-1,-1,2,15917,-1
15918,pre-test,15,16,111,119,"Similarly, pre-test scopolamine partially reversed the scopolamine-induced amnesia, but not significantly; and pre-test cycloheximide failed to reverse the cycloheximide-induced amnesia.",2273650_2,-1,-1,2,15918,-1
15921,pre-test,10,11,67,75,These results suggest that the facilitation of memory retrieval by pre-test morphine might be the direct action of morphine rather than a state dependent effect.,2273650_3,-1,-1,2,15921,-1
15922,state dependent effect,22,25,138,160,These results suggest that the facilitation of memory retrieval by pre-test morphine might be the direct action of morphine rather than a state dependent effect.,2273650_3,-1,-1,2,15922,-1
15938,central alpha-adrenoceptor stimulation,11,14,79,117,These findings indicate that in spontaneously hypertensive rats the effects of central alpha-adrenoceptor stimulation involve activation of opiate receptors.,227508_5,-1,-1,2,15938,-1
15947,neurotoxic reactions,9,11,50,70,An analysis is presented of 220 cases of possible neurotoxic reactions to halogenated hydroxyquinolines reported from outside Japan.,230316_1,-1,-1,2,15947,-1
15974,urethral pressure,12,14,79,96,"The restoration of continence was accompanied by a substantial rise in maximum urethral pressure, maximum urethral closure pressure, and functional urethral length.",2304736_6,-1,-1,2,15974,-1
15975,urethral closure pressure,16,19,106,131,"The restoration of continence was accompanied by a substantial rise in maximum urethral pressure, maximum urethral closure pressure, and functional urethral length.",2304736_6,-1,-1,2,15975,-1
16002,prerenal component,1,3,2,20,"A prerenal component could have contributed to renal failure because of a transient hypotension, due to an increasing ascitis, occurring just before anuria.",2320800_3,-1,-1,2,16002,-1
16008,nephrotoxic drug,4,6,22,38,Ifosfamide is a known nephrotoxic drug with demonstrated tubulopathies.,2320800_5,-1,-1,2,16008,-1
16014,nephrotoxic chemotherapy,10,12,67,91,We recommend careful use of ifosfamide in patients pretreated with nephrotoxic chemotherapy and inadequate renal perfusion.,2320800_7,-1,-1,2,16014,-1
16016,Nociceptive effects,0,2,0,19,"Nociceptive effects induced by intrathecal administration of prostaglandin D2, E2, or F2 alpha to conscious mice.",2322844_0,-1,-1,2,16016,-1
16021,conscious mice,16,18,98,112,"Nociceptive effects induced by intrathecal administration of prostaglandin D2, E2, or F2 alpha to conscious mice.",2322844_0,-1,-1,2,16021,-1
16022,intrathecal administration,3,5,15,41,The effects of intrathecal administration of prostaglandins on pain responses in conscious mice were evaluated by using hot plate and acetic acid writhing tests.,2322844_1,-1,-1,2,16022,-1
16025,hot plate,17,19,120,129,The effects of intrathecal administration of prostaglandins on pain responses in conscious mice were evaluated by using hot plate and acetic acid writhing tests.,2322844_1,-1,-1,2,16025,-1
16028,hyperalgesic action,10,12,40,59,Prostaglandin D2 (0.5-3 ng/mouse) had a hyperalgesic action on the response to a hot plate during a 3-60 min period after injection.,2322844_2,-1,-1,2,16028,-1
16029,hot plate,17,19,81,90,Prostaglandin D2 (0.5-3 ng/mouse) had a hyperalgesic action on the response to a hot plate during a 3-60 min period after injection.,2322844_2,-1,-1,2,16029,-1
16031,hyperalgesic effect,4,6,26,45,"Prostaglandin E2 showed a hyperalgesic effect at doses of 1 pg to 10 ng/mouse, but the effect lasted shorter (3-30 min) than that of prostaglandin D2.",2322844_3,-1,-1,2,16031,-1
16032,ng/mouse,13,14,69,77,"Prostaglandin E2 showed a hyperalgesic effect at doses of 1 pg to 10 ng/mouse, but the effect lasted shorter (3-30 min) than that of prostaglandin D2.",2322844_3,-1,-1,2,16032,-1
16036,hyperalgesic effect,1,3,4,23,"The hyperalgesic effect of prostaglandin D2 was blocked by simultaneous injection of a substance P antagonist (greater than or equal to 100 ng) but not by AH6809, a prostanoid EP1-receptor antagonist.",2322844_5,-1,-1,2,16036,-1
16058,treated with,13,15,82,94,"Case reports of 11 patients with severe, extensive localized scleroderma who were treated with D-penicillamine are summarized in this article.",2334179_3,-1,-1,2,16058,-1
16060,favorable effect,7,9,31,47,This drug was judged to have a favorable effect on the disease course in 7 (64%) of 11 patients.,2334179_4,-1,-1,2,16060,-1
16067,associated with,4,6,28,43,The dose of D-penicillamine associated with a favorable response was as low as 2 to 5 mg/kg per day given over a period ranging from 15 to 53 months.,2334179_7,-1,-1,2,16067,-1
16074,respiratory effects,3,5,18,37,Comparison of the respiratory effects of i.v.,2334618_0,-1,-1,2,16074,-1
16083,Holter ambulatory monitor,25,28,174,199,"Monitoring consisted of airflow detection by a carbon dioxide analyser, chest wall movement detected by pneumatic capsules, and continuous electrocardiograph recorded with a Holter ambulatory monitor.",2334618_4,-1,-1,2,16083,-1
16090,associated with,14,16,101,116,We describe a 42-year-old woman who developed superior sagittal and left transverse sinus thrombosis associated with prolonged epsilon-aminocaproic acid therapy for menorrhagia.,2339463_1,-1,-1,2,16090,-1
16099,risk factors,8,10,54,66,Seizure activity with imipenem therapy: incidence and risk factors.,2343592_0,-1,-1,2,16099,-1
16119,acid-base,11,12,85,94,The effects of aminophylline on the ventricular fibrillation threshold during normal acid-base conditions and during respiratory failure were studied in anesthetized open chest dogs.,234669_3,-1,-1,2,16119,-1
16126,partial pressures,23,25,136,153,"During the infusion of aminophylline, the ventricular fibrillation threshold was reduced by 30 to 40 percent of the control when pH and partial pressures of oxygen (PO2) and carbon dioxide (CO2) were kept within normal limits.",234669_5,-1,-1,2,16126,-1
16127,PO2,28,29,165,168,"During the infusion of aminophylline, the ventricular fibrillation threshold was reduced by 30 to 40 percent of the control when pH and partial pressures of oxygen (PO2) and carbon dioxide (CO2) were kept within normal limits.",234669_5,-1,-1,2,16127,-1
16130,PC02,13,14,75,79,"When respiratory failure was produced by hypoventilation (pH 7.05 to 7.25; PC02 70 to 100 mm Hg: P02 20 to 40 mm Hg), infusion of aminophylline resulted in an even greater decrease in ventricular fibrillation threshold to 60 percent of the control level.",234669_6,-1,-1,2,16130,-1
16132,control level,46,48,240,253,"When respiratory failure was produced by hypoventilation (pH 7.05 to 7.25; PC02 70 to 100 mm Hg: P02 20 to 40 mm Hg), infusion of aminophylline resulted in an even greater decrease in ventricular fibrillation threshold to 60 percent of the control level.",234669_6,-1,-1,2,16132,-1
16139,Dipyridamole-thallium-201 imaging,0,2,0,33,Dipyridamole-thallium-201 imaging is often performed in patients unable to exercise because of peripheral vascular disease.,2348231_1,-1,-1,2,16139,-1
16145,dipyridamole-thallium-201 imaging,18,20,151,184,Whether pentoxifylline inhibits dipyridamole-induced coronary hyperemia like other methylxanthines such as theophylline and should be stopped prior to dipyridamole-thallium-201 imaging is unknown.,2348231_3,-1,-1,2,16145,-1
16151,treatment groups,10,12,76,92,Baseline circumflex coronary blood flows did not differ significantly among treatment groups.,2348231_5,-1,-1,2,16151,-1
16155,coronary blood flow,12,15,102,121,"Neither dose of pentoxifylline significantly decreased the dipyridamole-induced hyperemia, while peak coronary blood flow was significantly lower after theophylline (p less than 0.01).",2348231_8,-1,-1,2,16155,-1
16167,general population,35,37,188,206,"Cerebral haemorrhage was the 11th most frequent cause of death, accounting for only 0.8% of deaths among the patients, whereas it was the 5th most common cause of death among the Japanese general population in 1985.",2355241_3,-1,-1,2,16167,-1
16170,hypotensive effect,20,22,115,133,The low incidence of cerebral haemorrhage as a cause of death in patients with Parkinson's disease may reflect the hypotensive effect of levodopa and a hypotensive mechanism due to reduced noradrenaline levels in the parkinsonian brain.,2355241_4,-1,-1,2,16170,-1
16176,intravenous administration,8,10,62,88,"Although generally consisted safe when given intramuscularly, intravenous administration is known to cause respiratory and cardiovascular depression.",2375138_2,-1,-1,2,16176,-1
16181,magnesium administration,6,8,47,71,Myasthenia gravis presenting as weakness after magnesium administration.,2385256_0,-1,-1,2,16181,-1
16191,magnesium administration,3,5,25,49,"Although paralysis after magnesium administration has been described in patients with known myasthenia gravis, it has not previously been reported to be the initial or only manifestation of the disease.",2385256_7,-1,-1,2,16191,-1
16195,No enhancement,0,2,0,14,No enhancement by phenobarbital of the hepatocarcinogenicity of a choline-devoid diet in the rat.,2396046_0,-1,-1,2,16195,-1
16196,hepatocarcinogenicity,6,7,39,60,No enhancement by phenobarbital of the hepatocarcinogenicity of a choline-devoid diet in the rat.,2396046_0,-1,-1,2,16196,-1
16198,choline-devoid diet,12,14,76,95,An experiment was performed to test whether inclusion of phenobarbital in a choline-devoid diet would increase the hepatocarcinogenicity of the diet.,2396046_1,-1,-1,2,16198,-1
16212,no enhancement,3,5,20,34,The results evinced no enhancement of the hepatocarcinogenicity of the choline-devoid diet by phenobarbital.,2396046_5,-1,-1,2,16212,-1
16213,hepatocarcinogenicity,7,8,42,63,The results evinced no enhancement of the hepatocarcinogenicity of the choline-devoid diet by phenobarbital.,2396046_5,-1,-1,2,16213,-1
16217,hypotensive effect,10,12,59,77,Midline B3 serotonin nerves in rat medulla are involved in hypotensive effect of methyldopa.,2422478_0,-1,-1,2,16217,-1
16218,microinjection,8,9,56,70,Previous experiments in this laboratory have shown that microinjection of methyldopa onto the ventrolateral cells of the B3 serotonin neurons in the medulla elicits a hypotensive response mediated by a projection descending into the spinal cord.,2422478_1,-1,-1,2,16218,-1
16219,ventrolateral cells,13,15,94,113,Previous experiments in this laboratory have shown that microinjection of methyldopa onto the ventrolateral cells of the B3 serotonin neurons in the medulla elicits a hypotensive response mediated by a projection descending into the spinal cord.,2422478_1,-1,-1,2,16219,-1
16221,hypotensive response,25,27,167,187,Previous experiments in this laboratory have shown that microinjection of methyldopa onto the ventrolateral cells of the B3 serotonin neurons in the medulla elicits a hypotensive response mediated by a projection descending into the spinal cord.,2422478_1,-1,-1,2,16221,-1
16224,midline cells,11,13,69,82,"The present experiments were designed to investigate the role of the midline cells of the B3 serotonin neurons in the medulla, coinciding with the raphe magnus.",2422478_2,-1,-1,2,16224,-1
16226,magnus,26,27,153,159,"The present experiments were designed to investigate the role of the midline cells of the B3 serotonin neurons in the medulla, coinciding with the raphe magnus.",2422478_2,-1,-1,2,16226,-1
16238,ascending pathways,18,20,103,121,"Further, 5,7-DHT lesion of serotonin nerves travelling in the median forebrain bundle, one of the main ascending pathways from the B3 serotonin cells, did not affect the fall in blood pressure associated with a midline B3 serotonin methyldopa injection.",2422478_5,-1,-1,2,16238,-1
16241,associated with,34,36,193,208,"Further, 5,7-DHT lesion of serotonin nerves travelling in the median forebrain bundle, one of the main ascending pathways from the B3 serotonin cells, did not affect the fall in blood pressure associated with a midline B3 serotonin methyldopa injection.",2422478_5,-1,-1,2,16241,-1
16245,descending projections,17,19,117,139,"It is concluded therefore that, unlike the ventrolateral B3 cells which mediate a methyldopa-induced hypotension via descending projections, the midline serotonin B3 cells in the medulla contribute to the hypotensive action of methyldopa, either by way of an ascending projection which does not pass through the median forebrain bundle, or through a projection restricted to the caudal brainstem.",2422478_6,-1,-1,2,16245,-1
16256,Wistar rats,7,9,49,60,Liver enlargement and muscle wastage occurred in Wistar rats following the subcutaneous administration of prednisolone.,2425813_1,-1,-1,2,16256,-1
16257,subcutaneous administration,11,13,75,102,Liver enlargement and muscle wastage occurred in Wistar rats following the subcutaneous administration of prednisolone.,2425813_1,-1,-1,2,16257,-1
16261,tissue-specific,11,12,55,70,It is suggested that the drug acted in a selective and tissue-specific manner to enhance ribosomal RNA synthesis in the liver and depress such synthesis in the muscle.,2425813_3,-1,-1,2,16261,-1
16265,two-stage coronary ligation-,1,4,6,34,"Using two-stage coronary ligation-, digitalis-, and adrenaline-induced canine ventricular arrhythmias, antiarrhythmic effects of cibenzoline were examined and the minimum effective plasma concentration for each arrhythmia model was determined.",2435991_1,-1,-1,2,16265,-1
16273,/-,31,32,203,205,"Cibenzoline suppressed all the arrhythmias, and the minimum effective plasma concentrations for arrhythmias induced by 24-h coronary ligation, 48-h coronary ligation, digitalis, and adrenaline were 1.9 +/- 0.9 (by 8 mg/kg i.v.), 1.6 +/- 0.5 (by 8 mg/kg i.v.), 0.6 +/- 0.2 (by 2 mg/kg i.v.), and 3.5 +/- 1.3 (by 5 mg/kg i.v.) micrograms/ml, respectively (mean +/- SDM, n = 6-7).",2435991_2,0,1,2,16273,-1
16274,/-,43,44,234,236,"Cibenzoline suppressed all the arrhythmias, and the minimum effective plasma concentrations for arrhythmias induced by 24-h coronary ligation, 48-h coronary ligation, digitalis, and adrenaline were 1.9 +/- 0.9 (by 8 mg/kg i.v.), 1.6 +/- 0.5 (by 8 mg/kg i.v.), 0.6 +/- 0.2 (by 2 mg/kg i.v.), and 3.5 +/- 1.3 (by 5 mg/kg i.v.) micrograms/ml, respectively (mean +/- SDM, n = 6-7).",2435991_2,0,1,2,16274,-1
16275,/-,55,56,265,267,"Cibenzoline suppressed all the arrhythmias, and the minimum effective plasma concentrations for arrhythmias induced by 24-h coronary ligation, 48-h coronary ligation, digitalis, and adrenaline were 1.9 +/- 0.9 (by 8 mg/kg i.v.), 1.6 +/- 0.5 (by 8 mg/kg i.v.), 0.6 +/- 0.2 (by 2 mg/kg i.v.), and 3.5 +/- 1.3 (by 5 mg/kg i.v.) micrograms/ml, respectively (mean +/- SDM, n = 6-7).",2435991_2,0,1,2,16275,-1
16276,/- SDM,83,85,360,366,"Cibenzoline suppressed all the arrhythmias, and the minimum effective plasma concentrations for arrhythmias induced by 24-h coronary ligation, 48-h coronary ligation, digitalis, and adrenaline were 1.9 +/- 0.9 (by 8 mg/kg i.v.), 1.6 +/- 0.5 (by 8 mg/kg i.v.), 0.6 +/- 0.2 (by 2 mg/kg i.v.), and 3.5 +/- 1.3 (by 5 mg/kg i.v.) micrograms/ml, respectively (mean +/- SDM, n = 6-7).",2435991_2,-1,-1,2,16276,-1
16283,clinical usefulness,27,29,167,186,"Because cibenzoline had only weak hypotensive and sinus node depressive effects and was found to be orally active when given to coronary ligation arrhythmia dogs, its clinical usefulness is expected.",2435991_5,-1,-1,2,16283,-1
16284,Differential effects,0,2,0,20,Differential effects of gamma-hexachlorocyclohexane (lindane) on pharmacologically-induced seizures.,2440413_0,-1,-1,2,16284,-1
16291,exposure to,28,30,171,182,"Gamma-hexachlorocyclohexane (gamma-HCH), the active ingredient of the insecticide lindane, has been shown to decrease seizure threshold to pentylenetrazol (PTZ) 3 h after exposure to gamma-HCH and conversely increase threshold to PTZ-induced seizures 24 h after exposure to gamma-HCH (Vohland et al. 1981).",2440413_1,-1,-1,2,16291,-1
16294,exposure to,41,43,262,273,"Gamma-hexachlorocyclohexane (gamma-HCH), the active ingredient of the insecticide lindane, has been shown to decrease seizure threshold to pentylenetrazol (PTZ) 3 h after exposure to gamma-HCH and conversely increase threshold to PTZ-induced seizures 24 h after exposure to gamma-HCH (Vohland et al. 1981).",2440413_1,-1,-1,2,16294,-1
16302,differential response,27,29,163,184,"One hour after the administration of gamma-HCH, the activity of seizure-inducing agents was increased, regardless of their mechanism, while 24 h after gamma-HCH a differential response was observed.",2440413_3,-1,-1,2,16302,-1
16307,MPA,23,24,137,140,"Seizure activity due to PTZ and picrotoxin (PTX) was significantly decreased; however, seizure activity due to 3-mercaptopropionic acid (MPA), bicuculline (BCC), methyl 6,7-dimethoxy-4-ethyl-B-carboline-3-carboxylate (DMCM), or strychnine (STR) was not different from control.",2440413_4,-1,-1,2,16307,-1
16312,In vitro,0,2,0,8,"In vitro, gamma-HCH, pentylenetetrazol and picrotoxin were shown to inhibit 3H-TBOB binding in mouse whole brain, with IC50 values of 4.6, 404 and 9.4 microM, respectively.",2440413_5,-1,-1,2,16312,-1
16317,MPA,0,1,0,3,"MPA, BCC, DMCM, and STR showed no inhibition of 3H-TBOB (t-butyl bicyclo-orthobenzoate) binding at concentrations of 100 micron.",2440413_6,-1,-1,2,16317,-1
16319,DMCM,4,5,10,14,"MPA, BCC, DMCM, and STR showed no inhibition of 3H-TBOB (t-butyl bicyclo-orthobenzoate) binding at concentrations of 100 micron.",2440413_6,-1,-1,2,16319,-1
16320,STR,7,8,20,23,"MPA, BCC, DMCM, and STR showed no inhibition of 3H-TBOB (t-butyl bicyclo-orthobenzoate) binding at concentrations of 100 micron.",2440413_6,-1,-1,2,16320,-1
16327,in vitro,1,3,4,12,The in vitro data suggest that the site responsible for the decrease in seizure activity 24 h after gamma-HCH may be the GABA-A receptor-linked chloride channel.,2440413_8,-1,-1,2,16327,-1
16335,AHF,16,17,104,107,Tolerance and antiviral effect of ribavirin was studied in 6 patients with Argentine hemorrhagic fever (AHF) of more than 8 days of evolution.,2445283_1,-1,-1,2,16335,-1
16337,adverse effect,6,8,33,47,A reversible anemia was the only adverse effect observed.,2445283_4,-1,-1,2,16337,-1
16343,Continuous ambulatory ECG,0,3,0,25,Continuous ambulatory ECG monitoring during fluorouracil therapy: a prospective study.,2466960_0,-1,-1,2,16343,-1
16344,prospective study,9,11,68,85,Continuous ambulatory ECG monitoring during fluorouracil therapy: a prospective study.,2466960_0,-1,-1,2,16344,-1
16345,anecdotal reports,4,6,25,42,"Although there have been anecdotal reports of cardiac toxicity associated with fluorouracil (5-FU) therapy, this phenomenon has not been studied in a systematic fashion.",2466960_1,-1,-1,2,16345,-1
16347,associated with,9,11,63,78,"Although there have been anecdotal reports of cardiac toxicity associated with fluorouracil (5-FU) therapy, this phenomenon has not been studied in a systematic fashion.",2466960_1,-1,-1,2,16347,-1
16349,systematic fashion,25,27,150,168,"Although there have been anecdotal reports of cardiac toxicity associated with fluorouracil (5-FU) therapy, this phenomenon has not been studied in a systematic fashion.",2466960_1,-1,-1,2,16349,-1
16353,/- 4 hours,6,9,32,42,"Patients were monitored for 23 +/- 4 hours before 5-FU infusion, and 98 +/- 9 hours during 5-FU infusion.",2466960_3,-1,-1,2,16353,-1
16355,/- 9 hours,16,19,73,83,"Patients were monitored for 23 +/- 4 hours before 5-FU infusion, and 98 +/- 9 hours during 5-FU infusion.",2466960_3,-1,-1,2,16355,-1
16365,/-,12,13,66,68,The incidence of ischemic episodes per patient per hour was 0.05 +/-,2466960_6,0,1,2,16365,-1
16367,/-,8,9,36,38,0.02 prior to 5-FU infusion v 0.13 +/- 0.03 during 5-FU infusion (P less than .001); the duration of ECG changes was 0.6 +/- 0.3 minutes per patient per hour before 5-FU v 1.9 +/- 0.5 minutes per patient per hour during 5-FU (P less than .01).,2466960_7,0,1,2,16367,-1
16371,/-,40,41,177,179,0.02 prior to 5-FU infusion v 0.13 +/- 0.03 during 5-FU infusion (P less than .001); the duration of ECG changes was 0.6 +/- 0.3 minutes per patient per hour before 5-FU v 1.9 +/- 0.5 minutes per patient per hour during 5-FU (P less than .01).,2466960_7,0,1,2,16371,-1
16377,associated with,6,8,34,49,"We conclude that 5-FU infusion is associated with a significant increase in silent ST segment deviation suggestive of ischemia, particularly among patients with coronary artery disease.",2466960_10,-1,-1,2,16377,-1
16382,general practitioners,12,14,84,105,Is the treatment of scabies hazardous?Treatment for scabies is usually initiated by general practitioners; most consider lindane (gamma benzene hexachloride) the treatment of choice.,2476560_0,-1,-1,2,16382,-1
16385,toxic profile,17,19,93,106,"Lindane is also widely used as an agricultural and industrial pesticide, and as a result the toxic profile of this insecticide is well understood.",2476560_1,-1,-1,2,16385,-1
16387,associated with,16,18,92,107,Evidence is accumulating that lindane can be toxic to the central nervous system and may be associated with aplastic anaemia.,2476560_2,-1,-1,2,16387,-1
16390,general practitioners,5,7,37,58,"This literature review suggests that general practitioners should prescribe scabicides with increased caution for certain at-risk groups, and give adequate warnings regarding potential toxicity.",2476560_4,-1,-1,2,16390,-1
16395,mouse motility,21,23,103,117,"The effect of amantadine hydrochloride, injected i.p. in 6 increments of 100 mg/kg each over 30 hr, on mouse motility and whole brain content of selected biogenic amines and major metabolites was studied in 4 strains of mice.",2484011_1,-1,-1,2,16395,-1
16397,albino Sprague-Dawley ICR,3,6,15,40,"These were the albino Sprague-Dawley ICR and BALB/C, the black C57BL/6 and the brown CDF-I mouse strains.",2484011_2,-1,-1,2,16397,-1
16399,C57BL/6,11,12,63,70,"These were the albino Sprague-Dawley ICR and BALB/C, the black C57BL/6 and the brown CDF-I mouse strains.",2484011_2,-1,-1,2,16399,-1
16401,biphasic effect,4,6,32,47,Amantadine treatment produced a biphasic effect on mouse motility.,2484011_3,-1,-1,2,16401,-1
16402,mouse motility,7,9,51,65,Amantadine treatment produced a biphasic effect on mouse motility.,2484011_3,-1,-1,2,16402,-1
16404,locomotor activity,6,8,41,59,The initial dose of amantadine depressed locomotor activity in all mouse strains studied with the BALB/C mice being the most sensitive.,2484011_4,-1,-1,2,16404,-1
16409,ICR mice,16,18,104,112,"The locomotor activity was decreased from corresponding controls in all strains studied, except for the ICR mice, during an overnight drug-free period following the fourth amantadine treatment.",2484011_6,-1,-1,2,16409,-1
16410,drug-free period,22,24,134,150,"The locomotor activity was decreased from corresponding controls in all strains studied, except for the ICR mice, during an overnight drug-free period following the fourth amantadine treatment.",2484011_6,-1,-1,2,16410,-1
16414,drug-free overnight period,6,9,40,66,"Readministration of amantadine, after a drug-free overnight period, increased motility from respective saline control in all strains with exception of the BALB/C mice where suppression of motility occurred.",2484011_7,-1,-1,2,16414,-1
16420,saline control,23,25,159,173,"Treatment with amantadine did not alter whole brain dopamine levels but decreased the amounts of 3,4-dihydroxyphenylacetic acid in the BALB/C mice compared to saline control.",2484011_8,-1,-1,2,16420,-1
16427,differential response,13,15,87,108,The results suggest a strain-dependent effect of amantadine on motility and indicate a differential response to the acute and multiple dose regimens used.,2484011_10,-1,-1,2,16427,-1
16438,BALB/C,44,45,304,310,The biochemical results of brain biogenic amines of BALB/C mouse strain suggest a probable decrease of catecholamine turnover rate and/or metabolism by monoamine oxidase and a resulting increase in O-methylation of norepinephrine which may account for a behavioral depression caused by amantadine in the BALB/C mice.,2484011_12,-1,-1,2,16438,-1
16448,experimental study,20,22,128,146,"Based on clinical data, indicating that chloroacetaldehyde (CAA) is an important metabolite of oxazaphosphorine cytostatics, an experimental study was carried out in order to elucidate the role of CAA in the development of hemorrhagic cystitis.",2505783_2,-1,-1,2,16448,-1
16454,urotoxic effects,9,11,53,69,"When instilled directly into the bladder, CAA exerts urotoxic effects, it is, however, susceptible to detoxification with mesna.",2505783_4,-1,-1,2,16454,-1
16457,site?Twenty,11,12,67,78,Source of pain and primitive dysfunction in migraine: an identical site?Twenty common migraine patients received a one sided frontotemporal application of nitroglycerin (10 patients) or placebo ointment (10 patients) in a double blind study.,2515254_0,-1,-1,2,16457,-1
16459,double blind study,36,39,222,240,Source of pain and primitive dysfunction in migraine: an identical site?Twenty common migraine patients received a one sided frontotemporal application of nitroglycerin (10 patients) or placebo ointment (10 patients) in a double blind study.,2515254_0,-1,-1,2,16459,-1
16466,migraine-inducing effect,2,4,9,33,"Thus the migraine-inducing effect of nitroglycerin seems to depend on direct stimulation of the habitual site of pain, suggesting that the frontotemporal region is of crucial importance in the development of a migraine crisis.",2515254_4,-1,-1,2,16466,-1
16469,consistent with,3,5,12,27,This is not consistent with a CNS origin of migraine attack.,2515254_5,-1,-1,2,16469,-1
16484,multicenter,38,39,246,257,"Nature, time course and dose dependence of zidovudine-related side effects: results from the Multicenter Canadian Azidothymidine Trial.To characterize the nature, time course and dose dependency of zidovudine-related side effects, we undertook a multicenter, prospective, dose-range finding study.",2528969_0,-1,-1,2,16484,-1
16485,dose-range finding study,42,45,272,296,"Nature, time course and dose dependence of zidovudine-related side effects: results from the Multicenter Canadian Azidothymidine Trial.To characterize the nature, time course and dose dependency of zidovudine-related side effects, we undertook a multicenter, prospective, dose-range finding study.",2528969_0,-1,-1,2,16485,-1
16486,study group,1,3,4,15,"Our study group consisted of 74 HIV-positive homosexual men belonging to groups II B, III and IV C2 from the Centers for Disease Control (CDC) classification of HIV disease.",2528969_1,-1,-1,2,16486,-1
16487,HIV-positive,6,7,32,44,"Our study group consisted of 74 HIV-positive homosexual men belonging to groups II B, III and IV C2 from the Centers for Disease Control (CDC) classification of HIV disease.",2528969_1,-1,-1,2,16487,-1
16490,observation period,3,5,19,37,"Following a 3-week observation period, volunteers were treated with zidovudine 600 mg/day for 18 weeks, 900 mg/day for 9 weeks and 1200 mg/day for 9 weeks, followed by a washout period of 6 weeks after which they were re-started on 1200 mg/day or the highest tolerated dose at 8-hourly intervals.",2528969_2,-1,-1,2,16490,-1
16494,8-hourly intervals,51,53,277,295,"Following a 3-week observation period, volunteers were treated with zidovudine 600 mg/day for 18 weeks, 900 mg/day for 9 weeks and 1200 mg/day for 9 weeks, followed by a washout period of 6 weeks after which they were re-started on 1200 mg/day or the highest tolerated dose at 8-hourly intervals.",2528969_2,-1,-1,2,16494,-1
16498,mg/day,17,18,109,115,Subjects were randomly assigned to 4-hourly or 8-hourly regimens within CDC groups while taking 600 and 1200 mg/day.,2528969_3,-1,-1,2,16498,-1
16500,3-week intervals,7,9,54,70,Clinical and laboratory evaluations were performed at 3-week intervals.,2528969_4,-1,-1,2,16500,-1
16502,reappearing briefly,5,7,35,54,"These were generally self-limited, reappearing briefly at each dose increment.",2528969_6,-1,-1,2,16502,-1
16504,red blood cell,1,4,2,16,"A red blood cell count decrease, a mean cell volume increase and a granulocyte count decrease developed early in a dose-independent fashion, reverting at least partially during the washout phase.",2528969_9,-1,-1,2,16504,-1
16505,mean cell volume,8,11,35,51,"A red blood cell count decrease, a mean cell volume increase and a granulocyte count decrease developed early in a dose-independent fashion, reverting at least partially during the washout phase.",2528969_9,-1,-1,2,16505,-1
16506,dose-independent fashion,21,23,115,139,"A red blood cell count decrease, a mean cell volume increase and a granulocyte count decrease developed early in a dose-independent fashion, reverting at least partially during the washout phase.",2528969_9,-1,-1,2,16506,-1
16507,washout phase,30,32,181,194,"A red blood cell count decrease, a mean cell volume increase and a granulocyte count decrease developed early in a dose-independent fashion, reverting at least partially during the washout phase.",2528969_9,-1,-1,2,16507,-1
16508,reticulocyte count,3,5,16,34,The decrease in reticulocyte count was dose related between 600 and 900 mg/day with no further change when the dose was escalated to 1200 mg/day.,2528969_10,-1,-1,2,16508,-1
16509,mg/day,12,13,72,78,The decrease in reticulocyte count was dose related between 600 and 900 mg/day with no further change when the dose was escalated to 1200 mg/day.,2528969_10,-1,-1,2,16509,-1
16510,mg/day,24,25,138,144,The decrease in reticulocyte count was dose related between 600 and 900 mg/day with no further change when the dose was escalated to 1200 mg/day.,2528969_10,-1,-1,2,16510,-1
16513,National project,0,2,0,16,"National project on the prevention of mother-to-infant infection by hepatitis B virus in Japan.In Japan, a nationwide prevention program against mother-to-infant infection by hepatitis B virus (HBV) started in 1985.",2533791_0,-1,-1,2,16513,-1
16516,nationwide prevention program,19,22,107,136,"National project on the prevention of mother-to-infant infection by hepatitis B virus in Japan.In Japan, a nationwide prevention program against mother-to-infant infection by hepatitis B virus (HBV) started in 1985.",2533791_0,-1,-1,2,16516,-1
16519,double screenings,4,6,25,42,This program consists of double screenings of pregnant women and prophylactic treatment to the infants born to both hepatitis B surface antigen (HBsAg) and hepatitis B e antigen (HBeAg) positive mothers.,2533791_1,-1,-1,2,16519,-1
16521,prophylactic treatment,10,12,65,87,This program consists of double screenings of pregnant women and prophylactic treatment to the infants born to both hepatitis B surface antigen (HBsAg) and hepatitis B e antigen (HBeAg) positive mothers.,2533791_1,-1,-1,2,16521,-1
16526,treated with,3,5,18,30,These infants are treated with two injections of hepatitis B immune globulin (HBIG) and at least three injections of plasma derived hepatitis B vaccine.,2533791_2,-1,-1,2,16526,-1
16529,hepatitis B vaccine,23,26,132,151,These infants are treated with two injections of hepatitis B immune globulin (HBIG) and at least three injections of plasma derived hepatitis B vaccine.,2533791_2,-1,-1,2,16529,-1
16532,positive rate,15,17,70,83,"93.4% pregnant women had the chance to be examined for HBsAg, and the positive rate was 1.4 to 1.5%.",2533791_4,-1,-1,2,16532,-1
16536,restricted areas,18,20,90,106,"Some problems may arise, because 27 to 30% of infants need the fourth vaccination in some restricted areas.",2533791_7,-1,-1,2,16536,-1
16570,dose-dependent,15,16,87,101,"Intradermal injection of mu, but not delta or kappa opioid-agonists, however, produced dose-dependent inhibition of prostaglandin E2-induced hyperalgesia.",2557556_2,-1,-1,2,16570,-1
16578,primary afferents,13,15,80,97,We conclude that the analgesic action of opioids on the peripheral terminals of primary afferents is via a binding site with characteristics of the mu-opioid receptor and that this action is mediated by inhibition of the cyclic adenosine monophosphate second messenger system.,2557556_5,-1,-1,2,16578,-1
16582,messenger system,40,42,259,275,We conclude that the analgesic action of opioids on the peripheral terminals of primary afferents is via a binding site with characteristics of the mu-opioid receptor and that this action is mediated by inhibition of the cyclic adenosine monophosphate second messenger system.,2557556_5,-1,-1,2,16582,-1
16583,enzyme inhibition,3,5,21,38,Effect of converting enzyme inhibition on the course of adriamycin-induced nephropathy.,2559236_0,-1,-1,2,16583,-1
16587,Munich-Wistar rats,14,16,78,96,The effect of the converting enzyme inhibitor (CEI) enalapril was assessed in Munich-Wistar rats with established adriamycin nephrosis.,2559236_1,-1,-1,2,16587,-1
16594,Groups 1,0,2,0,8,Groups 1 and 2 underwent micropuncture studies after 10 days.,2559236_4,-1,-1,2,16594,-1
16595,micropuncture studies,5,7,25,46,Groups 1 and 2 underwent micropuncture studies after 10 days.,2559236_4,-1,-1,2,16595,-1
16598,/- 3 mm Hg,18,22,99,109,"These short-term studies showed that enalapril reduced arterial blood pressure (101 +/- 2 vs. 124 +/- 3 mm Hg, group 2 vs. 1, P less than 0.05) and glomerular capillary pressure (54 +/- 1 vs. 61 +/- 2 mm Hg, P less than 0.05) without reducing albuminuria (617 +/- 50 vs. 570 +/- 47 mg/day) or GFR (1.03 +/- 0.04 vs. 1.04 +/- 0.11 ml/min).",2559236_5,-1,-1,2,16598,-1
16599,group 2,23,25,111,118,"These short-term studies showed that enalapril reduced arterial blood pressure (101 +/- 2 vs. 124 +/- 3 mm Hg, group 2 vs. 1, P less than 0.05) and glomerular capillary pressure (54 +/- 1 vs. 61 +/- 2 mm Hg, P less than 0.05) without reducing albuminuria (617 +/- 50 vs. 570 +/- 47 mg/day) or GFR (1.03 +/- 0.04 vs. 1.04 +/- 0.11 ml/min).",2559236_5,-1,-1,2,16599,-1
16604,/-,66,67,276,278,"These short-term studies showed that enalapril reduced arterial blood pressure (101 +/- 2 vs. 124 +/- 3 mm Hg, group 2 vs. 1, P less than 0.05) and glomerular capillary pressure (54 +/- 1 vs. 61 +/- 2 mm Hg, P less than 0.05) without reducing albuminuria (617 +/- 50 vs. 570 +/- 47 mg/day) or GFR (1.03 +/- 0.04 vs. 1.04 +/- 0.11 ml/min).",2559236_5,0,1,2,16604,-1
16605,mg/day,68,69,282,288,"These short-term studies showed that enalapril reduced arterial blood pressure (101 +/- 2 vs. 124 +/- 3 mm Hg, group 2 vs. 1, P less than 0.05) and glomerular capillary pressure (54 +/- 1 vs. 61 +/- 2 mm Hg, P less than 0.05) without reducing albuminuria (617 +/- 50 vs. 570 +/- 47 mg/day) or GFR (1.03 +/- 0.04 vs. 1.04 +/- 0.11 ml/min).",2559236_5,-1,-1,2,16605,-1
16608,/-,80,81,322,324,"These short-term studies showed that enalapril reduced arterial blood pressure (101 +/- 2 vs. 124 +/- 3 mm Hg, group 2 vs. 1, P less than 0.05) and glomerular capillary pressure (54 +/- 1 vs. 61 +/- 2 mm Hg, P less than 0.05) without reducing albuminuria (617 +/- 50 vs. 570 +/- 47 mg/day) or GFR (1.03 +/- 0.04 vs. 1.04 +/- 0.11 ml/min).",2559236_5,0,1,2,16608,-1
16612,Chronic enalapril treatment,0,3,0,27,Chronic enalapril treatment reduced blood pressure without reducing albuminuria in group 4.,2559236_7,-1,-1,2,16612,-1
16614,group 4,10,12,83,90,Chronic enalapril treatment reduced blood pressure without reducing albuminuria in group 4.,2559236_7,-1,-1,2,16614,-1
16615,Untreated group 3,0,3,0,17,"Untreated group 3 rats exhibited a progressive reduction in GFR (0.35 +/- 0.08 ml/min at 4 months, 0.27 +/- 0.07 ml/min at 6 months).",2559236_8,-1,-1,2,16615,-1
16617,/-,13,14,71,73,"Untreated group 3 rats exhibited a progressive reduction in GFR (0.35 +/- 0.08 ml/min at 4 months, 0.27 +/- 0.07 ml/min at 6 months).",2559236_8,0,1,2,16617,-1
16618,/-,22,23,105,107,"Untreated group 3 rats exhibited a progressive reduction in GFR (0.35 +/- 0.08 ml/min at 4 months, 0.27 +/- 0.07 ml/min at 6 months).",2559236_8,0,1,2,16618,-1
16621,group 4,11,13,68,75,"Enalapril treatment blunted but did not prevent reduction in GFR in group 4 (0.86 +/- 0.15 ml/min at 4 months, 0.69 +/- 0.13 ml/min at 6 months, both P less than 0.05 vs. group 3).",2559236_9,-1,-1,2,16621,-1
16622,/-,16,17,83,85,"Enalapril treatment blunted but did not prevent reduction in GFR in group 4 (0.86 +/- 0.15 ml/min at 4 months, 0.69 +/- 0.13 ml/min at 6 months, both P less than 0.05 vs. group 3).",2559236_9,0,1,2,16622,-1
16623,/-,25,26,117,119,"Enalapril treatment blunted but did not prevent reduction in GFR in group 4 (0.86 +/- 0.15 ml/min at 4 months, 0.69 +/- 0.13 ml/min at 6 months, both P less than 0.05 vs. group 3).",2559236_9,0,1,2,16623,-1
16625,associated with,4,6,21,36,Reduction in GFR was associated with the development of glomerular sclerosis in both treated and untreated rats.(ABSTRACT TRUNCATED AT 250 WORDS),2559236_10,-1,-1,2,16625,-1
16634,mechanism(s),26,28,171,183,"Whereas muscular rigidity is a well-known side effect that is associated with high-dose fentanyl anesthesia, a paucity of information exists with regard to its underlying mechanism(s).",2564649_1,-1,-1,2,16634,-1
16636,male Sprague-Dawley,19,21,111,130,"We investigated in this study the possible engagement of locus coeruleus of the pons in this phenomenon, using male Sprague-Dawley rats anesthetized with ketamine.",2564649_2,-1,-1,2,16636,-1
16645,pretreatment,24,25,158,170,"Such an induced muscular rigidity by the narcotic agent was significantly antagonized or even reduced by prior electrolytic lesions of the locus coeruleus or pretreatment with the alpha-adrenoceptor blocker, prazosin.",2564649_4,-1,-1,2,16645,-1
16651,coerulospinal noradrenergic fibers,14,17,85,119,It is speculated that the induction of muscular rigidity by fentanyl may involve the coerulospinal noradrenergic fibers to the spinal motoneurons.,2564649_6,-1,-1,2,16651,-1
16652,spinal motoneurons,19,21,127,145,It is speculated that the induction of muscular rigidity by fentanyl may involve the coerulospinal noradrenergic fibers to the spinal motoneurons.,2564649_6,-1,-1,2,16652,-1
16686,treatment group,14,16,82,97,ALF injection resulted in a marked increase in hindlimb EMG activity in the L-MED treatment group which was indistinguishable from that seen in animals treated with saline.,2569282_8,-1,-1,2,16686,-1
16687,treated with,24,26,152,164,ALF injection resulted in a marked increase in hindlimb EMG activity in the L-MED treatment group which was indistinguishable from that seen in animals treated with saline.,2569282_8,-1,-1,2,16687,-1
16690,dose-dependent,10,11,69,83,"In contrast, D-MED prevented alfentanil-induced muscle rigidity in a dose-dependent fashion.",2569282_9,-1,-1,2,16690,-1
16693,control animals,19,21,119,134,The small EMG values obtained in the high-dose D-MED group were comparable with those recorded in earlier studies from control animals not given any opiate.,2569282_10,-1,-1,2,16693,-1
16701,onset of,20,22,121,129,"We report the case of a patient who developed acute hepatitis with extensive hepatocellular necrosis, 7 months after the onset of administration of clotiazepam, a thienodiazepine derivative.",2572625_1,-1,-1,2,16701,-1
16706,interfere with,13,15,90,104,"The administration of several benzodiazepines, chemically related to clotiazepam, did not interfere with recovery and did not induce any relapse of hepatitis.",2572625_3,-1,-1,2,16706,-1
16711,central effects,1,3,5,20,Some central effects of repeated treatment with fluvoxamine.,2576810_0,-1,-1,2,16711,-1
16728,no effect,5,7,34,43,"Given three times fluvoxamine had no effect on the immobilization time in the ""behavioral despair"" test in rats.",2576810_5,-1,-1,2,16728,-1
16729,immobilization time,9,11,51,70,"Given three times fluvoxamine had no effect on the immobilization time in the ""behavioral despair"" test in rats.",2576810_5,-1,-1,2,16729,-1
16737,carcinogenic process,19,21,112,132,"To test the validity of the hypothesis that hypomethylation of DNA plays an important role in the initiation of carcinogenic process, 5-azacytidine (5-AzC) (10 mg/kg), an inhibitor of DNA methylation, was given to rats during the phase of repair synthesis induced by the three carcinogens, benzo[a]-pyrene (200 mg/kg), N-methyl-N-nitrosourea (60 mg/kg) and 1,2-dimethylhydrazine (1,2-DMH) (100 mg/kg).",2578334_1,-1,-1,2,16737,-1
16739,repair synthesis,45,47,239,255,"To test the validity of the hypothesis that hypomethylation of DNA plays an important role in the initiation of carcinogenic process, 5-azacytidine (5-AzC) (10 mg/kg), an inhibitor of DNA methylation, was given to rats during the phase of repair synthesis induced by the three carcinogens, benzo[a]-pyrene (200 mg/kg), N-methyl-N-nitrosourea (60 mg/kg) and 1,2-dimethylhydrazine (1,2-DMH) (100 mg/kg).",2578334_1,-1,-1,2,16739,-1
16746,2-week selection,19,21,129,145,The initiated hepatocytes in the liver were assayed as the gamma-glutamyltransferase (gamma-GT) positive foci formed following a 2-week selection regimen consisting of dietary 0.02% 2-acetylaminofluorene coupled with a necrogenic dose of CCl4.,2578334_2,-1,-1,2,16746,-1
16750,repair synthesis,14,16,94,110,"The results obtained indicate that with all three carcinogens, administration of 5-AzC during repair synthesis increased the incidence of initiated hepatocytes, for example 10-20 foci/cm2 in 5-AzC and carcinogen-treated rats compared with 3-5 foci/cm2 in rats treated with carcinogen only.",2578334_3,-1,-1,2,16750,-1
16753,treated with,42,44,260,272,"The results obtained indicate that with all three carcinogens, administration of 5-AzC during repair synthesis increased the incidence of initiated hepatocytes, for example 10-20 foci/cm2 in 5-AzC and carcinogen-treated rats compared with 3-5 foci/cm2 in rats treated with carcinogen only.",2578334_3,-1,-1,2,16753,-1
16755,repair synthesis,5,7,53,69,"Administration of [3H]-5-azadeoxycytidine during the repair synthesis induced by 1,2-DMH further showed that 0.019 mol % of cytosine residues in DNA were substituted by the analogue, indicating that incorporation of 5-AzC occurs during repair synthesis.",2578334_4,-1,-1,2,16755,-1
16757,repair synthesis,34,36,236,252,"Administration of [3H]-5-azadeoxycytidine during the repair synthesis induced by 1,2-DMH further showed that 0.019 mol % of cytosine residues in DNA were substituted by the analogue, indicating that incorporation of 5-AzC occurs during repair synthesis.",2578334_4,-1,-1,2,16757,-1
16759,gamma-GT positive,27,29,149,166,"In the absence of the carcinogen, 5-AzC given after a two thirds partial hepatectomy, when its incorporation should be maximum, failed to induce any gamma-GT positive foci.",2578334_5,-1,-1,2,16759,-1
16761,hypomethylation,19,20,112,127,"Perhaps two events might be necessary for initiation, the first caused by the carcinogen and a second involving hypomethylation of DNA.",2578334_7,-1,-1,2,16761,-1
16768,MBP,27,28,143,146,"Administration of the local anaesthetic bupivacaine (1.5 or 2 mg/kg, i.v.) to rats elicited a marked decrease of mean arterial blood pressure (MBP) and heart rate (HR) leading to death (in 67% or 90% of animals respectively).",2594614_1,-1,-1,2,16768,-1
16778,BN,1,2,5,7,"When BN 52021 (20 mg/kg i.v.) was injected immediately after bupivacaine (2 mg/kg), a partial reversion of the decrease of MBP and HR was observed, whereas the dose of 10 mg/kg was ineffective.",2594614_5,-1,-1,2,16778,-1
16780,partial reversion,20,22,86,103,"When BN 52021 (20 mg/kg i.v.) was injected immediately after bupivacaine (2 mg/kg), a partial reversion of the decrease of MBP and HR was observed, whereas the dose of 10 mg/kg was ineffective.",2594614_5,-1,-1,2,16780,-1
16783,pretreatment,10,11,77,89,A partial recovery of bupivacaine-induced ECG alterations was observed after pretreatment of the rats with BN 52021.,2594614_6,-1,-1,2,16783,-1
16791,consistent with,2,4,6,21,"Thus, consistent with its direct effect on heart, PAF appears to be implicated in bupivacaine-induced cardiovascular alterations.",2594614_8,-1,-1,2,16791,-1
16799,spontaneous reporting system,12,15,77,105,"Until physicians began reporting an unusual acute flank pain syndrome to the spontaneous reporting system, 700,000 persons used the drug in the United States. Through August 1986, a total of 163 cases of this syndrome were reported.",2598570_2,-1,-1,2,16799,-1
16800,United States,23,25,144,157,"Until physicians began reporting an unusual acute flank pain syndrome to the spontaneous reporting system, 700,000 persons used the drug in the United States. Through August 1986, a total of 163 cases of this syndrome were reported.",2598570_2,-1,-1,2,16800,-1
16801,case-control study,9,11,49,67,"To elucidate the epidemiology of the syndrome, a case-control study was performed, comparing 62 of the case patients who had been reported to the spontaneous reporting system to 185 suprofen-exposed control subjects who did not have the syndrome.",2598570_3,-1,-1,2,16801,-1
16802,case patients,18,20,103,116,"To elucidate the epidemiology of the syndrome, a case-control study was performed, comparing 62 of the case patients who had been reported to the spontaneous reporting system to 185 suprofen-exposed control subjects who did not have the syndrome.",2598570_3,-1,-1,2,16802,-1
16803,suprofen-exposed control subjects,31,34,182,215,"To elucidate the epidemiology of the syndrome, a case-control study was performed, comparing 62 of the case patients who had been reported to the spontaneous reporting system to 185 suprofen-exposed control subjects who did not have the syndrome.",2598570_3,-1,-1,2,16803,-1
16804,Case patients,0,2,0,13,"Case patients were more likely to be men (odds ratio, 3.8; 95% confidence interval, 1.2-12.1), suffer from hay fever and asthma (odds ratio, 3.4; 95% confidence interval, 1.0-11.9); to participate in regular exercise (odds ratio, 5.9; 95% confidence interval, 1.1-30.7), especially in the use of Nautilus equipment (p = 0.02); and to use alcohol (odds ratio, 4.4; 95% confidence interval, 1.1-17.5).",2598570_4,-1,-1,2,16804,-1
16806,confidence interval,16,18,63,82,"Case patients were more likely to be men (odds ratio, 3.8; 95% confidence interval, 1.2-12.1), suffer from hay fever and asthma (odds ratio, 3.4; 95% confidence interval, 1.0-11.9); to participate in regular exercise (odds ratio, 5.9; 95% confidence interval, 1.1-30.7), especially in the use of Nautilus equipment (p = 0.02); and to use alcohol (odds ratio, 4.4; 95% confidence interval, 1.1-17.5).",2598570_4,-1,-1,2,16806,-1
16809,confidence interval,38,40,150,169,"Case patients were more likely to be men (odds ratio, 3.8; 95% confidence interval, 1.2-12.1), suffer from hay fever and asthma (odds ratio, 3.4; 95% confidence interval, 1.0-11.9); to participate in regular exercise (odds ratio, 5.9; 95% confidence interval, 1.1-30.7), especially in the use of Nautilus equipment (p = 0.02); and to use alcohol (odds ratio, 4.4; 95% confidence interval, 1.1-17.5).",2598570_4,-1,-1,2,16809,-1
16812,confidence interval,59,61,239,258,"Case patients were more likely to be men (odds ratio, 3.8; 95% confidence interval, 1.2-12.1), suffer from hay fever and asthma (odds ratio, 3.4; 95% confidence interval, 1.0-11.9); to participate in regular exercise (odds ratio, 5.9; 95% confidence interval, 1.1-30.7), especially in the use of Nautilus equipment (p = 0.02); and to use alcohol (odds ratio, 4.4; 95% confidence interval, 1.1-17.5).",2598570_4,-1,-1,2,16812,-1
16813,Nautilus equipment,72,74,296,314,"Case patients were more likely to be men (odds ratio, 3.8; 95% confidence interval, 1.2-12.1), suffer from hay fever and asthma (odds ratio, 3.4; 95% confidence interval, 1.0-11.9); to participate in regular exercise (odds ratio, 5.9; 95% confidence interval, 1.1-30.7), especially in the use of Nautilus equipment (p = 0.02); and to use alcohol (odds ratio, 4.4; 95% confidence interval, 1.1-17.5).",2598570_4,-1,-1,2,16813,-1
16815,confidence interval,92,94,368,387,"Case patients were more likely to be men (odds ratio, 3.8; 95% confidence interval, 1.2-12.1), suffer from hay fever and asthma (odds ratio, 3.4; 95% confidence interval, 1.0-11.9); to participate in regular exercise (odds ratio, 5.9; 95% confidence interval, 1.1-30.7), especially in the use of Nautilus equipment (p = 0.02); and to use alcohol (odds ratio, 4.4; 95% confidence interval, 1.1-17.5).",2598570_4,-1,-1,2,16815,-1
16816,risk factors,1,3,9,21,"Possible risk factors included young age, concurrent use of other analgesic agents (especially ibuprofen), preexisting renal disease, a history of kidney stones, a history of gout, a recent increase in activity, a recent increase in sun exposure, and residence in the Sunbelt.",2598570_5,-1,-1,2,16816,-1
16823,statistical significance,11,13,72,96,These were findings that were suggestive but did not reach conventional statistical significance.,2598570_6,-1,-1,2,16823,-1
16824,consistent with,3,5,19,34,These findings are consistent with the postulated mechanism for this unusual syndrome: acute diffuse crystallization of uric acid in renal tubules.,2598570_7,-1,-1,2,16824,-1
16833,mood rating scale,16,19,140,157,Eighty-nine new referral hypertensive out-patients and 46 new referral non-hypertensive chronically physically ill out-patients completed a mood rating scale at regular intervals for one year.,26094_1,-1,-1,2,16833,-1
16834,regular intervals,20,22,161,178,Eighty-nine new referral hypertensive out-patients and 46 new referral non-hypertensive chronically physically ill out-patients completed a mood rating scale at regular intervals for one year.,26094_1,-1,-1,2,16834,-1
16835,hypertensive group,19,21,108,126,"The results showed a high prevalence of depression in both groups of patients, with no preponderance in the hypertensive group.",26094_2,-1,-1,2,16835,-1
16840,associated with,3,5,25,40,Chronic active hepatitis associated with diclofenac sodium therapy.,2611118_0,-1,-1,2,16840,-1
16857,plasma levels,4,6,14,27,"In patient 1, plasma levels of deoxycorticosterone and 11-deoxycortisol were elevated.",2632720_3,-1,-1,2,16857,-1
16862,plasma aldosterone values,16,19,98,123,"In patient 2, in addition to an increase in both deoxycorticosterone and 11-deoxycortisol levels, plasma aldosterone values were raised, with a concomitant suppression of renin levels.",2632720_4,-1,-1,2,16862,-1
16865,enzyme blockade,13,15,86,101,Our findings show that long-term treatment with high doses of ketoconazole may induce enzyme blockade leading to mineralocorticoid-related hypertension.,2632720_5,-1,-1,2,16865,-1
16888,glomerular filtration,12,14,61,82,"Captopril may, by the same mechanism, reduce the increase in glomerular filtration that is known to occur after an injection of thrombin, thereby diminishing the aggregation of fibrin monomers in the glomeruli, with the result that less fibrin will be deposited and thus less kidney damage will be produced.",2670794_8,-1,-1,2,16888,-1
16891,associated with,1,3,7,22,Stroke associated with cocaine use.,2673163_0,-1,-1,2,16891,-1
16894,(+,6,8,33,35,Among these 47 patients the mean (+/- SD) age was 32.5 +/- 12.1 years; 76% (34/45) were men.,2673163_2,0,1,2,16894,-1
16895,/-,15,16,56,58,Among these 47 patients the mean (+/- SD) age was 32.5 +/- 12.1 years; 76% (34/45) were men.,2673163_2,0,1,2,16895,-1
16897,intranasal,7,8,43,53,"Stroke followed cocaine use by inhalation, intranasal, intravenous, and intramuscular routes.",2673163_3,-1,-1,2,16897,-1
16917,randomized study,2,4,5,21,"In a randomized study, labetalol-induced hypotension and nitroprusside-induced hypotension were compared in 20 patients (10 in each group) scheduled for major orthopedic procedures.",2696505_1,-1,-1,2,16917,-1
16924,mmHg,25,26,146,150,Each patient was subjected to an identical anesthetic protocol and similar drug-induced reductions in mean arterial blood pressure (BP) (50 to 55 mmHg).,2696505_2,-1,-1,2,16924,-1
16926,associated with,3,5,27,42,Nitroprusside infusion was associated with a significant (p less than 0.05) increase in heart rate and cardiac output; rebound hypertension was observed in three patients after discontinuation of nitroprusside.,2696505_3,-1,-1,2,16926,-1
16931,associated with,4,6,33,48,Labetalol administration was not associated with any of these findings.,2696505_4,-1,-1,2,16931,-1
16932,PO2,1,2,9,12,Arterial PO2 decreased in both groups.,2696505_5,-1,-1,2,16932,-1
16938,ARF,42,43,243,246,"Because rats with streptozotocin-induced diabetes mellitus (DM) have a high solute diuresis (glycosuria of 10 to 12 g/day), we have suggested that this may in part be responsible for their resistance to gentamicin-induced acute renal failure (ARF).",2709684_1,-1,-1,2,16938,-1
16945,Sprague-Dawley rats,4,6,29,48,"Unanesthetized adult female, Sprague-Dawley rats were divided in four groups and studied for 15 days.",2709684_4,-1,-1,2,16945,-1
16946,mg/day,10,11,34,40,"Group 1 (P alone) received P, 360 mg/day, for 15 days; Group II (P + gentamicin); Group III (gentamicin alone) and Group IV (mild DM + gentamicin).",2709684_5,-1,-1,2,16946,-1
16950,mild DM,34,36,125,132,"Group 1 (P alone) received P, 360 mg/day, for 15 days; Group II (P + gentamicin); Group III (gentamicin alone) and Group IV (mild DM + gentamicin).",2709684_5,-1,-1,2,16950,-1
16951,Nephrotoxic doses,0,2,0,17,Nephrotoxic doses (40 mg/kg body wt/day) of gentamicin were injected during the last nine days of study to the animals of groups II to IV.,2709684_6,-1,-1,2,16951,-1
16953,Group I,1,3,3,10,"In Group I, P induced a moderate and stable glycosuria (3.9 +/- 0.1 g/day, SE), and no functional or morphologic evidence of renal dysfunction (baseline CCr 2.1 +/- 0.1 ml/min, undetectable lysozymuria) or damage (tubular necrosis score [maximum 4], zero).",2709684_7,-1,-1,2,16953,-1
16955,/-,14,15,61,63,"In Group I, P induced a moderate and stable glycosuria (3.9 +/- 0.1 g/day, SE), and no functional or morphologic evidence of renal dysfunction (baseline CCr 2.1 +/- 0.1 ml/min, undetectable lysozymuria) or damage (tubular necrosis score [maximum 4], zero).",2709684_7,0,1,2,16955,-1
16956,morphologic evidence,25,27,101,121,"In Group I, P induced a moderate and stable glycosuria (3.9 +/- 0.1 g/day, SE), and no functional or morphologic evidence of renal dysfunction (baseline CCr 2.1 +/- 0.1 ml/min, undetectable lysozymuria) or damage (tubular necrosis score [maximum 4], zero).",2709684_7,-1,-1,2,16956,-1
16958,CCr,32,33,153,156,"In Group I, P induced a moderate and stable glycosuria (3.9 +/- 0.1 g/day, SE), and no functional or morphologic evidence of renal dysfunction (baseline CCr 2.1 +/- 0.1 ml/min, undetectable lysozymuria) or damage (tubular necrosis score [maximum 4], zero).",2709684_7,-1,-1,2,16958,-1
16964,CCr,13,14,67,70,"In Group II, P did not prevent gentamicin-ARF (maximal decrease in CCr at day 9.89%, P less than 0.001; peak lysozymuria, 1863 +/- 321 micrograms/day; and tubular necrosis score, 3.9 +/- 0.1).",2709684_8,-1,-1,2,16964,-1
16965,peak lysozymuria,24,26,104,120,"In Group II, P did not prevent gentamicin-ARF (maximal decrease in CCr at day 9.89%, P less than 0.001; peak lysozymuria, 1863 +/- 321 micrograms/day; and tubular necrosis score, 3.9 +/- 0.1).",2709684_8,-1,-1,2,16965,-1
16966,/-,29,30,128,130,"In Group II, P did not prevent gentamicin-ARF (maximal decrease in CCr at day 9.89%, P less than 0.001; peak lysozymuria, 1863 +/- 321 micrograms/day; and tubular necrosis score, 3.9 +/- 0.1).",2709684_8,0,1,2,16966,-1
16967,micrograms/day,31,32,135,149,"In Group II, P did not prevent gentamicin-ARF (maximal decrease in CCr at day 9.89%, P less than 0.001; peak lysozymuria, 1863 +/- 321 micrograms/day; and tubular necrosis score, 3.9 +/- 0.1).",2709684_8,-1,-1,2,16967,-1
16969,/-,40,41,184,186,"In Group II, P did not prevent gentamicin-ARF (maximal decrease in CCr at day 9.89%, P less than 0.001; peak lysozymuria, 1863 +/- 321 micrograms/day; and tubular necrosis score, 3.9 +/- 0.1).",2709684_8,0,1,2,16969,-1
16970,Group III,8,10,46,55,"These values were not different from those of Group III: maximal decrease in CCr 73% (P less than 0.001); lysozymuria, 2147 +/- 701 micrograms/day; tubular necrosis score, 3.8 +/- 0.1.(ABSTRACT TRUNCATED AT 250 WORDS)",2709684_9,-1,-1,2,16970,-1
16971,CCr,14,15,77,80,"These values were not different from those of Group III: maximal decrease in CCr 73% (P less than 0.001); lysozymuria, 2147 +/- 701 micrograms/day; tubular necrosis score, 3.8 +/- 0.1.(ABSTRACT TRUNCATED AT 250 WORDS)",2709684_9,-1,-1,2,16971,-1
16973,/-,28,29,125,127,"These values were not different from those of Group III: maximal decrease in CCr 73% (P less than 0.001); lysozymuria, 2147 +/- 701 micrograms/day; tubular necrosis score, 3.8 +/- 0.1.(ABSTRACT TRUNCATED AT 250 WORDS)",2709684_9,0,1,2,16973,-1
16976,/-,38,39,177,179,"These values were not different from those of Group III: maximal decrease in CCr 73% (P less than 0.001); lysozymuria, 2147 +/- 701 micrograms/day; tubular necrosis score, 3.8 +/- 0.1.(ABSTRACT TRUNCATED AT 250 WORDS)",2709684_9,0,1,2,16976,-1
16999,widely-different,29,30,191,207,"While the mutual potentiation, antagonism and tolerance suggest common mechanisms for the induced catalepsy, differences in latency, rigidity and behavior, asymmetry of cross-tolerance and a widely-different ID50 for naloxone would argue against an action at a single opioid site.",2716967_9,-1,-1,2,16999,-1
17011,mm Hg,15,17,104,109,"Although diastolic blood pressure remained unchanged, systolic blood pressure increased from 119 to 135 mm Hg (SED +/- 3.4, p less than 0.01), associated with an increased cardiac output (5.85-7.73 l/min, SED +/- 0.46, p less than 0.01).",2722224_3,-1,-1,2,17011,-1
17013,/-,20,21,116,118,"Although diastolic blood pressure remained unchanged, systolic blood pressure increased from 119 to 135 mm Hg (SED +/- 3.4, p less than 0.01), associated with an increased cardiac output (5.85-7.73 l/min, SED +/- 0.46, p less than 0.01).",2722224_3,0,1,2,17013,-1
17014,associated with,29,31,143,158,"Although diastolic blood pressure remained unchanged, systolic blood pressure increased from 119 to 135 mm Hg (SED +/- 3.4, p less than 0.01), associated with an increased cardiac output (5.85-7.73 l/min, SED +/- 0.46, p less than 0.01).",2722224_3,-1,-1,2,17014,-1
17017,/-,43,44,210,212,"Although diastolic blood pressure remained unchanged, systolic blood pressure increased from 119 to 135 mm Hg (SED +/- 3.4, p less than 0.01), associated with an increased cardiac output (5.85-7.73 l/min, SED +/- 0.46, p less than 0.01).",2722224_3,0,1,2,17017,-1
17020,/-,14,15,78,80,"Total peripheral vascular resistance fell from 15.1 to 12.2 mm Hg/l/min (SED +/- 1.03, p less than 0.05).",2722224_4,0,1,2,17020,-1
17022,cold pressor test,13,16,87,104,"Resting forearm vascular resistance remained unchanged, but the reflex response to the cold pressor test was accentuated, the rise in resistance increasing from 10.5 mm Hg/ml/100 ml/min (R units) before treatment to 32.6 R units after treatment (SED +/- 6.4, p less than 0.025).",2722224_5,-1,-1,2,17022,-1
17023,Hg/ml/100,27,28,169,178,"Resting forearm vascular resistance remained unchanged, but the reflex response to the cold pressor test was accentuated, the rise in resistance increasing from 10.5 mm Hg/ml/100 ml/min (R units) before treatment to 32.6 R units after treatment (SED +/- 6.4, p less than 0.025).",2722224_5,-1,-1,2,17023,-1
17027,/-,44,45,251,253,"Resting forearm vascular resistance remained unchanged, but the reflex response to the cold pressor test was accentuated, the rise in resistance increasing from 10.5 mm Hg/ml/100 ml/min (R units) before treatment to 32.6 R units after treatment (SED +/- 6.4, p less than 0.025).",2722224_5,0,1,2,17027,-1
17034,/-,50,51,280,282,"The rise in forearm vascular resistance accompanying intra-arterial norepinephrine (25, 50, and 100 ng/min) was also significantly greater after hydrocortisone, increasing from an average of 14.9 +/- 2.4 R units before treatment to 35.1 +/- 5.5 R units after hydrocortisone (SED +/- 6.0, p less than 0.05).",2722224_6,0,1,2,17034,-1
17035,dose-response relation,7,9,27,49,A shift to the left in the dose-response relation and fall in threshold suggested increased sensitivity to norepinephrine after treatment.,2722224_7,-1,-1,2,17035,-1
17038,associated with,9,11,58,73,The rise in resting blood pressure with hydrocortisone is associated with an increased cardiac output (presumably due to increased blood volume).(ABSTRACT TRUNCATED AT 250 WORDS),2722224_9,-1,-1,2,17038,-1
17040,volume).(ABSTRACT TRUNCATED,21,23,137,164,The rise in resting blood pressure with hydrocortisone is associated with an increased cardiac output (presumably due to increased blood volume).(ABSTRACT TRUNCATED AT 250 WORDS),2722224_9,-1,-1,2,17040,-1
17054,Chronic oral CBZ,0,3,0,16,"Chronic oral CBZ inhibited the development of both lidocaine- and cocaine-induced seizures, but had little effect on the fully developed local anesthetic seizures.",2790457_2,-1,-1,2,17054,-1
17057,Chronic CBZ,0,2,0,11,Chronic CBZ also decreased the incidence of seizure-related mortality in the cocaine-injected rats.,2790457_3,-1,-1,2,17057,-1
17059,cocaine-injected,11,12,77,93,Chronic CBZ also decreased the incidence of seizure-related mortality in the cocaine-injected rats.,2790457_3,-1,-1,2,17059,-1
17061,no effect,14,16,50,59,Acute CBZ over a range of doses (15-50 mg/kg) had no effect on completed lidocaine-kindled or acute cocaine-induced seizures.,2790457_4,-1,-1,2,17061,-1
17062,lidocaine-kindled,18,19,73,90,Acute CBZ over a range of doses (15-50 mg/kg) had no effect on completed lidocaine-kindled or acute cocaine-induced seizures.,2790457_4,-1,-1,2,17062,-1
17066,differential effects,1,3,4,24,The differential effects of CBZ depending upon stage of seizure development suggest that distinct mechanisms underlie the development versus maintenance of local anesthetic-kindled seizures.,2790457_7,-1,-1,2,17066,-1
17068,intermittent injections,8,10,47,70,"The effectiveness of chronic but not repeated, intermittent injections of CBZ suggests that different biochemical consequences result from the different treatment regimens.",2790457_8,-1,-1,2,17068,-1
17069,CBZ,11,12,74,77,"The effectiveness of chronic but not repeated, intermittent injections of CBZ suggests that different biochemical consequences result from the different treatment regimens.",2790457_8,-1,-1,2,17069,-1
17071,chronic CBZ,4,6,24,35,"The possible utility of chronic CBZ in preventing the development of toxic side effects in human cocaine users is suggested by these data, but remains to be directly evaluated.",2790457_9,-1,-1,2,17071,-1
17078,salt-depleted,20,21,117,130,"The nephrotoxic potential of amphotericin B (5 mg/kg per day intraperitoneally for 3 weeks) has been investigated in salt-depleted, normal-salt, and salt-loaded rats.",2802551_1,-1,-1,2,17078,-1
17088,sodium-depleted group,4,6,16,37,All rats in the sodium-depleted group had histopathological evidence of patchy tubular cytoplasmic degeneration in tubules that was not observed in any normal-salt or salt-loaded rat.,2802551_4,-1,-1,2,17088,-1
17091,salt-loaded rat,24,26,167,182,All rats in the sodium-depleted group had histopathological evidence of patchy tubular cytoplasmic degeneration in tubules that was not observed in any normal-salt or salt-loaded rat.,2802551_4,-1,-1,2,17091,-1
17094,salt-depleted,21,22,108,121,"However, at the end of 3 weeks, amphotericin B levels in the kidneys and liver were significantly higher in salt-depleted and normal-salt rats than those in salt-loaded rats, with plasma/kidney ratios of 21, 14, and 8 in salt-depleted, normal-salt, and salt-loaded rats, respectively.",2802551_6,-1,-1,2,17094,-1
17097,plasma/kidney ratios,32,34,180,200,"However, at the end of 3 weeks, amphotericin B levels in the kidneys and liver were significantly higher in salt-depleted and normal-salt rats than those in salt-loaded rats, with plasma/kidney ratios of 21, 14, and 8 in salt-depleted, normal-salt, and salt-loaded rats, respectively.",2802551_6,-1,-1,2,17097,-1
17098,salt-depleted,42,43,221,234,"However, at the end of 3 weeks, amphotericin B levels in the kidneys and liver were significantly higher in salt-depleted and normal-salt rats than those in salt-loaded rats, with plasma/kidney ratios of 21, 14, and 8 in salt-depleted, normal-salt, and salt-loaded rats, respectively.",2802551_6,-1,-1,2,17098,-1
17103,chronic amphotericin B administration,13,17,94,131,"In conclusion, reductions in creatinine clearance and renal amphotericin B accumulation after chronic amphotericin B administration were enhanced by salt depletion and attenuated by sodium loading in rats.",2802551_7,-1,-1,2,17103,-1
17107,secondary to,7,9,57,69,"Magnetic resonance imaging of cerebral venous thrombosis secondary to ""low-dose"" birth control pills.",2819587_0,-1,-1,2,17107,-1
17111,white woman,13,15,91,102,The clinical and radiographic features of cerebral deep venous thrombosis in a 21-year-old white woman are presented.,2819587_1,-1,-1,2,17111,-1
17115,risk factor,3,5,15,26,"The only known risk factor was ""low-dose"" oral contraceptive pills.",2819587_3,-1,-1,2,17115,-1
17118,magnetic resonance image,1,4,4,28,"The magnetic resonance image (MRI) showed increased signal intensity from the internal cerebral veins, vein of Galen, and straight sinus.",2819587_4,-1,-1,2,17118,-1
17119,signal intensity,9,11,52,68,"The magnetic resonance image (MRI) showed increased signal intensity from the internal cerebral veins, vein of Galen, and straight sinus.",2819587_4,-1,-1,2,17119,-1
17126,terbutaline-induced hypokalemia,7,9,57,88,"The time course and concentration-effect relationship of terbutaline-induced hypokalemia was studied, using computer-aided pharmacokinetic-dynamic modeling.",2826064_1,-1,-1,2,17126,-1
17129,pharmacokinetic interaction,15,17,108,135,"Subsequently we investigated the efficacy of oxprenolol in antagonizing such hypokalemia, together with the pharmacokinetic interaction between both drugs.",2826064_2,-1,-1,2,17129,-1
17136,plasma samples,8,10,55,69,"In the 7-hour period after terbutaline administration, plasma samples were taken for determination of plasma potassium levels and drug concentrations.",2826064_4,-1,-1,2,17136,-1
17139,sigmoid Emax model,1,4,4,22,The sigmoid Emax model offered a good description of the relation between terbutaline concentrations and potassium effects.,2826064_5,-1,-1,2,17139,-1
17153,experimental results,2,4,12,32,The present experimental results indicated that peptidergic stimulation of the LC resulted in a NE-mediated inhibition of cerebellar Purkinje cells located at terminals of the ceruleo-cerebellar pathway.,2840807_2,-1,-1,2,17153,-1
17154,peptidergic stimulation,6,8,48,71,The present experimental results indicated that peptidergic stimulation of the LC resulted in a NE-mediated inhibition of cerebellar Purkinje cells located at terminals of the ceruleo-cerebellar pathway.,2840807_2,-1,-1,2,17154,-1
17156,NE-mediated,14,15,96,107,The present experimental results indicated that peptidergic stimulation of the LC resulted in a NE-mediated inhibition of cerebellar Purkinje cells located at terminals of the ceruleo-cerebellar pathway.,2840807_2,-1,-1,2,17156,-1
17157,cerebellar Purkinje cells,17,20,122,147,The present experimental results indicated that peptidergic stimulation of the LC resulted in a NE-mediated inhibition of cerebellar Purkinje cells located at terminals of the ceruleo-cerebellar pathway.,2840807_2,-1,-1,2,17157,-1
17160,LC,25,26,123,125,"However, it is not certain as to the following: (a) what receptors were stimulated by the ACTH N-terminal fragments at the LC that resulted in this disorder; (b) whether NE, released onto Purkinje cell synapses located at terminals of the ceruleo-cerebellar pathway, did indeed cause the long-term depression at Purkinje cell synapses (previously described by others) that resulted in the long duration of the movement disorder; (c) whether the inhibition of inhibitory Purkinje cells resulted in disinhibition or increased excitability of the unilateral cerebellar fastigial or interpositus nuclei, the output targets of the Purkinje cell axons, that may have been an important contributing factor to this disorder.",2840807_3,-1,-1,2,17160,-1
17179,infusion studies,2,4,13,29,"In long-term infusion studies, flestolol was well tolerated at the effective beta-blocking dose (5 micrograms/kg/min) for up to seven days.",2870085_4,-1,-1,2,17179,-1
17183,blood concentrations,1,3,10,30,Flestolol blood concentrations increased linearly with increasing dose and good correlation exists between blood concentrations of flestolol and beta-adrenergic blockade.,2870085_5,-1,-1,2,17183,-1
17184,blood concentrations,13,15,107,127,Flestolol blood concentrations increased linearly with increasing dose and good correlation exists between blood concentrations of flestolol and beta-adrenergic blockade.,2870085_5,-1,-1,2,17184,-1
17190,hemodynamic effects,2,4,23,42,Electrophysiologic and hemodynamic effects of flestolol are similar to those of other beta blockers.,2870085_7,-1,-1,2,17190,-1
17214,Renal catecholamine stores,0,3,0,26,Renal catecholamine stores and stimulus-induced overflow in the vehicle-treated group consisted of norepinephrine only.,2886572_2,-1,-1,2,17214,-1
17215,stimulus-induced overflow,4,6,31,56,Renal catecholamine stores and stimulus-induced overflow in the vehicle-treated group consisted of norepinephrine only.,2886572_2,-1,-1,2,17215,-1
17216,vehicle-treated group,8,10,64,85,Renal catecholamine stores and stimulus-induced overflow in the vehicle-treated group consisted of norepinephrine only.,2886572_2,-1,-1,2,17216,-1
17217,renal catecholamine stores,11,14,81,107,"However, epinephrine treatment resulted in the incorporation of epinephrine into renal catecholamine stores such that approximately 40% of the catecholamine present was epinephrine while the norepinephrine content was reduced by a similar degree.",2886572_3,-1,-1,2,17217,-1
17219,molar basis,9,11,54,65,Total tissue catecholamine content of the kidney on a molar basis was unchanged.,2886572_4,-1,-1,2,17219,-1
17220,Stimulus-induced fractional overflow,0,3,0,36,Stimulus-induced fractional overflow of neurotransmitter from the epinephrine-treated kidneys was approximately twice normal and consisted of both norepinephrine and epinephrine in proportions similar to those found in the kidney.,2886572_5,-1,-1,2,17220,-1
17221,epinephrine-treated kidneys,7,9,66,93,Stimulus-induced fractional overflow of neurotransmitter from the epinephrine-treated kidneys was approximately twice normal and consisted of both norepinephrine and epinephrine in proportions similar to those found in the kidney.,2886572_5,-1,-1,2,17221,-1
17222,fractional overflow,3,5,19,38,This difference in fractional overflow between groups was not affected by neuronal and extraneuronal uptake blockade.,2886572_6,-1,-1,2,17222,-1
17225,no effect,2,4,16,25,Propranolol had no effect on stimulus-induced overflow in either group.,2886572_7,-1,-1,2,17225,-1
17226,stimulus-induced overflow,5,7,29,54,Propranolol had no effect on stimulus-induced overflow in either group.,2886572_7,-1,-1,2,17226,-1
17227,stimulus-induced overflow,2,4,23,48,Phentolamine increased stimulus-induced overflow in both groups although the increment in overflow was greater in the epinephrine-treated group.,2886572_8,-1,-1,2,17227,-1
17229,prejunctional beta-adrenoceptor,5,7,32,63,"However, neither alterations in prejunctional beta-adrenoceptor influences nor alterations in neuronal and extraneuronal uptake mechanisms appear to be responsible for this alteration.",2886572_10,-1,-1,2,17229,-1
17233,morphometric studies,5,7,46,66,"Immunohistochemical, electron microscopic and morphometric studies of estrogen-induced rat prolactinomas after bromocriptine treatment.",2887062_0,-1,-1,2,17233,-1
17240,in vivo,9,11,62,69,"To clarify the effects of bromocriptine on prolactinoma cells in vivo, immunohistochemical, ultrastructural and morphometrical analyses were applied to estrogen-induced rat prolactinoma cells 1 h and 6 h after injection of bromocriptine (3 mg/kg of body weight).",2887062_1,-1,-1,2,17240,-1
17243,morphometrical analyses,16,18,112,135,"To clarify the effects of bromocriptine on prolactinoma cells in vivo, immunohistochemical, ultrastructural and morphometrical analyses were applied to estrogen-induced rat prolactinoma cells 1 h and 6 h after injection of bromocriptine (3 mg/kg of body weight).",2887062_1,-1,-1,2,17243,-1
17248,serum prolactin,5,7,23,38,"One h after treatment, serum prolactin levels decreased markedly.",2887062_2,-1,-1,2,17248,-1
17250,secretory granules,4,6,35,53,"Electron microscopy disclosed many secretory granules, slightly distorted rough endoplasmic reticulum, and partially dilated Golgi cisternae in the prolactinoma cells.",2887062_3,-1,-1,2,17250,-1
17251,endoplasmic reticulum,10,12,80,101,"Electron microscopy disclosed many secretory granules, slightly distorted rough endoplasmic reticulum, and partially dilated Golgi cisternae in the prolactinoma cells.",2887062_3,-1,-1,2,17251,-1
17252,Golgi cisternae,16,18,125,140,"Electron microscopy disclosed many secretory granules, slightly distorted rough endoplasmic reticulum, and partially dilated Golgi cisternae in the prolactinoma cells.",2887062_3,-1,-1,2,17252,-1
17254,Morphometric analysis,0,2,0,21,"Morphometric analysis revealed that the volume density of secretory granules increased, while the volume density of cytoplasmic microtubules decreased.",2887062_4,-1,-1,2,17254,-1
17255,volume density,5,7,40,54,"Morphometric analysis revealed that the volume density of secretory granules increased, while the volume density of cytoplasmic microtubules decreased.",2887062_4,-1,-1,2,17255,-1
17256,secretory granules,8,10,58,76,"Morphometric analysis revealed that the volume density of secretory granules increased, while the volume density of cytoplasmic microtubules decreased.",2887062_4,-1,-1,2,17256,-1
17257,volume density,14,16,98,112,"Morphometric analysis revealed that the volume density of secretory granules increased, while the volume density of cytoplasmic microtubules decreased.",2887062_4,-1,-1,2,17257,-1
17259,early phase,10,12,66,77,These findings suggest that lowered serum prolactin levels in the early phase of bromocriptine treatment may result from an impaired secretion of prolactin due to decreasing numbers of cytoplasmic microtubules.,2887062_5,-1,-1,2,17259,-1
17262,cytoplasmic microtubules,28,30,185,209,These findings suggest that lowered serum prolactin levels in the early phase of bromocriptine treatment may result from an impaired secretion of prolactin due to decreasing numbers of cytoplasmic microtubules.,2887062_5,-1,-1,2,17262,-1
17263,serum prolactin,6,8,24,39,"At 6 h after injection, serum prolactin levels were still considerably lower than in controls.",2887062_6,-1,-1,2,17263,-1
17265,vesiculated rough,11,13,63,80,"The prolactinoma cells at this time were well granulated, with vesiculated rough endoplasmic reticulum and markedly dilated Golgi cisternae.",2887062_7,-1,-1,2,17265,-1
17266,endoplasmic reticulum,13,15,81,102,"The prolactinoma cells at this time were well granulated, with vesiculated rough endoplasmic reticulum and markedly dilated Golgi cisternae.",2887062_7,-1,-1,2,17266,-1
17267,Golgi cisternae,18,20,124,139,"The prolactinoma cells at this time were well granulated, with vesiculated rough endoplasmic reticulum and markedly dilated Golgi cisternae.",2887062_7,-1,-1,2,17267,-1
17270,secretory granules,10,12,93,111,"Electron microscopical immunohistochemistry revealed positive reaction products noted on the secretory granules, Golgi cisternae, and endoplasmic reticulum of the untreated rat prolactinoma cells.",2887062_8,-1,-1,2,17270,-1
17271,Golgi cisternae,13,15,113,128,"Electron microscopical immunohistochemistry revealed positive reaction products noted on the secretory granules, Golgi cisternae, and endoplasmic reticulum of the untreated rat prolactinoma cells.",2887062_8,-1,-1,2,17271,-1
17277,volume density,4,6,19,33,"An increase in the volume density of secretory granules and a decrease in the volume densities of rough endoplasmic reticulum and microtubules was determined by morphometric analysis, suggesting that bromocriptine inhibits protein synthesis as well as bringing about a disturbance of the prolactin secretion.",2887062_10,-1,-1,2,17277,-1
17278,secretory granules,7,9,37,55,"An increase in the volume density of secretory granules and a decrease in the volume densities of rough endoplasmic reticulum and microtubules was determined by morphometric analysis, suggesting that bromocriptine inhibits protein synthesis as well as bringing about a disturbance of the prolactin secretion.",2887062_10,-1,-1,2,17278,-1
17280,morphometric analysis,25,27,161,182,"An increase in the volume density of secretory granules and a decrease in the volume densities of rough endoplasmic reticulum and microtubules was determined by morphometric analysis, suggesting that bromocriptine inhibits protein synthesis as well as bringing about a disturbance of the prolactin secretion.",2887062_10,-1,-1,2,17280,-1
17299,control values,17,19,88,102,"Naloxone (2.5 mg/kg, i.v.) reversed respiratory paralysis, glutamate and GABA levels to control values in brain stem and cortex with no changes in caudate or cerebellum.",2893236_6,-1,-1,2,17299,-1
17314,no change,10,12,69,78,"Intravenous pretreatment of the rats with diazepam, although causing no change in the adrenaline-induced pressor effect, did enhance the adrenaline-induced reflex bradycardia.",2894433_4,-1,-1,2,17314,-1
17323,associated with,31,33,209,224,"However, the diazepam enhancement of adrenaline-induced reflex bradycardia was antagonized by pretreatment of rats with an intravenous dose of picrotoxin (an agent blocks chloride channels by binding to sites associated with the benzodiazepine-GABA-chloride channel macromolecular complex).",2894433_5,-1,-1,2,17323,-1
17336,positive autoantibodies,13,15,95,118,"Pneumonitis, bilateral pleural effusions, echocardiographic evidence of cardiac tamponade, and positive autoantibodies developed in a 43-year-old man, who was receiving long-term sulfasalazine therapy for chronic ulcerative colitis.",2894766_1,-1,-1,2,17336,-1
17340,six-week course,9,11,57,72,"After cessation of the sulfasalazine and completion of a six-week course of corticosteroids, these problems resolved over a period of four to six months.",2894766_2,-1,-1,2,17340,-1
17352,metabolic balance studies,18,21,121,146,"To investigate the initial potassium loss and development of hypokalaemia during the administration of an oral diuretic, metabolic balance studies were performed in ten patients with essential hypertension who had shown hypokalaemia under prior oral diuretic treatment.",28952_1,-1,-1,2,17352,-1
17356,normal-sodium diet,4,6,24,42,Six patients received a normal-sodium diet and four a low-sodium (17 mmol/day) diet.,28952_3,-1,-1,2,17356,-1
17358,total body potassium,6,9,34,54,All patients had a normal initial total body potassium (40K).,28952_4,-1,-1,2,17358,-1
17360,aldosterone secretion rate,14,17,76,102,"The electrolyte balances, weight, bromide space, plasma renin activity, and aldosterone secretion rate were measured.",28952_5,-1,-1,2,17360,-1
17362,proportionally larger,9,11,51,72,"In both groups a potassium deficit developed, with proportionally larger losses from the extracellular than from the intracellular compartment.",28952_6,-1,-1,2,17362,-1
17364,potassium deficit,7,9,44,61,"In the normal-sodium group the highest mean potassium deficit was 176 mmol on day 9, after which some potassium was regained; in the low-sodium group the highest deficit was 276 mmol on day 13.",28952_7,-1,-1,2,17364,-1
17370,renin-angiotensin-aldosterone system,19,21,134,170,"It is concluded that dietary sodium restriction increases diuretic-induced potassium loss, presumably by an increased activity of the renin-angiotensin-aldosterone system, while sodium delivery to the distal renal tubules remains sufficiently high to allow increased potassium secretion.",28952_9,-1,-1,2,17370,-1
17382,cardiovascular effects,10,12,44,66,"We have compared, in 60 adult patients, the cardiovascular effects of glycopyrronium 5 micrograms kg-1 and 10 micrograms kg-1 given either simultaneously or 1 min before edrophonium 1 mg kg-1.",2917114_1,-1,-1,2,17382,-1
17385,kg-1,20,21,121,125,"We have compared, in 60 adult patients, the cardiovascular effects of glycopyrronium 5 micrograms kg-1 and 10 micrograms kg-1 given either simultaneously or 1 min before edrophonium 1 mg kg-1.",2917114_1,-1,-1,2,17385,-1
17387,kg-1,31,32,187,191,"We have compared, in 60 adult patients, the cardiovascular effects of glycopyrronium 5 micrograms kg-1 and 10 micrograms kg-1 given either simultaneously or 1 min before edrophonium 1 mg kg-1.",2917114_1,-1,-1,2,17387,-1
17391,confidence limits,20,22,100,117,Both groups receiving 10 micrograms kg-1 showed increases in heart rate of up to 30 beat min-1 (95% confidence limits 28-32 beat min-1).,2917114_3,-1,-1,2,17391,-1
17405,clinical studies,15,17,70,86,"Carbamazepine (CBZ), a commonly used AED, has been implicated in some clinical studies.",2924746_2,-1,-1,2,17405,-1
17406,effects of,8,10,41,51,A rat model was developed to examine the effects of chronic CBZ treatment on folate concentrations in the rat.,2924746_3,-1,-1,2,17406,-1
17414,maximal electroshock,25,27,144,164,Seizures induced by hexafluorodiethyl ether (HFDE) were also found to be a more sensitive measure of protection by CBZ than seizures induced by maximal electroshock (MES).,2924746_5,-1,-1,2,17414,-1
17422,adverse effect,7,9,40,54,"This treatment with CBZ had no apparent adverse effect on folate concentrations in the rat, and, indeed, the folate concentration increased in liver after 6 weeks of treatment and in plasma at 8 weeks of treatment.",2924746_8,-1,-1,2,17422,-1
17433,sympathoadrenal activity,2,4,14,38,Inhibition of sympathoadrenal activity by atrial natriuretic factor in dogs.,2951327_0,-1,-1,2,17433,-1
17435,mEq/kg/day,17,18,79,89,"In six conscious, trained dogs, maintained on a normal sodium intake of 2 to 4 mEq/kg/day, sympathetic activity was assessed as the release rate of norepinephrine and epinephrine during 15-minute i.v.",2951327_1,-1,-1,2,17435,-1
17439,control +,8,10,43,52,"Mean arterial pressure (as a percentage of control +/- SEM) during randomized infusions of 0.03, 0.1, 0.3, or 1.0 microgram/kg/min was 99 +/- 1, 95 +/- 1 (p less than 0.05), 93 +/- 1 (p less than 0.01), or 79 +/- 6% (p less than 0.001), respectively, but no tachycardia and no augmentation of the norepinephrine release rate (up to 0.3 microgram/kg/min) were observed, which is in contrast to comparable hypotension induced by hydralazine or nitroglycerin.",2951327_3,-1,-1,2,17439,-1
17449,/-,46,47,228,230,"The release rate of epinephrine (control, 6.7 +/- 0.6 ng/kg/min) declined immediately during infusions of atrial natriuretic factor to a minimum of 49 +/- 5% of control (p less than 0.001) during 0.1 microgram/kg/min and to 63 +/- 5% (0.1 greater than p greater than 0.05) or 95 +/- 13% (not significant) during 0.3 or 1.0 microgram/kg/min.",2951327_4,0,1,2,17449,-1
17450,/-,61,62,280,282,"The release rate of epinephrine (control, 6.7 +/- 0.6 ng/kg/min) declined immediately during infusions of atrial natriuretic factor to a minimum of 49 +/- 5% of control (p less than 0.001) during 0.1 microgram/kg/min and to 63 +/- 5% (0.1 greater than p greater than 0.05) or 95 +/- 13% (not significant) during 0.3 or 1.0 microgram/kg/min.",2951327_4,0,1,2,17450,-1
17451,Steady state,0,2,0,12,Steady state arterial plasma concentrations of atrial natriuretic factor were 39 +/- 10 pg/ml (n = 6) during infusions of saline and 284 +/- 24 pg/ml (n = 6) and 1520 +/- 300 pg/ml (n = 9) during 0.03 and 0.1 microgram/kg/min infusions of the factor.(ABSTRACT TRUNCATED AT 250 WORDS),2951327_5,-1,-1,2,17451,-1
17453,/-,27,28,138,140,Steady state arterial plasma concentrations of atrial natriuretic factor were 39 +/- 10 pg/ml (n = 6) during infusions of saline and 284 +/- 24 pg/ml (n = 6) and 1520 +/- 300 pg/ml (n = 9) during 0.03 and 0.1 microgram/kg/min infusions of the factor.(ABSTRACT TRUNCATED AT 250 WORDS),2951327_5,0,1,2,17453,-1
17455,factor.(ABSTRACT TRUNCATED AT 250 WORDS,54,59,243,282,Steady state arterial plasma concentrations of atrial natriuretic factor were 39 +/- 10 pg/ml (n = 6) during infusions of saline and 284 +/- 24 pg/ml (n = 6) and 1520 +/- 300 pg/ml (n = 9) during 0.03 and 0.1 microgram/kg/min infusions of the factor.(ABSTRACT TRUNCATED AT 250 WORDS),2951327_5,-1,-1,2,17455,-1
17480,urine-concentrating ability,3,5,21,48,Thyroid function and urine-concentrating ability during lithium treatment.,3001299_0,-1,-1,2,17480,-1
17483,urine-concentrating ability,5,7,32,59,We measured serum thyroxine and urine-concentrating ability (Umax) in response to desmopressin (DDAVP) in 85 patients receiving lithium.,3001299_2,-1,-1,2,17483,-1
17495,computer-assisted morphometric method,15,18,79,116,The neuropathy caused by a single dose of isoniazid in rats was studied with a computer-assisted morphometric method.,3015327_1,-1,-1,2,17495,-1
17497,quotient fibre diameter/axon diameter,7,11,33,70,"Scatter diagrams of the g ratio (quotient fibre diameter/axon diameter) define regenerating fibres as a distinct population, distinguishable from the surviving fibres by reduced sheath thickness and reduced axon calibre.",3015327_2,-1,-1,2,17497,-1
17498,axon calibre,31,33,207,219,"Scatter diagrams of the g ratio (quotient fibre diameter/axon diameter) define regenerating fibres as a distinct population, distinguishable from the surviving fibres by reduced sheath thickness and reduced axon calibre.",3015327_2,-1,-1,2,17498,-1
17499,fibre population,13,15,70,86,"There was also evidence of a subtle direct toxic effect on the entire fibre population, causing axon shrinkage masked by readjustment of the myelin sheath.",3015327_3,-1,-1,2,17499,-1
17503,corticotropin-releasing factor secretion,3,6,29,69,Inhibition of immunoreactive corticotropin-releasing factor secretion into the hypophysial-portal circulation by delayed glucocorticoid feedback.,3015567_0,-1,-1,2,17503,-1
17514,resting secretion,31,33,210,227,"Application of a delayed feedback signal, in the form of a 2-h systemic corticosterone infusion in urethane-anesthetized rats with pharmacological blockade of glucocorticoid synthesis, is without effect on the resting secretion of arginine vasopressin and oxytocin at any corticosterone feedback dose tested.",3015567_3,-1,-1,2,17514,-1
17520,central component,8,10,52,69,These studies provide further evidence for a strong central component of the delayed feedback process which is mediated by modulation of irCRF release.,3015567_6,-1,-1,2,17520,-1
17521,feedback process,13,15,85,101,These studies provide further evidence for a strong central component of the delayed feedback process which is mediated by modulation of irCRF release.,3015567_6,-1,-1,2,17521,-1
17539,control rats,35,37,205,217,"The cataleptogenic effect of THC was significantly reduced in rats treated with 6-OHDA and in rats with lesions of the locus coeruleus but not in rats treated with desipramine and 6-OHDA, as compared with control rats.",3031535_2,-1,-1,2,17539,-1
17548,Multicenter,0,1,0,11,"Multicenter, double-blind, multiple-dose, parallel-groups efficacy and safety trial of azelastine, chlorpheniramine, and placebo in the treatment of spring allergic rhinitis.",3057041_0,-1,-1,2,17548,-1
17562,multiple-dose,31,32,201,214,"Azelastine, a novel antiallergic medication, was compared with chlorpheniramine maleate and placebo for efficacy and safety in the treatment of spring allergic rhinitis in a multicenter, double-blind, multiple-dose, parallel-groups study.",3057041_1,-1,-1,2,17562,-1
17563,parallel-groups study,33,35,216,237,"Azelastine, a novel antiallergic medication, was compared with chlorpheniramine maleate and placebo for efficacy and safety in the treatment of spring allergic rhinitis in a multicenter, double-blind, multiple-dose, parallel-groups study.",3057041_1,-1,-1,2,17563,-1
17564,fifty-five subjects,2,4,12,31,One hundred fifty-five subjects participated.,3057041_2,-1,-1,2,17564,-1
17566,skin test,26,28,135,144,"Subjects ranged in age from 18 to 60 years of age and had at least a 2-year history of spring allergic rhinitis, confirmed by positive skin test to spring aeroallergens.",3057041_3,-1,-1,2,17566,-1
17573,4-week,17,18,114,120,Daily subject symptom cards were completed during a screening period to assess pretreatment symptoms and during a 4-week treatment period while subjects received study medications.,3057041_5,-1,-1,2,17573,-1
17579,serum chemistry values,6,9,27,49,"Vital signs, body weights, serum chemistry values, complete blood cell counts, urine studies, and electrocardiograms were obtained for each subject and compared among groups.",3057041_8,-1,-1,2,17579,-1
17580,complete blood cell counts,10,14,51,77,"Vital signs, body weights, serum chemistry values, complete blood cell counts, urine studies, and electrocardiograms were obtained for each subject and compared among groups.",3057041_8,-1,-1,2,17580,-1
17581,urine studies,15,17,79,92,"Vital signs, body weights, serum chemistry values, complete blood cell counts, urine studies, and electrocardiograms were obtained for each subject and compared among groups.",3057041_8,-1,-1,2,17581,-1
17587,statistical significance,23,25,143,167,"In contrast, although the chlorpheniramine group did have fewer symptoms than the placebo group during the study, the difference never reached statistical significance during any week of the study.",3057041_11,-1,-1,2,17587,-1
17589,treatment groups,10,12,49,65,There were no serious side effects in any of the treatment groups.,3057041_12,-1,-1,2,17589,-1
17604,chronic ACE,23,25,171,182,This indicates reversibility in captopril-induced renal failure even after its prolonged use and suggests that no organic damage occurs to glomerular arterioles following chronic ACE inhibition.,3070035_3,-1,-1,2,17604,-1
17606,best-known members,6,8,37,55,Lovastatin and simvastatin are the 2 best-known members of the class of hypolipidaemic agents known as HMG CoA reductase inhibitors.,3076126_2,-1,-1,2,17606,-1
17610,United States,6,8,36,49,Lovastatin has been marketed in the United States for over 6 months.,3076126_4,-1,-1,2,17610,-1
17611,clinical efficacy,4,6,29,46,"Both agents show substantial clinical efficacy, with reductions in total cholesterol of over 30% and in LDL-cholesterol of 40% in clinical studies.",3076126_5,-1,-1,2,17611,-1
17614,clinical studies,23,25,130,146,"Both agents show substantial clinical efficacy, with reductions in total cholesterol of over 30% and in LDL-cholesterol of 40% in clinical studies.",3076126_5,-1,-1,2,17614,-1
17618,treated with,6,8,52,64,Ophthalmological examinations in over 1100 patients treated with one or the other agent have revealed no evidence of significant short term (up to 2 years) cataractogenic potential.,3076126_8,-1,-1,2,17618,-1
17621,upper limit of normal,17,21,89,110,One to 2% of patients have elevations of serum transaminases to greater than 3 times the upper limit of normal.,3076126_9,-1,-1,2,17621,-1
17623,associated in,2,4,10,23,"Myopathy, associated in some cases with myoglobinuria, and in 2 cases with transient renal failure, has been rarely reported with lovastatin, especially in patients concomitantly treated with cyclosporin, gemfibrozil or niacin.",3076126_12,-1,-1,2,17623,-1
17625,treated with,29,31,179,191,"Myopathy, associated in some cases with myoglobinuria, and in 2 cases with transient renal failure, has been rarely reported with lovastatin, especially in patients concomitantly treated with cyclosporin, gemfibrozil or niacin.",3076126_12,-1,-1,2,17625,-1
17628,serum cholesterol,14,16,104,121,Lovastatin and simvastatin are both effective and well-tolerated agents for lowering elevated levels of serum cholesterol.,3076126_13,-1,-1,2,17628,-1
17631,remission inducing,3,5,16,34,Toxicity due to remission inducing drugs in rheumatoid arthritis.,3084782_0,-1,-1,2,17631,-1
17645,healthy controls,2,4,12,28,Compared to healthy controls a lower DR5 frequency was observed in patients with RA except for the Tiopronin related nephritis group.,3084782_4,-1,-1,2,17645,-1
17648,nephritis group,19,21,117,132,Compared to healthy controls a lower DR5 frequency was observed in patients with RA except for the Tiopronin related nephritis group.,3084782_4,-1,-1,2,17648,-1
17660,spared cells,25,27,171,183,"A substantial degree of contralateral preference was still evident when amphetamine was administered for the first time 24 days after lesioning, indicating involvement of spared cells in the contralateral rotation.",3088349_5,-1,-1,2,17660,-1
17667,post-lesion DA pool,11,14,74,93,These findings suggest that amphetamine has an irreversible effect on the post-lesion DA pool contributing to contralateral rotation.,3088349_7,-1,-1,2,17667,-1
17670,associated with,2,4,18,33,Hepatic reactions associated with ketoconazole in the United Kingdom.,3101906_0,-1,-1,2,17670,-1
17674,United Kingdom,5,7,35,49,Ketoconazole was introduced in the United Kingdom in 1981.,3101906_1,-1,-1,2,17674,-1
17676,associated with,16,18,105,120,"By November 1984 the Committee on Safety of Medicines had received 82 reports of possible hepatotoxicity associated with the drug, including five deaths.",3101906_2,-1,-1,2,17676,-1
17684,associated with,7,9,36,51,In two of the three deaths probably associated with ketoconazole treatment the drug had been continued after the onset of jaundice and other symptoms of hepatitis.,3101906_13,-1,-1,2,17684,-1
17687,regular intervals,5,7,39,56,Clinical and biochemical monitoring at regular intervals for evidence of hepatitis is advised during long term treatment with ketoconazole to prevent possible serious hepatic injury.,3101906_14,-1,-1,2,17687,-1
17699,consistent with,18,20,106,121,"There was no serologic evidence of viral infection, and a liver biopsy sample showed a histologic pattern consistent with drug-induced hepatitis.",3107448_4,-1,-1,2,17699,-1
17708,associated with,12,14,97,112,"It consists of microangiopathic hemolytic anemia, thrombocytopenia and progressive renal failure associated with mitomycin C treatment and affects about 10% of patients treated with this agent.",3108839_2,-1,-1,2,17708,-1
17710,treated with,24,26,169,181,"It consists of microangiopathic hemolytic anemia, thrombocytopenia and progressive renal failure associated with mitomycin C treatment and affects about 10% of patients treated with this agent.",3108839_2,-1,-1,2,17710,-1
17716,idiopathic HUS,8,10,43,57,"Renal lesions are similar to those seen in idiopathic HUS and include arteriolar fibrin thrombi, expanded subendothelial zones in glomerular capillary walls, ischemic wrinkling of glomerular basement membranes and mesangiolysis.",3108839_4,-1,-1,2,17716,-1
17717,arteriolar fibrin thrombi,12,15,70,95,"Renal lesions are similar to those seen in idiopathic HUS and include arteriolar fibrin thrombi, expanded subendothelial zones in glomerular capillary walls, ischemic wrinkling of glomerular basement membranes and mesangiolysis.",3108839_4,-1,-1,2,17717,-1
17720,glomerular basement membranes,27,30,180,209,"Renal lesions are similar to those seen in idiopathic HUS and include arteriolar fibrin thrombi, expanded subendothelial zones in glomerular capillary walls, ischemic wrinkling of glomerular basement membranes and mesangiolysis.",3108839_4,-1,-1,2,17720,-1
17729,pretreatment,1,2,11,23,Ketanserin pretreatment reverses alfentanil-induced muscle rigidity.,3115150_0,-1,-1,2,17729,-1
17736,subcutaneous electrodes,3,5,23,46,"Following placement of subcutaneous electrodes in each animal's left gastrocnemius muscle, rigidity was assessed by analyzing root-mean-square electromyographic activity.",3115150_2,-1,-1,2,17736,-1
17737,animal's,7,9,55,63,"Following placement of subcutaneous electrodes in each animal's left gastrocnemius muscle, rigidity was assessed by analyzing root-mean-square electromyographic activity.",3115150_2,-1,-1,2,17737,-1
17739,root-mean-square,18,19,126,142,"Following placement of subcutaneous electrodes in each animal's left gastrocnemius muscle, rigidity was assessed by analyzing root-mean-square electromyographic activity.",3115150_2,-1,-1,2,17739,-1
17744,pretreated,20,21,167,177,Intraperitoneal ketanserin administration at doses of 0.63 and 2.5 mg/kg prevented the alfentanil-induced increase in electromyographic activity compared with animals pretreated with saline.,3115150_3,-1,-1,2,17744,-1
17770,double-blind placebo-controlled trial,13,16,90,127,Antagonism of diazepam-induced effects by Ro15-1788 was investigated postoperatively in a double-blind placebo-controlled trial.,3120485_4,-1,-1,2,17770,-1
17780,performance test,11,13,60,76,The Ro15-1788 group showed a significant improvement in the performance test up to 120 min after administration of the drug.,3120485_7,-1,-1,2,17780,-1
17781,injection site,8,10,41,55,There was no evidence of reaction at the injection site.,3120485_8,-1,-1,2,17781,-1
17782,associated with,1,3,7,22,Chorea associated with oral contraception.,3123611_0,-1,-1,2,17782,-1
17791,ICP,3,4,23,26,Intracranial pressure (ICP) was measured during alfentanil-induced rigidity in rats.,3125768_1,-1,-1,2,17791,-1
17797,PCO2,9,10,65,69,"The animals were mechanically ventilated to achieve normocarbia (PCO2 = 42 +/- 1 mmHg, mean +/- SE).",3125768_3,-1,-1,2,17797,-1
17798,/- 1 mmHg,13,16,76,85,"The animals were mechanically ventilated to achieve normocarbia (PCO2 = 42 +/- 1 mmHg, mean +/- SE).",3125768_3,-1,-1,2,17798,-1
17801,ICP,9,10,50,53,"In the five rats that developed somatic rigidity, ICP and CVP increased significantly above baseline (delta ICP 7.5 +/- 1.0 mmHg, delta CVP 5.9 +/- 1.3 mmHg).",3125768_5,-1,-1,2,17801,-1
17802,CVP,11,12,58,61,"In the five rats that developed somatic rigidity, ICP and CVP increased significantly above baseline (delta ICP 7.5 +/- 1.0 mmHg, delta CVP 5.9 +/- 1.3 mmHg).",3125768_5,-1,-1,2,17802,-1
17804,CVP,26,27,136,139,"In the five rats that developed somatic rigidity, ICP and CVP increased significantly above baseline (delta ICP 7.5 +/- 1.0 mmHg, delta CVP 5.9 +/- 1.3 mmHg).",3125768_5,-1,-1,2,17804,-1
17807,ICP,9,10,40,43,"In five rats that did not become rigid, ICP and CVP did not change following alfentanil.",3125768_7,-1,-1,2,17807,-1
17808,CVP,11,12,48,51,"In five rats that did not become rigid, ICP and CVP did not change following alfentanil.",3125768_7,-1,-1,2,17808,-1
17825,co-administration,21,22,121,138,"In groups given 2% BHA, although marked hyperplastic changes of the forestomach epithelium were observed in all animals, co-administration of 0.25% RA significantly (P less than 0.05) increased the incidence of forestomach tumors (squamous cell papilloma and carcinoma) to 60% (9/15, 2 rats with carcinoma) from 15% (3/20, one rat with carcinoma) in the group given RA-free water.",3131282_3,-1,-1,2,17825,-1
17834,co-administration,30,31,102,119,"Tumors, all papillomas, were induced in 3 rats (17%) with 0.25% RA and in one rat (10%) with 0.05% RA co-administration.",3131282_5,-1,-1,2,17834,-1
17839,prospective study,1,3,2,19,"A prospective study on the dose dependency of cardiotoxicity induced by mitomycin C.Since 1975 mitomycin C (MMC) has been suggested to be cardiotoxic, especially when combined with or given following doxorubicin.",3137399_0,-1,-1,2,17839,-1
17842,MMC,17,18,108,111,"A prospective study on the dose dependency of cardiotoxicity induced by mitomycin C.Since 1975 mitomycin C (MMC) has been suggested to be cardiotoxic, especially when combined with or given following doxorubicin.",3137399_0,-1,-1,2,17842,-1
17845,prospective study,4,6,20,37,We have initiated a prospective study to obtain some more data on these subjects.,3137399_2,-1,-1,2,17845,-1
17849,electro-,12,13,75,83,"All patients were studied by repeated physical examinations, chest X-rays, electro- and echocardiography and radionuclide left ventricular ejection fraction (EF) determinations.",3137399_4,-1,-1,2,17849,-1
17855,EF,9,10,47,49,The cardiac failure was predicted by a drop in EF determined during a cold pressor test.,3137399_7,-1,-1,2,17855,-1
17856,cold pressor test,13,16,70,87,The cardiac failure was predicted by a drop in EF determined during a cold pressor test.,3137399_7,-1,-1,2,17856,-1
17860,dose dependent,19,21,116,130,"Based on the combined data from the present study and the literature, we suggest that MMC-related cardiotoxicity is dose dependent, occurring at cumulative dose levels of 30 mg m-2 or more, mainly in patients also (previously or simultaneously) treated with doxorubicin.",3137399_10,-1,-1,2,17860,-1
17862,treated with,43,45,245,257,"Based on the combined data from the present study and the literature, we suggest that MMC-related cardiotoxicity is dose dependent, occurring at cumulative dose levels of 30 mg m-2 or more, mainly in patients also (previously or simultaneously) treated with doxorubicin.",3137399_10,-1,-1,2,17862,-1
17863,risk group,13,15,58,68,The incidence is likely to be less than 10% even for this risk group.,3137399_11,-1,-1,2,17863,-1
17871,coincided with,8,10,48,62,We report a case in which myocardial infarction coincided with the introduction of captopril and the withdrawal of verapamil in a previously asymptomatic woman with severe hypertension.,3173179_3,-1,-1,2,17871,-1
17872,verapamil-related increase,5,7,35,61,Possible mechanisms that involve a verapamil-related increase in platelet and/or vascular alpha 2-adrenoreceptor affinity for catecholamines are discussed.,3173179_4,-1,-1,2,17872,-1
17883,associated with,3,5,28,43,Reversible cerebral lesions associated with tiazofurin usage: MR demonstration.,3183120_0,-1,-1,2,17883,-1
17888,magnetic resonance (MR,5,9,27,49,We report our results with magnetic resonance (MR) in demonstrating reversible cerebral abnormalities concurrent with the use of this drug.,3183120_2,-1,-1,2,17888,-1
17892,induction chemotherapy,4,6,31,53,Adverse cardiac effects during induction chemotherapy treatment with cis-platin and 5-fluorouracil.,3187073_0,-1,-1,2,17892,-1
17902,ECG recordings,12,14,83,97,Before treatment all patients had a cardiac evaluation and during treatment serial ECG recordings were performed.,3187073_5,-1,-1,2,17902,-1
17906,entire group,12,14,55,67,"The mean age of these patients was the same as for the entire group, 64 years.",3187073_8,-1,-1,2,17906,-1
17912,ST-T wave,10,12,57,66,"The most common signs of cardiotoxicity were chest pain, ST-T wave changes and atrial fibrillation.",3187073_10,-1,-1,2,17912,-1
17920,high-risk stage,13,15,94,109,Multiple cytotoxic drug administration is the generally accepted treatment of patients with a high-risk stage of choriocarcinoma.,3192036_1,-1,-1,2,17920,-1
17923,high-risk group,14,16,72,87,"Based on this principle a 27-year old woman, classified as being in the high-risk group (Goldstein and Berkowitz score: 11), was treated with multiple cytotoxic drugs.",3192036_2,-1,-1,2,17923,-1
17926,treated with,26,28,129,141,"Based on this principle a 27-year old woman, classified as being in the high-risk group (Goldstein and Berkowitz score: 11), was treated with multiple cytotoxic drugs.",3192036_2,-1,-1,2,17926,-1
17940,secondary to,42,44,233,245,"Formation of these plugs was probably due to extensive tumor necrosis at the level of the walls of the major uterine veins, which resulted in an open exchange of tumor plugs to the vascular spaces; decrease in tumor tissue coherence secondary to chemotherapy may have further contributed to the formation of tumor emboli.",3192036_6,-1,-1,2,17940,-1
17942,high risk,14,16,86,95,"Patients with large pelvic tumor loads are, according to existing classifications, at high risk to die and to develop drug resistance.",3192036_8,-1,-1,2,17942,-1
17944,response status,4,6,25,40,Close observation of the response status both clinically and with beta-hCG values may indicate whether and when more agressive combination chemotherapy should be started.(ABSTRACT TRUNCATED AT 250 WORDS),3192036_10,-1,-1,2,17944,-1
17946,started.(ABSTRACT TRUNCATED,23,25,162,189,Close observation of the response status both clinically and with beta-hCG values may indicate whether and when more agressive combination chemotherapy should be started.(ABSTRACT TRUNCATED AT 250 WORDS),3192036_10,-1,-1,2,17946,-1
17947,Receptor mechanisms,0,2,0,19,Receptor mechanisms of nicotine-induced locomotor hyperactivity in chronic nicotine-treated rats.,3220106_0,-1,-1,2,17947,-1
17949,chronic nicotine-treated rats,7,10,67,96,Receptor mechanisms of nicotine-induced locomotor hyperactivity in chronic nicotine-treated rats.,3220106_0,-1,-1,2,17949,-1
17951,pretreatment,5,6,19,31,"At the end of each pretreatment period, animals were used for (i) determining their locomotor response to acutely injected nicotine (0.2 mg/kg, s.c.) and (ii) measuring the density of L-[3H]nicotine and [3H]spiperone binding sites in the striatum.",3220106_2,-1,-1,2,17951,-1
17952,locomotor response,17,19,84,102,"At the end of each pretreatment period, animals were used for (i) determining their locomotor response to acutely injected nicotine (0.2 mg/kg, s.c.) and (ii) measuring the density of L-[3H]nicotine and [3H]spiperone binding sites in the striatum.",3220106_2,-1,-1,2,17952,-1
17955,nicotine-induced locomotor response,5,8,26,61,"We observed no changes in nicotine-induced locomotor response, striatal L-[3H]nicotine and [3H]spiperone binding in the animals pretreated with nicotine for 1 day.",3220106_3,-1,-1,2,17955,-1
17958,pretreated,17,18,128,138,"We observed no changes in nicotine-induced locomotor response, striatal L-[3H]nicotine and [3H]spiperone binding in the animals pretreated with nicotine for 1 day.",3220106_3,-1,-1,2,17958,-1
17959,nicotine-stimulated locomotor response,18,21,96,134,"In rats which were pretreated with nicotine for 5 days, there was a significant increase in the nicotine-stimulated locomotor response which was associated with an increase in the number of L-[3H]nicotine binding sites and also with an elevated dopamine (DA) level in the striatum.",3220106_4,-1,-1,2,17959,-1
17960,associated with,23,25,145,160,"In rats which were pretreated with nicotine for 5 days, there was a significant increase in the nicotine-stimulated locomotor response which was associated with an increase in the number of L-[3H]nicotine binding sites and also with an elevated dopamine (DA) level in the striatum.",3220106_4,-1,-1,2,17960,-1
17965,nicotine-induced locomotor response,10,13,53,88,"In animals pretreated with nicotine for 14 days, the nicotine-induced locomotor response remained to be potentiated.",3220106_6,-1,-1,2,17965,-1
17970,striatal DA,26,28,171,182,"However, this response was correlated with an elevated number of striatal [3H]spiperone binding sites, whereas the number of striatal L-[3H]nicotine binding sites and the striatal DA level were normal.",3220106_7,-1,-1,2,17970,-1
17974,DA receptor supersensitivity,32,35,226,254,"These results suggest that chronic nicotine-treated rats develop locomotor hyperactivity in response to nicotine initially due to increases of both the density of nicotinic receptors and DA concentration, followed by inducing DA receptor supersensitivity in the striatum.",3220106_8,-1,-1,2,17974,-1
17976,cardiovascular responses,3,5,20,44,Pulmonary shunt and cardiovascular responses to CPAP during nitroprusside-induced hypotension.,322550_0,-1,-1,2,17976,-1
17981,QS/QT,17,18,106,111,The effects of continuous positive airway pressure (CPAP) on cardiovascular dynamics and pulmonary shunt (QS/QT) were investigated in 12 dogs before and during sodium nitroprusside infusion that decreased mean arterial blood pressure 40-50 per cent.,322550_1,-1,-1,2,17981,-1
17990,QS/QT,36,37,205,210,"Before nitroprusside infusion, 5 cm H2O CPAP significantly, P less than .05, decreased arterial blood pressure, but did not significantly alter heart rate, cardiac output, systemic vascular resistance, or QS/QT.",322550_2,-1,-1,2,17990,-1
17996,QS/QT,25,26,173,178,Ten cm H2O CPAP before nitroprusside infusion produced a further decrease in arterial blood pressure and significantly increased heart rate and decreased cardiac output and QS/QT.,322550_3,-1,-1,2,17996,-1
18002,QS/QT,25,26,169,174,"Nitroprusside caused significant decreases in arterial blood pressure and systemic vascular resistance and increases in heart rate, but did not change cardiac output or QS/QT.",322550_4,-1,-1,2,18002,-1
18005,above-mentioned variables,13,15,71,96,Five cm H2O CPAP during nitroprusside did not further alter any of the above-mentioned variables.,322550_5,-1,-1,2,18005,-1
18009,QS/QT,15,16,79,84,"However, 10 cm H2O CPAP decreased arterial blood pressure, cardiac output, and QS/QT.",322550_6,-1,-1,2,18009,-1
18013,QS/QT,25,26,147,152,These data indicate that nitroprusside infusion rates that decrease mean arterial blood pressure by 40-50 per cent do not change cardiac output or QS/QT.,322550_7,-1,-1,2,18013,-1
18017,QS/QT,27,28,150,155,"During nitroprusside infusion low levels of CPAP do not markedly alter cardiovascular dynamics, but high levels of CPAP (10 cm H2O), while decreasing QS/QT, produce marked decreases in arterial blood pressure and cardiac output.",322550_8,-1,-1,2,18017,-1
18022,urine potassium,9,11,56,71,Timolol also reduced the rise in plasma aldosterone and urine potassium excretion following bendrofluazide and increased the urine sodium/potassium ratio.,326460_2,-1,-1,2,18022,-1
18024,urine sodium/potassium ratio,17,20,125,153,Timolol also reduced the rise in plasma aldosterone and urine potassium excretion following bendrofluazide and increased the urine sodium/potassium ratio.,326460_2,-1,-1,2,18024,-1
18025,extracellular space,14,16,76,95,There was no evidence of a shift of potassium from the intracellular to the extracellular space.,326460_3,-1,-1,2,18025,-1
18042,group I,1,3,3,10,"In group I, cyclosporine was given before the procedure at a loading dose of 17.5 mg/kg and then continued after the procedure to keep a whole blood level about 1000 ng/ml.",3311455_2,-1,-1,2,18042,-1
18065,SPV,5,6,33,36,"The systolic pressure variation (SPV), which is the difference between the maximal and minimal values of the systolic blood pressure (SBP) after one positive-pressure breath, was studied in ventilated dogs subjected to hypotension.",3341566_1,-1,-1,2,18065,-1
18067,SBP,24,25,134,137,"The systolic pressure variation (SPV), which is the difference between the maximal and minimal values of the systolic blood pressure (SBP) after one positive-pressure breath, was studied in ventilated dogs subjected to hypotension.",3341566_1,-1,-1,2,18067,-1
18076,heart rates,12,14,71,82,"The systemic, central venous, pulmonary capillary wedge pressures, and heart rates, were similar in the two groups.",3341566_4,-1,-1,2,18076,-1
18078,arterial pressure waveform,7,10,43,69,Analysis of the respiratory changes in the arterial pressure waveform enabled differentiation between the two groups.,3341566_5,-1,-1,2,18078,-1
18079,SPV,1,2,4,7,"The SPV during hypotension was 15.7 +/- 6.7 mm Hg in the HEM group, compared with 9.1 +/- 2.0 mm Hg in the SNP group (P less than 0.02).",3341566_6,-1,-1,2,18079,-1
18080,/-,7,8,37,39,"The SPV during hypotension was 15.7 +/- 6.7 mm Hg in the HEM group, compared with 9.1 +/- 2.0 mm Hg in the SNP group (P less than 0.02).",3341566_6,0,1,2,18080,-1
18081,HEM group,13,15,57,66,"The SPV during hypotension was 15.7 +/- 6.7 mm Hg in the HEM group, compared with 9.1 +/- 2.0 mm Hg in the SNP group (P less than 0.02).",3341566_6,-1,-1,2,18081,-1
18082,/-,20,21,87,89,"The SPV during hypotension was 15.7 +/- 6.7 mm Hg in the HEM group, compared with 9.1 +/- 2.0 mm Hg in the SNP group (P less than 0.02).",3341566_6,0,1,2,18082,-1
18083,delta down,1,3,4,14,"The delta down, which is the measure of decrease of SBP after a mechanical breath, was 20.3 +/- 8.4 and 10.1 +/- 3.8 mm Hg in the HEM and SNP groups, respectively, during hypotension (P less than 0.02).",3341566_7,-1,-1,2,18083,-1
18084,SBP,11,12,52,55,"The delta down, which is the measure of decrease of SBP after a mechanical breath, was 20.3 +/- 8.4 and 10.1 +/- 3.8 mm Hg in the HEM and SNP groups, respectively, during hypotension (P less than 0.02).",3341566_7,-1,-1,2,18084,-1
18086,/-,20,21,93,95,"The delta down, which is the measure of decrease of SBP after a mechanical breath, was 20.3 +/- 8.4 and 10.1 +/- 3.8 mm Hg in the HEM and SNP groups, respectively, during hypotension (P less than 0.02).",3341566_7,0,1,2,18086,-1
18087,/-,25,26,110,112,"The delta down, which is the measure of decrease of SBP after a mechanical breath, was 20.3 +/- 8.4 and 10.1 +/- 3.8 mm Hg in the HEM and SNP groups, respectively, during hypotension (P less than 0.02).",3341566_7,0,1,2,18087,-1
18088,SPV,7,8,38,41,It is concluded that increases in the SPV and the delta down are characteristic of a hypotensive state due to a predominant decrease in preload.,3341566_8,-1,-1,2,18088,-1
18089,delta down,10,12,50,60,It is concluded that increases in the SPV and the delta down are characteristic of a hypotensive state due to a predominant decrease in preload.,3341566_8,-1,-1,2,18089,-1
18091,preload,24,25,136,143,It is concluded that increases in the SPV and the delta down are characteristic of a hypotensive state due to a predominant decrease in preload.,3341566_8,-1,-1,2,18091,-1
18103,serum potassium level,8,11,66,87,Preoperative assessment should focus on cardiovascular status and serum potassium level.,3358181_3,-1,-1,2,18103,-1
18126,peripheral atropinic,26,28,174,194,"This suggests that benztropine is not the anticholinergic drug of choice in the treatment of neuroleptic-induced parkinsonian symptoms, because of its more toxic central and peripheral atropinic effect.",33969_4,-1,-1,2,18126,-1
18139,pair-matched,24,25,173,185,"The relationship of arthritis and sexual dysfunction was investigated among 169 patients with rheumatoid arthritis, osteoarthritis and spondyloarthropathy, 130 of whom were pair-matched to controls.",3409645_1,-1,-1,2,18139,-1
18142,CES-D,12,13,77,82,Assessments of marital happiness and depressed mood were also made using the CES-D and the Azrin Marital Happiness Scale (AMHS).,3409645_2,-1,-1,2,18142,-1
18144,AMHS,20,21,122,126,Assessments of marital happiness and depressed mood were also made using the CES-D and the Azrin Marital Happiness Scale (AMHS).,3409645_2,-1,-1,2,18144,-1
18146,associated with,14,16,80,95,Impotence was more common among male patients than controls and was found to be associated with co-morbidity and the taking of methotrexate.,3409645_4,-1,-1,2,18146,-1
18149,associated with,9,11,54,69,"Depressed mood was more common among patients and was associated with certain sexual difficulties, but not with impotence.",3409645_5,-1,-1,2,18149,-1
18152,AMHS scores,6,8,37,48,"Marital unhappiness, as indicated by AMHS scores, was not associated with arthritis but was associated with sexual dysfunction, sexual dissatisfaction and being female.",3409645_6,-1,-1,2,18152,-1
18153,associated with,11,13,58,73,"Marital unhappiness, as indicated by AMHS scores, was not associated with arthritis but was associated with sexual dysfunction, sexual dissatisfaction and being female.",3409645_6,-1,-1,2,18153,-1
18154,associated with,16,18,92,107,"Marital unhappiness, as indicated by AMHS scores, was not associated with arthritis but was associated with sexual dysfunction, sexual dissatisfaction and being female.",3409645_6,-1,-1,2,18154,-1
18168,renal papillary necrosis?The,6,9,44,72,"Does paracetamol cause urothelial cancer or renal papillary necrosis?The risk of developing renal papillary necrosis or cancer of the renal pelvis, ureter or bladder associated with consumption of either phenacetin or paracetamol was calculated from data acquired by questionnaire from 381 cases and 808 controls.",3412544_0,-1,-1,2,18168,-1
18172,associated with,25,27,166,181,"Does paracetamol cause urothelial cancer or renal papillary necrosis?The risk of developing renal papillary necrosis or cancer of the renal pelvis, ureter or bladder associated with consumption of either phenacetin or paracetamol was calculated from data acquired by questionnaire from 381 cases and 808 controls.",3412544_0,-1,-1,2,18172,-1
18191,rate-pressure product,11,13,90,111,"Exercise-induced myocardial ischemia was marked predominantly by increased heart rate and rate-pressure product with a minor contribution of end-diastolic volume, while epinephrine-induced ischemia was characterized by a marked increase in contractility and a less pronounced increase in heart rate and rate-pressure product.",3413271_5,-1,-1,2,18191,-1
18192,end-diastolic,18,19,141,154,"Exercise-induced myocardial ischemia was marked predominantly by increased heart rate and rate-pressure product with a minor contribution of end-diastolic volume, while epinephrine-induced ischemia was characterized by a marked increase in contractility and a less pronounced increase in heart rate and rate-pressure product.",3413271_5,-1,-1,2,18192,-1
18195,rate-pressure product,41,43,303,324,"Exercise-induced myocardial ischemia was marked predominantly by increased heart rate and rate-pressure product with a minor contribution of end-diastolic volume, while epinephrine-induced ischemia was characterized by a marked increase in contractility and a less pronounced increase in heart rate and rate-pressure product.",3413271_5,-1,-1,2,18195,-1
18201,Heinz body,14,16,71,81,A Cambodian woman with hemoglobin E trait (AE) and leprosy developed a Heinz body hemolytic anemia while taking a dose of dapsone (50 mg/day) not usually associated with clinical hemolysis.,3425586_1,-1,-1,2,18201,-1
18205,red blood cells,1,4,4,19,"Her red blood cells (RBCs) had increased incubated Heinz body formation, decreased reduced glutathione (GSH), and decreased GSH stability.",3425586_2,-1,-1,2,18205,-1
18206,Heinz body formation,10,13,51,71,"Her red blood cells (RBCs) had increased incubated Heinz body formation, decreased reduced glutathione (GSH), and decreased GSH stability.",3425586_2,-1,-1,2,18206,-1
18214,Heinz body formation,13,16,83,103,"Although the AE RBCs from an individual not taking dapsone had increased incubated Heinz body formation, the GSH content and GSH stability were normal.",3425586_4,-1,-1,2,18214,-1
18220,in vitro,14,16,77,85,"Thus, AE RBCs appear to have an increased sensitivity to oxidant stress both in vitro and in vivo, since dapsone does not cause hemolytic anemia at this dose in hematologically normal individuals.",3425586_6,-1,-1,2,18220,-1
18221,in vivo,17,19,90,97,"Thus, AE RBCs appear to have an increased sensitivity to oxidant stress both in vitro and in vivo, since dapsone does not cause hemolytic anemia at this dose in hematologically normal individuals.",3425586_6,-1,-1,2,18221,-1
18224,Southeast Asians,4,6,20,36,"Given the influx of Southeast Asians into the United States, oxidant medications should be used with caution, especially if an infection is present, in individuals of ethnic backgrounds that have an increased prevalence of hemoglobin E.",3425586_7,-1,-1,2,18224,-1
18225,United States,8,10,46,59,"Given the influx of Southeast Asians into the United States, oxidant medications should be used with caution, especially if an infection is present, in individuals of ethnic backgrounds that have an increased prevalence of hemoglobin E.",3425586_7,-1,-1,2,18225,-1
18227,clinical studies,3,5,23,39,"Recent preclinical and clinical studies with the thymidylate synthase inhibitor N10-propargyl-5,8-dideazafolic acid (CB 3717).CB 3717, N10-propargyl-5,8-dideazafolic acid, is a tight-binding inhibitor of thymidylate synthase (TS) whose cytotoxicity is mediated solely through the inhibition of this enzyme.",3431591_0,-1,-1,2,18227,-1
18234,preclinical studies,1,3,7,26,Recent preclinical studies have focused on the intracellular formation of CB 3717 polyglutamates.,3431591_1,-1,-1,2,18234,-1
18235,CB,10,11,74,76,Recent preclinical studies have focused on the intracellular formation of CB 3717 polyglutamates.,3431591_1,-1,-1,2,18235,-1
18237,exposure of,3,5,20,31,"Following a 12-hour exposure of L1210 cells to 50 microM [3H]CB 3717, 30% of the extractable radioactivity could be accounted for as CB 3717 tetra- and pentaglutamate, as determined by high-pressure liquid chromatography (HPLC) analyses.",3431591_2,-1,-1,2,18237,-1
18238,L1210 cells,5,7,32,43,"Following a 12-hour exposure of L1210 cells to 50 microM [3H]CB 3717, 30% of the extractable radioactivity could be accounted for as CB 3717 tetra- and pentaglutamate, as determined by high-pressure liquid chromatography (HPLC) analyses.",3431591_2,-1,-1,2,18238,-1
18240,CB,24,25,133,135,"Following a 12-hour exposure of L1210 cells to 50 microM [3H]CB 3717, 30% of the extractable radioactivity could be accounted for as CB 3717 tetra- and pentaglutamate, as determined by high-pressure liquid chromatography (HPLC) analyses.",3431591_2,-1,-1,2,18240,-1
18242,high-pressure liquid chromatography,33,36,185,220,"Following a 12-hour exposure of L1210 cells to 50 microM [3H]CB 3717, 30% of the extractable radioactivity could be accounted for as CB 3717 tetra- and pentaglutamate, as determined by high-pressure liquid chromatography (HPLC) analyses.",3431591_2,-1,-1,2,18242,-1
18243,L1210 TS,4,6,26,34,"As inhibitors of isolated L1210 TS, CB 3717 di-, tri-, tetra- and pentaglutamate are 26-, 87-, 119- and 114-fold more potent than CB 3717, respectively, and their formation may, therefore, be an important determinant of CB 3717 cytotoxicity.",3431591_3,-1,-1,2,18243,-1
18250,CB,5,6,31,33,"In early clinical studies with CB 3717, activity has been seen in breast cancer, ovarian cancer, hepatoma, and mesothelioma.",3431591_4,-1,-1,2,18250,-1
18255,drug precipitation,9,11,43,61,This latter effect is thought to be due to drug precipitation within the renal tubule as a result of the poor solubility of CB 3717 under acidic conditions.,3431591_6,-1,-1,2,18255,-1
18257,CB,23,24,124,126,This latter effect is thought to be due to drug precipitation within the renal tubule as a result of the poor solubility of CB 3717 under acidic conditions.,3431591_6,-1,-1,2,18257,-1
18258,acidic conditions,26,28,138,155,This latter effect is thought to be due to drug precipitation within the renal tubule as a result of the poor solubility of CB 3717 under acidic conditions.,3431591_6,-1,-1,2,18258,-1
18259,clinical trial,9,11,42,56,"In an attempt to overcome this problem, a clinical trial of CB 3717 administered with alkaline diuresis is under way.",3431591_7,-1,-1,2,18259,-1
18260,CB,12,13,60,62,"In an attempt to overcome this problem, a clinical trial of CB 3717 administered with alkaline diuresis is under way.",3431591_7,-1,-1,2,18260,-1
18270,CB,10,11,80,82,Pharmacokinetic investigations have shown that alkaline diuresis does not alter CB 3717 plasma levels or urinary excretion and that satisfactory urinary alkalinization can be readily achieved.,3431591_11,-1,-1,2,18270,-1
18272,urinary alkalinization,20,22,145,167,Pharmacokinetic investigations have shown that alkaline diuresis does not alter CB 3717 plasma levels or urinary excretion and that satisfactory urinary alkalinization can be readily achieved.,3431591_11,-1,-1,2,18272,-1
18276,Veterans Administration Cooperative Study,4,8,20,61,Final report of the Veterans Administration Cooperative Study.,343678_1,-1,-1,2,18276,-1
18281,double-blind trial,20,22,98,116,"Hepatitis B immune globulin (HBIG) and immune serum globulin (ISG) were examined in a randomized, double-blind trial to assess their relative efficacies in preventing type B hepatitis after needle-stick exposure to hepatitis B surface antigen (HBsAG)-positive donors.",343678_2,-1,-1,2,18281,-1
18284,exposure to,34,36,203,214,"Hepatitis B immune globulin (HBIG) and immune serum globulin (ISG) were examined in a randomized, double-blind trial to assess their relative efficacies in preventing type B hepatitis after needle-stick exposure to hepatitis B surface antigen (HBsAG)-positive donors.",343678_2,-1,-1,2,18284,-1
18300,statistically significant,7,9,36,61,Both DNAP and HBeAg showed a highly statistically significant correlation with the infectivity of HBsAg-positive donors.,343678_6,-1,-1,2,18300,-1
18301,infectivity,12,13,83,94,Both DNAP and HBeAg showed a highly statistically significant correlation with the infectivity of HBsAg-positive donors.,343678_6,-1,-1,2,18301,-1
18302,HBsAg-positive,14,15,98,112,Both DNAP and HBeAg showed a highly statistically significant correlation with the infectivity of HBsAg-positive donors.,343678_6,-1,-1,2,18302,-1
18304,ISG,8,9,63,66,Hepatitis B immune globulin remained significantly superior to ISG in preventing type B hepatitis even when the analysis was confined to these two high-risk subgroups.,343678_7,-1,-1,2,18304,-1
18306,high-risk subgroups,23,25,147,166,Hepatitis B immune globulin remained significantly superior to ISG in preventing type B hepatitis even when the analysis was confined to these two high-risk subgroups.,343678_7,-1,-1,2,18306,-1
18314,CCU,12,13,81,84,A 47-year-old patient suffering from coronary artery disease was admitted to the CCU in shock with III.,3437726_1,-1,-1,2,18314,-1
18319,blood sample,3,5,14,26,Analyses of a blood sample revealed unusually high plasma concentrations of metoprolol (greater than 3000 ng/ml) and diltiazem (526 ng/ml).,3437726_5,-1,-1,2,18319,-1
18326,metabolizer,8,9,32,43,"It was found that he was a poor metabolizer of all four drugs, indicating that their metabolism is under the same genetic control.",3437726_8,-1,-1,2,18326,-1
18327,genetic control,22,24,114,129,"It was found that he was a poor metabolizer of all four drugs, indicating that their metabolism is under the same genetic control.",3437726_8,-1,-1,2,18327,-1
18328,poor-metabolizer,6,7,37,53,"Therefore, patients belonging to the poor-metabolizer phenotype of sparteine/debrisoquine polymorphism in drug metabolism, which constitutes 6.4% of the German population, may experience adverse drug reactions when treated with standard doses of one of these drugs alone.",3437726_9,-1,-1,2,18328,-1
18331,German population,21,23,153,170,"Therefore, patients belonging to the poor-metabolizer phenotype of sparteine/debrisoquine polymorphism in drug metabolism, which constitutes 6.4% of the German population, may experience adverse drug reactions when treated with standard doses of one of these drugs alone.",3437726_9,-1,-1,2,18331,-1
18333,treated with,30,32,215,227,"Therefore, patients belonging to the poor-metabolizer phenotype of sparteine/debrisoquine polymorphism in drug metabolism, which constitutes 6.4% of the German population, may experience adverse drug reactions when treated with standard doses of one of these drugs alone.",3437726_9,-1,-1,2,18333,-1
18344,incubation periods,1,3,4,22,The incubation periods averaged 10.6 months.,3461217_2,-1,-1,2,18344,-1
18345,L-W,6,7,30,33,"Within the same timeframe, no L-W rat developed a similar palpable PA when treated only with TP.",3461217_3,-1,-1,2,18345,-1
18347,L-W,1,2,3,6,"In L-W rats, TP acted as a tumor enhancement agent, with primary emphasis on the development of prostate cancer.",3461217_4,-1,-1,2,18347,-1
18349,primary emphasis,13,15,57,73,"In L-W rats, TP acted as a tumor enhancement agent, with primary emphasis on the development of prostate cancer.",3461217_4,-1,-1,2,18349,-1
18351,double-blind trial,7,9,38,56,Clinical experiences in an open and a double-blind trial.,347884_0,-1,-1,2,18351,-1
18353,open conditions,11,13,64,79,"A total of sixty patients were trated with bromperidol first in open conditions (20 patients), then on a double blind basis (40 patients) with haloperidol as the reference substance.",347884_1,-1,-1,2,18353,-1
18354,double blind basis,21,24,105,123,"A total of sixty patients were trated with bromperidol first in open conditions (20 patients), then on a double blind basis (40 patients) with haloperidol as the reference substance.",347884_1,-1,-1,2,18354,-1
18361,statistical analysis,5,7,32,52,These results were confirmed by statistical analysis.,347884_5,-1,-1,2,18361,-1
18365,tolerability,13,14,97,109,The results of detailed laboratory tests and evaluations of various quantitative and qualitative tolerability parameters were not indicative of toxic effects.,347884_7,-1,-1,2,18365,-1
18367,double blind study,2,5,7,25,"In the double blind study with haloperidol, both substances were found to be highly effective in the treatment of psychotic syndromes belonging predominantly to the schizophrenia group.",347884_8,-1,-1,2,18367,-1
18369,Certain clues,0,2,0,13,"Certain clues, including the onset of action, seem to be indicative of the superiority of bromperidol.",347884_9,-1,-1,2,18369,-1
18370,onset of action,5,8,29,44,"Certain clues, including the onset of action, seem to be indicative of the superiority of bromperidol.",347884_9,-1,-1,2,18370,-1
18380,associated with,11,13,76,91,Jaundice occurred after administration of troleandomycin for 7 days and was associated with hypereosinophilia.,3496378_2,-1,-1,2,18380,-1
18413,Relative efficacy,0,2,0,17,Relative efficacy and toxicity of netilmicin and tobramycin in oncology patients.,3535719_0,-1,-1,2,18413,-1
18420,treated with,8,10,60,72,Nephrotoxicity occurred in a similar proportion in patients treated with netilmicin and tobramycin (17% vs 11%).,3535719_3,-1,-1,2,18420,-1
18424,piperacillin-treated patients,24,26,107,136,Ototoxicity occurred in four (9.5%) of 42 netilmicin and piperacillin and in 12 (22%) of 54 tobramycin and piperacillin-treated patients.,3535719_4,-1,-1,2,18424,-1
18427,piperacillin-treated patients,12,14,77,106,"Of those evaluated with posttherapy audiograms, three of four netilmicin and piperacillin-treated patients had auditory thresholds return to baseline compared with one of nine tobramycin and piperacillin-treated patients.",3535719_5,-1,-1,2,18427,-1
18429,piperacillin-treated patients,27,29,191,220,"Of those evaluated with posttherapy audiograms, three of four netilmicin and piperacillin-treated patients had auditory thresholds return to baseline compared with one of nine tobramycin and piperacillin-treated patients.",3535719_5,-1,-1,2,18429,-1
18431,piperacillin-treated patients,40,42,241,270,The number of greater than or equal to 15-dB increases in auditory threshold as a proportion of total greater than or equal to 15-dB changes (increases and decreases) was significantly lower in netilmicin and piperacillin- vs tobramycin and piperacillin-treated patients (18 of 78 vs 67 of 115).,3535719_6,-1,-1,2,18431,-1
18434,Intravenous administration,0,2,0,26,Intravenous administration of a single 50-mg bolus of lidocaine in a 67-year-old man resulted in profound depression of the activity of the sinoatrial and atrioventricular nodal pacemakers.,354896_1,-1,-1,2,18434,-1
18443,statistically significant,21,23,130,155,"Thirty-four patients with juvenile rheumatoid arthritis, who were treated with flurbiprofen at a maximum dose of 4 mg/kg/day, had statistically significant decreases from baseline in 6 arthritis indices after 12 weeks of treatment.",3560095_1,-1,-1,2,18443,-1
18453,associated with,1,3,13,28,Hyperkalemia associated with sulindac therapy.,3560096_0,-1,-1,2,18453,-1
18458,mEq/l,12,13,68,73,We describe 4 patients in whom hyperkalemia ranging from 6.1 to 6.9 mEq/l developed within 3 to 8 days of sulindac administration.,3560096_3,-1,-1,2,18458,-1
18460,serum potassium,5,7,22,37,In all of them normal serum potassium levels reached within 2 to 4 days of stopping sulindac.,3560096_4,-1,-1,2,18460,-1
18461,serum potassium,7,9,40,55,"As no other medications known to effect serum potassium had been given concomitantly, this course of events is suggestive of a cause-and-effect relationship between sulindac and hyperkalemia.",3560096_5,-1,-1,2,18461,-1
18462,associated with,11,13,72,87,These observations indicate that initial hopes that sulindac may not be associated with the adverse renal effects of other NSAID are probably not justified.,3560096_6,-1,-1,2,18462,-1
18473,intracerebral infusions,9,11,49,72,"Calcitonin receptors are found in the brain, and intracerebral infusions of calcitonin can produce behavioral effects.",3615541_1,-1,-1,2,18473,-1
18474,behavioral effects,15,17,99,117,"Calcitonin receptors are found in the brain, and intracerebral infusions of calcitonin can produce behavioral effects.",3615541_1,-1,-1,2,18474,-1
18475,behavioral effects,2,4,12,30,Among these behavioral effects are decreases in food intake and decreases in amphetamine-induced locomotor activity.,3615541_2,-1,-1,2,18475,-1
18479,local administration,13,15,79,99,In previous experiments we found that decreases in food intake were induced by local administration of calcitonin into several hypothalamic sites and into the nucleus accumbens.,3615541_3,-1,-1,2,18479,-1
18480,hypothalamic sites,19,21,127,145,In previous experiments we found that decreases in food intake were induced by local administration of calcitonin into several hypothalamic sites and into the nucleus accumbens.,3615541_3,-1,-1,2,18480,-1
18482,locomotor activity,6,8,47,65,In the present experiment calcitonin decreased locomotor activity when locally injected into the same sites where it decreases food intake.,3615541_4,-1,-1,2,18482,-1
18487,hematologic effects,1,3,4,23,The hematologic effects of cefonicid and cefazedone in the dog: a potential model of cephalosporin hematotoxicity in man.,3629586_0,-1,-1,2,18487,-1
18490,cephalosporin hematotoxicity,15,17,85,113,The hematologic effects of cefonicid and cefazedone in the dog: a potential model of cephalosporin hematotoxicity in man.,3629586_0,-1,-1,2,18490,-1
18493,pathogeneses,12,13,82,94,"Cephalosporin antibiotics cause a variety of hematologic disturbances in man, the pathogeneses and hematopathology of which remain poorly characterized.",3629586_1,-1,-1,2,18493,-1
18495,animal model,7,9,35,47,There is a need for a well-defined animal model in which these blood dyscrasias can be studied.,3629586_2,-1,-1,2,18495,-1
18497,toxicity studies,3,5,17,33,"In four subacute toxicity studies, the intravenous administration of cefonicid or cefazedone to beagle dogs caused a dose-dependent incidence of anemia, neutropenia, and thrombocytopenia after 1-3 months of treatment.",3629586_3,-1,-1,2,18497,-1
18507,rechallenge,1,2,5,16,"Upon rechallenge with either cephalosporin, the hematologic syndrome was reproduced in most dogs tested; cefonicid (but not cefazedone)-treated dogs showed a substantially reduced induction period (15 +/- 5 days) compared to that of the first exposure to the drug (61 +/- 24 days).",3629586_6,-1,-1,2,18507,-1
18511,exposure to,41,43,243,254,"Upon rechallenge with either cephalosporin, the hematologic syndrome was reproduced in most dogs tested; cefonicid (but not cefazedone)-treated dogs showed a substantially reduced induction period (15 +/- 5 days) compared to that of the first exposure to the drug (61 +/- 24 days).",3629586_6,-1,-1,2,18511,-1
18512,/-,48,49,269,271,"Upon rechallenge with either cephalosporin, the hematologic syndrome was reproduced in most dogs tested; cefonicid (but not cefazedone)-treated dogs showed a substantially reduced induction period (15 +/- 5 days) compared to that of the first exposure to the drug (61 +/- 24 days).",3629586_6,0,1,2,18512,-1
18514,hemolytic component,22,24,117,136,"This observation, along with the rapid rate of decline in red cell mass parameters of affected dogs, suggests that a hemolytic component complicated the red cell production problem and that multiple toxicologic mechanisms contributed to the cytopenia.",3629586_7,-1,-1,2,18514,-1
18522,Urinary enzymes,0,2,0,15,Urinary enzymes and protein patterns as indicators of injury to different regions of the kidney.,3653576_0,-1,-1,2,18522,-1
18528,HCBD,26,27,173,177,"Acute experimental models of renal damage to the proximal tubular, glomerular, and papillary regions of the rat were produced by administration of hexachloro-1:3-butadiene (HCBD), puromycin aminonucleoside (PAN), and 2-bromoethylamine (BEA), respectively.",3653576_1,-1,-1,2,18528,-1
18535,molecular weight,15,17,122,138,"Several routine indicators of nephrotoxicity, the enzymes alkaline phosphatase and N-acetyl-beta-glucosaminidase, and the molecular weight of protein excretion were determined on urine samples.",3653576_2,-1,-1,2,18535,-1
18536,urine samples,23,25,179,192,"Several routine indicators of nephrotoxicity, the enzymes alkaline phosphatase and N-acetyl-beta-glucosaminidase, and the molecular weight of protein excretion were determined on urine samples.",3653576_2,-1,-1,2,18536,-1
18541,molecular weight,15,17,101,117,"The latter was characterized by a pronounced increase in protein excretion, especially proteins with molecular weight greater than 40,000 Da.",3653576_4,-1,-1,2,18541,-1
18543,molecular weights,23,25,136,153,"In contrast, protein excretion in tubular damage was raised only slightly and characterized by excretion of proteins of a wide range of molecular weights.",3653576_5,-1,-1,2,18543,-1
18545,HCBD,5,6,34,38,Proximal tubular damage caused by HCBD and papillary damage caused by BEA were distinguished both by conventional urinalysis (volume and specific gravity) and by measurement of the two urinary enzymes.,3653576_6,-1,-1,2,18545,-1
18547,BEA,11,12,70,73,Proximal tubular damage caused by HCBD and papillary damage caused by BEA were distinguished both by conventional urinalysis (volume and specific gravity) and by measurement of the two urinary enzymes.,3653576_6,-1,-1,2,18547,-1
18548,urinary enzymes,30,32,185,200,Proximal tubular damage caused by HCBD and papillary damage caused by BEA were distinguished both by conventional urinalysis (volume and specific gravity) and by measurement of the two urinary enzymes.,3653576_6,-1,-1,2,18548,-1
18553,urinary enzymes,6,8,36,51,It is concluded that both selective urinary enzymes and the molecular weight pattern of urinary proteins can be used to provide diagnostic information about the possible site of renal damage.,3653576_8,-1,-1,2,18553,-1
18554,molecular weight pattern,10,13,60,84,It is concluded that both selective urinary enzymes and the molecular weight pattern of urinary proteins can be used to provide diagnostic information about the possible site of renal damage.,3653576_8,-1,-1,2,18554,-1
18561,Control criteria,14,16,72,88,"Of these, 20 cases met the US Public Health Service Centers for Disease Control criteria for the diagnosis of Reye syndrome.",3670965_2,-1,-1,2,18561,-1
18566,New South Wales,6,9,34,49,"The incidence of Reye syndrome in New South Wales, Australia, is estimated from this study to be approximately nine cases per 1 million children compared with recent US data of ten to 20 cases per 1 million children and three to seven cases per 1 million children in Great Britain.",3670965_5,-1,-1,2,18566,-1
18567,Great Britain,50,52,267,280,"The incidence of Reye syndrome in New South Wales, Australia, is estimated from this study to be approximately nine cases per 1 million children compared with recent US data of ten to 20 cases per 1 million children and three to seven cases per 1 million children in Great Britain.",3670965_5,-1,-1,2,18567,-1
18569,case-fatality rate,18,20,88,106,The mortality for these Reye syndrome cases in Australia was 45% as compared with a 32% case-fatality rate in the United States.,3670965_6,-1,-1,2,18569,-1
18570,United States,22,24,114,127,The mortality for these Reye syndrome cases in Australia was 45% as compared with a 32% case-fatality rate in the United States.,3670965_6,-1,-1,2,18570,-1
18578,cerebral metabolic rate,4,7,24,47,Cerebral blood flow and cerebral metabolic rate for oxygen were measured during isoflurane-induced hypotension in 10 patients subjected to craniotomy for clipping of a cerebral aneurysm.,3676049_1,-1,-1,2,18578,-1
18587,/-,29,30,152,154,"Anaesthesia was maintained with an inspired isoflurane concentration of 0.75% (plus 67% nitrous oxide in oxygen), during which CBF and CMRO2 were 34.3 +/- 2.1 ml/100 g min-1 and 2.32 +/- 0.16 ml/100 g min-1 at PaCO2 4.1 +/- 0.1 kPa (mean +/- SEM).",3676049_3,0,1,2,18587,-1
18588,min-1,33,34,168,173,"Anaesthesia was maintained with an inspired isoflurane concentration of 0.75% (plus 67% nitrous oxide in oxygen), during which CBF and CMRO2 were 34.3 +/- 2.1 ml/100 g min-1 and 2.32 +/- 0.16 ml/100 g min-1 at PaCO2 4.1 +/- 0.1 kPa (mean +/- SEM).",3676049_3,-1,-1,2,18588,-1
18589,/-,37,38,184,186,"Anaesthesia was maintained with an inspired isoflurane concentration of 0.75% (plus 67% nitrous oxide in oxygen), during which CBF and CMRO2 were 34.3 +/- 2.1 ml/100 g min-1 and 2.32 +/- 0.16 ml/100 g min-1 at PaCO2 4.1 +/- 0.1 kPa (mean +/- SEM).",3676049_3,0,1,2,18589,-1
18591,PaCO2,43,44,210,215,"Anaesthesia was maintained with an inspired isoflurane concentration of 0.75% (plus 67% nitrous oxide in oxygen), during which CBF and CMRO2 were 34.3 +/- 2.1 ml/100 g min-1 and 2.32 +/- 0.16 ml/100 g min-1 at PaCO2 4.1 +/- 0.1 kPa (mean +/- SEM).",3676049_3,-1,-1,2,18591,-1
18592,/-,46,47,221,223,"Anaesthesia was maintained with an inspired isoflurane concentration of 0.75% (plus 67% nitrous oxide in oxygen), during which CBF and CMRO2 were 34.3 +/- 2.1 ml/100 g min-1 and 2.32 +/- 0.16 ml/100 g min-1 at PaCO2 4.1 +/- 0.1 kPa (mean +/- SEM).",3676049_3,0,1,2,18592,-1
18593,/- SEM,52,54,239,245,"Anaesthesia was maintained with an inspired isoflurane concentration of 0.75% (plus 67% nitrous oxide in oxygen), during which CBF and CMRO2 were 34.3 +/- 2.1 ml/100 g min-1 and 2.32 +/- 0.16 ml/100 g min-1 at PaCO2 4.1 +/- 0.1 kPa (mean +/- SEM).",3676049_3,-1,-1,2,18593,-1
18595,mm Hg,10,12,50,55,"Controlled hypotension to an average MAP of 50-55 mm Hg was induced by increasing the dose of isoflurane, and maintained at an inspired concentration of 2.2 +/- 0.2%.",3676049_4,-1,-1,2,18595,-1
18596,/-,30,31,158,160,"Controlled hypotension to an average MAP of 50-55 mm Hg was induced by increasing the dose of isoflurane, and maintained at an inspired concentration of 2.2 +/- 0.2%.",3676049_4,0,1,2,18596,-1
18597,CMRO2,7,8,43,48,"This resulted in a significant decrease in CMRO2 (to 1.73 +/- 0.16 ml/100 g min-1), while CBF was unchanged.",3676049_5,-1,-1,2,18597,-1
18598,/-,12,13,59,61,"This resulted in a significant decrease in CMRO2 (to 1.73 +/- 0.16 ml/100 g min-1), while CBF was unchanged.",3676049_5,0,1,2,18598,-1
18599,ml/100 g min-1,14,17,67,81,"This resulted in a significant decrease in CMRO2 (to 1.73 +/- 0.16 ml/100 g min-1), while CBF was unchanged.",3676049_5,-1,-1,2,18599,-1
18613,associated with,7,9,43,58,Bromocriptine given in high doses has been associated with psychosis in patients receiving the drug for Parkinson's disease.,3686155_2,-1,-1,2,18613,-1
18630,serum lactate level,12,15,74,93,Nonketotic lactic acidosis was present in one and ketosis without a known serum lactate level was present in the other.,3703509_4,-1,-1,2,18630,-1
18635,CSA,5,6,26,29,The role of cyclosporine (CSA) alone or in combination with various chemotherapeutics in the development of renal toxicity was evaluated in rats.,3708922_1,-1,-1,2,18635,-1
18642,nephrotoxic potential,11,13,77,98,"The combined administration of CSA and various chemotherapeutic drugs with a nephrotoxic potential, such as gentamicin (at therapeutic doses), amphothericin B and ketoconazole, which are frequently used in immunosuppressed patients, did not aggravate the CSA induced toxicity in the rat model.",3708922_3,-1,-1,2,18642,-1
18651,CSA,6,7,36,39,"Thus, the nephrotoxicity induced by CSA has a different pathogenetic mechanism.",3708922_5,-1,-1,2,18651,-1
18652,pathogenetic mechanism,10,12,56,78,"Thus, the nephrotoxicity induced by CSA has a different pathogenetic mechanism.",3708922_5,-1,-1,2,18652,-1
18661,NTE activities,4,6,22,36,"Brain and spinal cord NTE activities were measured in Long-Evans male rats 1 hr post-exposure to various dosages of Mipafox (ip, 1-15 mg/kg).",3714122_2,-1,-1,2,18661,-1
18670,control values,37,39,173,187,Those dosages (greater than or equal to 10 mg/kg) that inhibited mean NTE activity in the spinal cord greater than or equal to 73% and brain greater than or equal to 67% of control values produced severe (greater than or equal to 3) cervical cord pathology in 85% of the rats.,3714122_4,-1,-1,2,18670,-1
18689,infusional chemotherapy,10,12,63,86,This reaction occurred during the sixth and seventh courses of infusional chemotherapy.,3719553_2,-1,-1,2,18689,-1
18695,plasma potassium,8,10,44,60,It has been proposed that modest changes in plasma potassium can alter the tendency towards cardiac arrhythmias.,3732088_1,-1,-1,2,18695,-1
18702,randomised study,43,45,283,299,"Thus, myocardial electrical excitability was measured in patients with mild essential hypertension and known coronary artery disease after 8 weeks of treatment with a potassium-conserving diuretic (amiloride) and a similar period on a potassium-losing diuretic (chlorthalidone) in a randomised study.",3732088_3,-1,-1,2,18702,-1
18708,associated with,9,11,62,77,"Compared to amiloride treatment, the chlorthalidone phase was associated with an increased frequency of ventricular ectopic beats (24-hour Holter monitoring) and a higher Lown grading, increased upslope and duration of the monophasic action potential, prolonged ventricular effective refractory period, and increased electrical instability during programmed ventricular stimulation.",3732088_6,-1,-1,2,18708,-1
18710,24-hour Holter monitoring,19,22,131,156,"Compared to amiloride treatment, the chlorthalidone phase was associated with an increased frequency of ventricular ectopic beats (24-hour Holter monitoring) and a higher Lown grading, increased upslope and duration of the monophasic action potential, prolonged ventricular effective refractory period, and increased electrical instability during programmed ventricular stimulation.",3732088_6,-1,-1,2,18710,-1
18711,Lown grading,26,28,171,183,"Compared to amiloride treatment, the chlorthalidone phase was associated with an increased frequency of ventricular ectopic beats (24-hour Holter monitoring) and a higher Lown grading, increased upslope and duration of the monophasic action potential, prolonged ventricular effective refractory period, and increased electrical instability during programmed ventricular stimulation.",3732088_6,-1,-1,2,18711,-1
18718,potassium-losing,6,7,40,56,"The above results indicate that because potassium-losing diuretic therapy can increase myocardial electrical excitability in patients with ischaemic heart disease, even minor falls in plasma potassium concentrations are probably best avoided in such patients.",3732088_7,-1,-1,2,18718,-1
18727,consistent with,12,14,84,99,"Although acetylcholine receptor antibodies were not detectable, the time course was consistent with an autoimmune process.",3750012_2,-1,-1,2,18727,-1
18734,treated with,20,22,139,151,"We studied a thiamine-dependent enzyme, transketolase, from fibroblasts of a diabetic patient who developed Wernicke's encephalopathy when treated with tolazamide, in order to delineate if this patient also had transketolase abnormality [high Km for thiamine pyrophosphate (TPP)], as previously reported in postalcoholic Wernicke-Korsakoff syndrome.",3762968_1,-1,-1,2,18734,-1
18739,normal controls,25,27,149,164,"In addition to this patient, we also studied this enzyme from three diabetic kindreds without any history of Wernicke's encephalopathy and from four normal controls.",3762968_2,-1,-1,2,18739,-1
18748,treated with,5,7,36,48,"A chronic schizophrenic patient was treated with an anticholinergic drug, trihexyphenidyl hydrochloride.",3769769_1,-1,-1,2,18748,-1
18772,Saline-pretreated controls,0,2,0,26,Saline-pretreated controls given a test dose of morphine (20 mg/kg i.p.) showed a pronounced rigidity recorded as tonic activity in the electromyogram.,3780846_2,-1,-1,2,18772,-1
18774,tonic activity,20,22,114,128,Saline-pretreated controls given a test dose of morphine (20 mg/kg i.p.) showed a pronounced rigidity recorded as tonic activity in the electromyogram.,3780846_2,-1,-1,2,18774,-1
18777,stereotyped (S),14,18,78,93,"The other rats showed a strong decrease in the rigidity and the occurrence of stereotyped (S) licking and/or gnawing in presence of akinetic or hyperkinetic (K) behaviour (AS/KS group), suggesting signs of dopaminergic activation.",3780846_4,-1,-1,2,18777,-1
18829,tubuloglomerular feedback,16,18,96,121,"We propose that amphotericin, in the setting of reduced effective arterial volume, may activate tubuloglomerular feedback, thereby contributing to acute renal failure.",3827439_3,-1,-1,2,18829,-1
18842,PPA,20,21,106,109,We report the case of a young woman who suffered a cerebral infarction after taking a single oral dose of PPA.,3828020_3,-1,-1,2,18842,-1
18860,treated with,11,13,87,99,Twenty children with acute lymphoblastic leukemia who developed meningeal disease were treated with a high-dose intravenous methotrexate regimen that was designed to achieve and maintain CSF methotrexate concentrations of 10(-5) mol/L without the need for concomitant intrathecal dosing.,3856631_1,-1,-1,2,18860,-1
18863,intrathecal dosing,37,39,268,286,Twenty children with acute lymphoblastic leukemia who developed meningeal disease were treated with a high-dose intravenous methotrexate regimen that was designed to achieve and maintain CSF methotrexate concentrations of 10(-5) mol/L without the need for concomitant intrathecal dosing.,3856631_1,-1,-1,2,18863,-1
18866,mg/m2/h,23,24,125,132,"The methotrexate was administered as a loading dose of 6,000 mg/m2 for a period of one hour followed by an infusion of 1,200 mg/m2/h for 23 hours.",3856631_2,-1,-1,2,18866,-1
18870,steady-state,50,51,268,280,"Leucovorin rescue was initiated 12 hours after the end of the infusion with a loading dose of 200 mg/m2 followed by 12 mg/m2 every three hours for six doses and then every six hours until the plasma methotrexate level decreased to less than 1 X 10(-7) mol/L. The mean steady-state plasma and CSF methotrexate concentrations achieved were 1.1 X 10(-3) mol/L and 3.6 X 10(-5) mol/L, respectively.",3856631_3,-1,-1,2,18870,-1
18895,T-cell,23,24,151,157,This report demonstrates for the first time that the pharmacodynamic properties of cyclosporin A may not be confined strictly to suppression of normal T-cell functions.,3865016_4,0,1,2,18895,-1
18898,associated with,6,8,41,56,A prospective study of adverse reactions associated with vancomycin therapy.,3934126_0,-1,-1,2,18898,-1
18900,prospective evaluation,1,3,2,24,A prospective evaluation of the efficacy and safety of vancomycin was conducted in 54 consecutive patients over a 16-month period.,3934126_1,-1,-1,2,18900,-1
18901,16-month period,18,20,114,129,A prospective evaluation of the efficacy and safety of vancomycin was conducted in 54 consecutive patients over a 16-month period.,3934126_1,-1,-1,2,18901,-1
18906,ototoxicity (1,31,34,125,139,"Reactions included thrombophlebitis (20 of 54 patients), rash (4 of 54), nephrotoxicity (4 of 50), proteinuria (1 of 50) and ototoxicity (1 of 11 patients tested by audiometry).",3934126_4,-1,-1,2,18906,-1
18915,treated with,4,6,22,34,Data from 60 patients treated with amikacin were analyzed for factors associated with nephrotoxicity.,3950060_1,-1,-1,2,18915,-1
18917,associated with,11,13,70,85,Data from 60 patients treated with amikacin were analyzed for factors associated with nephrotoxicity.,3950060_1,-1,-1,2,18917,-1
18919,associated with,11,13,56,71,"In 42 of these patients, data were examined for factors associated with clinical outcome.",3950060_2,-1,-1,2,18919,-1
18924,duration of therapy,17,20,101,120,"Variables evaluated included patient weight, age, sex, serum creatinine level, creatinine clearance, duration of therapy, total dose, mean daily dose, organism minimum inhibitory concentration (MIC), mean peak levels, mean trough levels, mean area under the serum concentration-time curve (AUC), total AUC, mean AUC greater than MIC, total AUC greater than MIC, mean Schumacher's intensity factor (IF), total IF, In (mean maximum concentration [Cmax]/MIC).",3950060_3,-1,-1,2,18924,-1
18930,mean area,44,46,238,247,"Variables evaluated included patient weight, age, sex, serum creatinine level, creatinine clearance, duration of therapy, total dose, mean daily dose, organism minimum inhibitory concentration (MIC), mean peak levels, mean trough levels, mean area under the serum concentration-time curve (AUC), total AUC, mean AUC greater than MIC, total AUC greater than MIC, mean Schumacher's intensity factor (IF), total IF, In (mean maximum concentration [Cmax]/MIC).",3950060_3,-1,-1,2,18930,-1
18931,serum concentration-time curve,48,51,258,288,"Variables evaluated included patient weight, age, sex, serum creatinine level, creatinine clearance, duration of therapy, total dose, mean daily dose, organism minimum inhibitory concentration (MIC), mean peak levels, mean trough levels, mean area under the serum concentration-time curve (AUC), total AUC, mean AUC greater than MIC, total AUC greater than MIC, mean Schumacher's intensity factor (IF), total IF, In (mean maximum concentration [Cmax]/MIC).",3950060_3,-1,-1,2,18931,-1
18934,Schumacher's intensity factor,71,75,367,396,"Variables evaluated included patient weight, age, sex, serum creatinine level, creatinine clearance, duration of therapy, total dose, mean daily dose, organism minimum inhibitory concentration (MIC), mean peak levels, mean trough levels, mean area under the serum concentration-time curve (AUC), total AUC, mean AUC greater than MIC, total AUC greater than MIC, mean Schumacher's intensity factor (IF), total IF, In (mean maximum concentration [Cmax]/MIC).",3950060_3,-1,-1,2,18934,-1
18936,IF,80,81,409,411,"Variables evaluated included patient weight, age, sex, serum creatinine level, creatinine clearance, duration of therapy, total dose, mean daily dose, organism minimum inhibitory concentration (MIC), mean peak levels, mean trough levels, mean area under the serum concentration-time curve (AUC), total AUC, mean AUC greater than MIC, total AUC greater than MIC, mean Schumacher's intensity factor (IF), total IF, In (mean maximum concentration [Cmax]/MIC).",3950060_3,-1,-1,2,18936,-1
18939,pharmacokinetic,1,2,16,31,Model-dependent pharmacokinetic parameters were calculated by computer based on a one-compartment model.,3950060_4,-1,-1,2,18939,-1
18940,one-compartment model,10,12,82,103,Model-dependent pharmacokinetic parameters were calculated by computer based on a one-compartment model.,3950060_4,-1,-1,2,18940,-1
18942,function analysis,6,8,37,54,"In contrast, a stepwise discriminant function analysis identified only duration of therapy (P less than .001) as an important factor.",3950060_6,-1,-1,2,18942,-1
18943,duration of therapy,10,13,71,90,"In contrast, a stepwise discriminant function analysis identified only duration of therapy (P less than .001) as an important factor.",3950060_6,-1,-1,2,18943,-1
18944,Bayes' theorem,6,9,27,41,"Based on this model and on Bayes' theorem, the predictive accuracy of identifying ""nephrotoxic"" patients increased from 0.17 to 0.39.",3950060_7,-1,-1,2,18944,-1
18945,predictive accuracy,11,13,47,66,"Based on this model and on Bayes' theorem, the predictive accuracy of identifying ""nephrotoxic"" patients increased from 0.17 to 0.39.",3950060_7,-1,-1,2,18945,-1
18946,IF,5,6,33,35,"When examined individually, mean IF, MIC, total dose, mean daily dose, and ln (mean Cmax/MIC) correlated significantly (P less than .05) with cure.",3950060_8,-1,-1,2,18946,-1
18951,multivariable analysis,5,7,28,50,"In contrast, a simultaneous multivariable analysis identified IF, MIC, and total dose according to one model and ln (mean Cmax/MIC) according to a second statistical model of parameters selected to have the greatest prospective value.",3950060_9,-1,-1,2,18951,-1
18952,IF,8,9,62,64,"In contrast, a simultaneous multivariable analysis identified IF, MIC, and total dose according to one model and ln (mean Cmax/MIC) according to a second statistical model of parameters selected to have the greatest prospective value.",3950060_9,-1,-1,2,18952,-1
18954,total dose,13,15,75,85,"In contrast, a simultaneous multivariable analysis identified IF, MIC, and total dose according to one model and ln (mean Cmax/MIC) according to a second statistical model of parameters selected to have the greatest prospective value.",3950060_9,-1,-1,2,18954,-1
18956,statistical model,29,31,154,171,"In contrast, a simultaneous multivariable analysis identified IF, MIC, and total dose according to one model and ln (mean Cmax/MIC) according to a second statistical model of parameters selected to have the greatest prospective value.",3950060_9,-1,-1,2,18956,-1
18957,prospective value,38,40,216,233,"In contrast, a simultaneous multivariable analysis identified IF, MIC, and total dose according to one model and ln (mean Cmax/MIC) according to a second statistical model of parameters selected to have the greatest prospective value.",3950060_9,-1,-1,2,18957,-1
18958,Bayes',2,4,9,15,"Based on Bayes' theorem and the first model, the predictive accuracy of identifying patients not cured increased from 0.19 to 0.83.",3950060_10,-1,-1,2,18958,-1
18959,predictive accuracy,11,13,49,68,"Based on Bayes' theorem and the first model, the predictive accuracy of identifying patients not cured increased from 0.19 to 0.83.",3950060_10,-1,-1,2,18959,-1
18960,predictive accuracy,6,8,26,45,"For the second model, the predictive accuracy increased from 0.19 to 0.50.(ABSTRACT TRUNCATED AT 250 WORDS)",3950060_11,-1,-1,2,18960,-1
18979,adverse effects,3,5,28,43,Dose-related beneficial and adverse effects of dietary corticosterone on organophosphorus-induced delayed neuropathy in chickens.,3961813_0,-1,-1,2,18979,-1
18985,White Leghorn,26,28,136,149,"Tri-ortho-tolyl phosphate (TOTP), 360 mg/kg, po, and 0,0'-diisopropyl phosphorofluoridate (DFP), 1 mg/kg sc, were administered to adult White Leghorn chickens 24 hr after they were placed on diets containing 0 to 300 ppm corticosterone.",3961813_1,-1,-1,2,18985,-1
18999,distal levels,7,9,52,65,Degenerating myelinated fibers were also evident in distal levels of the peripheral nerves of chickens given TOTP or DFP.,3961813_6,-1,-1,2,18999,-1
19015,Promotional effects,0,2,0,19,Promotional effects of testosterone and dietary fat on prostate carcinogenesis in genetically susceptible rats.,3969369_0,-1,-1,2,19015,-1
19019,Germfree (GF),0,4,0,13,"Germfree (GF) Lobund strain Wistar (LW) rats, fed vegetable diet L-485, have developed prostate adenocarcinomas spontaneously (10% incidence) at average age 34 months.",3969369_1,-1,-1,2,19019,-1
19022,LW,1,2,13,15,"Conventional LW rats, implanted with testosterone at age 4 months, developed a higher incidence of prostate cancer after an average interval of 14 months: 24% had developed gross tumors, and 40% when it included microscopic tumors.",3969369_2,-1,-1,2,19022,-1
19024,average interval,21,23,124,140,"Conventional LW rats, implanted with testosterone at age 4 months, developed a higher incidence of prostate cancer after an average interval of 14 months: 24% had developed gross tumors, and 40% when it included microscopic tumors.",3969369_2,-1,-1,2,19024,-1
19025,testosterone-treated LW,4,6,34,57,"Preliminary results indicate that testosterone-treated LW rats that were fed the same diet, which was supplemented with corn oil up to 20% fat, developed prostate cancer after intervals of 6-12 months.",3969369_3,-1,-1,2,19025,-1
19031,Experimental designs,0,2,0,20,Experimental designs should consider genetic susceptibility as a basic prerequisite for studies on experimental prostate cancer.,3969369_6,-1,-1,2,19031,-1
19043,maximal effects,9,11,45,60,"Since it takes three to 12 months to achieve maximal effects, those patients who are unable to continue the drug receive little benefit from it.",3970039_5,-1,-1,2,19043,-1
19044,treated with,1,3,9,21,"Patients treated with alkylating agents have an increased risk of development of acute nonlymphocytic leukemia, and both alkylating agents and azathioprine are associated with the development of non-Hodgkin's lymphoma.",3970039_6,-1,-1,2,19044,-1
19048,associated with,23,25,160,175,"Patients treated with alkylating agents have an increased risk of development of acute nonlymphocytic leukemia, and both alkylating agents and azathioprine are associated with the development of non-Hodgkin's lymphoma.",3970039_6,-1,-1,2,19048,-1
19052,treated with,11,13,80,92,There have been several long-term studies of patients with rheumatoid arthritis treated with azathioprine and cyclophosphamide and the incidence of most of the common cancers is not increased.,3970039_8,-1,-1,2,19052,-1
19060,QTC interval,4,6,27,39,"Time course alterations of QTC interval due to hypaque 76.Sequential measurement of QT interval during left ventricular angiography was made 30 seconds and one, three, five and ten minutes after injection of hypaque 76.",3973521_0,-1,-1,2,19060,-1
19062,QT interval,12,14,84,95,"Time course alterations of QTC interval due to hypaque 76.Sequential measurement of QT interval during left ventricular angiography was made 30 seconds and one, three, five and ten minutes after injection of hypaque 76.",3973521_0,-1,-1,2,19062,-1
19101,treated with,3,5,19,31,"An elderly patient treated with low dose Desipramine developed a delirium while her plasma level was in the ""subtherapeutic"" range.",4027862_1,-1,-1,2,19101,-1
19108,population studies,11,13,81,99,Therapeutic ranges for antidepressants that have been derived from general adult population studies may not be appropriate for the elderly.,4027862_3,-1,-1,2,19108,-1
19122,muscle fibers,9,11,63,76,Muscle degeneration is followed by regeneration of the damaged muscle fibers.,4038130_5,-1,-1,2,19122,-1
19125,exposure to,17,19,96,107,"In addition to muscle damage, severe damage was also seen in harderian glands, especially after exposure to mepivacaine and lidocaine plus epinephrine.",4038130_6,-1,-1,2,19125,-1
19134,Schiff (PAS) positive,3,8,23,44,"Numerous periodic acid Schiff (PAS) positive, diastase resistant cytoplasmic inclusion bodies which appeared as myelin figures in cytosegresomes under the electron microscope were identified in the proximal convoluted tubules.",4069770_3,-1,-1,2,19134,-1
19135,diastase resistant,9,11,46,64,"Numerous periodic acid Schiff (PAS) positive, diastase resistant cytoplasmic inclusion bodies which appeared as myelin figures in cytosegresomes under the electron microscope were identified in the proximal convoluted tubules.",4069770_3,-1,-1,2,19135,-1
19136,inclusion bodies,12,14,77,93,"Numerous periodic acid Schiff (PAS) positive, diastase resistant cytoplasmic inclusion bodies which appeared as myelin figures in cytosegresomes under the electron microscope were identified in the proximal convoluted tubules.",4069770_3,-1,-1,2,19136,-1
19137,myelin figures,17,19,112,126,"Numerous periodic acid Schiff (PAS) positive, diastase resistant cytoplasmic inclusion bodies which appeared as myelin figures in cytosegresomes under the electron microscope were identified in the proximal convoluted tubules.",4069770_3,-1,-1,2,19137,-1
19139,electron microscope,23,25,155,174,"Numerous periodic acid Schiff (PAS) positive, diastase resistant cytoplasmic inclusion bodies which appeared as myelin figures in cytosegresomes under the electron microscope were identified in the proximal convoluted tubules.",4069770_3,-1,-1,2,19139,-1
19141,rechallenge,6,7,56,67,Indomethacin-induced renal insufficiency: recurrence on rechallenge.,4071154_0,-1,-1,2,19141,-1
19151,plasma volume,21,23,138,151,Our case supports the hypothesis that endogenous renal prostaglandins play a role in the maintenance of renal blood flow when circulating plasma volume is diminished.,4071154_3,-1,-1,2,19151,-1
19153,interfere with,4,6,44,58,"Since nonsteroidal anti-inflammatory agents interfere with this compensatory mechanism and may cause acute renal failure, they should be used with caution in such patients.",4071154_4,-1,-1,2,19153,-1
19161,statistically significant,22,24,97,122,"At the 1.0% dosage level, 20% of rats of both sexes developed neoplastic nodules of the liver, a statistically significant incidence.",4090988_3,-1,-1,2,19161,-1
19168,paracetamol-treated rats,7,9,27,51,"Additionally, 20 to 25% of paracetamol-treated rats developed hyperplasia of the bladder epithelium, which was not coincident with the presence of bladder calculi.",4090988_7,-1,-1,2,19168,-1
19172,paracetamol-treated rats,8,10,46,70,An electron microscope study of the livers of paracetamol-treated rats revealed ultrastructural changes in the hepatocytes that resemble those that result from exposure to a variety of known hepatocarcinogens.,4090988_9,-1,-1,2,19172,-1
19175,hepatocarcinogens,28,29,191,208,An electron microscope study of the livers of paracetamol-treated rats revealed ultrastructural changes in the hepatocytes that resemble those that result from exposure to a variety of known hepatocarcinogens.,4090988_9,-1,-1,2,19175,-1
19194,episode of,20,22,130,140,The remaining patient in the series developed fulminant hepatitis when the drug was accidentally recommenced 1 year after a prior episode of methyldopa-induced hepatitis.,424937_8,-1,-1,2,19194,-1
19210,dose-response study,1,3,2,21,A dose-response study.,435349_1,-1,-1,2,19210,-1
19213,s-1,19,20,91,94,Suxamethonium chloride (Sch) was administered i.v. to 36 adult males at six rates: 0.25 mg s-1 to 20 mg s-1.,435349_2,-1,-1,2,19213,-1
19214,s-1,23,24,104,107,Suxamethonium chloride (Sch) was administered i.v. to 36 adult males at six rates: 0.25 mg s-1 to 20 mg s-1.,435349_2,-1,-1,2,19214,-1
19221,tetanus suppression,9,11,57,76,"The times to first fasciculation, twitch suppression and tetanus suppression were inversely related to the infusion rates.",435349_7,-1,-1,2,19221,-1
19240,overstimulation,13,14,89,104,These results fail to support the notion that levodopa-induced dyskinesias are caused by overstimulation of a separate group of dopamine receptors.,458486_4,-1,-1,2,19240,-1
19244,regular intervals,6,8,39,56,Liver biopsies should be undertaken at regular intervals if azathioprine therapy is continued so that structural liver damage may be detected at an early and reversible stage.,4812392_4,-1,-1,2,19244,-1
19246,reversible stage,25,27,158,174,Liver biopsies should be undertaken at regular intervals if azathioprine therapy is continued so that structural liver damage may be detected at an early and reversible stage.,4812392_4,-1,-1,2,19246,-1
19247,associated with,5,7,42,57,"Long-term administration of quinidine was associated with persistent elevation of serum concentrations of SGOT, lactic acid dehydrogenase, and alkaline phosphatase.",48362_1,-1,-1,2,19247,-1
19263,associated with,4,6,26,41,Angiosarcoma of the liver associated with diethylstilbestrol.,567256_0,-1,-1,2,19263,-1
19264,well-differentiated adenocarcinoma of,15,18,83,120,Angiosarcoma of the liver occurred in a 76-year-old man who had been treated for a well-differentiated adenocarcinoma of the liver with diethylstilbestrol for 13 years.,567256_1,-1,-1,2,19264,-1
19269,associated with,11,13,88,103,Arterial thromboembolism in patients receiving systemic heparin therapy: a complication associated with heparin-induced thrombocytopenia.,591536_0,-1,-1,2,19269,-1
19273,platelet-fibrin thrombi,8,10,54,77,"Characteristic of the entity is arterial occlusion by platelet-fibrin thrombi with distal ischemia occurring four to twenty days after the initiation of heparin therapy, preceded by profound thrombocytopenia with platelet counts in the range of 30,000 to 40,000 per cubic millimeter.",591536_2,-1,-1,2,19273,-1
19276,platelet counts,30,32,213,228,"Characteristic of the entity is arterial occlusion by platelet-fibrin thrombi with distal ischemia occurring four to twenty days after the initiation of heparin therapy, preceded by profound thrombocytopenia with platelet counts in the range of 30,000 to 40,000 per cubic millimeter.",591536_2,-1,-1,2,19276,-1
19291,subjective effects,3,5,18,36,Comparison of the subjective effects and plasma concentrations following oral and i.m.,6103707_0,-1,-1,2,19291,-1
19294,gas-liquid chromatography,8,10,52,77,"Plasma concentrations of the drug were estimated by gas-liquid chromatography, in a smaller number of the subjects.",6103707_4,-1,-1,2,19294,-1
19296,effects of,1,3,4,14,The effects of i.m. administration were apparent earlier and sometimes lasted longer than those following oral administration.,6103707_6,-1,-1,2,19296,-1
19298,oral administration,16,18,106,125,The effects of i.m. administration were apparent earlier and sometimes lasted longer than those following oral administration.,6103707_6,-1,-1,2,19298,-1
19302,GYKI-41 099,2,4,16,27,"Pharmacology of GYKI-41 099 (chlorpropanol, Tobanum) a new potent beta-adrenergic antagonist.",6111982_0,-1,-1,2,19302,-1
19309,in vitro,19,21,101,109,"The compound GYKI-41 099, as a beta-adrenergic antagonist, is 3-8 times more potent than propranolol in vitro and in vivo.",6111982_1,-1,-1,2,19309,-1
19310,in vivo,22,24,114,121,"The compound GYKI-41 099, as a beta-adrenergic antagonist, is 3-8 times more potent than propranolol in vitro and in vivo.",6111982_1,-1,-1,2,19310,-1
19316,cardioselective,11,12,66,81,GYKI-41 900 has a negligible cardiodepressant activity; it is not cardioselective.,6111982_3,-1,-1,2,19316,-1
19317,long lasting effect,6,9,31,50,The compound shows a rapid and long lasting effect.,6111982_4,-1,-1,2,19317,-1
19323,Medical Research Council Working Party,2,7,10,48,Report of Medical Research Council Working Party on Mild to Moderate Hypertension.,6115999_1,-1,-1,2,19323,-1
19324,Medical Research Council treatment trial,3,8,20,60,"Participants in the Medical Research Council treatment trial for mild hypertension are randomly allocated to one of four treatment groups: bendrofluazide, propranolol, or a placebo for either of these drugs.",6115999_2,-1,-1,2,19324,-1
19341,serum potassium level,1,4,5,26,"Mean serum potassium level fell, and urea and uric acid levels rose, in men and women taking bendrofluazide.",6115999_8,-1,-1,2,19341,-1
19345,serum potassium,5,7,26,41,"In the propranolol group, serum potassium and uric acid levels rose in both sexes, but the urea level rose significantly in women only.",6115999_9,-1,-1,2,19345,-1
19360,dose-dependent,15,16,71,85,"In doses of 3-10 mg/kg, the serotonin receptor agonist MK-212 caused a dose-dependent blockade of the response of muscimol.",6118280_5,-1,-1,2,19360,-1
19367,animal model,29,31,188,200,"Considering the fact that 5-HTP and the benzodiazepines have been found to be beneficial in the management of clinical myoclonus, the muscimol-induced myoclonus seems to be a satisfactory animal model that may prove useful for the development of new drug treatments for this condition.",6118280_8,-1,-1,2,19367,-1
19368,drug treatments,40,42,250,265,"Considering the fact that 5-HTP and the benzodiazepines have been found to be beneficial in the management of clinical myoclonus, the muscimol-induced myoclonus seems to be a satisfactory animal model that may prove useful for the development of new drug treatments for this condition.",6118280_8,-1,-1,2,19368,-1
19373,verapamil--report,7,10,63,80,Adverse interaction between beta-adrenergic blocking drugs and verapamil--report of three cases.,6127992_0,-1,-1,2,19373,-1
19376,combined therapy,15,17,115,131,"Three patients with ischaemic heart disease developed profound cardiac failure, hypotension and bradycardia during combined therapy with verapamil and beta-adrenergic blocking drugs.",6127992_1,-1,-1,2,19376,-1
19386,teratogenicity,1,2,9,23,Possible teratogenicity of sulphasalazine.,6133211_0,-1,-1,2,19386,-1
19397,Potter-type IIa,10,12,37,52,"The first twin, a female, had a left Potter-type IIa polycystic kidney and a rudimentary left uterine cornu.",6133211_4,-1,-1,2,19397,-1
19408,short-,19,20,142,148,The H2-histamine receptor antagonists ranitidine and cimetidine were compared for their abilities to control gastric acid hypersecretion on a short- and long-term basis in 22 patients with gastric acid hypersecretory states.,6150641_1,-1,-1,2,19408,-1
19413,onset of,3,5,13,21,The rates of onset of the action of cimetidine and ranitidine were the same.,6150641_3,-1,-1,2,19413,-1
19416,acute inhibition studies,11,14,70,94,"However, ranitidine was threefold more potent than cimetidine both in acute inhibition studies and in the median maintenance dose needed (1.2 g per day for ranitidine and 3.6 g per day for cimetidine).",6150641_5,-1,-1,2,19416,-1
19419,associated with,32,34,138,153,"Treatment with high doses of cimetidine (one to 60 months; median, 11 months) or ranitidine (two to 31 months; median, 14 months) was not associated with hepatic or hematologic toxicity or alterations of serum gastrin concentrations, but ranitidine therapy was associated with a significantly lower serum creatinine level than seen with cimetidine therapy.",6150641_7,-1,-1,2,19419,-1
19421,associated with,49,51,261,276,"Treatment with high doses of cimetidine (one to 60 months; median, 11 months) or ranitidine (two to 31 months; median, 14 months) was not associated with hepatic or hematologic toxicity or alterations of serum gastrin concentrations, but ranitidine therapy was associated with a significantly lower serum creatinine level than seen with cimetidine therapy.",6150641_7,-1,-1,2,19421,-1
19422,serum creatinine,54,56,299,315,"Treatment with high doses of cimetidine (one to 60 months; median, 11 months) or ranitidine (two to 31 months; median, 14 months) was not associated with hepatic or hematologic toxicity or alterations of serum gastrin concentrations, but ranitidine therapy was associated with a significantly lower serum creatinine level than seen with cimetidine therapy.",6150641_7,-1,-1,2,19422,-1
19428,exposure to,8,10,45,56,Three cases of EEG changes induced by single exposure to enflurane anesthesia are reported.,6153967_1,-1,-1,2,19428,-1
19442,associated with,5,7,45,60,Thrombotic microangiopathy and renal failure associated with antineoplastic chemotherapy.,6203452_0,-1,-1,2,19442,-1
19465,Wistar rats,10,12,67,78,The development of cardiac hypertrophy was studied in adult female Wistar rats following daily subcutaneous injections of isoproterenol (ISO) (0.3 mg/kg body weight).,6203632_1,-1,-1,2,19465,-1
19471,Ventricular RNA,0,2,0,15,Ventricular RNA content was elevated 26% after 24 h of a single injection and reached a maximal level following 8 days of therapy.,6203632_4,-1,-1,2,19471,-1
19472,half time,1,3,4,13,The half time for RNA accumulation was 2.0 days.,6203632_5,-1,-1,2,19472,-1
19473,early stage,7,9,49,60,Ventricular DNA content was unchanged during the early stage (1-4 days) of hypertrophic growth but increased to a new steady-state level 19% above the controls after 8 days of treatment.,6203632_7,-1,-1,2,19473,-1
19476,steady-state,23,24,118,130,Ventricular DNA content was unchanged during the early stage (1-4 days) of hypertrophic growth but increased to a new steady-state level 19% above the controls after 8 days of treatment.,6203632_7,-1,-1,2,19476,-1
19479,experimental animals,11,13,83,103,Intraventricular pressures and coronary flow measures were similar for control and experimental animals following 4 days of developed hypertrophy.,6203632_8,-1,-1,2,19479,-1
19480,dP/dt,2,3,9,14,"However, dP/dt in the ISO-treated hearts was slightly but significantly (P less than 0.05) elevated.",6203632_9,-1,-1,2,19480,-1
19481,ISO-treated,5,6,22,33,"However, dP/dt in the ISO-treated hearts was slightly but significantly (P less than 0.05) elevated.",6203632_9,-1,-1,2,19481,-1
19482,adaptive response,5,7,29,46,These data indicate that the adaptive response to ISO shows an early hypertrophic phase (1-4 days) characterized by a substantial increase in RNA content and cardiac mass in the absence of changes in DNA.,6203632_10,-1,-1,2,19482,-1
19484,early hypertrophic phase (1,11,16,63,90,These data indicate that the adaptive response to ISO shows an early hypertrophic phase (1-4 days) characterized by a substantial increase in RNA content and cardiac mass in the absence of changes in DNA.,6203632_10,-1,-1,2,19484,-1
19488,antiarrhythmic coronary trial,4,7,37,66,International mexiletine and placebo antiarrhythmic coronary trial: I. Report on arrhythmia and other findings.,6209318_0,-1,-1,2,19488,-1
19489,I. Report,8,10,68,77,International mexiletine and placebo antiarrhythmic coronary trial: I. Report on arrhythmia and other findings.,6209318_0,-1,-1,2,19489,-1
19490,Research Group,1,3,7,21,Impact Research Group.,6209318_1,-1,-1,2,19490,-1
19493,double-blind placebo trial,17,20,112,138,The antiarrhythmic effects of the sustained release form of mexiletine (Mexitil-Perlongets) were evaluated in a double-blind placebo trial in 630 patients with recent documented myocardial infarction.,6209318_2,-1,-1,2,19493,-1
19495,primary response variable,1,4,4,29,The primary response variable was based on central reading of 24 hour ambulatory electrocardiographic recordings and was defined as the occurrence of 30 or more single premature ventricular complexes in any two consecutive 30 minute blocks or one or more runs of two or more premature ventricular complexes in the entire 24 hour electrocardiographic recording.,6209318_3,-1,-1,2,19495,-1
19502,statistically significant,5,7,31,56,"Large differences, regarded as statistically significant, between the mexiletine and placebo groups were noted in that end point at months 1 and 4, but only trends were observed at month 12.",6209318_4,-1,-1,2,19502,-1
19505,statistically significant,26,28,111,136,There were more deaths in the mexiletine group (7.6%) than in the placebo group (4.8%); the difference was not statistically significant.,6209318_6,-1,-1,2,19505,-1
19520,treated with,30,32,185,197,"The skin lesion resembled elastosis perforans serpiginosa, which has been reported as a rare side effect in patients with Wilson's disease but not in patients with rheumatoid arthritis treated with penicillamine.",6216862_3,-1,-1,2,19520,-1
19525,double-blind study,18,20,112,130,"The effect of long-term timolol treatment on heart size after myocardial infarction was evaluated by X-ray in a double-blind study including 241 patients (placebo 126, timolol 115).",6229975_1,-1,-1,2,19525,-1
19526,timolol-treated patients,1,3,4,28,The timolol-treated patients showed a small but significant increase in heart size from baseline in contrast to a decrease in the placebo group.,6229975_3,-1,-1,2,19526,-1
19531,timolol-related,1,2,4,19,The timolol-related increase in heart size was observed only in patients with normal and borderline heart size.,6229975_5,-1,-1,2,19531,-1
19541,patients',10,12,62,71,The powders had been obtained from pharmacists unknown to the patients' medical practitioners.,625456_2,-1,-1,2,19541,-1
19542,medical practitioners,12,14,72,93,The powders had been obtained from pharmacists unknown to the patients' medical practitioners.,625456_2,-1,-1,2,19542,-1
19550,associated with,18,20,77,92,"Large parenteral doses of vitamin D3 (15 to 17.5 x 10(6) IU vitamin D3) were associated with prolonged hypercalcemia, hyperphosphatemia, and large increases of vitamin D3 and its metabolites in the blood plasma of nonlactating nonpregnant and pregnant Jersey cows.",6286738_1,-1,-1,2,19550,-1
19553,blood plasma,36,38,198,210,"Large parenteral doses of vitamin D3 (15 to 17.5 x 10(6) IU vitamin D3) were associated with prolonged hypercalcemia, hyperphosphatemia, and large increases of vitamin D3 and its metabolites in the blood plasma of nonlactating nonpregnant and pregnant Jersey cows.",6286738_1,-1,-1,2,19553,-1
19557,treated with,9,11,60,72,Calcium concentrations 1 day postpartum were higher in cows treated with vitamin D3 about 32 days prepartum (8.8 mg/100 ml) than in control cows (5.5 mg/100 ml).,6286738_2,-1,-1,2,19557,-1
19559,control cows,24,26,132,144,Calcium concentrations 1 day postpartum were higher in cows treated with vitamin D3 about 32 days prepartum (8.8 mg/100 ml) than in control cows (5.5 mg/100 ml).,6286738_2,-1,-1,2,19559,-1
19560,treated with,4,6,17,29,"None of the cows treated with vitamin D3 showed signs of milk fever during the peripartal period; however, 22% of the control cows developed clinical signs of milk fever during this period.",6286738_3,-1,-1,2,19560,-1
19564,control cows,24,26,118,130,"None of the cows treated with vitamin D3 showed signs of milk fever during the peripartal period; however, 22% of the control cows developed clinical signs of milk fever during this period.",6286738_3,-1,-1,2,19564,-1
19567,nonlactating,9,10,50,62,"Signs of vitamin D3 toxicity were not observed in nonlactating nonpregnant cows; however, pregnant cows commonly developed severe signs of vitamin D3 toxicity and 10 of 17 cows died.",6286738_4,-1,-1,2,19567,-1
19572,pregnant Jersey cows,9,12,49,69,"Because of the extreme toxicity of vitamin D3 in pregnant Jersey cows and the low margin of safety between doses of vitamin D3 that prevent milk fever and doses that induce milk fever, we concluded that vitamin D3 cannot be used practically to prevent milk fever when injected several weeks prepartum.",6286738_6,-1,-1,2,19572,-1
19573,low margin,14,16,78,88,"Because of the extreme toxicity of vitamin D3 in pregnant Jersey cows and the low margin of safety between doses of vitamin D3 that prevent milk fever and doses that induce milk fever, we concluded that vitamin D3 cannot be used practically to prevent milk fever when injected several weeks prepartum.",6286738_6,-1,-1,2,19573,-1
19579,prepartum,52,53,291,300,"Because of the extreme toxicity of vitamin D3 in pregnant Jersey cows and the low margin of safety between doses of vitamin D3 that prevent milk fever and doses that induce milk fever, we concluded that vitamin D3 cannot be used practically to prevent milk fever when injected several weeks prepartum.",6286738_6,-1,-1,2,19579,-1
19606,radiation fields,10,12,53,69,The cardiomyopathy is attributed 1) to the fact that radiation fields for left Wilms tumor include the lower portion of the heart and 2) to the interaction of doxorubicin and irradiation on cardiac muscle.,6292680_2,-1,-1,2,19606,-1
19610,sharply restricted,7,9,45,63,It is recommended that doxorubicin dosage be sharply restricted in children with Wilms tumor of the left kidney who receive postoperative irradiation.,6292680_3,-1,-1,2,19610,-1
19615,effects of,1,3,4,14,The effects of i.v.c.,6293644_1,-1,-1,2,19615,-1
19616,i.v.c,3,4,15,20,The effects of i.v.c.,6293644_1,-1,-1,2,19616,-1
19619,partial prevention,11,13,87,105,Calcitonin injection resulted in a potentiation of haloperidol-induced catalepsy and a partial prevention of apomorphine-induced hyperactivity.,6293644_3,-1,-1,2,19619,-1
19622,GAD activity,8,10,61,73,Moreover calcitonin induced a significant decrease in nigral GAD activity but no change in striatal DA and DOPAC concentration or GAD activity.,6293644_4,-1,-1,2,19622,-1
19623,striatal DA,14,16,91,102,Moreover calcitonin induced a significant decrease in nigral GAD activity but no change in striatal DA and DOPAC concentration or GAD activity.,6293644_4,-1,-1,2,19623,-1
19626,primary action,8,10,39,53,The results are discussed in view of a primary action of calcitonin on the striatonigral GABAergic pathway mediating the DA-related behavioral messages of striatal origin.,6293644_5,-1,-1,2,19626,-1
19629,DA-related,19,20,121,131,The results are discussed in view of a primary action of calcitonin on the striatonigral GABAergic pathway mediating the DA-related behavioral messages of striatal origin.,6293644_5,-1,-1,2,19629,-1
19635,pretreatment,9,10,39,51,Studies in DBA/2J mice showed that: 1) pretreatment with acetaminophen (100 mg/kg) increased the interval between the administration of caffeine (300 to 450 mg/kg IP) and the onset of fatal convulsions by a factor of about two; and 2) pretreatment with acetaminophen (75 mg/kg) reduced the incidence of audiogenic seizures produced in the presence of caffeine (12.5 to 75 mg/kg IP).,6308277_3,-1,-1,2,19635,-1
19636,pretreatment,47,48,235,247,Studies in DBA/2J mice showed that: 1) pretreatment with acetaminophen (100 mg/kg) increased the interval between the administration of caffeine (300 to 450 mg/kg IP) and the onset of fatal convulsions by a factor of about two; and 2) pretreatment with acetaminophen (75 mg/kg) reduced the incidence of audiogenic seizures produced in the presence of caffeine (12.5 to 75 mg/kg IP).,6308277_3,-1,-1,2,19636,-1
19645,pretreatment,1,2,11,23,"Naloxazone pretreatment modifies cardiorespiratory, temperature, and behavioral effects of morphine.",6308526_0,-1,-1,2,19645,-1
19646,behavioral effects,8,10,69,87,"Naloxazone pretreatment modifies cardiorespiratory, temperature, and behavioral effects of morphine.",6308526_0,-1,-1,2,19646,-1
19647,cardiorespiratory responses,2,4,15,42,"Behavioral and cardiorespiratory responses to a lethal dose of morphine were evaluated in rats pretreated with saline or naloxazone, an antagonist of high-affinity mu 1 opioid receptors.",6308526_1,-1,-1,2,19647,-1
19655,brain membranes,20,22,160,175,"Pretreatment with naloxazone significantly blocked morphine analgesia, catalepsy and hypothermia at a dose which completely eliminated high-affinity binding in brain membranes.",6308526_2,-1,-1,2,19655,-1
19661,cardiorespiratory responses,12,14,90,117,Results indicate that subpopulations of mu receptors may mediate selective behavioral and cardiorespiratory responses to morphine.,6308526_4,-1,-1,2,19661,-1
19667,morphine-treated mice,17,19,91,112,"Pretreatment with ammonium acetate (NH4Ac) (6 mmol/kg s.c.) approximately doubled the time morphine-treated mice remained on a hot surface and similarly increased muscular incoordination by diazepam, but NH4Ac treatment alone had no effect.",6323692_1,-1,-1,2,19667,-1
19670,no effect,37,39,230,239,"Pretreatment with ammonium acetate (NH4Ac) (6 mmol/kg s.c.) approximately doubled the time morphine-treated mice remained on a hot surface and similarly increased muscular incoordination by diazepam, but NH4Ac treatment alone had no effect.",6323692_1,-1,-1,2,19670,-1
19672,altering drug action,6,9,35,55,"Thus, hyperammonemia is capable of altering drug action and must be considered along with impaired drug metabolism in enhanced drug responses associated with liver disease.",6323692_2,-1,-1,2,19672,-1
19674,drug responses,20,22,127,141,"Thus, hyperammonemia is capable of altering drug action and must be considered along with impaired drug metabolism in enhanced drug responses associated with liver disease.",6323692_2,-1,-1,2,19674,-1
19675,associated with,22,24,142,157,"Thus, hyperammonemia is capable of altering drug action and must be considered along with impaired drug metabolism in enhanced drug responses associated with liver disease.",6323692_2,-1,-1,2,19675,-1
19677,in vitro,1,3,12,20,Experiments in vitro showed that acetylcholine-induced catecholamine release from bovine adrenal medulla is depressed as much as 50% by 0.3 mM NH4Ac and KCl-induced contractions of guinea-pig ileum were inhibited 20% by 5 mM NH4Ac.,6323692_3,-1,-1,2,19677,-1
19683,calcium-independent,12,13,72,91,"Addition of excess calcium reversed the depression in both tissues, but calcium-independent catecholamine release by acetaldehyde was not blocked by NH4Ac.",6323692_4,-1,-1,2,19683,-1
19686,ammonia blocks,4,6,29,43,These results suggested that ammonia blocks calcium channels.,6323692_5,-1,-1,2,19686,-1
19709,double-blind study,1,3,2,20,A double-blind study of the efficacy and safety of dothiepin hydrochloride in the treatment of major depressive disorder.,6386793_0,-1,-1,2,19709,-1
19713,parallel treatment study,4,7,25,49,"In a 6-week double-blind parallel treatment study, dothiepin and amitriptyline were compared to placebo in the treatment of 33 depressed outpatients.",6386793_1,-1,-1,2,19713,-1
19723,cardiovascular effects,6,8,38,60,Dothiepin also produced fewer CNS and cardiovascular effects.,6386793_4,-1,-1,2,19723,-1
19724,laboratory parameters,7,9,46,67,There were no clinically important changes in laboratory parameters.,6386793_5,-1,-1,2,19724,-1
19739,crossover design,61,63,317,333,"The effects of oral doses of diazepam (single dose of 10 mg and a median dose of 30 mg/day for 2 weeks) and propranolol (single dose of 80 mg and a median dose of 240 mg/day for 2 weeks) on psychological performance of patients with panic disorders and agoraphobia were investigated in a double-blind, randomized and crossover design.",6387529_1,-1,-1,2,19739,-1
19764,4-week cycle,59,61,331,343,The protective effect of oral administration of the thiol compound sodium 2-mercaptoethane sulphonate (MESNA) against urothelial toxicity induced by ifosfamide (IF) was tested in a group of 45 patients with inoperable lung cancer under treatment with IF (2250 mg/m2 on days 2-5) as part of a polychemotherapy regimen repeated in a 4-week cycle.,6402369_1,-1,-1,2,19764,-1
19786,IF,18,19,117,119,"Our results support the view that MESNA, given orally in conjunction with combined cytostatic regimens which include IF, simplifies the treatment and provides optimum protection for the urinary epithelium.",6402369_8,-1,-1,2,19786,-1
19792,treated with,9,11,35,47,"Five children, aged 3 to 11 years, treated with carbamazepine for epilepsy, had an acute aberrant reaction characterized by the onset of myoclonic, atypical absence and/or atonic (minor motor) seizures within a few days.",6415512_1,-1,-1,2,19792,-1
19818,mechanism(s),9,11,51,63,"These results suggest that PGs are involved in the mechanism(s) underlying fluorthyl- and PTZ-induced convulsions, but not picrotoxin-, electroshock-, or bicuculline-induced convulsions.",6433367_3,-1,-1,2,19818,-1
19819,blood ammonia,3,5,17,30,Acute changes of blood ammonia may predict short-term adverse effects of valproic acid.,6436733_0,-1,-1,2,19819,-1
19820,adverse effects,8,10,54,69,Acute changes of blood ammonia may predict short-term adverse effects of valproic acid.,6436733_0,-1,-1,2,19820,-1
19825,treated with,15,17,78,90,Valproic acid (VPA) was given to 24 epileptic patients who were already being treated with other antiepileptic drugs.,6436733_1,-1,-1,2,19825,-1
19831,continuous therapy,11,13,49,67,"Ammonia (NH3) was higher in patients who, during continuous therapy, complained of drowsiness (7 patients) than in those who were symptom-free (17 patients), although VPA plasma levels were similar in both groups.",6436733_3,-1,-1,2,19831,-1
19835,higher risk,17,19,98,109,"By measuring VPA-induced changes of blood NH3 content, it may be possible to identify patients at higher risk of obtundation when VPA is given chronically.",6436733_4,-1,-1,2,19835,-1
19838,aminonucleoside-induced proteinuria,6,8,40,75,Effect of captopril on pre-existing and aminonucleoside-induced proteinuria in spontaneously hypertensive rats.,6454943_0,-1,-1,2,19838,-1
19841,SHR,13,14,89,92,The possibility of reproducing the same renal abnormality with captopril was examined in SHR.,6454943_2,-1,-1,2,19841,-1
19842,Oral administration,0,2,0,19,Oral administration of captopril at 100 mg/kg for 14 days failed to aggravate proteinuria pre-existing in SHR.,6454943_3,-1,-1,2,19842,-1
19844,SHR,16,17,106,109,Oral administration of captopril at 100 mg/kg for 14 days failed to aggravate proteinuria pre-existing in SHR.,6454943_3,-1,-1,2,19844,-1
19847,SHR,18,19,136,139,"Also, captopril treatment failed to potentiate or facilitate development of massive proteinuria invoked by puromycin aminonucleoside in SHR.",6454943_4,-1,-1,2,19847,-1
19852,SHR,19,20,130,133,"However, ketone bodies were consistently present in urine and several lethalities occurred during multiple dosing of captopril in SHR.",6454943_6,-1,-1,2,19852,-1
19857,kg-1,17,18,113,117,The effectiveness of administration of glycopyrrolate 5 and 10 micrograms kg-1 and atropine 10 and 20 micrograms kg-1 i.v.,6466532_2,-1,-1,2,19857,-1
19859,control group,1,3,2,15,A control group was included for comparison with the lower dose range of glycopyrrolate and atropine.,6466532_4,-1,-1,2,19859,-1
19861,control group,11,13,51,64,"A frequency of bradycardia of 50% was noted in the control group, but this was not significantly different from the frequency with the active drugs.",6466532_5,-1,-1,2,19861,-1
19867,kg-1,8,9,59,63,"It is recommended that either glycopyrrolate 10 micrograms kg-1 or atropine 20 micrograms kg-1 i.v. should immediately precede induction of anaesthesia, in children, if the repeated administration of suxamethonium is anticipated.",6466532_7,-1,-1,2,19867,-1
19868,kg-1,13,14,90,94,"It is recommended that either glycopyrrolate 10 micrograms kg-1 or atropine 20 micrograms kg-1 i.v. should immediately precede induction of anaesthesia, in children, if the repeated administration of suxamethonium is anticipated.",6466532_7,-1,-1,2,19868,-1
19881,Small-,0,1,0,6,Small- and medium-sized hepatic veins were blocked by thrombosis.,6503301_4,-1,-1,2,19881,-1
19884,pertinent features,8,10,53,71,Published cases from the literature are reviewed and pertinent features discussed.,6503301_6,-1,-1,2,19884,-1
19898,exposed to,5,7,56,66,"Cross-sectional echocardiographic screening of newborns exposed to lithium during gestation can provide highly accurate, noninvasive assessment of the presence or absence of lithium-induced cardiac malformations.",6518066_4,-1,-1,2,19898,-1
19899,noninvasive assessment,15,17,121,143,"Cross-sectional echocardiographic screening of newborns exposed to lithium during gestation can provide highly accurate, noninvasive assessment of the presence or absence of lithium-induced cardiac malformations.",6518066_4,-1,-1,2,19899,-1
19904,effects of,1,3,4,14,"The effects of exercise on the severity of isoproterenol-induced myocardial infarction were studied in female albino rats of 20,40,60 and 80 weeks of age.",6534871_1,-1,-1,2,19904,-1
19907,histological methods,7,9,45,65,The occurrence of infarcts were confirmed by histological methods.,6534871_3,-1,-1,2,19907,-1
19910,exercise-controls,16,17,100,117,Elevations in the serum GOT and GPT were maximum in the sedentary-isoproterenols and minimum in the exercise-controls.,6534871_4,-1,-1,2,19910,-1
19911,associated with,7,9,46,61,These changes in the serum transaminases were associated with corresponding depletions in the cardiac GOT and GPT.,6534871_5,-1,-1,2,19911,-1
19912,cardiac GOT,13,15,94,105,These changes in the serum transaminases were associated with corresponding depletions in the cardiac GOT and GPT.,6534871_5,-1,-1,2,19912,-1
19913,GPT,16,17,110,113,These changes in the serum transaminases were associated with corresponding depletions in the cardiac GOT and GPT.,6534871_5,-1,-1,2,19913,-1
19914,interfere with,6,8,25,39,"However, age was seen to interfere with the responses exhibited by the young and old rats.",6534871_6,-1,-1,2,19914,-1
19925,chronic low-dose-ADR-associated lethality,8,11,56,97,PEG 400 impressively decreased both acute high-dose and chronic low-dose-ADR-associated lethality.,6538499_2,-1,-1,2,19925,-1
19937,pinealectomized chick,2,4,7,28,"In the pinealectomized chick, pretreatment with dopamine increased the duration of catatonia (DOC) after ketamine, but pretreatment with norepinephrine did not.",6540303_2,-1,-1,2,19937,-1
19938,pretreatment,5,6,30,42,"In the pinealectomized chick, pretreatment with dopamine increased the duration of catatonia (DOC) after ketamine, but pretreatment with norepinephrine did not.",6540303_2,-1,-1,2,19938,-1
19939,pretreatment,20,21,119,131,"In the pinealectomized chick, pretreatment with dopamine increased the duration of catatonia (DOC) after ketamine, but pretreatment with norepinephrine did not.",6540303_2,-1,-1,2,19939,-1
19944,blood-brain barrier,22,24,124,143,This study did not demonstrate a species difference regarding the role of the amines on the pineal in spite of the immature blood-brain barrier in the young chick and the intact barrier in the rat.,6540303_6,-1,-1,2,19944,-1
19945,young chick,26,28,151,162,This study did not demonstrate a species difference regarding the role of the amines on the pineal in spite of the immature blood-brain barrier in the young chick and the intact barrier in the rat.,6540303_6,-1,-1,2,19945,-1
19946,intact barrier,30,32,171,185,This study did not demonstrate a species difference regarding the role of the amines on the pineal in spite of the immature blood-brain barrier in the young chick and the intact barrier in the rat.,6540303_6,-1,-1,2,19946,-1
19953,patient's,20,22,127,136,"Laboratory testing has revealed a falling platelet count, increased resistance to heparin, and aggregation of platelets by the patient's plasma when heparin is added.",6615052_3,-1,-1,2,19953,-1
19954,Immunologic testing,0,2,0,19,Immunologic testing has demonstrated the presence of a heparin-dependent platelet membrane antibody.,6615052_4,-1,-1,2,19954,-1
19958,risk factors,1,3,9,21,"Specific risk factors have not been identified; therefore, all patients receiving heparin should be monitored.",6615052_6,-1,-1,2,19958,-1
19959,platelet count falls,2,5,7,27,"If the platelet count falls to less than 100,000/mm3, while the patient is receiving heparin, platelet aggregation testing, using the patient's plasma, is indicated.",6615052_7,-1,-1,2,19959,-1
19961,patient's,23,25,134,143,"If the platelet count falls to less than 100,000/mm3, while the patient is receiving heparin, platelet aggregation testing, using the patient's plasma, is indicated.",6615052_7,-1,-1,2,19961,-1
19983,sublingually,23,24,164,176,"Sublingual absorption of the quaternary ammonium antiarrhythmic agent, UM-272.UM-272 (N,N-dimethylpropranolol), a quaternary antiarrhythmic agent, was administered sublingually to dogs with ouabain-induced ventricular tachycardias.",6634932_0,-1,-1,2,19983,-1
19988,UM-272,1,2,11,17,Sublingual UM-272 converted ventricular tachycardia to sinus rhythm in all 5 dogs.,6634932_2,-1,-1,2,19988,-1
19992,absorption-limiting process,27,29,135,162,"The area under the plasma concentration time curve at 90 min was 4-12 times greater than for oral drug, suggesting the existence of an absorption-limiting process in the intestine, and providing an alternate form of administration for quaternary drugs.",6634932_3,-1,-1,2,19992,-1
19993,alternate form,36,38,198,212,"The area under the plasma concentration time curve at 90 min was 4-12 times greater than for oral drug, suggesting the existence of an absorption-limiting process in the intestine, and providing an alternate form of administration for quaternary drugs.",6634932_3,-1,-1,2,19993,-1
20002,mg/day,15,16,77,83,The loading dose was 800 mg/day for 6 weeks and the maintenance dose was 600 mg/day.,6637851_2,-1,-1,2,20002,-1
20006,/-,37,38,210,212,Sixty-nine percent of patients continued treatment with amiodarone and had no recurrence of symptomatic VT or ventricular fibrillation (VF) over a follow-up of 6 to 52 months (mean +/- standard deviation 14.2 +/- 8.2).,6637851_3,0,1,2,20006,-1
20018,clinical response,9,11,44,61,"However, when the dose is adjusted based on clinical response or the development of adverse effects, 75% of patients with VT or VF can be successfully managed with amiodarone.",6637851_9,-1,-1,2,20018,-1
20020,VF,25,26,128,130,"However, when the dose is adjusted based on clinical response or the development of adverse effects, 75% of patients with VT or VF can be successfully managed with amiodarone.",6637851_9,-1,-1,2,20020,-1
20035,drug itself,13,15,80,91,"The beneficial effect of Adriamycin appears obvious and might be related to the drug itself, the early and repeated instillations after TUR, or both.",6640832_13,-1,-1,2,20035,-1
20036,TUR,22,23,136,139,"The beneficial effect of Adriamycin appears obvious and might be related to the drug itself, the early and repeated instillations after TUR, or both.",6640832_13,-1,-1,2,20036,-1
20040,ultrastructure,15,16,95,109,The effect of high dose D-penicillamine treatment on aortic permeability to albumin and on the ultrastructure of the vessel.,6666578_1,-1,-1,2,20040,-1
20042,treated with,4,6,30,42,Male Sprague-Dawley rats were treated with D-penicillamine (D-pen) 500 mg/kg/day for 10 or 42 days.,6666578_2,-1,-1,2,20042,-1
20045,light-,7,8,46,52,Changes in aortic morphology were examined by light- and transmission-electron microscopy (TEM).,6666578_4,-1,-1,2,20045,-1
20046,transmission-electron microscopy,9,11,57,89,Changes in aortic morphology were examined by light- and transmission-electron microscopy (TEM).,6666578_4,-1,-1,2,20046,-1
20051,v. injection,26,28,147,159,"In addition, the endothelial permeability and the penetration through the aortic wall of albumin were studied 10 minutes, 24 and 48 hours after i. v. injection of human serum 131I-albumin (131I-HSA).",6666578_5,-1,-1,2,20051,-1
20053,TEM,0,1,0,3,"TEM revealed extensive elastolysis in the arterial wall of D-pen-treated rats, consistent with an inhibitory effect on crosslink formation.",6666578_6,-1,-1,2,20053,-1
20056,D-pen-treated rats,9,11,59,77,"TEM revealed extensive elastolysis in the arterial wall of D-pen-treated rats, consistent with an inhibitory effect on crosslink formation.",6666578_6,-1,-1,2,20056,-1
20057,consistent with,12,14,79,94,"TEM revealed extensive elastolysis in the arterial wall of D-pen-treated rats, consistent with an inhibitory effect on crosslink formation.",6666578_6,-1,-1,2,20057,-1
20065,aorta/serum-ratio,1,2,4,21,"The aorta/serum-ratio and the radioactive build-up 24 and 48 hours after injection of 131I-HSA was reduced in animals treated with D-pen for 42 days, indicating an impeded transmural transport of tracer which may be caused by a steric exclusion effect of abundant hyaluronate.",6666578_8,-1,-1,2,20065,-1
20067,treated with,18,20,118,130,"The aorta/serum-ratio and the radioactive build-up 24 and 48 hours after injection of 131I-HSA was reduced in animals treated with D-pen for 42 days, indicating an impeded transmural transport of tracer which may be caused by a steric exclusion effect of abundant hyaluronate.",6666578_8,-1,-1,2,20067,-1
20070,steric exclusion effect,38,41,228,251,"The aorta/serum-ratio and the radioactive build-up 24 and 48 hours after injection of 131I-HSA was reduced in animals treated with D-pen for 42 days, indicating an impeded transmural transport of tracer which may be caused by a steric exclusion effect of abundant hyaluronate.",6666578_8,-1,-1,2,20070,-1
20075,aorta/serum-ratio,16,17,111,128,"The endothelial ultrastructure was unaffected by D-pen, and no differences in aortic 131I-HSA radioactivity or aorta/serum-ratio were recorded between experimental and control groups 10 minutes after tracer injection, indicating that the permeability of the endothelial barrier to albumin remained unaffected by D-pen treatment.",6666578_9,-1,-1,2,20075,-1
20076,control groups,22,24,168,182,"The endothelial ultrastructure was unaffected by D-pen, and no differences in aortic 131I-HSA radioactivity or aorta/serum-ratio were recorded between experimental and control groups 10 minutes after tracer injection, indicating that the permeability of the endothelial barrier to albumin remained unaffected by D-pen treatment.",6666578_9,-1,-1,2,20076,-1
20077,endothelial barrier,36,38,258,277,"The endothelial ultrastructure was unaffected by D-pen, and no differences in aortic 131I-HSA radioactivity or aorta/serum-ratio were recorded between experimental and control groups 10 minutes after tracer injection, indicating that the permeability of the endothelial barrier to albumin remained unaffected by D-pen treatment.",6666578_9,-1,-1,2,20077,-1
20090,SAH,24,25,145,148,A case of necrotizing myopathy due to a short epsilon-aminocaproic acid (EACA) treatment in a 72 year-old patient with subarachnoid haemorrhage (SAH) is described.,6674249_1,-1,-1,2,20090,-1
20091,Pathogenetic hypotheses,0,2,0,23,Pathogenetic hypotheses are discussed.,6674249_2,-1,-1,2,20091,-1
20092,N-[4-(5-nitro-2-furyl)-2-thiazolyl]-formamide-induced,4,5,21,74,Effect of aspirin on N-[4-(5-nitro-2-furyl)-2-thiazolyl]-formamide-induced epithelial proliferation in the urinary bladder and forestomach of the rat.,6692345_0,-1,-1,2,20092,-1
20102,male F-344,6,8,43,53,An autoradiographic study was performed on male F-344 rats fed diet containing FANFT at a level of 0.2% and/or aspirin at a level of 0.5% to evaluate the effect of aspirin on the increased cell proliferation induced by FANFT in the forestomach and bladder.,6692345_2,-1,-1,2,20102,-1
20107,FANFT-induced cell proliferation,0,3,0,32,FANFT-induced cell proliferation in the bladder was significantly suppressed by aspirin co-administration after 4 weeks but not after 12 weeks.,6692345_3,-1,-1,2,20107,-1
20111,labeling index,18,20,96,110,"In the forestomach, and also in the liver, aspirin did not affect the FANFT-induced increase in labeling index.",6692345_4,-1,-1,2,20111,-1
20112,consistent with,4,6,24,39,"The present results are consistent with the carcinogenicity experiment suggesting that different mechanisms are involved in FANFT carcinogenesis in the bladder and forestomach, and that aspirin's effect on FANFT in the forestomach is not due to an irritant effect associated with increased cell proliferation.",6692345_5,-1,-1,2,20112,-1
20116,FANFT,30,31,206,211,"The present results are consistent with the carcinogenicity experiment suggesting that different mechanisms are involved in FANFT carcinogenesis in the bladder and forestomach, and that aspirin's effect on FANFT in the forestomach is not due to an irritant effect associated with increased cell proliferation.",6692345_5,-1,-1,2,20116,-1
20118,associated with,41,43,264,279,"The present results are consistent with the carcinogenicity experiment suggesting that different mechanisms are involved in FANFT carcinogenesis in the bladder and forestomach, and that aspirin's effect on FANFT in the forestomach is not due to an irritant effect associated with increased cell proliferation.",6692345_5,-1,-1,2,20118,-1
20120,chronic ingestion,13,15,59,76,"Also, there appears to be an adaptation by the rats to the chronic ingestion of aspirin.",6692345_6,-1,-1,2,20120,-1
20122,associated with,2,4,20,35,Cerebral hemorrhage associated with phenylpropanolamine in combination with caffeine.,6695415_0,-1,-1,2,20122,-1
20123,PPA,2,3,21,24,Phenylpropanolamine (PPA) is a drug that has been associated with serious side effects including stroke.,6695415_1,-1,-1,2,20123,-1
20124,associated with,10,12,50,65,Phenylpropanolamine (PPA) is a drug that has been associated with serious side effects including stroke.,6695415_1,-1,-1,2,20124,-1
20126,diet preparations,7,9,38,55,"It is often combined with caffeine in diet preparations and ""look-alike"" pills.",6695415_2,-1,-1,2,20126,-1
20132,hypertensive animals,17,19,105,125,A single PPA/caffeine administration (same dose) lead to acute hypertension in both the normotensive and hypertensive animals.,6695415_5,-1,-1,2,20132,-1
20146,factor predisposing,2,4,9,28,No other factor predisposing to RPN could be discovered.,6699841_2,-1,-1,2,20146,-1
20159,Nephrotoxic effects,0,2,0,19,Nephrotoxic effects of aminoglycoside treatment on renal protein reabsorption and accumulation.,6728084_0,-1,-1,2,20159,-1
20168,urinary measurements,8,10,59,79,"Scanning electron microscopy of the glomerular endothelia, urinary measurements of sodium, potassium, endogenous lysozyme, N-acetyl-beta-D-glucosaminidase (NAG) as well as clearance and accumulation experiments after i.v.",6728084_2,-1,-1,2,20168,-1
20172,treatment group,16,18,98,113,administration of egg-white lysozyme and measurements of inulin clearance (GFR) were done in each treatment group.,6728084_3,-1,-1,2,20172,-1
20180,no effect,6,8,52,61,administration of egg-white lysozyme netilmicin had no effect.,6728084_8,-1,-1,2,20180,-1
20183,tubular level,10,12,70,83,"Thus, aminoglycosides may act as nephrotoxicants at glomerular and/or tubular level inducing impairment of renal reabsorption and accumulation of proteins.",6728084_10,-1,-1,2,20183,-1
20194,rechallenge,1,2,2,13,A rechallenge with androgen produced symptoms of obstructive sleep apnea that abated upon withdrawal of the hormone.,6732043_3,-1,-1,2,20194,-1
20216,drug delivery system,29,32,190,210,"Thirty-six patients were treated with BCNU every 6 to 8 weeks, either by transfemoral catheterization of the internal carotid or vertebral artery or through a fully implantable intracarotid drug delivery system, beginning with a dose of 200 mg/sq m body surface area.",6747681_2,-1,-1,2,20216,-1
20220,radiation therapy,18,20,114,131,Twelve patients with Grade III or IV astrocytomas were treated after partial resection of the tumor without prior radiation therapy.,6747681_3,-1,-1,2,20220,-1
20221,contrast-enhanced computerized tomography scans,20,24,114,161,"After two to seven cycles of chemotherapy, nine patients showed a decrease in tumor size and surrounding edema on contrast-enhanced computerized tomography scans.",6747681_4,-1,-1,2,20221,-1
20222,chemotherapy response,8,10,43,64,"In the nine responders, median duration of chemotherapy response from the time of operation was 25 weeks (range 12 to more than 91 weeks).",6747681_5,-1,-1,2,20222,-1
20223,18-month,24,25,107,115,"The median duration of survival in the 12 patients was 54 weeks (range 21 to more than 156 weeks), with an 18-month survival rate of 42%.",6747681_6,-1,-1,2,20223,-1
20224,survival rate,25,27,116,129,"The median duration of survival in the 12 patients was 54 weeks (range 21 to more than 156 weeks), with an 18-month survival rate of 42%.",6747681_6,-1,-1,2,20224,-1
20226,irradiation therapy,13,15,84,103,"Twenty-four patients with recurrent Grade I to IV astrocytomas, whose resection and irradiation therapy had failed, received two to eight courses of intra-arterial BCNU therapy.",6747681_7,-1,-1,2,20226,-1
20234,leukemogenic effects,3,5,25,45,Cardiotoxic and possible leukemogenic effects of adriamycin in nonhuman primates.10 monkeys (macaques) received adriamycin by monthly intravenous injections at 12 mg/m2 (1 mg/kg).,6769133_0,-1,-1,2,20234,-1
20236,nonhuman primates.10 monkeys,8,11,63,91,Cardiotoxic and possible leukemogenic effects of adriamycin in nonhuman primates.10 monkeys (macaques) received adriamycin by monthly intravenous injections at 12 mg/m2 (1 mg/kg).,6769133_0,-1,-1,2,20236,-1
20252,normal subjects,24,26,174,189,"Provocation of postural hypotension by nitroglycerin in diabetic autonomic neuropathy?The effect of nitroglycerin on heart rate and systolic blood pressure was compared in 5 normal subjects, 12 diabetic subjects without autonomic neuropathy, and 5 diabetic subjects with autonomic neuropathy.",6773726_0,-1,-1,2,20252,-1
20259,lesser increase,34,36,213,228,"The magnitude and time course of the increase in heart rate and the decrease in systolic blood pressure after nitroglycerin were similar in the normal and diabetic subjects without autonomic neuropathy, whereas a lesser increase in heart rate and a greater decrease in systolic blood pressure occurred in the diabetic subjects with autonomic neuropathy.",6773726_1,-1,-1,2,20259,-1
20274,exposed to,24,26,158,168,"This is the first patient to initially manifest tricuspid regurgitation and atrial flutter, and the 11th described patient with cardiac disease among infants exposed to lithium compounds in the first trimester of pregnancy.",6794356_2,-1,-1,2,20274,-1
20289,exposed to,52,54,303,313,"The effect of aniracetam (Ro 13-5057, 1-anisoyl-2-pyrrolidinone) was studied on various forms of experimentally impaired cognitive functions (learning and memory) in rodents and produced the following effects: (1) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal hypercapnia immediately before the acquisition session; (2) partial (rats) or complete (mice) prevention of the scopolamine-induced short-term amnesia for a passive avoidance task; (3) complete protection against amnesia for a passive avoidance task in rats submitted to electroconvulsive shock immediately after avoidance acquisition; (4) prevention of the long-term retention- or retrieval-deficit for a passive avoidance task induced in rats and mice by chloramphenicol or cycloheximide administered immediately after acquisition; (5) reversal, when administered as late as 1 h before the retention test, of the deficit in retention or retrieval of a passive avoidance task induced by cycloheximide injected 2 days previously; (6) prevention of the deficit in the retrieval of an active avoidance task induced in mice by subconvulsant electroshock or hypercapnia applied immediately before retrieval testing (24 h after acquisition).",6817363_1,-1,-1,2,20289,-1
20294,retention-,116,117,692,702,"The effect of aniracetam (Ro 13-5057, 1-anisoyl-2-pyrrolidinone) was studied on various forms of experimentally impaired cognitive functions (learning and memory) in rodents and produced the following effects: (1) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal hypercapnia immediately before the acquisition session; (2) partial (rats) or complete (mice) prevention of the scopolamine-induced short-term amnesia for a passive avoidance task; (3) complete protection against amnesia for a passive avoidance task in rats submitted to electroconvulsive shock immediately after avoidance acquisition; (4) prevention of the long-term retention- or retrieval-deficit for a passive avoidance task induced in rats and mice by chloramphenicol or cycloheximide administered immediately after acquisition; (5) reversal, when administered as late as 1 h before the retention test, of the deficit in retention or retrieval of a passive avoidance task induced by cycloheximide injected 2 days previously; (6) prevention of the deficit in the retrieval of an active avoidance task induced in mice by subconvulsant electroshock or hypercapnia applied immediately before retrieval testing (24 h after acquisition).",6817363_1,-1,-1,2,20294,-1
20305,dose-response curves,3,5,15,35,"Generally, the dose-response curves were bell-shaped.",6817363_3,-1,-1,2,20305,-1
20307,therapeutic window',10,13,62,81,The mechanisms underlying the activity of aniracetam and its 'therapeutic window' are unknown.,6817363_4,-1,-1,2,20307,-1
20317,h-1 kg-1,18,20,85,93,"Sodium chloride solution (0.9%) or noradrenaline in doses of 4, 12 and 36 micrograms h-1 kg-1 was infused for five consecutive days, either intrarenally (by a new technique) or intravenously into rats with one kidney removed.",6861444_1,-1,-1,2,20317,-1
20321,intravenous infusion,3,5,25,45,Intrarenal compared with intravenous infusion of noradrenaline caused higher plasma noradrenaline concentrations and a shift of the plasma noradrenaline concentration-blood pressure effect curve towards lower plasma noradrenaline levels.,6861444_3,-1,-1,2,20321,-1
20322,concentration-blood pressure effect curve,19,23,153,194,Intrarenal compared with intravenous infusion of noradrenaline caused higher plasma noradrenaline concentrations and a shift of the plasma noradrenaline concentration-blood pressure effect curve towards lower plasma noradrenaline levels.,6861444_3,-1,-1,2,20322,-1
20329,DES-treated,16,17,66,77,"Over a range of 1-150 days of DES treatment, pairs of control and DES-treated rats were sacrificed, and their pituitaries dissociated enzymatically into single-cell preparations.",6888657_2,-1,-1,2,20329,-1
20330,single-cell preparations,27,29,153,177,"Over a range of 1-150 days of DES treatment, pairs of control and DES-treated rats were sacrificed, and their pituitaries dissociated enzymatically into single-cell preparations.",6888657_2,-1,-1,2,20330,-1
20331,cell populations,1,3,4,20,"The cell populations were examined regarding total cell recovery correlated with gland weight, intracellular prolactin (PRL) content and subsequent release in primary culture, immunocytochemical PRL staining, density and/or size alterations via separation on Ficoll-Hypaque and by unit gravity sedimentation, and cell cycle analysis, after acriflavine DNA staining, by laser flow cytometry.",6888657_3,-1,-1,2,20331,-1
20332,total cell,6,8,45,55,"The cell populations were examined regarding total cell recovery correlated with gland weight, intracellular prolactin (PRL) content and subsequent release in primary culture, immunocytochemical PRL staining, density and/or size alterations via separation on Ficoll-Hypaque and by unit gravity sedimentation, and cell cycle analysis, after acriflavine DNA staining, by laser flow cytometry.",6888657_3,-1,-1,2,20332,-1
20334,intracellular prolactin (PRL),14,19,95,124,"The cell populations were examined regarding total cell recovery correlated with gland weight, intracellular prolactin (PRL) content and subsequent release in primary culture, immunocytochemical PRL staining, density and/or size alterations via separation on Ficoll-Hypaque and by unit gravity sedimentation, and cell cycle analysis, after acriflavine DNA staining, by laser flow cytometry.",6888657_3,-1,-1,2,20334,-1
20335,primary culture,24,26,159,174,"The cell populations were examined regarding total cell recovery correlated with gland weight, intracellular prolactin (PRL) content and subsequent release in primary culture, immunocytochemical PRL staining, density and/or size alterations via separation on Ficoll-Hypaque and by unit gravity sedimentation, and cell cycle analysis, after acriflavine DNA staining, by laser flow cytometry.",6888657_3,-1,-1,2,20335,-1
20338,Ficoll-Hypaque,38,39,259,273,"The cell populations were examined regarding total cell recovery correlated with gland weight, intracellular prolactin (PRL) content and subsequent release in primary culture, immunocytochemical PRL staining, density and/or size alterations via separation on Ficoll-Hypaque and by unit gravity sedimentation, and cell cycle analysis, after acriflavine DNA staining, by laser flow cytometry.",6888657_3,-1,-1,2,20338,-1
20339,cell cycle analysis,46,49,313,332,"The cell populations were examined regarding total cell recovery correlated with gland weight, intracellular prolactin (PRL) content and subsequent release in primary culture, immunocytochemical PRL staining, density and/or size alterations via separation on Ficoll-Hypaque and by unit gravity sedimentation, and cell cycle analysis, after acriflavine DNA staining, by laser flow cytometry.",6888657_3,-1,-1,2,20339,-1
20341,laser flow cytometry,56,59,369,389,"The cell populations were examined regarding total cell recovery correlated with gland weight, intracellular prolactin (PRL) content and subsequent release in primary culture, immunocytochemical PRL staining, density and/or size alterations via separation on Ficoll-Hypaque and by unit gravity sedimentation, and cell cycle analysis, after acriflavine DNA staining, by laser flow cytometry.",6888657_3,-1,-1,2,20341,-1
20342,Total cell,0,2,0,10,Total cell yields from DES-treated pituitaries increased from 1.3 times control yields at 8 days of treatment to 58.9 times control values by day 150.,6888657_4,-1,-1,2,20342,-1
20344,control values,20,22,124,138,Total cell yields from DES-treated pituitaries increased from 1.3 times control yields at 8 days of treatment to 58.9 times control values by day 150.,6888657_4,-1,-1,2,20344,-1
20350,total population,20,22,114,130,"Beyond 8 days of DES exposure, the immunochemically PRL-positive proportion of cells increased to over 50% of the total population.",6888657_6,-1,-1,2,20350,-1
20353,cell population,15,17,89,104,Increased density and/or size and PRL content were indicated for the majority of the PRL cell population in both types of separation protocols.,6888657_7,-1,-1,2,20353,-1
20354,separation protocols,21,23,122,142,Increased density and/or size and PRL content were indicated for the majority of the PRL cell population in both types of separation protocols.,6888657_7,-1,-1,2,20354,-1
20357,cellular control mechanisms,21,24,124,151,"The data extend the findings of other investigators, further establishing the DES-induced tumor as a model for study of PRL cellular control mechanisms.",6888657_9,-1,-1,2,20357,-1
20364,group-housed,11,12,72,84,"The effect of calcium chloride injected into the cerebral ventricles of group-housed unanaesthetized cats upon vocalization (rage, hissing and snarling), fighting (attack with paws and claws, defense with paws and claws and biting), mydriasis, tremor and clonic-tonic convulsions produced by carbachol and eserine injected similarly was investigated.",6892185_1,-1,-1,2,20364,-1
20394,serum K,1,3,4,11,"The serum K during the control period was 4.5 +/- 0.2 mEq/l an on 50, 100, 150 and 200 mg HCTZ daily 3.9 +/- 0.3, 3.4 +/- 0.2, 2.9 +/- 0.2, and 2.4 +/- 0.3 mEq/l, respectively.",6942642_5,-1,-1,2,20394,-1
20395,control period,5,7,23,37,"The serum K during the control period was 4.5 +/- 0.2 mEq/l an on 50, 100, 150 and 200 mg HCTZ daily 3.9 +/- 0.3, 3.4 +/- 0.2, 2.9 +/- 0.2, and 2.4 +/- 0.3 mEq/l, respectively.",6942642_5,-1,-1,2,20395,-1
20396,/-,10,11,47,49,"The serum K during the control period was 4.5 +/- 0.2 mEq/l an on 50, 100, 150 and 200 mg HCTZ daily 3.9 +/- 0.3, 3.4 +/- 0.2, 2.9 +/- 0.2, and 2.4 +/- 0.3 mEq/l, respectively.",6942642_5,0,1,2,20396,-1
20397,mEq/l,12,13,54,59,"The serum K during the control period was 4.5 +/- 0.2 mEq/l an on 50, 100, 150 and 200 mg HCTZ daily 3.9 +/- 0.3, 3.4 +/- 0.2, 2.9 +/- 0.2, and 2.4 +/- 0.3 mEq/l, respectively.",6942642_5,-1,-1,2,20397,-1
20399,/-,27,28,106,108,"The serum K during the control period was 4.5 +/- 0.2 mEq/l an on 50, 100, 150 and 200 mg HCTZ daily 3.9 +/- 0.3, 3.4 +/- 0.2, 2.9 +/- 0.2, and 2.4 +/- 0.3 mEq/l, respectively.",6942642_5,0,1,2,20399,-1
20400,/-,32,33,119,121,"The serum K during the control period was 4.5 +/- 0.2 mEq/l an on 50, 100, 150 and 200 mg HCTZ daily 3.9 +/- 0.3, 3.4 +/- 0.2, 2.9 +/- 0.2, and 2.4 +/- 0.3 mEq/l, respectively.",6942642_5,0,1,2,20400,-1
20401,/-,37,38,132,134,"The serum K during the control period was 4.5 +/- 0.2 mEq/l an on 50, 100, 150 and 200 mg HCTZ daily 3.9 +/- 0.3, 3.4 +/- 0.2, 2.9 +/- 0.2, and 2.4 +/- 0.3 mEq/l, respectively.",6942642_5,0,1,2,20401,-1
20402,/-,43,44,149,151,"The serum K during the control period was 4.5 +/- 0.2 mEq/l an on 50, 100, 150 and 200 mg HCTZ daily 3.9 +/- 0.3, 3.4 +/- 0.2, 2.9 +/- 0.2, and 2.4 +/- 0.3 mEq/l, respectively.",6942642_5,0,1,2,20402,-1
20403,mEq/l,45,46,156,161,"The serum K during the control period was 4.5 +/- 0.2 mEq/l an on 50, 100, 150 and 200 mg HCTZ daily 3.9 +/- 0.3, 3.4 +/- 0.2, 2.9 +/- 0.2, and 2.4 +/- 0.3 mEq/l, respectively.",6942642_5,-1,-1,2,20403,-1
20404,Corresponding figures,0,2,0,21,"Corresponding figures for whole body K were 4107 +/- 208, 3722 +/- 319, 3628 +/- 257, 3551 +/- 336, and 3269 +/- 380 mEq, respectively.",6942642_6,-1,-1,2,20404,-1
20406,/-,9,10,50,52,"Corresponding figures for whole body K were 4107 +/- 208, 3722 +/- 319, 3628 +/- 257, 3551 +/- 336, and 3269 +/- 380 mEq, respectively.",6942642_6,0,1,2,20406,-1
20407,/-,14,15,64,66,"Corresponding figures for whole body K were 4107 +/- 208, 3722 +/- 319, 3628 +/- 257, 3551 +/- 336, and 3269 +/- 380 mEq, respectively.",6942642_6,0,1,2,20407,-1
20408,/-,19,20,78,80,"Corresponding figures for whole body K were 4107 +/- 208, 3722 +/- 319, 3628 +/- 257, 3551 +/- 336, and 3269 +/- 380 mEq, respectively.",6942642_6,0,1,2,20408,-1
20409,/-,24,25,92,94,"Corresponding figures for whole body K were 4107 +/- 208, 3722 +/- 319, 3628 +/- 257, 3551 +/- 336, and 3269 +/- 380 mEq, respectively.",6942642_6,0,1,2,20409,-1
20410,/-,30,31,110,112,"Corresponding figures for whole body K were 4107 +/- 208, 3722 +/- 319, 3628 +/- 257, 3551 +/- 336, and 3269 +/- 380 mEq, respectively.",6942642_6,0,1,2,20410,-1
20413,/-,6,7,29,31,"During rest we observed 0.6 +/- 0.08 PVC beats/min +/- SEM and during static and dynamic exercise 0.6 +/- 0.06 and 0.8 +/- 0.15, respectively.",6942642_8,0,1,2,20413,-1
20414,beats/min,9,10,41,50,"During rest we observed 0.6 +/- 0.08 PVC beats/min +/- SEM and during static and dynamic exercise 0.6 +/- 0.06 and 0.8 +/- 0.15, respectively.",6942642_8,-1,-1,2,20414,-1
20415,/- SEM,11,13,52,58,"During rest we observed 0.6 +/- 0.08 PVC beats/min +/- SEM and during static and dynamic exercise 0.6 +/- 0.06 and 0.8 +/- 0.15, respectively.",6942642_8,-1,-1,2,20415,-1
20416,dynamic exercise 0.6 +,17,21,81,103,"During rest we observed 0.6 +/- 0.08 PVC beats/min +/- SEM and during static and dynamic exercise 0.6 +/- 0.06 and 0.8 +/- 0.15, respectively.",6942642_8,-1,-1,2,20416,-1
20417,/-,26,27,120,122,"During rest we observed 0.6 +/- 0.08 PVC beats/min +/- SEM and during static and dynamic exercise 0.6 +/- 0.06 and 0.8 +/- 0.15, respectively.",6942642_8,0,1,2,20417,-1
20418,Corresponding figures,0,2,0,21,"Corresponding figures during HCTZ therapy 100 mg daily were 1.4 +/- 0.1, 3.6 +/- 0.7 and 5.7 4/- 0.8, respectively.",6942642_9,-1,-1,2,20418,-1
20420,/-,11,12,65,67,"Corresponding figures during HCTZ therapy 100 mg daily were 1.4 +/- 0.1, 3.6 +/- 0.7 and 5.7 4/- 0.8, respectively.",6942642_9,0,1,2,20420,-1
20421,/-,16,17,78,80,"Corresponding figures during HCTZ therapy 100 mg daily were 1.4 +/- 0.1, 3.6 +/- 0.7 and 5.7 4/- 0.8, respectively.",6942642_9,0,1,2,20421,-1
20422,serum K+,11,13,66,74,"The occurrence of PVC's correlated significantly with the fall in serum K+ observed r = 0.72, p less than 0.001.",6942642_10,-1,-1,2,20422,-1
20424,body potassium,12,14,82,96,In conclusion we found that thiazide diuretics cause hypokalemia and depletion of body potassium.,6942642_11,-1,-1,2,20424,-1
20438,serum acid protease activity,5,9,32,60,"A correlation was found between serum acid protease activity and prothrombin time, and the increase in cathepsin D activity was sustained over several days compared with aspartate aminotransferase, which showed a sharp early peak and then a fall.",7007443_3,-1,-1,2,20438,-1
20443,renal clearance,2,4,8,23,Age and renal clearance of cimetidine.,7053303_0,-1,-1,2,20443,-1
20444,serum samples,14,16,75,88,In 35 patients (ages 20 to 86 yr) receiving cimetidine therapeutically two serum samples and all urine formed in the interim were collected for analysis of cimetidine by high-pressure liquid chromatography and for creatinine.,7053303_1,-1,-1,2,20444,-1
20445,high-pressure liquid chromatography,30,33,170,205,In 35 patients (ages 20 to 86 yr) receiving cimetidine therapeutically two serum samples and all urine formed in the interim were collected for analysis of cimetidine by high-pressure liquid chromatography and for creatinine.,7053303_1,-1,-1,2,20445,-1
20449,/-,14,15,77,79,"The ratio of cimetidine clearance to creatinine clearance (Rc) averaged 4.8 +/- 2.0, indicating net tubular secretion for cimetidine.",7053303_4,0,1,2,20449,-1
20451,Rc,0,1,0,2,"Rc seemed to be independent of age and decreased with increasing serum concentration of cimetidine, suggesting that secretion of cimetidine is a saturable process.",7053303_5,-1,-1,2,20451,-1
20452,saturable,23,24,145,154,"Rc seemed to be independent of age and decreased with increasing serum concentration of cimetidine, suggesting that secretion of cimetidine is a saturable process.",7053303_5,-1,-1,2,20452,-1
20460,maintenance therapy,20,22,140,159,Clinically reversible veno-occlusive disease of the liver developed in a 23-year-old man with acute lymphocytic leukemia after 10 months of maintenance therapy with 6-thioguanine.,7053705_1,-1,-1,2,20460,-1
20469,treated with,6,8,46,58,A 65-year-old woman with adult-onset diabetes treated with chlorpropamide (Diabenese) had a toxic optic neuropathy that resolved with discontinuation of chlorpropamide therapy.,7059267_1,-1,-1,2,20469,-1
20478,urinary lipids,2,4,11,25,Plasma and urinary lipids and lipoproteins during the development of nephrotic syndrome induced in the rat by puromycin aminonucleoside.,7066357_0,-1,-1,2,20478,-1
20490,time-course study,11,13,66,83,"Since massive albuminuria occurred after 6 days of treatment, the time-course study was divided into two stages: pre-nephrotic stage (day 1-5) and nephrotic stage (day 6-11).",7066357_3,-1,-1,2,20490,-1
20491,pre-nephrotic stage,19,21,113,132,"Since massive albuminuria occurred after 6 days of treatment, the time-course study was divided into two stages: pre-nephrotic stage (day 1-5) and nephrotic stage (day 6-11).",7066357_3,-1,-1,2,20491,-1
20504,LDL density class,19,22,87,104,Plasma apolipoprotein A-I was found not only in HDL (1.063-1.210 g/ml) but also in the LDL density class (1.025-1.050 g/ml).,7066357_9,-1,-1,2,20504,-1
20508,plasma lipoproteins,18,20,114,133,"In the pre-nephrotic stage lipoproteinuria was negligible, while in the early nephrotic stage the urinary loss of plasma lipoproteins consisted mainly of HDL.",7066357_10,-1,-1,2,20508,-1
20510,plasma lipoproteins,7,9,66,85,These observations indicate that puromycin aminonucleoside alters plasma lipoproteins by lowering VLDL and increasing HDL.,7066357_11,-1,-1,2,20510,-1
20512,HDL metabolism,26,28,133,147,It is likely that the early and striking increase of plasma HDL found in nephrotic rats is related to a direct effect of the drug on HDL metabolism.,7066357_12,-1,-1,2,20512,-1
20520,associated with,7,9,39,54,The pattern of the aplastic anemia was associated with an idiosyncratic response to chloramphenicol.,7072798_3,-1,-1,2,20520,-1
20526,associated with,7,9,45,60,"Any other suspected cases of ocular toxicity associated with topically applied chloramphenicol should be reported to the National Registry of Drug-Induced Ocular Side Effects, Oregon Health Sciences University, Portland, OR 97201.",7072798_5,-1,-1,2,20526,-1
20530,electrophysiologic effects,4,6,28,54,Further observations on the electrophysiologic effects of oral amiodarone therapy.,7083920_0,-1,-1,2,20530,-1
20538,HV intervals,16,18,109,121,"His bundle recordings showed an atrial tachycardia with intermittent exit block and greatly prolonged BH and HV intervals (40 and 100 msec, respectively).",7083920_2,-1,-1,2,20538,-1
20547,DES-exposed,6,7,44,55,Development of clear cell adenocarcinoma in DES-exposed offspring under observation.,7088431_0,-1,-1,2,20547,-1
20559,sleep-inducing,19,20,104,118,"In patients premedicated with scopolamine + morphine (+5 mg nitrazepam the evening before surgery), the sleep-inducing effect of midazolam 0.15 mg/kg i.v. was clearly slower in onset than that of thiopentone 4.67 mg/kg i.v.",7102237_1,-1,-1,2,20559,-1
20571,EPS,7,8,46,49,The incidence of extrapyramidal side effects (EPS) was evaluated in 98 patients treated with haloperidol.,7161250_1,-1,-1,2,20571,-1
20572,treated with,14,16,80,92,The incidence of extrapyramidal side effects (EPS) was evaluated in 98 patients treated with haloperidol.,7161250_1,-1,-1,2,20572,-1
20599,behavioral response,4,6,30,49,REM sleep deprivation changes behavioral response to catecholaminergic and serotonergic receptor activation in rats.,7197363_0,-1,-1,2,20599,-1
20602,effects of,1,3,4,14,The effects of REM sleep deprivation (REMD) on apomorphine-induced aggressiveness and quipazine-induced head twitches in rats were determined.,7197363_1,-1,-1,2,20602,-1
20604,REMD,7,8,38,42,The effects of REM sleep deprivation (REMD) on apomorphine-induced aggressiveness and quipazine-induced head twitches in rats were determined.,7197363_1,-1,-1,2,20604,-1
20618,total volume,9,11,39,51,The possible role of low pH as well as total volume as potential factors in causing neurotoxicity was evaluated.,7199841_2,-1,-1,2,20618,-1
20648,treated with,10,12,59,71,"In four patients, the arrhythmia was rapidly diagnosed and treated with disappearance of further episodes of the arrhythmia.",7234705_5,-1,-1,2,20648,-1
20670,in vitro,10,12,75,83,Fatal aplastic anemia due to indomethacin--lymphocyte transformation tests in vitro.,7263204_0,-1,-1,2,20670,-1
20675,lymphocyte transformation test,2,5,11,41,A positive lymphocyte transformation test with indomethacin in vitro further substantiates the potential role of this drug in causing aplastic anemia in a susceptible patient.,7263204_4,-1,-1,2,20675,-1
20676,in vitro,7,9,60,68,A positive lymphocyte transformation test with indomethacin in vitro further substantiates the potential role of this drug in causing aplastic anemia in a susceptible patient.,7263204_4,-1,-1,2,20676,-1
20694,Dose-effect,0,1,0,11,Dose-effect and structure-function relationships in doxorubicin cardiomyopathy.,7282516_0,-1,-1,2,20694,-1
20699,dose-effect,23,24,128,139,The cardiomyopathy (CM) produced by the anticancer drug doxorubicin (DXR) (Adriamycin) provides a unique opportunity to analyze dose-effect and structure-function relationships during development of myocardial disease.,7282516_1,-1,-1,2,20699,-1
20706,DXR,26,27,195,198,We measured the degree of morphologic damage by ultrastructural examination of endomyocardial biopsy and the degree of performance abnormally by right heart catheterization in patients receiving DXR.,7282516_2,-1,-1,2,20706,-1
20710,curvilinear relationship,9,11,67,91,"Performance abnormalities correlated weakly with dose, exhibited a curvilinear relationship, and had a ""threshold"" for expression.",7282516_4,-1,-1,2,20710,-1
20714,DXR-CM,1,2,3,9,"In DXR-CM myocardial damage is proportional to the degree of cytotoxic insult (DXR dose) while myocardial function is preserved until a critical dose or degree of damage is reached, after which myocardial performance deteriorates rapidly.",7282516_6,-1,-1,2,20714,-1
20723,repetitive group,6,8,39,55,"Unusual features of the arrhythmia are repetitive group beating, progressive shortening of the R-R interval, progressive widening of the QRS complex with eventual failure of intraventricular conduction, and changes in direction of the QRS axis.",7292072_2,-1,-1,2,20723,-1
20724,R-R interval,14,16,95,107,"Unusual features of the arrhythmia are repetitive group beating, progressive shortening of the R-R interval, progressive widening of the QRS complex with eventual failure of intraventricular conduction, and changes in direction of the QRS axis.",7292072_2,-1,-1,2,20724,-1
20725,QRS complex,21,23,137,148,"Unusual features of the arrhythmia are repetitive group beating, progressive shortening of the R-R interval, progressive widening of the QRS complex with eventual failure of intraventricular conduction, and changes in direction of the QRS axis.",7292072_2,-1,-1,2,20725,-1
20727,QRS axis,36,38,235,243,"Unusual features of the arrhythmia are repetitive group beating, progressive shortening of the R-R interval, progressive widening of the QRS complex with eventual failure of intraventricular conduction, and changes in direction of the QRS axis.",7292072_2,-1,-1,2,20727,-1
20743,angiotensin system,6,8,23,41,The role of the renin--angiotensin system in the maintenance of blood pressure during halothane anesthesia and sodium nitroprusside (SNP)-induced hypotension was evaluated.,7352670_1,-1,-1,2,20743,-1
20752,control animals,5,7,28,43,"During the SNP infusion the control animals demonstrated a progressive increase in blood pressure to 61 torr, whereas the saralasin-treated animals showed no change.",7352670_5,-1,-1,2,20752,-1
20755,no change,23,25,155,164,"During the SNP infusion the control animals demonstrated a progressive increase in blood pressure to 61 torr, whereas the saralasin-treated animals showed no change.",7352670_5,-1,-1,2,20755,-1
20757,control animals,9,11,56,71,"Following discontinuation of SNP, blood pressure in the control animals rebounded to 94 torr, as compared with 78 torr in the saralasin-treated rats.",7352670_6,-1,-1,2,20757,-1
20763,angiotensin system,8,10,50,68,This demonstrates the participation of the renin--angiotensin system in antagonizing the combined hypotensive effects of halothane and SNP.,7352670_8,-1,-1,2,20763,-1
20771,control group,6,8,30,43,The patients of the study and control group (without digoxin) were of similar cardiac functional capacity and age (25-40 years) and were randomly selected from the rheumatic heart disease patients.,7416947_3,-1,-1,2,20771,-1
20776,control groups,10,12,60,74,"A subjective assessment of sexual behavior in the study and control groups was carried out, using parameters such as sexual desire, sexual excitement, and frequency of sexual relations.",7416947_4,-1,-1,2,20776,-1
20785,sexual excitement phase,17,20,102,125,"Tests used to evaluate the changes in sexual behavior showed a significant decrease in sexual desire, sexual excitement phase (erection), and frequency of sexual relations in the study group.",7416947_8,-1,-1,2,20785,-1
20787,study group,31,33,179,190,"Tests used to evaluate the changes in sexual behavior showed a significant decrease in sexual desire, sexual excitement phase (erection), and frequency of sexual relations in the study group.",7416947_8,-1,-1,2,20787,-1
20789,prospective study,1,3,2,19,A prospective study.,7420681_1,-1,-1,2,20789,-1
20795,clinical studies,15,17,116,132,Gentamicin sulfate and tobramycin sulfate continue to demonstrate ototoxicity and nephrotoxicity in both animal and clinical studies.,7420681_3,-1,-1,2,20795,-1
20803,tobramycin-treated patients,9,11,24,51,Five of 33 (15%) of the tobramycin-treated patients and 16 of 29 (55.2%) of the gentamicin-treated patients had renal failure.,7420681_6,-1,-1,2,20803,-1
20804,gentamicin-treated,21,22,80,98,Five of 33 (15%) of the tobramycin-treated patients and 16 of 29 (55.2%) of the gentamicin-treated patients had renal failure.,7420681_6,-1,-1,2,20804,-1
20806,associated with,4,6,21,36,"Thus, gentamicin was associated with renal failure more than three times as often as was tobramycin.",7420681_7,-1,-1,2,20806,-1
20822,model system,15,17,97,109,The cardiotoxic effects of adriamycin were studied in mammalian myocardial cells in culture as a model system.,7423039_1,-1,-1,2,20822,-1
20826,myocardial cells,10,12,81,97,Adriamycin inhibited cell growth and the rhythmic contractions characteristic of myocardial cells in culture.,7423039_2,-1,-1,2,20826,-1
20831,adriamycin-treated cells,26,28,176,200,"A possible involvement of energy metabolism was suggested previously, and in this study the adenylate energy charge and phosphorylcreatine mole fraction were determined in the adriamycin-treated cells.",7423039_3,-1,-1,2,20831,-1
20834,mole fraction,14,16,97,110,"The adenylate energy charge was found to be significantly decreased, while the phophorylcreatine mole fraction was unchanged.",7423039_4,-1,-1,2,20834,-1
20836,myocardial cell cultures,8,11,38,62,The addition of 1 mM adenosine to the myocardial cell cultures markedly increases the ATP concentration through a pathway reportedly leading to a compartmentalized ATP pool.,7423039_6,-1,-1,2,20836,-1
20837,adriamycin-treated cells,2,4,7,31,"In the adriamycin-treated cells, the addition of adenosine increased the adenylate charge and, concomitant with this inrcease, the cells' functional integrity, in terms of percentage of beating cells and rate of contractions, was maintained.",7423039_7,-1,-1,2,20837,-1
20840,cells',21,23,131,137,"In the adriamycin-treated cells, the addition of adenosine increased the adenylate charge and, concomitant with this inrcease, the cells' functional integrity, in terms of percentage of beating cells and rate of contractions, was maintained.",7423039_7,-1,-1,2,20840,-1
20841,beating cells,31,33,186,199,"In the adriamycin-treated cells, the addition of adenosine increased the adenylate charge and, concomitant with this inrcease, the cells' functional integrity, in terms of percentage of beating cells and rate of contractions, was maintained.",7423039_7,-1,-1,2,20841,-1
20844,osmolality,5,6,38,48,"Creatinine clearance, maximum urinary osmolality and 24 hour urine volume have been tested in 50 affectively ill patients who have been on long-term lithium for more than one year.",7437994_3,-1,-1,2,20844,-1
20845,urine volume,9,11,61,73,"Creatinine clearance, maximum urinary osmolality and 24 hour urine volume have been tested in 50 affectively ill patients who have been on long-term lithium for more than one year.",7437994_3,-1,-1,2,20845,-1
20846,No evidence,0,2,0,11,No evidence was found for any reduction of glomerular filtration during lithium treatment.,7437994_5,-1,-1,2,20846,-1
20847,glomerular filtration,8,10,43,64,No evidence was found for any reduction of glomerular filtration during lithium treatment.,7437994_5,-1,-1,2,20847,-1
20848,clearance values,1,3,4,20,Low clearance values found in several patients could be accounted for by their age and their pre-lithium values.,7437994_6,-1,-1,2,20848,-1
20849,pre-lithium values,16,18,93,111,Low clearance values found in several patients could be accounted for by their age and their pre-lithium values.,7437994_6,-1,-1,2,20849,-1
20851,litres/24 hours,3,5,17,32,Polyuria above 3 litres/24 hours was found in 10% of patients.,7437994_9,-1,-1,2,20851,-1
20852,Age-dependent sensitivity,0,2,0,25,Age-dependent sensitivity of the rat to neurotoxic effects of streptomycin.,7444978_0,-1,-1,2,20852,-1
20863,total dose,5,7,36,46,Cardiomyopathy is frequent when the total dose exceeds 600 mg/m2 and occurs within one to six months after cessation of therapy.,7449470_2,-1,-1,2,20863,-1
20870,red blood cells,24,27,142,157,"The effect of amiloride on lithium-induced polydipsia and polyuria and on the lithium concentration in the plasma, brain, kidney, thyroid and red blood cells was investigated in rats, chronically treated with LiCl.",7453952_1,-1,-1,2,20870,-1
20871,chronically treated with,32,35,184,208,"The effect of amiloride on lithium-induced polydipsia and polyuria and on the lithium concentration in the plasma, brain, kidney, thyroid and red blood cells was investigated in rats, chronically treated with LiCl.",7453952_1,-1,-1,2,20871,-1
20874,urine volume,5,7,35,47,Amiloride reduced the drinking and urine volume of rats in an acute (6 or 12 h) and a subacute (3 days) experiment.,7453952_2,-1,-1,2,20874,-1
20878,lithium levels,12,14,53,67,"At 12 h, all the tissues showed a slight increase in lithium levels.",7453952_4,-1,-1,2,20878,-1
20879,combined treatment,4,6,16,34,"After 3 days of combined treatment, a marked elevation in plasma and tissue lithium levels accompanied a reduction in water intake.",7453952_5,-1,-1,2,20879,-1
20880,tissue lithium levels,13,16,69,90,"After 3 days of combined treatment, a marked elevation in plasma and tissue lithium levels accompanied a reduction in water intake.",7453952_5,-1,-1,2,20880,-1
20890,treated with,9,11,70,82,Severe cardiovascular complications occurred in eight of 160 patients treated with terbutaline for preterm labor.,7468724_1,-1,-1,2,20890,-1
20895,predisposing factors,9,11,67,87,Associated corticosteroid therapy and twin gestations appear to be predisposing factors.,7468724_2,-1,-1,2,20895,-1
20906,out-patients,19,20,121,133,METHODS: Retrospective review of medical records of 236 patients with hyperthyroidism admitted in our department (in- or out-patients) from 1986 to 1992.,7504976_2,-1,-1,2,20906,-1
20916,retrospective study,5,7,23,42,Only 2 patients of our retrospective study experienced a mild or severe neutropenia.,7504976_8,-1,-1,2,20916,-1
20925,[Na]o,5,6,37,42,Interactive effects of variations in [Na]o and [Ca]o on rat atrial spontaneous frequency.,7516729_0,-1,-1,2,20925,-1
20926,[Ca]o,7,8,47,52,Interactive effects of variations in [Na]o and [Ca]o on rat atrial spontaneous frequency.,7516729_0,-1,-1,2,20926,-1
20932,Basal frequency,0,2,0,15,Basal frequency (BF) evaluated by surface electrogram was 223 +/- 4 beats/min.,7516729_2,-1,-1,2,20932,-1
20934,surface electrogram,7,9,34,53,Basal frequency (BF) evaluated by surface electrogram was 223 +/- 4 beats/min.,7516729_2,-1,-1,2,20934,-1
20936,beats/min,14,15,68,77,Basal frequency (BF) evaluated by surface electrogram was 223 +/- 4 beats/min.,7516729_2,-1,-1,2,20936,-1
20937,Ca (N,10,13,57,62,in control Krebs-Ringer containing 137 mM Na and 1.35 mM Ca (N).,7516729_3,-1,-1,2,20937,-1
20938,/-,5,6,20,22,"It decreased by 16 +/- 3% by lowering [Na]o to 78 mM (LNa), 23 +/- 2% by lowering simultaneously [Na]o to 78 mM and [Ca]o to 0.675 mM (LNa+LCa) and 31 +/- 5% by lowering [Na]o to 78 mM plus increasing [Ca]o to 3.6 mM (LNa+HCa).",7516729_4,0,1,2,20938,-1
20939,LNa,15,16,54,57,"It decreased by 16 +/- 3% by lowering [Na]o to 78 mM (LNa), 23 +/- 2% by lowering simultaneously [Na]o to 78 mM and [Ca]o to 0.675 mM (LNa+LCa) and 31 +/- 5% by lowering [Na]o to 78 mM plus increasing [Ca]o to 3.6 mM (LNa+HCa).",7516729_4,-1,-1,2,20939,-1
20940,/-,20,21,64,66,"It decreased by 16 +/- 3% by lowering [Na]o to 78 mM (LNa), 23 +/- 2% by lowering simultaneously [Na]o to 78 mM and [Ca]o to 0.675 mM (LNa+LCa) and 31 +/- 5% by lowering [Na]o to 78 mM plus increasing [Ca]o to 3.6 mM (LNa+HCa).",7516729_4,0,1,2,20940,-1
20941,[Ca]o,31,32,116,121,"It decreased by 16 +/- 3% by lowering [Na]o to 78 mM (LNa), 23 +/- 2% by lowering simultaneously [Na]o to 78 mM and [Ca]o to 0.675 mM (LNa+LCa) and 31 +/- 5% by lowering [Na]o to 78 mM plus increasing [Ca]o to 3.6 mM (LNa+HCa).",7516729_4,-1,-1,2,20941,-1
20942,LNa+LCa,36,37,135,142,"It decreased by 16 +/- 3% by lowering [Na]o to 78 mM (LNa), 23 +/- 2% by lowering simultaneously [Na]o to 78 mM and [Ca]o to 0.675 mM (LNa+LCa) and 31 +/- 5% by lowering [Na]o to 78 mM plus increasing [Ca]o to 3.6 mM (LNa+HCa).",7516729_4,-1,-1,2,20942,-1
20943,/-,41,42,152,154,"It decreased by 16 +/- 3% by lowering [Na]o to 78 mM (LNa), 23 +/- 2% by lowering simultaneously [Na]o to 78 mM and [Ca]o to 0.675 mM (LNa+LCa) and 31 +/- 5% by lowering [Na]o to 78 mM plus increasing [Ca]o to 3.6 mM (LNa+HCa).",7516729_4,0,1,2,20943,-1
20944,LNa+HCa,57,58,218,225,"It decreased by 16 +/- 3% by lowering [Na]o to 78 mM (LNa), 23 +/- 2% by lowering simultaneously [Na]o to 78 mM and [Ca]o to 0.675 mM (LNa+LCa) and 31 +/- 5% by lowering [Na]o to 78 mM plus increasing [Ca]o to 3.6 mM (LNa+HCa).",7516729_4,-1,-1,2,20944,-1
20945,[Ca]o,16,17,61,66,"At normal [Na]o, decrease (0.675 mM) or increase (3.6 mM) of [Ca]o did not modify BF; a reduction of ten times (0.135 mM of normal [Ca]o was effective to reduce BF by 40 +/- 13%.",7516729_5,-1,-1,2,20945,-1
20947,normal [Ca]o,31,33,124,136,"At normal [Na]o, decrease (0.675 mM) or increase (3.6 mM) of [Ca]o did not modify BF; a reduction of ten times (0.135 mM of normal [Ca]o was effective to reduce BF by 40 +/- 13%.",7516729_5,-1,-1,2,20947,-1
20949,/-,41,42,171,173,"At normal [Na]o, decrease (0.675 mM) or increase (3.6 mM) of [Ca]o did not modify BF; a reduction of ten times (0.135 mM of normal [Ca]o was effective to reduce BF by 40 +/- 13%.",7516729_5,0,1,2,20949,-1
20950,chronotropic effects,2,4,13,33,All negative chronotropic effects were BF-dependent.,7516729_6,-1,-1,2,20950,-1
20956,additive effects,3,5,20,36,"Independent but not additive effects of Na and Ca are shown by decreases in the values of [verapamil]o needed to reduce BF by 30% (IC30) with the following order of inhibitory potency: LNa > LCa > HCa > N, resulting LNa+HCa similar to LNa.",7516729_8,-1,-1,2,20956,-1
20959,LNa,36,37,185,188,"Independent but not additive effects of Na and Ca are shown by decreases in the values of [verapamil]o needed to reduce BF by 30% (IC30) with the following order of inhibitory potency: LNa > LCa > HCa > N, resulting LNa+HCa similar to LNa.",7516729_8,-1,-1,2,20959,-1
20961,HCa,40,41,197,200,"Independent but not additive effects of Na and Ca are shown by decreases in the values of [verapamil]o needed to reduce BF by 30% (IC30) with the following order of inhibitory potency: LNa > LCa > HCa > N, resulting LNa+HCa similar to LNa.",7516729_8,-1,-1,2,20961,-1
20962,LNa+HCa,45,46,216,223,"Independent but not additive effects of Na and Ca are shown by decreases in the values of [verapamil]o needed to reduce BF by 30% (IC30) with the following order of inhibitory potency: LNa > LCa > HCa > N, resulting LNa+HCa similar to LNa.",7516729_8,-1,-1,2,20962,-1
20963,LNa,48,49,235,238,"Independent but not additive effects of Na and Ca are shown by decreases in the values of [verapamil]o needed to reduce BF by 30% (IC30) with the following order of inhibitory potency: LNa > LCa > HCa > N, resulting LNa+HCa similar to LNa.",7516729_8,-1,-1,2,20963,-1
20967,LNa+HCa,19,20,103,110,The [verapamil]o that arrested atrial beating (AC) was also potentiated with the order LNa = LNa+LCa = LNa+HCa = LCa > HCa = N. The results indicate that rat atrial spontaneous beating is more dependent on [Na]o than on [Ca]o in a range of +/- 50% of their normal concentration.,7516729_9,-1,-1,2,20967,-1
20969,HCa,23,24,119,122,The [verapamil]o that arrested atrial beating (AC) was also potentiated with the order LNa = LNa+LCa = LNa+HCa = LCa > HCa = N. The results indicate that rat atrial spontaneous beating is more dependent on [Na]o than on [Ca]o in a range of +/- 50% of their normal concentration.,7516729_9,-1,-1,2,20969,-1
20971,/-,47,48,241,243,The [verapamil]o that arrested atrial beating (AC) was also potentiated with the order LNa = LNa+LCa = LNa+HCa = LCa > HCa = N. The results indicate that rat atrial spontaneous beating is more dependent on [Na]o than on [Ca]o in a range of +/- 50% of their normal concentration.,7516729_9,0,1,2,20971,-1
20973,LNa,13,14,83,86,Also the enhancement of verapamil effects on atrial beating was more pronounced at LNa than at LCa.(ABSTRACT TRUNCATED AT 250 WORDS),7516729_10,-1,-1,2,20973,-1
20974,LCa.(ABSTRACT TRUNCATED,16,18,95,118,Also the enhancement of verapamil effects on atrial beating was more pronounced at LNa than at LCa.(ABSTRACT TRUNCATED AT 250 WORDS),7516729_10,-1,-1,2,20974,-1
20985,glomerular filtration rate,33,36,154,180,"Cyclosporin A (CsA; 50 mg/kg) and Fujimycine (FK506; 5 mg/kg), but not the related macrolide immunosuppressant rapamycin (5 mg/kg), caused a reduction of glomerular filtration rate, degenerative changes of proximal tubular epithelium, and hypertrophy of the juxtaglomerular apparatus in male Wistar rats when given for 10 days.",7542793_1,-1,-1,2,20985,-1
20988,molecular mechanisms,1,3,4,24,The molecular mechanisms of CsA and FK506 toxicity were investigated.,7542793_2,-1,-1,2,20988,-1
20989,CsA,4,5,28,31,The molecular mechanisms of CsA and FK506 toxicity were investigated.,7542793_2,-1,-1,2,20989,-1
20993,intracytoplasmic receptors,8,10,50,76,"Cyclophilin A and FK506-binding protein, the main intracytoplasmic receptors for CsA and FK506, respectively, were each detected in renal tissue extract.",7542793_3,-1,-1,2,20993,-1
21006,nephrotoxic effects,5,7,31,50,These results suggest that the nephrotoxic effects of CsA and FK506 is likely mediated through binding to renal immunophilin and inhibiting calcineurin phosphatase.,7542793_6,-1,-1,2,21006,-1
21023,treated with,2,4,13,25,Two patients treated with parenteral paramethasone (Triniol) and dexamethasone (Sedionbel) are described.,7582165_1,-1,-1,2,21023,-1
21027,patients',12,14,59,68,"The purpose of our study was to determine the cause of the patients' reactions, the immunological mechanisms involved and whether these patients would be able to tolerate any kind of corticoid.",7582165_3,-1,-1,2,21027,-1
21032,prick test,17,19,87,97,"In the two patients, skin and ELISA tests with paramethasone were negative, as was the prick test with each of its excipients.",7582165_5,-1,-1,2,21032,-1
21038,parenteral challenges,6,8,29,50,We also carried out oral and parenteral challenges with other corticosteroids and found intolerance to some of them.,7582165_7,-1,-1,2,21038,-1
21055,clinical effects,29,31,178,194,"Among various oral antiplatelets, a combination of a novel prostacyclin analogue beraprost (BPT) and a potent phosphodiesterase inhibitor cilostazol (CLZ) may result in untoward clinical effects due to possible synergistic elevation of intracellular cAMP (cyclic adenosine 3',5'-monophosphate).",7596955_1,-1,-1,2,21055,-1
21056,synergistic elevation,34,36,211,232,"Among various oral antiplatelets, a combination of a novel prostacyclin analogue beraprost (BPT) and a potent phosphodiesterase inhibitor cilostazol (CLZ) may result in untoward clinical effects due to possible synergistic elevation of intracellular cAMP (cyclic adenosine 3',5'-monophosphate).",7596955_1,-1,-1,2,21056,-1
21059,combined administration,7,9,33,56,"Thereby, a clinical study of the combined administration of the two agents was attempted.",7596955_2,-1,-1,2,21059,-1
21064,time intervals,2,4,11,25,"At various time intervals, physical examination and blood collection for ex vivo platelet aggregation and determination of intraplatelet cAMP were performed.",7596955_4,-1,-1,2,21064,-1
21066,blood collection,8,10,52,68,"At various time intervals, physical examination and blood collection for ex vivo platelet aggregation and determination of intraplatelet cAMP were performed.",7596955_4,-1,-1,2,21066,-1
21069,intraplatelet cAMP,18,20,123,141,"At various time intervals, physical examination and blood collection for ex vivo platelet aggregation and determination of intraplatelet cAMP were performed.",7596955_4,-1,-1,2,21069,-1
21076,/-,11,12,78,80,Intraplatelet cAMP content was gradually but significantly increased to 9.84 +/- 4.59 pmol per 10(9) platelets at day 14 in comparison with the initial value (6.87 +/- 2.25 pmol).,7596955_8,0,1,2,21076,-1
21077,initial value,25,27,144,157,Intraplatelet cAMP content was gradually but significantly increased to 9.84 +/- 4.59 pmol per 10(9) platelets at day 14 in comparison with the initial value (6.87 +/- 2.25 pmol).,7596955_8,-1,-1,2,21077,-1
21079,platelet aggregability,1,3,4,26,The platelet aggregability was significantly suppressed at various time intervals but no additive or synergistic inhibitory effect by the combined administration was noted.,7596955_9,-1,-1,2,21079,-1
21080,time intervals,8,10,67,81,The platelet aggregability was significantly suppressed at various time intervals but no additive or synergistic inhibitory effect by the combined administration was noted.,7596955_9,-1,-1,2,21080,-1
21084,clinical effect,20,22,112,127,"In conclusion, the combined administration of BPT/CLZ is safe at doses used in the study, though the beneficial clinical effect of the combined administration has yet to be elucidated.",7596955_10,-1,-1,2,21084,-1
21085,combined administration,24,26,135,158,"In conclusion, the combined administration of BPT/CLZ is safe at doses used in the study, though the beneficial clinical effect of the combined administration has yet to be elucidated.",7596955_10,-1,-1,2,21085,-1
21088,associated with,6,8,38,53,"A case of acute inflammatory myopathy associated with the use of pravastatin, a new hydrophilic 3-hydroxy-3 methylglutaril coenzyme A reductase inhibitor, is reported.",7604176_2,-1,-1,2,21088,-1
21101,associated with,6,8,43,58,"While lovastatin and simvastatin have been associated with toxic myopathy, pravastatin-associated myopathy could represent a distinct, inflammatory entity.",7604176_8,-1,-1,2,21101,-1
21105,peripheral effect,10,12,46,63,Reversal of ammonia coma in rats by L-dopa: a peripheral effect.,761833_0,-1,-1,2,21105,-1
21106,intraperitonealinjection,13,14,64,88,Ammonia coma was produced in rats within 10 to 15 minutes of an intraperitonealinjection of 1.7 mmol NH4CL.,761833_1,-1,-1,2,21106,-1
21109,brain ammonia,12,14,65,78,"The effect of L-dopa was correlated with a decrease in blood and brain ammonia, an increase in brain dopamine, and an increase in renal excretion of ammonia and urea.",761833_3,-1,-1,2,21109,-1
21111,brain ammonia,25,27,154,167,Intraventricular infusion of dopamine sufficient to raise the brain dopamine to the same extent did not prevent the ammonia coma nor affect the blood and brain ammonia concentrations.,761833_4,-1,-1,2,21111,-1
21113,brain ammonia,11,13,78,91,Bilateral nephrectomy eliminated the beneficial effect of L-dopa on blood and brain ammonia and the ammonia coma was not prevented.,761833_5,-1,-1,2,21113,-1
21114,brain ammonia,7,9,33,46,"Thus, the reduction in blood and brain ammonia and the prevention of ammonia coma after L-dopa, can be accounted for by the peripheral effect of dopamine on renal function rather than its central action.",761833_6,-1,-1,2,21114,-1
21115,peripheral effect,24,26,124,141,"Thus, the reduction in blood and brain ammonia and the prevention of ammonia coma after L-dopa, can be accounted for by the peripheral effect of dopamine on renal function rather than its central action.",761833_6,-1,-1,2,21115,-1
21117,central action,34,36,188,202,"Thus, the reduction in blood and brain ammonia and the prevention of ammonia coma after L-dopa, can be accounted for by the peripheral effect of dopamine on renal function rather than its central action.",761833_6,-1,-1,2,21117,-1
21122,risk factors,18,20,112,124,"The occurrence of a myocardial infarction is reported after chemotherapy containing etoposide, in a man with no risk factors for coronary heart disease.",7619765_1,-1,-1,2,21122,-1
21124,causal mechanisms,1,3,9,26,Possible causal mechanisms are discussed.,7619765_2,-1,-1,2,21124,-1
21127,randomized study,3,5,15,31,"A prospective, randomized study was conducted to evaluate the role of vitamin B12 and folinic acid supplementation in preventing zidovudine (ZDV)-induced bone marrow suppression.",7628595_1,-1,-1,2,21127,-1
21133,cell counts,9,11,76,87,"Seventy-five human immunodeficiency virus (HIV)-infected patients with CD4+ cell counts < 500/mm3 were randomized to receive either ZDV (500 mg daily) alone (group I, n = 38) or in combination with folinic acid (15 mg daily) and intramascular vitamin B12 (1000 micrograms monthly) (group II, n = 37).",7628595_2,-1,-1,2,21133,-1
21134,group I,26,28,158,165,"Seventy-five human immunodeficiency virus (HIV)-infected patients with CD4+ cell counts < 500/mm3 were randomized to receive either ZDV (500 mg daily) alone (group I, n = 38) or in combination with folinic acid (15 mg daily) and intramascular vitamin B12 (1000 micrograms monthly) (group II, n = 37).",7628595_2,-1,-1,2,21134,-1
21139,group I,24,26,104,111,"Finally, 15 patients were excluded from the study (noncompliance 14, death 1); thus, 60 patients (31 in group I and 29 in group II) were eligible for analysis.",7628595_3,-1,-1,2,21139,-1
21144,platelet counts,35,37,203,218,"During the study, vitamin B12 and folate levels were significantly higher in group II patients; however, no differences in hemoglobin, hematocrit, mean corpuscular volume, and white-cell, neutrophil and platelet counts were observed between groups at 3, 6, 9 and 12 months.",7628595_5,-1,-1,2,21144,-1
21145,group I,20,22,120,127,Severe hematologic toxicity (neutrophil count < 1000/mm3 and/or hemoglobin < 8 g/dl) occurred in 4 patients assigned to group I and 7 assigned to group II.,7628595_6,-1,-1,2,21145,-1
21155,liver adducts,3,5,29,42,Halogenated anesthetics form liver adducts and antigens that cross-react with halothane-induced antibodies.,7647582_0,-1,-1,2,21155,-1
21156,cross-react,8,9,61,72,Halogenated anesthetics form liver adducts and antigens that cross-react with halothane-induced antibodies.,7647582_0,-1,-1,2,21156,-1
21159,associated with,10,12,65,80,"Two halogenated anesthetics, enflurane and isoflurane, have been associated with an allergic-type hepatic injury both alone and following previous exposure to halothane.",7647582_1,-1,-1,2,21159,-1
21160,allergic-type,13,14,84,97,"Two halogenated anesthetics, enflurane and isoflurane, have been associated with an allergic-type hepatic injury both alone and following previous exposure to halothane.",7647582_1,-1,-1,2,21160,-1
21163,antibody response,1,3,3,20,An antibody response to a protein-bound biotransformation product (trifluoroacetyl adduct) has been detected on halothane hepatitis patients.,7647582_3,-1,-1,2,21163,-1
21165,cross-reactivity,6,7,38,54,This study was performed to determine cross-reactivity between enflurane and isoflurane with the hypersensitivity induced by halothane.,7647582_4,-1,-1,2,21165,-1
21167,lobular production,3,5,20,38,"The subcellular and lobular production of hepatic neoantigens recognized by halothane-induced antibodies following enflurane and isoflurane, and the biochemical nature of these neoantigens was investigated in two animal models.",7647582_5,-1,-1,2,21167,-1
21172,Enflurane administration,0,2,0,24,Enflurane administration resulted in neoantigens detected in both the microsomal and cytosolic fraction of liver homogenates and in the centrilobular region of the liver.,7647582_6,-1,-1,2,21172,-1
21175,liver homogenates,14,16,107,124,Enflurane administration resulted in neoantigens detected in both the microsomal and cytosolic fraction of liver homogenates and in the centrilobular region of the liver.,7647582_6,-1,-1,2,21175,-1
21177,biochemical analysis,5,7,19,39,"In the same liver, biochemical analysis detected fluorinated liver adducts that were up to 20-fold greater in guinea pigs than in rats.",7647582_7,-1,-1,2,21177,-1
21179,liver adducts,9,11,61,74,"In the same liver, biochemical analysis detected fluorinated liver adducts that were up to 20-fold greater in guinea pigs than in rats.",7647582_7,-1,-1,2,21179,-1
21189,Red blood cell,0,3,0,14,Red blood cell and serum cholinesterase levels were severely depressed and symptoms resolved spontaneously following discontinuation of the eye drops.,7650771_2,-1,-1,2,21189,-1
21195,reverse sedation,8,10,59,75,Flumazenil is a benzodiazepine receptor antagonist used to reverse sedation and respiratory depression induced by benzodiazepines.,7651879_1,-1,-1,2,21195,-1
21202,Phase I trial,0,3,0,13,Phase I trial of 13-cis-retinoic acid in children with neuroblastoma following bone marrow transplantation.,7707116_0,-1,-1,2,21202,-1
21205,cell lines,5,7,36,46,PURPOSE: Treatment of neuroblastoma cell lines with 13-cis-retinoic acid (cis-RA) can cause sustained inhibition of proliferation.,7707116_1,-1,-1,2,21205,-1
21207,clinical responses,4,6,30,48,"Since cis-RA has demonstrated clinical responses in neuroblastoma patients, it may be effective in preventing relapse after cytotoxic therapy.",7707116_2,-1,-1,2,21207,-1
21209,phase I trial,1,4,5,18,"This phase I trial was designed to determine the maximal-tolerated dosage (MTD), toxicities, and pharmacokinetics of cis-RA administered on an intermittent schedule in children with neuroblastoma following bone marrow transplantation (BMT).",7707116_3,-1,-1,2,21209,-1
21214,BMT,35,36,235,238,"This phase I trial was designed to determine the maximal-tolerated dosage (MTD), toxicities, and pharmacokinetics of cis-RA administered on an intermittent schedule in children with neuroblastoma following bone marrow transplantation (BMT).",7707116_3,-1,-1,2,21214,-1
21216,mg/m2/d,8,9,39,46,The dose was escalated from 100 to 200 mg/m2/d until dose-limiting toxicity (DLT) was observed.,7707116_5,-1,-1,2,21216,-1
21218,DLT,13,14,77,80,The dose was escalated from 100 to 200 mg/m2/d until dose-limiting toxicity (DLT) was observed.,7707116_5,-1,-1,2,21218,-1
21219,MTD,3,4,13,16,RESULTS: The MTD of cis-RA was 160 mg/m2/d.,7707116_7,-1,-1,2,21219,-1
21221,mg/m2/d,8,9,35,42,RESULTS: The MTD of cis-RA was 160 mg/m2/d.,7707116_7,-1,-1,2,21221,-1
21223,mg/m2/d,9,10,56,63,"Dose-limiting toxicities in six of nine patients at 200 mg/m2/d included hypercalcemia (n = 3), rash (n = 2), and anemia/thrombocytopenia/emesis/rash (n = 1).",7707116_8,-1,-1,2,21223,-1
21227,/-,5,6,21,23,Serum levels of 7.4 +/- 3.0 mumol/L (peak) and 4.0 +/- 2.8 mumol/L (trough) at the MTD were maintained during 14 days of therapy.,7707116_11,0,1,2,21227,-1
21228,/-,14,15,52,54,Serum levels of 7.4 +/- 3.0 mumol/L (peak) and 4.0 +/- 2.8 mumol/L (trough) at the MTD were maintained during 14 days of therapy.,7707116_11,0,1,2,21228,-1
21229,MTD,22,23,83,86,Serum levels of 7.4 +/- 3.0 mumol/L (peak) and 4.0 +/- 2.8 mumol/L (trough) at the MTD were maintained during 14 days of therapy.,7707116_11,-1,-1,2,21229,-1
21230,DLT,1,2,4,7,The DLT correlated with serum levels > or = 10 mumol/L. CONCLUSION: The MTD of cis-RA given on this intermittent schedule was 160 mg/m2/d.,7707116_12,-1,-1,2,21230,-1
21231,serum levels,4,6,24,36,The DLT correlated with serum levels > or = 10 mumol/L. CONCLUSION: The MTD of cis-RA given on this intermittent schedule was 160 mg/m2/d.,7707116_12,-1,-1,2,21231,-1
21234,mg/m2/d,24,25,130,137,The DLT correlated with serum levels > or = 10 mumol/L. CONCLUSION: The MTD of cis-RA given on this intermittent schedule was 160 mg/m2/d.,7707116_12,-1,-1,2,21234,-1
21235,in vitro,8,10,57,65,Serum levels known to be effective against neuroblastoma in vitro were achieved at this dose.,7707116_13,-1,-1,2,21235,-1
21236,DLT,1,2,4,7,"The DLT included hypercalcemia, and may be predicted by serum cis-RA levels.",7707116_14,-1,-1,2,21236,-1
21237,serum calcium,2,4,14,27,Monitoring of serum calcium and cis-RA levels is indicated in future trials.,7707116_15,-1,-1,2,21237,-1
21244,venous blood samples,1,4,11,31,"Peripheral venous blood samples were withdrawn from the femoral vein four times (once every 5 min) before ischemia (0 time) and 5, 15, and 30 min after ischemia.",7710775_2,-1,-1,2,21244,-1
21245,femoral vein four times,8,12,56,79,"Peripheral venous blood samples were withdrawn from the femoral vein four times (once every 5 min) before ischemia (0 time) and 5, 15, and 30 min after ischemia.",7710775_2,-1,-1,2,21245,-1
21246,liquid chromatographic method,9,12,69,98,"Plasma extracts were analyzed by a highly sensitive high-performance liquid chromatographic method for the direct determination of malondialdehyde, oxypurines, and nucleosides.",7710775_3,-1,-1,2,21246,-1
21251,zero time,10,12,63,72,"Plasma malondialdehyde, which was present in minimal amount at zero time (0.058 mumol/liter plasma; SD 0.015), increased after 5 min of ischemia, resulting in a fivefold increase after 30 min of carotid occlusion (0.298 mumol/liter plasma; SD 0.078).",7710775_5,-1,-1,2,21251,-1
21254,mumol/liter plasma,41,43,220,238,"Plasma malondialdehyde, which was present in minimal amount at zero time (0.058 mumol/liter plasma; SD 0.015), increased after 5 min of ischemia, resulting in a fivefold increase after 30 min of carotid occlusion (0.298 mumol/liter plasma; SD 0.078).",7710775_5,-1,-1,2,21254,-1
21256,experimental model,16,18,104,122,"Increased plasma malondialdehyde was also recorded in two other groups of animals subjected to the same experimental model, one receiving 20 mg/kg b.w. of the cyclooxygenase inhibitor acetylsalicylate intravenously immediately before ischemia, the other receiving 650 micrograms/kg b.w. of the hypotensive drug nitroprusside at a flow rate of 103 microliters/min intravenously during ischemia, although in this latter group malondialdehyde was significantly higher.",7710775_6,-1,-1,2,21256,-1
21259,flow rate,49,51,330,339,"Increased plasma malondialdehyde was also recorded in two other groups of animals subjected to the same experimental model, one receiving 20 mg/kg b.w. of the cyclooxygenase inhibitor acetylsalicylate intravenously immediately before ischemia, the other receiving 650 micrograms/kg b.w. of the hypotensive drug nitroprusside at a flow rate of 103 microliters/min intravenously during ischemia, although in this latter group malondialdehyde was significantly higher.",7710775_6,-1,-1,2,21259,-1
21260,microliters/min,53,54,347,362,"Increased plasma malondialdehyde was also recorded in two other groups of animals subjected to the same experimental model, one receiving 20 mg/kg b.w. of the cyclooxygenase inhibitor acetylsalicylate intravenously immediately before ischemia, the other receiving 650 micrograms/kg b.w. of the hypotensive drug nitroprusside at a flow rate of 103 microliters/min intravenously during ischemia, although in this latter group malondialdehyde was significantly higher.",7710775_6,-1,-1,2,21260,-1
21271,control animals,23,25,97,112,"In normal rats, 2/6 rats given free doxorubicin (DX) (5 mg/kg) died within one week, whereas all control animals and all rats having received free NP or DXNP survived.",7724492_2,-1,-1,2,21271,-1
21273,treated with,8,10,49,61,A 3 times higher proteinuria appeared in animals treated with DXNP than in those treated with DX.,7724492_3,-1,-1,2,21273,-1
21275,treated with,14,16,81,93,A 3 times higher proteinuria appeared in animals treated with DXNP than in those treated with DX.,7724492_3,-1,-1,2,21275,-1
21279,free DX,13,15,76,83,"Two hr post-injection, DXNP was 2.7 times more concentrated in kidneys than free DX (p < 0.025).",7724492_5,-1,-1,2,21279,-1
21283,DX,37,38,187,189,"Proteinuria appeared in all series, but was 2-5 times more intense (p > 0.001) and prolonged after doxorubicin treatment (400-700 mg/day), without significant difference between DXNP and DX.",7724492_7,-1,-1,2,21283,-1
21284,experimental conditions,7,9,41,64,"These results demonstrate that, in these experimental conditions, DXNP killed less animals than free DX, despite of an enhanced renal toxicity of the former.",7724492_9,-1,-1,2,21284,-1
21285,DXNP killed less,10,13,66,82,"These results demonstrate that, in these experimental conditions, DXNP killed less animals than free DX, despite of an enhanced renal toxicity of the former.",7724492_9,-1,-1,2,21285,-1
21286,free DX,15,17,96,103,"These results demonstrate that, in these experimental conditions, DXNP killed less animals than free DX, despite of an enhanced renal toxicity of the former.",7724492_9,-1,-1,2,21286,-1
21289,mononuclear phagocyte system,22,25,118,146,"Both effects (better survival and nephrosis) are most probably related to an enhanced capture of DXNP by cells of the mononuclear phagocyte system, including mesangial cells.",7724492_10,-1,-1,2,21289,-1
21304,contractant,23,24,153,164,"Intra-arterially given PGE2 produced a distinct increase in bladder pressure before initiating a micturition reflex, indicating that the PG had a direct contractant effect on the detrusor smooth muscle.",7752389_2,-1,-1,2,21304,-1
21305,detrusor smooth muscle,27,30,179,201,"Intra-arterially given PGE2 produced a distinct increase in bladder pressure before initiating a micturition reflex, indicating that the PG had a direct contractant effect on the detrusor smooth muscle.",7752389_2,-1,-1,2,21305,-1
21317,intravesically,4,5,20,34,"However, when given intravesically, PGE2 may stimulate micturition by releasing tachykinins from nerves in and/or immediately below the urothelium.",7752389_5,-1,-1,2,21317,-1
21336,use of,22,24,176,182,A seventy-eight-year-old woman presented with complete heart block and refractory hypotension two days after a therapeutic dose of sustained-release verapamil with concomitant use of metoprolol.,7785794_2,-1,-1,2,21336,-1
21351,treated with,17,19,121,133,OBJECTIVE: To evaluate the possible protective effects of misoprostol on renal function in hospitalized elderly patients treated with indomethacin.,7791169_1,-1,-1,2,21351,-1
21354,mg/day,31,32,196,202,"METHODS: Forty-five hospitalized elderly patients (> 65 years old) who required therapy with nonsteroidal antiinflammatory drugs (NSAID) were randomly assigned to receive either indomethacin, 150 mg/day (Group A), or indomethacin 150 mg/day plus misoprostol at 0.6 mg/day (Group B).",7791169_2,-1,-1,2,21354,-1
21356,mg/day,40,41,234,240,"METHODS: Forty-five hospitalized elderly patients (> 65 years old) who required therapy with nonsteroidal antiinflammatory drugs (NSAID) were randomly assigned to receive either indomethacin, 150 mg/day (Group A), or indomethacin 150 mg/day plus misoprostol at 0.6 mg/day (Group B).",7791169_2,-1,-1,2,21356,-1
21358,mg/day,45,46,265,271,"METHODS: Forty-five hospitalized elderly patients (> 65 years old) who required therapy with nonsteroidal antiinflammatory drugs (NSAID) were randomly assigned to receive either indomethacin, 150 mg/day (Group A), or indomethacin 150 mg/day plus misoprostol at 0.6 mg/day (Group B).",7791169_2,-1,-1,2,21358,-1
21360,Laboratory variables,0,2,0,20,"Laboratory variables of renal function [serum creatinine, blood urea nitrogen (BUN) and electrolytes] were evaluated before initiation of therapy and every 2 days, until termination of the study (a period of at least 6 days).",7791169_3,-1,-1,2,21360,-1
21365,Group B. BUN,15,18,73,85,"RESULTS: Forty-two patients completed the study, 22 in Group A and 20 in Group B. BUN and creatinine increased by > 50% of baseline levels in 54 and 45% of Group A patients, respectively, compared to only 20 and 10% of Group B patients (p < 0.05).",7791169_5,-1,-1,2,21365,-1
21369,mEq/l,7,8,31,36,"Potassium (K) increment of 0.6 mEq/l or more was observed in 50% of Group A, but in only 15% of Group B patients (p < 0.05).",7791169_6,-1,-1,2,21369,-1
21374,A. Response,30,32,131,142,"The mean increments in BUN, creatinine, and K were reduced by 63, 80, and 42%, respectively, in Group B patients compared to Group A. Response to treatment did not differ significantly between the 2 groups.",7791169_7,-1,-1,2,21374,-1
21381,Controlled study,0,2,0,16,Controlled study in agoraphobia with panic disorder.,7802851_1,-1,-1,2,21381,-1
21386,drug groups,21,23,131,142,"The efficacy of alprazolam and placebo in panic disorder with agoraphobia, and the side-effect and adverse effect profiles of both drug groups were measured.",7802851_3,-1,-1,2,21386,-1
21387,DSM-III criteria,10,12,51,67,METHOD: In London and Toronto 154 patients who met DSM-III criteria for panic disorder with agoraphobia were randomised to alprazolam or placebo.,7802851_4,-1,-1,2,21387,-1
21389,drug group,3,5,17,27,Subjects in each drug group also received either exposure or relaxation.,7802851_5,-1,-1,2,21389,-1
21390,placebo subjects,2,4,14,30,"Compared with placebo subjects, alprazolam patients developed more adverse reactions (21% v. 0%) of depression, enuresis, disinhibition and aggression; and more side-effects, particularly sedation, irritability, impaired memory, weight loss and ataxia.",7802851_8,-1,-1,2,21390,-1
21397,drop-out rate,4,6,18,31,"Despite this, the drop-out rate was low.",7802851_10,-1,-1,2,21397,-1
21407,Bornstein 1968,3,5,17,31,Initial studies (Bornstein 1968) showed that it possessed no respiratory suppressant effects and no addiction liability.,7803371_2,-1,-1,2,21407,-1
21417,McCarthy 1971,61,63,323,336,"The drug is known to cause a variety of acute toxic effects, ranging from nausea, restlessness, insomnia, ataxia, slurred speech and nystagmus to mood changes, perceptual alterations, inattention, disorientation and aggressive behavior (Rammer et al 1988; Katona and Watson 1986; Isbell and Fraser 1953; Devlin et al 1985; McCarthy 1971; Dodds and Revai 1967; Degkwitz 1964; Hildebrand et al 1989).",7803371_4,-1,-1,2,21417,-1
21418,Dodds,64,65,338,343,"The drug is known to cause a variety of acute toxic effects, ranging from nausea, restlessness, insomnia, ataxia, slurred speech and nystagmus to mood changes, perceptual alterations, inattention, disorientation and aggressive behavior (Rammer et al 1988; Katona and Watson 1986; Isbell and Fraser 1953; Devlin et al 1985; McCarthy 1971; Dodds and Revai 1967; Degkwitz 1964; Hildebrand et al 1989).",7803371_4,-1,-1,2,21418,-1
21419,DM overdoses,8,10,50,62,There have also been two reported fatalities from DM overdoses (Fleming 1986).,7803371_5,-1,-1,2,21419,-1
21420,effects of,8,10,45,55,"However, there are no reports describing the effects of chronic abuse.",7803371_6,-1,-1,2,21420,-1
21423,use of,11,13,81,87,This report describes a case of cognitive deterioration resulting from prolonged use of DM.,7803371_7,-1,-1,2,21423,-1
21429,effects of,1,3,4,14,"The effects of digitalis glycosides on myocardial oxygen supply and demand are of particular interest in the presence of obstructive coronary artery disease, but have not been measured previously in man.",783197_2,-1,-1,2,21429,-1
21442,mean+/-SE,8,9,62,71,Left ventricular end-diastolic pressure fell from 11.5+/-1.4 (mean+/-SE) to 5.6+/-0.9 mm Hg (P less than 0.001) and left ventricular end-diastolic volume fell from 100+/-17 to 82+/-12 ml/m2 (P less than 0.01) 1 h after ouabain infusion was completed.,783197_6,-1,-1,2,21442,-1
21445,maximum velocity,1,3,4,20,The maximum velocity of contractile element shortening increased from 1.68+/-0.11 ml/s to 2.18+/-0.21 muscle-lengths/s (P less than 0.05) and is consistent with an increase in contractility.,783197_7,-1,-1,2,21445,-1
21446,contractile element,4,6,24,43,The maximum velocity of contractile element shortening increased from 1.68+/-0.11 ml/s to 2.18+/-0.21 muscle-lengths/s (P less than 0.05) and is consistent with an increase in contractility.,783197_7,-1,-1,2,21446,-1
21447,consistent with,22,24,145,160,The maximum velocity of contractile element shortening increased from 1.68+/-0.11 ml/s to 2.18+/-0.21 muscle-lengths/s (P less than 0.05) and is consistent with an increase in contractility.,783197_7,-1,-1,2,21447,-1
21449,control patients,9,11,58,74,No significant change in these parameters occurred in the control patients.,783197_8,-1,-1,2,21449,-1
21454,control patients,31,33,201,217,No significant change in myocardial oxygen consumption occurred after ouabain administration but this may be related to a greater decrease in mean arterial pressure in the ouabain patients than in the control patients.,783197_9,-1,-1,2,21454,-1
21458,associated with,5,7,26,41,"Though this fall would be associated with a decrease in wall tension, and, therefore, of myocardial oxygen consumption, it may not be of sufficient magnitude to prevent a net increase in myocardial oxygen consumption.",783197_11,-1,-1,2,21458,-1
21463,associated with,3,5,41,56,Crescentic fibrillary glomerulonephritis associated with intermittent rifampin therapy for pulmonary tuberculosis.,7834920_0,-1,-1,2,21463,-1
21471,electron dense fibrillar deposits,8,12,64,97,"Renal biopsy revealed severe glomerulonephritis with crescents, electron dense fibrillar deposits and moderate lymphocytic interstitial infiltrate.",7834920_3,-1,-1,2,21471,-1
21474,treated with,18,20,148,160,This report documents the unusual occurrence of rapidly progressive glomerulonephritis with crescents and fibrillar glomerulonephritis in a patient treated with rifampin.,7834920_5,-1,-1,2,21474,-1
21479,outflow facility,15,17,100,116,"The purpose of this study was to determine whether glucocorticoid treatment can directly affect the outflow facility of isolated, perfusion-cultured human eyes.",7843916_2,-1,-1,2,21479,-1
21483,constant flow,17,19,92,105,"METHODS: The anterior segments of human donor eyes from regional eye banks were placed in a constant flow, variable pressure perfusion culture system.",7843916_3,-1,-1,2,21483,-1
21484,variable pressure,20,22,107,124,"METHODS: The anterior segments of human donor eyes from regional eye banks were placed in a constant flow, variable pressure perfusion culture system.",7843916_3,-1,-1,2,21484,-1
21488,light microscopy,9,11,65,81,"After incubation, the eyes were morphologically characterized by light microscopy, transmission and scanning electron microscopy, and scanning laser confocal microscopy.",7843916_6,-1,-1,2,21488,-1
21489,scanning electron microscopy,14,17,100,128,"After incubation, the eyes were morphologically characterized by light microscopy, transmission and scanning electron microscopy, and scanning laser confocal microscopy.",7843916_6,-1,-1,2,21489,-1
21490,scanning laser confocal microscopy,19,23,134,168,"After incubation, the eyes were morphologically characterized by light microscopy, transmission and scanning electron microscopy, and scanning laser confocal microscopy.",7843916_6,-1,-1,2,21490,-1
21492,average pressure,22,24,132,148,RESULTS: A significant increase in intraocular pressure developed in 13 of the 44 pairs of eyes perfused with dexamethasone with an average pressure rise of 17.5 +/- 3.8 mm Hg after 12 days of dexamethasone exposure.,7843916_7,-1,-1,2,21492,-1
21493,/-,28,29,163,165,RESULTS: A significant increase in intraocular pressure developed in 13 of the 44 pairs of eyes perfused with dexamethasone with an average pressure rise of 17.5 +/- 3.8 mm Hg after 12 days of dexamethasone exposure.,7843916_7,0,1,2,21493,-1
21496,dexamethasone-treated hypertensive eyes,4,7,17,56,"In contrast, the dexamethasone-treated hypertensive eyes had thickened trabecular beams, decreased intertrabecular spaces, thickened juxtacanalicular tissue, activated trabecular meshwork cells, and increased amounts of amorphogranular extracellular material, especially in the juxtacanalicular tissue and beneath the endothelial lining of the canal of Schlemm.",7843916_10,-1,-1,2,21496,-1
21500,trabecular meshwork,21,23,168,187,"In contrast, the dexamethasone-treated hypertensive eyes had thickened trabecular beams, decreased intertrabecular spaces, thickened juxtacanalicular tissue, activated trabecular meshwork cells, and increased amounts of amorphogranular extracellular material, especially in the juxtacanalicular tissue and beneath the endothelial lining of the canal of Schlemm.",7843916_10,-1,-1,2,21500,-1
21503,endothelial lining,41,43,318,336,"In contrast, the dexamethasone-treated hypertensive eyes had thickened trabecular beams, decreased intertrabecular spaces, thickened juxtacanalicular tissue, activated trabecular meshwork cells, and increased amounts of amorphogranular extracellular material, especially in the juxtacanalicular tissue and beneath the endothelial lining of the canal of Schlemm.",7843916_10,-1,-1,2,21503,-1
21504,canal of Schlemm,45,48,344,360,"In contrast, the dexamethasone-treated hypertensive eyes had thickened trabecular beams, decreased intertrabecular spaces, thickened juxtacanalicular tissue, activated trabecular meshwork cells, and increased amounts of amorphogranular extracellular material, especially in the juxtacanalicular tissue and beneath the endothelial lining of the canal of Schlemm.",7843916_10,-1,-1,2,21504,-1
21505,dexamethasone-treated nonresponder,1,3,4,38,"The dexamethasone-treated nonresponder eyes appeared to be morphologically similar to the untreated eyes, although several subtle dexamethasone-induced morphologic changes were evident.",7843916_11,-1,-1,2,21505,-1
21506,dexamethasone-induced morphologic changes,17,20,130,171,"The dexamethasone-treated nonresponder eyes appeared to be morphologically similar to the untreated eyes, although several subtle dexamethasone-induced morphologic changes were evident.",7843916_11,-1,-1,2,21506,-1
21508,dexamethasone-treated eyes,23,25,152,178,"CONCLUSION: Dexamethasone treatment of isolated, perfusion-cultured human eyes led to the generation of ocular hypertension in approximately 30% of the dexamethasone-treated eyes.",7843916_12,-1,-1,2,21508,-1
21513,acute model,5,7,27,38,This system may provide an acute model in which to study the pathogenic mechanisms involved in steroid glaucoma and primary open angle glaucoma.,7843916_14,-1,-1,2,21513,-1
21514,pathogenic mechanisms,12,14,61,82,This system may provide an acute model in which to study the pathogenic mechanisms involved in steroid glaucoma and primary open angle glaucoma.,7843916_14,-1,-1,2,21514,-1
21519,treated with,4,6,22,34,"A 61-year-old man was treated with combination chemotherapy incorporating cisplatinum, etoposide, high-dose 5-fluorouracil (2,250 mg/m2/24 hours) and folinic acid for an inoperable gastric adenocarcinoma.",7858459_1,-1,-1,2,21519,-1
21535,associated with,7,9,40,55,"Because folinic acid was unlikely to be associated with this condition, neurotoxicity due to high-dose 5-fluorouracil was highly suspected.",7858459_4,-1,-1,2,21535,-1
21552,clinical deteriotation,6,8,32,54,None of the patients showed any clinical deteriotation during the following 3-6 months.,7862923_4,-1,-1,2,21552,-1
21564,IBPB,22,23,139,143,We performed an audiometric study in 20 patients who underwent surgery of the shoulder region under an interscalene brachial plexus block (IBPB).,7880714_1,-1,-1,2,21564,-1
21581,treated with,2,4,10,22,"Rats were treated with a single IV injection of puromycin aminonucleoside, (PAN, 7.5 mg/kg) and 24 hour urine samples were obtained prior to sacrifice on days 3,5,7,10,17,27,41 (N = 5-10 per group).",7881871_3,-1,-1,2,21581,-1
21583,urine samples,21,23,104,117,"Rats were treated with a single IV injection of puromycin aminonucleoside, (PAN, 7.5 mg/kg) and 24 hour urine samples were obtained prior to sacrifice on days 3,5,7,10,17,27,41 (N = 5-10 per group).",7881871_3,-1,-1,2,21583,-1
21584,"3,5,7,10,17,27,41",30,31,159,176,"Rats were treated with a single IV injection of puromycin aminonucleoside, (PAN, 7.5 mg/kg) and 24 hour urine samples were obtained prior to sacrifice on days 3,5,7,10,17,27,41 (N = 5-10 per group).",7881871_3,-1,-1,2,21584,-1
21589,lipid extracts,12,14,74,88,Tissue lipid peroxidation was measured in whole homogenates as well as in lipid extracts from homogenates as thiobarbituric acid reactive substances.,7881871_6,-1,-1,2,21589,-1
21597,associated with,5,7,35,50,Composition of gall bladder stones associated with octreotide: response to oral ursodeoxycholic acid.,7890216_0,-1,-1,2,21597,-1
21607,Hounsfield units,25,27,150,166,"In the remaining 12 patients, localised computed tomography of the gall bladder showed that eight had stones with maximum attenuation scores of < 100 Hounsfield units (values of < 100 HU predict cholesterol rich, dissolvable stones).",7890216_4,-1,-1,2,21607,-1
21613,cholesterol saturation index,11,14,53,81,"All six patients had supersaturated bile (mean (SEM) cholesterol saturation index of 1.19 (0.08) (range 1.01-1.53)) and all had abnormally rapid cholesterol microcrystal nucleation times (< 4 days (range 1-4)), whilst in four, the bile contained cholesterol microcrystals immediately after sampling.",7890216_6,-1,-1,2,21613,-1
21631,CD4 cells/mm3.We,21,23,135,151,"The safety and efficacy of combination N-butyl-deoxynojirimycin (SC-48334) and zidovudine in patients with HIV-1 infection and 200-500 CD4 cells/mm3.We conducted a double-blind, randomized phase II study to evaluate the safety and activity of combination therapy with N-butyl-deoxynojirimycin (SC-48334) (an alpha-glucosidase I inhibitor) and zidovudine versus zidovudine alone.",7905523_0,-1,-1,2,21631,-1
21633,randomized phase II study,27,31,178,203,"The safety and efficacy of combination N-butyl-deoxynojirimycin (SC-48334) and zidovudine in patients with HIV-1 infection and 200-500 CD4 cells/mm3.We conducted a double-blind, randomized phase II study to evaluate the safety and activity of combination therapy with N-butyl-deoxynojirimycin (SC-48334) (an alpha-glucosidase I inhibitor) and zidovudine versus zidovudine alone.",7905523_0,-1,-1,2,21633,-1
21638,CD4 cells/mm3,5,7,25,38,Patients with 200 to 500 CD4 cells/mm3 who tolerated < or = 12 weeks of prior zidovudine therapy received SC-48334 (1000 mg every 8 h) and zidovudine (100 mg every 8 h) or zidovudine and placebo.,7905523_1,-1,-1,2,21638,-1
21642,steady-state,3,4,18,30,The mean SC-48334 steady-state trough level (4.04 +/- 0.99 micrograms/ml) was below the in vitro inhibitory concentration for human immunodeficiency virus (HIV).,7905523_4,-1,-1,2,21642,-1
21643,/-,9,10,51,53,The mean SC-48334 steady-state trough level (4.04 +/- 0.99 micrograms/ml) was below the in vitro inhibitory concentration for human immunodeficiency virus (HIV).,7905523_4,0,1,2,21643,-1
21647,CD4 cells,11,13,63,72,"For patients with prior zidovudine therapy, the mean change in CD4 cells in the combination and zidovudine groups was 63.7 cells/mm3 and 4.9 cells/mm3 at week 8 and 6.8 cells/mm3 and -45.1 cells/mm3 at week 16, respectively.",7905523_6,-1,-1,2,21647,-1
21658,predisposing factors,31,33,187,207,"The long-term use of nondepolarizing neuromuscular blocking agents (ND-NMBA) has recently been implicated as a cause of prolonged muscle weakness, although the site of the lesion and the predisposing factors have been unclear.",7910951_1,-1,-1,2,21658,-1
21663,Electrophysiologic studies,0,2,0,26,"Electrophysiologic studies revealed low amplitude compound motor action potentials, normal sensory studies, and fibrillations.",7910951_5,-1,-1,2,21663,-1
21664,low amplitude compound,3,6,36,58,"Electrophysiologic studies revealed low amplitude compound motor action potentials, normal sensory studies, and fibrillations.",7910951_5,-1,-1,2,21664,-1
21668,decremental response,7,9,40,60,Repetitive stimulation at 2 Hz showed a decremental response in 2 patients.,7910951_6,-1,-1,2,21668,-1
21675,risk factors,6,8,50,62,Hepatic dysfunction and acidosis are contributing risk factors.,7910951_9,-1,-1,2,21675,-1
21684,treated with,3,5,16,28,The patient was treated with methylprednisolone and gradually improved.,7919560_4,-1,-1,2,21684,-1
21686,Macrophage-migration inhibition (MIF) test,0,6,0,42,Macrophage-migration inhibition (MIF) test with ampicillin was positive.,7919560_5,-1,-1,2,21686,-1
21689,MIF test,1,3,9,17,Positive MIF test for ampicillin showed sensitization of the patient's lymphocytes to ampicillin.,7919560_7,-1,-1,2,21689,-1
21690,patient's,9,11,61,70,Positive MIF test for ampicillin showed sensitization of the patient's lymphocytes to ampicillin.,7919560_7,-1,-1,2,21690,-1
21695,secretory rate,20,22,122,136,"The present study was undertaken to examine the role of sleep disturbance, induced by clomipramine administration, on the secretory rate of prolactin (PRL) in addition to the direct drug effect.",7930386_1,-1,-1,2,21695,-1
21697,drug effect,32,34,182,193,"The present study was undertaken to examine the role of sleep disturbance, induced by clomipramine administration, on the secretory rate of prolactin (PRL) in addition to the direct drug effect.",7930386_1,-1,-1,2,21697,-1
21698,placebo-controlled conditions,8,10,49,78,"Two groups of supine subjects were studied under placebo-controlled conditions, one during the night, when sleeping (n = 7) and the other at daytime, when awake (n = 6).",7930386_2,-1,-1,2,21698,-1
21699,orally 2 hours,11,14,64,78,Each subject received a single 50 mg dose of clomipramine given orally 2 hours before blood collection.,7930386_3,-1,-1,2,21699,-1
21703,secretory rates,11,13,75,90,Plasma PRL concentrations were analysed at 10 min intervals and underlying secretory rates calculated by a deconvolution procedure.,7930386_4,-1,-1,2,21703,-1
21704,deconvolution procedure,16,18,107,130,Plasma PRL concentrations were analysed at 10 min intervals and underlying secretory rates calculated by a deconvolution procedure.,7930386_4,-1,-1,2,21704,-1
21706,PRL,11,12,69,72,"For both experiments the drug intake led to significant increases in PRL secretion, acting preferentially on tonic secretion as pulse amplitude and frequency did not differ significantly from corresponding control values.",7930386_5,-1,-1,2,21706,-1
21708,pulse amplitude,20,22,128,143,"For both experiments the drug intake led to significant increases in PRL secretion, acting preferentially on tonic secretion as pulse amplitude and frequency did not differ significantly from corresponding control values.",7930386_5,-1,-1,2,21708,-1
21709,control values,30,32,206,220,"For both experiments the drug intake led to significant increases in PRL secretion, acting preferentially on tonic secretion as pulse amplitude and frequency did not differ significantly from corresponding control values.",7930386_5,-1,-1,2,21709,-1
21713,time studies,23,25,135,147,"As the relative increase in PRL secretion expressed as a percentage of the mean did not significantly differ between the night and day time studies (46 +/- 19% vs 34 +/- 10%), it can be concluded that the observed sleep disturbance did not interfere with the drug action per se.",7930386_7,-1,-1,2,21713,-1
21714,/-,28,29,153,155,"As the relative increase in PRL secretion expressed as a percentage of the mean did not significantly differ between the night and day time studies (46 +/- 19% vs 34 +/- 10%), it can be concluded that the observed sleep disturbance did not interfere with the drug action per se.",7930386_7,0,1,2,21714,-1
21715,/-,34,35,167,169,"As the relative increase in PRL secretion expressed as a percentage of the mean did not significantly differ between the night and day time studies (46 +/- 19% vs 34 +/- 10%), it can be concluded that the observed sleep disturbance did not interfere with the drug action per se.",7930386_7,0,1,2,21715,-1
21717,interfere with,50,52,240,254,"As the relative increase in PRL secretion expressed as a percentage of the mean did not significantly differ between the night and day time studies (46 +/- 19% vs 34 +/- 10%), it can be concluded that the observed sleep disturbance did not interfere with the drug action per se.",7930386_7,-1,-1,2,21717,-1
21718,drug action,53,55,259,270,"As the relative increase in PRL secretion expressed as a percentage of the mean did not significantly differ between the night and day time studies (46 +/- 19% vs 34 +/- 10%), it can be concluded that the observed sleep disturbance did not interfere with the drug action per se.",7930386_7,-1,-1,2,21718,-1
21720,secretory pulse amplitude,15,18,78,103,"The presence of REM sleep was shown not to be a determining factor either for secretory pulse amplitude and frequency, as, for both, mean nocturnal values were similar with and without prior clomipramine ingestion.",7930386_8,-1,-1,2,21720,-1
21721,nocturnal values,27,29,138,154,"The presence of REM sleep was shown not to be a determining factor either for secretory pulse amplitude and frequency, as, for both, mean nocturnal values were similar with and without prior clomipramine ingestion.",7930386_8,-1,-1,2,21721,-1
21726,Topcon,29,30,169,175,"METHODS: We sent a questionnaire concerning complications of indocyanine green to 32 institutions in Japan, which were selected on the basis of the client list from the Topcon Company, which manufactures the indocyanine green fundus camera.",7977601_2,-1,-1,2,21726,-1
21738,intravenous administration,3,5,25,51,Angioedema following the intravenous administration of metoprolol.,7988234_0,-1,-1,2,21738,-1
21748,beta-blocking drug exposure,4,7,20,47,She had no previous beta-blocking drug exposure.,7988234_5,-1,-1,2,21748,-1
21753,associated with,4,6,28,43,The morbidity and mortality associated with heparin-induced thrombosis remain high despite numerous empirical therapies.,8012887_1,-1,-1,2,21753,-1
21761,associated with,2,4,19,34,Water intoxication associated with oxytocin administration during saline-induced abortion.,803783_0,-1,-1,2,21761,-1
21776,cellular mediated immunity,4,7,28,54,Light chain proteinuria and cellular mediated immunity in rifampin treated patients with tuberculosis.,804391_0,-1,-1,2,21776,-1
21778,treated with,11,13,67,79,Light chain proteinuria was found in 9 of 17 tuberculosis patients treated with rifampin.,804391_1,-1,-1,2,21778,-1
21779,cellular mediated immunity,3,6,21,47,Concomitant assay of cellular mediated immunity in these patients using skin test antigen and a lymphokine in vitro test provided results that were different.,804391_2,-1,-1,2,21779,-1
21780,skin test antigen,10,13,72,89,Concomitant assay of cellular mediated immunity in these patients using skin test antigen and a lymphokine in vitro test provided results that were different.,804391_2,-1,-1,2,21780,-1
21781,in vitro test,16,19,107,120,Concomitant assay of cellular mediated immunity in these patients using skin test antigen and a lymphokine in vitro test provided results that were different.,804391_2,-1,-1,2,21781,-1
21783,hyper-responsiveness,19,20,117,137,"Response to Varidase skin test antigen was negative for all eight tuberculosis patients tested, but there occurred a hyper-responsiveness of the lymphocytes of these eight patients to phytomitogen (PHA-P).",804391_3,-1,-1,2,21783,-1
21785,PHA-P,30,31,198,203,"Response to Varidase skin test antigen was negative for all eight tuberculosis patients tested, but there occurred a hyper-responsiveness of the lymphocytes of these eight patients to phytomitogen (PHA-P).",804391_3,-1,-1,2,21785,-1
21787,serum binding,12,14,70,83,This last finding may be related to time of testing and/or endogenous serum binding of rifampin which could have inhibited mitogen activity for the lymphocyte.,804391_5,-1,-1,2,21787,-1
21793,Oral administration,0,2,0,19,"Oral administration of KF17837 (2.5, 10.0 and 30.0 mg/kg) significantly ameliorated the cataleptic responses induced by intracerebroventricular administration of an adenosine A2A receptor agonist, CGS 21680 (10 micrograms), in a dose-dependent manner.",8045270_2,-1,-1,2,21793,-1
21802,dependently,6,7,49,60,"These anticataleptic effects were exhibited dose dependently at doses from 0.625 and 2.5 mg/kg p.o., respectively.",8045270_4,-1,-1,2,21802,-1
21816,Conium maculatum,5,7,26,42,"Coniine, an alkaloid from Conium maculatum (poison hemlock), has been shown to be teratogenic in livestock.",8073369_1,-1,-1,2,21816,-1
21828,coniine,14,15,87,94,All concentrations of nicotine sulfate caused some lethality but a no effect level for coniine lethality was 0.75%.,8073369_7,-1,-1,2,21828,-1
21834,sulfate-treated chicks,31,33,190,212,"No histopathological alterations or differences in bone formation were seen in the limbs or toes of any chicks from any group; however, extensive cranial hemorrhage occurred in all nicotine sulfate-treated chicks.",8073369_9,-1,-1,2,21834,-1
21835,statistically significant,3,5,12,37,There was a statistically significant (P < or = 0.01) decrease in movement in coniine and nicotine sulfate treated chicks as determined by ultrasound.,8073369_10,-1,-1,2,21835,-1
21838,Control chicks,0,2,0,14,"Control chicks were in motion an average of 33.67% of the time, while coniine-treated chicks were only moving 8.95% of a 5-min interval, and no movement was observed for nicotine sulfate treated chicks.",8073369_11,-1,-1,2,21838,-1
21839,coniine-treated chicks,15,17,70,92,"Control chicks were in motion an average of 33.67% of the time, while coniine-treated chicks were only moving 8.95% of a 5-min interval, and no movement was observed for nicotine sulfate treated chicks.",8073369_11,-1,-1,2,21839,-1
21850,controlled challenge tests,17,20,92,118,"A detailed clinical history, together with skin tests, RAST (radioallergosorbent test), and controlled challenge tests, was used to establish whether patients allergic to beta-lactam antibiotics had selective immediate allergic responses to amoxicillin (AX) or were cross-reacting with other penicillin derivatives.",8092427_2,-1,-1,2,21850,-1
21853,cross-reacting,43,44,266,280,"A detailed clinical history, together with skin tests, RAST (radioallergosorbent test), and controlled challenge tests, was used to establish whether patients allergic to beta-lactam antibiotics had selective immediate allergic responses to amoxicillin (AX) or were cross-reacting with other penicillin derivatives.",8092427_2,-1,-1,2,21853,-1
21859,RAST,0,1,0,4,RAST for BPO-PLL and AX-PLL was done.,8092427_4,-1,-1,2,21859,-1
21864,BPO,7,8,33,36,"When both skin test and RAST for BPO were negative, single-blind, placebo-controlled challenge tests were done to ensure tolerance of PG or sensitivity to AX.",8092427_5,-1,-1,2,21864,-1
21865,single-blind,11,12,52,64,"When both skin test and RAST for BPO were negative, single-blind, placebo-controlled challenge tests were done to ensure tolerance of PG or sensitivity to AX.",8092427_5,-1,-1,2,21865,-1
21866,placebo-controlled challenge tests,13,16,66,100,"When both skin test and RAST for BPO were negative, single-blind, placebo-controlled challenge tests were done to ensure tolerance of PG or sensitivity to AX.",8092427_5,-1,-1,2,21866,-1
21869,good tolerance,14,16,62,76,We selected the 54 (30.5%) cases of immediate AX allergy with good tolerance of PG.,8092427_7,-1,-1,2,21869,-1
21871,skin test negative,4,7,22,40,"All the patients were skin test negative to BPO; 49 of 51 (96%) were also negative to MDM, and 44 of 46 (96%) to PG.",8092427_9,-1,-1,2,21871,-1
21872,BPO,8,9,44,47,"All the patients were skin test negative to BPO; 49 of 51 (96%) were also negative to MDM, and 44 of 46 (96%) to PG.",8092427_9,-1,-1,2,21872,-1
21873,MDM,21,22,86,89,"All the patients were skin test negative to BPO; 49 of 51 (96%) were also negative to MDM, and 44 of 46 (96%) to PG.",8092427_9,-1,-1,2,21873,-1
21875,Skin tests,0,2,0,10,Skin tests with AX were positive in 34 (63%) patients.,8092427_10,-1,-1,2,21875,-1
21877,BPO,14,15,53,56,RAST was positive for AX in 22 patients (41%) and to BPO in just 5 (9%).,8092427_11,-1,-1,2,21877,-1
21878,RAST,6,7,31,35,None of the sera with negative RAST for AX were positive to BPO.,8092427_12,-1,-1,2,21878,-1
21879,BPO,12,13,60,63,None of the sera with negative RAST for AX were positive to BPO.,8092427_12,-1,-1,2,21879,-1
21880,Challenge tests,0,2,0,15,"Challenge tests with AX were performed in 23 subjects (43%) to establish the diagnosis of immediate allergic reaction to AX, and in 15 cases (28%) both skin test and RAST for AX were negative.",8092427_13,-1,-1,2,21880,-1
21887,AX-related,10,11,61,71,Diagnosis of these patients can be achieved only if specific AX-related reagents are employed.,8092427_16,-1,-1,2,21887,-1
21888,diagnostic methods,18,20,107,125,Further studies are necessary to determine the exact extent of this problem and to improve the efficacy of diagnostic methods.,8092427_17,-1,-1,2,21888,-1
21896,/-,20,21,148,150,"Ten patients with acute transmural myocardial infarctions received intravenous nitroglycerin, sufficient to reduce mean arterial pressure from 107 +/- 6 to 85 +/- 6 mm Hg (P less than 0.001), for 60 minutes.",809711_3,0,1,2,21896,-1
21897,/-,25,26,160,162,"Ten patients with acute transmural myocardial infarctions received intravenous nitroglycerin, sufficient to reduce mean arterial pressure from 107 +/- 6 to 85 +/- 6 mm Hg (P less than 0.001), for 60 minutes.",809711_3,0,1,2,21897,-1
21900,/- 2 mm Hg,13,17,65,75,Left ventricular filling pressure decreased from 19 +/- 2 to 11 +/- 2 mm Hg (P less than 0.001).,809711_4,-1,-1,2,21900,-1
21904,Subsequent addition,0,2,0,19,"Subsequent addition of phenylephrine infusion, sufficient to re-elevate mean arterial pressure to 106 +/- 4 mm Hg (P less than 0.001) for 30 minutes, increased left ventricular filling pressure to 17 +/- 2 mm Hg (P less than 0.05) and also significantly increased sigmaST (P less than 0.05).",809711_6,-1,-1,2,21904,-1
21905,re-elevate,8,9,61,71,"Subsequent addition of phenylephrine infusion, sufficient to re-elevate mean arterial pressure to 106 +/- 4 mm Hg (P less than 0.001) for 30 minutes, increased left ventricular filling pressure to 17 +/- 2 mm Hg (P less than 0.05) and also significantly increased sigmaST (P less than 0.05).",809711_6,-1,-1,2,21905,-1
21906,/- 4 mm Hg,15,19,103,113,"Subsequent addition of phenylephrine infusion, sufficient to re-elevate mean arterial pressure to 106 +/- 4 mm Hg (P less than 0.001) for 30 minutes, increased left ventricular filling pressure to 17 +/- 2 mm Hg (P less than 0.05) and also significantly increased sigmaST (P less than 0.05).",809711_6,-1,-1,2,21906,-1
21908,/- 2 mm Hg,37,41,201,211,"Subsequent addition of phenylephrine infusion, sufficient to re-elevate mean arterial pressure to 106 +/- 4 mm Hg (P less than 0.001) for 30 minutes, increased left ventricular filling pressure to 17 +/- 2 mm Hg (P less than 0.05) and also significantly increased sigmaST (P less than 0.05).",809711_6,-1,-1,2,21908,-1
21911,MPTP-treated monkeys,8,10,65,85,Effect of nondopaminergic drugs on L-dopa-induced dyskinesias in MPTP-treated monkeys.,8106150_0,-1,-1,2,21911,-1
21939,infusion-time,6,7,30,43,The incidence may be dose and infusion-time related.,8111719_8,-1,-1,2,21939,-1
21962,mg/kg/i.p,63,64,296,305,"For each of the three tested calcium channel blockers (diltiazem, verapamil and bepridil) 6 groups of mice were treated by two different doses, i.e. 2 and 10 mg/kg/i.p., or an equal volume of saline for the control group (n = 20); 15 minutes later, all the animals were injected with a single 50 mg/kg/i.p.",8231633_2,-1,-1,2,21962,-1
21965,mortality rate,12,14,65,79,"The convulsant activity, the time of latency to convulse and the mortality rate were assessed in each group.",8231633_4,-1,-1,2,21965,-1
21980,drug/light interaction,8,10,67,89,The photodistribution of the telangiectasia suggests a significant drug/light interaction.,8251368_5,-1,-1,2,21980,-1
21981,Penicillamine-induced,0,1,0,21,Penicillamine-induced rapidly progressive glomerulonephritis in a patient with rheumatoid arthritis.,8267029_0,-1,-1,2,21981,-1
21988,inflammatory cells,18,20,124,142,Light microscopy study showed severe glomerulonephritis with crescent formation in 60% of the glomeruli and infiltration of inflammatory cells in the wall of an arteriole.,8267029_2,-1,-1,2,21988,-1
21992,treated with,3,5,16,28,"The patient was treated with steroid pulse, plasmapheresis, cyclophosphamide and antiplatelet agents.",8267029_4,-1,-1,2,21992,-1
22001,vigorous treatment,6,8,50,68,The prompt discontinuation of D-penicillamine and vigorous treatment measures could allow for a good prognosis as in this case.,8267029_7,-1,-1,2,22001,-1
22003,treated with,11,13,67,79,A case of polymyositis in a patient with primary biliary cirrhosis treated with D-penicillamine.,8268147_0,-1,-1,2,22003,-1
22017,treated with,7,9,55,67,Hyperalgesia and myoclonus in terminal cancer patients treated with continuous intravenous morphine.,8278214_0,-1,-1,2,22017,-1
22019,treated with,10,12,60,72,Eight cancer patients in the terminal stages of the disease treated with high doses of intravenous morphine developed hyperalgesia.,8278214_1,-1,-1,2,22019,-1
22026,animal studies,21,23,159,173,"Although only few clinical descriptions of the relationship between hyperalgesia/myoclonus and high doses of morphine are available, experimental support from animal studies indicates that morphine, or its metabolites, plays a causative role for the observed behavioural syndrome.",8278214_5,-1,-1,2,22026,-1
22027,causative role,33,35,227,241,"Although only few clinical descriptions of the relationship between hyperalgesia/myoclonus and high doses of morphine are available, experimental support from animal studies indicates that morphine, or its metabolites, plays a causative role for the observed behavioural syndrome.",8278214_5,-1,-1,2,22027,-1
22028,treatment proposals,6,8,42,61,The possible mechanisms are discussed and treatment proposals given suggesting the use of more efficacious opioids with less excitatory potency in these situations.,8278214_6,-1,-1,2,22028,-1
22041,heat clearance method,33,36,171,192,"To evaluate the effect of prostaglandin E1 (PGE1) or trimethaphan (TMP) induced hypotension on epidural blood flow (EBF) during spinal surgery, EBF was measured using the heat clearance method in 30 patients who underwent postero-lateral interbody fusion under isoflurane anaesthesia.",8302922_1,-1,-1,2,22041,-1
22043,isoflurane anaesthesia,45,47,261,283,"To evaluate the effect of prostaglandin E1 (PGE1) or trimethaphan (TMP) induced hypotension on epidural blood flow (EBF) during spinal surgery, EBF was measured using the heat clearance method in 30 patients who underwent postero-lateral interbody fusion under isoflurane anaesthesia.",8302922_1,-1,-1,2,22043,-1
22044,microgram.kg-1.min-1,5,6,23,43,"An initial dose of 0.1 microgram.kg-1.min-1 of PGE1 (15 patients), or 10 micrograms.kg-1.min-1 of TMP (15 patients) was administered intravenously after the dural opening and the dose was adjusted to maintain the mean arterial blood pressure (MAP) at about 60 mmHg.",8302922_2,-1,-1,2,22044,-1
22046,micrograms.kg-1.min-1,15,16,73,94,"An initial dose of 0.1 microgram.kg-1.min-1 of PGE1 (15 patients), or 10 micrograms.kg-1.min-1 of TMP (15 patients) was administered intravenously after the dural opening and the dose was adjusted to maintain the mean arterial blood pressure (MAP) at about 60 mmHg.",8302922_2,-1,-1,2,22046,-1
22049,mmHg,47,48,260,264,"An initial dose of 0.1 microgram.kg-1.min-1 of PGE1 (15 patients), or 10 micrograms.kg-1.min-1 of TMP (15 patients) was administered intravenously after the dural opening and the dose was adjusted to maintain the mean arterial blood pressure (MAP) at about 60 mmHg.",8302922_2,-1,-1,2,22049,-1
22056,preinfusion values,18,20,102,120,"After starting PGE1 or TMP, MAP and rate pressure product (RPP) decreased significantly compared with preinfusion values (P < 0.01), and the degree of hypotension due to PGE1 remained constant until 60 min after its discontinuation.",8302922_4,-1,-1,2,22056,-1
22065,/-,31,32,155,157,"EBFF did not change during PGE1 infusion whereas in the TMP group, EBF decreased significantly at 30 and 60 min after the start of TMP (preinfusion: 45.9 +/- 13.9 ml/100g/min.",8302922_6,0,1,2,22065,-1
22066,/- 9.9 ml/100,5,8,14,27,30 min: 32.3 +/- 9.9 ml/100 g/min (P < 0.05).,8302922_7,-1,-1,2,22066,-1
22067,/-,5,6,12,14,60 min: 30 +/- 7.5 ml/100 g/min (P < 0.05)).,8302922_8,0,1,2,22067,-1
22076,phase II study,9,12,55,69,Liposomal daunorubicin in advanced Kaposi's sarcoma: a phase II study.,8305357_0,-1,-1,2,22076,-1
22078,clinical trial,6,8,36,50,We report a non-randomized Phase II clinical trial to assess the efficacy and safety of liposomal daunorubicin (DaunoXome) in the treatment of AIDS related Kaposi's sarcoma.,8305357_1,-1,-1,2,22078,-1
22083,target',11,13,59,66,"Changes in size, colour and associated oedema of selected 'target' lesions were measured.",8305357_3,-1,-1,2,22083,-1
22084,Ten subjects,0,2,0,12,Ten subjects were evaluated.,8305357_5,-1,-1,2,22084,-1
22098,oral administration,31,33,218,237,"The appearance of nephrotic syndromes such as proteinuria, hypoalbuminemia, hypercholesterolemia and increase in blood nitrogen urea, induced in rats by injection of puromycin aminonucleoside was markedly inhibited by oral administration of Dup 753 (losartan), a novel angiotensin II receptor antagonist, at a dose of 1 or 2 mg/kg per day.",8319760_1,-1,-1,2,22098,-1
22110,A1,12,13,77,79,Tonotopic organization is an essential feature of the primary auditory area (A1) of primate cortex.,8372922_1,-1,-1,2,22110,-1
22120,A1,19,20,118,120,"Under anesthesia, the superior temporal gyrus of adult macaque monkeys was exposed, and the tonotopic organization of A1 was mapped using conventional microelectrode recording techniques.",8372922_4,-1,-1,2,22120,-1
22123,A1,5,6,30,32,"Three months after deafening, A1 was remapped.",8372922_7,-1,-1,2,22123,-1
22124,remapped,7,8,37,45,"Three months after deafening, A1 was remapped.",8372922_7,-1,-1,2,22124,-1
22125,cytoarchitectural features,1,3,11,37,Postmortem cytoarchitectural features identifying A1 were correlated with the electrophysiologic data.,8372922_8,-1,-1,2,22125,-1
22126,A1,4,5,50,52,Postmortem cytoarchitectural features identifying A1 were correlated with the electrophysiologic data.,8372922_8,-1,-1,2,22126,-1
22127,electrophysiologic data,9,11,78,101,Postmortem cytoarchitectural features identifying A1 were correlated with the electrophysiologic data.,8372922_8,-1,-1,2,22127,-1
22128,A1,8,9,47,49,The results indicate that the deprived area of A1 undergoes extensive reorganization and becomes responsive to intact cochlear frequencies.,8372922_9,-1,-1,2,22128,-1
22132,treated with,6,8,43,55,Forty patients with Non-Hodgkin's Lymphoma treated with vincristine between 1984 and 1990 (cumulative dose 12 mg in 18-24 weeks) were investigated in order to evaluate the long term effects of vincristine on the peripheral nervous system.,8384253_1,-1,-1,2,22132,-1
22154,randomized study,25,27,151,167,"In an attempt to determine whether penile pain associated with intracorporeal injections could be due to the acidity of the medication, we performed a randomized study comparing the incidence of penile pain following intracorporeal injections with or without the addition of sodium bicarbonate to the intracorporeal medications.",8386779_1,-1,-1,2,22154,-1
22158,intracorporeal medications,46,48,301,327,"In an attempt to determine whether penile pain associated with intracorporeal injections could be due to the acidity of the medication, we performed a randomized study comparing the incidence of penile pain following intracorporeal injections with or without the addition of sodium bicarbonate to the intracorporeal medications.",8386779_1,-1,-1,2,22158,-1
22167,antibody-positive,11,12,48,65,The use and toxicity of didanosine (ddI) in HIV antibody-positive individuals intolerant to zidovudine (AZT)One hundred and fifty-one patients intolerant to zidovudine (AZT) received didanosine (ddI) to a maximum dose of 12.5 mg/kg/day.,8387218_0,-1,-1,2,22167,-1
22170,CD4+,7,9,47,51,"Patient response was assessed using changes in CD4+ lymphocyte subset count, HIV p24 antigen, weight, and quality of life.",8387218_1,-1,-1,2,22170,-1
22171,lymphocyte subset count,9,12,52,75,"Patient response was assessed using changes in CD4+ lymphocyte subset count, HIV p24 antigen, weight, and quality of life.",8387218_1,-1,-1,2,22171,-1
22176,lymphocyte subset,6,8,27,44,"Only minor changes in CD4+ lymphocyte subset count were observed in AIDS patients, although a more significant rise occurred in those with earlier stages of disease.",8387218_3,-1,-1,2,22176,-1
22178,positive response,16,18,80,97,"Of those positive for p24 antigen at the commencement of the study 67% showed a positive response, and this was most likely in those with CD4+ lymphocyte subset counts above 100 mm3.",8387218_4,-1,-1,2,22178,-1
22179,CD4+,27,29,138,142,"Of those positive for p24 antigen at the commencement of the study 67% showed a positive response, and this was most likely in those with CD4+ lymphocyte subset counts above 100 mm3.",8387218_4,-1,-1,2,22179,-1
22180,lymphocyte subset counts,29,32,143,167,"Of those positive for p24 antigen at the commencement of the study 67% showed a positive response, and this was most likely in those with CD4+ lymphocyte subset counts above 100 mm3.",8387218_4,-1,-1,2,22180,-1
22181,mm3,34,35,178,181,"Of those positive for p24 antigen at the commencement of the study 67% showed a positive response, and this was most likely in those with CD4+ lymphocyte subset counts above 100 mm3.",8387218_4,-1,-1,2,22181,-1
22182,weight response,2,4,11,26,A positive weight response was seen in 16% of patients.,8387218_5,-1,-1,2,22182,-1
22183,global score,8,10,62,74,Most patients showed improvement in individual parameters and global score of quality of life.,8387218_6,-1,-1,2,22183,-1
22188,serum amylase,5,7,37,50,Thirteen patients developed a raised serum amylase without abdominal pain.,8387218_10,-1,-1,2,22188,-1
22196,associated with,12,14,77,92,"Two cases of hepatic adenoma and one of focal nodular hyperplasia presumably associated with the use of oral contraceptives, are reported.",839274_1,-1,-1,2,22196,-1
22200,Liver-function tests,0,2,0,20,"Liver-function tests are of little diagnostic value, but valuable information may be obtained from both liver scanning and hepatic angiography.",839274_3,-1,-1,2,22200,-1
22201,diagnostic value,5,7,35,51,"Liver-function tests are of little diagnostic value, but valuable information may be obtained from both liver scanning and hepatic angiography.",839274_3,-1,-1,2,22201,-1
22208,Immunohistochemical studies,0,2,0,27,Immunohistochemical studies with antibodies to neurofilament proteins on axonal damage in experimental focal lesions in rat.,8410052_0,-1,-1,2,22208,-1
22225,Immunohistochemical staining,0,2,0,28,Immunohistochemical staining for NFs showed characteristic terminal clubs of axons in the borderzone of lesions.,8410052_4,-1,-1,2,22225,-1
22227,borderzone,12,13,90,100,Immunohistochemical staining for NFs showed characteristic terminal clubs of axons in the borderzone of lesions.,8410052_4,-1,-1,2,22227,-1
22228,molecular weight,13,15,101,117,Differences in the labelling pattern occurred with different antibodies which apparently depended on molecular weight class of NFs and phosphorylation state.,8410052_5,-1,-1,2,22228,-1
22230,phosphorylation state,19,21,135,156,Differences in the labelling pattern occurred with different antibodies which apparently depended on molecular weight class of NFs and phosphorylation state.,8410052_5,-1,-1,2,22230,-1
22248,time intervals,40,42,260,274,"In situ hybridization histochemistry, using a digoxigenin-labeled GAD cRNA probe, demonstrated a substantial decrease in the number of GAD mRNA-containing neurons in the hilus of the dentate gyrus in the pilocarpine-treated rats as compared to controls at all time intervals.",8410199_3,-1,-1,2,22248,-1
22249,neuronanatomical studies,1,3,11,35,"Additional neuronanatomical studies, including cresyl violet staining, neuronal degeneration methods, and histochemical localization of glial fibrillary acidic protein, suggested that the decrease in the number of GAD mRNA-containing neurons was related to neuronal loss rather than to a decrease in GAD mRNA levels.",8410199_4,-1,-1,2,22249,-1
22251,neuronal degeneration methods,9,12,71,100,"Additional neuronanatomical studies, including cresyl violet staining, neuronal degeneration methods, and histochemical localization of glial fibrillary acidic protein, suggested that the decrease in the number of GAD mRNA-containing neurons was related to neuronal loss rather than to a decrease in GAD mRNA levels.",8410199_4,-1,-1,2,22251,-1
22252,histochemical localization,14,16,106,132,"Additional neuronanatomical studies, including cresyl violet staining, neuronal degeneration methods, and histochemical localization of glial fibrillary acidic protein, suggested that the decrease in the number of GAD mRNA-containing neurons was related to neuronal loss rather than to a decrease in GAD mRNA levels.",8410199_4,-1,-1,2,22252,-1
22255,relative preservation,12,14,73,94,The loss of GAD mRNA-containing neurons in the hilus contrasted with the relative preservation of labeled putative basket cells along the inner margin of the granule cell layer.,8410199_5,-1,-1,2,22255,-1
22256,putative basket cells,16,19,106,127,The loss of GAD mRNA-containing neurons in the hilus contrasted with the relative preservation of labeled putative basket cells along the inner margin of the granule cell layer.,8410199_5,-1,-1,2,22256,-1
22258,granule cell layer,25,28,158,176,The loss of GAD mRNA-containing neurons in the hilus contrasted with the relative preservation of labeled putative basket cells along the inner margin of the granule cell layer.,8410199_5,-1,-1,2,22258,-1
22259,Quantitative analyses,0,2,0,21,Quantitative analyses of labeled neurons in three regions of the dentate gyrus in the 1 and 2 week groups showed statistically significant decreases in the mean number of GAD mRNA-containing neurons in the hilus of both groups of experimental animals.,8410199_6,-1,-1,2,22259,-1
22261,statistically significant,20,22,113,138,Quantitative analyses of labeled neurons in three regions of the dentate gyrus in the 1 and 2 week groups showed statistically significant decreases in the mean number of GAD mRNA-containing neurons in the hilus of both groups of experimental animals.,8410199_6,-1,-1,2,22261,-1
22262,experimental animals,38,40,230,250,Quantitative analyses of labeled neurons in three regions of the dentate gyrus in the 1 and 2 week groups showed statistically significant decreases in the mean number of GAD mRNA-containing neurons in the hilus of both groups of experimental animals.,8410199_6,-1,-1,2,22262,-1
22264,molecular layer,7,9,45,60,"No significant differences were found in the molecular layer or the granule cell layer, which included labeled neurons along the lower margin of the granule cell layer.",8410199_7,-1,-1,2,22264,-1
22265,granule cell layer,11,14,68,86,"No significant differences were found in the molecular layer or the granule cell layer, which included labeled neurons along the lower margin of the granule cell layer.",8410199_7,-1,-1,2,22265,-1
22266,granule cell layer,25,28,149,167,"No significant differences were found in the molecular layer or the granule cell layer, which included labeled neurons along the lower margin of the granule cell layer.",8410199_7,-1,-1,2,22266,-1
22271,clinical studies,2,4,20,36,Pharmacokinetic and clinical studies in patients with cimetidine-associated mental confusion.15 cases of cimetidine-associated mental confusion have been reported.,84204_0,-1,-1,2,22271,-1
22272,cimetidine-associated mental confusion.15,7,10,54,95,Pharmacokinetic and clinical studies in patients with cimetidine-associated mental confusion.15 cases of cimetidine-associated mental confusion have been reported.,84204_0,-1,-1,2,22272,-1
22273,cimetidine-associated,12,13,105,126,Pharmacokinetic and clinical studies in patients with cimetidine-associated mental confusion.15 cases of cimetidine-associated mental confusion have been reported.,84204_0,-1,-1,2,22273,-1
22276,M.S.,13,14,76,80,"In order that this syndrome might be investigated changes in mental status (M.S.) were correlated with serum concentrations and renal and hepatic function in 36 patients, 30 patients had no M.S. change on cimetidine and 6 had moderate to severe changes.",84204_1,-1,-1,2,22276,-1
22279,M.S.,33,34,190,194,"In order that this syndrome might be investigated changes in mental status (M.S.) were correlated with serum concentrations and renal and hepatic function in 36 patients, 30 patients had no M.S. change on cimetidine and 6 had moderate to severe changes.",84204_1,-1,-1,2,22279,-1
22286,serum ratio,4,6,25,36,The cerebrospinal fluid: serum ratio of cimetidine concentrations was 0.24:1 and indicates that cimetidine passes the blood-brain barrier; it also raises the possibility that M.S. changes are due to blockade of histamine H2-receptors in the central nervous system.,84204_4,-1,-1,2,22286,-1
22287,blood-brain barrier,17,19,118,137,The cerebrospinal fluid: serum ratio of cimetidine concentrations was 0.24:1 and indicates that cimetidine passes the blood-brain barrier; it also raises the possibility that M.S. changes are due to blockade of histamine H2-receptors in the central nervous system.,84204_4,-1,-1,2,22287,-1
22288,M.S.,26,27,175,179,The cerebrospinal fluid: serum ratio of cimetidine concentrations was 0.24:1 and indicates that cimetidine passes the blood-brain barrier; it also raises the possibility that M.S. changes are due to blockade of histamine H2-receptors in the central nervous system.,84204_4,-1,-1,2,22288,-1
22294,Prospective study,0,2,0,17,Prospective study of the long-term effects of somatostatin analog (octreotide) on gallbladder function and gallstone formation in Chinese acromegalic patients.,8421099_0,-1,-1,2,22294,-1
22302,micrograms/day,33,34,218,232,This article reports the changes in gallbladder function examined by ultrasonography in 20 Chinese patients with active acromegaly treated with sc injection of the somatostatin analog octreotide in dosages of 300-1500 micrograms/day for a mean of 24.2 +/- 13.9 months.,8421099_1,-1,-1,2,22302,-1
22303,/-,40,41,253,255,This article reports the changes in gallbladder function examined by ultrasonography in 20 Chinese patients with active acromegaly treated with sc injection of the somatostatin analog octreotide in dosages of 300-1500 micrograms/day for a mean of 24.2 +/- 13.9 months.,8421099_1,0,1,2,22303,-1
22327,hypotensive group,16,18,129,146,Twenty-four patients were anaesthetized for middle-ear surgery with deliberate hypotension induced by labetalol with isoflurane (hypotensive group).,8424298_2,-1,-1,2,22327,-1
22328,control group,7,9,51,64,Seventeen patients without hypotension served as a control group.,8424298_3,-1,-1,2,22328,-1
22330,/- 2 mmHg,7,10,35,44,"The mean arterial pressure was 77 +/- 2 mmHg (10.3 +/- 0.3 kPa) before hypotension and 50 +/- 0 mmHg (6.7 +/- 0.0 kPa) during hypotension in the hypotensive group, and 86 +/- 2 mmHg (11.5 +/- 0.3 kPa) during anaesthesia in the control group.",8424298_4,-1,-1,2,22330,-1
22332,/- 0 mmHg,22,25,91,100,"The mean arterial pressure was 77 +/- 2 mmHg (10.3 +/- 0.3 kPa) before hypotension and 50 +/- 0 mmHg (6.7 +/- 0.0 kPa) during hypotension in the hypotensive group, and 86 +/- 2 mmHg (11.5 +/- 0.3 kPa) during anaesthesia in the control group.",8424298_4,-1,-1,2,22332,-1
22333,/-,28,29,107,109,"The mean arterial pressure was 77 +/- 2 mmHg (10.3 +/- 0.3 kPa) before hypotension and 50 +/- 0 mmHg (6.7 +/- 0.0 kPa) during hypotension in the hypotensive group, and 86 +/- 2 mmHg (11.5 +/- 0.3 kPa) during anaesthesia in the control group.",8424298_4,0,1,2,22333,-1
22334,hypotensive group,36,38,145,162,"The mean arterial pressure was 77 +/- 2 mmHg (10.3 +/- 0.3 kPa) before hypotension and 50 +/- 0 mmHg (6.7 +/- 0.0 kPa) during hypotension in the hypotensive group, and 86 +/- 2 mmHg (11.5 +/- 0.3 kPa) during anaesthesia in the control group.",8424298_4,-1,-1,2,22334,-1
22335,/- 2 mmHg,42,45,172,181,"The mean arterial pressure was 77 +/- 2 mmHg (10.3 +/- 0.3 kPa) before hypotension and 50 +/- 0 mmHg (6.7 +/- 0.0 kPa) during hypotension in the hypotensive group, and 86 +/- 2 mmHg (11.5 +/- 0.3 kPa) during anaesthesia in the control group.",8424298_4,-1,-1,2,22335,-1
22336,/-,48,49,189,191,"The mean arterial pressure was 77 +/- 2 mmHg (10.3 +/- 0.3 kPa) before hypotension and 50 +/- 0 mmHg (6.7 +/- 0.0 kPa) during hypotension in the hypotensive group, and 86 +/- 2 mmHg (11.5 +/- 0.3 kPa) during anaesthesia in the control group.",8424298_4,0,1,2,22336,-1
22337,control group,56,58,227,240,"The mean arterial pressure was 77 +/- 2 mmHg (10.3 +/- 0.3 kPa) before hypotension and 50 +/- 0 mmHg (6.7 +/- 0.0 kPa) during hypotension in the hypotensive group, and 86 +/- 2 mmHg (11.5 +/- 0.3 kPa) during anaesthesia in the control group.",8424298_4,-1,-1,2,22337,-1
22339,subtests,8,9,55,63,"The following psychological tests were performed: four subtests of the Wechsler Adult Intelligence Scale (similarities, digit span, vocabulary and digit symbol), Trail-Making tests A and B, Zung tests (self-rating anxiety scale and self-rating depression scale) and two-part memory test battery with immediate and delayed recall.",8424298_5,-1,-1,2,22339,-1
22340,Wechsler Adult Intelligence Scale,11,15,71,104,"The following psychological tests were performed: four subtests of the Wechsler Adult Intelligence Scale (similarities, digit span, vocabulary and digit symbol), Trail-Making tests A and B, Zung tests (self-rating anxiety scale and self-rating depression scale) and two-part memory test battery with immediate and delayed recall.",8424298_5,-1,-1,2,22340,-1
22344,Zung tests,33,35,190,200,"The following psychological tests were performed: four subtests of the Wechsler Adult Intelligence Scale (similarities, digit span, vocabulary and digit symbol), Trail-Making tests A and B, Zung tests (self-rating anxiety scale and self-rating depression scale) and two-part memory test battery with immediate and delayed recall.",8424298_5,-1,-1,2,22344,-1
22349,statistically significant,3,5,14,39,There were no statistically significant differences between the groups in any of the tests in the changes from preoperative value to postoperative value.,8424298_7,-1,-1,2,22349,-1
22350,postoperative value,21,23,133,152,There were no statistically significant differences between the groups in any of the tests in the changes from preoperative value to postoperative value.,8424298_7,-1,-1,2,22350,-1
22351,harmful effects,13,15,94,109,The results indicate that hypotension induced by labetalol with isoflurane has no significant harmful effects on mental functions compared to normotensive anaesthesia.,8424298_8,-1,-1,2,22351,-1
22355,associated with,2,4,13,28,Sinus arrest associated with continuous-infusion cimetidine.,8437969_0,-1,-1,2,22355,-1
22356,associated with,10,12,87,102,The administration of intermittent intravenous infusions of cimetidine is infrequently associated with the development of bradyarrhythmias.,8437969_1,-1,-1,2,22356,-1
22361,mg/hour,25,26,177,184,"A 40-year-old man with leukemia and no history of cardiac disease developed recurrent, brief episodes of apparent sinus arrest while receiving continuous-infusion cimetidine 50 mg/hour.",8437969_2,-1,-1,2,22361,-1
22364,associated with,9,11,48,63,This is the first reported case of sinus arrest associated with continuous-infusion cimetidine.,8437969_4,-1,-1,2,22364,-1
22369,BMT,23,24,144,147,We describe the induction of sustained remissions and possible cure of severe erosive rheumatoid arthritis (RA) by bone marrow transplantation (BMT) in 2 patients.,8441146_1,-1,-1,2,22369,-1
22374,BMT,8,9,53,56,"Although short term remission of severe RA following BMT has been reported, these are the first cases for which prolonged followup has been available.",8441146_4,-1,-1,2,22374,-1
22384,associated with,4,6,33,48,"Pentamidine isethionate has been associated with ventricular tachyarrhythmias, including torsade de pointes.",8475949_1,-1,-1,2,22384,-1
22386,torsade de pointes,10,13,89,107,"Pentamidine isethionate has been associated with ventricular tachyarrhythmias, including torsade de pointes.",8475949_1,-1,-1,2,22386,-1
22395,Torsade de pointes,0,3,0,18,"Torsade de pointes can be treated when recognized early, possibly without discontinuation of pentamidine.",8475949_6,-1,-1,2,22395,-1
22399,tolerability,2,3,13,25,Efficacy and tolerability of lovastatin in 3390 women with moderate hypercholesterolemia.,8480959_0,-1,-1,2,22399,-1
22402,double-blind,16,17,85,97,"DESIGN: The Expanded Clinical Evaluation of Lovastatin (EXCEL) Study, a multicenter, double-blind, diet- and placebo-controlled trial, in which participants were randomly assigned to receive placebo or lovastatin at doses of 20 or 40 mg once daily, or 20 or 40 mg twice daily for 48 weeks.",8480959_2,-1,-1,2,22402,-1
22403,diet- and placebo-controlled trial,18,22,99,133,"DESIGN: The Expanded Clinical Evaluation of Lovastatin (EXCEL) Study, a multicenter, double-blind, diet- and placebo-controlled trial, in which participants were randomly assigned to receive placebo or lovastatin at doses of 20 or 40 mg once daily, or 20 or 40 mg twice daily for 48 weeks.",8480959_2,-1,-1,2,22403,-1
22405,participating centers,7,9,46,67,SETTING: Ambulatory patients recruited by 362 participating centers throughout the United States.,8480959_3,-1,-1,2,22405,-1
22407,Plasma total,2,4,14,26,"MEASUREMENTS: Plasma total, low-density lipoprotein (LDL), and high-density lipoprotein (HDL) cholesterol, and triglycerides; and laboratory and clinical evidence of adverse events monitored periodically throughout the study.",8480959_5,-1,-1,2,22407,-1
22411,dose-related changes,20,22,86,106,"RESULTS: Among women, lovastatin (20 to 80 mg/d) produced sustained (12- to 48-week), dose-related changes (P < 0.001): decreases in LDL cholesterol (24% to 40%) and triglycerides (9% to 18%), and increases in HDL cholesterol (6.7% to 8.6%).",8480959_6,-1,-1,2,22411,-1
22414,lovastatin-treated,12,13,42,60,"Depending on the dose, from 82% to 95% of lovastatin-treated women achieved the National Cholesterol Education Program goal of LDL cholesterol levels less than 4.14 mmol/L (160 mg/dL), and 40% to 87% achieved the goal of 3.36 mmol/L (130 mg/dL).",8480959_7,-1,-1,2,22414,-1
22418,upper limit of normal,8,12,64,85,Successive transaminase elevations greater than three times the upper limit of normal occurred in 0.1% of women and were dose dependent above the 20-mg dose.,8480959_8,-1,-1,2,22418,-1
22421,upper limit of normal,15,19,95,116,"Myopathy, defined as muscle symptoms with creatine kinase elevations greater than 10 times the upper limit of normal, was rare and associated with the highest recommended daily dose of lovastatin (80 mg).",8480959_9,-1,-1,2,22421,-1
22425,no effect,5,7,46,55,Estrogen-replacement therapy appeared to have no effect on either the efficacy or safety profile of lovastatin.,8480959_10,-1,-1,2,22425,-1
22435,effects of,25,27,120,130,"Symptomatic hypokalemia has been reported in such patients (3-7) and in one case hypocalcemia was observed (8), but the effects of magnesium depletion were not noted in these patients.",8492347_4,-1,-1,2,22435,-1
22439,associated with,1,3,15,30,Nephrotoxicity associated with ciprofloxacin is uncommon.,8494478_1,-1,-1,2,22439,-1
22441,serum creatinine,4,6,24,40,"Other than elevation of serum creatinine levels, characteristic clinical manifestations and abnormal laboratory findings are not frequently present.",8494478_3,-1,-1,2,22441,-1
22444,pathological-process,9,10,65,85,Allergic interstitial nephritis is believed to be the underlying pathological-process.,8494478_4,-1,-1,2,22444,-1
22448,presumptive diagnosis,15,17,108,129,An improvement in renal function that followed the discontinuation of the offending antibiotic supports the presumptive diagnosis of ciprofloxacin-induced acute renal failure.,8494478_6,-1,-1,2,22448,-1
22463,injection site,5,7,27,41,Swelling and warmth at the injection site were not significantly different between the two groups.,8514073_6,-1,-1,2,22463,-1
22468,no effect,26,28,150,159,"Smoking, nonsteroidal anti-inflammatory drug use, intravenous catheter site, dwell time of the needle, alcohol use, and pain during the injection had no effect on the incidence of venous complications.",8514073_7,-1,-1,2,22468,-1
22479,CAPD,22,23,130,134,We describe such a case in a patient with end-stage renal disease (ESRD) maintained on continuous ambulatory peritoneal dialysis (CAPD).,8546130_3,-1,-1,2,22479,-1
22482,anephric patient,18,20,111,127,"The combination of a relatively high dose of clarithromycin in face of chronic renal failure in a functionally anephric patient, with underlying aluminum intoxication, may have facilitated the appearance of this neurotoxic side effect.",8546130_4,-1,-1,2,22482,-1
22487,medication therapy,29,31,178,196,"It is important to understand the pharmacokinetics of medications in face of chronic renal failure, the possibility of drug interactions, and how these factors should help guide medication therapy in the ESRD patient.",8546130_5,-1,-1,2,22487,-1
22488,ESRD,33,34,204,208,"It is important to understand the pharmacokinetics of medications in face of chronic renal failure, the possibility of drug interactions, and how these factors should help guide medication therapy in the ESRD patient.",8546130_5,-1,-1,2,22488,-1
22492,Peroxisomes,0,1,0,11,Peroxisomes in hepatomas and hyperplastic preneoplastic liver lesions induced in mice by 500 ppm alpha-benzene hexachloride were examined histochemically and electron microscopically.,85485_1,-1,-1,2,22492,-1
22495,histochemically,18,19,138,153,Peroxisomes in hepatomas and hyperplastic preneoplastic liver lesions induced in mice by 500 ppm alpha-benzene hexachloride were examined histochemically and electron microscopically.,85485_1,-1,-1,2,22495,-1
22502,inducibility,13,14,70,82,"Within the nodules, foci of proliferation of the cells that showed no inducibility of proliferation of peroxisomes appeared.",85485_5,-1,-1,2,22502,-1
22508,Phase II trial,0,3,0,14,Phase II trial of vinorelbine in metastatic squamous cell esophageal carcinoma.,8558192_0,-1,-1,2,22508,-1
22512,Cooperative Group,11,13,89,106,European Organization for Research and Treatment of Cancer Gastrointestinal Treat Cancer Cooperative Group.PURPOSE: To evaluate the response rate and toxic effects of vinorelbine (VNB) administered as a single agent in metastatic squamous cell esophageal carcinoma. PATIENTS AND METHODS: Forty-six eligible patients with measurable lesions were included and were stratified according to previous chemotherapy.,8558192_1,-1,-1,2,22512,-1
22516,VNB,27,28,180,183,European Organization for Research and Treatment of Cancer Gastrointestinal Treat Cancer Cooperative Group.PURPOSE: To evaluate the response rate and toxic effects of vinorelbine (VNB) administered as a single agent in metastatic squamous cell esophageal carcinoma. PATIENTS AND METHODS: Forty-six eligible patients with measurable lesions were included and were stratified according to previous chemotherapy.,8558192_1,-1,-1,2,22516,-1
22521,VNB,0,1,0,3,VNB was administered weekly as a 25-mg/m2 short intravenous (i.v.) infusion.,8558192_3,-1,-1,2,22521,-1
22522,partial response,15,17,72,88,"RESULTS: Six of 30 patients (20%) without prior chemotherapy achieved a partial response (PR) (95% confidence interval [CI], 8% to 39%).",8558192_4,-1,-1,2,22522,-1
22523,confidence interval,23,25,99,118,"RESULTS: Six of 30 patients (20%) without prior chemotherapy achieved a partial response (PR) (95% confidence interval [CI], 8% to 39%).",8558192_4,-1,-1,2,22523,-1
22524,complete response (,13,16,54,73,"One of 16 patients (6%) with prior chemotherapy had a complete response (CR) of 31 weeks' duration (95% CI, 0% to 30%).",8558192_6,-1,-1,2,22524,-1
22525,weeks',20,22,83,89,"One of 16 patients (6%) with prior chemotherapy had a complete response (CR) of 31 weeks' duration (95% CI, 0% to 30%).",8558192_6,-1,-1,2,22525,-1
22529,VNB,0,1,0,3,VNB was well tolerated and zero instances of WHO grade 4 nonhematologic toxicity occurred.,8558192_9,-1,-1,2,22529,-1
22546,captopril-treated,10,11,79,96,Contribution of the sympathetic nervous system to salt-sensitivity in lifetime captopril-treated spontaneously hypertensive rats.,8586822_0,-1,-1,2,22546,-1
22547,captopril-treated,10,11,52,69,"OBJECTIVE: To test the hypothesis that, in lifetime captopril-treated spontaneously hypertensive rats (SHR), the sympathetic nervous system contributes importantly to the hypertensive effect of dietary sodium chloride supplementation.",8586822_1,-1,-1,2,22547,-1
22548,SHR,15,16,103,106,"OBJECTIVE: To test the hypothesis that, in lifetime captopril-treated spontaneously hypertensive rats (SHR), the sympathetic nervous system contributes importantly to the hypertensive effect of dietary sodium chloride supplementation.",8586822_1,-1,-1,2,22548,-1
22550,hypertensive effect,26,28,171,190,"OBJECTIVE: To test the hypothesis that, in lifetime captopril-treated spontaneously hypertensive rats (SHR), the sympathetic nervous system contributes importantly to the hypertensive effect of dietary sodium chloride supplementation.",8586822_1,-1,-1,2,22550,-1
22552,Male SHR,2,4,9,17,METHODS: Male SHR (aged 6 weeks) that had been treated from conception onward with either captopril or vehicle remained on a basal sodium chloride diet or were fed a high sodium chloride diet.,8586822_2,-1,-1,2,22552,-1
22562,SHR,22,23,146,149,Infusion of the central nervous system alpha2-adrenergic receptor agonist clonidine also resulted in a greater reduction in MAP in both groups of SHR that were fed the high (compared with the basal) sodium chloride diet.,8586822_6,-1,-1,2,22562,-1
22564,captopril-treated,5,6,30,47,"CONCLUSIONS: In both lifetime captopril-treated and control SHR, the sympathetic nervous system contributes to the pressor effects of a high sodium chloride diet.",8586822_7,-1,-1,2,22564,-1
22565,control SHR,7,9,52,63,"CONCLUSIONS: In both lifetime captopril-treated and control SHR, the sympathetic nervous system contributes to the pressor effects of a high sodium chloride diet.",8586822_7,-1,-1,2,22565,-1
22581,ocular hypotensive effects,1,4,4,30,The ocular hypotensive effects were statistically significant for apraclonidine-treated eyes throughout the study and also statistically significant for contralateral eyes from three hours after topical administration of 1% apraclonidine.,8590259_3,-1,-1,2,22581,-1
22582,statistically significant,5,7,36,61,The ocular hypotensive effects were statistically significant for apraclonidine-treated eyes throughout the study and also statistically significant for contralateral eyes from three hours after topical administration of 1% apraclonidine.,8590259_3,-1,-1,2,22582,-1
22583,apraclonidine-treated,8,9,66,87,The ocular hypotensive effects were statistically significant for apraclonidine-treated eyes throughout the study and also statistically significant for contralateral eyes from three hours after topical administration of 1% apraclonidine.,8590259_3,-1,-1,2,22583,-1
22584,statistically significant,15,17,123,148,The ocular hypotensive effects were statistically significant for apraclonidine-treated eyes throughout the study and also statistically significant for contralateral eyes from three hours after topical administration of 1% apraclonidine.,8590259_3,-1,-1,2,22584,-1
22590,pulse rate,8,10,52,62,"No significant changes in diastolic blood pressure, pulse rate and basal tear secretion were noted.",8590259_5,-1,-1,2,22590,-1
22597,pretreatment,1,2,12,24,Thiopentone pretreatment for propofol injection pain in ambulatory patients.,8595686_0,-1,-1,2,22597,-1
22604,double-blind trial,4,6,17,35,"In a randomized, double-blind trial, 90 women were allocated to receive one of three treatments prior to induction of anaesthesia with propofol.",8595686_2,-1,-1,2,22604,-1
22607,Group T,24,26,89,96,"Patients in Group C received 2 ml normal saline, Group L, 2 ml, lidocaine 2% (40 mg) and Group T, 2 ml thiopentone 2.5% (50 mg).",8595686_3,-1,-1,2,22607,-1
22613,micrograms.kg-1.min-1,27,28,150,171,Venous discomfort was assessed with a visual analogue scale (VAS) 5-15 sec after commencing propofol administration using an infusion pump (rate 1000 micrograms.kg-1.min-1).,8595686_4,-1,-1,2,22613,-1
22614,Visual analogue scores,9,12,45,67,Loss of consciousness occurred in 60-90 sec. Visual analogue scores (mean +/- SD) during induction were lower in Groups L (3.3 +/- 2.5) and T (4.1 +/- 2.7) than in Group C (5.6 +/- 2.3); P = 0.0031.,8595686_5,-1,-1,2,22614,-1
22615,/- SD,15,17,75,80,Loss of consciousness occurred in 60-90 sec. Visual analogue scores (mean +/- SD) during induction were lower in Groups L (3.3 +/- 2.5) and T (4.1 +/- 2.7) than in Group C (5.6 +/- 2.3); P = 0.0031.,8595686_5,-1,-1,2,22615,-1
22623,VAS scores,1,3,4,14,The VAS scores for recall of pain in the recovery room were correlated with the VAS scores during induction (r = 0.7045; P < 0.0001).,8595686_7,-1,-1,2,22623,-1
22625,VAS scores,15,17,80,90,The VAS scores for recall of pain in the recovery room were correlated with the VAS scores during induction (r = 0.7045; P < 0.0001).,8595686_7,-1,-1,2,22625,-1
22627,discharge times,2,4,14,29,Recovery room discharge times were similar: C (75.9 +/- 19.4 min); L 73.6 +/- 21.6 min); T (77.1 +/- 18.9 min).,8595686_8,-1,-1,2,22627,-1
22636,associated with,1,3,11,26,Angioedema associated with droperidol administration.,8599504_0,-1,-1,2,22636,-1
22652,signal averaged ECG,15,18,86,105,"The evaluation consisted of a history, physical examination, electrocardiogram (ECG), signal averaged ECG, 24-hour ambulatory ECG, echocardiography and radionuclide angiography.",8600333_4,-1,-1,2,22652,-1
22653,24-hour ambulatory ECG,19,22,107,129,"The evaluation consisted of a history, physical examination, electrocardiogram (ECG), signal averaged ECG, 24-hour ambulatory ECG, echocardiography and radionuclide angiography.",8600333_4,-1,-1,2,22653,-1
22662,length of follow-up,7,10,54,73,The incidence of cardiac abnormalities increased with length of follow-up (P< or = .05).,8600333_6,-1,-1,2,22662,-1
22667,LVPW index,14,16,83,93,"When adjusted to body surface area, the left ventricular posterior wall thickness (LVPW index) was decreased in all patients.",8600333_8,-1,-1,2,22667,-1
22672,LVPW index,11,13,65,75,The results of our study suggest that heart rate variability and LVPW index could be sensitive indicators for cardiotoxicity.,8600333_11,-1,-1,2,22672,-1
22679,BP,16,17,91,93,Borderline hypertensive men (n = 24) were selected with screening systolic blood pressure (BP) of 140 to 160 mm Hg and/or diastolic BP 90 to 99 mm Hg.,8607407_3,-1,-1,2,22679,-1
22680,mm Hg,22,24,109,114,Borderline hypertensive men (n = 24) were selected with screening systolic blood pressure (BP) of 140 to 160 mm Hg and/or diastolic BP 90 to 99 mm Hg.,8607407_3,-1,-1,2,22680,-1
22681,diastolic BP,25,27,122,134,Borderline hypertensive men (n = 24) were selected with screening systolic blood pressure (BP) of 140 to 160 mm Hg and/or diastolic BP 90 to 99 mm Hg.,8607407_3,-1,-1,2,22681,-1
22684,screening BP,15,17,80,92,Low-risk controls (n = 24) reported no parental history of hypertension and had screening BP < 130/85 mm Hg.,8607407_4,-1,-1,2,22684,-1
22686,Caffeine-induced changes,0,2,0,24,"Caffeine-induced changes in diastolic BP were 2 to 3 times larger in borderline subjects than in controls (+8.4 vs +3.8 mm Hg, p < 0.0001), and were attributable to larger changes in impedance-derived measures of systemic vascular resistance (+135 vs +45 dynes.s.cm-5, p < 0.004).",8607407_6,-1,-1,2,22686,-1
22687,diastolic BP,3,5,28,40,"Caffeine-induced changes in diastolic BP were 2 to 3 times larger in borderline subjects than in controls (+8.4 vs +3.8 mm Hg, p < 0.0001), and were attributable to larger changes in impedance-derived measures of systemic vascular resistance (+135 vs +45 dynes.s.cm-5, p < 0.004).",8607407_6,-1,-1,2,22687,-1
22688,borderline subjects,12,14,69,88,"Caffeine-induced changes in diastolic BP were 2 to 3 times larger in borderline subjects than in controls (+8.4 vs +3.8 mm Hg, p < 0.0001), and were attributable to larger changes in impedance-derived measures of systemic vascular resistance (+135 vs +45 dynes.s.cm-5, p < 0.004).",8607407_6,-1,-1,2,22688,-1
22690,impedance-derived measures,38,40,183,209,"Caffeine-induced changes in diastolic BP were 2 to 3 times larger in borderline subjects than in controls (+8.4 vs +3.8 mm Hg, p < 0.0001), and were attributable to larger changes in impedance-derived measures of systemic vascular resistance (+135 vs +45 dynes.s.cm-5, p < 0.004).",8607407_6,-1,-1,2,22690,-1
22693,borderline subjects,3,5,18,37,The percentage of borderline subjects in whom diastolic BP changes exceeded the median control response was 96%.,8607407_8,-1,-1,2,22693,-1
22694,diastolic BP,7,9,46,58,The percentage of borderline subjects in whom diastolic BP changes exceeded the median control response was 96%.,8607407_8,-1,-1,2,22694,-1
22695,resting predrug,10,12,80,95,"Consequently, whereas all participants exhibited normotensive levels during the resting predrug baseline, 33% of borderline subjects achieved hypertensive BP levels after caffeine ingestion.",8607407_9,-1,-1,2,22695,-1
22696,borderline subjects,17,19,113,132,"Consequently, whereas all participants exhibited normotensive levels during the resting predrug baseline, 33% of borderline subjects achieved hypertensive BP levels after caffeine ingestion.",8607407_9,-1,-1,2,22696,-1
22697,hypertensive BP,20,22,142,157,"Consequently, whereas all participants exhibited normotensive levels during the resting predrug baseline, 33% of borderline subjects achieved hypertensive BP levels after caffeine ingestion.",8607407_9,-1,-1,2,22697,-1
22699,diastolic BP,15,17,92,104,"Thus, in borderline hypertensive men, exaggerated responses to caffeine were: selective for diastolic BP, consistent with greater vasoconstriction, replicated in 2 protocols, and representative of nearly all borderline hypertensives.",8607407_10,-1,-1,2,22699,-1
22700,consistent with,18,20,106,121,"Thus, in borderline hypertensive men, exaggerated responses to caffeine were: selective for diastolic BP, consistent with greater vasoconstriction, replicated in 2 protocols, and representative of nearly all borderline hypertensives.",8607407_10,-1,-1,2,22700,-1
22706,placebo-controlled study,5,7,31,55,"This double-blind, randomized, placebo-controlled study evaluated the effects of haloperidol alone and haloperidol plus sertraline on cognitive and psychomotor function in 24 healthy male subjects.",8617710_1,-1,-1,2,22706,-1
22709,Day 1,7,9,41,46,METHOD: All subjects received placebo on Day 1 and haloperidol 2 mg on Days 2 and 25.,8617710_2,-1,-1,2,22709,-1
22710,Days 2,14,16,71,77,METHOD: All subjects received placebo on Day 1 and haloperidol 2 mg on Days 2 and 25.,8617710_2,-1,-1,2,22710,-1
22714,24-hour period,10,12,66,80,"Cognitive function testing was performed before dosing and over a 24-hour period after dosing on Days 1, 2, and 25.",8617710_4,-1,-1,2,22714,-1
22716,Day 2,17,19,107,112,RESULTS: Impairment of cognitive function was observed 6 to 8 hours after administration of haloperidol on Day 2 but was not evident 23 hours after dosing.,8617710_5,-1,-1,2,22716,-1
22718,treatment groups,22,24,133,149,"When single-dose haloperidol was given again 25 days later, greater impairment with earlier onset was noted in several tests in both treatment groups, suggesting enhancement of this effect.",8617710_6,-1,-1,2,22718,-1
22734,associated with,20,22,139,154,"Atracurium besylate, a short-acting benzylisoquinolinium NMBA that is eliminated independently of renal or hepatic function, has also been associated with persistent paralysis, but only when used with corticosteroids.",8638206_3,-1,-1,2,22734,-1
22735,treated with,18,20,112,124,We report a case of atracurium-related paralysis persisting for approximately 50 hours in a patient who was not treated with corticosteroids.,8638206_4,-1,-1,2,22735,-1
22743,parenteral use,19,21,126,140,"A forty-six year-old premenopausal woman developed headache, nausea and vomiting, left hemiparesis and seizure two days after parenteral use of progesterone and estradiol.",8638876_2,-1,-1,2,22743,-1
22767,phase II trials,1,4,4,19,Two phase II trials of 24-hour paclitaxel infusions in chemotherapy-naive patients with stage IIIB or IV non-small cell lung cancer (NSCLC) reported response rates of 21% and 24%.,8643966_2,-1,-1,2,22767,-1
22772,NSCLC,21,22,133,138,Two phase II trials of 24-hour paclitaxel infusions in chemotherapy-naive patients with stage IIIB or IV non-small cell lung cancer (NSCLC) reported response rates of 21% and 24%.,8643966_2,-1,-1,2,22772,-1
22773,response rates,24,26,149,163,Two phase II trials of 24-hour paclitaxel infusions in chemotherapy-naive patients with stage IIIB or IV non-small cell lung cancer (NSCLC) reported response rates of 21% and 24%.,8643966_2,-1,-1,2,22773,-1
22774,dose limiting,2,4,15,28,Leukopenia was dose limiting: as many as 62.5% of patients experienced grade 4 leukopenia.,8643966_3,-1,-1,2,22774,-1
22776,phase II trial,13,16,79,93,We investigated the efficacy and toxicity of a 3-hour paclitaxel infusion in a phase II trial in patients with inoperable stage IIIB or IV NSCLC.,8643966_4,-1,-1,2,22776,-1
22778,NSCLC,24,25,139,144,We investigated the efficacy and toxicity of a 3-hour paclitaxel infusion in a phase II trial in patients with inoperable stage IIIB or IV NSCLC.,8643966_4,-1,-1,2,22778,-1
22779,stage IV,7,9,26,34,Most patients (72.4%) had stage IV NSCLC.,8643966_6,-1,-1,2,22779,-1
22780,NSCLC,9,10,35,40,Most patients (72.4%) had stage IV NSCLC.,8643966_6,-1,-1,2,22780,-1
22782,mg/m2,2,3,15,20,Paclitaxel 225 mg/m2 was infused over 3 hours every 3 weeks with standard prophylactic premedication.,8643966_7,-1,-1,2,22782,-1
22800,patient population,9,11,50,68,"Paclitaxel is thus an active single agent in this patient population, with a 3-hour infusion proving comparably effective to a 24-hour infusion and superior in terms of the incidence of hematologic and nonhematologic toxicity.",8643966_13,-1,-1,2,22800,-1
22803,phase II studies,1,4,8,24,"Further phase II studies with paclitaxel combined with other drugs active against NSCLC are indicated, and phase III studies comparing paclitaxel with standard chemotherapy remain to be completed.",8643966_14,-1,-1,2,22803,-1
22805,NSCLC,12,13,82,87,"Further phase II studies with paclitaxel combined with other drugs active against NSCLC are indicated, and phase III studies comparing paclitaxel with standard chemotherapy remain to be completed.",8643966_14,-1,-1,2,22805,-1
22809,phase I/II study,1,4,2,18,A phase I/II study of paclitaxel plus cisplatin as first-line therapy for head and neck cancers: preliminary results.,8643971_0,-1,-1,2,22809,-1
22816,Eastern Cooperative Oncology Group study,4,9,26,66,"Preliminary results of an Eastern Cooperative Oncology Group study of single-agent paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) reported a 37% response rate in patients with head and neck cancer, and the paclitaxel/cisplatin combination has been used successfully and has significantly improved median response duration in ovarian cancer patients.",8643971_2,-1,-1,2,22816,-1
22820,response rate,27,29,162,175,"Preliminary results of an Eastern Cooperative Oncology Group study of single-agent paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) reported a 37% response rate in patients with head and neck cancer, and the paclitaxel/cisplatin combination has been used successfully and has significantly improved median response duration in ovarian cancer patients.",8643971_2,-1,-1,2,22820,-1
22823,median response,49,51,314,329,"Preliminary results of an Eastern Cooperative Oncology Group study of single-agent paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) reported a 37% response rate in patients with head and neck cancer, and the paclitaxel/cisplatin combination has been used successfully and has significantly improved median response duration in ovarian cancer patients.",8643971_2,-1,-1,2,22823,-1
22825,phase I/II trial,3,6,15,31,We initiated a phase I/II trial to determine the response and toxicity of escalating paclitaxel doses combined with fixed-dose cisplatin with granulocyte colony-stimulating factor support in patients with untreated locally advanced inoperable head and neck carcinoma.,8643971_3,-1,-1,2,22825,-1
22830,good performance,13,15,50,66,"To date, 23 men with a median age of 50 years and good performance status have entered the trial.",8643971_4,-1,-1,2,22830,-1
22841,intrapatient,9,10,61,73,"The dose levels incorporate escalating paclitaxel doses, and intrapatient escalations within a given dose level are permitted if toxicity permits.",8643971_8,-1,-1,2,22841,-1
22842,dose level 4,7,10,29,41,"At the time of this writing, dose level 4 (260, 270, and 280 mg/m2) is being evaluated; three patients from this level are evaluable.",8643971_9,-1,-1,2,22842,-1
22846,partial response,24,26,105,121,"Of 18 patients evaluable for response, seven (39%) achieved a complete response and six (33%) achieved a partial response.",8643971_11,-1,-1,2,22846,-1
22848,response rate,2,4,12,25,The overall response rate is 72%.,8643971_13,-1,-1,2,22848,-1
22850,radical radiotherapy,7,9,66,86,Eleven responding patients had subsequent surgery/radiotherapy or radical radiotherapy.,8643971_14,-1,-1,2,22850,-1
22859,dose-response effect,5,7,28,48,Results thus far suggest no dose-response effect for paclitaxel doses above 200 mg/m2.,8643971_19,-1,-1,2,22859,-1
22863,first-line treatment,6,8,44,64,Paclitaxel combined with carboplatin in the first-line treatment of advanced ovarian cancer.,8643973_0,-1,-1,2,22863,-1
22865,phase I study,2,5,5,18,"In a phase I study to determine the maximum tolerated dose of paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) given as a 3-hour infusion in combination with carboplatin administered every 21 days to women with advanced ovarian cancer, paclitaxel doses were escalated as follows: level 1, 135 mg/m2; level 2, 160 mg/m2; level 3, 185 mg/m2; and level 4,210 mg/m2.",8643973_1,-1,-1,2,22865,-1
22875,concentration-time curve,18,20,91,115,The fixed dose of carboplatin at levels 1 through 4 was given to achieve an area under the concentration-time curve (AUC) of 5 using the Calvert formula.,8643973_2,-1,-1,2,22875,-1
22876,Calvert formula,27,29,137,152,The fixed dose of carboplatin at levels 1 through 4 was given to achieve an area under the concentration-time curve (AUC) of 5 using the Calvert formula.,8643973_2,-1,-1,2,22876,-1
22880,Eastern Cooperative Oncology Group,15,19,79,113,"To date, 30 previously untreated patients, all with a good performance status (Eastern Cooperative Oncology Group 0 to 2) have been entered into this ongoing study.",8643973_4,-1,-1,2,22880,-1
22893,phase III studies,4,7,25,42,The recommended dose for phase III studies is paclitaxel 185 mg/m2 and carboplatin AUC 6.,8643973_10,-1,-1,2,22893,-1
22913,treated with,12,14,77,89,Occasional case reports have shown that acute myopathy may occur in patients treated with massive doses of corticosteroids.,8665051_1,-1,-1,2,22913,-1
22918,steroid-treated groups,51,53,257,279,"Therefore, 60 male rats were randomly assigned to receive daily injection of saline (C), methylprednisolone (M), or triamcinolone (T) 80 mg/kg/d for 5 d. Nutritional intake, measured daily in 15 animals, showed a significant reduction of food intake in the steroid-treated groups (-50 and -79% in M and T, respectively).",8665051_3,-1,-1,2,22918,-1
22919,associated with,2,4,9,24,This was associated with a similar loss in body weight.,8665051_4,-1,-1,2,22919,-1
22921,histopathologic features,9,11,57,81,"In the 45 remaining animals, diaphragm contractility and histopathologic features of several muscles were studied.",8665051_5,-1,-1,2,22921,-1
22923,C group,9,11,52,59,"Maximal twitches of the diaphragm were lower in the C group (653 +/- 174 g/cm(2)) than in the M group (837 +/- 171 g/cm(2); p < 0.05) and the T group (765 +/- 145 g/cm(2), NS).",8665051_7,-1,-1,2,22923,-1
22924,/-,14,15,66,68,"Maximal twitches of the diaphragm were lower in the C group (653 +/- 174 g/cm(2)) than in the M group (837 +/- 171 g/cm(2); p < 0.05) and the T group (765 +/- 145 g/cm(2), NS).",8665051_7,0,1,2,22924,-1
22925,M group,22,24,94,101,"Maximal twitches of the diaphragm were lower in the C group (653 +/- 174 g/cm(2)) than in the M group (837 +/- 171 g/cm(2); p < 0.05) and the T group (765 +/- 145 g/cm(2), NS).",8665051_7,-1,-1,2,22925,-1
22926,/-,27,28,108,110,"Maximal twitches of the diaphragm were lower in the C group (653 +/- 174 g/cm(2)) than in the M group (837 +/- 171 g/cm(2); p < 0.05) and the T group (765 +/- 145 g/cm(2), NS).",8665051_7,0,1,2,22926,-1
22928,/- 145,43,45,156,162,"Maximal twitches of the diaphragm were lower in the C group (653 +/- 174 g/cm(2)) than in the M group (837 +/- 171 g/cm(2); p < 0.05) and the T group (765 +/- 145 g/cm(2), NS).",8665051_7,-1,-1,2,22928,-1
22929,Half-relaxation time,0,2,0,20,"Half-relaxation time was prolonged in both steroid groups, and time to peak tension was longer with M, whereas tetanic tensions were similar.",8665051_8,-1,-1,2,22929,-1
22930,peak tension,12,14,71,83,"Half-relaxation time was prolonged in both steroid groups, and time to peak tension was longer with M, whereas tetanic tensions were similar.",8665051_8,-1,-1,2,22930,-1
22932,force-frequency curve,9,11,55,76,Steroid treatment also induced a leftward shift of the force-frequency curve at 25 and 50 Hz when compared with saline treatment (p < 0.05).,8665051_9,-1,-1,2,22932,-1
22933,saline treatment,19,21,112,128,Steroid treatment also induced a leftward shift of the force-frequency curve at 25 and 50 Hz when compared with saline treatment (p < 0.05).,8665051_9,-1,-1,2,22933,-1
22940,pair-fed (PF) study,3,8,11,30,"Finally, a pair-fed (PF) study, performed in 18 rats (C, T, and PF), showed that muscle atrophy was considerably less pronounced in PF animals than in T-treated animals.",8665051_11,-1,-1,2,22940,-1
22943,PF,31,32,132,134,"Finally, a pair-fed (PF) study, performed in 18 rats (C, T, and PF), showed that muscle atrophy was considerably less pronounced in PF animals than in T-treated animals.",8665051_11,-1,-1,2,22943,-1
22946,massive doses,9,11,47,60,"We conclude that (1) short-term treatment with massive doses of steroids induced severe respiratory and limb muscle wasting; (2) both types of steroids induced predominantly type IIb atrophy, resulting in the expected alterations in diaphragm contractile properties; (3) neither steroid caused muscle necrosis; (4) type IIb atrophy was not caused by acute nutritional deprivation alone.",8665051_12,-1,-1,2,22946,-1
22955,risk factor,6,8,35,46,Habitual use of acetaminophen as a risk factor for chronic renal failure: a comparison with phenacetin.,8669433_0,-1,-1,2,22955,-1
22957,epidemiologic studies,1,3,4,25,"Six epidemiologic studies in the United States and Europe indicate that habitual use of phenacetin is associated with the development of chronic renal failure and end-stage renal disease (ESRD), with a relative risk in the range of 4 to 19.",8669433_1,-1,-1,2,22957,-1
22959,associated with,16,18,102,117,"Six epidemiologic studies in the United States and Europe indicate that habitual use of phenacetin is associated with the development of chronic renal failure and end-stage renal disease (ESRD), with a relative risk in the range of 4 to 19.",8669433_1,-1,-1,2,22959,-1
22962,ESRD,29,30,188,192,"Six epidemiologic studies in the United States and Europe indicate that habitual use of phenacetin is associated with the development of chronic renal failure and end-stage renal disease (ESRD), with a relative risk in the range of 4 to 19.",8669433_1,-1,-1,2,22962,-1
22963,relative risk,34,36,202,215,"Six epidemiologic studies in the United States and Europe indicate that habitual use of phenacetin is associated with the development of chronic renal failure and end-stage renal disease (ESRD), with a relative risk in the range of 4 to 19.",8669433_1,-1,-1,2,22963,-1
22964,case control studies,3,6,15,35,"However, three case control studies, one each in North Carolina, northern Maryland, and West Berlin, Germany, showed that habitual use of acetaminophen is also associated with chronic renal failure and ESRD, with a relative risk in the range of 2 to 4.",8669433_3,-1,-1,2,22964,-1
22965,North Carolina,10,12,49,63,"However, three case control studies, one each in North Carolina, northern Maryland, and West Berlin, Germany, showed that habitual use of acetaminophen is also associated with chronic renal failure and ESRD, with a relative risk in the range of 2 to 4.",8669433_3,-1,-1,2,22965,-1
22966,northern Maryland,13,15,65,82,"However, three case control studies, one each in North Carolina, northern Maryland, and West Berlin, Germany, showed that habitual use of acetaminophen is also associated with chronic renal failure and ESRD, with a relative risk in the range of 2 to 4.",8669433_3,-1,-1,2,22966,-1
22968,habitual use,24,26,122,134,"However, three case control studies, one each in North Carolina, northern Maryland, and West Berlin, Germany, showed that habitual use of acetaminophen is also associated with chronic renal failure and ESRD, with a relative risk in the range of 2 to 4.",8669433_3,-1,-1,2,22968,-1
22969,associated with,30,32,160,175,"However, three case control studies, one each in North Carolina, northern Maryland, and West Berlin, Germany, showed that habitual use of acetaminophen is also associated with chronic renal failure and ESRD, with a relative risk in the range of 2 to 4.",8669433_3,-1,-1,2,22969,-1
22971,ESRD,36,37,202,206,"However, three case control studies, one each in North Carolina, northern Maryland, and West Berlin, Germany, showed that habitual use of acetaminophen is also associated with chronic renal failure and ESRD, with a relative risk in the range of 2 to 4.",8669433_3,-1,-1,2,22971,-1
22972,relative risk,40,42,215,228,"However, three case control studies, one each in North Carolina, northern Maryland, and West Berlin, Germany, showed that habitual use of acetaminophen is also associated with chronic renal failure and ESRD, with a relative risk in the range of 2 to 4.",8669433_3,-1,-1,2,22972,-1
22977,Continuous subcutaneous administration,0,3,0,38,Continuous subcutaneous administration of mesna to prevent ifosfamide-induced hemorrhagic cystitis.,8677458_0,-1,-1,2,22977,-1
22985,intravenous route,6,8,39,56,"Mesna is generally administered by the intravenous route, although experience with oral delivery of the drug has increased.",8677458_2,-1,-1,2,22985,-1
22986,oral delivery,12,14,83,96,"Mesna is generally administered by the intravenous route, although experience with oral delivery of the drug has increased.",8677458_2,-1,-1,2,22986,-1
22987,subcutaneous administration,2,4,15,42,The continuous subcutaneous administration of mesna has the advantage of not requiring intravenous access.,8677458_3,-1,-1,2,22987,-1
22992,associated with,12,14,73,88,"In addition, subcutaneous delivery of the neutralizing agent will not be associated with the risk of inadequate urinary mesna concentrations, such as in a patient taking oral mesna who experiences severe ifosfamide-induced emesis and is unable to absorb the drug.",8677458_4,-1,-1,2,22992,-1
22997,economic method,17,19,116,131,"Limited clinical experience with continuous subcutaneous mesna administration suggests it is a safe, practical, and economic method of drug delivery that permits ifosfamide to be administered successfully in the outpatient setting.",8677458_5,-1,-1,2,22997,-1
23017,associated with,5,7,24,39,Leg and/or back pain is associated with the intrathecal use of hyperbaric 5% lignocaine.,8686832_5,-1,-1,2,23017,-1
23022,sulphate-associated,3,4,21,40,Reduction of heparan sulphate-associated anionic sites in the glomerular basement membrane of rats with streptozotocin-induced diabetic nephropathy.,8690168_0,-1,-1,2,23022,-1
23024,glomerular basement membrane,8,11,62,90,Reduction of heparan sulphate-associated anionic sites in the glomerular basement membrane of rats with streptozotocin-induced diabetic nephropathy.,8690168_0,-1,-1,2,23024,-1
23027,sulphate-associated,1,2,8,27,"Heparan sulphate-associated anionic sites in the glomerular basement membrane were studied in rats 8 months after induction of diabetes by streptozotocin and in age- adn sex-matched control rats, employing the cationic dye cuprolinic blue.",8690168_1,-1,-1,2,23027,-1
23029,glomerular basement membrane,6,9,49,77,"Heparan sulphate-associated anionic sites in the glomerular basement membrane were studied in rats 8 months after induction of diabetes by streptozotocin and in age- adn sex-matched control rats, employing the cationic dye cuprolinic blue.",8690168_1,-1,-1,2,23029,-1
23031,adn,24,25,166,169,"Heparan sulphate-associated anionic sites in the glomerular basement membrane were studied in rats 8 months after induction of diabetes by streptozotocin and in age- adn sex-matched control rats, employing the cationic dye cuprolinic blue.",8690168_1,-1,-1,2,23031,-1
23035,computerized image processor,10,13,73,101,Morphometric analysis at the ultrastructural level was performed using a computerized image processor.,8690168_2,-1,-1,2,23035,-1
23037,sulphate specificity,2,4,12,32,"The heparan sulphate specificity of the cuprolinic blue staining was demonstrated by glycosaminoglycan-degrading enzymes, showing that pretreatment of the sections with heparitinase abolished all staining, whereas chondroitinase ABC had no effect.",8690168_3,-1,-1,2,23037,-1
23043,no effect,31,33,237,246,"The heparan sulphate specificity of the cuprolinic blue staining was demonstrated by glycosaminoglycan-degrading enzymes, showing that pretreatment of the sections with heparitinase abolished all staining, whereas chondroitinase ABC had no effect.",8690168_3,-1,-1,2,23043,-1
23044,anionic sites,3,5,16,29,The majority of anionic sites (74% in diabetic and 81% in control rats) were found within the lamina rara externa of the glomerular basement membrane.,8690168_4,-1,-1,2,23044,-1
23045,control rats,14,16,58,70,The majority of anionic sites (74% in diabetic and 81% in control rats) were found within the lamina rara externa of the glomerular basement membrane.,8690168_4,-1,-1,2,23045,-1
23046,lamina rara externa,21,24,94,113,The majority of anionic sites (74% in diabetic and 81% in control rats) were found within the lamina rara externa of the glomerular basement membrane.,8690168_4,-1,-1,2,23046,-1
23047,glomerular basement membrane,26,29,121,149,The majority of anionic sites (74% in diabetic and 81% in control rats) were found within the lamina rara externa of the glomerular basement membrane.,8690168_4,-1,-1,2,23047,-1
23050,lamina rara interna,12,15,75,94,"A minority of anionic sites were scattered throughout the lamina densa and lamina rara interna, and were significantly smaller than those in the lamina rara externa of the glomerular basement membrane (p<0.001 and p<0.01 for diabetic and control rats, respectively).",8690168_5,-1,-1,2,23050,-1
23051,lamina rara externa,24,27,145,164,"A minority of anionic sites were scattered throughout the lamina densa and lamina rara interna, and were significantly smaller than those in the lamina rara externa of the glomerular basement membrane (p<0.001 and p<0.01 for diabetic and control rats, respectively).",8690168_5,-1,-1,2,23051,-1
23052,glomerular basement membrane,29,32,172,200,"A minority of anionic sites were scattered throughout the lamina densa and lamina rara interna, and were significantly smaller than those in the lamina rara externa of the glomerular basement membrane (p<0.001 and p<0.01 for diabetic and control rats, respectively).",8690168_5,-1,-1,2,23052,-1
23053,control rats,39,41,238,250,"A minority of anionic sites were scattered throughout the lamina densa and lamina rara interna, and were significantly smaller than those in the lamina rara externa of the glomerular basement membrane (p<0.001 and p<0.01 for diabetic and control rats, respectively).",8690168_5,-1,-1,2,23053,-1
23054,control animals,21,23,118,133,"Diabetic rats progressively developed albuminuria reaching 40.3 (32.2-62.0) mg/24 h after 8 months in contrast to the control animals (0.8 (0.2-0.9) mg/24 h, p<0.002).",8690168_6,-1,-1,2,23054,-1
23057,anionic site,15,17,77,89,"At the same time, the number of heparan sulphate anionic sites and the total anionic site surface (number of anionic sites x mean anionic site surface) in the lamina rara externa of the glomerular basement membrane was reduced by 19% (p<0.021) and by 26% (p<0.02), respectively.",8690168_7,-1,-1,2,23057,-1
23059,anionic site,25,27,130,142,"At the same time, the number of heparan sulphate anionic sites and the total anionic site surface (number of anionic sites x mean anionic site surface) in the lamina rara externa of the glomerular basement membrane was reduced by 19% (p<0.021) and by 26% (p<0.02), respectively.",8690168_7,-1,-1,2,23059,-1
23061,basement membrane,37,39,197,214,"At the same time, the number of heparan sulphate anionic sites and the total anionic site surface (number of anionic sites x mean anionic site surface) in the lamina rara externa of the glomerular basement membrane was reduced by 19% (p<0.021) and by 26% (p<0.02), respectively.",8690168_7,-1,-1,2,23061,-1
23062,anionic site,3,5,17,29,Number and total anionic site surface in the remaining part of the glomerular basement membrane (lamina densa and lamina rara interna) were not significantly changed.,8690168_8,-1,-1,2,23062,-1
23063,glomerular basement membrane,12,15,67,95,Number and total anionic site surface in the remaining part of the glomerular basement membrane (lamina densa and lamina rara interna) were not significantly changed.,8690168_8,-1,-1,2,23063,-1
23065,lamina rara interna,19,22,114,133,Number and total anionic site surface in the remaining part of the glomerular basement membrane (lamina densa and lamina rara interna) were not significantly changed.,8690168_8,-1,-1,2,23065,-1
23069,barrier/density,18,19,128,143,"We conclude that in streptozotocin-diabetic rats with an increased urinary albumin excretion, a reduced heparan sulphate charge barrier/density is found at the lamina rara externa of the glomerular basement membrane.",8690168_9,-1,-1,2,23069,-1
23070,lamina rara externa,23,26,160,179,"We conclude that in streptozotocin-diabetic rats with an increased urinary albumin excretion, a reduced heparan sulphate charge barrier/density is found at the lamina rara externa of the glomerular basement membrane.",8690168_9,-1,-1,2,23070,-1
23071,glomerular basement membrane,28,31,187,215,"We conclude that in streptozotocin-diabetic rats with an increased urinary albumin excretion, a reduced heparan sulphate charge barrier/density is found at the lamina rara externa of the glomerular basement membrane.",8690168_9,-1,-1,2,23071,-1
23077,MAO-inhibited dogs,27,29,150,168,L-Dopa (5 mg/kg i.v.) decreased blood pressure and heart rate after extracerebral decarboxylase inhibition with MK-486 (25 mg/kg i.v.) in anesthetize MAO-inhibited dogs.,869641_1,-1,-1,2,23077,-1
23083,reflex responses,26,28,182,198,"In addition, reflex bradycardia caused by injected norepinephrine was significantly enhanced by L-dopa, DL-Threo-dihydroxyphenylserine had no effect on blood pressure, heart rate or reflex responses to norepinephrine.",869641_2,-1,-1,2,23083,-1
23092,chronotropic effect,17,19,108,127,Removal of the carotid sinuses caused an elevation blood pressure and heart rate and abolished the negative chronotropic effect of norepinephrine.,869641_5,-1,-1,2,23092,-1
23098,central alpha-receptor stimulation,9,12,64,98,It is concluded that L-dopa enhances reflex bradycardia through central alpha-receptor stimulation.,869641_8,-1,-1,2,23098,-1
23108,plasma exchange,10,12,59,74,"In both cases, discontinuation of FK506 and treatment with plasma exchange, fresh frozen plasma replacement, corticosteroids, aspirin, and dipyridamole led to resolution of MAHA.",8701950_2,-1,-1,2,23108,-1
23123,sulfation,1,2,10,19,Increased sulfation and decreased 7alpha-hydroxylation of deoxycholic acid in ethinyl estradiol-induced cholestasis in rats.,873132_0,-1,-1,2,23123,-1
23129,transport capacity,4,6,30,48,"Deoxycholic acid conjugation, transport capacity, and metabolism were compared in control and ethinyl estradiol-treated rats.",873132_1,-1,-1,2,23129,-1
23131,estradiol-treated,15,16,102,119,"Deoxycholic acid conjugation, transport capacity, and metabolism were compared in control and ethinyl estradiol-treated rats.",873132_1,-1,-1,2,23131,-1
23140,estradiol-treated,25,26,161,178,"During [24-14C]sodium deoxycholate infusion, [14C]biliary bile acid secretion increased, but bile flow did not change significantly in either control or ethinyl estradiol-treated rats.",873132_3,-1,-1,2,23140,-1
23142,estradiol-treated,1,2,8,25,"Ethinyl estradiol-treated animals excreted significantly less 14C as taurocholic acid than did control animals, consistent with an impairment of 7alpha-hydroxylation of taurodeoxycholic acid.",873132_4,-1,-1,2,23142,-1
23143,14C,6,7,62,65,"Ethinyl estradiol-treated animals excreted significantly less 14C as taurocholic acid than did control animals, consistent with an impairment of 7alpha-hydroxylation of taurodeoxycholic acid.",873132_4,-1,-1,2,23143,-1
23145,consistent with,15,17,112,127,"Ethinyl estradiol-treated animals excreted significantly less 14C as taurocholic acid than did control animals, consistent with an impairment of 7alpha-hydroxylation of taurodeoxycholic acid.",873132_4,-1,-1,2,23145,-1
23152,consistent with,3,5,18,33,These results are consistent with the hypothesis that the rat has a poorer tolerance for deoxycholic acid than do certain other species.,873132_6,-1,-1,2,23152,-1
23153,poorer tolerance,12,14,68,84,These results are consistent with the hypothesis that the rat has a poorer tolerance for deoxycholic acid than do certain other species.,873132_6,-1,-1,2,23153,-1
23160,sulfation,10,11,67,76,"When this conversion is impaired with ethinyl estradiol treatment, sulfation may be an important alternate pathway for excretion of this potentially harmful bile acid.",873132_8,-1,-1,2,23160,-1
23161,alternate pathway,15,17,97,114,"When this conversion is impaired with ethinyl estradiol treatment, sulfation may be an important alternate pathway for excretion of this potentially harmful bile acid.",873132_8,-1,-1,2,23161,-1
23165,nephrotoxic action,1,3,4,22,"The nephrotoxic action of anticancer drugs such as nitrogranulogen (NG), methotrexate (MTX), 5-fluorouracil (5-FU) and cyclophosphamide (CY) administered alone or in combination [MTX + 5-FU + CY (CMF)] was evaluated in experiments on Wistar rats.",8739323_1,-1,-1,2,23165,-1
23176,CMF,39,40,196,199,"The nephrotoxic action of anticancer drugs such as nitrogranulogen (NG), methotrexate (MTX), 5-fluorouracil (5-FU) and cyclophosphamide (CY) administered alone or in combination [MTX + 5-FU + CY (CMF)] was evaluated in experiments on Wistar rats.",8739323_1,-1,-1,2,23176,-1
23187,statistically significant,11,13,54,79,"After the administration of NG, 5-FU and CY neither a statistically significant increase in creatinine concentration nor an increase in creatinine clearance was observed compared to the group receiving no cytostatics.",8739323_5,-1,-1,2,23187,-1
23191,CMF,5,6,39,42,"Following polytherapy according to the CMF regimen, a statistically significant decrease (p = 0.0343) in creatinine clearance was found, but creatinine concentration did not increase significantly compared to controls.",8739323_6,-1,-1,2,23191,-1
23192,statistically significant,9,11,54,79,"Following polytherapy according to the CMF regimen, a statistically significant decrease (p = 0.0343) in creatinine clearance was found, but creatinine concentration did not increase significantly compared to controls.",8739323_6,-1,-1,2,23192,-1
23203,joint administration,25,27,134,154,"Histologic changes were found in rat kidneys after administration of MTX, CY and NG, while no such change was observed after 5-FU and joint administration of MTX + 5-FU + CY compared to controls.",8739323_8,-1,-1,2,23203,-1
23213,nicotine's,4,6,38,48,The interpeduncular nucleus regulates nicotine's effects on free-field activity.,8741744_0,-1,-1,2,23213,-1
23214,free-field activity,8,10,60,79,The interpeduncular nucleus regulates nicotine's effects on free-field activity.,8741744_0,-1,-1,2,23214,-1
23218,sham-operated controls,2,4,14,36,"Compared with sham-operated controls, lesions significantly (p < 0.25) blunted the early (<60 min) free-field locomotor hypoactivity caused by nicotine (0.5 mg kg(-1), i.m.), enhanced the later (60-120 min) nicotine-induced hyperactivity, and raised spontaneous nocturnal activity.",8741744_2,-1,-1,2,23218,-1
23222,immunohistological staining,5,7,30,57,"Lesions reduced the extent of immunohistological staining for choline acetyltransferase in the interpeduncular nucleus (p <0.025), but not for tyrosine hydroxylase in the surrounding catecholaminergic A10 region.",8741744_3,-1,-1,2,23222,-1
23228,locomotor activity,10,12,78,96,We conclude that the interpeduncular nucleus mediates nicotinic depression of locomotor activity and dampens nicotinic arousal mechanisms located elsewhere in the brain.,8741744_4,-1,-1,2,23228,-1
23230,arousal mechanisms,15,17,119,137,We conclude that the interpeduncular nucleus mediates nicotinic depression of locomotor activity and dampens nicotinic arousal mechanisms located elsewhere in the brain.,8741744_4,-1,-1,2,23230,-1
23231,diet free,2,4,13,22,Influence of diet free of NAD-precursors on acetaminophen hepatotoxicity in mice.,8742498_0,-1,-1,2,23231,-1
23240,effects of,5,7,35,45,"The present study investigates the effects of a diet free of precursors of NAD, the substrate on which PARP acts, in female NMRI mice with AAP hepatitis and evaluates the influence of simultaneous ethanol consumption in these animals.",8742498_2,-1,-1,2,23240,-1
23241,diet free of,8,11,48,60,"The present study investigates the effects of a diet free of precursors of NAD, the substrate on which PARP acts, in female NMRI mice with AAP hepatitis and evaluates the influence of simultaneous ethanol consumption in these animals.",8742498_2,-1,-1,2,23241,-1
23243,NMRI mice,24,26,124,133,"The present study investigates the effects of a diet free of precursors of NAD, the substrate on which PARP acts, in female NMRI mice with AAP hepatitis and evaluates the influence of simultaneous ethanol consumption in these animals.",8742498_2,-1,-1,2,23243,-1
23244,AAP,27,28,139,142,"The present study investigates the effects of a diet free of precursors of NAD, the substrate on which PARP acts, in female NMRI mice with AAP hepatitis and evaluates the influence of simultaneous ethanol consumption in these animals.",8742498_2,-1,-1,2,23244,-1
23246,serum activities,5,7,34,50,Liver injuries were quantified as serum activities of glutamate-oxaloacetate transaminase (GOT) and glutamate-pyruvate transaminase (GPT).,8742498_3,-1,-1,2,23246,-1
23249,GPT,17,18,133,136,Liver injuries were quantified as serum activities of glutamate-oxaloacetate transaminase (GOT) and glutamate-pyruvate transaminase (GPT).,8742498_3,-1,-1,2,23249,-1
23251,serum transaminase activities,7,10,41,70,"While AAP caused a 117-fold elevation of serum transaminase activities in mice kept on a standard laboratory diet, which was significantly exacerbated by ethanol and inhibited by nicotinic acid amide (NAA), adverse effects were noted in animals fed a diet free of precursors of NAD.",8742498_4,-1,-1,2,23251,-1
23252,laboratory diet,16,18,98,113,"While AAP caused a 117-fold elevation of serum transaminase activities in mice kept on a standard laboratory diet, which was significantly exacerbated by ethanol and inhibited by nicotinic acid amide (NAA), adverse effects were noted in animals fed a diet free of precursors of NAD.",8742498_4,-1,-1,2,23252,-1
23256,diet free of,43,46,251,263,"While AAP caused a 117-fold elevation of serum transaminase activities in mice kept on a standard laboratory diet, which was significantly exacerbated by ethanol and inhibited by nicotinic acid amide (NAA), adverse effects were noted in animals fed a diet free of precursors of NAD.",8742498_4,-1,-1,2,23256,-1
23258,AAP,17,18,105,108,"In these animals, only minor increases of serum transaminase activities were measured in the presence of AAP, and unlike the exacerbation caused by ethanol in mice on a standard diet, the liver damage was inhibited by 50% by ethanol.",8742498_5,-1,-1,2,23258,-1
23259,standard diet,30,32,169,182,"In these animals, only minor increases of serum transaminase activities were measured in the presence of AAP, and unlike the exacerbation caused by ethanol in mice on a standard diet, the liver damage was inhibited by 50% by ethanol.",8742498_5,-1,-1,2,23259,-1
23267,enzyme's,30,32,186,194,Our results provide evidence that the AAP-induced hepatitis and its exacerbation by ethanol can either be reduced by end-product inhibition of PARP by NAA or by dietary depletion of the enzyme's substrate NAD.,8742498_7,-1,-1,2,23267,-1
23268,substrate NAD,32,34,195,208,Our results provide evidence that the AAP-induced hepatitis and its exacerbation by ethanol can either be reduced by end-product inhibition of PARP by NAA or by dietary depletion of the enzyme's substrate NAD.,8742498_7,-1,-1,2,23268,-1
23272,treated with,25,27,157,169,We see the main application of NAA as for the combinational use in pharmaceutical preparations of acetaminophen in order to avoid hepatic damage in patients treated with this widely used analgesic.,8742498_8,-1,-1,2,23272,-1
23276,case series,14,16,97,108,Lithium-associated cognitive and functional deficits reduced by a switch to divalproex sodium: a case series.,8752018_0,-1,-1,2,23276,-1
23289,preliminary report,4,6,20,38,"CONCLUSION: In this preliminary report, divalproex sodium was a superior alternative to lithium in bipolar patients experiencing cognitive deficits, loss of creativity, and functional impairments.",8752018_6,-1,-1,2,23289,-1
23318,CaCl2,0,1,0,5,CaCl2 and 4-aminopyridine.,8800187_5,-1,-1,2,23318,-1
23328,QRS prolongation,11,13,57,73,RESULTS: NaHCO3 briefly (5 min) reversed hypotension and QRS prolongation.,8800187_9,-1,-1,2,23328,-1
23365,alpha activity,28,30,189,203,"The patient with nitrazepam overdose and two of those with chlormethiazole intoxication conformed to the criteria of 'alpha coma', showing non-reactive generalized or frontally predominant alpha activity in the EEG.",88336_3,-1,-1,2,23365,-1
23368,slow beta range,15,18,126,141,The fourth patient who was unconscious after chlormethiazole administration exhibite generalized non-reactive activity in the slow beta range.,88336_4,-1,-1,2,23368,-1
23371,effects of,4,6,29,39,The similarities between the effects of structural lesions and pharmacological depression of the brain stem reticular formation are discussed.,88336_6,-1,-1,2,23371,-1
23388,double-blind fashion,16,18,113,133,METHODS: One hundred sixty-eight adult outpatients with mild to moderate hypertension were randomly allocated in double-blind fashion and equal number to receive 80 mg valsartan or 5 mg amlodipine for 12 weeks.,8841157_2,-1,-1,2,23388,-1
23393,Secondary variables,0,2,0,19,Secondary variables included change in sitting systolic blood pressure and responder rates.,8841157_6,-1,-1,2,23393,-1
23397,statistically significant,10,12,56,81,"Similar decreases were observed in both groups, with no statistically significant differences between the groups for any variable analyzed.",8841157_8,-1,-1,2,23397,-1
23398,primary variable,2,4,8,24,"For the primary variable the difference was 0.5 mm Hg in favor of valsartan (p = 0.68; 95% confidence interval, -2.7 to 1.7).",8841157_9,-1,-1,2,23398,-1
23399,confidence interval,21,23,91,110,"For the primary variable the difference was 0.5 mm Hg in favor of valsartan (p = 0.68; 95% confidence interval, -2.7 to 1.7).",8841157_9,-1,-1,2,23399,-1
23400,Responder rates,0,2,0,15,Responder rates at 8 weeks were 66.7% for valsartan and 60.2% for amlodipine (p = 0.39).,8841157_10,-1,-1,2,23400,-1
23415,CIP,3,4,26,29,Cocaine-induced paranoia (CIP) remains an important drug-induced model of idiopathic paranoia for which no psychophysiologic marker has yet emerged.,8854309_1,-1,-1,2,23415,-1
23418,psychophysiologic marker,16,18,107,131,Cocaine-induced paranoia (CIP) remains an important drug-induced model of idiopathic paranoia for which no psychophysiologic marker has yet emerged.,8854309_1,-1,-1,2,23418,-1
23421,CIP,18,19,131,134,Measures of pupillary oscillation were able to significantly distinguish a group of abstinent crack cocaine abusers endorsing past CIP (n = 32) from another group of crack addicts who denied past CIP (n = 29).,8854309_2,-1,-1,2,23421,-1
23423,CIP,33,34,196,199,Measures of pupillary oscillation were able to significantly distinguish a group of abstinent crack cocaine abusers endorsing past CIP (n = 32) from another group of crack addicts who denied past CIP (n = 29).,8854309_2,-1,-1,2,23423,-1
23424,Magnetic resonance volumetry,0,3,0,28,Magnetic resonance volumetry of the cerebellum in epileptic patients after phenytoin overdosages.,8864707_0,-1,-1,2,23424,-1
23429,circular polarized head coil,22,26,99,127,"Five females and 6 males, 21-59 years of age, were examined with a 1.5-T whole-body system using a circular polarized head coil.",8864707_2,-1,-1,2,23429,-1
23430,spin echo images,1,4,13,29,Conventional spin echo images were acquired in the sagittal and transverse orientation.,8864707_3,-1,-1,2,23430,-1
23431,transverse orientation,10,12,64,86,Conventional spin echo images were acquired in the sagittal and transverse orientation.,8864707_3,-1,-1,2,23431,-1
23432,high-resolution 3D,6,8,28,46,"In addition, we performed a high-resolution 3D gradient echo, T1-weighted sequences at a 1-mm slice thickness.",8864707_4,-1,-1,2,23432,-1
23433,T1-weighted sequences,11,13,62,83,"In addition, we performed a high-resolution 3D gradient echo, T1-weighted sequences at a 1-mm slice thickness.",8864707_4,-1,-1,2,23433,-1
23435,patient group,4,6,26,39,Cerebellar volume for the patient group ranged between 67.66 and 131.08 ml (mean 108.9 ml).,8864707_6,-1,-1,2,23435,-1
23436,data sets,5,7,29,38,In addition 3D gradient echo data sets from 10 healthy male and 10 healthy female age-matched volunteers were used to compare cerebellar volumes.,8864707_7,-1,-1,2,23436,-1
23440,daily dosage,6,8,37,49,"However, multiple regression for the daily dosage, duration of phenytoin treatment and cerebellar volume revealed a correlation of these parameters.",8864707_9,-1,-1,2,23440,-1
23445,Quantitative morphometric studies,0,3,0,33,Quantitative morphometric studies of the cerebellum provide valuable insights into the pathogenesis of cerebellar disorders.,8864707_11,-1,-1,2,23445,-1
23460,120/67,6,7,33,39,"Vital signs were: blood pressure 120/67 mm Hg, heart rate 127/min, respiratory rate 28/min, and temperature 97 F. After 180 mg of diazepam i.v. he remained tremulous with muscle rigidity and clenched jaws.",8888541_9,-1,-1,2,23460,-1
23461,heart rate 127/min,10,13,47,65,"Vital signs were: blood pressure 120/67 mm Hg, heart rate 127/min, respiratory rate 28/min, and temperature 97 F. After 180 mg of diazepam i.v. he remained tremulous with muscle rigidity and clenched jaws.",8888541_9,-1,-1,2,23461,-1
23467,patient's,1,3,4,13,The patient's maximal temperature was 101.2 F and his CPK remained < 500 units/L with no other evidence of rhabdomyolysis.,8888541_12,-1,-1,2,23467,-1
23468,CPK,10,11,54,57,The patient's maximal temperature was 101.2 F and his CPK remained < 500 units/L with no other evidence of rhabdomyolysis.,8888541_12,-1,-1,2,23468,-1
23479,treated with,2,4,8,20,"She was treated with heparin, dipyridamole and hemodialysis; and after more than three months, her urinary output rose above 500 ml; and six months after the onset of anuria, dialysis treatment was stopped.",891050_2,-1,-1,2,23479,-1
23497,treated with,5,7,28,40,Of the 5 patients initially treated with endoscopic resection alone only 1 is alive without disease.,8911359_4,-1,-1,2,23497,-1
23508,chronic administration,5,7,47,69,Morphological features of encephalopathy after chronic administration of the antiepileptic drug valproate to rats.,8919272_0,-1,-1,2,23508,-1
23519,structural elements,5,7,37,56,The first ultrastructural changes in structural elements of the blood-brain-barrier (BBB) in the cerebellar cortex were detectable after 3 months of the experiment.,8919272_3,-1,-1,2,23519,-1
23520,blood-brain-barrier,9,10,64,83,The first ultrastructural changes in structural elements of the blood-brain-barrier (BBB) in the cerebellar cortex were detectable after 3 months of the experiment.,8919272_3,-1,-1,2,23520,-1
23521,BBB,11,12,85,88,The first ultrastructural changes in structural elements of the blood-brain-barrier (BBB) in the cerebellar cortex were detectable after 3 months of the experiment.,8919272_3,-1,-1,2,23521,-1
23525,endothelial cells,7,9,46,63,Lesions of the capillary included necrosis of endothelial cells.,8919272_5,-1,-1,2,23525,-1
23526,cristae,21,22,128,135,"Organelles of these cells, in particular the mitochondria (increased number and size, distinct degeneration of their matrix and cristae) and Golgi apparatus were altered.",8919272_6,-1,-1,2,23526,-1
23527,Golgi apparatus,24,26,141,156,"Organelles of these cells, in particular the mitochondria (increased number and size, distinct degeneration of their matrix and cristae) and Golgi apparatus were altered.",8919272_6,-1,-1,2,23527,-1
23529,endothelial cells,11,13,69,86,Reduced size of capillary lumen and occlusion were caused by swollen endothelial cells which had luminal protrusions and swollen microvilli.,8919272_7,-1,-1,2,23529,-1
23531,swollen microvilli,18,20,121,139,Reduced size of capillary lumen and occlusion were caused by swollen endothelial cells which had luminal protrusions and swollen microvilli.,8919272_7,-1,-1,2,23531,-1
23534,necrotic endothelial cells,2,5,13,39,Fragments of necrotic endothelial cells were in the vascular lumens and in these there was loosening and breaking of tight cellular junctions.,8919272_9,-1,-1,2,23534,-1
23536,tight cellular junctions,19,22,117,141,Fragments of necrotic endothelial cells were in the vascular lumens and in these there was loosening and breaking of tight cellular junctions.,8919272_9,-1,-1,2,23536,-1
23538,neuroglial cells,10,12,60,76,"Damage to the capillary was accompanied by marked damage to neuroglial cells, mainly to perivascular processes of astrocytes.",8919272_11,-1,-1,2,23538,-1
23540,Bergmann's,5,7,33,43,The proliferation of astrocytes (Bergmann's in particular) and occasionally of oligodendrocytes was found.,8919272_12,-1,-1,2,23540,-1
23541,structural elements,3,5,19,38,Alterations in the structural elements of the BBB coexisted with marked lesions of neurons of the cerebellum (Purkinje cells are earliest).,8919272_13,-1,-1,2,23541,-1
23543,Purkinje cells,18,20,110,124,Alterations in the structural elements of the BBB coexisted with marked lesions of neurons of the cerebellum (Purkinje cells are earliest).,8919272_13,-1,-1,2,23543,-1
23545,antiluminal,6,7,41,52,In electron micrographs both luminal and antiluminal sides of the BBB of the cerebellar cortex had similar lesions.,8919272_14,-1,-1,2,23545,-1
23546,BBB,10,11,66,69,In electron micrographs both luminal and antiluminal sides of the BBB of the cerebellar cortex had similar lesions.,8919272_14,-1,-1,2,23546,-1
23554,paramedic misjudgment,5,7,21,42,We present a case of paramedic misjudgment in the execution of a protocol for the treatment of allergic reaction in a case of pulmonary edema with wheezing.,8953972_1,-1,-1,2,23554,-1
23567,Cellular mechanisms,0,2,0,19,Cellular mechanisms which account for disruption the blood-brain barrier during acute hypertension are not clear.,8955532_1,-1,-1,2,23567,-1
23576,quantitated,6,7,44,55,Permeability of the blood-brain barrier was quantitated by clearance of fluorescent-labeled dextran before and during phenylephrine-induced acute hypertension in rats treated with vehicle and Hoe-140 (0.1 microM).,8955532_3,-1,-1,2,23576,-1
23589,phase I clinical study,1,5,2,24,A phase I clinical study of the antipurine antifolate lometrexol (DDATHF) given with oral folic acid.,8958188_0,-1,-1,2,23589,-1
23598,purine synthesis,19,21,129,145,"Lometrexol is an antifolate which inhibits glycinamide ribonucleotide formyltransferase (GARFT), an enzyme essential for de novo purine synthesis.",8958188_1,-1,-1,2,23598,-1
23608,Phase I clinical study,4,8,28,50,This observation prompted a Phase I clinical study of lometrexol given with folic acid supplementation which has confirmed that the toxicity of lometrexol can be markedly reduced by folic acid supplementation.,8958188_5,-1,-1,2,23608,-1
23614,Associated studies,0,2,0,18,Associated studies demonstrated that lometrexol plasma pharmacokinetics were not altered by folic acid administration indicating that supplementation is unlikely to reduce toxicity by enhancing lometrexol plasma clearance.,8958188_8,-1,-1,2,23614,-1
23628,consistent with,5,7,36,51,"The epidemiologic findings are most consistent with the hypothesis that chronic cocaine use disrupts dopaminergic function and, when coupled with recent cocaine use, may precipitate agitation, delirium, aberrant thermoregulation, rhabdomyolysis, and sudden death.",8988571_6,-1,-1,2,23628,-1
23629,chronic cocaine use disrupts,10,14,72,100,"The epidemiologic findings are most consistent with the hypothesis that chronic cocaine use disrupts dopaminergic function and, when coupled with recent cocaine use, may precipitate agitation, delirium, aberrant thermoregulation, rhabdomyolysis, and sudden death.",8988571_6,-1,-1,2,23629,-1
23635,Risk factors,0,2,0,12,Risk factors of sensorineural hearing loss in preterm infants.,8996652_0,-1,-1,2,23635,-1
23640,Perinatal risk factors,0,3,0,22,Perinatal risk factors of infants with hearing loss were compared with those of two control groups matched for gestation and birth weight and for perinatal complications.,8996652_2,-1,-1,2,23640,-1
23642,control groups,14,16,84,98,Perinatal risk factors of infants with hearing loss were compared with those of two control groups matched for gestation and birth weight and for perinatal complications.,8996652_2,-1,-1,2,23642,-1
23662,associated in,5,7,31,44,Pemoline has not been commonly associated in the literature as a cause of acute movement disorders.,9022662_2,-1,-1,2,23662,-1
23671,treated with,12,14,89,101,The children had a medical history significant for attention deficit disorder previously treated with methylphenidate without success.,9022662_5,-1,-1,2,23671,-1
23681,Forty-eight hours,0,2,0,17,"Forty-eight hours after admission, the children appeared to be at their baseline and were discharged home.",9022662_11,-1,-1,2,23681,-1
23699,pharmacodynamics,5,6,42,58,"Based on nonoverdose pharmacokinetics and pharmacodynamics of venlafaxine and the potential risks of available interventions, no emergent therapy was instituted.",9034419_6,-1,-1,2,23699,-1
23703,myopic excimer laser,2,5,10,30,Effect of myopic excimer laser photorefractive keratectomy on the electrophysiologic function of the retina and optic nerve.,9041081_0,-1,-1,2,23703,-1
23709,PRK,13,14,92,95,PURPOSE: To assess by electrophysiologic testing the effect of photorefractive keratectomy (PRK) on the retina and optic nerve.,9041081_1,-1,-1,2,23709,-1
23712,Salvatore,6,7,24,33,"SETTING: Eye Clinic, S. Salvatore Hospital, L'Aquila University, Italy.",9041081_2,-1,-1,2,23712,-1
23713,L'Aquila University,9,11,44,63,"SETTING: Eye Clinic, S. Salvatore Hospital, L'Aquila University, Italy.",9041081_2,-1,-1,2,23713,-1
23715,P-ERGs,6,7,46,52,METHODS: Standard pattern electroretinograms (P-ERGs) and standard pattern visual evoked potentials (P-VEPs) were done in 25 eyes of 25 patients who had myopic PRK for an attempted correction between 5.00 and 15.00 diopters (D) (mean 8.00 D).,9041081_3,-1,-1,2,23715,-1
23717,PRK,28,29,160,163,METHODS: Standard pattern electroretinograms (P-ERGs) and standard pattern visual evoked potentials (P-VEPs) were done in 25 eyes of 25 patients who had myopic PRK for an attempted correction between 5.00 and 15.00 diopters (D) (mean 8.00 D).,9041081_3,-1,-1,2,23717,-1
23720,corticosteroid therapy,21,23,121,143,"During the follow-up, 3 patients (12%) developed steroid-induced elevated intraocular pressure (IOP) that resolved after corticosteroid therapy was discontinued.",9041081_6,-1,-1,2,23720,-1
23721,No statistically significant,2,5,9,37,RESULTS: No statistically significant differences were seen between treated and control eyes nor between treated eyes preoperatively and postoperatively.,9041081_7,-1,-1,2,23721,-1
23722,control eyes,11,13,80,92,RESULTS: No statistically significant differences were seen between treated and control eyes nor between treated eyes preoperatively and postoperatively.,9041081_7,-1,-1,2,23722,-1
23726,transient steroid-induced IOP,1,4,4,33,The transient steroid-induced IOP rise did not seem to cause functional impairment.,9041081_9,-1,-1,2,23726,-1
23734,ALF,24,25,157,160,Defects in superoxide and hydrogen peroxide production may be implicated in the high incidence of bacterial infections in patients with acute liver failure (ALF).,9061311_1,-1,-1,2,23734,-1
23735,ALF,11,12,65,68,"In the present study, oxygen radical production in patients with ALF due to paracetamol overdose was compared with that of healthy volunteers.",9061311_2,-1,-1,2,23735,-1
23737,healthy volunteers,21,23,123,141,"In the present study, oxygen radical production in patients with ALF due to paracetamol overdose was compared with that of healthy volunteers.",9061311_2,-1,-1,2,23737,-1
23738,ALF,3,4,20,23,Neutrophils from 14 ALF patients were stimulated via the complement receptors using zymosan opsonized with ALF or control serum.,9061311_3,-1,-1,2,23738,-1
23747,control subjects,21,23,156,172,Superoxide and hydrogen peroxide production by ALF neutrophils stimulated with zymosan opsonized with ALF serum was significantly reduced compared with the control subjects (P < 0.01).,9061311_4,-1,-1,2,23747,-1
23753,ALF,17,18,138,141,Superoxide and hydrogen peroxide production in neutrophils stimulated with formyl-methionyl-leucyl-phenylalanine (fMLP) from a further 18 ALF patients was unaffected compared with control neutrophils.,9061311_6,-1,-1,2,23753,-1
23755,ALF,8,9,57,60,Serum C3 complement levels were significantly reduced in ALF patients compared with control subjects (P < 0.0005).,9061311_7,-1,-1,2,23755,-1
23756,control subjects,12,14,84,100,Serum C3 complement levels were significantly reduced in ALF patients compared with control subjects (P < 0.0005).,9061311_7,-1,-1,2,23756,-1
23757,ALF,7,8,49,52,"These results demonstrate a neutrophil defect in ALF due to paracetamol overdose, that is complement dependent but independent of serum complement, possibly connected to the complement receptor.",9061311_8,-1,-1,2,23757,-1
23767,tris salt (CS) administration,14,20,91,120,"In addition to its use as a stabilizer/rigidifier of membranes, cholesteryl hemisuccinate, tris salt (CS) administration has also been shown to protect rats from the hepatotoxic effects of carbon tetrachloride (CCl4).",9067481_1,-1,-1,2,23767,-1
23778,organ system,17,19,113,125,"The results of these studies demonstrated that CS-mediated protection is not selective for a particular species, organ system or toxic chemical.",9067481_3,-1,-1,2,23778,-1
23780,pretreatment,2,3,7,19,"A 24-h pretreatment of both rats and mice with a single dose of CS (100mg/kg, i.p.), resulted in significant protection against the hepatotoxic effects of CCl4, CHCl3, acetaminophen and galactosamine and against the lethal (and presumably cardiotoxic) effect of adriamycin administration.",9067481_4,-1,-1,2,23780,-1
23788,experimental animals,6,8,47,67,Maximal CS-mediated protection was observed in experimental animals pretreated 24 h prior to the toxic insult.,9067481_5,-1,-1,2,23788,-1
23790,CS intervenes,4,6,24,37,These data suggest that CS intervenes in a critical cellular event that is an important common pathway to toxic cell death.,9067481_6,-1,-1,2,23790,-1
23791,cellular event,9,11,52,66,These data suggest that CS intervenes in a critical cellular event that is an important common pathway to toxic cell death.,9067481_6,-1,-1,2,23791,-1
23795,anionic CS molecule,15,18,93,112,"Our findings do suggest that CS-mediated protection is dependent on the action of the intact anionic CS molecule (non-hydrolyzable CSE was as protective as CS), whose mechanism has yet to be defined.",9067481_9,-1,-1,2,23795,-1
23814,haematocrit values,28,30,160,178,"Haemodilution in groups B and C was produced by withdrawing approximately 1000 mL of blood and replacing it with the same amount of dextran solution, and final haematocrit values were 21 or 22%.",9088814_3,-1,-1,2,23814,-1
23819,mmHg,19,20,110,114,Controlled hypotension in groups A and C was induced with PGE1 to maintain mean arterial blood pressure at 55 mmHg for 180 min.,9088814_4,-1,-1,2,23819,-1
23826,no change,7,9,50,59,"AKBR and biological hepatic function tests showed no change throughout the time course in groups A and B. In group C, AKBR showed a significant decrease at 120 min (-40%) and at 180 min (-49%) after the start of hypotension and at 60 min (-32%) after recovery of normotension, and SGOT, SGPT, LDH and total bilirubin showed significant increases after operation.",9088814_6,-1,-1,2,23826,-1
23829,B.,17,18,103,105,"AKBR and biological hepatic function tests showed no change throughout the time course in groups A and B. In group C, AKBR showed a significant decrease at 120 min (-40%) and at 180 min (-49%) after the start of hypotension and at 60 min (-32%) after recovery of normotension, and SGOT, SGPT, LDH and total bilirubin showed significant increases after operation.",9088814_6,-1,-1,2,23829,-1
23843,noncastrated rats,16,18,94,111,OBJECTIVE: The aim of this study was to investigate whether fluoxetine given to castrated and noncastrated rats caused hyperprolactinemia and its effects with respect to adenomyosis.,9098464_1,-1,-1,2,23843,-1
23845,effects with,22,24,146,158,OBJECTIVE: The aim of this study was to investigate whether fluoxetine given to castrated and noncastrated rats caused hyperprolactinemia and its effects with respect to adenomyosis.,9098464_1,-1,-1,2,23845,-1
23847,Wistar Albino rats,12,15,65,83,"DESIGN: Fluoxetine, a serotonin reuptake inhibitor, was given to Wistar Albino rats for 98 days to produce hyperprolactinemia.",9098464_2,-1,-1,2,23847,-1
23849,noncastrated,11,12,61,73,The drug was given to two groups consisting of castrated and noncastrated rats and compared to two groups of castrated and noncastrated controls.,9098464_3,-1,-1,2,23849,-1
23850,noncastrated controls,21,23,123,144,The drug was given to two groups consisting of castrated and noncastrated rats and compared to two groups of castrated and noncastrated controls.,9098464_3,-1,-1,2,23850,-1
23851,Prolactin levels,0,2,0,16,Prolactin levels were measured and the uteri of the rats were removed for histopathological analysis at the end of 98 days.,9098464_4,-1,-1,2,23851,-1
23860,noncastrated groups,8,10,47,66,RESULTS: The prolactin levels of castrated and noncastrated groups treated with fluoxetine were statistically significantly higher when compared to their respective control groups.,9098464_7,-1,-1,2,23860,-1
23861,treated with,10,12,67,79,RESULTS: The prolactin levels of castrated and noncastrated groups treated with fluoxetine were statistically significantly higher when compared to their respective control groups.,9098464_7,-1,-1,2,23861,-1
23862,control groups,22,24,165,179,RESULTS: The prolactin levels of castrated and noncastrated groups treated with fluoxetine were statistically significantly higher when compared to their respective control groups.,9098464_7,-1,-1,2,23862,-1
23864,noncastrated group,11,13,70,88,"Histological studies revealed 11 cases of adenomyosis, all within the noncastrated group receiving fluoxetine.",9098464_8,-1,-1,2,23864,-1
23865,serum prolactin,7,9,39,54,CONCLUSION: It was suggested that high serum prolactin levels cause degeneration of myometrial cells in the presence of ovarian steroids that results in a myometrial invasion by endometrial stroma.,9098464_9,-1,-1,2,23865,-1
23875,general induce,14,16,94,108,The present study was designed to investigate the hypothesis that calcium channel blockers in general induce cardiovascular malformations indicating a pharmacologic class effect.,9100294_2,-1,-1,2,23875,-1
23883,exposure to,9,11,67,78,"A low incidence of cardiovascular malformations was observed after exposure to each of the four calcium channel blockers, but this incidence was statistically significant only for verapamil and nifedipine.",9100294_5,-1,-1,2,23883,-1
23885,statistically significant,23,25,145,170,"A low incidence of cardiovascular malformations was observed after exposure to each of the four calcium channel blockers, but this incidence was statistically significant only for verapamil and nifedipine.",9100294_5,-1,-1,2,23885,-1
23886,associated with,4,6,21,36,"All four agents were associated with aortic arch branching variants, although significantly increased only for Ro 40-5967 and verapamil.",9100294_6,-1,-1,2,23886,-1
23890,associated with,4,6,41,56,Postinfarction ventricular septal defect associated with long-term steroid therapy.,9105126_0,-1,-1,2,23890,-1
23892,favourable outcome,17,19,118,136,Two cases of postinfarction ventricular septal rupture in patients on long-term steroid therapy are presented and the favourable outcome in both cases described.,9105126_1,-1,-1,2,23892,-1
23922,protective index values,28,31,216,239,"Although the neuroactive steroids were considerably less potent than the benzodiazepine clonazepam in protecting against pilocarpine seizures, steroids with the 5 alpha,3 alpha-configuration had comparable or higher protective index values (TD50 for motor impairment divided by ED50 for seizure protection) than clonazepam, indicating that some neuroactive steroids may have lower relative toxicity.",9121607_4,-1,-1,2,23922,-1
23930,dose-dependent,13,14,84,98,"Steroids with the 5 alpha,3 alpha- or 5 beta,3 alpha-configurations also produced a dose-dependent delay in the onset of limbic seizures induced by kainic acid (32 mg/kg, s.c.), but did not completely protect against the seizures.",9121607_5,-1,-1,2,23930,-1
23942,gene expression,4,6,41,56,Hepatic and extrahepatic angiotensinogen gene expression in rats with acute nephrotic syndrome.,9154656_0,-1,-1,2,23942,-1
23954,pair-fed (PF,45,48,249,261,"In this work the messenger ribonucleic acid (mRNA) levels of angiotensinogen (Ao) were analyzed with the slot-blot hybridization technique in liver and other extrahepatic tissues: kidney, heart, brain, and adrenal gland from control, nephrotic, and pair-fed (PF) rats.",9154656_2,-1,-1,2,23954,-1
23956,half-normal,6,7,39,50,"Although a great urinary excretion and half-normal plasma levels of Ao were observed on day 6 after PAN injection, when NS was clearly established, hepatic Ao mRNA levels did not change.",9154656_4,-1,-1,2,23956,-1
23961,hepatic levels,23,25,112,126,"Furthermore, the Ao mRNA levels did not change in any of the extrahepatic tissues studied on day 6, nor did its hepatic levels at days 1, 3, 5, or 7 after PAN injection.",9154656_5,-1,-1,2,23961,-1
23963,Ao,8,9,53,55,These data suggest that the hepatic and extrahepatic Ao mRNA levels are unaltered during the development of the acute NS induced by PAN.,9154656_6,-1,-1,2,23963,-1
23964,acute NS,18,20,112,120,These data suggest that the hepatic and extrahepatic Ao mRNA levels are unaltered during the development of the acute NS induced by PAN.,9154656_6,-1,-1,2,23964,-1
23978,monotherapy,8,9,67,78,A 73-year-old woman developed neuroleptic malignant syndrome after monotherapy with risperidone.,9165568_5,-1,-1,2,23978,-1
24007,Treatment strategies,0,2,0,20,Treatment strategies aimed at avoiding retinal toxicity are discussed.,9199746_6,-1,-1,2,24007,-1
24031,postsynaptic dopamine,4,6,24,45,Carteolol did not evoke postsynaptic dopamine receptor-stimulating behavioral signs such as stereotypy and hyperlocomotion in rats.,9201797_6,-1,-1,2,24031,-1
24042,physostigmine-induced lethality,6,8,35,66,"Finally, carteolol did not inhibit physostigmine-induced lethality in rats.",9201797_9,-1,-1,2,24042,-1
24047,postsynaptic dopamine,33,35,268,289,These results strongly suggest that carteolol improves haloperidol-induced catalepsy via its beta-adrenoceptor antagonistic activity and is expected to be effective in the treatment of akathisia without attenuating neuroleptic-induced antipsychotic effects due to its postsynaptic dopamine receptor antagonistic activity.,9201797_10,-1,-1,2,24047,-1
24050,associated with,6,8,34,49,Granulosa cell tumor of the ovary associated with antecedent tamoxifen use.,9205462_0,-1,-1,2,24050,-1
24052,treated with,7,9,45,57,CASE: A 52-year-old postmenopausal woman was treated with tamoxifen for stage II estrogen receptor-positive breast carcinoma.,9205462_3,-1,-1,2,24052,-1
24065,early stage,36,38,237,248,It is generally assumed that DNA elongation is stopped by the insertion of AZT into the chain in place of thymidine thus preventing the phosphate hydroxyl linkages and therefore suppresses hemopoietic progenitor cell proliferation in an early stage of differentiation.,9209318_2,-1,-1,2,24065,-1
24066,CBA/Ca,0,1,0,6,"CBA/Ca male mice started on AZT 0.75 mg/ml H2O at 84 days of age and kept on it for 687 days when dosage reduced to 0.5 mg/ml H2O for a group, another group removed from AZT to see recovery, and third group remained on 0.75 mg.",9209318_3,-1,-1,2,24066,-1
24070,histological patterns,3,5,13,34,A variety of histological patterns was observed.,9209318_6,-1,-1,2,24070,-1
24075,bizarre nuclei,24,26,181,195,"There were two cases of hypocellular myelodysplasia, two cases of hypersegmented myelodysplastic granulocytosis, two cases of hypercellular marrow with abnormal megakaryocytes with bizarre nuclei, one case of megakaryocytic myelosis associated with a hyperplastic marrow, dysmyelopoiesis and a hypocellular marrow and two cases of myelodysplasia with dyserythropoiesis, hemosiderosis and a hypocellular marrow.",9209318_7,-1,-1,2,24075,-1
24085,hemopoietic progenitor cells,13,16,95,123,"Above mentioned AZT incorporation may have induced an ineffective hemopoiesis in the primitive hemopoietic progenitor cells, which is known to be seen commonly in the myelodysplastic syndrome.",9209318_8,-1,-1,2,24085,-1
24087,Biphasic response,0,2,0,17,Biphasic response of the SA node of the dog heart in vivo to selective administration of ketamine.,921394_0,-1,-1,2,24087,-1
24089,in vivo,10,12,50,57,Biphasic response of the SA node of the dog heart in vivo to selective administration of ketamine.,921394_0,-1,-1,2,24089,-1
24091,in vivo,13,15,63,70,Effect of ketamine on the SA node of the dog heart was studied in vivo using a selective perfusion technique of the SA node artery.,921394_1,-1,-1,2,24091,-1
24092,nodal activity,20,22,107,121,Injections of ketamine in doses from 100 microgram to 3 mg into the artery produced a depression of the SA nodal activity by a direct action.,921394_2,-1,-1,2,24092,-1
24093,direct action,24,26,127,140,Injections of ketamine in doses from 100 microgram to 3 mg into the artery produced a depression of the SA nodal activity by a direct action.,921394_2,-1,-1,2,24093,-1
24097,reserpinized dogs,28,30,194,211,"Bilateral vagotomy and sympathectomy or prior administration of a ganglion blocker failed to inhibit the occurrence of the ketamine-induced tachycardia, while it was completely abolished in the reserpinized dogs or by a prior injection of a beta-blocking agent into the SA node artery.",921394_4,-1,-1,2,24097,-1
24103,associated with,5,7,27,42,"Estrogens, which have been associated with several types of human and animal cancers, can induce tumor angiogenesis in the pituitary of Fischer 344 rats.",9214597_1,-1,-1,2,24103,-1
24104,mechanistic details,1,3,4,23,"The mechanistic details of tumor angiogenesis induction, during estrogen carcinogenesis, are still unknown.",9214597_2,-1,-1,2,24104,-1
24106,blood vessels,22,24,122,135,"To elucidate the role of estrogen in the regulation of tumor angiogenesis in the pituitary of female rats, the density of blood vessels was analysed using factor VIII related antigen (FVIIIRAg) immunohistochemistry and the expression of vascular endothelial growth factor/vascular permeability factor (VEGF/VPF) was examined by Western blot and immunohistochemical analysis.",9214597_3,-1,-1,2,24106,-1
24112,Western blot,51,53,328,340,"To elucidate the role of estrogen in the regulation of tumor angiogenesis in the pituitary of female rats, the density of blood vessels was analysed using factor VIII related antigen (FVIIIRAg) immunohistochemistry and the expression of vascular endothelial growth factor/vascular permeability factor (VEGF/VPF) was examined by Western blot and immunohistochemical analysis.",9214597_3,-1,-1,2,24112,-1
24121,associated with,6,8,40,55,The high tumor angiogenic potential was associated with an elevated VEGF/VPF protein expression in the E2 exposed pituitary of ovariectomized (OVEX) rats.,9214597_6,-1,-1,2,24121,-1
24123,ovariectomized (,19,21,127,143,The high tumor angiogenic potential was associated with an elevated VEGF/VPF protein expression in the E2 exposed pituitary of ovariectomized (OVEX) rats.,9214597_6,-1,-1,2,24123,-1
24127,binding studies,11,13,82,97,"VEGF/VPF and FVIIIRAg immunohistochemistry and endothelial specific lectin (UEA1) binding studies, indicate that the elevation of VEGF protein expression initially occurred in both blood vessels and non-endothelial cells.",9214597_7,-1,-1,2,24127,-1
24130,non-endothelial cells,29,31,199,220,"VEGF/VPF and FVIIIRAg immunohistochemistry and endothelial specific lectin (UEA1) binding studies, indicate that the elevation of VEGF protein expression initially occurred in both blood vessels and non-endothelial cells.",9214597_7,-1,-1,2,24130,-1
24132,non-endothelial cell population,13,16,66,97,"After 15 days of E2 exposure, VEGF/VPF protein expression, in the non-endothelial cell population, sharply declined and was restricted to the blood vessels.",9214597_8,-1,-1,2,24132,-1
24133,sharply declined,17,19,99,115,"After 15 days of E2 exposure, VEGF/VPF protein expression, in the non-endothelial cell population, sharply declined and was restricted to the blood vessels.",9214597_8,-1,-1,2,24133,-1
24135,non-endothelial-derived,3,4,16,39,The function of non-endothelial-derived VEGF is not clear.,9214597_9,-1,-1,2,24135,-1
24137,immunohistochemical studies,2,4,13,40,"Furthermore, immunohistochemical studies demonstrated that VEGFR-2 (flk-1/KDR), expression was elevated significantly in the endothelial cells of microblood vessels after 7 days of E2 exposure.",9214597_10,-1,-1,2,24137,-1
24139,endothelial cells,17,19,125,142,"Furthermore, immunohistochemical studies demonstrated that VEGFR-2 (flk-1/KDR), expression was elevated significantly in the endothelial cells of microblood vessels after 7 days of E2 exposure.",9214597_10,-1,-1,2,24139,-1
24140,microblood vessels,20,22,146,164,"Furthermore, immunohistochemical studies demonstrated that VEGFR-2 (flk-1/KDR), expression was elevated significantly in the endothelial cells of microblood vessels after 7 days of E2 exposure.",9214597_10,-1,-1,2,24140,-1
24145,lithium therapy,5,7,52,67,Persistent nephrogenic diabetes insipidus following lithium therapy.,9226773_0,-1,-1,2,24145,-1
24150,lithium therapy,15,17,103,118,"Ten years previously he had been diagnosed to have lithium-induced nephrogenic diabetes insipidus, and lithium therapy had been discontinued.",9226773_2,-1,-1,2,24150,-1
24165,human red blood cells,13,17,82,103,"NIK-247, tacrine and E-2020 all strongly inhibited acetylcholinesterase (AChE) in human red blood cells (IC50s = 1.0 x 10(-6), 2.9 x 10(-7) and 3.7 x 10(-8) M, respectively).",9228650_2,-1,-1,2,24165,-1
24166,IC50s,18,19,105,110,"NIK-247, tacrine and E-2020 all strongly inhibited acetylcholinesterase (AChE) in human red blood cells (IC50s = 1.0 x 10(-6), 2.9 x 10(-7) and 3.7 x 10(-8) M, respectively).",9228650_2,-1,-1,2,24166,-1
24172,mixed inhibition,4,6,25,41,All three drugs produced mixed inhibition of AChE activity.,9228650_4,-1,-1,2,24172,-1
24182,mechanistic studies,3,5,19,38,"Animal studies and mechanistic studies indicate that nicotine could play a role in accelerating atherosclerosis, but evidence among humans is too inadequate to be definitive about such an effect.",9245658_2,-1,-1,2,24182,-1
24184,effects of,20,22,143,153,"Almost certainly, nicotine via its hemodynamic effects contributes to acute cardiovascular events, although current evidence suggests that the effects of nicotine are much less important than are the prothrombotic effects of cigarette smoking or the effects of carbon monoxide.",9245658_3,-1,-1,2,24184,-1
24187,effects of,37,39,250,260,"Almost certainly, nicotine via its hemodynamic effects contributes to acute cardiovascular events, although current evidence suggests that the effects of nicotine are much less important than are the prothrombotic effects of cigarette smoking or the effects of carbon monoxide.",9245658_3,-1,-1,2,24187,-1
24193,dose response,3,5,13,26,"Finally, the dose response for cardiovascular events of nicotine appears to be flat, suggesting that if nicotine is involved, adverse effects might be seen with relatively low-level cigarette exposures.",9245658_6,-1,-1,2,24193,-1
24196,cigarette exposures,30,32,182,201,"Finally, the dose response for cardiovascular events of nicotine appears to be flat, suggesting that if nicotine is involved, adverse effects might be seen with relatively low-level cigarette exposures.",9245658_6,-1,-1,2,24196,-1
24205,QRS,0,1,0,3,"QRS without preexcitation, caused by junctional escape beats after verapamil or unidirectional antegrade block of accessory pathway after catheter ablation, established frequent AVRT attack.",9249847_2,-1,-1,2,24205,-1
24214,acute study,14,16,85,96,"Potential therapeutic use of the selective dopamine D1 receptor agonist, A-86929: an acute study in parkinsonian levodopa-primed monkeys.",9270571_0,-1,-1,2,24214,-1
24216,levodopa-primed,18,19,113,128,"Potential therapeutic use of the selective dopamine D1 receptor agonist, A-86929: an acute study in parkinsonian levodopa-primed monkeys.",9270571_0,-1,-1,2,24216,-1
24225,duration of action,34,37,308,326,"The therapeutic use of selective DA D1 receptor agonists such as SKF-82958 (6-chloro-7,8-dihydroxy-3-allyl-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzaze pine hydrobromide) and A-77636 ([1R, 3S] 3-[1'-admantyl]-1-aminomethyl-3,4-dihydro-5,6-dihydroxy-1H-2-benzo pyran hydrochloride) seems limited because of their duration of action, which is too short for SKF-82958 (< 1 hr) and too long for A-77636 (> 20 hr, leading to behavioral tolerance).",9270571_2,-1,-1,2,24225,-1
24229,acute dose-response study,5,8,35,60,"We therefore conducted the present acute dose-response study in four 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-exposed cynomolgus monkeys primed to exhibit levodopa-induced dyskinesias to evaluate the locomotor and dyskinetic effects on challenge with four doses (from 0.03 to 1.0 mg/kg) of A-86929 ([-]-[5aR,11bS]-4,5,5a,6,7,11b-hexahydro-2-propyl-3-thia-5-+ ++azacyclopent-1- ena[c]phenathrene-9-10-diol), a selective and full DA D1-like receptor agonist with an intermediate duration of action.",9270571_3,-1,-1,2,24229,-1
24245,Selective stimulation,0,2,0,21,Selective stimulation of the DA D1 receptor may provide better integration of neural inputs transmitted to the internal segment of the globus pallidus (referred to as the basal ganglia output) compared with levodopa and selective DA D2 receptor agonist.,9270571_6,-1,-1,2,24245,-1
24247,neural inputs transmitted,12,15,78,103,Selective stimulation of the DA D1 receptor may provide better integration of neural inputs transmitted to the internal segment of the globus pallidus (referred to as the basal ganglia output) compared with levodopa and selective DA D2 receptor agonist.,9270571_6,-1,-1,2,24247,-1
24253,intermediate duration,7,9,37,58,Potent DA D1 receptor agents with an intermediate duration of efficacy such as A-86929 (approximately 4 hr at higher doses tested) are potential therapeutic tools in PD and merit further attention.,9270571_7,-1,-1,2,24253,-1
24258,ozone-depleting,14,15,98,113,BACKGROUND: Hydrochlorofluorocarbons (HCFCs) are used increasingly in industry as substitutes for ozone-depleting chlorofluorocarbons (CFCs).,9284778_1,-1,-1,2,24258,-1
24259,Limited studies,0,2,0,15,Limited studies in animals indicate potential hepatotoxicity of some of these compounds.,9284778_2,-1,-1,2,24259,-1
24270,immunohistochemical stainings,10,12,59,88,METHODS: For one severely affected worker liver biopsy and immunohistochemical stainings for the presence of trifluoroacetyl protein adducts were done.,9284778_7,-1,-1,2,24270,-1
24275,liver biopsy sample,3,6,14,33,FINDINGS: The liver biopsy sample showed hepatocellular necrosis which was prominent in perivenular zone three and extended focally from portal tracts to portal tracts and centrilobular areas (bridging necrosis).,9284778_9,-1,-1,2,24275,-1
24283,associated with,8,10,51,66,"Autoantibodies against P450 2E1 or P58, previously associated with halothane hepatitis, were detected in the serum of five affected workers.",9284778_11,-1,-1,2,24283,-1
24284,exposure of,3,5,25,36,INTERPRETATION: Repeated exposure of human beings to HCFCs 123 and 124 can result in serious liver injury in a large proportion of the exposed population.,9284778_12,-1,-1,2,24284,-1
24286,exposed population,24,26,135,153,INTERPRETATION: Repeated exposure of human beings to HCFCs 123 and 124 can result in serious liver injury in a large proportion of the exposed population.,9284778_12,-1,-1,2,24286,-1
24297,clinical features,11,13,62,79,"If the patient develops a liver mass, because of non-specific clinical features and imaging appearances, biopsy may be the only way to achieve a definitive diagnosis.",9293063_3,-1,-1,2,24297,-1
24300,pilocarpine model,4,6,39,56,Neuropeptide-Y immunoreactivity in the pilocarpine model of temporal lobe epilepsy.,9305828_0,-1,-1,2,24300,-1
24303,NPY,2,3,16,19,Neuropeptide-Y (NPY) is expressed by granule cells and mossy fibres of the hippocampal dentate gyrus during experimental temporal lobe epilepsy (TLE).,9305828_1,-1,-1,2,24303,-1
24304,granule cells,7,9,37,50,Neuropeptide-Y (NPY) is expressed by granule cells and mossy fibres of the hippocampal dentate gyrus during experimental temporal lobe epilepsy (TLE).,9305828_1,-1,-1,2,24304,-1
24309,TLE,23,24,145,148,Neuropeptide-Y (NPY) is expressed by granule cells and mossy fibres of the hippocampal dentate gyrus during experimental temporal lobe epilepsy (TLE).,9305828_1,-1,-1,2,24309,-1
24310,damping mechanism,6,8,44,61,This expression may represent an endogenous damping mechanism since NPY has been shown to block seizure-like events following high-frequency stimulation in hippocampal slices.,9305828_2,-1,-1,2,24310,-1
24311,NPY,9,10,68,71,This expression may represent an endogenous damping mechanism since NPY has been shown to block seizure-like events following high-frequency stimulation in hippocampal slices.,9305828_2,-1,-1,2,24311,-1
24312,high-frequency,18,19,126,140,This expression may represent an endogenous damping mechanism since NPY has been shown to block seizure-like events following high-frequency stimulation in hippocampal slices.,9305828_2,-1,-1,2,24312,-1
24314,acute period,12,14,64,76,The pilocarpine (PILO) model of epilepsy is characterized by an acute period of status epilepticus followed by spontaneous recurrent seizures and related brain damage.,9305828_3,-1,-1,2,24314,-1
24319,immunostaining,3,4,36,50,We report peroxidase-antiperoxidase immunostaining for NPY in several brain regions in this model.,9305828_4,-1,-1,2,24319,-1
24320,NPY,5,6,55,58,We report peroxidase-antiperoxidase immunostaining for NPY in several brain regions in this model.,9305828_4,-1,-1,2,24320,-1
24322,PILO-injected,0,1,0,13,"PILO-injected animals exhibited NPY immunoreactivity in the region of the mossy fibre terminals, in the dentate gyrus inner molecular layer and, in a few cases, within presumed granule cells.",9305828_5,-1,-1,2,24322,-1
24323,NPY,3,4,32,35,"PILO-injected animals exhibited NPY immunoreactivity in the region of the mossy fibre terminals, in the dentate gyrus inner molecular layer and, in a few cases, within presumed granule cells.",9305828_5,-1,-1,2,24323,-1
24325,mossy fibre terminals,10,13,74,95,"PILO-injected animals exhibited NPY immunoreactivity in the region of the mossy fibre terminals, in the dentate gyrus inner molecular layer and, in a few cases, within presumed granule cells.",9305828_5,-1,-1,2,24325,-1
24328,granule cells,30,32,177,190,"PILO-injected animals exhibited NPY immunoreactivity in the region of the mossy fibre terminals, in the dentate gyrus inner molecular layer and, in a few cases, within presumed granule cells.",9305828_5,-1,-1,2,24328,-1
24334,injected animals,4,6,18,34,"In addition, PILO injected animals exhibited a reduction in the number of NPY-immunoreactive interneurons compared with controls.",9305828_7,-1,-1,2,24334,-1
24336,interneurons,14,15,93,105,"In addition, PILO injected animals exhibited a reduction in the number of NPY-immunoreactive interneurons compared with controls.",9305828_7,-1,-1,2,24336,-1
24338,granule cells,13,15,84,97,"The results demonstrate that changes in NPY expression, including expression in the granule cells and mossy fibres and the loss of vulnerable NPY neurons, are present in the PILO model of TLE.",9305828_8,-1,-1,2,24338,-1
24339,mossy fibres,16,18,102,114,"The results demonstrate that changes in NPY expression, including expression in the granule cells and mossy fibres and the loss of vulnerable NPY neurons, are present in the PILO model of TLE.",9305828_8,-1,-1,2,24339,-1
24343,NPY,9,10,55,58,"However, the significance of this changed synthesis of NPY remains to be determined.",9305828_9,-1,-1,2,24343,-1
24344,Posteroventral medial pallidotomy,0,3,0,33,Posteroventral medial pallidotomy in advanced Parkinson's disease.,9321531_0,-1,-1,2,24344,-1
24350,medical regimens,28,30,161,177,"METHODS: Forty patients with Parkinson's disease underwent serial, detailed assessments both after drug withdrawal (""off"" period) and while taking their optimal medical regimens (""on"" period).",9321531_2,-1,-1,2,24350,-1
24352,off-period score,12,14,65,81,"RESULTS: The percent improvements at six months were as follows: off-period score for overall motor function, 28 percent (95 percent confidence interval, 19 to 38 percent), with most of the improvement in the contralateral limbs; off-period score for activities of daily living, 29 percent (95 percent confidence interval, 19 to 39 percent); on-period score for contralateral dyskinesias, 82 percent (95 percent confidence interval, 72 to 91 percent); and on-period score for ipsilateral dyskinesias, 44 percent (95 percent confidence interval, 29 to 59 percent).",9321531_4,-1,-1,2,24352,-1
24354,confidence interval,24,26,133,152,"RESULTS: The percent improvements at six months were as follows: off-period score for overall motor function, 28 percent (95 percent confidence interval, 19 to 38 percent), with most of the improvement in the contralateral limbs; off-period score for activities of daily living, 29 percent (95 percent confidence interval, 19 to 39 percent); on-period score for contralateral dyskinesias, 82 percent (95 percent confidence interval, 72 to 91 percent); and on-period score for ipsilateral dyskinesias, 44 percent (95 percent confidence interval, 29 to 59 percent).",9321531_4,-1,-1,2,24354,-1
24356,off-period score,43,45,230,246,"RESULTS: The percent improvements at six months were as follows: off-period score for overall motor function, 28 percent (95 percent confidence interval, 19 to 38 percent), with most of the improvement in the contralateral limbs; off-period score for activities of daily living, 29 percent (95 percent confidence interval, 19 to 39 percent); on-period score for contralateral dyskinesias, 82 percent (95 percent confidence interval, 72 to 91 percent); and on-period score for ipsilateral dyskinesias, 44 percent (95 percent confidence interval, 29 to 59 percent).",9321531_4,-1,-1,2,24356,-1
24357,confidence interval,56,58,302,321,"RESULTS: The percent improvements at six months were as follows: off-period score for overall motor function, 28 percent (95 percent confidence interval, 19 to 38 percent), with most of the improvement in the contralateral limbs; off-period score for activities of daily living, 29 percent (95 percent confidence interval, 19 to 39 percent); on-period score for contralateral dyskinesias, 82 percent (95 percent confidence interval, 72 to 91 percent); and on-period score for ipsilateral dyskinesias, 44 percent (95 percent confidence interval, 29 to 59 percent).",9321531_4,-1,-1,2,24357,-1
24358,on-period score,65,67,342,357,"RESULTS: The percent improvements at six months were as follows: off-period score for overall motor function, 28 percent (95 percent confidence interval, 19 to 38 percent), with most of the improvement in the contralateral limbs; off-period score for activities of daily living, 29 percent (95 percent confidence interval, 19 to 39 percent); on-period score for contralateral dyskinesias, 82 percent (95 percent confidence interval, 72 to 91 percent); and on-period score for ipsilateral dyskinesias, 44 percent (95 percent confidence interval, 29 to 59 percent).",9321531_4,-1,-1,2,24358,-1
24359,confidence interval,76,78,412,431,"RESULTS: The percent improvements at six months were as follows: off-period score for overall motor function, 28 percent (95 percent confidence interval, 19 to 38 percent), with most of the improvement in the contralateral limbs; off-period score for activities of daily living, 29 percent (95 percent confidence interval, 19 to 39 percent); on-period score for contralateral dyskinesias, 82 percent (95 percent confidence interval, 72 to 91 percent); and on-period score for ipsilateral dyskinesias, 44 percent (95 percent confidence interval, 29 to 59 percent).",9321531_4,-1,-1,2,24359,-1
24360,on-period score,86,88,456,471,"RESULTS: The percent improvements at six months were as follows: off-period score for overall motor function, 28 percent (95 percent confidence interval, 19 to 38 percent), with most of the improvement in the contralateral limbs; off-period score for activities of daily living, 29 percent (95 percent confidence interval, 19 to 39 percent); on-period score for contralateral dyskinesias, 82 percent (95 percent confidence interval, 72 to 91 percent); and on-period score for ipsilateral dyskinesias, 44 percent (95 percent confidence interval, 29 to 59 percent).",9321531_4,-1,-1,2,24360,-1
24361,confidence interval,97,99,524,543,"RESULTS: The percent improvements at six months were as follows: off-period score for overall motor function, 28 percent (95 percent confidence interval, 19 to 38 percent), with most of the improvement in the contralateral limbs; off-period score for activities of daily living, 29 percent (95 percent confidence interval, 19 to 39 percent); on-period score for contralateral dyskinesias, 82 percent (95 percent confidence interval, 72 to 91 percent); and on-period score for ipsilateral dyskinesias, 44 percent (95 percent confidence interval, 29 to 59 percent).",9321531_4,-1,-1,2,24361,-1
24362,total scores,6,8,40,52,"The improvements in dyskinesias and the total scores for off-period parkinsonism, contralateral bradykinesia, and rigidity were sustained in the 11 patients examined at two years.",9321531_5,-1,-1,2,24362,-1
24375,methylation,7,8,41,52,It differs from erythromycin only in the methylation of the hydroxyl group at position 6.,9326871_2,-1,-1,2,24375,-1
24376,hydroxyl group,10,12,60,74,It differs from erythromycin only in the methylation of the hydroxyl group at position 6.,9326871_2,-1,-1,2,24376,-1
24389,cost-effective strategy,12,14,86,109,"Endocrine screening in 1,022 men with erectile dysfunction: clinical significance and cost-effective strategy.",9334596_0,-1,-1,2,24389,-1
24394,effects of,36,38,248,258,"PURPOSE: We reviewed the results of serum testosterone and prolactin determination in 1,022 patients referred because of erectile dysfunction and compared the data with history, results of physical examination, other etiological investigations and effects of endocrine therapy to refine the rules of cost-effective endocrine screening and to pinpoint actual responsibility for hormonal abnormalities.",9334596_1,-1,-1,2,24394,-1
24399,Prolactin results,0,2,0,17,"Prolactin results were compared with those of a previous personal cohort of 1,340 patients with erectile dysfunction and systematic prolactin determination.",9334596_5,-1,-1,2,24399,-1
24400,personal cohort,9,11,57,72,"Prolactin results were compared with those of a previous personal cohort of 1,340 patients with erectile dysfunction and systematic prolactin determination.",9334596_5,-1,-1,2,24400,-1
24403,clinical criteria,1,3,5,22,"Main clinical criteria tested regarding efficiency in hormone determination were low sexual desire, small testes and gynecomastia.",9334596_6,-1,-1,2,24403,-1
24424,effects of,5,7,33,43,CONCLUSIONS: Low prevalences and effects of low testosterone and high prolactin in erectile dysfunction cannot justify their routine determination.,9334596_22,-1,-1,2,24424,-1
24439,pharmacologic profile,8,10,59,80,Previous clinical studies have proposed that risperidone's pharmacologic profile may produce improved efficacy for negative psychotic symptoms and decreased propensity for extrapyramidal side effects; features shared by so-called 'atypical' neuroleptics.,9351491_2,-1,-1,2,24439,-1
24443,associated with,7,9,49,64,"To determine if routine risperidone treatment is associated with a unique degree of D2 receptor occupancy and pattern of clinical effects, we used [123I]IBZM SPECT to determine D2 occupancy in subjects treated with routine clinical doses of risperidone (n = 12) or haloperidol (n = 7).",9351491_3,-1,-1,2,24443,-1
24445,clinical effects,19,21,121,137,"To determine if routine risperidone treatment is associated with a unique degree of D2 receptor occupancy and pattern of clinical effects, we used [123I]IBZM SPECT to determine D2 occupancy in subjects treated with routine clinical doses of risperidone (n = 12) or haloperidol (n = 7).",9351491_3,-1,-1,2,24445,-1
24448,treated with,32,34,202,214,"To determine if routine risperidone treatment is associated with a unique degree of D2 receptor occupancy and pattern of clinical effects, we used [123I]IBZM SPECT to determine D2 occupancy in subjects treated with routine clinical doses of risperidone (n = 12) or haloperidol (n = 7).",9351491_3,-1,-1,2,24448,-1
24449,clinical doses,35,37,223,237,"To determine if routine risperidone treatment is associated with a unique degree of D2 receptor occupancy and pattern of clinical effects, we used [123I]IBZM SPECT to determine D2 occupancy in subjects treated with routine clinical doses of risperidone (n = 12) or haloperidol (n = 7).",9351491_3,-1,-1,2,24449,-1
24453,clinical doses,16,18,107,121,Both risperidone and haloperidol produced D2 occupancy levels between approximately 60 and 90% at standard clinical doses.,9351491_4,-1,-1,2,24453,-1
24456,treated with,6,8,51,63,Drug-induced parkinsonism was observed in subjects treated with risperidone (42%) and haloperidol (29%) and was observed at occupancy levels above 60%.,9351491_6,-1,-1,2,24456,-1
24483,treated with,4,6,24,36,Seven patients had been treated with anthracycline.,9390208_6,-1,-1,2,24483,-1
24485,Median number,0,2,0,13,Median number of courses of MFL regimen given was six and the median cumulative dose of mitoxantrone was 68.35 mg/m2.,9390208_8,-1,-1,2,24485,-1
24490,response rate,3,5,22,35,The overall objective response rate was 7.6%.,9390208_10,-1,-1,2,24490,-1
24497,high rate,14,16,91,100,The MFL regimen achieves little palliative benefit and induces severe toxicity at a fairly high rate.,9390208_17,-1,-1,2,24497,-1
24502,English literature,19,21,124,142,"In this study, three Chinese patients with ticlopidine-induced aplastic anemia were reported and another 13 patients in the English literature were reviewed.",9401499_1,-1,-1,2,24502,-1
24503,risk factors,9,11,59,71,"We attempted to find underlying similarities, evaluate the risk factors, and identify appropriate treatment for this complication.",9401499_2,-1,-1,2,24503,-1
24504,risk factor,7,9,28,39,"Therefore, old age may be a risk factor for developing this complication.",9401499_4,-1,-1,2,24504,-1
24506,white cell,15,17,96,106,"Agranulocytosis occurred 3-20 weeks after initiation of ticlopidine, so frequent examination of white cell count during treatment is recommended.",9401499_5,-1,-1,2,24506,-1
24524,Li-treated,11,12,72,82,Plasma sodium concentrations were found to be slightly increased in the Li-treated rats compared with those in controls.,9406968_4,-1,-1,2,24524,-1
24528,Li-treated,19,20,111,121,Plasma concentration of AVP and transcripts of AVP gene in the PVN and SON were significantly increased in the Li-treated rats compared with controls.,9406968_5,-1,-1,2,24528,-1
24529,upregulation,22,23,143,155,These results suggest that dehydration and/or the activation of visceral afferent inputs may contribute to the elevation of plasma AVP and the upregulation of AVP gene expression in the PVN and the SON of the Li-induced diabetes insipidus rat.,9406968_6,-1,-1,2,24529,-1
24531,gene expression,25,27,163,178,These results suggest that dehydration and/or the activation of visceral afferent inputs may contribute to the elevation of plasma AVP and the upregulation of AVP gene expression in the PVN and the SON of the Li-induced diabetes insipidus rat.,9406968_6,-1,-1,2,24531,-1
24544,peak activity,11,13,86,99,"RESULTS: Prostigmine-morphine provocation caused significant increases in the time to peak activity (Tmax) over the hepatic hilum (HH: 34.33 +/- 5.05 vs. 22.77 +/- 3.26) and the common bile duct (CBD: 60.44 +/- 5.99 vs. 40.0 +/- 2.88) and in the half-time of excretion (T1/2) over the liver parenchyma (LP: 120.04 +/- 16.01 vs. 27.37 +/- 2.19), HH (117.61 +/- 14.71 vs. 31.85 +/- 3.99) and CBD (158.11 +/- 9.18 vs. 40.1 +/- 6.24), indicating a complete spasm at the level of the sphincter of Oddi.",9431903_4,-1,-1,2,24544,-1
24547,HH,21,22,131,133,"RESULTS: Prostigmine-morphine provocation caused significant increases in the time to peak activity (Tmax) over the hepatic hilum (HH: 34.33 +/- 5.05 vs. 22.77 +/- 3.26) and the common bile duct (CBD: 60.44 +/- 5.99 vs. 40.0 +/- 2.88) and in the half-time of excretion (T1/2) over the liver parenchyma (LP: 120.04 +/- 16.01 vs. 27.37 +/- 2.19), HH (117.61 +/- 14.71 vs. 31.85 +/- 3.99) and CBD (158.11 +/- 9.18 vs. 40.1 +/- 6.24), indicating a complete spasm at the level of the sphincter of Oddi.",9431903_4,-1,-1,2,24547,-1
24553,/-,48,49,226,228,"RESULTS: Prostigmine-morphine provocation caused significant increases in the time to peak activity (Tmax) over the hepatic hilum (HH: 34.33 +/- 5.05 vs. 22.77 +/- 3.26) and the common bile duct (CBD: 60.44 +/- 5.99 vs. 40.0 +/- 2.88) and in the half-time of excretion (T1/2) over the liver parenchyma (LP: 120.04 +/- 16.01 vs. 27.37 +/- 2.19), HH (117.61 +/- 14.71 vs. 31.85 +/- 3.99) and CBD (158.11 +/- 9.18 vs. 40.1 +/- 6.24), indicating a complete spasm at the level of the sphincter of Oddi.",9431903_4,0,1,2,24553,-1
24554,T1/2,58,59,270,274,"RESULTS: Prostigmine-morphine provocation caused significant increases in the time to peak activity (Tmax) over the hepatic hilum (HH: 34.33 +/- 5.05 vs. 22.77 +/- 3.26) and the common bile duct (CBD: 60.44 +/- 5.99 vs. 40.0 +/- 2.88) and in the half-time of excretion (T1/2) over the liver parenchyma (LP: 120.04 +/- 16.01 vs. 27.37 +/- 2.19), HH (117.61 +/- 14.71 vs. 31.85 +/- 3.99) and CBD (158.11 +/- 9.18 vs. 40.1 +/- 6.24), indicating a complete spasm at the level of the sphincter of Oddi.",9431903_4,-1,-1,2,24554,-1
24557,/-,74,75,335,337,"RESULTS: Prostigmine-morphine provocation caused significant increases in the time to peak activity (Tmax) over the hepatic hilum (HH: 34.33 +/- 5.05 vs. 22.77 +/- 3.26) and the common bile duct (CBD: 60.44 +/- 5.99 vs. 40.0 +/- 2.88) and in the half-time of excretion (T1/2) over the liver parenchyma (LP: 120.04 +/- 16.01 vs. 27.37 +/- 2.19), HH (117.61 +/- 14.71 vs. 31.85 +/- 3.99) and CBD (158.11 +/- 9.18 vs. 40.1 +/- 6.24), indicating a complete spasm at the level of the sphincter of Oddi.",9431903_4,0,1,2,24557,-1
24558,HH,78,79,345,347,"RESULTS: Prostigmine-morphine provocation caused significant increases in the time to peak activity (Tmax) over the hepatic hilum (HH: 34.33 +/- 5.05 vs. 22.77 +/- 3.26) and the common bile duct (CBD: 60.44 +/- 5.99 vs. 40.0 +/- 2.88) and in the half-time of excretion (T1/2) over the liver parenchyma (LP: 120.04 +/- 16.01 vs. 27.37 +/- 2.19), HH (117.61 +/- 14.71 vs. 31.85 +/- 3.99) and CBD (158.11 +/- 9.18 vs. 40.1 +/- 6.24), indicating a complete spasm at the level of the sphincter of Oddi.",9431903_4,-1,-1,2,24558,-1
24560,/-,87,88,377,379,"RESULTS: Prostigmine-morphine provocation caused significant increases in the time to peak activity (Tmax) over the hepatic hilum (HH: 34.33 +/- 5.05 vs. 22.77 +/- 3.26) and the common bile duct (CBD: 60.44 +/- 5.99 vs. 40.0 +/- 2.88) and in the half-time of excretion (T1/2) over the liver parenchyma (LP: 120.04 +/- 16.01 vs. 27.37 +/- 2.19), HH (117.61 +/- 14.71 vs. 31.85 +/- 3.99) and CBD (158.11 +/- 9.18 vs. 40.1 +/- 6.24), indicating a complete spasm at the level of the sphincter of Oddi.",9431903_4,0,1,2,24560,-1
24562,/-,95,96,403,405,"RESULTS: Prostigmine-morphine provocation caused significant increases in the time to peak activity (Tmax) over the hepatic hilum (HH: 34.33 +/- 5.05 vs. 22.77 +/- 3.26) and the common bile duct (CBD: 60.44 +/- 5.99 vs. 40.0 +/- 2.88) and in the half-time of excretion (T1/2) over the liver parenchyma (LP: 120.04 +/- 16.01 vs. 27.37 +/- 2.19), HH (117.61 +/- 14.71 vs. 31.85 +/- 3.99) and CBD (158.11 +/- 9.18 vs. 40.1 +/- 6.24), indicating a complete spasm at the level of the sphincter of Oddi.",9431903_4,0,1,2,24562,-1
24563,/-,100,101,421,423,"RESULTS: Prostigmine-morphine provocation caused significant increases in the time to peak activity (Tmax) over the hepatic hilum (HH: 34.33 +/- 5.05 vs. 22.77 +/- 3.26) and the common bile duct (CBD: 60.44 +/- 5.99 vs. 40.0 +/- 2.88) and in the half-time of excretion (T1/2) over the liver parenchyma (LP: 120.04 +/- 16.01 vs. 27.37 +/- 2.19), HH (117.61 +/- 14.71 vs. 31.85 +/- 3.99) and CBD (158.11 +/- 9.18 vs. 40.1 +/- 6.24), indicating a complete spasm at the level of the sphincter of Oddi.",9431903_4,0,1,2,24563,-1
24564,Oddi,115,116,492,496,"RESULTS: Prostigmine-morphine provocation caused significant increases in the time to peak activity (Tmax) over the hepatic hilum (HH: 34.33 +/- 5.05 vs. 22.77 +/- 3.26) and the common bile duct (CBD: 60.44 +/- 5.99 vs. 40.0 +/- 2.88) and in the half-time of excretion (T1/2) over the liver parenchyma (LP: 120.04 +/- 16.01 vs. 27.37 +/- 2.19), HH (117.61 +/- 14.71 vs. 31.85 +/- 3.99) and CBD (158.11 +/- 9.18 vs. 40.1 +/- 6.24), indicating a complete spasm at the level of the sphincter of Oddi.",9431903_4,-1,-1,2,24564,-1
24569,HH,25,26,173,175,"Glyceryl trinitrate infusion completely normalized the prostigmine-morphine-induced alterations in these quantitative parameters (TmaX over the LP: 11.33 +/- 1.13; over the HH: 18.88 +/- 1.48; and over the CBD: 36.22 +/- 1.92; and T1/2 over the LP: 28.21 +/- 1.83; over the HH: 33.42 +/- 3.10; and over the CBD: 41.66 +/- 6.33), suggesting an effective sphincter-relaxing effect of glyceryl trinitrate.",9431903_5,-1,-1,2,24569,-1
24572,/-,39,40,218,220,"Glyceryl trinitrate infusion completely normalized the prostigmine-morphine-induced alterations in these quantitative parameters (TmaX over the LP: 11.33 +/- 1.13; over the HH: 18.88 +/- 1.48; and over the CBD: 36.22 +/- 1.92; and T1/2 over the LP: 28.21 +/- 1.83; over the HH: 33.42 +/- 3.10; and over the CBD: 41.66 +/- 6.33), suggesting an effective sphincter-relaxing effect of glyceryl trinitrate.",9431903_5,0,1,2,24572,-1
24573,T1/2,43,44,231,235,"Glyceryl trinitrate infusion completely normalized the prostigmine-morphine-induced alterations in these quantitative parameters (TmaX over the LP: 11.33 +/- 1.13; over the HH: 18.88 +/- 1.48; and over the CBD: 36.22 +/- 1.92; and T1/2 over the LP: 28.21 +/- 1.83; over the HH: 33.42 +/- 3.10; and over the CBD: 41.66 +/- 6.33), suggesting an effective sphincter-relaxing effect of glyceryl trinitrate.",9431903_5,-1,-1,2,24573,-1
24574,/-,50,51,256,258,"Glyceryl trinitrate infusion completely normalized the prostigmine-morphine-induced alterations in these quantitative parameters (TmaX over the LP: 11.33 +/- 1.13; over the HH: 18.88 +/- 1.48; and over the CBD: 36.22 +/- 1.92; and T1/2 over the LP: 28.21 +/- 1.83; over the HH: 33.42 +/- 3.10; and over the CBD: 41.66 +/- 6.33), suggesting an effective sphincter-relaxing effect of glyceryl trinitrate.",9431903_5,0,1,2,24574,-1
24578,/-,69,70,319,321,"Glyceryl trinitrate infusion completely normalized the prostigmine-morphine-induced alterations in these quantitative parameters (TmaX over the LP: 11.33 +/- 1.13; over the HH: 18.88 +/- 1.48; and over the CBD: 36.22 +/- 1.92; and T1/2 over the LP: 28.21 +/- 1.83; over the HH: 33.42 +/- 3.10; and over the CBD: 41.66 +/- 6.33), suggesting an effective sphincter-relaxing effect of glyceryl trinitrate.",9431903_5,0,1,2,24578,-1
24579,sphincter-relaxing effect,76,78,353,378,"Glyceryl trinitrate infusion completely normalized the prostigmine-morphine-induced alterations in these quantitative parameters (TmaX over the LP: 11.33 +/- 1.13; over the HH: 18.88 +/- 1.48; and over the CBD: 36.22 +/- 1.92; and T1/2 over the LP: 28.21 +/- 1.83; over the HH: 33.42 +/- 3.10; and over the CBD: 41.66 +/- 6.33), suggesting an effective sphincter-relaxing effect of glyceryl trinitrate.",9431903_5,-1,-1,2,24579,-1
24594,i.c.v,48,49,259,264,"Antinociceptive and antiamnesic properties of the presynaptic cholinergic amplifier PG-9.The antinociceptive effect of 3 alpha-tropyl 2-(p-bromophenyl)propionate [(+/-)-PG-9] (10-40 mg kg-1 s.c.; 30-60 mg kg-1 p.o.; 10-30 mg kg-1 i.v.; 10-30 micrograms/mouse i.c.v.) was examined in mice, rats and guinea pigs by use of the hot-plate, abdominal-constriction, tail-flick and paw-pressure tests.",9495837_0,-1,-1,2,24594,-1
24595,guinea pigs,58,60,298,309,"Antinociceptive and antiamnesic properties of the presynaptic cholinergic amplifier PG-9.The antinociceptive effect of 3 alpha-tropyl 2-(p-bromophenyl)propionate [(+/-)-PG-9] (10-40 mg kg-1 s.c.; 30-60 mg kg-1 p.o.; 10-30 mg kg-1 i.v.; 10-30 micrograms/mouse i.c.v.) was examined in mice, rats and guinea pigs by use of the hot-plate, abdominal-constriction, tail-flick and paw-pressure tests.",9495837_0,-1,-1,2,24595,-1
24596,hot-plate,64,65,324,333,"Antinociceptive and antiamnesic properties of the presynaptic cholinergic amplifier PG-9.The antinociceptive effect of 3 alpha-tropyl 2-(p-bromophenyl)propionate [(+/-)-PG-9] (10-40 mg kg-1 s.c.; 30-60 mg kg-1 p.o.; 10-30 mg kg-1 i.v.; 10-30 micrograms/mouse i.c.v.) was examined in mice, rats and guinea pigs by use of the hot-plate, abdominal-constriction, tail-flick and paw-pressure tests.",9495837_0,-1,-1,2,24596,-1
24633,central potentiation,18,20,106,126,"Based on these data, it can be postulated that (+/-)-PG-9 exerted an antinociceptive effect mediated by a central potentiation of cholinergic transmission.",9495837_3,-1,-1,2,24633,-1
24641,mouse passive-avoidance test,36,39,140,168,(+/-)-PG-9 (10-40 mg kg-1 i.p.) was able to prevent amnesia induced by scopolamine (1 mg kg-1 i.p.) and dicyclomine (2 mg kg-1 i.p.) in the mouse passive-avoidance test.,9495837_4,-1,-1,2,24641,-1
24642,Affinity profiles,0,2,0,17,"Affinity profiles of (+/-)-PG-9 for muscarinic receptor subtypes, determined by functional studies (rabbit vas deferens for M1, guinea pig atrium for M2, guinea pig ileum for M3 and immature guinea pig uterus for putative M4), have shown an M4/M1 selectivity ratio of 10.2 that might be responsible for the antinociception and the anti-amnesic effect induced by (+/-)-PG-9 through an increase in acetylcholine extracellular levels.",9495837_5,-1,-1,2,24642,-1
24645,functional studies,11,13,80,98,"Affinity profiles of (+/-)-PG-9 for muscarinic receptor subtypes, determined by functional studies (rabbit vas deferens for M1, guinea pig atrium for M2, guinea pig ileum for M3 and immature guinea pig uterus for putative M4), have shown an M4/M1 selectivity ratio of 10.2 that might be responsible for the antinociception and the anti-amnesic effect induced by (+/-)-PG-9 through an increase in acetylcholine extracellular levels.",9495837_5,-1,-1,2,24645,-1
24648,guinea pig,26,28,154,164,"Affinity profiles of (+/-)-PG-9 for muscarinic receptor subtypes, determined by functional studies (rabbit vas deferens for M1, guinea pig atrium for M2, guinea pig ileum for M3 and immature guinea pig uterus for putative M4), have shown an M4/M1 selectivity ratio of 10.2 that might be responsible for the antinociception and the anti-amnesic effect induced by (+/-)-PG-9 through an increase in acetylcholine extracellular levels.",9495837_5,-1,-1,2,24648,-1
24649,guinea pig,33,35,191,201,"Affinity profiles of (+/-)-PG-9 for muscarinic receptor subtypes, determined by functional studies (rabbit vas deferens for M1, guinea pig atrium for M2, guinea pig ileum for M3 and immature guinea pig uterus for putative M4), have shown an M4/M1 selectivity ratio of 10.2 that might be responsible for the antinociception and the anti-amnesic effect induced by (+/-)-PG-9 through an increase in acetylcholine extracellular levels.",9495837_5,-1,-1,2,24649,-1
24658,rota-rod test,17,19,112,125,"In the antinociceptive and antiamnesic dose range, (+/-)-PG-9 did not impair mouse performance evaluated by the rota-rod test and Animex apparatus.",9495837_6,-1,-1,2,24658,-1
24659,Animex apparatus,20,22,130,146,"In the antinociceptive and antiamnesic dose range, (+/-)-PG-9 did not impair mouse performance evaluated by the rota-rod test and Animex apparatus.",9495837_6,-1,-1,2,24659,-1
24667,mesangial matrix,13,15,97,113,"Light microscopy of renal biopsy samples showed minimal glomerular capillary wall thickening and mesangial matrix increase, or no departure from normal.",950631_2,-1,-1,2,24667,-1
24669,electron-dense deposits,7,9,53,76,"Electron microscopy, however, revealed subepithelial electron-dense deposits, fusion of epithelial cell foot processes, and evidence of mesangial cell hyperactivity.",950631_3,-1,-1,2,24669,-1
24672,Immunofluorescence microscopy,0,2,0,29,Immunofluorescence microscopy demonstrated granular capillary wall deposits of IgG and C3.,950631_4,-1,-1,2,24672,-1
24678,classical pathway,10,12,65,82,It is tentatively concluded that complement was activated by the classical pathway.,950631_6,-1,-1,2,24678,-1
24683,experimental pain study,7,10,40,63,"To test this hypothesis we performed an experimental pain study in seven healthy volunteers, using the same positioning in the PET scanner as in the migraine patients.",9514561_3,-1,-1,2,24683,-1
24729,Prospective multicentre studies,0,3,0,31,Prospective multicentre studies with a large population and a long follow-up should be performed in order to evaluate the incidence of this unusual side effect.,9522152_4,-1,-1,2,24729,-1
24748,prospective double-blind study,5,8,26,56,"Accordingly, the present, prospective double-blind study compares prilocaine with lidocaine and bupivacaine with respect to duration of action and relative risk of TNSs.",9523805_4,-1,-1,2,24748,-1
24751,duration of action,17,20,124,142,"Accordingly, the present, prospective double-blind study compares prilocaine with lidocaine and bupivacaine with respect to duration of action and relative risk of TNSs.",9523805_4,-1,-1,2,24751,-1
24752,relative risk,21,23,147,160,"Accordingly, the present, prospective double-blind study compares prilocaine with lidocaine and bupivacaine with respect to duration of action and relative risk of TNSs.",9523805_4,-1,-1,2,24752,-1
24761,discharge criteria,17,19,93,111,"Details of spinal puncture, extension and regression of spinal block, and the times to reach discharge criteria were noted.",9523805_7,-1,-1,2,24761,-1
24762,drug administered,19,21,102,119,"In the evening of postoperative day 1, patients were evaluated for TNSs by a physician unaware of the drug administered and the details of the anesthetic procedure.",9523805_8,-1,-1,2,24762,-1
24769,duration of action,17,20,110,128,CONCLUSIONS: Prilocaine may be preferable to lidocaine for short surgical procedures because it has a similar duration of action but a lower incidence of TNSs.,9523805_11,-1,-1,2,24769,-1
24772,associated with,9,11,77,92,Value of methylprednisolone in prevention of the arthralgia-myalgia syndrome associated with the total dose infusion of iron dextran: a double blind randomized trial.,9523850_0,-1,-1,2,24772,-1
24775,double blind randomized trial,20,24,136,165,Value of methylprednisolone in prevention of the arthralgia-myalgia syndrome associated with the total dose infusion of iron dextran: a double blind randomized trial.,9523850_0,-1,-1,2,24775,-1
24781,prospective study,8,10,46,63,"The purpose of this randomized, double-blind, prospective study was to investigate whether intravenous (i.v.) administration of methylprednisolone (MP) prevents this complication.",9523850_3,-1,-1,2,24781,-1
24787,group 2,10,12,48,55,"Fifty-eight percent of group 1 patients, 33% of group 2, and 26% of group 3 had reactions to TDI.",9523850_8,-1,-1,2,24787,-1
24790,two-sided Fisher's exact test,5,10,26,55,Data were analyzed by the two-sided Fisher's exact test using 95% confidence intervals with the approximation of Woolf.,9523850_10,-1,-1,2,24790,-1
24791,confidence intervals,13,15,66,86,Data were analyzed by the two-sided Fisher's exact test using 95% confidence intervals with the approximation of Woolf.,9523850_10,-1,-1,2,24791,-1
24796,QT interval,3,5,20,31,Prolongation of the QT interval related to cisapride-diltiazem interaction.,9545159_0,-1,-1,2,24796,-1
24812,QT-interval,8,9,40,51,The patient was in near syncope and had QT-interval prolongation.,9545159_4,-1,-1,2,24812,-1
24814,QT interval,5,7,35,46,"After discontinuing cisapride, the QT interval returned to normal and symptoms did not recur.",9545159_5,-1,-1,2,24814,-1
24825,normal subjects,70,72,376,391,"We have studied the regional cerebral blood flow (rCBF) changes induced by the execution of a finger-to-thumb opposition motor task in the supplementary and primary motor cortex of two groups of parkinsonian patients on L-dopa medication, the first one without L-dopa induced dyskinesia (n = 23) and the other with moderate peak-dose dyskinesia (n = 15), and of a group of 14 normal subjects.",9549528_1,-1,-1,2,24825,-1
24827,rCBF,6,7,30,34,133Xe was used to measure the rCBF changes.,9549528_3,-1,-1,2,24827,-1
24829,normal subjects,17,19,116,131,"The dyskinetic parkinsonian patients exhibited a pattern of response which was markedly different from those of the normal subjects and non-dyskinetic parkinsonian patients, with a significant overactivation in the supplementary motor area and the ipsi- and contralateral primary motor areas.",9549528_4,-1,-1,2,24829,-1
24833,ipsi-,35,36,248,253,"The dyskinetic parkinsonian patients exhibited a pattern of response which was markedly different from those of the normal subjects and non-dyskinetic parkinsonian patients, with a significant overactivation in the supplementary motor area and the ipsi- and contralateral primary motor areas.",9549528_4,-1,-1,2,24833,-1
24854,pre-therapy,15,16,101,112,Microbiologic cure rates were determined on the basis of presumed plus documented eradication of the pre-therapy pathogen(s).,9564988_5,-1,-1,2,24854,-1
24855,pathogen(s),16,18,113,124,Microbiologic cure rates were determined on the basis of presumed plus documented eradication of the pre-therapy pathogen(s).,9564988_5,-1,-1,2,24855,-1
24863,microbiologic eradication rate,1,4,4,34,The microbiologic eradication rate (presumed plus documented) among 138 microbiologically evaluable patients was 92%.,9564988_9,-1,-1,2,24863,-1
24866,S. pneumoniae,25,27,130,143,Microbiologic eradication rates (presumed plus documented) of the most common pathogens ranged from 93% (M. catarrhalis) to 100% (S. pneumoniae) at the post-therapy visit.,9564988_10,-1,-1,2,24866,-1
24869,follow-up visit,18,20,100,115,All but one of the 265 patients who were cured or improved at post-therapy returned for a long-term follow-up visit; 243 (92%) remained well 4 to 6 weeks after therapy; and 21 (8%) had a relapse of symptoms.,9564988_11,-1,-1,2,24869,-1
24878,French case-control study,13,16,87,112,Iatrogenic risks of endometrial carcinoma after treatment for breast cancer in a large French case-control study.,9579567_0,-1,-1,2,24878,-1
24883,case-control study,22,24,142,160,We have investigated the association between endometrial cancer and tamoxifen use or other treatments in women treated for breast cancer in a case-control study.,9579567_2,-1,-1,2,24883,-1
24887,survival time,29,31,154,167,"Cases of endometrial cancer diagnosed after breast cancer (n = 135) and 467 controls matched for age, year of diagnosis of breast cancer and hospital and survival time with an intact uterus were included.",9579567_3,-1,-1,2,24887,-1
24890,crude relative risk,20,23,125,144,"Women who had received tamoxifen were significantly more likely to have endometrial cancer diagnosed than those who had not (crude relative risk = 4.9, p = 0.0001).",9579567_4,-1,-1,2,24890,-1
24893,daily dose,35,37,185,195,"Univariate and adjusted analyses showed that the risk increased with the length of treatment (p = 0.0001) or the cumulative dose of tamoxifen received (p = 0.0001), irrespective of the daily dose.",9579567_5,-1,-1,2,24893,-1
24895,higher risk,9,11,55,66,"Women who had undergone pelvic radiotherapy also had a higher risk (crude relative risk = 7.8, p = 0.0001).",9579567_6,-1,-1,2,24895,-1
24896,crude relative risk,12,15,68,87,"Women who had undergone pelvic radiotherapy also had a higher risk (crude relative risk = 7.8, p = 0.0001).",9579567_6,-1,-1,2,24896,-1
24897,confounding factors,3,5,20,39,"After adjusting for confounding factors, the risk was higher for tamoxifen users (p = 0.0012), treatment for more than 3 years (all p < 0.03) and pelvic radiotherapy (p = 0.012).",9579567_7,-1,-1,2,24897,-1
24905,iatrogenic factor,6,8,41,58,Pelvic radiotherapy may be an additional iatrogenic factor for women with breast cancer.,9579567_10,-1,-1,2,24905,-1
24908,treated with,5,7,39,51,Endometrial cancers diagnosed in women treated with tamoxifen have poorer prognosis.,9579567_11,-1,-1,2,24908,-1
24910,gynaecological surveillance,10,12,64,91,Women who receive tamoxifen for breast cancer should be offered gynaecological surveillance during and after treatment.,9579567_12,-1,-1,2,24910,-1
24911,risk-benefit ratio,5,7,30,48,A long-term evaluation of the risk-benefit ratio of tamoxifen as a preventive treatment for breast cancer is clearly warranted.,9579567_13,-1,-1,2,24911,-1
24929,associated with,13,15,81,96,"It is postulated that her death was caused by hypersensitivity to suxamethonium, associated with her 5-day immobilization.",9587734_7,-1,-1,2,24929,-1
24942,intermediate-caudal parts,11,13,66,91,Contribution of the glycine site of NMDA receptors in rostral and intermediate-caudal parts of the striatum to the regulation of muscle tone in rats.,9630698_0,-1,-1,2,24942,-1
24947,electromyographic method,8,10,53,77,"Muscle tone was examined using a combined mechanoand electromyographic method, which measured simultaneously the muscle resistance (MMG) of the rat's hind foot to passive extension and flexion in the ankle joint and the electromyographic activity (EMG) of the antagonistic muscles of that joint: gastrocnemius and tibialis anterior.",9630698_2,-1,-1,2,24947,-1
24949,MMG,18,19,132,135,"Muscle tone was examined using a combined mechanoand electromyographic method, which measured simultaneously the muscle resistance (MMG) of the rat's hind foot to passive extension and flexion in the ankle joint and the electromyographic activity (EMG) of the antagonistic muscles of that joint: gastrocnemius and tibialis anterior.",9630698_2,-1,-1,2,24949,-1
24961,MMG,38,39,237,240,"5,7-dichlorokynurenic acid (5,7-DCKA), a selective glycine site antagonist, injected in doses of 2.5 and 4.5 microg/0.5 microl bilaterally, into the rostral region of the striatum, decreased both the haloperidol-induced muscle rigidity (MMG) and the enhanced electromyographic activity (EMG).",9630698_4,-1,-1,2,24961,-1
24965,no effect,24,26,161,170,"5,7-DCKA injected bilaterally in a dose of 4.5 microg/0.5 microl into the intermediate-caudal region of the striatum of rats not pretreated with haloperidol had no effect on the muscle tone.",9630698_5,-1,-1,2,24965,-1
24979,polychemotherapy,16,17,104,120,"However, the use of CBDCA higher-intensity schedules and the association with other neurotoxic drugs in polychemotherapy may cause some concern about its safety with respect to peripheral nervous system damage.",9636837_2,-1,-1,2,24979,-1
24987,analytical effects,25,27,161,179,"Neurotoxicity was assessed for behavioral (tail-flick test), neurophysiological (nerve conduction velocity in the tail nerve), morphological, morphometrical and analytical effects.",9636837_4,-1,-1,2,24987,-1
24997,lesser extent,10,12,50,63,"The dorsal root ganglia sensory neurons and, to a lesser extent, satellite cells showed the same changes as those induced by CDDP, mainly affecting the nucleus and nucleolus of ganglionic sensory neurons.",9636837_7,-1,-1,2,24997,-1
24998,satellite cells,13,15,65,80,"The dorsal root ganglia sensory neurons and, to a lesser extent, satellite cells showed the same changes as those induced by CDDP, mainly affecting the nucleus and nucleolus of ganglionic sensory neurons.",9636837_7,-1,-1,2,24998,-1
25018,up-regulation,7,8,67,80,Repeated trimipramine induces dopamine D2/D3 and alpha1-adrenergic up-regulation.,9660111_0,-1,-1,2,25018,-1
25028,Albino Swiss mice,9,12,43,60,TRI was given to male Wistar rats and male Albino Swiss mice perorally twice daily for 14 days.,9660111_4,-1,-1,2,25028,-1
25030,acute experiment TRI,2,5,7,27,In the acute experiment TRI (given i.p.) does not antagonize the reserpine hypothermia in mice and does not potentiate the 5-hydroxytryptophan head twitches in rats.,9660111_5,-1,-1,2,25030,-1
25032,head twitches,24,26,143,156,In the acute experiment TRI (given i.p.) does not antagonize the reserpine hypothermia in mice and does not potentiate the 5-hydroxytryptophan head twitches in rats.,9660111_5,-1,-1,2,25032,-1
25044,open field test,18,21,116,131,"It increases the behaviour stimulation evoked by phenylephrine (given intraventricularly) in rats, evaluated in the open field test as well as the aggressiveness evoked by clonidine in mice, both these effects being mediated by an alpha1-adrenergic receptor.",9660111_8,-1,-1,2,25044,-1
25051,reuptake inhibition,5,7,30,49,"A question arises whether the reuptake inhibition is of any importance to the adaptive changes induced by repeated antidepressants, suggested to be responsible for the antidepressant activity.",9660111_10,-1,-1,2,25051,-1
25053,Effects of,0,2,0,10,Effects of cisapride on symptoms and postcibal small-bowel motor function in patients with irritable bowel syndrome.,9669632_0,-1,-1,2,25053,-1
25064,IBS,29,30,172,175,"Our aim was to assess the effects of long-term treatment with a prokinetic agent, cisapride, on postprandial jejunal motility and symptoms in the irritable bowel syndrome (IBS).",9669632_2,-1,-1,2,25064,-1
25075,mean contraction amplitude,5,8,56,82,"In cisapride-treated diarrhoea-predominant patients the mean contraction amplitude was higher (29.3 +/- 3.2 versus 24.9 +/- 2.6 mm Hg, cisapride versus placebo (P < 0.001); pretreatment, 25.7 +/- 6.0 mm Hg), the mean contraction duration longer (3.4 +/- 0.2 versus 3.0 +/- 0.2 sec, cisapride versus placebo (P < 0.001); pretreatment, 3.1 +/- 0.5 sec), and the mean contraction frequency lower (2.0 +/- 0.2 versus 2.5 +/- 0.4 cont./min, cisapride versus placebo (P < 0.001); pretreatment, 2.5 +/- 1.1 cont./min] than patients treated with placebo.",9669632_5,-1,-1,2,25075,-1
25079,pretreatment,32,33,173,185,"In cisapride-treated diarrhoea-predominant patients the mean contraction amplitude was higher (29.3 +/- 3.2 versus 24.9 +/- 2.6 mm Hg, cisapride versus placebo (P < 0.001); pretreatment, 25.7 +/- 6.0 mm Hg), the mean contraction duration longer (3.4 +/- 0.2 versus 3.0 +/- 0.2 sec, cisapride versus placebo (P < 0.001); pretreatment, 3.1 +/- 0.5 sec), and the mean contraction frequency lower (2.0 +/- 0.2 versus 2.5 +/- 0.4 cont./min, cisapride versus placebo (P < 0.001); pretreatment, 2.5 +/- 1.1 cont./min] than patients treated with placebo.",9669632_5,-1,-1,2,25079,-1
25080,/-,36,37,193,195,"In cisapride-treated diarrhoea-predominant patients the mean contraction amplitude was higher (29.3 +/- 3.2 versus 24.9 +/- 2.6 mm Hg, cisapride versus placebo (P < 0.001); pretreatment, 25.7 +/- 6.0 mm Hg), the mean contraction duration longer (3.4 +/- 0.2 versus 3.0 +/- 0.2 sec, cisapride versus placebo (P < 0.001); pretreatment, 3.1 +/- 0.5 sec), and the mean contraction frequency lower (2.0 +/- 0.2 versus 2.5 +/- 0.4 cont./min, cisapride versus placebo (P < 0.001); pretreatment, 2.5 +/- 1.1 cont./min] than patients treated with placebo.",9669632_5,0,1,2,25080,-1
25082,/-,55,56,270,272,"In cisapride-treated diarrhoea-predominant patients the mean contraction amplitude was higher (29.3 +/- 3.2 versus 24.9 +/- 2.6 mm Hg, cisapride versus placebo (P < 0.001); pretreatment, 25.7 +/- 6.0 mm Hg), the mean contraction duration longer (3.4 +/- 0.2 versus 3.0 +/- 0.2 sec, cisapride versus placebo (P < 0.001); pretreatment, 3.1 +/- 0.5 sec), and the mean contraction frequency lower (2.0 +/- 0.2 versus 2.5 +/- 0.4 cont./min, cisapride versus placebo (P < 0.001); pretreatment, 2.5 +/- 1.1 cont./min] than patients treated with placebo.",9669632_5,0,1,2,25082,-1
25084,pretreatment,68,69,320,332,"In cisapride-treated diarrhoea-predominant patients the mean contraction amplitude was higher (29.3 +/- 3.2 versus 24.9 +/- 2.6 mm Hg, cisapride versus placebo (P < 0.001); pretreatment, 25.7 +/- 6.0 mm Hg), the mean contraction duration longer (3.4 +/- 0.2 versus 3.0 +/- 0.2 sec, cisapride versus placebo (P < 0.001); pretreatment, 3.1 +/- 0.5 sec), and the mean contraction frequency lower (2.0 +/- 0.2 versus 2.5 +/- 0.4 cont./min, cisapride versus placebo (P < 0.001); pretreatment, 2.5 +/- 1.1 cont./min] than patients treated with placebo.",9669632_5,-1,-1,2,25084,-1
25087,/-,86,87,399,401,"In cisapride-treated diarrhoea-predominant patients the mean contraction amplitude was higher (29.3 +/- 3.2 versus 24.9 +/- 2.6 mm Hg, cisapride versus placebo (P < 0.001); pretreatment, 25.7 +/- 6.0 mm Hg), the mean contraction duration longer (3.4 +/- 0.2 versus 3.0 +/- 0.2 sec, cisapride versus placebo (P < 0.001); pretreatment, 3.1 +/- 0.5 sec), and the mean contraction frequency lower (2.0 +/- 0.2 versus 2.5 +/- 0.4 cont./min, cisapride versus placebo (P < 0.001); pretreatment, 2.5 +/- 1.1 cont./min] than patients treated with placebo.",9669632_5,0,1,2,25087,-1
25088,/-,91,92,418,420,"In cisapride-treated diarrhoea-predominant patients the mean contraction amplitude was higher (29.3 +/- 3.2 versus 24.9 +/- 2.6 mm Hg, cisapride versus placebo (P < 0.001); pretreatment, 25.7 +/- 6.0 mm Hg), the mean contraction duration longer (3.4 +/- 0.2 versus 3.0 +/- 0.2 sec, cisapride versus placebo (P < 0.001); pretreatment, 3.1 +/- 0.5 sec), and the mean contraction frequency lower (2.0 +/- 0.2 versus 2.5 +/- 0.4 cont./min, cisapride versus placebo (P < 0.001); pretreatment, 2.5 +/- 1.1 cont./min] than patients treated with placebo.",9669632_5,0,1,2,25088,-1
25089,cont./min,93,94,425,434,"In cisapride-treated diarrhoea-predominant patients the mean contraction amplitude was higher (29.3 +/- 3.2 versus 24.9 +/- 2.6 mm Hg, cisapride versus placebo (P < 0.001); pretreatment, 25.7 +/- 6.0 mm Hg), the mean contraction duration longer (3.4 +/- 0.2 versus 3.0 +/- 0.2 sec, cisapride versus placebo (P < 0.001); pretreatment, 3.1 +/- 0.5 sec), and the mean contraction frequency lower (2.0 +/- 0.2 versus 2.5 +/- 0.4 cont./min, cisapride versus placebo (P < 0.001); pretreatment, 2.5 +/- 1.1 cont./min] than patients treated with placebo.",9669632_5,-1,-1,2,25089,-1
25091,pretreatment,104,105,474,486,"In cisapride-treated diarrhoea-predominant patients the mean contraction amplitude was higher (29.3 +/- 3.2 versus 24.9 +/- 2.6 mm Hg, cisapride versus placebo (P < 0.001); pretreatment, 25.7 +/- 6.0 mm Hg), the mean contraction duration longer (3.4 +/- 0.2 versus 3.0 +/- 0.2 sec, cisapride versus placebo (P < 0.001); pretreatment, 3.1 +/- 0.5 sec), and the mean contraction frequency lower (2.0 +/- 0.2 versus 2.5 +/- 0.4 cont./min, cisapride versus placebo (P < 0.001); pretreatment, 2.5 +/- 1.1 cont./min] than patients treated with placebo.",9669632_5,-1,-1,2,25091,-1
25092,/- 1.1 cont./min,108,111,493,509,"In cisapride-treated diarrhoea-predominant patients the mean contraction amplitude was higher (29.3 +/- 3.2 versus 24.9 +/- 2.6 mm Hg, cisapride versus placebo (P < 0.001); pretreatment, 25.7 +/- 6.0 mm Hg), the mean contraction duration longer (3.4 +/- 0.2 versus 3.0 +/- 0.2 sec, cisapride versus placebo (P < 0.001); pretreatment, 3.1 +/- 0.5 sec), and the mean contraction frequency lower (2.0 +/- 0.2 versus 2.5 +/- 0.4 cont./min, cisapride versus placebo (P < 0.001); pretreatment, 2.5 +/- 1.1 cont./min] than patients treated with placebo.",9669632_5,-1,-1,2,25092,-1
25093,treated with,114,116,525,537,"In cisapride-treated diarrhoea-predominant patients the mean contraction amplitude was higher (29.3 +/- 3.2 versus 24.9 +/- 2.6 mm Hg, cisapride versus placebo (P < 0.001); pretreatment, 25.7 +/- 6.0 mm Hg), the mean contraction duration longer (3.4 +/- 0.2 versus 3.0 +/- 0.2 sec, cisapride versus placebo (P < 0.001); pretreatment, 3.1 +/- 0.5 sec), and the mean contraction frequency lower (2.0 +/- 0.2 versus 2.5 +/- 0.4 cont./min, cisapride versus placebo (P < 0.001); pretreatment, 2.5 +/- 1.1 cont./min] than patients treated with placebo.",9669632_5,-1,-1,2,25093,-1
25096,constipation-predominant,10,11,65,89,No significant differences in jejunal motility were found in the constipation-predominant IBS group.,9669632_6,-1,-1,2,25096,-1
25098,visual analogue scale,6,9,34,55,Symptoms were assessed by using a visual analogue scale before and after treatment.,9669632_7,-1,-1,2,25098,-1
25101,/-,20,21,138,140,"Symptom scores relating to the severity of constipation were lower in cisapride-treated constipation-predominant IBS patients [score, 54 +/- 5 versus 67 +/- 14 mm, cisapride versus placebo (P < 0.05); pretreatment, 62 +/- 19 mm].",9669632_8,0,1,2,25101,-1
25102,/-,25,26,154,156,"Symptom scores relating to the severity of constipation were lower in cisapride-treated constipation-predominant IBS patients [score, 54 +/- 5 versus 67 +/- 14 mm, cisapride versus placebo (P < 0.05); pretreatment, 62 +/- 19 mm].",9669632_8,0,1,2,25102,-1
25104,pretreatment,38,39,201,213,"Symptom scores relating to the severity of constipation were lower in cisapride-treated constipation-predominant IBS patients [score, 54 +/- 5 versus 67 +/- 14 mm, cisapride versus placebo (P < 0.05); pretreatment, 62 +/- 19 mm].",9669632_8,-1,-1,2,25104,-1
25105,/-,42,43,219,221,"Symptom scores relating to the severity of constipation were lower in cisapride-treated constipation-predominant IBS patients [score, 54 +/- 5 versus 67 +/- 14 mm, cisapride versus placebo (P < 0.05); pretreatment, 62 +/- 19 mm].",9669632_8,0,1,2,25105,-1
25106,Diarrhoea-predominant IBS,0,2,0,25,"Diarrhoea-predominant IBS patients had a higher pain score after cisapride therapy [score, 55 +/- 15 versus 34 +/- 12 mm, cisapride versus placebo (P < 0.05); pretreatment, 67 +/- 19 mm].",9669632_9,-1,-1,2,25106,-1
25109,/-,16,17,95,97,"Diarrhoea-predominant IBS patients had a higher pain score after cisapride therapy [score, 55 +/- 15 versus 34 +/- 12 mm, cisapride versus placebo (P < 0.05); pretreatment, 67 +/- 19 mm].",9669632_9,0,1,2,25109,-1
25110,/-,21,22,112,114,"Diarrhoea-predominant IBS patients had a higher pain score after cisapride therapy [score, 55 +/- 15 versus 34 +/- 12 mm, cisapride versus placebo (P < 0.05); pretreatment, 67 +/- 19 mm].",9669632_9,0,1,2,25110,-1
25113,/-,38,39,177,179,"Diarrhoea-predominant IBS patients had a higher pain score after cisapride therapy [score, 55 +/- 15 versus 34 +/- 12 mm, cisapride versus placebo (P < 0.05); pretreatment, 67 +/- 19 mm].",9669632_9,0,1,2,25113,-1
25120,Tamoxifen Prevention Study,1,4,8,34,Italian Tamoxifen Prevention Study.,9672273_1,-1,-1,2,25120,-1
25123,associated with,17,19,102,117,"BACKGROUND: Tamoxifen is a candidate chemopreventive agent in breast cancer, although the drug may be associated with the development of endometrial cancer.",9672273_2,-1,-1,2,25123,-1
25125,hysterectomised,6,7,28,43,Therefore we did a trial in hysterectomised women of tamoxifen as a chemopreventive.,9672273_3,-1,-1,2,25125,-1
25130,trialists,6,7,19,28,"In June, 1997, the trialists and the data-monitoring committee decided to end recruitment primarily because of the number of women dropping out of the study.",9672273_7,-1,-1,2,25130,-1
25131,data-monitoring committee,9,11,37,62,"In June, 1997, the trialists and the data-monitoring committee decided to end recruitment primarily because of the number of women dropping out of the study.",9672273_7,-1,-1,2,25131,-1
25132,primary endpoints,1,3,4,21,The primary endpoints are the occurrence of and deaths from breast cancer.,9672273_9,-1,-1,2,25132,-1
25135,intention-to-treat,7,8,46,64,This preliminary interim analysis is based on intention-to-treat.,9672273_10,-1,-1,2,25135,-1
25139,statistically significant,3,5,11,36,"There is a statistically significant reduction of breast cancer among women receiving tamoxifen who also used hormone-replacement therapy during the trial: among 390 women on such therapy and allocated to placebo, we found eight cases of breast cancer compared with one case among 362 women allocated to tamoxifen.",9672273_14,-1,-1,2,25139,-1
25143,placebo group,3,5,18,31,"Compared with the placebo group, there was a significantly increased risk of vascular events and hypertriglyceridaemia among women on tamoxifen.",9672273_15,-1,-1,2,25143,-1
25146,preliminary analysis,4,6,30,50,"INTERPRETATION: Although this preliminary analysis has low power, in this cohort of women at low-to-normal risk of breast cancer, the postulated protective effects of tamoxifen are not yet apparent.",9672273_16,-1,-1,2,25146,-1
25147,low-to-normal risk,16,18,93,111,"INTERPRETATION: Although this preliminary analysis has low power, in this cohort of women at low-to-normal risk of breast cancer, the postulated protective effects of tamoxifen are not yet apparent.",9672273_16,-1,-1,2,25147,-1
25161,associated with,10,12,66,81,Both plasma pethidine and norpethidine were elevated in the range associated with clinical manifestations of central nervous system excitation.,9672936_3,-1,-1,2,25161,-1
25164,risk factors,2,4,9,21,No other risk factors for CNS toxicity were identified.,9672936_4,-1,-1,2,25164,-1
25167,short time intervals,8,11,57,77,This method allowed frequent self-dosing of pethidine at short time intervals and rapid accumulation of pethidine and norpethidine.,9672936_5,-1,-1,2,25167,-1
25179,ASA,26,27,157,160,"An increase in blood pressure, accompanied by atrial fibrillation, agitation, incomprehensible shouts and loss of consciousness, was observed in an elderly, ASA classification group II, cardiovascularly medicated male, 12 min after performance of axillary block with mepivacaine 850 mg containing adrenaline 0.225 mg, for correction of Dupuytren's contracture.",9698967_1,-1,-1,2,25179,-1
25191,cardiovascular medications,30,32,196,222,Both the temporal relationship of events and the response to treatment suggest that a rapid systemic absorption of mepivacaine with adrenaline and/or interaction of these drugs with the patient's cardiovascular medications were responsible for the perioperative complications.,9698967_5,-1,-1,2,25191,-1
25197,well-recognized,4,5,30,45,"Stevens-Johnson syndrome is a well-recognized immune complex-mediated hypersensitivity reaction that affects all age groups, is drug or infection induced, and has classic systemic, mucosal, and dermatologic manifestations.",9721172_3,-1,-1,2,25197,-1
25199,age groups,12,14,113,123,"Stevens-Johnson syndrome is a well-recognized immune complex-mediated hypersensitivity reaction that affects all age groups, is drug or infection induced, and has classic systemic, mucosal, and dermatologic manifestations.",9721172_3,-1,-1,2,25199,-1
25204,associated with,26,28,178,193,"A previously healthy child who developed acute, severe, rapidly progressive vanishing bile duct syndrome shortly after Stevens-Johnson syndrome is described; this was temporally associated with ibuprofen use.",9721172_4,-1,-1,2,25204,-1
25211,age group,12,14,85,94,This case documents acute drug-related vanishing bile duct syndrome in the pediatric age group and suggests shared immune mechanisms in the pathogenesis of both Stevens-Johnson syndrome and vanishing bile duct syndrome.,9721172_6,-1,-1,2,25211,-1
25212,immune mechanisms,17,19,115,132,This case documents acute drug-related vanishing bile duct syndrome in the pediatric age group and suggests shared immune mechanisms in the pathogenesis of both Stevens-Johnson syndrome and vanishing bile duct syndrome.,9721172_6,-1,-1,2,25212,-1
25216,associated with,6,8,49,64,High incidence of primary pulmonary hypertension associated with appetite suppressants in Belgium.,9727773_0,-1,-1,2,25216,-1
25219,associated with,15,17,92,107,"Primary pulmonary hypertension is a rare, progressive and incurable disease, which has been associated with the intake of appetite suppressant drugs.",9727773_1,-1,-1,2,25219,-1
25223,matched controls,8,10,64,80,Thirty-five patients with primary pulmonary hypertension and 85 matched controls were recruited over 32 months (1992-1994) in Belgium.,9727773_3,-1,-1,2,25223,-1
25224,Exposure to,0,2,0,11,Exposure to appetite-suppressants was assessed on the basis of hospital records and standardized interview.,9727773_4,-1,-1,2,25224,-1
25227,standardized interview,12,14,84,106,Exposure to appetite-suppressants was assessed on the basis of hospital records and standardized interview.,9727773_4,-1,-1,2,25227,-1
25233,exposed to,5,7,26,36,"The patients who had been exposed to appetite suppressants tended to be on average more severely ill, and to have a shorter median delay between onset of symptoms and diagnosis.",9727773_8,-1,-1,2,25233,-1
25252,treated with,7,9,49,61,"Frequency of absences increased in four children treated with carbamazepine and two of these developed myoclonic jerks, which resolved on withdrawal of carbamazepine.",9746003_4,-1,-1,2,25252,-1
25260,associated with,2,4,25,40,Choreoathetoid movements associated with rapid adjustment to methadone.,9754849_0,-1,-1,2,25260,-1
25265,neurobiological phenomena,2,4,20,45,Possible underlying neurobiological phenomena are discussed.,9754849_4,-1,-1,2,25265,-1
25266,Epileptogenic activity,0,2,0,22,Epileptogenic activity of folic acid after drug induces SLE (folic acid and epilepsy)OBJECTIVE: To study the effect of folic acid-containing multivitamin supplementation in epileptic women before and during pregnancy in order to determine the rate of structural birth defects and epilepsy-related side effects.,9758264_0,-1,-1,2,25266,-1
25269,epilepsy)OBJECTIVE,13,14,76,94,Epileptogenic activity of folic acid after drug induces SLE (folic acid and epilepsy)OBJECTIVE: To study the effect of folic acid-containing multivitamin supplementation in epileptic women before and during pregnancy in order to determine the rate of structural birth defects and epilepsy-related side effects.,9758264_0,-1,-1,2,25269,-1
25274,randomised trial,5,7,22,38,"STUDY DESIGN: First a randomised trial, later periconception care including in total 12225 females.",9758264_1,-1,-1,2,25274,-1
25275,periconception care,9,11,46,65,"STUDY DESIGN: First a randomised trial, later periconception care including in total 12225 females.",9758264_1,-1,-1,2,25275,-1
25282,periconception,10,11,63,77,Another patient exhibited with a cluster of seizures after the periconception period using another multivitamin.,9758264_4,-1,-1,2,25282,-1
25301,Working Group,1,3,14,27,Collaborative Working Group on Clinical Trial Evaluations.,9766615_1,-1,-1,2,25301,-1
25307,patients',20,22,131,140,"Thus, clinicians should address patients' concerns about adverse effects and attempt to choose medications that will improve their patients' quality of life as well as overall health.",9766615_3,-1,-1,2,25307,-1
25311,associated with,3,5,24,39,"Conventional agents are associated with unwanted central nervous system effects, including extrapyramidal symptoms (EPS), tardive dyskinesia, sedation, and possible impairment of some cognitive measures, as well as cardiac effects, orthostatic hypotension, hepatic changes, anticholinergic side effects, sexual dysfunction, and weight gain.",9766615_5,-1,-1,2,25311,-1
25315,cognitive measures,28,30,184,202,"Conventional agents are associated with unwanted central nervous system effects, including extrapyramidal symptoms (EPS), tardive dyskinesia, sedation, and possible impairment of some cognitive measures, as well as cardiac effects, orthostatic hypotension, hepatic changes, anticholinergic side effects, sexual dysfunction, and weight gain.",9766615_5,-1,-1,2,25315,-1
25329,atypicals,13,14,86,95,"Since the incidence and severity of specific adverse effects differ among the various atypicals, the clinician should carefully consider which side effects are most likely to lead to the individual's dissatisfaction and noncompliance before choosing an antipsychotic for a particular patient.",9766615_7,-1,-1,2,25329,-1
25331,individual's,30,32,187,199,"Since the incidence and severity of specific adverse effects differ among the various atypicals, the clinician should carefully consider which side effects are most likely to lead to the individual's dissatisfaction and noncompliance before choosing an antipsychotic for a particular patient.",9766615_7,-1,-1,2,25331,-1
25333,case series,19,21,120,131,The association of cocaine and amphetamine use with hemorrhagic and ischemic stroke is based almost solely on data from case series.,9799166_1,-1,-1,2,25333,-1
25334,epidemiologic studies,4,6,22,43,The limited number of epidemiologic studies of stroke and use of cocaine and/or amphetamine have been done in settings that serve mostly the poor and/or minorities.,9799166_2,-1,-1,2,25334,-1
25336,Kaiser Permanente,12,14,86,103,This case-control study was conducted in the defined population comprising members of Kaiser Permanente of Northern and Southern California.,9799166_3,-1,-1,2,25336,-1
25337,Southern California,17,19,120,139,This case-control study was conducted in the defined population comprising members of Kaiser Permanente of Northern and Southern California.,9799166_3,-1,-1,2,25337,-1
25338,3-year,16,17,81,87,"We attempted to identify all incident strokes in women ages 15-44 years during a 3-year period using hospital admission and discharge records, emergency department logs, and payment requests for out-of-plan hospitalizations.",9799166_4,-1,-1,2,25338,-1
25341,emergency department logs,25,28,143,168,"We attempted to identify all incident strokes in women ages 15-44 years during a 3-year period using hospital admission and discharge records, emergency department logs, and payment requests for out-of-plan hospitalizations.",9799166_4,-1,-1,2,25341,-1
25342,out-of-plan hospitalizations,33,35,195,223,"We attempted to identify all incident strokes in women ages 15-44 years during a 3-year period using hospital admission and discharge records, emergency department logs, and payment requests for out-of-plan hospitalizations.",9799166_4,-1,-1,2,25342,-1
25343,usual care,10,12,53,63,"We selected controls, matched on age and facility of usual care, at random from healthy members of the health plan.",9799166_5,-1,-1,2,25343,-1
25344,healthy members,16,18,80,95,"We selected controls, matched on age and facility of usual care, at random from healthy members of the health plan.",9799166_5,-1,-1,2,25344,-1
25345,health plan,20,22,103,114,"We selected controls, matched on age and facility of usual care, at random from healthy members of the health plan.",9799166_5,-1,-1,2,25345,-1
25348,confidence interval,21,23,116,135,The univariate matched odds ratio for stroke in women who admitted to using cocaine and/or amphetamine was 8.5 (95% confidence interval = 3.6-20.0).,9799166_8,-1,-1,2,25348,-1
25349,confounders,5,6,39,50,"After further adjustment for potential confounders, the odds ratio in women who reported using cocaine and/or amphetamine was 7.0 (95% confidence interval = 2.8-17.9).",9799166_9,-1,-1,2,25349,-1
25351,confidence interval,23,25,135,154,"After further adjustment for potential confounders, the odds ratio in women who reported using cocaine and/or amphetamine was 7.0 (95% confidence interval = 2.8-17.9).",9799166_9,-1,-1,2,25351,-1
25352,risk factor,9,11,50,61,"The use of cocaine and/or amphetamine is a strong risk factor for stroke in this socioeconomically heterogeneous, insured urban population.",9799166_10,-1,-1,2,25352,-1
25353,urban population,19,21,122,138,"The use of cocaine and/or amphetamine is a strong risk factor for stroke in this socioeconomically heterogeneous, insured urban population.",9799166_10,-1,-1,2,25353,-1
25354,placebo-controlled,3,4,14,32,"A randomized, placebo-controlled dose-comparison trial of haloperidol for psychosis and disruptive behaviors in Alzheimer's disease.",9812111_0,-1,-1,2,25354,-1
25360,random-assignment,5,6,20,37,"METHOD: In a 6-week random-assignment, double-blind, placebo-controlled trial (phase A), haloperidol, 2-3 mg/day (standard dose), and haloperidol, 0.50-0.75 mg/day (low dose), were compared in 71 outpatients with Alzheimer's disease.",9812111_2,-1,-1,2,25360,-1
25361,double-blind,7,8,39,51,"METHOD: In a 6-week random-assignment, double-blind, placebo-controlled trial (phase A), haloperidol, 2-3 mg/day (standard dose), and haloperidol, 0.50-0.75 mg/day (low dose), were compared in 71 outpatients with Alzheimer's disease.",9812111_2,-1,-1,2,25361,-1
25362,placebo-controlled trial,9,11,53,77,"METHOD: In a 6-week random-assignment, double-blind, placebo-controlled trial (phase A), haloperidol, 2-3 mg/day (standard dose), and haloperidol, 0.50-0.75 mg/day (low dose), were compared in 71 outpatients with Alzheimer's disease.",9812111_2,-1,-1,2,25362,-1
25373,phase A,8,10,43,50,"RESULTS: For the 60 patients who completed phase A, standard-dose haloperidol was efficacious and superior to both low-dose haloperidol and placebo for scores on the Brief Psychiatric Rating Scale psychosis factor and on psychomotor agitation.",9812111_4,-1,-1,2,25373,-1
25378,Response rates,0,2,0,14,Response rates according to three sets of criteria were greater with the standard dose (55%-60%) than the low dose (25%-35%) and placebo (25%-30%).,9812111_5,-1,-1,2,25378,-1
25389,mg/day,17,18,99,105,"CONCLUSIONS: The results indicated a favorable therapeutic profile for haloperidol in doses of 2-3 mg/day, although a subgroup developed moderate to severe extrapyramidal signs.",9812111_8,-1,-1,2,25389,-1
25392,mg/day with,5,7,21,32,"A starting dose of 1 mg/day with gradual, upward dose titration is recommended.",9812111_9,-1,-1,2,25392,-1
25398,follow-up study,1,3,2,17,A follow-up study of cases reported earlier.,982002_1,-1,-1,2,25398,-1
25408,131I-hippuran renography,6,8,32,56,In three cases the excretion at 131I-hippuran renography was slightly slowed.,982002_10,-1,-1,2,25408,-1
25420,subcellular components,24,26,139,161,"Infusions of epinephrine (4 mug per kilogram per minute for 6 hours) increased radiocalcium uptakes into intact myocardium and each of its subcellular components with the mitochondrial fraction showing the most consistent changes when compared to saline-infused control animals (4,957 vs. 827 counts per minute per gram of dried tissue or fraction).",983936_2,-1,-1,2,25420,-1
25421,mitochondrial,28,29,171,184,"Infusions of epinephrine (4 mug per kilogram per minute for 6 hours) increased radiocalcium uptakes into intact myocardium and each of its subcellular components with the mitochondrial fraction showing the most consistent changes when compared to saline-infused control animals (4,957 vs. 827 counts per minute per gram of dried tissue or fraction).",983936_2,0,1,2,25421,-1
25422,saline-infused control animals,38,41,247,277,"Infusions of epinephrine (4 mug per kilogram per minute for 6 hours) increased radiocalcium uptakes into intact myocardium and each of its subcellular components with the mitochondrial fraction showing the most consistent changes when compared to saline-infused control animals (4,957 vs. 827 counts per minute per gram of dried tissue or fraction).",983936_2,-1,-1,2,25422,-1
25424,fat-free dry weight,16,19,98,117,Myocardial concentrations of calcium also increased significantly (12.0 vs. 5.0 mg.per 100 Gm. of fat-free dry weight).,983936_3,-1,-1,2,25424,-1
25426,raise serum,6,8,44,55,Infusions of calcium chloride sufficient to raise serum calcium concentrations 2 mEq.,983936_4,-1,-1,2,25426,-1
25430,Mitochondrial,0,1,0,13,"Mitochondrial radiocalcium uptakes were significantly decreased in animals pretreated with acetylsalicylic acid or dipyridamole or when hydrocortisone was added to the epinephrine infusion (2,682,2,803, and 3,424 counts per minute per gram of dried fraction, respectively).",983936_6,0,1,2,25430,-1
25431,pretreated,8,9,75,85,"Mitochondrial radiocalcium uptakes were significantly decreased in animals pretreated with acetylsalicylic acid or dipyridamole or when hydrocortisone was added to the epinephrine infusion (2,682,2,803, and 3,424 counts per minute per gram of dried fraction, respectively).",983936_6,-1,-1,2,25431,-1
25434,dried fraction,34,36,243,257,"Mitochondrial radiocalcium uptakes were significantly decreased in animals pretreated with acetylsalicylic acid or dipyridamole or when hydrocortisone was added to the epinephrine infusion (2,682,2,803, and 3,424 counts per minute per gram of dried fraction, respectively).",983936_6,-1,-1,2,25434,-1
25435,calcium concentrations,1,3,11,33,"Myocardial calcium concentrations also were decreased (11.2, 8.3, and 8.9 mg. per 100 Gm. of fat-free dry weight, respectively) in the three treatment groups, being significantly decreased only in the last two.",983936_7,-1,-1,2,25435,-1
25437,treatment groups,29,31,141,157,"Myocardial calcium concentrations also were decreased (11.2, 8.3, and 8.9 mg. per 100 Gm. of fat-free dry weight, respectively) in the three treatment groups, being significantly decreased only in the last two.",983936_7,-1,-1,2,25437,-1
25439,treatment groups,12,14,70,86,Evidence of microscopic damage was graded as less severe in the three treatment groups.,983936_8,-1,-1,2,25439,-1
25443,Chronic effects,0,2,0,15,Chronic effects of a novel synthetic anthracycline derivative (SM-5887) on normal heart and doxorubicin-induced cardiomyopathy in beagle dogs.,9848575_0,-1,-1,2,25443,-1
25499,minimal-type,10,11,52,64,"Of the nonepisode biopsies, 7 and 4 biopsies showed minimal-type and mild-type chronic FK506 nephropathy, respectively.",9855119_5,-1,-1,2,25499,-1
25507,striped form,36,38,219,231,"Chronic FK506 nephropathy consisted of rough and foamy tubular vacuolization (5 biopsies), arteriolopathy (angiodegeneration of the arteriolar wall; 20 biopsies), focal segmental glomerulosclerosis (4 biopsies) and the striped form of interstitial fibrosis (11 biopsies).",9855119_6,-1,-1,2,25507,-1
25509,serum creatinine,1,3,4,20,"The serum creatinine levels of patients in the mild-type chronic FK506 nephropathy group, which included 7 episode biopsies, were statistically higher than those in the minimum-type chronic FK506-nephropathy group (P< 0.001).",9855119_7,-1,-1,2,25509,-1
25511,episode biopsies,17,19,107,123,"The serum creatinine levels of patients in the mild-type chronic FK506 nephropathy group, which included 7 episode biopsies, were statistically higher than those in the minimum-type chronic FK506-nephropathy group (P< 0.001).",9855119_7,-1,-1,2,25511,-1
25512,statistically higher,21,23,130,150,"The serum creatinine levels of patients in the mild-type chronic FK506 nephropathy group, which included 7 episode biopsies, were statistically higher than those in the minimum-type chronic FK506-nephropathy group (P< 0.001).",9855119_7,-1,-1,2,25512,-1
25513,minimum-type chronic FK506-nephropathy group,27,31,169,213,"The serum creatinine levels of patients in the mild-type chronic FK506 nephropathy group, which included 7 episode biopsies, were statistically higher than those in the minimum-type chronic FK506-nephropathy group (P< 0.001).",9855119_7,-1,-1,2,25513,-1
25525,Hepatocyte tight junctions,0,3,0,26,"Hepatocyte tight junctions (TJs), the only intercellular barrier between the sinusoidal and the canalicular spaces, play a key role in bile formation.",9862868_1,-1,-1,2,25525,-1
25527,intercellular barrier,9,11,43,64,"Hepatocyte tight junctions (TJs), the only intercellular barrier between the sinusoidal and the canalicular spaces, play a key role in bile formation.",9862868_1,-1,-1,2,25527,-1
25528,canalicular spaces,16,18,96,114,"Hepatocyte tight junctions (TJs), the only intercellular barrier between the sinusoidal and the canalicular spaces, play a key role in bile formation.",9862868_1,-1,-1,2,25528,-1
25536,7H6,8,9,55,58,"Recently, several TJ-associated proteins like ZO-1 and 7H6 have been identified and characterized.",9862868_3,-1,-1,2,25536,-1
25537,Immunolocalization,0,1,0,18,Immunolocalization of 7H6 appears to closely correlate with paracellular permeability.,9862868_4,-1,-1,2,25537,-1
25538,7H6,2,3,22,25,Immunolocalization of 7H6 appears to closely correlate with paracellular permeability.,9862868_4,-1,-1,2,25538,-1
25544,BDL,22,23,135,138,We used rat models of intrahepatic cholestasis by ethinyl estradiol (EE) treatment and extrahepatic cholestasis by bile duct ligation (BDL) to precisely determine the site of TJ damage.,9862868_5,-1,-1,2,25544,-1
25545,TJ,30,31,175,177,We used rat models of intrahepatic cholestasis by ethinyl estradiol (EE) treatment and extrahepatic cholestasis by bile duct ligation (BDL) to precisely determine the site of TJ damage.,9862868_5,-1,-1,2,25545,-1
25548,double-immunolabeling,7,8,47,68,Alterations in hepatocyte TJs were assessed by double-immunolabeling for 7H6 and ZO-1 using a confocal laser scanning microscope.,9862868_6,-1,-1,2,25548,-1
25549,7H6,9,10,73,76,Alterations in hepatocyte TJs were assessed by double-immunolabeling for 7H6 and ZO-1 using a confocal laser scanning microscope.,9862868_6,-1,-1,2,25549,-1
25550,ZO-1,11,12,81,85,Alterations in hepatocyte TJs were assessed by double-immunolabeling for 7H6 and ZO-1 using a confocal laser scanning microscope.,9862868_6,-1,-1,2,25550,-1
25551,confocal laser scanning microscope,14,18,94,128,Alterations in hepatocyte TJs were assessed by double-immunolabeling for 7H6 and ZO-1 using a confocal laser scanning microscope.,9862868_6,-1,-1,2,25551,-1
25552,control rats,1,3,3,15,"In control rats, immunostaining for 7H6 and ZO-1 colocalized to outline bile canaliculi in a continuous fashion.",9862868_7,-1,-1,2,25552,-1
25553,immunostaining,4,5,17,31,"In control rats, immunostaining for 7H6 and ZO-1 colocalized to outline bile canaliculi in a continuous fashion.",9862868_7,-1,-1,2,25553,-1
25554,7H6,6,7,36,39,"In control rats, immunostaining for 7H6 and ZO-1 colocalized to outline bile canaliculi in a continuous fashion.",9862868_7,-1,-1,2,25554,-1
25557,continuous fashion,16,18,93,111,"In control rats, immunostaining for 7H6 and ZO-1 colocalized to outline bile canaliculi in a continuous fashion.",9862868_7,-1,-1,2,25557,-1
25558,7H6,3,4,13,16,"In contrast, 7H6 and ZO-1 immunostaining was more discontinuous, outlining the bile canaliculi after BDL.",9862868_8,-1,-1,2,25558,-1
25560,immunostaining,6,7,26,40,"In contrast, 7H6 and ZO-1 immunostaining was more discontinuous, outlining the bile canaliculi after BDL.",9862868_8,-1,-1,2,25560,-1
25562,BDL,16,17,101,104,"In contrast, 7H6 and ZO-1 immunostaining was more discontinuous, outlining the bile canaliculi after BDL.",9862868_8,-1,-1,2,25562,-1
25563,Immunostaining,0,1,0,14,"Immunostaining for 7H6, not ZO-1, decreased and predominantly appeared as discrete signals in the submembranous cytoplasm of periportal hepatocytes after BDL.",9862868_9,-1,-1,2,25563,-1
25564,7H6,2,3,19,22,"Immunostaining for 7H6, not ZO-1, decreased and predominantly appeared as discrete signals in the submembranous cytoplasm of periportal hepatocytes after BDL.",9862868_9,-1,-1,2,25564,-1
25568,BDL,22,23,154,157,"Immunostaining for 7H6, not ZO-1, decreased and predominantly appeared as discrete signals in the submembranous cytoplasm of periportal hepatocytes after BDL.",9862868_9,-1,-1,2,25568,-1
25569,immunostaining,6,7,31,45,"After EE treatment, changes in immunostaining for 7H6 and ZO-1 were similar to those seen in periportal hepatocytes after BDL, but distributed more diffusely throughout the lobule.",9862868_10,-1,-1,2,25569,-1
25570,7H6,8,9,50,53,"After EE treatment, changes in immunostaining for 7H6 and ZO-1 were similar to those seen in periportal hepatocytes after BDL, but distributed more diffusely throughout the lobule.",9862868_10,-1,-1,2,25570,-1
25573,BDL,20,21,122,125,"After EE treatment, changes in immunostaining for 7H6 and ZO-1 were similar to those seen in periportal hepatocytes after BDL, but distributed more diffusely throughout the lobule.",9862868_10,-1,-1,2,25573,-1
25614,mouse passive-avoidance test,2,5,7,35,"In the mouse passive-avoidance test, PG-9 (10-30 mg/kg, i.p.), administered 20 min before the training session, prevented amnesia induced by both the non selective antimuscarinic drug scopolamine and the M1-selective antagonist S-(-)-ET-126.",9869257_1,-1,-1,2,25614,-1
25616,training session,22,24,94,110,"In the mouse passive-avoidance test, PG-9 (10-30 mg/kg, i.p.), administered 20 min before the training session, prevented amnesia induced by both the non selective antimuscarinic drug scopolamine and the M1-selective antagonist S-(-)-ET-126.",9869257_1,-1,-1,2,25616,-1
25619,experimental conditions,3,5,12,35,"In the same experimental conditions, PG-9 (5-20 microg per mouse, i.c.v.) was also able to prevent antimuscarine-induced amnesia, demonstrating a central localization of the activity.",9869257_2,-1,-1,2,25619,-1
25622,i.c.v,15,16,66,71,"In the same experimental conditions, PG-9 (5-20 microg per mouse, i.c.v.) was also able to prevent antimuscarine-induced amnesia, demonstrating a central localization of the activity.",9869257_2,-1,-1,2,25622,-1
25629,in vitro,11,13,58,66,PG-9 was also able to increase the amount of NGF secreted in vitro by astrocytes in a dose-dependent manner.,9869257_4,-1,-1,2,25629,-1
25632,control value,11,13,64,77,The maximal NGF contents obtained by PG-9 were 17.6-fold of the control value.,9869257_5,-1,-1,2,25632,-1
25638,astroglial cells,22,24,142,158,The current work indicates the ability of PG-9 to induce beneficial effects on cognitive processes and stimulate activity of NGF synthesis in astroglial cells.,9869257_7,-1,-1,2,25638,-1
25646,steady-state,17,18,98,110,OBJECTIVE: To evaluate the effect of dosage regimen (once-daily vs. twice-daily) of tobramicyn on steady-state serum concentrations and toxicity.,9875685_1,-1,-1,2,25646,-1
25653,Peak concentrations,0,2,0,19,Peak concentrations were > 6 microg/ml in 100% of the OD group and in 67% of the TD group (P< 0.01).,9875685_9,-1,-1,2,25653,-1
25655,peak concentrations,1,3,5,24,Mean peak concentrations were markedly different: 11.00+/-2.89 microg/ml in OD vs. 6.53+/-1.45 microg/ml in TD (P< 0.01).,9875685_10,-1,-1,2,25655,-1
25656,11.00+/-2.89,7,8,50,62,Mean peak concentrations were markedly different: 11.00+/-2.89 microg/ml in OD vs. 6.53+/-1.45 microg/ml in TD (P< 0.01).,9875685_10,-1,-1,2,25656,-1
25659,t1/2,17,18,89,93,"The pharmacokinetics parameters were: Ke, (0.15+/-0.03/h in OD vs. 0.24+/-0.06/h in TD), t1/2, (4.95+/-1.41 h in OD vs. 3.07+/-0.71 h in TD), Vd (0.35+/-0.11 l/kg in OD vs. 0.33+/-0.09 l/kg in TD), Cl (0.86+/-0.29 ml/min/kg in OD vs. 1.28+/-0.33 ml/min/kg in TD).",9875685_11,-1,-1,2,25659,-1
25662,ml/min/kg,47,48,214,223,"The pharmacokinetics parameters were: Ke, (0.15+/-0.03/h in OD vs. 0.24+/-0.06/h in TD), t1/2, (4.95+/-1.41 h in OD vs. 3.07+/-0.71 h in TD), Vd (0.35+/-0.11 l/kg in OD vs. 0.33+/-0.09 l/kg in TD), Cl (0.86+/-0.29 ml/min/kg in OD vs. 1.28+/-0.33 ml/min/kg in TD).",9875685_11,-1,-1,2,25662,-1
25663,ml/min/kg,52,53,246,255,"The pharmacokinetics parameters were: Ke, (0.15+/-0.03/h in OD vs. 0.24+/-0.06/h in TD), t1/2, (4.95+/-1.41 h in OD vs. 3.07+/-0.71 h in TD), Vd (0.35+/-0.11 l/kg in OD vs. 0.33+/-0.09 l/kg in TD), Cl (0.86+/-0.29 ml/min/kg in OD vs. 1.28+/-0.33 ml/min/kg in TD).",9875685_11,-1,-1,2,25663,-1
25668,TD,1,2,3,5,"In TD group, three patients developed decreased auditory function, of which one presented with an auditory loss of -30 dB, whereas in the OD group only one patient presented decreased auditory function.",9875685_13,-1,-1,2,25668,-1
25672,small study,3,5,17,28,CONCLUSION: This small study suggests that a once-daily dosing regimen of tobramycin is at least as effective as and is no more and possibly less toxic than the twice-daily regimen.,9875685_14,-1,-1,2,25672,-1
25675,peak concentration determination,5,8,29,61,"Using a single-dose therapy, peak concentration determination is not necessary, only trough samples should be monitored to ensure levels below 2 microg/ml.",9875685_15,-1,-1,2,25675,-1
25696,chronic effects,12,14,73,88,"To clarify the mechanisms of FK 506-induced hypertension, we studied the chronic effects of FK 506 on the synthesis of endothelin-1 (ET-1), the expression of mRNA of ET-1 and endothelin-converting enzyme-1 (ECE-1), the endothelial nitric oxide synthase (eNOS) activity, and the expression of mRNA of eNOS and C-type natriuretic peptide (CNP) in rat blood vessels.",9931093_2,-1,-1,2,25696,-1
25714,102+/-13,10,11,52,60,"d-1 given for 4 weeks, elevated blood pressure from 102+/-13 to 152+/-15 mm Hg and increased the synthesis of ET-1 and the levels of ET-1 mRNA in the mesenteric artery (240% and 230%, respectively).",9931093_6,-1,-1,2,25714,-1
25715,mm Hg,13,15,73,78,"d-1 given for 4 weeks, elevated blood pressure from 102+/-13 to 152+/-15 mm Hg and increased the synthesis of ET-1 and the levels of ET-1 mRNA in the mesenteric artery (240% and 230%, respectively).",9931093_6,-1,-1,2,25715,-1
25732,gene expression,18,20,138,153,Structural and functional impairment of mitochondria in adriamycin-induced cardiomyopathy in mice: suppression of cytochrome c oxidase II gene expression.,9952311_0,-1,-1,2,25732,-1
25739,enzyme activity,16,18,105,120,Earlier observations that ADR interacts with mitochondrial cytochrome c oxidase (COX) and suppresses its enzyme activity led us to investigate ADR's action on the cardiovascular functions and heart mitochondrial morphology in Balb-c mice i.p. treated with ADR for several weeks.,9952311_2,-1,-1,2,25739,-1
25744,treated with,38,40,243,255,Earlier observations that ADR interacts with mitochondrial cytochrome c oxidase (COX) and suppresses its enzyme activity led us to investigate ADR's action on the cardiovascular functions and heart mitochondrial morphology in Balb-c mice i.p. treated with ADR for several weeks.,9952311_2,-1,-1,2,25744,-1
25748,electron microscopy,21,23,144,163,"At various times during treatment, the animals were assessed for cardiovascular functions by electrocardiography and for heart tissue damage by electron microscopy.",9952311_3,-1,-1,2,25748,-1
25751,Northern blot hybridization,15,18,85,112,"In parallel, total RNA was extracted from samples of dissected heart and analyzed by Northern blot hybridization to determine the steady-state level of three RNA transcripts encoded by the COXII, COXIII, and COXIV genes.",9952311_4,-1,-1,2,25751,-1
25752,steady-state,21,22,130,142,"In parallel, total RNA was extracted from samples of dissected heart and analyzed by Northern blot hybridization to determine the steady-state level of three RNA transcripts encoded by the COXII, COXIII, and COXIV genes.",9952311_4,-1,-1,2,25752,-1
25755,COXIII,32,33,196,202,"In parallel, total RNA was extracted from samples of dissected heart and analyzed by Northern blot hybridization to determine the steady-state level of three RNA transcripts encoded by the COXII, COXIII, and COXIV genes.",9952311_4,-1,-1,2,25755,-1
25756,COXIV genes,35,37,208,219,"In parallel, total RNA was extracted from samples of dissected heart and analyzed by Northern blot hybridization to determine the steady-state level of three RNA transcripts encoded by the COXII, COXIII, and COXIV genes.",9952311_4,-1,-1,2,25756,-1
25757,comparative studies,14,16,81,100,"Similarly, samples obtained from the liver of the same animals were analyzed for comparative studies.",9952311_5,-1,-1,2,25757,-1
25760,ventricular depolarization time,20,23,134,165,"Our results indicated that 1) treatment of mice with ADR caused cardiovascular arrhythmias characterized by bradycardia, extension of ventricular depolarization time (tQRS), and failure of QRS at high concentrations (10-14 mg/kg body weight cumulative dose); 2) the heart mitochondria underwent swelling, fusion, dissolution, and/or disruption of mitochondrial cristae after several weeks of treatment.",9952311_6,-1,-1,2,25760,-1
25763,body weight cumulative dose,39,43,229,256,"Our results indicated that 1) treatment of mice with ADR caused cardiovascular arrhythmias characterized by bradycardia, extension of ventricular depolarization time (tQRS), and failure of QRS at high concentrations (10-14 mg/kg body weight cumulative dose); 2) the heart mitochondria underwent swelling, fusion, dissolution, and/or disruption of mitochondrial cristae after several weeks of treatment.",9952311_6,-1,-1,2,25763,-1
25768,COXII gene,25,27,132,142,"Such abnormalities were not observed in the mitochondria of liver tissue; and 3) among the three genes of COX enzyme examined, only COXII gene expression was suppressed by ADR treatment, mainly after 8 weeks in both heart and liver.",9952311_7,-1,-1,2,25768,-1
